<SEC-DOCUMENT>0001125376-24-000018.txt : 20240201
<SEC-HEADER>0001125376-24-000018.hdr.sgml : 20240201
<ACCEPTANCE-DATETIME>20240201160504
ACCESSION NUMBER:		0001125376-24-000018
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		127
CONFORMED PERIOD OF REPORT:	20231231
FILED AS OF DATE:		20240201
DATE AS OF CHANGE:		20240201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ENSIGN GROUP, INC
		CENTRAL INDEX KEY:			0001125376
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-SKILLED NURSING CARE FACILITIES [8051]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		IRS NUMBER:				330861263
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33757
		FILM NUMBER:		24586875

	BUSINESS ADDRESS:	
		STREET 1:		29222 RANCHO VIEJO RD.
		STREET 2:		SUITE 127
		CITY:			SAN JUAN CAPISTRANO
		STATE:			CA
		ZIP:			92675
		BUSINESS PHONE:		(949) 487-9500

	MAIL ADDRESS:	
		STREET 1:		29222 RANCHO VIEJO RD.
		STREET 2:		SUITE 127
		CITY:			SAN JUAN CAPISTRANO
		STATE:			CA
		ZIP:			92675

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ENSIGN GROUP INC
		DATE OF NAME CHANGE:	20000930
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ensg-20231231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:ensg="http://www.ensigngroup.net/20231231" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ensg-20231231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001125376</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-35">false</ix:nonNumeric><ix:nonNumeric contextRef="c-53" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-498">P3Y0M0D</ix:nonNumeric><ix:nonNumeric contextRef="c-53" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-504">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="c-55" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="f-508">P4M0D</ix:nonNumeric><ix:nonNumeric contextRef="c-388" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-1456">P5Y0M</ix:nonNumeric><ix:nonNumeric contextRef="c-390" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-1458">P3Y0M</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList" id="f-1530">http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax</ix:nonNumeric><ix:nonNumeric contextRef="c-442" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1611">334</ix:nonNumeric><ix:nonNumeric contextRef="c-445" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-1612">231</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ensg-20231231.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-01-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="facility"><xbrli:measure>ensg:facility</xbrli:measure></xbrli:unit><xbrli:unit id="bed"><xbrli:measure>ensg:bed</xbrli:measure></xbrli:unit><xbrli:unit id="senior_living_unit"><xbrli:measure>ensg:senior_living_unit</xbrli:measure></xbrli:unit><xbrli:unit id="property"><xbrli:measure>ensg:property</xbrli:measure></xbrli:unit><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">us-gaap:WhollyOwnedPropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:OperatingEntityAxis">ensg:ThirdPartyOperatorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="operation"><xbrli:measure>ensg:operation</xbrli:measure></xbrli:unit><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="lease"><xbrli:measure>ensg:lease</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>ensg:option</xbrli:measure></xbrli:unit><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:BlanketAggregateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:BlanketAggregateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:LossSensitiveLimitPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:StopLossInsuranceLimitPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:HealthLiabilityInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:StopLossInsuranceLimitPerClaimMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:HealthLiabilityInsuranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">us-gaap:WhollyOwnedPropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:OperatingEntityAxis">ensg:ThirdPartiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:OwnedPropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:OwnedPropertiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="skilled_nursing_property"><xbrli:measure>ensg:skilled_nursing_property</xbrli:measure></xbrli:unit><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="renewal"><xbrli:measure>ensg:renewal</xbrli:measure></xbrli:unit><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceIncentiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:ManagementServiceTotalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ensg:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ensg:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:RealEstatePurchasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="business"><xbrli:measure>ensg:business</xbrli:measure></xbrli:unit><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:RealEstatePurchasesOfPreviousOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>ensg:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ensg:SeniorLivingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-08</xbrli:startDate><xbrli:endDate>2022-04-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:TwentyThreeSubsidiariesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="subsidiary"><xbrli:measure>ensg:subsidiary</xbrli:measure></xbrli:unit><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:FirstThreeYearsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:InTheFourthYearMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:YearsFiveThroughTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:AfterYearTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:A53PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:A53PromissoryNoteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="plan"><xbrli:measure>ensg:plan</xbrli:measure></xbrli:unit><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>ensg:installment</xbrli:measure></xbrli:unit><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSixMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeEightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeNineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeElevenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-08-27</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-27</xbrli:startDate><xbrli:endDate>2019-08-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>ensg:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:PurchaseOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:NewMasterLeaseAgreeementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:NewMasterLeaseAgreeementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-02-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeaseOfCampusOperationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeaseOfCampusOperationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">us-gaap:ProfessionalMalpracticeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">us-gaap:ProfessionalMalpracticeLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-19</xbrli:startDate><xbrli:endDate>2024-01-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-02-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:August2023RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-08-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:August2023RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-29</xbrli:startDate><xbrli:endDate>2023-08-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:July2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:July2022RepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-28</xbrli:startDate><xbrli:endDate>2022-07-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001125376</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iee29a48a3be7475b9147c6a5457e7413_7"></div><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:13pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-4"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-3">December&#160;31</ix:nonNumeric>, 2023</ix:nonNumeric>. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:5.342%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:92.458%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the transition period from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> to</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;.</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-33757</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">_____________________________</span></div><div style="margin-top:3pt;text-align:center"><img src="ensg-20231231_g1.jpg" alt="ensignlogoofficiala01.jpg" style="height:40px;margin-bottom:5pt;vertical-align:text-bottom;width:64px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:22pt;font-weight:700;line-height:120%">THE <ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ENSIGN GROUP, INC</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:47.726%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.074%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">33-0861263</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or Other Jurisdiction of</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Identification No.)</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">29222 Rancho Viejo Road, Suite 127</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">San Juan Capistrano</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-12">CA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">92675</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">949</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">487-9500</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:35.953%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.090%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.657%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ENSG</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">NASDAQ Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.970%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.227%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.269%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #566b39;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Indicate by check mark:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #566b39;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-19">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-20">No</ix:nonNumeric></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#226600;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-21">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether the registrant has submitted electronically, every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#226600;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-22">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether the registrant is a large accelerated filer, an accelerated filer, non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule&#160;12b-2 of the Exchange Act:</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-23">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-24">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-right:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If an emerging growth company, indicate if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section-404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-26">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If securities are registered pursuant to Section 12(b) of the Act, whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#226600;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-27">&#254;</ix:nonNumeric></span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-bottom:1pt solid #000;border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b).</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#226600;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#254;</span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-left:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#3d6702;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#226600;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">&#254;</ix:nonNumeric></span></td><td colspan="3" style="border-right:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">No</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="42" style="border-bottom:1pt solid #3d6702;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As of June 30, 2023, the aggregate market value of the Registrant's Common Stock held by non-affiliates was: </span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="30" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common Stock</span></td><td colspan="12" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-3" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-29">3,156,373,000</ix:nonFraction></span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The aggregate market value of Common Stock was computed by reference to the closing price as of the last business day of the registrant's most recently completed second fiscal quarter. Shares of Common Stock held by each executive officer, director and each person owning more than 10% of the outstanding Common Stock of the registrant have been excluded (in the amount of $2,014,396,000)</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">in that such persons may be deemed to be affiliates of the registrant. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of January&#160;29, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">56,665,741</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.001 par value, were outstanding.</span></div><div style="margin-top:10pt"><span><br/></span></div><div style="margin-top:10pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE:</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-31" escape="true"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.</span></div></ix:nonNumeric><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><span><br/></span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_22"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEX TO ANNUAL REPORT ON FORM 10-K</span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023 </span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.972%"><tr><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.236%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.103%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART I</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_340">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_340">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_340">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_304">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_304">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_304">31</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_358">Item 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_358">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_358">63</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_3514">Item 1C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_3514">Cybersecurity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_358">63</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_361">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_361">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_361">65</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_301">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_301">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_301">67</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_319">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_319">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_319">69</a></span></div></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART II.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_370">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_370">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_370">69</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_376">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_376">[RESERVED]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_376">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_241">Item 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_241">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_241">71</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_289">Item 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_289">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_289">90</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_382">Item 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_382">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_382">91</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_394">Item 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_394">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_394">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_397">Item 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_397">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_397">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_322">Item 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_322">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_322">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_403">Item 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_403">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_403">127</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART III.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_409">Item 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_409">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_409">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_412">Item 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_412">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_412">127</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_415">Item 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_415">Security Ownership of Certain Beneficial Owners and Management and Related Stockholders Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_415">128</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_418">Item 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_418">Certain Relationships and Related Transactions and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_418">128</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_421">Item 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_421">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_421">128</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">PART IV.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_427">Item 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_427">Exhibits, Financial Statements and Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_427">129</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_433">Item 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_433">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_433">131</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_334">Signatures</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_334">132</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><span><br/></span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_25"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span><span style="color:#3d6702;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form&#160;10-K contains forward-looking statements, which include, but are not limited to our expected future financial position, results of operations, cash flows, financing plans, business strategy, budgets, capital expenditures, competitive positions, growth opportunities and plans and objectives of management. Forward-looking statements can often be identified by words such as &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;believes,&#8221; &#8220;seeks,&#8221; &#8220;estimates,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;ongoing,&#8221; similar expressions, and variations or negatives of these words. These statements are subject to the safe harbors under Private Securities Litigation Reform Act of 1995.  These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors, some of which are listed under the section &#8220;Risk Factors&#8221; in Part&#160;I, Item&#160;1A of this Annual Report on Form&#160;10-K. Accordingly, you should not rely upon forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this Annual Report, and are based on our current expectations, estimates and projections about our industry and business, management's beliefs, and certain assumptions made by us, all of which are subject to change. We undertake no obligation to revise or update publicly any forward-looking statement for any reason, except as otherwise required by law. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Annual Report on Form&#160;10-K, the words, "Ensign," "Company," &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; refer to The Ensign Group, Inc. and its consolidated subsidiaries. All of our independent subsidiaries, the Service Center (defined below) and our wholly-owned captive insurance subsidiary (the Captive Insurance) and captive real estate investment trust called Standard Bearer Healthcare REIT, Inc. (Standard Bearer) are operated by separate, wholly-owned, independent subsidiaries that have their own management, employees and assets. References herein to the consolidated &#8220;Company&#8221; and &#8220;its&#8221; assets and activities, as well as the use of the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms in this Annual Report  on Form 10-K are not meant to imply, nor should it be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. is a holding company with no direct operating assets, employees or revenues. In addition, certain of our wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries.  The Captive Insurance provides some claims-made coverage to our independent subsidiaries for general and professional liability, as well as for certain workers' compensation insurance liabilities. Standard Bearer owns and manages our real estate business. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Service Center address is 29222 Rancho Viejo Rd Suite 127, San Juan Capistrano, CA 92675, and our telephone number is (949)&#160;487-9500. Our corporate website is located at </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.ensigngroup.net. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:3.9pt;font-weight:400;line-height:120%;position:relative;top:-2.1pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is our United States trademark. All other trademarks and trade names appearing in this annual report are the property of their respective owners. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:justify"><span><br/></span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_28"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART I. </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_340"></div><div style="text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 1. BUSINESS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Founded in 1999, The Ensign Group, Inc. ("Ensign") is a holding company with independent subsidiaries that provide skilled nursing, senior living and rehabilitative services, as well as other ancillary businesses (including mobile diagnostics and medical transportation), in 13 states. As part of our investment strategy, we also acquire, lease and own healthcare real estate to service the post-acute care continuum through acquisition and investment opportunities in healthcare properties. For the year ended December&#160;31, 2023, we generated approximately 96.0% of our revenue from our skilled nursing facilities. The remainder of our revenue is primarily generated from our real estate properties, senior living services and other ancillary services.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OPERATIONS</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, we offered skilled nursing, senior living and rehabilitative care services through 297 skilled nursing and senior living facilities. Of the 297 facilities, we operated 214 facilities under long-term lease arrangements and have options to purchase 11 of those 214 facilities. Our real estate portfolio includes 113 owned real estate properties, which included 83</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities operated and managed by us, 30 operations leased to and operated by third-party operators, and the Service Center's California location. Of the 30 real estate operations leased to third-party operators, one senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Unique Approach and Structure</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The name "Ensign" is synonymous with a "flag" or a "standard" and refers to our goal of setting the standard by which all others in our industry are measured. We believe that through our efforts and leadership, we can foster a new level of patient care and professional competence at our independent subsidiaries, and set a new industry standard for each patient we service. We view healthcare services primarily as a local business. We believe our success is largely driven by our proven ability to build strong relationships with key stakeholders in local healthcare communities, in part, by leveraging our reputation for providing superior care. Accordingly, our brand strategy and organizational structure promotes the empowerment of local leadership and staff to make their facility the &#8220;operation of choice&#8221; in their community. This is accomplished by allowing local leadership to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then work to create a superior service offering for, and reputation in, their particular community. This local empowerment is unique within the healthcare services industry. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our localized approach encourages prospective patients and referral sources to choose or recommend our local operations. In addition, our leaders are enabled and motivated to share real-time operating data and otherwise benchmark clinical and operational performance against their peers in order to improve clinical care, enhance patient satisfaction and augment operational efficiencies, promoting the sharing of best practices.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We organize our independent subsidiaries into portfolio companies, which we believe has enabled us to maintain a local, field-driven organizational structure, attract additional qualified leadership talent, and to identify, acquire, and improve operations at a generally faster rate. Each of our portfolio companies has its own leader. These leaders, who are generally taken from the ranks of operational CEOs, serve as leadership resources within their own portfolio companies, and have the primary responsibility for recruiting qualified talent, finding potential acquisition targets, and identifying other internal and external growth opportunities. We believe this organizational structure has improved the quality of our recruiting and will continue to facilitate successful acquisitions. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we spun-off our owned real estate properties into a public real estate investment trust (REIT) in 2014, we have continued to expand our real estate portfolio. Following the real estate spin-off, we have acquired and currently own 113 real estate properties, including 30 real estate properties that are leased to a third parties under triple-net long-term leases. We manage and operate the remaining real estate properties, including the Service Center's California location. We are committed to growing our real estate portfolio, which we believe will further enhance our earnings and maximize long-term shareholder value.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To continue with our growth strategy on our real estate portfolio, in January 2022, we formed Standard Bearer. Standard Bearer owns and manages our real estate business. The REIT structure allows us to better demonstrate the growing value of our owned real estate and provide us with an efficient vehicle for future acquisitions of properties that could be operated by our independent subsidiaries or other third parties. We believe this structure gives us new pathways to growth with transactions we would not have considered in the past. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. The real estate portfolio in Standard Bearer consists of 108 of our 113 owned real estate properties. During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stand-alone skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of these additions, the three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation acquired are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent subsidiaries</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The remaining </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">campus operation is leased to a third-party operator. For further details on the Standard Bearer REIT, refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in Notes to the Consolidated Financial Statements of this Annual Report on Form 10-K.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SEGMENTS</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own independent subsidiaries and third-party operators. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also report an &#8220;all other&#8221; category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate, and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. We have presented our segment results in this Annual Report on Form 10-K on a comparative basis to conform to the segment structure. For more information about our operating segments, as well as financial information, see Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Notes to the Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Services</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our skilled nursing companies provided skilled nursing care at 286 operations, with 30,602 operational beds, in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. We provide short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly. Our residents are often high-acuity patients that come to our facilities to recover from strokes, cardiovascular and respiratory conditions, neurological conditions, joint replacements, and other muscular or skeletal disorders. We use interdisciplinary teams of experienced medical professionals to provide services prescribed by physicians. These medical professionals provide individualized comprehensive nursing care to our short-stay and long-stay patients. Many of our skilled nursing facilities are equipped to provide specialty care, such as on-site dialysis, ventilator care, cardiac and pulmonary management. We also provide standard services such as room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. We are dedicated to ensuring our residents are happy, comfortable, and motivated to achieve their health goals through the provision of quality care. We generate our skilled services revenue from Medicaid, Medicare, managed care, commercial insurance, and private pay. During the year ended December&#160;31, 2023, approximately</span><span style="color:#242424;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 46.9% and 27.5% </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of our skilled services revenue was derived from Medicaid and Medicare programs, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We engage in the acquisition and leasing of skilled nursing and senior living properties. We generate rental revenue primarily by leasing post-acute care properties we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December&#160;31, 2023, our real estate portfolio within Standard Bearer is comprised of 108 real estate properties located in Arizona, California, Colorado, Idaho, Kansas, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Of these properties, 79 are leased to our independent subsidiaries and 30 are leased to operations wholly-owned and managed by third-party operators. Of the 30 real estate operations leased to third-party operators, one senior living operation is located on the same real estate property as a skilled nursing facility that we own and operate. During the year ended December 31, 2023, we generated rental revenues of $82.5 million, of which $66.7 million was derived from our independent subsidiaries, and therefore eliminated in consolidation.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations comprise approximately 4.2% of our annual revenue. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Living &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, we had an aggregate of 3,121 senior living units across 38 operations, of which 27 were located on the same site location as our skilled nursing care operations. Our senior living communities located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Texas, Utah and Washington, provide residential accommodations, activities, meals, housekeeping and assistance in the activities of daily living to seniors who are independent or who require some support, but not the level of nursing care provided in a skilled nursing operation. Our independent living units are non-licensed independent living apartments in which residents are independent and require no support with the activities of daily living.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior living operations comprise approximately 2.0% of our annual revenue. We generate revenue at these units primarily from private pay sources, with a small portion derived from Medicaid or other state-specific programs. Specifically, during the year ended December&#160;31, 2023, approximately 60.7% of our senior living revenue was derived from private pay sources.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ancillary &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we held a majority membership interest of ancillary operations located in Arizona, California, Colorado, Idaho, Texas, Utah and Washington. We have invested in and are exploring new business lines that are complementary to our existing skilled services and senior living services. These new business lines consist of mobile ancillary services, including digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities. To date, these businesses were not meaningful contributors to our operating results.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GROWTH</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an established track record of successful acquisitions. Much of our historical growth can be attributed to implementing our expertise in acquiring real estate or leasing both under-performing and performing post-acute care operations and transforming them into market leaders in clinical quality, staff competency, employee loyalty and financial performance. With each acquisition, we apply our core operating expertise to improve these operations, both clinically and financially. In years where pricing has been high, we have focused on the integration and improvement of our existing independent subsidiaries while limiting our acquisitions to strategically situated properties.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From January 1, 2013 through December&#160;31, 2023, we acquired 238 facilities, which added 20,485 operational skilled nursing beds and 4,803 senior living units to our independent subsidiaries, including the operations that were contributed in the spin-off to Pennant Group, Inc. (Pennant) in 2019. The following table summarizes cumulative skilled nursing and senior living operations, operational skilled nursing beds and senior living unit counts at the end of 2013 and each of the last five years to reflect our growth over a ten-year period and five-year period as a result of the acquisition of these facilities:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.130%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:6.917%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.820%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.917%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.922%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2013</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative number of skilled nursing and senior living operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative number of operational skilled nursing beds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,949&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,625&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,172&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,032&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,130&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,602&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative number of senior living units</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,154&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,254&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,237&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,021&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,121&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Number of operational beds and number of operations for 2019 include operational beds and operations that we no longer operated. The number of operations and operational beds do not include the closed facilities beginning in the year of their closures.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Included in the 2013 number of operational units and number of operations are the operational units and senior living operations that we contributed to Pennant in 2019. In 2019 and forward, the number of operations and operational units do not include operations transferred to Pennant.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also invested in new business lines that are complementary to our existing businesses, such as ancillary services. We plan to continue to grow our revenue and earnings by: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">continuing to grow our talent base and develop future leaders;</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">increasing the overall percentage or &#8220;mix&#8221; of higher acuity patients;</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">focusing on organic growth and internal operating efficiencies;</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">continuing to acquire additional operations in existing and new markets; </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">expanding and renovating our existing operations, and</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:8.52pt">strategically investing in and integrating other post-acute care healthcare businesses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New Market CEO and New Ventures Programs.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;In order to broaden our reach into new markets, and in an effort to provide existing leaders in our company with the entrepreneurial opportunity and challenge of entering a new market and starting a new business, we established our New Market CEO program in 2006. Supported by our Service Center and other resources, a New Market CEO evaluates a target market, develops a comprehensive business plan, and relocates to the target market to find talent and connect with other providers, regulators and the healthcare community in that market, with the goal of ultimately acquiring businesses and establishing an operating platform for future growth. In addition, this program includes other lines of business that are closely related to the skilled nursing industry. The New Ventures program encourages our local leaders to evaluate service offerings with the goal of establishing an operating platform in new markets and new businesses. We believe that this program will not only continue to drive growth, but will also provide a valuable training ground for our next generation of leaders, who will have experienced the challenges of growing and operating a new business.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OPERATION EXPANSIONS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, we expanded through a combination of long-term leases and real estate purchases, with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations and one campus operation, which were leased back to Ensign's independent subsidiaries. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by our independent subsidiaries. Additionally, we invested in new ancillary services that are complementary to our existing businesses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, we expanded through a long-term lease, with the addition of two stand-alone skilled nursing operations totaling 241 operational skilled nursing beds to be operated by our independent subsidiaries, including one in a new state, Tennessee. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further discussion of our acquisitions, see Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Notes to the Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">QUALITY OF CARE MEASURES </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Improvement in Acquired Facilities </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Five-Star Quality Rating System introduced by the Centers for Medicare and Medicaid Services (CMS) intends to help consumers, their families and caregivers compare nursing homes more easily. The Five-Star Quality Rating System gives each skilled nursing operation a rating between one and five stars in various categories including health inspections, staffing and quality measures (QM). We have a strong history of quickly improving the quality of care in the facilities we acquire. Thus, as new assessments are conducted post-acquisition, the star ratings see consistent improvement. At the time of acquisition, the majority of our facilities have 1 and 2-Star ratings. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last few years, CMS has modified the star rating requirements. These changes have been significant and made it more difficult to achieve a 4 or 5-Star rating, resulting in certain skilled nursing operations losing stars in their "Quality" and "Staffing" ratings, which negatively impacted the "Overall" ratings. Nevertheless, we continue to demonstrate strong performance in the Five-Star Quality Rating System. We believe compliance and quality outcomes are precursors to outstanding financial performance. Thus, we strive to aggressively increase quality and compliance in every facility we acquire, and to adjust our overall policies to adapt to CMS&#8217;s changing criteria for the Five-Star Quality Rating System. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2023, a significant change impacting the QM category was a shift in focus from a resident's functional status to their functional abilities and goals, commonly referred to as the Minimum Data Set (MDS) Section G to Section GG. The transition will result in numerous QM modifications and changes which will impact the Five-Star rating. As part of this change, starting in April 2024, CMS will freeze the associated new and modified quality measures as part of the transition on the Nursing Home Compare website. Starting in October 2024, CMS will replace the short-stay functionality QM with the new cross-setting functionality QM, which is used in the SNF Quality Reporting Program (QRP). The remaining three measures will continue to be frozen until January 2025 while the data for the equivalent measures are collected. Therefore, the predictability and movement in the QM ratings during 2024 will not necessarily be consistent with our current quality performance. In addition, what and how we are measuring the QM will not be consistent with the historical practice and accordingly will be not comparable. Therefore, depending on the changes, we may experience periods of time where the number of facilities with 4 or 5-Star ratings decline. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below summarizes the number of our facilities with 4 and 5-Star ratings since 2019:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:65.321%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:4.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.938%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.232%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 and 5-Star Quality Rated skilled nursing facilities</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Above-Average Ratings </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, despite the fact that Ensign&#8217;s acquisition of facilities with 1 or 2-Star ratings skews our company-wide ratings, our mean score on the Five-Star Quality Rating System is 65.4%, which exceeds the national average score of 57.2%. Our average cycle 1 health inspections for all of our facilities, which is based on the latest inspections, is 7.9% better than the national average. </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_343"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">INDUSTRY TRENDS</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The post-acute care industry has evolved to meet the growing demand for post-acute and custodial healthcare services generated by an aging population, increasing life expectancies and the trend toward shifting patient care to lower cost settings. The industry has evolved in recent years, which we believe has led to a number of favorable improvements in the industry, as described below:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Shift of Patient Care to Lower Cost Alternatives </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The growth of the senior population in the U.S. continues to increase healthcare costs, often faster than the available funding from government-sponsored healthcare programs. In response, federal and state governments have adopted cost-containment measures that encourage the treatment of patients in more cost-effective settings such as skilled nursing facilities, for which the staffing requirements and associated costs are often significantly lower than acute care hospitals and other post-acute care settings. As a result, skilled nursing facilities are generally serving a larger population of higher acuity patients than in the past.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Significant Acquisition and Consolidation Opportunities </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing industry is large and highly fragmented, characterized predominantly by numerous local and regional providers. Due to the increasing demands from hospitals and insurance carriers to implement sophisticated and expensive reporting systems, we believe this fragmentation provides us with significant acquisition and consolidation opportunities.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Improving Supply and Demand Balance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The number of skilled nursing facilities has declined modestly over the past several years. We expect that the supply and demand balance in the skilled nursing industry will continue to improve due to the shift of patient care to lower cost settings, an aging population and increasing life expectancies.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Increased Demand Driven by Aging Populations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As seniors account for an increasing percentage of the total U.S. population, we believe the demand for skilled nursing and senior living services will continue to increase. According to the census projection released by the U.S. Census Bureau in early 2020, between 2016 and 2030, the number of individuals over 65 years old is projected to be one of the fastest growing segments of the United States population, growing from 15% to 21%. The Bureau expects this segment to increase nearly 50% to 73&#160;million, as compared to the total U.S. population which is projected to increase by 10% over that time period. Furthermore, the generation currently retiring has accumulated less savings than prior generations, creating demand for more affordable senior housing and skilled nursing services. As a high-quality provider in lower cost settings, we believe we are well-positioned to benefit from this trend.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Value-based Care and Reimbursement Reform </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In response to rising healthcare spending in the United States, commercial, government and other payors are generally shifting away from fee-for-service (FFS) payment models towards value-based models, including risk-based payment models that tie financial incentives to quality, efficiency and coordination of care. We believe that patient-centered outcomes driven reimbursement models will continue to grow in prominence. Many of our operations already receive value-based payments, and as valued-based payment systems continue to increase in prominence, it is our view that our strong clinical outcomes will be increasingly rewarded.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant goal of U.S. federal health care reform is to transform the delivery of health care by changing reimbursement to reflect and support a focus on equity, payment for value, and efficacious delivery of person-centered care. Reimbursement models and demonstrations that increase accountability and provide financial incentives to encourage efficiency, affordability, and high-quality care, have been developed and implemented by government and commercial third-party payers. Special focus is placed on increasing the number of beneficiaries in care relationships with accountability for quality and total cost of care, improvements in care coordination, reducing inequities at the population level, and supporting care innovation to close care gaps and increase access. The most prominent value-based models designed to accomplish these aims include Accountable Care Models (e.g., MSSP ACOs, ACO REACH) and Disease-Specific &amp; Episode-Based Models (e.g., BPCI Advanced, GUIDE Model, CJR). These models, alongside State &amp; Community, Statutory, and Health Plan Models, are aimed at alignment across payers and care settings, leveraging effective clinical tools, outcomes-focused payment approaches, and stakeholder-led policy development.  Reimbursement methodology reform includes Value-Based Purchasing (VBP), in which a portion of provider reimbursement is redistributed based on relative performance, or improvement on designated economic, clinical quality and patient satisfaction metrics. These reimbursement methodologies and similar programs are likely to continue and expand, both in government and commercial health plans. Many of our operations already participate in value-based initiatives and models. With our focus on quality care and strong clinical outcomes, Ensign is well-positioned to benefit from these outcome-based payment models. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the post-acute industry has been and will continue to be impacted by several other trends. The use of long-term care insurance is increasing among seniors as a means of planning for the costs of skilled nursing services. In addition, as a result of increased mobility in society, reduction of average family size and the increased number of two-wage earner couples, more residents are looking for alternatives outside the family for their care.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is affected by seasonal fluctuations in occupancy and acuity which are most prominent when comparing the summer and winter months of the calendar year.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_346"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REVENUE SOURCES  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive revenue primarily from the Medicaid and Medicare programs, managed care and commercial insurance payors and private pay patients. The majority of our revenue is derived from skilled nursing, which is highly dependent upon the Medicaid and Medicare programs. Thus, any changes to payment models, reimbursements and budgets impact our revenue, some positively and some negatively. A detailed discussion of the regulatory framework impacting our business is found in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section below. See also, Item 1A., </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A brief overview of each of our revenue sources is as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Medicaid is a program financed by state funds and matching federal funds administered by the states and their political subdivisions, and often go by state-specific names, such as Medi-Cal in California and the Arizona Healthcare Cost Containment System in Arizona. Medicaid programs generally provide health benefits for qualifying individuals, and may supplement Medicare benefits for the disabled and for persons aged 65 and older meeting financial eligibility requirements. Medicaid reimbursement formulas are established by each state with the approval of the federal government in accordance with federal guidelines. Seniors who enter skilled nursing facilities as private pay clients can become eligible for Medicaid once they have substantially depleted their assets. Medicaid is generally the largest source of funding for most skilled nursing facilities. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid reimbursement varies from state to state and is based upon a number of different systems, including cost-based, prospective payment; case mixed adjusted payments and negotiated rate systems. Rates are subject to a state&#8217;s annual budgetary requirements and funding, statutory and regulatory changes and interpretations and rulings by individual state agencies and State Plan Amendments approved by CMS.  </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid typically covers patients that require standard room and board services and provides reimbursement rates that are generally lower than rates earned from other sources. We monitor our payor mix to measure the level received from each payor across each of our business units. We intend to continue to focus on enhancing our care offerings to accommodate more high acuity patients.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Approximately 87.2% of our Medicaid revenue comes from Arizona, California, Colorado, Texas, Utah and Washington. In California, the state enacted legislation expanding their Medicaid program, which in recent years has continued to see budget increases, but will see Medicaid spending decrease in the 2023-2024 period. It is projected that California General Fund spending on California Medicaid will be $225.9 billion for the 2023-2024 budget year, which is a decrease of 3.7% from its 2022-2023 budget estimate. California also estimates that the 2024-2025 budget year's Medicaid spending will decrease by $0.4 billion to $36.6 billion. Over the longer term, however, California expects its Medicaid spending to increase, reaching more than $43 billion by the 2027-2028 budget year. Texas is one of the remaining states that has not expanded Medicaid under the Affordable Care Act. Texas lawmakers have, in the past, underfunded Medicaid, requiring an infusion of state and federal funds. Funding for the 2023-2024 Texas biennium includes approximately $144.0 billion in general revenue funds, which is an increase of 10.5% in general funds from the 2022-2023 biennium amounts. In Arizona, the state enacted legislation expanding their Medicaid program in 2013, but has seen decreased Medicaid enrollments in recent years. Their 2023 budget for the state Medicaid program included $16.8 billion from the general fund, a decrease of 2.8% from the 2022. The 2024 budget is expected to increase by 2.0% from 2023 to $17.8 billion. In Utah, the fiscal year 2022 Medicaid spending was $4.6 billion and the state&#8217;s budget for 2023 fiscal year Medicaid spending, which will continue into 2024, is expected to be similar. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Medicare is a federal program that provides healthcare benefits to individuals who are 65&#160;years of age or older or are disabled. To achieve and maintain Medicare certification, a skilled nursing facility must sign a Medicare provider agreement and meet the CMS &#8220;Conditions of Participation&#8221; on an ongoing basis, as determined in periodic facility inspections or &#8220;surveys&#8221; conducted primarily by the state licensing agency in the state where the facility is located. Medicare pays for inpatient skilled nursing facility services under the prospective payment system (PPS). Under PPS, facilities are paid a predetermined amount per patient, per day, for certain services. Medicare Part A skilled nursing facility coverage is limited to 100&#160;days per episode of illness for those beneficiaries who require daily care following discharge from an acute care hospital.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Medicare beneficiaries who qualify for the Medicare Part A coverage, rehabilitation services are included in the per diem payment. For beneficiaries who do not meet the coverage criteria for Part A services, rehabilitation services may qualify for the services to be provided under Medicare Part B. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Managed Care and Private Insurance </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Managed care patients consist of individuals who are insured by certain third-party entities, or who are Medicare beneficiaries who have assigned their Medicare benefits to a senior managed care organization plan. Another type of insurance, long-term care insurance, is also becoming more available to consumers, but is not expected to contribute significantly to industry revenues in the near term.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Private and Other Payors </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Private and other payors consist primarily of individuals, family members or other third parties who directly pay for the services we provide. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Real estate rental revenue is generated by leasing post-acute care properties that we acquired to healthcare operators under triple-net lease arrangements, whereby the tenant is solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following charts sets forth our total service revenue by payor source generated by our consolidated operations and skilled services segment as a percentage of total revenue for the year ended December 31, 2023 and 2022, respectively:</span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED SERVICE REVENUE BY PAYOR</span></div><div style="margin-top:10pt;text-align:center"><img src="ensg-20231231_g2.jpg" alt="6531" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/><img src="ensg-20231231_g3.jpg" alt="6532" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SKILLED SERVICES REVENUE BY PAYOR</span></div><div style="margin-top:10pt;text-align:center"><img src="ensg-20231231_g4.jpg" alt="6568" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/><img src="ensg-20231231_g5.jpg" alt="6569" style="height:305px;margin-bottom:5pt;vertical-align:text-bottom;width:340px"/></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Sources as a Percentage of Skilled Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The following table sets forth our percentage of skilled nursing patient days by payor source:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.106%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.932%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage of Skilled Nursing Days:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SKILLED MIX</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SKILLED NURSING</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">REIMBURSEMENT FOR SPECIFIC SERVICES  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement for Skilled Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Skilled nursing facility revenue is primarily derived from Medicaid, Medicare, managed care and private payors. Our skilled nursing operations provide Medicaid-covered services to eligible individuals consisting of nursing care, room and board and social services. In addition, states may, at their option, cover other services such as physical, occupational and speech therapies.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, adjustments to reimbursement under Medicare and Medicaid have had a significant effect on our revenue and results of operations.&#160;Recently enacted, pending and proposed legislation and administrative rulemaking at the federal and state levels could have similar effects on our business.&#160;Efforts to impose reduced reimbursement rates, greater discounts and more stringent cost controls by government and other payors are expected to continue for the foreseeable future and could adversely affect our business, financial condition and results of operations.&#160;Additionally, any delay or default by the federal or state governments in making Medicare and/or Medicaid reimbursement payments could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement for Rehabilitation Therapy Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Rehabilitation therapy revenue is primarily received from private pay, managed care and Medicare for services provided at skilled nursing operations and senior living operations. The payments are based on negotiated patient per diem rates or a negotiated fee schedule based on the type of service rendered. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement for Senior Living </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Senior living facility revenue is primarily derived from private pay patients at rates we established, with only a small portion of such revenue derived from state-specific programs such as Medicaid.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reimbursement for Other Ancillary Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Other ancillary revenue, such as mobile diagnostics and medical transportation, is primarily derived from Medicare Part B, Medicaid, managed care and private payors at rates we establish based upon the services we provide and market conditions in the area of operation.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">RENTAL REVENUE</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental revenue from third-party rental property tenants </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's owned properties are leased pursuant to non-cancelable operating leases, generally with an initial term of 10 to 20 years. All of the leases for post-acute care healthcare properties contain renewal options. The leases provide for fixed minimum base rent during the initial and renewal periods. Standard Bearer's leases contain provisions for specified annual increases over the rents of the prior year and those increases are generally calculated based on the Consumer Price Index. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each lease is a triple net lease which requires the lessee to pay all taxes, insurance, maintenance and repairs, capital and non-capital expenditures and other costs necessary in the operations of the facilities. In addition, Standard Bearer's leases with third-parties are typically structured as master leases. The master leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a lessee makes payments for taxes and insurance directly to a third-party on our behalf, we are required to exclude these payments from variable payments and from revenue recognition in our consolidated statements of income. Otherwise, tenant reimbursements paid to us for taxes and insurance are classified as additional rental revenue recognized by us on a gross basis.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental revenue from our independent subsidiaries </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rental revenue from our independent subsidiaries is based on mutually agreed-upon base rents that are subject to change from time to time. Intercompany revenue is eliminated in consolidation, along with the corresponding intercompany rent expenses of the related healthcare facilities. </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_349"></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">COMPETITION</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The post-acute care industry is highly competitive, and we expect that the industry will become increasingly competitive in the future. The industry is highly fragmented and characterized by numerous local and regional providers, in addition to large national providers that have achieved geographic diversity and economies of scale. Our independent subsidiaries also compete with inpatient rehabilitation facilities and long-term acute care hospitals. Increasingly, we are competing with home health and community-based providers who have developed programs designed to provide services to seniors outside a facility-based setting, potentially decreasing the time they need the higher level of care provided in a skilled nursing facility.&#160;Competitiveness may vary significantly from location to location, depending upon factors such as the number of competing facilities, availability of services, expertise of staff, and the physical appearance and amenities of each location. We believe that the primary competitive factors in the post-acute care industry are: </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:13.02pt">ability to attract and to retain qualified management and caregivers;</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:13.02pt">reputation and achievements of quality healthcare outcomes;</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:13.02pt">attractiveness and location of facilities;</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:13.02pt">the expertise and commitment of the management team and employees; and</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:80%;padding-left:13.02pt">community value, including amenities and ancillary services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to compete effectively in each market by establishing a reputation within the local community as the &#8220;operation of choice.&#8221; This means that the operation leaders are generally free to discern and address the unique needs and priorities of healthcare professionals, customers and other stakeholders in the local community or market, and then create a superior service offering and reputation for that particular community or market that is calculated to encourage prospective customers and referral sources to choose or recommend the operation. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased competition could limit our ability to attract and retain patients, maintain or increase rates or to expand our business. Some of our competitors have greater financial and other resources than we have, may have greater brand recognition and may be more established in their respective communities than we are. Competing companies may also offer newer facilities or different programs or services than we offer, and may therefore attract individuals who are currently patients of our facilities, potential patients of our facilities, or who are otherwise receiving our healthcare services. Other competitors may have lower expenses or other competitive advantages than us and, therefore, provide services at lower prices than we offer. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other services, such as senior living facilities and other ancillary services, also compete with local, regional, and national companies. The primary competitive factors in these businesses are similar to those for our skilled nursing facilities and include reputation, cost of services, quality of clinical services, responsiveness to patient/resident needs, location and the ability to provide support in other areas such as third-party reimbursement, information management and patient recordkeeping.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Standard Bearer segment competes for real property investments with healthcare providers, healthcare-related REITs, real estate partnerships, banks, private equity funds, venture capital funds and other investors. Some of these competitors are significantly larger and have greater financial resources and lower costs of capital than us. Our ability to compete successfully for real property investments will be determined by numerous factors, including our ability to identify suitable acquisition targets, our ability to negotiate acceptable terms for any such acquisition and our cost of capital in the event an acquisition requires debt or equity financing.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">OUR COMPETITIVE STRENGTHS</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are well positioned to benefit from the ongoing changes within our industry. We believe that our ability to acquire, integrate and improve our facilities is a direct result of the following key competitive strengths: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Experienced and Dedicated Employees </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We believe that our independent subsidiaries' employees are among the best in their respective industries. We believe each of our independent subsidiaries is led by an experienced and caring leadership team, including dedicated front-line care staff, who participates daily in the clinical and operational improvement of their individual operations. We have been successful in attracting, training, incentivizing and retaining a core group of outstanding business and clinical leaders to spearhead our independent subsidiaries. These leaders operate as separate local businesses. With broad local control, these talented leaders and their care staffs are able to quickly meet the needs of their patients and residents, employees and local communities, without waiting for permission to act or being bound to a &#8220;one-size-fits-all&#8221; corporate strategy. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unique Incentive Programs </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We believe that our employee compensation programs are unique within the industry.  Employee stock options and performance bonuses, based on achieving target clinical quality, cultural, compliance and financial benchmarks, represent a significant component of total compensation for our operational leaders. We believe that these compensation programs assist us in encouraging our leaders and key employees to act with a shared ownership mentality. Furthermore, our leaders are motivated to help local operations within a defined &#8220;cluster&#8221; and "market," which is a group of geographically proximate operations that share clinical best practices, real-time financial data and other resources and information. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Staff and Leadership Development </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a company-wide commitment to ongoing education, training and professional development. Accordingly, our operational leaders participate in regular training. Most participate in training sessions at Ensign University, our in-house educational system. Other training opportunities are generally offered via on-demand training tools, including podcasts. In addition, we offer weekly cultural and interactive educational topics including leadership development, our values, updates on Medicaid and Medicare billing requirements, updates on new regulations or legislation, infection control, emerging healthcare service alternatives and other relevant clinical, business and industry specific coursework. Additionally, we encourage and provide ongoing education classes for our clinical staff to maintain licensing and increase the breadth of their knowledge and expertise. We believe that our commitment to, and substantial investment in, ongoing education will further strengthen the quality of our operational leaders and staff, and the quality of the care they provide to our patients and residents.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Innovative Service Center Approach </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We do not maintain a corporate headquarters; rather, we operate a Service Center to support the efforts of each operation. Our Service Center is a dedicated service organization that acts as a resource and provides centralized information technology, human resources, accounting, payroll, legal, risk management, educational and other back office support services, so that local leaders can focus on delivering top-quality care and efficient business operations. Our Service Center approach allows individual operations to function with the strength, synergies and economies of scale found in larger organizations, but without what we believe are the disadvantages of a top-down management structure or corporate hierarchy. We believe our Service Center approach is unique within the industry, and allows us to preserve the &#8220;one-operation-at-a-time&#8221; focus and culture that has contributed to our success. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proven Track Record of Successful Acquisitions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We have established a disciplined acquisition strategy that is focused on selectively acquiring operations within our target markets. Our acquisition strategy is driven by our operations team. Prospective leaders are included in the decision-making process and compensated as these acquired operations reach pre-established clinical quality and financial benchmarks, helping to ensure that we only undertake acquisitions that key leaders believe can become clinically sound and contribute to our financial performance. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023,</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we have expanded to 297 facilities with an aggregate of 30,602 operational skilled nursing beds and 3,121 senior living units, through both long-term leases and real estate purchases. We believe our experience in acquiring these operations and our demonstrated success in significantly improving their operations enables us to consider a broad range of acquisition targets. In addition, we believe we have developed expertise in transitioning newly acquired operations to our unique organizational culture and systems, which enables us to acquire operations with limited disruption to patients, residents and operating staff, while significantly improving quality of care. We have also constructed new facilities to target demand, which exists for high-end healthcare facilities when we determine that market conditions justify the cost of new construction in some of our markets. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful Real Estate Investment Strategy </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our Standard Bearer segment, we maintain a real estate portfolio of long-term healthcare facilities diversified by geographic location and operated by a diverse group of established healthcare providers. We are focused on selectively acquiring real estate properties based on our industry experience and opportunistic strategy, which we believe provides us with greater investment and purchasing opportunities. Due to our credit strength, we have the ability to acquire large portfolios of real estate properties; a portion of which can be managed and operated by our independent subsidiaries and their established healthcare leaders and a portion of which can be leased to third parties. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, our real estate portfolio consists of 113 owned facilities, which include properties leased to and operated by third parties and properties we managed and operated. We believe our real estate investment strategy has allowed us to accumulate a portfolio that aids our healthcare operators in improving performance and generating additional returns through leases with third parties.   </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reputation for Quality Care </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We believe that we have achieved a reputation for high-quality and cost-effective care and services to our patients and residents within the communities we serve. We believe that our achievement of quality outcomes enhances our reputation for quality, that when coupled with the integrated services that we offer, allows us to attract patients that require more intensive and medically complex care and generally result in higher reimbursement rates than lower acuity patients. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Community Focused Approach </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We view our services primarily as a local, community-based business. Our local leadership-centered management culture enables each operation's nursing support staff and leaders to meet the unique needs of their patients and local communities. We believe that our commitment to this &#8220;one-operation-at-a-time&#8221; philosophy helps to ensure that each operation, its patients, their family members and the community will receive the individualized attention they need. By serving our patients, their families, the community and our fellow healthcare professionals, we strive to make each individual business the operation of choice in its local community. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We further believe that when choosing a healthcare provider, consumers usually choose a person or people they know and trust, rather than a corporation or business. Therefore, rather than pursuing a traditional organization-wide branding strategy, we actively seek to develop the operations brand at the local level, serving and marketing one-on-one to caregivers, our patients, their families, the community and our fellow healthcare professionals in the local market. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investment in Information Technology </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We utilize information technology that enables our operational leaders to access, and to share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams are able to share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed software and touch-screen interface systems in each operation to enable our clinical staff to more efficiently monitor and deliver patient care and record patient information. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR GROWTH STRATEGY </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the following strategies are primarily responsible for our growth to date, and will continue to drive the growth of our business: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Grow Talent Base and Develop Future Leaders </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our primary growth strategy is to expand our talent base and develop future leaders. A key component of our organizational culture is our belief that strong local leadership is a primary key to the success of each operation. While we believe that significant acquisition opportunities exist, we have generally followed a disciplined approach to growth that permits us to acquire an operation only when we believe, among other things, that we will have qualified leadership for that operation. To develop these leaders, we have a rigorous &#8220;CEO-in-Training Program&#8221; that attracts proven business leaders from various industries and backgrounds, and provides them the knowledge and hands-on training they need to successfully lead one of our independent subsidiaries. We generally have between 25 and 30 prospective administrators progressing through the various stages of this training program, which is generally much more rigorous, hands-on and intensive than the minimum 1,000&#160;hours of training mandated by the licensing requirements of most states where we do business. Once administrators are licensed and assigned to an operation, they continue to learn and develop in our operational Chief Executive Officer Program (CEO Program), which facilitates the continued development of these talented business leaders into outstanding operational chief executive officers, through regular peer review, our Ensign University and on-the-job training. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our Chief Operating Officer Program (COO Program) recruits and trains highly qualified Directors of Nursing to lead the clinical programs in our operations. Working together with their operational CEO and/or administrator, other key operational leaders and front-line staff, these experienced nurses manage delivery of care and other clinical personnel and programs to optimize both clinical outcomes and employee and patient satisfaction. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increase Mix of High Acuity Patients </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Many skilled nursing facilities are serving an increasingly larger population of patients who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, as a result of government and other payors seeking lower-cost alternatives to traditional acute-care hospitals. We generally receive higher reimbursement rates for providing care for these medically complex patients. In addition, many of these patients require therapy and other rehabilitative services, which we are able to provide as part of our integrated service offerings. Where higher complex services are medically necessary and prescribed by a patient's physician or other appropriate healthcare professional, we generally receive additional revenue in connection with the provision of those services. By making these integrated services available to such patients, and maintaining established clinical standards in the delivery of those services, we are able to increase our overall revenues. We believe that we can continue to attract high acuity patients to our operations by maintaining and enhancing our reputation for quality care and continuing our community focused approach. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Focus on Organic Growth and Internal Operating Efficiencies </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We plan to continue to grow organically by focusing on increasing patient occupancy within our existing operations. Although some of the facilities we have acquired were in good physical and operating condition, the majority have been clinically and financially troubled, with some facilities having had occupancy rates as low as 30% at the time of acquisition. Additionally, we believe that incremental operating margins on the last 20% of our beds/units are significantly higher than on the first 80%, offering opportunities to improve financial performance within our existing facilities.  Our overall occupancy is impacted significantly by the number of facilities acquired and the operational occupancy on the acquisition date. Therefore, consolidated occupancy will vary significantly based on these factors. Our average occupancy rates for our skilled nursing facilities were 78.5% and 75.3% for the years ended December 31, 2023 and 2022, respectively. Our average occupancy rates in 2023 continue to rebound from pandemic levels and as we shift to an endemic, we anticipate the return of our seasonal occupancy and skilled mix. Throughout most of our history, our seasonality trends for skilled nursing occupancy and skilled mix typically included the greatest growth during the first and fourth quarters and softening in the second and third quarters. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe we can generate organic growth by improving operating efficiencies and the quality of care at the patient level. By focusing on staff development, clinical systems and the efficient delivery of quality patient care, we believe we are able to deliver higher quality care at lower costs than many of our competitors. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have achieved incremental occupancy and revenue growth by creating or expanding clinical service offerings in existing operations. For example, by expanding clinical programs to provide outpatient therapy services in many markets, we are able to increase revenue while spreading the fixed costs of maintaining these programs over a larger patient base. Outpatient therapy has also proven to be an effective marketing tool, raising the visibility of our facilities in their local communities and enhancing the reputation of our facilities with short-stay rehabilitation patients. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Add New Facilities and Expand Existing Facilities </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;One of our growth strategies includes the acquisition of new and existing facilities from third parties and the expansion and upgrade of current facilities. In the near term, we plan to take advantage of the fragmented skilled nursing industry by acquiring operations within select geographic markets and may consider the construction of new facilities. In addition, we have targeted facilities that we believed were performing and operations that were underperforming, where we believed we could improve service delivery, occupancy rates and cash flow. With experienced leaders in place at the community level and demonstrated success in significantly improving operating conditions at acquired facilities, we believe that we are well positioned for continued growth. While the integration of underperforming facilities generally has a negative short-term effect on overall operating margins, these facilities are typically accretive to earnings within 12 to 18&#160;months following their acquisition. For the facilities that we acquired from 2002 through 2023, the aggregate EBITDAR as a percentage of revenue improved from 15.9% during the first full three months of operations to 17.6% during the thirteenth through fifteenth months of operation and to 18.9% during the 45th quarter of operation. </span></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer Portfolio Growth </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy hinges on our ability to successfully identify, secure and consummate beneficial transactions. We have a proven track record of acquiring properties that we have determined are investment opportunities and develop these into thriving properties that are well-suited for operational purposes. We then use these properties for our skilled nursing or senior living operations, or we lease the properties to other long-term care facility operators. We expect that our REIT structure will allow us to expand our real estate footprint while bringing the best operational practices to our own and other operators in the industry. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">HUMAN CAPITAL</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2023, we had approximately 35,300 full-time equivalent employees who were employed by our Service Center and our independent subsidiaries. For the year ended December&#160;31, 2023, approximately 60.0% of our total expenses were payroll related. Periodically, market forces, which vary by region, require that we increase wages in excess of general inflation or in excess of increases in reimbursement rates we receive. We believe that we staff appropriately, focusing primarily on the acuity level and day-to-day needs of our patients and residents. In most of the states where we operate, our skilled nursing facilities are subject to state mandated minimum staffing ratios, so our ability to reduce costs by decreasing staff, notwithstanding decreases in acuity or need, is limited and subject to government audits and penalties in some states. We seek to manage our labor costs by improving staff retention, improving operating efficiencies, maintaining competitive wage rates and benefits and reducing reliance on overtime compensation and temporary nursing agency services. The Service Center's Chief Human Capital Officer, together with its Diversity, Equity and Inclusion (DEI) and Environmental, Social and Governance (ESG) Committees, oversee the following human capital initiatives:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Culture </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operation of our skilled nursing and senior living facilities requires a large number of highly skilled healthcare professionals and support staff. Our employees are at the heart of our Company and we are committed to their health, professional development and workplace satisfaction. Our core values, which focuses on developing our employees, fostering an ownership mentality and allowing for intelligent risk taking, guide us in our decision making and inspire us to be better people, both professionally and personally.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry as a whole has been experiencing shortages of qualified professional clinical staff. We believe that our ability to attract and retain qualified professional clinical staff stems from our ability to offer attractive wage and benefits packages, a high level of employee training, an empowered culture that provides incentives for individual efforts and a quality work environment. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity and Inclusion </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We value diversity in our recruiting, hiring and career development practices. Our commitment is to provide equal opportunity and fair treatment to all individuals based on merit and without discrimination. In 2022, we formed our DEI Committee, a multidisciplinary group led by our Chief Executive Officer, to advance our DEI initiatives throughout the organization.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Training and Development </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide training and development to all employees. We have many training programs at all levels such as our CEO in Training, Director of Nursing in Training, Director of Rehab in Training, nursing certified assistant schools, weekly culture trainings, boot camps and annual meetings, where we focus on both career and professional development. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Social Sustainability </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We continuously work towards bridging the gap between what the healthcare system currently provides and the basic needs of individuals. We aim to have an enduring impact on the communities in which we live and work. Elevate Charities is a non-profit organization that is dedicated to elevating the condition and quality of life for members of the senior healthcare community - employees, caregivers, family members, patients and residents. Elevate Charities has three unique funds: Heritage Fund, Heritage Scholarship Fund and the Emergency Fund. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Heritage Fund and the Heritage Scholarship Fund engage in a mission to enhance the quality of life for seniors in our communities through caring service, fulfilling essential needs and providing education to caregivers. The Heritage Fund helps the caregiver identify specific and practical ways to meet the needs of those under their care. This can help provide a better life, improved experience and greater satisfaction for our aging population. The financial support provided by the Heritage Fund benefits seniors directly. In addition, the Heritage Scholarship Fund helps qualified clinical professionals who may not be able to afford to advance in the field of long-term care. Through grants and scholarships, the fund helps these qualified professionals gain the education needed to advance in the field of senior-focused healthcare. Since 2019, we awarded 191 scholarships to employees in our workforce. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lastly, the Emergency Fund is a way of passing the hat to help our co-workers whose lives are affected by tragedy. This program is funded for our team members by our team members. All team members can contribute to the fund either through a one-time donation or by recurring payroll deduction. In 2023, approximately 86% of those employed by our independent subsidiaries contributed to the Emergency Fund. In 2023, we distributed approximately $3.2 million in grants to members of our independent subsidiaries. To date, the Emergency Fund has distributed over 14,600 grants totaling almost $15.7 million to members of our independent subsidiaries in their time of need. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on human capital matters, please see our most recent proxy statement or ESG report, each of which is available on our website at www.ensigngroup.net. For additional information on Elevate Charities, please visit www.elevatecharities.org. The information contained in, or that can be accessed through, either of the foregoing websites does not constitute a part of this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_244"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">GOVERNMENT REGULATION</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare is an area of extensive and frequent regulatory change. Changes in the law or new interpretations of existing laws may have a significant impact on our revenue, costs and business operations. Our independent subsidiaries that provide healthcare services are subject to federal, state and local laws relating to, among other things, licensure, quality and adequacy of care, physical plant requirements, life safety, personnel and operating policies. In addition, these same subsidiaries are subject to federal and state laws that govern billing and reimbursement, relationships with vendors, business relationships with physicians and workplace protection for healthcare staff. Such laws include (but are not limited to) the Anti-Kickback Statute (AKS), the federal False Claims Act (FCA), the Stark Law and state corporate practice of medicine statutes. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental and other authorities periodically inspect our independent subsidiaries to verify continued compliance with applicable regulations and standards. The operations must pass these inspections to remain licensed under state laws and to comply with Medicare and Medicaid provider agreements and applicable Conditions of Participation. The operations can only participate in these third-party payment programs if inspections by regulatory authorities reveal that the operations are in substantial compliance with applicable state and federal requirements. In the ordinary course of business, federal or state regulatory authorities may issue notices to the operations alleging deficiencies in certain regulatory practices, which may require corrective action to regain and maintain compliance. In some cases, federal or state regulators may impose other remedies including imposition of civil monetary penalties, temporary admission and/or payment bans, loss of certification as a provider in the Medicare or Medicaid program, or revocation of a state operating license. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the regulatory environment surrounding the healthcare industry subjects providers to intense scrutiny. In the ordinary course of business, providers are subject to inquiries, investigations and audits by federal and state agencies related to compliance with participation and payment rules under government payment programs. These inquiries may originate from HHS, Office of the Inspector General (OIG), state Medicaid agencies, state Attorney Generals, local and state ombudsman offices and CMS Recovery Audit Contractors, among other agencies. In response to the inquiries, investigations and audits, federal and state agencies continue to impose citations for regulatory deficiencies and other regulatory penalties, including demands for refund of overpayments, expanded civil monetary penalties that extend over long periods of time and date back to incidents prior to surveyor visits, Medicare and Medicaid payment bans and terminations from those programs, which may be temporary or permanent in nature. We vigorously contest each such regulatory outcome when appropriate; however, there are significant legal and other expenses involved that consume our financial and personnel resources. Expansion of enforcement activity could adversely affect our business, financial condition or the results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed, Anticipated and Recently Issued Rulemaking and Administrative Actions</span></div><div style="margin-bottom:9pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government, through CMS rulemaking, Presidential executive actions or Congressional legislation, and state and local governments have recently released the following proposed rulemaking or administrative actions that may have an impact on our independent Skilled Nursing Facilities (SNFs) or assisted living facilities:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biden-Harris Administration's Nursing Home Care Priorities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Biden-Harris Administration is seeking reform around reimbursement, staffing levels, standards of care, increased transparency and public disclosure of ownership, and enhanced civil remedies as a means of enforcement against those facilities that do not satisfy CMS&#8217;s standards. Proposed rules based on these directives have already been published in 2023, including those highlighted below and observers expect additional rules to be issued this year and in the future. Final rules will follow publication of these proposed rules after a notice-and-comment period required by law. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ownership Transparency Final Rule </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2023, CMS published its final rule requiring SNFs to publicly disclose certain additional information regarding their ownership and managerial relationships. The final rule requires disclosures to include the identity of any person or legal entity that: (1) exercises financial, operational, or managerial control over any facility or part of a facility, or provides services to a facility that include its policies and procedures or cash management services; (2) leases or subleases real property to the facility, or owns 5% or more of the real property&#8217;s total value; and (3) provides any management or administrative services (or consults regarding the same), or provides accounting or financial services to the SNF. The rule also expands ownership and control interest disclosures to include information about each member of the facilities governing body, individuals or entities serving as officers, directors, members, partners or managing employees, and a comprehensive breakdown of the organizational structure of any additional disclosable party that is not a natural person along with a description of their relationships with the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states have adopted laws reflecting their concerns regarding ownership transparency. For example, in July 2023, Iowa adopted laws requiring disclosure of ownership information not previously required for licensure to promote transparency. Additionally, in July 2023, the California Department of Health Care Access and Information of the California Health and Human Services Agency issued a notice of proposed rulemaking containing regulations that would implement financial and ownership transparency requirements for California-licensed SNFs that are required by California law passed in 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Legislation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; On March 9, 2023, the Home and Community-Based Services</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(HCBS) Access Act was introduced to expand access to and resources available for HCBS. This bill provides Medicaid funding to individuals who provide direct home- and community-based care to adults over the age of 60 or people who have disabilities. This bill also provides financial resources for the training of these direct care providers, who are intended to provide services to the elderly or disabled that range from advocacy and community integration to transportation and daily assistance tasks ranging from bathing and laundry to meal preparation and housekeeping. As of the date of filing, no further action has been taken on the HCBS Access Act since its introduction and referral to the House of Representatives committees.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 24, 2023, the HCBS Relief Act was introduced to provide additional funds to states to stabilize their HCBS service delivery networks, recruit and retain HCBS direct care workers, and meet long-term service and support needs of people eligible for Medicaid home and community-based services. Under the HCBS Relief act, states would receive a temporary 10% increase in the applicable Federal Medical Assistance Percentage (FMAP) under Medicaid for certain approved home and community-based services that are provided during FY 2024 through FY 2025.To qualify for the enhanced rate, a state much commit to initiatives aimed at improving the provision of services. This includes offering additional advantages to home health aides and assisting individuals in transition from nursing facilities back to their homes. As of the date of this filing, no action has been taken on the HCBS Relief Act since its introduction and referral to the Senate Committee on Finance.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Legislation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Many states in which our independent subsidiaries operate have introduced or passed legislation that would create or change laws and regulations related to our business and industry. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, California had discussed issuing proposed regulations on direct care spending requirements that may have affected our business and SNFs operating within that state. These proposals have included requirements for healthcare facilities certified by CMS, including SNFs, to report all annual revenues to the State of California by June 30 of each year and certify that a stated percentage of all non-Medicare revenues should be used for direct patient-related services, including staffing and operational costs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2023, the California Governor signed into law a bill that impacts the minimum wages of healthcare workers. Effective June 1, 2024, the law raises the minimum wage for California healthcare employees and sets a new wage threshold for those who are considered exempt healthcare employees. The bill only becomes effective for SNFs if a patient care minimum spending requirement bill is also passed. We anticipate that a minimum spending bill will be proposed in the near future.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Final Rule Fiscal Year 2024 Skilled Nursing Facility Prospective Payment System (SNF PPS)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 31, 2023, CMS published its final rule updating the Medicare payment rates within the SNF PPS for FY 2024 (SNF PPS FY 2024 Final Rule). The SNF PPS FY 2024 Final Rule modifies the SNF Quality Reporting Program (QRP) and the SNF Value-Based Purchasing (VBP) Program. The SNF PPS FY 2024 Final Rule finalized the rates to be paid in the 2024 fiscal year.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF PPS FY 2024 Final Rule increases the Medicare payment rate aggregate net market basket by 4.0%. The increase includes a 6.4% net market basket update to the payment rates of 3.0%, plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment, as well as a negative 2.3% in the FY 2024 SNF PPS rates due to the second phase of the Patient Driven Payment Model (PDPM) parity adjustment recalibration. The net effect of these changes is expected to be an overall 4.0% increase in payments to SNFs in FY 2024. This final rule also updates the SNF QRP for FY 2024 and future years, including the adoption of two new quality reporting measures, modification of one measure and removal of three measures resulting in public reporting of four QRP measures. Additionally, the SNF PPS FY 2024 Final Rule makes changes to the SNF VBP Program. Specifically, this final rule adopts four new measures: the nursing staff turnover measure, the discharge function score measure, the long stay hospitalization measure per 1,000 resident days and the percent of residents experiencing one or more falls with a major injury (long stay); the existing SNF 30-day all-cause readmission measure (SNFRM) is replaced with the SNF within stay potentially preventable readmissions (SNF WS PPR) measure beginning in FY 2028.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SNF PPS FY 2024 Final Rule adopted the Nursing Staff Turnover (NST) measure for the SNF VBP program beginning with the FY 2026 program year. This is a structural measure that has been collected and publicly reported on Care Compare, and the measure assesses the stability of the staffing within a SNF using nursing staff turnover. The NST measure uses facility-reported, electronic data from CMS&#8217; Payroll-Based Journal (PBJ) system to calculate annual turnover rates for nursing staff, including RNs, LPNs, and nurse assistants. Facilities would begin reporting this measure in FY 2024, with payment effects beginning in FY 2026. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NST measure looks at six consecutive quarters of data. It starts with a baseline quarter and the first two quarters of the performance period to identify eligible employees. Then, it uses the next four quarters to find the number of employment cycles that ended in turnover. Finally, the data from the sixth quarter is validated to identify gaps in days worked that began in the last 60 days of the fifth quarter used for the measure. The measure score is then calculated by comparing the total number of eligible employees with 60-day gaps in working during the specified periods. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proposed CMS Minimum Staffing Mandate </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, CMS issued its proposed rule that would establish minimum staffing standards for long-term care facilities. This proposed rule contains three primary staffing proposals: 1) minimum staffing standards of 0.55 hours per resident per day (HPRD) for registered nurses (RNs) and 2.45 HPRD for certified nurse aids (CNAs); 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, including a possible hardship exemption for select facilities. As this is a proposed rule, CMS has requested and received stakeholder feedback on all components of this regulation so that these comments may be considered prior to CMS's publication of a final rule. Additionally, the proposed rule would increase the reporting and transparency of Medicaid payments made to a facility for its direct care, including state-level reporting requirements and provisions for states and CMS to make information about payments made to long-term care facilities public.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facility self-assessments would also be enhanced under this proposed rule. CMS proposes that the facility self-assessment be updated regarding staffing to contain or clarify: 1) that facilities must use evidence-based methods when planning for resident care, including accommodation of behavioral health needs; 2) requiring facilities to use the self-assessment to assess the specific needs of each resident, with adjustments made for changes in the resident population; 3) requiring that facilities include the input of staff, including leadership, management, nurse staff and other direct care providers who render other services to residents; 4) requiring that the staffing plan maximize recruitment and retention of staff in a manner consistent with the President&#8217;s April 2023 Executive Order on increasing access to high-quality care and supporting caregivers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hardship exemption for CMS&#8217;s proposed minimum staffing standards is also set forth in the proposed rule.  Long-term care facilities could qualify for a temporary hardship exemption from new minimum staffing ratios upon meeting specific criteria that demonstrate: 1) workforce unavailability based on an absence of providers relative to individuals in the age group of recipients within a specific geographic location; 2) a facility&#8217;s good faith efforts to hire and retain staff through a recruitment and retention plan; and 3) a financial commitment to staffing by documenting the total annual amount spent on direct care staff.  A survey would be required to assess the residents&#8217; health and safety before CMS would consider granting such a hardship exemption. Any facility that received a hardship exemption from the minimum staffing requirement would have this exemption noted on the Care Compare website rating skilled nursing facilities.  Further, facilities would not be eligible to receive an exemption if they: 1) failed to submit their data to the payroll-based journal system; 2) have been identified as a special focus facility; or 3) have been identified at any time within the preceding 12 months as having insufficient staffing that was either widespread or a pattern, with resulting actual harm to residents, or receiving an immediate jeopardy citation regarding insufficient staffing.  Even after receiving an exemption, a facility would still be required to maintain sufficient staff around-the-clock to provide care and monitor resident health.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If finalized, this proposed rule would have a staggered and phased implementation over a period of three years, with the phases differentiated between rural and non-rural facilities. For facilities in urban areas, the final rule&#8217;s facility assessment requirements would become effective within 60 days of the final rule&#8217;s publication, with the proposed rule&#8217;s round-the-clock on-site RN requirement becoming effective two years after the final rule&#8217;s publication; and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect three years after the final rule&#8217;s publication. For rural facilities, the final rule&#8217;s facility assessment requirements would still become effective within 60 days of the final rule&#8217;s publication but the proposed rule&#8217;s round-the-clock on-site RN requirement would become effective three years after the final rule&#8217;s publication, and the above-referenced minimum staffing of 0.55 HPRD for RNs and 2.45 HPRD for NAs would take effect five years after the final rule&#8217;s publication.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This minimum staffing proposed rule also seeks further information from stakeholders regarding alternative policies for establishing minimum nurse staffing standards. In particular, CMS seeks comment on an alternative total nurse staffing standard of 3.48 HPRD (among other alternatives), which would include minimum individual standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs, in addition to other nurse staffing as needed to attain a total of 3.48 HPRD across all nurse types.  CMS also seeks stakeholder comments regarding the benefits and trade-offs of using different standards, evidence, or methodologies used by states that have adopted minimum nursing standards to inform its own standard-setting. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since the minimum staffing rule was proposed, there have been two bills (one in the House and a companion bill in the Senate), that were introduced that would block the rule from taking effect. The Senate bill has garnered broad bi-partisan support and is endorsed by over 90 organizations. These bills reason that the proposed minimum staffing standard would endanger rural nursing facilities, subjecting them to potential fines and closures for failure to comply and might require them to discharge residents or limit the number of residents they accept in an effort to meeting the requirements of the bill. It is uncertain which if any of these bills will pass and we will ultimately need to comply with the any final rules congress enacts.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coronavirus</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March of 2020, in an effort to promote efficient care delivery and to decrease the spread of COVID-19, federal, state and local regulators implemented new regulations and waived, (in some cases temporarily), certain existing regulations, including those discussed below. These new regulations and waivers of the other regulations expired on May 11, 2023. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Temporary suspension of certain patient coverage criteria and documentation and care requirements </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS issued a series of temporary waivers, rules, and guidance, suspending various Medicare patient coverage criteria as it related to the COVID-19 pandemic to ensure patients continued to have adequate access to care, notwithstanding the burdens placed on healthcare providers HHS also waived requirements specific to SNFs. During this time, CMS also suspended and reduced the priority of standard audit activities in order to focus on patient care. While all of these waivers expired with the termination of the PHE on May 11, 2023, others were terminated at various points in 2021 and 2022 during the PHE. Certain rules, such as requirements for COVID-19 reporting, testing, and vaccination remained in place through the end of the PHE. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Testing requirements </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in April 2020, authorities in several states in which our independent subsidiaries are located began to mandate widespread COVID-19 testing at all SNFs and assisted living facilities based on guidance from the Centers for Disease Control and Prevention (CDC). During the PHE, CMS issued revised parameters for testing, requiring routine testing of only unvaccinated staff and then further revised its guidance in September of 2022 to specify only symptomatic individuals and their close contacts, (including staff and residents), should be tested for COVID-19. On June 5, 2023, CMS published a final rule containing changes to COVID-19 vaccination, reporting, testing, and other requirements (Omnibus Final Rule), which took effect August 4th, 2023, and ended the COVID-19 testing and reporting requirements for SNFs and assisted living facilities imposed during the PHE. All of the federal, state and local government vaccines mandates have been rescinded since the end of the PHE.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to Medicaid Reimbursement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In March of 2020, the Families First Coronavirus Relief Act (FFCRA) provided a 6.2% increase to the Federal Medicaid Assistance Percentage (FMAP) during the PHE. The FFCRA also imposed conditions restricting the disenrollment and standards for re-enrolling Medicaid beneficiaries to promote continuous care of beneficiaries during the PHE. The Consolidated Appropriations Act of 2023 (CAA 2023) amended these Medicaid enrollment protections and increased FMAP funding provided in the FFCRA. In the first quarter of 2023, the FMAP increase CMS provides to the states remained elevated by 6.2%, but this amount decreased to 5% for April through June 2023, 2.5% for July through September 2023, and 1.5% for October through December 2023 before tapering to 0% by the end of 2023. The ultimate amount of Medicaid funding provided from each state varied substantially based on each state's policies.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the CAA 2023, states were allowed to begin disenrolling Medicaid beneficiaries and resuming Medicaid eligibility determinations beginning on April 1, 2023 upon satisfying conditions that include reviewing Medicaid beneficiaries' eligibility and have begun doing so. On August 30, 2023, CMS advised all 50 states in a letter to their respective Medicaid administrators to observe federal Medicaid regulations in making these redeterminations, including requirements to make eligibility determinations on an individual basis rather than a per-household basis.  CMS has worked with 12 states regarding their respective redetermination and disenrollment processes, and previously paused policy in six states.  As a result of this activity, the redetermination and disenrollment period that began on April 1, 2023 has not proceeded as rapidly as some may have expected.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare presently accounts for approximately 27.5% of our skilled nursing services revenue year-to-date, being our second-largest payor. The Medicare program and its reimbursement rates and rules are subject to frequent change. These include statutory and regulatory changes, rate adjustments, administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services. Budget pressures often lead the federal government to reduce or place limits on reimbursement rates under Medicare. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient-Driven Payment Model (PDPM)</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF PPS Rule became effective October 1, 2019. The SNF PPS Rule included a new case mix model that focuses on the patient&#8217;s condition (clinically relevant factors) and resulting care needs, rather than on the volume of care provided, to determine Medicare reimbursement. The case mix model is called the PDPM, which utilizes clinically relevant factors for determining Medicare payment by using diagnosis codes and other patient characteristics as the basis for patient classification. PDPM utilizes five case-mix adjusted payment components: physician therapy, occupational therapy, speech language pathology, nursing and social services and non-therapy ancillary services. It also uses a sixth non-case mix component to cover utilization of SNFs' resources that do not vary depending on resident characteristics. PDPM replaces the existing methodology and is intended to achieve a more value-based, unified post-acute care payment system. For example, PDPM adjusts Medicare payments based on each aspect of a resident&#8217;s care. Under the SNF PPS PDPM system, the payment to SNFs and nursing homes is based heavily on the patient&#8217;s condition rather than the specific services provided by each SNF. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Nursing Facility - Quality Reporting Program (SNF QRP)</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Improving Medicare Post-Acute Care Transformation Act of 2014 (IMPACT Act) provided data reporting requirements for certain Post-Acute-Care (PAC) providers. If a SNF does not submit required quality data as required by the IMPACT Act, its payment rates are reduced by 2.0% for each such fiscal year, which may result in payment rates for a fiscal year being less than the preceding fiscal year.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF QRP standardized patient assessment data elements. The SNF QRP applies to freestanding SNFs, SNFs affiliated with acute care facilities and all non-critical access hospital swing-bed rural hospitals. These data elements are the subject of frequent change and adjustment. CMS's rulemaking often identifies new data elements to be reported. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July of 2022, CMS announced revisions to calculating its five-star ratings for the Nursing Home Compare website.  Under this new calculation, points are assigned to a SNF based on its performance across six measures: (1) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident per day; (2) case-mix adjusted registered nurse staffing levels, measured by hours per resident per day; (3) case-mix adjusted total nurse staffing levels (including registered nurses, licensed practical nurses, and nursing aides), measured by hours per resident day on the weekend; (4) total nurse turnover, defined as the percentage of nursing staff that left the nursing home over a 12-month period; (5) registered nurse turnover, defined as the percentage of registered nursing staff that left the nursing home over a 12-month period; and (6) administrator turnover, defined as the percentage of administrators that left the nursing home over a 12-month period. These six measures will be measured on a quarterly basis. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These six new measures were included in the five-star rating in October 2022. In addition, CMS also implemented a planned increase to the quality measure reporting thresholds, increasing each threshold by one-half of the average improvement of quality measure scores since CMS last set quality measure thresholds. Going forward, CMS plans to implement similar rating threshold increases every six months.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, CMS announced the adoption of a process measure for influenza vaccination coverage among healthcare personnel within SNFs. This measure will be determined by the percentage of SNF healthcare personnel who receive an influenza vaccine any time from when it first becomes available through March 31 of the following year. SNFs began submitting this data on October 1, 2022.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2023, CMS published the SNF PPS FY 2024 Final Rule, which included changes to the SNF QRP, including adopting, removing and modifying specific measures. The final rule also includes policy changes and the public reporting of four measures. The final rule adopts the Discharge Function Score (DC Function) measure, which determines the functional condition of residents by examining the proportion of SNF residents who achieve or surpass a projected discharge functionality score. The assessment includes consideration of mobility and self-care, utilizing data from the Minimum Data Set (MDS). The DC Function will replace the current process and is scheduled to go into effect for the FY 2025 SNF QRP.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS will adopt two measures for the SNF QRP starting in FY 2026. First, CMS will raise the Data Completion Thresholds for the MDS. SNFs must report required quality measure data and standardized resident assessment data gathered using the MDS for at least 90% of the assessments they submit to CMS. SNFs who fail to meet this requirement will be subject to a 2% reduction on their applicable fiscal year payment starting in FY 2026. Second, CMS will adopt the Patient/Resident COVID-19 Vaccine metric. This metric highlights the number of patient stays in which SNF patients received the COVID-19 vaccine.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF PPS FY 2024 Final Rule also modifies the SNF QRP&#8217;s Healthcare Professional (HCP) Covid Vaccine Measure. The measure will track the proportion of healthcare staff vaccinated for COVID-19 and have kept their vaccination status current per the CDC recommendations. Previously, SNFs were only obligated to disclose whether their healthcare workers had completed the initial vaccination series for COVID-19. Now, there is an added requirement to report the total count of healthcare employees who have maintained their COVID-19 vaccination status in line with CDC recommendations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF PPS FY 2024 Final Rule also removed the Application of Functional Assessment/Care Plan measures from the SNF QRP. CMS stated the decision stemmed from two primary reasons: first, the consistently high-performance levels among SNFs make it challenging for CMS to identify significant advancements; and second, the DC Function measure aligns more closely with the preferred functional outcomes for residents.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Annual Payment Rule</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS is required to calculate an annual Medicare market-basket update to the payment rates. On July 31, 2023, CMS issued the SNF PPS FY 2024 Final Rule, which will result in a net increase of 4.0% in Medicare payments to SNFs in fiscal year 2024. This increase results from the 6.4% net market basket update to the payment rates, which is based on a 3.0% SNF market basket increase plus a 3.6% market basket forecast error adjustment, less a 0.2% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, CMS issued a final rule for fiscal year 2023 that increased the Medicare payment rates to aggregate net market basket by 2.7%. The increase results from the 5.1% update to the market basket, which is based on a 3.9% current year market basket increase plus a 1.5% market basket error adjustment, less a 0.3% productivity adjustment and a negative 2.3% adjustment as a result of the recalibrated parity adjustment. The recalibrated parity adjustment is being phased in at a rate of 2.3% per year on both the SNF PPS FY 2024 and FY 2023 Final Rules. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sequestration of Medicare Rates</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Budget Control Act of 2011 requires a mandatory, across the board reduction in federal spending, called a sequestration. Medicare FFS claims with dates of service or dates of discharge on or after April 1, 2013 incur a 2.0% reduction in Medicare payments through at least 2023, unless Congress takes further action. Under the CARES Act, there was a temporary suspension of the 2.0% reduction of Medicare claim reimbursements as a result of the COVID-19 pandemic which lasted until June 2022. Under the CAA 2023, a further 4% cut to Medicare spending that would have been required under the Statutory Pay-As-You-Go Act of 2010 (PAYGO) was waived for fiscal years 2023 and 2024. Instead, the CAA 2023 deferred any further Medicare sequestration under PAYGO until fiscal year 2025. The CAA 2023 also offset planned Medicare sequestrations that would have been as high as 4.0% and instead maintained fee schedule cuts of approximately 2%.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Nursing Facility Value-Based Purchasing (SNF-VBP) Program</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF-VBP Program rewards SNFs with incentive payments based on the quality of care they provide to Medicare beneficiaries, as measured by a hospital readmissions measure. CMS annually adjusts its payment rules for SNFs using the SNF-VBP Program. The program also introduced quality measures to assess how health information is shared and adopted a number of standardized patient assessment data elements that assess factors such as cognitive function and mental status, special services and social determinants of health. CMS uses regulations to specify how it measures the performance for SNFs as well as the data that SNFs are to report to CMS. The deadlines for baseline period quality measure quarterly reporting and performance periods and standards began in the 2023 program year. The final rule for the fiscal year 2023 SNF PPS also provided for SNF-VBP program expansion beyond the use of its single, all-cause hospital readmission measure to determine payment, with the inclusion of measures in fiscal year 2026 for SNF healthcare associated infections requiring hospitalization (SNF HAI) and total nursing hours per resident day measures and in fiscal year 2027, the discharge to community post-acute care measure for SNFs, which assess the rate of successful discharges to the community from a SNF setting.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SNF PPS FY 2024 Final Rule elected to replace the SNFRM measure with the SNF within-stay (WS) potentially preventable readmission (PPR) measure beginning in the FY 2028 program year. The PPR measure assesses the risk-standardized rate of unplanned and potentially avoidable readmissions during SNF stays for Medicare fee-for-service beneficiaries. The new SNF WS PPR measure refines the original Skilled Nursing Facility 30-Day Potentially Preventable Readmission (SNFPPR) measure, which followed the requirements of the Protecting Access to Medicare Act (PAMA) of 2014. The refinement in the SNF WS PPR measure shifts the observation window from a fixed 30-day post-hospital discharge to the duration of the SNF stay. Moreover, the time gap allowed between the prior inpatient discharge and the SNF admission has been extended from one day to 30 days. These changes, based on feedback from expert panels and a 2015 partnership, better align the measure with the IMPACT Act's provisions and enhance the reliability of tracking preventable readmissions. Additionally, the SNF WS PPR measure's calculations use two years of Medicare claims data to generate a provider-specific risk-standardized readmission rate.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Part B Rehabilitation Requirements</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our revenue is paid by the Medicare Part B program under a fee schedule. Part B services are limited with a payment cap by combined speech-language pathology services (SLP), physical therapy (PT) services and a separate annual cap for occupational therapy (OT) services. The Bipartisan Budget Act of 2018 (BBA) establishes coding modifier requirements to obtain payments beyond certain payment thresholds, discussed below and reaffirms the specific $3,000 claim audit threshold requirements for Medicare Administrative Contractors. For PT and SLP combined the threshold for coding modifier requirements was $2,230 for CY 2023 with the same threshold for OT services. The KX modifier is added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient&#8217;s medical records. This modifier is intended for use where the services will exceed the threshold for those services set by the BBA and updated by annual fee schedule rules, yet are still appropriate and medically necessary, and thus should be compensated by Medicare.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with CMS&#8217;s &#8220;Patients over Paperwork&#8221; initiative, the agency has also been moving toward eliminating burdensome claims-based functional reporting requirements. Beginning in 2021, CMS rescinded 21 problematic National Correct Coding Initiative edits impacting outpatient therapy services, including services furnished under Medicare Part B primarily related to PT and OT services, removing a coding burden caused by requirements for additional documentation and claim modifier coding. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Multiple Procedure Payment Reduction (MPPR) continues at a 50% reduction, which is applied to therapy procedures by reducing payments for practice expense of the second and subsequent procedures when services provided beyond one unit of one procedure are provided on the same day. The implementation of MPPR includes (1) facilities that provide Medicare Part B speech-language pathology, occupational therapy and physical therapy services and bill under the same provider number; and (2) providers in private practice, including speech-language pathologists, who perform and bill for multiple services in a single day.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through the end of coverage year 2024, certain of our Part B services provided through telehealth will still qualify for Medicare reimbursement based on flexibility first provided under the Emergency Waivers, which added physical therapy, occupational therapy and speech-language pathology to the list of approved telehealth Providers for the Medicare Part B programs provided by a SNF. During the PHE, CMS added certain PT and OT services to the list of Medicare-covered telehealth services on a temporary basis, some of which were made permanent for use and new codes were added for PT, OT, or SLP telehealth services&#8212;including some &#8220;sometimes therapy&#8221; codes that were not subject to MPPR. The CAA 2023 extended certain, but not all, telehealth flexibilities until December 31, 2024, allowing certain telehealth flexibilities to continue after the PHE's expiration. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  On November 2, 2023, CMS published the CY 2024 Physician Fee Schedule (CY 2024 PFS Final Rule), which changes Medicare payments under the Physician Fee Schedule (PFS) and other Medicare Part B components. The CY 2024 PFS Final Rule contains a conversion factor of $32.74, which is a decrease of $1.15 from the calendar year 2023 PFS conversion factor of $33.89. This CY 2024 conversion factor is 3.4% lower than the CY 2023 conversion factor. Under the CY 2024 PFS Final Rule, overall payment rates for Medicare Part B services are to be reduced by 1.25% compared to calendar year 2023.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The CY 2024 PFS Final Rule contains provisions to make payments when physicians and certain non-physician practitioners, such as physician assistants, nurse practitioners, physical therapists, occupational therapists and clinical psychologists, involve caregivers in implementing an individualized plan of treatment or therapy. These provisions incentivize the training of caregivers and provide additional funds to offset the costs of training these caregivers through participation in licensed healthcare providers&#8217; course of care for patients and residents. For PT and SLP combined, the threshold for coding modifier requirements increases to $2,330 for CY 2024 with the same threshold for OT services. The KX modifier is added to medical claims to indicate the providing clinician attests that the services corresponding to that claim were medically necessary and that the justification for those services is contained within the patient&#8217;s medical records. A new Caregiver Education Code has been made available to therapists providing face-to-face education to patient caregivers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CY 2024 PFS Final Rule will allow for general supervision of therapy assistants by PTs and OTs for remote therapeutic monitoring (RTM) services. This change may affect the rate of reimbursement for PT and OT services in the future and may affect the desirability and utilization of physical therapy assistants and occupational therapy assistants for certain patient services. Additionally, the CY 2024 PFS Final rule adds certain health and well-being coaching services that Medicare will reimburse on a temporary basis for CY 2024. The final rule also adds risk assessments for social determinants of health to the list of telehealth services Medicare will reimburse on a permanent basis.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Programs of All-Inclusive Care for the Elderly</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The requirements under the Programs of All-Inclusive Care for the Elderly (PACE) provide greater operational flexibility and update information under the Medicare and Medicaid programs, including leniency in compliance with program requirements during and after a 3-year trial period and relieving restrictions placed on the team that assesses and provides for the needs of each PACE participant. Further, non-physician primary care providers can provide certain services in place of primary care physicians. On February 1, 2023, CMS issued its final rule, which takes effect on April 3, 2023, requiring the collection of data by Medicare Advantage organizations and their service providers and the submission of data to CMS for risk adjustment data validation (RADV) audits. The purpose of these RADV audits is to maintain the accuracy of risk-adjusted payments made to Medicare Advantage organizations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Decisions Regarding Skilled Nursing Facility Payment  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reimbursement rates and rules are subject to frequent change that historically, have had a significant effect on our revenue. The federal government and state governments continue to focus on efforts to curb spending on healthcare programs such as Medicare and Medicaid. We are not able to predict the outcome of the legislative process. We also cannot predict the extent to which proposals will be adopted or, if adopted and implemented, what effect, if any, such proposals and existing new legislation will have on us. Efforts to impose reduced allowances, greater discounts and more stringent cost controls by government and other payors are expected to continue and could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These include statutory and regulatory changes, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions influenced by budgetary or political pressures, may materially adversely affect the rates at which Medicare reimburses us for our services. Implementation of these and other types of measures has in the past, and could in the future, result in substantial reductions in our revenue and operating margins. For a discussion of historic adjustments and recent changes to the Medicare program and other reimbursement rates, see Part I, Item 1A </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under the headings Risks Related to Our Business and Industry.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Protection and Affordable Care Act</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various healthcare reform provisions became law upon enactment of the ACA. The reforms contained in the ACA have affected our independent subsidiaries in some manner and are directed in large part at increased quality and cost reductions.&#160;Several of the reforms are very significant and could ultimately change the nature of our services, the methods of payment for our services and the underlying regulatory environment. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Inflation Reduction Act of 2022 (IRA), which continued and expanded certain provisions of the ACA, extended the premium subsidies paid by the federal government, until the end of 2024, resulting in subsidies being available to offset or reduce the costs of private health insurance policies for qualifying individuals. This may aid older patients in obtaining or keeping their health insurance in order to pay for long-term care services. The CAA 2023 revised the funds available to fund Medicare in 2023 and deferred the PAYGO sequestration of Medicare expenses.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2024 presidential election may significantly alter the current regulatory framework and impact our business and the health care industry, including any further extensions or expansions of certain ACA provisions, namely recent rulemaking activity regarding ACA Section 1557's anti-discrimination provisions. We continually monitor these developments so we can respond to the changing regulatory environment impacting our business. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Requirements of Participation</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has requirements that providers, including SNFs, must meet in order to participate in the Medicare and Medicaid Programs. Some of these requirements can be burdensome and costly. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One such requirement of participation in the Medicare and Medicaid programs involves limitations around the use of pre-dispute, binding arbitration agreements by SNFs. CMS has issued guidance and direction around arbitration that must be satisfied for any agreement to be enforceable and which may result in adverse consequences for our business if not followed. Congress has routinely introduced, but not passed, legislation addressing the issue of arbitration agreements used by SNFs. While legislative action is possible in the future, federal regulations and state/federal laws remain our primary source of authority over the use of pre-dispute binding arbitration agreements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the Requirements of Participation. CMS distributed these updates to surveyors and state agencies in order to, among other things, enhance responses to resident complaints and reported incidents. This guidance focuses on the following topics: (1) resident abuse and neglect (including reporting of abuse); (2) admission, transfer and discharge; (3) mental health and substance abuse disorders; (4) nurse staffing and reporting of payroll to evaluate staffing sufficiency; (5) residents&#8217; rights (including visitation); (6) potential inaccurate diagnoses or assessments; (7) prescription and use of pharmaceuticals, including psychotropics and drugs that act like psychotropics; (8) infection prevention and control; (9) arbitration of disputes between facilities and residents; (10) psychosocial outcomes and related severity; and (11) the timeliness and completion of state investigations to improve consistency in the application of standards among various states.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 29, 2022, CMS updated the Medicare Requirements of Participation for SNFs, which includes the modification of requirements associated with a facility's physical environment to minimize unnecessary renovation expenses in order to avoid closure of SNFs due to the related expense. CMS "grandfathered" certain facilities and will allow SNFs that were participating in Medicare before July 5, 2016 and that previously used the Fire Safety Evaluation System (FSES) to continue using the 2001 FSES mandatory values when determining compliance with applicable standards. CMS also updated the Requirements of Participation to revise existing qualification requirements for directors of food and nutrition services in SNFs, while "grandfathering" in directors with two or more years of experience and certain minimum training in food safety so they may continue in that role without satisfying further educational requirements.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 17, 2023, CMS revised the survey resources that CMS and state surveyors use in evaluating SNFs&#8217; compliance with federal Requirements for Participation. This revision incorporated the recent changes to CMS&#8217; focused infection control survey item, which CMS had removed in favor of standard infection control survey measures. These changes were made to the most recent revision of long-term care facility survey documents that CMS had last revised in October of 2022. These updates provided more information for state surveyors to utilize when evaluating SNFs&#8217; compliance with the Medicare Requirements of Participation, as well as included guidance for facilities on operationalizing compliance with these requirements based on how surveyors would measure and evaluate facility performance. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil and Criminal Fraud and Abuse Laws and Enforcement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various complex federal and state laws exist which govern a wide array of referrals, relationships and arrangements, and prohibit fraud by healthcare providers. Governmental agencies are devoting increasing attention and resources to such anti-fraud efforts. The Balanced Budget Act of 1997 expanded the penalties for healthcare fraud. Additionally, the government or those acting on its behalf may bring an action under the FCA, alleging that a healthcare provider has defrauded the government by submitting a claim for items or services not rendered as claimed, which may include coding errors, billing for services not provided and submitting false or erroneous cost reports. The FCA clarifies that if an item or service is provided in violation of the AKS, the claim submitted for those items or services is a false claim that may be prosecuted under the FCA as a false claim. Under the qui tam or &#8220;whistleblower&#8221; provisions of the FCA, a private individual with knowledge of fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government&#8217;s recovery. The Biden-Harris Administration has also signaled an increasing focus on nursing home performance and the reimbursement nursing homes receive from federal healthcare payment programs. Many states also have a false claim prohibition that mirrors or closely tracks the federal FCA.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal law also provides that the OIG has the authority to exclude individuals and entities from federally funded health care programs on a number of grounds, including, but not limited to, certain types of criminal offenses, licensure revocations or suspensions and exclusion from state or other federal healthcare programs. CMS can recover overpayments from health care providers up to six years following the year in which payment was made. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, the OIG released the result of an audit finding that Medicare overpaid millions of dollars for chronic care management (CCM) services. The OIG's 2021 report found that in calendar years 2017 and 2018, Medicare overpaid millions of dollars in CCM claims. In 2022, the OIG released an audit revealing that CMS had not collected $226 million, or 45%, of identified overpayments within that period, potentially affecting SNFs. These investigatory actions by OIG demonstrate its increased scrutiny into post-hospital SNF care provided to beneficiaries and may encourage additional oversight or stricter compliance standards. In 2023, representatives of the DOJ speaking at certain industry events, including the American Health Law Association&#8217;s Fraud and Compliance Forum, have indicated that its healthcare enforcement trends would emphasize opioid prescribing, Medicare Advantage and managed care plan fraud, and COVID-19 related fraud, including under various relief programs available during and in conjunction with the pandemic. In November of 2023, OIG added to its work plan an audit of nursing homes' nurse staffing hours reported in CMS's payroll-based journal, for which OIG expects to issue a report in FY 2025. In addition, the OIG identified the following areas as its "key goals" for oversight: (1) protecting residents from fraud, abuse, neglect, and promoting quality of care; (2) promoting emergency preparedness and emergency response efforts: (3) strengthening frontline oversight; and (4) supporting federal monitoring of nursing homes to mitigate risks to residents. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model, like those of some other for-profit operators, is based in part on seeking out higher acuity patients whom we believe are generally more profitable. Over time our overall patient mix has consistently shifted to higher acuity in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording services in order to, among other things, increase reimbursement to levels appropriate for the care actually delivered. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Healthcare Reform</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Five-Star Quality Reporting Metrics </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quality Payment Program (QPP) was created under the Medicare Access and Children's Health Insurance Program (CHIP) Reauthorization Act of 2015. This program was based on the Merit-based Incentive Payment System (MIPS) or the use of Alternative Payment Models (APM), which relied on quality data CMS gathered and evaluated using the Five-Star Quality Rating system, which includes a rating of one to five in various categories. These categories include (but are not limited to) the results of surveys conducted by state inspectors, other health inspection outcomes, staffing, spending, readmissions and stay durations; the data collected and its weighting in determining a rating on a scale of one to five stars is subject to periodic and ongoing revision, re-balancing and adjustment by CMS to reflect market conditions and CMS&#8217;s priorities in patient care. Since 2020, CMS&#8217;s measurement of the data reported by providers, including SNFs, has become more competitive and resulted in a reduction of four- and five-star rankings available under CMS&#8217;s Five-Star Quality Rating system. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Five-Star Quality reporting system for nursing homes is displayed on CMS's consumer-based Nursing Home Compare website, along with a consumer alert icon next to nursing homes that have been cited for incidents of abuse, neglect, or exploitation on the Nursing Home Compare website. The Nursing Home Compare website is updated monthly with CMS&#8217;s refresh of survey inspection results on that website. Additionally, in April of 2022, the Nursing Home Compare website began publishing the ownership information for Medicare-enrolled nursing facilities based on disclosures made to CMS from 2016 through 2022 due to mergers, acquisitions, or other changes in ownership, to allow for the identification of common ownership of nursing facilities. In addition, the Five Star Quality Ratings incorporated staffing data such as staff tenure and SNF weekend staffing beginning with the October 2022 refresh of the Nursing Home Compare website. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Nursing Home Five-Star Quality Rating System&#8217;s Technical Users&#8217; Guide updated in 2023, CMS will be auditing schizophrenia coding within the MDS reported to CMS, with adjustments to quality ratings based on any inaccuracies in this schizophrenia-related data. Additionally, the outcome of citations that a facility has informally disputed will only be included in the calculation of a facility&#8217;s star rating once the dispute is completed and the underlying survey considered final. CMS also revised the nursing-home level exclusion criteria used on the administrator turnover measure, adding information regarding its calculation of the staff turnover measure and publishing an updated ratings table, which identifies the points needed for each nursing facility to obtain certain star ratings within its state. Importantly, the new guidelines limit only 10% of nursing facilities can receive a five-star rating in the state where it operates.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website&#8217;s data. This freeze is implemented to accommodate changes to the MDS so that information that will be added to the MDS can be gathered. For three months, until the July 2024 refresh of the Nursing Home Compare website rankings, CMS will freeze the staffing level measures for all SNFs. Beginning with the July 2024 refresh, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM, which is discussed above. The Nursing Home Compare website will then begin posting staffing level measures that use this PDPM methodology. To incentivize SNFs to submit accurate staffing data, CMS will revise the staffing methodology to penalize SNFs that fail to submit staffing data, or submit erroneous data, by awarding them the lowest possible score for those measures beginning in April of 2024.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State Legislation Concerning Nursing Home Supervision</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> California passed into law a bill which changes the limitations, or &#8220;caps,&#8221; on non-economic damages that can be awarded in medical negligence cases filed against healthcare providers (including skilled nursing and long-term care facilities). Beginning on January 1, 2023, non-economic damages (i.e., pain and suffering) available to plaintiffs suing healthcare providers in medical malpractice and professional negligence cases increased from $0.25 million to $0.35 million, and will then increase over the following ten years up to a $0.75 million cap. Once the limit reaches $0.75 million, a 2% annual inflationary adjustment will attach beginning on January 1, 2034. In wrongful death cases that arise from claims of medical malpractice and professional negligence, the cap on non-economic damages increased from $0.25 million to $0.50 million on January 1, 2023, and increase every year thereafter for ten years until the cap on non-economic damages in such cases is $1.0 million; thereafter, this cap will also be subject to an annual 2% increase. The caps are separate as to each claim, meaning that there is one cap for negligence and one cap for wrongful death. The new limits on non-economic damages apply prospectively to lawsuits filed on and after January 1, 2023.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 27, 2022, California&#8217;s Governor signed into law the Skilled Nursing Facility Ownership and Management Reform Act of 2022. This law increases the oversight authority of the California Department of Public Health, and changes several provisions regarding SNF licensing in the State of California. This includes eliminating previous regulatory provisions that permitted SNFs to operate in advance of receiving their formal license from the State. This law also requires SNF license applicants to disclose additional information in connection with a license application and evaluates more data regarding the applicant&#8217;s prior operations, including prior citations, CMS sanctions and legal proceedings against the applicant or other facilities owned or managed by the applicant before issuing a license.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">United States Supreme Court Decisions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; On June 8, 2023, the United States Supreme Court issued its opinion in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health and Hospital Corporation of Marion County, Indiana (HHC) v. Talevski</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which pertained to claims of mistreatment in a nursing home. The nursing home was publicly owned by the government county where it operated, rather than privately owned. The question before the Supreme Court was whether the Nursing Home Reform Act, passed as part of the Omnibus Budget Reconciliation Act of 1987, gave Talevski the right to sue HHC for a violation of his civil rights under 42 U.S.C. &#167; 1983, a specific statute that allows for claims against persons who act for and on behalf of any government entity. The Supreme Court held that Talevski&#8217;s civil rights claim against HHC could proceed. While the facts of this case are of limited precedential value to our independent subsidiaries, which are not owned by and do not act on behalf of any government entity, this decision may draw wider public interest into claims against SNFs and assisted living facilities generally.</span></div><div style="margin-top:9pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Monitoring Compliance in Our Facilities</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#160;</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governmental agencies and other authorities periodically inspect our independent subsidiaries to assess compliance with various standards, rules and regulations, with potential fines, sanctions and other penalties for noncompliance. Unannounced surveys or inspections generally occur at least annually and may also follow a government agency's receipt of a complaint about a facility. Facilities must pass these inspections to maintain licensure under state law, to obtain or maintain certification under the Medicare and Medicaid programs, to continue participation in the Veterans Administration program at some facilities, and to comply with provider contracts with managed care clients at many facilities. From time to time, our independent subsidiaries, like others in the healthcare industry, may receive notices from federal and state regulatory agencies of an alleged failure to substantially comply with applicable standards, rules or regulations. These notices may require corrective action, may impose civil monetary penalties for noncompliance, and may threaten or impose other operating restrictions on SNFs such as admission holds, provisional skilled nursing license, or increased staffing requirements. If our independent subsidiaries fail to comply with these directives or otherwise fail to comply substantially with licensure and certification laws, rules and regulations, the facility could lose its certification as a Medicare or Medicaid provider, or lose its license permitting operation in the State. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities with otherwise acceptable regulatory histories generally are given an opportunity to correct deficiencies and continue their participation in the Medicare and Medicaid programs by a certain date, usually within six months of inspection; however, although where denial of payment remedies are asserted, such interim remedies go into effect much sooner. Facilities with deficiencies that immediately jeopardize patient health and safety and those that are classified as poor performing facilities, however, may not be given an opportunity to correct their deficiencies prior to the imposition of remedies and other enforcement actions. Moreover, facilities with poor regulatory histories continue to be classified by CMS as poor performing facilities notwithstanding any intervening change in ownership, unless the new owner obtains a new Medicare provider agreement instead of assuming the facility's existing agreement. However, new owners nearly always assume the existing Medicare provider agreement due to the difficulty and time delays generally associated with obtaining new Medicare certifications, especially in previously certified locations with sub-par operating histories. Accordingly, facilities that have poor regulatory histories before acquisition by our independent subsidiaries and that develop new deficiencies after acquisition are more likely to have sanctions imposed upon them by CMS or state regulators. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, CMS has increased its focus on facilities with a history of serious or sustained quality of care problems through the special focus facility (SFF) initiative. SFFs receive heightened scrutiny and more frequent regulatory surveys. Failure to improve the quality of care can result in fines and termination from participation in Medicare and Medicaid. A facility &#8220;graduates&#8221; from the program once it demonstrates significant improvements in quality of care that are continued over a defined period of time. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2022, CMS issued a Memorandum identifying the changes it intends to make in connection with the oversight of those facilities that fall under the SFF Program, including increased penalties for SFFs that fail to improve their performance upon further inspection by CMS, increasing the standards SFFs must meet to graduate from the SFF program, maintaining heightened oversight of any SFF for a period of three years after it graduates and increasing the technical assistance CMS provides to SFFs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sanctions such as denial of payment for new admissions often are scheduled to go into effect before surveyors return to verify compliance. Generally, if the surveyors confirm that the facility is in compliance upon their return, the sanctions never take effect. However, if they determine that the facility is not in compliance, the denial of payment goes into effect retroactive to the date given in the original notice, leaving operators with the task of deciding whether to continue accepting patients after the potential denial of payment date--risking the retroactive denial of revenue. Some of our independent subsidiaries have been or will be in denial of payment status due to findings of continued regulatory deficiencies, resulting in an actual loss of revenue associated with patients admitted after the denial of payment date. Additional sanctions could ensue and, if imposed, could include various remedies up to and including decertification.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has undertaken several initiatives to increase or intensify Medicaid and Medicare survey and enforcement activities, including federal oversight of state surveyors. CMS is taking steps to focus more survey and enforcement efforts on facilities with findings of substandard care or repeat violations of Medicaid and Medicare standards and to identify multi-facility providers with patterns of noncompliance. CMS is also increasing its oversight of state survey agencies and requiring state agencies to use enforcement sanctions and remedies more promptly when substandard care or repeat violations are identified, to investigate complaints more promptly, and to survey facilities more consistently. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations Regarding Financial Arrangements&#160;&#160;</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to federal and state laws that regulate financial arrangement by and between healthcare providers, such as the federal and state anti-kickback laws, the Stark laws, and various state anti-referral laws.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Social Security Act prohibits the knowing and willful offer, payment, solicitation, or receipt of any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce the referral of an individual, in return for recommending, or to arrange for, the referral of an individual for any item or service payable under any federal healthcare program, including Medicare or Medicaid. The OIG has issued regulations that create &#8220;safe harbors&#8221; for certain conduct and business relationships that are deemed protected under the Social Security Act. In order to receive safe harbor protection, all of the requirements of a safe harbor must be met. The fact that a given business arrangement does not fall within one of these safe harbors does not render the arrangement per se illegal. Business arrangements of healthcare service providers that fail to satisfy the applicable safe harbor criteria, if investigated, will be evaluated on a case-by-case basis based upon all facts and circumstances and risk increased scrutiny and possible sanctions by enforcement authorities. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the Social Security Act can result in inflation-adjusted criminal penalties of more than $0.1 million and ten years imprisonment. It can also result in inflation-adjusted civil monetary penalties of more than $0.1 million per violation and an assessment of up to three times the total amount of remuneration offered, paid, solicited, or received. It may also result in an individual's or organization's exclusion from future participation in federal healthcare programs. State Medicaid programs are required to enact an anti-kickback statute. Many states in which our independent subsidiaries operate have adopted or are considering similar legislative proposals, some of which extend beyond that state's Medicaid program, to prohibit the payment or receipt of remuneration for the referral of patients regardless of the source of payment for the care. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the "Stark Law" of the Social Security Act provides that a physician may not refer a Medicare or Medicaid patient for a &#8220;designated health service&#8221; to an entity with which the physician or an immediate family member has a financial relationship unless the financial arrangement meets an exception under the Stark Law or its regulations. Designated health services include, in relevant part, inpatient and outpatient hospital services, PT, OT, SLP, durable medical equipment, prosthetics, orthotics and supplies, diagnostic imaging, and home health services. Under the Stark Law, a &#8220;financial relationship&#8221; is defined as an ownership or investment interest or a compensation arrangement. If such a financial relationship exists and does not meet a Stark Law exception, the entity is disallowed from seeking payment under the Medicare or Medicaid programs or from collecting from the patient or other payor. Statutory and regulatory exceptions and exemptions to this exist and have specific rules that must be followed to qualify for such exception or exemption. Any funds collected for an item or service resulting from a referral that violates the Stark Law are not eligible for payment by federal healthcare programs and must be repaid. Violations of the Stark Law may result in the imposition of civil monetary penalties, including, treble damages. Individuals and organizations may also be excluded from participation in federal healthcare programs for Stark Law violations. Many states have enacted healthcare provider referral laws that go beyond physician self-referrals or apply to a greater range of services than just the designated health services under the Stark Law. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulations Regarding Patient Record Confidentiality</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers are also subject to laws and regulations enacted to protect the confidentiality of patient health information and patients' right to access such information. For example, HHS has issued rules pursuant to HIPAA, including the Health Information Technology for Economic and Clinical Health (HITECH) Act which governs our use and disclosure of protected health information of patients. We and our independent subsidiaries have established policies and procedures to comply with HIPAA privacy and security requirements and our independent subsidiaries have adopted and implemented HIPAA compliance plans, which we believe comply with the HIPAA privacy and security regulations, which impose significant costs for ongoing compliance activities. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous other laws and legislative and regulatory initiatives at the federal and state levels addressing privacy and security concerns. Our independent subsidiaries are also subject to any federal or state privacy-related laws that are more restrictive than the privacy regulations issued under HIPAA. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 17, 2024, CMS published the CMS Interoperability and Prior Authorization Final Rule (Interoperability Final Rule), which affects the data standards and application programming interfaces (APIs) used by entities that are payors for our services, including but not limited to Medicare Advantage organizations, Medicaid fee-for-service providers, and managed care organizations. This new rule requires these payor entities to adopt new patient access APIs beginning January 1, 2026, and to complete implementation of both patient and provider access APIs by January 1, 2027, to facilitate the sharing of payor information with payors and providers. While the purpose of this final rule is predominantly oriented to sharing information in the clinical setting and expediting the exchange of prior authorization data, this new rule may have implications for our business and how information is shared among our independent subsidiaries that participate in these programs, the payors, residents, and residents&#8217; families involved in their care.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Antitrust Laws&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to federal and state antitrust laws. Enforcement of the antitrust laws against healthcare providers is common, and antitrust liability may arise in a wide variety of circumstances, including third party contracting, physician relations, joint venture, merger, affiliation and acquisition activities. On February 3, 2023, the DOJ&#8217;s Antitrust Division withdrew its support for three policies that had been jointly created by the DOJ and the Federal Trade Commission (FTC) in 1993, 1996, and 2011, announcing instead, without providing further alternative guidance, that the DOJ would take a case-by-case enforcement approach to evaluate conduct in the healthcare industry, citing that the previous policies were outdated and overly permissive. Similarly, on July 14, 2023, the FTC withdrew two antitrust policy statements related to enforcement in healthcare markets. Moving forward, the FTC will evaluate mergers and conduct in healthcare markets on a case-by-case basis using principles of antitrust enforcement and competition policy. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 19, 2023, the DOJ and FTC released a draft joint statement of antitrust policy that outlines 13 guidelines to be used when determining if a merger is unlawfully anticompetitive under antitrust laws. These guidelines cover various aspects of antitrust enforcement relevant to SNF and senior living facilities, such as market concentration, competition between firms, risk of coordination, elimination of potential entrants, control of products or services, vertical mergers, dominant positions, trends toward concentration, series of multiple acquisitions, multi-sided platforms, competing buyers, partial ownership or minority interests and overall impact on competition. The draft joint statement also includes detailed sections on the application of the guidelines, defining relevant markets and approaches to rebuttal evidence. These proposed statements are not exhaustive and the DOJ and FTC may focus on one or multiple guidelines depending on the specific circumstances of each merger. These proposed general statements of antitrust policy, once finalized, may be a prelude to a new joint statement of healthcare antitrust policy of the DOJ and FTC, with the agencies&#8217; finalized general statements providing insight into whether healthcare-specific statements will be issued. This development and potential new guidance regarding DOJ and FTC antitrust policy increases risk and uncertainty regarding transactions that may be subject to criminal and civil enforcement by federal and state agencies, as well as by private litigants.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Americans with Disabilities Act</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent subsidiaries must also comply with the ADA, and similar state and local laws to the extent that the facilities are "public accommodations" as defined in those laws. The obligation to comply with the ADA and other similar laws is an ongoing obligation, and the independent subsidiaries continue to assess their facilities relative to ADA compliance and make appropriate modifications as needed.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Civil Rights </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 25, 2024, the Office for Civil Rights (OCR) for HHS issued guidance to hospitals and long-term care facilities, emphasizing their obligation under CMS regulations to ensure non-discriminatory visitation policies, especially during public health emergencies. This guidance, part of the U.S. National Strategy to Counter Antisemitism, clarifies that these facilities cannot discriminate based on religion or other classes or characteristics protected against discrimination under federal civil rights laws. The guidance includes examples where non-compliance occurred, such as unequal treatment based on religious affiliation or dietary restrictions, and stricter screening processes for certain religious groups. OCR offers assistance to facilities to obtain compliance with these standards and encourages residents and other affected individuals to file complaints with OCR for potential administrative or civil action in cases of civil rights violations.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Investment Trust (REIT) Qualification</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We elected for Standard Bearer to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022. Standard Bearer's qualification as a REIT will depend upon its ability to meet, on a continuing basis, various complex requirements under the Internal Revenue Code, relating to, among other things, the sources of its gross income, the composition and value of its assets, distribution levels to its shareholders and the concentration of ownership of its capital stock. We believe that Standard Bearer is organized in conformity with the requirements for qualification and taxation as a REIT under the Code and that its manner of operation has and will enable it to continue to meet the requirements for qualification and taxation as a REIT. </span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATIONS SPECIFIC TO SENIOR LIVING COMMUNITIES AND ANCILLARY SERVICES </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously mentioned, senior living services revenue (approximately 2.0% of total revenue) is primarily derived from private pay residents, with a small portion of senior living revenue derived from Medicaid funds. Thus, some of the regulations discussed above applicable to Medicaid providers, also apply to senior living.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A majority of states provide, or are approved to provide, Medicaid payments for personal care and medical services to some residents in licensed senior living communities. As rates paid to senior living community operators are generally lower than rates paid to SNF operators, some states use Medicaid funding of senior living services as a means of lowering the cost of services for residents who may not need the higher level of health services provided in SNFs. States that administer Medicaid programs for services in senior living communities are responsible for monitoring the participating communities and, as a result of the growth of senior living in recent years, these states have adopted licensing standards applicable to senior living communities. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS has continued to commence a series of actions to increase its oversight of state quality assurance programs for senior living communities and has provided guidance and technical assistance to states to improve their ability to monitor and improve the quality of services paid through Medicaid waiver programs. CMS is encouraging state Medicaid programs to expand their use of home and community-based services as alternatives to facility-based services, pursuant to provisions of the ACA, and other authorities, through the use of several programs. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The types of laws and statutes affecting the regulatory landscape of the post-acute industry continue to expand and the pressure to enforce those laws by federal and state authorities continues to grow as well. In order to operate our businesses, we and our independent subsidiaries must comply with federal, state and local laws from healthcare including provisions regarding patient safety, staffing, and prescription drugs to environmental issues. Changes in the law or new interpretations of existing laws may have an adverse impact on our methods and costs of doing business.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_352"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ENVIRONMENTAL MATTERS </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We strive to reduce our environmental impact through initiatives to modernize our facilities, conserve water, optimize waste, work towards a paperless office and partner with green vendors. Our ongoing and planned facility modernization initiatives include solar projects, heating, ventilation and air condition (HVAC) upgrades, water systems updates, lighting retrofits and utility upgrades. Additionally, we track and evaluate the utilities used by our facilities to drive our initiatives. For the year ended December 31, 2023, we spent $106.2 million on purchases of property improvements and equipment which included facility modernization initiatives. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management and Strategy</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identify and assess environmental risk to the organization by: </span></div><div style="margin-bottom:3pt;margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Conducting assessments of transition risks, which are risks related to the transition to a lower-carbon economy, and physical risks, which are risks related to the physical impacts of climate change.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Identifying climate-related opportunities, which includes programs to reduce electricity usage and carbon emissions at our independent subsidiaries. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Identifying the potential financial impact of transition risks, physical risks and climate-related opportunities.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Developing and implementing our strategy, which focuses on monitoring environmental policy and on-going developments, ensuring community resiliency, evaluating usage of energy management systems and tools, building operational and emergency response systems, performing hazard vulnerability assessments and tracking and responding to developing natural disasters. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign's environmental management team (EMT) is part of our ESG Committee. The EMT is led by the Service Center's leadership team members including Construction and Asset Development as well as its Executive Management. The EMT is responsible for:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Implementation and continuous execution of our environment management system and policy.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Development of the Company's environmental management policy.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Identification of climate related risks under the Task Force on Climate-Related Financial Disclosures framework.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Providing structure and support to our independent subsidiaries that are led by local operators to make decisions on their capital expenditure projects at their facilities. The team advises our local field operators on best practices and identifies opportunities for them to assess priorities of projects that may be chosen to be executed. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Overseeing environmental programs which include the evaluation and installation of LED lighting, solar panel, improved doors and insulation, automated HVAC controls and thermal efficiency projects related to micro-turbine, demand control ventilation.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Development of target goals for reduction of carbon emissions, savings and ENERGY STAR scores.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Tracking and monitoring of currently available environmental metrics such as utility usage and development of an energy management system that tracks greenhouse gas emissions and more. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Preparing for applicable environmental audits in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a variety of federal, state and local environmental laws and regulations. As a healthcare provider, we face regulatory requirements in areas of air and water quality control, medical and low-level radioactive waste management and disposal, asbestos management, response to mold and lead-based paint in our facilities and employee safety.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an owner or operator of our facilities, we also may be required to investigate and remediate hazardous substances that are located on and/or under the property, including any such substances that may have migrated off, or may have been discharged or transported from the property. Part of our operations involves the handling, use, storage, transportation, disposal and discharge of medical, biological, infectious, toxic, flammable and other hazardous materials, wastes, pollutants or contaminants. In addition, we are sometimes unable to determine with certainty whether prior uses of our facilities and properties or surrounding properties may have produced continuing environmental contamination or noncompliance, particularly where the timing or cost of making such determinations is not deemed cost-effective. These activities, as well as the possible presence of such materials in, on and under our properties, may result in damage to individuals, property or the environment; may interrupt operations or increase costs; may result in legal liability, damages, injunctions or fines; may result in investigations, administrative proceedings, penalties or other governmental agency actions; and may not be covered by insurance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we are in material compliance with applicable environmental and occupational health and safety requirements. However, we cannot assure you that we will not encounter liabilities with respect to these regulations in the future, and such liabilities may result in material adverse consequences to our operations or financial condition.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the reporting requirements under the Securities Exchange Act of 1934, as amended (the Exchange Act). Consequently, we are required to file reports and information with the Securities and Exchange Commission (SEC), including reports on the following forms: annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K, and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act. These reports, proxy and information statements and other information concerning our company may be accessed through the SEC's website at http://www.sec.gov.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You may also find on our website at www.ensigngroup.net, electronic copies of our annual reports on Form&#160;10-K, quarterly reports on Form&#160;10-Q, current reports on Form&#160;8-K and amendments to those reports filed or furnished pursuant to Section&#160;13(a) or 15(d) of the Exchange Act. Such filings are placed on our website as soon as reasonably possible after they are filed with the SEC. All such filings are available free of charge. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_304"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. RISK FACTORS </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing the following summary of the risk factors contained in our Form 10-K to enhance the readability and accessibility of our risk factor disclosures. We encourage our stockholders to carefully review the risk factors contained in this Form 10-K in their entirety for additional information regarding the risks and uncertainties that could cause our actual results to vary materially from recent results or from our anticipated future results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to our Business and Industry</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Reforms to the U.S. healthcare system, including new regulations under the ACA, new transparency and disclosure requirements, potential federal and state standards for minimum nurse staffing levels, continue to impose new requirements upon us that could materially impact our business.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Changes in the U.S. political environment may result in significant changes to the regulatory framework, enforcement, and reimbursements in our industry.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, loss of licensure, the imposition of fines and sanctions.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Public and government calls for increased enforcement efforts toward SNFs, potential rulemaking that may result in enhanced enforcement and penalties, and new guidance for surveyors regarding the review of SNFs and enforcement of their Requirements of Participation, could result in increased scrutiny by state and federal survey agencies, including sanctions that could negatively affect our financial condition and results of operations.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">CMS&#8217;s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Future cost containment initiatives undertaken by payors may limit our revenue and profitability.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We face numerous risks related to the COVID-19 PHE's expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We may be subject to increased investigation and enforcement activities related to HIPAA violations.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">If our independent subsidiaries are not fully reimbursed for all services for which each facility bills through consolidated billing, our revenue, financial condition and results of operations could be adversely affected. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Increased competition for, or a shortage of, nurses and other skilled personnel, could increase our staffing and labor costs and subject us to monetary fines resulting from a failure to maintain minimum staffing requirements, or may affect reimbursement.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Annual caps, uncertainty regarding reimbursement and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Increased scrutiny of our activities and billing practices by the OIG or other regulatory authorities may result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Newly enacted legislation in the States where our independent subsidiaries are located may impact the volume of cases filed and the overall cost of those cases from a defense and indemnity standpoint. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Changes to federal and state employment-related laws and regulations could increase our cost of doing business.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Compliance with federal and state fair housing, fire, safety, staffing, and other regulations may require us to incur unexpected expenses, which could be costly to us.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our independent subsidiaries as well as payor mix and payment methodologies.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards. Similarly, a change in the enforceability of arbitration provisions between SNFs and senior living facilities and residents and patients may affect the risks we face from claims and potential litigation. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">If our regular internal investigations into the care delivery, recordkeeping and billing processes of our independent subsidiaries detect instances of noncompliance, efforts to correct such non-compliance could materially decrease our revenue.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We may be unable to complete future facility or business acquisitions at attractive prices or at all, or may elect to dispose of underperforming or non-strategic independent subsidiaries, either of which could decrease our revenue. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We may not be able to successfully integrate acquired facilities and businesses into our operations, or we may be exposed to costs, liabilities and regulatory issues that may adversely affect our operations. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected, and our self-insurance programs may expose us to significant and unexpected costs and losses. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The geographic concentration of our independent subsidiaries could leave us vulnerable to economic downturn, regulatory changes or acts of nature in those areas. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The risks associated with leased property where our independent subsidiaries operate could adversely affect our business, financial position or results of operations.   </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our independent subsidiaries and cause us to lose facilities or experience foreclosures. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">A continued housing slowdown or housing downturn could decrease demand for senior living services. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We may need additional capital to fund our independent subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The condition of the financial markets could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Delays in reimbursement may cause liquidity problems. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">The utilization and expansion of managed care organizations may contribute to delays or reductions in our reimbursement, including Managed Medicaid.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Failure to safeguard our patient trust funds may subject us to citations, fines and penalties. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">We are a holding company with no operations and rely upon our multiple independent subsidiaries.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:9.42pt">Standard Bearer's failure to qualify as a REIT may cause it to be subject to U.S. federal income tax. Additionally, legislative or other actions affecting REITs could have a negative effect on Standard Bearer.</span></div><div style="margin-bottom:3pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:3pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:9.42pt">We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price. </span></div><div style="margin-bottom:3pt;padding-left:12.67pt;text-align:justify;text-indent:-14.4pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:110%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:110%;padding-left:9.42pt">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">You should carefully consider each of the following risk factors and all other information set forth in this information statement. The risk factors generally have been separated into two categories: risks relating to our business and our industry and risks relating to our common stock. Based on the information currently known to us, we believe that the following information identifies the most significant risk factors affecting our company in each of these categories of risks. However, the risks and uncertainties we face are not limited to those set forth in the risk factors described below. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also adversely affect our business. In addition, past financial performance may not be a reliable indicator of future performance and historical trends should not be used to anticipate results or trends in future periods.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#160;If any of the following risks and uncertainties develops into actual events, these events could have a material adverse effect on our business, financial condition or results of operations. In such case, the trading price of our common stock could decline. You should carefully read the following risk factors, together with the financial statements, related notes and other information contained in this Annual Report on Form 10-K. This Annual Report on Form 10-K contains forward-looking statements that contain risks and uncertainties. Please refer to the section entitled "Cautionary Note Regarding Forward-Looking Statements" on page 1 of this Annual Report on Form 10-K in connection with your consideration of the risk factors and other important factors that may affect future results described below.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The rules of Medicare and Medicaid, including reductions of reimbursement rates, changes to spending requirements, data reporting, measurement and evaluation standards could have a material, adverse effect on our revenues, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derived 26.6% and 27.7% of our service revenue from the Medicare programs for the year ended December 31, 2023 and 2022, respectively. In addition, many other payors may use published Medicare rates as a basis for reimbursements. Accordingly, if Medicare reimbursement rates are reduced or fail to increase as quickly as our costs, if there are changes in the rules governing the Medicare program that are disadvantageous to our business or industry, or if there are delays in Medicare payments, our business and results of operations will be adversely affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare program and its reimbursement rates and rules are subject to frequent change, including statutory and regulatory changes, rate adjustments (including retroactive adjustments), annual caps that limit the amount that can be paid (including deductible and coinsurance amounts), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which Medicare reimburses us for our services.&#160;See Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sequestration of Medicare Rates, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further information</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Implementation of these and other types of measures has in the past and could in the future result in substantial reductions in our revenue and operating margins. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, payments can be delayed or declined due to determinations that certain costs are not reimbursable or reasonable because either adequate or additional documentation was not provided or because certain services were not covered or considered medically necessary. Additionally, revenue from these payors can be retroactively adjusted after a new examination during the claims settlement process or as a result of post-payment audits. New legislation and regulatory proposals could impose further limitations on government payments to healthcare providers.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS often changes the rules governing the Medicare program, including those governing reimbursement. Changes to the Medicare program that could adversely affect our business could include, but are not limited to the following: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">administrative or legislative changes to base rates or the bases for payment; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">limits on the services or types of providers for which Medicare will provide reimbursement; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in methodology for patient assessment and/or determination of payment levels; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in staff requirements (i.e., requiring all workers to be vaccinated against COVID-19 and receive booster injections for those vaccinations) as a condition of payment or eligibility for Medicare reimbursement (See also, Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the reduction or elimination of annual rate increases, or the end of the reduced payments deferment (See also, Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">); and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">an increase in co-payments or deductibles payable by beneficiaries. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among the changes being implemented by CMS are provisions of the IMPACT Act, which imposes a stringent timeline for implementing benchmark quality measures and data metrics across facilities that include SNFs. The enactment mandates specific actions to design a unified payment methodology for post-acute providers, which CMS implements through ongoing regulations. The costs of final implementation may be significant, with potential fines and payment reductions resulting from a failure to meet CMS's implementation requirements. &#160; </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reductions in reimbursement rates or the scope of services being reimbursed could have a material, adverse effect on our revenue, financial condition and results of operations or even result in reimbursement rates that are insufficient to cover our operating costs. Congress&#8217;s budgetary planning has also resulted in a difficulty to financially forecast, as the Medicare conversion factor paid under the CAA 2023 was 2.5% greater than the conversion factor provided for in the CY 2023 PFS final rule. Nonetheless, the 2023 conversion factor for CY 2023 was lower than CY 2022 PFS's conversion factor. In contrast, the CY 2024 PFS conversion factor decreased 3.34% from the CY 2023 PFS conversion factor. This decrease takes into account the expiration of the 2.5% statutory payment increase for 2023, the addition of a 1.25% statutory payment increase for 2024, a 0% conversion factor update, and a 2.17% budget-neutrality adjustment. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 31, 2023, the CMS released its final rule for the SNF PPS for FY 2024 which will increase payments by a net 4.0% in FY 2024 compared to FY 2023. The final rule includes updates to the SNF Quality Reporting Program and SNF Value-based Purchasing Program that assess staff turnover, discharge success, res-hospitalization, and resident falls with injuries, which may adversely affect revenues obtained through the Medicare program. The SNF FY 2024 Final Rule may result in an increase in payments relative to FY 2023 depending on the performance of our individual independent subsidiaries as evaluated by CMS. The final rule will also replace the SNF 30-day All-cause Readmission measure with the SNF Within Stay Potentially Reasonable Readmissions standard beginning in fiscal year 2025, which may also reduce the compensation our independent subsidiaries may receive under the SNF VBP program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in more detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CMS implemented a final rule in October 2019 implementing a new case-mix classification system, PDPM, that focuses on the clinical condition of the patient. CMS may make future adjustments to reimbursement levels and underlying reimbursement formulae as it continues to monitor the impact of PDPM on patient outcomes and budget neutrality. The Biden-Harris Administration continues to study the nursing home industry and for HHS to issue proposed rules based on those studies, including changes to SNF facility reimbursement, including the SNF-VBP Program, may also adversely affect our reimbursement. These metrics potentially affecting our revenues and expenses in future government fiscal years include the SNF healthcare-associated infections (HAI) measurement, total nursing hours per resident day measures, and discharge to community - post acute care measure. The Interoperability Final Rule&#8217;s implementation beginning in 2026, and to be completed by January 1, 2027, may also adversely affect our reimbursement paid through Medicare, specifically including Medicare Advantage.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss of Medicare reimbursement, or a delay or default by the government in making Medicare payments, would also have a material adverse effect on our revenue. Non-compliance with Medicare regulations exist, and any penalty, suspension, termination, or other sanction under any state&#8217;s Medicaid program could lead to reciprocal and commensurate penalties being imposed under the Medicare program, up to termination or rescission of our Medicare participation and payor agreements as noted above. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of reimbursement for skilled nursing services comes from Medicaid. In fact, Medicaid is our largest source of revenue, accounting for 46.0% of our revenue for both the year ended December 31, 2023 and 2022, respectively. Medicaid is a state-administered program financed by both state funds and matching federal funds. Medicaid spending has increased rapidly in recent years, becoming a significant component of state budgets, which has led both the federal government and many states to institute measures aimed at controlling the growth of Medicaid spending, and in some instances reducing aggregate Medicaid spending. Since a significant portion of our revenue is generated from our skilled nursing independent subsidiaries in California, Texas and Arizona, any budget reductions or delays in these states could adversely affect our net patient service revenue and profitability. Due to recent fluctuations in state budgets many of the states in which we operate (including those with current budget surpluses), are seeking to contain costs on Medicaid outlays for SNFs, and any such decline could adversely affect our financial condition and results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid program and its reimbursement rates and rules are subject to frequent change at both the federal and state level, including through changes in laws, regulations, rate adjustments (including retroactive adjustments), administrative or executive orders and government funding restrictions, all of which may materially adversely affect the rates at which our services are reimbursed by state Medicaid plans or the amount of expense we incur. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To generate funds to pay for the increasing costs of the Medicaid program, many states utilize financial arrangements commonly referred to as provider taxes. Under provider tax arrangements, states collect taxes from healthcare providers and then use the revenue to pay the providers as a Medicaid expenditure, which allows the states to then claim additional federal matching funds on the additional reimbursements. Current federal law provides for a cap on the maximum allowable provider tax as a percentage of the providers' total revenue. There can be no assurance that federal law will continue to provide matching federal funds on state Medicaid expenditures funded through provider taxes, or that the current caps on provider taxes will not be reduced. Any discontinuance or reduction in federal matching of provider tax-related Medicaid expenditures could have a significant and adverse effect on states' Medicaid expenditures, and as a result could have a material and adverse effect on our business, financial condition or results of operations.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAA 2023 provided for the wind-down and termination of increased FMAP payments under the FFCRA, and also provided for the disenrollment of Medicaid beneficiaries who have participated in the program since early in the COVID-19 pandemic.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS&#8217;s increased FMAP payments declined from 6.2% to 5% in the second quarter of 2023, 2.5% in the third quarter, and 1.5% in the fourth quarter before CMS&#8217;s increased FMAP spending ends entirely.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAA 2023 granted CMS the authority to impose fines, penalties, and other sanctions upon states that do not comply with this law&#8217;s requirements for the unwinding of increased FMAP payments. As a result, these reductions may impose further burdens on the Medicaid programs in states where we operate in the form of fines and penalties, which may result in reduced payments.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning on April 1, 2023, states were allowed to begin disenrolling Medicaid beneficiaries. CMS guidance allowing for a return to Medicaid&#8217;s historical renewal, enrollment, and eligibility determination practices permits states up to 14 months to initiate and process traditional Medicaid renewals.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CAA 2023&#8217;s allowance of disenrollment and return to traditional Medicaid renewal processes, which will include pre-COVID eligibility determinations, may result in a reduction of the number of Medicaid beneficiaries and may result in a reduction of our current and potential patient population. As a result, there may be fewer current or potential patients able to pay for our independent subsidiaries&#8217; services, and increased competition for Medicaid beneficiaries able to provide reimbursement for those services. As of December 2023, nearly 12 million people were reported to be disenrolled from Medicaid as part of this disenrollment process. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS is concerned that states are terminating enrollees without definitively establishing their eligibility due to state residents not receiving eligibility forms or understanding instructions. CMS is monitoring states' compliance with federal requirements and is working with the affected states to address issues related to renewal requirements. States risk losing federal Medicaid matching funds for non-compliance with CMS&#8217;s instructions, which could result in reduced Medicaid funds available for timely reimbursement of the Company&#8217;s independent subsidiaries for their operations. Estimates suggest that roughly 17 million people may lose Medicaid coverage during the redetermination process through their scheduled completion in May of 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid is an important source of funding for our independent subsidiaries. The Company may be adversely affected by the disenrollment of Medicaid beneficiaries, which may lead to a reduction in reimbursement that may adversely impact our revenue and profit. The temporary restoration of Medicaid benefits in states where redetermination has been paused can help relieve some of these economic concerns. The disruption caused by the temporary pauses and restoration of Medicaid coverage for beneficiaries can also create operational challenges for our independent subsidiaries, including adverse effects on cash flow, available funds to pay wages for staffing, and overall financial stability. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ultimate impact of Medicaid disenrollment on the Company&#8217;s finances and operations will depend on individual states' specific circumstances and actions. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State-Level Direct Spending Requirements could negatively impact our results of operations</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain states where the Company operates have implemented direct spending requirements requiring SNFs to spend a portion of their revenue, particularly including Medicaid-derived revenue, on expenses directly relating to care. These spending requirements could affect our operational results and place the Company at higher risk of suffering non-compliance consequences, such as penalties, pay-backs, restrict admissions and/or operational/financial penalties.  </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, Washington state incorporates the costs of direct care, indirect care, and capital expenditures for SNF services in computing the State&#8217;s Medicaid payments to nursing facilities. Using periodically updated calculations that account for factors including case acuity, fair market value of capital expenditures, inflation, and facility performance, Washington sets facility compensation so that the majority of Medicaid reimbursement paid to a skilled nursing facility is used for care-related activities, with limitations on how much a facility&#8217;s reimbursement may increase from year to year. Washington state first adopted this care-based payment model in 2015 and has periodically updated it since, including in 2020, 2022, and 2023; it is expected that Washington will continue to amend this law in the future. For state fiscal year 2024, Texas requires all nursing facilities must show that funds paid to SNFs by Texas&#8217;s Medicaid program, including both fee-for-service and managed care reimbursement, were expanded for direct care activities, including direct care staff wages and benefits. In addition, California in the past has proposed bills that, if passed, would require nursing facilities to spend a stated percentage of revenue on direct patient-related services. While the most recent attempt by the California Assembly (Bill 1537) to impose direct spending requirements on SNFs has been placed in suspense with no action has been taken on, similar legislation in the future may seek to impose identical or analogous funding requirements for SNFs operating in California.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reforms to the U.S. healthcare system, including new regulations under the ACA, continue to impose new requirements upon us that could materially impact our business</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in greater detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the ACA has resulted in significant changes to our operations and reimbursement models for services we provide. CMS continues to issue rules to implement the ACA, including most recently, new rules regarding the implementation of the anti-discrimination provisions and proposed rules requiring the disclosure of SNF ownership, organization, management and the identity of the real property owners from which the SNF leases or subleases its operating space. With the passage of the IRA in August of 2022, Congress continues to expand and supplement the ACA, including through the continuation of federally funded insurance premium subsidies. This modification of the ACA by the IRA indicates that Congress may continue to change and expand the ACA in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The efficacy of the ACA is the subject of much debate among members of Congress and the public and it has been the subject of extensive litigation before numerous courts, including the United States Supreme Court, with varying outcomes &#8212; some expanding and others limiting the ACA. If the ACA is repealed or</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any elements of the ACA that are beneficial to our business are materially amended or changed, such as provisions regarding the health insurance industry, reimbursement and insurance coverage by payers, our business, operating results and financial condition could be harmed. Thus, the future impact of the ACA on our business is difficult to predict and its continued uncertain future may negatively impact our business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the midterm election in 2022, including a repeal or material amendment of the ACA, could harm our business, operating results and financial condition. The ACA continues to be a salient political topic and proposed changes to it may become the subject of campaign promises, litigation, administrative action, or legislation leading up to or following the 2024 Presidential election. In addition, even if the ACA is not amended or repealed, the President and the executive branch of the federal government, as well as CMS and HHS have a significant impact on the implementation of the provisions of the ACA, and a new administration could make changes impacting the implementation and enforcement of the ACA, which could harm our business, operating results and financial condition. We have already seen this with regulatory activity promulgating rules regarding anti-discrimination under Section 1557 of the ACA and most recently proposed rulemaking requiring the disclosure of SNF ownership and service providers under Section 6101 of the ACA. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the Nursing Home Improvement Act proposed during the prior Congress may be re-introduced in the future and could ultimately have an impact on our business due to the proposed 2% decrease in payments to SNFs, as well as the staffing and reporting requirements contained within the bill. While it is difficult to determine whether the Nursing Home Improvement Act or an identical bill will even be reintroduced, if ultimately signed into law, this bill may negatively impact our business, with the scope and nature of its consequences unknown. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2023, CMS issued a final rule that, requires SNFs to disclose certain information regarding their ownership and managerial relationships, which is more invasive and comprehensive than the ownership information already disclosed through Medicare's Nursing Home Compare website. Refer to Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information. The breadth of disclosure required by this new rule may be adverse to our business interests and detrimental to our operations, revenue, and profitability and may have a chilling effect on investment due to the depth of the new reporting and transparency requirements. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict what effect future reforms to the U.S. healthcare system will have on our business, including the demand for our services or the amount of reimbursement available for those services. However, it is possible these new laws may lower reimbursement or increase the cost of doing business and adversely affect our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The changes in Congress due to the most recent U.S. midterm elections in 2022, changes in representation, and actions in anticipation of the 2024 Presidential election may result in significant changes to regulatory framework, enforcements and reimbursements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most recent midterm elections in 2022 and resulting change in control of the House of Representatives, and representative departures that are expected to further narrow the margin of Republican control over the House of Representatives, could result in significant changes in, and has resulted in uncertainty with respect to, legislation, regulation, implementation or repeal of laws and rules related to government health programs, including Medicare and Medicaid. Democratic proposals for Medicare for All or significant expansion of Medicare, could significantly impact our business and the healthcare industry if implemented, although the implementation of such proposals remains unlikely under the political party currently holding a majority within the House of Representatives. Additionally, Congress&#8217;s passage of the IRA in August of 2022, which expanded upon and continued certain provisions of the ACA, indicates that additional legislative changes to the ACA may be forthcoming. If proposed policies specific to nursing facilities are implemented, these may result in significant regulatory changes, increased survey frequency and scope, and increased penalties for non-compliance. As both political parties have begun their Presidential primaries and congressional elections in 2024, each of them may seek to introduce or pass legislation that would either expand or reduce the scope of the ACA as a credential for future campaigning. Based on the IRA and inflationary pressures in the economy, the ACA and affordability of healthcare generally may be a campaign issue and lead to promises, administrative action, or legislation that could adversely affect our business. As a result, future legislation may be proposed or passed that may adversely affect our business, operating results and financial condition.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continually monitor these developments in order to respond to the changing regulatory environment impacting our business. While it is not possible to predict whether and when any such changes will occur, specific proposals discussed during and after the election, including a repeal or material amendment of the ACA (whether to increase or decrease its scope), could harm our business, operating results and financial condition. If we are slow or unable to adapt to any such changes, our business, operating results and financial condition could be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to various government reviews, audits and investigations that could adversely affect our business, including an obligation to refund amounts previously paid to us, potential criminal charges, the imposition of fines, and/or the loss of our right to participate in Medicare and Medicaid programs.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our participation in the Medicaid and Medicare programs, we are subject to various governmental reviews, audits and investigations to verify our compliance with the rules associated with these programs and related applicable laws and regulations, including our claims for payments submitted to those programs, which are subject to reviews by Recovery Audit Contractors, Zone Program Integrity Contractors, Program Safeguard Contractors, Unified Program Integrity Contractors, Supplemental Medical Review Contractors and Medicaid Integrity Contractors programs, (collectively referred to as Reviews). In these Reviews, third-party firms engaged by CMS conduct extensive analysis of claims data and medical and other records to identify potential improper payments under the federal and state programs. As discussed above, the Biden-Harris Administration has called for HHS and CMS to increase the level of scrutiny of SNF facilities and requested those agencies to adopt rules that would impose greater penalties upon non-compliant SNF operators. On February 17, 2023, CMS most recently updated the survey resources that CMS and state surveyors use in evaluating our SNFs&#8217; compliance with federal Requirements for Participation, incorporating recent changes to CMS&#8217;s methods for surveying infection control procedures.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2022, CMS announced updated guidance for Phase 2 and 3 of the requirements of participation, discussed in greater detail in Item 1., under Government Regulation. The application of CMS&#8217;s new guidance could result in more aggressive and stringent surveys, and potential fines, penalties, sanctions, or administrative actions taken against our independent subsidiaries. Also described in Item 1., under Government Regulation, the Interoperability Final Rule and its changes intended to facilitate data exchange between and among patients, providers, and payors, will be implemented beginning in 2026 and must be fully implemented by January 1, 2027.  This rule and the greater access to and use of data between and among payors transmitting funds for state and federal healthcare programs, may also trigger additional scrutiny or review of facilities such as ours, and may adversely affect our reimbursement paid through state and federal programs including Medicaid.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS announced a new nationwide audit the &#8220;SNF 5-Claim Probe &amp; Educate Review&#8221; in which the Medicare Administrative Contractors will review five claims from each of the facilities to check for compliance with PDPM billings, which could result in individual claim payment denials if errors are identified. All facilities that are not undergoing Targeted Probe and Educate (TPE) reviews, or have not recently passed a TPE review, will be subject to the nationwide audit.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Private pay sources also reserve the right to conduct audits. We believe that billing and reimbursement errors and disagreements are common in our industry, and thus we are regularly engaged in reviews, audits and appeals of our claims for reimbursement due to the subjectivities inherent in the process related to patient diagnosis and care, record keeping, claims processing and other aspects of the patient service and reimbursement processes, and the errors and disagreements those subjectivities can produce. An adverse review, audit or investigation could result in:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-11.25pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">an obligation to refund amounts previously paid to us pursuant to the Medicare or Medicaid programs or from private payors, in amounts that could be material to our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">state or federal agencies imposing fines, penalties or other sanctions on us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">temporary or permanent loss of our right to participate in the Medicare or Medicaid programs or one or more private payor networks;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">an increase in private litigation against us; and</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-11.25pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.27pt">damage to our reputation in the geographies served by our independent subsidiaries.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have always been subject to post-payment audits and reviews, more intensive &#8220;probe reviews&#8221; performed by Medicare administrative contractors in recent years appear to be a regular procedure with our fiscal intermediaries. All findings of overpayment from CMS contractors are eligible for appeal. With the exception of rare findings of overpayment related to objective errors in Medicare payment methodology or claims processing, we utilize all defenses reasonably available to us to demonstrate that the services provided meet all clinical and regulatory requirements for reimbursement.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In cases where claim and documentation review by a CMS contractor results in repeated unsatisfactory results, an operation can be subjected to protracted regulatory oversight. This CMS oversight may include education and sampling of claims, extended pre-payment review, referral of the operating business to recovery audit or integrity contractors, or extrapolation of an error rate to other reimbursement made outside of specifically reviewed claims. Ongoing failure to demonstrate improvement towards meeting all claim filing and documentation requirements could ultimately lead to Medicare decertification. As of December&#160;31, 2023 and through the filing date of this report, 40 of our independent subsidiaries had reviews scheduled or in process, either pre- or post-payment. We anticipate that these reviews could increase in frequency in the future.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, both federal and state government agencies have heightened and coordinated civil and criminal enforcement efforts as part of numerous ongoing investigations of healthcare companies and, in particular, SNFs. The focus of these investigations includes, among other things, billing and cost reporting practices; quality of care provided; financial relationships with referral sources; and the medical necessity of rendered services. For example, refer to the matter discussed in Item 3.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Legal Proceedings</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we should agree to a settlement of claims or obligations under Medicare statutes, the FCA, or similar federal or state statutes and related regulations, our business, financial condition and results of operations and cash flows could be materially and adversely affected, and our stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged civil violations and may also include our assumption of specific procedural and financial obligations going forward under a corporate integrity agreement or other arrangement with the government.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the government or a court were to conclude that errors and deficiencies constitute criminal violations and/or that such errors and deficiencies resulted in the submission of false claims to federal healthcare programs, or were to discover other problems in addition to the ones identified by the probe reviews that rose to actionable levels, we and certain of our officers might face potential criminal charges and civil claims, administrative sanctions and penalties for amounts that could be material to our business, results of operations and financial condition. In addition, we or some of the key personnel of our independent subsidiaries could be temporarily or permanently excluded from future participation in state and federal healthcare reimbursement programs such as Medicaid and Medicare. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our independent subsidiaries is decertified or loses its licenses, our revenue, financial condition or results of operations would be adversely affected. In addition, the report of such issues at any of our independent subsidiaries could harm our reputation for quality care and lead to a reduction in the patient referrals to and ultimately a reduction in occupancy at these facilities. Also, responding to auditing and enforcement efforts diverts material time, resources and attention away from our management team and our staff, and could have a materially detrimental impact on our results of operations during and after any such investigation or proceedings, regardless of whether we prevail on the underlying claim.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive and complex laws and government regulations. If we are not operating in compliance with these laws and regulations or if these laws and regulations change, we could be required to make significant expenditures or change our operations in order to bring our facilities and operations into compliance. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with other companies in the healthcare industry, are required to comply with extensive and complex laws and regulations at the federal, state and local government levels relating to, among other things:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">licensure and certification; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disclosure of ownership and affiliated parties;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adequacy and quality of healthcare services; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">qualifications of healthcare and support personnel; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state-specified and potential federal mandates for specific nurse staffing levels;</span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quality and maintenance of medical equipment and facilities; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">confidentiality, maintenance and security issues associated with medical records and claims processing; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">relationships with physicians and other referral sources and recipients; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">constraints on protective contractual provisions with patients and third-party payors; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">operating policies and procedures; </span></div><div style="margin-bottom:2pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">addition of facilities and services; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">billing for services. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws and regulations governing our operations, along with the terms of participation in various government programs, regulate how we conduct our business, the services we offer, and our interactions with patients and other healthcare providers. These laws and regulations are subject to frequent change. As noted above, the Biden-Harris Administration has called upon HHS and CMS to study and propose new rules regarding staffing requirements and reimbursement for the nursing home industry, including tying reimbursement to staffing levels, salary, benefits, and retention. CMS's recently finalized ownership transparency rule, discussed in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, may provide an additional basis for further investigation, administrative action and ultimately fines, penalties, or sanctions if finalized, and may dissuade parties from working with us or our independent subsidiaries due to the reporting and disclosure obligations of being an Additional Disclosable Party under that final rule. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that such regulations that may adversely affect our business, operation and profitability may increase in the future and we cannot predict the ultimate content, timing or impact on us of any healthcare reform legislation. If we fail to comply with these applicable laws and regulations, or their interpretations as determined by courts or enforced by regulators, we could suffer civil or criminal penalties and other detrimental consequences, including denial of reimbursement, imposition of fines, temporary suspension of admission of new patients, suspension or decertification from the Medicaid and Medicare programs, restrictions on our ability to acquire new facilities or expand or operate existing facilities, the loss of our licenses to operate and the loss of our ability to participate in federal and state reimbursement programs. Additionally, in the future, different interpretations or enforcement of these laws and regulations could subject our current or past practices to allegations of impropriety or illegality or could require us to make changes in our facilities, equipment, personnel, services, capital expenditure programs and operating expenses. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in greater detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we are subject to federal and state laws intended to prevent healthcare fraud and abuse. Possible sanctions for violation of any of these laws and regulations include loss of eligibility to participate in federal and state reimbursement programs and civil and criminal penalties. If we fail to comply, even inadvertently, with any of these requirements, we could be required to alter our operations, refund payments to the government, enter into a corporate integrity agreement, deferred prosecution or similar agreements with state or federal government agencies, and become subject to significant civil and criminal penalties. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These anti-fraud and abuse laws and regulations are complex, and we do not always have the benefit of significant regulatory or judicial interpretation of these laws and regulations. While we do not believe we are in violation of these prohibitions, we cannot assure you that governmental officials charged with the responsibility for enforcing these prohibitions will not assert that we are violating the provisions of such laws and regulations. Our company is currently aware of litigation filed by an individual related to allegations that certain of our independent SNFs may have violated the FCA or the AKS with respect to the relationships between certain SNFs and persons who served as medical directors. While our independent subsidiaries maintain policies and procedures to promote compliance with the FCA, the AKS, and other applicable regulatory requirements, we cannot predict when the investigation will be resolved, the outcome of the investigation or its potential impact on our company.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 1, 2023, CMS issued a proposed rule setting forth proposed minimum nurse staffing requirements for SNFs. As discussed in more detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, this proposed rule contains three primary staffing proposals: 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments. The proposed rule features a staggered implementation of these requirements, with potential accommodations for facilities that can demonstrate financial hardship and a delayed implementation schedule for rural facilities. Within this proposed rule, CMS also seeks comments about other staffing models, including alternate, higher standards for imposing staffing minimums, which will have a potentially adverse effect on our operations and profitability, the extent of which currently is not known. Pending legislation in both the House of Representative and the Senate has been introduced to prevent CMS's proposed minimum staffing rule from taking effect, however the outcome of this legislation is unknown and we cannot predict proposed legislation might be finalized.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are unable to predict the future course of federal, state and local regulation or legislation, including as it pertains to Medicare, Medicaid, or fraud and abuse laws, and how they are enforced. Changes in the regulatory framework, our failure to obtain or renew required regulatory approvals, credentials, qualifications, or licenses or to comply with applicable regulatory requirements, or the imposition of other enforcement sanctions, fines or penalties could have a material adverse effect upon our business, financial condition or results of operations. Furthermore, should we lose licenses or certifications for a number of our facilities or other businesses as a result of regulatory action or legal proceedings, we could be deemed to be in default under some of our agreements, including agreements governing outstanding indebtedness. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public and government calls for increased survey and enforcement efforts toward SNFs, and potential rulemaking that may result in enhanced enforcement and penalties, could result in increased scrutiny by state and federal survey agencies. In addition, potential sanctions and remedies based upon alleged regulatory deficiencies could negatively affect our financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As CMS turns its attention to enhancing enforcement activities towards SNFs, as discussed in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, state survey agencies will have more accountability for their survey and enforcement efforts. The enhanced penalties against SFFs under the Biden-Harris Administration, discussed in greater detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, represents further federal calls for oversight and penalties for low-ranked and underperforming SNFs. These enhanced penalties and enforcement activities precedes greater focus by CMS in obtaining oversight over SFFs, and continuing that oversight even after those SFFs improve, and subjecting them to more exacting and routine oversight. The likely result may be more frequent surveys of our independent subsidiaries, with more substantial penalties, fines and consequences if they do not perform well. For low-performing facilities in the SFF program, the standards for successfully emerging from that program and not being subject to ongoing and enhanced government oversight will be higher and measured over a longer period of time, prolonging the risks of monetary penalties, fines and potential suspension or exclusion from the Medicare and Medicaid programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, from time to time in the ordinary course of business, we receive deficiency reports from state and federal regulatory bodies resulting from such inspections or surveys. CMS's updated guidance to these surveyors incorporate recent changes to CMS&#8217;s methods for surveying infection control procedures. Additionally, CMS's recently finalized rule requiring disclosure of ownership and financial relationships between nursing facilities and property owners or management entities, as well as other state rules over ownership transparency, may provide an additional basis for further investigation, administrative action, and ultimately fines, penalties, or sanctions and could dissuade individuals and businesses from doing business with us or our independent subsidiaries. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most inspection deficiencies are resolved through an agreed-upon plan of corrective action, the reviewing agency typically has the authority to take further action against a licensed or certified facility. These remedial actions could result in the imposition of fines, imposition of a license to a conditional or provisional status, suspension or revocation of a license, suspension or denial of payment for new admissions, loss of certification as a provider under state or federal healthcare programs, or imposition of other sanctions, including criminal penalties. In the past, we have experienced inspection deficiencies that have resulted in the imposition of a provisional license and could experience these results in the future. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, in some states, citation of one independent subsidiaries could negatively impact other independent subsidiaries in the same state. Revocation of a license at a given facility could therefore impair our ability to obtain new licenses or to renew, or maintain, existing licenses at other facilities, which may also trigger defaults or cross-defaults under our leases and our credit arrangements, or adversely affect our ability to operate or obtain financing in the future. CMS&#8217;s proposed rules requiring disclosure of ownership, management and the owners of real property lessors or sublessors, which are greater and more intrusive than existing disclosure requirements heighten this risk. Our failure to comply with applicable legal and regulatory requirements in any single facility could negatively impact our financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have opted to voluntarily stop accepting new patients pending completion of a new state survey, in order to avoid possible denial of payment for new admissions during the deficiency cure period, or simply to avoid straining staff and other resources while retraining staff, upgrading operating systems or making other operational improvements. If we elect to voluntary close any operations in the future or to opt to stop accepting new patients pending completion of a state or federal survey, it could negatively impact our financial condition and results of operation.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received notices of potential sanctions and remedies based upon alleged regulatory deficiencies from time to time, and such sanctions have been imposed on some of our independent subsidiaries. We have had independent subsidiaries placed on SFF status in the past and other independent subsidiaries may be identified for such status in the future. We currently have one facility placed on SFF status.  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CMS&#8217;s changes to the SFF program and its look-back period may create greater risk of our facilities being subject to this program and subject to potential fines and sanctions, even after graduating from the SFF program.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in discussed in greater detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in October of 2022 CMS updated the SFF program with the intent to reduce the amount of time a SNF spends as an SFF and increase the number of nursing homes that progress through the SFF program. CMS clarified certain details of the SFF program updates in 2023 and how they are to be implemented by each state survey agency (SA). As part of the revisions to the SFF program, a priority in revising the SFF program was to address &#8220;yo-yo&#8221; noncompliance of SNFs that would graduate from the SFF program only to later see their compliance and quality measures regress after graduation, potentially requiring readmission to the SFF program. Among the measures implemented to avoid this issue of &#8220;yo-yo&#8221; noncompliance was a three-year lookback period for facilities that graduate from the SFF program to ensure that the quality and compliance improvements achieved through the SFF program were sustained. Facilities that graduate from the SFF program but continue to demonstrate poor compliance as evidenced by any SA&#8217;s survey, such as for actual harm, substandard quality of care, or immediate jeopardy deficiencies, may be subject to enhanced enforcement by CMS, up to and including termination from the Medicare and/or Medicaid programs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This three-year lookback for sustained improvements by facilities that graduate the SFF program poses risk for our independent subsidiaries, specifically those that may be subject to the SFF program or that have been subject to the SFF program in the past. As of December&#160;31, 2023, we have three facilities graduated from the SFF program within the past three years. First, for SNFs that are selected by CMS for participation in the SFF program, or which currently are in the SFF program, even graduation from the program is no longer an assurance that the SNF will be able to continue its operations. Even one survey with a significant compliance deficiency, such as actual harm or an immediate jeopardy deficiency, may result in CMS&#8212;acting solely within its discretion&#8212;terminating the SNF&#8217;s Medicare or Medicaid participation, likely triggering the termination of other payor contracts and rendering the facility economically unviable. Second, and relatedly, for SNFs that have graduated from the SFF program, they are subject to a three-year period of enhanced scrutiny where adverse findings by a SA and a single survey&#8217;s finding of poor compliance may result in CMS discretionarily terminating that facility&#8217;s Medicare and/or Medicaid participation, which would likely cause other payors to terminate their agreements with the facility as well. As a result, the financial and manpower resources needed for graduation from the SFF program may be for nothing if, in the three years following graduation from the SFF program, a SNF receives a poor survey result and permits CMS to impose fines and penalties up to the termination of the facility&#8217;s Medicare and Medicaid participation.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed above, Medicare and Medicaid represent significant sources of payment for our independent subsidiaries. Any of our facilities&#8217; loss of a Medicare or Medicaid contract would significantly harm the financial performance of that facility. Additionally, if CMS perceived there to be common upstream ownership of multiple facilities that were participants in or graduates of the SFF program, CMS may seek to take enforcement actions against those other facilities due to their common ownership based on another facility&#8217;s deficiencies after graduating the SFF program, with CMS imposing penalties up to and potentially including termination of those SNFs&#8217; participation in the Medicare and/or Medicaid programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Federal minimum staffing mandates may adversely affect our labor costs, ability to maintain desired levels of patient or resident capacity, and profitability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, CMS issued a proposed rule setting forth proposed minimum nurse staffing requirements for SNFs. As discussed in more detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, this proposed rule contains three primary staffing proposals: 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; 2) a requirement to have a RN on-site 24 hours per day, seven days per week; and 3) requirements for enhanced facility assessments.  The proposed rule features a staggered implementation of these requirements, with potential accommodations for facilities that can demonstrate financial hardship and a delayed implementation schedule for rural facilities. Within this proposed rule, CMS also seeks comments about other staffing models, including alternate, higher standards for imposing staffing minimums, which will have a potentially adverse effect on our operations and profitability, the extent of which currently is not known.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the full effects of these proposed federal staff level minimums are not fully known at this time, the expected effects likely will be studied by industry groups in the coming months, to include within responsive comments submitted to CMS for consideration while any final rule is being prepared. The exact effects of these proposed minimum staffing levels cannot be ascertained without a final rule that will specify the required number of staff for the Company&#8217;s independent subsidiaries to comply with such a regulation, we expect that such a mandate will have adverse financial consequences upon our business. Depending on the requirements of a final mandate and the time period over which its requirements are phased in, we may be required to hire substantially more staff members, particularly nurse practitioners, registered nurses, licensed practical nurses and nursing aides than currently staffed. Additionally, a federal mandate of this nature would place similar pressure on our competitors and result in sudden, expanded demand for nursing staff across the SNF industry. This sudden demand across the SNF industry may exacerbate an already difficult labor market, with demand for nursing staff far outstripping the supply of qualified individuals, and the salary requirements of both current and prospective staff increasing markedly to increase the likelihood of recruiting and retaining skilled caregivers.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future cost containment initiatives undertaken by private third-party payors may limit our revenue and profitability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our non-Medicare and non-Medicaid revenue and profitability are affected by continuing efforts of third-party payors to maintain or reduce costs of healthcare, such as by lowering payment rates, narrowing the scope of covered services, increasing case management review of services and negotiating pricing. In addition, sustained unfavorable economic conditions may affect the number of patients enrolled in managed care programs and the profitability of managed care companies, which could result in reduced payment rates. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors may not make timely payments for our services, and we may be unable to maintain our current payor or revenue mix. We are continuing our efforts to develop our non-Medicare and non-Medicaid sources of revenue and any changes in payment levels from current or future third-party payors could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Medicare reimbursements for physician and non-physician services could impact reimbursement for medical professionals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in greater detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, MACRA revised the payment system for physician and non-physician services. The changes to the therapy caps imposed on Medicare Part B outpatient therapy from this law have been changed by the BBA, and are subject to future budgetary changes through rulemaking and legislation, resulting in ongoing uncertainty regarding payment for these Medicare Part B services. Under the CY 2024 PF Final Rule, reductions in conversion factor, payments to providers and conditions imposed in exchange for higher payments may impose operational requirements and working conditions that further detract from and reduce our financial performance. Similarly, new final rules concerning the PACE program and the information it will collect from our independent subsidiaries may adversely affect the risk-adjusted reimbursement.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face numerous risks related to the COVID-19 PHE&#8217;s expiration and surrounding wind-down and uncertainty, which could individually or in the aggregate have a material adverse effect on our business, financial condition, liquidity, results of operations and prospects.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which the COVID-19 PHE's termination will affect our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence. The remains uncertainty as to what changes will be made to HHS&#8217;s emergency response requirements for our SNFs and senior living facilities in order to better respond to the issues experienced during the COVID-19 PHE. Additionally, the expiration of the Emergency Waivers and other flexibilities allowed under the COVID-19 PHE create the risk of non-compliance and delays in operation as more attention is required to ensure that our operations comply with applicable laws and regulations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, federal, state and local regulators implemented new regulations and waived existing regulations to promote care delivery during the COVID-19 PHE, which ended as of May 11, 2023. The ending of the Emergency Waivers and wind-down of other flexibilities may require and continue to require operational change requirements on short notice. The reinstatement of waived state and federal regulations has not occurred simultaneously, requiring heightened monitoring to ensure compliance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our independent subsidiaries may face continued challenges from ongoing infection control and emergency preparedness requirements made part of state laws or regulations as a result of the COVID-19 endemic. Additionally, the long-term effects of the COVID-19 pandemic may include long-term decline in demand for care in SNFs and senior living facilities, which will be borne out only through time. The extent and duration of the impact of the COVID-19 pandemic on our stock price is uncertain, our stock price may be more volatile, and our ability to raise capital could be impacted.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to increased investigation and enforcement activities related to HIPAA violations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the HITECH Act, requires us to adopt and maintain business procedures and systems designed to protect the privacy, security and integrity of patients' individual health information, in addition to state laws governing the privacy of patient information.&#160;We must comply with these state privacy laws to the extent that they are more protective of healthcare information or provide additional protections not afforded by HIPAA. The regulations enacting HIPAA periodically change and the last proposed change was issued in late 2022. This proposed rulemaking may be made final in 2023 and, if adopted as proposed, may require our independent subsidiaries to modify certain policies, procedures and practices regarding the disclosure of residents&#8217; information. If we fail to comply with these state and federal laws, we could be subject to criminal penalties, civil sanctions, litigation, and be forced to modify our policies and procedures, in addition to undertaking costly breach notification and remediation efforts, as well as sustaining reputational harm. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to breaches of protected patient information, under HIPAA and the 21st Century Cures Act (Cures Act) and other federal regulations, healthcare entities are also required to afford patients with certain rights of access to their health information and to promote sharing of patient data between and among healthcare providers involved in the same patient's course of care. Recently, the Office for Civil Rights, the agency responsible for HIPAA enforcement, has targeted investigative and enforcement efforts on violations of patients&#8217; rights of access, imposing significant fines for violations largely initiated from patient complaints. If we fail to comply with our obligations under HIPAA, we could face significant fines. Likewise, if we fail to comply with our obligations under the Cures Act, we could face fines from the Office of the National Coordinator for Health Information Technology, the agency responsible for Cures Act enforcement.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security breaches and other cyber-security incidents could violate security laws and subject us to significant liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare businesses are increasingly the target of cyberattacks whereby hackers disrupt business operations or obtain protected health information, often demanding large ransoms. At the end of the first quarter of 2023, the healthcare sector saw a 60% increase in the average weekly number of cyberattacks over 2021. By August of 2023, industry observers note that cybersecurity breaches in the healthcare industry had become less frequent, but larger in scope and affecting more patients than the prior year. Our business is dependent on the proper functioning and availability of our computer systems and networks. We cannot assure you that our safety and security measures and disaster recovery plan will prevent damage, interruption or breach of our information systems and operations. Additionally, we cannot control the safety and security of our information held by third-party vendors with whom we contract. The techniques used to obtain unauthorized access, disable or degrade service, or sabotage systems change frequently and may be difficult to detect, and as such we (or third-party vendors) may be unable to anticipate these techniques or implement adequate preventive measures. In addition, hardware, software or applications we (or third-party vendors) develop or procure from third parties may contain defects in design or manufacture or other problems that could unexpectedly compromise the security of information systems. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unauthorized parties may attempt to gain access to our systems or facilities, or those of third parties with whom we do business, through fraud or other forms of deception.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On occasion, we have acquired additional information systems through our business acquisitions, and these acquired systems may expose us to risk. We also license certain third-party software to support our operations and information systems. Our inability, or the inability of third-party vendors, to continue to maintain and upgrade information systems and software could disrupt or reduce the efficiency of our operations. In addition, costs and potential problems and interruptions associated with the implementation of new or upgraded systems and technology or with maintenance or adequate support of existing systems also could disrupt or reduce the efficiency of our operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A cyber-attack or other incident that bypasses the security measures of our information systems could cause a security breach, which may lead to a material disruption to our information systems infrastructure or business, significant costs to remediate (e.g., data recovery) and may involve a significant loss of business or patient health information. If a cyber-attack or other unauthorized attempt to access our systems or facilities were successful, it could also result in the theft, destruction, loss, misappropriation or release of confidential information or intellectual property, and could cause operational or business delays that may materially impact our ability to provide various healthcare services. Any successful cyber-attack or other unauthorized attempt to access our systems or facilities also could result in negative publicity which could damage our reputation or brand with our patients, referral sources, payors or other third parties and could subject us to a number of adverse consequences, the vast majority of which are not insurable, including but not limited to, disruptions in our operations, regulatory and other civil and criminal penalties, fines, investigations and enforcement actions (including, but not limited to, those arising from the SEC, Federal Trade Commission, Office of Civil Rights, the OIG or state attorneys general), fines, private litigation with those affected by the data breach (including class action litigation), loss of customers, disputes with payors and increased operating expense, which either individually or in the aggregate could have a material adverse effect on our business, financial position, results of operations, liquidity, and stock price.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be fully reimbursed for all services for which each facility bills through consolidated billing, which could adversely affect our revenue, financial condition and results of operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SNFs are required to perform consolidated billing for certain items and services furnished to patients and residents. The consolidated billing requirement requires the SNF to effectively bill for the entire package of care that its patients receive in these situations. Post-hospitalization skilled nursing services must be &#8220;bundled&#8221; into the hospital's diagnostic related group (DRG) payment in certain circumstances, in which case the hospital and SNF must effectively divide the payment that otherwise would have been made to the hospital.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although this practice is uncommon, it adversely affects SNF utilization and payments, whether due to the practical difficulty of this apportionment or hospitals being reluctant to lose revenue by discharging patients to a SNF. If more payments are required to be bundled in the future, this trend may continue, with our SNFs not receiving full reimbursement for all the services they provide, and have a further adverse effect on SNF utilization and revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increased competition for, or a shortage of, nurses and other skilled personnel could increase our staffing and labor costs and subject us to monetary fines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends upon our ability to retain and attract nurses and other skilled personnel, such as Certified Nurse Assistants, social workers and speech, physical and occupational therapists, as well as skilled management personnel responsible for day-to-day facility operation. Each facility has a facility leader responsible for the overall day-to-day operations of the facility, including quality of care, social services and financial performance. Depending upon the size of the facility, each facility leader is supported by facility staff who are directly responsible for day-to-day care of the patients, marketing and community outreach programs. Other key positions supporting each facility may include individuals responsible for physical, occupational and speech therapy, food service and maintenance. We compete with various healthcare service providers, including other skilled nursing providers, in retaining and attracting qualified and skilled personnel.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent SNFs are located in the states of Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. All states follow the current federal regulation relative to staffing, which establishes that SNFs are required to staff to meet the needs of the residents present in the facility. In addition, several states have established minimum staffing requirements for facilities operating in those states.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with these requirements can, among other things, jeopardize a facility's compliance with the conditions of participation under relevant state and federal healthcare programs. If a facility is determined to be out of compliance with these requirements, it may be subject to a notice of deficiency, a citation, or a significant fine or litigation risk, with penalties including the suspension of patient admissions and the termination of Medicaid participation, or the suspension, revocation or non-renewal of the SNF's license. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, CMS published a long-awaited proposed rule setting forth proposed SNF minimum staffing requirements at the federal level. In relevant part, these proposed federal standards require 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; and 2) a requirement to have a RN on-site 24 hours per day, seven days per week. This proposed rule contains numerous other provisions discussed in more detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Comments are still being submitted for this proposed rule, and the substance of both the comments and any revisions to the later-issued final rule setting forth minimum staffing requirements may influence the effect that this rule has on our business and its financial performance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nonetheless, for the federal government or any state government to materially change the way compliance with the minimum staffing standard is calculated or enforced, our labor costs could increase and the current shortage of healthcare workers could impact us more significantly. The broader labor market where we compete is in a state of disequilibrium where the needs of businesses such as ours outstrip the supply of available and willing workers. There is additional upward pressure on wages from different industries and more generally due to the current rate of inflation. Some of these industries compete with us for labor and others that do not, which makes it difficult to make significant hourly wage and salary increases due to the fixed nature of our reimbursement under insurance contracts as well as Medicare and Medicaid, in addition to our increasing variable costs. Due to the limited supply of qualified applicants who seek or are willing to accept employment, these broader concerns, may increase our labor costs or lead to potential staffing shortages, reduced operations to comply with applicable laws and regulations, or difficulty complying with those laws and regulations at current operational levels. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal laws and regulations, including the proposed minimum nurse staffing levels if they are made final, may increase our costs of maintaining qualified nursing and skilled personnel, or make it more difficult for us to attract or retain qualified nurses and skilled staff members. Proposed legislation, such as the previously proposed Nursing Home Improvement Act and the proposed HCBS Access Act, may make it more expensive to compete for, hire, and retain nursing staff, if passed into law in substantially the same form as previously introduced to Congress. The Biden-Harris Administration's desire to increase staffing level requirements for the nursing home industry and to tie reimbursement to the salary, benefits, and retention of staff also may increase our labor costs. CMS has published guidance to surveyors addressing topics that specifically include nurse staffing and collection of payroll data to evaluate appropriate staffing levels, which may lead to future regulation that increase our staffing requirements and labor costs or lower revenues.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar state-level requirements in the states where our independent SNFs operate, whether such requirements are passed by statute, regulation, or executive order, may result in a shortage or inability to obtain nurses and skilled staff. Prior concerns about the COVID-19 vaccination IFR may be abated by the Omnibus Final Rule&#8217;s withdrawal of that IFR.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The withdrawal of the COVID-19 vaccination IFR may allow for nursing and other personnel unwilling to receive the COVID-19 vaccination to re-enter the workforce for Medicare-certified facilities and increase the pool of hirable talent.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Increased competition for, or a shortage of, nurses or other trained personnel, or general ongoing inflationary pressures may require that we enhance our pay and benefits packages to compete effectively for such personnel. Turnover rates and the magnitude of the shortage of nurses or other trained personnel vary substantially from facility to facility, and may adversely affect those facilities' quality ratings based on data reported to CMS. In addition, state laws regarding minimum wage increases, such as California&#8217;s minimum wage increases for both health care and fast-food workers, may intensify competition for unskilled labor in both skilled and unskilled settings. For skilled workers within the skilled care market where we operate, the costs of skilled labor, which are already greater than unskilled labor, could increase further. Similarly, the increased minimum wage of unskilled labor will not only increase the cost of unskilled labor, but may also have effects that dissuade workers from training to join the skilled workforce to earn higher wage growth, resulting in a smaller pool of available skilled workers and further increased competition&#8212;and higher wages&#8212;for them. If we fail to attract and retain qualified and skilled personnel, our ability to conduct our business operations could be harmed. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Annual caps and other cost-reductions for outpatient therapy services may reduce our future revenue and profitability or cause us to incur losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, sub-heading </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part B Rehabilitation Requirements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, several government actions have been taken in recent years to try and contain the costs of rehabilitation therapy services provided under Medicare Part B, including the MPPR, institution of annual caps, mandatory medical reviews for annual claims beyond a certain monetary threshold, and a reduction in reimbursement rates for therapy assistant claim modifiers. Of specific concern has been CMS efforts to lower Medicare Part B reimbursement rates for outpatient therapy services in 2021, 2022 and 2023. Such cost-containment measures and ongoing payment changes could have an adverse effect on our revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Office of the Inspector General or other regulatory authorities may choose to more closely scrutinize billing practices in areas where we operate or propose to expand, which could result in an increase in regulatory monitoring and oversight, decreased reimbursement rates, or otherwise adversely affect our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in greater detail in Item 1., under Government Regulation, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Civil and Criminal Fraud and Abuse Laws and Enforcement</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the OIG regularly conducts investigations regarding certain payment or compliance issues within the healthcare industry. The OIG identified SNF compliance as an issue of concern in its 2021 and 2022 semi-annual reports to Congress, and its January 2023 study regarding SNF emergency preparedness identified the need for further oversight and addition of SNF emergency readiness to the OIG's 2023 work plan. In November of 2023, OIG added to its work plan an audit of nursing homes' nurse staffing hours reported in CMS's payroll-based journal, for which OIG expects to issue a report in FY 2025. Nursing homes were also a topic of discussion in the OIG&#8217;s 2023 semiannual report to Congress, which emphasized the continued protection and oversight of care that nursing facilities provide to residents. Among other things, the OIG recommended a reduction in the use of psychotropic drugs in nursing homes and urged CMS to evaluate the appropriateness of psychotropic drug use among residents, including the use of data to identify nursing homes with higher rates of use for potential further scrutiny and action. Based on this information, SNFs in particular are potential targets for more robust scrutiny and examination by regulators. Recent publications and statements by the Biden-Harris Administration have also called for greater scrutiny of SNF facilities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To respond to the local community needs and the shifting of higher acuity patients from the acute care setting to the SNF setting, over time our overall patient mix has consistently shifted to higher acuity and higher-resource utilization patients in most facilities we operate. We also use specialized care-delivery software that assists our caregivers in more accurately capturing and recording activities of daily living services, among other things. These efforts may place us under greater scrutiny with the OIG, CMS, our fiscal intermediaries, recovery audit contractors and others.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State efforts to regulate or deregulate the healthcare services industry or the construction or expansion of healthcare facilities could impair our ability to expand our operations, or could result in increased competition.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states require healthcare providers, including SNFs, to obtain prior approval, known as a certificate of need, for: (1) the purchase, construction or expansion of healthcare facilities; (2) capital expenditures exceeding a prescribed amount; or (3) changes in services or bed capacity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other states that do not require certificates of need have effectively barred the expansion of existing facilities and the establishment of new ones by placing partial or complete moratoria on the number of new Medicaid beds those states will certify in certain areas or throughout the entire state. Still other states have established such stringent development standards and approval procedures for constructing new healthcare facilities that the construction of new facilities, or the expansion or renovation of existing facilities, may become cost-prohibitive or extremely time-consuming. In addition, some states require the approval of the state Attorney General for acquisition of a facility being operated by a non-profit organization.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to acquire or construct new facilities or expand or provide new services at existing facilities would be adversely affected if we are unable to obtain the necessary approvals, if there are changes in the standards applicable to those approvals, or if we experience delays and increased expenses associated with obtaining those approvals. We may not be able to obtain licensure, certificate of need approval, Medicaid certification, state Attorney General approval or other necessary approvals for future expansion projects. Conversely, the elimination or reduction of state regulations that limit the construction, expansion or renovation of new or existing facilities could result in increased competition to us or result in overbuilding of facilities in some of our markets. If overbuilding in the skilled nursing industry in the markets in which we operate were to occur, it could reduce the occupancy rates of existing facilities and, in some cases, might reduce the private rates that we charge for our services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly enacted and proposed legislation in the States where our independent subsidiaries are located may affect our operations in terms of individual litigation and the broader regulatory environment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A bill in the State of California was recently signed into law which increases the cap of non-economic damages awarded to plaintiffs who are successful in medical malpractice litigation. The cap increases from $0.25 million to $0.35 million beginning on January 1, 2023, then increases over the following 10 years until the cap reaches a maximum of $0.75 million, with further adjustments for inflation. In wrongful death cases, the cap increases from $0.25 million to $0.5 million on January 1, 2023, with incremental increases over the following 10 years until the cap reaches a maximum of $1.0 million, with adjustments for inflation. Due to California's influence on other states, other jurisdictions where we operate may enact similar laws. Similar to the potential incentive of increased damages caps, the Supreme Court&#8217;s recent decision in certain case may increase public interest in potential claims against SNFs and senior living facilities, particularly pertaining to specific civil rights claims against governmental actors rather than general liability claims against privately owned SNFs such as those operated by our independent subsidiaries. While there may be additional claims and litigation that arise from the Supreme Court's decision that have an adverse impact on our cash flow, it is not expected that the decision will have a significant impact on our business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Another example, California&#8217;s adoption of the Skilled Nursing Facility Ownership and Management Reform Act of 2022, discussed in Item 1., </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, imposes new requirements for obtaining licenses to operate SNFs. These new requirements may delay or limit the ability to obtain new SNF licenses within that state, whether through acquisition of existing facilities or opening a new facility. This new law's obligations may increase the costs of obtaining licensure, make applications more time-consuming and complex, and may result in civil penalties and other sanctions against our independent subsidiaries in the event they are not compliant with these new licensure application requirements. As a result, this new law may delay or impede growth within California. As with the bill that increases the cap of non-economic damages for medical malpractice litigation, California&#8217;s influence on other states may result in this legislation becoming a model for other states and having similar, potentially adverse effects within those jurisdictions as well.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, California&#8217;s legislature has proposed bills related to increasing the minimum wage for workers, spending requirements and increased disclosure. As discussed in Item 1., </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, these proposed bills would create new and costly obligations on our independent subsidiaries if they became law and if enacted, would adversely affect our business, operations, and profitability.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As another example, Texas passed a bill which partially restored Medicaid state relief funding for SNFs through August 31, 2023, while it also considered legislation that contained direct care spending requirements and ownership, similar to proposed federal rulemaking discussed in Item 1., </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. While this bill provided financial relief to our independent subsidiaries in Texas, other proposed bills may impose the same regulatory requirements and limitations inherent in both the proposed legislation in other states and the federally proposed rule requiring disclosure of such information in applications and change-of-ownership disclosures, which may adversely affect our business, operations, and profitability.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to federal and state employment-related laws and regulations could increase our cost of doing business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent subsidiaries are subject to a variety of federal and state employment-related laws and regulations, including, but not limited to, the U.S. Fair Labor Standards Act that governs such matters as minimum wages, overtime and other working conditions, the ADA and similar state laws that provide civil rights protections to individuals with disabilities in the context of employment, public accommodations and other areas, the National Labor Relations Act, regulations of the EEOC, regulations of the Office of Civil Rights, regulations of state attorney generals, family leave mandates and a variety of similar laws enacted by the federal and state governments that govern these and other employment law matters. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 13, 2023, the California Governor signed into law a bill that impacts the minimum wage of healthcare workers. Effective June 1, 2024, the law raises the minimum wage for California healthcare employees and sets a new standard salary threshold for those who are considered exempt healthcare employees. The bill only becomes effective for SNFs if a patient care minimum spending bill is also passed, which is expected to be introduced in the near future. If the minimum wage that must be paid to SNF employees in California increases, this would result in increased labor costs and challenges achieving or maintaining profitability within the state. Further, as states raise industry specific minimum wages employees will anticipate higher pay, placing additional pressure on our business to meet wage demands and compete for skilled talent in an already challenging labor market. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Biden-Harris Administration has requested HHS and CMS study and issue proposed rules regarding care-based careers, including improving access to training, increasing the attractiveness of compensation in care-based positions, and improving the retention and career progression of care workers. The administration has sought proposed rules that tie some of these issues, such as wages and retention, to Medicare reimbursement for facilities. Other pending legislation, such as the HCBS Access Act, indicate a legislative priority of providing funding for care-based careers that may affect our pool of desired workers. Rising operating costs due to labor shortages, greater compensation and incentives required to attract and retain qualified personnel and higher-than-usual inflation on items including energy, utilities, food and other goods used in our facilities and the costs for transporting these items could increase our cost and decrease our profits.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 1, 2023, CMS published a long-awaited proposed rule setting forth proposed SNF minimum staffing requirements at the federal level. In relevant part, these proposed federal standards require 1) minimum nurse staffing standards of 0.55 HPRD for RNs and 2.45 HPRD for NAs; and 2) a requirement to have a RN on-site 24 hours per day, seven days per week. This proposed rule contains numerous other provisions discussed in more detail in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Comments are still being submitted for this proposed rule, and the substance of both the comments and any revisions to the later-issued final rule setting forth minimum staffing requirements may influence the effect that this rule has on our business and its financial performance. Any implementation of this proposed rule, however, is likely to increase demand for labor, including skilled caregivers, increase our costs, and may adversely affect our financial performance.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compliance costs associated with these laws and evolving regulations could be substantial. By way of example, all of our independent subsidiaries are required to comply with the ADA, which has separate compliance requirements for &#8220;public accommodations&#8221; and &#8220;commercial properties,&#8221; but generally requires that buildings be made accessible to people with disabilities. Compliance with ADA requirements could require removal of access barriers and non-compliance could result in imposition of government fines or an award of damages to private litigants. Further legislation may impose additional burdens or restrictions with respect to access by disabled persons. In addition, federal proposals to introduce a system of mandated health insurance and flexible work time and other similar initiatives could, if implemented, adversely affect our operations. We also may be subject to employee-related claims such as wrongful discharge, discrimination or violation of equal employment law. While we are insured for these types of claims, we could be subject to damages that are not covered by our insurance policies or that exceed our insurance limits, and we may be required to pay such damages directly, which would negatively impact our cash flow from operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Required regulatory approvals could delay or prohibit transfers of our healthcare operations, which could result in periods in which we are unable to receive reimbursement for such properties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operations of our independent subsidiaries must be licensed under applicable state law and, depending upon the type of operation, certified or approved as providers under the Medicare and/or Medicaid programs. In the process of acquiring or transferring operating assets, our operations must receive change of ownership approvals from state licensing agencies, Medicare and Medicaid as well as third-party payors.&#160;Proposed rules regarding the disclosure of SNF facility ownership, if made effective, may increase the scrutiny placed on companies that operate, directly or indirectly, multiple SNFs, and may subject our licensing and approval process to additional scrutiny or delays. If there are any delays in receiving regulatory approvals from the applicable federal, state or local government agencies, or the inability to receive such approvals, such delays or denials could result in delayed or lost reimbursement related to periods of service prior to the receipt of such approvals, which could negatively impact our cash position. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with federal and state fair housing, fire, safety and other regulations may require us to make unanticipated expenditures, which could be costly to us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must comply with the federal Fair Housing Act and similar state laws, which prohibit us from discriminating against individuals if it would cause such individuals to face barriers in gaining residency in any of our independent subsidiaries. Additionally, the Fair Housing Act and other similar state laws require that we advertise our services in such a way that we promote diversity and not limit it. We may be required, among other things, to change our marketing techniques to comply with these requirements.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our independent subsidiaries are required to operate in compliance with applicable fire and safety regulations, building codes and other land use regulations and food licensing or certification requirements as they may be adopted by governmental agencies and bodies from time to time. Like other healthcare facilities, our independent SNFs are subject to periodic surveys or inspections by governmental authorities to assess and assure compliance with regulatory requirements. Surveys occur on a regular (often annual or biannual) schedule, and special surveys may result from a specific complaint filed by a patient, a family member or one of our competitors. We may be required to make substantial capital expenditures to comply with these requirements. In some cases, we may be unable to comply with new regulations prior to their effective date exposing us to potential fines or regulatory action.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend largely upon reimbursement from third-party payors, and our revenue, financial condition and results of operations could be negatively impacted by any changes in the acuity mix of patients in our independent subsidiaries as well as payor mix and payment methodologies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is affected by the percentage of the patients of our independent subsidiaries who require a high level of skilled nursing and rehabilitative care, whom we refer to as high acuity patients, and by our mix of payment sources. Changes in the acuity level of patients we attract, as well as our payor mix among Medicaid, Medicare, private payors and managed care companies, significantly affect our profitability. We generally receive higher reimbursement rates for high acuity patients, and payors reimburse us at different rates. For the year ended December 31, 2023 and 2022, 72.6% and 73.7%, of our revenue was provided by government payors that reimburse us at predetermined rates, respectively. If our labor or other operating costs increase, we will be unable to recover such increased costs from government payors. Accordingly, if we fail to maintain our proportion of high acuity patients or if there is any significant increase in the percentage of the patients of our independent subsidiaries for whom we receive Medicaid reimbursement, our results of operations may be adversely affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initiatives undertaken by major insurers and managed care companies to contain healthcare costs may adversely affect our business. These tactics include contracting with healthcare providers to obtain services on a discounted basis. We believe that this trend will continue and may limit reimbursements for healthcare services. If insurers or managed care companies from whom we receive substantial payments were to reduce the amounts they pay for services and we did not wish to accept such reductions, we may lose patients if we choose not to renew our contracts with these insurers at lower rates. Additionally, trade publications within the healthcare industry have reported on the trend of payors using the No Surprises Act as a means to force re-negotiation of reimbursement rates for providers and facilities, leading to litigation between these providers and/or facilities against payors and it may adversely affect us as well.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed under Item 1., </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Biden-Harris Administration has requested HHS and CMS conduct studies to evaluate potential staffing, data reporting, employee compensation and retention, and resident experience regulations that may result in a reduction of our revenue from Medicare and Medicaid. CMS first requested information regarding these priorities in 2022 and subsequently published further requests for information from the public in the Federal Register to aid in studies and anticipated rulemaking. CMS's proposed rule regarding disclosure of significant information regarding their ownership, operations, management and the owners of real property leased or subleased by our independent subsidiaries, may result in additional regulatory requirements for participation in those programs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to litigation that could result in significant legal costs and large settlement amounts or damage awards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing business involves a significant risk of liability given the age and health of the patients and residents of our independent subsidiaries and the services we provide. The industry has experienced an increased trend in the number and severity of litigation claims, due in part to the number of large verdicts, including large punitive damage awards. These claims are filed based upon a wide variety of claims and theories, including deficiencies under conditions of participation under certain state and federal healthcare programs. Plaintiffs' attorneys have become increasingly more aggressive in their pursuit of claims against healthcare providers, including skilled nursing providers, employing a wide variety of advertising and solicitation activities to generate more claims. The increased caps on damages awarded in such actions, as discussed above, may trigger a larger number of these lawsuits against our independent subsidiaries in California and other states that adopt similar legislation. The defense of lawsuits has in the past, and may in the future, result in significant legal costs, regardless of the outcome. Additionally, increases to the frequency and/or severity of losses from such claims and suits may result in increased liability insurance premiums or a decline in available insurance coverage levels, which could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have in the past been subject to class action litigation involving claims of violations of various regulatory requirements and been able to settle these claims without an ongoing material adverse effect on our business. Future claims could be brought that may materially affect our business, financial condition and results of operations. Other claims and suits, including class actions, continue to be filed against us and other companies in our industry. For example, there has been a general increase in the number of wage and hour class action claims filed in several of the jurisdictions where we operate, typically based on alleged failures to permit or properly compensate for meal and rest periods, or failure to pay for time worked. If there were a significant increase in the number of these claims against us or an increase in amounts owing should plaintiffs be successful in their claims, this could have a material adverse effect to our business, financial condition, results of operations and cash flows. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. Under the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. For example,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> d</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">espite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. Refer to Item 3. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on this case. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond our skilled nursing business, we engage in numerous ancillary businesses through one or more of our subsidiaries. These ancillary businesses generally support and provide services complementary to our operations, including but not limited to non-emergent ground transportation for patients and residents. Our ancillary businesses may also be the subject of claims, lawsuits, and regulatory oversight that are specific to the particular services they offer. Noncompliance with the laws and regulations that may apply to our ancillary businesses may result in fines, penalties, and civil claims paid by our affected independent subsidiaries. Specific to our non-emergent ground transportation business, the drivers employed by this business may be subject to additional state-specific regulations regarding working time allowed to be spent driving, waiting time, and break or rest periods, and violations of these rules may lead to regulatory fines, penalties, or claims to be paid to individual drivers, in addition to the general employment risks described above.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ancillary businesses also are susceptible to general liability claims based on facts and circumstances that are specific to their activities and operations</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> such as claims for automobile-involved accidents against our non-emergent ground transportation business. The defense of claims and lawsuits relating to our ancillary businesses in the past, and may in the future, result in significant legal costs, regardless of the outcome. As our ancillary businesses grow, the independent subsidiaries may be subject to increased frequency and/or severity of losses from such claims and suits which may result in increased liability insurance premiums and decline in available coverage as described above, which could materially and adversely affect our business, financial condition and results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we contract with a variety of landlords, lenders, vendors, suppliers, consultants and other individuals and businesses. These contracts typically contain covenants and default provisions. If the other party to one or more of our contracts were to allege that we have violated the contract terms, we could be subject to civil liabilities which could have a material adverse effect on our financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If litigation is instituted against one or more of our subsidiaries, a successful plaintiff might attempt to hold us or another subsidiary liable for the alleged wrongdoing of the subsidiary principally targeted by the litigation. If a court in such litigation decided to disregard the corporate form, the resulting judgment could increase our liability and adversely affect our financial condition and results of operations.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Congress has repeatedly considered, without passage, a bill that would require, among other things, that agreements to arbitrate nursing home disputes be made after the dispute has arisen rather than before prospective patients move in, to prevent nursing home operators and prospective patients from mutually entering into a pre-admission pre-dispute arbitration agreement. This bill, known as the Fairness in Nursing Home Arbitration Act, was introduced in the House of Representatives in 2021; the bill and its analogue introduced in the Senate have never made it out of the committees to which they were referred for discussion. This legislation or similar bills have not yet been introduced in the current session of Congress, which commenced at the beginning of 2023.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent subsidiaries use arbitration agreements, which have generally been favored by the courts, to streamline the dispute resolution process and reduce our exposure to legal fees and excessive jury awards. CMS has identified these arbitration agreements as an area of focus and issued guidance to state surveyors regarding federal requirements for the use of arbitration agreements in nursing home care, with non-compliance potentially resulting in fines and other sanctions. If we are not able to secure pre-admission arbitration agreements, our litigation exposure and costs of defense in patient liability actions could increase, our liability insurance premiums could increase, and our business may be adversely affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The outcomes of any of these litigation matters are difficult to predict and litigation and other legal claims are subject to inherent uncertainties. Those uncertainties include, but are not limited to, litigation costs and attorneys&#8217; fees, unpredictable judicial or jury decisions and the differing laws and judicial proclivities regarding damage awards among the states in which we operate. A further complication is that even where the possibility of an adverse outcome is remote under traditional legal analysis, juries sometimes substitute their subjective views in place of facts and established legal principles. Unexpected outcomes in such legal proceedings, or changes in management&#8217;s evaluation or predictions of the likely outcomes of such proceedings (possibly resulting in changes in established reserves) could have a material adverse effect on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We conduct regular internal investigations into the care delivery, recordkeeping and billing processes of our independent subsidiaries. These reviews sometimes detect instances of noncompliance which we attempt to correct, which can decrease our revenue.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an operator of healthcare facilities, we have a program to help us comply with various requirements of federal and private healthcare programs.&#160;Our compliance program includes, among other things, (1) policies and procedures modeled after applicable laws, regulations, sub-regulatory guidance and industry practices and customs that govern the clinical, reimbursement and operational aspects of our subsidiaries; (2) training about our compliance process for all of the employees of our independent subsidiaries, our directors and officers, and training about Medicare and Medicaid laws, fraud and abuse prevention, clinical standards and practices, and claim submission and reimbursement policies and procedures for appropriate employees; and (3) internal controls that monitor, among other things, the accuracy of claims, reimbursement submissions, cost reports and source documents, provision of patient care, services, and supplies as required by applicable standards and laws, accuracy of clinical assessment and treatment documentation, and implementation of judicial and regulatory requirements (i.e., background checks, licensing and training).</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our systems and controls highlight potential compliance issues, which we investigate as they arise. Historically, we have, and will continue to do so in the future, initiated internal inquiries into possible recordkeeping and related irregularities at our independent SNFs, which were detected by our internal compliance team in the course of its ongoing reviews.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through these internal inquiries, we have identified potential deficiencies in the assessment of and recordkeeping for small subsets of patients. We have assisted in implementing, targeted improvements in the assessment and recordkeeping practices to make them consistent with the existing standards and policies applicable to our independent SNFs. We continue to monitor the measures implemented for effectiveness and perform follow-up reviews to ensure compliance. Consistent with healthcare industry accounting practices, we record any charge for refunded payments against revenue in the period in which the claim adjustment becomes known.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If additional reviews result in identification and quantification of additional amounts to be refunded, we will accrue additional liabilities for claim costs and interest, and repay any amounts due in normal course and within the time permitted by law. Failure to refund overpayments within required time frames (as described in greater detail above) could result in FCA liability and our business, financial condition and results of operations could be materially and adversely affected and our stock price could decline.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to complete future facility or business acquisitions at attractive prices or at all, which may adversely affect our revenue; we may also elect to dispose of underperforming or non-strategic independent subsidiaries, which would also decrease our revenue. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our revenue growth has been significantly impacted by our acquisition of new facilities and businesses. Subject to general market conditions and the availability of essential resources and leadership within our company, we continue to seek both single-and multi-facility acquisition and business acquisition opportunities that are consistent with our geographic, financial and operating objectives.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition for the acquisition of facilities and businesses and expect this competition to increase. Based upon factors such as our ability to identify suitable acquisition candidates, future regulations affecting our ability to purchase facilities, the purchase price of the facilities, increasing interest rates for debt-financed purchases, prevailing market conditions, the availability of leadership to manage new facilities and our own willingness to take on new operations, the rate at which we have historically acquired facilities has fluctuated significantly. In the future, we anticipate the rate at which we may acquire facilities will continue to fluctuate, which may affect our revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also previously acquired a few facilities, which were or have proven to be non-strategic or less desirable, and we may consider disposing of such facilities or exchanging them for facilities that are more desirable, either because they were included in larger, indivisible groups of facilities or under other circumstances. To the extent we dispose of such a facility without simultaneously acquiring a facility in exchange, our revenue may decrease.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to successfully integrate acquired facilities and businesses into our operations, and we may not achieve the benefits we expect from any of our facility acquisitions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to successfully or efficiently integrate new acquisitions of facilities and businesses with our existing independent subsidiaries, culture and systems. The process of integrating acquisitions into our existing operations may result in unforeseen operating difficulties, divert management's attention from existing operations, or require an unexpected commitment of staff and financial resources, and may ultimately be unsuccessful. Existing operations available for acquisition frequently serve or target different markets than those that we currently serve. We also may determine that renovations of acquired facilities and changes in staff and operating management personnel are necessary to successfully integrate those acquisitions into our existing operations. We may not be able to recover the costs incurred to reposition or renovate newly independent subsidiaries. The financial benefits we expect to realize from many of our acquisitions are largely dependent upon our ability to improve clinical performance, overcome regulatory deficiencies, rehabilitate or improve the reputation of the operations in the community, increase and maintain occupancy, control costs, and in some cases change the patient acuity mix. If we are unable to accomplish any of these objectives at the independent subsidiaries we acquire, we will not realize the anticipated benefits and we may experience lower than anticipated profits, or even losses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we expanded our operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 26 skilled nursing operations. This growth has placed and will continue to place significant demands on our current management resources. Our ability to manage our growth effectively and to successfully integrate new acquisitions into our existing business will require us to continue to expand our operational, financial and management information systems and to continue to retain, attract, train, motivate and manage key employees, including facility-level leaders and our local directors of nursing. We may not be successful in attracting qualified individuals necessary for future acquisitions to be successful, and our management team may expend significant time and energy working to attract qualified personnel to manage facilities we may acquire in the future. Also, the newly acquired facilities may require us to spend significant time improving services that have historically been substandard, and if we are unable to improve such facilities quickly enough, we may be subject to litigation and/or loss of licensure or certification. If we are not able to successfully overcome these and other integration challenges, we may not achieve the benefits we expect from any of our acquisitions, and our business may suffer. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In undertaking acquisitions, we may be adversely impacted by costs, liabilities and regulatory issues that may adversely affect our operations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In undertaking acquisitions, we also may be adversely impacted by unforeseen liabilities attributable to the prior providers who operated those facilities, against whom we may have little or no recourse. Many facilities we have historically acquired were underperforming financially and had clinical and regulatory issues prior to and at the time of acquisition. Even where we have improved independent subsidiaries and patient care at facilities that we have acquired, we still may face post-acquisition regulatory issues related to pre-acquisition events. These may include, without limitation, payment recoupment related to our predecessors' prior noncompliance, the imposition of fines, penalties, operational restrictions or special regulatory status. Further, we may incur post-acquisition compliance risk due to the difficulty or impossibility of immediately or quickly bringing non-compliant facilities into full compliance. Diligence materials pertaining to acquisition targets, especially the underperforming facilities that often represent the greatest opportunity for return, are often inadequate, inaccurate or impossible to obtain, sometimes requiring us to make acquisition decisions with incomplete information. Despite our due diligence procedures, facilities that we have acquired or may acquire in the future may generate unexpectedly low returns, may cause us to incur substantial losses, may require unexpected levels of management time, expenditures or other resources, or may otherwise not meet a risk profile that our investors find acceptable. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we might encounter unanticipated difficulties and expenditures relating to any of the acquired facilities, including contingent liabilities. For example, when we acquire a facility, we generally assume the facility's existing Medicare provider number for purposes of billing Medicare for services. If CMS later determines that the prior owner of the facility had received overpayments from Medicare for the period of time during which it operated the facility, or had incurred fines in connection with the operation of the facility, CMS could hold us liable for repayment of the overpayments or fines. We may be unable to improve every facility that we acquire. In addition, operation of these facilities may divert management time and attention from other operations and priorities, negatively impact cash flows, result in adverse or unanticipated accounting charges, or otherwise damage other areas of our company if they are not timely and adequately improved.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also incur regulatory risk in acquiring certain facilities due to the licensing, certification and other regulatory requirements affecting our right to operate the acquired facilities. For example, in order to acquire facilities on a predictable schedule, or to acquire declining operations quickly to prevent further pre-acquisition declines, we frequently acquire such facilities prior to receiving license approval or provider certification. We operate such facilities as the interim manager for the outgoing licensee, assuming financial responsibility, among other obligations for the facility. To the extent that we may be unable or delayed in obtaining a license, we may need to operate the facility under a management agreement from the prior operator. Any inability in obtaining consent from the prior operator of a target acquisition to utilizing its license in this manner could impact our ability to acquire additional facilities. Further, anticipated future regulations may cause delays in acquiring the required licenses and certifications, if it is possible to do so at all. If we were subsequently denied licensure or certification for any reason, we might not realize the expected benefits of the acquisition and would likely incur unanticipated costs and other challenges which could cause our business to suffer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we do not achieve or maintain competitive quality of care ratings from CMS or private organizations engaged in similar monitoring activities, our business may be negatively affected. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Item 1., under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS provides comparative public data, rating every SNF operating in each state based upon quality-of-care indicators. Certain private organizations engage in similar monitoring and ranking activities. CMS&#8217;s system is the Five-Star Quality Rating System which gives each nursing home a rating of between one and five stars in various categories, with five-star ratings harder to obtain over time. The ratings are available on a consumer-facing website, Nursing Home Compare. In cases of acquisitions, the previous operator's clinical ratings are included in our overall Five-Star Quality Rating and the rating may not reflect the improvements we were able to make until it is recalculated. Based on CMS's guidance and regulations, we expect more data to be collected by CMS and reported on the Nursing Home Compare website in the future. Additionally, CMS's ownership transparency final rule, which requires the disclosure of SNF ownership and affiliated parties, will ultimately provide for the public disclosure of information reported to CMS under that rule. This publicly available information may result in potential residents perceiving our highly rated facilities to be less desirable if they share ownership with lower rated facilities, even if the lower rated facility is a new acquisition or has a lower score for reasons beyond our control. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS continues to increase quality measure thresholds, making it more difficult to achieve upward and five-star ratings. CMS increased its quality measure thresholds in October of 2022, making it more difficult for facilities to obtain or maintain four- and five-star ratings, which were most recently re-calculated in July of 2023, allowing only 10% of nursing facilities within a state to receive a five-star rating. CMS discloses the increasing standards for four- and five-star ratings in its star rating cut point table, which discloses the points needed for each star rating within every state. CMS has indicated that it will increase these quality measure thresholds every six months. Some facilities may see a decline in their overall five-star rating absent any new inspection information, and as a result the five-star ratings of our independent subsidiaries may decline even as their quality measures remain unchanged or improve. Additionally, on the Nursing Home Compare website, CMS recently began displaying a consumer alert icon next to nursing homes that have been cited on inspection reports for incidents of abuse, neglect, or exploitation. In July of 2022, CMS updated the scoring measures used for SNFs to include six dimensions of staffing and turnover, which may adversely affect the rating of our facilities on the Nursing Home Compare website. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, CMS revised the nursing-home level exclusion criteria used on the administrator turnover measure, adding information regarding its calculation of the staff turnover measure and publishing an updated ratings table, which identifies the points needed for each nursing facility to obtain certain star ratings within its state. This change made it more competitive to obtain a five-star rating, and more difficult to maintain such a rating once achieved. Only 10% of nursing facilities can receive a five-star rating in the state where it operates. The July 2023 change also increases the pressure on our independent subsidiaries to obtain a smaller number of available five-star ratings, as lower ratings may make it more difficult to attract prospective residents to receive our services.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2023, CMS announced that it will update the staffing level case-mix adjustment methodology and freeze four of the quality measures used in the Nursing Home Five-Star Quality Rating System beginning with the April 2024 refresh of the Nursing Home Compare website data. In July 2024, CMS will change the staffing case-mix adjustment methodology to a model based on PDPM. The Nursing Home Compare website will then begin posting staffing level measures that use this methodology. CMS will revise the staffing rating thresholds to maintain the same distribution of points for staffing measures that will be affected by this freeze and replacement. Further, CMS will penalize SNFs that submit erroneous data, or fail to submit data, by awarding them the lowest possible rating on that measure. We may be significantly affected if any of our independent subsidiaries fail to submit information for the MDS in 2024, or if CMS deems their MDS submissions to be erroneous. In addition to the uncertainty created by coming changes to CMS&#8217;s five-star ratings that currently are unknown, the potential negative consequences of freezing unfavorable data may adversely affect our star rating and negatively impact our ability to attract residents.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providing quality patient care is the cornerstone of our business. We believe that hospitals, physicians and other referral sources refer patients to us in large part because of our reputation for delivering quality care. If we should fail to achieve our internal rating goals or fail to exceed the national average rating on the Five-Star Quality Rating System, including due to nursing and administrative staffing and turnover, or have facilities displaying a consumer alert icon for incidents of abuse, neglect, or exploitation, it may affect our ability to generate referrals, which could have a material adverse effect upon our business and consolidated financial condition, results of operations and cash flows.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, our business may be adversely affected. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may become more difficult and costly for us to obtain coverage for resident care liabilities and other risks, including property, automobile and casualty insurance. For example, the following circumstances may adversely affect our ability to obtain insurance at favorable rates: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">we experience higher-than-expected professional liability, property and casualty, or other types of claims or losses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">we receive survey deficiencies or citations of higher-than-normal scope or severity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">we acquire especially troubled operations or facilities that present unattractive risks to current or prospective insurers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">insurers choose to stop operating or offering policies in certain states due to changes in economic conditions or laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">insurers tighten underwriting standards applicable to us or our industry; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">insurers or reinsurers are unable or unwilling to insure us or the industry at historical premiums and coverage levels.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these potential circumstances were to occur, our insurance carriers may cancel or not renew our policies, or require us to significantly increase our self-insured retention levels or pay substantially higher premiums for the same or reduced coverage for insurance, including workers compensation, property and casualty, automobile, employment practices liability, directors and officers liability, employee healthcare and general and professional liability coverages.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some states, the law prohibits or limits insurance coverage for the risk of punitive damages arising from professional liability and general liability claims or litigation. Other states where we operate have experienced a withdrawal of insurers from the marketplace due to prior losses, or are at risk of insurers leaving the market due to changes in the law that make it difficult for those insurers to operate within the state. Coverage for punitive damages is also excluded under some insurance policies. As a result, we may be liable for punitive damage awards in these states that either are not covered or are in excess of our insurance policy limits. Claims against us, regardless of their merit or eventual outcome, could also inhibit our ability to attract patients or expand our business and could require our management to devote time to matters unrelated to the day-to-day operation of our business.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With few exceptions, workers compensation and employee health insurance costs have also increased markedly in recent years and are expected to increase in the future. To partially offset these increases, we have increased the amounts of our self-insured retention and deductibles in connection with general and professional liability claims. We also have implemented a self-insurance program for workers compensation in all states, and elected non-subscriber status for workers compensation in Texas. Due to the nature of our business and the residents we serve, including the risk of claims from residents as well as potential governmental action, it may be difficult to complete the underwriting process and obtain insurance at commercially reasonable rates. If we are unable to obtain insurance, or if insurance becomes more costly for us to obtain, or if the coverage levels we can economically obtain decline, our business may be adversely affected.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our self-insurance programs may expose us to significant and unexpected costs and losses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have maintained general and professional liability insurance since 2002 and workers compensation insurance since 2005 through a wholly-owned captive insurance subsidiary to insure our self-insurance reimbursements and deductibles as part of a continually evolving overall risk management strategy. We establish the insurance loss reserves based on an estimation process that uses information obtained from both company-specific and industry data. The estimation process requires us to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and our assumptions about emerging trends, we, along with an independent actuary, develop information about the size of ultimate claims based on our historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damages with respect to unpaid claims. It is possible, however, that the actual liabilities may exceed our estimates of loss. We may also experience an unexpectedly large number of successful claims or claims that result in costs or liability significantly in excess of our projections. For these and other reasons, our self-insurance reserves could prove to be inadequate, resulting in liabilities in excess of our available insurance and self-insurance. If a successful claim is made against us and it is not covered by our insurance or exceeds the insurance policy limits, our business may be negatively and materially impacted.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, because our self-insurance reimbursements under our general and professional liability and workers compensation programs applies on a per claim basis, there is no limit to the maximum number of claims or the total amount for which we could incur liability in any policy period.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also self-insure our employee health benefits. With respect to our health benefits self-insurance, our reserves and premiums are computed based on a mix of company specific and general industry data that is not specific to our own company. Even with a combination of limited company-specific loss data and general industry data, our loss reserves are based on actuarial estimates that may not correlate to actual loss experience in the future. Therefore, our reserves may prove to be insufficient and we may be exposed to significant and unexpected losses.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The geographic concentration of our independent subsidiaries could leave us vulnerable to an economic downturn, regulatory changes or acts of nature in those areas. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent subsidiaries located in Arizona, California, and Texas account for the majority of our total revenue. As a result of this concentration, the conditions of local economies and real estate markets, changes in governmental rules, presence and participation of insurers, regulations and reimbursement rates or criteria, changes in demographics, state funding, acts of nature and other factors that may result in a decrease in demand and/or reimbursement for skilled nursing services in these states could have a disproportionately adverse effect on our revenue, costs and results of operations. Moreover, since over 24% of our independent subsidiaries are located in California, we are particularly susceptible to revenue loss, cost increase or damage caused by natural disasters such as electrical power shortages, fires, earthquakes or mudslides, or increased liabilities that may arise from regulations as discussed within Item 1.,<a style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_244"> under </a></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our independent subsidiaries in Iowa, Nebraska, Kansas, South Carolina, Washington and Texas are more susceptible to revenue loss, cost increases or damage caused by natural disasters including hurricanes, tornadoes and flooding. These acts of nature may cause disruption to us, the employees of our independent subsidiaries, which could have an adverse impact on the patients of our independent subsidiaries and our business. In order to provide care for the patients of our independent subsidiaries, we are dependent on consistent and reliable delivery of food, pharmaceuticals, utilities and other goods to our independent subsidiaries, and the availability of employees to provide services. If the delivery of goods or the ability of employees to reach our independent subsidiaries were interrupted in any material respect due to a natural disaster or other reasons, it would have a significant impact on our independent subsidiaries and our business. Furthermore, the impact, or impending threat, of a natural disaster may require that we evacuate one or more facilities, which would be costly and would involve risks, including potentially fatal risks, for the patients. The impact of disasters and similar events is inherently uncertain. Such events could harm the patients and employees of our independent subsidiaries, severely damage or destroy one or more of our independent subsidiaries, harm our business, reputation and financial performance, or otherwise cause our business to suffer in ways that we currently cannot predict.</span></div><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The actions of a national labor union that has pursued a negative publicity campaign criticizing our business in the past may adversely affect our revenue and our profitability. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to maintain our right to inform the employees of our independent subsidiaries about our views of the potential impact of unionization upon the workplace generally and upon individual employees. Historically, the staff at our independent subsidiaries that have been approached to unionize have uniformly rejected union organizing efforts. Forthcoming proposed rules from CMS, which, based on the Biden-Harris Administration's executive orders discussed under </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Item 1., as well as potential legislation such as the HCBS Access Act aimed toward providing more resources to those considering care-based careers, may increase the likelihood of employee unionization due to increased emphasis on care-based careers in SNF facilities. If employees decide to unionize, our cost of doing business could increase, and we could experience contract delays, difficulty in adapting to a changing regulatory and economic environment, cultural conflicts between unionized and non-unionized employees, strikes and work stoppages, and we may conclude that affected facilities or operations would be uneconomical to continue operating.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we lease the majority of our independent subsidiaries, we are subject to risks associated with leased real property, including risks relating to lease termination, lease extensions and special charges, any of which could adversely affect our business, financial position or results of operations.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, we leased 214 of our 297 independent subsidiaries. Most of our leases are triple-net leases, which means that, in addition to rent, we are required to pay for the costs related to the property (including property taxes, insurance, and maintenance and repair costs). We are responsible for paying these costs notwithstanding the fact that some of the benefits associated with paying these costs accrue to the landlords as owners of the associated facilities.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each lease provides that the landlord may terminate the lease for a variety of reasons, including the default in any payment of rent, taxes or other payment obligations or the breach of any other covenant or agreement in the lease. Termination of a lease could result in a default under our debt agreements and could adversely affect our business, financial position or results of operations. There can be no assurance that we will be able to comply with all of our obligations under the leases in the future.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to generate sufficient cash flow to cover required payments or meet operating covenants under our long-term debt, mortgages and long-term operating leases could result in defaults under such agreements and cross-defaults under other debt, mortgage or operating lease arrangements, which could harm our independent subsidiaries and cause us to lose facilities or experience foreclosures. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Credit Facility has a borrowing capacity of up to $600.0 million in aggregate principal amount. As of December&#160;31, 2023 and through the filing date of this report, we had no outstanding borrowings under our Credit Facility. Twenty-three of our subsidiaries have mortgage loans insured with the Department of Housing and Urban Development (HUD) for an aggregate amount of $150.2 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The terms of the mortgage loans range from 25- to 35-years.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also have one outstanding promissory note with an aggregate principal amount of approximately $2.1 million as of December&#160;31, 2023. The term of the note is 12 years. Because this promissory note is insured with HUD, our borrower subsidiary under the note is subject to HUD oversight and periodic inspections. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we had $2.7 billion of future operating lease obligations as of December&#160;31, 2023. We intend to continue financing our independent subsidiaries through mortgage financing, long-term operating leases and other types of financing, including borrowings under our lines of credit and future credit facilities we may obtain. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not generate sufficient cash flow from operations to cover required interest, principal and lease payments. In addition, our outstanding Credit Facility and mortgage loans contain restrictive covenants and require us to maintain or satisfy specified coverage tests on a consolidated basis and on a facility or facilities basis. These restrictions and operating covenants include, among other things, requirements with respect to occupancy, debt service coverage, project yield, net leverage ratios, minimum interest coverage ratios and minimum asset coverage ratios. These restrictions may interfere with our ability to obtain additional advances under our Credit Facility or to obtain new financing or to engage in other business activities, which may inhibit our ability to grow our business and increase revenue.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the financial performance of one or more of our mortgaged facilities may not comply with the required operating covenants under the terms of the mortgage. Any non-payment, noncompliance or other default under our financing arrangements could, subject to cure provisions, cause the lender to foreclose upon the facility or facilities securing such indebtedness or, in the case of a lease, cause the lessor to terminate the lease, each with a consequent loss of revenue and asset value to us or a loss of property. Furthermore, in many cases, indebtedness is secured by both a mortgage on one or more facilities, and a guaranty by us. In the event of a default under one of these scenarios, the lender could avoid judicial procedures required to foreclose on real property by declaring all amounts outstanding under the guaranty immediately due and payable, and requiring us to fulfill our obligations to make such payments. If any of these scenarios were to occur, our financial condition would be adversely affected. For tax purposes, a foreclosure on any of our properties would be treated as a sale of the property for a price equal to the outstanding balance of the debt secured by the mortgage. If the outstanding balance of the debt secured by the mortgage exceeds our tax basis in the property, we would recognize taxable income on foreclosure, but would not receive any cash proceeds, which would negatively impact our earnings and cash position. Further, because our mortgages and operating leases generally contain cross-default and cross-collateralization provisions, a default by us related to one facility could affect a significant number of other facilities and their corresponding financing arrangements and operating leases.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because our term loans, promissory note, bonds, mortgages and lease obligations are fixed expenses and secured by specific assets, and because our revolving loan obligations are secured by virtually all of our assets, if reimbursement rates, patient acuity mix or occupancy levels decline, or if for any reason we are unable to meet our loan or lease obligations, we may not be able to cover our costs and some or all of our assets may become at risk. Our ability to make payments of principal and interest on our indebtedness and to make lease payments on our operating leases depends upon our future performance, which will be subject to general economic conditions, industry cycles and financial, business and other factors affecting our independent subsidiaries, many of which are beyond our control. If we are unable to generate sufficient cash flow from operations in the future to service our debt or to make lease payments on our operating leases, we may be required, among other things, to seek additional financing in the debt or equity markets, refinance or restructure all or a portion of our indebtedness, sell selected assets, reduce or delay planned capital expenditures or delay or abandon desirable acquisitions. Such measures might not be sufficient to enable us to service our debt or to make lease payments on our operating leases. The failure to make required payments on our debt or operating leases or the delay or abandonment of our planned growth strategy could result in an adverse effect on our future ability to generate revenue and sustain profitability. In addition, any such financing, refinancing or sale of assets might not be available on terms that are economically favorable to us, or at all. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Move-in and occupancy rates may remain unpredictable even after the COVID-19 pandemic is over.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Occupancy levels at our operations have not returned to pre-COVID-19 rates despite the end of the PHE. Facilities experiencing decreases in move-in rates cite resident or family member concerns as the basis for such decreases. These and other similar concerns may continue to impact our ability to attract new residents and our ability to retain existing residents.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A housing downturn could decrease demand for senior living services. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seniors often use the proceeds of home sales to fund their admission to senior living facilities. A downturn in the housing markets, including reductions in sales prices caused by increasing mortgage interest rates, economic uncertainty, recession, or a reduction in activity in the market for residential real estate, could adversely affect seniors&#8217; ability to afford our resident fees and entrance fees. If national or local housing markets enter a persistent decline, our occupancy rates, revenues, results of operations and cash flow could be negatively impacted. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As we continue to acquire and lease real estate assets, we may not be successful in identifying and consummating these transactions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We lease 30 of our properties to third-party operators.&#160;In the future, we might expand our leasing property portfolio to additional tenants. We have very limited control over the success or failure of our tenants&#8217; and operators&#8217; businesses and, at any time, a tenant or operator may experience a downturn in its business that weakens its financial condition. If that happens, the tenant or operator may fail to make its payments to us when due. Although our lease agreements give us the right to exercise certain remedies in the event of default on the obligations owing to us, we may determine not to do so if we believe that enforcement of our rights would be more detrimental to our business than seeking alternative approaches.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An important part of our business strategy is to continue to expand and diversify our real estate portfolio through accretive acquisition and investment opportunities in healthcare properties. Our execution of this strategy by successfully identifying, securing and consummating beneficial transactions is made more challenging by increased competition and can be affected by many factors, including our relationships with current and prospective tenants, our ability to obtain debt and equity capital at costs comparable to or better than our competitors and our ability to negotiate favorable terms with property owners seeking to sell and other contractual counterparties. Our competitors for these opportunities include healthcare REITs, real estate partnerships, healthcare providers, healthcare lenders and other investors, including developers, banks, insurance companies, pension funds, government-sponsored entities and private equity firms, some of whom may have greater financial resources and lower costs of capital than we do. Potential regulations may affect the ability of these entities, as well as ourselves, to compete for these opportunities or enter into transactions for real estate related to our business. If we are unsuccessful at identifying and capitalizing on investment or acquisition opportunities, our growth and profitability in our real estate investment portfolio may be adversely affected.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in and acquisitions of healthcare properties entail risks associated with real estate investments generally, including risks that the investment will not achieve expected returns, that the cost estimates for necessary property improvements will prove inaccurate or that the tenant or operator will fail to meet performance expectations.&#160;Income from properties and yields from investments in our properties may be affected by many factors, including changes in governmental regulation (such as licensing and government payment), general or local economic conditions (such as fluctuations in interest rates, senior savings, and employment conditions), the available local supply of and demand for improved real estate, a reduction in rental income as the result of an inability to maintain occupancy levels, natural disasters (such as hurricanes, earthquakes and floods) or similar factors. Furthermore, healthcare properties are often highly customized, and the development or redevelopment of such properties may require costly tenant-specific improvements. As a result, we cannot assure you that we will achieve the economic benefit we expect from acquisition or investment opportunities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">As we expand our presence in other relevant healthcare industries, we would become subject to risks in a market in which we have limited experience. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our independent subsidiaries have historically been SNFs. As we expand our presence in other relevant healthcare industries, our existing overall business model will continue to change and expose our company to risks in markets in which we have limited experience, such as the Eliminating Kickbacks in Recovery Act and other state laws that are not as well-developed in regulation and decisional authority as their federal equivalents. We expect that we will have to adjust certain elements of our existing business model, which could have an adverse effect on our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our referral sources fail to view us as an attractive skilled nursing provider, or if our referral sources otherwise refer fewer patients, our patient base may decrease. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely significantly on appropriate referrals from hospitals, physicians, and other healthcare providers in the communities in which we deliver our services to attract appropriate residents and patients to our independent subsidiaries. Our referral sources are not obligated to refer business to us and may refer business to other healthcare providers. We believe many of our referral sources refer business to us as a result of the quality of our patient care and our efforts to establish and build a relationship with our referral sources. If we lose, or fail to maintain, existing relationships with our referral resources, fail to develop new relationships, or if we are perceived by our referral sources as not providing high quality patient care, our occupancy rate and the quality of our patient mix could suffer. In addition, if any of our referral sources have a reduction in patients whom they can refer due to a decrease in their business, our occupancy rate and the quality of our patient mix could suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional capital to fund our independent subsidiaries and finance our growth, and we may not be able to obtain it on terms acceptable to us, or at all, which may limit our ability to grow. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to maintain and enhance our independent subsidiaries and equipment in a suitable condition to meet regulatory standards, operate efficiently and remain competitive in our markets requires us to commit substantial resources to continued investment in our independent subsidiaries and equipment. We are sometimes more aggressive than our competitors in capital spending to address issues that arise in connection with aging and obsolete facilities and equipment. In addition, continued expansion of our business through the acquisition of existing facilities, expansion of our existing facilities and construction of new facilities may require additional capital, particularly if we were to accelerate our acquisition and expansion plans. Financing may not be available to us or may be available to us only on terms that are not favorable, including being subject to interest rates that are higher than those incurred in the recent past. In addition, some of our outstanding indebtedness and long-term leases restrict, among other things, our ability to incur additional debt. If we are unable to raise additional funds or obtain additional funds on terms acceptable to us, we may have to delay or abandon some or all of our growth strategies. Further, if additional funds are raised through the issuance of additional equity securities, the percentage ownership of our stockholders would be diluted. Any newly issued equity securities may have rights, preferences or privileges senior to those of our common stock.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The condition of the financial markets, including volatility and deterioration in the capital and credit markets, could limit the availability of debt and equity financing sources to fund the capital and liquidity requirements of our business, as well as negatively impact or impair the value of our current portfolio of cash, cash equivalents and investments, including U.S. Treasury securities and U.S.-backed investments.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and investments are held in a variety of interest-bearing instruments, including U.S. treasury securities. As a result of the uncertain domestic and global political, economic, credit and financial market conditions, including the significant increases in the federal funds rate since 2021, an increase in the Consumer Price Index of 7% in 2022, expected Consumer Price Index increases above historical norms for 2023, investments in these types of financial instruments pose risks arising from liquidity and credit concerns. Given that future deterioration in the U.S. and global credit and financial markets is a possibility, no assurance can be made that losses or significant deterioration in the fair value of our cash, cash equivalents, or investments will not occur. Uncertainty surrounding the trading market for U.S. government securities or impairment of the U.S. government's ability to satisfy its obligations under such treasury securities could impact the liquidity or valuation of our current portfolio of cash, cash equivalents, and investments, a substantial portion of which were invested in U.S. treasury securities. Further, continued domestic and international political uncertainty, along with credit, and financial market uncertainty, may make it difficult for us to liquidate our investments prior to their maturity without incurring a loss, which would have a material adverse effect on our consolidated financial position, results of operations or cash flows.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may need additional capital if a substantial acquisition or other growth opportunity becomes available or if unexpected events occur or opportunities arise. U.S. capital markets can be volatile. We cannot assure you that additional capital will be available or available on terms acceptable to us. If capital is not available, we may not be able to fund internal or external business expansion or respond to competitive pressures or other market conditions.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in reimbursement may cause liquidity problems. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience problems with our billing information systems or if issues arise with Medicare, Medicaid or other payors, we may encounter delays in our payment cycle. From time to time, we have experienced such delays as a result of government payors instituting planned reimbursement delays for budget balancing purposes or as a result of prepayment reviews. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some states in which we operate are operating with budget deficits or could have budget deficit in the future, which may delay reimbursement in a manner that would adversely affect our liquidity. In addition, from time to time, procedural issues require us to resubmit or appeal claims before payment is remitted, which contributes to our aged receivables. Unanticipated delays in receiving reimbursement from state programs or commercial payors due to changes in their policies or billing or audit procedures may adversely impact our liquidity and working capital.</span></div><div style="margin-top:10pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The continued use and growth of managed care organizations (MCOs) may contribute to delays or reductions in our reimbursement, including Managed Medicaid.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In forty-one states, including some of the largest where we operate, state Medicaid benefits are administered through MCOs. Typically, these MCOs manage commercial health and federal Medicare Advantage benefits under a managed care contract. Nationally, MCOs cover approximately 57 million and 30 million Medicaid and Medicare Advantage beneficiaries, respectively. MCOs may be more aggressive than state Medicaid and federal Medicare agencies in denying claims or seeking recoupment of payments so that their services under these managed contracts are profitable. The additional steps created by the use of MCOs in disbursement of funds creates more risk of delayed, reduced, or recouped payments for our independent subsidiaries, and additional avenues for risks that include fines and other sanctions, including suspension or exclusion from participation in various governmental programs.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with the regulations of the Department of Housing and Urban Development may require us to make unanticipated expenditures which could increase our costs.</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Twenty-three of our independent subsidiaries are currently subject to regulatory agreements with HUD that give the Commissioner of HUD broad authority to require us to be replaced as the operator of those facilities in the event that the Commissioner determines there are operational deficiencies at such facilities under HUD regulations. Compliance with HUD's requirements can often be difficult because these requirements are not always consistent with the requirements of other federal and state agencies. Appealing a failed inspection can be costly and time-consuming and, if we do not successfully remediate the failed inspection, we could be precluded from obtaining HUD financing in the future or we may encounter limitations or prohibitions on our operation of HUD-insured facilities. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to safeguard the monies held in our patient trust funds, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our independent subsidiaries is required by federal law to maintain a patient trust fund to safeguard certain assets of their residents and patients. If any money held in a patient trust fund is misappropriated, we are required to reimburse the patient trust fund for the amount of money that was misappropriated. If any monies held in our patient trust funds are misappropriated in the future and are unrecoverable, we will be required to reimburse such monies, and we may be subject to citations, fines and penalties pursuant to federal and state laws.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a holding company with no operations and rely upon our multiple independent subsidiaries to provide us with the funds necessary to meet our financial obligations. Liabilities of any one or more of our subsidiaries could be imposed upon us or our other subsidiaries.</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a holding company with no direct operating assets, employees or revenue. Each of our independent subsidiaries is operated through a separate, wholly-owned, independent subsidiary, which has its own management, employees and assets. Our principal assets are the equity interests we directly or indirectly hold in our multiple operating and real estate holding subsidiaries. As a result, we are dependent upon distributions from our subsidiaries to generate the funds necessary to meet our financial obligations and pay dividends. Our subsidiaries are legally distinct from us and have no obligation to make funds available to us. The ability of our subsidiaries to make distributions to us will depend substantially on their respective operating results and will be subject to restrictions under, among other things, the laws of their jurisdiction of organization, which may limit the amount of funds available for distribution to investors or stockholders, agreements of those subsidiaries, the terms of our financing arrangements and the terms of any future financing arrangements of our subsidiaries.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the separation of Pennant fails to qualify as generally tax-free for U.S. federal income tax purposes, we and our stockholders could be subject to significant tax liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The spin-off in 2019 is intended to qualify for tax-free treatment to us and our stockholders for U.S. federal income tax purposes. Accordingly, completion of the transaction was conditioned upon, among other things, our receipt of opinions from outside tax advisors that the distributions would qualify as a transaction that is intended to be tax-free to both us and our stockholders for U.S. federal income tax purposes under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code. The opinions were based on and relied on, among other things, certain facts and assumptions, as well as certain representations, statements and undertakings, including those relating to the past and future conduct. If any of these facts, assumptions, representations, statements or undertakings is, or becomes, inaccurate or incomplete, or if any of the parties' breach any of their respective covenants relating to the transactions, the tax opinions may be invalid. Moreover, the opinions are not binding on the IRS or any courts. Accordingly, notwithstanding receipt of the opinion, the IRS could determine that the distribution and certain related transactions should be treated as taxable transactions for U.S. federal income tax purposes.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the spin-off fails to qualify as a transaction that is generally tax-free under Sections 355 and 368(a)(1)(D) of the Internal Revenue Code, in general, for U.S. federal income tax purposes, we would recognize taxable gain with respect to the distributed securities and our stockholders who received securities in such distribution would be subject to tax as if they had received a taxable distribution equal to the fair market value of such shares.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have obligations to provide indemnification to a number of parties as a result of the transaction. Any indemnity obligations for tax issues or other liabilities related to the spin-off, could be significant and could adversely impact our business.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain directors who serve on our Board of Directors also serve as directors of Pennant, and ownership of shares of Pennant common stock by our directors and executive officers may create, or appear to create, conflicts of interest.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our directors who serve on our Board of Directors also serve on the board of directors of Pennant. This may create, or appear to create, conflicts of interest when our, or Pennant's management and directors face decisions that could have different implications for us and Pennant, including the resolution of any dispute regarding the terms of the agreements governing the spin-off transaction and the relationship between us and Pennant after the spin-off transaction or any other commercial agreements entered into in the future between us and Pennant and the allocation of such directors&#8217; time between us and Pennant.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our executive officers and some of our non-employee directors own shares of the common stock of Pennant. The continued ownership of such common stock by our directors and executive officers following the spin-off creates, or may create, the appearance of a conflict of interest when these directors and executive officers are faced with decisions that could have different implications for us and Pennant.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If Standard Bearer fails to qualify or remain qualified as a REIT, it will be subject to U.S. federal income tax as a regular corporation and could face substantial tax liability.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer currently operates, and intends to continue to operate, in a manner that allows it to qualify to be taxed as a REIT for U.S. federal income tax purposes. Standard Bearer elected to be taxed as a REIT for U.S. federal income tax purposes beginning with its taxable year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If Standard Bearer fails to qualify to be taxed as a REIT in any year, it would be subject to U.S. federal income tax, including any applicable alternative minimum tax, on our taxable income at regular corporate rates, and dividends paid to its shareholders would not be deductible by it in computing its taxable income. Any resulting corporate liability could be substantial and would reduce the amount of cash available for distribution to its shareholders. Unless it was entitled to relief under certain Code provisions, it also would be disqualified from re-electing to be taxed as a REIT for the four taxable years following the year in which it failed to qualify to be taxed as a REIT.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or other actions affecting REITs could have a negative effect on Standard Bearer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rules dealing with U.S. federal income taxation are constantly under review by persons involved in the legislative process and by the IRS and the U.S. Department of the Treasury (Treasury). Changes to the tax laws or interpretations thereof, with or without retroactive application, could materially and adversely affect Standard Bearer's investors or Standard Bearer. We cannot predict how changes in the tax laws, including any tax reform called for by the current presidential administration, might affect Standard Bearer or its investors. New legislation, Treasury regulations, administrative interpretations or court decisions could significantly and negatively affect its ability to qualify to be taxed as a REIT or the U.S. federal income tax consequences to Standard Bearer or its investors of such qualification. For instance, the Tax Cuts and Jobs Act (TCJA) significantly changed the U.S. federal income tax laws applicable to businesses and their owners, including REITs and their shareholders. Technical corrections or other amendments to the TCJA or administrative guidance interpreting the TCJA may be forthcoming at any time. We cannot predict the long-term effect of the TCJA or any future law changes on REITs or their shareholders. Changes to the U.S. federal tax laws and interpretations thereof, whether under the TCJA or otherwise, could adversely affect an investment in our stock. Additionally, REIT's that are related to our operation will likely be subject to the disclosure requirements of CMS's ownership transparency final rule, and may subject these REITs to additional public scrutiny. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No prediction can be made regarding whether new legislation or regulation (including new tax measures) will be enacted by legislative bodies or governmental agencies, nor can we predict what consequences would result from this legislation or regulation. Accordingly, no assurance can be given that the currently anticipated tax treatment of an investment will not be modified by legislative, judicial or administrative changes, possibly with retroactive effect.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer could fail to qualify to be taxed as a REIT if income it receives from our tenants is not treated as qualifying income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable provisions of the Code, Standard Bearer will not be treated as a REIT unless it satisfies various requirements, including requirements relating to the sources of its gross income. Rents received or accrued by it from its tenants will not be treated as qualifying rent for purposes of these requirements if the leases are not respected as true leases for U.S. federal income tax purposes and are instead treated as service contracts, joint ventures or other arrangements. If the leases are not respected as true leases for U.S. federal income tax purposes, Standard Bearer will likely fail to qualify to be taxed as a REIT.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if Standard Bearer remains qualified as a REIT, it may face other tax liabilities that reduce its cash flow.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if Standard Bearer remain qualified for taxation as a REIT, it may be subject to certain U.S. federal, state, and local taxes on its income and assets, including taxes on any undistributed income and state or local income, property and transfer taxes. For example, Standard Bearer may hold some of its assets or conduct certain of its activities through one or more taxable REIT subsidiaries (each, a TRS) or other subsidiary corporations that will be subject to U.S. federal, state, and local corporate-level income taxes as regular C corporations. In addition, it may incur a 100% excise tax on transactions with a TRS if they are not conducted on an arm&#8217;s-length basis. Any of these taxes would decrease cash available for distribution to its shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Ownership of our Common Stock</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to pay or maintain dividends and the failure to do so would adversely affect our stock price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to pay and maintain cash dividends is based on many factors, including our ability to make and finance acquisitions, our ability to negotiate favorable lease and other contractual terms, anticipated operating cost levels, the level of demand for occupancy at our facilities, the rates we charge and actual results that may vary substantially from estimates. Some of the factors are beyond our control and a change in any such factor could affect our ability to pay or maintain dividends. The Credit Facility restricts our ability to pay dividends to stockholders if we receive notice that we are in default under the agreement. The failure to pay or maintain dividends could adversely affect our stock price.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law contain provisions that could discourage transactions resulting in a change in control, which may negatively affect the market price of our common stock. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that may enable our Board of Directors to resist a change in control. These provisions may discourage, delay or prevent a change in the ownership of our company or a change in our management, even if doing so might be beneficial to our stockholders. In addition, these provisions could limit the price that investors would be willing to pay in the future for shares of our common stock. Such provisions set forth in our amended and restated certificate of incorporation or our amended and restated bylaws include: </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">our Board of Directors is authorized, without prior stockholder approval, to create and issue preferred stock, commonly referred to as &#8220;blank check&#8221; preferred stock, with rights senior to those of common stock;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">advance notice requirements for stockholders to nominate individuals to serve on our Board of Directors or to submit proposals that can be acted upon at stockholder meetings;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">our Board of Directors is classified so not all members of our board are elected at one time, which may make it more difficult for a person who acquires control of a majority of our outstanding voting stock to replace our directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">stockholder action by written consent is limited;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">special meetings of the stockholders are permitted to be called only by the chairman of our Board of Directors, our chief executive officer or by a majority of our Board of Directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">stockholders are not permitted to cumulate their votes for the election of directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">newly created directorships resulting from an increase in the authorized number of directors or vacancies on our Board of Directors are filled only by majority vote of the remaining directors;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">our Board of Directors is expressly authorized to make, alter or repeal our bylaws; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-13.5pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:8.52pt">stockholders are permitted to amend our bylaws only upon receiving the affirmative vote of at least a majority of our outstanding common stock.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to the anti-takeover provisions of Section 203 of the General Corporation Law of the State of Delaware. Under these provisions, if anyone becomes an &#8220;interested stockholder,&#8221; we may not enter into a &#8220;business combination&#8221; with that person for three years without special approval, which could discourage a third-party from making a takeover offer and could delay or prevent a change of control. For purposes of Section 203, &#8220;interested stockholder&#8221; means, generally, someone owning more than 15% or more of our outstanding voting stock or an affiliate of ours that owned 15% or more of our outstanding voting stock during the past three years, subject to certain exceptions as described in Section 203.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other provisions in our amended and restated certificate of incorporation, amended and restated bylaws and Delaware law could discourage acquisition proposals and make it more difficult or expensive for stockholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board of Directors, including delaying or impeding a merger, tender offer or proxy contest involving us. Any delay or prevention of a change of control transaction or changes in our Board of Directors could cause the market price of our common stock to decline.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_358"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. UNRESOLVED STAFF COMMENTS </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_3514"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. CYBERSECURITY</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We utilize information technology that enables our operational leaders to access and share with their peers, both clinical and financial performance data in real time. Armed with relevant and current information, our operation leaders and their management teams can share best practices and the latest information, adjust to challenges and opportunities on a timely basis, improve quality of care, mitigate risk and improve both clinical outcomes and financial performance. We have also invested in specialized healthcare technology systems to assist our nursing and support staff. We have installed software and touch-screen interface systems in each operation to enable our clinical staff to monitor and deliver patient care and record patient information more efficiently. We believe these systems have improved the quality of our medical and billing records, while improving the productivity of our staff. Such uses of information systems give rise to cybersecurity risks, including system disruption, security breach, ransomware, theft, espionage and inadvertent release of information. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK MANAGEMENT AND STRATEGY </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess and identify security risk to the organization by: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">conducting assessments of risk including likelihood and magnitude from unauthorized access, use, disclosure, disruption, modification or destruction of information systems and the related information processes, stored, or transmitted. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">performing risk assessments and producing security assessment reports that document the results of the assessment for use and review by information technology (IT) senior leadership, including the Service Center's Chief Information Officer. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">ensuring security controls are assessed for effectiveness, are implemented correctly, operating as intended and producing the desired outcome; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">continuously scanning for vulnerabilities and remedying all vulnerabilities in accordance with the associated risk. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Monitoring</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established a continuous monitoring strategy and program, which includes: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a set of defined security metrics to be monitored. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">performance of security control assessments on an ongoing basis. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">addressing results of analysis and reporting security status to the executive team. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">monitoring information systems to detect attacks and indicators of potential attacks. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">identification of unauthorized use of the information system resources; and </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">deployment of monitoring devices strategically within the information system environment. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data Protection </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have implemented an Information Security Management System (ISMS) Program to secure sensitive data protected by us. This program includes: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Establishing policies governing data security. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Monitoring data access throughout the organization&#8217;s independent subsidiaries. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Providing continuous security training and awareness. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Establishing controls over devices on the network which are actively tracked, monitored and evaluated for new, missing, or updated software needed to strengthen security on the device, patch known vulnerabilities, or stabilize software or operating system issues. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Protecting sensitive data through encryption techniques. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Designing and implementing systems to include backup and recoverability principles, such as periodic data backups and safeguards in the case of a disaster. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incident Management Plan </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cybersecurity incident management plan comprises the following six-step process: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Service Center's Chief Information Officer and Director of Information Security lead its Information Security Office (ISO) team in the development, documentation, review and testing of security procedures and incident management procedures. Beyond initial creation, procedures are continually re-assessed, updated and tested on an ongoing basis. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Service Center's Chief Information Officer and Director of Information Security work with the Executive Team on the identification, assessment, verification and classification of incidents to determine affected stakeholders and appropriate parties for contact. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Service Center's Chief Information Officer and Director of Information Security are responsible for launching the Incident Response Team (IRT) if necessary and for notification to the Executive Team, who in turn will contact the Board of Directors and the Audit Committee to validate that the response is being addressed appropriately. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The IRT, in consultation with outside experts if needed, is responsible for the following: </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Initial containment by making tactical changes to the computing environment to mitigate active threats based on currently known information. </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Analysis to establish the root cause of incidents, identification and evidence collection from all affected machines and log sources, threat intelligence and other information sources. Once all appropriate information has been collected, we perform a careful analysis using forensically-sound tools and methods to prevent any contamination of evidence. </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Incident containment by further analyzing additional information and further identifying any additional compromised machines or resources not previously identified. </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Incident eradication by re-assessing the root cause of incidents where solutions are then implemented to solve underlying problems and prevent re-occurrence. </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Recovery and restoring normal business functionality, which includes the reversal of any damage caused by the incident and responding as necessary. </span></div><div style="margin-bottom:3pt;padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.27pt">Review after closure of each incident and conducting a lessons learned analysis to improve prevention and help to make incident response processes more efficient and effective. Also, the IRT evaluates competency and any additional training requirements needed. A final incident report will then be provided to key stakeholders and IRT members, which includes, but is not limited to the summary of the incident and its impact, a timeline of events, a detailed description of the incident, an evaluation of the organizational response and an assessment of the damages. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have not experienced a material cybersecurity breach in the past five years and, as a result, there have been no charges related to a breach in the past five years. Moreover, no risks from cybersecurity threats have materially affected our business strategy, results of operations, or financial condition.  While we have implemented processes and procedures that we believe are tailored to address and mitigate the cybersecurity threats that our Company faces, there can be no assurances that such an incident will not occur despite our efforts, as more fully described in Item 1A. Risk Factors.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNANCE</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Audit Committee receives quarterly reports on our information security and cyber fraud prevention programs from the Service Center's Chief Information Officer and Director of Information Security, who each have over 24 years of experience in IT, including various leadership roles at other large corporations. One of the three members of our Audit Committee is a cybersecurity expert.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ISO has been established by the Service Center's Chief Information Officer, with dedicated cyber security staff focusing on security monitoring, vulnerability management, incident response, risk assessments, employee training, security engineering and management of cyber security policies, standards and regulatory compliance. Like many organizations, we align to a Cyber Security Framework and take a risk-based approach during control assessment and implementation. We align to the National Institute of Standards and Technology (NIST) Special Publication 800-53 Revision 4, a globally recognized cyber security framework of Policies, Standards and Controls that comprises of five categories of defense &#8211; Identify, Protect, Detect, Respond and Recover. We are committed to the protection of our data, systems, network and continually invest in enhancements to mitigate or reduce the impact from a cyber security threat. We conduct periodic tests to maintain readiness and resiliency while regularly reviewing policies in the interest of protecting data security. External companies or agencies may be called upon to provide consulting, guidance, assistance, or some other form of support in response to a cybersecurity incident. The regular training of employees, at least annually, on the ever-present threat of cybersecurity helps maintain data security. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_361"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160; PROPERTIES</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Center </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Our primary Service Center is located at our San Juan Capistrano, California campus, which we acquired for a purchase price of $31.0 million to accommodate our growing Service Center team. The property consists of approximately 108,058 square feet of usable office space. In addition, we lease a portion of the space within the campus to third-party tenants. We also have service centers located in Tempe, Arizona, San Antonio, Texas and Salt Lake City, Utah.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Facilities </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate 297 independent subsidiaries in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, with the operational capacity to serve approximately 34,000 patients as of December&#160;31, 2023. Of the 297 facilities, we operate 214 facilities under long-term lease arrangements and have options to purchase 11 of those 214 facilities.  The results of our independent subsidiaries are reflected in our skilled services segment for our skilled nursing operations and in the "All Other" category for our senior living operations. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summary information regarding the location of our facilities, operational beds and units by property type as of December&#160;31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.274%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:9.133%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.143%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operated Facilities </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leased without a Purchase Option </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Leased with a Purchase Option</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owned </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="6" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beds/Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facilities</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beds/Units</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,734</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,227</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,961</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,929</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">714</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,914</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,557</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,336</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,930</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,311</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,668</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">582</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">203</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,377</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,323</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,723</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the location of our facilities and the number of operational beds and units located at our skilled nursing, senior living and campus facilities as of December&#160;31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.969%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.599%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Facility Counts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Bed / Unit Counts </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Nursing Operations</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Communities </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Campus Operations</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Nursing Beds </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Senior Living Units </span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Beds / Units</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,961</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,954</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">603</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,557</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,535</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">731</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,266</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,986</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">723</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,709</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,413</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">413</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">341</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,126</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">259</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">297</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,602</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,121</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33,723</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Real Estate Properties </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As of December&#160;31, 2023, we owned 113 real estate properties in Arizona, California, Colorado, Idaho, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin, which include 83</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">of the 297 facilities that we operate and manage. Of our 113 real estate properties, 30 operations are leased to and operated by third-party operators. One senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate. We further own the real estate property of our Service Center's California location and continue to lease a portion of the office space to third-party tenants. Our Standard Bearer segment reflects the results of operations for 108 of the 113 owned real estate properties. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides summary information regarding the location of our owned real estate properties as of December&#160;31, 2023: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.618%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owned and Operated by Ensign</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Owned and Leased to Third-Party Operators</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Service Center</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Properties</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Colorado </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington </span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Idaho </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kansas </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">83</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">113</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) One senior living operation in Texas, which is owned by Ensign and leased to a third-party operator, is located on the same real estate property as a skilled nursing facility that we own and operate. In this situation, the senior living operation is included in the total under "Owned and Leased to Third Party Operators" and the skilled nursing operation is included in the total under "Owned and Operated by Ensign", however, the amount reflected under "Total Properties" only recognizes the operation as a single property.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_301"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160; LEGAL PROCEEDINGS </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we enter into certain types of contracts that contingently require us to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which we may be required to indemnify property owners or prior facility operators for post-transfer environmental or other liabilities and other claims arising from our use of the applicable premises, (ii) operations transfer agreements, in which we agree to indemnify past operators of facilities we acquire against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to our independent subsidiary, (iii) certain lending agreements, under which we may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with our officers, directors and others, under which we may be required to indemnify such persons for liabilities based on the nature of their relationship to us. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on our balance sheets for any of the periods presented.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off transaction in 2019, certain landlords required, in exchange for their consent to the transaction, that our lease guarantees remain in place for a certain period of time following the spin-off. These guarantees could result in significant additional liabilities and obligations for us if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action with fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by our independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of our independent subsidiaries in late November 2023. We intend to appeal the verdict. We have in the past appealed and have in some circumstances received returned decisions in our favor. Although we intend to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which we have or have had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that we and or our independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing and post-acute care industry is heavily regulated. As such, we and our independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. We believe that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on our financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, we and our independent subsidiaries received a document and information request from the House Select Subcommittee. We and our independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, we and our independent subsidiaries received follow up requests for additional documents and information. We and our independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also, we, on behalf of our independent subsidiaries, received a Civil Investigative Demand (CID) from the U.S. Department of Justice (DOJ) in January of 2024 indicating that the DOJ is investigating the Company to determine whether we have caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016 to the present. As a general matter, our independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including, but not limited to those relating to the presentation of claims for reimbursement for services provided. We intend to fully cooperate with the DOJ in response to the CID. However, we cannot predict the outcome of the investigation or its potential impact to the consolidated financial statements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, we and our independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on our financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on May 31, 2018, we, on behalf of our independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of our independent subsidiaries and persons who serve or have served as medical directors. We fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, we were advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding our success in early pre-trial motions, we continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, we entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48.0 million, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or our independent subsidiaries, and we maintain that we have and continue to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS). </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, we and our independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets where our independent subsidiaries do business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and our independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action &#8220;staffing&#8221; suits have the potential to result in large jury verdicts and settlements. We expect the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our independent subsidiaries have been, and continue to be, subject to claims, findings and legal actions that arise in the ordinary course of the various businesses, including in connection with the delivery of healthcare and non-healthcare services. These claims include but are not limited to potential claims related to patient care and treatment (professional negligence claims) as well as employment related claims. In addition, we and our independent subsidiaries, and others in the industry, are subject to claims and lawsuits in connection with COVID-19 and facility preparation for and/or response to the COVID-19 pandemic. While we have been able to settle or otherwise resolve many of these types of claims without an ongoing material adverse effect on our business, a significant increase in the number of these claims, or an increase in the amounts owing should plaintiffs be successful in their prosecution of remaining or future claims, could materially adversely affect our business, financial condition, results of operations and cash flows. In addition, these claims could impact our ability to procure insurance to cover our exposure related to the various services provided by our independent subsidiaries to their residents, customers and patients.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims and suits, including class actions, continue to be filed against our independent subsidiaries and other companies in the post-acute care industry. We and our independent subsidiaries have been subjected to, and/or are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour law as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and other such similar causes of action. We do not believe that the ultimate resolution of these actions will have a material adverse effect on our business, cash flows, financial condition or results of operations. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments resulting from reviews conducted via RAC, Program Safeguard Contractors, and Medicaid Integrity Contractors (collectively referred to as Reviews). For several months during the COVID-19 pandemic, CMS suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. We anticipate that these Reviews could increase in frequency in the future. As of December 31, 2023, and through the filing date of this report, 40 of our independent subsidiaries had Reviews scheduled or in process. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, CMS announced a new nationwide audit, the &#8220;SNF 5-Claim Probe &amp; Educate Review&#8221;, in which the Medicare Administrative Contractors will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe &amp; Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a &#8220;misunderstanding&#8221; by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than the three rounds that typically occur in the TPE Program. Additionally, CMS&#8217;s education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program will apply only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_319"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160; MINE SAFETY DISCLOSURES </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_298"></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART II.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_370"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.&#160;&#160;&#160;&#160; MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:9pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has been traded under the symbol &#8220;ENSG&#8221; on the NASDAQ Global Select Market since our initial public offering on November&#160;8, 2007. Prior to that time, there was no public market for our common stock. As of January&#160;29, 2024, there were approximately 315 holders of record of our common stock. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notwithstanding anything to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, including the Annual Report on Form 10-K, in whole or in part, the Stock Performance Graph and supporting data which follows shall not be deemed to be incorporated by reference into any such filings except to the extent that we specifically incorporate any such information into any such future filings.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The graph below shows the cumulative total stockholder return of investment of $100 (and the reinvestment of any dividends thereafter) on December 31, 2018 in (i) our common stock, (ii) the Skilled Nursing Facilities Peer Group 1 and (iii) the NASDAQ Market Index. Our stock price performance shown in the graph below is not indicative of future stock price performance.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 1999, we completed the spin-off of two independent publicly traded companies. On June 1, 2014, Ensign completed the spin-off of CareTrust REIT, Inc. (CareTrust) into an independent publicly traded company. On October 1, 2019, Ensign completed the spin-off of The Pennant Group, Inc. (Pennant) with the pro rata distribution of 1.18 shares of Pennant&#8217;s common stock for every share of Ensign&#8217;s common stock to our stockholders, pursuant to which Pennant became an independent company. Pennant's stock traded at $6.15 at opening price on the first day of trading and closed at $15.09. Ensign's stock price was reduced by the same value on the same day. For the purpose of this graph, the effect of the final separation of Pennant is reflected in the cumulative total return of Ensign Common Stock as a reinvested dividend.</span></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPARISON OF 60 MONTH CUMULATIVE TOTAL RETURN*</span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Among Ensign Group, the NASDAQ Composite Index and Our Peer Group</span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">December 2023 </span></div><div style="text-align:center;text-indent:24.75pt"><span><br/></span></div><div style="text-align:center;text-indent:24.75pt"><img src="ensg-20231231_g6.jpg" alt="2018" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:750px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Assumes $100 invested on December 31, 2018 in stock in index, including reinvestment of dividends.</span></div><div style="text-align:center;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Fiscal year ended December 31.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Ensign Group, Inc.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">127.85&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.31&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">238.12&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268.99&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.74&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NASDAQ Market Index</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.69&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.10&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.03&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.17&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peer Group</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123.99&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128.11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141.47&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) The current composition of our Peer Group is as follows: Amedysis, Inc., CareTrust REIT Inc., Encompass Healthcare Corp., LTC Properties, Inc., National Healthcare Corporation, National Health Investors, Inc., Omega Healthcare Investors, Inc., Select Medical Holdings Corp. and Welltower Inc. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) The value displayed only incorporates the value of The Ensign Group, Inc. stock and does not incorporate the value shareholders received in connection with our spin-off of The Pennant Group, Inc. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividend Policy </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have a formal dividend policy, but we currently intend to continue to pay regular quarterly dividends to the holders of our common stock. We have been a dividend-paying company since 2002 and have increased our dividend every year for the last 21 years.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Issuer Repurchases of Equity Securities</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Repurchase Programs </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from September&#160;1, 2023. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. We did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Previously on July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we could repurchase up to $20.0 million of our common stock under the program for a period of approximately 12 months from August&#160;2, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. We did not purchase any shares pursuant to this stock repurchase program. </span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_376"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160; [RESERVED]</span></div><div style="margin-top:10pt;padding-left:4.5pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_241"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.&#160;&#160;&#160;&#160; MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion should be read in conjunction with the consolidated financial statements and accompanying notes, which appear elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Annual Report on Form 10-K. See Part I. Item 1A. Risk Factors and Cautionary Note Regarding Forward-Looking Statements. </span></div><div style="margin-bottom:5pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">For discussion of 2021 items and year-over-year comparisons between 2022 and 2021 that are not included in this 2023 Form 10-K, refer to &#8220;Item 7. &#8211; Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; found in our Form 10-K for the year ended December&#160;31, 2022, that was filed with the Securities and Exchange Commission on February&#160;2, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a provider of health care services across the post-acute care continuum. We engage in the operation, ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare related properties and ancillary businesses located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Our independent subsidiaries, each of which strive to be the operation of choice in the community they serve, provide a broad spectrum of services. As of December&#160;31, 2023, we offered skilled nursing, senior living and rehabilitative care services through 297 skilled nursing and senior living facilities. Our real estate portfolio includes 113 owned real estate properties, which includes 83</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities operated and managed by us, 30 operations leased to and operated by third-party operators and the Service Center location. Of the 30 real estate operations leased to third-party operators, one senior living facility is located on the same real estate property as a skilled nursing facility that we own and operate.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensign is a holding company with no direct operating assets, employees or revenues. Our subsidiaries are operated by separate, independent entities, each of which has its own management, employees and assets. In addition, certain of our wholly-owned subsidiaries including Ensign Services, Inc. and Cornet Limited, Inc., referred to collectively as the Service Center, provide centralized accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. We also have a wholly-owned captive insurance subsidiary that provides some claims-made coverage to our independent subsidiaries for general and professional liability, as well as coverage for certain workers&#8217; compensation insurance liabilities and our captive real estate trust owns and operates our real estate portfolio. Our captive real estate investment trust, Standard Bearer, owns and manages our real estate business. References herein to the consolidated &#8220;Company&#8221; and &#8220;its&#8221; assets and activities, as well as the use of the terms &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our&#8221; and similar terms in this Annual Report, are not meant to imply, nor should they be construed as meaning, that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries are operated by The Ensign Group.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Activities</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operational Update</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 11, 2023, the United States Department of Health and Human Services (HHS) ended the public health emergency (PHE). Our primary focus has always been and continues to be the health and safety of our patients, residents, employees and their respective families. Even with the end of the PHE, we continue to implement new measures and maintain existing ones to provide the safest possible environment within our sites of service, taking into consideration the vulnerable nature of our patients.</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to execute on key initiatives to rebuild occupancy lost due to the pandemic. Our combined Same Facilities and Transitioning Facilities occupancy is 78.9%, which represents a 3.2% increase compared to the prior year and is closer to our pre-pandemic occupancy levels, which was 80.1% in March 2020. As we shift to an endemic, we believe that we will continue to see the return of our seasonal occupancy and skilled mix. Throughout most of our history, our seasonality trends for skilled nursing occupancy and skilled mix typically included the greatest growth during the first and fourth quarters and softening in the second and third quarters. As we exited the pandemic and enter the endemic, we saw a shift towards pre-pandemic occupancy and skilled mix levels. This was possible due to the innovative approaches and strategic partnerships developed during the pandemic which supported our occupancy improvements and continue to enable us to gain additional market share. These key initiatives together with our dedication to our cultural and operational fundamentals resulted in a strong 2023 results. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive relief funding from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. We use this funding, which reimburses the recipient for healthcare and labor related patient care services and expenses that are attributable to the COVID-19 pandemic. The end of the PHE created a gradual phase down of the temporary increase in FMAP funding in 2023. State specific approaches have been developed including various states having increased their base rates to account for increases in expenses in the post-pandemic environment. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023 and 2022, we recognized $64.8 million and $81.8 million, respectively, of combined state relief funding as revenue. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer Update</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January of 2022, we formed</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer Healthcare REIT, Inc. or Standard Bearer, a captive REIT. Standard Bearer is a holding company with subsidiaries that own a majority of our real estate portfolio. We expect the REIT structure to allow us to better demonstrate the growing value of our owned real estate and provide us with an efficient vehicle for future acquisitions of properties that could be operated by our independent subsidiaries or other third parties. This structure gives us new pathways to growth with transactions we would not have considered in the past.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stand-alone skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operations for an aggregate purchase price of $65.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Of these additions, the three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation acquired are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operated by our </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the other campus operation is leased to a new third-party operator. Our existing relationship with third-party operators within our industry allowed us to expand our growing REIT structure to operators outside of our organization. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the fair value of Standard Bearer's real estate portfolio is approximately $1.1 billion. The fair value was determined by a third-party independent valuation specialist and incorporated each property's rental income, capitalization rate, rental yield rate and discount rate. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Expansion into a New State</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, we expanded our operations into the state of Tennessee with the addition of one stand-alone skilled nursing operation. This expansion is part of our strategic vision to further strengthen our growing national presence in both existing and new attractive markets. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Repurchase Program</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0&#160;million of our common stock under the program for a period of approximately 12 months from September&#160;1, 2023. We did not repurchase any shares pursuant to this program during the fiscal year 2023.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In regard to the proceeding discussed in Item 3. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the parties agreed to settle the litigation for $48.0 million, subject to the review and approval of all parties, including the DOJ. The settlement does not include admissions on the part of the Company and the Company maintains that it has at all times complied and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS).</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Performance Indicators</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage the fiscal aspects of our business by monitoring key performance indicators that affect our financial performance. Revenue associated with these metrics is generated based on contractually agreed-upon amounts or rate, excluding the estimates of variable consideration under the revenue recognition standard, Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606. These indicators and their definitions include the following:</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Services</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Routine revenue </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Routine revenue is generated by the contracted daily rate charged for all contractually inclusive skilled nursing services. The inclusion of therapy and other ancillary treatments varies by payor source and by contract. Services provided outside of the routine contractual agreement are recorded separately as ancillary revenue, including Medicare Part&#160;B therapy services, and are not included in the routine revenue definition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Skilled revenue </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of routine revenue generated from patients in the skilled nursing facilities who are receiving higher levels of care under Medicare, managed care, Medicaid, or other skilled reimbursement programs. The other skilled patients who are included in this population represent very high acuity patients who are receiving high levels of nursing and ancillary services which are reimbursed by payors other than Medicare or managed care. Skilled revenue excludes any revenue generated from our senior living services.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Skilled mix </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The amount of our skilled revenue as a percentage of our total skilled nursing routine revenue. Skilled mix (in days) represents the number of days our Medicare, managed care, or other skilled patients are receiving skilled nursing services at the skilled nursing facilities divided by the total number of days patients from all payor sources are receiving skilled nursing services at the skilled nursing facilities for any given period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Average daily rates </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The routine revenue by payor source for a period at the skilled nursing facilities divided by actual patient days for that revenue source for that given period. These rates exclude additional state relief funding, which includes ARPA, FFCRA and other state relief programs.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Occupancy percentage (operational beds) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The total number of patients occupying a bed in a skilled nursing facility as a percentage of the beds in a facility which are available for occupancy during the measurement period.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:13.02pt">Number of facilities and operational beds </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The total number of skilled nursing facilities that we own or operate and the total number of operational beds associated with these facilities.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Mix </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Like most skilled nursing providers, we measure both patient days and revenue by payor. Medicare, managed care and other skilled patients, whom we refer to as high acuity patients, typically require a higher level of skilled nursing and rehabilitative care. Accordingly, Medicare and managed care reimbursement rates are typically higher than from other payors. In most states, Medicaid reimbursement rates are generally the lowest of all payor types. Changes in the payor mix can significantly affect our revenue and profitability.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our overall skilled mix from our skilled nursing services for the periods indicated as a percentage of our total skilled nursing routine revenue and as a percentage of total skilled nursing patient days:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.584%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Mix:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Days</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Occupancy </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We define occupancy derived from our skilled services as the ratio of actual patient days (one patient day equals one patient occupying one bed for one day) during any measurement period to the number of beds in facilities which are available for occupancy during the measurement period. The number of beds in a skilled nursing facility that are actually operational and available for occupancy may be less than the total official licensed bed capacity. This sometimes occurs due to the permanent dedication of bed space to alternative purposes, such as enhanced therapy treatment space or other desirable uses calculated to improve service offerings and/or operational efficiencies in a facility. In some cases, three- and four-bed wards have been reduced to two-bed rooms for resident comfort, and larger wards have been reduced to conform to changes in Medicare requirements. These beds are seldom expected to be placed back into service. We believe that reporting occupancy based on operational beds is consistent with industry practices and provides a more useful measure of actual occupancy performance from period to period.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our overall occupancy statistics for skilled nursing operations for the periods indicated:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Occupancy for skilled services:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operational beds at end of period</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,602&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,130&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available patient days</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,940,320&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,614,460&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual patient days</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590,995&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,243,781&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy percentage (based on operational beds)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="border-bottom:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segments</span><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of select properties owned by us through our captive REIT and leased to skilled nursing and senior living operations, including our own independent subsidiaries and third-party operators. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also reported an &#8220;all other&#8221; category that includes operating results from our senior living operations, mobile diagnostics, transportation, other real estate and other ancillary operations. These businesses are neither significant individually, nor in aggregate and therefore do not constitute a reportable segment. Our Chief Executive Officer, who is our chief operating decision maker, or CODM, reviews financial information at the operating segment level. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Sources</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="39" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.607%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">        </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Services</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our skilled nursing operations, we generate revenue from Medicaid, private pay, managed care and Medicare payors.&#160;We believe that our skilled mix, which we define as the number of days Medicare, managed care and other skilled patients are receiving services at our skilled nursing operations divided by the total number of days patients are receiving services at our skilled nursing operations, from all payor sources (less days from senior living services) for any given period, is an important indicator of our success in attracting high-acuity patients because it represents the percentage of our patients who are reimbursed by Medicare, managed care and other skilled payors, for whom we receive higher reimbursement rates.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in supplemental payment programs and quality improvement programs in various states that provide supplemental Medicaid payments for skilled nursing facilities that are licensed to non-state government-owned entities such as city and county hospital districts. Numerous independent subsidiaries entered into transactions with various hospital districts providing for the transfer of the licenses for those skilled nursing facilities to the hospital districts. Each affected independent subsidiary agreement between the hospital district and our subsidiary is terminable by either party to fully restore the prior license status. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate rental revenue primarily by leasing post-acute care properties that we acquired to healthcare operators under triple-net lease arrangements, whereby the tenants are solely responsible for the costs related to the property, including property taxes, insurance and maintenance and repair costs, subject to certain exceptions. As of December&#160;31, 2023, our real estate portfolio within Standard Bearer is comprised of 108 real estate properties. Of these properties, 79 are leased to our independent subsidiaries and 30 are leased to facilities wholly-owned and managed by third-party operators. During the year ended December 31, 2023, we generated rental revenues of $82.5 million, of which $66.7 million, was derived from our independent subsidiaries' operators and therefore eliminated in consolidation. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within our senior living operations, we generate revenue primarily from private pay sources, with a portion earned from Medicaid payors or through other state-specific programs. In addition, we hold majority membership interests in certain of our other ancillary operations. Payment for these services varies and is based upon the service provided. The payment is adjusted for an inability to obtain appropriate billing documentation or authorizations acceptable to the payor and other reasons unrelated to credit risk.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Primary Components of Expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(exclusive of rent and depreciation and amortization shown separately) </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our cost of services represents the costs of operating our independent subsidiaries, which primarily consists of payroll and related benefits, supplies, purchased services, and ancillary expenses such as the cost of pharmacy and therapy services provided to patients. Cost of services also includes the cost of general and professional liability insurance, rent expenses related to leasing our operational facilities that are not included in facility rent - cost of services, and other general cost of services with respect to our operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility Rent - Cost of Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Rent - cost of services consists solely of base minimum rent amounts payable under lease agreements to third-party real estate owners. Our independent subsidiaries lease and operate but do not own the underlying real estate and these amounts do not include taxes, insurance, impounds, capital reserves or other charges payable under the applicable lease agreements.  Expenses related to leasing our operations are included in cost of services. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expense </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense consists primarily of payroll and related benefits and travel expenses for our Service Center personnel, including training and other operational support. General and administrative expense also includes professional fees (including accounting and legal fees), litigation expense related to specific proceedings that are outside the ordinary course of business, costs relating to our information systems and stock-based compensation related to our Service Center employees.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and Amortization </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are recorded at their original historical cost. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets. The following is a summary of the depreciable lives of our depreciable assets:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.502%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:66.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Minimum of three years to a maximum of 59 years, generally 45&#160;years</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shorter of the lease term or estimated useful life, generally 5 to 15&#160;years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 10&#160;years</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The preparation of these financial statements and related disclosures requires us to make judgments, estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. We believe that the application of the following accounting policies, which are important to our financial position and results of operations, require significant judgments and estimates on the part of management. For a summary of our significant accounting policies, including the accounting policies discussed below, see Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Notes to Consolidated Financial Statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Variable consideration within revenue recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. We determine the transaction price based on contractually agreed-upon amounts or rates, adjusted for estimates of variable consideration. We use the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration which is included in the transaction price may be constrained and is included in the net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from our estimates, we adjust these estimates, which would affect net service revenue in the period such variances become known. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-insurance for general and professional liability</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The self-insured retention and deductible limits for general and professional liability for all states are self-insured through our wholly-owned captive insurance subsidiary (the Captive Insurance), the related assets and liabilities of which are included in the accompanying consolidated balance sheets. Our general and professional liability as of the year ended December 31, 2023 and 2022 was $117.7 million and $87.0 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy is to accrue amounts equal to the actuarially estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. We develop information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluate the estimates for claim loss exposure on a quarterly basis. We use actuarial valuations to estimate the liability based on historical experience and industry information.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_256"></div><div style="margin-top:10pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we exist to dignify and transform post-acute care. We set out a strategy to achieve our goal of ensuring our patients are receiving the best possible care through our ability to acquire, integrate and improve our operations. Our results serve as a strong indicator that our strategy is working and our transformation is underway. Over the last five years, our total revenue increased by $2.0 billion, or 112.5%, representing a 16.3% compound annual growth rate (CAGR) while our diluted GAAP earning per share (EPS) from continued operations grew by $2.56 from 2018 to $3.65 in 2023, representing a 27.4% CAGR. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenue for the year ended December 31, 2023 increased $703.9 million, or 23.3%, compared to the year ended December 31, 2022. Throughout 2023, we have continued to make progress on targeted initiatives related to increasing occupancy in our facilities, attracting and developing our people and acquiring new skilled nursing operations and integrating them with our proven cultural and operational principals. We continue to experience healthy growth in both revenue and operational earnings. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our combined Same Facilities and Transitioning Facilities occupancy increased by 3.2% compared to 2022.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our census continues to return to pre-pandemic levels, we anticipate a return to our historical seasonality trends, which typically result in higher occupancy and skilled mix during the first and fourth quarters and softening in the second and third quarters. See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for our operational update. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, we added 26 new operations, which included 17 operations in California. These California facilities include a group of highly skilled team members who will further our mission of dignifying long term care. We continue to work diligently with existing and recently acquired operations so that each can reach its full clinical and financial potential. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strength remains in our operating model, which empowers each operator to form their own market-specific strategy and adjust to the needs of their local medical communities, including methods for attracting new healthcare professionals into our workforce and retaining and developing existing staff. Despite continued labor pressures, there are positive trends on both turnover and agency usage in some of our markets. During 2023, we added over 5,000 team members, or 18%, to our independent subsidiaries and the Service Center.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth details of operating results for our revenue, expenses and earnings, and their respective components, as a percentage of total revenue for the periods indicated:</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REVENUE:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expenses:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent&#8212;cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL EXPENSES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.3)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET INCOME</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;Net income attributable to The Ensign Group, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.730%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SEGMENT INCOME</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,925&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NON-GAAP&#160;FINANCIAL MEASURES:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PERFORMANCE METRICS </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBT</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">365,310&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,609&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EBITDA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">327,303&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">359,209&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDA </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419,496&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383,570&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FFO for Standard Bearer</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,270&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,484&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VALUATION METRICS</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted EBITDAR</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">616,854&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Segment income represents operating results of the reportable segments excluding gain and loss on sale of assets, real estate insurance recoveries and losses, impairment charges and provision for income taxes. Included in segment income for Standard Bearer are expenses for intercompany management fees between Standard Bearer and the Service Center and intercompany interest expense. Segment income is reconciled to the Consolidated Statement of Income in Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Business Segments </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">in Notes to Financial Statements of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Standard Bearer segment income includes rental revenue and expenses from our independent subsidiaries.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) EBITDA includes litigation related to specific proceedings arising outside of the ordinary course of business as discussed in Item 3. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion includes references to Adjusted EBT, EBITDA, Adjusted EBITDA, Adjusted EBITDAR and Funds from Operations (FFO) which are non-GAAP financial measures (collectively, the Non-GAAP Financial Measures). Regulation G, Conditions for Use of Non-GAAP Financial Measures, and other provisions of the Securities Exchange Act of 1934, as amended (the Exchange Act), define and prescribe the conditions for use of certain non-GAAP financial information. These Non-GAAP Financial Measures are used in addition to and in conjunction with results presented in accordance with GAAP. These Non-GAAP Financial Measures should not be relied upon to the exclusion of GAAP financial measures. These Non-GAAP Financial Measures reflect an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the accompanying reconciliations to corresponding GAAP financial measures, provide a more complete understanding of factors and trends affecting our business.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the presentation of certain Non-GAAP Financial Measures are useful to investors and other external users of our financial statements regarding our results of operations because:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">they are widely used by investors and analysts in our industry as a supplemental measure to evaluate the overall performance of companies in our industry without regard to items such as other income (expense), net and depreciation and amortization, which can vary substantially from company to company depending on the book value of assets, capital structure and the method by which assets were acquired; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">they help investors evaluate and compare the results of our operations from period to period by removing the impact of our capital structure and asset base from our operating results.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the Non-GAAP Financial Measures:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">as measurements of our operating performance to assist us in comparing our operating performance on a consistent basis;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">to allocate resources to enhance the financial performance of our business;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">to assess the value of a potential acquisition;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">to assess the value of a transformed operation's performance;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">to evaluate the effectiveness of our operational strategies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">to compare our operating performance to that of our competitors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use certain Non-GAAP Financial Measures to compare the operating performance of each operation. These measures are useful in this regard because they do not include such costs as other expense, income taxes, depreciation and amortization expense, which may vary from period-to-period depending upon various factors, including the method used to finance operations, the amount of debt that we have incurred, whether an operation is owned or leased, the date of acquisition of a facility or business, and the tax law of the state in which a business unit operates.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also establish compensation programs and bonuses for our leaders that are partially based upon the achievement of Adjusted EBITDAR targets. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite the importance of these measures in analyzing our underlying business, designing incentive compensation and for our goal setting, the Non-GAAP Financial Measures have no standardized meaning defined by GAAP. Therefore, certain of our Non-GAAP Financial Measures have limitations as analytical tools, and they should not be considered in isolation, or as a substitute for analysis of our results as reported in accordance with GAAP. Some of these limitations are:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">they do not reflect our current or future cash requirements for capital expenditures or contractual commitments;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">they</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">do not reflect changes in, or cash requirements for, our working capital needs;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">they</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">do not reflect the interest expense, or the cash requirements necessary to service interest or principal payments, on our debt;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">they do not reflect rent expenses, which are necessary to operate our leased operations, in the case of Adjusted EBITDAR;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">they</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">do not reflect any income tax payments we may be required to make;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">although</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">depreciation and amortization are non-cash charges, the assets being depreciated and amortized will often have to be replaced in the future, and do not reflect any cash requirements for such replacements; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%;padding-left:13.02pt">other</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:90%">companies in our industry may calculate these measures differently than we do, which may limit their usefulness as comparative measures.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compensate for these limitations by using them only to supplement net income on a basis prepared in accordance with GAAP in order to provide a more complete understanding of the factors and trends affecting our business. Management strongly encourages investors to review our consolidated financial statements in their entirety and to not rely on any single financial measure. Because these Non-GAAP Financial Measures are not standardized, it may not be possible to compare these financial measures with other companies&#8217; Non-GAAP financial measures having the same or similar names. These Non-GAAP Financial Measures should not be considered a substitute for, nor superior to, financial results and measures determined or calculated in accordance with GAAP. We strongly urge you to review the reconciliation of income from operations to the Non-GAAP Financial Measures in the table below, along with our Financial Statements and related notes included elsewhere in this document. </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the following Non-GAAP financial measures that we believe are useful to investors as key valuation and operating performance measures:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PERFORMANCE MEASURES</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBT</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust income before provision for income taxes (Adjusted EBT) when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance. We believe that the presentation of Adjusted EBT, when combined with income before provision for income taxes and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor&#8217;s complete understanding of our operating performance. We use this performance measure as an indicator of business performance, as well as for operational planning, decision-making purposes and to determine compensation in our executive compensation plan.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBT is income before provision for income taxes adjusted for non-core business items, which for the reported periods includes, to the extent applicable: </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">stock-based compensation expense;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">gain on sale of assets and business interruption of recoveries; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">write-off of deferred financing fees;</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">acquisition related costs; </span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">costs incurred related to new systems implementation; and</span></div><div style="margin-bottom:5pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">depreciation and amortization of patient base intangible assets.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EBITDA</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe EBITDA is useful to investors in evaluating our operating performance because it helps investors evaluate and compare the results of our operations from period to period by removing the impact of our asset base (depreciation and amortization expense) from our operating results.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate EBITDA as net income, adjusted for net losses attributable to noncontrolling interest, before (a) other income (expense), net, (b) provision for income taxes, and (c) depreciation and amortization.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBITDA </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We adjust EBITDA when evaluating our performance because we believe that the exclusion of certain additional items described below provides useful supplemental information to investors regarding our ongoing operating performance, in the case of Adjusted EBITDA. We believe that the presentation of Adjusted EBITDA, when combined with EBITDA and GAAP net income attributable to The Ensign Group, Inc., is beneficial to an investor&#8217;s complete understanding of our operating performance. &#160;</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adjusted EBITDA is EBITDA adjusted for the same non-core business items as listed in Adjusted EBT, except for depreciation and amortization of patient base intangible assets and write-off of deferred financing fees.</span></div><div style="margin-bottom:5pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-bottom:5pt;margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funds from Operations (FFO)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider FFO to be a useful supplemental measure of the operating performance of Standard Bearer. Historical cost accounting for real estate assets in accordance with U.S. GAAP implicitly assumes that the value of real estate assets diminishes predictably over time as evidenced by the provision for depreciation. However, since real estate values have historically risen or fallen with market conditions, many real estate investors and analysts have considered presentations of operating results for real estate companies that use historical cost accounting to be insufficient. In response, the National Association of Real Estate Investment Trusts (NAREIT) created FFO as a supplemental measure of operating performance for REITs, which excludes historical cost depreciation from net income. We define (in accordance with the definition used by NAREIT) FFO to consist of Standard Bearer segment income, excluding depreciation and amortization related to real estate, gains or losses from the sale of real estate, insurance recoveries related to real estate and impairment of depreciable real estate assets.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">VALUATION MEASURE</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adjusted EBITDAR</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;We use Adjusted EBITDAR as one measure in determining the value of prospective acquisitions. It is also a commonly used measure by our management, research analysts and investors, to compare the enterprise value of different companies in the healthcare industry, without regard to differences in capital structures and leasing arrangements. Adjusted EBITDAR is a financial valuation measure that is not specified in GAAP. This measure is not displayed as a performance measure as it excludes rent expense, which is a normal and recurring operating expense, and is therefore presented only for the current period.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adjustments made and previously described in the computation of Adjusted EBITDA are also made when computing Adjusted EBITDAR. We calculate Adjusted EBITDAR by excluding rent-cost of services from Adjusted EBITDA.  </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the use of Adjusted EBITDAR allows the investor to compare operational results of companies who have operating and capital leases. A significant portion of capital lease expenditures are recorded in interest, whereas operating lease expenditures are recorded in rent expense.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles income before provision for income taxes to Adjusted EBT for the periods presented:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated statements of income data:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,762&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289,089&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,781&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and business interruption recoveries </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Write-off of deferred financing fees</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">566&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred related to new systems implementation</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization - patient base</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">355&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADJUSTED EBT</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">365,310</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">314,609</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which includes the portion attributable to non-controlling interests. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) Represents the write-off of deferred financing fees associated with the amendment of the Credit Facility.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(c) Costs incurred to acquire operations that are not capitalizable. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(d) Included in depreciation and amortization are amortization expenses related to patient base intangible assets at newly acquired skilled nursing and senior living facilities.</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below reconciles net income to EBITDA, Adjusted EBITDA and Adjusted EBITDAR for the periods presented:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:74.046%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.036%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated statements of income data:</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Add: Other (income) expense, net</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,395)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,736&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,912&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,437&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,387&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EBITDA</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">327,303</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">359,209</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,767&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,720&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a) </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,781&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,280&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and business interruption recoveries </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,132)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,380)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition related costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">669&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs incurred related to new systems implementation</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">963&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADJUSTED EBITDA</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">419,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">383,570</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent&#8212;cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ADJUSTED EBITDAR </span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">616,854</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(a) Litigation relates to specific proceedings arising outside of the ordinary course of business, which excludes the portion attributable to non-controlling interests. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(b) Costs incurred to acquire operations that are not capitalizable. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_268"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Year Ended December&#160;31, 2023 Compared to the Year Ended December&#160;31, 2022</span></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth details of operating results for our revenue and earnings, and their respective components, by our reportable segment for the periods indicated.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.321%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.871%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Eliminations</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,578,855&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">82,486&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">155,804&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,729,355&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses, including other income (expense), net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,113,930&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">53,421&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">377,055&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,456,616&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">464,925&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">29,065&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(221,251)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272,739&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">272,762</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:12pt;padding-right:-9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.603%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.903%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">All Other</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Eliminations</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Consolidated</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue </span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,906,215&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">72,937&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">122,610&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(76,294)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,025,468&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total expenses, including other income (expense), net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,497,483&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">45,066&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">273,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(76,294)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">2,739,646&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">408,732&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">27,871&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">285,822&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.164%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenue increased $703.9 million, or 23.3%, compared to the year ended December 31, 2022. The increase in revenue was primarily driven by an increase in occupancy of 3.2% from our skilled services Same Facilities and Transitioning Facilities coupled with increasing daily revenue rates and the impact of acquisitions. Specifically, our skilled services Recently Acquired Facilities increased total revenue by $450.0 million, when compared to the same period in 2022, with 52.0% of these operations being acquired in 2023. We believe this demonstrates our ability to increase our market share through strategic acquisitions of operations that have higher skilled mix and higher occupancy than our typical acquisitions. These increases are offset by a decrease in state relief revenue of $17.1 million as the end of the PHE created a gradual phase down of the temporary increase in FMAP funding. All state relief revenue is included in Medicaid revenue. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Skilled Services Segment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the skilled services revenue and key performance metrics by category during the year ended December 31, 2023 and 2022:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL FACILITY RESULTS:</span></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled services revenue</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,855&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672,640&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities at period end</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of campuses at period end</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual patient days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590,995&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,243,781&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,214&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy percentage &#8212; Operational beds</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.5&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing revenue</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.2&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.0&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SAME FACILITY RESULTS:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled services revenue</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,771,633&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,569,807&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">201,826&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities at period end</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of campuses at period end</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual patient days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,563,672&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,299,331&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264,341&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy percentage &#8212; Operational beds</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.0&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing revenue</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.4&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.3&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITIONING FACILITY RESULTS:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled services revenue</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,872&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231,100&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,772&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities at period end</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of campuses at period end</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual patient days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,659&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625,085&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,574&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy percentage &#8212; Operational beds</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.1&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing revenue</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.4&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.139%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RECENTLY ACQUIRED FACILITY RESULTS:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled services revenue</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555,350&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,308&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450,042&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of facilities at period end</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Number of campuses at period end</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual patient days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,371,664&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,365&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052,299&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Occupancy percentage &#8212; Operational beds</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.8&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67.9&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing days</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.5&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skilled mix by nursing revenue</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Campus represents a facility that offers both skilled nursing and senior living services. Revenue and expenses related to skilled nursing and senior living services have been allocated and recorded in the respective operating segment. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Same Facility results represent all facilities purchased prior to January&#160;1, 2020. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Transitioning Facility results represent all facilities purchased from January&#160;1, 2020 to December&#160;31, 2021.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Recently Acquired Facility (Acquisitions) results represent all facilities purchased on or subsequent to January&#160;1, 2022. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Skilled services revenue increased $672.6 million, or 23.1%, compared to the year ended December 31, 2022. The increases in skilled services revenue were across all payer types including increases in Medicaid revenue of $315.9 million, or 23.2%, Medicare revenue of $153.6 million, or 18.5%, managed care revenue of $140.4 million, or 26.7% and private revenue of $62.7 million, or 33.1%.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in skilled services revenue was driven by strong performance across our existing skilled services operations as our census continued to recover in 2023, as well as the favorable impact of skilled census from our recent acquisitions. Our consolidated occupancy increased by 3.2% during the year ended December 31, 2023 compared to the same period in 2022.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue in our Same Facilities increased $201.8 million, or 7.9%, compared to the same period in 2022, due to increases in occupancy from both skilled and long-term care patients and revenue per patient day. Our diligent efforts to strengthen our partnerships with various managed care organizations, hospitals and the local communities we operate in, increased our managed care revenue by 14.8%, mainly due to increases in managed care days of 7.2% and revenue per patient day of 5.3%. We continued to see a shift in our patient population from Medicare to managed care as Medicare Advantage enrollment accounts for a larger portion of the overall population. In addition, Medicaid revenue increased by $116.7 million or 9.9%, mainly from the increases in Medicaid days and revenue per patient day.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue generated by our Transitioning Facilities increased $20.8 million, or 9.0%,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily due to improved occupancy growth and an increase in revenue per patient day. Our Medicaid revenue increased by </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10.9%, Managed Care revenue increased by 12.3% and private revenue increased by 18.1%, demonstrating our ability to focus on increasing occupancy across payer types. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Skilled services revenue generated by </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently Acquired Facilities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased by approximately $450.0 million compared to the year ended December 31, 2022. The increases were primarily due to 26 operational expansions in 2023 as well as the full year impact of the 24 operational expansions in 2022.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, if we acquire additional turnaround or start-up operations, we typically expect to see lower occupancy rates and skilled mix and these metrics are expected to vary from period to period based upon the maturity of the facilities within our portfolio. Historically, we have generally experienced lower occupancy rates and lower skilled mix at Recently Acquired Facilities and therefore, we anticipate generally lower overall occupancy during years of growth. Included in our metrics for Recently Acquired Facilities are 17 facilities we acquired that are mature and have higher occupancy rates, higher skilled mix days and higher skilled mix revenue than our typical acquisitions.</span></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the change in skilled nursing average daily revenue rates by payor source, excluding services that are not covered by the daily rate </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="45" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Same Facility</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transitioning</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="48" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SKILLED NURSING AVERAGE DAILY REVENUE RATES </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722.96&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694.63&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696.37&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668.05&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788.00&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652.15&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733.47&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">691.25&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">537.29&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510.18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">536.93&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">501.73&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555.55&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">455.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539.25&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508.53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other skilled</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598.35&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.46&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.08&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">530.18&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441.89&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">429.84&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575.34&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563.56&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total skilled revenue</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">617.55&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">598.14&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.58&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">593.66&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">660.87&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521.24&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">623.70&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">595.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275.82&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259.89&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270.67&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254.08&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256.51&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227.21&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272.14&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.81&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253.15&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.63&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.71&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.34&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.93&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total skilled nursing revenue</span></div></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.56&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370.57&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342.57&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332.09&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.46&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296.15&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.02&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.97&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) These rates exclude state relief funding </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">and include sequestration reversal of 1% for the second quarter in 2022 and 2% for the first quarter of 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare daily rates at Same Facilities and Transitioning Facilities increased by 4.1% and 4.2%, respectively, compared to the year ended December 31, 2022. The increase is attributable to the 2.7% and 4.0% net market basket increase that became effective in October 2022 and October 2023, respectively, offset by the phased reinstatement of the sequestration. During the year ended December 31, 2022, Medicare daily rates included three months of sequestration suspension of 1%, three months of sequestration suspension of 2% and six months of no sequestration suspension. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our average Medicaid rates increased 5.6% due to state reimbursement increases and our participation in supplemental Medicaid payment programs and quality improvement programs in various states. Medicaid rates exclude the amount of state relief revenue we recorded.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Payor Sources as a Percentage of Skilled Nursing Services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use our skilled mix as a measure of the quality of reimbursements we receive at our independent skilled nursing facilities over various periods. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our percentage of skilled nursing patient revenue and days by payor source:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="45" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Same Facility</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Transitioning</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Acquisitions</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PERCENTAGE OF SKILLED NURSING REVENUE</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.5&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled mix</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">53.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">38.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">42.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">50.2</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.2&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SKILLED NURSING</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.455%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.955%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="45" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Same Facility</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Transitioning</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Acquisitions</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PERCENTAGE OF SKILLED NURSING DAYS</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.9&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled mix</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.9</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">33.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27.5</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.8</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.1&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SKILLED NURSING</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Services </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth total cost of services for our skilled services segment for the periods indicated (dollars in thousands): </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of service</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832,012&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,267,691&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue percentage</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.1&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.0&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of services related to our skilled services segment increased by $564.3 million, or 24.9% from prior year. Cost of services as a percentage of revenue increased to 79.1% from 78.0%, due to increased costs related to general and professional liabilities reserves and wage expenses as a result of the labor environment. In addition, included in cost of services during the year ended December 31, 2023 is the expense related to the deferred compensation investment program of $2.4&#160;million compared to a gain of $2.6&#160;million during the year ended December 31, 2022.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Standard Bearer</span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.666%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue generated from third-party tenants</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,774&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,970&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">804&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue generated from Ensign's independent subsidiaries</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,712&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,745&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL RENTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,194&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,592&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FFO</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,270</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">49,484</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,786</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental revenue </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our rental revenue, including revenue generated from our independent subsidiaries, increased by $9.5 million, or 13.1%, to $82.5 million, compared to the year ended December 31, 2022. The increase in revenue is primarily attributable to five real estate purchases as well as annual rent increases since the year ended December 31, 2022. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FFO </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our FFO increased by $4.8 million, or 9.7%, to $54.3 million, compared to the year ended December 31, 2022. The increase in rental revenue of $9.5 million is offset by increases in interest expense of $4.3 million associated with the intercompany debt arrangements between Standard Bearer and us, as we continue to grow our real estate portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">All Other Revenue </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our other revenue increased by $33.2 million, or 27.1%, to $155.8 million, compared to the year ended December 31, 2022. Other revenue for 2023 includes senior living revenue of $76.4 million, revenue from other ancillary services of $68.3 million and rental income of $11.1 million. The increase in other revenue is primarily attributable to our other ancillary services as well as senior living operations' occupancy starting to rebound from COVID-19.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Financial Expenses</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rent-cost of services </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our rent-cost of services as a percentage of total revenue increased by 0.2% to 5.3%, primarily due to lease obligations acquired as part of our 22 operational expansions with long-term leases since the year ended December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and administrative expense </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expense increased $104.2 million or 65.6%, to $263.0 million. General and administrative expense as a percentage of revenue increased by 1.9% to 7.1%. This increase was primarily due to increases in litigation expense related to specific proceedings that are outside the ordinary course of business, system implementation costs, bonuses due to enhanced performance and headcount due to acquisition activity. Excluding the litigation expense, general and administrative expense as a percentage of revenue increased by 0.2% to 5.4%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Depreciation and amortization </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense increased $10.0 million, or 16.1%, to $72.4 million. This increase was primarily related to the additional depreciation and amortization incurred as a result of our newly acquired operations and capital expenditures. Depreciation and amortization decreased 0.2%, to 1.9%, as a percentage of revenue. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other income (expense), net </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other income (expense), net as a percentage of revenue increased by 0.8%. Other income primarily includes interest income from our investments offset by interest expense related to our debt. Additionally, our deferred investment program may incur gains or losses depending on market performance. During the year ended December 31, 2023, the deferred compensation investment program had a gain of $4.6 million. During the year ended December 31, 2022, the deferred compensation investment program had a loss of $4.2 million. The offsetting expenses or reduction in expenses are allocated between cost of services and general and administrative expenses.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for income taxes </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022. The effective tax rate for both periods is driven by the impact of excess tax benefits from stock-based compensation, partially offset by non-deductible expenses, including non-deductible compensation. See Note 14, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in the Financial Statements for further discussion. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_280"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our primary sources of liquidity have historically been derived from our cash flows from operations and long-term debt secured by our real property and our Credit Facility. Our liquidity as of December&#160;31, 2023 is impacted by cash generated from strong operational performance and increased acquisition and share repurchase activities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have primarily financed the majority of our acquisitions through mortgages on our properties, our Credit Facility and cash generated from operations. Cash paid to fund acquisitions was $69.0 million and $101.1 million for the year ended December 31, 2023 and 2022, respectively. Total capital expenditures for property and equipment were $106.2 million and $87.5 million for the year ended December 31, 2023 and 2022, respectively. We currently have approximately $110.0 million budgeted for renovation projects in 2024. We believe our current cash balances, our cash flow from operations and the amounts available for borrowing under our Credit Facility will be sufficient to cover our operating needs for at least the next 12 months.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may, in the future, seek to raise additional capital to fund growth, capital renovations, operations and other business activities, but such additional capital may not be available on acceptable terms, on a timely basis, or at all.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents as of December&#160;31, 2023 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December&#160;31, 2023, we held investments of approximately $109.9 million. We believe our investments that were in an unrealized loss position as of December&#160;31, 2023 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As mentioned above, our primary source of cash is from our ongoing operations. Our positive cash flows have supported our business and have allowed us to pay regular dividends to our stockholders. We currently anticipate that existing cash and total investments as of December&#160;31, 2023, along with projected operating cash flows and available financing, will support our normal business operations for the foreseeable future. </span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0&#160;million of our common stock under the program for a period of approximately 12 months from September&#160;1, 2023. Under this program, we are authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. We did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which we may repurchase up to $20.0&#160;million of our common stock under the program for a period of approximately 12 months from August 2, 2022. Under this program, we were authorized to repurchase our issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate us to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents selected data from our consolidated statement of cash flows for the periods presented:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.467%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY/(USED IN):</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">376,666&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">272,513&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(182,698)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(186,182)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(612)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(32,262)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">193,356</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">54,069</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents beginning of period</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">316,270&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">262,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Cash and cash equivalents at end of period</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">509,626</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">316,270</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities is net income adjusted for certain non-cash items and changes in operating assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $104.2 million increase in cash provided by operating activities for the year ended December 31, 2023 compared to the same period in 2022 w</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as due to cash generated from improved results at our local operations as well as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$24.2 million that was paid for deferred social security taxes in 2022, which did not occur in 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing cash flows consist primarily of capital expenditures, investment activities, insurance proceeds and cash used for acquisitions. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $3.5 million decrease in cash used in investing activities for the year ended December 31, 2023 compared to the same period in 2022 was primarily due to a decrease in cash used for operational expansions of $32.1&#160;million, offset by an increase in cash used for capital expenditures of $18.6&#160;million, an increase in investments of $3.1&#160;million and a decrease of cash proceeds from the sale of fixed assets and insurance proceeds of $7.7 million.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing cash flows consist primarily of payment of dividends to stockholders, issuance and repayment of short-term and long-term debt, payment for share repurchases and sale of subsidiary shares. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $31.7 million decrease in cash used in financing activities for the year ended December 31, 2023 compared to the same period in 2022, was primarily due to $29.9&#160;million of share repurchases as part of our </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock repurchase program in 2022.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A discussion of our cash flows for the year ended December 31, 2021 is included in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources, included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission on February 2, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material cash requirements from known contractual and other obligations</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total long-term debt obligations outstanding as of the end of each fiscal year were as follows: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.999%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2019</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit facilities and term loans</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,806&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,388</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">156,271</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">159,967</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">117,806</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">330,350</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant contractual obligations as of December 31, 2023 were as follows, including the future periods in which payments are expected:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.439%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(In thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,675,643&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,449&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest payments on long-term debt</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,623&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,487&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,207&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,091&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,436&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,190&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199,842</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199,631</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">198,585</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">197,094</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,909,144</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,904,221</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not included in the table above are our actuarially determined self-insured general and professional malpractice liability, workers' compensation and medical (including prescription drugs) and dental healthcare obligations, which are broken out between current and long-term liabilities in our financial statements included in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the proceeding discussed in Item 3. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the parties agreed to settle the litigation for $48.0 million, subject to the review and approval of all parties, including the DOJ and other relevant government entities. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a revolving credit facility with Truist Securities (Truist) (the Credit Facility) with availability up to $600.0 million in aggregate principal amount. The maturity date of the Credit Facility is April&#160;8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at our option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio.</span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Note</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, 23 of our subsidiaries have mortgage loans insured with HUD for an aggregate amount of $150.2 million, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates at a range of 3.1% to 4.2%, including fixed interest rates at a range of 2.4% to 3.3% per annum. In addition to the interest rate, we incur other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees of the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0%, and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans, one of our subsidiaries has a promissory note that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was used for an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases</span></div><div style="margin-top:12pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2023, 214 of our facilities are under long-term lease arrangements, of which 96 of the operations are under nine triple-net Master Leases and one stand-alone lease with CareTrust REIT, Inc. (CareTrust). The Master Leases consist of multiple leases, each with its own pool of properties, that have varying maturities and diversity in property geography. Under each master lease, our individual subsidiaries that operate those properties are the tenants and CareTrust's individual subsidiaries that own the properties subject to the Master Leases are the landlords. The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of the percentage change in the Consumer Price Index (but not less than zero) or 2.5%. At our option, we can extend the Master Leases for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. If we elect to renew the term of a Master Lease, the renewal will be effective as to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that we can exercise starting on December 1, 2024. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also lease certain facilities and our administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from five to 20 years and is subject to annual escalation equal to the percentage change in the Consumer Price Index with a stated cap percentage. In addition, we lease certain of our equipment under non-cancelable operating leases with initial terms ranging from three to five years. Most of these leases contain renewal options, certain of which involve rent increases. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eighty of our independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases from CareTrust, are operated under 13 separate master lease arrangements. Under these master leases, a default at a single facility could subject one or more of the other independent subsidiaries covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of our leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in our outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically derived a substantial portion of our revenue from the Medicare program. We also derive revenue from state Medicaid and similar reimbursement programs. Payments under these programs generally provide for reimbursement levels that are adjusted for inflation annually based upon the state&#8217;s fiscal year for the Medicaid programs and in each October for the Medicare program. These adjustments may not continue in the future, and even if received, such adjustments may not reflect the actual increase in our costs for providing healthcare services.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Labor, supply expenses and capital expenditures make up a substantial portion of our cost of services. Those expenses can be subject to increase in periods of rising inflation and when labor shortages occur in the marketplace. To date, we have generally been able to implement cost control measures or obtain increases in reimbursement sufficient to offset increases in these expenses. There can be no assurance that we will be able to anticipate fully or otherwise respond to any future inflationary pressures. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_289"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to risks associated with market changes in interest rates through our borrowing arrangements and investments. In particular, our Credit Facility exposes us to variability in interest payments due to changes in SOFR interest rates. We manage our exposure to this market risk by monitoring available financing alternatives. Our mortgages and promissory note require principal and interest payments through maturity pursuant to amortization schedules. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mortgages generally contain provisions that allow us to make repayments earlier than the stated maturity date. In some cases, we are not allowed to make early repayment prior to a cutoff date. Where prepayment is permitted, we are generally allowed to make prepayments only at a premium which is often designed to preserve a stated yield to the note holder. These prepayment rights may afford us opportunities to mitigate the risk of refinancing our debts at maturity at higher rates by refinancing prior to maturity.</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a Credit Facility with Truist of up to $600.0 million in aggregate principal amount. We have no outstanding borrowings under our Credit Facility as of December&#160;31, 2023 and through the filing date of this report. In addition, we have outstanding indebtedness under mortgage loans insured with HUD and a promissory note payable to a third party of $152.4 million, all of which are at fixed interest rates.</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents as of December&#160;31, 2023 consisted of bank term deposits, money market funds and U.S. Treasury bill related investments. In addition, as of December&#160;31, 2023, we held investments of approximately $109.9 million. We believe our investments that were in an unrealized loss position as of December&#160;31, 2023 do not require an allowance for expected credit losses, nor has any event occurred subsequent to that date that would indicate so. Our market risk exposure is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates. The primary objective of our investment activities is to preserve principal, while at the same time maximizing the income we receive from our investments without significantly increasing risk. Due to the low risk profile of our investment portfolio, an immediate 10.0% change in interest rates would not have a material effect on the fair market value of our portfolio. Accordingly, we would not expect our operating results or cash flows to be affected to any significant degree by the effect of a sudden change in market interest rates on our securities portfolio.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The above only incorporates those exposures that exist as of December&#160;31, 2023 and does not consider those exposures or positions which could arise after that date. If we diversify our investment portfolio into securities and other investment alternatives, we may face increased risk and exposures as a result of interest risk and the securities markets in general.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_382"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8.&#160;&#160;&#160;&#160; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_388"></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">THE ENSIGN GROUP, INC. </span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AND FINANCIAL STATEMENT SCHEDULE</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:86.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.364%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_391">Report of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_391">92</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">Consolidated Financial Statements:</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#160;</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_34">Consolidated Balance Sheets as of December 31, 2023 and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_34">93</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_40">Consolidated Statements of Income for the Years Ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_40">94</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_46">Consolidated Statements of Stockholders' Equity for the Years Ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_46">95</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_49">Consolidated Statements of Cash Flows for the Years Ended December&#160;31, 2023, 2022, and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_49">96</a></span></div></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_58">Notes to </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_58">the </a><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_58">Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%"><a style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_58">97</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_391"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Juan Capistrano, California </span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of The Ensign Group Inc. and subsidiaries (the "Company") as of December 31, 2023, and 2022, the related consolidated statements of income, stockholders' equity, and cash flows, for each of the three years in the period ended December 31, 2023, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2023, and 2022, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February 1, 2024, expressed  an unqualified opinion on the Company's internal control over financial reporting.</span><span style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Self-Insurance Liabilities (General and Professional Liability Claims) - Refer to Notes 2 and 19 to the financial statements </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's self-insurance liabilities for general and professional liability claims totaled $117.7 million at December 31, 2023. The Company develops information about the size of the ultimate claims based on historical experience, current industry information, and actuarial analysis.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of reserves for general and professional liability claims is highly subjective. Given the significant judgments in estimating the general and professional liability claims, we have determined this to be a critical audit matter. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to evaluate the reasonableness of management estimates of reserves for open claims as well as for claims that are incurred but not reported (IBNR).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to management&#8217;s judgment regarding the estimation of the reserve for general and professional liability claims included the following, among others:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">We tested the effectiveness of controls over the reserve for general and professional liabilities, including those related to both the determination of reserves for open claims and estimation of the IBNR claims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">We obtained an understanding of the factors considered and assumptions made by management and its external actuarial specialists in developing the estimate of the general and professional liability reserves, including the sources of data relevant to these factors and assumptions. We tested underlying claims data, including testing the completeness and accuracy of open cases.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">We involved our actuarial specialists to assist in our evaluation of the methodologies applied by management's specialist and to develop an independent range of expected reserves.  We compared the recorded reserves to the estimated independent range. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">We performed a retrospective review in which we compared the prior-year recorded amounts for ultimate losses and current liabilities to the subsequent claim emergence.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-36">DELOITTE &amp; TOUCHE LLP</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-37">Costa Mesa, California</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;1, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 1999.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_34"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except par values)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.422%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current assets: </span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-38">509,626</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-39">316,270</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts receivable&#8212;less allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">9,348</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-41">7,802</ix:nonFraction> at December&#160;31, 2023 and 2022, respectively</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-42">485,039</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-43">408,432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Investments&#8212;current</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-44">17,229</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="f-45">15,441</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-46">35,036</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-47">40,982</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-48">1,046,930</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-49">781,125</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-50">1,090,771</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-51">992,010</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Right-of-use assets </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-52">1,756,430</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-53">1,450,995</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Insurance subsidiary deposits and investments </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:InsuranceSubsidiaryDepositsAndInvestments" format="ixt:num-dot-decimal" scale="3" id="f-54">92,687</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:InsuranceSubsidiaryDepositsAndInvestments" format="ixt:num-dot-decimal" scale="3" id="f-55">67,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Deferred tax assets</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-56">67,124</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-57">39,643</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Restricted and other assets </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:RestrictedAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">40,205</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:RestrictedAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-59">37,291</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Intangible assets, net </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-60">6,525</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-61">6,437</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-62">76,869</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-63">76,869</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL ASSETS</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-64">4,177,541</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-65">3,452,022</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">92,811</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">77,087</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued wages and related liabilities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">332,568</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">289,810</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Lease liabilities&#8212;current </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">82,526</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-71">65,796</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued self-insurance liabilities&#8212;current</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-72">54,664</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SelfInsuranceReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-73">48,187</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other accrued liabilities </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-74">168,228</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-75">97,309</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Current maturities of long-term debt</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-76">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-77">3,883</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 43.75pt;text-align:left;text-indent:-13.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-78">734,747</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-79">582,072</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term debt&#8212;less current maturities</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" format="ixt:num-dot-decimal" scale="3" id="f-80">145,497</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" format="ixt:num-dot-decimal" scale="3" id="f-81">149,269</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Long-term lease liabilities&#8212;less current portion </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-82">1,639,326</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-83">1,355,113</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Accrued self-insurance liabilities&#8212;less current portion</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SelfInsuranceReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-84">111,246</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SelfInsuranceReserveNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-85">83,495</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:DeferredRentAndOtherLongTermLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-86">49,408</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:DeferredRentAndOtherLongTermLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-87">33,273</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL LIABILITIES</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-88">2,680,224</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-89">2,203,222</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Commitments and contingencies (Notes 15 and 20)</span></div></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-90"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-91"></ix:nonFraction></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">EQUITY</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Ensign Group, Inc. stockholders' equity:</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock: $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-92"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-93">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-94">150,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-95">59,987</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-96">56,597</ix:nonFraction> shares authorized, shares issued and shares outstanding at December&#160;31, 2023, respectively, and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-97">100,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-98">59,029</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-99">55,661</ix:nonFraction> shares authorized, shares issued and shares outstanding at December 31, 2022, respectively </span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-100">60</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-101">59</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-102">465,707</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-103">415,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-104">1,142,653</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-105">946,339</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Common stock in treasury, at cost, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-106">3,390</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-107">3,368</ix:nonFraction> shares at December&#160;31, 2023 and 2022, respectively </span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-108">116,555</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="3" id="f-109">114,626</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total Ensign Group, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-110">1,491,865</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-111">1,247,332</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 41.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Non-controlling interest</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-112">5,452</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-113">1,468</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 55pt;text-align:left;text-indent:-22.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Total equity</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-114">1,497,317</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-115">1,248,800</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 66.25pt;text-align:left;text-indent:-36pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL LIABILITIES AND EQUITY</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-116">4,177,541</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-117">3,452,022</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_40"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">  THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.147%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.665%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands, except per share data)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">REVENUE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Service revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-118">3,708,071</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-119">3,008,711</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-120">2,611,476</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rental revenue</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-121">21,284</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-122">16,757</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-123">15,985</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-124">3,729,355</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-125">3,025,468</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-126">2,627,461</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Expense:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Cost of services</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-127">2,941,238</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-128">2,354,434</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-129">2,019,879</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Rent&#8212;cost of services </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:RentCostOfServices" format="ixt:num-dot-decimal" scale="3" id="f-130">197,358</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:RentCostOfServices" format="ixt:num-dot-decimal" scale="3" id="f-131">153,049</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:RentCostOfServices" format="ixt:num-dot-decimal" scale="3" id="f-132">139,371</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-133">263,005</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-134">158,805</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-135">151,761</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-136">72,387</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-137">62,355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-138">55,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">TOTAL EXPENSES</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-139">3,473,988</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-140">2,728,643</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="3" id="f-141">2,366,996</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">255,367</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">296,825</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">260,465</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-145">8,087</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-146">8,931</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-147">6,849</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Other income</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-148">25,482</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-149">1,195</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-150">4,388</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Other income (expense), net</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-151">17,395</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-152">7,736</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-153">2,461</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-154">272,762</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-155">289,089</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-156">258,004</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-157">62,912</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-158">64,437</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-159">60,279</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">NET INCOME</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-160">209,850</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-161">224,652</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-162">197,725</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Less: </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-163">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-164">29</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">3,073</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-166">209,399</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-167">224,681</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-168">194,652</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 1.75pt;text-align:left;text-indent:4.49pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-169">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-170">4.09</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-171">3.57</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 1.75pt;text-align:left;text-indent:4.49pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-172">3.65</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-173">3.95</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-174">3.42</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-175">55,708</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-176">54,887</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-177">54,486</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-178">57,323</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-179">56,871</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-180">56,925</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_46"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"> THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.110%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.952%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.099%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.513%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.544%"/><td style="width:0.1%"/></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Non-Controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BALANCE&#160;- JANUARY&#160;1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-14" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-181">54,626</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-182">58</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">338,177</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-184">551,055</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-185">2,791</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">71,213</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-187">150</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-188">818,227</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-189">516</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-190">9,180</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-191">9,180</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-192">201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-193">3,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-194">3,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock used to satisfy tax withholding obligations</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-195">21</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-196">21</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-197">1,711</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-198">1,711</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-199">0.2125</ix:nonFraction> per share)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-200">11,715</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-201">11,715</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock award compensation</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-202">18,678</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-203">18,678</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock (Note 21)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-204">132</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-22" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-205">132</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-206">10,118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-207">10,118</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deconsolidation of an ancillary business</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="f-208">1,369</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="f-209">1,369</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest holder</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-210">2,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-211">2,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-212">3,073</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-213">3,073</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest attributable to subsidiary equity plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-214">2,908</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-215">2,908</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to the Ensign Group, Inc.</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-216">194,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-217">194,652</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BALANCE&#160;- DECEMBER&#160;31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-218">55,190</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-219">58</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-220">369,760</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-221">733,992</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-28" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-222">2,944</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-223">83,042</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-224">946</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-225">1,021,714</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to employees and directors resulting from the exercise of stock options</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-226">688</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-227">1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-228">12,676</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-229">12,677</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-230">207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-231">5,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-232">5,241</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock used to satisfy tax withholding obligations</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-233">20</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-234">20</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-235">1,702</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-236">1,702</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-237">0.2225</ix:nonFraction> per share)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-238">12,334</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-239">12,334</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock award compensation</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-240">22,720</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">22,720</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock (Note 21)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-242">404</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-243">404</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-244">29,882</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-245">29,882</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of noncontrolling interest shares</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" format="ixt:num-dot-decimal" scale="3" id="f-246">1,539</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-247">835</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-248">704</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of noncontrolling interests through subsidiary equity plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-249">6,693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-250">6,693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-251">29</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-252">29</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest attributable to subsidiary equity plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="f-253">9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="f-254">284</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="f-255">275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to the Ensign Group, Inc.</span></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-256">224,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-257">224,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BALANCE&#160;- DECEMBER&#160;31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-258">55,661</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-259">59</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">415,560</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">946,339</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-262">3,368</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-263">114,626</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-264">1,468</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">1,248,800</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock to employees and directors resulting from the exercise of stock options</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-266">759</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-267">1</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-268">18,368</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-269">18,369</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of restricted stock, net of forfeitures</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="3" id="f-270">199</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-271">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" format="ixt:num-dot-decimal" scale="3" id="f-272">5,068</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares of common stock used to satisfy tax withholding obligations</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-273">22</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="3" id="f-274">22</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-275">1,929</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-276">1,929</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dividends declared ($<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-277">0.2325</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-278">13,085</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Dividends" format="ixt:num-dot-decimal" scale="3" id="f-279">13,085</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock award compensation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-280">30,754</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-281">30,754</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquisition of noncontrolling interest shares</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-282">256</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromRedemptions" scale="3" id="f-283">256</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interest</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-284">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-285">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Noncontrolling interest attributable to subsidiary equity plan</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-286">3,787</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" format="ixt:num-dot-decimal" scale="3" id="f-287">3,533</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="3" id="f-288">254</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to the Ensign Group, Inc.</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-289">209,399</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-290">209,399</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">BALANCE&#160;- DECEMBER&#160;31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-291">56,597</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-292">60</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-293">465,707</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-294">1,142,653</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-3" name="us-gaap:TreasuryStockCommonShares" format="ixt:num-dot-decimal" scale="3" id="f-295">3,390</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-296">116,555</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-297">5,452</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">1,497,317</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_49"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.043%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net income </span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-299">209,850</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-300">224,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-301">197,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-302">72,387</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-303">62,355</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-304">55,985</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of deferred financing fees</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-305">1,067</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-306">1,036</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="f-307">859</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash leasing arrangement </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:NonCashLeaseExpense" scale="3" id="f-308">870</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:NonCashLeaseExpense" scale="3" id="f-309">493</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:NonCashLeaseExpense" scale="3" id="f-310">485</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Write-off of deferred financing fees</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:fixed-zero" scale="3" id="f-311">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" id="f-312">566</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" format="ixt:fixed-zero" scale="3" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-314">27,481</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-315">6,496</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-316">724</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provision for doubtful accounts </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-317">3,408</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-318">2,390</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProvisionForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-319">2,609</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-320">30,767</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-321">22,720</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-322">18,678</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received from insurance proceeds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-323">1,396</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-324">1,282</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-325">2,382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of assets </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="f-326">123</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="f-327">3,467</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="3" id="f-328">1,371</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain)/loss on insurance claims, legal matters and asset disposals</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-329">1,368</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets" format="ixt:num-dot-decimal" scale="3" id="f-330">3,926</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets" scale="3" id="f-331">977</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Litigation</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="3" id="f-332">48,000</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="f-333">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="3" id="f-334">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in operating assets and liabilities</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-335">79,818</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-336">82,426</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-337">30,771</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid income taxes</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="f-338">814</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" scale="3" id="f-339">809</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidTaxes" format="ixt:num-dot-decimal" scale="3" id="f-340">4,228</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-341">6,993</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-342">9,141</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-343">4,898</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:29.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred employer portion of social security taxes (Note 3)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" format="ixt:fixed-zero" scale="3" id="f-344">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" format="ixt:num-dot-decimal" scale="3" id="f-345">24,155</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" format="ixt:num-dot-decimal" scale="3" id="f-346">24,154</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash surrender value of life insurance policy premiums</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue" format="ixt:num-dot-decimal" scale="3" id="f-347">16,072</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue" format="ixt:num-dot-decimal" scale="3" id="f-348">7,614</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue" format="ixt:num-dot-decimal" scale="3" id="f-349">10,953</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred compensation liability</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="f-350">16,044</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="f-351">7,637</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredCompensation" format="ixt:num-dot-decimal" scale="3" id="f-352">11,078</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease obligations</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-353">6,564</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="f-354">345</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-355">5,814</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-356">15,924</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-357">17,870</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-358">7,117</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued wages and related liabilities</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-359">47,967</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-360">38,982</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-361">47,701</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-362">23,828</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-363">3,010</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-364">1,297</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued self-insurance liabilities</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInSelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-365">28,827</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncreaseDecreaseInSelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-366">17,785</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncreaseDecreaseInSelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-367">13,724</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="3" id="f-368">50</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="3" id="f-369">46</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherDeferredLiability" scale="3" id="f-370">66</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET CASH PROVIDED BY OPERATING ACTIVITIES</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-371">376,666</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-372">272,513</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-373">275,684</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of property and equipment</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:PaymentsToAcquirePropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-374">106,180</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:PaymentsToAcquirePropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-375">87,545</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:PaymentsToAcquirePropertyAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-376">69,550</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments for business acquisitions (Note 7)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-378">16,400</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="3" id="f-379">6,000</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments for asset acquisitions (Note 7)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:PaymentsToAcquireAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-380">67,798</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:PaymentsToAcquireAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-381">84,736</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:PaymentsToAcquireAssetAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-382">98,224</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" format="ixt:num-dot-decimal" scale="3" id="f-383">1,216</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" format="ixt:fixed-zero" scale="3" id="f-384">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" scale="3" id="f-385">100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash from insurance proceeds</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-386">2,029</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-387">1,339</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-388">6,899</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash proceeds from the sale of assets </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="3" id="f-389">248</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-390">8,630</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleOfProductiveAssets" format="ixt:num-dot-decimal" scale="3" id="f-391">1,854</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deconsolidation of an ancillary business</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="3" id="f-392">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:fixed-zero" scale="3" id="f-393">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashDivestedFromDeconsolidation" format="ixt:num-dot-decimal" scale="3" id="f-394">1,984</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash payments for Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:PaymentsForMedicareAndMedicaidLicenses" format="ixt:fixed-zero" scale="3" id="f-395">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:PaymentsForMedicareAndMedicaidLicenses" format="ixt:fixed-zero" scale="3" id="f-396">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:PaymentsForMedicareAndMedicaidLicenses" scale="3" id="f-397">106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-398">29,603</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-399">21,975</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-400">32,257</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-401">18,852</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-402">14,356</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-403">27,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other restricted assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-404">970</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="3" id="f-405">149</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-406">2,120</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET CASH USED IN INVESTING ACTIVITIES </span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-407">182,698</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-408">186,182</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-409">173,907</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from debt (Note 15)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="f-410">150</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="3" id="f-411">411</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-412">45,218</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments on debt (Note 15)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-413">4,033</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-414">4,106</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-415">3,056</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of options</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-416">18,369</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-417">12,677</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-418">9,180</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of shares of common stock to satisfy tax withholding obligations</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-419">1,929</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-420">1,702</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-421">1,711</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of shares of common stock (Note 21)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-423">29,882</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-424">10,118</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-425">12,890</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-426">12,168</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfDividends" format="ixt:num-dot-decimal" scale="3" id="f-427">11,548</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sale of subsidiary shares (Note 6)</span></div></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" format="ixt:fixed-zero" scale="3" id="f-428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" format="ixt:num-dot-decimal" scale="3" id="f-429">6,693</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" format="ixt:fixed-zero" scale="3" id="f-430">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-controlling interest distribution</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="f-431">4</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" scale="3" id="f-432">284</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsToMinorityShareholders" format="ixt:num-dot-decimal" scale="3" id="f-433">2,908</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of non-controlling interest</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:PurchasesOfNonControllingInterest" scale="3" id="f-434">256</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:PurchasesOfNonControllingInterest" scale="3" id="f-435">704</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="ensg:PurchasesOfNonControllingInterest" format="ixt:num-dot-decimal" scale="3" id="f-436">2,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments of deferred financing costs</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" scale="3" id="f-437">19</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-438">3,197</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-439">1,172</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" format="ixt:fixed-zero" scale="3" id="f-440">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" format="ixt:fixed-zero" scale="3" id="f-441">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" format="ixt:num-dot-decimal" scale="3" id="f-442">11,637</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" format="ixt:fixed-zero" scale="3" id="f-443">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" format="ixt:num-dot-decimal" scale="3" id="f-445">113,660</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">NET CASH USED IN FINANCING ACTIVITIES</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="f-446">612</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-447">32,262</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-448">76,138</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-449">193,356</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-450">54,069</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-451">25,639</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents beginning of period</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-452">316,270</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-453">262,201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-454">236,562</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents end of period</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-455">509,626</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-456">316,270</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" format="ixt:num-dot-decimal" scale="3" id="f-457">262,201</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_52"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"/><td style="width:63.354%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.537%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In thousands)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash paid during the period for:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-458">7,025</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-459">7,604</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-460">5,690</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-461">89,730</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-462">70,055</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="3" id="f-463">65,547</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-464">196,942</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-465">151,870</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-466">138,795</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-cash financing and investing activity</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued capital expenditures</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-467">4,600</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-468">4,800</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-469">3,700</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued dividends declared</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-470">3,396</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">3,201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">3,035</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for new and modified operating lease obligations</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-473">376,550</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-474">370,753</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-475">198,593</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_58"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:107%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">THE ENSIGN GROUP, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(Dollars, shares and options in thousands, except per share data)</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_61"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="f-476-1"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December&#160;31, 2023, the Company's independent subsidiaries operated <ix:nonFraction unitRef="facility" contextRef="c-4" decimals="0" name="ensg:NumberOfHealthCareFacilities" scale="0" id="f-477">297</ix:nonFraction> facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December&#160;31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately <ix:nonFraction unitRef="bed" contextRef="c-4" decimals="-2" name="ensg:OperationalSkilledNursingBeds" format="ixt:num-dot-decimal" scale="0" id="f-478">30,600</ix:nonFraction> operational skilled nursing beds and <ix:nonFraction unitRef="senior_living_unit" contextRef="c-4" decimals="-2" name="ensg:OperationalSeniorLivingUnits" format="ixt:num-dot-decimal" scale="0" id="f-479">3,100</ix:nonFraction> senior living units. As of December&#160;31, 2023, the Company's independent subsidiaries operated <ix:nonFraction unitRef="facility" contextRef="c-4" decimals="0" name="ensg:NumberOfRealEstatePropertiesLeased" scale="0" id="f-480">214</ix:nonFraction> facilities under long-term lease arrangements and had options to purchase <ix:nonFraction unitRef="facility" contextRef="c-4" decimals="0" name="ensg:NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" scale="0" id="f-481">11</ix:nonFraction> of those <ix:nonFraction unitRef="facility" contextRef="c-4" decimals="0" name="ensg:NumberOfRealEstatePropertiesLeased" scale="0" id="f-482">214</ix:nonFraction> facilities. The Company's real estate portfolio includes <ix:nonFraction unitRef="property" contextRef="c-4" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-483">113</ix:nonFraction> owned real estate properties, which includes <ix:nonFraction unitRef="facility" contextRef="c-51" decimals="0" name="ensg:NumberOfFacilities" scale="0" id="f-484">83</ix:nonFraction> facilities operated and managed by the Company's independent subsidiaries, <ix:nonFraction unitRef="operation" contextRef="c-52" decimals="0" name="ensg:NumberOfOperations" scale="0" id="f-485">30</ix:nonFraction> operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those <ix:nonFraction unitRef="operation" contextRef="c-52" decimals="0" name="ensg:NumberOfOperations" scale="0" id="f-486">30</ix:nonFraction> operations, <ix:nonFraction unitRef="facility" contextRef="c-52" decimals="0" name="ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" format="ixt-sec:numwordsen" scale="0" id="f-487">one</ix:nonFraction> senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company&#8217;s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers&#8217; compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on Standard Bearer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated &#8220;Company&#8221; and &#8220;its&#8221; assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_67"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-488" continuedAt="f-488-1" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-488-1" continuedAt="f-488-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-489" continuedAt="f-489-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-489-1"> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.</ix:continuation> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-490" continuedAt="f-490-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-490-1">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-491" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-488-2" continuedAt="f-488-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="f-492" continuedAt="f-492-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Considerations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments&#8217; recorded values approximate fair values because of their nature or respective short durations. </span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-492-1" continuedAt="f-492-2">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.</ix:continuation> See Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-492-2">The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-493" continuedAt="f-493-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div></ix:nonNumeric><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-493-1">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company&#8217;s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.</ix:continuation> </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-488-3" continuedAt="f-488-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:TradeAndOtherAccountsReceivablePolicy" id="f-494" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-495" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on &#8220;Level&#160;1&#8221; inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-496" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-497" continuedAt="f-497-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-497-1"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:f-498">three</span> to <ix:nonNumeric contextRef="c-54" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-499">59</ix:nonNumeric> years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-500" continuedAt="f-500-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December&#160;31, 2023, the Company has <ix:nonFraction unitRef="lease" contextRef="c-4" decimals="INF" name="ensg:NumberOfFinancingLeases" format="ixt-sec:numwordsen" scale="0" id="f-501">one</ix:nonFraction> financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of <ix:nonNumeric contextRef="c-4" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-502">ten years</ix:nonNumeric> or more and typically include <ix:nonFraction unitRef="option" contextRef="c-1" decimals="INF" name="ensg:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-503">one</ix:nonFraction> or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:f-504">ten</span> to <ix:nonNumeric contextRef="c-54" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="f-505">15</ix:nonNumeric> years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-488-4" continuedAt="f-488-5"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-500-1">The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-506" continuedAt="f-506-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-506-1">The Company reviews the carrying value of long-lived assets that are held and used in the Company&#8217;s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management&#8217;s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.</ix:continuation> Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-507" continuedAt="f-507-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:f-508">four</span> to <ix:nonNumeric contextRef="c-56" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:durwordsen" id="f-509">eight months</ix:nonNumeric>, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over <ix:nonNumeric contextRef="c-57" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-510">30</ix:nonNumeric> years&#160;and customer relationships are amortized over a period of up to <ix:nonNumeric contextRef="c-58" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-511">20</ix:nonNumeric> years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><ix:continuation id="f-507-1" continuedAt="f-507-2"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#160;</span></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-507-2">(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="f-512">7,410</ix:nonFraction>, since inception in 1999. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SelfInsuranceReservePolicyTextBlock" id="f-513" continuedAt="f-513-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-514">500</ix:nonFraction> per claim, subject to an additional one-time deductible of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-515">1,250</ix:nonFraction> for the Company's independent subsidiaries in California and a separate, one-time, deductible of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-516">1,250</ix:nonFraction> for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-517">1,000</ix:nonFraction> per claim, $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-518">3,000</ix:nonFraction> per operation, with a $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-519">5,000</ix:nonFraction> blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-520">1,000</ix:nonFraction> per claim and $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-521">3,000</ix:nonFraction> per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the self-insured retention is $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-522">750</ix:nonFraction> per claim, subject to an additional one-time deductible of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-523">1,500</ix:nonFraction> for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-524">650</ix:nonFraction> per claim, subject to an additional one-time deductible of $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-525">1,350</ix:nonFraction>. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-526">1,000</ix:nonFraction> per claim, $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-527">3,000</ix:nonFraction> per operation, with a $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:SelfInsuranceReserve" format="ixt:num-dot-decimal" scale="3" id="f-528">10,000</ix:nonFraction> blanket aggregate limit and an additional state-specific aggregate where required by state law. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-488-5" continuedAt="f-488-6"><ix:continuation id="f-513-1"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent subsidiaries are self-insured for workers&#8217; compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-529">625</ix:nonFraction> per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers&#8217; compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-530">750</ix:nonFraction> per occurrence. The Company&#8217;s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-531">350</ix:nonFraction> per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-532">500</ix:nonFraction> per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-533">525</ix:nonFraction> for each covered person for fiscal years 2023 and 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:SelfInsuranceReserve" scale="3" id="f-534">500</ix:nonFraction> for each covered person for fiscal year 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers&#8217; compensation, healthcare benefits and related services provided to date. The amount of the Company&#8217;s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company&#8217;s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company&#8217;s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company&#8217;s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-535" continuedAt="f-535-1" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company&#8217;s estimates and assumptions, actual results could differ.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-488-6" continuedAt="f-488-7"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-535-1">Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.</ix:continuation> </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><ix:nonNumeric contextRef="c-1" name="ensg:NoncontrollingInterestPolicyTextBlock" id="f-536" continuedAt="f-536-1" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-536-1">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-537" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.</span></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-538" continuedAt="f-538-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Issued But Not Yet Adopted by the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, the FASB issued ASU 2023-06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative", </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. </span></div></ix:nonNumeric></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><ix:continuation id="f-538-1" continuedAt="f-538-2"><ix:continuation id="f-488-7" continuedAt="f-488-8"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-538-2"><ix:continuation id="f-488-8">", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.</ix:continuation></ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_79"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-539" continuedAt="f-539-1" escape="true">REVENUE AND ACCOUNTS RECEIVABLE</ix:nonNumeric></span></div><ix:continuation id="f-539-1" continuedAt="f-539-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for <ix:nonFraction unitRef="number" contextRef="c-80" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-540">72.6</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-541">73.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-542">73.6</ix:nonFraction>% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company&#8217;s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-543" escape="true"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.086%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.582%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-544">1,459,449</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-545">39.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-546">1,183,156</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-547">39.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-548">1,022,460</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-549">39.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-550">985,749</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-551">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-552">832,160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-553">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-554">727,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-555">27.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid &#8212; skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-556">245,663</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-557">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-558">200,878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-559">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-560">172,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-561">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-562">2,690,861</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-563">72.6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-564">2,216,194</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-565">73.7</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-566">1,922,333</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-567">73.6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-568">666,129</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-569">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-570">525,710</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-571">17.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-572">456,728</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-573">17.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-574">351,081</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-575">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-576">266,807</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-577">8.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-578">232,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-579">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-580">3,708,071</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-581">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-582">3,008,711</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-583">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-584">2,611,476</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-585">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to state relief funding</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $<ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-586">21,284</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-587">16,757</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-588">15,985</ix:nonFraction> for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-539-2"><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:AccruedLiabilitiesStateReliefContractLiabilities" scale="3" id="f-589">486</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:AccruedLiabilitiesStateReliefContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-590">1,001</ix:nonFraction> in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:FamilyFirstCoronavirusResponseActPaymentsReceived" format="ixt:num-dot-decimal" scale="3" id="f-591">64,238</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:FamilyFirstCoronavirusResponseActPaymentsReceived" format="ixt:num-dot-decimal" scale="3" id="f-592">81,057</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:FamilyFirstCoronavirusResponseActPaymentsReceived" format="ixt:num-dot-decimal" scale="3" id="f-593">70,484</ix:nonFraction> in state relief funding and recognized $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-594">64,753</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-595">81,837</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" format="ixt:num-dot-decimal" scale="3" id="f-596">75,231</ix:nonFraction>, respectively, as revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Federal relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" format="ixt:num-dot-decimal" scale="3" id="f-597">11,637</ix:nonFraction> in Provider Relief Funds.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company applied for and received $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="ensg:MedicareAcceleratedAndAdvancePaymentCARESACT" format="ixt:num-dot-decimal" scale="3" id="f-598">105,255</ix:nonFraction> through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" format="ixt:num-dot-decimal" scale="3" id="f-599">3,232</ix:nonFraction> of the funds in 2020 and the remaining funds of $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" format="ixt:num-dot-decimal" scale="3" id="f-600">102,023</ix:nonFraction> in March 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="ensg:LiabilitiesDeferredTaxPaymentsUnderCARESAct" format="ixt:num-dot-decimal" scale="3" id="f-601">48,309</ix:nonFraction> of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company&#8217;s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="f-602" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 and 2022, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.861%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-603">178,285</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-604">157,878</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-605">125,907</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-606">95,940</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-607">85,512</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-608">76,526</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-609">104,683</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-610">85,890</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-611">494,387</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableGross" format="ixt:num-dot-decimal" scale="3" id="f-612">416,234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-613">9,348</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-614">7,802</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-615">485,039</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-616">408,432</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_85"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-617" continuedAt="f-617-1" escape="true">COMPUTATION OF NET INCOME PER COMMON SHARE</ix:nonNumeric></span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><ix:continuation id="f-617-1" continuedAt="f-617-2"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="f-618" continuedAt="f-618-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-617-2"><ix:continuation id="f-618-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-619">209,850</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-620">224,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-621">197,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="f-622">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="f-623">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="f-624">3,073</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-625">209,399</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-626">224,681</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-627">194,652</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-628">55,708</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-629">54,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-630">54,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-631">3.76</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-632">4.09</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-633">3.57</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="f-634" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.818%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-635">209,850</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-636">224,652</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-637">197,725</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="f-638">451</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" scale="3" id="f-639">29</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" format="ixt:num-dot-decimal" scale="3" id="f-640">3,073</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-641">209,399</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-642">224,681</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-643">194,652</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-644">55,708</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-645">54,887</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-646">54,486</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-647">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-648">1,984</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:num-dot-decimal" scale="3" id="f-649">2,439</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-650">57,323</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-651">56,871</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-652">56,925</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-653">3.65</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-654">3.95</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-655">3.42</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-656">1,429</ix:nonFraction>, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-657">780</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-658">198</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div></ix:nonNumeric></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_91"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-659" continuedAt="f-659-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-659-1"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="f-660">59,530</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:InvestmentsAndCash" format="ixt:num-dot-decimal" scale="3" id="f-661">53,924</ix:nonFraction> as of December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December&#160;31, 2023, and 2022, the fair value of the investment funds was $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-662">41,216</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="3" id="f-663">25,144</ix:nonFraction>, respectively, which are derived using Level 2 inputs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_97"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="ensg:StandardBearerTextBlock" id="f-664" continuedAt="f-664-1" escape="true">STANDARD BEARER</ix:nonNumeric></span></div><ix:continuation id="f-664-1" continuedAt="f-664-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's real estate portfolio consists of <ix:nonFraction unitRef="property" contextRef="c-134" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-665">108</ix:nonFraction> of the Company's <ix:nonFraction unitRef="property" contextRef="c-4" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-666">113</ix:nonFraction> owned real estate properties, of which <ix:nonFraction unitRef="operation" contextRef="c-135" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-667">79</ix:nonFraction> are operated and managed by the Company's independent subsidiaries and <ix:nonFraction unitRef="operation" contextRef="c-136" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-668">30</ix:nonFraction> are leased to and operated by third-party operators. Of those <ix:nonFraction unitRef="operation" contextRef="c-52" decimals="0" name="ensg:NumberOfOperations" scale="0" id="f-669">30</ix:nonFraction> operations, <ix:nonFraction unitRef="facility" contextRef="c-52" decimals="0" name="ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" format="ixt-sec:numwordsen" scale="0" id="f-670">one</ix:nonFraction> senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="property" contextRef="c-137" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-671">three</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stand-alone skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="operation" contextRef="c-138" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-672">two</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operations for an aggregate purchase price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-673">65,899</ix:nonFraction>. Of these additions, the <ix:nonFraction unitRef="property" contextRef="c-137" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-674">three</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="operation" contextRef="c-137" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-675">one</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation acquired are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="property" contextRef="c-140" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-676">ten</ix:nonFraction> skilled nursing facilities for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-3" name="us-gaap:AssetAcquisitionConsiderationTransferred" format="ixt:num-dot-decimal" scale="3" id="f-677">84,656</ix:nonFraction>, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="skilled_nursing_property" contextRef="c-142" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-678">three</ix:nonFraction> of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer, certain of the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany master lease agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's independent subsidiaries and <ix:nonFraction unitRef="operation" contextRef="c-135" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-679">79</ix:nonFraction> Standard Bearer independent real estate subsidiaries have entered into <ix:nonFraction unitRef="lease" contextRef="c-143" decimals="INF" name="ensg:NumberOfLeaseArrangements" format="ixt-sec:numwordsen" scale="0" id="f-680">five</ix:nonFraction> triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from <ix:nonNumeric contextRef="c-144" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-681">15</ix:nonNumeric> to <ix:nonNumeric contextRef="c-145" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-682">19</ix:nonNumeric> years with <ix:nonFraction unitRef="renewal" contextRef="c-146" decimals="INF" name="ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="f-683">three</ix:nonFraction> <ix:nonNumeric contextRef="c-146" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-684">five-year</ix:nonNumeric> renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than <ix:nonFraction unitRef="number" contextRef="c-144" decimals="INF" name="us-gaap:LesseeOperatingLeaseDiscountRate" format="ixt:fixed-zero" scale="0" id="f-685">zero</ix:nonFraction>) or (2) <ix:nonFraction unitRef="number" contextRef="c-146" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-686">2.5</ix:nonFraction>%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-687">66,712</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-688">57,967</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-689">44,165</ix:nonFraction> for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany management agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to <ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="ensg:PropertyManagementFeePercentFeeOfTotalRevenues" scale="-2" id="f-690">5</ix:nonFraction>% of total rental revenue and an incentive management fee that is equal to <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="ensg:PropertyManagementFeePercentFeeOfFundsFromOperations" scale="-2" id="f-691">5</ix:nonFraction>% of funds from operations (FFO) and is capped at <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="ensg:PropertyManagementFeePercentFeeOfTotalRevenues" scale="-2" id="f-692">1</ix:nonFraction>% of total rental revenue, for a total of <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="ensg:PropertyManagementFeePercentFeeOfTotalRevenues" scale="-2" id="f-693">6</ix:nonFraction>%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-3" name="us-gaap:ManagementFeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-694">4,948</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-3" name="us-gaap:ManagementFeeExpense" format="ixt:num-dot-decimal" scale="3" id="f-695">4,367</ix:nonFraction>, respectively. <ix:nonFraction unitRef="usd" contextRef="c-154" decimals="INF" name="us-gaap:ManagementFeeExpense" format="ixt:fixed-zero" scale="0" id="f-696">No</ix:nonFraction> management fees were recorded in 2021, which was prior to the formation of Standard Bearer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany debt arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-697">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-698">1.25</ix:nonFraction>% per annum or SOFR plus a margin range from <ix:nonFraction unitRef="number" contextRef="c-157" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-699">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-158" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-700">2.25</ix:nonFraction>% per annum. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these debts. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-664-2"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of <ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-701">five years</ix:nonNumeric> or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than <ix:nonNumeric contextRef="c-159" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" format="ixt-sec:durwordsen" id="f-702">six months</ix:nonNumeric> after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-703">6,544</ix:nonFraction>. During the year ended December 31, 2023 and 2022, the Company did <ix:nonFraction unitRef="shares" contextRef="c-161" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-704"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-705"><ix:nonFraction unitRef="shares" contextRef="c-160" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-706"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-707">not</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $<ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" scale="3" id="f-708">149</ix:nonFraction>. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_103"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-709" continuedAt="f-709-1" escape="true">OPERATION EXPANSIONS</ix:nonNumeric></span></div><ix:continuation id="f-709-1" continuedAt="f-709-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of <ix:nonFraction unitRef="operation" contextRef="c-164" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="f-710">25</ix:nonFraction> stand-alone skilled nursing operations and <ix:nonFraction unitRef="operation" contextRef="c-165" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-711">one</ix:nonFraction> campus operation. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="property" contextRef="c-137" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-712">three</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="operation" contextRef="c-137" decimals="INF" name="ensg:NumberOfPropertiesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-713">one</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation, which were leased back to the Company's independent subsidiaries.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the purchase of real estate properties. These new operations added a total of <ix:nonFraction unitRef="bed" contextRef="c-166" decimals="INF" name="ensg:OperationalSkilledNursingBeds" format="ixt:num-dot-decimal" scale="0" id="f-714">2,483</ix:nonFraction> operational skilled nursing beds and <ix:nonFraction unitRef="senior_living_unit" contextRef="c-167" decimals="INF" name="ensg:OperationalSeniorLivingUnits" scale="0" id="f-715">94</ix:nonFraction> operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, the Company expanded its operations through a long-term lease, with the addition of <ix:nonFraction unitRef="operation" contextRef="c-168" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-716">two</ix:nonFraction> stand-alone skilled nursing operations, totaling <ix:nonFraction unitRef="bed" contextRef="c-169" decimals="INF" name="ensg:OperationalSkilledNursingBeds" scale="0" id="f-717">241</ix:nonFraction> operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the addition of <ix:nonFraction unitRef="operation" contextRef="c-170" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="f-718">23</ix:nonFraction> stand-alone skilled nursing operations and <ix:nonFraction unitRef="operation" contextRef="c-171" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-719">one</ix:nonFraction> campus operation. Of these additions, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="operation" contextRef="c-170" decimals="INF" name="ensg:NumberOfLeaseArrangements" format="ixt-sec:numwordsen" scale="0" id="f-720">seven</ix:nonFraction> of the stand-alone skilled nursing operations, which were leased back to Ensign's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information on the purchases of real estate properties. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company added <ix:nonFraction unitRef="operation" contextRef="c-172" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-721">five</ix:nonFraction> senior living operations that were transferred from The Pennant Group, Inc. (Pennant), <ix:nonFraction unitRef="operation" contextRef="c-172" decimals="INF" name="ensg:NumberOfLivingOperationsTransferredFromThirdParties" format="ixt-sec:numwordsen" scale="0" id="f-722">three</ix:nonFraction> of which are part of campuses operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. These new operations added a total of <ix:nonFraction unitRef="bed" contextRef="c-173" decimals="INF" name="ensg:OperationalSkilledNursingBeds" format="ixt:num-dot-decimal" scale="0" id="f-723">3,058</ix:nonFraction> operational skilled nursing beds and <ix:nonFraction unitRef="senior_living_unit" contextRef="c-174" decimals="INF" name="ensg:OperationalSeniorLivingUnits" scale="0" id="f-724">674</ix:nonFraction> operational senior living units to be operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-709-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-725">16,400</ix:nonFraction> was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and a real estate purchase,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of <ix:nonFraction unitRef="operation" contextRef="c-176" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="f-726">17</ix:nonFraction> stand-alone skilled nursing operations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and <ix:nonFraction unitRef="business" contextRef="c-177" decimals="INF" name="ensg:NumberOfAssetAcquisitions" format="ixt-sec:numwordsen" scale="0" id="f-727">five</ix:nonFraction> real estate purchases, <ix:nonFraction unitRef="business" contextRef="c-178" decimals="INF" name="ensg:NumberOfAssetAcquisitions" format="ixt-sec:numwordsen" scale="0" id="f-728">four</ix:nonFraction> of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of <ix:nonFraction unitRef="bed" contextRef="c-179" decimals="INF" name="ensg:OperationalSkilledNursingBeds" format="ixt:num-dot-decimal" scale="0" id="f-729">1,832</ix:nonFraction> operational skilled nursing beds operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-3" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="3" id="f-730">6,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-731" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, 2022, and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.642%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.600%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-732">7,794</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-733">15,527</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-734">19,928</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-735">57,488</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-736">65,070</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-737">77,975</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-738">1,840</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="3" id="f-739">1,618</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" id="f-740">217</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" id="f-741">346</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" id="f-742">367</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="3" id="f-743">29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-745">16,400</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-746">6,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ensg:LeasedAssetsAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ensg:LeasedAssetsAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-748">1,909</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ensg:LeasedAssetsAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-750">330</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-751">245</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-752">75</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-753">67,798</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-754">101,136</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="3" id="f-755">104,224</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company&#8217;s current operating results or indicative of the integration potential of its newly acquired </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent subsidiaries</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets added during the&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> balance sheets of the Company, and the operating results have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> statements of income of the Company since the date the Company gained effective control.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_109"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-756" continuedAt="f-756-1" escape="true">BUSINESS SEGMENTS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-756-1" continuedAt="f-756-2"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-757">two</ix:nonFraction> reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the skilled services segment includes <ix:nonFraction unitRef="operation" contextRef="c-4" decimals="INF" name="ensg:SkilledServiceFacilities" scale="0" id="f-758">259</ix:nonFraction> skilled nursing operations and <ix:nonFraction unitRef="operation" contextRef="c-4" decimals="0" name="ensg:SkilledServicesAndSeniorLivingCampuses" scale="0" id="f-759">27</ix:nonFraction> campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of <ix:nonFraction unitRef="property" contextRef="c-134" decimals="0" name="us-gaap:NumberOfRealEstateProperties" scale="0" id="f-760">108</ix:nonFraction> owned real estate properties. </span></div></ix:continuation><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-756-2" continuedAt="f-756-3"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reports an &#8220;All Other&#8221; category that includes results from its senior living operations, which includes <ix:nonFraction unitRef="facility" contextRef="c-4" decimals="INF" name="ensg:SeniorLivingFacilities" scale="0" id="f-761">11</ix:nonFraction> stand-alone senior living operations and the senior living operations at <ix:nonFraction unitRef="operation" contextRef="c-4" decimals="0" name="ensg:SkilledServicesAndSeniorLivingCampuses" scale="0" id="f-762">27</ix:nonFraction> campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the &#8220;All Other&#8221; category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it is part of the CODM financial information. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-763" continuedAt="f-763-1" escape="true"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-764">3,578,855</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-766">144,667</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-767">15,451</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-768">3,708,071</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-770">82,486</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-771">11,137</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-772">72,339</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-773">21,284</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-774">3,578,855</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-775">82,486</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-776">155,804</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-777">87,790</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-778">3,729,355</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-779">464,925</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-780">29,065</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" sign="-" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-781">221,251</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-783">272,739</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProfitLossFromRealEstateOperations" scale="3" id="f-784">23</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-785">272,762</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-786">38,766</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-787">25,205</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-788">8,416</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-789">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-790">72,387</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-792">19,761</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-793">1,228</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" sign="-" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-794">12,902</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-795">8,087</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-796">3,897</ix:nonFraction> for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-756-3" continuedAt="f-756-4"><ix:continuation id="f-763-1" continuedAt="f-763-2"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-797">2,906,215</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-798">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-799">115,214</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-800">12,718</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-801">3,008,711</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-802">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-803">72,937</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-804">7,396</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-805">63,576</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-806">16,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-807">2,906,215</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-808">72,937</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-809">122,610</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-810">76,294</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-811">3,025,468</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-812">408,732</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-813">27,871</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" sign="-" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-814">150,781</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-816">285,822</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ProfitLossFromRealEstateOperations" format="ixt:num-dot-decimal" scale="3" id="f-817">3,267</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-818">289,089</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-819">33,224</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-820">21,613</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-821">7,518</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-823">62,355</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-825">15,707</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-826">1,870</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" sign="-" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-827">8,646</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-828">8,931</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.603%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-829">2,523,234</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-831">95,276</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-832">7,034</ix:nonFraction>)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-833">2,611,476</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-834">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-835">58,127</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-836">7,409</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-837">49,551</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-838">15,985</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-839">2,523,234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-840">58,127</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-841">102,685</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" sign="-" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-842">56,585</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-843">2,627,461</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-844">373,603</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-845">31,876</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" sign="-" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-846">147,915</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:SegmentIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-848">257,564</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ProfitLossFromRealEstateOperations" scale="3" id="f-849">440</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-850">258,004</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-851">30,681</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-852">17,558</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-853">7,746</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:fixed-zero" scale="3" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-855">55,985</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-856">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-857">6,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="f-858">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-860">6,849</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-763-2">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="f-861" continuedAt="f-861-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.378%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-862">1,429,473</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-863">29,976</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-864">1,459,449</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-865">39.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-866">985,749</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-867">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-868">985,749</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-90" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-869">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-870">245,663</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-872">245,663</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-873">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-874">2,660,885</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-875">29,976</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-876">2,690,861</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-80" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-877">72.6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-878">666,129</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-880">666,129</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-106" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-881">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-882">251,841</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-883">99,240</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-884">351,081</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-885">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-886">3,578,855</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-887">129,216</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-888">3,708,071</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-117" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-889">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-861-1"><ix:continuation id="f-756-4"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.355%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-890">1,158,309</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-891">24,847</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-892">1,183,156</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-893">39.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-894">832,160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-895">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-896">832,160</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-92" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-897">27.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-898">200,878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-900">200,878</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-901">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-902">2,191,347</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-903">24,847</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-904">2,216,194</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-905">73.7</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-906">525,710</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-907">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-908">525,710</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-108" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-909">17.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-910">189,158</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-911">77,649</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-912">266,807</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-114" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-913">8.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-914">2,906,215</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-915">102,496</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-916">3,008,711</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-917">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.379%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-918">1,007,061</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-919">15,399</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-920">1,022,460</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-88" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-921">39.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-922">727,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-923">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-924">727,103</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-94" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-925">27.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-926">172,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-927">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-928">172,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-929">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-930">1,906,934</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-931">15,399</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-932">1,922,333</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-933">73.6</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-934">456,728</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-935">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-936">456,728</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-110" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-937">17.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-938">159,572</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-939">72,843</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-940">232,415</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-941">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-942">2,523,234</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-943">88,242</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-944">2,611,476</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-119" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-945">100.0</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div></ix:continuation></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_118"></div><div style="margin-top:12pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-946" continuedAt="f-946-1" escape="true">PROPERTY AND EQUIPMENT - NET</ix:nonNumeric></span></div><ix:continuation id="f-946-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-947" escape="true"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-948">142,656</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-949">134,864</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-950">803,155</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-951">728,231</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-952">172,064</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-953">150,903</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-954">339,383</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-955">295,739</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-956">4,192</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-957">4,544</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-958">25,563</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-959">17,521</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-960">1,487,013</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-961">1,331,802</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-962">396,242</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-963">339,792</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-964">1,090,771</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-965">992,010</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company completed the sale of assets for a sale price of $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-966">8,607</ix:nonFraction> and recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="3" id="f-967">3,467</ix:nonFraction> within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge&#160;for the fiscal years ended 2023, 2022, and 2021. See also Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the year ended December 31, 2023.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_124"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-968" continuedAt="f-968-1" escape="true">INTANGIBLE ASSETS - NET</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-968-1" continuedAt="f-968-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-969" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.682%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-284" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-970">0.3</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-971">781</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-972">742</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-973">39</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-974">435</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-975">388</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-976">47</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-287" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-977">30.0</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-978">733</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-979">439</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-980">294</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="3" id="f-981">733</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="3" id="f-982">415</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="3" id="f-983">318</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-289" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-984">18.4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-985">4,582</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-986">2,692</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-987">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-988">4,582</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-989">2,482</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-990">2,100</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-991">6,096</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-992">3,873</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-993">2,223</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-994">5,750</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-995">3,285</ix:nonFraction>)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-996">2,465</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-997">1,790</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-998">1,714</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-999">1,435</ix:nonFraction>, respectively, of which $<ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1000">1,202</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1001">1,160</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1002">1,158</ix:nonFraction> was related to the amortization of right-of-use assets, respectively. The Company did <ix:nonFraction unitRef="usd" contextRef="c-12" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-1003"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-1004"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="f-1005">no</ix:nonFraction></ix:nonFraction></ix:nonFraction>t record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1006" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December&#160;31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.837%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.382%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.381%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="3" id="f-1007">274</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="3" id="f-1008">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="3" id="f-1009">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="3" id="f-1010">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="3" id="f-1011">234</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1012">1,013</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1013">2,223</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" id="f-1014" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-1015">889</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="3" id="f-1016">889</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1017">3,413</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1018">3,083</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1019">4,302</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="f-1020">3,972</ix:nonFraction>&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-968-2">During the year ended December 31, 2023, the Company acquired $<ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-1021">330</ix:nonFraction> in Medicare and Medicaid licenses compared to $<ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-1022">245</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-3" name="us-gaap:IndefinitelivedIntangibleAssetsAcquired" scale="3" id="f-1023">181</ix:nonFraction> in the fiscal years 2022 and 2021, respectively.</ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_133"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillDisclosureTextBlock" id="f-1024" continuedAt="f-1024-1" escape="true">GOODWILL </ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1024-1" continuedAt="f-1024-2"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December&#160;31, 2023. All of the Company's acquisitions during the year ended December&#160;31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December&#160;31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1025" continuedAt="f-1025-1" escape="true">The following table represents activity in goodwill by skilled service segment and "all other" category as of December&#160;31, 2023, 2022 and 2021:</ix:nonNumeric></span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1025-1"><ix:continuation id="f-1024-2"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.578%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1026">45,486</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1027">8,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1028">54,469</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1029">6,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-1030">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1031">6,000</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1032">51,486</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1033">8,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1034">60,469</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1035">16,400</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="3" id="f-1036">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="3" id="f-1037">16,400</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1038">67,886</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1039">8,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1040">76,869</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1041">67,886</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1042">8,983</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-1043">76,869</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div id="iee29a48a3be7475b9147c6a5457e7413_142"></div><div style="margin-top:12pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:OtherAssetsDisclosureTextBlock" id="f-1044" continuedAt="f-1044-1" escape="true">RESTRICTED AND OTHER ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-1044-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" id="f-1045" escape="true"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.935%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="3" id="f-1046">2,883</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet" format="ixt:num-dot-decimal" scale="3" id="f-1047">3,753</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="3" id="f-1048">15,913</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="3" id="f-1049">10,512</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherRestrictedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1050">4,870</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherRestrictedAssets" format="ixt:num-dot-decimal" scale="3" id="f-1051">6,446</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="3" id="f-1052">2,661</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SecurityDeposit" format="ixt:num-dot-decimal" scale="3" id="f-1053">2,527</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EscrowDeposit" format="ixt:num-dot-decimal" scale="3" id="f-1054">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:EscrowDeposit" format="ixt:fixed-zero" scale="3" id="f-1055">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1056">12,662</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1057">14,053</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:RestrictedAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1058">40,205</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:RestrictedAndOtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1059">37,291</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included in restricted and other assets as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_148"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-1060" continuedAt="f-1060-1" escape="true">OTHER ACCRUED LIABILITIES</ix:nonNumeric></span></div><div style="text-indent:24.75pt"><span><br/></span></div><ix:continuation id="f-1060-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1061" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:QualityAssuranceFee" format="ixt:num-dot-decimal" scale="3" id="f-1062">14,035</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:QualityAssuranceFee" format="ixt:num-dot-decimal" scale="3" id="f-1063">7,701</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:ResidentRefundsPayable" format="ixt:num-dot-decimal" scale="3" id="f-1064">51,248</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:ResidentRefundsPayable" format="ixt:num-dot-decimal" scale="3" id="f-1065">40,783</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1066">10,834</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1067">9,698</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:AccruedLiabilitiesStateReliefContractLiabilities" scale="3" id="f-1068">486</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:AccruedLiabilitiesStateReliefContractLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1069">1,001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:CashHeldInTrustForResidents" format="ixt:num-dot-decimal" scale="3" id="f-1070">6,215</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:CashHeldInTrustForResidents" format="ixt:num-dot-decimal" scale="3" id="f-1071">6,400</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1072">3,396</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DividendsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1073">3,201</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1074">12,875</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1075">10,926</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation (Note 20)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1076">51,734</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LitigationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1077">4,553</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1078">17,405</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1079">13,046</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1080">168,228</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1081">97,309</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_157"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1082" continuedAt="f-1082-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-1082-1" continuedAt="f-1082-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-1083" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1084">73,092</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1085">56,717</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1086">49,105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1087">17,301</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1088">14,216</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1089">11,898</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1090">90,393</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1091">70,933</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1092">61,003</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1093">22,280</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1094">5,158</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="3" id="f-1095">716</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1096">5,201</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1097">1,338</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-1098">8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1099">27,481</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1100">6,496</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" sign="-" name="us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit" scale="3" id="f-1101">724</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1102">62,912</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1103">64,437</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-1104">60,279</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1105" escape="true"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1106">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1107">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1108">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes&#160;- net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1109">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1110">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1111">3.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1112">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1113">2.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" scale="-2" id="f-1114">2.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1115">4.2</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1116">3.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="f-1117">3.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1118">0.6</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1119">0.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1120">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1121">23.1</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1122">22.3</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1123">23.4</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate was <ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1124">23.1</ix:nonFraction>% for the year ended December 31, 2023, compared to <ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1125">22.3</ix:nonFraction>% for the same period in 2022 and <ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1126">23.4</ix:nonFraction>% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-1127" continuedAt="f-1127-1" escape="true"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are summarized below. </span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1082-2"><ix:continuation id="f-1127-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1128">81,502</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1129">61,685</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-1130">23,714</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" format="ixt:num-dot-decimal" scale="3" id="f-1131">18,046</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1132">1,192</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1133">1,742</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" format="ixt:num-dot-decimal" scale="3" id="f-1134">16,864</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" format="ixt:num-dot-decimal" scale="3" id="f-1135">11,910</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1136">444,590</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1137">364,408</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" format="ixt:fixed-zero" scale="3" id="f-1138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsStateTaxes" scale="3" id="f-1139">28</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1140">567,862</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-1141">457,819</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1142">789</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1143">789</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1144">567,073</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-1145">457,030</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:DeferredTaxLiabilitiesStateTaxes" scale="3" id="f-1146">280</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:DeferredTaxLiabilitiesStateTaxes" format="ixt:fixed-zero" scale="3" id="f-1147">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1148">52,334</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-1149">49,146</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1150">4,113</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:num-dot-decimal" scale="3" id="f-1151">5,150</ix:nonFraction>)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1152">443,222</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:DeferredTaxLiabilitiesRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-1153">363,091</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1154">499,949</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-1155">417,387</ix:nonFraction>)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1156">67,124</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-1157">39,643</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had state credit carryforwards as of December 31, 2023 and 2022 of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1158">1,192</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-1159">1,742</ix:nonFraction>, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1160"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="f-1161">789</ix:nonFraction></ix:nonFraction>, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_163"></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1162" continuedAt="f-1162-1" escape="true">DEBT</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-1163" escape="true"><ix:continuation id="f-1162-1" continuedAt="f-1162-2"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:62.788%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.592%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1164">152,388</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1165">156,271</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1166">3,950</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1167">3,883</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-1168">2,941</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="3" id="f-1169">3,119</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1170">145,497</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1171">149,269</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1162-2" continuedAt="f-1162-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $<ix:nonFraction unitRef="usd" contextRef="c-313" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="3" id="f-1172">600,000</ix:nonFraction> in aggregate principal amount with a maturity date of April&#160;8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="c-155" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1173">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-156" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1174">1.25</ix:nonFraction>% per annum or SOFR plus a margin range from <ix:nonFraction unitRef="number" contextRef="c-157" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1175">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-158" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="f-1176">2.25</ix:nonFraction>% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from <ix:nonFraction unitRef="number" contextRef="c-314" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1177">0.20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-315" decimals="INF" name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" scale="-2" id="f-1178">0.40</ix:nonFraction>% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:WriteOffOfDeferredDebtIssuanceCost" scale="3" id="f-1179">566</ix:nonFraction> and additional deferred financing costs of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="3" id="f-1180">3,197</ix:nonFraction> were capitalized during the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company&#8217;s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than <ix:nonFraction unitRef="number" contextRef="c-316" decimals="INF" name="ensg:TotalNetDebtRatioMaximum" scale="0" id="f-1181">3.00</ix:nonFraction>:1.00; provided that if the aggregate consideration for approved acquisitions in a <ix:nonNumeric contextRef="c-316" name="ensg:LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" format="ixt-sec:durwordsen" id="f-1182">six month</ix:nonNumeric> period is greater than $<ix:nonFraction unitRef="usd" contextRef="c-316" decimals="INF" name="ensg:LongTermDebtThresholdForEBITDARatioIncreaseElection" format="ixt:num-dot-decimal" scale="3" id="f-1183">50,000</ix:nonFraction>, then the ratio can be increased at the election of the Company with notice to the administrative agent to <ix:nonFraction unitRef="number" contextRef="c-316" decimals="INF" name="ensg:TotalNetDebtRatioMaximumAfterIncreaseElection" scale="0" id="f-1184">3.50</ix:nonFraction>:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than <ix:nonFraction unitRef="number" contextRef="c-316" decimals="INF" name="ensg:TotalNetDebtRatioMinimum" scale="0" id="f-1185">1.50</ix:nonFraction>:1.00). As of December&#160;31, 2023, there was <ix:nonFraction unitRef="usd" contextRef="c-313" decimals="INF" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:fixed-zero" scale="3" id="f-1186">no</ix:nonFraction> outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Note</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="subsidiary" contextRef="c-317" decimals="INF" name="ensg:NumberOfOperatingSubsidiaries" scale="0" id="f-1187">23</ix:nonFraction> subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1188">150,244</ix:nonFraction>, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of <ix:nonFraction unitRef="number" contextRef="c-318" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1189">3.1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-319" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-1190">4.2</ix:nonFraction>%, including fixed interest rates in a range of <ix:nonFraction unitRef="number" contextRef="c-318" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1191">2.4</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-319" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1192">3.3</ix:nonFraction>% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is <ix:nonFraction unitRef="number" contextRef="c-320" decimals="INF" name="ensg:PrepaymentPenalty" scale="-2" id="f-1193">10.0</ix:nonFraction>% and is reduced by <ix:nonFraction unitRef="number" contextRef="c-321" decimals="INF" name="ensg:ReductionInPrepaymentPenalty" scale="-2" id="f-1194">3.0</ix:nonFraction>% in the fourth year of the loan, and reduced by <ix:nonFraction unitRef="number" contextRef="c-322" decimals="INF" name="ensg:ReductionInPrepaymentPenalty" scale="-2" id="f-1195">1.0</ix:nonFraction>%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years five through ten of the loan. There is <ix:nonFraction unitRef="number" contextRef="c-323" decimals="INF" name="ensg:PrepaymentPenalty" format="ixt:fixed-zero" scale="0" id="f-1196">no</ix:nonFraction> prepayment penalty after year ten. The terms for all the mortgage loans are <ix:nonNumeric contextRef="c-324" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1197">25</ix:nonNumeric> to <ix:nonNumeric contextRef="c-325" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1198">35</ix:nonNumeric> years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has a promissory note of $<ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-3" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1199">2,144</ix:nonFraction> that bears a fixed interest rate of <ix:nonFraction unitRef="number" contextRef="c-326" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1200">5.3</ix:nonFraction>% per annum and has a term of <ix:nonNumeric contextRef="c-327" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:duryear" id="f-1201">12</ix:nonNumeric> years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-1202" escape="true"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:87.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1203">3,950</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1204">4,086</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1205">4,227</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1206">3,897</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1207">3,779</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1208">132,449</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-1209">152,388</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1162-3"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LettersOfCreditOutstandingAmount" format="ixt:num-dot-decimal" scale="3" id="f-1210">6,255</ix:nonFraction> of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $<ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-3" sign="-" name="us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet" scale="3" id="f-1211">455</ix:nonFraction> from prior year.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_175"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1212" continuedAt="f-1212-1" escape="true">OPTIONS AND AWARDS</ix:nonNumeric></span></div><ix:continuation id="f-1212-1" continuedAt="f-1212-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company&#8217;s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Omnibus Incentive Plan (2022 Plan)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has <ix:nonFraction unitRef="plan" contextRef="c-4" decimals="INF" name="ensg:NumberOfOptionPlans" format="ixt-sec:numwordsen" scale="0" id="f-1213">one</ix:nonFraction> active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-329" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-1214">3,452</ix:nonFraction> shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) <ix:nonFraction unitRef="number" contextRef="c-330" decimals="INF" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" format="ixt-sec:numwordsen" scale="0" id="f-1215">one</ix:nonFraction> share for each share that relates to an option or stock appreciation right award and (ii) <ix:nonFraction unitRef="number" contextRef="c-330" decimals="INF" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" format="ixt-sec:numwordsen" scale="0" id="f-1216">two</ix:nonFraction> shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in <ix:nonFraction unitRef="installment" contextRef="c-331" decimals="INF" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" format="ixt-sec:numwordsen" scale="0" id="f-1217">three</ix:nonFraction> equal annual installments, or the length of the term if less than <ix:nonNumeric contextRef="c-331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" format="ixt-sec:durwordsen" id="f-1218">three years</ix:nonNumeric>, on the completion of each year of service measured from the grant date. All other options generally vest over <ix:nonNumeric contextRef="c-330" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1219">five years</ix:nonNumeric> at <ix:nonFraction unitRef="number" contextRef="c-330" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1220">20</ix:nonFraction>% per year on the anniversary of the grant date. Options expire <ix:nonNumeric contextRef="c-330" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-1221">ten years</ix:nonNumeric> from the date of grant. At December&#160;31, 2023, the total number of shares available for issuance under the 2022 Plan was <ix:nonFraction unitRef="shares" contextRef="c-329" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-1222">1,454</ix:nonFraction>.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Company utilizes its own experience to calculate estimated volatility for options granted. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The risk-free rate is based on the implied yield of U.S.&#160;Treasury notes as of the grant date with a remaining term approximately equal to the expected term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Estimated forfeiture rate of approximately <ix:nonFraction unitRef="number" contextRef="c-4" decimals="4" name="ensg:ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" scale="-2" id="f-1223">5.08</ix:nonFraction>% per year is based on the Company's historical forfeiture activity of unvested stock options.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1224">1,008</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1225">581</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1226">621</ix:nonFraction> stock options during the years ended December 31, 2023, 2022, and 2021, respectively. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-1227" continuedAt="f-1227-1" escape="true">The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:</ix:nonNumeric></span></div><ix:continuation id="f-1227-1"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1228">1,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1229">4.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1230">6.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1231">41.3</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1232">0.2</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1233">581</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1234">2.8</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-12" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1235">6.2</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1236">42.1</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-12" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1237">0.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1238">621</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-1239">1.0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-13" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-1240">6.2</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="f-1241">42.4</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-13" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-1242">0.3</ix:nonFraction>%</span></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="f-1243" continuedAt="f-1243-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1212-2" continuedAt="f-1212-3"><ix:continuation id="f-1243-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1244">1,008</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1245">95.05</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1246">43.85</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1247">581</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1248">85.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1249">37.83</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1250">621</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1251">80.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1252">32.82</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" id="f-1253"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" id="f-1254"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" scale="0" id="f-1255">0</ix:nonFraction></ix:nonFraction></ix:nonFraction> at the date of grant.  </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" id="f-1256" escape="true"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.777%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1257">4,038</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1258">27.71</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1259">2,148</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1260">16.66</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1261">621</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1262">80.19</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-1263">105</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1264">44.76</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1265">516</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-13" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1266">17.80</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1267">4,038</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1268">36.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1269">2,183</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-30" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1270">21.02</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="f-1271">581</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1272">85.74</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-1273">98</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1274">59.52</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1275">688</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-12" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1276">18.43</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1277">3,833</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1278">46.72</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1279">2,069</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1280">28.87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-1281">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1282">95.05</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" scale="3" id="f-1283">91</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-1284">71.44</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-1285">759</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-1286">24.21</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1287">3,991</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-1288">62.65</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-1289">1,887</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-1290">39.58</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="f-1291" escape="true"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December&#160;31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.332%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.892%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1292">8.94</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-332" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1293">16.05</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1294">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" scale="3" id="f-1295">484</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-332" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1296">1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-333" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1297">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1298">18.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-334" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1299">21.39</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1300">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1301">1,369</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-334" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1302">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-335" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1303">175</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1304">15.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-336" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1305">16.86</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1306">155</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" scale="3" id="f-1307">916</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-336" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1308">3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-337" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1309">155</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1310">15.80</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-338" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1311">19.41</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1312">194</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1313">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-338" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1314">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-339" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1315">194</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-340" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1316">22.49</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-340" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1317">32.71</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1318">336</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1319">3,523</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-340" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1320">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-341" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1321">336</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1322">41.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-342" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1323">45.76</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-343" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1324">510</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1325">8,014</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-342" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1326">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-343" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1327">383</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1328">44.84</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-344" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1329">59.49</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1330">476</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1331">9,383</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-344" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1332">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-345" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1333">257</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1334">73.47</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-346" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1335">83.64</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-347" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1336">513</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1337">16,844</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-346" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1338">8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-347" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1339">189</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-348" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1340">79.79</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-348" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1341">94.88</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1342">540</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1343">20,466</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-348" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1344">9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-349" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="f-1345">99</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-350" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="f-1346">89.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-350" decimals="INF" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="f-1347">98.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="3" id="f-1348">993</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1349">43,566</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-350" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1350">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-351" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:fixed-zero" scale="0" id="f-1351">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="f-1352">3,991</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" format="ixt:num-dot-decimal" scale="3" id="f-1353">105,703</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="f-1354">1,887</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" id="f-1355" continuedAt="f-1355-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1212-3" continuedAt="f-1212-4"><ix:continuation id="f-1355-1"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.349%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1356">197,819</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1357">183,593</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1358">191,242</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1359">137,048</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1360">136,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-1361">137,382</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1362">56,759</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1363">43,232</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1364">48,548</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, 2022 and 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December&#160;31, 2023, 2022 and 2021 was</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="f-1365">31,658</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="f-1366">27,955</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" format="ixt:num-dot-decimal" scale="3" id="f-1367">27,731</ix:nonFraction>, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December&#160;31, 2023, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1368">56,186</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1369">47,441</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-1370">34,278</ix:nonFraction>, respectively. </span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1371">219</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1372">233</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and <ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1373">222</ix:nonFraction> restricted stock awards during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. All awards were granted at an issue price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="0" name="ensg:SharebasedCompensationRestrictedAwardsExercisePrice" scale="0" id="f-1374">0</ix:nonFraction> and generally vest over <ix:nonNumeric contextRef="c-355" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1375">five years</ix:nonNumeric>. The fair value per share of restricted awards granted during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usdPerShare" contextRef="c-358" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1376">89.83</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-359" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1377">98.31</ix:nonFraction>,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usdPerShare" contextRef="c-360" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1378">73.17</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-361" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1379">94.88</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-362" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1380">72.84</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-363" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1381">93.31</ix:nonFraction>, respectively. The fair value per share includes quarterly stock awards to non-employee directors.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of December&#160;31, 2023 and changes during the years ended December&#160;31, 2023, 2022 and 2021 is presented below:</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="f-1382" escape="true"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:60.157%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.954%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-364" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1383">591</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-364" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1384">38.90</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1385">222</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1386">81.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1387">244</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1388">47.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-357" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-1389">20</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-357" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1390">45.64</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-365" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1391">549</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-365" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1392">52.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1393">233</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1394">81.57</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1395">269</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1396">54.06</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-356" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-1397">26</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-356" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1398">57.29</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-366" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1399">487</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-366" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1400">64.92</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1401">219</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1402">92.04</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-1403">255</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1404">64.21</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-355" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" scale="3" id="f-1405">20</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-355" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-1406">71.53</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-367" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-1407">431</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"/><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-367" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-1408">78.91</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="c-368" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-1409">18</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-369" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1410">89.94</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-370" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-1411">98.31</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on the market price on the grant date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of <ix:nonFraction unitRef="shares" contextRef="c-371" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="3" id="f-1412">500</ix:nonFraction> shares of Pennant restricted stock. The shares are vested over <ix:nonNumeric contextRef="c-372" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-1413">five years</ix:nonNumeric> at <ix:nonFraction unitRef="number" contextRef="c-372" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-1414">20</ix:nonFraction>% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $<ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1415">827</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1416">836</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-1417">854</ix:nonFraction> for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div></ix:continuation><div style="margin-top:9pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1212-4"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1418" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.915%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1419">17,221</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1420">11,361</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1421">8,459</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1422">11,845</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1423">9,920</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1424">8,385</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1425">1,688</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1426">1,439</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1427">1,834</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1428">30,754</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1429">22,720</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-1430">18,678</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1431">67,750</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1432">29,245</ix:nonFraction> in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December&#160;31, 2023. Future stock-based compensation expense will be recognized over <ix:nonNumeric contextRef="c-352" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1433">3.9</ix:nonNumeric> and <ix:nonNumeric contextRef="c-355" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-1434">3.4</ix:nonNumeric> weighted average years for unvested options and restricted stock awards, respectively. There were <ix:nonFraction unitRef="shares" contextRef="c-379" decimals="-3" name="ensg:EmployeeServiceShareBasedCompensationNonvestedAwards" format="ixt:num-dot-decimal" scale="3" id="f-1435">2,104</ix:nonFraction> unvested and outstanding options as of December&#160;31, 2023, of which <ix:nonFraction unitRef="shares" contextRef="c-379" decimals="-3" name="ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" format="ixt:num-dot-decimal" scale="3" id="f-1436">1,940</ix:nonFraction> shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December&#160;31, 2023 was&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-1437">6.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_187"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1439" continuedAt="f-1439-1" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="f-1438" continuedAt="f-1438-1" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="f-1439-1" continuedAt="f-1439-2"><ix:continuation id="f-1438-1" continuedAt="f-1438-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with <ix:nonFraction unitRef="facility" contextRef="c-380" decimals="INF" name="ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities" scale="0" id="f-1440">97</ix:nonFraction> independent skilled nursing and senior living facilities used in the Company&#8217;s operations, <ix:nonFraction unitRef="facility" contextRef="c-381" decimals="INF" name="ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities" scale="0" id="f-1441">96</ix:nonFraction> of which are under <ix:nonFraction unitRef="agreement" contextRef="c-381" decimals="INF" name="ensg:MasterLeaseAgreements" format="ixt-sec:numwordsen" scale="0" id="f-1442">nine</ix:nonFraction> &#8220;triple-net&#8221; master lease agreements (collectively, the Master Leases), which range in terms from <ix:nonNumeric contextRef="c-382" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1443">13</ix:nonNumeric> to <ix:nonNumeric contextRef="c-383" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1444">20</ix:nonNumeric> years. At the Company&#8217;s option, the Master Leases may be extended for <ix:nonFraction unitRef="renewal" contextRef="c-382" decimals="INF" name="ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="f-1445">two</ix:nonFraction> or <ix:nonFraction unitRef="renewal" contextRef="c-383" decimals="INF" name="ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" format="ixt-sec:numwordsen" scale="0" id="f-1446">three</ix:nonFraction> <ix:nonNumeric contextRef="c-381" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1447">five-year</ix:nonNumeric> renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, <ix:nonFraction unitRef="facility" contextRef="c-384" decimals="INF" name="ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities" format="ixt-sec:numwordsen" scale="0" id="f-1448">four</ix:nonFraction> of the <ix:nonFraction unitRef="facility" contextRef="c-380" decimals="INF" name="ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities" scale="0" id="f-1449">97</ix:nonFraction> facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust&#8217;s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust&#8217;s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than <ix:nonFraction unitRef="number" contextRef="c-380" decimals="INF" name="ensg:LesseeOperatingLeaseConsumerPriceIndex" format="ixt:fixed-zero" scale="0" id="f-1450">zero</ix:nonFraction>) or (2) <ix:nonFraction unitRef="number" contextRef="c-380" decimals="3" name="us-gaap:LesseeOperatingLeaseDiscountRate" scale="-2" id="f-1451">2.5</ix:nonFraction>%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the <ix:nonFraction unitRef="lease" contextRef="c-385" decimals="INF" name="ensg:LesseeOperatingLeaseNumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-1452">one</ix:nonFraction> stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $<ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1453">66,439</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1454">64,178</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1455">59,571</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December&#160;31, 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1439-2" continuedAt="f-1439-3"><ix:continuation id="f-1438-2" continuedAt="f-1438-3"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:f-1456">five</span> to <ix:nonNumeric contextRef="c-389" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1457">20</ix:nonNumeric> years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:f-1458">three</span> to <ix:nonNumeric contextRef="c-391" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-1459">five years</ix:nonNumeric>. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $<ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1460">197,856</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1461">153,174</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-3" name="us-gaap:OperatingLeaseExpense" format="ixt:num-dot-decimal" scale="3" id="f-1462">139,458</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="facility" contextRef="c-395" decimals="INF" name="ensg:FacilitiesUnderMasterLeaseArrangement" format="ixt-sec:numwordsen" scale="0" id="f-1463">Eighty</ix:nonFraction> of the Company&#8217;s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under <ix:nonFraction unitRef="agreement" contextRef="c-395" decimals="INF" name="ensg:MasterLeaseAgreements" scale="0" id="f-1464">13</ix:nonFraction> separate master lease arrangements. During 2023, the Company expanded its operations through <ix:nonFraction unitRef="agreement" contextRef="c-396" decimals="INF" name="ensg:AmendedSeparateMasterLeases" format="ixt-sec:numwordsen" scale="0" id="f-1465">three</ix:nonFraction> separate master lease arrangements for <ix:nonFraction unitRef="operation" contextRef="c-397" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="f-1466">22</ix:nonFraction> stand-alone skilled nursing operations, of which <ix:nonFraction unitRef="operation" contextRef="c-398" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" scale="0" id="f-1467">19</ix:nonFraction> are operated by the Company's independent subsidiaries and the remaining <ix:nonFraction unitRef="lease" contextRef="c-399" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-1468">three</ix:nonFraction> are subleased to a third-party operator. These <ix:nonFraction unitRef="agreement" contextRef="c-396" decimals="INF" name="ensg:AmendedSeparateMasterLeases" format="ixt-sec:numwordsen" scale="0" id="f-1469">three</ix:nonFraction> master leases increased the lease liabilities and right-of-use assets by $<ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1470">346,789</ix:nonFraction> to reflect the new lease obligations and have initial lease terms of <ix:nonNumeric contextRef="c-401" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1471">18</ix:nonNumeric>, <ix:nonNumeric contextRef="c-402" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1472">20</ix:nonNumeric> and <ix:nonNumeric contextRef="c-403" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1473">20</ix:nonNumeric> years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company&#8217;s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company&#8217;s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-1474" escape="true"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.619%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.449%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1475">197,358</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1476">153,049</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1477">139,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-1478">498</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-1479">125</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-1480">87</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1481">1,202</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1482">1,160</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1483">1,158</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1484">20,454</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1485">16,938</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1486">14,077</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1487">219,512</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1488">171,272</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1489">154,693</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:DeferredRentAdjustment" scale="3" id="f-1490">870</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="ensg:DeferredRentAdjustment" scale="3" id="f-1491">493</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:DeferredRentAdjustment" scale="3" id="f-1492">485</ix:nonFraction> for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $<ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1493">10,259</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1494">5,878</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-3" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-1495">3,702</ix:nonFraction> for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-1496" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.718%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.352%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1497">191,352</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-1498">191,269</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-1499">191,058</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-1500">190,481</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1501">189,224</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-1502">1,722,259</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-1503">2,675,643</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-1504">953,791</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1505">1,721,852</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-1506">82,526</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1507">1,639,326</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of&#160;December&#160;31, 2023 and 2022, the weighted average remaining lease term is&#160;<ix:nonNumeric contextRef="c-4" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1508">14.9</ix:nonNumeric> years and <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-1509">15.0</ix:nonNumeric> years and the weighted average discount rate used to determine the operating lease liabilities is&#160;<ix:nonFraction unitRef="number" contextRef="c-4" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1510">6.5</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-1511">6.7</ix:nonFraction>%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, the Company amended an existing separate master lease arrangement to add <ix:nonFraction unitRef="operation" contextRef="c-410" decimals="INF" name="us-gaap:NumberOfBusinessesAcquired" format="ixt-sec:numwordsen" scale="0" id="f-1512">two</ix:nonFraction> stand-alone skilled nursing facilities and extend the initial term to <ix:nonNumeric contextRef="c-411" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1513">20</ix:nonNumeric> years. This added a total of <ix:nonFraction unitRef="bed" contextRef="c-411" decimals="INF" name="ensg:OperationalSkilledNursingBeds" scale="0" id="f-1514">241</ix:nonFraction> operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $<ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-1515">30,980</ix:nonFraction>.</span></div></ix:continuation></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1439-3" continuedAt="f-1439-4"><ix:continuation id="f-1438-3" continuedAt="f-1438-4"><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its owned real estate properties to third-party operators, of which <ix:nonFraction unitRef="lease" contextRef="c-412" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" scale="0" id="f-1516">29</ix:nonFraction> senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from <ix:nonNumeric contextRef="c-413" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1517">14</ix:nonNumeric> to <ix:nonNumeric contextRef="c-414" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1518">16</ix:nonNumeric> years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company entered into a sublease agreement for <ix:nonFraction unitRef="lease" contextRef="c-399" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-1519">three</ix:nonFraction> stand-alone skilled nursing operations with a third-party operator with an initial lease term of <ix:nonNumeric contextRef="c-401" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1520">18</ix:nonNumeric> years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for <ix:nonFraction unitRef="lease" contextRef="c-415" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" format="ixt-sec:numwordsen" scale="0" id="f-1521">one</ix:nonFraction> campus operation with an initial lease term of <ix:nonNumeric contextRef="c-416" name="us-gaap:LessorOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-1522">15</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock" id="f-1523" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1524">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1525">14,915</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1526">14,073</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1527">6,236</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1528">1,842</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1529">1,912</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1531">21,284</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1532">16,757</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-3" name="us-gaap:OperatingLeaseLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1533">15,985</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $<ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-3" name="us-gaap:OperatingLeaseVariableLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1534">1,296</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-3" name="us-gaap:OperatingLeaseVariableLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1535">1,318</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-3" name="us-gaap:OperatingLeaseVariableLeaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1536">1,199</ix:nonFraction> during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was <ix:nonFraction unitRef="lease" contextRef="c-412" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" scale="0" id="f-1537">29</ix:nonFraction> during the year ended December 31, 2023 and decreased from <ix:nonFraction unitRef="lease" contextRef="c-418" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" scale="0" id="f-1538">32</ix:nonFraction> to <ix:nonFraction unitRef="lease" contextRef="c-417" decimals="INF" name="ensg:LessorOperatingLeaseNumberOfLeases" scale="0" id="f-1539">29</ix:nonFraction> during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1540">3,897</ix:nonFraction> for the year ended December 31, 2023. There was <ix:nonFraction unitRef="usd" contextRef="c-214" decimals="INF" name="us-gaap:SubleaseIncome" format="ixt-sec:numwordsen" scale="0" id="f-1541"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="INF" name="us-gaap:SubleaseIncome" format="ixt-sec:numwordsen" scale="0" id="f-1542">no</ix:nonFraction></ix:nonFraction> sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" id="f-1543" continuedAt="f-1543-1" escape="true"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-1544">22,191</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears" format="ixt:num-dot-decimal" scale="3" id="f-1545">21,565</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears" format="ixt:num-dot-decimal" scale="3" id="f-1546">21,269</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears" format="ixt:num-dot-decimal" scale="3" id="f-1547">21,176</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears" format="ixt:num-dot-decimal" scale="3" id="f-1548">21,151</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter" format="ixt:num-dot-decimal" scale="3" id="f-1549">129,586</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="3" id="f-1550">236,938</ix:nonFraction></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-1543-1"><ix:continuation id="f-1439-4"><ix:continuation id="f-1438-4">(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.</ix:continuation></ix:continuation></ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_193"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> 18. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-1551" continuedAt="f-1551-1" escape="true">DEFINED CONTRIBUTION PLANS</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-1551-1" continuedAt="f-1551-2"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to <ix:nonFraction unitRef="number" contextRef="c-425" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-1552">90</ix:nonFraction>% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $<ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1553">2,836</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1554">2,418</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-3" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="3" id="f-1555">2,121</ix:nonFraction> during the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to&#160;<ix:nonFraction unitRef="number" contextRef="c-428" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="f-1556">100</ix:nonFraction>% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021. </span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1551-2" continuedAt="f-1551-3"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December&#160;31, 2023 and 2022, the Company accrued $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1557">49,201</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-1558">33,017</ix:nonFraction>, respectively, as long term deferred compensation in other long term liabilities&#160;on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the funds.</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1551-3">For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1559">4,634</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1560">1,612</ix:nonFraction>, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="ensg:InvestmentExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1561">4,887</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="ensg:InvestmentExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1562">1,758</ix:nonFraction>, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-1563">4,188</ix:nonFraction>, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="ensg:InvestmentExpenseIncome" format="ixt:num-dot-decimal" scale="3" id="f-1564">4,051</ix:nonFraction>, which is allocated between cost of services and general and administrative expenses.</ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_214"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="c-1" name="us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" id="f-1565" continuedAt="f-1565-1" escape="true">SELF INSURANCE LIABILITIES</ix:nonNumeric></span></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><ix:continuation id="f-1565-1" continuedAt="f-1565-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" id="f-1566" escape="true"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.595%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January&#160;1, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1567">110,139</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1568">115,793</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1569">98,007</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1570">3,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1571">131,682</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1572">164,627</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1573">135,799</ix:nonFraction>)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1574">5,400</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1575">165,910</ix:nonFraction>&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1565-2">Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $<ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1576">117,744</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-3" name="us-gaap:LiabilityForFuturePolicyBenefits" format="ixt:num-dot-decimal" scale="3" id="f-1577">87,000</ix:nonFraction> as of December&#160;31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.</ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_199"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-1578" continuedAt="f-1578-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-1578-1" continuedAt="f-1578-2"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company&#8217;s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company&#8217;s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company&#8217;s consolidated balance sheets for any of the periods presented.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div></ix:continuation><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1578-2" continuedAt="f-1578-3"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company&#8217;s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company&#8217;s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company&#8217;s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company, on behalf of its independent subsidiaries, received a </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Justice (DOJ)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1578-3" continuedAt="f-1578-4"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company&#8217;s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company&#8217;s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $<ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-3" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="3" id="f-1579">48,000</ix:nonFraction>, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS). </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action &#8220;staffing&#8221; suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company&#8217;s business, cash flows, financial condition or results of operations.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><ix:continuation id="f-1578-4"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December&#160;31, 2023 and through the filing date of this report, <ix:nonFraction unitRef="subsidiary" contextRef="c-432" decimals="INF" name="ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews" scale="0" id="f-1580"><ix:nonFraction unitRef="subsidiary" contextRef="c-4" decimals="INF" name="ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews" scale="0" id="f-1581">40</ix:nonFraction></ix:nonFraction> of the Company's independent subsidiaries had Reviews scheduled or in process.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, CMS announced a new nationwide audit, the &#8220;SNF 5-Claim Probe &amp; Educate Review&#8221;, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe &amp; Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from Medicare and Medicaid payor programs accounted for <ix:nonFraction unitRef="number" contextRef="c-433" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1582">53.4</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-434" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1583">56.3</ix:nonFraction>% of its total accounts receivable as of December&#160;31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for <ix:nonFraction unitRef="number" contextRef="c-435" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1584">72.6</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-81" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1585">73.7</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-436" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-1586">73.6</ix:nonFraction>% of the Company's revenue for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December&#160;31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.</span></div></ix:continuation><div id="iee29a48a3be7475b9147c6a5457e7413_205"></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">&#160;&#160;&#160;&#160;</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:100%">THE ENSIGN GROUP, INC.</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS - (Continued)</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">21. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1587" continuedAt="f-1587-1" escape="true">COMMON STOCK REPURCHASE PROGRAM</ix:nonNumeric></span></div><ix:continuation id="f-1587-1" continuedAt="f-1587-2"><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-437" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1588">20,000</ix:nonFraction> of its common stock under the program for a period of approximately <ix:nonNumeric contextRef="c-438" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durmonth" id="f-1589">12</ix:nonNumeric> months from September&#160;1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-439" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="3" id="f-1590">20,000</ix:nonFraction> of its common stock under the program for a period of approximately <ix:nonNumeric contextRef="c-440" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durmonth" id="f-1591">12</ix:nonNumeric> months from August&#160;2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. </span></div></ix:continuation><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1587-2">In addition, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-12" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-1592">404</ix:nonFraction> shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1593">29,882</ix:nonFraction> during the year ended December 31, 2022, and <ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" scale="3" id="f-1594">132</ix:nonFraction> shares of its common stock for $<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="f-1595">10,118</ix:nonFraction> during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect.</ix:continuation> </span></div><div id="iee29a48a3be7475b9147c6a5457e7413_394"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.&#160;&#160;&#160;&#160; CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_397"></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. CONTROLS AND PROCEDURES </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(a)  Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures that are designed to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating our disclosure controls and procedures, our management recognized that any system of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of this Annual Report on Form 10-K our management evaluated, with the participation of our Chief Executive Officer and our Chief Financial Officer, the effectiveness of our disclosure controls and procedures, as such term is defined under Rule&#160;13a-15(e) promulgated under the Exchange Act. Based on this evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form&#160;10-K. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(b)  Management's Report on Internal Control over Financial Reporting</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule&#160;13a-15(f) promulgated under the Exchange Act. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our internal control over financial reporting using the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#160;- Integrated Framework (2013).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As a result of this assessment, management concluded that, as of December&#160;31, 2023, our internal control over financial reporting was effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm, Deloitte&#160;&amp; Touche LLP, has audited the consolidated financial statements included in this Annual Report on Form&#160;10-K and, as part of their audit, has issued an audit report, included herein, on the effectiveness of our internal control over financial reporting. Their report is set forth below. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c)  Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:3pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting, as defined in Rule&#160;13a-15(f) promulgated under the Exchange Act, that occurred during the fourth quarter of fiscal 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(d)  Report of Independent Registered Public Accounting Firm</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Stockholders and the Board of Directors of </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc.</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Juan Capistrano, California</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:111%">We have audited the internal control over financial reporting of The Ensign Group, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2023, based on criteria established in Internal Control &#8212; Integrated Framework (2013) issued by COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:111%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31,2023, of the Company and our report dated February 1, 2024, expressed an unqualified opinion on those financial statements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:111%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:111%">/s/ DELOITTE &amp; TOUCHE LLP </span></div><div style="padding-left:4.5pt;padding-right:391.5pt"><span><br/></span></div><div style="padding-left:4.5pt;padding-right:391.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costa Mesa, California February&#160;1, 2024</span></div><div style="text-align:justify"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_322"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. OTHER INFORMATION </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-441" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1596"><ix:nonNumeric contextRef="c-441" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1597"><ix:nonNumeric contextRef="c-441" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1598">Rule 10b5-1 Plan Elections</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-443" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1600" escape="true"><ix:nonNumeric contextRef="c-442" name="ecd:TrdArrIndName" id="f-1599">Christopher R. Christensen</ix:nonNumeric>, <ix:nonNumeric contextRef="c-442" name="ecd:TrdArrIndTitle" id="f-1601">Co-founder, Executive Chairman and Chairman of the Board</ix:nonNumeric>, <ix:nonNumeric contextRef="c-442" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1602">entered into</ix:nonNumeric> a Rule 10b5-1 trading arrangement on <ix:nonNumeric contextRef="c-442" name="ecd:TrdArrAdoptionDate" id="f-1603">November 2, 2023</ix:nonNumeric> (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to <ix:nonFraction unitRef="shares" contextRef="c-444" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1604">110,700</ix:nonFraction> shares of the Company's common stock between February 6, 2024 and December 31, 2024.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-446" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-1606" escape="true"><ix:nonNumeric contextRef="c-445" name="ecd:TrdArrIndName" id="f-1605">Beverly B. Wittekind</ix:nonNumeric>, <ix:nonNumeric contextRef="c-445" name="ecd:TrdArrIndTitle" id="f-1607">Vice President &amp; General Counsel</ix:nonNumeric>, <ix:nonNumeric contextRef="c-445" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-1608">entered into</ix:nonNumeric> a Rule 10b5-1 trading arrangement on <ix:nonNumeric contextRef="c-445" name="ecd:TrdArrAdoptionDate" id="f-1609">December 8, 2023</ix:nonNumeric> (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to <ix:nonFraction unitRef="shares" contextRef="c-447" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-1610">10,000</ix:nonFraction> shares of the Company's common stock between March 14, 2024 and October 31, 2024.</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These Rule 10b5-1 trading arrangements were entered into during open trading windows and are intended to satisfy the affirmative defense conditions of Rule 10b5-1 (c) under the Securities Exchange Act of 1934, as amended, and the Company's policies regarding transactions in Company securities.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_403"></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_406"></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART III.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_409"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a code of ethics and business conduct that applies to all employees, including our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), and employees of our subsidiaries, as well as each member of our Board of Directors. The code of ethics and business conduct is available on our website at www.ensigngroup.net under the Investor Relations section. The information contained in, or that can be accessed through, our website does not constitute a part of this Annual Report on Form 10-K. We intend to satisfy any disclosure requirement under Item 5.05 of Form 8-K regarding an amendment to, or waiver from, a provision of the code of ethics by posting such information on our website, at the address specified above.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_412"></div><div style="margin-top:12pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. EXECUTIVE COMPENSATION</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_415"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_418"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_421"></div><div style="margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is hereby incorporated by reference to our definitive proxy statement for the 2024 Annual Meeting of Stockholders. Our principal accountant is Deloitte &amp; Touche LLP (PCAOB ID No.<ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1613">34</ix:nonNumeric>).</span></div><div style="text-align:justify"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_424"></div><div style="text-align:center"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PART IV.</span></div><div id="iee29a48a3be7475b9147c6a5457e7413_427"></div><div style="-sec-extract:summary;margin-top:12pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. EXHIBITS, FINANCIAL STATEMENTS AND SCHEDULES </span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as a part of this report: </span></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) (1)&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Financial Statements described in Part II. Item&#160;8 and beginning on page <a style="-sec-extract:exhibit;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_388">91</a> are filed as part of this Annual Report on Form 10-K.</span></div></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) (3)&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits:</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The following exhibits are filed or furnished with or incorporated by reference this Annual Report on Form 10-K.</span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit Description*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Herewith</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000110465907090660/a07-31302_1ex3d1.htm">3.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on November 15, 2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/21/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537620000018/ensg123119ex32.htm">3.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on February 4, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/5/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537623000149/ensgq22023ex33.htm">3.3</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Fifth Amended and Restated Certificate of Incorporation of The Ensign Group, Inc., filed with the Delaware Secretary of State on May 18, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/27/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000110465907090660/a07-31302_1ex3d2.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Bylaws of The Ensign Group, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-Q</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12/21/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537614000082/exhit32.htm">3.5</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to the Amended and Restated Bylaws, dated August 5, 2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8/8/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537620000018/ensg123119ex41.htm">4.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Common stock of The Ensign Group, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/5/2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007452/a2179557zex-4_1.htm">4.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Specimen common stock certificate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007452/a2179557zex-10_3.htm">10.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Ensign Group, Inc. 2007 Omnibus Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000095012309026413/c88415exv99w2.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to The Ensign Group, Inc. 2007 Omnibus Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/28/2009</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007452/a2179557zex-10_4.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2007 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142797</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007452/a2179557zex-10_5.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2007 Omnibus Incentive Plan Restricted Stock Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007452/a2179557zex-10_6.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnification Agreement entered into between The Ensign Group, Inc. and its directors, officers and certain key employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/5/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907004101/a2175777zex-10_41.htm">10.6</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Independent Consulting and Centralized Services Agreement between Ensign Facility Services, Inc. and certain of its subsidiaries</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.41&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/14/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_48.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Health Insurance Benefit Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Medicare program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_49.htm">10.8</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Medi-Cal Provider Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the California Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_50.htm">10.9</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Provider Participation Agreement pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Arizona Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.50&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit Description*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_51.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Contract to Provide Nursing Facility Services under the Texas Medical Assistance Program pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Texas Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.51&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_52.htm">10.11</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Client Service Contract pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Washington Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_53.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Provider Agreement for Medicaid and UMAP pursuant to which certain subsidiaries of The Ensign Group, Inc. participate in the Utah Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000104746907007770/a2180032zex-10_54.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Medicaid Provider Agreement pursuant to which a subsidiary of The Ensign Group, Inc. participates in the Idaho Medicaid program</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">S-1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333-142897</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.54&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/19/2007</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537614000008/ensg123113ex1074.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate Integrity Agreement between the Office of Inspector General of the Department of Health and Human Services and The Ensign Group, Inc. dated October 1, 2013.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/13/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537614000031/ensg33114ex1075.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlement agreement dated October 1, 2013, entered into among the United States of America, acting through the United States Department of Justice and on behalf of the Office of Inspector General ("OIG-HHS") of the Department of Health and Human Services ("HHS") (collectively the "United States") and the Company.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/8/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000119312514226138/d737181dex101.htm">10.16</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Master Lease by and among certain subsidiaries of The Ensign Group, Inc. and certain subsidiaries of CareTrust REIT, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/5/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000119312514226138/d737181dex102.htm">10.17</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Guaranty of Master Lease by The Ensign Group, Inc. in favor of certain subsidiaries of CareTrust REIT, Inc., as landlords under the Master Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6/5/2014</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537616000139/amendedandrestatedsuntrust.htm">10.18</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Credit Agreement as of February 5, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537616000214/secondarcreditagreementv57.htm">10.19</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amended Credit Agreement as of July 19, 2016, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7/25/2016</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537617000035/a2016proxystatement.htm#s79c1f29a0e9c477ca771e6b5687c20a1">10.20</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Ensign Group, Inc. 2017 Omnibus Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/13/2017</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537618000028/ensgex1087.htm">10.21</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2017 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537618000028/ensgex1088.htm">10.22</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2017 Omnibus Incentive Plan Restricted Stock Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.88&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/8/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537618000006/exhibit101hudnote.htm">10.23</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of U.S. Department of Housing and Urban Development Healthcare Facility Note and schedule of individual subsidiary loans, by and among The Ensign Group, Inc.'s subsidiaries listed therein and U.S. Department of Housing and Urban Development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537618000006/exhibit102securityinstrume.htm">10.24</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of U.S. Department of Housing and Urban Development Security Instrument/Mortgage/Deed of Trust</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/3/2018</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537619000134/exhibit104.htm">10.25</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third Amended and Restated Credit Agreement, dated as of October 1, 2019, by and among The Ensign Group, Inc., SunTrust Bank, now known as Truist, as administrative agent, and the lenders party thereto</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/1/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537619000134/exhibit105.htm">10.26</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease Agreement, dated as of October 1, 2019, by and between The Ensign Group, Inc. and The Pennant Group, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10/1/2019</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="-sec-extract:summary;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:none" href="#iee29a48a3be7475b9147c6a5457e7413_22">Table of Contents</a></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.902%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.170%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">File</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Filed</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exhibit Description*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537621000020/ensg123120ex1096.htm">10.27</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Ensign Services, Inc. Deferred Compensation Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537621000020/ensg123120ex1097.htm">10.28</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to The Ensign Services, Inc. Deferred Compensation Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/3/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537622000019/ensg123121ex101.htm">10.29</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to Third Amended and Restated Credit Agreement, dated as of February 8, 2022, by and among The Ensign Group, Inc., Standard Bearer Healthcare REIT, Inc., Truist Bank (as successor by merger to SunTrust Bank), as administrative agent, and the lenders party thereto</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/9/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537622000060/ex101.htm">10.30</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to Third Amended and Restated Credit Agreement, dated as of April 8, 2022, by and among The Ensign Group, Inc. and Truist Bank, as administrative agent, and the lenders party thereto. </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/12/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537622000062/a2021proxystatement.htm#i175cebcaa24a45a3a49df6587d41941e_112">10.31</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Ensign Group, Inc. 2022 Omnibus Incentive Plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DEF 14A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/14/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537623000018/ensg123122ex102.htm">10.32</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2022 Omnibus Incentive Plan Notice of Grant of Stock Options; and form of Non-Incentive Stock Option Award Terms and Conditions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.32&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/2/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="http://www.sec.gov/Archives/edgar/data/1125376/000112537623000018/ensg123122ex103.htm">10.33</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of 2022 Omnibus Incentive Plan Restricted Stock Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10-K</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">001-33757</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.33&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/2/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensg123123ex211.htm">21.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries of The Ensign Group, Inc., as amended</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensg123123ex231.htm">23.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Deloitte &amp; Touche LLP</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensgq42023ex311.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensgq42023ex312.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensgq42023ex321.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensgq42023ex322.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="-sec-extract:exhibit;color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="ensg123123ex97.htm">97.0</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Policy for Recovery of Erroneously Awarded Incentive-Based Compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">X</span></td></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive data file (furnished electronically herewith pursuant to Rule 406T of Regulations S-T)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104</span><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indicates management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Documents not filed herewith are incorporated by reference to the prior filings identified in the table above.</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div id="iee29a48a3be7475b9147c6a5457e7413_433"></div><div style="text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Item 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY </span></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><div id="iee29a48a3be7475b9147c6a5457e7413_334"></div><hr style="page-break-after:always"/><div style="min-height:49.5pt;width:100%"><div style="text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.927%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.093%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">THE ENSIGN GROUP, INC.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BY:&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ SUZANNE D. SNAPPER &#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzanne D. Snapper&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Executive Vice President and Director (Principal Financial Officer and Accounting Officer and Duly Authorized Officer)&#160;</span></div></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:36.436%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.207%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.591%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ BARRY R. PORT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and Director (principal executive officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry R. Port</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;SUZANNE D. SNAPPER</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzanne D. Snapper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ CHRISTOPHER R. CHRISTENSEN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Chairman and Chairman of the Board</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher R. Christensen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;ANN S. BLOUIN</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ann S. Blouin</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;SWATI B. ABBOTT</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swati B. Abbott</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;DAREN J. SHAW</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Daren J. Shaw</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;JOHN O. AGWUNOBI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">John O. Agwunobi</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;BARRY M. SMITH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 1, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry M. Smith</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>ensg123123ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i7915dd009ffa430cbf9b7bc2217a84b9_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXHIBIT 21.1</font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b6b6b6;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Legal Name</font></td><td colspan="3" style="background-color:#b6b6b6;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">President Company&#47; Owner</font></td><td colspan="3" style="background-color:#b6b6b6;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Jurisdiction of Organization &#47; Formation</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2016 Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2020 Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">2410 Stillhouse Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">24th Street Healthcare Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Adipiscor, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Agape Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alice Branch Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Allen Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Alvarado Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Amelia Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">American Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">American Pika Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">American Robin Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ann Arbor Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Anza Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Apache Trail Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Appaloosa Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ellis Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Apple Springs Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Armstrong Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arris Health Services LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Covalence Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arvada Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ascent Health Services LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridge Holding Company, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Atlantic Memorial Healthcare Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Avalanche Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Avenues Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Avocado Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Aztec Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bainbridge Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp, L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMD Investments, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arizona</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Banner Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bardwell Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Baseline Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bayside Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Baywood Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beacon Hill Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Beacon Purchasing LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Banner Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bear Creek Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bell Villa Care Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bennett Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bernardo Heights Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bertetti Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Best SW Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Big Blue Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bijou Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bijou Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Black Ridge Canyon Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Blackbird Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bluebird Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bluebonnet Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bouverie Healthcare Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brackenridge Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bremer Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brenwood Park Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridge Holding Company, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridger Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridgestone Living LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Broken Ridge Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Brownsville Care Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bruce Neenah Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Buffalo Creek Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Burch Creek Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">C Street Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Calavaras Creek Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Camarillo Community Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Canary Bend Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cane Island Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Canyon Springs Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridgestone Living LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Resources, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cardiff Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cardinal Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Carolina Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Carrollton Heights Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Castle Pines Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Castle Rock Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cedar City Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cedar Ridge Transportation LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Woodland Transportation Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Central Avenue Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chaparral Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chateau Julia Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cherokee Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cherry Hills Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chickadee Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Circle Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">City Heights Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Claremont Foothills Health Associates LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Clark Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Claydelle Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Clear Skies Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cloverleaf Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Coalescence Health Services, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridge Holding Company, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Coldwater Springs Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Columbia River Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Concord Avenue Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Congaree Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Conrad Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Constitution Road Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Conway Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Copeland Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cornet Limited, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arizona</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Costa Victoria Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Covalence Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cow Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cress Creek Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Crown Hill Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Crystal Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cypress Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">D3T Enterprise, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Woodland Transportation Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Texas</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Da Vinci Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Daffodil Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dark Sky Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Davis Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">De Moisy Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Deer Creek Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Deergrass Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Desert Cove Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Desert Lily Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Desert Mallow Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dessau Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Devonshire Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Diamond Valley Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Discovery Trail Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dorothy Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Downey Community Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Duck Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Dusk Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Eagle Harbor Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">East Mesa Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">East River Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Echo Canyon Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Eiffel Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Elati Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Turnberry Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Elkhorn Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ellis Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Empirecare Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensidium Investments, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Cloverdale LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Montgomery LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Palm I LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Panorama LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Pleasanton LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Sabino LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign San Dimas LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Santa Rosa LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Sonoma LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Whittier East LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Whittier West LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ensign Willits LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fawn Meadows Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flintrock Falls Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Floyde Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Forney Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Forrest Hill Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fossil Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Founders Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Founders RX LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Founders Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fox Sparrow Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Franklin Avenue Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Franklin Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Fullerton Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Garwood Health Holdings II LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gate Three Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gem Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Getzendaner Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Glendale Healthcare Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Glimmer Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Golden Eagle Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Golden Oaks Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Golden Years Program, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goldenstar Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Goldfield Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Good Hope Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gooding Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Graceland Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Grand Avenue Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Grand Villa PHX, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Grassland Healthcare and Rehabilitation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Green Bay Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Green Heron Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Green Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Green Mountain Personalized Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Green Valley Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gypsum Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Harlan Heights Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Harlingen Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Harmony Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Harrison Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hartwell Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">HB Healthcare Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Healthlift Medical Transportation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Heartland Health Holdings II LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Highcross Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Highland Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Higley Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hill Country Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Holford Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hollyleaf Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Holman Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Homedale Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hoquiam Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hub City Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hueneme Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Huntington Beach Convalescent Hospital Asset LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Longboard Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hutchins Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hyrum Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Immediate Clinic Seattle, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Immediate Clinic Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ionic Health Services LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Covalence Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">California</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Iron Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Iron Horse Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jack Finney Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">JARR Transportation Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arizona</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jefferson Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Jordan Health Associates, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">JRT Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kenosha Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kettle Creek Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Kingston Falls Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Klement Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Knight Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Krypton Health Services LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Covalence Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">La Jolla Skilled LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">La Veta Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lake Cassidy Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lake Island Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lake Pleasant Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lake Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lake Washington Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lakewood Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lakewood Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ledbetter Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Legend Lake Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lemon Grove Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lightning Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lil&#8217; Tots Day Program, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lilly Road Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lindahl Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Link Support Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Cornet Limited, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Little Blue Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Little Mountain Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Little Village Day Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Littleton Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Livingston Care Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lone Pine Ridge Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lone Star MTC, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Longboard Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lookout Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lowell Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lucky Peak Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ludden Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Lynnwood Health Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Madison Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Madison Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Magic Valley Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridgestone Living LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Manitowoc Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Manor Park Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Manzanita Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Maple Hills Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Marguerite Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mariano Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Marion Health Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Marshall Lake Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mason Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MavStar Medical Transportation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">McAllen Care Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">McAllen Community Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">McCall Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">McFarland Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">MedStar Medical Transportation, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">JARR Transporation Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arizona</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Menomonee Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Meridian Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Midland Nampa Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Midland Nampa Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Midnight Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mission Trails Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Misty Willow Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mockingbird Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Monroe Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Montebella Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Moon Cove Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Moonflower Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Moonrise Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Morning Glory Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mount Lemmon Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mountain View Retirement, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mountain Violet Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Murphy Health Holdings II LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mussel Rock Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Mustang Ridge Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Myrtle Springs Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ellis Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nautilus Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">NB Brown Rock Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">New England Medical Transportation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nightfall Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nobel Health Properties LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nordic Valley Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">North Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">North Parkway Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">North Parkway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Northern Oaks Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Oak Point Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Oceanview Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ocotillo Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Old Pueblo Medical Transportation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Olmstead Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Olympic Marmot Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Olympus Health, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Orange Grove Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Orchard Bay Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ottawa Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pacific Mobile Diagnostics Holdings (CA), LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMD Investments, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Padua Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Palm Valley Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Panorama Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Park Waverly Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Parkside Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Peoria Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Percheron Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ellis Pointe Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Permunitum LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Perris Hills Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pikes Peak Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pine Forest Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Piney Lufkin Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pleasant Run Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMD Investments, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMD X-Ray Services, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMDAZ, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMDCO, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMDTC, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">PMDUT, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bakorp L.L.C.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pocatello Health Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pointe Meadow Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pomerado Ranch Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ponderosa Pine Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Portside Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Powderhorn Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Powers Park Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prairie Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Prairie Ridge Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Presidio Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Price Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Primrose Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Primrose Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Quail Creek Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Queenston Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Quorum Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Quorum Ventures, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Racine Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Radiant Hills Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Railroad Crossing Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Ramon Healthcare Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Randolph Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Raven Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rocky Top Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Red Cliffs Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Red Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Redbrook Healthcare Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">RenewCare of Scottsdale, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Respire Health Services LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Covalence Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Richmond Senior Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rio Hondo Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rio Mesa Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">River Otter Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Riverside Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Riverview Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Riverview Village Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Riverwalk Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Roadrunner Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rock Canyon Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rock Hill Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rocky Mountain Medical Transportation Company, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rocky Top Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rose Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rose Park Healthcare Associates, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rosemead Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Rowlett Creek Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Royal View Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sage Meadow Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sage Terrace Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sagebrush Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Salado Creek Senior Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Saltwater Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sand Hollow Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sandpiper Senior Living LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Santa Catalina Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Santa Maria Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Santiago Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Santiago Personal Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Savoy Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sawtooth Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Scandinavian Court Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Second West Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sedgewood Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sentinel Peak Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sheboygan Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sherman Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sherwood Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sidewinder Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Siena Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Somers Kenosha Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Songbird Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South C Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">South Valley Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Southern Charm Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Southern Oaks Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Southland Management LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Southside Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stagecoach Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare Merger Sub, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Maryland</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP GP, LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare REIT, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Bearer Healthcare REIT, Inc.&#59;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Standard Bearer Healthcare OP GP, LLC</font></div></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare REIT, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Maryland</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standardbearer Insurance Company, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Arizona</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stanton Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Starburst Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Starling Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Statler Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Steelhead Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stevens Point Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stoney Hill Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Hopewell Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Storm Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Stoughton Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Streetcar Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Subacute Facility Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Successor Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Summit Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Summit Trail Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sunflower Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sungazer Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sunland Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sunny Acres Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sunny Acres Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sunrise Mountain Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Sweet Bay Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Terrace Court Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">N&#47;A</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TheraTroopers CA, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Theratroopers Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Theratroopers Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">TheraTroopers, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Theratroopers Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thompson Peak Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thorntree Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thunder Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare North LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Thunderbird Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Top City Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tortolita Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Towers Park Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Towers Park Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Towers Park Personal Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Town East Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tradewind Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Treasure Hills Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Treasure Valley Senior Living, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bridgestone Living LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Treaty Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tree City Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Truckee Meadows Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tulip Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Turnberry Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Tustin Hills Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Two Rivers Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Two Trails Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Union Hill Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Upland Community Care, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Valley Ranch Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Valley View Health Services, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Velda Rose Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Victoria Ventura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare Central LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Victory Medical Transportation, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Viewpoint Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Vista Woods Health Associates LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wallsville Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Washington Heights Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Waterfall Canyon Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Watson Woods Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wellington Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West 5600 Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West 5600 Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Ashby Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Escondido Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Flagstone Healthcare South LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Meadow Health Holdings II LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div><div style="margin-bottom:8pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.845%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Olive Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Owyhee Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Pine Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">West Van Buren Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Western Canal Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Western Edge Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Turnberry Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Whispering Pines Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wildcreek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wildwood Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Willard Peak Group Home, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Willow Canyon Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Willow Springs Creek Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Windsor Lake Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Endura Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wisconsin Rapids Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wolf Point Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wolf River Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Gateway Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Wood Bayou Healthcare, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Woodard Creek Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Pennant Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Woodland Transportation Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Capstone Transportation Investments, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Yellow Rose Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">The Ensign Group, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Yellowstar Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Keystone Care LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Youngtown Health, Inc.</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Bandera Healthcare LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Yucca Flats Health Holdings LLC</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Standard Bearer Healthcare OP, LP</font></td><td colspan="3" style="border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr><tr><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Zion Healthcare, Inc.</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Milestone Healthcare LLC</font></td><td colspan="3" style="border-bottom:1.5pt solid #000000;border-left:1.5pt solid #000000;border-right:1.5pt solid #000000;border-top:1.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Nevada</font></td></tr></table></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:8pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>ensg123123ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3cb656651465445089723a8d35ec7f85_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">EXHIBIT 23.1</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consent to the incorporation by reference in Registration Statement No. 333&#8208;268018 on Form S&#8208;8 of our reports dated February 1, 2024, relating to the financial statements of The Ensign Group, Inc. and the effectiveness of The Ensign Group, Inc.&#8217;s internal control over financial reporting, appearing in this Annual Report on Form 10&#8208;K for the year ended December 31, 2023.</font></div><div style="text-align:justify;text-indent:22.5pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#47;s&#47; DELOITTE &#38; TOUCHE LLP </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costa Mesa, California </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February 1, 2024</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>ensgq42023ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="icd1785df61984ecdb4e1f6358289d2e7_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Barry R. Port, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Annual Report on Form 10-K of The Ensign Group, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;1, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.665%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Barry R. Port &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry R. Port</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director (principal executive officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>ensgq42023ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i3057eb74cb6b4a0baedf34385746679d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="text-align:right"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Suzanne D. Snapper, certify that&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this  Annual Report on Form 10-K of The Ensign Group, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.91pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div style="padding-left:54pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;1, 2024</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.507%"></td><td style="width:0.1%"></td></tr><tr><td colspan="18" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Suzanne D. Snapper &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzanne D. Snapper&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="18" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>ensgq42023ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i43bb162d980041d998016fe523de0cbe_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. &#167;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Barry R. Port, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.275%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.378%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.952%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)))&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Barry R. Port</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Barry R. Port&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and Director (principal executive officer)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160; </font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by 18 U.S.C. Section&#160;1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>ensgq42023ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="ia542da6ea5f949cca90d9b9d661ad48b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. &#167;1350, </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of The Ensign Group, Inc. (the Company) on Form 10-K for the period ended December&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Suzanne D. Snapper, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58; </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:2.585%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.084%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.838%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)))&#59; and</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Suzanne D. Snapper &#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;&#160;&#160;</font></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Suzanne D. Snapper&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;&#160;&#160;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer, Executive Vice President and Director (principal financial officer and accounting officer and duly authorized officer)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February&#160;1, 2024</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A signed original of this written statement required by 18 U.S.C. Section&#160;1350 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. </font></div><div><font><br></font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160; </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97.0
<SEQUENCE>8
<FILENAME>ensg123123ex97.htm
<DESCRIPTION>EX-97.0
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2024 Workiva -->
<title>Document</title></head><body><div id="i08c00e349cee4fe78543cbc148ce3bc7_34"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">THE ENSIGN GROUP, INC. </font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED INCENTIVE-BASED COMPENSATION</font></div><div><font><br></font></div><div style="text-align:center;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">(Effective November 2, 2023)</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Purpose</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Ensign Group, Inc. (the &#8220;Company&#8221;) is adopting this policy to provide for the Company&#8217;s criteria and process of recovering certain incentive-based compensation erroneously awarded to or earned or received by certain officers under certain circumstances. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This policy is designed to comply with, and shall be interpreted to be consistent with, Section 954 of the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, as codified in Section 10D of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), Rule 10D-1 promulgated under the Exchange Act (&#8220;Rule 10D-1&#8221;) and Listing Rule 5608 of the corporate governance rules (the &#8220;Listing Standards&#8221;) of The Nasdaq Stock Market (&#8220;Nasdaq&#8221;). Unless otherwise defined in this policy, capitalized terms shall have the meaning ascribed to such terms in Section 2.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. As used in this policy, the following capitalized terms shall have the meanings set forth below.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.97pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Accounting Restatement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means an accounting restatement of the Company&#8217;s financial statements due to the Company&#8217;s material noncompliance with any financial reporting requirement under the securities laws, including any required accounting restatement to correct an error in previously issued financial statements that is material to the previously issued financial statements (i.e., a &#8220;Big R&#8221; restatement), or to correct an error that is not material to the previously issued financial statements, but that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period (i.e., a &#8220;little r&#8221; restatement).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.46pt"> &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Accounting Restatement Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means the earlier to occur of (i) the date the Board, a committee of the Board, or the officer or officers of the Company authorized to take such action if the Board&#8217;s action is not required, concludes, or reasonably should have concluded, that the Company is required to prepare an Accounting Restatement and (ii) the date a court, regulator, or other legally authorized body directs the Company to prepare an Accounting Restatement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.58pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Applicable Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means, with respect to any Accounting Restatement, the three completed fiscal years immediately preceding the Accounting Restatement Date, as well as any transition period (that results from a change in the Company&#8217;s fiscal year) within or immediately following those three completed fiscal years (except that a transition period that comprises a period of at least nine months shall count as a completed fiscal year).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">d.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.46pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Board</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means the board of directors of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">e.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.76pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means the U.S. Internal Revenue Code of 1986, as amended. Any reference to a section of the Code or regulation thereunder includes such section or regulation, any valid regulation or other official guidance promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing, or superseding such section or regulation.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">f.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:11.88pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Covered Executive Officer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means an individual who is currently or previously served as the Company&#8217;s principal executive officer, principal financial officer, principal accounting officer (or, if there is no such accounting officer, the controller), vice president of the Company in charge of a principal business unit, division, or function (such as sales, administration, or finance), an officer who performs (or performed) a policy-making function, or any other person who performs (or performed) similar policy-making functions for the Company or is otherwise determined to be an executive officer of the Company pursuant to Item 401(b) of Regulation S-K. An executive officer of the Company&#8217;s parent or subsidiary is deemed a &#8220;Covered Executive Officer&#8221; if the executive officer performs (or performed) such policy-making functions for the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">g.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.06pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means, in the event of an Accounting Restatement, the amount of Incentive-Based Compensation previously received that exceeds the amount of Incentive-Based Compensation that otherwise would have been received had it been determined based on the restated amounts in such Accounting Restatement, and must be computed without regard to any taxes paid by the relevant Covered Executive Officer&#59; provided, however, that for Incentive-Based Compensation based on stock price or total stockholder return, where the amount of Erroneously Awarded Compensation is not subject to mathematical recalculation directly from the information in an Accounting Restatement&#58; (i) the amount of Erroneously Awarded Compensation must be based on a reasonable estimate of the effect of the Accounting Restatement on the stock price or total stockholder return upon which the Incentive-Based Compensation was received and (ii) the Company must maintain documentation of the determination of that reasonable estimate and provide such documentation to Nasdaq.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">h.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.46pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Financial Reporting Measure</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means any measure that is determined and presented in accordance with the accounting principles used in preparing the Company&#8217;s financial statements and any measure that is derived wholly or in part from such measure. A Financial Reporting Measure is not required to be presented within the Company&#8217;s financial statements or included in a filing with the U.S. Securities and Exchange Commission to qualify as a &#8220;Financial Reporting Measure.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">i.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.71pt">&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;text-decoration:underline">Incentive-Based Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8221; means any compensation (including, annual cash and stock award bonuses and other short- and long-term cash incentives) that is granted, earned, or vested based wholly or in part upon the attainment of a Financial Reporting Measure. The Company&#8217;s principal element of compensation that is considered Incentive-Based Compensation is annual cash bonuses, which is primarily based upon a Financial Reporting Measure and modified utilizing other measures including but not limited to clinical metrics. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">For the avoidance of doubt, the following forms of compensation shall not be considered Incentive-Based Compensation for purposes of this policy&#58;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Salaries&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Bonuses paid solely by satisfying subjective standards&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Non-equity incentive plan awards earned solely by satisfying strategic or operational measures&#59;</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Wholly time-based equity awards&#59; or</font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">Discretionary bonuses or other compensation that is paid on a discretionary basis and not based wholly or in part on the attainment of a Financial Reporting Measure.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Incentive-Based Compensation is deemed &#8220;received&#8221; for purposes of this policy in the Company&#8217;s fiscal period during which the Financial Reporting Measure specified in the Incentive-Based Compensation award is attained, even if the payment or grant of such Incentive-Based Compensation occurs after the end of that period. </font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Administration</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This policy shall be administered by the Compensation Committee of the Board (the &#8220;Compensation Committee&#8221;). The Compensation Committee is authorized to interpret and construe this policy and to make all determinations necessary, appropriate or advisable for the administration of this policy, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. All determinations and decisions made by the Compensation Committee pursuant to the provisions of this policy shall be final, conclusive and binding on all persons, including the Company, its affiliates, its stockholders and Covered Executive Officers, and need not be uniform with respect to each person covered by this policy.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%"> </font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">In the administration of this policy, the Compensation Committee is authorized and directed to consult with the full Board or such other committees of the Board as may be necessary or appropriate as to matters within the scope of such other committee&#8217;s responsibility and authority. Subject to any limitation of applicable law, the Compensation Committee may authorize and empower any officer or employee of the Company to take any and all actions necessary or appropriate to carry out the purpose and intent of this policy (other than with respect to any recovery under this policy involving such officer or employee). Any action or inaction by the Compensation Committee  with respect to a Covered Executive Officer under this policy in no way limits the Compensation Committee&#8217;s decision to act or not to act with respect to any other Covered Executive Officer under this policy or under any similar policy, agreement or arrangement, nor shall any such action or inaction serve as a waiver of any rights the Company may have against any Covered Executive Officer other than as set forth in this policy.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Application of this Policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This policy applies to all Incentive-Based Compensation received by a person&#58; (a) after beginning service as a Covered Executive Officer&#59; (b) who served as a Covered Executive Officer at any time during the performance period for such Incentive-Based Compensation&#59; (c) while the Company had a listed class of securities on a national securities exchange&#59; and (d) during the Applicable Period. For the avoidance of doubt, Incentive-Based Compensation that is subject to both a Financial Reporting Measure vesting condition and a service-based vesting condition shall be considered received when the relevant Financial Reporting Measure is achieved, even if the Incentive-Based Compensation continues to be subject to the service-based vesting condition. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Recovery Erroneously Awarded Compensation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. In the event of an Accounting Restatement, the Company must recover Erroneously Awarded Compensation reasonably promptly, in amounts determined pursuant to this policy. The Company&#8217;s obligation to recover Erroneously Awarded Compensation is not dependent on the filing of restated financial statements. Recovery under this policy with respect to a Covered Executive Officer shall not require the finding of any misconduct by such Covered Executive Officer or such Covered Executive Officer being found responsible for the accounting error leading to an Accounting Restatement. In the event of an Accounting Restatement, the method for recouping Erroneously Awarded Compensation shall be determined by the Compensation Committee in its sole and absolute discretion, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">Recovery may include, without limitation, (i) reimbursement of all or a portion of any incentive compensation award, (ii) cancellation of incentive compensation awards, and (iii) any other method authorized by applicable law or contract.</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:115%">The Company is authorized and directed pursuant to this policy to recover Erroneously Awarded Compensation in compliance with this policy unless the Compensation Committee has determined that recovery would be impracticable solely for the following limited reasons, and subject to the following procedural and disclosure requirements&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">a.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.97pt">The direct expenses paid to a third party to assist in enforcing this policy would exceed the amount to be recovered. Before reaching such conclusion, the Compensation Committee must make a reasonable attempt to recover such Erroneously Awarded Compensation, document such reasonable attempt(s) to recover, and provide that documentation to Nasdaq&#59;</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">b.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.46pt">Recovery would violate home country law where that law was adopted prior to November 28, 2022. Before reaching such conclusion, the Compensation Committee must obtain an opinion of home country counsel, acceptable to Nasdaq, that recovery would result in such a violation, and must provide such opinion to Nasdaq&#59; or</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:108pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">c.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:10.58pt">Recovery would likely cause an otherwise tax-qualified retirement plan, under which benefits are broadly available to employees of the Company, to fail to meet the requirements of Section 401(a)(13) or Section 411(a) of the Code.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Prohibition on Indemnification and Insurance Reimbursement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company is prohibited from indemnifying any Covered Executive Officer against the loss of any Erroneously Awarded Compensation. Further, the Company is prohibited from paying or reimbursing a Covered Executive Officer for the cost of purchasing insurance to cover any such loss. The Company is also prohibited from entering into any agreement or arrangement whereby this policy would not apply or fail to be enforced against a Covered Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Required Policy-Related Disclosure and Filings</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Company shall file all disclosures with respect to this policy in accordance with the requirements of the federal securities laws, including disclosures required by U.S. Securities and Exchange Commission filings. A copy of this policy and any amendments hereto shall be posted on the Company&#8217;s website and filed as an exhibit to the Company&#8217;s annual report on Form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Amendment&#59; Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Board may amend this policy from time to time in its sole and absolute discretion and shall amend this policy as it deems necessary to reflect the Listing Standards or to comply with (or maintain an exemption from the application of) Section 409A of the Code. The Board may terminate this policy at any time&#59; provided, that the termination of this policy would not cause the Company to violate any federal securities laws, or rules promulgated by the U.S. Securities and Exchange Commission or the Listing Standards.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:9.66pt;text-decoration:underline">Other Recovery Obligations&#59; General Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. The Board intends that this policy shall be applied in accordance with, and to the fullest extent of, applicable law. To the extent that the application of this policy would provide for recovery of Incentive-Based Compensation that the Company already recovered pursuant to Section 304 of the Sarbanes-Oxley Act or other recovery obligations, any such amount recovered from a Covered Executive Officer will be credited to any recovery required under this policy in respect of such Covered Executive Officer.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:4.09pt;text-decoration:underline">Effective Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">. This policy shall be effective as of November 2, 2023. The terms of this policy shall apply to any Incentive-Based Compensation that is received by Covered Executive Officers on or after October 2, 2023, even if such Incentive-Based Compensation was approved, awarded or granted to Covered Executive Officers prior to such date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This policy shall not limit the rights of the Company to take any other actions or pursue other remedies that the Company may deem appropriate under the circumstances and under applicable law, in each case, to the extent permitted under the Listing Standards and in compliance with (or pursuant to an exemption from the application of) Section 409A of the Code. </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">This policy is binding and enforceable against all Covered Executive Officers and their beneficiaries, heirs, executors, administrators or other legal representatives.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>ensg-20231231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:19b8c51b-a068-4377-9653-a6d716d75b12,g:d8e1560a-118b-412f-95df-e14f0751e57c-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ensg="http://www.ensigngroup.net/20231231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ensigngroup.net/20231231">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ensg-20231231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ensg-20231231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ensg-20231231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ensg-20231231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ensigngroup.net/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.ensigngroup.net/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETS" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS">
        <link:definition>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFINCOME" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME">
        <link:definition>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY">
        <link:definition>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS">
        <link:definition>0000009 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDACCOUNTSRECEIVABLE" roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE">
        <link:definition>0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPUTATIONOFNETINCOMEPERCOMMONSHARE" roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE">
        <link:definition>0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTS" roleURI="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS">
        <link:definition>0000013 - Disclosure - FAIR VALUE MEASUREMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STANDARDBEARER" roleURI="http://www.ensigngroup.net/role/STANDARDBEARER">
        <link:definition>0000014 - Disclosure - STANDARD BEARER</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATIONEXPANSIONS" roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONS">
        <link:definition>0000015 - Disclosure - OPERATION EXPANSIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTS" roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTS">
        <link:definition>0000016 - Disclosure - BUSINESS SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNET" roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET">
        <link:definition>0000017 - Disclosure - PROPERTY AND EQUIPMENT&#8212; NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNET" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNET">
        <link:definition>0000018 - Disclosure - INTANGIBLE ASSETS &#8212; NET</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILL" roleURI="http://www.ensigngroup.net/role/GOODWILL">
        <link:definition>0000019 - Disclosure - GOODWILL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDANDOTHERASSETS" roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS">
        <link:definition>0000020 - Disclosure - RESTRICTED AND OTHER ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERACCRUEDLIABILITIES" roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES">
        <link:definition>0000021 - Disclosure - OTHER ACCRUED LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.ensigngroup.net/role/INCOMETAXES">
        <link:definition>0000022 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBT" roleURI="http://www.ensigngroup.net/role/DEBT">
        <link:definition>0000023 - Disclosure - DEBT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDS" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDS">
        <link:definition>0000024 - Disclosure - OPTIONS AND AWARDS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.ensigngroup.net/role/LEASES">
        <link:definition>0000025 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEFINEDCONTRIBUTIONPLANS" roleURI="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS">
        <link:definition>0000026 - Disclosure - DEFINED CONTRIBUTION PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELFINSURANCELIABILITIES" roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES">
        <link:definition>0000027 - Disclosure - SELF INSURANCE LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKREPURCHASEPROGRAM" roleURI="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM">
        <link:definition>0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies">
        <link:definition>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDACCOUNTSRECEIVABLETables" roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables">
        <link:definition>9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables">
        <link:definition>9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATIONEXPANSIONSTables" roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables">
        <link:definition>9954474 - Disclosure - OPERATION EXPANSIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTSTables" roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables">
        <link:definition>9954475 - Disclosure - BUSINESS SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETTables" roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables">
        <link:definition>9954476 - Disclosure - PROPERTY AND EQUIPMENT&#8212; NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETTables" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables">
        <link:definition>9954477 - Disclosure - INTANGIBLE ASSETS &#8212; NET (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLTables" roleURI="http://www.ensigngroup.net/role/GOODWILLTables">
        <link:definition>9954478 - Disclosure - GOODWILL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDANDOTHERASSETSTables" roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables">
        <link:definition>9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERACCRUEDLIABILITIESTables" roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables">
        <link:definition>9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.ensigngroup.net/role/INCOMETAXESTables">
        <link:definition>9954481 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTTables" roleURI="http://www.ensigngroup.net/role/DEBTTables">
        <link:definition>9954482 - Disclosure - DEBT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSTables" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables">
        <link:definition>9954483 - Disclosure - OPTIONS AND AWARDS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESTables" roleURI="http://www.ensigngroup.net/role/LEASESTables">
        <link:definition>9954484 - Disclosure - LEASES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELFINSURANCELIABILITIESTables" roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables">
        <link:definition>9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails">
        <link:definition>9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails">
        <link:definition>9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails">
        <link:definition>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails">
        <link:definition>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails">
        <link:definition>9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails">
        <link:definition>9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails">
        <link:definition>9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails">
        <link:definition>9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTSDetails" roleURI="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails">
        <link:definition>9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STANDARDBEARERDetails" roleURI="http://www.ensigngroup.net/role/STANDARDBEARERDetails">
        <link:definition>9954496 - Disclosure - STANDARD BEARER (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATIONEXPANSIONSNarrativeDetails" roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails">
        <link:definition>9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPERATIONEXPANSIONSPurchasePriceAllocationDetails" roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails">
        <link:definition>9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTSNarrativeDetails" roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails">
        <link:definition>9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails">
        <link:definition>9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails">
        <link:definition>9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails">
        <link:definition>9954502 - Disclosure - PROPERTY AND EQUIPMENT&#8212; NET - Schedule of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PROPERTYANDEQUIPMENTNETNarrativeDetails" roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails">
        <link:definition>9954503 - Disclosure - PROPERTY AND EQUIPMENT&#8212; NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails">
        <link:definition>9954504 - Disclosure - INTANGIBLE ASSETS &#8212; NET - Schedule of Finite Lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETNarrativeDetails" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails">
        <link:definition>9954505 - Disclosure - INTANGIBLE ASSETS &#8212; NET - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETFutureAmortizationDetails" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails">
        <link:definition>9954506 - Disclosure - INTANGIBLE ASSETS &#8212; NET - Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails">
        <link:definition>9954507 - Disclosure - INTANGIBLE ASSETS &#8212; NET - Schedule of Indefinite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GOODWILLDetails" roleURI="http://www.ensigngroup.net/role/GOODWILLDetails">
        <link:definition>9954508 - Disclosure - GOODWILL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRICTEDANDOTHERASSETSDetails" roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails">
        <link:definition>9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OTHERACCRUEDLIABILITIESDetails" roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails">
        <link:definition>9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESExpenseDetails" roleURI="http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails">
        <link:definition>9954511 - Disclosure - INCOME TAXES - Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTaxRateDetails" roleURI="http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails">
        <link:definition>9954512 - Disclosure - INCOME TAXES - Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeYEDetails" roleURI="http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails">
        <link:definition>9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTScheduleofLongtermDebtDetails" roleURI="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails">
        <link:definition>9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" roleURI="http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails">
        <link:definition>9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" roleURI="http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails">
        <link:definition>9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEBTLongtermDebtArrangementsDetails" roleURI="http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails">
        <link:definition>9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSStockOptionsNarrativeDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails">
        <link:definition>9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSValuationAssumptionsDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails">
        <link:definition>9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSExercisePriceandFairValueDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails">
        <link:definition>9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails">
        <link:definition>9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails">
        <link:definition>9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSIntrinsicValuesDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails">
        <link:definition>9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails">
        <link:definition>9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails">
        <link:definition>9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSLongTermIncentivePlanDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails">
        <link:definition>9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OPTIONSANDAWARDSCompensationExpenseDetails" roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails">
        <link:definition>9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLesseeNarrativeDetails" roleURI="http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails">
        <link:definition>9954529 - Disclosure - LEASES - Lessee Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLesseeLeaseCostDetails" roleURI="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails">
        <link:definition>9954530 - Disclosure - LEASES - Lessee Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLesseeFutureMinimumLeasePaymentsDetails" roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails">
        <link:definition>9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLesseeFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1">
        <link:definition>9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLessorNarrativeDetails" roleURI="http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails">
        <link:definition>9954532 - Disclosure - LEASES - Lessor Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLessorRentalIncomeDetails" roleURI="http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails">
        <link:definition>9954533 - Disclosure - LEASES - Lessor Rental Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" roleURI="http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails">
        <link:definition>9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DEFINEDCONTRIBUTIONPLANSDetails" roleURI="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails">
        <link:definition>9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SELFINSURANCELIABILITIESDetails" roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails">
        <link:definition>9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMONSTOCKREPURCHASEPROGRAMDetails" roleURI="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails">
        <link:definition>9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ensg_AmendedSeparateMasterLeases" abstract="false" name="AmendedSeparateMasterLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_HealthLiabilityInsuranceMember" abstract="true" name="HealthLiabilityInsuranceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LesseeOperatingLeaseConsumerPriceIndex" abstract="false" name="LesseeOperatingLeaseConsumerPriceIndex" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" abstract="false" name="RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_NumberOfHealthCareFacilities" abstract="false" name="NumberOfHealthCareFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" abstract="true" name="OtherStatesExceptCaliforniaTexasAndWashingtonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_AcquiredOperationsMember" abstract="true" name="AcquiredOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_PrepaymentFeePeriodDomain" abstract="true" name="PrepaymentFeePeriodDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_OwnedPropertiesMember" abstract="true" name="OwnedPropertiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ExercisePriceRangeElevenMember" abstract="true" name="ExercisePriceRangeElevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PropertyManagementFeePercentFeeOfTotalRevenues" abstract="false" name="PropertyManagementFeePercentFeeOfTotalRevenues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_July2022RepurchaseProgramMember" abstract="true" name="July2022RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" abstract="false" name="LiabilitiesDeferredTaxPaymentsUnderCARESAct" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_AccruedLiabilitiesStateReliefContractLiabilities" abstract="false" name="AccruedLiabilitiesStateReliefContractLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_NumberOfLivingOperationsTransferredFromThirdParties" abstract="false" name="NumberOfLivingOperationsTransferredFromThirdParties" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_BusinessAndAssetAcquisitionsDomain" abstract="true" name="BusinessAndAssetAcquisitionsDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_BlanketAggregateMember" abstract="true" name="BlanketAggregateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NoncontrollingInterestPolicyTextBlock" abstract="false" name="NoncontrollingInterestPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" abstract="false" name="RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" abstract="false" name="TotalNetDebtRatioMaximumAfterIncreaseElection" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ensg_NumberOfFinancingLeases" abstract="false" name="NumberOfFinancingLeases" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ExercisePriceRangeSevenMember" abstract="true" name="ExercisePriceRangeSevenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ExercisePriceRangeNineMember" abstract="true" name="ExercisePriceRangeNineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PaymentsToAcquireAssetAcquisitions" abstract="false" name="PaymentsToAcquireAssetAcquisitions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_BusinessAndAssetAcquisitionsAxis" abstract="true" name="BusinessAndAssetAcquisitionsAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_StandardBearerMasterLeasesMember" abstract="true" name="StandardBearerMasterLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_AmendedMasterLeaseMember" abstract="true" name="AmendedMasterLeaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_MasterLeaseAgreements" abstract="false" name="MasterLeaseAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_HUDInsuredMortgagesMember" abstract="true" name="HUDInsuredMortgagesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_LeaseOfCampusOperationMember" abstract="true" name="LeaseOfCampusOperationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_OperatingEntityDomain" abstract="true" name="OperatingEntityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_StandardBearerEquityPlanMember" abstract="true" name="StandardBearerEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ensg_ExercisePriceRangeSixMember" abstract="true" name="ExercisePriceRangeSixMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NewMasterLeaseAgreeementMember" abstract="true" name="NewMasterLeaseAgreeementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfOperatingSubsidiaries" abstract="false" name="NumberOfOperatingSubsidiaries" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_SkilledServicesSegmentMember" abstract="true" name="SkilledServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_TwentyThreeSubsidiariesMember" abstract="true" name="TwentyThreeSubsidiariesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_SeniorLivingOperationsMember" abstract="true" name="SeniorLivingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" abstract="false" name="LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ensg_StandardBearerTextBlock" abstract="false" name="StandardBearerTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="ensg_OperationalSkilledNursingBeds" abstract="false" name="OperationalSkilledNursingBeds" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" abstract="false" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_DeferredRentAndOtherLongTermLiabilities" abstract="false" name="DeferredRentAndOtherLongTermLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_PaymentsForMedicareAndMedicaidLicenses" abstract="false" name="PaymentsForMedicareAndMedicaidLicenses" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ThirdPartiesMember" abstract="true" name="ThirdPartiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_RentalMember" abstract="true" name="RentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfOperations" abstract="false" name="NumberOfOperations" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" abstract="false" name="LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_ManagementServiceTotalMember" abstract="true" name="ManagementServiceTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PerOccurenceMember" abstract="true" name="PerOccurenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_A2019LTIPlanMember" abstract="true" name="A2019LTIPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" abstract="false" name="FamilyFirstCoronavirusResponseActPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_StopLossInsuranceLimitPerClaimMember" abstract="true" name="StopLossInsuranceLimitPerClaimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" abstract="false" name="LongTermDebtThresholdForEBITDARatioIncreaseElection" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_LeaseArrangementDomain" abstract="true" name="LeaseArrangementDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_TotalNetDebtRatioMinimum" abstract="false" name="TotalNetDebtRatioMinimum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ensg_TripleNetLeaseArrangementsMember" abstract="true" name="TripleNetLeaseArrangementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" abstract="false" name="SkilledNursingSeniorLivingAndIndependentLivingFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_InsuranceSubsidiaryDepositsAndInvestments" abstract="false" name="InsuranceSubsidiaryDepositsAndInvestments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_VariousLandlordsMember" abstract="true" name="VariousLandlordsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_A53PromissoryNoteMember" abstract="true" name="A53PromissoryNoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_TotalNetDebtRatioMaximum" abstract="false" name="TotalNetDebtRatioMaximum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ensg_SeniorLivingFacilities" abstract="false" name="SeniorLivingFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" abstract="false" name="LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_SecuredOvernightFinancingRateSOFRMember" abstract="true" name="SecuredOvernightFinancingRateSOFRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LossSensitiveLimitPerClaimMember" abstract="true" name="LossSensitiveLimitPerClaimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_RealEstatePurchasesOfPreviousOperationsMember" abstract="true" name="RealEstatePurchasesOfPreviousOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_InsuranceCoverageLimitTypeAxis" abstract="true" name="InsuranceCoverageLimitTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_NumberOfLeaseArrangements" abstract="false" name="NumberOfLeaseArrangements" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LessorOperatingLeaseNumberOfLeases" abstract="false" name="LessorOperatingLeaseNumberOfLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_MedicaidAndMedicareMember" abstract="true" name="MedicaidAndMedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ChristopherRChristensenMember" abstract="true" name="ChristopherRChristensenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_QualityAssuranceFee" abstract="false" name="QualityAssuranceFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_SelfInsuranceRetentionPerClaimMember" abstract="true" name="SelfInsuranceRetentionPerClaimMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_RentCostOfServices" abstract="false" name="RentCostOfServices" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" abstract="false" name="NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_PayorAxis" abstract="true" name="PayorAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_ExercisePriceRangeTenMember" abstract="true" name="ExercisePriceRangeTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_CampusOperationMember" abstract="true" name="CampusOperationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NonCashLeaseExpense" abstract="false" name="NonCashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_AllStatesExceptColoradoMember" abstract="true" name="AllStatesExceptColoradoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_FacilitiesUnderMasterLeaseArrangement" abstract="false" name="FacilitiesUnderMasterLeaseArrangement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_RealEstatePurchasesMember" abstract="true" name="RealEstatePurchasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" abstract="false" name="NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_A2022PlanMember" abstract="true" name="A2022PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_StandardBearerSegmentMember" abstract="true" name="StandardBearerSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PrepaymentFeePeriodAxis" abstract="true" name="PrepaymentFeePeriodAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_YearsFiveThroughTenMember" abstract="true" name="YearsFiveThroughTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" abstract="false" name="PropertyManagementFeePercentFeeOfFundsFromOperations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_CareTrustREITMember" abstract="true" name="CareTrustREITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PurchaseOptionMember" abstract="true" name="PurchaseOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ensg_InsuranceCoverageLimitTypeDomain" abstract="true" name="InsuranceCoverageLimitTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfRealEstatePropertiesLeased" abstract="false" name="NumberOfRealEstatePropertiesLeased" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_OperatingEntityAxis" abstract="true" name="OperatingEntityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_August2023RepurchaseProgramMember" abstract="true" name="August2023RepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_AssembledOccupancyAcquiredMember" abstract="true" name="AssembledOccupancyAcquiredMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_AggregateDeductibleMember" abstract="true" name="AggregateDeductibleMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_CashHeldInTrustForResidents" abstract="false" name="CashHeldInTrustForResidents" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_LeasesToThirdPartyOperatorsMember" abstract="true" name="LeasesToThirdPartyOperatorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_LeasedAssetsAcquiredDuringPeriod" abstract="false" name="LeasedAssetsAcquiredDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" abstract="false" name="ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_NumberOfAssetAcquisitions" abstract="false" name="NumberOfAssetAcquisitions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_PayorDomain" abstract="true" name="PayorDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PrepaymentPenalty" abstract="false" name="PrepaymentPenalty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_NonCaliforniaMember" abstract="true" name="NonCaliforniaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_RestrictedAndOtherAssetsNoncurrent" abstract="false" name="RestrictedAndOtherAssetsNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ReductionInPrepaymentPenalty" abstract="false" name="ReductionInPrepaymentPenalty" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_InTheFourthYearMember" abstract="true" name="InTheFourthYearMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" abstract="false" name="EmployeeServiceShareBasedCompensationNonvestedAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="ensg_SharebasedCompensationRestrictedAwardsExercisePrice" abstract="false" name="SharebasedCompensationRestrictedAwardsExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="ensg_ThirdPartyTenantsMember" abstract="true" name="ThirdPartyTenantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfOptionPlans" abstract="false" name="NumberOfOptionPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_DeferredTaxLiabilitiesRightOfUseAsset" abstract="false" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_PrivatePayAndOtherMember" abstract="true" name="PrivatePayAndOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" abstract="false" name="GainLossOnInsuranceClaimsAndDisposalOfAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" abstract="false" name="BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ensg_StockAwardsMember" abstract="true" name="StockAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" abstract="false" name="IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_TruistBankMember" abstract="true" name="TruistBankMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_AfterYearTenMember" abstract="true" name="AfterYearTenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_ThirdPartyOperatorsMember" abstract="true" name="ThirdPartyOperatorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_LesseeOperatingLeaseNumberOfLeases" abstract="false" name="LesseeOperatingLeaseNumberOfLeases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_MedicaidSkilledMember" abstract="true" name="MedicaidSkilledMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" abstract="false" name="CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ResidentRefundsPayable" abstract="false" name="ResidentRefundsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_BeverlyBWittekindMember" abstract="true" name="BeverlyBWittekindMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_DeferredTaxLiabilitiesStateTaxes" abstract="false" name="DeferredTaxLiabilitiesStateTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ensg_SeniorLivingFacilitiesMember" abstract="true" name="SeniorLivingFacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_DeferredRentAdjustment" abstract="false" name="DeferredRentAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_MedicareandMedicaidLicensesMember" abstract="true" name="MedicareandMedicaidLicensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LeaseArrangementAxis" abstract="true" name="LeaseArrangementAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="ensg_SegmentIncomeLoss" abstract="false" name="SegmentIncomeLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_PurchasesOfNonControllingInterest" abstract="false" name="PurchasesOfNonControllingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_StandardBearerHealthcareREITIncMember" abstract="true" name="StandardBearerHealthcareREITIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_NumberOfPropertiesAcquired" abstract="false" name="NumberOfPropertiesAcquired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_OperationalSeniorLivingUnits" abstract="false" name="OperationalSeniorLivingUnits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" abstract="false" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_AmendedMasterLeaseAgreementMember" abstract="true" name="AmendedMasterLeaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" abstract="false" name="ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" abstract="false" name="MedicareAcceleratedAndAdvancePaymentCARESACT" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_InvestmentExpenseIncome" abstract="false" name="InvestmentExpenseIncome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_ExercisePriceRangeEightMember" abstract="true" name="ExercisePriceRangeEightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" abstract="false" name="IndependentOperatingSubsidiariesUnderMedicareProbeReviews" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_SkilledNursingOperationsMember" abstract="true" name="SkilledNursingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PerFacilityMember" abstract="true" name="PerFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ManagedCareMember" abstract="true" name="ManagedCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" abstract="true" name="SubleaseOfStandAlongSkilledNursingOperationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_DepreciationAndAmortizationMember" abstract="true" name="DepreciationAndAmortizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_SkilledServicesAndSeniorLivingCampuses" abstract="false" name="SkilledServicesAndSeniorLivingCampuses" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_ThePennantGroupInc.Member" abstract="true" name="ThePennantGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_PaymentsToAcquirePropertyAndEquipment" abstract="false" name="PaymentsToAcquirePropertyAndEquipment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ensg_NumberOfFacilities" abstract="false" name="NumberOfFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ensg_FirstThreeYearsMember" abstract="true" name="FirstThreeYearsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ensg_CostofSalesandGeneralandAdministrativeExpenseMember" abstract="true" name="CostofSalesandGeneralandAdministrativeExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="ensg_SkilledServiceFacilities" abstract="false" name="SkilledServiceFacilities" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>ensg-20231231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:19b8c51b-a068-4377-9653-a6d716d75b12,g:d8e1560a-118b-412f-95df-e14f0751e57c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf70d627-fca4-4a4a-ad56-e608278ccdb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c2c8633e-aeaf-4e59-ac12-ba16f2ebee24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf70d627-fca4-4a4a-ad56-e608278ccdb7" xlink:to="loc_us-gaap_Liabilities_c2c8633e-aeaf-4e59-ac12-ba16f2ebee24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e60a59ae-b661-4042-bad1-9f5e4191a424" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf70d627-fca4-4a4a-ad56-e608278ccdb7" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e60a59ae-b661-4042-bad1-9f5e4191a424" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3a0014c-be23-4f63-a95e-022530ec22ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_cf70d627-fca4-4a4a-ad56-e608278ccdb7" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c3a0014c-be23-4f63-a95e-022530ec22ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RestrictedAndOtherAssetsNoncurrent_39dcd09f-790d-4cdc-a3ba-6bc01aeffab9" xlink:href="ensg-20231231.xsd#ensg_RestrictedAndOtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_ensg_RestrictedAndOtherAssetsNoncurrent_39dcd09f-790d-4cdc-a3ba-6bc01aeffab9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_77326ba5-404d-405a-bdd7-7fffd4c50b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_77326ba5-404d-405a-bdd7-7fffd4c50b26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_286d6f87-d9cb-4cd0-a88d-f708012b1cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_286d6f87-d9cb-4cd0-a88d-f708012b1cc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_22426fe0-f1b4-49ec-9281-02925e7497a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_AssetsCurrent_22426fe0-f1b4-49ec-9281-02925e7497a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments_a2ca8e84-c49f-47f8-9130-ae71c15bc1fa" xlink:href="ensg-20231231.xsd#ensg_InsuranceSubsidiaryDepositsAndInvestments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments_a2ca8e84-c49f-47f8-9130-ae71c15bc1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95f4db6f-0035-4c1d-83a5-2e124ba85ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_Goodwill_95f4db6f-0035-4c1d-83a5-2e124ba85ca2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0420ca1-0e4d-4515-8feb-364d88383fdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0420ca1-0e4d-4515-8feb-364d88383fdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafa655d-2bee-4b4f-8096-9b99ea786516" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f3970461-98a9-40f6-a624-4ca588f57970" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_aafa655d-2bee-4b4f-8096-9b99ea786516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_169a627b-17df-4364-a71b-b406f8747641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_6a26bd39-9600-408d-bd81-7a85ab1bb54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_169a627b-17df-4364-a71b-b406f8747641" xlink:to="loc_us-gaap_ShortTermInvestments_6a26bd39-9600-408d-bd81-7a85ab1bb54c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_813d2599-5656-47a1-b4a1-4410d1f7f645" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_169a627b-17df-4364-a71b-b406f8747641" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_813d2599-5656-47a1-b4a1-4410d1f7f645" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e66ec5e-59ac-4fcb-9b89-ec6d482fe5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_169a627b-17df-4364-a71b-b406f8747641" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1e66ec5e-59ac-4fcb-9b89-ec6d482fe5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_94acfcb0-f2d0-48e2-8789-b931db819741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_169a627b-17df-4364-a71b-b406f8747641" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_94acfcb0-f2d0-48e2-8789-b931db819741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b9a8253-b072-4934-9669-b8af5448cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3abf9da8-339e-4285-b2d6-88f932a1bf68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b9a8253-b072-4934-9669-b8af5448cdfc" xlink:to="loc_us-gaap_CommonStockValue_3abf9da8-339e-4285-b2d6-88f932a1bf68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_42af293d-384e-47f7-b0be-a2d1c1701c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b9a8253-b072-4934-9669-b8af5448cdfc" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_42af293d-384e-47f7-b0be-a2d1c1701c7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc7c4279-c818-4735-8cce-986add114b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b9a8253-b072-4934-9669-b8af5448cdfc" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fc7c4279-c818-4735-8cce-986add114b7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_bf095147-5cb9-4349-873f-c511828c2d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b9a8253-b072-4934-9669-b8af5448cdfc" xlink:to="loc_us-gaap_TreasuryStockCommonValue_bf095147-5cb9-4349-873f-c511828c2d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_13df0e50-5e21-4c87-8516-90140de04d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:to="loc_us-gaap_LiabilitiesCurrent_13df0e50-5e21-4c87-8516-90140de04d1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_12302943-928c-48d6-b6f8-3e1339825184" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:to="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_12302943-928c-48d6-b6f8-3e1339825184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ae46ca5-29f0-473b-bc98-dd32234d71e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4ae46ca5-29f0-473b-bc98-dd32234d71e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_279ed1f8-a592-45cd-865a-fc62ba31bc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_279ed1f8-a592-45cd-865a-fc62ba31bc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAndOtherLongTermLiabilities_6e3c11a2-7e12-4f98-9ef9-dfa4bdc72077" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAndOtherLongTermLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_bc8ad79e-98ba-41f5-bd6f-73bd4c2ecc8c" xlink:to="loc_ensg_DeferredRentAndOtherLongTermLiabilities_6e3c11a2-7e12-4f98-9ef9-dfa4bdc72077" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d00d86b-a29c-4b43-bebe-22812c2c30e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8fde04cf-01c8-40a0-926b-72fc60a81110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d00d86b-a29c-4b43-bebe-22812c2c30e2" xlink:to="loc_us-gaap_StockholdersEquity_8fde04cf-01c8-40a0-926b-72fc60a81110" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_2e687568-7a79-4327-90d5-283389311d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1d00d86b-a29c-4b43-bebe-22812c2c30e2" xlink:to="loc_us-gaap_MinorityInterest_2e687568-7a79-4327-90d5-283389311d2f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_3685f8d5-105d-456c-a2a5-6536db0d19dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_AccountsPayableCurrent_3685f8d5-105d-456c-a2a5-6536db0d19dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bafd12f3-d79b-490f-a878-221d6b1e5047" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bafd12f3-d79b-490f-a878-221d6b1e5047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d56d2571-8c9b-4dde-96fe-f8efbb17772f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d56d2571-8c9b-4dde-96fe-f8efbb17772f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_712a0c4c-5ea3-4664-8feb-cdaeca5ffc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_712a0c4c-5ea3-4664-8feb-cdaeca5ffc3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b39ab499-c7c1-489e-a18b-b101eb48846d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b39ab499-c7c1-489e-a18b-b101eb48846d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_748b6c18-d868-47ff-9e1c-8c87f0292361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1ad2cc1f-2b7c-4d86-8f86-7d63407be084" xlink:to="loc_us-gaap_LongTermDebtCurrent_748b6c18-d868-47ff-9e1c-8c87f0292361" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_93f777d2-532f-4f16-8fcf-4dab5def6eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9796c7c5-36b3-42b9-a28b-b34c47a0d4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_93f777d2-532f-4f16-8fcf-4dab5def6eaa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9796c7c5-36b3-42b9-a28b-b34c47a0d4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_aa9312ca-c382-48f8-9404-2706b69c0225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_93f777d2-532f-4f16-8fcf-4dab5def6eaa" xlink:to="loc_us-gaap_InterestExpense_aa9312ca-c382-48f8-9404-2706b69c0225" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f1c3e09e-ef43-49df-8a9d-83f7b98db98b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_33a6a739-a96f-4aa7-9e08-b8e8f4dc3106" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f1c3e09e-ef43-49df-8a9d-83f7b98db98b" xlink:to="loc_us-gaap_ProfitLoss_33a6a739-a96f-4aa7-9e08-b8e8f4dc3106" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c3cd1bd5-f589-4cf9-8b98-8a3d71bf626a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_f1c3e09e-ef43-49df-8a9d-83f7b98db98b" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c3cd1bd5-f589-4cf9-8b98-8a3d71bf626a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_6510c083-54b5-49be-b367-4733e9318f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712aaad9-f362-488c-b907-1c0e76a9c1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6510c083-54b5-49be-b367-4733e9318f0e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_712aaad9-f362-488c-b907-1c0e76a9c1f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_e24bfe18-6bbf-4bf2-b7ae-d61f8905708e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_6510c083-54b5-49be-b367-4733e9318f0e" xlink:to="loc_us-gaap_CostsAndExpenses_e24bfe18-6bbf-4bf2-b7ae-d61f8905708e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_7c2aec2f-ab87-45ce-b2d0-000bdb0d4eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5769fbcf-0fdb-47f3-be4a-bcd9df3647f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7c2aec2f-ab87-45ce-b2d0-000bdb0d4eff" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5769fbcf-0fdb-47f3-be4a-bcd9df3647f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentCostOfServices_5edea0c6-706d-4525-a615-8f82c2b4bd4e" xlink:href="ensg-20231231.xsd#ensg_RentCostOfServices"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7c2aec2f-ab87-45ce-b2d0-000bdb0d4eff" xlink:to="loc_ensg_RentCostOfServices_5edea0c6-706d-4525-a615-8f82c2b4bd4e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_80b60ee5-c8dd-470f-88d5-24f56a30815d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7c2aec2f-ab87-45ce-b2d0-000bdb0d4eff" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_80b60ee5-c8dd-470f-88d5-24f56a30815d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d2eb0364-f04d-487a-bd0a-3ac1ce8a3eea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_7c2aec2f-ab87-45ce-b2d0-000bdb0d4eff" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d2eb0364-f04d-487a-bd0a-3ac1ce8a3eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7c18d4b5-b5c6-41ac-baed-ba7e654e30b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e64132b8-6543-4471-8a4a-0d7508292ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7c18d4b5-b5c6-41ac-baed-ba7e654e30b1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e64132b8-6543-4471-8a4a-0d7508292ac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_538b0f7c-f2b4-4c43-bc04-befe016c8e5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_7c18d4b5-b5c6-41ac-baed-ba7e654e30b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_538b0f7c-f2b4-4c43-bc04-befe016c8e5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_139aeba2-f8fb-4eb3-bef9-63b2a23fcc41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_39bd5505-7eee-4026-83ae-518db18e773e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_139aeba2-f8fb-4eb3-bef9-63b2a23fcc41" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_39bd5505-7eee-4026-83ae-518db18e773e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7391933c-0d02-4e20-80ec-458e8ca0d5a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_139aeba2-f8fb-4eb3-bef9-63b2a23fcc41" xlink:to="loc_us-gaap_OperatingIncomeLoss_7391933c-0d02-4e20-80ec-458e8ca0d5a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquirePropertyAndEquipment_fb3d53f3-2b59-4db0-b527-8b0ea9867a7b" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquirePropertyAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_ensg_PaymentsToAcquirePropertyAndEquipment_fb3d53f3-2b59-4db0-b527-8b0ea9867a7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsForMedicareAndMedicaidLicenses_4f29a3d5-0f1b-4c87-8e8c-2c7f06f70f26" xlink:href="ensg-20231231.xsd#ensg_PaymentsForMedicareAndMedicaidLicenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_ensg_PaymentsForMedicareAndMedicaidLicenses_4f29a3d5-0f1b-4c87-8e8c-2c7f06f70f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_dc57a47a-c220-4655-8409-98406fb03cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_dc57a47a-c220-4655-8409-98406fb03cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquireAssetAcquisitions_aab5d3db-f6c9-4bcb-b7aa-342939a18554" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquireAssetAcquisitions"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_ensg_PaymentsToAcquireAssetAcquisitions_aab5d3db-f6c9-4bcb-b7aa-342939a18554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_4c711acc-b01a-4c7b-8e37-7079bc5d6adb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_4c711acc-b01a-4c7b-8e37-7079bc5d6adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_d4bba089-093f-4022-b7c2-91beb8350d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_d4bba089-093f-4022-b7c2-91beb8350d71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c87d779c-e1d5-42a8-a544-7bdac9804c52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_c87d779c-e1d5-42a8-a544-7bdac9804c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_95f16526-2ad0-4faa-b648-57d52e31374d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_95f16526-2ad0-4faa-b648-57d52e31374d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_3be1d28c-6e0e-44d7-992a-9cf3dd7bbe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_3be1d28c-6e0e-44d7-992a-9cf3dd7bbe5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eeaf437b-58b3-4110-b965-fe6fd742d898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_eeaf437b-58b3-4110-b965-fe6fd742d898" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4df9e135-dbd8-42b1-bb62-04ed04c67f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_922ebc76-434e-43fb-aa19-3d44e675572f" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_4df9e135-dbd8-42b1-bb62-04ed04c67f4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7621446d-ca6b-40c0-9afb-de2318aa01e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7eebac22-d66a-4ca5-ba07-1828bbd79f55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7621446d-ca6b-40c0-9afb-de2318aa01e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7eebac22-d66a-4ca5-ba07-1828bbd79f55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60d63376-bf3d-4834-aec7-6463bf353278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7621446d-ca6b-40c0-9afb-de2318aa01e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_60d63376-bf3d-4834-aec7-6463bf353278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1651c541-a39b-45e2-8219-0258be529eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7621446d-ca6b-40c0-9afb-de2318aa01e2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1651c541-a39b-45e2-8219-0258be529eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8af08408-5105-43bf-884d-33f3cbac1fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8af08408-5105-43bf-884d-33f3cbac1fb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_6b72b45c-7537-4739-bbcf-7f11a0d4c8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_6b72b45c-7537-4739-bbcf-7f11a0d4c8a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_bf7ff933-dd7e-40a1-b3b0-7c66cd5a1e28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_bf7ff933-dd7e-40a1-b3b0-7c66cd5a1e28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2e9379a-3e0b-4b60-8cc2-80b89533e7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_a2e9379a-3e0b-4b60-8cc2-80b89533e7a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4cbc558e-d082-4a5f-933c-21b5d59815b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4cbc558e-d082-4a5f-933c-21b5d59815b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_088c587a-52e7-4276-827b-c888e6251713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_088c587a-52e7-4276-827b-c888e6251713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_714bf055-4e0c-4037-8f8e-167d22381a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_ProfitLoss_714bf055-4e0c-4037-8f8e-167d22381a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_d067316d-ed64-4e3c-9a81-3ed3503d6af5" xlink:href="ensg-20231231.xsd#ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_d067316d-ed64-4e3c-9a81-3ed3503d6af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f761c554-98d4-4663-aeed-181d940e974f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f761c554-98d4-4663-aeed-181d940e974f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_2367042d-2e05-4529-90a9-fc070e928b66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_2367042d-2e05-4529-90a9-fc070e928b66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_bba275a8-19c1-4979-a4d2-59acf4c1f90b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_bba275a8-19c1-4979-a4d2-59acf4c1f90b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_736f0691-c6dd-4a72-a9be-afd32ee08f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_736f0691-c6dd-4a72-a9be-afd32ee08f8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d99e1772-9e67-40ee-b6fe-3f387691ed0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_d99e1772-9e67-40ee-b6fe-3f387691ed0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_906a81a9-c2ba-4a8f-a86c-8fd853c04179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_906a81a9-c2ba-4a8f-a86c-8fd853c04179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCashLeaseExpense_77464a42-d518-4976-b078-8a34011dc029" xlink:href="ensg-20231231.xsd#ensg_NonCashLeaseExpense"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_ensg_NonCashLeaseExpense_77464a42-d518-4976-b078-8a34011dc029" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_591e47d6-8e27-49f5-8e80-ccab303d85fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_591e47d6-8e27-49f5-8e80-ccab303d85fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_798b835c-2e5e-492c-8c33-f881168b631b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="17" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_798b835c-2e5e-492c-8c33-f881168b631b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_05f254d2-b4f5-4830-a335-cadf251860af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue"/>
    <link:calculationArc order="18" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_05f254d2-b4f5-4830-a335-cadf251860af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21beaf66-5d81-4990-971b-64e4c769c0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="19" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_21beaf66-5d81-4990-971b-64e4c769c0fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_9f6b0e86-dad4-4ac2-8c8e-a3ee08e4e98f" xlink:href="ensg-20231231.xsd#ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct"/>
    <link:calculationArc order="20" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_9f6b0e86-dad4-4ac2-8c8e-a3ee08e4e98f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_5304a419-a3fd-46ba-8dfc-0bd5920fd8a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSelfInsuranceReserve"/>
    <link:calculationArc order="21" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_5304a419-a3fd-46ba-8dfc-0bd5920fd8a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_f4832ea9-90af-4d5c-a68c-49f42a86ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:calculationArc order="22" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_f4832ea9-90af-4d5c-a68c-49f42a86ff29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_c1e491ef-b497-407b-bb4e-c615492bff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="23" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_ShareBasedCompensation_c1e491ef-b497-407b-bb4e-c615492bff5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_b8fb27d4-5e52-4673-b9cc-b73257371469" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:calculationArc order="24" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_55eeabcb-9a7c-4c14-97de-d5d773e84f1b" xlink:to="loc_us-gaap_LitigationSettlementExpense_b8fb27d4-5e52-4673-b9cc-b73257371469" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_992c957b-db65-4663-8568-b2ea7ce1122a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_992c957b-db65-4663-8568-b2ea7ce1122a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7f1e10e-bff3-4b5b-a60f-9e64deb2f892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7f1e10e-bff3-4b5b-a60f-9e64deb2f892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_2e83dfed-f984-44d9-9730-21f6f9fd3e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_2e83dfed-f984-44d9-9730-21f6f9fd3e8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e54f99f7-99c3-4129-8ddc-c6f6ee4d0d52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e54f99f7-99c3-4129-8ddc-c6f6ee4d0d52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_84345f4b-2deb-4bf1-a62b-84fe1bda5361" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_84345f4b-2deb-4bf1-a62b-84fe1bda5361" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_c623461b-9ff9-4f51-8e87-65b7651f4892" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_PaymentsOfDividends_c623461b-9ff9-4f51-8e87-65b7651f4892" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_61c949dd-915b-4746-93cc-a4d3f377a486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_61c949dd-915b-4746-93cc-a4d3f377a486" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9a810cbd-69a6-4cac-9d48-0d8f8daf6279" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_9a810cbd-69a6-4cac-9d48-0d8f8daf6279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_8e973af0-0f65-47b4-972f-6375116acb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_8e973af0-0f65-47b4-972f-6375116acb0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_97cd67bb-dd8c-4719-8fa7-3c88fb4d4725" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_97cd67bb-dd8c-4719-8fa7-3c88fb4d4725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchasesOfNonControllingInterest_19472759-2133-4c90-bbf0-5d65d868f65a" xlink:href="ensg-20231231.xsd#ensg_PurchasesOfNonControllingInterest"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_ensg_PurchasesOfNonControllingInterest_19472759-2133-4c90-bbf0-5d65d868f65a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_6d8c5b50-b675-463c-9964-d12639f01371" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cb2f9aa6-7f33-4759-aad1-dddb76648a3e" xlink:to="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_6d8c5b50-b675-463c-9964-d12639f01371" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_0168a795-8064-42da-8de1-7e76fe51ceda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_76e3c430-8e5d-4de1-b779-0c9a601bb71d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0168a795-8064-42da-8de1-7e76fe51ceda" xlink:to="loc_us-gaap_AccountsReceivableGross_76e3c430-8e5d-4de1-b779-0c9a601bb71d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c6be9085-ebea-405f-b9a0-6486bb99e4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_0168a795-8064-42da-8de1-7e76fe51ceda" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_c6be9085-ebea-405f-b9a0-6486bb99e4e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_600edcc0-bc72-4786-8e61-35f45d40da8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7f210499-1387-4458-b4a6-023e62b478a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_600edcc0-bc72-4786-8e61-35f45d40da8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_7f210499-1387-4458-b4a6-023e62b478a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7532277e-2ee6-4441-a8d3-3a1f01f389cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_600edcc0-bc72-4786-8e61-35f45d40da8a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_7532277e-2ee6-4441-a8d3-3a1f01f389cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ff3c1b3-beaa-4532-bb6d-dafc56eb2104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe389c61-d0a2-473c-81ac-fdc247e24ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ff3c1b3-beaa-4532-bb6d-dafc56eb2104" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fe389c61-d0a2-473c-81ac-fdc247e24ed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7079c0b9-bda7-4a0b-a91d-48851ba8677f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5ff3c1b3-beaa-4532-bb6d-dafc56eb2104" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_7079c0b9-bda7-4a0b-a91d-48851ba8677f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0200a34f-97c3-4f84-becf-4f7a30aea798" xlink:href="ensg-20231231.xsd#ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_22f7b274-d055-4ccd-b6d6-90dda7608b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0200a34f-97c3-4f84-becf-4f7a30aea798" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_22f7b274-d055-4ccd-b6d6-90dda7608b6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_6a96c926-eb58-40ee-9772-2b6e93c27fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0200a34f-97c3-4f84-becf-4f7a30aea798" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_6a96c926-eb58-40ee-9772-2b6e93c27fee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_a895f62d-1843-4e4a-9696-673ecf02cbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0200a34f-97c3-4f84-becf-4f7a30aea798" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_a895f62d-1843-4e4a-9696-673ecf02cbd7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasedAssetsAcquiredDuringPeriod_655b4027-885c-4a80-b3a7-7a98101d2987" xlink:href="ensg-20231231.xsd#ensg_LeasedAssetsAcquiredDuringPeriod"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_0200a34f-97c3-4f84-becf-4f7a30aea798" xlink:to="loc_ensg_LeasedAssetsAcquiredDuringPeriod_655b4027-885c-4a80-b3a7-7a98101d2987" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_939bed48-45b7-43e2-b9e0-486e090ffa2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SegmentIncomeLoss_b43e3d4b-d2bd-49d0-834f-af923fdeb9a0" xlink:href="ensg-20231231.xsd#ensg_SegmentIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_939bed48-45b7-43e2-b9e0-486e090ffa2c" xlink:to="loc_ensg_SegmentIncomeLoss_b43e3d4b-d2bd-49d0-834f-af923fdeb9a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLossFromRealEstateOperations_bd6306c1-75fe-453a-b3a4-a42e7791948c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLossFromRealEstateOperations"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_939bed48-45b7-43e2-b9e0-486e090ffa2c" xlink:to="loc_us-gaap_ProfitLossFromRealEstateOperations_bd6306c1-75fe-453a-b3a4-a42e7791948c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0ef3ad49-2be7-4cd3-8f41-52164cc1911e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_8f9ecf73-e719-495d-937d-34d27a6cdaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ef3ad49-2be7-4cd3-8f41-52164cc1911e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_8f9ecf73-e719-495d-937d-34d27a6cdaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae9a5103-2380-47ff-a6d6-95db52ded362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0ef3ad49-2be7-4cd3-8f41-52164cc1911e" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ae9a5103-2380-47ff-a6d6-95db52ded362" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9dbc7a2a-ce76-484d-a44d-d8a64a814d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8b6b2762-2499-438b-99ab-3d4a1d2c606a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9dbc7a2a-ce76-484d-a44d-d8a64a814d0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_8b6b2762-2499-438b-99ab-3d4a1d2c606a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_01245e6f-e9a8-45eb-8a70-1bf5ecd2ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9dbc7a2a-ce76-484d-a44d-d8a64a814d0d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_01245e6f-e9a8-45eb-8a70-1bf5ecd2ed56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b37c3613-7602-441a-9999-d8a21e45a0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b37c3613-7602-441a-9999-d8a21e45a0ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5bbfdc04-6d00-45fb-a25f-829b761be124" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_5bbfdc04-6d00-45fb-a25f-829b761be124" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_cd1fc125-99ac-4c80-ab80-fa1110194c39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_cd1fc125-99ac-4c80-ab80-fa1110194c39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a6fe25c6-d7c3-4165-8bb8-90fb796b0d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_a6fe25c6-d7c3-4165-8bb8-90fb796b0d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4e32a4e3-0a8b-4b2a-a97b-b7b36b5da191" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4e32a4e3-0a8b-4b2a-a97b-b7b36b5da191" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ce96fb4c-8d2c-4ac0-8bd6-d6df9e29b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1451c5ff-79f2-42ef-9e17-4aad9781925e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ce96fb4c-8d2c-4ac0-8bd6-d6df9e29b0a5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#RESTRICTEDANDOTHERASSETSDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:href="ensg-20231231.xsd#ensg_RestrictedAndOtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestrictedAssets_0283691b-42e4-4270-a629-3e2823745d76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_OtherRestrictedAssets_0283691b-42e4-4270-a629-3e2823745d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_ce8f3e12-d936-4db5-ac65-83f34bc49ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_EscrowDeposit_ce8f3e12-d936-4db5-ac65-83f34bc49ae6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2b11eb30-d804-404e-b45c-fdb714af260e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_OtherAssetsCurrent_2b11eb30-d804-404e-b45c-fdb714af260e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_ee18c2eb-1bea-401a-95c9-f53c237ffaa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_SecurityDeposit_ee18c2eb-1bea-401a-95c9-f53c237ffaa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_49ef19a4-b35f-41e7-8602-1866089085bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_49ef19a4-b35f-41e7-8602-1866089085bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_97d6b194-4f61-4a37-9981-dd93b6a70ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent_fc9e5ffd-1fc2-4468-a081-19bee1294eb6" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_97d6b194-4f61-4a37-9981-dd93b6a70ac0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OTHERACCRUEDLIABILITIESDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_01cd2c54-8772-4e81-bfde-4758ee454e27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_01cd2c54-8772-4e81-bfde-4758ee454e27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8e1cc236-6b1b-4d31-82f7-0ed9ed6299fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8e1cc236-6b1b-4d31-82f7-0ed9ed6299fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ResidentRefundsPayable_42824750-8afc-47de-b9e6-ef7d48f6e2fd" xlink:href="ensg-20231231.xsd#ensg_ResidentRefundsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_ensg_ResidentRefundsPayable_42824750-8afc-47de-b9e6-ef7d48f6e2fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_QualityAssuranceFee_031824b9-33e2-4c0f-989e-c2d07e24ac78" xlink:href="ensg-20231231.xsd#ensg_QualityAssuranceFee"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_ensg_QualityAssuranceFee_031824b9-33e2-4c0f-989e-c2d07e24ac78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_1f79636d-1e20-48ca-a7e6-b79656c15e23" xlink:href="ensg-20231231.xsd#ensg_AccruedLiabilitiesStateReliefContractLiabilities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_1f79636d-1e20-48ca-a7e6-b79656c15e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_f0d3ffa8-510b-4c00-8dff-a901ed87270f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_us-gaap_LitigationReserveCurrent_f0d3ffa8-510b-4c00-8dff-a901ed87270f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_e17ad6d3-ada2-4dac-8f6e-ce9535ba4314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_e17ad6d3-ada2-4dac-8f6e-ce9535ba4314" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95bf9885-109e-4b9f-a8e0-e2eff54fb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_95bf9885-109e-4b9f-a8e0-e2eff54fb9f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CashHeldInTrustForResidents_8e4a7b7e-f3e9-436f-97ed-e1b8b2c5e197" xlink:href="ensg-20231231.xsd#ensg_CashHeldInTrustForResidents"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ea169583-68ca-4b56-b37e-571352ff40ee" xlink:to="loc_ensg_CashHeldInTrustForResidents_8e4a7b7e-f3e9-436f-97ed-e1b8b2c5e197" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d52bb8f3-cd60-4391-8a83-9232c52c8455" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cd9b2135-14ee-442b-b089-cb09b3488671" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d52bb8f3-cd60-4391-8a83-9232c52c8455" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_cd9b2135-14ee-442b-b089-cb09b3488671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c33ee08e-733b-4f20-b05c-900020d06bec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_d52bb8f3-cd60-4391-8a83-9232c52c8455" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_c33ee08e-733b-4f20-b05c-900020d06bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b54df8c6-63dc-4b4f-8454-c5f66f848dd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55d4abe9-46a9-443f-a33b-787a69a2c4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b54df8c6-63dc-4b4f-8454-c5f66f848dd3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_55d4abe9-46a9-443f-a33b-787a69a2c4e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_9fdb3ac1-c0ea-4a34-bce7-a99a1685d4ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_b54df8c6-63dc-4b4f-8454-c5f66f848dd3" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_9fdb3ac1-c0ea-4a34-bce7-a99a1685d4ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_5be37dd0-620b-4644-8e1c-d373280feea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7d1bf930-6093-4bca-b90b-a10b808fa574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_5be37dd0-620b-4644-8e1c-d373280feea5" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7d1bf930-6093-4bca-b90b-a10b808fa574" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_49ea527d-2057-4a91-9c84-84e655c0b237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_5be37dd0-620b-4644-8e1c-d373280feea5" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_49ea527d-2057-4a91-9c84-84e655c0b237" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78c35e7e-fd1a-4a46-81ce-ecc851f51d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_78c35e7e-fd1a-4a46-81ce-ecc851f51d6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2156d0da-e6b0-4919-80a9-aaa5b7ea28e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_2156d0da-e6b0-4919-80a9-aaa5b7ea28e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_8b46f269-37dc-4deb-88b4-aacd297861ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_8b46f269-37dc-4deb-88b4-aacd297861ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4b5fe5ce-312a-4874-9a1e-b9c759fff9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_4b5fe5ce-312a-4874-9a1e-b9c759fff9c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_63ce062c-2932-4dab-a131-3e0e1ae4e0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8a0e760d-8fd7-4c9a-bcb7-25ca69b1eec0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_63ce062c-2932-4dab-a131-3e0e1ae4e0fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a70b8ec9-f0d1-4624-9bc7-6125dceabc87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_a70b8ec9-f0d1-4624-9bc7-6125dceabc87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_f44c4a80-4c34-4859-a61a-057a9bf46b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_f44c4a80-4c34-4859-a61a-057a9bf46b32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_37f1386b-941c-48d4-822e-aa2e7f567c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_37f1386b-941c-48d4-822e-aa2e7f567c07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_4a20a5b4-ab80-4958-a54c-dab2ba82be2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_4a20a5b4-ab80-4958-a54c-dab2ba82be2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_72c7ae41-1360-463d-b8d9-9762ea8116a1" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_72c7ae41-1360-463d-b8d9-9762ea8116a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_48aab5eb-17de-4420-bccc-4cc742387849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b9b0d5be-291a-4b2f-b198-afc9d1145fc3" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_48aab5eb-17de-4420-bccc-4cc742387849" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_32dac960-2795-4488-99a3-c7c00f38f180" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_42162c3a-2f5b-49c8-b31a-1c02de7a47b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_32dac960-2795-4488-99a3-c7c00f38f180" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_42162c3a-2f5b-49c8-b31a-1c02de7a47b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_d11f1b1f-5b5c-4887-b305-25e0596338a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_32dac960-2795-4488-99a3-c7c00f38f180" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_d11f1b1f-5b5c-4887-b305-25e0596338a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f3ec9c81-658c-4261-9908-6065e9b6b49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_b7bb31d1-d291-42b3-9e00-02b1c45ad50f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f3ec9c81-658c-4261-9908-6065e9b6b49e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_b7bb31d1-d291-42b3-9e00-02b1c45ad50f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_b5a0aef4-e7d2-4d6c-b848-5f536fb8a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_f3ec9c81-658c-4261-9908-6065e9b6b49e" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_b5a0aef4-e7d2-4d6c-b848-5f536fb8a1ef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb65ddf-f9cf-46ef-b303-9dcaafea31bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_6b26ce17-e1b0-4165-96f5-6daac735204a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb65ddf-f9cf-46ef-b303-9dcaafea31bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_6b26ce17-e1b0-4165-96f5-6daac735204a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesStateTaxes_01b9c8a7-bbdb-4118-9c27-ecf7a89b9dff" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesStateTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb65ddf-f9cf-46ef-b303-9dcaafea31bd" xlink:to="loc_ensg_DeferredTaxLiabilitiesStateTaxes_01b9c8a7-bbdb-4118-9c27-ecf7a89b9dff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset_08799cd2-2dd3-47fa-87b5-a0c767e8c8f2" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb65ddf-f9cf-46ef-b303-9dcaafea31bd" xlink:to="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset_08799cd2-2dd3-47fa-87b5-a0c767e8c8f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a8111749-9673-42f4-a404-0ca572921b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_5fb65ddf-f9cf-46ef-b303-9dcaafea31bd" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_a8111749-9673-42f4-a404-0ca572921b4a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTScheduleofLongtermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_645a34be-67ea-4859-847c-834d8c9e6c27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_0b6012b7-7d04-4432-b2ed-7b8214783c99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_645a34be-67ea-4859-847c-834d8c9e6c27" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_0b6012b7-7d04-4432-b2ed-7b8214783c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c5d64ee5-0e65-40c0-be46-0acd0e24c5c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_645a34be-67ea-4859-847c-834d8c9e6c27" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c5d64ee5-0e65-40c0-be46-0acd0e24c5c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_cc85efa0-7fe5-4aec-b647-7be1a52a712d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_645a34be-67ea-4859-847c-834d8c9e6c27" xlink:to="loc_us-gaap_LongTermDebtCurrent_cc85efa0-7fe5-4aec-b647-7be1a52a712d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTLongtermDebtArrangementsDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4f9241aa-6f4f-4e08-8c87-ece8e24df98c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_4f9241aa-6f4f-4e08-8c87-ece8e24df98c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_bc21c8ff-0b3f-403f-8c36-0bb82dc69a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_bc21c8ff-0b3f-403f-8c36-0bb82dc69a8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1edd1a0d-f5a9-4b0f-9d36-e982051ecd1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_1edd1a0d-f5a9-4b0f-9d36-e982051ecd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0ad9dc47-4908-442b-9778-04e45a6769c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_0ad9dc47-4908-442b-9778-04e45a6769c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6be68087-85a8-417a-8c13-aa52b03bd56f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6be68087-85a8-417a-8c13-aa52b03bd56f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3d05d4c7-bddf-47d4-997a-202838be0dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_5bcaa809-a0c2-4b71-ac52-9873049cbfbe" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_3d05d4c7-bddf-47d4-997a-202838be0dbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_680c3ecf-28f6-42f4-b1f4-529e9d49f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c7b9fc67-603b-4f8d-9aaf-43f27d0fd9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_680c3ecf-28f6-42f4-b1f4-529e9d49f8fc" xlink:to="loc_us-gaap_OperatingLeaseCost_c7b9fc67-603b-4f8d-9aaf-43f27d0fd9d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_a86fd038-0fc1-4a68-ada4-352b73f8e9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_680c3ecf-28f6-42f4-b1f4-529e9d49f8fc" xlink:to="loc_us-gaap_VariableLeaseCost_a86fd038-0fc1-4a68-ada4-352b73f8e9ce" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_3e393063-b5e1-4682-9277-e2e4086e8885" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35fd559a-9da0-4190-a87f-529a5cb0155f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3e393063-b5e1-4682-9277-e2e4086e8885" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_35fd559a-9da0-4190-a87f-529a5cb0155f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_3313ccef-018e-4c61-b0ea-6ffb53573a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_3e393063-b5e1-4682-9277-e2e4086e8885" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_3313ccef-018e-4c61-b0ea-6ffb53573a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93e88358-2841-4b90-8b57-480d4da22964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_93e88358-2841-4b90-8b57-480d4da22964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5a36d304-01c7-4b3f-8459-4be9b5b4d262" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5a36d304-01c7-4b3f-8459-4be9b5b4d262" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a3a23470-9dfa-401d-be63-da6cb9277b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_a3a23470-9dfa-401d-be63-da6cb9277b22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3d60f8dc-104c-4d8a-97f3-8a88a677422e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3d60f8dc-104c-4d8a-97f3-8a88a677422e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d76114e-51dd-4919-98a1-8e293b4de3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_7d76114e-51dd-4919-98a1-8e293b4de3d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb112c09-18c9-42d1-b0fd-a57bb53c2e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_287aba8f-89b5-4d72-b216-553cc176db6b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_cb112c09-18c9-42d1-b0fd-a57bb53c2e68" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d83c3cfd-cb60-4887-baaa-dcfc68fec422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_91c46a64-524d-442b-af51-a39a97942b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d83c3cfd-cb60-4887-baaa-dcfc68fec422" xlink:to="loc_us-gaap_OperatingLeaseLiability_91c46a64-524d-442b-af51-a39a97942b03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6a81521-ff5e-4c98-a811-bbe5a282f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d83c3cfd-cb60-4887-baaa-dcfc68fec422" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6a81521-ff5e-4c98-a811-bbe5a282f52b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"/>
  <link:calculationLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_383877d2-02d5-4e52-993f-64adf3ac8081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_383877d2-02d5-4e52-993f-64adf3ac8081" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_d5c53df4-436a-47a9-ae0f-894bf72b59ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_d5c53df4-436a-47a9-ae0f-894bf72b59ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_9dd20bd6-cd3c-4328-a869-969a16a406b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_9dd20bd6-cd3c-4328-a869-969a16a406b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_c5949668-f919-4a0f-b0ac-5102e015c00d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_c5949668-f919-4a0f-b0ac-5102e015c00d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_3c681ab7-b3d7-4ebb-9c62-38a42b1bb290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_3c681ab7-b3d7-4ebb-9c62-38a42b1bb290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_0ecfd7c5-7a99-456e-8ff2-a151a910f103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_672c9a0e-fe45-4c8f-bba8-b52457ce2549" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_0ecfd7c5-7a99-456e-8ff2-a151a910f103" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>ensg-20231231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:19b8c51b-a068-4377-9653-a6d716d75b12,g:d8e1560a-118b-412f-95df-e14f0751e57c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:to="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_62bb06fe-afdc-49f4-9ec8-9dcc52222a91_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:to="loc_srt_ProductsAndServicesDomain_62bb06fe-afdc-49f4-9ec8-9dcc52222a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:to="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1954bf64-fdf2-4ff1-8f7e-985982dfb984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:to="loc_us-gaap_ServiceMember_1954bf64-fdf2-4ff1-8f7e-985982dfb984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_93464e72-c200-4143-814b-199fe0ea5e44" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:to="loc_ensg_RentalMember_93464e72-c200-4143-814b-199fe0ea5e44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a8c584d-fa8d-4f24-b1a1-1914733ce76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a8c584d-fa8d-4f24-b1a1-1914733ce76f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89c57ce4-6453-467b-a309-db944acbf3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_89c57ce4-6453-467b-a309-db944acbf3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentCostOfServices_1c9b999e-944a-4796-abed-21edaca673f3" xlink:href="ensg-20231231.xsd#ensg_RentCostOfServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_ensg_RentCostOfServices_1c9b999e-944a-4796-abed-21edaca673f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f40d344a-beb6-448e-acae-ff4f6952bc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f40d344a-beb6-448e-acae-ff4f6952bc7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_697f7715-0a64-46f7-93fd-88dc81867ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_697f7715-0a64-46f7-93fd-88dc81867ac5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f87e167d-e767-45df-904b-b4be4a76f364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_CostsAndExpenses_f87e167d-e767-45df-904b-b4be4a76f364" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_09ff63f5-041e-45f4-a054-2b2771847d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_OperatingIncomeLoss_09ff63f5-041e-45f4-a054-2b2771847d59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_73e6a4c8-bef1-490b-a988-1998d2cd170d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_InterestExpense_73e6a4c8-bef1-490b-a988-1998d2cd170d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7d37735-5c07-483a-b7be-e30485ea867d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7d37735-5c07-483a-b7be-e30485ea867d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6c84b61b-21ef-43d5-aa73-d763656cd501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6c84b61b-21ef-43d5-aa73-d763656cd501" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c908ee79-7d40-4874-980b-8e0d91b90fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c908ee79-7d40-4874-980b-8e0d91b90fde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea1958dd-1ab5-414b-8800-6e425efaf79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea1958dd-1ab5-414b-8800-6e425efaf79d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9036c3c9-3da0-41ad-9ba2-ace923dffd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_ProfitLoss_9036c3c9-3da0-41ad-9ba2-ace923dffd0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a45d9221-4fb8-4cb5-bae8-3996abae2329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a45d9221-4fb8-4cb5-bae8-3996abae2329" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83791502-209a-4106-a62c-2486afcbc0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_NetIncomeLoss_83791502-209a-4106-a62c-2486afcbc0af" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_faed624a-143b-45a9-af9a-9f4f9a1a2678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:to="loc_us-gaap_EarningsPerShareBasic_faed624a-143b-45a9-af9a-9f4f9a1a2678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_69ec8cee-0a74-48e5-90f4-17ee2a4242cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_69ec8cee-0a74-48e5-90f4-17ee2a4242cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203c0181-149f-4c2e-b9d0-22133710e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203c0181-149f-4c2e-b9d0-22133710e73b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb8b8d3c-ab95-47ba-9e8b-b6a5ddc603cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb8b8d3c-ab95-47ba-9e8b-b6a5ddc603cb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:to="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7efc0140-e133-4ce6-8c84-7715e5c6a4bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:to="loc_us-gaap_EquityComponentDomain_7efc0140-e133-4ce6-8c84-7715e5c6a4bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:to="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07a914ab-7e79-4b1b-9004-e1d57627d2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_CommonStockMember_07a914ab-7e79-4b1b-9004-e1d57627d2e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f3987071-3a7f-418e-9b3b-b477c79c4d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f3987071-3a7f-418e-9b3b-b477c79c4d9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b96ef356-9960-4e1c-b27e-10799ceb53be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_RetainedEarningsMember_b96ef356-9960-4e1c-b27e-10799ceb53be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_cf5e3934-7c78-4411-a392-0201e7599ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_TreasuryStockCommonMember_cf5e3934-7c78-4411-a392-0201e7599ee4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3875aa40-f331-43b9-a30e-b06ae3f92d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3875aa40-f331-43b9-a30e-b06ae3f92d4b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a0bea466-ddb3-4aa3-94d4-0084b674bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a0bea466-ddb3-4aa3-94d4-0084b674bbd7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0f9749e-d281-4b8a-978b-900eeec4138d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0f9749e-d281-4b8a-978b-900eeec4138d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0193cb6a-b6dd-4776-80b7-c65ded7280a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0193cb6a-b6dd-4776-80b7-c65ded7280a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_680160dd-7610-4451-b2a8-e79b7c214b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_680160dd-7610-4451-b2a8-e79b7c214b40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97fc56e2-98db-42dc-bf9a-3ed7f86f0790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97fc56e2-98db-42dc-bf9a-3ed7f86f0790" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_59448343-d532-4d48-a6b0-689d07616c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_59448343-d532-4d48-a6b0-689d07616c47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_317eb2d5-1d09-4a20-a26e-470e7aab354d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_317eb2d5-1d09-4a20-a26e-470e7aab354d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a64d3ee5-8fba-4185-a5b0-5384ad40868e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a64d3ee5-8fba-4185-a5b0-5384ad40868e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bec87b70-15d8-43ba-9b0b-575231078a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bec87b70-15d8-43ba-9b0b-575231078a78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8f4c5a16-cca9-4d04-9860-028acec21658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_Dividends_8f4c5a16-cca9-4d04-9860-028acec21658" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a8caa11-74e8-41c6-b12c-b5a9ccd43723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a8caa11-74e8-41c6-b12c-b5a9ccd43723" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30653be0-3be4-4eed-b053-2b3723ef5422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30653be0-3be4-4eed-b053-2b3723ef5422" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01be448c-e5c6-4207-a0ea-f38f4a60dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01be448c-e5c6-4207-a0ea-f38f4a60dba7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc817aca-5900-42b0-a2cf-370a4f3e1bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc817aca-5900-42b0-a2cf-370a4f3e1bd3" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d1ea7105-189b-49de-bc4b-dca9319cd34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d1ea7105-189b-49de-bc4b-dca9319cd34c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a8026db5-a029-4a88-bfbc-2c2fa689e955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a8026db5-a029-4a88-bfbc-2c2fa689e955" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20ecef23-9c8e-4655-9dc6-86b4d8da9003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20ecef23-9c8e-4655-9dc6-86b4d8da9003" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_50981af5-62c0-4b27-aa0e-4cc3d2f2ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_50981af5-62c0-4b27-aa0e-4cc3d2f2ce6d" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d9207d4-73c7-48a6-8724-498831ce39a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NetIncomeLoss_9d9207d4-73c7-48a6-8724-498831ce39a0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1fd46bf-357a-4584-aa29-17e2a694a0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc6773c-4585-42e9-b0a4-35a0c22f4898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_61003745-4394-41b4-8c1e-cf5df168904e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_8ba24367-7c42-4e7e-8473-350ae79af1be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_8ba24367-7c42-4e7e-8473-350ae79af1be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WhollyOwnedPropertiesMember_8ed69942-9195-4458-be8c-424d1d29e750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WhollyOwnedPropertiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:to="loc_us-gaap_WhollyOwnedPropertiesMember_8ed69942-9195-4458-be8c-424d1d29e750" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:to="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_58bedc33-5446-4cae-8ecf-14914990ba9c_default" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:to="loc_ensg_OperatingEntityDomain_58bedc33-5446-4cae-8ecf-14914990ba9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:to="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyOperatorsMember_7712789e-4131-4061-8ce0-085ee9cdd6f4" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyOperatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:to="loc_ensg_ThirdPartyOperatorsMember_7712789e-4131-4061-8ce0-085ee9cdd6f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfHealthCareFacilities_92013fd1-a40f-4a73-ad3f-60ee5db2a007" xlink:href="ensg-20231231.xsd#ensg_NumberOfHealthCareFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfHealthCareFacilities_92013fd1-a40f-4a73-ad3f-60ee5db2a007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_9681fbd5-bf00-4715-8587-008ba615d713" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_OperationalSkilledNursingBeds_9681fbd5-bf00-4715-8587-008ba615d713" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSeniorLivingUnits_41723e85-89e4-4d99-8aea-41fcec8eef8d" xlink:href="ensg-20231231.xsd#ensg_OperationalSeniorLivingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_OperationalSeniorLivingUnits_41723e85-89e4-4d99-8aea-41fcec8eef8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeased_69d1fd2e-c02c-4ec0-a974-fa494aceb524" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfRealEstatePropertiesLeased_69d1fd2e-c02c-4ec0-a974-fa494aceb524" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_3d03a11b-9eb0-4b7f-9ae4-fce021393e52" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_3d03a11b-9eb0-4b7f-9ae4-fce021393e52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_8c9a1a16-9bc3-4aeb-8adc-26f5cb5024ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_8c9a1a16-9bc3-4aeb-8adc-26f5cb5024ee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFacilities_d39a6b80-1ab2-46fc-a8ab-a8505385ef06" xlink:href="ensg-20231231.xsd#ensg_NumberOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfFacilities_d39a6b80-1ab2-46fc-a8ab-a8505385ef06" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperations_41aa84d3-e712-4afa-a5a7-8d84b71634ab" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfOperations_41aa84d3-e712-4afa-a5a7-8d84b71634ab" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_e45b0f18-8c14-445f-a698-04af2e13732e" xlink:href="ensg-20231231.xsd#ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_e45b0f18-8c14-445f-a698-04af2e13732e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:to="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e53ae6ff-8abf-469d-aebf-2bd8026c3080_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:to="loc_srt_RangeMember_e53ae6ff-8abf-469d-aebf-2bd8026c3080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:to="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6e876df-b221-4e52-b0ef-884285bb49cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:to="loc_srt_MinimumMember_c6e876df-b221-4e52-b0ef-884285bb49cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ab6e7fb-2df8-47de-bec9-d6b0222192ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:to="loc_srt_MaximumMember_8ab6e7fb-2df8-47de-bec9-d6b0222192ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aafbd6e9-b0bf-4a39-9600-b89b4d82438c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aafbd6e9-b0bf-4a39-9600-b89b4d82438c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:to="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fc4e589c-ee0b-4c23-83be-fca0b1073d5e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:to="loc_srt_RangeMember_fc4e589c-ee0b-4c23-83be-fca0b1073d5e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:to="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_784eb24b-284a-4484-a82b-4e6039180dab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:to="loc_srt_MinimumMember_784eb24b-284a-4484-a82b-4e6039180dab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_81905d24-74e9-43c2-ac54-129c15ecb4cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:to="loc_srt_MaximumMember_81905d24-74e9-43c2-ac54-129c15ecb4cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFinancingLeases_088e489d-8a65-45cb-b694-094d973bb63d" xlink:href="ensg-20231231.xsd#ensg_NumberOfFinancingLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_ensg_NumberOfFinancingLeases_088e489d-8a65-45cb-b694-094d973bb63d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2eb23f42-77f0-404e-8fd4-f250aaeee507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2eb23f42-77f0-404e-8fd4-f250aaeee507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_2eeeac73-fa28-494e-b34d-24d5ad0c9ec5" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_2eeeac73-fa28-494e-b34d-24d5ad0c9ec5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f3073fd6-aa36-449d-99de-b747b790b967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f3073fd6-aa36-449d-99de-b747b790b967" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:to="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_96302d72-7be2-41b7-bbeb-145afb8d7420_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:to="loc_srt_RangeMember_96302d72-7be2-41b7-bbeb-145afb8d7420_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:to="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fae83c01-0270-46ed-9b34-93ef45e7ab56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:to="loc_srt_MinimumMember_fae83c01-0270-46ed-9b34-93ef45e7ab56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8ec674c-e70e-403f-a776-1abe6bd130f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:to="loc_srt_MaximumMember_c8ec674c-e70e-403f-a776-1abe6bd130f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6545142c-9f6a-4fc0-bc89-eb702e0e784e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6545142c-9f6a-4fc0-bc89-eb702e0e784e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_896337f8-aa40-4972-9132-08c918a681d6" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_896337f8-aa40-4972-9132-08c918a681d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ff21e300-8a65-43f6-afbf-5cc6db4afad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_us-gaap_TradeNamesMember_ff21e300-8a65-43f6-afbf-5cc6db4afad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_62c31870-aacb-43a7-99b6-911a1022d876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_us-gaap_CustomerRelationshipsMember_62c31870-aacb-43a7-99b6-911a1022d876" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1cdb65a6-0729-4eed-9fab-1577bcf12904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1cdb65a6-0729-4eed-9fab-1577bcf12904" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f8d1721-91d7-4ef6-9441-6acf5b160597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f8d1721-91d7-4ef6-9441-6acf5b160597" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeDomain_d6275aef-1b7f-4085-826d-8022634b5ddd_default" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:to="loc_ensg_InsuranceCoverageLimitTypeDomain_d6275aef-1b7f-4085-826d-8022634b5ddd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:to="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SelfInsuranceRetentionPerClaimMember_1e167045-f9c0-4f2b-a717-83a83e0f6428" xlink:href="ensg-20231231.xsd#ensg_SelfInsuranceRetentionPerClaimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_SelfInsuranceRetentionPerClaimMember_1e167045-f9c0-4f2b-a717-83a83e0f6428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AggregateDeductibleMember_8a2bdb08-5b6a-4a73-a374-4bc85d71c99d" xlink:href="ensg-20231231.xsd#ensg_AggregateDeductibleMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_AggregateDeductibleMember_8a2bdb08-5b6a-4a73-a374-4bc85d71c99d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerOccurenceMember_4453caf6-a9da-4eb6-afc1-07ab5f0a2c78" xlink:href="ensg-20231231.xsd#ensg_PerOccurenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_PerOccurenceMember_4453caf6-a9da-4eb6-afc1-07ab5f0a2c78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerFacilityMember_665d8559-e702-49c8-8636-d4a2fd18680a" xlink:href="ensg-20231231.xsd#ensg_PerFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_PerFacilityMember_665d8559-e702-49c8-8636-d4a2fd18680a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BlanketAggregateMember_60a7cc52-c966-473e-b7c4-4802a8e5ea9a" xlink:href="ensg-20231231.xsd#ensg_BlanketAggregateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_BlanketAggregateMember_60a7cc52-c966-473e-b7c4-4802a8e5ea9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LossSensitiveLimitPerClaimMember_a82cf049-6d2c-4a76-a5bb-3f680b23ed05" xlink:href="ensg-20231231.xsd#ensg_LossSensitiveLimitPerClaimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_LossSensitiveLimitPerClaimMember_a82cf049-6d2c-4a76-a5bb-3f680b23ed05" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StopLossInsuranceLimitPerClaimMember_0070ec7a-3649-4ebf-afe7-2057845a5faf" xlink:href="ensg-20231231.xsd#ensg_StopLossInsuranceLimitPerClaimMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_StopLossInsuranceLimitPerClaimMember_0070ec7a-3649-4ebf-afe7-2057845a5faf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:href="ensg-20231231.xsd#ensg_PayorAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorDomain_bb4b98ad-16f4-4931-828a-95796f1e1070_default" xlink:href="ensg-20231231.xsd#ensg_PayorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:to="loc_ensg_PayorDomain_bb4b98ad-16f4-4931-828a-95796f1e1070_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:href="ensg-20231231.xsd#ensg_PayorDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:to="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_980c1e31-b1d9-408f-a9a3-79ce1e9119f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:to="loc_srt_ParentCompanyMember_980c1e31-b1d9-408f-a9a3-79ce1e9119f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ524292_d914b31e-60c1-4f21-addc-02fad7497b6b" xlink:href="https://xbrl.sec.gov/naics/2023/naics-2023.xsd#naics_ZZ524292"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:to="loc_naics_ZZ524292_d914b31e-60c1-4f21-addc-02fad7497b6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_df75170c-c8e9-40e0-8d04-2b2b25dca92d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:to="loc_srt_ProductsAndServicesDomain_df75170c-c8e9-40e0-8d04-2b2b25dca92d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:to="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralLiabilityMember_9c27bc4d-7446-4e85-b4ff-9e647f7f3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_us-gaap_GeneralLiabilityMember_9c27bc4d-7446-4e85-b4ff-9e647f7f3be4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationInsuranceMember_ef2ea985-f91d-4844-841b-f7ac40ff5437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_us-gaap_WorkersCompensationInsuranceMember_ef2ea985-f91d-4844-841b-f7ac40ff5437" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HealthLiabilityInsuranceMember_02391d31-3fd6-4d6b-911e-d39e51471419" xlink:href="ensg-20231231.xsd#ensg_HealthLiabilityInsuranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_ensg_HealthLiabilityInsuranceMember_02391d31-3fd6-4d6b-911e-d39e51471419" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fc831ea8-faf3-4100-aeb9-0825005f8d37_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:to="loc_srt_SegmentGeographicalDomain_fc831ea8-faf3-4100-aeb9-0825005f8d37_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:to="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_88f8237a-cb7d-4931-9811-3c22962f3618" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_CA_88f8237a-cb7d-4931-9811-3c22962f3618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCaliforniaMember_22c13637-52ec-49fd-85d3-8071594829d4" xlink:href="ensg-20231231.xsd#ensg_NonCaliforniaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_NonCaliforniaMember_22c13637-52ec-49fd-85d3-8071594829d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AllStatesExceptColoradoMember_3c5fc81c-d0a3-4b82-a9fe-17c5c62a63a7" xlink:href="ensg-20231231.xsd#ensg_AllStatesExceptColoradoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_AllStatesExceptColoradoMember_3c5fc81c-d0a3-4b82-a9fe-17c5c62a63a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CO_1a088e0f-b582-4da9-b8a6-96d2f89a9065" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_CO_1a088e0f-b582-4da9-b8a6-96d2f89a9065" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_26f62b98-8670-4fc3-8496-5091fe43001c" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_TX_26f62b98-8670-4fc3-8496-5091fe43001c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_82b83ebf-f169-434e-9004-b60b2125a882" xlink:href="ensg-20231231.xsd#ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_82b83ebf-f169-434e-9004-b60b2125a882" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_899e3dfd-fb50-49dc-8049-d3a96314f68d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_899e3dfd-fb50-49dc-8049-d3a96314f68d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e376924f-6885-448b-acac-54a556d4a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:to="loc_us-gaap_SubsequentEventMember_e376924f-6885-448b-acac-54a556d4a1f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_6467880c-42d9-4348-96ac-df990557c232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:to="loc_us-gaap_SelfInsuranceReserve_6467880c-42d9-4348-96ac-df990557c232" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b4da43f0-0790-4ba0-ac5f-dabd0844f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b4da43f0-0790-4ba0-ac5f-dabd0844f6df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb32b91e-5ae5-4103-b427-8538d412bf2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb32b91e-5ae5-4103-b427-8538d412bf2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4d8f2f1a-e974-4a88-a555-775a47335d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:to="loc_us-gaap_SalesRevenueNetMember_4d8f2f1a-e974-4a88-a555-775a47335d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:to="loc_srt_NameOfMajorCustomerDomain_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:to="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_a45de9e7-146e-41a6-84e3-56ef4425b6f9" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:to="loc_ensg_MedicaidAndMedicareMember_a45de9e7-146e-41a6-84e3-56ef4425b6f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_43185cae-efd8-41bf-8b80-6fd5d9d90a88_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:to="loc_srt_ProductsAndServicesDomain_43185cae-efd8-41bf-8b80-6fd5d9d90a88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:to="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_e882ad3c-d32f-4830-b0d1-59a20351bdab" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:to="loc_ensg_RentalMember_e882ad3c-d32f-4830-b0d1-59a20351bdab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c002e57c-761c-4ebc-9a43-195d731ee395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c002e57c-761c-4ebc-9a43-195d731ee395" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f96e6a8-de60-4bca-9442-8c106013d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f96e6a8-de60-4bca-9442-8c106013d2e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_cfeea04e-65de-44ee-96a2-84517a47238d" xlink:href="ensg-20231231.xsd#ensg_AccruedLiabilitiesStateReliefContractLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_cfeea04e-65de-44ee-96a2-84517a47238d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_98c5a9d7-7931-44e8-a3f4-5e5c30cc20df" xlink:href="ensg-20231231.xsd#ensg_FamilyFirstCoronavirusResponseActPaymentsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_98c5a9d7-7931-44e8-a3f4-5e5c30cc20df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_51dee312-666d-4070-8dce-89c57f83beac" xlink:href="ensg-20231231.xsd#ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_51dee312-666d-4070-8dce-89c57f83beac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_ab473479-8261-45c2-9693-b56b38b8b797" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_ab473479-8261-45c2-9693-b56b38b8b797" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_73e63e40-76d5-4e92-bb64-b0b688b689fe" xlink:href="ensg-20231231.xsd#ensg_MedicareAcceleratedAndAdvancePaymentCARESACT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_73e63e40-76d5-4e92-bb64-b0b688b689fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_d424a826-d60f-4f43-a391-fdb38e323999" xlink:href="ensg-20231231.xsd#ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_d424a826-d60f-4f43-a391-fdb38e323999" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_965b8f4b-3a6a-4bf9-a9d0-2ef9ab2bb5de" xlink:href="ensg-20231231.xsd#ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_965b8f4b-3a6a-4bf9-a9d0-2ef9ab2bb5de" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d3678459-343d-443e-9c62-0fa30904f8f1_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:to="loc_srt_ProductsAndServicesDomain_d3678459-343d-443e-9c62-0fa30904f8f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:to="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2a4a7c5a-dbb9-4159-8a58-4fb17b78dd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:to="loc_us-gaap_ServiceMember_2a4a7c5a-dbb9-4159-8a58-4fb17b78dd9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:to="loc_srt_NameOfMajorCustomerDomain_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_43a3ab1b-65a3-48ef-8a4c-d61d024f2bda" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicaidMember_43a3ab1b-65a3-48ef-8a4c-d61d024f2bda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_a706d23b-9615-421f-82d4-4f0993473cbd" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicareMember_a706d23b-9615-421f-82d4-4f0993473cbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidSkilledMember_bf927d39-faec-4f6d-ac2c-2b02ddc5e199" xlink:href="ensg-20231231.xsd#ensg_MedicaidSkilledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicaidSkilledMember_bf927d39-faec-4f6d-ac2c-2b02ddc5e199" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_442f98c6-6790-439c-81cc-ac88aece3b71" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_ManagedCareMember_442f98c6-6790-439c-81cc-ac88aece3b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_1a0397fe-accc-4c9d-b73f-f5118efc1fd2" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_PrivatePayAndOtherMember_1a0397fe-accc-4c9d-b73f-f5118efc1fd2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aaf1d5be-2b7f-43df-a10c-d9d407ba4b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aaf1d5be-2b7f-43df-a10c-d9d407ba4b17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_267b99e4-e44c-463f-8600-73207bb53501_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_267b99e4-e44c-463f-8600-73207bb53501_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0c6da0ee-8a64-490d-87eb-252f3ff3a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:to="loc_us-gaap_SalesRevenueNetMember_0c6da0ee-8a64-490d-87eb-252f3ff3a14c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ac2146a-16e7-4b46-a58a-b86f4bd03117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ac2146a-16e7-4b46-a58a-b86f4bd03117" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f9b480f3-700b-4e08-99f5-d742c7c190e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f9b480f3-700b-4e08-99f5-d742c7c190e3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:to="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5a1182f4-dca7-4cf2-9ded-356a509991eb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:to="loc_srt_NameOfMajorCustomerDomain_5a1182f4-dca7-4cf2-9ded-356a509991eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:to="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_17131212-34ed-4988-904b-253b5dfcf637" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_MedicaidMember_17131212-34ed-4988-904b-253b5dfcf637" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_7e848499-290d-43d9-a6e5-b903d0525f72" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_ManagedCareMember_7e848499-290d-43d9-a6e5-b903d0525f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_65caa3a9-1d3c-4ca4-bad4-c7555c5f2883" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_MedicareMember_65caa3a9-1d3c-4ca4-bad4-c7555c5f2883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_bc2f8eca-55ee-49af-950b-ecfd768e566c" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_PrivatePayAndOtherMember_bc2f8eca-55ee-49af-950b-ecfd768e566c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_781b6956-b56a-4c28-9ec9-11bbd3d85887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AccountsReceivableGross_781b6956-b56a-4c28-9ec9-11bbd3d85887" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db7b9a74-49d4-4ba7-8bdc-5be19b62c9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db7b9a74-49d4-4ba7-8bdc-5be19b62c9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3200c9de-0b39-468e-bbce-3328b7ca0bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3200c9de-0b39-468e-bbce-3328b7ca0bc5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24340530-c8ca-45eb-8d40-19d9945008a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_24340530-c8ca-45eb-8d40-19d9945008a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9860c699-b219-4f35-a729-2bc775d0bbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9860c699-b219-4f35-a729-2bc775d0bbe6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_f238081a-c94f-41cb-8f72-f31e34111e41_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:to="loc_srt_ConsolidatedEntitiesDomain_f238081a-c94f-41cb-8f72-f31e34111e41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_aa9b1e24-021d-4584-8680-4fce3b11e503" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:to="loc_srt_SubsidiariesMember_aa9b1e24-021d-4584-8680-4fce3b11e503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_f88e8a1e-3744-4b90-b9a0-6eed6555a616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:to="loc_us-gaap_InvestmentsAndCash_f88e8a1e-3744-4b90-b9a0-6eed6555a616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_1cbec62e-b0ac-4da2-91d6-30a1fec8cb60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_1cbec62e-b0ac-4da2-91d6-30a1fec8cb60" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/STANDARDBEARERDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#STANDARDBEARERDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/STANDARDBEARERDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_39afb434-9dd0-4210-9d2d-8ffb147db846_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:to="loc_dei_EntityDomain_39afb434-9dd0-4210-9d2d-8ffb147db846_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:to="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_afc26209-ed35-4550-bc35-5301782ceba9" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_afc26209-ed35-4550-bc35-5301782ceba9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_fb7817a5-4dc4-4c7e-8e35-298c1643c298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_fb7817a5-4dc4-4c7e-8e35-298c1643c298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WhollyOwnedPropertiesMember_94e5c6d1-edd1-4f76-a0ae-b2c8b11db849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WhollyOwnedPropertiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:to="loc_us-gaap_WhollyOwnedPropertiesMember_94e5c6d1-edd1-4f76-a0ae-b2c8b11db849" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_47dff857-1f1a-4bb4-9882-ebb85ee3c30b_default" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:to="loc_ensg_OperatingEntityDomain_47dff857-1f1a-4bb4-9882-ebb85ee3c30b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:to="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartiesMember_f6f512c9-633f-42ea-b752-c20474c6b605" xlink:href="ensg-20231231.xsd#ensg_ThirdPartiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:to="loc_ensg_ThirdPartiesMember_f6f512c9-633f-42ea-b752-c20474c6b605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyOperatorsMember_5319c9ea-d7f1-44c6-a3ca-82330c417a99" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyOperatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:to="loc_ensg_ThirdPartyOperatorsMember_5319c9ea-d7f1-44c6-a3ca-82330c417a99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac22040d-2486-4ea6-90c4-8904e648d39a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ac22040d-2486-4ea6-90c4-8904e648d39a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OwnedPropertiesMember_396ca77b-931c-4830-8c25-ad70e4444bfa" xlink:href="ensg-20231231.xsd#ensg_OwnedPropertiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:to="loc_ensg_OwnedPropertiesMember_396ca77b-931c-4830-8c25-ad70e4444bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_82fc3ecb-1af3-4c95-9483-2e9948c57025_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:to="loc_us-gaap_AssetAcquisitionDomain_82fc3ecb-1af3-4c95-9483-2e9948c57025_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_ee3deac3-bbc6-48d4-8d92-a00d60200955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_ee3deac3-bbc6-48d4-8d92-a00d60200955" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_3b3bc65a-46ba-437c-a088-d088fd12924d" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:to="loc_ensg_SkilledNursingOperationsMember_3b3bc65a-46ba-437c-a088-d088fd12924d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_fc0d6502-f320-4d92-b387-8d20ea94d627_default" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:to="loc_ensg_LeaseArrangementDomain_fc0d6502-f320-4d92-b387-8d20ea94d627_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:to="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerMasterLeasesMember_d31f0d37-a73e-4e29-8f04-faccb01c01d4" xlink:href="ensg-20231231.xsd#ensg_StandardBearerMasterLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:to="loc_ensg_StandardBearerMasterLeasesMember_d31f0d37-a73e-4e29-8f04-faccb01c01d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a16d3606-ee5d-4120-8a64-538499a14436_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:to="loc_srt_RangeMember_a16d3606-ee5d-4120-8a64-538499a14436_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:to="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fac8c19-8cea-4f04-9313-5744101a12b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:to="loc_srt_MinimumMember_8fac8c19-8cea-4f04-9313-5744101a12b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1350f1c1-1a97-4db0-961a-a465db727d95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:to="loc_srt_MaximumMember_1350f1c1-1a97-4db0-961a-a465db727d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2557ddba-a88a-473c-9247-31653f132160_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:to="loc_srt_ProductsAndServicesDomain_2557ddba-a88a-473c-9247-31653f132160_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:to="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:href="ensg-20231231.xsd#ensg_ManagementServiceTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:to="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceBaseMember_a99d88f7-3d88-4ce9-a1d0-e2fc24943023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceBaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:to="loc_us-gaap_ManagementServiceBaseMember_a99d88f7-3d88-4ce9-a1d0-e2fc24943023" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceIncentiveMember_6aec5f87-6ea9-4cf6-9df2-84a09813344d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceIncentiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:to="loc_us-gaap_ManagementServiceIncentiveMember_6aec5f87-6ea9-4cf6-9df2-84a09813344d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_6bac450b-01ed-4af8-bd26-381a52788017_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:to="loc_us-gaap_CreditFacilityDomain_6bac450b-01ed-4af8-bd26-381a52788017_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:to="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7eb608b4-2df5-4858-ae16-28ac8a082725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7eb608b4-2df5-4858-ae16-28ac8a082725" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_508f7038-7959-480e-b9c9-6e32615e8286_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_508f7038-7959-480e-b9c9-6e32615e8286_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TruistBankMember_025bc297-f416-4ed7-aeca-9e8b314be654" xlink:href="ensg-20231231.xsd#ensg_TruistBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:to="loc_ensg_TruistBankMember_025bc297-f416-4ed7-aeca-9e8b314be654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_7ed5d25f-52ec-4172-b80d-25fd4374751f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:to="loc_us-gaap_VariableRateDomain_7ed5d25f-52ec-4172-b80d-25fd4374751f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:to="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0d20838f-0a36-4324-8b88-a9bb7ef566fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:to="loc_us-gaap_BaseRateMember_0d20838f-0a36-4324-8b88-a9bb7ef566fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SecuredOvernightFinancingRateSOFRMember_be4585c9-095f-42b0-ab7a-599498ba55a5" xlink:href="ensg-20231231.xsd#ensg_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:to="loc_ensg_SecuredOvernightFinancingRateSOFRMember_be4585c9-095f-42b0-ab7a-599498ba55a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7a9c7a8a-37fd-4a86-86ba-c889e5460f20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:to="loc_us-gaap_PlanNameDomain_7a9c7a8a-37fd-4a86-86ba-c889e5460f20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:to="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerEquityPlanMember_d1757c97-b17e-43c8-8721-d6900b3a07c6" xlink:href="ensg-20231231.xsd#ensg_StandardBearerEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:to="loc_ensg_StandardBearerEquityPlanMember_d1757c97-b17e-43c8-8721-d6900b3a07c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c1abbbbd-9a02-441b-8b2f-8604249631e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:to="loc_us-gaap_RestrictedStockMember_c1abbbbd-9a02-441b-8b2f-8604249631e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_f06642cf-b329-489b-b409-b1e20b40707d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_f06642cf-b329-489b-b409-b1e20b40707d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperations_eff62176-6846-4cbe-9b09-391b7ae2bbf5" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfOperations_eff62176-6846-4cbe-9b09-391b7ae2bbf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_38cdbc89-6428-49bf-b6ed-8f1bce004201" xlink:href="ensg-20231231.xsd#ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_38cdbc89-6428-49bf-b6ed-8f1bce004201" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfPropertiesAcquired_6e0fbd4a-356d-4364-96fa-d132721b97f4" xlink:href="ensg-20231231.xsd#ensg_NumberOfPropertiesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfPropertiesAcquired_6e0fbd4a-356d-4364-96fa-d132721b97f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_5289c8b6-c384-41a8-a91c-4e773168e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_5289c8b6-c384-41a8-a91c-4e773168e38c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLeaseArrangements_6b3cb7a2-e852-4a40-bc95-2a2a07923f4e" xlink:href="ensg-20231231.xsd#ensg_NumberOfLeaseArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfLeaseArrangements_6b3cb7a2-e852-4a40-bc95-2a2a07923f4e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42c8cf0b-a418-4795-8328-d3d1a5572f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42c8cf0b-a418-4795-8328-d3d1a5572f5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_9ff21720-524f-4ff4-9664-e035786b2d65" xlink:href="ensg-20231231.xsd#ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_9ff21720-524f-4ff4-9664-e035786b2d65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a5a32195-2d32-42ce-b01f-2f2bb401e8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a5a32195-2d32-42ce-b01f-2f2bb401e8bd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_390cf433-9291-4030-b641-1fceea3b2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_390cf433-9291-4030-b641-1fceea3b2c6e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_b57ce77e-7ea0-4a49-9a50-6202090ef4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_b57ce77e-7ea0-4a49-9a50-6202090ef4ce" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_eafd95c8-dc34-4647-89a0-839731760354" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfTotalRevenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_eafd95c8-dc34-4647-89a0-839731760354" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_dd98cf62-005a-4e81-9875-5f8f31b788f9" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfFundsFromOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_dd98cf62-005a-4e81-9875-5f8f31b788f9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_e12d233e-5845-4680-ba54-56bed1097e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ManagementFeeExpense_e12d233e-5845-4680-ba54-56bed1097e92" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7dd83aa9-0139-4a4e-acfa-2d26dbd61cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7dd83aa9-0139-4a4e-acfa-2d26dbd61cc7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da2b26d2-eebf-4c78-a94a-78f13e83a77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da2b26d2-eebf-4c78-a94a-78f13e83a77f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_2d9a2a17-0d2b-4800-baf9-4dad841aded0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_2d9a2a17-0d2b-4800-baf9-4dad841aded0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9f7a2b5-2c0f-4624-8d1e-bef85580e9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9f7a2b5-2c0f-4624-8d1e-bef85580e9ff" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1f8e65-8c60-418f-a482-234168831f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1f8e65-8c60-418f-a482-234168831f50" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86eba735-8517-4a1d-a906-262c8ef9094b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86eba735-8517-4a1d-a906-262c8ef9094b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_25e58480-56fc-41a3-bec0-15c643c3a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_25e58480-56fc-41a3-bec0-15c643c3a9c9" xlink:type="arc" order="20"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa413447-8d34-427e-80a2-24631a246010_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fa413447-8d34-427e-80a2-24631a246010_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_02903d9e-a443-4ec6-816f-c1dc0a255f24" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_SkilledNursingOperationsMember_02903d9e-a443-4ec6-816f-c1dc0a255f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CampusOperationMember_01eacb5f-8d0a-4dec-9511-8f585f31fc1c" xlink:href="ensg-20231231.xsd#ensg_CampusOperationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_CampusOperationMember_01eacb5f-8d0a-4dec-9511-8f585f31fc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OwnedPropertiesMember_15bb68ef-1209-4938-8ba0-be7bee177acd" xlink:href="ensg-20231231.xsd#ensg_OwnedPropertiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_OwnedPropertiesMember_15bb68ef-1209-4938-8ba0-be7bee177acd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilitiesMember_fe75c8ab-1839-4fd8-af88-ee40e1b07607" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_SeniorLivingFacilitiesMember_fe75c8ab-1839-4fd8-af88-ee40e1b07607" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1af6a6b5-5455-43e3-8265-a356f7affc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1af6a6b5-5455-43e3-8265-a356f7affc89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_f7eeb15f-328b-4688-8ce9-260a90c6143c_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:to="loc_dei_EntityDomain_f7eeb15f-328b-4688-8ce9-260a90c6143c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:to="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_91d99d1d-68c1-428e-80e1-7c9fd998cf5b" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_91d99d1d-68c1-428e-80e1-7c9fd998cf5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5ae8c820-f30a-4787-bb68-bdcc5c839210_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5ae8c820-f30a-4787-bb68-bdcc5c839210_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8c4a93ed-bd08-4605-b6f3-d5a6ca3ce634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:to="loc_us-gaap_SubsequentEventMember_8c4a93ed-bd08-4605-b6f3-d5a6ca3ce634" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_cc414e67-a0af-480b-a3c8-aaaa35d5bc73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:to="loc_us-gaap_AssetAcquisitionDomain_cc414e67-a0af-480b-a3c8-aaaa35d5bc73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:to="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_2514de24-264d-4ca2-b5cf-d96f3b908394" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_SkilledNursingOperationsMember_2514de24-264d-4ca2-b5cf-d96f3b908394" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesMember_465938c3-5327-4105-abf7-8c4cc590e805" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_RealEstatePurchasesMember_465938c3-5327-4105-abf7-8c4cc590e805" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember_04b4d027-0db6-4914-a9a8-ac23d908650a" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesOfPreviousOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember_04b4d027-0db6-4914-a9a8-ac23d908650a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_522650a4-1f15-4bd2-b2f1-c974eeca5cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_522650a4-1f15-4bd2-b2f1-c974eeca5cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfPropertiesAcquired_09b56a36-85a0-4411-8260-b25d87244fc5" xlink:href="ensg-20231231.xsd#ensg_NumberOfPropertiesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfPropertiesAcquired_09b56a36-85a0-4411-8260-b25d87244fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSeniorLivingUnits_5f77ae5a-352d-48fe-bb7a-f8ef24500ed8" xlink:href="ensg-20231231.xsd#ensg_OperationalSeniorLivingUnits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_OperationalSeniorLivingUnits_5f77ae5a-352d-48fe-bb7a-f8ef24500ed8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_077b189a-4ccf-4aa6-b19d-ffda96646d87" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_OperationalSkilledNursingBeds_077b189a-4ccf-4aa6-b19d-ffda96646d87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLeaseArrangements_4622fcd3-a268-4232-855c-762b6e23345f" xlink:href="ensg-20231231.xsd#ensg_NumberOfLeaseArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfLeaseArrangements_4622fcd3-a268-4232-855c-762b6e23345f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties_71743c17-56e3-408d-a5b8-bd45bb11588f" xlink:href="ensg-20231231.xsd#ensg_NumberOfLivingOperationsTransferredFromThirdParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties_71743c17-56e3-408d-a5b8-bd45bb11588f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_07afcdad-7acd-418f-b48c-7e9852d82cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_07afcdad-7acd-418f-b48c-7e9852d82cc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfAssetAcquisitions_5d28024e-347a-465a-844b-90658c00b0e1" xlink:href="ensg-20231231.xsd#ensg_NumberOfAssetAcquisitions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfAssetAcquisitions_5d28024e-347a-465a-844b-90658c00b0e1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1b62ff8f-14b3-4efa-aad7-c1fd81959183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1b62ff8f-14b3-4efa-aad7-c1fd81959183" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d26b945f-fdaf-470b-92f6-6af7f56a2628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d26b945f-fdaf-470b-92f6-6af7f56a2628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_e01ea7af-5f32-4503-84f0-d280d5b85f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_LandMember_e01ea7af-5f32-4503-84f0-d280d5b85f21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_d38a1c9d-6b15-4074-8c83-3da1b601475e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_d38a1c9d-6b15-4074-8c83-3da1b601475e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_928ec256-0129-4e0e-9695-c1a030f42b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_928ec256-0129-4e0e-9695-c1a030f42b7e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_0e939536-8906-420f-90e8-3235e62bf869" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_0e939536-8906-420f-90e8-3235e62bf869" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:to="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsDomain_7786cff3-b7e7-43b0-aad3-4c0a55cb665a_default" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:to="loc_ensg_BusinessAndAssetAcquisitionsDomain_7786cff3-b7e7-43b0-aad3-4c0a55cb665a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:to="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AcquiredOperationsMember_309280d5-2bf9-4a35-9b43-129a5c59dbd0" xlink:href="ensg-20231231.xsd#ensg_AcquiredOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:to="loc_ensg_AcquiredOperationsMember_309280d5-2bf9-4a35-9b43-129a5c59dbd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_d292a315-6aeb-4dba-b20d-d1f3d15612cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_d292a315-6aeb-4dba-b20d-d1f3d15612cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c9bc4fb6-cb3d-4891-9058-8a24c7b2bb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c9bc4fb6-cb3d-4891-9058-8a24c7b2bb3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasedAssetsAcquiredDuringPeriod_e3c5ae56-5cb7-4ec3-9f1e-a89314e216be" xlink:href="ensg-20231231.xsd#ensg_LeasedAssetsAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_ensg_LeasedAssetsAcquiredDuringPeriod_e3c5ae56-5cb7-4ec3-9f1e-a89314e216be" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_e40def79-213b-4a80-a74f-ec3d6427e200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_e40def79-213b-4a80-a74f-ec3d6427e200" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_9ea85fa3-4992-442f-919c-654196bd2000" xlink:href="ensg-20231231.xsd#ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_9ea85fa3-4992-442f-919c-654196bd2000" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:to="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_671c2afa-f457-4f8c-bbec-b8de2736bc67_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:to="loc_dei_EntityDomain_671c2afa-f457-4f8c-bbec-b8de2736bc67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:to="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_38602335-382c-477a-bf44-0903524d681b" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_38602335-382c-477a-bf44-0903524d681b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_df57d5da-8450-421e-ba1d-7bcbe2c357b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_us-gaap_NumberOfReportableSegments_df57d5da-8450-421e-ba1d-7bcbe2c357b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServiceFacilities_35f0a0b5-291f-46b6-ba2c-073aba1bbb43" xlink:href="ensg-20231231.xsd#ensg_SkilledServiceFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SkilledServiceFacilities_35f0a0b5-291f-46b6-ba2c-073aba1bbb43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesAndSeniorLivingCampuses_4d8714fc-0552-4f60-a7e0-d7c515f2c94e" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesAndSeniorLivingCampuses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SkilledServicesAndSeniorLivingCampuses_4d8714fc-0552-4f60-a7e0-d7c515f2c94e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_0ba2b765-07cb-4c64-95db-9813549c21c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_0ba2b765-07cb-4c64-95db-9813549c21c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilities_58ff51f5-f542-49ba-af64-9aebbc1d076a" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SeniorLivingFacilities_58ff51f5-f542-49ba-af64-9aebbc1d076a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b113a395-b84a-46ea-894e-787937b7e88e_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:to="loc_srt_ConsolidationItemsDomain_b113a395-b84a-46ea-894e-787937b7e88e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:to="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ddfaa18c-3683-4a88-8f54-876ef60730d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:to="loc_us-gaap_OperatingSegmentsMember_ddfaa18c-3683-4a88-8f54-876ef60730d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_459c52a8-6e02-400d-88b4-0d496b6f283a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:to="loc_srt_ConsolidationEliminationsMember_459c52a8-6e02-400d-88b4-0d496b6f283a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2446be24-1526-4033-875f-1c7c7d794426_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:to="loc_us-gaap_SegmentDomain_2446be24-1526-4033-875f-1c7c7d794426_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:to="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_9a97b6cb-964b-4f9d-b65e-1e2816ba739a" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_ensg_SkilledServicesSegmentMember_9a97b6cb-964b-4f9d-b65e-1e2816ba739a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerSegmentMember_e844163d-4d24-45df-ac4e-c44081bede0d" xlink:href="ensg-20231231.xsd#ensg_StandardBearerSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_ensg_StandardBearerSegmentMember_e844163d-4d24-45df-ac4e-c44081bede0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_da07c000-2619-40e5-98ac-dd0c9095064f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_us-gaap_AllOtherSegmentsMember_da07c000-2619-40e5-98ac-dd0c9095064f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c19bf573-0119-4632-969c-7a45e0792617_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:to="loc_srt_ProductsAndServicesDomain_c19bf573-0119-4632-969c-7a45e0792617_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:to="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9e922829-fc21-457e-9e21-466a3bd216c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:to="loc_us-gaap_ServiceMember_9e922829-fc21-457e-9e21-466a3bd216c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_b7e46170-fb1b-4df4-9e1a-3c9fdeff3f52" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:to="loc_ensg_RentalMember_b7e46170-fb1b-4df4-9e1a-3c9fdeff3f52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b8b61ba-2a00-4ad5-82b1-13352c7d5db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b8b61ba-2a00-4ad5-82b1-13352c7d5db9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SegmentIncomeLoss_8a4153b2-3b30-46d2-8a99-b0bf805f9d60" xlink:href="ensg-20231231.xsd#ensg_SegmentIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_ensg_SegmentIncomeLoss_8a4153b2-3b30-46d2-8a99-b0bf805f9d60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLossFromRealEstateOperations_919b9fe3-8a12-408d-8ced-49f4f40ae5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLossFromRealEstateOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_ProfitLossFromRealEstateOperations_919b9fe3-8a12-408d-8ced-49f4f40ae5e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de777f7e-6575-4e87-a6cb-9e8cb9911abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de777f7e-6575-4e87-a6cb-9e8cb9911abd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_187a934d-301f-4aa5-a903-6bc9e3669810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_187a934d-301f-4aa5-a903-6bc9e3669810" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3070ec2e-24ec-4bd0-a2f4-15f51bbad710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_InterestExpense_3070ec2e-24ec-4bd0-a2f4-15f51bbad710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e8917453-8729-49b0-a9ec-c8f95da70864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_SubleaseIncome_e8917453-8729-49b0-a9ec-c8f95da70864" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9a6029bc-bd2d-43e4-b570-80f8aa13fb48_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:to="loc_srt_ProductsAndServicesDomain_9a6029bc-bd2d-43e4-b570-80f8aa13fb48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:to="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f6deb381-c5c4-4f5e-87e0-ccf3c7d262e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:to="loc_us-gaap_ServiceMember_f6deb381-c5c4-4f5e-87e0-ccf3c7d262e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_17fb617e-e3ae-4536-a57d-38a44374523b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:to="loc_srt_NameOfMajorCustomerDomain_17fb617e-e3ae-4536-a57d-38a44374523b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:to="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_1aec5094-3b6a-44ac-a432-f843c59af8c5" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicaidMember_1aec5094-3b6a-44ac-a432-f843c59af8c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_26283261-85f7-429d-b590-4994a350bc8c" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicareMember_26283261-85f7-429d-b590-4994a350bc8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidSkilledMember_38f518d7-3133-4cb7-b848-ab2a88bcded8" xlink:href="ensg-20231231.xsd#ensg_MedicaidSkilledMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicaidSkilledMember_38f518d7-3133-4cb7-b848-ab2a88bcded8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_0f94cd71-917b-4ec7-a98a-7a248f3487dd" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_ManagedCareMember_0f94cd71-917b-4ec7-a98a-7a248f3487dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_b1af0b92-d6dc-4799-bef9-6a0ff5e863d5" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_PrivatePayAndOtherMember_b1af0b92-d6dc-4799-bef9-6a0ff5e863d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_87f8d795-971a-495a-8aea-85aeb2bb1c55_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:to="loc_srt_ConsolidationItemsDomain_87f8d795-971a-495a-8aea-85aeb2bb1c55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:to="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c364938c-0354-4ab7-903e-e2267aa7c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:to="loc_us-gaap_OperatingSegmentsMember_c364938c-0354-4ab7-903e-e2267aa7c8d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_00e03179-2999-409b-afe3-c293db1dc9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_00e03179-2999-409b-afe3-c293db1dc9d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08bb1026-c31c-449b-a41d-1ab7de4658c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:to="loc_us-gaap_SegmentDomain_08bb1026-c31c-449b-a41d-1ab7de4658c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:to="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_edc5dedc-9be3-4ded-8200-f779ece9b699" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:to="loc_ensg_SkilledServicesSegmentMember_edc5dedc-9be3-4ded-8200-f779ece9b699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_40ec66b5-551f-4a01-a4a9-bfeb36a97442_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_40ec66b5-551f-4a01-a4a9-bfeb36a97442_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8d4ac0ec-6c33-492f-a20f-7f0a34555a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:to="loc_us-gaap_SalesRevenueNetMember_8d4ac0ec-6c33-492f-a20f-7f0a34555a65" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c41afab5-b791-4940-8ab9-1741b12b86ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c41afab5-b791-4940-8ab9-1741b12b86ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dd0abeb9-13c2-4912-9707-6955a139b9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dd0abeb9-13c2-4912-9707-6955a139b9e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62bd8837-0752-432d-b2e5-5a275d6f4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62bd8837-0752-432d-b2e5-5a275d6f4ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fe361298-3d89-4b14-92d1-5f1732b93707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fe361298-3d89-4b14-92d1-5f1732b93707" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_e3a3ba15-1fc4-46a5-a576-7571d7b41251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_LandMember_e3a3ba15-1fc4-46a5-a576-7571d7b41251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fbb00d6e-d9a5-46f5-98c6-1bacd571163e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fbb00d6e-d9a5-46f5-98c6-1bacd571163e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16fd3dc8-8b2e-4f9c-bfc2-ea3d5d1c7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16fd3dc8-8b2e-4f9c-bfc2-ea3d5d1c7fb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fa9ee91a-5200-4f37-a87b-a520ae1ccff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_EquipmentMember_fa9ee91a-5200-4f37-a87b-a520ae1ccff6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_62d548b8-07b7-40da-8bf9-c6090e485db1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_62d548b8-07b7-40da-8bf9-c6090e485db1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_47213110-d2b7-4f97-9628-f5b8cee428a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_47213110-d2b7-4f97-9628-f5b8cee428a9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_604b33c4-f0cd-4c66-8141-58488ac73031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_604b33c4-f0cd-4c66-8141-58488ac73031" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7d67f79-af02-4cd7-9b89-cca3a7f65fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7d67f79-af02-4cd7-9b89-cca3a7f65fa7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e19b2a-98ef-44fd-8bad-4df62cdd9f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e19b2a-98ef-44fd-8bad-4df62cdd9f20" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingOperationsMember_f5c2fb0d-9ac7-454d-895e-73099d703804" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:to="loc_ensg_SeniorLivingOperationsMember_f5c2fb0d-9ac7-454d-895e-73099d703804" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_c88f208e-db88-44d8-8d7b-2942b0a59280_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_c88f208e-db88-44d8-8d7b-2942b0a59280_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6cc00f4-be0c-4d05-a2c9-a332c4aa77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6cc00f4-be0c-4d05-a2c9-a332c4aa77a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2aff067-4980-452d-b61a-96d1136724b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2aff067-4980-452d-b61a-96d1136724b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_60c361b1-c08e-4bf4-a522-3684264d9cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_60c361b1-c08e-4bf4-a522-3684264d9cce" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c90cf90b-61c0-4d99-a838-f9e6da7c59f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c90cf90b-61c0-4d99-a838-f9e6da7c59f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_8718dede-24ad-4fa8-aaf1-79a2d02cacf9" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_8718dede-24ad-4fa8-aaf1-79a2d02cacf9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c8c775a5-312f-4fc8-be74-224cbb7f422f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_us-gaap_TradeNamesMember_c8c775a5-312f-4fc8-be74-224cbb7f422f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e2fe54f-ddfd-47c2-b263-4dd30558271f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e2fe54f-ddfd-47c2-b263-4dd30558271f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4ebab34f-04b3-415a-aa11-fa37693109e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4ebab34f-04b3-415a-aa11-fa37693109e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4add845-ff6d-429e-afcf-a7164968edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4add845-ff6d-429e-afcf-a7164968edd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47337c88-edf3-4507-a160-cc21f669ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47337c88-edf3-4507-a160-cc21f669ce35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b576600-84ed-42b9-afd0-e207221ded99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b576600-84ed-42b9-afd0-e207221ded99" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_23efcb17-6db9-448c-beb6-31171eb5c8dc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_23efcb17-6db9-448c-beb6-31171eb5c8dc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DepreciationAndAmortizationMember_1e2b5eab-87a4-4272-916a-824160d79973" xlink:href="ensg-20231231.xsd#ensg_DepreciationAndAmortizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:to="loc_ensg_DepreciationAndAmortizationMember_1e2b5eab-87a4-4272-916a-824160d79973" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8b83796e-2170-4637-b1ae-49cd9e458fa9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8b83796e-2170-4637-b1ae-49cd9e458fa9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareandMedicaidLicensesMember_3e9ab3f1-6584-46dc-843f-3baa0b389062" xlink:href="ensg-20231231.xsd#ensg_MedicareandMedicaidLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:to="loc_ensg_MedicareandMedicaidLicensesMember_3e9ab3f1-6584-46dc-843f-3baa0b389062" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_65b6b437-6992-42b0-a6ef-04c37a4c1d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_65b6b437-6992-42b0-a6ef-04c37a4c1d45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_56e590a9-d6e2-4d51-8a79-fd6ab91fa3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_OperatingLeaseCost_56e590a9-d6e2-4d51-8a79-fd6ab91fa3bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2cb9a76d-d3ea-4255-a155-66fa384c08fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2cb9a76d-d3ea-4255-a155-66fa384c08fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6fe03f0b-2681-41ae-9dd5-0e8e709e012c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6fe03f0b-2681-41ae-9dd5-0e8e709e012c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_107cd938-b473-4ed7-9a90-180d424d4626_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_107cd938-b473-4ed7-9a90-180d424d4626_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d8b1bf0d-a06b-45c2-9bea-cfe421af852c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:to="loc_us-gaap_TradeNamesMember_d8b1bf0d-a06b-45c2-9bea-cfe421af852c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareandMedicaidLicensesMember_3072d568-86e2-4d51-beda-54c67feacf9b" xlink:href="ensg-20231231.xsd#ensg_MedicareandMedicaidLicensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:to="loc_ensg_MedicareandMedicaidLicensesMember_3072d568-86e2-4d51-beda-54c67feacf9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33d65441-fb4a-42a6-90ac-9f2c937c0875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33d65441-fb4a-42a6-90ac-9f2c937c0875" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/GOODWILLDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#GOODWILLDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/GOODWILLDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:to="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_8b158b74-e01d-45bb-abfb-3209917e3772_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:to="loc_srt_ConsolidationItemsDomain_8b158b74-e01d-45bb-abfb-3209917e3772_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:to="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c1e823c3-99e2-4717-a913-5b54d88fef46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:to="loc_us-gaap_OperatingSegmentsMember_c1e823c3-99e2-4717-a913-5b54d88fef46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cf62dc01-78d2-4263-9a2c-fc3f4e5ecd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cf62dc01-78d2-4263-9a2c-fc3f4e5ecd48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a74b2f03-e684-424b-9e37-367818b239f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:to="loc_us-gaap_SegmentDomain_a74b2f03-e684-424b-9e37-367818b239f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:to="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_6f1ccc86-dcd5-4799-8965-e10b481f038a" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:to="loc_ensg_SkilledServicesSegmentMember_6f1ccc86-dcd5-4799-8965-e10b481f038a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d24fd8dd-2020-4f6d-8deb-f11d02795596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:to="loc_us-gaap_Goodwill_d24fd8dd-2020-4f6d-8deb-f11d02795596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_acf061ce-5630-4f49-87e4-b198e5dcf2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_acf061ce-5630-4f49-87e4-b198e5dcf2e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTScheduleofLongtermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_adb6ac90-a271-4f24-8762-f08b2928ecce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_adb6ac90-a271-4f24-8762-f08b2928ecce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralizedDebtObligationsMember_0af46462-6766-488c-86a7-71af56fa73ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralizedDebtObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:to="loc_us-gaap_CollateralizedDebtObligationsMember_0af46462-6766-488c-86a7-71af56fa73ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d1561f19-d91c-4756-a25d-524ec6bf99f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d1561f19-d91c-4756-a25d-524ec6bf99f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_23ff158d-027d-4304-96ed-e14baa58b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_LongTermDebtCurrent_23ff158d-027d-4304-96ed-e14baa58b4b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b6953513-6c4f-4789-a535-146cf5698337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b6953513-6c4f-4789-a535-146cf5698337" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_914b8dc2-8fba-4423-9943-3b70dcb0e431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_914b8dc2-8fba-4423-9943-3b70dcb0e431" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_aa458d2b-c1fd-4506-baf2-547e3aa4dc73_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:to="loc_us-gaap_CreditFacilityDomain_aa458d2b-c1fd-4506-baf2-547e3aa4dc73_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:to="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_18ca85b9-159b-41e3-8f11-9f3d544ffe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_18ca85b9-159b-41e3-8f11-9f3d544ffe0f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_00ebcf3f-17b1-4b72-881a-f55da552de74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_00ebcf3f-17b1-4b72-881a-f55da552de74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TruistBankMember_97c6e934-5d8b-4b54-80fe-0807e11989ab" xlink:href="ensg-20231231.xsd#ensg_TruistBankMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:to="loc_ensg_TruistBankMember_97c6e934-5d8b-4b54-80fe-0807e11989ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:to="loc_us-gaap_VariableRateDomain_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:to="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b805323-18a2-4fd9-bcb7-80f08ff19251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:to="loc_us-gaap_BaseRateMember_8b805323-18a2-4fd9-bcb7-80f08ff19251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SecuredOvernightFinancingRateSOFRMember_65c4f9eb-bce5-4804-983b-4a57c9cd9bc6" xlink:href="ensg-20231231.xsd#ensg_SecuredOvernightFinancingRateSOFRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:to="loc_ensg_SecuredOvernightFinancingRateSOFRMember_65c4f9eb-bce5-4804-983b-4a57c9cd9bc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:to="loc_srt_RangeMember_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:to="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5eb5b8c-4968-418e-a51d-24a643e63d6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:to="loc_srt_MinimumMember_e5eb5b8c-4968-418e-a51d-24a643e63d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3310c51-e0ea-47c6-9029-fe9dadbd41b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:to="loc_srt_MaximumMember_c3310c51-e0ea-47c6-9029-fe9dadbd41b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8363301-afdb-44f0-8b71-976f1187a820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8363301-afdb-44f0-8b71-976f1187a820" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9ac8871d-6a49-48f7-b75a-76b8ac75acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9ac8871d-6a49-48f7-b75a-76b8ac75acfd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c9daa534-9647-452c-8049-5f2b79120dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c9daa534-9647-452c-8049-5f2b79120dd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_9c3266ff-95db-4f02-a122-250341beb09e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_9c3266ff-95db-4f02-a122-250341beb09e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_e4381e54-118b-4bc0-a615-737e712f0f10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_e4381e54-118b-4bc0-a615-737e712f0f10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximum_86e9a28c-5a53-43b4-bc20-752bf53d2d16" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMaximum_86e9a28c-5a53-43b4-bc20-752bf53d2d16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_0aaf0678-6f17-403c-893f-a7e8546d7f1d" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_0aaf0678-6f17-403c-893f-a7e8546d7f1d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_b62a2dec-9a7e-48fc-8a5d-e4c04f6929c1" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_b62a2dec-9a7e-48fc-8a5d-e4c04f6929c1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_04bad640-47d1-4f16-9a42-2a083d4c6e89" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximumAfterIncreaseElection"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_04bad640-47d1-4f16-9a42-2a083d4c6e89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMinimum_adf62158-1df4-4fc2-9c52-cac8c8dc2857" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMinimum_adf62158-1df4-4fc2-9c52-cac8c8dc2857" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_db663761-9ae1-423a-ae29-9b49f87a4300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_db663761-9ae1-423a-ae29-9b49f87a4300" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2717166f-3ca9-46ca-98ad-c4eed90e33fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2717166f-3ca9-46ca-98ad-c4eed90e33fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralizedDebtObligationsMember_cd627d5b-116c-42b7-a8c6-329945fa6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralizedDebtObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:to="loc_us-gaap_CollateralizedDebtObligationsMember_cd627d5b-116c-42b7-a8c6-329945fa6b1b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_35afdfdc-95fd-41eb-b749-a2ff778be8cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_35afdfdc-95fd-41eb-b749-a2ff778be8cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HUDInsuredMortgagesMember_7aa9ffa5-2c8e-4c8c-bd2c-f240b4d60537" xlink:href="ensg-20231231.xsd#ensg_HUDInsuredMortgagesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:to="loc_ensg_HUDInsuredMortgagesMember_7aa9ffa5-2c8e-4c8c-bd2c-f240b4d60537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A53PromissoryNoteMember_e386073c-8d9f-434a-9ce6-2b9c315c26d0" xlink:href="ensg-20231231.xsd#ensg_A53PromissoryNoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:to="loc_ensg_A53PromissoryNoteMember_e386073c-8d9f-434a-9ce6-2b9c315c26d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_87c206fc-d2a8-45a7-8191-ece582099f91_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:to="loc_dei_EntityDomain_87c206fc-d2a8-45a7-8191-ece582099f91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:to="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TwentyThreeSubsidiariesMember_5bccc3e5-f909-4180-ba80-f7dc7a16a10d" xlink:href="ensg-20231231.xsd#ensg_TwentyThreeSubsidiariesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:to="loc_ensg_TwentyThreeSubsidiariesMember_5bccc3e5-f909-4180-ba80-f7dc7a16a10d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_88b166b7-af90-4388-bcda-2c89ae49e917_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:to="loc_srt_RangeMember_88b166b7-af90-4388-bcda-2c89ae49e917_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:to="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8350a338-1fdc-4021-9b8a-de4957360005" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:to="loc_srt_MinimumMember_8350a338-1fdc-4021-9b8a-de4957360005" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_28020f86-deb7-47de-8b86-a9ba48452b32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:to="loc_srt_MaximumMember_28020f86-deb7-47de-8b86-a9ba48452b32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodDomain_303075a2-8d59-49a0-9625-15de5241a849_default" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:to="loc_ensg_PrepaymentFeePeriodDomain_303075a2-8d59-49a0-9625-15de5241a849_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:to="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FirstThreeYearsMember_d1c9eb6c-2569-49b1-a122-ce7af54ebe27" xlink:href="ensg-20231231.xsd#ensg_FirstThreeYearsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_FirstThreeYearsMember_d1c9eb6c-2569-49b1-a122-ce7af54ebe27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InTheFourthYearMember_095c7247-8a96-42c5-ada0-945fc620d872" xlink:href="ensg-20231231.xsd#ensg_InTheFourthYearMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_InTheFourthYearMember_095c7247-8a96-42c5-ada0-945fc620d872" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_YearsFiveThroughTenMember_1b3ea6e6-e553-4bc9-872c-b0a58def2395" xlink:href="ensg-20231231.xsd#ensg_YearsFiveThroughTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_YearsFiveThroughTenMember_1b3ea6e6-e553-4bc9-872c-b0a58def2395" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AfterYearTenMember_6322248a-1499-4f62-95ca-f898e2f1ae3f" xlink:href="ensg-20231231.xsd#ensg_AfterYearTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_AfterYearTenMember_6322248a-1499-4f62-95ca-f898e2f1ae3f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_78f42c59-19be-41eb-9e68-7500a1b50a49_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:to="loc_us-gaap_CreditFacilityDomain_78f42c59-19be-41eb-9e68-7500a1b50a49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:to="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_3f50fd5e-52d0-4d5c-bc2a-c1a7ff63ad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:to="loc_us-gaap_LetterOfCreditMember_3f50fd5e-52d0-4d5c-bc2a-c1a7ff63ad7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperatingSubsidiaries_53d77576-381c-4a48-891a-7d16cb8ca8bb" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperatingSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_NumberOfOperatingSubsidiaries_53d77576-381c-4a48-891a-7d16cb8ca8bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ea180683-1118-44f2-a0e6-e77c3f390fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ea180683-1118-44f2-a0e6-e77c3f390fc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8f33e63e-94d0-4c9f-8482-e3de83a09c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8f33e63e-94d0-4c9f-8482-e3de83a09c54" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63899dbc-a447-4380-94a1-ae0de645616a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63899dbc-a447-4380-94a1-ae0de645616a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentPenalty_79263ca4-57e4-466c-962b-e2aff581fd07" xlink:href="ensg-20231231.xsd#ensg_PrepaymentPenalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_PrepaymentPenalty_79263ca4-57e4-466c-962b-e2aff581fd07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ReductionInPrepaymentPenalty_68125a22-390e-4d4f-9ff8-b75c62cabb13" xlink:href="ensg-20231231.xsd#ensg_ReductionInPrepaymentPenalty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_ReductionInPrepaymentPenalty_68125a22-390e-4d4f-9ff8-b75c62cabb13" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e9725b51-9dc5-41aa-be64-3c98a6a2e2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentTerm_e9725b51-9dc5-41aa-be64-3c98a6a2e2d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0b30d024-572a-4dd2-95a4-5d7f23f4095a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0b30d024-572a-4dd2-95a4-5d7f23f4095a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_5b8c381d-2a3b-4327-a733-c5d5739a50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_5b8c381d-2a3b-4327-a733-c5d5739a50d0" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSStockOptionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_4c2c07e4-373e-49ed-88ad-82e320083b6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:to="loc_us-gaap_PlanNameDomain_4c2c07e4-373e-49ed-88ad-82e320083b6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:to="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2022PlanMember_f33dec8f-7fb4-49a0-b57d-4acd2597c920" xlink:href="ensg-20231231.xsd#ensg_A2022PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:to="loc_ensg_A2022PlanMember_f33dec8f-7fb4-49a0-b57d-4acd2597c920" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_2c3785c8-8cbc-4703-a8e6-57b9789fc687_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:to="loc_us-gaap_GranteeStatusDomain_2c3785c8-8cbc-4703-a8e6-57b9789fc687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:to="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7f0d6192-6810-4f62-b761-2a746ffad791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7f0d6192-6810-4f62-b761-2a746ffad791" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b0a9729-4263-41dd-8f21-228d7a790b38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0b0a9729-4263-41dd-8f21-228d7a790b38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f470d315-e57f-4106-92c0-09f39673c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f470d315-e57f-4106-92c0-09f39673c61b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOptionPlans_7fcdd3dd-601b-45d8-9659-1746cc5202cf" xlink:href="ensg-20231231.xsd#ensg_NumberOfOptionPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_NumberOfOptionPlans_7fcdd3dd-601b-45d8-9659-1746cc5202cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4a22e1b-bcbd-42ed-b388-0aa8c746048d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4a22e1b-bcbd-42ed-b388-0aa8c746048d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_c094dcc2-804d-4add-8e13-082e6e2990bf" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_c094dcc2-804d-4add-8e13-082e6e2990bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_68f4b511-0d29-4778-8c54-fdfec3c3257d" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_68f4b511-0d29-4778-8c54-fdfec3c3257d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_3325932b-7bb8-474f-8a67-107e3b3a8cb7" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_3325932b-7bb8-474f-8a67-107e3b3a8cb7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f25ea7cc-2dff-47f3-8f06-5e2bf20e4757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f25ea7cc-2dff-47f3-8f06-5e2bf20e4757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c98bd588-2330-4a84-ae5c-c914560066d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c98bd588-2330-4a84-ae5c-c914560066d0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c93c95cf-8dfc-417f-ab89-b87e670c4c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c93c95cf-8dfc-417f-ab89-b87e670c4c2c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b97a838b-eb13-45cb-9d48-d8f98bb6680a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b97a838b-eb13-45cb-9d48-d8f98bb6680a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d54afa2-b190-4ca0-b8ff-ee708877de71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d54afa2-b190-4ca0-b8ff-ee708877de71" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_ae2ea5ba-0a0b-483a-bc97-e680955805d0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_ae2ea5ba-0a0b-483a-bc97-e680955805d0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dafd9c1f-126f-4906-a7a4-4b69f05bfeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dafd9c1f-126f-4906-a7a4-4b69f05bfeff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_fb917ffb-d9ca-471f-ab3e-0e1e09698940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_fb917ffb-d9ca-471f-ab3e-0e1e09698940" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_4f3a569c-5be1-45af-88c7-ffcd54aa75e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_4f3a569c-5be1-45af-88c7-ffcd54aa75e9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_74132258-a88f-4e1c-991c-a1f205d37e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_74132258-a88f-4e1c-991c-a1f205d37e89" xlink:type="arc" order="14"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b7c64d13-e4ba-4c29-9423-a10bd62fb825_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_b7c64d13-e4ba-4c29-9423-a10bd62fb825_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTwoMember_54c6bd1f-6b47-4916-9e22-f8a11713f5e1" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeTwoMember_54c6bd1f-6b47-4916-9e22-f8a11713f5e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeThreeMember_e7cdc812-8e6d-4a35-8145-a5c44305e751" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeThreeMember_e7cdc812-8e6d-4a35-8145-a5c44305e751" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFourMember_42eb706f-68ef-4fb4-bec0-d3f67dc9b2ae" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeFourMember_42eb706f-68ef-4fb4-bec0-d3f67dc9b2ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFiveMember_8d8ea9ea-be6b-4a1c-95fb-edcd38980629" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeFiveMember_8d8ea9ea-be6b-4a1c-95fb-edcd38980629" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSixMember_a36a0a0b-aaa2-4d7e-b3e7-699ae412cd08" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSixMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeSixMember_a36a0a0b-aaa2-4d7e-b3e7-699ae412cd08" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSevenMember_9148769c-61b4-4228-9e57-542dd1ebf8e5" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeSevenMember_9148769c-61b4-4228-9e57-542dd1ebf8e5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeEightMember_08129951-7847-4103-90b7-e7ac6f445a8d" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeEightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeEightMember_08129951-7847-4103-90b7-e7ac6f445a8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeNineMember_1a9ccafd-d71f-4cb6-b17b-ea6f93a6adc6" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeNineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeNineMember_1a9ccafd-d71f-4cb6-b17b-ea6f93a6adc6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTenMember_43540ffb-cb26-4f93-adb2-f1e843f4d8b1" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeTenMember_43540ffb-cb26-4f93-adb2-f1e843f4d8b1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeElevenMember_41a43c8e-0b38-438d-a36b-5bdae48acf7c" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeElevenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeElevenMember_41a43c8e-0b38-438d-a36b-5bdae48acf7c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b62c19cd-723e-4f19-b07b-fec929f5c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b62c19cd-723e-4f19-b07b-fec929f5c5ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a13a687d-9d49-4818-8799-859e42673f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a13a687d-9d49-4818-8799-859e42673f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7eec002b-e8f7-482d-b372-11c4060ef9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7eec002b-e8f7-482d-b372-11c4060ef9f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_6ac183cb-bea5-4383-9cd7-61466888261f" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_6ac183cb-bea5-4383-9cd7-61466888261f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_b76a3691-b84b-4f0e-8a1e-622cf8db78a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_b76a3691-b84b-4f0e-8a1e-622cf8db78a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2646a78a-cf1b-4c0e-bc64-4baba2049926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2646a78a-cf1b-4c0e-bc64-4baba2049926" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12c57fbb-0042-4b0a-815f-56d8b7195589_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_12c57fbb-0042-4b0a-815f-56d8b7195589_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5120fd7a-d6c8-4ff8-bbdb-d25d3cb489c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:to="loc_us-gaap_RestrictedStockMember_5120fd7a-d6c8-4ff8-bbdb-d25d3cb489c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_734d4ea2-0125-43b7-8083-d186fda07f4d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:to="loc_srt_RangeMember_734d4ea2-0125-43b7-8083-d186fda07f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:to="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e2114a4d-3700-487b-a0e1-3b0e3acde854" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:to="loc_srt_MinimumMember_e2114a4d-3700-487b-a0e1-3b0e3acde854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7417853-33b8-48eb-b6fc-dd2635fc9db2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:to="loc_srt_MaximumMember_f7417853-33b8-48eb-b6fc-dd2635fc9db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_743ad3ba-1715-47d4-a16b-8ef826a05b6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:to="loc_us-gaap_GranteeStatusDomain_743ad3ba-1715-47d4-a16b-8ef826a05b6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:to="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8984be01-aced-4e76-978d-f21b95b38866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8984be01-aced-4e76-978d-f21b95b38866" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fd32d11-e318-46b1-8fd3-03569deca2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fd32d11-e318-46b1-8fd3-03569deca2f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_5b9ba3d0-12af-4e1b-815a-c225eb1be84c" xlink:href="ensg-20231231.xsd#ensg_SharebasedCompensationRestrictedAwardsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_5b9ba3d0-12af-4e1b-815a-c225eb1be84c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6f8c6c7a-b052-4297-8a41-09c4d338fd73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6f8c6c7a-b052-4297-8a41-09c4d338fd73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57cce6bf-fda8-40ed-84d9-0569c0277b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57cce6bf-fda8-40ed-84d9-0569c0277b5b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:to="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_242685d5-a4f1-4540-87bb-2a71b6ddc6c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_242685d5-a4f1-4540-87bb-2a71b6ddc6c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5eab90f9-7600-4234-abc0-abbffe4eb927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:to="loc_us-gaap_RestrictedStockMember_5eab90f9-7600-4234-abc0-abbffe4eb927" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b50e7ba5-a109-41e5-9d56-a5ce4da868c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b50e7ba5-a109-41e5-9d56-a5ce4da868c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_da17b035-b9f1-4580-871f-cc574c03ff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_da17b035-b9f1-4580-871f-cc574c03ff6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bf4b242-b0c6-4218-93f6-140fef154cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bf4b242-b0c6-4218-93f6-140fef154cc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e3250a1b-a96a-4cea-89e3-ccc762b3f6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e3250a1b-a96a-4cea-89e3-ccc762b3f6ef" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2909b1db-ed8f-4cc6-ac9b-54d53a5ac690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09d902ed-45da-423d-93f0-273e05cf3f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09d902ed-45da-423d-93f0-273e05cf3f60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f669d522-a58e-4ce4-9d74-b4ec8d325230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f669d522-a58e-4ce4-9d74-b4ec8d325230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_293372b4-6049-4627-a09f-dd71e7811c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_293372b4-6049-4627-a09f-dd71e7811c60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_608a2933-f84c-4935-9ee6-665a28deb658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_608a2933-f84c-4935-9ee6-665a28deb658" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_072c2c4f-b2f1-4e77-8206-e9ee81007741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSLongTermIncentivePlanDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2628f97f-4a71-4bd2-be09-bc5aa58ec464_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2628f97f-4a71-4bd2-be09-bc5aa58ec464_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpinoffMember_21559ccf-b5f8-4ad1-b66b-f2b000dee460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SpinoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:to="loc_us-gaap_SpinoffMember_21559ccf-b5f8-4ad1-b66b-f2b000dee460" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:to="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_b7dc921b-d4db-498f-bbf5-ff25fdef115b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:to="loc_us-gaap_PlanNameDomain_b7dc921b-d4db-498f-bbf5-ff25fdef115b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:to="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2019LTIPlanMember_be484092-4879-48ac-b80d-8399d27db280" xlink:href="ensg-20231231.xsd#ensg_A2019LTIPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:to="loc_ensg_A2019LTIPlanMember_be484092-4879-48ac-b80d-8399d27db280" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_35b010d5-d269-4d52-b677-63f3c37a9a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_35b010d5-d269-4d52-b677-63f3c37a9a09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfa8e420-ea36-4da5-b907-a5d77d80cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfa8e420-ea36-4da5-b907-a5d77d80cb1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f4cd69af-eb0f-4c50-b1cc-6d9be83c5261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f4cd69af-eb0f-4c50-b1cc-6d9be83c5261" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_96b78a99-a5e4-4d2f-9fe4-7f9152c36d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_96b78a99-a5e4-4d2f-9fe4-7f9152c36d71" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:to="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9793379-304f-4944-99c3-98fa61f8c114_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a9793379-304f-4944-99c3-98fa61f8c114_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_86c7bb78-6cd3-4333-940d-2b1045d7175b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_86c7bb78-6cd3-4333-940d-2b1045d7175b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2aac7ee2-0569-4879-84f6-296d4f1c4481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_us-gaap_RestrictedStockMember_2aac7ee2-0569-4879-84f6-296d4f1c4481" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StockAwardsMember_fc258f07-bb1b-4d39-93dc-5b8eeb8d164d" xlink:href="ensg-20231231.xsd#ensg_StockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_ensg_StockAwardsMember_fc258f07-bb1b-4d39-93dc-5b8eeb8d164d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47099a53-efd2-4bc2-9e12-34d520e35566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47099a53-efd2-4bc2-9e12-34d520e35566" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cef8110-de65-4565-a298-6cdb6ab3fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cef8110-de65-4565-a298-6cdb6ab3fdb0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e7c83976-5bba-45b0-adca-156a1354f852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e7c83976-5bba-45b0-adca-156a1354f852" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_74299328-3f2b-409c-a389-3e51450e3285" xlink:href="ensg-20231231.xsd#ensg_EmployeeServiceShareBasedCompensationNonvestedAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_74299328-3f2b-409c-a389-3e51450e3285" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_d5afa0b5-a656-4517-85cf-35c6ae1bb4a0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_d5afa0b5-a656-4517-85cf-35c6ae1bb4a0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47957f47-26cb-40df-912f-4b96858b1004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47957f47-26cb-40df-912f-4b96858b1004" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2affa7ad-772d-4922-83c3-19ebf9337197_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_2affa7ad-772d-4922-83c3-19ebf9337197_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CareTrustREITMember_87a9b230-5cc1-4590-9374-9d87db915c44" xlink:href="ensg-20231231.xsd#ensg_CareTrustREITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_CareTrustREITMember_87a9b230-5cc1-4590-9374-9d87db915c44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_VariousLandlordsMember_1e94439c-cf93-4c67-a95b-77ae0a2b6b46" xlink:href="ensg-20231231.xsd#ensg_VariousLandlordsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_VariousLandlordsMember_1e94439c-cf93-4c67-a95b-77ae0a2b6b46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_c6173ffb-6551-43ee-a0c1-9205c5690a00" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_ThePennantGroupInc.Member_c6173ffb-6551-43ee-a0c1-9205c5690a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_dd78a268-1184-43d3-b863-53333ee3436b_default" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:to="loc_ensg_LeaseArrangementDomain_dd78a268-1184-43d3-b863-53333ee3436b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:to="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TripleNetLeaseArrangementsMember_04ecd41a-527c-4621-9d4f-37feb6abde7a" xlink:href="ensg-20231231.xsd#ensg_TripleNetLeaseArrangementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_TripleNetLeaseArrangementsMember_04ecd41a-527c-4621-9d4f-37feb6abde7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchaseOptionMember_521317f7-b5c9-4528-8055-aa9b538ae66b" xlink:href="ensg-20231231.xsd#ensg_PurchaseOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_PurchaseOptionMember_521317f7-b5c9-4528-8055-aa9b538ae66b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseAgreementMember_fde6638a-12d2-4310-bb34-8841708213a7" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_AmendedMasterLeaseAgreementMember_fde6638a-12d2-4310-bb34-8841708213a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NewMasterLeaseAgreeementMember_cd7e9682-cf57-467d-a4e2-c25c6a6ac91e" xlink:href="ensg-20231231.xsd#ensg_NewMasterLeaseAgreeementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_NewMasterLeaseAgreeementMember_cd7e9682-cf57-467d-a4e2-c25c6a6ac91e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseMember_d148687e-f9fb-47ba-a1d6-00dc960394e4" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_AmendedMasterLeaseMember_d148687e-f9fb-47ba-a1d6-00dc960394e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_b42cd883-29fe-4388-82ba-106ceb88efaa" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_b42cd883-29fe-4388-82ba-106ceb88efaa" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_fea29ec0-883c-4406-9b50-36171ffd9fc6" xlink:href="ensg-20231231.xsd#ensg_SubleaseOfStandAlongSkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_fea29ec0-883c-4406-9b50-36171ffd9fc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseOfCampusOperationMember_14c44ce8-7d5a-4fbe-8a16-100bac582a70" xlink:href="ensg-20231231.xsd#ensg_LeaseOfCampusOperationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_LeaseOfCampusOperationMember_14c44ce8-7d5a-4fbe-8a16-100bac582a70" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c6c4448e-8537-458c-9656-428b03a08f03_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:to="loc_srt_RangeMember_c6c4448e-8537-458c-9656-428b03a08f03_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:to="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93f2d88f-f33a-4714-a34d-3092821f2346" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:to="loc_srt_MinimumMember_93f2d88f-f33a-4714-a34d-3092821f2346" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_947cd0b6-dfa6-4c0f-9017-34a143584d6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:to="loc_srt_MaximumMember_947cd0b6-dfa6-4c0f-9017-34a143584d6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc6c4ce-6653-4f4a-81ca-ab118d08316c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8dc6c4ce-6653-4f4a-81ca-ab118d08316c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_da63a558-565d-48af-a198-2f41ee7c86f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:to="loc_us-gaap_EquipmentMember_da63a558-565d-48af-a198-2f41ee7c86f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_015bc35e-e4ef-4973-922a-985b75c41e29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_015bc35e-e4ef-4973-922a-985b75c41e29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_905d4dd1-be44-4267-b4b6-a588fbd3b1f0" xlink:href="ensg-20231231.xsd#ensg_CostofSalesandGeneralandAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:to="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_905d4dd1-be44-4267-b4b6-a588fbd3b1f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c08c517c-a275-45f2-bf0c-58f436b61ccc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c08c517c-a275-45f2-bf0c-58f436b61ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_dd8aa395-465b-428b-aa0e-04c39a99e2b4" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:to="loc_ensg_SkilledNursingOperationsMember_dd8aa395-465b-428b-aa0e-04c39a99e2b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_0c476429-f4c0-4195-addd-3ddf3331e681_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_0c476429-f4c0-4195-addd-3ddf3331e681_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eede6b99-9015-4007-8b97-2dda6f956a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:to="loc_us-gaap_SubsequentEventMember_eede6b99-9015-4007-8b97-2dda6f956a55" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_2d753b99-16f3-4743-be40-0e0768a556b0" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_2d753b99-16f3-4743-be40-0e0768a556b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MasterLeaseAgreements_276ba9e7-0f0e-44d4-ae3c-3d07e08298d6" xlink:href="ensg-20231231.xsd#ensg_MasterLeaseAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_MasterLeaseAgreements_276ba9e7-0f0e-44d4-ae3c-3d07e08298d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f9ec644-e4d6-4d57-ac6d-834425f3ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f9ec644-e4d6-4d57-ac6d-834425f3ec6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_4b359681-53e6-4223-bdbb-62aff39b39f3" xlink:href="ensg-20231231.xsd#ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_4b359681-53e6-4223-bdbb-62aff39b39f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8fc2572d-4a11-49c9-9b80-0456a2131ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8fc2572d-4a11-49c9-9b80-0456a2131ce1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex_1e3b711f-403f-4b53-a9d0-0a6b0a02c557" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseConsumerPriceIndex"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex_1e3b711f-403f-4b53-a9d0-0a6b0a02c557" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_88dba568-bedf-4c10-b092-165468448dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_88dba568-bedf-4c10-b092-165468448dab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfLeases_06640d4d-8fbc-4588-b498-b141a8e832fd" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeOperatingLeaseNumberOfLeases_06640d4d-8fbc-4588-b498-b141a8e832fd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0296939c-d285-4a4b-a33d-d5ff71d95536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseExpense_0296939c-d285-4a4b-a33d-d5ff71d95536" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FacilitiesUnderMasterLeaseArrangement_6a08c598-c878-485d-9856-07d753789a2d" xlink:href="ensg-20231231.xsd#ensg_FacilitiesUnderMasterLeaseArrangement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_FacilitiesUnderMasterLeaseArrangement_6a08c598-c878-485d-9856-07d753789a2d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedSeparateMasterLeases_30ffa0c7-81e6-4040-9690-a975da7c6776" xlink:href="ensg-20231231.xsd#ensg_AmendedSeparateMasterLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_AmendedSeparateMasterLeases_30ffa0c7-81e6-4040-9690-a975da7c6776" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_497b096b-34c8-48c1-a7c8-047435b75cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_497b096b-34c8-48c1-a7c8-047435b75cc8" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_c7eabb42-56a0-4a4e-9076-7b41ebc7ac66" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_c7eabb42-56a0-4a4e-9076-7b41ebc7ac66" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0611fe0-aea7-410f-ba1a-ac334214db43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0611fe0-aea7-410f-ba1a-ac334214db43" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_f941914a-1227-4692-b465-ede8a8d9ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_f941914a-1227-4692-b465-ede8a8d9ab1d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ccab150-e343-47ac-b443-1ca0677af7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ccab150-e343-47ac-b443-1ca0677af7fa" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dafeccf5-8815-4888-be60-210e44ab48c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dafeccf5-8815-4888-be60-210e44ab48c4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_456457e5-2c4a-4780-b94d-ccd9609065ca" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_OperationalSkilledNursingBeds_456457e5-2c4a-4780-b94d-ccd9609065ca" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeLeaseCostDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_db3c8a0e-6c94-4d33-854f-b89a99a1f97b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_db3c8a0e-6c94-4d33-854f-b89a99a1f97b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d99d1468-1db2-40fb-b0f8-414723650e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_us-gaap_CostOfSalesMember_d99d1468-1db2-40fb-b0f8-414723650e7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7aba8e9-2402-4e43-8aa6-5762737fc87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7aba8e9-2402-4e43-8aa6-5762737fc87c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DepreciationAndAmortizationMember_41fc26a1-696f-4abf-a303-4dcc098c3b03" xlink:href="ensg-20231231.xsd#ensg_DepreciationAndAmortizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_ensg_DepreciationAndAmortizationMember_41fc26a1-696f-4abf-a303-4dcc098c3b03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e4e80e8a-1329-4ad0-b747-bcf0f0950d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_OperatingLeaseCost_e4e80e8a-1329-4ad0-b747-bcf0f0950d16" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ab97c4ad-de0a-4a06-908d-7d5c0e3b6728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_VariableLeaseCost_ab97c4ad-de0a-4a06-908d-7d5c0e3b6728" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8f98ec70-2cff-4058-b6bb-5740f0ed7546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_LeaseCost_8f98ec70-2cff-4058-b6bb-5740f0ed7546" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAdjustment_37415f40-7d90-4fb3-be69-0c4c54a552a8" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_ensg_DeferredRentAdjustment_37415f40-7d90-4fb3-be69-0c4c54a552a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_edf58804-040f-422e-b7bb-68ce2071b02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_ShortTermLeaseCost_edf58804-040f-422e-b7bb-68ce2071b02a" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:to="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_ee79166a-ddb1-47c4-9560-43b03f7bbfa2_default" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:to="loc_ensg_LeaseArrangementDomain_ee79166a-ddb1-47c4-9560-43b03f7bbfa2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:to="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_e4eb5b79-66b3-4c94-a91b-db14f5f60310" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_e4eb5b79-66b3-4c94-a91b-db14f5f60310" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_c06597e9-64fe-4c67-97aa-bb27f6199260" xlink:href="ensg-20231231.xsd#ensg_SubleaseOfStandAlongSkilledNursingOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_c06597e9-64fe-4c67-97aa-bb27f6199260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseOfCampusOperationMember_6b156783-dfe9-4674-a3f8-14689022e02d" xlink:href="ensg-20231231.xsd#ensg_LeaseOfCampusOperationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_LeaseOfCampusOperationMember_6b156783-dfe9-4674-a3f8-14689022e02d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15bd537d-c902-4861-8573-f55302e27be2_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_15bd537d-c902-4861-8573-f55302e27be2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_cadd1322-be14-414f-9831-496c14d72424" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:to="loc_ensg_ThePennantGroupInc.Member_cadd1322-be14-414f-9831-496c14d72424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8e4253d-ceb6-474a-a775-723c8018aa02_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:to="loc_srt_RangeMember_b8e4253d-ceb6-474a-a775-723c8018aa02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:to="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f6908c9-5ea9-43c7-9e83-922cefc85f9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:to="loc_srt_MinimumMember_6f6908c9-5ea9-43c7-9e83-922cefc85f9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24a19986-f382-49c2-85ef-389dc30b6ff5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:to="loc_srt_MaximumMember_24a19986-f382-49c2-85ef-389dc30b6ff5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_961aca56-6e71-4c0a-b5e4-0534fb5f318e" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_961aca56-6e71-4c0a-b5e4-0534fb5f318e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2fbe64cf-a2d6-41d3-bd14-5f47e00ae1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2fbe64cf-a2d6-41d3-bd14-5f47e00ae1da" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorRentalIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76715dc-e9ef-4ec6-8666-2497a35bb687_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_b76715dc-e9ef-4ec6-8666-2497a35bb687_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_92e7a2c1-531b-43a5-bc27-972ac51d83a3" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:to="loc_ensg_ThePennantGroupInc.Member_92e7a2c1-531b-43a5-bc27-972ac51d83a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyTenantsMember_05af5b97-add5-47a8-ac59-52d902d9f9d7" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyTenantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:to="loc_ensg_ThirdPartyTenantsMember_05af5b97-add5-47a8-ac59-52d902d9f9d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_371f183f-1e6a-4036-856d-d28be895e6ae_default" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:to="loc_ensg_LeaseArrangementDomain_371f183f-1e6a-4036-856d-d28be895e6ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:to="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_71b229df-b3cd-4472-a019-122d89bcf6a6" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_71b229df-b3cd-4472-a019-122d89bcf6a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_15a0447b-0115-4d83-ba44-ae4bbc3223df_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:to="loc_srt_ConsolidationItemsDomain_15a0447b-0115-4d83-ba44-ae4bbc3223df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:to="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_69d75013-58a8-4309-a006-22e661c81c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:to="loc_us-gaap_OperatingSegmentsMember_69d75013-58a8-4309-a006-22e661c81c3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8bb03da-6c54-4a7c-909d-c1d95221db54_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:to="loc_srt_ProductsAndServicesDomain_a8bb03da-6c54-4a7c-909d-c1d95221db54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:to="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_0298d384-072a-4366-9ab7-da1e8b561998" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:to="loc_ensg_RentalMember_0298d384-072a-4366-9ab7-da1e8b561998" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a42e8867-c686-4751-afaa-4ce458321bbf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:to="loc_us-gaap_SegmentDomain_a42e8867-c686-4751-afaa-4ce458321bbf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:to="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_15013c0a-3234-4353-912e-001df23727e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_15013c0a-3234-4353-912e-001df23727e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_0a951838-fbcc-439b-852b-4f546ac87ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_0a951838-fbcc-439b-852b-4f546ac87ac4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_fe0f07d0-dbad-4a67-b16a-b6f023bf97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_fe0f07d0-dbad-4a67-b16a-b6f023bf97eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseVariableLeaseIncome_a8cdea7b-dea8-401d-9ec7-f6fe4b6eb19a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseVariableLeaseIncome_a8cdea7b-dea8-401d-9ec7-f6fe4b6eb19a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_e56d33a3-d18f-4621-bcda-b0f520da1693" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_e56d33a3-d18f-4621-bcda-b0f520da1693" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_dfd91932-c298-48bb-a94f-b1e5115ba3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_SubleaseIncome_dfd91932-c298-48bb-a94f-b1e5115ba3db" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEFINEDCONTRIBUTIONPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_492cf4c6-5580-4284-bd25-9802de02a07b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_492cf4c6-5580-4284-bd25-9802de02a07b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember_3c5864fb-84e6-4eea-9859-44f1a0732694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:to="loc_us-gaap_QualifiedPlanMember_3c5864fb-84e6-4eea-9859-44f1a0732694" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_3f6e50c4-8703-4ad0-aec0-813a9a913c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:to="loc_us-gaap_NonqualifiedPlanMember_3f6e50c4-8703-4ad0-aec0-813a9a913c5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1078b39e-837f-418b-b8df-2d3c3186735a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1078b39e-837f-418b-b8df-2d3c3186735a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_25e9eb3f-263e-4ff6-a1a0-6ee8c21184c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_25e9eb3f-263e-4ff6-a1a0-6ee8c21184c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b605ff61-bb68-4573-8b23-0e9d6e6a9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b605ff61-bb68-4573-8b23-0e9d6e6a9fdf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6074ade3-9121-448e-ad99-420f403e43a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_GainLossOnInvestments_6074ade3-9121-448e-ad99-420f403e43a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InvestmentExpenseIncome_9efc50c1-d2da-4354-856c-541b11ea8b58" xlink:href="ensg-20231231.xsd#ensg_InvestmentExpenseIncome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_ensg_InvestmentExpenseIncome_9efc50c1-d2da-4354-856c-541b11ea8b58" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SELFINSURANCELIABILITIESDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:to="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeAndTierIdentifierDomain_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:to="loc_us-gaap_TypeAndTierIdentifierDomain_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:to="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalMalpracticeLiabilityMember_d8f6ecc2-d7fe-4183-b439-90bae330d1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalMalpracticeLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:to="loc_us-gaap_ProfessionalMalpracticeLiabilityMember_d8f6ecc2-d7fe-4183-b439-90bae330d1db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:to="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_13de6c9b-1176-4d3b-910a-3d576484be07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_13de6c9b-1176-4d3b-910a-3d576484be07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_4a6227e8-08ec-4d2f-81c8-5f78bcff3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_4a6227e8-08ec-4d2f-81c8-5f78bcff3b6e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_2f579816-2569-4192-a1db-6600854b22d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_2f579816-2569-4192-a1db-6600854b22d4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_369d14e8-9114-473b-ab8f-69897a46e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_369d14e8-9114-473b-ab8f-69897a46e09d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_3019542e-afe1-4ba6-9f3a-0291a3ce040c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d361e0a5-a911-4aae-ad8b-46d6e2854737_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d361e0a5-a911-4aae-ad8b-46d6e2854737_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dd9f2611-ce50-4a5a-9707-ae5b92f9ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:to="loc_us-gaap_SubsequentEventMember_dd9f2611-ce50-4a5a-9707-ae5b92f9ce28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_194967a6-f698-45d1-9b9b-fb39cd19a55f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_194967a6-f698-45d1-9b9b-fb39cd19a55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bf09ad39-42e4-4d0a-959c-61ff79f49c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bf09ad39-42e4-4d0a-959c-61ff79f49c5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e739b6c7-84af-49fc-a623-b00d69feadbe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_e739b6c7-84af-49fc-a623-b00d69feadbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_6e0f7d87-4742-46b1-a5df-288440d4b4b1" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:to="loc_ensg_MedicaidAndMedicareMember_6e0f7d87-4742-46b1-a5df-288440d4b4b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9b656108-ffa8-4085-a65f-603812af737d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9b656108-ffa8-4085-a65f-603812af737d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4d56ae07-7def-4099-94df-0dd54991c7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:to="loc_us-gaap_AccountsReceivableMember_4d56ae07-7def-4099-94df-0dd54991c7c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cfdba168-fb09-46ba-bd89-393bb4b7d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:to="loc_us-gaap_SalesRevenueNetMember_cfdba168-fb09-46ba-bd89-393bb4b7d3ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3fe1768a-e8f1-46cc-a345-c3105dac91f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3fe1768a-e8f1-46cc-a345-c3105dac91f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_5b713d0f-6df4-4750-8d73-2ddbc6628b62" xlink:href="ensg-20231231.xsd#ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_5b713d0f-6df4-4750-8d73-2ddbc6628b62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1040343a-6b88-423a-9788-15e280d0d93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1040343a-6b88-423a-9788-15e280d0d93d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMONSTOCKREPURCHASEPROGRAMDetails"/>
  <link:definitionLink xlink:role="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_August2023RepurchaseProgramMember_b641945c-ad6d-4546-b35f-74bcbdd850e9" xlink:href="ensg-20231231.xsd#ensg_August2023RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:to="loc_ensg_August2023RepurchaseProgramMember_b641945c-ad6d-4546-b35f-74bcbdd850e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_July2022RepurchaseProgramMember_fb247306-790e-4019-ab80-a8fa13d64c12" xlink:href="ensg-20231231.xsd#ensg_July2022RepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:to="loc_ensg_July2022RepurchaseProgramMember_fb247306-790e-4019-ab80-a8fa13d64c12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8d2777d0-4a4c-4432-b7ac-7c75954d4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8d2777d0-4a4c-4432-b7ac-7c75954d4f80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_0cfd8b57-fa71-45ec-b93f-4159dc1f07ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_0cfd8b57-fa71-45ec-b93f-4159dc1f07ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a573c4c8-3085-4a1e-a757-0e62702f977f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a573c4c8-3085-4a1e-a757-0e62702f977f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b9e24a92-b994-49c6-a79d-059db9313445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b9e24a92-b994-49c6-a79d-059db9313445" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StockAwardsMember_cf84bc92-25d5-4b2f-b37f-3604b32a2138" xlink:href="ensg-20231231.xsd#ensg_StockAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ensg_StockAwardsMember_cf84bc92-25d5-4b2f-b37f-3604b32a2138" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ChristopherRChristensenMember_1bb48e68-2a72-4881-a628-79af1f042062" xlink:href="ensg-20231231.xsd#ensg_ChristopherRChristensenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ensg_ChristopherRChristensenMember_1bb48e68-2a72-4881-a628-79af1f042062" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BeverlyBWittekindMember_b84f833d-b004-442e-9cd5-58e1c45f7f44" xlink:href="ensg-20231231.xsd#ensg_BeverlyBWittekindMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ensg_BeverlyBWittekindMember_b84f833d-b004-442e-9cd5-58e1c45f7f44" xlink:type="arc" order="3"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>ensg-20231231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:19b8c51b-a068-4377-9653-a6d716d75b12,g:d8e1560a-118b-412f-95df-e14f0751e57c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AllStatesExceptColoradoMember_b052783f-6d01-4a29-8d6b-1b905bf4181f_terseLabel_en-US" xlink:label="lab_ensg_AllStatesExceptColoradoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All States Except Colorado</link:label>
    <link:label id="lab_ensg_AllStatesExceptColoradoMember_label_en-US" xlink:label="lab_ensg_AllStatesExceptColoradoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All States Except Colorado [Member]</link:label>
    <link:label id="lab_ensg_AllStatesExceptColoradoMember_documentation_en-US" xlink:label="lab_ensg_AllStatesExceptColoradoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All States Except Colorado [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AllStatesExceptColoradoMember" xlink:href="ensg-20231231.xsd#ensg_AllStatesExceptColoradoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AllStatesExceptColoradoMember" xlink:to="lab_ensg_AllStatesExceptColoradoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_128543f6-2ac2-465e-a88c-ce21969c56b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Outstanding, Vested and Related Details</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e45a8486-a4a1-4399-a82d-75ae3e7f4c98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ThirdPartyTenantsMember_9461ed64-4b32-48d7-823a-5a291aa5ca85_terseLabel_en-US" xlink:label="lab_ensg_ThirdPartyTenantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other third-party</link:label>
    <link:label id="lab_ensg_ThirdPartyTenantsMember_label_en-US" xlink:label="lab_ensg_ThirdPartyTenantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party Tenants [Member]</link:label>
    <link:label id="lab_ensg_ThirdPartyTenantsMember_documentation_en-US" xlink:label="lab_ensg_ThirdPartyTenantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party Tenants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyTenantsMember" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyTenantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ThirdPartyTenantsMember" xlink:to="lab_ensg_ThirdPartyTenantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CashHeldInTrustForResidents_753cf4ac-2318-400a-94e1-e4af27d0ce88_terseLabel_en-US" xlink:label="lab_ensg_CashHeldInTrustForResidents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held in trust for patients</link:label>
    <link:label id="lab_ensg_CashHeldInTrustForResidents_label_en-US" xlink:label="lab_ensg_CashHeldInTrustForResidents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Held in Trust for Residents</link:label>
    <link:label id="lab_ensg_CashHeldInTrustForResidents_documentation_en-US" xlink:label="lab_ensg_CashHeldInTrustForResidents" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CashHeldInTrustForResidents" xlink:href="ensg-20231231.xsd#ensg_CashHeldInTrustForResidents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CashHeldInTrustForResidents" xlink:to="lab_ensg_CashHeldInTrustForResidents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ad186792-b8c4-4f45-bbd0-3cc6b98cd627_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_a202fde0-6d0f-4d41-a63e-9f0455161891_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in operating assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeFiveMember_f6d4a1f7-7cf3-44c4-a4e0-c3a9dcb584c2_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2017</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFiveMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeFiveMember" xlink:to="lab_ensg_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_467162e3-d56f-4d81-91d0-6eac894673ac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a119beb-54a2-4bc3-b07f-23e0ca7b642a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_800c1e34-2ba9-4e75-9e51-34538c6bc262_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_11c43c87-1324-446a-a0ec-58cd263f85b1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire businesses, gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_e60d4434-0eea-4ba2-a83d-09384135aa9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Purchase Price Allocation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_1272773d-c917-48b1-8027-ea28c1e191af_terseLabel_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees, as a percentage of funds from operations</link:label>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_label_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Management Fee, Percent Fee of Funds from Operations</link:label>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_documentation_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Management Fee, Percent Fee of Funds from Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfFundsFromOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:to="lab_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_HealthLiabilityInsuranceMember_6134bdf5-93f6-4734-b0c3-6de6d1a449ee_terseLabel_en-US" xlink:label="lab_ensg_HealthLiabilityInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Liability Insurance</link:label>
    <link:label id="lab_ensg_HealthLiabilityInsuranceMember_label_en-US" xlink:label="lab_ensg_HealthLiabilityInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Liability Insurance [Member]</link:label>
    <link:label id="lab_ensg_HealthLiabilityInsuranceMember_documentation_en-US" xlink:label="lab_ensg_HealthLiabilityInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Liability Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HealthLiabilityInsuranceMember" xlink:href="ensg-20231231.xsd#ensg_HealthLiabilityInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_HealthLiabilityInsuranceMember" xlink:to="lab_ensg_HealthLiabilityInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StandardBearerTextBlock_7d94d177-eee7-49f8-90ff-7bb07c369d7b_terseLabel_en-US" xlink:label="lab_ensg_StandardBearerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STANDARD BEARER</link:label>
    <link:label id="lab_ensg_StandardBearerTextBlock_label_en-US" xlink:label="lab_ensg_StandardBearerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer [Text Block]</link:label>
    <link:label id="lab_ensg_StandardBearerTextBlock_documentation_en-US" xlink:label="lab_ensg_StandardBearerTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerTextBlock" xlink:href="ensg-20231231.xsd#ensg_StandardBearerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StandardBearerTextBlock" xlink:to="lab_ensg_StandardBearerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_03d794d1-a3eb-490d-aebf-48edd6993130_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SkilledNursingOperationsMember_743436ad-151e-43e4-81bb-0dd0e00f081c_terseLabel_en-US" xlink:label="lab_ensg_SkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Nursing Operations</link:label>
    <link:label id="lab_ensg_SkilledNursingOperationsMember_label_en-US" xlink:label="lab_ensg_SkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Nursing Operations [Member]</link:label>
    <link:label id="lab_ensg_SkilledNursingOperationsMember_documentation_en-US" xlink:label="lab_ensg_SkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Nursing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SkilledNursingOperationsMember" xlink:to="lab_ensg_SkilledNursingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_4de5bd5d-1463-471a-9298-59a3228e84fd_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_7ee2ae80-9ce7-42e6-8a3a-82ae300d020a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_37c8b135-acea-4411-aaaf-5dc18dcb13a1_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMON STOCK REPURCHASE PROGRAM</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LeasesToThirdPartyOperatorsMember_9d7bb4fd-cdeb-4167-94c9-eb61d77277ef_terseLabel_en-US" xlink:label="lab_ensg_LeasesToThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases To Third Party Operators</link:label>
    <link:label id="lab_ensg_LeasesToThirdPartyOperatorsMember_label_en-US" xlink:label="lab_ensg_LeasesToThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases To Third Party Operators [Member]</link:label>
    <link:label id="lab_ensg_LeasesToThirdPartyOperatorsMember_documentation_en-US" xlink:label="lab_ensg_LeasesToThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases To Third Party Operators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LeasesToThirdPartyOperatorsMember" xlink:to="lab_ensg_LeasesToThirdPartyOperatorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_3cc7748a-6581-473e-acb5-9818faebe7db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Dividend Yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_fbb85d0b-9157-40de-a3cf-2a42a2e0552c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_99e127f1-d71e-4f91-b100-cf84aa891a9e_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_5b3991c2-c38b-4002-8569-4c20bbb37c2d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_6132e652-4097-4320-baa1-4c30361411b9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_1108d8a8-b8cd-4cf8-b5a1-688c37a6d1fc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, accumulated impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b48d4f55-f04a-4d35-8e5f-86f214fd1cca_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ChristopherRChristensenMember_label_en-US" xlink:label="lab_ensg_ChristopherRChristensenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christopher R. Christensen [Member]</link:label>
    <link:label id="lab_ensg_ChristopherRChristensenMember_documentation_en-US" xlink:label="lab_ensg_ChristopherRChristensenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Christopher R. Christensen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ChristopherRChristensenMember" xlink:href="ensg-20231231.xsd#ensg_ChristopherRChristensenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ChristopherRChristensenMember" xlink:to="lab_ensg_ChristopherRChristensenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_d5ed6aef-085c-4be9-810f-003eaa6ae258_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_540f9c21-ba94-4235-8770-297c6fc994db_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_dde0f541-ec41-43bd-a9df-fabed232a099_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net income per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RestrictedAndOtherAssetsNoncurrent_bd385742-b23e-4db1-a5f1-78ac9a8a7121_terseLabel_en-US" xlink:label="lab_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and other assets</link:label>
    <link:label id="lab_ensg_RestrictedAndOtherAssetsNoncurrent_d4dacb90-11bb-4fd3-bd08-1076a6490be9_totalLabel_en-US" xlink:label="lab_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRICTED AND OTHER ASSETS</link:label>
    <link:label id="lab_ensg_RestrictedAndOtherAssetsNoncurrent_label_en-US" xlink:label="lab_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Other Assets, Noncurrent</link:label>
    <link:label id="lab_ensg_RestrictedAndOtherAssetsNoncurrent_documentation_en-US" xlink:label="lab_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted And Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:href="ensg-20231231.xsd#ensg_RestrictedAndOtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:to="lab_ensg_RestrictedAndOtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestrictedAssets_2236d954-7343-4e0b-9654-c6c8b491b3c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestrictedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital improvement reserves with landlords and lenders</link:label>
    <link:label id="lab_us-gaap_OtherRestrictedAssets_label_en-US" xlink:label="lab_us-gaap_OtherRestrictedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restricted Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestrictedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestrictedAssets" xlink:to="lab_us-gaap_OtherRestrictedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_e53b0029-6bce-4c42-b4db-734764668b4a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable&#8212;less allowance for doubtful accounts of $9,348 and $7,802 at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_cdacbf1e-deb6-434f-9c06-ffe9f7dcb404_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCOUNTS RECEIVABLE, NET</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_f436f0e5-2679-4815-a27a-bda617dfa5eb_terseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AssembledOccupancyAcquiredMember_c7fc11b1-bec9-4ca5-9993-35b0c8275472_terseLabel_en-US" xlink:label="lab_ensg_AssembledOccupancyAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled occupancy</link:label>
    <link:label id="lab_ensg_AssembledOccupancyAcquiredMember_cd56e565-45ec-4898-bdb5-866240c7c0c0_verboseLabel_en-US" xlink:label="lab_ensg_AssembledOccupancyAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled occupancy</link:label>
    <link:label id="lab_ensg_AssembledOccupancyAcquiredMember_label_en-US" xlink:label="lab_ensg_AssembledOccupancyAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled Occupancy Acquired [Member]</link:label>
    <link:label id="lab_ensg_AssembledOccupancyAcquiredMember_documentation_en-US" xlink:label="lab_ensg_AssembledOccupancyAcquiredMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assembled occupancy acquired [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AssembledOccupancyAcquiredMember" xlink:to="lab_ensg_AssembledOccupancyAcquiredMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_67e34577-51bd-480a-a0d7-cfcfd90e0be4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b918b552-12d0-477c-9a0d-4597396b11ff_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_629e134c-0963-4603-b649-7a7662ae73c2_terseLabel_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of credit outstanding, pledged amount</link:label>
    <link:label id="lab_us-gaap_LettersOfCreditOutstandingAmount_label_en-US" xlink:label="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letters of Credit Outstanding, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LettersOfCreditOutstandingAmount" xlink:to="lab_us-gaap_LettersOfCreditOutstandingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_d42a3dfb-a253-4007-b5be-c1c65b25e336_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_cd0533c0-a46e-42a0-989a-c8d433fa9d1c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_c9398acb-a1e1-410b-ba5e-9278bee5c1f6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_5a696cec-5aaf-41dc-aa9b-e2c376f62c97_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_548835ab-2fd1-438a-9a75-025ad1607f5c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_f13c186f-bdc5-4ab2-af2c-54f2e7fbd6a3_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_0fc32c62-cb3b-43f6-8f19-abd336285cf7_totalLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e29a781d-359b-4536-ae73-2b481cc4c3f2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ensign Group, Inc. stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_42b88c1e-4217-4fc5-a2df-1aa75f893a31_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Asset Acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Asset Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceBaseMember_e344c051-f627-480e-be5e-7eec64eb88cc_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceBaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Management Fee</link:label>
    <link:label id="lab_us-gaap_ManagementServiceBaseMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceBaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service, Base [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceBaseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceBaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceBaseMember" xlink:to="lab_us-gaap_ManagementServiceBaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_fe52cd28-c2ff-4b7e-814c-009556e334f2_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_98a7d7cb-c9c7-4056-8e4f-523476fcefb1_terseLabel_en-US" xlink:label="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Of Stand Along Skilled Nursing Operations</link:label>
    <link:label id="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_label_en-US" xlink:label="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Of Stand Along Skilled Nursing Operations [Member]</link:label>
    <link:label id="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_documentation_en-US" xlink:label="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Of Stand Along Skilled Nursing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:href="ensg-20231231.xsd#ensg_SubleaseOfStandAlongSkilledNursingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:to="lab_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_333ea194-0a20-4e2c-a1db-d4f97194b95f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Vested Restricted Awards</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0f270e8e-9878-48ac-927f-0eb9d79699ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PrepaymentFeePeriodAxis_888fd123-00da-4c26-8d25-ae7f571b485f_terseLabel_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period [Axis]</link:label>
    <link:label id="lab_ensg_PrepaymentFeePeriodAxis_label_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period [Axis]</link:label>
    <link:label id="lab_ensg_PrepaymentFeePeriodAxis_documentation_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodAxis" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PrepaymentFeePeriodAxis" xlink:to="lab_ensg_PrepaymentFeePeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_ff7e517d-7f03-4e1b-b771-5ee21e250e7a_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL DEFERRED TAX ASSETS</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_a156680d-70ff-4d79-82c3-b54192aba3d2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2c91df8c-a3ba-4c95-b783-edf9553f84d5_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_71781339-250c-4bed-ba68-5c7560ec6c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_90233baf-890a-4c93-be39-6415a302768a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_26198c3b-b9f2-431d-b20c-f89c27433952_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_3c384f81-f042-4bb0-9b9c-daeca2affb87_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_4151acc3-2e8b-4c91-aca5-e6ae5504ef8c_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Service Revenue by Major Payor Source</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NoncontrollingInterestPolicyTextBlock_db01f393-7c9a-4c53-b746-ea44a0d20196_terseLabel_en-US" xlink:label="lab_ensg_NoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest</link:label>
    <link:label id="lab_ensg_NoncontrollingInterestPolicyTextBlock_label_en-US" xlink:label="lab_ensg_NoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Policy Text Block]</link:label>
    <link:label id="lab_ensg_NoncontrollingInterestPolicyTextBlock_documentation_en-US" xlink:label="lab_ensg_NoncontrollingInterestPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NoncontrollingInterestPolicyTextBlock" xlink:href="ensg-20231231.xsd#ensg_NoncontrollingInterestPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NoncontrollingInterestPolicyTextBlock" xlink:to="lab_ensg_NoncontrollingInterestPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_756e3473-5a9b-456c-bf99-54f8e6200356_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_373b2a69-96d0-4fb2-8eed-64e6e7556713_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2dfee6ed-6728-4056-9134-0b928c6e5025_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_4ad6d955-b0fd-4136-a5db-69e50166fb1d_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_17aa2f7b-dc3b-470d-b122-b00f0146ea40_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_dddce1eb-4234-4bed-8659-6d6f31de2c56_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ReductionInPrepaymentPenalty_03749c3a-d2e3-492a-98e1-0b39b051979c_terseLabel_en-US" xlink:label="lab_ensg_ReductionInPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in prepayment penalty</link:label>
    <link:label id="lab_ensg_ReductionInPrepaymentPenalty_label_en-US" xlink:label="lab_ensg_ReductionInPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction In Prepayment Penalty</link:label>
    <link:label id="lab_ensg_ReductionInPrepaymentPenalty_documentation_en-US" xlink:label="lab_ensg_ReductionInPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage that the prepayment penalty percentage is reduced during the fourth year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ReductionInPrepaymentPenalty" xlink:href="ensg-20231231.xsd#ensg_ReductionInPrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ReductionInPrepaymentPenalty" xlink:to="lab_ensg_ReductionInPrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_23453a67-fa28-43c7-a6e8-c585df84ba68_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeaseDescriptionTable_e9de5263-4177-498d-9b8f-26f8934f85c0_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LessorLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LessorLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable" xlink:to="lab_us-gaap_LessorLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SelfInsuranceRetentionPerClaimMember_d9acef39-ca1a-4eb1-90a0-071cb82c8374_terseLabel_en-US" xlink:label="lab_ensg_SelfInsuranceRetentionPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insurance Retention Per Claim</link:label>
    <link:label id="lab_ensg_SelfInsuranceRetentionPerClaimMember_label_en-US" xlink:label="lab_ensg_SelfInsuranceRetentionPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insurance Retention Per Claim [Member]</link:label>
    <link:label id="lab_ensg_SelfInsuranceRetentionPerClaimMember_documentation_en-US" xlink:label="lab_ensg_SelfInsuranceRetentionPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-insurance retention per claim [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SelfInsuranceRetentionPerClaimMember" xlink:href="ensg-20231231.xsd#ensg_SelfInsuranceRetentionPerClaimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SelfInsuranceRetentionPerClaimMember" xlink:to="lab_ensg_SelfInsuranceRetentionPerClaimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WhollyOwnedPropertiesMember_2f4bfdb0-c5cc-459b-8013-e75341f0d0a6_terseLabel_en-US" xlink:label="lab_us-gaap_WhollyOwnedPropertiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owned Properties</link:label>
    <link:label id="lab_us-gaap_WhollyOwnedPropertiesMember_label_en-US" xlink:label="lab_us-gaap_WhollyOwnedPropertiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholly Owned Properties [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WhollyOwnedPropertiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WhollyOwnedPropertiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WhollyOwnedPropertiesMember" xlink:to="lab_us-gaap_WhollyOwnedPropertiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c9009b75-a933-4454-a6f7-189a1ce6b684_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_6f066203-5f40-47ce-ae45-80f5cb457a4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock used to satisfy tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AfterYearTenMember_a3ce6de0-19a6-4b73-bc4d-8d5dd158b42f_terseLabel_en-US" xlink:label="lab_ensg_AfterYearTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Year Ten</link:label>
    <link:label id="lab_ensg_AfterYearTenMember_label_en-US" xlink:label="lab_ensg_AfterYearTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Year Ten [Member]</link:label>
    <link:label id="lab_ensg_AfterYearTenMember_documentation_en-US" xlink:label="lab_ensg_AfterYearTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After Year Ten</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AfterYearTenMember" xlink:href="ensg-20231231.xsd#ensg_AfterYearTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AfterYearTenMember" xlink:to="lab_ensg_AfterYearTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_710bd9ff-519a-4d70-89bf-1cca84f9a833_terseLabel_en-US" xlink:label="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales and General and Administrative Expense</link:label>
    <link:label id="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_label_en-US" xlink:label="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales and General and Administrative Expense [Member]</link:label>
    <link:label id="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_documentation_en-US" xlink:label="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Primary financial statement caption encompassing cost of services and general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:href="ensg-20231231.xsd#ensg_CostofSalesandGeneralandAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:to="lab_ensg_CostofSalesandGeneralandAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementFeeExpense_f43ca105-b685-4797-b75e-8b14ce2f2614_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees</link:label>
    <link:label id="lab_us-gaap_ManagementFeeExpense_label_en-US" xlink:label="lab_us-gaap_ManagementFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementFeeExpense" xlink:to="lab_us-gaap_ManagementFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_b25174f6-73ba-4b71-9e1d-3780e4b03ee5_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7de8afb9-1e21-4ca0-8ea2-70f7fe40c17a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_3842fe95-63eb-4bdb-b5af-312e5dbf14b0_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_b2896519-5227-4c5b-b9ba-8fa70f406a26_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_28990d04-2d89-4f02-8b26-2f04d500c3b9_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e98ec8ff-96e0-41e1-83be-57b5f5929991_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_bc54c680-c3cf-41de-927c-a020e039f1da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_6b333d0a-5f21-4872-9e8a-11e2b96b8f83_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb866e12-b869-4d02-b8eb-07d57fc9ef9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_50fd479c-cfc3-4cb0-b5aa-86b846c90e19_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1ec4df53-cb95-4fc7-af86-f4a7ff10b9d9_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_8a5f9c72-8686-49ad-acf4-7de8f1584314_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_8baba707-3b98-462a-bf72-f514056e9718_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f50c1070-6f36-4d97-b4ab-94493d940664_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for new and modified operating lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6a870535-0094-4cb2-a050-33064ab76328_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_f0e6169c-ed54-45d2-b89a-5890b46db1df_terseLabel_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of real estate properties leased with an option to purchase</link:label>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_label_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Real Estate Properties Leased with an Option to Purchase</link:label>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_documentation_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Real Estate Properties Leased with an Option to Purchase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:to="lab_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_27dfdd49-510c-490f-8911-b74d66c0a352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b628ae61-8c29-4249-b080-8f641122e7a4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities&#8212;current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_e05061d5-e77f-4fb7-89d1-afd7dbd0cfce_negatedLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_fcb9b3f8-e32d-4897-a4bb-90685d9e28fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restricted and Other Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_718c4a15-9ac2-487b-abfd-f21e1e8df0d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash surrender value of life insurance policy premiums</link:label>
    <link:label id="lab_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_label_en-US" xlink:label="lab_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Life Insurance, Corporate or Bank Owned, Change in Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue" xlink:to="lab_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4668486e-fc50-46d0-91bd-ac2e62953bd8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_ccc04b9b-cd84-41e6-a381-2e483cd36c4c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Letter of credit increase</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Increase (Decrease), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:to="lab_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_f65f1f0e-c8dc-479b-b894-cf2c703e4e17_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cf40d932-1656-4c18-b812-bf91d9fb669f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6393235f-6ee9-497c-beae-34b4c4221c66_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_244f5129-175b-4746-b999-6524bba620c9_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_label_en-US" xlink:label="lab_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:to="lab_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_eaf89e87-3567-4fe0-b754-a2cd23307e1f_terseLabel_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, threshold for EBITDA ratio increase election</link:label>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_label_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Threshold For EBITDA Ratio Increase Election</link:label>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_documentation_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Threshold For EBITDA Ratio Increase Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:to="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_d7c91b35-a2b8-4af2-baf2-b1a49034ea80_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_57677bbf-8ea8-4855-9c9c-de4a42151e98_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Revenue Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingRevenueReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_caa79cb4-b108-46e1-ad1b-990c49b5e87f_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_efae0f69-72d2-4f58-993b-a824ff3246f9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_6aae4114-048f-4310-8021-376efe020058_negatedTerseLabel_en-US" xlink:label="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred employer portion of social security taxes (Note 3)</link:label>
    <link:label id="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_label_en-US" xlink:label="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Due To Deferred Employer Taxes, CARES Act</link:label>
    <link:label id="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_documentation_en-US" xlink:label="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) Due To Deferred Employer Taxes, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:href="ensg-20231231.xsd#ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:to="lab_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableGross_452b96bf-3c84-49a2-8fa9-45d52c43b2f2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, gross</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableGross_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableGross" xlink:to="lab_us-gaap_AccountsReceivableGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RentalMember_c989f72f-8420-4ff0-a2a5-d3ab1c70d640_terseLabel_en-US" xlink:label="lab_ensg_RentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental revenue</link:label>
    <link:label id="lab_ensg_RentalMember_label_en-US" xlink:label="lab_ensg_RentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental [Member]</link:label>
    <link:label id="lab_ensg_RentalMember_documentation_en-US" xlink:label="lab_ensg_RentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RentalMember" xlink:to="lab_ensg_RentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_a7f0e1d9-d55b-48e5-8957-ae8c060e87ef_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resident advances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_fbfd3045-d698-4538-a83c-36faff1af7ad_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions for Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7204a88f-ed05-4e60-bb7f-799afb7e2993_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_551d301b-7e9e-463a-a6ce-b257f11bc02a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c2c1923e-0661-409b-b24c-2bd70b2445f1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_53302c04-a930-4b63-9f95-9be79cc1ebaf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e94374ed-881a-4446-ace2-a2c3ccde60bb_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_900d6324-5a72-4f47-ae75-0facc70d0e86_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Subsidiary Deposits and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_bb82f488-3a1b-4e76-a402-8e94f3055fdd_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL EXPENSES</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4deeaf1a-31f7-4b67-a39a-419ca1c2d591_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_VariousLandlordsMember_e78b6e45-3778-46f3-8226-0eaab8b8d4b1_terseLabel_en-US" xlink:label="lab_ensg_VariousLandlordsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Landlords</link:label>
    <link:label id="lab_ensg_VariousLandlordsMember_label_en-US" xlink:label="lab_ensg_VariousLandlordsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Landlords [Member]</link:label>
    <link:label id="lab_ensg_VariousLandlordsMember_documentation_en-US" xlink:label="lab_ensg_VariousLandlordsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Various Landlords[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_VariousLandlordsMember" xlink:href="ensg-20231231.xsd#ensg_VariousLandlordsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_VariousLandlordsMember" xlink:to="lab_ensg_VariousLandlordsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_369b4efb-4348-4a0e-bd37-3257715c284b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, nonvested awards, cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_847267f8-8194-4b8e-bfeb-c5a6e48d79a9_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_35d5288f-9170-4d6a-8f1c-cca82c88e350_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_cc62d896-a50b-452b-8436-29c8031b613f_netLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b93abb6f-9f5b-4c36-a1d8-b652ebda7ddc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_2c4ca3c8-7052-458a-8bb0-358c381c1f58_terseLabel_en-US" xlink:label="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, FMAP payments received</link:label>
    <link:label id="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_label_en-US" xlink:label="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized</link:label>
    <link:label id="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_documentation_en-US" xlink:label="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:href="ensg-20231231.xsd#ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:to="lab_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_95df266d-34c8-44fd-a5bf-374a9b175a24_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (Note 21)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_4050b254-e56f-4463-a714-eeb36ca9a3fc_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, value</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7d72cd0e-0ccc-4692-bb0a-42e87c4fcf9c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_93c6b2c6-4280-4e15-95a9-5d0adb1c8e72_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPTIONS AND AWARDS</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_88793a7f-644e-4c2c-ba88-da48fa7bf962_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c3d588ca-60bd-4e10-b77c-4a08d2f6960f_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeNineMember_218d608e-c4f4-407e-b7fe-d328940e5b2f_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeNineMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeNineMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeNineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Nine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeNineMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeNineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeNineMember" xlink:to="lab_ensg_ExercisePriceRangeNineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfFinancingLeases_4091b06c-8261-4363-86a7-4bc918557734_terseLabel_en-US" xlink:label="lab_ensg_NumberOfFinancingLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of financing lease</link:label>
    <link:label id="lab_ensg_NumberOfFinancingLeases_label_en-US" xlink:label="lab_ensg_NumberOfFinancingLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Financing Leases</link:label>
    <link:label id="lab_ensg_NumberOfFinancingLeases_documentation_en-US" xlink:label="lab_ensg_NumberOfFinancingLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Financing Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFinancingLeases" xlink:href="ensg-20231231.xsd#ensg_NumberOfFinancingLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfFinancingLeases" xlink:to="lab_ensg_NumberOfFinancingLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_3ad820b0-4c0a-416f-a473-9be9465f33d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_fe7dae76-e623-4455-bc74-7f9914785e4f_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_0548585c-fcf1-45be-a49c-83fe0c621ef0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_27abcf59-7b13-4ad3-9ed2-5f72acbce828_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_8de7f91b-7778-4ee9-bf06-7eda7018a4a6_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in long-term insurance losses recoverable</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_1972fc12-416d-4468-8d9e-06fc79a7ce59_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self-Insurance</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReservePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:to="lab_us-gaap_SelfInsuranceReservePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8a9f3420-718a-4f3b-94ca-2f51f23f3bd9_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstatePropertiesDomain_280c3ace-647c-4b19-9f0b-65457b74f9bd_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Domain]</link:label>
    <link:label id="lab_us-gaap_RealEstatePropertiesDomain_label_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstatePropertiesDomain" xlink:to="lab_us-gaap_RealEstatePropertiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_5c65ca57-7a3a-4bea-8eed-3b78624a66af_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_9dc25091-1146-4736-9135-1625b224607d_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_be49e386-8b28-4b53-af2f-07110a6e41f2_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_7af7201f-1a7c-4c60-994a-1fc1c8ecac49_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_1f8a5b47-ea1f-42bd-b79b-7e9af3da4bde_terseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_df1b9a91-036a-4edc-bf37-6b13a71db9d3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATION EXPANSIONS</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0ca578b2-6ba0-44d4-a98b-a0478cf2c61a_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other indefinite-lived intangibles</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_961d1d61-9dcc-4c26-95b6-f7755439f0e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4e3cb1a3-a026-4129-acf8-bdda0048c859_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_6b4e0f4b-ca14-457b-a063-13504cb28476_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_6b3e8860-1337-40d3-b326-6466766aed84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PaymentsToAcquirePropertyAndEquipment_78a7a6be-51c1-41d5-8b59-1c8885b6234c_negatedLabel_en-US" xlink:label="lab_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:label id="lab_ensg_PaymentsToAcquirePropertyAndEquipment_label_en-US" xlink:label="lab_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Property And Equipment</link:label>
    <link:label id="lab_ensg_PaymentsToAcquirePropertyAndEquipment_documentation_en-US" xlink:label="lab_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquirePropertyAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:to="lab_ensg_PaymentsToAcquirePropertyAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_a65f6c7a-dcec-4bdd-96d0-aa4d46d6ca7a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest distribution</link:label>
    <link:label id="lab_us-gaap_PaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_PaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToMinorityShareholders" xlink:to="lab_us-gaap_PaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_5bdb2255-0737-4221-b9cf-1364d5af3e57_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0a03dfbe-7d39-4f72-963f-94694617598d_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_8e0ffdd4-b160-48fa-af70-646d47ee0926_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_c8b4a02b-261a-4382-84b0-b89a3d18b05a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of an ancillary business</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:to="lab_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_3bc9d5d2-b5f6-4f54-8e94-8cd66ef099f8_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c8800b8a-22f0-4d93-883c-697cc73a08da_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_QualifiedPlanMember_cbe7e10a-7d09-4ffe-add4-cbe3299ab48b_terseLabel_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plan</link:label>
    <link:label id="lab_us-gaap_QualifiedPlanMember_label_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember" xlink:to="lab_us-gaap_QualifiedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_331d311a-403e-4e1c-b0a5-71b2e413ea97_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_ac45ffe6-ab5a-442e-b2d3-0c0f98c957eb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_cee2dbf6-daf4-492c-81dc-73f12af5b75b_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of operating lease</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LessorOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9b744f7e-91c7-4ea9-b02a-dfd7222de110_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_4edb0088-11e5-4a9b-ae49-b02306dca0e5_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cbe4f281-8826-48dd-afa7-8fc29e80ad39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StandardBearerMasterLeasesMember_4d39e415-be0e-4d0b-b494-2028f2071d74_terseLabel_en-US" xlink:label="lab_ensg_StandardBearerMasterLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Master Leases</link:label>
    <link:label id="lab_ensg_StandardBearerMasterLeasesMember_label_en-US" xlink:label="lab_ensg_StandardBearerMasterLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Master Leases [Member]</link:label>
    <link:label id="lab_ensg_StandardBearerMasterLeasesMember_documentation_en-US" xlink:label="lab_ensg_StandardBearerMasterLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Master Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerMasterLeasesMember" xlink:href="ensg-20231231.xsd#ensg_StandardBearerMasterLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StandardBearerMasterLeasesMember" xlink:to="lab_ensg_StandardBearerMasterLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LeaseOfCampusOperationMember_6de0a666-6f6a-41b9-b5bd-b35477226df0_terseLabel_en-US" xlink:label="lab_ensg_LeaseOfCampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Of Campus Operation</link:label>
    <link:label id="lab_ensg_LeaseOfCampusOperationMember_label_en-US" xlink:label="lab_ensg_LeaseOfCampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Of Campus Operation [Member]</link:label>
    <link:label id="lab_ensg_LeaseOfCampusOperationMember_documentation_en-US" xlink:label="lab_ensg_LeaseOfCampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Of Campus Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseOfCampusOperationMember" xlink:href="ensg-20231231.xsd#ensg_LeaseOfCampusOperationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LeaseOfCampusOperationMember" xlink:to="lab_ensg_LeaseOfCampusOperationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9d48e8d0-26bb-49df-9e7c-87dc3539ba30_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_06ebca85-f17c-49aa-a32a-bfcf2c919e24_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue Recognition, Rental Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_ad6fe393-7343-4bd3-a283-0449920850e2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TotalNetDebtRatioMinimum_6dc58dca-9dff-424e-8208-b4e799b96b55_terseLabel_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net debt ratio, minimum</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMinimum_label_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Minimum</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMinimum_documentation_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMinimum" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TotalNetDebtRatioMinimum" xlink:to="lab_ensg_TotalNetDebtRatioMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecurityDeposit_2ed31943-0670-4dad-92d7-4ddc4f3fb6e5_terseLabel_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits with landlords</link:label>
    <link:label id="lab_us-gaap_SecurityDeposit_label_en-US" xlink:label="lab_us-gaap_SecurityDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecurityDeposit" xlink:to="lab_us-gaap_SecurityDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_cc94bf2a-ba10-4f99-9b6c-95f1588109ec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_a78329cd-b114-4c8e-b601-334350565718_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_d98f7958-7946-47e3-864c-4345ffc5b991_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsStateTaxes_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, State Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsStateTaxes" xlink:to="lab_us-gaap_DeferredTaxAssetsStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_12efc5b7-d56b-40ba-b0b4-c5e5aa8d1987_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_75fb901f-8cde-4d49-b389-e2e5afbf732c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ff0544ff-7b87-4642-99a7-7c84bd310083_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d3d258c3-8f60-46d2-8a0f-93283101df13_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_ece9b8ff-1a80-4154-a77e-30ff60243ab0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_HUDInsuredMortgagesMember_48ed3940-3cec-46d7-8670-88ad389a2a20_terseLabel_en-US" xlink:label="lab_ensg_HUDInsuredMortgagesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HUD Insured Mortgages</link:label>
    <link:label id="lab_ensg_HUDInsuredMortgagesMember_label_en-US" xlink:label="lab_ensg_HUDInsuredMortgagesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HUD Insured Mortgages [Member]</link:label>
    <link:label id="lab_ensg_HUDInsuredMortgagesMember_documentation_en-US" xlink:label="lab_ensg_HUDInsuredMortgagesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HUD Insured Mortgages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HUDInsuredMortgagesMember" xlink:href="ensg-20231231.xsd#ensg_HUDInsuredMortgagesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_HUDInsuredMortgagesMember" xlink:to="lab_ensg_HUDInsuredMortgagesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Dividends_0d07e17e-ffc1-47b5-95c2-628c26b1df3e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared</link:label>
    <link:label id="lab_us-gaap_Dividends_label_en-US" xlink:label="lab_us-gaap_Dividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NewMasterLeaseAgreeementMember_aac14903-80b4-47a6-82fe-c40e70bba359_terseLabel_en-US" xlink:label="lab_ensg_NewMasterLeaseAgreeementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Master Lease Agreeement</link:label>
    <link:label id="lab_ensg_NewMasterLeaseAgreeementMember_label_en-US" xlink:label="lab_ensg_NewMasterLeaseAgreeementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Master Lease Agreeement [Member]</link:label>
    <link:label id="lab_ensg_NewMasterLeaseAgreeementMember_documentation_en-US" xlink:label="lab_ensg_NewMasterLeaseAgreeementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Master Lease Agreeement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NewMasterLeaseAgreeementMember" xlink:href="ensg-20231231.xsd#ensg_NewMasterLeaseAgreeementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NewMasterLeaseAgreeementMember" xlink:to="lab_ensg_NewMasterLeaseAgreeementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_42639e7f-1370-4a34-a17a-2d1daac056ef_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued self-insurance liabilities&#8212;current</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveCurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveCurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_2a8c16e6-b347-4dcb-b2ae-a866accafc32_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Annual Rental Income</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_7ec6d1c9-9c62-4887-ad3e-87f755302355_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralLiabilityMember_e3bdc4de-81b2-4f8f-8a50-c1b6593e398b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Liability</link:label>
    <link:label id="lab_us-gaap_GeneralLiabilityMember_label_en-US" xlink:label="lab_us-gaap_GeneralLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralLiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralLiabilityMember" xlink:to="lab_us-gaap_GeneralLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_fc961696-4e99-4ce0-87b3-718b0c02a6e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Employee Stock Option Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Common Stock Outstanding Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_646bbea1-4d2b-4291-89b5-668edf28df97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_0064c6cd-d9ad-4a49-8950-ba898f444c45_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_148da449-352c-45ea-a760-319851f55203_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued litigation (Note 20)</link:label>
    <link:label id="lab_us-gaap_LitigationReserveCurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveCurrent" xlink:to="lab_us-gaap_LitigationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfLeases_aeab3730-a0e2-4834-a638-8e3816be6495_terseLabel_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stand-alone leases</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfLeases_label_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfLeases_documentation_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:to="lab_ensg_LesseeOperatingLeaseNumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b5c23b1c-e9cd-4d3a-bc9f-526c4bb41dee_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED IN INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_b1143ba4-0843-400a-b132-e0ee0e23bf47_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SegmentIncomeLoss_d40d3290-77cb-4adc-aa17-6815672e21c9_terseLabel_en-US" xlink:label="lab_ensg_SegmentIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment income (loss)</link:label>
    <link:label id="lab_ensg_SegmentIncomeLoss_label_en-US" xlink:label="lab_ensg_SegmentIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Income (Loss)</link:label>
    <link:label id="lab_ensg_SegmentIncomeLoss_documentation_en-US" xlink:label="lab_ensg_SegmentIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SegmentIncomeLoss" xlink:href="ensg-20231231.xsd#ensg_SegmentIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SegmentIncomeLoss" xlink:to="lab_ensg_SegmentIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DeferredRentAndOtherLongTermLiabilities_3deee7dd-9f0d-4537-9ad7-c87708428fb3_verboseLabel_en-US" xlink:label="lab_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_ensg_DeferredRentAndOtherLongTermLiabilities_label_en-US" xlink:label="lab_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent and other long-term liabilities</link:label>
    <link:label id="lab_ensg_DeferredRentAndOtherLongTermLiabilities_documentation_en-US" xlink:label="lab_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental expense in excess of actual rental payments and other long-term liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAndOtherLongTermLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:to="lab_ensg_DeferredRentAndOtherLongTermLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_b1a5f2b4-0ab9-4302-803c-1ef31a21f2eb_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_153f40be-dd75-4e6e-a74b-8a77ae9d0e52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9e0f994d-75b1-4a5f-adec-7816a1c58cb8_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_59602391-500e-450b-934a-7d498630a20b_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e5d2c9d8-e644-4ee3-b1f1-178288a987a8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_63f80ff1-81e8-4a86-930e-087583b1f296_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT&#8212; NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_8a84a387-f363-4a34-bd43-ee6c16b5a54c_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_c9f8b0b7-64ca-4882-9b40-f48d97f3c2aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_3279cc22-bd50-4651-953d-8b7c114c941e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_ca724603-d754-4c65-ac1e-92e55bc326c7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_58f800ca-a4b2-43ff-8e3c-feb89dfa9371_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_781143dd-f442-40a6-8eb6-83f3a4ed1020_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1f1d0e64-0d80-4817-a0b0-9d45a6eaeb63_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_e99460b6-ab4c-422a-8332-fd3a24655d8c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_3960ace5-ad6b-4b01-af88-4a863bfef856_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_f93a6f24-a24e-4fc8-89b4-a5d7fe62305a_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">% of Revenue</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_a465994e-8281-409b-b494-77975498e64f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue %</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_425f4412-54ca-4121-bdb3-9a17702dd821_netLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_02c132e0-be0e-417b-ae40-3c228d6eb4f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash from insurance proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_e1e1b8ea-7763-407e-a714-81c0a7294c7b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes&#160;- net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember_25fd6685-9afa-4368-be51-30e057f2d823_terseLabel_en-US" xlink:label="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases Of Previous Operations</link:label>
    <link:label id="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember_label_en-US" xlink:label="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases Of Previous Operations [Member]</link:label>
    <link:label id="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember_documentation_en-US" xlink:label="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases Of Previous Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesOfPreviousOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:to="lab_ensg_RealEstatePurchasesOfPreviousOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_74d694d3-2eb9-45b3-b389-75b148125a54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_483ea3e7-e7be-44ab-812f-8fbbf722b76e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeFourMember_5b59f9c0-c959-4fde-85e3-e882cfa29906_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFourMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeFourMember" xlink:to="lab_ensg_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_b986bd27-93e4-4b86-a587-281a0d546835_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_71fd1991-8d8d-41fc-a7a8-6d23ecb8e6d7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH PROVIDED BY OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_4d0f9ce1-5d27-414f-a443-ba4309a5188e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_7db6318f-4b72-45c2-a3ca-c11c147d372a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfHealthCareFacilities_ac56b65e-3af0-4f51-ae74-f9abce58f88e_terseLabel_en-US" xlink:label="lab_ensg_NumberOfHealthCareFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health care facilities</link:label>
    <link:label id="lab_ensg_NumberOfHealthCareFacilities_label_en-US" xlink:label="lab_ensg_NumberOfHealthCareFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Health Care Facilities</link:label>
    <link:label id="lab_ensg_NumberOfHealthCareFacilities_documentation_en-US" xlink:label="lab_ensg_NumberOfHealthCareFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Health Care Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfHealthCareFacilities" xlink:href="ensg-20231231.xsd#ensg_NumberOfHealthCareFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfHealthCareFacilities" xlink:to="lab_ensg_NumberOfHealthCareFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeAxis_8b77f91e-75ba-4c8f-93a3-1d17d386b9f2_terseLabel_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Axis]</link:label>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeAxis_label_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Axis]</link:label>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeAxis_documentation_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeAxis" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_InsuranceCoverageLimitTypeAxis" xlink:to="lab_ensg_InsuranceCoverageLimitTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_19ebb7e9-f7f8-4f1d-b0aa-32f874252bc8_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_22708be6-eaba-41fa-8fea-0fc7dd4da38a_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_bb013705-e5a4-4d67-93f8-f5ecd1c31722_netLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_81429c93-fa99-49e3-bea3-5fef8e0d6064_verboseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment, furniture, and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_7ac10b39-7d0d-4a6b-904c-d8871182f0e4_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PrepaymentPenalty_1c8191b3-6f93-4e5b-bacb-f0e20e9c9490_terseLabel_en-US" xlink:label="lab_ensg_PrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment penalty</link:label>
    <link:label id="lab_ensg_PrepaymentPenalty_label_en-US" xlink:label="lab_ensg_PrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Penalty</link:label>
    <link:label id="lab_ensg_PrepaymentPenalty_documentation_en-US" xlink:label="lab_ensg_PrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage that the prepayment penalty percentage is reduced during the first three years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentPenalty" xlink:href="ensg-20231231.xsd#ensg_PrepaymentPenalty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PrepaymentPenalty" xlink:to="lab_ensg_PrepaymentPenalty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_f03e8360-ea14-4b25-b475-6056bb66185e_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAndCash_aa0162a7-eccd-44a8-ad42-6fac8aa2a048_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance subsidiary's deposits and investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsAndCash_label_en-US" xlink:label="lab_us-gaap_InvestmentsAndCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAndCash" xlink:to="lab_us-gaap_InvestmentsAndCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_43ac148f-3d4e-41f4-a1c9-71dabf8dc3c3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_48cb11df-b7db-45ae-bd25-a6475351218a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e4cc2d8f-0985-4de2-ba83-111dfbb85477_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_e19c81c3-09d6-4b89-b207-0992b18232fe_terseLabel_en-US" xlink:label="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of medicare accelerated and advance payment program</link:label>
    <link:label id="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_label_en-US" xlink:label="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act</link:label>
    <link:label id="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_documentation_en-US" xlink:label="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:href="ensg-20231231.xsd#ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:to="lab_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfPropertiesAcquired_72782009-7fdf-4c74-9a36-04be9129e92a_terseLabel_en-US" xlink:label="lab_ensg_NumberOfPropertiesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of real estate skilled nursing properties acquired</link:label>
    <link:label id="lab_ensg_NumberOfPropertiesAcquired_label_en-US" xlink:label="lab_ensg_NumberOfPropertiesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Properties Acquired</link:label>
    <link:label id="lab_ensg_NumberOfPropertiesAcquired_documentation_en-US" xlink:label="lab_ensg_NumberOfPropertiesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Properties Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfPropertiesAcquired" xlink:href="ensg-20231231.xsd#ensg_NumberOfPropertiesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfPropertiesAcquired" xlink:to="lab_ensg_NumberOfPropertiesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties_336351f1-de0c-4360-822c-eeea9fccfe28_terseLabel_en-US" xlink:label="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operations transferred from third parties</link:label>
    <link:label id="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties_label_en-US" xlink:label="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Living Operations Transferred From Third-Parties</link:label>
    <link:label id="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties_documentation_en-US" xlink:label="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Living Operations Transferred From Third-Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:href="ensg-20231231.xsd#ensg_NumberOfLivingOperationsTransferredFromThirdParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:to="lab_ensg_NumberOfLivingOperationsTransferredFromThirdParties" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicaidMember_dfb5fcfd-270d-4997-a5a0-595751a9c42d_terseLabel_en-US" xlink:label="lab_ensg_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_ensg_MedicaidMember_label_en-US" xlink:label="lab_ensg_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_ensg_MedicaidMember_documentation_en-US" xlink:label="lab_ensg_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Medicaid for custodial services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicaidMember" xlink:to="lab_ensg_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_11354604-66dc-4733-92f8-64ac79cb1640_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_8a079f32-ee10-4d47-a8a0-13a3c1d06be7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRICTED AND OTHER ASSETS</link:label>
    <link:label id="lab_us-gaap_OtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_OtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_4666dad0-a01a-4684-be24-b8108340fa1a_terseLabel_en-US" xlink:label="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, nonvested awards (in shares)</link:label>
    <link:label id="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_label_en-US" xlink:label="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards</link:label>
    <link:label id="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_documentation_en-US" xlink:label="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:href="ensg-20231231.xsd#ensg_EmployeeServiceShareBasedCompensationNonvestedAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:to="lab_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_e86d0440-0ca6-4ee3-92f9-75479e9ca9d1_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_7bdf2b63-4e68-47f3-b8ac-d9a5322928ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_8c82fc5a-9ad8-46b7-9e53-ef8ddafddf2a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_57208718-165b-4610-ad67-1367fce093a2_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_122bb5f0-5f5a-461b-b76d-cb8c5ee4d25f_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_eeb4c0b5-6e4e-4d02-90a2-ba31e5179cac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Rental Income from Third-Party Sources</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2435246a-1b20-4523-83e6-437b7ae2dc21_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfAssetAcquisitions_d8a5c69b-44cb-4c59-8b8e-37b27477be28_terseLabel_en-US" xlink:label="lab_ensg_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of asset acquisitions</link:label>
    <link:label id="lab_ensg_NumberOfAssetAcquisitions_label_en-US" xlink:label="lab_ensg_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Asset Acquisitions</link:label>
    <link:label id="lab_ensg_NumberOfAssetAcquisitions_documentation_en-US" xlink:label="lab_ensg_NumberOfAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfAssetAcquisitions" xlink:href="ensg-20231231.xsd#ensg_NumberOfAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfAssetAcquisitions" xlink:to="lab_ensg_NumberOfAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NonCaliforniaMember_a767a6bd-c158-4f32-ad8e-bb1f4d46a94e_terseLabel_en-US" xlink:label="lab_ensg_NonCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-california</link:label>
    <link:label id="lab_ensg_NonCaliforniaMember_label_en-US" xlink:label="lab_ensg_NonCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-California [Member]</link:label>
    <link:label id="lab_ensg_NonCaliforniaMember_documentation_en-US" xlink:label="lab_ensg_NonCaliforniaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-California [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCaliforniaMember" xlink:href="ensg-20231231.xsd#ensg_NonCaliforniaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NonCaliforniaMember" xlink:to="lab_ensg_NonCaliforniaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximum_89deaaba-fe93-4f9b-bd55-165c34aeba10_terseLabel_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net debt ratio, maximum</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximum_label_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Maximum</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximum_documentation_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximum" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TotalNetDebtRatioMaximum" xlink:to="lab_ensg_TotalNetDebtRatioMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_8852776d-8cc9-443f-ad5a-6d0249f62f20_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black-Scholes Fair Value</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:to="lab_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_384fa20e-9185-4da4-94df-8059113a66ad_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_930e106e-ee1e-42e8-b8a0-21fa3d30dd4f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of preferred shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_732d09f3-de94-4dc3-a973-0c311e6bdf2e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_602777a5-c5a3-4ac1-8d16-cb146c60ef1e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_7180c88b-8add-4aea-a13e-1bce8ebd11f2_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SELF INSURANCE LIABILITIES</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a8c339d3-2cdf-4d5f-b541-d388f7d59f26_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_ced64957-cf6d-47f1-b214-7e244430ff6e_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a46c78b1-0509-4877-89bb-d01e12afd185_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_f822ad65-6c8e-4add-8ab0-4e3d32cf4158_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest attributable to subsidiary equity plan</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MasterLeaseAgreements_d0d39e07-9b6c-48b5-809b-146bf775e69b_terseLabel_en-US" xlink:label="lab_ensg_MasterLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master lease agreements</link:label>
    <link:label id="lab_ensg_MasterLeaseAgreements_label_en-US" xlink:label="lab_ensg_MasterLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Lease Agreements</link:label>
    <link:label id="lab_ensg_MasterLeaseAgreements_documentation_en-US" xlink:label="lab_ensg_MasterLeaseAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Master Lease agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MasterLeaseAgreements" xlink:href="ensg-20231231.xsd#ensg_MasterLeaseAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MasterLeaseAgreements" xlink:to="lab_ensg_MasterLeaseAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4ad49a13-732e-4591-afbe-db8dbd2d66be_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a37ac8a0-33f6-4985-a939-9d80a4233b7f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_56645971-c2db-4e2e-a863-fc5aaf997062_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DENOMINATOR:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3b82eea7-b029-4f85-8144-b63aeb174aac_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_c6823607-9330-478b-a219-44706b0be9c7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROPERTY AND EQUIPMENT, NET</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeThreeMember_419ad076-fda3-4a29-b0a0-17bba458eee0_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2015</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeThreeMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeThreeMember" xlink:to="lab_ensg_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LeaseArrangementDomain_926893f9-42a4-48b5-b046-7bded6f743b0_terseLabel_en-US" xlink:label="lab_ensg_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_ensg_LeaseArrangementDomain_label_en-US" xlink:label="lab_ensg_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Domain]</link:label>
    <link:label id="lab_ensg_LeaseArrangementDomain_documentation_en-US" xlink:label="lab_ensg_LeaseArrangementDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LeaseArrangementDomain" xlink:to="lab_ensg_LeaseArrangementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_b25dda78-86a6-4b0d-a02a-ed0abef8ac97_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term insurance losses recoverable asset</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_a9b2be40-eddf-42e6-9dd0-ca6d01aede5e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposits</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Deposits on Real Estate Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" xlink:to="lab_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_67e8e156-b9ae-4473-987b-f4338b1014b3_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of real estate properties</link:label>
    <link:label id="lab_us-gaap_NumberOfRealEstateProperties_label_en-US" xlink:label="lab_us-gaap_NumberOfRealEstateProperties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Real Estate Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfRealEstateProperties" xlink:to="lab_us-gaap_NumberOfRealEstateProperties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_3707ece6-b60a-4629-bb1f-fff2cb3ed198_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_147e75c3-9d91-4394-81ab-52b4e78e67a3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d58ffea7-95cc-431c-be16-4d38bf84c141_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_de0239e7-0cea-4d6b-bf90-c31af42fc758_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt (Note 15)</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_7fc314b8-85f5-4048-a96f-a0c01f0e69f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease obligations</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_fdc8f7e9-82bb-4c57-8bc3-53de398ae7d3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares of common stock to satisfy tax withholding obligations</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfessionalMalpracticeLiabilityMember_91e0176f-5f6b-4b4b-894a-e85c0dccb47f_terseLabel_en-US" xlink:label="lab_us-gaap_ProfessionalMalpracticeLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Professional Liability</link:label>
    <link:label id="lab_us-gaap_ProfessionalMalpracticeLiabilityMember_label_en-US" xlink:label="lab_us-gaap_ProfessionalMalpracticeLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional Malpractice Liability Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalMalpracticeLiabilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalMalpracticeLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfessionalMalpracticeLiabilityMember" xlink:to="lab_us-gaap_ProfessionalMalpracticeLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f5846b8d-a6a4-4a29-bea7-38731367123f_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET CASH USED IN FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_3c4f56e6-19fc-4442-a0fb-fa8beffc1b6c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_37e51861-bfa1-4fc2-8ffc-b5557656459b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c8b1092d-3248-432f-8c19-45871221cc15_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_ed64a257-7942-4e5b-aa15-54bbcef23065_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restricted assets</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_aacf381a-ab63-40e4-ab81-478945b4f31b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_e0358c41-af00-4851-901a-a8646c229ed9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_78b74329-92e6-47bd-b025-5a61706b63e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current maturities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8d055459-546c-4def-b888-f29d5273470e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4a37b5f7-9f27-4c7b-baa6-92f08532e36b_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net income per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_9715c1fe-494e-4a34-99d2-0008d8bbb467_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_bdced5f9-91b9-45b0-b2f2-faf11c88432a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_7035cbaf-50c5-4e4c-afa4-6210a733c893_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_b31e243b-092a-49f7-848a-de41270ed854_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_abc1b278-1284-4590-a91d-5e46e4ce0b0d_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET DEFERRED TAX ASSETS</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_234b2383-7320-473b-b191-8590847b546b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised in period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OperationalSeniorLivingUnits_06c68479-e08f-46a6-ac78-6f94e4ba1119_terseLabel_en-US" xlink:label="lab_ensg_OperationalSeniorLivingUnits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational senior living units</link:label>
    <link:label id="lab_ensg_OperationalSeniorLivingUnits_label_en-US" xlink:label="lab_ensg_OperationalSeniorLivingUnits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational Senior Living Units</link:label>
    <link:label id="lab_ensg_OperationalSeniorLivingUnits_documentation_en-US" xlink:label="lab_ensg_OperationalSeniorLivingUnits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational Assisted Living and Independent Living Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSeniorLivingUnits" xlink:href="ensg-20231231.xsd#ensg_OperationalSeniorLivingUnits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OperationalSeniorLivingUnits" xlink:to="lab_ensg_OperationalSeniorLivingUnits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_bfb70042-15d9-496c-b033-a3652716aeac_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining Contractual Life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9382ee2d-6101-4d75-84e2-fbb5f8a3dcf0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicaidSkilledMember_012f0378-cef4-4c1e-99ae-0f14b6cf0f55_terseLabel_en-US" xlink:label="lab_ensg_MedicaidSkilledMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid &#8212; skilled</link:label>
    <link:label id="lab_ensg_MedicaidSkilledMember_6293a594-26f8-4938-b295-e91728f189e2_verboseLabel_en-US" xlink:label="lab_ensg_MedicaidSkilledMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid-skilled</link:label>
    <link:label id="lab_ensg_MedicaidSkilledMember_label_en-US" xlink:label="lab_ensg_MedicaidSkilledMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid-skilled [Member]</link:label>
    <link:label id="lab_ensg_MedicaidSkilledMember_documentation_en-US" xlink:label="lab_ensg_MedicaidSkilledMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Medicaid for skilled services [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidSkilledMember" xlink:href="ensg-20231231.xsd#ensg_MedicaidSkilledMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicaidSkilledMember" xlink:to="lab_ensg_MedicaidSkilledMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PurchaseOptionMember_e285a260-5bec-4d64-807c-8f99f2940297_terseLabel_en-US" xlink:label="lab_ensg_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option</link:label>
    <link:label id="lab_ensg_PurchaseOptionMember_label_en-US" xlink:label="lab_ensg_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option [Member]</link:label>
    <link:label id="lab_ensg_PurchaseOptionMember_documentation_en-US" xlink:label="lab_ensg_PurchaseOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchaseOptionMember" xlink:href="ensg-20231231.xsd#ensg_PurchaseOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PurchaseOptionMember" xlink:to="lab_ensg_PurchaseOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_b1b293b1-a632-4561-9825-45691a5b5706_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_ac90d740-ac63-45ed-8cd2-3432339a5e3f_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain" xlink:to="lab_us-gaap_RetirementPlanTaxStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_eb17a223-d468-45c7-a5e5-94b526e0ae28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_34eaf24a-fc23-44bc-8750-ae1e9d9384fa_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion to reduce shares availability</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_July2022RepurchaseProgramMember_1afd963a-af2d-455b-a454-3624b06ef98b_terseLabel_en-US" xlink:label="lab_ensg_July2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2022 Repurchase Program</link:label>
    <link:label id="lab_ensg_July2022RepurchaseProgramMember_label_en-US" xlink:label="lab_ensg_July2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2022 Repurchase Program [Member]</link:label>
    <link:label id="lab_ensg_July2022RepurchaseProgramMember_documentation_en-US" xlink:label="lab_ensg_July2022RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">July 2022 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_July2022RepurchaseProgramMember" xlink:href="ensg-20231231.xsd#ensg_July2022RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_July2022RepurchaseProgramMember" xlink:to="lab_ensg_July2022RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_318de70e-ae3e-468b-887d-d51d3e32a5b2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_f35d1728-5072-43ce-ab77-22327d1b662f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year provisions</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_7697cc29-a372-43aa-b326-e7a188ca6b12_terseLabel_en-US" xlink:label="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of subsidiary shares (Note 6)</link:label>
    <link:label id="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_label_en-US" xlink:label="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans</link:label>
    <link:label id="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_documentation_en-US" xlink:label="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:to="lab_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_19bf9d56-605a-42eb-856c-b1cc4111897f_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_2cf968f4-f325-4ecb-bb83-5c07dcfebc15_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash financing and investing activity</link:label>
    <link:label id="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_921ad02a-9bcf-4a1d-b864-2affc0371ca9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfLeaseArrangements_94ef2b2b-1fd4-460f-94b1-6c1cdcda0fec_terseLabel_en-US" xlink:label="lab_ensg_NumberOfLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of master lease arrangements</link:label>
    <link:label id="lab_ensg_NumberOfLeaseArrangements_label_en-US" xlink:label="lab_ensg_NumberOfLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Lease Arrangements</link:label>
    <link:label id="lab_ensg_NumberOfLeaseArrangements_documentation_en-US" xlink:label="lab_ensg_NumberOfLeaseArrangements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLeaseArrangements" xlink:href="ensg-20231231.xsd#ensg_NumberOfLeaseArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfLeaseArrangements" xlink:to="lab_ensg_NumberOfLeaseArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_30fb8000-c3cd-4c30-983b-a347449f5ff4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans and promissory note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_efd418c6-5cf7-4d1c-9592-04ab2f8123a0_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeTwoMember_d7239240-1230-4c1a-9f83-b095a64fc010_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTwoMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeTwoMember" xlink:to="lab_ensg_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeased_ec717bc6-bccf-457e-a189-afacc70f2c5c_terseLabel_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of real estate properties leased</link:label>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeased_label_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Real Estate Properties Leased</link:label>
    <link:label id="lab_ensg_NumberOfRealEstatePropertiesLeased_documentation_en-US" xlink:label="lab_ensg_NumberOfRealEstatePropertiesLeased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Real Estate Properties Leased</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeased" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfRealEstatePropertiesLeased" xlink:to="lab_ensg_NumberOfRealEstatePropertiesLeased" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TruistBankMember_3a6e8dc9-78e6-4221-8691-29616e88fd3f_terseLabel_en-US" xlink:label="lab_ensg_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truist</link:label>
    <link:label id="lab_ensg_TruistBankMember_label_en-US" xlink:label="lab_ensg_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truist Bank [Member]</link:label>
    <link:label id="lab_ensg_TruistBankMember_documentation_en-US" xlink:label="lab_ensg_TruistBankMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Truist Bank [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TruistBankMember" xlink:href="ensg-20231231.xsd#ensg_TruistBankMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TruistBankMember" xlink:to="lab_ensg_TruistBankMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_141e614c-d8c5-450d-b51b-fc3d31239c1a_terseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_e9688767-4c73-49d5-bbb6-8396ef619551_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_bd37a515-2f18-4571-8d34-0b227c02b267_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationEliminationsMember_eace5831-e270-43ad-afd2-32c6b4b54652_terseLabel_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intercompany Elimination</link:label>
    <link:label id="lab_srt_ConsolidationEliminationsMember_label_en-US" xlink:label="lab_srt_ConsolidationEliminationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Eliminations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationEliminationsMember" xlink:to="lab_srt_ConsolidationEliminationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8dd80930-4693-455f-8a31-d35bbac13c12_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_54fe10e6-bdb3-49d2-8c37-d67e1c0b4aaa_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OperatingEntityDomain_47b62394-21ad-444c-9388-9b12dbcc7d51_terseLabel_en-US" xlink:label="lab_ensg_OperatingEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Entity [Domain]</link:label>
    <link:label id="lab_ensg_OperatingEntityDomain_label_en-US" xlink:label="lab_ensg_OperatingEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Entity [Domain]</link:label>
    <link:label id="lab_ensg_OperatingEntityDomain_documentation_en-US" xlink:label="lab_ensg_OperatingEntityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Operating Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OperatingEntityDomain" xlink:to="lab_ensg_OperatingEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_0ff28f3e-4833-474a-bf79-25a719a391f9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WorkersCompensationInsuranceMember_a058d74c-3463-4784-b54b-55346eb8fd2f_terseLabel_en-US" xlink:label="lab_us-gaap_WorkersCompensationInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation</link:label>
    <link:label id="lab_us-gaap_WorkersCompensationInsuranceMember_label_en-US" xlink:label="lab_us-gaap_WorkersCompensationInsuranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workers' Compensation Insurance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationInsuranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationInsuranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WorkersCompensationInsuranceMember" xlink:to="lab_us-gaap_WorkersCompensationInsuranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_758a2c34-35cf-4b37-baef-615a8ba74a1f_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Restatement Recovery Analysis [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeDomain_1e44b1b9-c5bb-4531-9570-18e7cc56798e_terseLabel_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Domain]</link:label>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeDomain_label_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Domain]</link:label>
    <link:label id="lab_ensg_InsuranceCoverageLimitTypeDomain_documentation_en-US" xlink:label="lab_ensg_InsuranceCoverageLimitTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Coverage Limit Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeDomain" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain" xlink:to="lab_ensg_InsuranceCoverageLimitTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_bf5383a1-2683-48c9-9a23-ec32166fab11_terseLabel_en-US" xlink:label="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt&#8212;less current maturities</link:label>
    <link:label id="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_label_en-US" xlink:label="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, net of Current Maturities and Debt Discount</link:label>
    <link:label id="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_documentation_en-US" xlink:label="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, net of Current Maturities and Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:to="lab_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PayorDomain_617d3eec-788b-4956-bae1-95250bb2178d_terseLabel_en-US" xlink:label="lab_ensg_PayorDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Domain]</link:label>
    <link:label id="lab_ensg_PayorDomain_label_en-US" xlink:label="lab_ensg_PayorDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Domain]</link:label>
    <link:label id="lab_ensg_PayorDomain_documentation_en-US" xlink:label="lab_ensg_PayorDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorDomain" xlink:href="ensg-20231231.xsd#ensg_PayorDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PayorDomain" xlink:to="lab_ensg_PayorDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_819d028d-440c-4f00-8744-079ac1cf02a5_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StopLossInsuranceLimitPerClaimMember_df569740-a0f4-4e0b-a5a9-0886d97bc59d_terseLabel_en-US" xlink:label="lab_ensg_StopLossInsuranceLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop-Loss Insurance Limit Per Claim</link:label>
    <link:label id="lab_ensg_StopLossInsuranceLimitPerClaimMember_label_en-US" xlink:label="lab_ensg_StopLossInsuranceLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop-Loss Insurance Limit Per Claim [Member]</link:label>
    <link:label id="lab_ensg_StopLossInsuranceLimitPerClaimMember_documentation_en-US" xlink:label="lab_ensg_StopLossInsuranceLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stop-Loss Insurance limit per claim[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StopLossInsuranceLimitPerClaimMember" xlink:href="ensg-20231231.xsd#ensg_StopLossInsuranceLimitPerClaimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StopLossInsuranceLimitPerClaimMember" xlink:to="lab_ensg_StopLossInsuranceLimitPerClaimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_3ff23ed9-d85e-4cde-875b-444781955529_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_f04501e6-7aa3-4434-868e-f8c8fe625688_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims paid and direct expenses</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_b6981a5b-081c-4e42-8d7a-e629917f1374_terseLabel_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_AllOtherSegmentsMember_label_en-US" xlink:label="lab_us-gaap_AllOtherSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllOtherSegmentsMember" xlink:to="lab_us-gaap_AllOtherSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a4951fa0-6b1b-48c6-b29d-b37da4f78302_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plus: incremental shares from assumed conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_d9539396-eb1e-475c-b7f0-34bd0309c77e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, upper range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e1d02696-517a-486c-b6ed-ee9954c6b9b1_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of real estate</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_c0f9acfd-07e6-4b00-a703-189c22ac0425_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SeniorLivingFacilities_23836e5d-0cd7-43db-9ab3-19c62fd357fd_terseLabel_en-US" xlink:label="lab_ensg_SeniorLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior living facilities</link:label>
    <link:label id="lab_ensg_SeniorLivingFacilities_label_en-US" xlink:label="lab_ensg_SeniorLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Facilities</link:label>
    <link:label id="lab_ensg_SeniorLivingFacilities_documentation_en-US" xlink:label="lab_ensg_SeniorLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Assisted and Independent Living Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilities" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SeniorLivingFacilities" xlink:to="lab_ensg_SeniorLivingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_August2023RepurchaseProgramMember_8e5f2164-b2e9-4f1d-91ff-8503c52d6e39_terseLabel_en-US" xlink:label="lab_ensg_August2023RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Repurchase Program</link:label>
    <link:label id="lab_ensg_August2023RepurchaseProgramMember_label_en-US" xlink:label="lab_ensg_August2023RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Repurchase Program [Member]</link:label>
    <link:label id="lab_ensg_August2023RepurchaseProgramMember_documentation_en-US" xlink:label="lab_ensg_August2023RepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">August 2023 Repurchase Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_August2023RepurchaseProgramMember" xlink:href="ensg-20231231.xsd#ensg_August2023RepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_August2023RepurchaseProgramMember" xlink:to="lab_ensg_August2023RepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_0ab0fd79-ad7d-45b2-ba3e-fcff35355fca_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_6884e65f-a2b2-40f9-a748-d7415fb50965_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_A2019LTIPlanMember_48bdc569-cf13-47e8-aed4-2939b60a66c8_terseLabel_en-US" xlink:label="lab_ensg_A2019LTIPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 LTI Plan</link:label>
    <link:label id="lab_ensg_A2019LTIPlanMember_label_en-US" xlink:label="lab_ensg_A2019LTIPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 LTI Plan [Member]</link:label>
    <link:label id="lab_ensg_A2019LTIPlanMember_documentation_en-US" xlink:label="lab_ensg_A2019LTIPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 LTI Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2019LTIPlanMember" xlink:href="ensg-20231231.xsd#ensg_A2019LTIPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_A2019LTIPlanMember" xlink:to="lab_ensg_A2019LTIPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_5a24e3e6-7461-40c8-be0d-561063f78946_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_03fd1d13-5f2f-4498-aa3c-f3ddc724a68c_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_08bfc2c6-c89a-4dd8-af5a-8375b3ddb7cf_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sales property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_dea34196-3196-47f6-831c-8fd82da759bb_terseLabel_en-US" xlink:label="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of senior living operations sharing property with skilled nursing facilities</link:label>
    <link:label id="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_label_en-US" xlink:label="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities</link:label>
    <link:label id="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_documentation_en-US" xlink:label="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:href="ensg-20231231.xsd#ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:to="lab_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8e0077d9-8d4e-478b-8086-a0e7d7366e28_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_74123930-52b0-46c1-b30b-954b9f55fbee_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_198e100a-5af7-41d7-836a-2bbffda1d1c1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Classified, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ManagementServiceIncentiveMember_bde1a2b9-1f0d-4e30-8828-5fe1179f8219_terseLabel_en-US" xlink:label="lab_us-gaap_ManagementServiceIncentiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Management Fee</link:label>
    <link:label id="lab_us-gaap_ManagementServiceIncentiveMember_label_en-US" xlink:label="lab_us-gaap_ManagementServiceIncentiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service, Incentive [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceIncentiveMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceIncentiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ManagementServiceIncentiveMember" xlink:to="lab_us-gaap_ManagementServiceIncentiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_cdcef7ae-5ec3-4bd2-9eff-e462331524eb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_57ac4c87-f750-4a68-b11e-872593941632_terseLabel_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Write-off of deferred financing fees</link:label>
    <link:label id="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost_label_en-US" xlink:label="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Debt Issuance Cost, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:to="lab_us-gaap_WriteOffOfDeferredDebtIssuanceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_74d9a4ea-3746-434e-ab89-8a58b613e2b6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lender Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis" xlink:to="lab_us-gaap_LineOfCreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_d3085253-a6b2-40ee-8431-ece75e3c9577_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EQUITY</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3256ba05-10de-4884-8b92-ffb4969598d1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_865e64d1-cf79-4f15-9ca6-4372c1c201a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases of lessee, contingent rentals, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDiscountRate_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:to="lab_us-gaap_LesseeOperatingLeaseDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_d496b0f1-9bc2-4368-a703-74c37b5a3234_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SeniorLivingFacilitiesMember_59c884fe-e1ea-455a-b8e9-fff29620a449_terseLabel_en-US" xlink:label="lab_ensg_SeniorLivingFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Facilities</link:label>
    <link:label id="lab_ensg_SeniorLivingFacilitiesMember_label_en-US" xlink:label="lab_ensg_SeniorLivingFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Facilities [Member]</link:label>
    <link:label id="lab_ensg_SeniorLivingFacilitiesMember_documentation_en-US" xlink:label="lab_ensg_SeniorLivingFacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assisted Living Facilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilitiesMember" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SeniorLivingFacilitiesMember" xlink:to="lab_ensg_SeniorLivingFacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeEightMember_539cc22f-feca-4d9f-8cad-61f6b4f74600_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeEightMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeEightMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeEightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eight [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeEightMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeEightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeEightMember" xlink:to="lab_ensg_ExercisePriceRangeEightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_3a0096a8-7a17-4c72-9290-0e40327e4200_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_40a853e4-d699-4b8b-b4df-fd77a7ab2f78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for business acquisitions (Note 7)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_126feb82-0fdd-47e8-b8ed-ebc69e7595fe_terseLabel_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock used to satisfy tax withholding obligations (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_f5c704ab-0569-4919-8501-0203b8d53e07_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant date intrinsic value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_143b6ccc-21ea-474f-8028-73a247ba9b65_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_a53ba787-b98a-4273-90ab-84a313aa8d4e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_b8438615-0ba7-41d1-a186-ad2a91bb2780_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9687c4db-939c-4750-9aef-ecdb3cbdcf14_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate margin</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_4f00febd-516a-471a-83d9-8a4ba61110b0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_bd80a936-f115-48dc-bcfa-9cec8c41215f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received from insurance proceeds</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CareTrustREITMember_d1e34fa2-91f7-45db-98fd-4374f13398e7_terseLabel_en-US" xlink:label="lab_ensg_CareTrustREITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareTrust REIT</link:label>
    <link:label id="lab_ensg_CareTrustREITMember_label_en-US" xlink:label="lab_ensg_CareTrustREITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareTrust REIT [Member]</link:label>
    <link:label id="lab_ensg_CareTrustREITMember_documentation_en-US" xlink:label="lab_ensg_CareTrustREITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CareTrust REIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CareTrustREITMember" xlink:href="ensg-20231231.xsd#ensg_CareTrustREITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CareTrustREITMember" xlink:to="lab_ensg_CareTrustREITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_bf607605-5e90-4d39-81e1-45ca6311825b_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUE AND ACCOUNTS RECEIVABLE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_abfb5a18-bc7c-4c98-9b6d-bad53d994b56_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_725ccd76-19e8-43d6-a94a-d1e0461220b4_terseLabel_en-US" xlink:label="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liability</link:label>
    <link:label id="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_label_en-US" xlink:label="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability</link:label>
    <link:label id="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_documentation_en-US" xlink:label="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:to="lab_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_68d8edb5-97e0-40d1-9394-0c6bda5ccb8b_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_9dddd017-56ad-4bc4-9238-ec7bef393bb9_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_094ace6f-db4a-4189-a46d-12e2db126b62_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue related reserves</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PaymentsToAcquireAssetAcquisitions_07051163-6b3b-43f0-bda8-bee0671e17bc_negatedTerseLabel_en-US" xlink:label="lab_ensg_PaymentsToAcquireAssetAcquisitions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for asset acquisitions (Note 7)</link:label>
    <link:label id="lab_ensg_PaymentsToAcquireAssetAcquisitions_label_en-US" xlink:label="lab_ensg_PaymentsToAcquireAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments To Acquire Asset Acquisitions</link:label>
    <link:label id="lab_ensg_PaymentsToAcquireAssetAcquisitions_documentation_en-US" xlink:label="lab_ensg_PaymentsToAcquireAssetAcquisitions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid to acquire acquisitions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquireAssetAcquisitions" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquireAssetAcquisitions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PaymentsToAcquireAssetAcquisitions" xlink:to="lab_ensg_PaymentsToAcquireAssetAcquisitions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_bfe9cdc3-c601-40e3-97b4-0d631a260430_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_33d2ee65-b750-4584-85d1-8f99a1808672_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SecuredOvernightFinancingRateSOFRMember_c95539fc-21b7-4ce0-9dd3-c8c374a2b68b_terseLabel_en-US" xlink:label="lab_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:label id="lab_ensg_SecuredOvernightFinancingRateSOFRMember_label_en-US" xlink:label="lab_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR) [Member]</link:label>
    <link:label id="lab_ensg_SecuredOvernightFinancingRateSOFRMember_documentation_en-US" xlink:label="lab_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Overnight Financing Rate (SOFR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:href="ensg-20231231.xsd#ensg_SecuredOvernightFinancingRateSOFRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:to="lab_ensg_SecuredOvernightFinancingRateSOFRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_c0c4f898-3fa4-4362-991f-e899f1d31413_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeSevenMember_b6ac034a-1bfc-45d8-a2ac-dec206013ebc_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeSevenMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeSevenMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeSevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Seven [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSevenMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeSevenMember" xlink:to="lab_ensg_ExercisePriceRangeSevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_1c5d498f-8c9f-4bf8-add8-30db3f10d60e_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of businesses acquired</link:label>
    <link:label id="lab_us-gaap_NumberOfBusinessesAcquired_label_en-US" xlink:label="lab_us-gaap_NumberOfBusinessesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Businesses Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfBusinessesAcquired" xlink:to="lab_us-gaap_NumberOfBusinessesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_674d0591-538e-47a0-8490-940502ef57f3_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued self-insurance liabilities&#8212;less current portion</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserveNoncurrent" xlink:to="lab_us-gaap_SelfInsuranceReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_5cb6ad7b-9447-4799-b651-b863f8aeb9fe_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividends_286940df-4b0a-4d76-aed2-cc68406f32a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividends" xlink:to="lab_us-gaap_PaymentsOfDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_7f9ca352-a58b-48d4-b494-5b321a60b7ef_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LEASE PAYMENTS</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_7bf54bf0-8bc4-4804-a951-1ddfb8bed7e6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_b069233e-57f7-4cca-8aca-2df56aca60d8_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments&#8212;current</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AmendedSeparateMasterLeases_020197c1-981d-493a-a308-19ee7c8138c8_terseLabel_en-US" xlink:label="lab_ensg_AmendedSeparateMasterLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended of separate master leases</link:label>
    <link:label id="lab_ensg_AmendedSeparateMasterLeases_label_en-US" xlink:label="lab_ensg_AmendedSeparateMasterLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Separate Master Leases</link:label>
    <link:label id="lab_ensg_AmendedSeparateMasterLeases_documentation_en-US" xlink:label="lab_ensg_AmendedSeparateMasterLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Separate Master Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedSeparateMasterLeases" xlink:href="ensg-20231231.xsd#ensg_AmendedSeparateMasterLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AmendedSeparateMasterLeases" xlink:to="lab_ensg_AmendedSeparateMasterLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_bc0cc7d3-f671-4929-989e-36c48b63b0b9_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEFINED CONTRIBUTION PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_1939644f-ce7a-4245-9070-8922ba75ff62_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, purchase price</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferred_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_9b6ff67d-40f7-4f3d-af1c-402f0ecd63e7_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BUSINESS SEGMENTS</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2536ae32-d7b4-4eb3-b472-e017f294f067_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_5e7ee07b-0919-47c2-b22b-d25effafe9b3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_d6349518-c0d4-4266-82d7-9c8703c7c43c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfFacilities_7ad237f7-bd0a-4973-a783-8682a4385f43_terseLabel_en-US" xlink:label="lab_ensg_NumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of facilities</link:label>
    <link:label id="lab_ensg_NumberOfFacilities_label_en-US" xlink:label="lab_ensg_NumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Facilities</link:label>
    <link:label id="lab_ensg_NumberOfFacilities_documentation_en-US" xlink:label="lab_ensg_NumberOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFacilities" xlink:href="ensg-20231231.xsd#ensg_NumberOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfFacilities" xlink:to="lab_ensg_NumberOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DepreciationAndAmortizationMember_2dbc536a-fe40-4929-94e7-7fe722d97104_terseLabel_en-US" xlink:label="lab_ensg_DepreciationAndAmortizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_ensg_DepreciationAndAmortizationMember_7b92d190-824c-4021-a7dc-c170f0642266_verboseLabel_en-US" xlink:label="lab_ensg_DepreciationAndAmortizationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_ensg_DepreciationAndAmortizationMember_label_en-US" xlink:label="lab_ensg_DepreciationAndAmortizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization [Member]</link:label>
    <link:label id="lab_ensg_DepreciationAndAmortizationMember_documentation_en-US" xlink:label="lab_ensg_DepreciationAndAmortizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DepreciationAndAmortizationMember" xlink:href="ensg-20231231.xsd#ensg_DepreciationAndAmortizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DepreciationAndAmortizationMember" xlink:to="lab_ensg_DepreciationAndAmortizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fce2e122-85bc-45c2-85ff-6c9e16b373ba_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_fd8d1671-1a24-4685-9bd1-759a5668149e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_0c81c09e-9a8d-4cc5-8d5c-305f264329c0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OwnedPropertiesMember_0b0a7538-4dc1-4d29-9459-c2fe830d76ad_terseLabel_en-US" xlink:label="lab_ensg_OwnedPropertiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owned Properties</link:label>
    <link:label id="lab_ensg_OwnedPropertiesMember_label_en-US" xlink:label="lab_ensg_OwnedPropertiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owned Properties [Member]</link:label>
    <link:label id="lab_ensg_OwnedPropertiesMember_documentation_en-US" xlink:label="lab_ensg_OwnedPropertiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Owned Properties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OwnedPropertiesMember" xlink:href="ensg-20231231.xsd#ensg_OwnedPropertiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OwnedPropertiesMember" xlink:to="lab_ensg_OwnedPropertiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AggregateDeductibleMember_ca21ac75-c433-4e66-8e60-494cea4d54bf_terseLabel_en-US" xlink:label="lab_ensg_AggregateDeductibleMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Deductible</link:label>
    <link:label id="lab_ensg_AggregateDeductibleMember_label_en-US" xlink:label="lab_ensg_AggregateDeductibleMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Deductible [Member]</link:label>
    <link:label id="lab_ensg_AggregateDeductibleMember_documentation_en-US" xlink:label="lab_ensg_AggregateDeductibleMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Deductible [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AggregateDeductibleMember" xlink:href="ensg-20231231.xsd#ensg_AggregateDeductibleMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AggregateDeductibleMember" xlink:to="lab_ensg_AggregateDeductibleMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_8f1f7a59-9d43-49b0-967b-3b7e57a96269_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL DEFERRED TAX LIABILITIES</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_b8e9a118-4b86-4689-a775-d29121d1cb4c_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_cdb5a4b3-8035-449d-bacb-2293c7b10512_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_f8d04f47-9816-4db2-97d2-71d51ad18f98_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_e008edfd-38a3-4229-8390-25e0ad3c8c89_negatedLabel_en-US" xlink:label="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain)/loss on insurance claims, legal matters and asset disposals</link:label>
    <link:label id="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_label_en-US" xlink:label="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Insurance Claims And Disposal Of Assets</link:label>
    <link:label id="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_documentation_en-US" xlink:label="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Insurance Claims And Disposal Of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:href="ensg-20231231.xsd#ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:to="lab_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_7ed1acc1-0c14-464d-8713-933b666c35c3_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_A2022PlanMember_8215cfc5-5563-4042-993f-4b5da33996f4_terseLabel_en-US" xlink:label="lab_ensg_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Plan</link:label>
    <link:label id="lab_ensg_A2022PlanMember_label_en-US" xlink:label="lab_ensg_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Plan [Member]</link:label>
    <link:label id="lab_ensg_A2022PlanMember_documentation_en-US" xlink:label="lab_ensg_A2022PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2022PlanMember" xlink:href="ensg-20231231.xsd#ensg_A2022PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_A2022PlanMember" xlink:to="lab_ensg_A2022PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_a248ffc7-3427-4313-8257-015a979a3d43_terseLabel_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self insurance reserve</link:label>
    <link:label id="lab_us-gaap_SelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_SelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SelfInsuranceReserve" xlink:to="lab_us-gaap_SelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstatePropertiesLineItems_5ec49904-21ca-43d8-acb1-5ade4f859c07_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Line Items]</link:label>
    <link:label id="lab_us-gaap_RealEstatePropertiesLineItems_label_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Properties [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems" xlink:to="lab_us-gaap_RealEstatePropertiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_cf7b3e8b-1c3e-47ba-8e32-30b10b934698_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SkilledServiceFacilities_e3efc0f5-af15-48f2-a38e-7a6f73391450_terseLabel_en-US" xlink:label="lab_ensg_SkilledServiceFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transitional and skilled service facilities</link:label>
    <link:label id="lab_ensg_SkilledServiceFacilities_label_en-US" xlink:label="lab_ensg_SkilledServiceFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Service Facilities</link:label>
    <link:label id="lab_ensg_SkilledServiceFacilities_documentation_en-US" xlink:label="lab_ensg_SkilledServiceFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Service Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServiceFacilities" xlink:href="ensg-20231231.xsd#ensg_SkilledServiceFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SkilledServiceFacilities" xlink:to="lab_ensg_SkilledServiceFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_e06463be-67ed-4ae3-9d69-aa8e24a92ec7_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_acb8f797-07a1-4408-a19d-559edc995ea1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_9d487de3-4731-41fe-a18d-23b625adcd26_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_91b22180-b2a3-41b4-bb2a-7f31ef02fe08_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_bf854d76-ae25-4248-9d9f-b08ac1652ad6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-employee Directors</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonemployee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementNonemployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsDomain_a93ae936-5dd0-45d7-8b58-5b92ee5291ef_terseLabel_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions [Domain]</link:label>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsDomain_label_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions [Domain]</link:label>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsDomain_documentation_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsDomain" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsDomain" xlink:to="lab_ensg_BusinessAndAssetAcquisitionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicaidAndMedicareMember_27af87c8-7a2c-40a8-a030-95c57dc13ce6_terseLabel_en-US" xlink:label="lab_ensg_MedicaidAndMedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Medicare and Medicaid</link:label>
    <link:label id="lab_ensg_MedicaidAndMedicareMember_bbe1042e-2a9e-4758-95d6-bef3f3e97a14_verboseLabel_en-US" xlink:label="lab_ensg_MedicaidAndMedicareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Medicaid and Medicare</link:label>
    <link:label id="lab_ensg_MedicaidAndMedicareMember_label_en-US" xlink:label="lab_ensg_MedicaidAndMedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid and Medicare [Member]</link:label>
    <link:label id="lab_ensg_MedicaidAndMedicareMember_documentation_en-US" xlink:label="lab_ensg_MedicaidAndMedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue from Medicaid and Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicaidAndMedicareMember" xlink:to="lab_ensg_MedicaidAndMedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_ce860ff7-e74a-43a4-80d9-5a64661d7abf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsAxis_ec3a4267-305c-4680-b1d5-38abae7c45df_terseLabel_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions [Axis]</link:label>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsAxis_label_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions [Axis]</link:label>
    <link:label id="lab_ensg_BusinessAndAssetAcquisitionsAxis_documentation_en-US" xlink:label="lab_ensg_BusinessAndAssetAcquisitionsAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business And Asset Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsAxis" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsAxis" xlink:to="lab_ensg_BusinessAndAssetAcquisitionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c4d11650-b5f3-4974-b8ab-8a4012f3bda0_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ab61e5cc-4b3e-42a9-a4d1-71e31a3fd5bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4ba23007-740e-465d-b64e-608899dda355_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonvested at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_a41bb839-52ac-4ecc-b38c-66fb0de2c078_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DEBT</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfOptionPlans_6e753d1f-553b-43c3-a052-5bbb7348f9bf_terseLabel_en-US" xlink:label="lab_ensg_NumberOfOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of option plans</link:label>
    <link:label id="lab_ensg_NumberOfOptionPlans_label_en-US" xlink:label="lab_ensg_NumberOfOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Option Plans</link:label>
    <link:label id="lab_ensg_NumberOfOptionPlans_documentation_en-US" xlink:label="lab_ensg_NumberOfOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOptionPlans" xlink:href="ensg-20231231.xsd#ensg_NumberOfOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfOptionPlans" xlink:to="lab_ensg_NumberOfOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_617f6845-279a-475c-83c9-b7008d40eb37_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_983fd545-6fb6-497c-8fc8-aaa56e433570_terseLabel_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, number of renewal options</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_ensg_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_218034a2-5992-4fae-809b-027d15a8580e_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving credit facility with Truist</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_d8817485-5f18-4a9d-9d0a-681f43b00a89_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_72db016d-a979-474b-b6eb-88e2d60c755e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_a4580fae-05e8-450b-861b-0178c342a080_terseLabel_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total net debt ratio, maximum after increase election</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_label_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Maximum After Increase Election</link:label>
    <link:label id="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_documentation_en-US" xlink:label="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Debt Ratio, Maximum After Increase Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximumAfterIncreaseElection"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:to="lab_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralizedDebtObligationsMember_5804a43b-34d1-44f4-a268-9fed38ad303c_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralizedDebtObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage loans and promissory note</link:label>
    <link:label id="lab_us-gaap_CollateralizedDebtObligationsMember_label_en-US" xlink:label="lab_us-gaap_CollateralizedDebtObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralizedDebtObligationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralizedDebtObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralizedDebtObligationsMember" xlink:to="lab_us-gaap_CollateralizedDebtObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1a853ead-6dfc-4fff-9b66-f45853dfe284_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d4a7ac13-d4b5-4d1a-ab4e-65973c5b6bd5_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense at statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_f362245f-7613-48b4-ae8e-d9fea66df6df_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Notes 15 and 20)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_267e6744-53c4-424c-8378-a3964a308dd4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Year</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_8089a9df-fb24-4bf3-82b3-bed48374d98b_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_8b99b048-0584-4010-aca8-6ecf5060f40e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_75defd3f-45da-415d-abc4-ba0490d8cae9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0eb504ea-14c5-44fb-9d6e-26fa0b75b646_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_5095409b-a0f4-4e0e-af18-ebfb977bfeb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_55f5bc33-2acf-47fe-85b7-03f318fa67b4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_377b3b45-89d9-4cbf-bdb8-d973da748d14_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_b53b6fb9-cb27-4d5c-802f-cd5052e82dd6_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Plan</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember" xlink:to="lab_us-gaap_NonqualifiedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_1f7990e6-25b6-4880-91d2-b03b5e4e69d0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_743b54bb-a482-4238-8d9e-801e81095b1f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_6d521a68-368a-4f3c-b3a1-85d7026e17b9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e4010c92-47e5-4eb9-a863-588f99eebb2e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_24329be6-ac75-42d3-8a3a-85065900d03e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_FacilitiesUnderMasterLeaseArrangement_6dd4213c-f524-4f8f-8b3d-372a8e500782_terseLabel_en-US" xlink:label="lab_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities under master lease arrangement</link:label>
    <link:label id="lab_ensg_FacilitiesUnderMasterLeaseArrangement_label_en-US" xlink:label="lab_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities Under Master Lease Arrangement</link:label>
    <link:label id="lab_ensg_FacilitiesUnderMasterLeaseArrangement_documentation_en-US" xlink:label="lab_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:href="ensg-20231231.xsd#ensg_FacilitiesUnderMasterLeaseArrangement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:to="lab_ensg_FacilitiesUnderMasterLeaseArrangement" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AmendedMasterLeaseMember_66c19609-f587-4335-8818-7e77f0b30ca8_terseLabel_en-US" xlink:label="lab_ensg_AmendedMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease</link:label>
    <link:label id="lab_ensg_AmendedMasterLeaseMember_label_en-US" xlink:label="lab_ensg_AmendedMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease [Member]</link:label>
    <link:label id="lab_ensg_AmendedMasterLeaseMember_documentation_en-US" xlink:label="lab_ensg_AmendedMasterLeaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseMember" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AmendedMasterLeaseMember" xlink:to="lab_ensg_AmendedMasterLeaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_0909b856-a3b3-4717-a9f2-452d4a858df7_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares in treasury, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_94c53b4e-1ff2-45e2-a538-7684fe64c5e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_0e112c4a-734c-48d0-92b6-6b6e84b1536a_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_cc8f0085-31e8-48ee-b2ba-1ecc56108dfe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f2564221-86c3-46aa-88c0-904c4906e6cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period, (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6ee2aefc-47e3-4579-a983-dfb2f59e920a_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period, (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_ff42b1e7-c8a4-4d43-9d64-91c2b1dd74bf_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_a223ad53-a503-4a75-a9ce-1e2d9dd2d7a2_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PayorAxis_caa58e0c-6af3-41f9-a316-31c8b9ae9375_terseLabel_en-US" xlink:label="lab_ensg_PayorAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Axis]</link:label>
    <link:label id="lab_ensg_PayorAxis_label_en-US" xlink:label="lab_ensg_PayorAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Axis]</link:label>
    <link:label id="lab_ensg_PayorAxis_documentation_en-US" xlink:label="lab_ensg_PayorAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payor [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorAxis" xlink:href="ensg-20231231.xsd#ensg_PayorAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PayorAxis" xlink:to="lab_ensg_PayorAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bc144501-997f-4a15-b876-801d64f9505b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Fair Value of Options (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_28572e7f-0cd8-480f-a4bd-eb7a403e4a5f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to The Ensign Group, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f93ea0c5-c64c-4662-a357-05d5d3a30b0a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to the Ensign Group, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_b4dbb4ae-d0e9-4d94-8d42-41dc5e898cf6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LeaseArrangementAxis_9710ee04-b1ff-4229-ace4-861af45f2ac6_terseLabel_en-US" xlink:label="lab_ensg_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_ensg_LeaseArrangementAxis_label_en-US" xlink:label="lab_ensg_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Arrangement [Axis]</link:label>
    <link:label id="lab_ensg_LeaseArrangementAxis_documentation_en-US" xlink:label="lab_ensg_LeaseArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information by group of related lease arrangements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LeaseArrangementAxis" xlink:to="lab_ensg_LeaseArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_9d13e853-7d2c-4586-8241-de19bf9155cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_81b8d2fe-cd03-4774-afaa-031522c69b42_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_c7b25977-dc4b-4bf1-85cb-89e18526b020_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_BlanketAggregateMember_9643cc82-2d79-4571-b754-83dadfa31272_terseLabel_en-US" xlink:label="lab_ensg_BlanketAggregateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blanket Aggregate</link:label>
    <link:label id="lab_ensg_BlanketAggregateMember_label_en-US" xlink:label="lab_ensg_BlanketAggregateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blanket Aggregate [Member]</link:label>
    <link:label id="lab_ensg_BlanketAggregateMember_documentation_en-US" xlink:label="lab_ensg_BlanketAggregateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Blanket Aggregate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BlanketAggregateMember" xlink:href="ensg-20231231.xsd#ensg_BlanketAggregateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_BlanketAggregateMember" xlink:to="lab_ensg_BlanketAggregateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_4fbd6893-c5cc-45e3-a389-ed191e634282_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_af4134aa-82f6-44e1-a3fd-770a9098b4da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OperatingEntityAxis_504338be-0ff9-4bb1-9eae-35f7cbdd3267_terseLabel_en-US" xlink:label="lab_ensg_OperatingEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Entity [Axis]</link:label>
    <link:label id="lab_ensg_OperatingEntityAxis_label_en-US" xlink:label="lab_ensg_OperatingEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Entity [Axis]</link:label>
    <link:label id="lab_ensg_OperatingEntityAxis_documentation_en-US" xlink:label="lab_ensg_OperatingEntityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityAxis" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OperatingEntityAxis" xlink:to="lab_ensg_OperatingEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f2f3de39-be76-4ddc-ad2a-2d5079e91656_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of services</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_491accce-c060-49f1-884d-ccd99c560932_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_9d544881-4bee-451e-9d55-a0198701a7ce_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds from the sale of assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_6cf62823-fb07-4887-90d8-b83f640c76f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_YearsFiveThroughTenMember_8fea81a0-c713-47fc-9664-78c9119a5025_terseLabel_en-US" xlink:label="lab_ensg_YearsFiveThroughTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years Five Through Ten</link:label>
    <link:label id="lab_ensg_YearsFiveThroughTenMember_label_en-US" xlink:label="lab_ensg_YearsFiveThroughTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years Five Through Ten [Member]</link:label>
    <link:label id="lab_ensg_YearsFiveThroughTenMember_documentation_en-US" xlink:label="lab_ensg_YearsFiveThroughTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Years Five Through Ten</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_YearsFiveThroughTenMember" xlink:href="ensg-20231231.xsd#ensg_YearsFiveThroughTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_YearsFiveThroughTenMember" xlink:to="lab_ensg_YearsFiveThroughTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_56913c2f-256f-4bad-892f-9b32f1ee0894_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Life (Years)</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_3c1cf8b5-c603-4079-948a-b23df7430178_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_5f63106c-0ca0-4443-b65e-a05156311831_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_fc791f79-f456-41fd-ab1d-5cbd8c721522_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_324ff97a-f24d-4053-a997-3afb16e7ece5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ThePennantGroupInc.Member_98597ce5-5674-45a6-b88e-a8d45fa85a93_terseLabel_en-US" xlink:label="lab_ensg_ThePennantGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Pennant Group, Inc.</link:label>
    <link:label id="lab_ensg_ThePennantGroupInc.Member_0c2392f9-e719-4612-be0b-87ba66af0d30_verboseLabel_en-US" xlink:label="lab_ensg_ThePennantGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennant</link:label>
    <link:label id="lab_ensg_ThePennantGroupInc.Member_label_en-US" xlink:label="lab_ensg_ThePennantGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Pennant Group, Inc. [Member]</link:label>
    <link:label id="lab_ensg_ThePennantGroupInc.Member_documentation_en-US" xlink:label="lab_ensg_ThePennantGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The Pennant Group, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ThePennantGroupInc.Member" xlink:to="lab_ensg_ThePennantGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AuditInformationAbstract_label_en-US" xlink:label="lab_ensg_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_ensg_AuditInformationAbstract_documentation_en-US" xlink:label="lab_ensg_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AuditInformationAbstract" xlink:href="ensg-20231231.xsd#ensg_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AuditInformationAbstract" xlink:to="lab_ensg_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SubsidiariesMember_0ac8aa6e-a2fc-4e50-a8be-3793a97001df_terseLabel_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captive Insurance Subsidiary</link:label>
    <link:label id="lab_srt_SubsidiariesMember_label_en-US" xlink:label="lab_srt_SubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiaries [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SubsidiariesMember" xlink:to="lab_srt_SubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_44266fc9-b683-4f1f-a323-fe0906131f1a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_8b89c760-0b31-443e-b5bb-26b38eab19d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealEstatePropertiesAxis_4f3dcfff-4605-488a-9188-ff3420bf2b9a_terseLabel_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Property Ownership [Axis]</link:label>
    <link:label id="lab_us-gaap_RealEstatePropertiesAxis_label_en-US" xlink:label="lab_us-gaap_RealEstatePropertiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Property Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealEstatePropertiesAxis" xlink:to="lab_us-gaap_RealEstatePropertiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_100c2cab-117e-4c85-b7a3-b3d1c2ad9033_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term lease liabilities&#8212;less current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_6e15d8cf-399b-4daa-92c7-a8817c1accc6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM OPERATING LEASE LIABILITIES</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6c2acc68-bf77-477d-b823-43ccfc5653c2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_a851fc98-e280-456d-9117-74bbedb748c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_3c13829d-2e69-4e83-a981-bd8385791f40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRealEstatePropertiesTable_9713aa5e-6816-4f6f-b55d-a4b7c7c8821b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Real Estate Properties [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRealEstatePropertiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Real Estate Properties [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:to="lab_us-gaap_ScheduleOfRealEstatePropertiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_c567bd88-d029-4106-935c-de70b36aefca_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3e09ec21-e037-4147-82c7-b69a57bdd584_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_b8324702-8133-408c-b7c4-e9ef34447b00_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanTable_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_f9f623f2-dd7c-48ad-8561-5a33cb98439a_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b8f839d1-ff67-40cc-8d49-48121d3ddaef_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_cf785531-ac21-4e40-9edb-9eed974bc537_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Lease Expenses</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_c1053e31-a7a0-491e-ab93-39420ae56374_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_f5b93e0b-9fb0-4375-be6b-857704a9d2a4_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_d099a98d-9e60-4ba3-b2f9-f417a0b8a1e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_f7fd248f-5031-4be4-91ec-4658f508ed51_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8c534c0a-fadc-4320-8021-83b3d83daeaf_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SkilledServicesSegmentMember_1bac6e01-625b-4fd1-9ecf-81ad80045635_terseLabel_en-US" xlink:label="lab_ensg_SkilledServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Services</link:label>
    <link:label id="lab_ensg_SkilledServicesSegmentMember_label_en-US" xlink:label="lab_ensg_SkilledServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Services Segment [Member]</link:label>
    <link:label id="lab_ensg_SkilledServicesSegmentMember_documentation_en-US" xlink:label="lab_ensg_SkilledServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SkilledServicesSegmentMember" xlink:to="lab_ensg_SkilledServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_d5ed82d3-fd7a-4f42-a125-8f5d1e847708_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_928762e9-1cb6-4763-b19b-4f6796ff2eec_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, options outstanding, weighted average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_230e080d-b250-4771-9ec1-b2adcce7ffc6_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_86dbffef-46f1-4159-bc2a-6ca891cc3227_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6f2469c3-20e8-46ed-9449-f4b99faf412e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_5dab0915-1723-4d7f-9c9f-a0486acdbd85_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_1d552ce2-6c97-4320-a87a-fae13cdc34db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_fcf792ee-986e-4998-b6be-adb3d630f4e9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_89653397-3b4a-4aa0-a3c8-a03d3984791c_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_80242d2c-7ccb-4c4c-a98a-bf2f0b731b2e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b9fecdbe-c00b-4a4e-8a7f-b597fcdd8071_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_99e328fa-e33f-4da9-85f2-6f64e4b070f7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7a7aef4d-52ab-4f1d-a5de-87066b7c704c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ThirdPartiesMember_8ff3019b-1855-4b25-8bb5-97a567b95eed_terseLabel_en-US" xlink:label="lab_ensg_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties</link:label>
    <link:label id="lab_ensg_ThirdPartiesMember_label_en-US" xlink:label="lab_ensg_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties [Member]</link:label>
    <link:label id="lab_ensg_ThirdPartiesMember_documentation_en-US" xlink:label="lab_ensg_ThirdPartiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartiesMember" xlink:href="ensg-20231231.xsd#ensg_ThirdPartiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ThirdPartiesMember" xlink:to="lab_ensg_ThirdPartiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OperationalSkilledNursingBeds_919cf5fc-952e-4335-bb6e-178f4fbb4a67_terseLabel_en-US" xlink:label="lab_ensg_OperationalSkilledNursingBeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational skilled nursing beds</link:label>
    <link:label id="lab_ensg_OperationalSkilledNursingBeds_label_en-US" xlink:label="lab_ensg_OperationalSkilledNursingBeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operational Skilled Nursing Beds</link:label>
    <link:label id="lab_ensg_OperationalSkilledNursingBeds_documentation_en-US" xlink:label="lab_ensg_OperationalSkilledNursingBeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of skilled nursing beds available for use at a skilled nursing facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OperationalSkilledNursingBeds" xlink:to="lab_ensg_OperationalSkilledNursingBeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_fc9095e8-3d60-4847-9445-377fce8f95bd_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease, costs</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_45d9dd16-b1ed-4e77-9b58-23012ada1320_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_203a90b1-09b0-4148-b58e-825d119fdfd4_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1327da28-31ce-430d-a989-72bf159d3eca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_2cf468d4-9a12-42cb-b499-d2aa673380f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c19d775d-337f-494a-867f-e1ad45d30339_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_8648a43c-bfd0-4071-a407-63dee3f5bb5a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_e1dfd22b-d3ec-48f2-912b-848c09c1ac50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock in treasury, at cost, 3,390 and 3,368 shares at December&#160;31, 2023 and 2022, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_BeverlyBWittekindMember_label_en-US" xlink:label="lab_ensg_BeverlyBWittekindMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beverly B. Wittekind [Member]</link:label>
    <link:label id="lab_ensg_BeverlyBWittekindMember_documentation_en-US" xlink:label="lab_ensg_BeverlyBWittekindMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beverly B. Wittekind</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BeverlyBWittekindMember" xlink:href="ensg-20231231.xsd#ensg_BeverlyBWittekindMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_BeverlyBWittekindMember" xlink:to="lab_ensg_BeverlyBWittekindMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_19cfb246-3529-4d33-8de0-5e5ddf85e429_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_5f0bf27a-558c-46d3-b8d1-ab6672e202b4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8db909b5-1db8-4e72-8306-5dc0b3e1baf5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, nonvested awards, cost not yet recognized, period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_91fb7806-4bd2-461d-8b9b-c56271fd45cf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_c6fed698-f4ca-410b-b9f6-232ab3f5406a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CPI increases and short term-lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_524c6c1c-ae0c-47c6-ab10-3d938085d272_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options that vested in period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_a963b7f1-e7a2-4661-9391-7bd7164c304d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_aa3a47c6-d44f-4594-aeb3-0d083cbdd684_negatedTerseLabel_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</link:label>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_label_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds Repaid</link:label>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_documentation_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds, Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:to="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StandardBearerHealthcareREITIncMember_0be48816-c9c3-4bd7-bd3d-ba84a85a6ee2_terseLabel_en-US" xlink:label="lab_ensg_StandardBearerHealthcareREITIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Healthcare REIT, Inc.</link:label>
    <link:label id="lab_ensg_StandardBearerHealthcareREITIncMember_label_en-US" xlink:label="lab_ensg_StandardBearerHealthcareREITIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Healthcare REIT, Inc. [Member]</link:label>
    <link:label id="lab_ensg_StandardBearerHealthcareREITIncMember_documentation_en-US" xlink:label="lab_ensg_StandardBearerHealthcareREITIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Healthcare REIT, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StandardBearerHealthcareREITIncMember" xlink:to="lab_ensg_StandardBearerHealthcareREITIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_18555f3d-9fa4-45c2-bff6-73880c676943_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Aggregate Intrinsic Value of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_713f7b7f-44d1-4c68-9f0d-8904d66645bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_f222e158-6b36-4d5f-b203-79b903310820_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LossSensitiveLimitPerClaimMember_97710c86-8dfb-4a70-8707-1eb5ec39be91_terseLabel_en-US" xlink:label="lab_ensg_LossSensitiveLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss-Sensitive Limit Per Claim</link:label>
    <link:label id="lab_ensg_LossSensitiveLimitPerClaimMember_label_en-US" xlink:label="lab_ensg_LossSensitiveLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss-Sensitive Limit Per Claim [Member]</link:label>
    <link:label id="lab_ensg_LossSensitiveLimitPerClaimMember_documentation_en-US" xlink:label="lab_ensg_LossSensitiveLimitPerClaimMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss-Sensitive limit per claim [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LossSensitiveLimitPerClaimMember" xlink:href="ensg-20231231.xsd#ensg_LossSensitiveLimitPerClaimMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LossSensitiveLimitPerClaimMember" xlink:to="lab_ensg_LossSensitiveLimitPerClaimMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_6c8337ae-b443-43cb-b383-63d11fd39cd4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_68073ae3-b06b-4edb-89e9-54b5795686a8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_31f12ef2-1fa5-4e19-b720-6660a73f6995_terseLabel_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) funds received and returned</link:label>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_label_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds Received And Returned</link:label>
    <link:label id="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_documentation_en-US" xlink:label="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds Received And Returned</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:to="lab_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1acc168a-2411-4380-b038-dc5bfc482bb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TwentyThreeSubsidiariesMember_1976f0f3-80c9-4058-b05c-877e0d5f254a_terseLabel_en-US" xlink:label="lab_ensg_TwentyThreeSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Three Subsidiaries</link:label>
    <link:label id="lab_ensg_TwentyThreeSubsidiariesMember_label_en-US" xlink:label="lab_ensg_TwentyThreeSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Three Subsidiaries [Member]</link:label>
    <link:label id="lab_ensg_TwentyThreeSubsidiariesMember_documentation_en-US" xlink:label="lab_ensg_TwentyThreeSubsidiariesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Twenty Three Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TwentyThreeSubsidiariesMember" xlink:href="ensg-20231231.xsd#ensg_TwentyThreeSubsidiariesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TwentyThreeSubsidiariesMember" xlink:to="lab_ensg_TwentyThreeSubsidiariesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7a89dce2-1241-4a65-9373-8253486c1ee8_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_cf1e94e2-9657-4249-b664-b58d82047544_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_bea453d7-3334-442b-af91-d313b23b773d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_734f808d-5bed-4394-a080-b59f5e5ca5ba_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NUMERATOR:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_91e1bdfa-9a04-4eeb-bf2f-918d1103f953_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicareMember_d20e4e20-cd04-433f-bd57-c72817d70941_terseLabel_en-US" xlink:label="lab_ensg_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ensg_MedicareMember_40c635a1-024e-456f-825c-a43ae32765de_verboseLabel_en-US" xlink:label="lab_ensg_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ensg_MedicareMember_348ac79d-e6b9-4936-a26b-9eb0f9b7e945_netLabel_en-US" xlink:label="lab_ensg_MedicareMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_ensg_MedicareMember_label_en-US" xlink:label="lab_ensg_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_ensg_MedicareMember_documentation_en-US" xlink:label="lab_ensg_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Medicare [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicareMember" xlink:to="lab_ensg_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_418d3af5-4398-4518-a2c1-e6d37beebe46_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis" xlink:to="lab_us-gaap_RetirementPlanTaxStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_a0d873d2-8930-4475-a982-9d4f23b9ac9f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_90a58104-8f0d-458f-aae3-e0443a1415ee_verboseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_7953a3e4-4275-437b-838d-76888a3d39eb_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PerOccurenceMember_f865a53c-3a1e-4637-9982-0a1849a35b6c_terseLabel_en-US" xlink:label="lab_ensg_PerOccurenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Occurence</link:label>
    <link:label id="lab_ensg_PerOccurenceMember_label_en-US" xlink:label="lab_ensg_PerOccurenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Occurence [Member]</link:label>
    <link:label id="lab_ensg_PerOccurenceMember_documentation_en-US" xlink:label="lab_ensg_PerOccurenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Occurence [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerOccurenceMember" xlink:href="ensg-20231231.xsd#ensg_PerOccurenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PerOccurenceMember" xlink:to="lab_ensg_PerOccurenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_bd17e626-6109-4d34-b7ac-0d448ae6c5d9_terseLabel_en-US" xlink:label="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, restricted awards, exercise price (in dollars per share)</link:label>
    <link:label id="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_label_en-US" xlink:label="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Restricted Awards, Exercise Price</link:label>
    <link:label id="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_documentation_en-US" xlink:label="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Restricted Awards, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:href="ensg-20231231.xsd#ensg_SharebasedCompensationRestrictedAwardsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:to="lab_ensg_SharebasedCompensationRestrictedAwardsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeElevenMember_b67bed25-153d-4420-a4ad-c1e3a47bc839_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeElevenMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeElevenMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeElevenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Eleven</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeElevenMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeElevenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeElevenMember" xlink:to="lab_ensg_ExercisePriceRangeElevenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_7062239c-c6ba-40b0-84bb-78290f47ea5e_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold event period after vesting of restricted awards or exercise of stock options</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_b73e13c2-07b1-48f1-abe8-cfaa80f34a8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_651a0cea-ec30-447f-b2d7-8f53203c0601_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of shares of common stock (Note 21)</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6bd139de-6ad6-4d22-8582-8d0b01b2e17a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RealEstatePurchasesMember_16e533e8-8657-4353-a742-0fbdd9ebac89_terseLabel_en-US" xlink:label="lab_ensg_RealEstatePurchasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases</link:label>
    <link:label id="lab_ensg_RealEstatePurchasesMember_label_en-US" xlink:label="lab_ensg_RealEstatePurchasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases [Member]</link:label>
    <link:label id="lab_ensg_RealEstatePurchasesMember_documentation_en-US" xlink:label="lab_ensg_RealEstatePurchasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Real Estate Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesMember" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RealEstatePurchasesMember" xlink:to="lab_ensg_RealEstatePurchasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_32eb61f8-f0e7-4c0f-be69-44b01fbe62f5_terseLabel_en-US" xlink:label="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities under medicare probe reviews</link:label>
    <link:label id="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_label_en-US" xlink:label="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Independent Operating Subsidiaries Under Medicare Probe Reviews</link:label>
    <link:label id="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_documentation_en-US" xlink:label="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:href="ensg-20231231.xsd#ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:to="lab_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_5034fb29-00e3-4bea-9d86-4fe3282ae1c9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_2f94434f-f8ee-46d7-ae49-02a11f71f6a8_terseLabel_en-US" xlink:label="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FMAP payments received</link:label>
    <link:label id="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_label_en-US" xlink:label="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Family First Coronavirus Response Act, Payments Received</link:label>
    <link:label id="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_documentation_en-US" xlink:label="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Family First Coronavirus Response Act, Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:href="ensg-20231231.xsd#ensg_FamilyFirstCoronavirusResponseActPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:to="lab_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_f59c31f3-5f80-48d0-9d7e-9588c463a509_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred rent receivable</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_54f4c499-bdf9-4ca9-8762-7bc2217e5247_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_021805ca-a8e0-4a86-8bc4-a8fc3ef273f5_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_2867543b-5b93-4bc7-aa74-e8a67a56d1bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_c6c927b5-2972-4021-85c1-720902d6949c_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected to vest</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_d89af420-9da1-43e8-ab56-656fde0a77d0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfOperations_63d15577-a0b1-4ac5-9c79-cc2ba7ae0f30_terseLabel_en-US" xlink:label="lab_ensg_NumberOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operations lease and operated by third parties</link:label>
    <link:label id="lab_ensg_NumberOfOperations_label_en-US" xlink:label="lab_ensg_NumberOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operations</link:label>
    <link:label id="lab_ensg_NumberOfOperations_documentation_en-US" xlink:label="lab_ensg_NumberOfOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperations" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfOperations" xlink:to="lab_ensg_NumberOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_aee1eab2-52fc-47d8-a87b-3fcdc8ed529b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_8709f0cf-e168-4b83-b45c-7065fa3bfbdf_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AcquiredOperationsMember_d9f10bbc-62ee-4c1c-a8dc-416c46a59f27_terseLabel_en-US" xlink:label="lab_ensg_AcquiredOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Operations</link:label>
    <link:label id="lab_ensg_AcquiredOperationsMember_label_en-US" xlink:label="lab_ensg_AcquiredOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Operations [Member]</link:label>
    <link:label id="lab_ensg_AcquiredOperationsMember_documentation_en-US" xlink:label="lab_ensg_AcquiredOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AcquiredOperationsMember" xlink:href="ensg-20231231.xsd#ensg_AcquiredOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AcquiredOperationsMember" xlink:to="lab_ensg_AcquiredOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SkilledServicesAndSeniorLivingCampuses_f7f3cea1-8961-40e7-9d5d-ac3fa1aeaa4b_terseLabel_en-US" xlink:label="lab_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transitional and skilled services and senior living campuses</link:label>
    <link:label id="lab_ensg_SkilledServicesAndSeniorLivingCampuses_label_en-US" xlink:label="lab_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Services And Senior Living Campuses</link:label>
    <link:label id="lab_ensg_SkilledServicesAndSeniorLivingCampuses_documentation_en-US" xlink:label="lab_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transitional and Skilled Services and Assistant and Independent Living Campuses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesAndSeniorLivingCampuses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:to="lab_ensg_SkilledServicesAndSeniorLivingCampuses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_5d5d46e2-fb2a-42a6-9f24-118a4350b517_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_25e7ef99-ecc1-4993-a83f-5eb2fa397d7e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CO_877d12dc-adbd-439d-bab9-3df2243841ee_terseLabel_en-US" xlink:label="lab_stpr_CO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado</link:label>
    <link:label id="lab_stpr_CO_label_en-US" xlink:label="lab_stpr_CO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLORADO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CO" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CO" xlink:to="lab_stpr_CO" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_4ae5d76f-9b11-4952-bdee-5cfee0b9b5e6_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation, options expected to vest, number (in shares)</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_15220f78-8437-4f2f-9ac0-64ab7e46a3a5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_54201a90-ade9-43e6-b7c9-f69cdcc019d8_terseLabel_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions</link:label>
    <link:label id="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_label_en-US" xlink:label="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="lab_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_c0e07a7c-9f22-4d29-8429-1cdf6a360a53_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_42f1e160-d565-4a3b-a76a-477e895fb0ae_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PerFacilityMember_2fad7817-b83d-4916-8d12-382e6005c48b_terseLabel_en-US" xlink:label="lab_ensg_PerFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Facility</link:label>
    <link:label id="lab_ensg_PerFacilityMember_label_en-US" xlink:label="lab_ensg_PerFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Facility [Member]</link:label>
    <link:label id="lab_ensg_PerFacilityMember_documentation_en-US" xlink:label="lab_ensg_PerFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Per Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerFacilityMember" xlink:href="ensg-20231231.xsd#ensg_PerFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PerFacilityMember" xlink:to="lab_ensg_PerFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_80e96bef-31d8-4617-92a7-b09058bde096_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_a21a1ee8-8b05-4906-a412-8dcd0b23d1b3_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefits_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, before Reinsurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefits" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_78b21b3e-6a08-4e12-832f-bc3a46532331_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_3f519c1b-d4e0-4c38-9b29-704bcebedc5e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLossFromRealEstateOperations_2a5f472b-424d-413c-85d6-3306ac687142_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLossFromRealEstateOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of assets and insurance recoveries from real estate, net</link:label>
    <link:label id="lab_us-gaap_ProfitLossFromRealEstateOperations_label_en-US" xlink:label="lab_us-gaap_ProfitLossFromRealEstateOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit (Loss) from Real Estate Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLossFromRealEstateOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLossFromRealEstateOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLossFromRealEstateOperations" xlink:to="lab_us-gaap_ProfitLossFromRealEstateOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_cf9440b3-aad6-4f04-a3f7-41f24f8f57ba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contributions per employee</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9d36323e-a2bf-4ce2-8fd0-ecb8d43b4eb1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_46177e30-2b8b-4570-a435-94bdf848721f_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_FirstThreeYearsMember_ce4cc543-53ae-4853-9843-68a99cb6d287_terseLabel_en-US" xlink:label="lab_ensg_FirstThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Years</link:label>
    <link:label id="lab_ensg_FirstThreeYearsMember_label_en-US" xlink:label="lab_ensg_FirstThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Years [Member]</link:label>
    <link:label id="lab_ensg_FirstThreeYearsMember_documentation_en-US" xlink:label="lab_ensg_FirstThreeYearsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Three Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FirstThreeYearsMember" xlink:href="ensg-20231231.xsd#ensg_FirstThreeYearsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_FirstThreeYearsMember" xlink:to="lab_ensg_FirstThreeYearsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_65b9a8d5-013a-4b39-a58a-4dc524f64574_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_a8f524e2-76e6-4fc6-a60c-744ab9670842_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1d1e33fd-b67f-45ce-9149-31cbf1750ef4_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL INCOME TAX PROVISION</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_a250162e-f9d1-4f56-a39a-c3c250af102f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_a96f6401-eefd-45f2-a509-1bf99266e4ac_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PRESENT VALUE OF TOTAL LEASE LIABILITIES</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock_11e688af-f902-4b97-9d08-38f6f8d5470b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Future Policy Benefits, by Product Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_bee36911-d5e5-42c7-b57d-315ffd5a13ee_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_d33a4f4c-8458-4a20-afc3-60db904e5c00_terseLabel_en-US" xlink:label="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled nursing, assisted living and independent living facilities</link:label>
    <link:label id="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_label_en-US" xlink:label="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Nursing, Senior Living and Independent Living Facilities</link:label>
    <link:label id="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_documentation_en-US" xlink:label="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skilled Nursing, Senior Living and Independent Living Facilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:to="lab_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_c7f53c8c-6951-4cde-9702-d553df60b33e_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service revenue</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_5e16083f-966b-42c8-8cf0-1ab8d1d59530_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_48fa0bc1-d15f-4177-a8f6-a68015bec487_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b1f58ab9-f9df-43b7-a65d-2b3f3a4b0119_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_2e7741f4-b702-4b86-ae5d-00873bad65a0_terseLabel_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt threshold for EBITDA ratio increase election period</link:label>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_label_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Threshold For EBITDA Ratio Increase Election Period</link:label>
    <link:label id="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_documentation_en-US" xlink:label="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt Threshold For EBITDA Ratio Increase Election Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:to="lab_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_72f1c8a3-dbc5-4c16-9fa2-0be69d33bbe8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeAndTierIdentifierDomain_9df95d98-ea3b-405e-8384-9a2286b4a82b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeAndTierIdentifierDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type and Tier Identifier [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeAndTierIdentifierDomain_label_en-US" xlink:label="lab_us-gaap_TypeAndTierIdentifierDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type and Tier Identifier [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeAndTierIdentifierDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeAndTierIdentifierDomain" xlink:to="lab_us-gaap_TypeAndTierIdentifierDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_273da680-f31d-4891-874c-96afbcf7deaf_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution plan, cost</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_00b2964f-ee29-4ef9-ac97-a4868ccb839b_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_eb02b547-bceb-405e-9596-47de7859f890_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ACCRUED LIABILITIES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_fb1caca3-ecc1-4886-8b6d-58ce0ef73334_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_f3c53681-d68b-4ee5-9798-f3713a987c33_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_c3bce701-4bcb-4662-a6ca-f3db3a078b1c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_3cbd224c-0f94-4252-a10e-dfa3afa61e38_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7f38b5ac-cf78-4753-97fd-8c674a35fa3d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December&#160;31, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ad1b7cb7-71f7-4cc9-885b-bc22ab6adbe8_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_d53be890-8b08-48bb-b819-d21f8d8313b9_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_dd9cf022-8628-4648-83c2-40505cb44975_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility trade name</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability_977a8fce-c809-4906-ae40-97ab3b805318_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Deferred Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_4fa9b9f6-a527-4630-9352-d3a11804b4d8_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_7ac4065d-8c65-49cf-8400-7864374e527f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued self-insurance liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInSelfInsuranceReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Self Insurance Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSelfInsuranceReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve" xlink:to="lab_us-gaap_IncreaseDecreaseInSelfInsuranceReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_25c4dfc5-00e7-4485-86f0-f40f603a263d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_51f88e9b-e9f1-4616-b10a-0a3ce4092e9e_terseLabel_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property taxes</link:label>
    <link:label id="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrual for Taxes Other than Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_208c3310-eb63-4e79-b687-e0e0d2a1b68d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_0aca4b30-1df4-4685-a849-b443a0dcc94a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_8d54dd1d-6b17-4152-8c6e-4ad9c8a6dd5b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_57a3fc3c-ab8c-4b56-bf03-4a87d2ec4efa_verboseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_5bca2143-dedc-47c3-8516-32bd215542a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fac0519f-db16-4643-b3ac-bedf4dd91ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_fd717250-62e3-477f-bcfd-4be2f468de6c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, by Product Segment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, by Product Segment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DeferredRentAdjustment_c367a006-a8d0-42f7-a7ad-3efb152c4689_terseLabel_en-US" xlink:label="lab_ensg_DeferredRentAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred rent</link:label>
    <link:label id="lab_ensg_DeferredRentAdjustment_label_en-US" xlink:label="lab_ensg_DeferredRentAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Rent Adjustment</link:label>
    <link:label id="lab_ensg_DeferredRentAdjustment_documentation_en-US" xlink:label="lab_ensg_DeferredRentAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAdjustment" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DeferredRentAdjustment" xlink:to="lab_ensg_DeferredRentAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_223d13ba-bd2e-46c8-b1b3-1db761a1cae8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_90cb41ee-15c3-4a85-882a-b2af0d767cec_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_e1adde9e-1a07-476d-b237-4f5d810cbfe8_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_4b28e0ad-4461-4fe4-8165-b72e1b1f5cfe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_05334594-c9db-4497-9480-6a4cc51fdf97_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SpinoffMember_c98ea90f-3d03-4a00-9200-c13551dc7734_terseLabel_en-US" xlink:label="lab_us-gaap_SpinoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinoff</link:label>
    <link:label id="lab_us-gaap_SpinoffMember_label_en-US" xlink:label="lab_us-gaap_SpinoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spinoff [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpinoffMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SpinoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SpinoffMember" xlink:to="lab_us-gaap_SpinoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NonCashLeaseExpense_8e783d89-68f6-4e09-b028-074f3759fbad_terseLabel_en-US" xlink:label="lab_ensg_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash leasing arrangement</link:label>
    <link:label id="lab_ensg_NonCashLeaseExpense_label_en-US" xlink:label="lab_ensg_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:label id="lab_ensg_NonCashLeaseExpense_documentation_en-US" xlink:label="lab_ensg_NonCashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCashLeaseExpense" xlink:href="ensg-20231231.xsd#ensg_NonCashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NonCashLeaseExpense" xlink:to="lab_ensg_NonCashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_8842e18e-401f-486f-aa79-aa5f388503b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b82f0fb4-1b16-4fd7-ae99-da060b9c975a_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER ACCRUED LIABILITIES</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_2409c753-2883-4377-8828-38e1c16fc869_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Other</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LessorOperatingLeaseNumberOfLeases_c0d44013-3ee0-4d2b-b95b-ca93404d9328_terseLabel_en-US" xlink:label="lab_ensg_LessorOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_ensg_LessorOperatingLeaseNumberOfLeases_label_en-US" xlink:label="lab_ensg_LessorOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Number Of Leases</link:label>
    <link:label id="lab_ensg_LessorOperatingLeaseNumberOfLeases_documentation_en-US" xlink:label="lab_ensg_LessorOperatingLeaseNumberOfLeases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Number Of New Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LessorOperatingLeaseNumberOfLeases" xlink:to="lab_ensg_LessorOperatingLeaseNumberOfLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_d7cd0bff-7816-4249-997a-81d18f0ec80b_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_19305cd6-183c-4d4b-9c4e-f222cf0080c0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_76312ca0-e4b3-4eb8-924d-8d45880cf721_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_166b5329-0767-4daa-9c69-c43d190479f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued wages and related liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_73ab02d5-ab46-454b-a6a8-ecb85aa28087_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_6d8c751d-9ffc-41c6-892b-dfdf5eb32ccd_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Ensign Group, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e5203b5b-9c05-4e5f-9e3b-a100860fd4c2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities_564cd679-bc9f-40bd-ba02-5414af892582_terseLabel_en-US" xlink:label="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unapplied state relief funds</link:label>
    <link:label id="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities_label_en-US" xlink:label="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, State Relief Contract Liabilities</link:label>
    <link:label id="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities_documentation_en-US" xlink:label="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, State Relief Contract Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:href="ensg-20231231.xsd#ensg_AccruedLiabilitiesStateReliefContractLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:to="lab_ensg_AccruedLiabilitiesStateReliefContractLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_eb77b3cf-a764-4d70-b388-e3453d64eb99_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_8c341670-4ea6-4dd8-bb55-1c664874b20b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to restricted stock awards</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76a0b626-8833-438c-b47d-09f254f69291_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_98712787-d03c-4cdb-857c-15f634b4a0ad_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_5c812c58-3e8a-4fd6-9b28-032b6539a134_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_27fcda81-53f2-4c51-bd4c-ab1caca87464_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d63f659b-da1f-4623-8471-ce2296e37df0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_de307e4f-f832-42a2-ae59-e6fae3473023_terseLabel_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_label_en-US" xlink:label="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Line of Credit Arrangements, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:to="lab_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_CampusOperationMember_92778ad9-6486-4bc3-81bc-66fafc785a85_terseLabel_en-US" xlink:label="lab_ensg_CampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Operation</link:label>
    <link:label id="lab_ensg_CampusOperationMember_label_en-US" xlink:label="lab_ensg_CampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Operation [Member]</link:label>
    <link:label id="lab_ensg_CampusOperationMember_documentation_en-US" xlink:label="lab_ensg_CampusOperationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Campus Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CampusOperationMember" xlink:href="ensg-20231231.xsd#ensg_CampusOperationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_CampusOperationMember" xlink:to="lab_ensg_CampusOperationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_4b586b31-e0ff-4c99-8a08-3c30b3afacd6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8471bfda-7bca-44bc-a9ca-78bae159445e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, effective percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_94314586-0870-4f94-8ac0-bea9c87061f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_ca955950-13d2-4d71-9486-5a388d9c614f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: net income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_31bd8f83-28e7-42f1-b34e-ddb5f357abcc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_950f80e7-d175-4601-b4e1-a8a148675a86_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, by Product Segment [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Future Policy Benefit, by Product Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable" xlink:to="lab_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f8a3dabe-1884-40f9-9331-fa9188d69b80_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_6abf74c7-00d5-40b0-80e0-63f25e9ba1fc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_f7e3a018-eafd-45dd-ad20-704c765bb02d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_710901c5-bc7b-44a2-91eb-53a7a8ed760e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f3ae6292-6ae7-44ff-8941-3f5bf365873b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e66d1c89-5e0a-438d-9020-59275aa84c80_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_094e1597-d27a-4065-bc0b-5979152289ae_terseLabel_en-US" xlink:label="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee leasing arrangements, operating leases, number of renewal terms</link:label>
    <link:label id="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_label_en-US" xlink:label="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms</link:label>
    <link:label id="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_documentation_en-US" xlink:label="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:href="ensg-20231231.xsd#ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:to="lab_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PaymentsForMedicareAndMedicaidLicenses_772abf05-709e-43ed-b30d-9cecc077c92c_negatedTerseLabel_en-US" xlink:label="lab_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments for Medicare and Medicaid licenses</link:label>
    <link:label id="lab_ensg_PaymentsForMedicareAndMedicaidLicenses_label_en-US" xlink:label="lab_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medicare and Medicaid Licenses</link:label>
    <link:label id="lab_ensg_PaymentsForMedicareAndMedicaidLicenses_documentation_en-US" xlink:label="lab_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Medicare and Medicaid Licenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:href="ensg-20231231.xsd#ensg_PaymentsForMedicareAndMedicaidLicenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:to="lab_ensg_PaymentsForMedicareAndMedicaidLicenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_d4faa94d-8615-48de-a7c3-5d11be5aa096_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, period in force</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_A53PromissoryNoteMember_f2776d70-8222-4c69-8645-c8e7e4282d4d_terseLabel_en-US" xlink:label="lab_ensg_A53PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.3% Promissory Note</link:label>
    <link:label id="lab_ensg_A53PromissoryNoteMember_label_en-US" xlink:label="lab_ensg_A53PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.3% Promissory Note [Member]</link:label>
    <link:label id="lab_ensg_A53PromissoryNoteMember_documentation_en-US" xlink:label="lab_ensg_A53PromissoryNoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.3% Promissory Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A53PromissoryNoteMember" xlink:href="ensg-20231231.xsd#ensg_A53PromissoryNoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_A53PromissoryNoteMember" xlink:to="lab_ensg_A53PromissoryNoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_99c59b26-6d95-4ec2-9950-b5b174b94fd6_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_78d64d88-6f30-4135-b81a-22326ca8d923_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMPUTATION OF NET INCOME PER COMMON SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_48aaf591-02dd-4b7e-9fd8-445ffb5d5c85_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StandardBearerEquityPlanMember_0c6e834e-abe3-4727-8a2f-ccd35769e298_terseLabel_en-US" xlink:label="lab_ensg_StandardBearerEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Equity Plan</link:label>
    <link:label id="lab_ensg_StandardBearerEquityPlanMember_label_en-US" xlink:label="lab_ensg_StandardBearerEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Equity Plan [Member]</link:label>
    <link:label id="lab_ensg_StandardBearerEquityPlanMember_documentation_en-US" xlink:label="lab_ensg_StandardBearerEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerEquityPlanMember" xlink:href="ensg-20231231.xsd#ensg_StandardBearerEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StandardBearerEquityPlanMember" xlink:to="lab_ensg_StandardBearerEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_QualityAssuranceFee_d7c9abc9-5e65-425e-90b0-466fe74a7eab_terseLabel_en-US" xlink:label="lab_ensg_QualityAssuranceFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance fee</link:label>
    <link:label id="lab_ensg_QualityAssuranceFee_label_en-US" xlink:label="lab_ensg_QualityAssuranceFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality Assurance Fee</link:label>
    <link:label id="lab_ensg_QualityAssuranceFee_documentation_en-US" xlink:label="lab_ensg_QualityAssuranceFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_QualityAssuranceFee" xlink:href="ensg-20231231.xsd#ensg_QualityAssuranceFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_QualityAssuranceFee" xlink:to="lab_ensg_QualityAssuranceFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_07c2c3fd-e5ce-45bb-b3e6-f0751143c391_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_4ee5100f-56d7-4e9c-b8de-39818997091a_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PrivatePayAndOtherMember_152d87a9-001f-460e-9bbf-2a27e8be2d19_verboseLabel_en-US" xlink:label="lab_ensg_PrivatePayAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private and other</link:label>
    <link:label id="lab_ensg_PrivatePayAndOtherMember_0c298a6e-4840-47e1-800a-b9969478ef3c_terseLabel_en-US" xlink:label="lab_ensg_PrivatePayAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private and other payors</link:label>
    <link:label id="lab_ensg_PrivatePayAndOtherMember_label_en-US" xlink:label="lab_ensg_PrivatePayAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Pay and Other [Member]</link:label>
    <link:label id="lab_ensg_PrivatePayAndOtherMember_documentation_en-US" xlink:label="lab_ensg_PrivatePayAndOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from self-pay and Other payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PrivatePayAndOtherMember" xlink:to="lab_ensg_PrivatePayAndOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_c3dc1565-2750-4f46-b6ff-70e85f711f97_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_naics_ZZ524292_69c68e0b-fc5d-4867-b865-1e2b1fe7824d_terseLabel_en-US" xlink:label="lab_naics_ZZ524292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third-Party Payor</link:label>
    <link:label id="lab_naics_ZZ524292_label_en-US" xlink:label="lab_naics_ZZ524292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">524292 Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ524292" xlink:href="https://xbrl.sec.gov/naics/2023/naics-2023.xsd#naics_ZZ524292"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_naics_ZZ524292" xlink:to="lab_naics_ZZ524292" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_28e4b42b-46f0-4e21-bdaf-c63ace5c19ad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b7257b6c-783c-40f7-ac5d-eaf63a6884bf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price, lower range limit (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a9d56d42-11a1-4c19-a3bc-a53508d2f867_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_842ba69e-4f57-4362-b080-77714fc25c89_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cce01d40-05cb-444a-87ef-266d93bef4cc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_e314b45c-2fa5-46d9-b8a2-3ee35bf6e6a1_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_1e5bd8ab-5095-448e-9fac-2b7c6478f95a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_84f498d4-97c8-4000-a56e-2294a19a6a26_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payment to be Received, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_InvestmentExpenseIncome_218e46e1-12fe-459e-8a51-fc5488e38c35_terseLabel_en-US" xlink:label="lab_ensg_InvestmentExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offsetting expense (income)</link:label>
    <link:label id="lab_ensg_InvestmentExpenseIncome_label_en-US" xlink:label="lab_ensg_InvestmentExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Expense (Income)</link:label>
    <link:label id="lab_ensg_InvestmentExpenseIncome_documentation_en-US" xlink:label="lab_ensg_InvestmentExpenseIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Expense (Income)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InvestmentExpenseIncome" xlink:href="ensg-20231231.xsd#ensg_InvestmentExpenseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_InvestmentExpenseIncome" xlink:to="lab_ensg_InvestmentExpenseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_NumberOfOperatingSubsidiaries_590915be-5f82-411f-a1b8-07020ebfca8e_terseLabel_en-US" xlink:label="lab_ensg_NumberOfOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating subsidiaries</link:label>
    <link:label id="lab_ensg_NumberOfOperatingSubsidiaries_label_en-US" xlink:label="lab_ensg_NumberOfOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Operating Subsidiaries</link:label>
    <link:label id="lab_ensg_NumberOfOperatingSubsidiaries_documentation_en-US" xlink:label="lab_ensg_NumberOfOperatingSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of operating subsidiaries entered into mortgage loans that are insured with HUD.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperatingSubsidiaries" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperatingSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_NumberOfOperatingSubsidiaries" xlink:to="lab_ensg_NumberOfOperatingSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_7c1bf030-b3e8-4f36-b6ae-8903708dc57c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_ca541ccb-8c8d-48cd-85f4-ae23c7e7ddb6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeTenMember_232732da-608b-4fec-8c0e-41e07bd7ec90_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeTenMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeTenMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeTenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Ten [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTenMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeTenMember" xlink:to="lab_ensg_ExercisePriceRangeTenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4aca4c7b-4688-4dea-94d3-9d267585ffcf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Risk-Free Rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_cd1bed94-7944-4f6d-b484-f2bcd4baab59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b2d50c58-3bb7-4450-ac6b-d1bb63b09232_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_80a2f1e1-3090-48f1-81d4-3466db83b0a7_terseLabel_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management fees, as a percentage of total revenues</link:label>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_label_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Management Fee, Percent Fee of Total Revenues</link:label>
    <link:label id="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_documentation_en-US" xlink:label="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Management Fee, Percent Fee of Total Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfTotalRevenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:to="lab_ensg_PropertyManagementFeePercentFeeOfTotalRevenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex_e7bfbf81-a875-47b5-8f39-d8fe9f868165_terseLabel_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer price index</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex_label_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Consumer Price Index</link:label>
    <link:label id="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex_documentation_en-US" xlink:label="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Consumer Price Index</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseConsumerPriceIndex"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:to="lab_ensg_LesseeOperatingLeaseConsumerPriceIndex" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset_3df0040e-77f8-4215-a541-8212ce215318_negatedLabel_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right of use asset</link:label>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset_label_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset_documentation_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="lab_ensg_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_09c56e94-7fad-4ebc-9078-affdd9c91aa2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_1189dc1d-4f21-4981-8cd9-8a4faf59e723_terseLabel_en-US" xlink:label="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other States, Except California, Texas and Washington</link:label>
    <link:label id="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_label_en-US" xlink:label="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other states, except California, Texas and Washington [Member]</link:label>
    <link:label id="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_documentation_en-US" xlink:label="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other states, except California, Texas and Washington</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:href="ensg-20231231.xsd#ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:to="lab_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_aa8b834b-af74-43a4-a1ec-d0ab74aefb8f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_2ac330d2-daa7-4f52-a841-73a5ac16291a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LeasedAssetsAcquiredDuringPeriod_ffd7deec-1d62-4a47-98bc-5ee9091014f1_terseLabel_en-US" xlink:label="lab_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased asset</link:label>
    <link:label id="lab_ensg_LeasedAssetsAcquiredDuringPeriod_label_en-US" xlink:label="lab_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Assets, Acquired During Period</link:label>
    <link:label id="lab_ensg_LeasedAssetsAcquiredDuringPeriod_documentation_en-US" xlink:label="lab_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leased Assets, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:href="ensg-20231231.xsd#ensg_LeasedAssetsAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:to="lab_ensg_LeasedAssetsAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_92123a8a-3c5a-4202-b2a3-0956be8dcb22_terseLabel_en-US" xlink:label="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</link:label>
    <link:label id="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_label_en-US" xlink:label="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program</link:label>
    <link:label id="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_documentation_en-US" xlink:label="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:to="lab_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_5dafcc1a-c111-4392-b037-cd704bbd7ff4_terseLabel_en-US" xlink:label="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare accelerated and advance payment</link:label>
    <link:label id="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_label_en-US" xlink:label="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated And Advance Payment, CARES ACT</link:label>
    <link:label id="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_documentation_en-US" xlink:label="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Accelerated And Advance Payment, CARES ACT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:href="ensg-20231231.xsd#ensg_MedicareAcceleratedAndAdvancePaymentCARESACT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:to="lab_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_539f24cf-518e-4ae2-8cf2-77afefc716d4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deconsolidation of an ancillary business</link:label>
    <link:label id="lab_us-gaap_CashDivestedFromDeconsolidation_label_en-US" xlink:label="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Divested from Deconsolidation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashDivestedFromDeconsolidation" xlink:to="lab_us-gaap_CashDivestedFromDeconsolidation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_9e4f2602-d146-483a-a357-713b636b8469_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Considerations</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_c8bf0041-7c2a-4b12-883f-7edd805572f5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of noncontrolling interest shares</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromRedemptions_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromRedemptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fcd7ac16-f09d-4bd0-843c-6a42e5739dee_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ManagementServiceTotalMember_b4faac41-fabf-43dc-b5d3-1d59f2d621fd_terseLabel_en-US" xlink:label="lab_ensg_ManagementServiceTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Management Fee</link:label>
    <link:label id="lab_ensg_ManagementServiceTotalMember_label_en-US" xlink:label="lab_ensg_ManagementServiceTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service, Total [Member]</link:label>
    <link:label id="lab_ensg_ManagementServiceTotalMember_documentation_en-US" xlink:label="lab_ensg_ManagementServiceTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Management Service, Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagementServiceTotalMember" xlink:href="ensg-20231231.xsd#ensg_ManagementServiceTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ManagementServiceTotalMember" xlink:to="lab_ensg_ManagementServiceTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_58ca7e2e-22b6-47f7-9a49-7bc80d24cc53_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLenderDomain_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Lender [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain" xlink:to="lab_us-gaap_LineOfCreditFacilityLenderDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments_189fae26-1070-4afe-81fa-be9e3c7dbefb_terseLabel_en-US" xlink:label="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance subsidiary deposits and investments</link:label>
    <link:label id="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments_label_en-US" xlink:label="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Subsidiary Deposits And Investments</link:label>
    <link:label id="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments_documentation_en-US" xlink:label="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:href="ensg-20231231.xsd#ensg_InsuranceSubsidiaryDepositsAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:to="lab_ensg_InsuranceSubsidiaryDepositsAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_83755aa0-036d-47d6-b384-398ed464bb16_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_27cdc581-8766-49f8-83b7-0ff835328f1e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_7dd71643-0368-47e4-a23d-6b2640cee4df_verboseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_2188d675-508d-4b14-bf2f-96328176c4ac_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_17c865ce-7713-4e06-ae70-83d442d7d21e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_b011a9c2-98b5-4677-9ddb-e140f8ecd857_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on deferral investment</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EscrowDeposit_32342f91-1362-49c9-bee0-28a1fd6d6092_terseLabel_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow deposits</link:label>
    <link:label id="lab_us-gaap_EscrowDeposit_label_en-US" xlink:label="lab_us-gaap_EscrowDeposit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Escrow Deposit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EscrowDeposit" xlink:to="lab_us-gaap_EscrowDeposit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_0dae2ae7-67b3-46d1-bb89-d3c2c5646cf4_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Liability for Future Policy Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Movement in Liability for Future Policy Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward" xlink:to="lab_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c5284839-0d89-4b20-8c0f-d3490a409e4a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_e7004063-6663-4003-86d6-7b81a578926f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ccea52e3-d598-459d-96ce-3ef2b7031acf_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f1ff393e-42bc-4fef-a634-a6238f748bb5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PurchasesOfNonControllingInterest_aac5a849-e4c4-4a1d-8647-d1b9051cd107_negatedLabel_en-US" xlink:label="lab_ensg_PurchasesOfNonControllingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of non-controlling interest</link:label>
    <link:label id="lab_ensg_PurchasesOfNonControllingInterest_label_en-US" xlink:label="lab_ensg_PurchasesOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Non-Controlling Interest</link:label>
    <link:label id="lab_ensg_PurchasesOfNonControllingInterest_documentation_en-US" xlink:label="lab_ensg_PurchasesOfNonControllingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of Non-Controlling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchasesOfNonControllingInterest" xlink:href="ensg-20231231.xsd#ensg_PurchasesOfNonControllingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PurchasesOfNonControllingInterest" xlink:to="lab_ensg_PurchasesOfNonControllingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ManagedCareMember_f224c637-b0db-4e68-8e8b-643b190cd215_terseLabel_en-US" xlink:label="lab_ensg_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ensg_ManagedCareMember_7888432b-4045-425c-bd38-c956e389b509_verboseLabel_en-US" xlink:label="lab_ensg_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ensg_ManagedCareMember_95fed8d6-af2e-4d77-b068-a8acb2b0a84e_netLabel_en-US" xlink:label="lab_ensg_ManagedCareMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed care</link:label>
    <link:label id="lab_ensg_ManagedCareMember_label_en-US" xlink:label="lab_ensg_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Managed Care [Member]</link:label>
    <link:label id="lab_ensg_ManagedCareMember_documentation_en-US" xlink:label="lab_ensg_ManagedCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from managed care payors [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ManagedCareMember" xlink:to="lab_ensg_ManagedCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_182e5a82-d620-48b2-bb4f-c7a4488d70b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_6f741c3f-dff6-47a1-8bf7-ac0847ef3793_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_4f8da1d5-4101-48e9-8dcd-1e9e80d3e64d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_bee8a44b-c603-449e-bcf6-7c6a37d0250f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Services</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_2496433e-6cc7-4ede-a4f1-ab7c9947873c_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax expense (benefit)</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_eedbeecd-2539-4928-a3f7-023b2b604084_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-controlling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_AmendedMasterLeaseAgreementMember_995a6f46-64db-4eaa-bbb9-f4c3f71f9e4c_terseLabel_en-US" xlink:label="lab_ensg_AmendedMasterLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease Agreement</link:label>
    <link:label id="lab_ensg_AmendedMasterLeaseAgreementMember_label_en-US" xlink:label="lab_ensg_AmendedMasterLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease Agreement [Member]</link:label>
    <link:label id="lab_ensg_AmendedMasterLeaseAgreementMember_documentation_en-US" xlink:label="lab_ensg_AmendedMasterLeaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Master Lease Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseAgreementMember" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_AmendedMasterLeaseAgreementMember" xlink:to="lab_ensg_AmendedMasterLeaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_71257e3c-c7fb-4485-ba0e-9e38a832741a_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_cdeff29c-cbf4-42fa-9a17-279a8c772fce_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredCompensation_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_618017b3-fced-43b6-9e97-2dc75aa49bff_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_e9d5db79-e9ae-49f0-b2cc-4ada2832518a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of restricted stock, net of forfeitures</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_71108c0a-8ed7-46f5-b4e9-7f34885ee101_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_bdb3578d-f50d-42dd-9e13-a29f6c0c2694_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price of Options Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_PrepaymentFeePeriodDomain_c8bbf566-4076-4c8e-a448-7fb0d0b907f2_terseLabel_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period [Domain]</link:label>
    <link:label id="lab_ensg_PrepaymentFeePeriodDomain_label_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period [Domain]</link:label>
    <link:label id="lab_ensg_PrepaymentFeePeriodDomain_documentation_en-US" xlink:label="lab_ensg_PrepaymentFeePeriodDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepayment Fee, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodDomain" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_PrepaymentFeePeriodDomain" xlink:to="lab_ensg_PrepaymentFeePeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_3e413ef0-515c-4d43-8423-e3a933736eac_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_2298b3b9-92d7-4b73-82b5-1c72fc0bdbd2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments on debt (Note 15)</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_06f247e1-a4f1-45e9-b4c6-e9e0e5b54aac_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_43b439e9-9ddc-40bf-b6b1-fe926f61c4a7_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing fees</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1782bbe6-0c18-4489-a3c9-896bbb905d13_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8cfafc15-5d8f-4d38-80d8-dd5e788e2a41_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to stock options</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_199d7ad7-4a64-443e-bd57-e84974d7fb90_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_RentCostOfServices_29e0d44f-a8c9-4c7c-963e-418c5d8fb705_terseLabel_en-US" xlink:label="lab_ensg_RentCostOfServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent&#8212;cost of services</link:label>
    <link:label id="lab_ensg_RentCostOfServices_label_en-US" xlink:label="lab_ensg_RentCostOfServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent Cost Of Services</link:label>
    <link:label id="lab_ensg_RentCostOfServices_documentation_en-US" xlink:label="lab_ensg_RentCostOfServices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent cost of services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentCostOfServices" xlink:href="ensg-20231231.xsd#ensg_RentCostOfServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_RentCostOfServices" xlink:to="lab_ensg_RentCostOfServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_dcf08665-0db2-4084-8bc7-4867197d80d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible expenses</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ThirdPartyOperatorsMember_47b4991b-e21a-49e9-b9c0-081cf8b32f5d_terseLabel_en-US" xlink:label="lab_ensg_ThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party Operators</link:label>
    <link:label id="lab_ensg_ThirdPartyOperatorsMember_label_en-US" xlink:label="lab_ensg_ThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party Operators [Member]</link:label>
    <link:label id="lab_ensg_ThirdPartyOperatorsMember_documentation_en-US" xlink:label="lab_ensg_ThirdPartyOperatorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third Party Operators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyOperatorsMember" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyOperatorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ThirdPartyOperatorsMember" xlink:to="lab_ensg_ThirdPartyOperatorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_dfbc6cbe-af72-45b1-994f-43abb549f23b_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued wages and related liabilities</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_a141d95b-9fae-4d05-83c9-01956d56c7ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_d54acca6-2ae8-4e38-aa33-6b247be8671c_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_e1b8f1ae-101c-407a-b7f8-9d1d3e7289e8_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_6458ede2-baeb-4085-8094-bcd8bfb3ace5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8d3725b6-1b45-4a38-a960-ba758f8ea170_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeaseDescriptionLineItems_31168f3f-ded4-4440-bd61-3c87b0067801_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LessorLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LessorLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LessorLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f56790b5-8236-4f7d-be70-b2e9fc128a13_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL REVENUE</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c8dcbcab-79f8-4d95-a1f0-d54b76ad4e3e_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4873abeb-9e8d-4415-8a31-c3f3a37280ed_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Service Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_217e770d-f7de-43a0-aa7b-8e5f02e96e17_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_34966090-ab1a-4029-ab68-0351c19001c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_de950dec-151b-4554-b2f4-7e38dd4481cb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_InTheFourthYearMember_369904bc-9a99-4450-b027-db7c3c7f3e8c_terseLabel_en-US" xlink:label="lab_ensg_InTheFourthYearMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In The Fourth Year</link:label>
    <link:label id="lab_ensg_InTheFourthYearMember_label_en-US" xlink:label="lab_ensg_InTheFourthYearMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In The Fourth Year [Member]</link:label>
    <link:label id="lab_ensg_InTheFourthYearMember_documentation_en-US" xlink:label="lab_ensg_InTheFourthYearMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In The Fourth Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InTheFourthYearMember" xlink:href="ensg-20231231.xsd#ensg_InTheFourthYearMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_InTheFourthYearMember" xlink:to="lab_ensg_InTheFourthYearMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_0a663403-d296-410a-af68-ba5138edc891_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS &#8212; NET</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_MedicareandMedicaidLicensesMember_ec208902-ad8a-4e15-b6e4-9e34d8f037a8_terseLabel_en-US" xlink:label="lab_ensg_MedicareandMedicaidLicensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid licenses</link:label>
    <link:label id="lab_ensg_MedicareandMedicaidLicensesMember_label_en-US" xlink:label="lab_ensg_MedicareandMedicaidLicensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare and Medicaid Licenses [Member]</link:label>
    <link:label id="lab_ensg_MedicareandMedicaidLicensesMember_documentation_en-US" xlink:label="lab_ensg_MedicareandMedicaidLicensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare licenses for home health and hospice segment and all other segment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareandMedicaidLicensesMember" xlink:href="ensg-20231231.xsd#ensg_MedicareandMedicaidLicensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_MedicareandMedicaidLicensesMember" xlink:to="lab_ensg_MedicareandMedicaidLicensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_9fd9b714-408d-49e2-bb41-514d6a305ba8_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_8a3681bd-2d4a-4dae-86d9-b22c163dd209_totalLabel_en-US" xlink:label="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ACQUISITIONS</link:label>
    <link:label id="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:label id="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_documentation_en-US" xlink:label="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="ensg-20231231.xsd#ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_5c3a88b5-13a8-4a31-af92-8edd0a4b8238_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_115359cb-10dc-47cd-9721-d18c4b26f13e_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StandardBearerSegmentMember_91afbe18-0661-4276-9a77-3a68105e4517_terseLabel_en-US" xlink:label="lab_ensg_StandardBearerSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer</link:label>
    <link:label id="lab_ensg_StandardBearerSegmentMember_label_en-US" xlink:label="lab_ensg_StandardBearerSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Segment [Member]</link:label>
    <link:label id="lab_ensg_StandardBearerSegmentMember_documentation_en-US" xlink:label="lab_ensg_StandardBearerSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Standard Bearer Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerSegmentMember" xlink:href="ensg-20231231.xsd#ensg_StandardBearerSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StandardBearerSegmentMember" xlink:to="lab_ensg_StandardBearerSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_SeniorLivingOperationsMember_3e26d007-5e05-4d02-889c-78d7e6b99c03_terseLabel_en-US" xlink:label="lab_ensg_SeniorLivingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Operations</link:label>
    <link:label id="lab_ensg_SeniorLivingOperationsMember_label_en-US" xlink:label="lab_ensg_SeniorLivingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Operations [Member]</link:label>
    <link:label id="lab_ensg_SeniorLivingOperationsMember_documentation_en-US" xlink:label="lab_ensg_SeniorLivingOperationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Living Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingOperationsMember" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_SeniorLivingOperationsMember" xlink:to="lab_ensg_SeniorLivingOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_c8399e58-eea3-4b67-bdb3-0ea9cd31b502_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LONG-TERM DEBT LESS CURRENT MATURITIES</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesStateTaxes_8528598a-e21e-4d4e-a041-690b50aeb9b5_negatedTerseLabel_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesStateTaxes_label_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, State Taxes</link:label>
    <link:label id="lab_ensg_DeferredTaxLiabilitiesStateTaxes_documentation_en-US" xlink:label="lab_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, State Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:to="lab_ensg_DeferredTaxLiabilitiesStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_35508eb4-c250-46be-b7ff-9627f267321c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GOODWILL</link:label>
    <link:label id="lab_us-gaap_GoodwillDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_bdad2f87-76a3-483b-8096-8584f293d453_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3ecc4b75-50bb-4244-b97f-68fd8ee9dd96_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_18bd2f34-c5c4-48e5-bba1-b5f40351dbcc_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted weighted average common shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_892202af-51b5-474b-8a8e-92f793172cb7_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_d777ff83-d2df-4c41-bb56-28d6ed67827f_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_b2584727-b97e-4161-85db-42a353469df2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired_label_en-US" xlink:label="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:to="lab_us-gaap_IndefinitelivedIntangibleAssetsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_f810d248-5aa5-4b2b-935b-523c3e4d3b25_terseLabel_en-US" xlink:label="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred payment of social security taxes</link:label>
    <link:label id="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_label_en-US" xlink:label="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Deferred Tax Payments Under CARES Act</link:label>
    <link:label id="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_documentation_en-US" xlink:label="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Deferred Tax Payments Under CARES Act</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:href="ensg-20231231.xsd#ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:to="lab_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseVariableLeaseIncome_26b5c579-8e37-4700-8b85-2b44f7e9b36a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseVariableLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, variable lease income</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseVariableLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseVariableLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Variable Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseVariableLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseVariableLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseVariableLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_abae5b7f-3a91-4ea2-8ae8-0a8bc74c9602_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_0ae1a607-a1ee-49a3-9531-b4af021c4121_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TOTAL ASSETS</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_6d18b514-00d8-440d-be81-04c2e06351ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_f3668086-d2fc-4761-a9c4-ab11e89208ee_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ResidentRefundsPayable_ce1e6030-e11b-4f9e-9f18-c22b5628b0b3_terseLabel_en-US" xlink:label="lab_ensg_ResidentRefundsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refunds payable</link:label>
    <link:label id="lab_ensg_ResidentRefundsPayable_label_en-US" xlink:label="lab_ensg_ResidentRefundsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resident Refunds Payable</link:label>
    <link:label id="lab_ensg_ResidentRefundsPayable_documentation_en-US" xlink:label="lab_ensg_ResidentRefundsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resident refunds payable includes amounts due to residents for overpayments and duplicate payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ResidentRefundsPayable" xlink:href="ensg-20231231.xsd#ensg_ResidentRefundsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ResidentRefundsPayable" xlink:to="lab_ensg_ResidentRefundsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e6d60ba6-ee04-4cca-8f4d-d59b0f769b27_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock award compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_85f2fc57-da0c-4068-8fc3-228e4fac1353_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_StockAwardsMember_2acd15ed-cd7f-4691-9882-ac0304dd0eb0_terseLabel_en-US" xlink:label="lab_ensg_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</link:label>
    <link:label id="lab_ensg_StockAwardsMember_label_en-US" xlink:label="lab_ensg_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards [Member]</link:label>
    <link:label id="lab_ensg_StockAwardsMember_documentation_en-US" xlink:label="lab_ensg_StockAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock awards [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StockAwardsMember" xlink:href="ensg-20231231.xsd#ensg_StockAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_StockAwardsMember" xlink:to="lab_ensg_StockAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ExercisePriceRangeSixMember_f59a8de5-ce2f-4a5b-a48d-f3d2e98a35ae_terseLabel_en-US" xlink:label="lab_ensg_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2018</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeSixMember_label_en-US" xlink:label="lab_ensg_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:label id="lab_ensg_ExercisePriceRangeSixMember_documentation_en-US" xlink:label="lab_ensg_ExercisePriceRangeSixMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Six [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSixMember" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSixMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ExercisePriceRangeSixMember" xlink:to="lab_ensg_ExercisePriceRangeSixMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_a72a9145-7a52-4b41-bab1-669d6c275e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_693c548c-165a-4522-871c-92c259dec847_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_70a5d697-c851-4d66-adff-9dacc53c7708_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_9642938e-dd20-4c9d-86b4-ec5b29fe08f0_terseLabel_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than options, conversion to reduce shares availability</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_label_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability</link:label>
    <link:label id="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_documentation_en-US" xlink:label="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:to="lab_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_79ba8445-4b75-455e-bfd7-b1ef3f9a4f5a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_357e633d-6f87-49ff-89cb-76916283bbd3_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e60974de-9aa0-4e4e-91b8-0a7f19ba3e95_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ensg_TripleNetLeaseArrangementsMember_1bdbd512-4246-4c74-b19a-8e77c1a45538_terseLabel_en-US" xlink:label="lab_ensg_TripleNetLeaseArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triple Net Lease Arrangements</link:label>
    <link:label id="lab_ensg_TripleNetLeaseArrangementsMember_label_en-US" xlink:label="lab_ensg_TripleNetLeaseArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triple Net Lease Arrangements [Member]</link:label>
    <link:label id="lab_ensg_TripleNetLeaseArrangementsMember_documentation_en-US" xlink:label="lab_ensg_TripleNetLeaseArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Triple Net Lease Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TripleNetLeaseArrangementsMember" xlink:href="ensg-20231231.xsd#ensg_TripleNetLeaseArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ensg_TripleNetLeaseArrangementsMember" xlink:to="lab_ensg_TripleNetLeaseArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_0b4ce8ed-4d8b-451f-9b95-83627e8eec74_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_318fa574-cd29-4725-abe8-7cb3a3cd7c55_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_c22a2d49-018a-4215-b8f4-71dea9de0649_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_be59aaa1-3ac9-4634-b0ac-b88f2553a4e3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Type and Tier Identifier [Axis]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Type and Tier Identifier [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:to="lab_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_4f6a93f0-1be4-479c-8a9a-8a0e4c7a3c72_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_097d915c-f514-4d65-9b6c-9203a081b05e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Forfeited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_cef7b566-609b-4611-8b80-b2d3ee528108_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncome_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncome" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_5d61e956-ad5e-4bc1-b9ba-22255bb06da6_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of credit facility, unused capacity, commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_828254fe-cbab-40ad-b0c4-9d55f39912df_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_56eedc32-dac8-4e2e-a4fd-84e99090b99d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_3e3875cc-374e-434a-9504-40d3bf5b79b6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_25d1ebd5-792e-46cb-8498-952ed7d20703_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_cf34b0b7-98d9-400a-bb70-91d8a47019e9_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>ensg-20231231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:19b8c51b-a068-4377-9653-a6d716d75b12,g:d8e1560a-118b-412f-95df-e14f0751e57c-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ensigngroup.net/role/Cover" xlink:type="simple" xlink:href="ensg-20231231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0a08b349-00f6-4c92-aea4-51e6bd741ba5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentType_0a08b349-00f6-4c92-aea4-51e6bd741ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b24e270b-a572-4eb1-828c-19458e887d2e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentAnnualReport_b24e270b-a572-4eb1-828c-19458e887d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cb4f3011-9eca-4606-b090-fb2f302dc737" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_CurrentFiscalYearEndDate_cb4f3011-9eca-4606-b090-fb2f302dc737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_51807b14-4473-4f5f-add0-83c9b141776f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentPeriodEndDate_51807b14-4473-4f5f-add0-83c9b141776f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_95e0e99c-1cff-4ad3-a1cf-d1a35551878e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentTransitionReport_95e0e99c-1cff-4ad3-a1cf-d1a35551878e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e7ff385f-73ee-4782-a4e3-5d1e7fef0195" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityFileNumber_e7ff385f-73ee-4782-a4e3-5d1e7fef0195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_a7dec616-3ac9-4899-bae9-72324a6502c7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityRegistrantName_a7dec616-3ac9-4899-bae9-72324a6502c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_bb660b0d-599e-48c8-94a5-9f40cf7baf0c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityIncorporationStateCountryCode_bb660b0d-599e-48c8-94a5-9f40cf7baf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_74754e46-e1ae-46e3-b15e-6318372834d1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityTaxIdentificationNumber_74754e46-e1ae-46e3-b15e-6318372834d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5f915209-63e0-4c96-87b8-242a557d3614" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityAddressAddressLine1_5f915209-63e0-4c96-87b8-242a557d3614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_38d39fc0-e7ce-41f3-9f55-cee0b4671557" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityAddressCityOrTown_38d39fc0-e7ce-41f3-9f55-cee0b4671557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_694b16a5-31a2-48ff-a97c-720a24535fee" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityAddressStateOrProvince_694b16a5-31a2-48ff-a97c-720a24535fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_fecbdba5-82db-440c-9912-f9b4606383f2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityAddressPostalZipCode_fecbdba5-82db-440c-9912-f9b4606383f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_be2797fa-de3e-49dd-b1f0-e143154f5d9f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_CityAreaCode_be2797fa-de3e-49dd-b1f0-e143154f5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_01a7717c-040d-4197-8a61-bb37b4d34fcd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_LocalPhoneNumber_01a7717c-040d-4197-8a61-bb37b4d34fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2c317bdb-f003-4e63-87ef-44ff09fdc7fd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_Security12bTitle_2c317bdb-f003-4e63-87ef-44ff09fdc7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_b1f37030-e3d8-447c-8a49-1dbf54d1ef05" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_TradingSymbol_b1f37030-e3d8-447c-8a49-1dbf54d1ef05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_de345784-aac3-4256-8b49-f77baca60b01" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_SecurityExchangeName_de345784-aac3-4256-8b49-f77baca60b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a10fcc5c-2f87-4128-91e2-5d88b8bba47e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a10fcc5c-2f87-4128-91e2-5d88b8bba47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_70936f86-87cc-4eb2-883b-67236de4e9f3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityVoluntaryFilers_70936f86-87cc-4eb2-883b-67236de4e9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_191569eb-2186-44f4-9c2f-d61d57282a70" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityCurrentReportingStatus_191569eb-2186-44f4-9c2f-d61d57282a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_b889f153-0b25-4417-99b2-6ffe6d4552cb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityInteractiveDataCurrent_b889f153-0b25-4417-99b2-6ffe6d4552cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c77b1081-0882-496e-8b5d-07fc822d1fd7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityFilerCategory_c77b1081-0882-496e-8b5d-07fc822d1fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e221bc03-682a-4b60-99f2-0737e7db73cd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntitySmallBusiness_e221bc03-682a-4b60-99f2-0737e7db73cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5dcd1ea7-93e9-47e7-b07c-6d74f83b4632" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityEmergingGrowthCompany_5dcd1ea7-93e9-47e7-b07c-6d74f83b4632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_9678b938-784f-4e4a-a30f-23e6159bfff2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_IcfrAuditorAttestationFlag_9678b938-784f-4e4a-a30f-23e6159bfff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_e65a1c59-b2d7-4969-aeb6-11d2b1f2726e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_e65a1c59-b2d7-4969-aeb6-11d2b1f2726e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8854d805-0b87-47c0-82d4-012ecf94304b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityShellCompany_8854d805-0b87-47c0-82d4-012ecf94304b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_92881d3e-97c8-4f04-ad66-e087afef595d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityPublicFloat_92881d3e-97c8-4f04-ad66-e087afef595d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f0be2fa8-f5f5-43b6-b1ab-9f670a969009" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f0be2fa8-f5f5-43b6-b1ab-9f670a969009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_bf239356-b482-45dd-bfb5-8a85df4cc6a2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_bf239356-b482-45dd-bfb5-8a85df4cc6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_d7ebd537-946d-4dd0-b71f-6e9d54a550d6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_EntityCentralIndexKey_d7ebd537-946d-4dd0-b71f-6e9d54a550d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_d3a07c4a-00ea-4798-b28d-040b41f58bbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentFiscalYearFocus_d3a07c4a-00ea-4798-b28d-040b41f58bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_c048f326-02c3-4af8-a4cb-c54d33da40bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_DocumentFiscalPeriodFocus_c048f326-02c3-4af8-a4cb-c54d33da40bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4acc0289-a566-4917-a56b-6671e5f93fb2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_ab340d43-213e-4c2b-b019-09dd4b5c4be3" xlink:to="loc_dei_AmendmentFlag_4acc0289-a566-4917-a56b-6671e5f93fb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/AuditInformation" xlink:type="simple" xlink:href="ensg-20231231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AuditInformationAbstract_74f5e058-e61b-4641-a2e3-7806ba166502" xlink:href="ensg-20231231.xsd#ensg_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_9703fd54-3efc-4405-8f84-b6e3aa860339" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_AuditInformationAbstract_74f5e058-e61b-4641-a2e3-7806ba166502" xlink:to="loc_dei_AuditorName_9703fd54-3efc-4405-8f84-b6e3aa860339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_6b4370a9-d3ab-4a04-bbed-3626ddcc6b73" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_AuditInformationAbstract_74f5e058-e61b-4641-a2e3-7806ba166502" xlink:to="loc_dei_AuditorLocation_6b4370a9-d3ab-4a04-bbed-3626ddcc6b73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_ded2b1c8-3ec4-44cb-9bf2-6706c9915e31" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_AuditInformationAbstract_74f5e058-e61b-4641-a2e3-7806ba166502" xlink:to="loc_dei_AuditorFirmId_ded2b1c8-3ec4-44cb-9bf2-6706c9915e31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_393af4b1-5d39-46dc-b8e3-2802ec9f9509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_393af4b1-5d39-46dc-b8e3-2802ec9f9509" xlink:to="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da51fb7c-6396-4242-b16c-1396f1fe9995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_da51fb7c-6396-4242-b16c-1396f1fe9995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_f660db9c-565c-48fc-abec-43c08af5df0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_f660db9c-565c-48fc-abec-43c08af5df0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_9e9a16a1-0dbe-43e0-af60-b785f0e4da66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:to="loc_us-gaap_ShortTermInvestments_9e9a16a1-0dbe-43e0-af60-b785f0e4da66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb9eb972-97ac-41a7-8102-9d462be77513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cb9eb972-97ac-41a7-8102-9d462be77513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_35f55df4-ff14-4385-9574-1264eb255315" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_1a7b1282-80ea-4b6b-a5a9-330f3632f891" xlink:to="loc_us-gaap_AssetsCurrent_35f55df4-ff14-4385-9574-1264eb255315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f5d2a9c6-9d4c-4a2b-9c12-bdcc6804b68c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f5d2a9c6-9d4c-4a2b-9c12-bdcc6804b68c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8bd4e242-4c06-486f-9231-fe16ed3c0a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8bd4e242-4c06-486f-9231-fe16ed3c0a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments_e4ad4386-94f8-468c-98a9-931a6b9ede78" xlink:href="ensg-20231231.xsd#ensg_InsuranceSubsidiaryDepositsAndInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_ensg_InsuranceSubsidiaryDepositsAndInvestments_e4ad4386-94f8-468c-98a9-931a6b9ede78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_f67ca346-7dfc-4beb-a192-f996516a216c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_f67ca346-7dfc-4beb-a192-f996516a216c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RestrictedAndOtherAssetsNoncurrent_5f503fb2-6a18-4b57-9d75-21c74e5d61a1" xlink:href="ensg-20231231.xsd#ensg_RestrictedAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_ensg_RestrictedAndOtherAssetsNoncurrent_5f503fb2-6a18-4b57-9d75-21c74e5d61a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cd96ef85-10f5-42c6-ba05-743a97383f08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_cd96ef85-10f5-42c6-ba05-743a97383f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4d70d275-0cbd-498a-89fd-93506a5f8818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_Goodwill_4d70d275-0cbd-498a-89fd-93506a5f8818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84a69084-f02a-4473-b5cf-6c02c9e7733a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_8d3def60-4b20-4f03-8553-9ed6c80bd04f" xlink:to="loc_us-gaap_Assets_84a69084-f02a-4473-b5cf-6c02c9e7733a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_393af4b1-5d39-46dc-b8e3-2802ec9f9509" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_11ae90f9-9a89-4b1c-94a3-13c07defeb90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_AccountsPayableCurrent_11ae90f9-9a89-4b1c-94a3-13c07defeb90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e04380bf-682f-4cab-b86b-eeba1d0be763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_e04380bf-682f-4cab-b86b-eeba1d0be763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a6ed50c-e4f4-4125-8d60-d8ef49f8cb35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5a6ed50c-e4f4-4125-8d60-d8ef49f8cb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveCurrent_08a4b743-5d42-404b-8204-99adefebaa49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_SelfInsuranceReserveCurrent_08a4b743-5d42-404b-8204-99adefebaa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b794d38d-5496-4107-8778-2ec65ce9eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_b794d38d-5496-4107-8778-2ec65ce9eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_61a3bdd8-5161-41c4-a48b-2e42816ce50b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_LongTermDebtCurrent_61a3bdd8-5161-41c4-a48b-2e42816ce50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bd60af06-b42c-4bbc-a0e1-5591e9062513" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_9576e725-48d5-4c72-8467-8d82cfe47782" xlink:to="loc_us-gaap_LiabilitiesCurrent_bd60af06-b42c-4bbc-a0e1-5591e9062513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_3b67f361-305c-4541-a6f3-bc76a1702732" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount_3b67f361-305c-4541-a6f3-bc76a1702732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bdeaade-f951-4b4a-acb3-3acf51eb32db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_7bdeaade-f951-4b4a-acb3-3acf51eb32db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserveNoncurrent_1eca9431-58ad-4984-adfd-87ced34a48c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserveNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_SelfInsuranceReserveNoncurrent_1eca9431-58ad-4984-adfd-87ced34a48c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAndOtherLongTermLiabilities_69ecef6a-2650-4a20-accf-adc73adab6f9" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAndOtherLongTermLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_ensg_DeferredRentAndOtherLongTermLiabilities_69ecef6a-2650-4a20-accf-adc73adab6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f59c8b18-4c3b-4608-a954-6f979bd0698a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_Liabilities_f59c8b18-4c3b-4608-a954-6f979bd0698a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_cfdc90fb-940d-4ee1-91ec-741222d1688b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_CommitmentsAndContingencies_cfdc90fb-940d-4ee1-91ec-741222d1688b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b8f4f7b8-fffb-4dbd-b6ae-df97dac08c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_EquityAbstract_b8f4f7b8-fffb-4dbd-b6ae-df97dac08c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b8f4f7b8-fffb-4dbd-b6ae-df97dac08c4a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_ea1f314a-502d-4fa0-8f25-d887a3bc689c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:to="loc_us-gaap_CommonStockValue_ea1f314a-502d-4fa0-8f25-d887a3bc689c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_73b0cd74-57cf-4bb8-93ac-b7fe61dc8f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_73b0cd74-57cf-4bb8-93ac-b7fe61dc8f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_394d4475-9cb6-487b-944d-798c80eb19ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_394d4475-9cb6-487b-944d-798c80eb19ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_cca6d53e-1b74-4447-af18-67ee21357783" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:to="loc_us-gaap_TreasuryStockCommonValue_cca6d53e-1b74-4447-af18-67ee21357783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6966ab05-3cc1-4238-9cb9-3de942810bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_807116b9-8aaf-4296-a982-617b718a703e" xlink:to="loc_us-gaap_StockholdersEquity_6966ab05-3cc1-4238-9cb9-3de942810bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3cefcc26-a7ad-405a-b4b4-d34da7359c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b8f4f7b8-fffb-4dbd-b6ae-df97dac08c4a" xlink:to="loc_us-gaap_MinorityInterest_3cefcc26-a7ad-405a-b4b4-d34da7359c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2236e7ec-e627-48c6-ae64-41549e2bc071" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b8f4f7b8-fffb-4dbd-b6ae-df97dac08c4a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2236e7ec-e627-48c6-ae64-41549e2bc071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2eadae3e-b7a3-4239-9dbd-6c0705d3a2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a44f25b3-04fe-46c5-a66d-0b22d384bc56" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2eadae3e-b7a3-4239-9dbd-6c0705d3a2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_145603c4-10c5-47d3-a17b-f2a1291ea1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_145603c4-10c5-47d3-a17b-f2a1291ea1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d36fbf42-0326-47b8-bb85-7e09ac605ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d36fbf42-0326-47b8-bb85-7e09ac605ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_5874977c-5366-46bd-9994-cffc78a742e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_5874977c-5366-46bd-9994-cffc78a742e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8bbf31e4-3eb4-407b-82a8-e696c33c898f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_CommonStockSharesIssued_8bbf31e4-3eb4-407b-82a8-e696c33c898f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5a09f1ff-5cf2-4cf3-9ee9-f19d3b62ddab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5a09f1ff-5cf2-4cf3-9ee9-f19d3b62ddab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_f599f74f-d5f7-492f-8be5-4d4feda1581a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_d27f101c-2ac7-4754-b470-fc5cf4dfee7e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_f599f74f-d5f7-492f-8be5-4d4feda1581a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFINCOME"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_91b3ed05-8f69-4388-b418-5fff33308e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_91b3ed05-8f69-4388-b418-5fff33308e5d" xlink:to="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:to="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_62bb06fe-afdc-49f4-9ec8-9dcc52222a91" xlink:to="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1954bf64-fdf2-4ff1-8f7e-985982dfb984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:to="loc_us-gaap_ServiceMember_1954bf64-fdf2-4ff1-8f7e-985982dfb984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_93464e72-c200-4143-814b-199fe0ea5e44" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_63a2c9ad-97a6-4c89-92ed-36ccf2c3d1c0" xlink:to="loc_ensg_RentalMember_93464e72-c200-4143-814b-199fe0ea5e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_5d814803-1016-4d42-86ba-896e6717b1d7" xlink:to="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a8c584d-fa8d-4f24-b1a1-1914733ce76f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9a8c584d-fa8d-4f24-b1a1-1914733ce76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_89c57ce4-6453-467b-a309-db944acbf3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_89c57ce4-6453-467b-a309-db944acbf3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentCostOfServices_1c9b999e-944a-4796-abed-21edaca673f3" xlink:href="ensg-20231231.xsd#ensg_RentCostOfServices"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_ensg_RentCostOfServices_1c9b999e-944a-4796-abed-21edaca673f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_f40d344a-beb6-448e-acae-ff4f6952bc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_f40d344a-beb6-448e-acae-ff4f6952bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_697f7715-0a64-46f7-93fd-88dc81867ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_697f7715-0a64-46f7-93fd-88dc81867ac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f87e167d-e767-45df-904b-b4be4a76f364" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_d9168887-2a98-495d-86d7-742fd3fda9b7" xlink:to="loc_us-gaap_CostsAndExpenses_f87e167d-e767-45df-904b-b4be4a76f364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_09ff63f5-041e-45f4-a054-2b2771847d59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_OperatingIncomeLoss_09ff63f5-041e-45f4-a054-2b2771847d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_73e6a4c8-bef1-490b-a988-1998d2cd170d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_InterestExpense_73e6a4c8-bef1-490b-a988-1998d2cd170d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a7d37735-5c07-483a-b7be-e30485ea867d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a7d37735-5c07-483a-b7be-e30485ea867d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6c84b61b-21ef-43d5-aa73-d763656cd501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_2a86d8d7-0fad-44ba-8d06-a361060e7baa" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6c84b61b-21ef-43d5-aa73-d763656cd501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c908ee79-7d40-4874-980b-8e0d91b90fde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c908ee79-7d40-4874-980b-8e0d91b90fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ea1958dd-1ab5-414b-8800-6e425efaf79d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ea1958dd-1ab5-414b-8800-6e425efaf79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9036c3c9-3da0-41ad-9ba2-ace923dffd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_ProfitLoss_9036c3c9-3da0-41ad-9ba2-ace923dffd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a45d9221-4fb8-4cb5-bae8-3996abae2329" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract_e388a908-622a-4167-b534-ee90e0acba76" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a45d9221-4fb8-4cb5-bae8-3996abae2329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_83791502-209a-4106-a62c-2486afcbc0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_NetIncomeLoss_83791502-209a-4106-a62c-2486afcbc0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_faed624a-143b-45a9-af9a-9f4f9a1a2678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:to="loc_us-gaap_EarningsPerShareBasic_faed624a-143b-45a9-af9a-9f4f9a1a2678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_69ec8cee-0a74-48e5-90f4-17ee2a4242cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0cae3581-81b2-4028-80a2-e720119dd01d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_69ec8cee-0a74-48e5-90f4-17ee2a4242cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f05cdeaf-458a-4c78-980a-2c00d2aaa77d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203c0181-149f-4c2e-b9d0-22133710e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_203c0181-149f-4c2e-b9d0-22133710e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb8b8d3c-ab95-47ba-9e8b-b6a5ddc603cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_a0b88c80-ca7a-43bb-9e81-e52766548d97" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb8b8d3c-ab95-47ba-9e8b-b6a5ddc603cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_30e6b696-c22b-4c57-9044-f13ea2d56a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_30e6b696-c22b-4c57-9044-f13ea2d56a78" xlink:to="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7efc0140-e133-4ce6-8c84-7715e5c6a4bd" xlink:to="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_07a914ab-7e79-4b1b-9004-e1d57627d2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_CommonStockMember_07a914ab-7e79-4b1b-9004-e1d57627d2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f3987071-3a7f-418e-9b3b-b477c79c4d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f3987071-3a7f-418e-9b3b-b477c79c4d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b96ef356-9960-4e1c-b27e-10799ceb53be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_RetainedEarningsMember_b96ef356-9960-4e1c-b27e-10799ceb53be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_cf5e3934-7c78-4411-a392-0201e7599ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_TreasuryStockCommonMember_cf5e3934-7c78-4411-a392-0201e7599ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_3875aa40-f331-43b9-a30e-b06ae3f92d4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_79af3af4-ebc2-4fff-a47d-7c7c3c06aaef" xlink:to="loc_us-gaap_NoncontrollingInterestMember_3875aa40-f331-43b9-a30e-b06ae3f92d4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4cb8647a-74f9-4b58-aede-9ead6c63a247" xlink:to="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_96e9d3e4-145e-481e-b8a7-1d781a5cba80" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_a0bea466-ddb3-4aa3-94d4-0084b674bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_a0bea466-ddb3-4aa3-94d4-0084b674bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0f9749e-d281-4b8a-978b-900eeec4138d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a0f9749e-d281-4b8a-978b-900eeec4138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_0193cb6a-b6dd-4776-80b7-c65ded7280a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_0193cb6a-b6dd-4776-80b7-c65ded7280a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_680160dd-7610-4451-b2a8-e79b7c214b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_680160dd-7610-4451-b2a8-e79b7c214b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97fc56e2-98db-42dc-bf9a-3ed7f86f0790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_97fc56e2-98db-42dc-bf9a-3ed7f86f0790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_59448343-d532-4d48-a6b0-689d07616c47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_59448343-d532-4d48-a6b0-689d07616c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_317eb2d5-1d09-4a20-a26e-470e7aab354d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_317eb2d5-1d09-4a20-a26e-470e7aab354d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a64d3ee5-8fba-4185-a5b0-5384ad40868e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_a64d3ee5-8fba-4185-a5b0-5384ad40868e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bec87b70-15d8-43ba-9b0b-575231078a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_bec87b70-15d8-43ba-9b0b-575231078a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Dividends_8f4c5a16-cca9-4d04-9860-028acec21658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Dividends"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_Dividends_8f4c5a16-cca9-4d04-9860-028acec21658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a8caa11-74e8-41c6-b12c-b5a9ccd43723" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_8a8caa11-74e8-41c6-b12c-b5a9ccd43723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_30653be0-3be4-4eed-b053-2b3723ef5422" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_30653be0-3be4-4eed-b053-2b3723ef5422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01be448c-e5c6-4207-a0ea-f38f4a60dba7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_01be448c-e5c6-4207-a0ea-f38f4a60dba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc817aca-5900-42b0-a2cf-370a4f3e1bd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromRedemptions"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromRedemptions_cc817aca-5900-42b0-a2cf-370a4f3e1bd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d1ea7105-189b-49de-bc4b-dca9319cd34c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation_d1ea7105-189b-49de-bc4b-dca9319cd34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a8026db5-a029-4a88-bfbc-2c2fa689e955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_a8026db5-a029-4a88-bfbc-2c2fa689e955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20ecef23-9c8e-4655-9dc6-86b4d8da9003" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_20ecef23-9c8e-4655-9dc6-86b4d8da9003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_50981af5-62c0-4b27-aa0e-4cc3d2f2ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_50981af5-62c0-4b27-aa0e-4cc3d2f2ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9d9207d4-73c7-48a6-8724-498831ce39a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_NetIncomeLoss_9d9207d4-73c7-48a6-8724-498831ce39a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_c1fd46bf-357a-4584-aa29-17e2a694a0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_c1fd46bf-357a-4584-aa29-17e2a694a0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc6773c-4585-42e9-b0a4-35a0c22f4898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4dc6773c-4585-42e9-b0a4-35a0c22f4898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_61003745-4394-41b4-8c1e-cf5df168904e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_086afefb-d26d-4d5b-847a-a85cb61ed67e" xlink:to="loc_us-gaap_TreasuryStockCommonShares_61003745-4394-41b4-8c1e-cf5df168904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_6974f6bf-c195-4d0e-be25-719eb9309156" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_21e50731-8629-4cc3-a900-b1a8d69c86d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_6974f6bf-c195-4d0e-be25-719eb9309156" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_21e50731-8629-4cc3-a900-b1a8d69c86d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="ensg-20231231.xsd#CONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bd7694-fe77-4d2d-8d76-e43bf0e5452d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bd7694-fe77-4d2d-8d76-e43bf0e5452d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_800a0ada-392b-4c56-895b-7efe4e1e7324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bd7694-fe77-4d2d-8d76-e43bf0e5452d" xlink:to="loc_us-gaap_ProfitLoss_800a0ada-392b-4c56-895b-7efe4e1e7324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bd7694-fe77-4d2d-8d76-e43bf0e5452d" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_12d22e1e-26ef-4b4d-9677-af5ec24bde7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_12d22e1e-26ef-4b4d-9677-af5ec24bde7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2419aadc-15cd-48b1-9940-e7b5ce2e2ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_2419aadc-15cd-48b1-9940-e7b5ce2e2ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCashLeaseExpense_1b2604bb-06fe-451d-ab58-4ee7ee027859" xlink:href="ensg-20231231.xsd#ensg_NonCashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_ensg_NonCashLeaseExpense_1b2604bb-06fe-451d-ab58-4ee7ee027859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_8b821433-9128-4a84-810a-6392d554e162" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_8b821433-9128-4a84-810a-6392d554e162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d4479e64-18cb-4be0-b9de-b02104d3d64c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d4479e64-18cb-4be0-b9de-b02104d3d64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_c4ef7f41-f291-4fe5-8c2d-d084f8d51e66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_c4ef7f41-f291-4fe5-8c2d-d084f8d51e66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1e73283a-e623-4e89-825d-f64dcc742964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_ShareBasedCompensation_1e73283a-e623-4e89-825d-f64dcc742964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_436f5ce5-eacd-4219-91b3-0d8672b0de45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities_436f5ce5-eacd-4219-91b3-0d8672b0de45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b4c70a9f-aef8-4ec0-bf1e-acd84a80a129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b4c70a9f-aef8-4ec0-bf1e-acd84a80a129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_142c63ea-379c-4078-83e6-52f44544927e" xlink:href="ensg-20231231.xsd#ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets_142c63ea-379c-4078-83e6-52f44544927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_496a121b-5962-4e78-a404-54a1517148ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_LitigationSettlementExpense_496a121b-5962-4e78-a404-54a1517148ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_08da8c04-4956-4305-b846-7850f3f674a5" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2cc9f50-950b-485c-be3c-90cad90e1fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_f2cc9f50-950b-485c-be3c-90cad90e1fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_6ca681ef-2296-4eee-82aa-c9dc00a1e2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidTaxes_6ca681ef-2296-4eee-82aa-c9dc00a1e2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b14f54e-5574-497c-96f6-91f3843096ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_5b14f54e-5574-497c-96f6-91f3843096ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_1b1b62f4-0780-4842-af89-7bae35421072" xlink:href="ensg-20231231.xsd#ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct_1b1b62f4-0780-4842-af89-7bae35421072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_c84fc359-44b9-4e7f-ab48-806d7187ca0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue_c84fc359-44b9-4e7f-ab48-806d7187ca0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_879b6e39-638e-41b9-82c2-5aa26215794c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredCompensation_879b6e39-638e-41b9-82c2-5aa26215794c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d5ccd5c4-3c8c-45c0-8fc7-6ea6e8532f22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_d5ccd5c4-3c8c-45c0-8fc7-6ea6e8532f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_18b0ce4d-9342-4e41-bcc6-6755996b9063" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_18b0ce4d-9342-4e41-bcc6-6755996b9063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8d7e9f35-da96-4902-af08-0c903dba96c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_8d7e9f35-da96-4902-af08-0c903dba96c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_91903739-a7bf-4e74-b331-ca9b36137493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_91903739-a7bf-4e74-b331-ca9b36137493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_7f8ca265-e501-4739-a18f-06dcef7b1cff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInSelfInsuranceReserve"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInSelfInsuranceReserve_7f8ca265-e501-4739-a18f-06dcef7b1cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_019866e0-1e90-40fa-8c08-4c45082d44c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5377f94d-918b-450e-8414-3bd68cda2628" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeferredLiability_019866e0-1e90-40fa-8c08-4c45082d44c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_782154a1-6072-4d68-80a6-2a6dd6e1b780" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bd7694-fe77-4d2d-8d76-e43bf0e5452d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_782154a1-6072-4d68-80a6-2a6dd6e1b780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquirePropertyAndEquipment_1dc4de46-73af-4ee3-80a2-ce5b2935b1ec" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquirePropertyAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_ensg_PaymentsToAcquirePropertyAndEquipment_1dc4de46-73af-4ee3-80a2-ce5b2935b1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4ad87722-7169-4669-878c-e1106a5430c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4ad87722-7169-4669-878c-e1106a5430c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsToAcquireAssetAcquisitions_bb4aec48-2834-4472-b4f7-85bc43e71ff7" xlink:href="ensg-20231231.xsd#ensg_PaymentsToAcquireAssetAcquisitions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_ensg_PaymentsToAcquireAssetAcquisitions_bb4aec48-2834-4472-b4f7-85bc43e71ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_a7b3a222-b576-433f-a64d-9dac5a1b6313" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions_a7b3a222-b576-433f-a64d-9dac5a1b6313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_9a31456b-c940-4896-bb23-7d838a70ada5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_9a31456b-c940-4896-bb23-7d838a70ada5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_958e5987-b93b-4a0f-88be-66f60b4ba5b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_958e5987-b93b-4a0f-88be-66f60b4ba5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashDivestedFromDeconsolidation_cc2256e8-0e2f-440c-8cfe-23c3ef654fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashDivestedFromDeconsolidation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_CashDivestedFromDeconsolidation_cc2256e8-0e2f-440c-8cfe-23c3ef654fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PaymentsForMedicareAndMedicaidLicenses_dbac7aee-cb4f-4976-93cf-9e9862af6fce" xlink:href="ensg-20231231.xsd#ensg_PaymentsForMedicareAndMedicaidLicenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_ensg_PaymentsForMedicareAndMedicaidLicenses_dbac7aee-cb4f-4976-93cf-9e9862af6fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_372ea8e2-9098-4d81-afbb-79a2842d4331" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_372ea8e2-9098-4d81-afbb-79a2842d4331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1bc266e-b7e6-4322-99f2-3306ab27cf79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b1bc266e-b7e6-4322-99f2-3306ab27cf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d8121d4-be5c-49e7-af33-615903004b39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_3d8121d4-be5c-49e7-af33-615903004b39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17effbf2-ec4d-433d-b130-a1432b0d9520" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_628374f9-3dfc-41f0-800f-4664a4184b1e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17effbf2-ec4d-433d-b130-a1432b0d9520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_19336d09-bd4c-424b-888e-d51abe5cecac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_19336d09-bd4c-424b-888e-d51abe5cecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_078e3467-0d3f-4ca7-ab7c-3ab8a1fd5856" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_078e3467-0d3f-4ca7-ab7c-3ab8a1fd5856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f6ce4c49-9888-4bbd-8cd7-14fbe910f056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f6ce4c49-9888-4bbd-8cd7-14fbe910f056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d8b554b1-d678-4602-93c0-9bf4a0c2887b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_d8b554b1-d678-4602-93c0-9bf4a0c2887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c0b24024-a84d-45aa-9dc1-0ae89be46233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c0b24024-a84d-45aa-9dc1-0ae89be46233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividends_ba8dfb82-b151-49fa-969b-2223f21a319e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_PaymentsOfDividends_ba8dfb82-b151-49fa-969b-2223f21a319e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_73f85dc1-a6c0-4f0c-a14f-99ff44597828" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans_73f85dc1-a6c0-4f0c-a14f-99ff44597828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToMinorityShareholders_0f98fca8-579e-4aa0-b76d-060d921c6394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToMinorityShareholders"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_PaymentsToMinorityShareholders_0f98fca8-579e-4aa0-b76d-060d921c6394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchasesOfNonControllingInterest_f6efa7df-5798-4097-8a68-d15d0729a6c7" xlink:href="ensg-20231231.xsd#ensg_PurchasesOfNonControllingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_ensg_PurchasesOfNonControllingInterest_f6efa7df-5798-4097-8a68-d15d0729a6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_028de934-9b91-4ec8-b19b-0f95356616e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_028de934-9b91-4ec8-b19b-0f95356616e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_bde21a7b-d7a6-4c7c-aaf1-634314ebb1a1" xlink:href="ensg-20231231.xsd#ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram_bde21a7b-d7a6-4c7c-aaf1-634314ebb1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_838e288d-8d66-4399-9021-ce6c63eb2d93" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid_838e288d-8d66-4399-9021-ce6c63eb2d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75440a5d-6230-4ac4-a5a0-47166fed49d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_3f636549-476b-45af-a73b-6fcde98c6653" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_75440a5d-6230-4ac4-a5a0-47166fed49d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85d2c38c-9e06-4b14-924c-92fd0109bff3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_85d2c38c-9e06-4b14-924c-92fd0109bff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f3a046d2-52d1-4d40-aa4f-5102108634cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_f3a046d2-52d1-4d40-aa4f-5102108634cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e7c3a4ab-ec35-4efc-92ac-6b7cf1601f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_e7c3a4ab-ec35-4efc-92ac-6b7cf1601f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_859b9071-14f2-4283-9997-7ca4dc47240e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_51b890a7-774b-4d27-b300-86f5d545a799" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_859b9071-14f2-4283-9997-7ca4dc47240e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5ef7949a-a45f-4779-92ac-65717ea88cae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_859b9071-14f2-4283-9997-7ca4dc47240e" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5ef7949a-a45f-4779-92ac-65717ea88cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_e3a8e137-0c39-4d8c-b15d-39c4fbbbef75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5ef7949a-a45f-4779-92ac-65717ea88cae" xlink:to="loc_us-gaap_InterestPaidNet_e3a8e137-0c39-4d8c-b15d-39c4fbbbef75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_fc118f4f-3722-4dc2-930d-771af6dc0af5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5ef7949a-a45f-4779-92ac-65717ea88cae" xlink:to="loc_us-gaap_IncomeTaxesPaid_fc118f4f-3722-4dc2-930d-771af6dc0af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_7985dc2f-bf7d-4386-a8a8-2ef444096fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_5ef7949a-a45f-4779-92ac-65717ea88cae" xlink:to="loc_us-gaap_OperatingLeasePayments_7985dc2f-bf7d-4386-a8a8-2ef444096fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_a55116f8-c51c-422a-bfd6-8dc2f49a32d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_859b9071-14f2-4283-9997-7ca4dc47240e" xlink:to="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_a55116f8-c51c-422a-bfd6-8dc2f49a32d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5f03700b-8ab1-4a75-b6c4-8941dd20efa1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_a55116f8-c51c-422a-bfd6-8dc2f49a32d4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5f03700b-8ab1-4a75-b6c4-8941dd20efa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_363b345a-35e2-4eac-8b43-32a8976dc1ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_a55116f8-c51c-422a-bfd6-8dc2f49a32d4" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_363b345a-35e2-4eac-8b43-32a8976dc1ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c319b056-2c8a-45f3-8fac-d1744691f0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract_a55116f8-c51c-422a-bfd6-8dc2f49a32d4" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c319b056-2c8a-45f3-8fac-d1744691f0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="ensg-20231231.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d340466b-8cd5-4d03-b14f-48d320dfc0fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a4a7f67f-99ba-4ce5-b5df-9ec7316f76b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d340466b-8cd5-4d03-b14f-48d320dfc0fb" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_a4a7f67f-99ba-4ce5-b5df-9ec7316f76b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_30723fd9-c47f-48d0-b6ba-e0b170d06863" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f95047f3-8624-468d-b254-2548461b41a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_30723fd9-c47f-48d0-b6ba-e0b170d06863" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_f95047f3-8624-468d-b254-2548461b41a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLE"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_67c6ea8f-88f6-4ae0-946c-8bbd612eaa41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a8e3ef3d-1449-4cb1-82e8-31fa0232c00b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_67c6ea8f-88f6-4ae0-946c-8bbd612eaa41" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_a8e3ef3d-1449-4cb1-82e8-31fa0232c00b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMPUTATIONOFNETINCOMEPERCOMMONSHARE"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0ea637ee-dc9d-47cd-a549-9ddf18809e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_432df1ad-a70f-4849-af06-a03084dbbed1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0ea637ee-dc9d-47cd-a549-9ddf18809e56" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_432df1ad-a70f-4849-af06-a03084dbbed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS" xlink:type="simple" xlink:href="ensg-20231231.xsd#FAIRVALUEMEASUREMENTS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3dac2aa2-016b-4255-8e4b-217b46025e99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_036e9af0-151b-429b-9ccb-a0cef7daa347" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3dac2aa2-016b-4255-8e4b-217b46025e99" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_036e9af0-151b-429b-9ccb-a0cef7daa347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/STANDARDBEARER" xlink:type="simple" xlink:href="ensg-20231231.xsd#STANDARDBEARER"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/STANDARDBEARER" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_aca801f4-197d-4864-847f-2b6c5ae895fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerTextBlock_ac5553e7-3c8a-4d5d-9875-68117e7c0beb" xlink:href="ensg-20231231.xsd#ensg_StandardBearerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_aca801f4-197d-4864-847f-2b6c5ae895fe" xlink:to="loc_ensg_StandardBearerTextBlock_ac5553e7-3c8a-4d5d-9875-68117e7c0beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONS" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b53d7260-0afe-45b8-b7ae-bcce2cf121a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8d3540f8-6a96-4ea3-8d73-6e7951ce387b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_b53d7260-0afe-45b8-b7ae-bcce2cf121a2" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_8d3540f8-6a96-4ea3-8d73-6e7951ce387b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTS" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a6daffb4-d522-455e-bae6-f0231c98866b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e6c0bde6-903d-47b1-b099-122b2094e287" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a6daffb4-d522-455e-bae6-f0231c98866b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e6c0bde6-903d-47b1-b099-122b2094e287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNET"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a8c5f0d6-2b51-42cd-b01a-aed898db84b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e94d695e-0473-421a-81a9-d657b9ee2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a8c5f0d6-2b51-42cd-b01a-aed898db84b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_e94d695e-0473-421a-81a9-d657b9ee2be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNET" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNET"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNET" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21c069fc-0dcd-4aa0-b85d-20bd20942e85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8c90fd9b-b271-4d30-bbd7-4640daaecd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_21c069fc-0dcd-4aa0-b85d-20bd20942e85" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_8c90fd9b-b271-4d30-bbd7-4640daaecd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/GOODWILL" xlink:type="simple" xlink:href="ensg-20231231.xsd#GOODWILL"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/GOODWILL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1325562b-34ac-4feb-b027-02bdbb0c6c72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillDisclosureTextBlock_e9b144ec-f503-403a-b21c-cce1a9d772e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1325562b-34ac-4feb-b027-02bdbb0c6c72" xlink:to="loc_us-gaap_GoodwillDisclosureTextBlock_e9b144ec-f503-403a-b21c-cce1a9d772e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS" xlink:type="simple" xlink:href="ensg-20231231.xsd#RESTRICTEDANDOTHERASSETS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e49ddeff-176b-48d8-b96e-4fc347328ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsDisclosureTextBlock_e1db803d-fc8a-46ef-a4be-d11ff973afbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_e49ddeff-176b-48d8-b96e-4fc347328ad0" xlink:to="loc_us-gaap_OtherAssetsDisclosureTextBlock_e1db803d-fc8a-46ef-a4be-d11ff973afbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES" xlink:type="simple" xlink:href="ensg-20231231.xsd#OTHERACCRUEDLIABILITIES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d35bd819-cff7-4835-ab81-66b3f7ddad3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2ef5282a-073b-4f68-bcce-575dac0b33eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d35bd819-cff7-4835-ab81-66b3f7ddad3a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_2ef5282a-073b-4f68-bcce-575dac0b33eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXES" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7044f4e6-dbb2-4785-b9eb-7f879dd3e873" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c2fdb3ca-3720-48c1-af3d-1d875462dddf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7044f4e6-dbb2-4785-b9eb-7f879dd3e873" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c2fdb3ca-3720-48c1-af3d-1d875462dddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBT" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBT"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_38c14d13-59a3-484c-ad41-7cd1200d84fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f301c331-02c7-47ce-87e9-1d63431c40f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_38c14d13-59a3-484c-ad41-7cd1200d84fc" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f301c331-02c7-47ce-87e9-1d63431c40f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDS" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c43bfb43-57cf-4920-b651-75bc3e7303d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2e1ca42-93f2-48f9-afe3-e8e21dc0aa67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c43bfb43-57cf-4920-b651-75bc3e7303d9" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d2e1ca42-93f2-48f9-afe3-e8e21dc0aa67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASES" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6eeea9aa-b735-4af1-89a3-a823990f6631" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_21b94f45-7a6e-4bfa-a013-eb5884e33cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6eeea9aa-b735-4af1-89a3-a823990f6631" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_21b94f45-7a6e-4bfa-a013-eb5884e33cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_ae72c387-636c-4a1e-a399-bd47ccea4f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6eeea9aa-b735-4af1-89a3-a823990f6631" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_ae72c387-636c-4a1e-a399-bd47ccea4f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEFINEDCONTRIBUTIONPLANS"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c0845730-8b4f-4c50-8510-ce8050843aff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6e85d1da-a361-49cf-b3f3-2c1b87ff6604" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c0845730-8b4f-4c50-8510-ce8050843aff" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_6e85d1da-a361-49cf-b3f3-2c1b87ff6604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES" xlink:type="simple" xlink:href="ensg-20231231.xsd#SELFINSURANCELIABILITIES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_e754967d-3381-4fe9-919f-fd24b70d2be5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_e2de6fe3-d0d8-48a8-9fef-2744f7f982f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_e754967d-3381-4fe9-919f-fd24b70d2be5" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock_e2de6fe3-d0d8-48a8-9fef-2744f7f982f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d104a00-6b3a-40d9-bbb0-8895d7f11ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0aeccea8-9534-4440-b606-8c50e9bc65f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0d104a00-6b3a-40d9-bbb0-8895d7f11ec3" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0aeccea8-9534-4440-b606-8c50e9bc65f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMONSTOCKREPURCHASEPROGRAM"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_53cb2314-b0ca-4208-bcce-7a399259f652" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33affa44-d626-41ec-9479-6c9ea432f9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_53cb2314-b0ca-4208-bcce-7a399259f652" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_33affa44-d626-41ec-9479-6c9ea432f9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5ef25914-d687-4e05-83da-e5be7236c76a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_5ef25914-d687-4e05-83da-e5be7236c76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8bd9f2a1-119e-4498-a0fb-421d833bf39e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8bd9f2a1-119e-4498-a0fb-421d833bf39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_29e79e24-e36f-4d10-a458-d3f5c5a57188" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_UseOfEstimates_29e79e24-e36f-4d10-a458-d3f5c5a57188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8070a8d4-af85-476f-a792-e4bc4a864d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_8070a8d4-af85-476f-a792-e4bc4a864d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f8d4d1b5-e99a-4060-b38a-4eb963acc6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f8d4d1b5-e99a-4060-b38a-4eb963acc6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_63868dae-b6dc-4c26-9d9c-9cf26549dee5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_63868dae-b6dc-4c26-9d9c-9cf26549dee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c275c8c-687c-4289-8051-2aa43d6ea4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_0c275c8c-687c-4289-8051-2aa43d6ea4b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_5917e7a4-bcf6-491b-a077-6626e9d1613e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_5917e7a4-bcf6-491b-a077-6626e9d1613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_44bf80c3-bac5-4009-b4da-d7aa77206339" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_44bf80c3-bac5-4009-b4da-d7aa77206339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_e8c435fb-c79e-4314-abe8-724210ac718d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_e8c435fb-c79e-4314-abe8-724210ac718d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_eb8d7b97-ff6f-40ab-8220-754b7f131def" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_eb8d7b97-ff6f-40ab-8220-754b7f131def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ef245674-3d28-4eaf-be70-c33d65862112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_ef245674-3d28-4eaf-be70-c33d65862112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_d378726a-5b34-4f42-bc09-a35c70cc957f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReservePolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_SelfInsuranceReservePolicyTextBlock_d378726a-5b34-4f42-bc09-a35c70cc957f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_73701c88-c968-4ce7-b4ba-6adf4e9af8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_73701c88-c968-4ce7-b4ba-6adf4e9af8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NoncontrollingInterestPolicyTextBlock_39499b23-19b8-4dfe-ac99-b34aac5fe3c0" xlink:href="ensg-20231231.xsd#ensg_NoncontrollingInterestPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_ensg_NoncontrollingInterestPolicyTextBlock_39499b23-19b8-4dfe-ac99-b34aac5fe3c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a61517e3-2faa-46ed-9d70-a2000321cb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_a61517e3-2faa-46ed-9d70-a2000321cb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb8800ce-511c-42b9-9d63-663321ab8ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6fc8520-a676-4353-b96f-3997602e00ed" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_eb8800ce-511c-42b9-9d63-663321ab8ad1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLETables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_463ac51d-4714-46ce-bf72-951782ff26df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a7fe0e04-667b-44e2-a8b3-051b3fac790e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_463ac51d-4714-46ce-bf72-951782ff26df" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_a7fe0e04-667b-44e2-a8b3-051b3fac790e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1a38c008-bd6b-425a-afa8-e1904253bf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_463ac51d-4714-46ce-bf72-951782ff26df" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1a38c008-bd6b-425a-afa8-e1904253bf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMPUTATIONOFNETINCOMEPERCOMMONSHARETables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_314fa97d-600d-4869-b9a2-1f56487bdd37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_6307c46d-eff3-49ca-ba64-9714a2b9b749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_314fa97d-600d-4869-b9a2-1f56487bdd37" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_6307c46d-eff3-49ca-ba64-9714a2b9b749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_8c3b9d59-e25c-4422-ba1c-246324b6488b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_314fa97d-600d-4869-b9a2-1f56487bdd37" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_8c3b9d59-e25c-4422-ba1c-246324b6488b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c53e76f0-ddb4-43a3-a0c6-a6fd109489b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_693bb2a3-2b94-41b9-b24a-4e8c758503fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_c53e76f0-ddb4-43a3-a0c6-a6fd109489b5" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_693bb2a3-2b94-41b9-b24a-4e8c758503fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_36060b64-951f-490b-8799-3cc8d019e005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_412e8fde-d89d-4537-a49d-b607d367bec1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36060b64-951f-490b-8799-3cc8d019e005" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_412e8fde-d89d-4537-a49d-b607d367bec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_1814c8fa-8792-4b51-a887-2ddcc3fb685f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_36060b64-951f-490b-8799-3cc8d019e005" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_1814c8fa-8792-4b51-a887-2ddcc3fb685f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d2e5b82a-82a0-4079-a36c-e1150079989b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_65db9944-86fa-4e8c-9662-86efbe6e7e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d2e5b82a-82a0-4079-a36c-e1150079989b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_65db9944-86fa-4e8c-9662-86efbe6e7e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_424ebfed-f40c-4c72-a5b8-a924ac305bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4aa2012c-77c2-4ef8-bc79-176f0bc0dce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_424ebfed-f40c-4c72-a5b8-a924ac305bb7" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_4aa2012c-77c2-4ef8-bc79-176f0bc0dce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fa5f8ae1-a878-473c-8ef3-438598c2a905" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_424ebfed-f40c-4c72-a5b8-a924ac305bb7" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_fa5f8ae1-a878-473c-8ef3-438598c2a905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_cea7bb44-cbe0-4eb2-bd38-1481a0663be9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_424ebfed-f40c-4c72-a5b8-a924ac305bb7" xlink:to="loc_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock_cea7bb44-cbe0-4eb2-bd38-1481a0663be9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/GOODWILLTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#GOODWILLTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/GOODWILLTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_badae8f8-ec57-4712-b600-1f2c6f8f12c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a6c87f21-2432-4904-af78-db6c68a2370f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_badae8f8-ec57-4712-b600-1f2c6f8f12c8" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a6c87f21-2432-4904-af78-db6c68a2370f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#RESTRICTEDANDOTHERASSETSTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9dcf1bdf-3e29-42d1-80e0-48e3a1ba0bca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_e68e7e9c-3ba3-4542-bf83-2e44e4cbd970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_9dcf1bdf-3e29-42d1-80e0-48e3a1ba0bca" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_e68e7e9c-3ba3-4542-bf83-2e44e4cbd970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#OTHERACCRUEDLIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_c491b6f2-7eec-4639-8db5-ee91c5fd7a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0303bd86-e20c-4eca-abd0-fb9754474e12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_c491b6f2-7eec-4639-8db5-ee91c5fd7a7b" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_0303bd86-e20c-4eca-abd0-fb9754474e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4604d651-639f-486e-85c7-8aedc2dc3d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9a445e75-2291-4fde-8658-b9545fa23d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4604d651-639f-486e-85c7-8aedc2dc3d3e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_9a445e75-2291-4fde-8658-b9545fa23d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_eadb366d-b89b-4eca-97b9-bd9816b1107c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4604d651-639f-486e-85c7-8aedc2dc3d3e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_eadb366d-b89b-4eca-97b9-bd9816b1107c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_245dc260-a11f-4bcb-b515-e0d4494c296f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4604d651-639f-486e-85c7-8aedc2dc3d3e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_245dc260-a11f-4bcb-b515-e0d4494c296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBTTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_78d41f3d-5d66-4b3f-881a-4d56e3674cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fa7e54a2-3bcb-47e9-85c7-06ee99abc0af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78d41f3d-5d66-4b3f-881a-4d56e3674cfe" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fa7e54a2-3bcb-47e9-85c7-06ee99abc0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fc482092-a400-4da8-ad5d-b4aed9b14345" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_78d41f3d-5d66-4b3f-881a-4d56e3674cfe" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_fc482092-a400-4da8-ad5d-b4aed9b14345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_230c8029-ce2b-4313-8c22-ffb88e66b83a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_230c8029-ce2b-4313-8c22-ffb88e66b83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_87d13b1e-f87e-419b-9431-1a2682cc9d35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_87d13b1e-f87e-419b-9431-1a2682cc9d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_a74737af-32cd-4bb6-9b4d-4e3475c42213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock_a74737af-32cd-4bb6-9b4d-4e3475c42213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fff6f0c1-2782-4a5d-a6b7-3e91cbd29c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_fff6f0c1-2782-4a5d-a6b7-3e91cbd29c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_efd2c348-3c8b-4c04-8d48-15fef75b3aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_efd2c348-3c8b-4c04-8d48-15fef75b3aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a84adde0-9817-46a9-a7de-240c3dfbf309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_a84adde0-9817-46a9-a7de-240c3dfbf309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d15e8450-7a55-467b-b893-d70a825831de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_aae750d7-fac2-463a-b83f-4c8f1f5925b8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_d15e8450-7a55-467b-b893-d70a825831de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dc92b2a5-b47c-41dd-9cb3-be9b81a205af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5f9c2923-69db-4bb1-8e67-0c2386b9bb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc92b2a5-b47c-41dd-9cb3-be9b81a205af" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5f9c2923-69db-4bb1-8e67-0c2386b9bb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_69ba525f-d464-43ab-9394-f49addff12fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc92b2a5-b47c-41dd-9cb3-be9b81a205af" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_69ba525f-d464-43ab-9394-f49addff12fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_bea0a283-e8a7-43c1-b20b-439bca11bd5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc92b2a5-b47c-41dd-9cb3-be9b81a205af" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_bea0a283-e8a7-43c1-b20b-439bca11bd5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_e57cbe15-043e-42ea-b5ec-52da47d34cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dc92b2a5-b47c-41dd-9cb3-be9b81a205af" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock_e57cbe15-043e-42ea-b5ec-52da47d34cfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables" xlink:type="simple" xlink:href="ensg-20231231.xsd#SELFINSURANCELIABILITIESTables"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_ea4a6531-1d62-4c75-9f94-100cb1788749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock_765af9f9-4d47-4b8e-b76d-3aa9260b296f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_ea4a6531-1d62-4c75-9f94-100cb1788749" xlink:to="loc_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock_765af9f9-4d47-4b8e-b76d-3aa9260b296f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cb91049-8d78-4e95-a99c-9519c47a5abe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7cb91049-8d78-4e95-a99c-9519c47a5abe" xlink:to="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_8ba24367-7c42-4e7e-8473-350ae79af1be" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WhollyOwnedPropertiesMember_8ed69942-9195-4458-be8c-424d1d29e750" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WhollyOwnedPropertiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_541e7580-8c87-4c16-8e2d-ae829aa4c02e" xlink:to="loc_us-gaap_WhollyOwnedPropertiesMember_8ed69942-9195-4458-be8c-424d1d29e750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:to="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_OperatingEntityAxis_58bedc33-5446-4cae-8ecf-14914990ba9c" xlink:to="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyOperatorsMember_7712789e-4131-4061-8ce0-085ee9cdd6f4" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyOperatorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_OperatingEntityDomain_bd9cb45e-e5b3-4a22-9c0c-42eff2845386" xlink:to="loc_ensg_ThirdPartyOperatorsMember_7712789e-4131-4061-8ce0-085ee9cdd6f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_01d9e8db-dc0f-41de-a55a-eb6bf77ed040" xlink:to="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfHealthCareFacilities_92013fd1-a40f-4a73-ad3f-60ee5db2a007" xlink:href="ensg-20231231.xsd#ensg_NumberOfHealthCareFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfHealthCareFacilities_92013fd1-a40f-4a73-ad3f-60ee5db2a007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_9681fbd5-bf00-4715-8587-008ba615d713" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_OperationalSkilledNursingBeds_9681fbd5-bf00-4715-8587-008ba615d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSeniorLivingUnits_41723e85-89e4-4d99-8aea-41fcec8eef8d" xlink:href="ensg-20231231.xsd#ensg_OperationalSeniorLivingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_OperationalSeniorLivingUnits_41723e85-89e4-4d99-8aea-41fcec8eef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeased_69d1fd2e-c02c-4ec0-a974-fa494aceb524" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeased"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfRealEstatePropertiesLeased_69d1fd2e-c02c-4ec0-a974-fa494aceb524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_3d03a11b-9eb0-4b7f-9ae4-fce021393e52" xlink:href="ensg-20231231.xsd#ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase_3d03a11b-9eb0-4b7f-9ae4-fce021393e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_8c9a1a16-9bc3-4aeb-8adc-26f5cb5024ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_8c9a1a16-9bc3-4aeb-8adc-26f5cb5024ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFacilities_d39a6b80-1ab2-46fc-a8ab-a8505385ef06" xlink:href="ensg-20231231.xsd#ensg_NumberOfFacilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfFacilities_d39a6b80-1ab2-46fc-a8ab-a8505385ef06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperations_41aa84d3-e712-4afa-a5a7-8d84b71634ab" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfOperations_41aa84d3-e712-4afa-a5a7-8d84b71634ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_e45b0f18-8c14-445f-a698-04af2e13732e" xlink:href="ensg-20231231.xsd#ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_a28c222b-01e9-4246-af25-97e360427d41" xlink:to="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_e45b0f18-8c14-445f-a698-04af2e13732e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c8f9a479-2d7d-4d39-bf5d-e65bfeef44be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c8f9a479-2d7d-4d39-bf5d-e65bfeef44be" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:to="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e53ae6ff-8abf-469d-aebf-2bd8026c3080" xlink:to="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c6e876df-b221-4e52-b0ef-884285bb49cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:to="loc_srt_MinimumMember_c6e876df-b221-4e52-b0ef-884285bb49cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_8ab6e7fb-2df8-47de-bec9-d6b0222192ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e28de00e-9cd7-4ed0-b9d6-60c8952cd091" xlink:to="loc_srt_MaximumMember_8ab6e7fb-2df8-47de-bec9-d6b0222192ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0d305419-bee7-49ce-b20f-54be8875fa9c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aafbd6e9-b0bf-4a39-9600-b89b4d82438c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_36d21a7a-0e68-476d-9c43-e49b58ed3cc3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_aafbd6e9-b0bf-4a39-9600-b89b4d82438c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2fd607f2-e042-48ea-af95-ebd97e18ccd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRealEstatePropertiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2fd607f2-e042-48ea-af95-ebd97e18ccd7" xlink:to="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:to="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fc4e589c-ee0b-4c23-83be-fca0b1073d5e" xlink:to="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_784eb24b-284a-4484-a82b-4e6039180dab" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:to="loc_srt_MinimumMember_784eb24b-284a-4484-a82b-4e6039180dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_81905d24-74e9-43c2-ac54-129c15ecb4cb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_46a4ea27-a5f3-4d6c-9f8f-3b50095891f3" xlink:to="loc_srt_MaximumMember_81905d24-74e9-43c2-ac54-129c15ecb4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRealEstatePropertiesTable_386074ca-d243-47d2-91eb-a0590a3228fa" xlink:to="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfFinancingLeases_088e489d-8a65-45cb-b694-094d973bb63d" xlink:href="ensg-20231231.xsd#ensg_NumberOfFinancingLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_ensg_NumberOfFinancingLeases_088e489d-8a65-45cb-b694-094d973bb63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2eb23f42-77f0-404e-8fd4-f250aaeee507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_2eb23f42-77f0-404e-8fd4-f250aaeee507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_2eeeac73-fa28-494e-b34d-24d5ad0c9ec5" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_ensg_LesseeOperatingLeaseNumberOfRenewalOptions_2eeeac73-fa28-494e-b34d-24d5ad0c9ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f3073fd6-aa36-449d-99de-b747b790b967" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesLineItems_2358ea06-6fee-494a-a7b4-f70fc0d13441" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f3073fd6-aa36-449d-99de-b747b790b967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5cce8b61-0a71-4b71-bde2-8edb56034c84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5cce8b61-0a71-4b71-bde2-8edb56034c84" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:to="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_96302d72-7be2-41b7-bbeb-145afb8d7420" xlink:to="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fae83c01-0270-46ed-9b34-93ef45e7ab56" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:to="loc_srt_MinimumMember_fae83c01-0270-46ed-9b34-93ef45e7ab56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c8ec674c-e70e-403f-a776-1abe6bd130f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_17cc8056-0039-45eb-829f-eb7de5b474bd" xlink:to="loc_srt_MaximumMember_c8ec674c-e70e-403f-a776-1abe6bd130f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6545142c-9f6a-4fc0-bc89-eb702e0e784e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_896337f8-aa40-4972-9132-08c918a681d6" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_896337f8-aa40-4972-9132-08c918a681d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_ff21e300-8a65-43f6-afbf-5cc6db4afad3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_us-gaap_TradeNamesMember_ff21e300-8a65-43f6-afbf-5cc6db4afad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_62c31870-aacb-43a7-99b6-911a1022d876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_67aba47a-1c40-4c35-930c-5daf35a38459" xlink:to="loc_us-gaap_CustomerRelationshipsMember_62c31870-aacb-43a7-99b6-911a1022d876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_054bad70-072a-4a01-aa4e-2f8ea99a2e0a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1cdb65a6-0729-4eed-9fab-1577bcf12904" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1cdb65a6-0729-4eed-9fab-1577bcf12904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f8d1721-91d7-4ef6-9441-6acf5b160597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2f7f9e62-8701-44b0-851a-4ffee39541bf" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_3f8d1721-91d7-4ef6-9441-6acf5b160597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_097b2db2-11a8-4d37-a40e-fcf6cc1926c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_097b2db2-11a8-4d37-a40e-fcf6cc1926c4" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:href="ensg-20231231.xsd#ensg_InsuranceCoverageLimitTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeAxis_d6275aef-1b7f-4085-826d-8022634b5ddd" xlink:to="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SelfInsuranceRetentionPerClaimMember_1e167045-f9c0-4f2b-a717-83a83e0f6428" xlink:href="ensg-20231231.xsd#ensg_SelfInsuranceRetentionPerClaimMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_SelfInsuranceRetentionPerClaimMember_1e167045-f9c0-4f2b-a717-83a83e0f6428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AggregateDeductibleMember_8a2bdb08-5b6a-4a73-a374-4bc85d71c99d" xlink:href="ensg-20231231.xsd#ensg_AggregateDeductibleMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_AggregateDeductibleMember_8a2bdb08-5b6a-4a73-a374-4bc85d71c99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerOccurenceMember_4453caf6-a9da-4eb6-afc1-07ab5f0a2c78" xlink:href="ensg-20231231.xsd#ensg_PerOccurenceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_PerOccurenceMember_4453caf6-a9da-4eb6-afc1-07ab5f0a2c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PerFacilityMember_665d8559-e702-49c8-8636-d4a2fd18680a" xlink:href="ensg-20231231.xsd#ensg_PerFacilityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_PerFacilityMember_665d8559-e702-49c8-8636-d4a2fd18680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BlanketAggregateMember_60a7cc52-c966-473e-b7c4-4802a8e5ea9a" xlink:href="ensg-20231231.xsd#ensg_BlanketAggregateMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_BlanketAggregateMember_60a7cc52-c966-473e-b7c4-4802a8e5ea9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LossSensitiveLimitPerClaimMember_a82cf049-6d2c-4a76-a5bb-3f680b23ed05" xlink:href="ensg-20231231.xsd#ensg_LossSensitiveLimitPerClaimMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_LossSensitiveLimitPerClaimMember_a82cf049-6d2c-4a76-a5bb-3f680b23ed05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StopLossInsuranceLimitPerClaimMember_0070ec7a-3649-4ebf-afe7-2057845a5faf" xlink:href="ensg-20231231.xsd#ensg_StopLossInsuranceLimitPerClaimMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_InsuranceCoverageLimitTypeDomain_1aff8661-f42d-47d5-adf1-fd7037103ba1" xlink:to="loc_ensg_StopLossInsuranceLimitPerClaimMember_0070ec7a-3649-4ebf-afe7-2057845a5faf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:href="ensg-20231231.xsd#ensg_PayorAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:href="ensg-20231231.xsd#ensg_PayorDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PayorAxis_bb4b98ad-16f4-4931-828a-95796f1e1070" xlink:to="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_980c1e31-b1d9-408f-a9a3-79ce1e9119f3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:to="loc_srt_ParentCompanyMember_980c1e31-b1d9-408f-a9a3-79ce1e9119f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_naics_ZZ524292_d914b31e-60c1-4f21-addc-02fad7497b6b" xlink:href="https://xbrl.sec.gov/naics/2023/naics-2023.xsd#naics_ZZ524292"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PayorDomain_fcb31daf-c334-451e-9638-b5d92634bd21" xlink:to="loc_naics_ZZ524292_d914b31e-60c1-4f21-addc-02fad7497b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_df75170c-c8e9-40e0-8d04-2b2b25dca92d" xlink:to="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralLiabilityMember_9c27bc4d-7446-4e85-b4ff-9e647f7f3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_us-gaap_GeneralLiabilityMember_9c27bc4d-7446-4e85-b4ff-9e647f7f3be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WorkersCompensationInsuranceMember_ef2ea985-f91d-4844-841b-f7ac40ff5437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WorkersCompensationInsuranceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_us-gaap_WorkersCompensationInsuranceMember_ef2ea985-f91d-4844-841b-f7ac40ff5437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HealthLiabilityInsuranceMember_02391d31-3fd6-4d6b-911e-d39e51471419" xlink:href="ensg-20231231.xsd#ensg_HealthLiabilityInsuranceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b675d9c7-9013-4a14-be5b-83c32cfa7a08" xlink:to="loc_ensg_HealthLiabilityInsuranceMember_02391d31-3fd6-4d6b-911e-d39e51471419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fc831ea8-faf3-4100-aeb9-0825005f8d37" xlink:to="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_88f8237a-cb7d-4931-9811-3c22962f3618" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_CA_88f8237a-cb7d-4931-9811-3c22962f3618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NonCaliforniaMember_22c13637-52ec-49fd-85d3-8071594829d4" xlink:href="ensg-20231231.xsd#ensg_NonCaliforniaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_NonCaliforniaMember_22c13637-52ec-49fd-85d3-8071594829d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AllStatesExceptColoradoMember_3c5fc81c-d0a3-4b82-a9fe-17c5c62a63a7" xlink:href="ensg-20231231.xsd#ensg_AllStatesExceptColoradoMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_AllStatesExceptColoradoMember_3c5fc81c-d0a3-4b82-a9fe-17c5c62a63a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CO_1a088e0f-b582-4da9-b8a6-96d2f89a9065" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CO"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_CO_1a088e0f-b582-4da9-b8a6-96d2f89a9065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_26f62b98-8670-4fc3-8496-5091fe43001c" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_TX"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_stpr_TX_26f62b98-8670-4fc3-8496-5091fe43001c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_82b83ebf-f169-434e-9004-b60b2125a882" xlink:href="ensg-20231231.xsd#ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ae9af003-60ee-405a-b921-b0fffbe8435d" xlink:to="loc_ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember_82b83ebf-f169-434e-9004-b60b2125a882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_899e3dfd-fb50-49dc-8049-d3a96314f68d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e376924f-6885-448b-acac-54a556d4a1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c4f71e22-ac81-48cf-aa0e-6c0eb4a0d9f5" xlink:to="loc_us-gaap_SubsequentEventMember_e376924f-6885-448b-acac-54a556d4a1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_a22e8e4b-9201-46cc-99c6-c79f41262095" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SelfInsuranceReserve_6467880c-42d9-4348-96ac-df990557c232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SelfInsuranceReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_82c73fe1-0576-4464-90a9-f1f15cbcef02" xlink:to="loc_us-gaap_SelfInsuranceReserve_6467880c-42d9-4348-96ac-df990557c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bf3e278b-3ab4-46ca-af75-54cf8cfd7a38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_bf3e278b-3ab4-46ca-af75-54cf8cfd7a38" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_a04a6539-24c9-4b7c-89ee-bc7f1f7a831e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_b4da43f0-0790-4ba0-ac5f-dabd0844f6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_5a1a4dcf-4c30-4dfc-9631-d02426496086" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_b4da43f0-0790-4ba0-ac5f-dabd0844f6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb32b91e-5ae5-4103-b427-8538d412bf2e" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4d8f2f1a-e974-4a88-a555-775a47335d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_dfef124d-e7ef-4d99-a8e4-d4613a60a934" xlink:to="loc_us-gaap_SalesRevenueNetMember_4d8f2f1a-e974-4a88-a555-775a47335d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_adbf9da3-afa7-4ea1-911e-bb6c1bd90e26" xlink:to="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_a45de9e7-146e-41a6-84e3-56ef4425b6f9" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_14414786-977c-400c-a7af-a225f72c4e85" xlink:to="loc_ensg_MedicaidAndMedicareMember_a45de9e7-146e-41a6-84e3-56ef4425b6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_43185cae-efd8-41bf-8b80-6fd5d9d90a88" xlink:to="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_e882ad3c-d32f-4830-b0d1-59a20351bdab" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a8411138-b6fe-4966-ac04-a9f5540dbf23" xlink:to="loc_ensg_RentalMember_e882ad3c-d32f-4830-b0d1-59a20351bdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8296b6e9-189c-4e0c-b7e1-4d68cea562f7" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_c002e57c-761c-4ebc-9a43-195d731ee395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_c002e57c-761c-4ebc-9a43-195d731ee395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f96e6a8-de60-4bca-9442-8c106013d2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3f96e6a8-de60-4bca-9442-8c106013d2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_cfeea04e-65de-44ee-96a2-84517a47238d" xlink:href="ensg-20231231.xsd#ensg_AccruedLiabilitiesStateReliefContractLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_cfeea04e-65de-44ee-96a2-84517a47238d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_98c5a9d7-7931-44e8-a3f4-5e5c30cc20df" xlink:href="ensg-20231231.xsd#ensg_FamilyFirstCoronavirusResponseActPaymentsReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived_98c5a9d7-7931-44e8-a3f4-5e5c30cc20df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_51dee312-666d-4070-8dce-89c57f83beac" xlink:href="ensg-20231231.xsd#ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized_51dee312-666d-4070-8dce-89c57f83beac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_ab473479-8261-45c2-9693-b56b38b8b797" xlink:href="ensg-20231231.xsd#ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned_ab473479-8261-45c2-9693-b56b38b8b797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_73e63e40-76d5-4e92-bb64-b0b688b689fe" xlink:href="ensg-20231231.xsd#ensg_MedicareAcceleratedAndAdvancePaymentCARESACT"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT_73e63e40-76d5-4e92-bb64-b0b688b689fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_d424a826-d60f-4f43-a391-fdb38e323999" xlink:href="ensg-20231231.xsd#ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct_d424a826-d60f-4f43-a391-fdb38e323999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_965b8f4b-3a6a-4bf9-a9d0-2ef9ab2bb5de" xlink:href="ensg-20231231.xsd#ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_a27a7ec7-a849-445a-a77a-f840ea44334c" xlink:to="loc_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct_965b8f4b-3a6a-4bf9-a9d0-2ef9ab2bb5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f30d0b0-b0c2-4bed-97f0-22d30695fd03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0f30d0b0-b0c2-4bed-97f0-22d30695fd03" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d3678459-343d-443e-9c62-0fa30904f8f1" xlink:to="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_2a4a7c5a-dbb9-4159-8a58-4fb17b78dd9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_742f8977-6b11-49e8-a59a-c8c4456c9dc8" xlink:to="loc_us-gaap_ServiceMember_2a4a7c5a-dbb9-4159-8a58-4fb17b78dd9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3c705d2a-8ce4-4a09-a41f-1a2f7de55d25" xlink:to="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_43a3ab1b-65a3-48ef-8a4c-d61d024f2bda" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicaidMember_43a3ab1b-65a3-48ef-8a4c-d61d024f2bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_a706d23b-9615-421f-82d4-4f0993473cbd" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicareMember_a706d23b-9615-421f-82d4-4f0993473cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidSkilledMember_bf927d39-faec-4f6d-ac2c-2b02ddc5e199" xlink:href="ensg-20231231.xsd#ensg_MedicaidSkilledMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_c1af0fc0-798a-4213-8910-268196899045" xlink:to="loc_ensg_MedicaidSkilledMember_bf927d39-faec-4f6d-ac2c-2b02ddc5e199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_442f98c6-6790-439c-81cc-ac88aece3b71" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_ManagedCareMember_442f98c6-6790-439c-81cc-ac88aece3b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_1a0397fe-accc-4c9d-b73f-f5118efc1fd2" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5b0c3c53-acc6-4e9b-a68d-313c73e00775" xlink:to="loc_ensg_PrivatePayAndOtherMember_1a0397fe-accc-4c9d-b73f-f5118efc1fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_bed6ca5a-9bf5-44a7-86dc-5dd7992bcb75" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_aaf1d5be-2b7f-43df-a10c-d9d407ba4b17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_3962c0f8-5491-401c-bcbe-e053c15dfc23" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_aaf1d5be-2b7f-43df-a10c-d9d407ba4b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_267b99e4-e44c-463f-8600-73207bb53501" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_0c6da0ee-8a64-490d-87eb-252f3ff3a14c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5517f143-f952-43b1-a0a7-48d378c36281" xlink:to="loc_us-gaap_SalesRevenueNetMember_0c6da0ee-8a64-490d-87eb-252f3ff3a14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0eaa4610-995c-4d79-a9ac-97f77c98e23d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ac2146a-16e7-4b46-a58a-b86f4bd03117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_9ac2146a-16e7-4b46-a58a-b86f4bd03117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f9b480f3-700b-4e08-99f5-d742c7c190e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_67f8708d-7a39-482e-8557-7267184def24" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f9b480f3-700b-4e08-99f5-d742c7c190e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3e2d936c-ab6d-4aca-94d7-2a83e8f051d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3e2d936c-ab6d-4aca-94d7-2a83e8f051d7" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:to="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_5a1182f4-dca7-4cf2-9ded-356a509991eb" xlink:to="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_17131212-34ed-4988-904b-253b5dfcf637" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_MedicaidMember_17131212-34ed-4988-904b-253b5dfcf637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_7e848499-290d-43d9-a6e5-b903d0525f72" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_ManagedCareMember_7e848499-290d-43d9-a6e5-b903d0525f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_65caa3a9-1d3c-4ca4-bad4-c7555c5f2883" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_MedicareMember_65caa3a9-1d3c-4ca4-bad4-c7555c5f2883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_bc2f8eca-55ee-49af-950b-ecfd768e566c" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_23af6f96-9e14-4e6c-8d1a-f9fd958651b2" xlink:to="loc_ensg_PrivatePayAndOtherMember_bc2f8eca-55ee-49af-950b-ecfd768e566c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_8ffd97a5-44c7-44bb-9650-22902f358232" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableGross_781b6956-b56a-4c28-9ec9-11bbd3d85887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AccountsReceivableGross_781b6956-b56a-4c28-9ec9-11bbd3d85887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db7b9a74-49d4-4ba7-8bdc-5be19b62c9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_db7b9a74-49d4-4ba7-8bdc-5be19b62c9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_3200c9de-0b39-468e-bbce-3328b7ca0bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_5d56f8b8-5d71-4eea-9d8e-79e7e8fcea31" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_3200c9de-0b39-468e-bbce-3328b7ca0bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_cdebce62-e9a9-4d90-afbb-dc7df54fab4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:to="loc_us-gaap_NetIncomeLossAbstract_cdebce62-e9a9-4d90-afbb-dc7df54fab4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_761a9759-3432-4bc8-b739-716e7e8f27f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cdebce62-e9a9-4d90-afbb-dc7df54fab4e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_761a9759-3432-4bc8-b739-716e7e8f27f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0136d65b-aa8e-441f-a47e-87e89693c92e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cdebce62-e9a9-4d90-afbb-dc7df54fab4e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_0136d65b-aa8e-441f-a47e-87e89693c92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bbe6fb5c-b5de-4e3c-87c6-2a5c35597736" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cdebce62-e9a9-4d90-afbb-dc7df54fab4e" xlink:to="loc_us-gaap_NetIncomeLoss_bbe6fb5c-b5de-4e3c-87c6-2a5c35597736" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1530587a-9e66-4e77-b736-ce370981a5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1530587a-9e66-4e77-b736-ce370981a5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb1f1ba9-5c96-48ff-8812-161813beccfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1530587a-9e66-4e77-b736-ce370981a5f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cb1f1ba9-5c96-48ff-8812-161813beccfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c21bda3a-890b-40c5-af3c-72faf351462d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1530587a-9e66-4e77-b736-ce370981a5f2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_c21bda3a-890b-40c5-af3c-72faf351462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3cec6afb-676e-4919-b02a-f75f2f1ffa65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_1530587a-9e66-4e77-b736-ce370981a5f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3cec6afb-676e-4919-b02a-f75f2f1ffa65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f83afc9a-423d-4602-bcf8-93caabcc0072" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:to="loc_us-gaap_EarningsPerShareBasic_f83afc9a-423d-4602-bcf8-93caabcc0072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a404c69e-b66b-4da2-88a1-7ee4cfef7ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:to="loc_us-gaap_EarningsPerShareDiluted_a404c69e-b66b-4da2-88a1-7ee4cfef7ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a918228a-8214-4564-a987-70f013534b61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e289013a-af9d-4e15-ae52-b8ce3989b3d7" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_a918228a-8214-4564-a987-70f013534b61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#FAIRVALUEMEASUREMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cb9fa38a-a8b4-4acd-beb4-c47bc1295c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cb9fa38a-a8b4-4acd-beb4-c47bc1295c79" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_24340530-c8ca-45eb-8d40-19d9945008a8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_9860c699-b219-4f35-a729-2bc775d0bbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c81443dd-45a5-4ae7-bb89-2b4ca1cc2382" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_9860c699-b219-4f35-a729-2bc775d0bbe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:to="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_f238081a-c94f-41cb-8f72-f31e34111e41" xlink:to="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SubsidiariesMember_aa9b1e24-021d-4584-8680-4fce3b11e503" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_7bdf9f73-9cc9-4227-af2b-e96e8a3137f6" xlink:to="loc_srt_SubsidiariesMember_aa9b1e24-021d-4584-8680-4fce3b11e503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_412441cd-c084-49c0-a9a1-a4247ae80b74" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAndCash_f88e8a1e-3744-4b90-b9a0-6eed6555a616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsAndCash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:to="loc_us-gaap_InvestmentsAndCash_f88e8a1e-3744-4b90-b9a0-6eed6555a616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_1cbec62e-b0ac-4da2-91d6-30a1fec8cb60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_4f74210c-32c5-4007-8acf-14b9317f4c26" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_1cbec62e-b0ac-4da2-91d6-30a1fec8cb60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/STANDARDBEARERDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#STANDARDBEARERDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/STANDARDBEARERDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_00f0df22-8183-429b-a47e-fc93c270392c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_00f0df22-8183-429b-a47e-fc93c270392c" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_39afb434-9dd0-4210-9d2d-8ffb147db846" xlink:to="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_afc26209-ed35-4550-bc35-5301782ceba9" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_89b24f79-8662-4d82-93de-b562ee853000" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_afc26209-ed35-4550-bc35-5301782ceba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealEstatePropertiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesAxis_fb7817a5-4dc4-4c7e-8e35-298c1643c298" xlink:to="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WhollyOwnedPropertiesMember_94e5c6d1-edd1-4f76-a0ae-b2c8b11db849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WhollyOwnedPropertiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RealEstatePropertiesDomain_ec52dfaa-9518-4374-a1a5-024c0de98146" xlink:to="loc_us-gaap_WhollyOwnedPropertiesMember_94e5c6d1-edd1-4f76-a0ae-b2c8b11db849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:href="ensg-20231231.xsd#ensg_OperatingEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_OperatingEntityAxis_47dff857-1f1a-4bb4-9882-ebb85ee3c30b" xlink:to="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartiesMember_f6f512c9-633f-42ea-b752-c20474c6b605" xlink:href="ensg-20231231.xsd#ensg_ThirdPartiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:to="loc_ensg_ThirdPartiesMember_f6f512c9-633f-42ea-b752-c20474c6b605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyOperatorsMember_5319c9ea-d7f1-44c6-a3ca-82330c417a99" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyOperatorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_OperatingEntityDomain_026533f5-0397-4842-a35a-f27ff424ccb7" xlink:to="loc_ensg_ThirdPartyOperatorsMember_5319c9ea-d7f1-44c6-a3ca-82330c417a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ac22040d-2486-4ea6-90c4-8904e648d39a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OwnedPropertiesMember_396ca77b-931c-4830-8c25-ad70e4444bfa" xlink:href="ensg-20231231.xsd#ensg_OwnedPropertiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8ef2745d-6685-494a-ad4a-8f0e3d047c0c" xlink:to="loc_ensg_OwnedPropertiesMember_396ca77b-931c-4830-8c25-ad70e4444bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_82fc3ecb-1af3-4c95-9483-2e9948c57025" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_ee3deac3-bbc6-48d4-8d92-a00d60200955" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember_ee3deac3-bbc6-48d4-8d92-a00d60200955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_3b3bc65a-46ba-437c-a088-d088fd12924d" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_ae09a51a-79f2-47c3-90ea-6befbc0668ad" xlink:to="loc_ensg_SkilledNursingOperationsMember_3b3bc65a-46ba-437c-a088-d088fd12924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementAxis_fc0d6502-f320-4d92-b387-8d20ea94d627" xlink:to="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerMasterLeasesMember_d31f0d37-a73e-4e29-8f04-faccb01c01d4" xlink:href="ensg-20231231.xsd#ensg_StandardBearerMasterLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_eadfb308-52b9-46c3-b395-1e7e76cae9f3" xlink:to="loc_ensg_StandardBearerMasterLeasesMember_d31f0d37-a73e-4e29-8f04-faccb01c01d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a16d3606-ee5d-4120-8a64-538499a14436" xlink:to="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8fac8c19-8cea-4f04-9313-5744101a12b1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:to="loc_srt_MinimumMember_8fac8c19-8cea-4f04-9313-5744101a12b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1350f1c1-1a97-4db0-961a-a465db727d95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_00df6f9c-3db9-43fd-a0bb-cfb19d45b402" xlink:to="loc_srt_MaximumMember_1350f1c1-1a97-4db0-961a-a465db727d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2557ddba-a88a-473c-9247-31653f132160" xlink:to="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:href="ensg-20231231.xsd#ensg_ManagementServiceTotalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_596bc3f7-484f-4e91-8f63-8d2bcfdcae40" xlink:to="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceBaseMember_a99d88f7-3d88-4ce9-a1d0-e2fc24943023" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceBaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:to="loc_us-gaap_ManagementServiceBaseMember_a99d88f7-3d88-4ce9-a1d0-e2fc24943023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementServiceIncentiveMember_6aec5f87-6ea9-4cf6-9df2-84a09813344d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementServiceIncentiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_ManagementServiceTotalMember_260a06af-cc3a-4a7c-b9c0-0511d4f9e495" xlink:to="loc_us-gaap_ManagementServiceIncentiveMember_6aec5f87-6ea9-4cf6-9df2-84a09813344d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_6bac450b-01ed-4af8-bd26-381a52788017" xlink:to="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_7eb608b4-2df5-4858-ae16-28ac8a082725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_57a0eae0-3981-4abd-95df-397a091c5eb5" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_7eb608b4-2df5-4858-ae16-28ac8a082725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_508f7038-7959-480e-b9c9-6e32615e8286" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TruistBankMember_025bc297-f416-4ed7-aeca-9e8b314be654" xlink:href="ensg-20231231.xsd#ensg_TruistBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_a6f07cc1-7e7f-440f-8355-ee7265afc5ed" xlink:to="loc_ensg_TruistBankMember_025bc297-f416-4ed7-aeca-9e8b314be654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_7ed5d25f-52ec-4172-b80d-25fd4374751f" xlink:to="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_0d20838f-0a36-4324-8b88-a9bb7ef566fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:to="loc_us-gaap_BaseRateMember_0d20838f-0a36-4324-8b88-a9bb7ef566fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SecuredOvernightFinancingRateSOFRMember_be4585c9-095f-42b0-ab7a-599498ba55a5" xlink:href="ensg-20231231.xsd#ensg_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_0917ba62-5f7c-484b-b2f8-70e22cef7a47" xlink:to="loc_ensg_SecuredOvernightFinancingRateSOFRMember_be4585c9-095f-42b0-ab7a-599498ba55a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7a9c7a8a-37fd-4a86-86ba-c889e5460f20" xlink:to="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerEquityPlanMember_d1757c97-b17e-43c8-8721-d6900b3a07c6" xlink:href="ensg-20231231.xsd#ensg_StandardBearerEquityPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_981314ec-4b85-41b0-8335-8bbc3f8f7c9d" xlink:to="loc_ensg_StandardBearerEquityPlanMember_d1757c97-b17e-43c8-8721-d6900b3a07c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aa04c1e5-58e2-4d0b-a113-8a683b7a8d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c1abbbbd-9a02-441b-8b2f-8604249631e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42c93d92-dfe0-48cd-af23-c57375e4ec89" xlink:to="loc_us-gaap_RestrictedStockMember_c1abbbbd-9a02-441b-8b2f-8604249631e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_40c2802d-c0c8-4794-a169-ba3161cc0bf4" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_f06642cf-b329-489b-b409-b1e20b40707d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_f06642cf-b329-489b-b409-b1e20b40707d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperations_eff62176-6846-4cbe-9b09-391b7ae2bbf5" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfOperations_eff62176-6846-4cbe-9b09-391b7ae2bbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_38cdbc89-6428-49bf-b6ed-8f1bce004201" xlink:href="ensg-20231231.xsd#ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities_38cdbc89-6428-49bf-b6ed-8f1bce004201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfPropertiesAcquired_6e0fbd4a-356d-4364-96fa-d132721b97f4" xlink:href="ensg-20231231.xsd#ensg_NumberOfPropertiesAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfPropertiesAcquired_6e0fbd4a-356d-4364-96fa-d132721b97f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferred_5289c8b6-c384-41a8-a91c-4e773168e38c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionConsiderationTransferred"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferred_5289c8b6-c384-41a8-a91c-4e773168e38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLeaseArrangements_6b3cb7a2-e852-4a40-bc95-2a2a07923f4e" xlink:href="ensg-20231231.xsd#ensg_NumberOfLeaseArrangements"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_NumberOfLeaseArrangements_6b3cb7a2-e852-4a40-bc95-2a2a07923f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42c8cf0b-a418-4795-8328-d3d1a5572f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_42c8cf0b-a418-4795-8328-d3d1a5572f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_9ff21720-524f-4ff4-9664-e035786b2d65" xlink:href="ensg-20231231.xsd#ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_9ff21720-524f-4ff4-9664-e035786b2d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a5a32195-2d32-42ce-b01f-2f2bb401e8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_a5a32195-2d32-42ce-b01f-2f2bb401e8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_390cf433-9291-4030-b641-1fceea3b2c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_390cf433-9291-4030-b641-1fceea3b2c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_b57ce77e-7ea0-4a49-9a50-6202090ef4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_b57ce77e-7ea0-4a49-9a50-6202090ef4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_eafd95c8-dc34-4647-89a0-839731760354" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfTotalRevenues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_PropertyManagementFeePercentFeeOfTotalRevenues_eafd95c8-dc34-4647-89a0-839731760354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_dd98cf62-005a-4e81-9875-5f8f31b788f9" xlink:href="ensg-20231231.xsd#ensg_PropertyManagementFeePercentFeeOfFundsFromOperations"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations_dd98cf62-005a-4e81-9875-5f8f31b788f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ManagementFeeExpense_e12d233e-5845-4680-ba54-56bed1097e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ManagementFeeExpense"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ManagementFeeExpense_e12d233e-5845-4680-ba54-56bed1097e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7dd83aa9-0139-4a4e-acfa-2d26dbd61cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_7dd83aa9-0139-4a4e-acfa-2d26dbd61cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da2b26d2-eebf-4c78-a94a-78f13e83a77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_da2b26d2-eebf-4c78-a94a-78f13e83a77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_2d9a2a17-0d2b-4800-baf9-4dad841aded0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions_2d9a2a17-0d2b-4800-baf9-4dad841aded0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9f7a2b5-2c0f-4624-8d1e-bef85580e9ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_d9f7a2b5-2c0f-4624-8d1e-bef85580e9ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1f8e65-8c60-418f-a482-234168831f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cd1f8e65-8c60-418f-a482-234168831f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86eba735-8517-4a1d-a906-262c8ef9094b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_86eba735-8517-4a1d-a906-262c8ef9094b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_25e58480-56fc-41a3-bec0-15c643c3a9c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d4c1b5f4-b23e-4596-b632-90d1676d57ca" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_25e58480-56fc-41a3-bec0-15c643c3a9c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b1ecebc-8df0-40b3-bf32-7fa9577da4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_4b1ecebc-8df0-40b3-bf32-7fa9577da4b9" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_fa413447-8d34-427e-80a2-24631a246010" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_02903d9e-a443-4ec6-816f-c1dc0a255f24" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_SkilledNursingOperationsMember_02903d9e-a443-4ec6-816f-c1dc0a255f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CampusOperationMember_01eacb5f-8d0a-4dec-9511-8f585f31fc1c" xlink:href="ensg-20231231.xsd#ensg_CampusOperationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_CampusOperationMember_01eacb5f-8d0a-4dec-9511-8f585f31fc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OwnedPropertiesMember_15bb68ef-1209-4938-8ba0-be7bee177acd" xlink:href="ensg-20231231.xsd#ensg_OwnedPropertiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_OwnedPropertiesMember_15bb68ef-1209-4938-8ba0-be7bee177acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilitiesMember_fe75c8ab-1839-4fd8-af88-ee40e1b07607" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_ensg_SeniorLivingFacilitiesMember_fe75c8ab-1839-4fd8-af88-ee40e1b07607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1af6a6b5-5455-43e3-8265-a356f7affc89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ce3abf19-c5e1-47f6-af81-211a7d6470c8" xlink:to="loc_us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_1af6a6b5-5455-43e3-8265-a356f7affc89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_f7eeb15f-328b-4688-8ce9-260a90c6143c" xlink:to="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_91d99d1d-68c1-428e-80e1-7c9fd998cf5b" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_fde8c17f-49bc-47e0-b0b9-2261a37e127e" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_91d99d1d-68c1-428e-80e1-7c9fd998cf5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_5ae8c820-f30a-4787-bb68-bdcc5c839210" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_8c4a93ed-bd08-4605-b6f3-d5a6ca3ce634" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d2200f6e-c70f-4868-b7ea-b410fe359e43" xlink:to="loc_us-gaap_SubsequentEventMember_8c4a93ed-bd08-4605-b6f3-d5a6ca3ce634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_cc414e67-a0af-480b-a3c8-aaaa35d5bc73" xlink:to="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_2514de24-264d-4ca2-b5cf-d96f3b908394" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_SkilledNursingOperationsMember_2514de24-264d-4ca2-b5cf-d96f3b908394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesMember_465938c3-5327-4105-abf7-8c4cc590e805" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_RealEstatePurchasesMember_465938c3-5327-4105-abf7-8c4cc590e805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember_04b4d027-0db6-4914-a9a8-ac23d908650a" xlink:href="ensg-20231231.xsd#ensg_RealEstatePurchasesOfPreviousOperationsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_254c0ef5-3bab-4550-8169-cc723e11b82b" xlink:to="loc_ensg_RealEstatePurchasesOfPreviousOperationsMember_04b4d027-0db6-4914-a9a8-ac23d908650a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_36a21453-0227-4dd5-9a8f-376ef9cda007" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_522650a4-1f15-4bd2-b2f1-c974eeca5cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_522650a4-1f15-4bd2-b2f1-c974eeca5cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfPropertiesAcquired_09b56a36-85a0-4411-8260-b25d87244fc5" xlink:href="ensg-20231231.xsd#ensg_NumberOfPropertiesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfPropertiesAcquired_09b56a36-85a0-4411-8260-b25d87244fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSeniorLivingUnits_5f77ae5a-352d-48fe-bb7a-f8ef24500ed8" xlink:href="ensg-20231231.xsd#ensg_OperationalSeniorLivingUnits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_OperationalSeniorLivingUnits_5f77ae5a-352d-48fe-bb7a-f8ef24500ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_077b189a-4ccf-4aa6-b19d-ffda96646d87" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_OperationalSkilledNursingBeds_077b189a-4ccf-4aa6-b19d-ffda96646d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLeaseArrangements_4622fcd3-a268-4232-855c-762b6e23345f" xlink:href="ensg-20231231.xsd#ensg_NumberOfLeaseArrangements"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfLeaseArrangements_4622fcd3-a268-4232-855c-762b6e23345f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties_71743c17-56e3-408d-a5b8-bd45bb11588f" xlink:href="ensg-20231231.xsd#ensg_NumberOfLivingOperationsTransferredFromThirdParties"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfLivingOperationsTransferredFromThirdParties_71743c17-56e3-408d-a5b8-bd45bb11588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_07afcdad-7acd-418f-b48c-7e9852d82cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_07afcdad-7acd-418f-b48c-7e9852d82cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfAssetAcquisitions_5d28024e-347a-465a-844b-90658c00b0e1" xlink:href="ensg-20231231.xsd#ensg_NumberOfAssetAcquisitions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_ensg_NumberOfAssetAcquisitions_5d28024e-347a-465a-844b-90658c00b0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_1b62ff8f-14b3-4efa-aad7-c1fd81959183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0deee416-6a9d-4b57-b81e-cf464919fb7a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_1b62ff8f-14b3-4efa-aad7-c1fd81959183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPERATIONEXPANSIONSPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ec51ccd-ba26-4359-b26d-ff73df01d99a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_2ec51ccd-ba26-4359-b26d-ff73df01d99a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_d26b945f-fdaf-470b-92f6-6af7f56a2628" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_e01ea7af-5f32-4503-84f0-d280d5b85f21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_LandMember_e01ea7af-5f32-4503-84f0-d280d5b85f21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_d38a1c9d-6b15-4074-8c83-3da1b601475e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_d38a1c9d-6b15-4074-8c83-3da1b601475e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_928ec256-0129-4e0e-9695-c1a030f42b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_928ec256-0129-4e0e-9695-c1a030f42b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_0e939536-8906-420f-90e8-3235e62bf869" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_db80cace-b7a8-4334-9b74-f83ff5602eff" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_0e939536-8906-420f-90e8-3235e62bf869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:to="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:href="ensg-20231231.xsd#ensg_BusinessAndAssetAcquisitionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsAxis_7786cff3-b7e7-43b0-aad3-4c0a55cb665a" xlink:to="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AcquiredOperationsMember_309280d5-2bf9-4a35-9b43-129a5c59dbd0" xlink:href="ensg-20231231.xsd#ensg_AcquiredOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_BusinessAndAssetAcquisitionsDomain_cc1ae499-53cf-4428-92fd-5f4c108bd947" xlink:to="loc_ensg_AcquiredOperationsMember_309280d5-2bf9-4a35-9b43-129a5c59dbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_34731830-2780-416e-9d97-4f6c6f457bd1" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_d292a315-6aeb-4dba-b20d-d1f3d15612cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_d292a315-6aeb-4dba-b20d-d1f3d15612cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c9bc4fb6-cb3d-4891-9058-8a24c7b2bb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c9bc4fb6-cb3d-4891-9058-8a24c7b2bb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasedAssetsAcquiredDuringPeriod_e3c5ae56-5cb7-4ec3-9f1e-a89314e216be" xlink:href="ensg-20231231.xsd#ensg_LeasedAssetsAcquiredDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_ensg_LeasedAssetsAcquiredDuringPeriod_e3c5ae56-5cb7-4ec3-9f1e-a89314e216be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_e40def79-213b-4a80-a74f-ec3d6427e200" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_e40def79-213b-4a80-a74f-ec3d6427e200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_9ea85fa3-4992-442f-919c-654196bd2000" xlink:href="ensg-20231231.xsd#ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_2f164456-9eb9-4fca-b9da-772643fcc499" xlink:to="loc_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet_9ea85fa3-4992-442f-919c-654196bd2000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_55e0875c-7cb3-4187-9736-68b5f6b94100" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_55e0875c-7cb3-4187-9736-68b5f6b94100" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:to="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_671c2afa-f457-4f8c-bbec-b8de2736bc67" xlink:to="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerHealthcareREITIncMember_38602335-382c-477a-bf44-0903524d681b" xlink:href="ensg-20231231.xsd#ensg_StandardBearerHealthcareREITIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_9904ebb7-0149-4738-9090-de4d8aa5d492" xlink:to="loc_ensg_StandardBearerHealthcareREITIncMember_38602335-382c-477a-bf44-0903524d681b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_52224453-64f0-4635-b3bc-988e61f9fd5b" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_df57d5da-8450-421e-ba1d-7bcbe2c357b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_us-gaap_NumberOfReportableSegments_df57d5da-8450-421e-ba1d-7bcbe2c357b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServiceFacilities_35f0a0b5-291f-46b6-ba2c-073aba1bbb43" xlink:href="ensg-20231231.xsd#ensg_SkilledServiceFacilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SkilledServiceFacilities_35f0a0b5-291f-46b6-ba2c-073aba1bbb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesAndSeniorLivingCampuses_4d8714fc-0552-4f60-a7e0-d7c515f2c94e" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesAndSeniorLivingCampuses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SkilledServicesAndSeniorLivingCampuses_4d8714fc-0552-4f60-a7e0-d7c515f2c94e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfRealEstateProperties_0ba2b765-07cb-4c64-95db-9813549c21c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfRealEstateProperties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_us-gaap_NumberOfRealEstateProperties_0ba2b765-07cb-4c64-95db-9813549c21c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingFacilities_58ff51f5-f542-49ba-af64-9aebbc1d076a" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingFacilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c7d4efc1-482e-41ac-a221-e8cfbfd3c055" xlink:to="loc_ensg_SeniorLivingFacilities_58ff51f5-f542-49ba-af64-9aebbc1d076a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_a0bca5e0-bf65-407f-bbb6-068d4d51e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_a0bca5e0-bf65-407f-bbb6-068d4d51e14b" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_b113a395-b84a-46ea-894e-787937b7e88e" xlink:to="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_ddfaa18c-3683-4a88-8f54-876ef60730d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:to="loc_us-gaap_OperatingSegmentsMember_ddfaa18c-3683-4a88-8f54-876ef60730d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationEliminationsMember_459c52a8-6e02-400d-88b4-0d496b6f283a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationEliminationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_72557ea2-c2ae-4fe7-b0da-adde2aa724d1" xlink:to="loc_srt_ConsolidationEliminationsMember_459c52a8-6e02-400d-88b4-0d496b6f283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2446be24-1526-4033-875f-1c7c7d794426" xlink:to="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_9a97b6cb-964b-4f9d-b65e-1e2816ba739a" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_ensg_SkilledServicesSegmentMember_9a97b6cb-964b-4f9d-b65e-1e2816ba739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StandardBearerSegmentMember_e844163d-4d24-45df-ac4e-c44081bede0d" xlink:href="ensg-20231231.xsd#ensg_StandardBearerSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_ensg_StandardBearerSegmentMember_e844163d-4d24-45df-ac4e-c44081bede0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_da07c000-2619-40e5-98ac-dd0c9095064f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3424f136-6708-4ba8-b4a4-067a647b5b53" xlink:to="loc_us-gaap_AllOtherSegmentsMember_da07c000-2619-40e5-98ac-dd0c9095064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c19bf573-0119-4632-969c-7a45e0792617" xlink:to="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_9e922829-fc21-457e-9e21-466a3bd216c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:to="loc_us-gaap_ServiceMember_9e922829-fc21-457e-9e21-466a3bd216c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_b7e46170-fb1b-4df4-9e1a-3c9fdeff3f52" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7d951ff-738d-4b96-9f51-bc8d33461316" xlink:to="loc_ensg_RentalMember_b7e46170-fb1b-4df4-9e1a-3c9fdeff3f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9de749c0-4162-4ef7-aa6e-2af294c2f154" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b8b61ba-2a00-4ad5-82b1-13352c7d5db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2b8b61ba-2a00-4ad5-82b1-13352c7d5db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SegmentIncomeLoss_8a4153b2-3b30-46d2-8a99-b0bf805f9d60" xlink:href="ensg-20231231.xsd#ensg_SegmentIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_ensg_SegmentIncomeLoss_8a4153b2-3b30-46d2-8a99-b0bf805f9d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLossFromRealEstateOperations_919b9fe3-8a12-408d-8ced-49f4f40ae5e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLossFromRealEstateOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_ProfitLossFromRealEstateOperations_919b9fe3-8a12-408d-8ced-49f4f40ae5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de777f7e-6575-4e87-a6cb-9e8cb9911abd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_de777f7e-6575-4e87-a6cb-9e8cb9911abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_187a934d-301f-4aa5-a903-6bc9e3669810" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_187a934d-301f-4aa5-a903-6bc9e3669810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3070ec2e-24ec-4bd0-a2f4-15f51bbad710" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_InterestExpense_3070ec2e-24ec-4bd0-a2f4-15f51bbad710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_e8917453-8729-49b0-a9ec-c8f95da70864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_cce44ccc-feaa-4cbc-b1e1-de2c0927f8b1" xlink:to="loc_us-gaap_SubleaseIncome_e8917453-8729-49b0-a9ec-c8f95da70864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9cd55145-6048-48d0-8a03-25e8b3181a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9cd55145-6048-48d0-8a03-25e8b3181a9c" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9a6029bc-bd2d-43e4-b570-80f8aa13fb48" xlink:to="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_f6deb381-c5c4-4f5e-87e0-ccf3c7d262e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a2fd45de-7dd9-4332-bbea-6698aad33456" xlink:to="loc_us-gaap_ServiceMember_f6deb381-c5c4-4f5e-87e0-ccf3c7d262e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_17fb617e-e3ae-4536-a57d-38a44374523b" xlink:to="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidMember_1aec5094-3b6a-44ac-a432-f843c59af8c5" xlink:href="ensg-20231231.xsd#ensg_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicaidMember_1aec5094-3b6a-44ac-a432-f843c59af8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareMember_26283261-85f7-429d-b590-4994a350bc8c" xlink:href="ensg-20231231.xsd#ensg_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicareMember_26283261-85f7-429d-b590-4994a350bc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidSkilledMember_38f518d7-3133-4cb7-b848-ab2a88bcded8" xlink:href="ensg-20231231.xsd#ensg_MedicaidSkilledMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_MedicaidAndMedicareMember_8242232c-d102-40b1-baa8-6134949f5cfc" xlink:to="loc_ensg_MedicaidSkilledMember_38f518d7-3133-4cb7-b848-ab2a88bcded8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ManagedCareMember_0f94cd71-917b-4ec7-a98a-7a248f3487dd" xlink:href="ensg-20231231.xsd#ensg_ManagedCareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_ManagedCareMember_0f94cd71-917b-4ec7-a98a-7a248f3487dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrivatePayAndOtherMember_b1af0b92-d6dc-4799-bef9-6a0ff5e863d5" xlink:href="ensg-20231231.xsd#ensg_PrivatePayAndOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e4bf9974-363b-4e10-8bfc-f7ee0e51d299" xlink:to="loc_ensg_PrivatePayAndOtherMember_b1af0b92-d6dc-4799-bef9-6a0ff5e863d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_87f8d795-971a-495a-8aea-85aeb2bb1c55" xlink:to="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c364938c-0354-4ab7-903e-e2267aa7c8d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:to="loc_us-gaap_OperatingSegmentsMember_c364938c-0354-4ab7-903e-e2267aa7c8d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_00e03179-2999-409b-afe3-c293db1dc9d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5fd9356d-bb11-44b8-96ac-dec27c65a0b4" xlink:to="loc_us-gaap_CorporateNonSegmentMember_00e03179-2999-409b-afe3-c293db1dc9d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_08bb1026-c31c-449b-a41d-1ab7de4658c7" xlink:to="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_edc5dedc-9be3-4ded-8200-f779ece9b699" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8e255560-7af4-41cd-a6fd-2f9fbf154338" xlink:to="loc_ensg_SkilledServicesSegmentMember_edc5dedc-9be3-4ded-8200-f779ece9b699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_40ec66b5-551f-4a01-a4a9-bfeb36a97442" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_8d4ac0ec-6c33-492f-a20f-7f0a34555a65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_5daac09a-2f16-47af-9708-96fee0429587" xlink:to="loc_us-gaap_SalesRevenueNetMember_8d4ac0ec-6c33-492f-a20f-7f0a34555a65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_c41afab5-b791-4940-8ab9-1741b12b86ac" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_dd0abeb9-13c2-4912-9707-6955a139b9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a46d7787-d0e5-4123-8b17-3b3e14b89d6b" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_dd0abeb9-13c2-4912-9707-6955a139b9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingRevenueReconcilingItemLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable_7cda683f-6d57-4285-b1d5-899c25bee25b" xlink:to="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62bd8837-0752-432d-b2e5-5a275d6f4ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62bd8837-0752-432d-b2e5-5a275d6f4ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fe361298-3d89-4b14-92d1-5f1732b93707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingRevenueReconcilingItemLineItems_9541f7c7-58a6-40ce-9b09-d8d9146ba733" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fe361298-3d89-4b14-92d1-5f1732b93707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84890892-5889-4de4-ba2c-cd38d7212e35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_84890892-5889-4de4-ba2c-cd38d7212e35" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_c2803bfb-abf5-48b6-8239-c0fa6b1f8f17" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_e3a3ba15-1fc4-46a5-a576-7571d7b41251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_LandMember_e3a3ba15-1fc4-46a5-a576-7571d7b41251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_fbb00d6e-d9a5-46f5-98c6-1bacd571163e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_fbb00d6e-d9a5-46f5-98c6-1bacd571163e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_16fd3dc8-8b2e-4f9c-bfc2-ea3d5d1c7fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_16fd3dc8-8b2e-4f9c-bfc2-ea3d5d1c7fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_fa9ee91a-5200-4f37-a87b-a520ae1ccff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_EquipmentMember_fa9ee91a-5200-4f37-a87b-a520ae1ccff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_62d548b8-07b7-40da-8bf9-c6090e485db1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_62d548b8-07b7-40da-8bf9-c6090e485db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_47213110-d2b7-4f97-9628-f5b8cee428a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8173f9c5-e86d-4637-a1e0-7ed5ef5fb8ee" xlink:to="loc_us-gaap_ConstructionInProgressMember_47213110-d2b7-4f97-9628-f5b8cee428a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_6ce7daf3-4e83-4bc3-8c98-ee1f1e0219dc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_604b33c4-f0cd-4c66-8141-58488ac73031" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_604b33c4-f0cd-4c66-8141-58488ac73031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7d67f79-af02-4cd7-9b89-cca3a7f65fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f7d67f79-af02-4cd7-9b89-cca3a7f65fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e19b2a-98ef-44fd-8bad-4df62cdd9f20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_3e270cee-1343-4e7b-9fb4-f782f63ef5e4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_f0e19b2a-98ef-44fd-8bad-4df62cdd9f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#PROPERTYANDEQUIPMENTNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_655658c9-a17c-4f39-a562-15b935c4f9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_655658c9-a17c-4f39-a562-15b935c4f9b9" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b6bb9317-af12-4d5a-8bb9-f32ac4b265c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SeniorLivingOperationsMember_f5c2fb0d-9ac7-454d-895e-73099d703804" xlink:href="ensg-20231231.xsd#ensg_SeniorLivingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b9119d46-5594-4813-901f-747e20a0ff90" xlink:to="loc_ensg_SeniorLivingOperationsMember_f5c2fb0d-9ac7-454d-895e-73099d703804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_c88f208e-db88-44d8-8d7b-2942b0a59280" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6cc00f4-be0c-4d05-a2c9-a332c4aa77a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_72e209a6-1ec7-43e4-aa2e-4440b70292f0" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_d6cc00f4-be0c-4d05-a2c9-a332c4aa77a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_0ad2c07f-3db6-476d-b1aa-544e6b1ccd3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2aff067-4980-452d-b61a-96d1136724b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_d2aff067-4980-452d-b61a-96d1136724b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_60c361b1-c08e-4bf4-a522-3684264d9cce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_1c391f81-deab-45e6-964c-a773d3098d10" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_60c361b1-c08e-4bf4-a522-3684264d9cce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42c30da8-54d5-428e-ba24-a1ed6044d708" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_42c30da8-54d5-428e-ba24-a1ed6044d708" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_c90cf90b-61c0-4d99-a838-f9e6da7c59f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AssembledOccupancyAcquiredMember_8718dede-24ad-4fa8-aaf1-79a2d02cacf9" xlink:href="ensg-20231231.xsd#ensg_AssembledOccupancyAcquiredMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_ensg_AssembledOccupancyAcquiredMember_8718dede-24ad-4fa8-aaf1-79a2d02cacf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_c8c775a5-312f-4fc8-be74-224cbb7f422f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_us-gaap_TradeNamesMember_c8c775a5-312f-4fc8-be74-224cbb7f422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0e2fe54f-ddfd-47c2-b263-4dd30558271f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_89ad96c6-7cd9-4d50-aa54-950fea0e025d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0e2fe54f-ddfd-47c2-b263-4dd30558271f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_51334c6d-70cb-41db-8c60-6282991862c4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4ebab34f-04b3-415a-aa11-fa37693109e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_4ebab34f-04b3-415a-aa11-fa37693109e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4add845-ff6d-429e-afcf-a7164968edd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_c4add845-ff6d-429e-afcf-a7164968edd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47337c88-edf3-4507-a160-cc21f669ce35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_47337c88-edf3-4507-a160-cc21f669ce35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b576600-84ed-42b9-afd0-e207221ded99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8503aaa-1a75-4f5c-a5a1-366b24307cda" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4b576600-84ed-42b9-afd0-e207221ded99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_666af744-444d-4e4c-8322-15abc133f7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_666af744-444d-4e4c-8322-15abc133f7cf" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_23efcb17-6db9-448c-beb6-31171eb5c8dc" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DepreciationAndAmortizationMember_1e2b5eab-87a4-4272-916a-824160d79973" xlink:href="ensg-20231231.xsd#ensg_DepreciationAndAmortizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a749a611-8a98-4166-a3bb-88ba214f169f" xlink:to="loc_ensg_DepreciationAndAmortizationMember_1e2b5eab-87a4-4272-916a-824160d79973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_8b83796e-2170-4637-b1ae-49cd9e458fa9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareandMedicaidLicensesMember_3e9ab3f1-6584-46dc-843f-3baa0b389062" xlink:href="ensg-20231231.xsd#ensg_MedicareandMedicaidLicensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_34755fbb-af99-4032-ab53-985d128b5d53" xlink:to="loc_ensg_MedicareandMedicaidLicensesMember_3e9ab3f1-6584-46dc-843f-3baa0b389062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_e268d08d-dff1-49fa-9eae-5b8abf4478b1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_65b6b437-6992-42b0-a6ef-04c37a4c1d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_65b6b437-6992-42b0-a6ef-04c37a4c1d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_56e590a9-d6e2-4d51-8a79-fd6ab91fa3bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_OperatingLeaseCost_56e590a9-d6e2-4d51-8a79-fd6ab91fa3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2cb9a76d-d3ea-4255-a155-66fa384c08fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_2cb9a76d-d3ea-4255-a155-66fa384c08fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6fe03f0b-2681-41ae-9dd5-0e8e709e012c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefinitelivedIntangibleAssetsAcquired"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_0eca60f2-8992-4911-bca2-1d0c583659aa" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsAcquired_6fe03f0b-2681-41ae-9dd5-0e8e709e012c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_76e1e73a-7945-4a74-aef7-918ddac61d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_76e1e73a-7945-4a74-aef7-918ddac61d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_406a292d-df50-4013-9c40-005556b51170" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_406a292d-df50-4013-9c40-005556b51170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2d6db34-85af-4365-917b-760b7f5ae208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_f2d6db34-85af-4365-917b-760b7f5ae208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f87ac662-f0af-44f5-862c-bd388b0961ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_f87ac662-f0af-44f5-862c-bd388b0961ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23d0eb39-a76e-40bd-827a-e6f4379b265f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_23d0eb39-a76e-40bd-827a-e6f4379b265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa95120f-4c2c-4f95-a6cd-966aec62352c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_fa95120f-4c2c-4f95-a6cd-966aec62352c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41c562f-68c7-46c5-a51b-f305dfff4f1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6a911dae-f4c0-402e-a231-a9214a63526c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a41c562f-68c7-46c5-a51b-f305dfff4f1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c730a5b4-e485-4ee8-9912-072fc92229e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c730a5b4-e485-4ee8-9912-072fc92229e2" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_107cd938-b473-4ed7-9a90-180d424d4626" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_d8b1bf0d-a06b-45c2-9bea-cfe421af852c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:to="loc_us-gaap_TradeNamesMember_d8b1bf0d-a06b-45c2-9bea-cfe421af852c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicareandMedicaidLicensesMember_3072d568-86e2-4d51-beda-54c67feacf9b" xlink:href="ensg-20231231.xsd#ensg_MedicareandMedicaidLicensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_512615d1-8de4-4621-b4d0-6aa2f99c7b57" xlink:to="loc_ensg_MedicareandMedicaidLicensesMember_3072d568-86e2-4d51-beda-54c67feacf9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_e1a893a6-3f9d-451e-a5ca-eb271bc3e991" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33d65441-fb4a-42a6-90ac-9f2c937c0875" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_6d9e8c3d-1cc8-46c0-9128-5f641c273db9" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_33d65441-fb4a-42a6-90ac-9f2c937c0875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/GOODWILLDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#GOODWILLDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/GOODWILLDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0ca63807-97f4-43f0-ae8c-aa523e605eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0ca63807-97f4-43f0-ae8c-aa523e605eee" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:to="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_8b158b74-e01d-45bb-abfb-3209917e3772" xlink:to="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_c1e823c3-99e2-4717-a913-5b54d88fef46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:to="loc_us-gaap_OperatingSegmentsMember_c1e823c3-99e2-4717-a913-5b54d88fef46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_cf62dc01-78d2-4263-9a2c-fc3f4e5ecd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_d71e0683-d3b5-4d7e-8108-9139ce557a95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_cf62dc01-78d2-4263-9a2c-fc3f4e5ecd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a74b2f03-e684-424b-9e37-367818b239f2" xlink:to="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledServicesSegmentMember_6f1ccc86-dcd5-4799-8965-e10b481f038a" xlink:href="ensg-20231231.xsd#ensg_SkilledServicesSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6256bed6-55b0-4f4c-95f6-b6b3dfb93447" xlink:to="loc_ensg_SkilledServicesSegmentMember_6f1ccc86-dcd5-4799-8965-e10b481f038a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_c564e5b6-e4f0-4250-8cc6-e93a4c94cf47" xlink:to="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_d24fd8dd-2020-4f6d-8deb-f11d02795596" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:to="loc_us-gaap_Goodwill_d24fd8dd-2020-4f6d-8deb-f11d02795596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_acf061ce-5630-4f49-87e4-b198e5dcf2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a57cab73-3275-41d2-9bb5-ebb919f6d06f" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_acf061ce-5630-4f49-87e4-b198e5dcf2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#RESTRICTEDANDOTHERASSETSDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_098c6d0d-797b-4e1c-b791-435743b65109" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet_098c6d0d-797b-4e1c-b791-435743b65109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_45d75519-bb27-425f-81df-f3cc9571f7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_45d75519-bb27-425f-81df-f3cc9571f7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestrictedAssets_956d71f8-0342-42d2-8fa1-5b98f77c5268" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherRestrictedAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_OtherRestrictedAssets_956d71f8-0342-42d2-8fa1-5b98f77c5268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecurityDeposit_fcbd4f18-296f-42fe-aa49-e38c55c09e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SecurityDeposit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_SecurityDeposit_fcbd4f18-296f-42fe-aa49-e38c55c09e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EscrowDeposit_50bb1666-f54a-46ba-87a0-6f48471a6464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EscrowDeposit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_EscrowDeposit_50bb1666-f54a-46ba-87a0-6f48471a6464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_959966af-c5d9-4ce3-9d54-a87bdf6cb4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_us-gaap_OtherAssetsCurrent_959966af-c5d9-4ce3-9d54-a87bdf6cb4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RestrictedAndOtherAssetsNoncurrent_ea7a6b58-a181-472b-97cf-464f22917c67" xlink:href="ensg-20231231.xsd#ensg_RestrictedAndOtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_75d21f29-9661-4276-9d25-12138017e9b7" xlink:to="loc_ensg_RestrictedAndOtherAssetsNoncurrent_ea7a6b58-a181-472b-97cf-464f22917c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OTHERACCRUEDLIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_QualityAssuranceFee_453d9fee-48bb-499f-b40c-1c236cbffb70" xlink:href="ensg-20231231.xsd#ensg_QualityAssuranceFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_ensg_QualityAssuranceFee_453d9fee-48bb-499f-b40c-1c236cbffb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ResidentRefundsPayable_7d33b5c0-a4b9-4675-9916-4b046d18feee" xlink:href="ensg-20231231.xsd#ensg_ResidentRefundsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_ensg_ResidentRefundsPayable_7d33b5c0-a4b9-4675-9916-4b046d18feee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cefed667-cf25-4eb7-bc23-3182f1ac6229" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_cefed667-cf25-4eb7-bc23-3182f1ac6229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_fdb1e609-1cdf-42fc-acb5-38efd60d4480" xlink:href="ensg-20231231.xsd#ensg_AccruedLiabilitiesStateReliefContractLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_ensg_AccruedLiabilitiesStateReliefContractLiabilities_fdb1e609-1cdf-42fc-acb5-38efd60d4480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CashHeldInTrustForResidents_3b2172ca-2ebc-4866-82b1-21c7d852d8bc" xlink:href="ensg-20231231.xsd#ensg_CashHeldInTrustForResidents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_ensg_CashHeldInTrustForResidents_3b2172ca-2ebc-4866-82b1-21c7d852d8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_2aeec8c3-a801-4b10-96b2-0fb01d5180d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_2aeec8c3-a801-4b10-96b2-0fb01d5180d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_4335747e-165b-4567-9fc4-30826ed86199" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent_4335747e-165b-4567-9fc4-30826ed86199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveCurrent_35592cda-ecc5-44d6-bcd0-215ac04e2b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_LitigationReserveCurrent_35592cda-ecc5-44d6-bcd0-215ac04e2b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e6869e4a-ce69-4815-9e27-308668f50813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e6869e4a-ce69-4815-9e27-308668f50813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77972c4e-5110-4005-94d9-31cbcf011707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_fca199de-b440-4e9e-9143-b128c82c11e8" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_77972c4e-5110-4005-94d9-31cbcf011707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_063699f6-83f7-44e2-a14c-e0470a2037ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7f73146f-d047-4696-b0f4-0e1bd70c995c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_063699f6-83f7-44e2-a14c-e0470a2037ac" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7f73146f-d047-4696-b0f4-0e1bd70c995c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9050fd32-2c7d-4c9c-961c-f5790faae7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7f73146f-d047-4696-b0f4-0e1bd70c995c" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_9050fd32-2c7d-4c9c-961c-f5790faae7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ab66ff6f-d367-4e17-816d-f3dcc6221f37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7f73146f-d047-4696-b0f4-0e1bd70c995c" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ab66ff6f-d367-4e17-816d-f3dcc6221f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c79d6c59-7f4d-4e4e-b44c-dd99fb45b247" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_7f73146f-d047-4696-b0f4-0e1bd70c995c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c79d6c59-7f4d-4e4e-b44c-dd99fb45b247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3d0cf930-5143-4bc2-b8a0-bd3d989efdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_063699f6-83f7-44e2-a14c-e0470a2037ac" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3d0cf930-5143-4bc2-b8a0-bd3d989efdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_565e3d28-98d9-4cbd-b6de-cec3e2598f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3d0cf930-5143-4bc2-b8a0-bd3d989efdb3" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_565e3d28-98d9-4cbd-b6de-cec3e2598f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cda8940e-db28-4ff5-90bb-ccb9893fcb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3d0cf930-5143-4bc2-b8a0-bd3d989efdb3" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_cda8940e-db28-4ff5-90bb-ccb9893fcb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_b427aa2c-0af9-490b-9654-8c20fffe098e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3d0cf930-5143-4bc2-b8a0-bd3d989efdb3" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_b427aa2c-0af9-490b-9654-8c20fffe098e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_43121606-72b7-4a81-abb9-62c4eb99b714" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_063699f6-83f7-44e2-a14c-e0470a2037ac" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_43121606-72b7-4a81-abb9-62c4eb99b714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ff77f01d-ef8c-4487-922f-c2172693ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ff77f01d-ef8c-4487-922f-c2172693ddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_35c4b34c-fcc8-430b-8758-9f6e8f00197f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_35c4b34c-fcc8-430b-8758-9f6e8f00197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1bf99900-1b91-4a62-bb33-be466ceca985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_1bf99900-1b91-4a62-bb33-be466ceca985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_40a743da-4c05-41c2-b7ec-f8bed9c2086c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_40a743da-4c05-41c2-b7ec-f8bed9c2086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9d86650f-fa5e-44c3-9b09-23700a2a5fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9d86650f-fa5e-44c3-9b09-23700a2a5fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_416d21fb-14d0-4796-96db-b3d5a1352cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_89faa42a-84d3-43d3-b290-c91eb084899a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_416d21fb-14d0-4796-96db-b3d5a1352cdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESNarrativeYEDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9cde20-6d52-4e0b-96af-6479997fa309" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8de65498-e047-4643-9d9e-f1e1a4bd73e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9cde20-6d52-4e0b-96af-6479997fa309" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_8de65498-e047-4643-9d9e-f1e1a4bd73e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ab3ef6cd-3554-4b2c-bee6-a58306f6041a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9cde20-6d52-4e0b-96af-6479997fa309" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ab3ef6cd-3554-4b2c-bee6-a58306f6041a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d57a0eef-2eb1-4144-b016-8afe6e1c57c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ba9cde20-6d52-4e0b-96af-6479997fa309" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_d57a0eef-2eb1-4144-b016-8afe6e1c57c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6d8850b2-ab66-4d38-862f-7340ad2b8aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_6d8850b2-ab66-4d38-862f-7340ad2b8aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_5e591401-09dc-4a30-b15b-95c9b72a2bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts_5e591401-09dc-4a30-b15b-95c9b72a2bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1bf55327-7f8a-4052-b3cd-a1345354632d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_1bf55327-7f8a-4052-b3cd-a1345354632d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_f042998b-3b38-44c8-a3dd-aaf77c893998" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance_f042998b-3b38-44c8-a3dd-aaf77c893998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_f2a45567-be2c-474f-86e2-7663ad89b210" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability_f2a45567-be2c-474f-86e2-7663ad89b210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsStateTaxes_1fd1ec70-d69c-4c07-9690-3aa05fdaa58a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsStateTaxes"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsStateTaxes_1fd1ec70-d69c-4c07-9690-3aa05fdaa58a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_369242f0-012a-413d-b1cf-b817437252d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_369242f0-012a-413d-b1cf-b817437252d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_44c3e4e2-3a30-456b-a224-0f5fd5875669" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_44c3e4e2-3a30-456b-a224-0f5fd5875669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e05bc35c-0b27-4885-8a85-0e67bd027c68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e05bc35c-0b27-4885-8a85-0e67bd027c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesStateTaxes_28fe774e-d2ad-47e5-82a1-203216c2524f" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesStateTaxes"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_ensg_DeferredTaxLiabilitiesStateTaxes_28fe774e-d2ad-47e5-82a1-203216c2524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cfbf501e-85f4-4485-920b-569bc0947045" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_cfbf501e-85f4-4485-920b-569bc0947045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1d74bcee-a854-496a-b6a2-9a2357f8f8cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_1d74bcee-a854-496a-b6a2-9a2357f8f8cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset_df72f194-d4c8-4c61-be4f-e75c7e136a3f" xlink:href="ensg-20231231.xsd#ensg_DeferredTaxLiabilitiesRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_ensg_DeferredTaxLiabilitiesRightOfUseAsset_df72f194-d4c8-4c61-be4f-e75c7e136a3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_cb813089-6f9a-4249-a71e-eb729eb8a16f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_cb813089-6f9a-4249-a71e-eb729eb8a16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_88aac13a-6b4a-4f96-b806-b69d14ea5989" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cb99828-47b3-4c94-9d52-61dfc0588295" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_88aac13a-6b4a-4f96-b806-b69d14ea5989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTScheduleofLongtermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ffbe4925-d0b3-4f3c-9c9c-74c8b55ffc8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ffbe4925-d0b3-4f3c-9c9c-74c8b55ffc8d" xlink:to="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_adb6ac90-a271-4f24-8762-f08b2928ecce" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralizedDebtObligationsMember_0af46462-6766-488c-86a7-71af56fa73ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralizedDebtObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_d5858643-b326-4f2c-9d15-393b6f2465ac" xlink:to="loc_us-gaap_CollateralizedDebtObligationsMember_0af46462-6766-488c-86a7-71af56fa73ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_d62759b1-ee30-4b50-80ad-9f7f7b72e855" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_d1561f19-d91c-4756-a25d-524ec6bf99f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_d1561f19-d91c-4756-a25d-524ec6bf99f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_23ff158d-027d-4304-96ed-e14baa58b4b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_LongTermDebtCurrent_23ff158d-027d-4304-96ed-e14baa58b4b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_b6953513-6c4f-4789-a535-146cf5698337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_b6953513-6c4f-4789-a535-146cf5698337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_914b8dc2-8fba-4423-9943-3b70dcb0e431" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c75cf3c4-ee8e-4e96-8b30-f84cd35121e9" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_914b8dc2-8fba-4423-9943-3b70dcb0e431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ce56d638-5d39-4602-a8d5-3abe265d2b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ce56d638-5d39-4602-a8d5-3abe265d2b7c" xlink:to="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_aa458d2b-c1fd-4506-baf2-547e3aa4dc73" xlink:to="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_18ca85b9-159b-41e3-8f11-9f3d544ffe0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2a355ae5-e666-4b54-95f7-4b34c67a4cec" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_18ca85b9-159b-41e3-8f11-9f3d544ffe0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLenderDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityAxis_00ebcf3f-17b1-4b72-881a-f55da552de74" xlink:to="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TruistBankMember_97c6e934-5d8b-4b54-80fe-0807e11989ab" xlink:href="ensg-20231231.xsd#ensg_TruistBankMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLenderDomain_0b533166-fa71-45ac-924b-1d79eefd3ab9" xlink:to="loc_ensg_TruistBankMember_97c6e934-5d8b-4b54-80fe-0807e11989ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_c48c0713-32a4-4a7b-8cd3-cc71de5a3cb1" xlink:to="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_8b805323-18a2-4fd9-bcb7-80f08ff19251" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:to="loc_us-gaap_BaseRateMember_8b805323-18a2-4fd9-bcb7-80f08ff19251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SecuredOvernightFinancingRateSOFRMember_65c4f9eb-bce5-4804-983b-4a57c9cd9bc6" xlink:href="ensg-20231231.xsd#ensg_SecuredOvernightFinancingRateSOFRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_67d44574-6222-4ddf-a81a-5010ab73fe65" xlink:to="loc_ensg_SecuredOvernightFinancingRateSOFRMember_65c4f9eb-bce5-4804-983b-4a57c9cd9bc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f0124beb-0775-4fcb-93a1-e2a8e2ec2dfc" xlink:to="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e5eb5b8c-4968-418e-a51d-24a643e63d6d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:to="loc_srt_MinimumMember_e5eb5b8c-4968-418e-a51d-24a643e63d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c3310c51-e0ea-47c6-9029-fe9dadbd41b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0b766d58-e68b-44e5-b04d-db731f84d980" xlink:to="loc_srt_MaximumMember_c3310c51-e0ea-47c6-9029-fe9dadbd41b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5250dac6-267a-4755-930d-773fd199cd1f" xlink:to="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8363301-afdb-44f0-8b71-976f1187a820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e8363301-afdb-44f0-8b71-976f1187a820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9ac8871d-6a49-48f7-b75a-76b8ac75acfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9ac8871d-6a49-48f7-b75a-76b8ac75acfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c9daa534-9647-452c-8049-5f2b79120dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_c9daa534-9647-452c-8049-5f2b79120dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_9c3266ff-95db-4f02-a122-250341beb09e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WriteOffOfDeferredDebtIssuanceCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_WriteOffOfDeferredDebtIssuanceCost_9c3266ff-95db-4f02-a122-250341beb09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_e4381e54-118b-4bc0-a615-737e712f0f10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_e4381e54-118b-4bc0-a615-737e712f0f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximum_86e9a28c-5a53-43b4-bc20-752bf53d2d16" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMaximum_86e9a28c-5a53-43b4-bc20-752bf53d2d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_0aaf0678-6f17-403c-893f-a7e8546d7f1d" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod_0aaf0678-6f17-403c-893f-a7e8546d7f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_b62a2dec-9a7e-48fc-8a5d-e4c04f6929c1" xlink:href="ensg-20231231.xsd#ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection_b62a2dec-9a7e-48fc-8a5d-e4c04f6929c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_04bad640-47d1-4f16-9a42-2a083d4c6e89" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMaximumAfterIncreaseElection"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection_04bad640-47d1-4f16-9a42-2a083d4c6e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TotalNetDebtRatioMinimum_adf62158-1df4-4fc2-9c52-cac8c8dc2857" xlink:href="ensg-20231231.xsd#ensg_TotalNetDebtRatioMinimum"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_ensg_TotalNetDebtRatioMinimum_adf62158-1df4-4fc2-9c52-cac8c8dc2857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_db663761-9ae1-423a-ae29-9b49f87a4300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_951981ad-c113-4484-8478-01e99cb8b3b5" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_db663761-9ae1-423a-ae29-9b49f87a4300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6ba4af32-9f8b-4128-80fc-bdf95de52387" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6ba4af32-9f8b-4128-80fc-bdf95de52387" xlink:to="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2717166f-3ca9-46ca-98ad-c4eed90e33fb" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralizedDebtObligationsMember_cd627d5b-116c-42b7-a8c6-329945fa6b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollateralizedDebtObligationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_ea0e7e01-7b86-4248-94c9-2ed9a0925678" xlink:to="loc_us-gaap_CollateralizedDebtObligationsMember_cd627d5b-116c-42b7-a8c6-329945fa6b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_35afdfdc-95fd-41eb-b749-a2ff778be8cb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_HUDInsuredMortgagesMember_7aa9ffa5-2c8e-4c8c-bd2c-f240b4d60537" xlink:href="ensg-20231231.xsd#ensg_HUDInsuredMortgagesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:to="loc_ensg_HUDInsuredMortgagesMember_7aa9ffa5-2c8e-4c8c-bd2c-f240b4d60537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A53PromissoryNoteMember_e386073c-8d9f-434a-9ce6-2b9c315c26d0" xlink:href="ensg-20231231.xsd#ensg_A53PromissoryNoteMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0d4e91a2-0271-4e97-b4a6-278bae3f2514" xlink:to="loc_ensg_A53PromissoryNoteMember_e386073c-8d9f-434a-9ce6-2b9c315c26d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_87c206fc-d2a8-45a7-8191-ece582099f91" xlink:to="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TwentyThreeSubsidiariesMember_5bccc3e5-f909-4180-ba80-f7dc7a16a10d" xlink:href="ensg-20231231.xsd#ensg_TwentyThreeSubsidiariesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_c648dd82-8687-48eb-bff1-5824046a07a8" xlink:to="loc_ensg_TwentyThreeSubsidiariesMember_5bccc3e5-f909-4180-ba80-f7dc7a16a10d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_88b166b7-af90-4388-bcda-2c89ae49e917" xlink:to="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8350a338-1fdc-4021-9b8a-de4957360005" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:to="loc_srt_MinimumMember_8350a338-1fdc-4021-9b8a-de4957360005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_28020f86-deb7-47de-8b86-a9ba48452b32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5050d504-bd6b-444f-8067-d75ac7a75669" xlink:to="loc_srt_MaximumMember_28020f86-deb7-47de-8b86-a9ba48452b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:href="ensg-20231231.xsd#ensg_PrepaymentFeePeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PrepaymentFeePeriodAxis_303075a2-8d59-49a0-9625-15de5241a849" xlink:to="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FirstThreeYearsMember_d1c9eb6c-2569-49b1-a122-ce7af54ebe27" xlink:href="ensg-20231231.xsd#ensg_FirstThreeYearsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_FirstThreeYearsMember_d1c9eb6c-2569-49b1-a122-ce7af54ebe27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InTheFourthYearMember_095c7247-8a96-42c5-ada0-945fc620d872" xlink:href="ensg-20231231.xsd#ensg_InTheFourthYearMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_InTheFourthYearMember_095c7247-8a96-42c5-ada0-945fc620d872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_YearsFiveThroughTenMember_1b3ea6e6-e553-4bc9-872c-b0a58def2395" xlink:href="ensg-20231231.xsd#ensg_YearsFiveThroughTenMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_YearsFiveThroughTenMember_1b3ea6e6-e553-4bc9-872c-b0a58def2395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AfterYearTenMember_6322248a-1499-4f62-95ca-f898e2f1ae3f" xlink:href="ensg-20231231.xsd#ensg_AfterYearTenMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_PrepaymentFeePeriodDomain_21a929d0-112f-45b7-9b79-ad6c780209de" xlink:to="loc_ensg_AfterYearTenMember_6322248a-1499-4f62-95ca-f898e2f1ae3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_78f42c59-19be-41eb-9e68-7500a1b50a49" xlink:to="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_3f50fd5e-52d0-4d5c-bc2a-c1a7ff63ad7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_9a310882-713a-4bd0-be46-8abe727d67af" xlink:to="loc_us-gaap_LetterOfCreditMember_3f50fd5e-52d0-4d5c-bc2a-c1a7ff63ad7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_f4c4e409-87c9-469f-bf3f-2a84161fdef6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOperatingSubsidiaries_53d77576-381c-4a48-891a-7d16cb8ca8bb" xlink:href="ensg-20231231.xsd#ensg_NumberOfOperatingSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_NumberOfOperatingSubsidiaries_53d77576-381c-4a48-891a-7d16cb8ca8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_ea180683-1118-44f2-a0e6-e77c3f390fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_ea180683-1118-44f2-a0e6-e77c3f390fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8f33e63e-94d0-4c9f-8482-e3de83a09c54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_8f33e63e-94d0-4c9f-8482-e3de83a09c54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63899dbc-a447-4380-94a1-ae0de645616a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_63899dbc-a447-4380-94a1-ae0de645616a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PrepaymentPenalty_79263ca4-57e4-466c-962b-e2aff581fd07" xlink:href="ensg-20231231.xsd#ensg_PrepaymentPenalty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_PrepaymentPenalty_79263ca4-57e4-466c-962b-e2aff581fd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ReductionInPrepaymentPenalty_68125a22-390e-4d4f-9ff8-b75c62cabb13" xlink:href="ensg-20231231.xsd#ensg_ReductionInPrepaymentPenalty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_ensg_ReductionInPrepaymentPenalty_68125a22-390e-4d4f-9ff8-b75c62cabb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e9725b51-9dc5-41aa-be64-3c98a6a2e2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_DebtInstrumentTerm_e9725b51-9dc5-41aa-be64-3c98a6a2e2d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LettersOfCreditOutstandingAmount_0b30d024-572a-4dd2-95a4-5d7f23f4095a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_LettersOfCreditOutstandingAmount_0b30d024-572a-4dd2-95a4-5d7f23f4095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_5b8c381d-2a3b-4327-a733-c5d5739a50d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_00497c34-048e-4acf-a83b-164e8fe198ae" xlink:to="loc_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet_5b8c381d-2a3b-4327-a733-c5d5739a50d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEBTLongtermDebtArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_67101353-52c3-4315-a62e-128be54d6594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_67101353-52c3-4315-a62e-128be54d6594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9ce04b46-2834-4882-b3cf-bc8012ac47f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_9ce04b46-2834-4882-b3cf-bc8012ac47f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_93fbe502-ec25-4ec6-ba27-747a8ea88e26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_93fbe502-ec25-4ec6-ba27-747a8ea88e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4274c40d-f727-4279-955f-5ea69a591774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_4274c40d-f727-4279-955f-5ea69a591774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8dc1e3e5-540d-4fa4-a1ca-e303e6f3e37b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_8dc1e3e5-540d-4fa4-a1ca-e303e6f3e37b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1b55088b-9c95-4a14-a3e5-f8202a0f1a78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_1b55088b-9c95-4a14-a3e5-f8202a0f1a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_44d34b90-d27b-440d-879f-79354372370f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f44949ba-6059-4ec4-8298-b83913849871" xlink:to="loc_us-gaap_LongTermDebt_44d34b90-d27b-440d-879f-79354372370f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSStockOptionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5833d9-abb2-4df7-b7fe-32fc715b98cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2a5833d9-abb2-4df7-b7fe-32fc715b98cc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_4c2c07e4-373e-49ed-88ad-82e320083b6d" xlink:to="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2022PlanMember_f33dec8f-7fb4-49a0-b57d-4acd2597c920" xlink:href="ensg-20231231.xsd#ensg_A2022PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d67bb44f-f43c-4197-a152-ec7a1be7248c" xlink:to="loc_ensg_A2022PlanMember_f33dec8f-7fb4-49a0-b57d-4acd2597c920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_2c3785c8-8cbc-4703-a8e6-57b9789fc687" xlink:to="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7f0d6192-6810-4f62-b761-2a746ffad791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_c09b7bc7-0e75-4c0a-bb13-aa7a60acdfd6" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_7f0d6192-6810-4f62-b761-2a746ffad791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0b0a9729-4263-41dd-8f21-228d7a790b38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f470d315-e57f-4106-92c0-09f39673c61b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c1a8c383-6ffb-436b-b63b-c4ddbf7af3b4" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f470d315-e57f-4106-92c0-09f39673c61b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1ff3703e-897b-42fe-a0ff-14eb818ba2c5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NumberOfOptionPlans_7fcdd3dd-601b-45d8-9659-1746cc5202cf" xlink:href="ensg-20231231.xsd#ensg_NumberOfOptionPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_NumberOfOptionPlans_7fcdd3dd-601b-45d8-9659-1746cc5202cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4a22e1b-bcbd-42ed-b388-0aa8c746048d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_e4a22e1b-bcbd-42ed-b388-0aa8c746048d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_c094dcc2-804d-4add-8e13-082e6e2990bf" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability_c094dcc2-804d-4add-8e13-082e6e2990bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_68f4b511-0d29-4778-8c54-fdfec3c3257d" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability_68f4b511-0d29-4778-8c54-fdfec3c3257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_3325932b-7bb8-474f-8a67-107e3b3a8cb7" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments_3325932b-7bb8-474f-8a67-107e3b3a8cb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f25ea7cc-2dff-47f3-8f06-5e2bf20e4757" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_f25ea7cc-2dff-47f3-8f06-5e2bf20e4757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c98bd588-2330-4a84-ae5c-c914560066d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_c98bd588-2330-4a84-ae5c-c914560066d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c93c95cf-8dfc-417f-ab89-b87e670c4c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_c93c95cf-8dfc-417f-ab89-b87e670c4c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b97a838b-eb13-45cb-9d48-d8f98bb6680a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b97a838b-eb13-45cb-9d48-d8f98bb6680a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d54afa2-b190-4ca0-b8ff-ee708877de71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3d54afa2-b190-4ca0-b8ff-ee708877de71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_ae2ea5ba-0a0b-483a-bc97-e680955805d0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate_ae2ea5ba-0a0b-483a-bc97-e680955805d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dafd9c1f-126f-4906-a7a4-4b69f05bfeff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_dafd9c1f-126f-4906-a7a4-4b69f05bfeff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_fb917ffb-d9ca-471f-ab3e-0e1e09698940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue_fb917ffb-d9ca-471f-ab3e-0e1e09698940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_4f3a569c-5be1-45af-88c7-ffcd54aa75e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_4f3a569c-5be1-45af-88c7-ffcd54aa75e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_74132258-a88f-4e1c-991c-a1f205d37e89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a4b7d2e4-6996-453c-b9aa-e580418622cf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_74132258-a88f-4e1c-991c-a1f205d37e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4340c48b-ca28-49be-8f17-9d9415efa5ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4340c48b-ca28-49be-8f17-9d9415efa5ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02689aae-c10c-4b99-b81e-dae8d79b20c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02689aae-c10c-4b99-b81e-dae8d79b20c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7830d85c-72b9-49b3-bcaa-4b4cab851223" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7830d85c-72b9-49b3-bcaa-4b4cab851223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3567a3e7-eeb0-42a1-bae8-957f27b93e2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_3567a3e7-eeb0-42a1-bae8-957f27b93e2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_798ccf20-c1e9-4370-9d44-db2ee063a7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9c471d70-af60-4078-b83e-e4d3b1782f38" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_798ccf20-c1e9-4370-9d44-db2ee063a7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSExercisePriceandFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af458813-79dd-4079-94c8-3bf34cb8e4a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9493d14d-adc9-4c3b-9949-e8cc61f9d790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af458813-79dd-4079-94c8-3bf34cb8e4a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9493d14d-adc9-4c3b-9949-e8cc61f9d790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e718f2a5-9f5e-4d50-9602-e7671a51fb93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af458813-79dd-4079-94c8-3bf34cb8e4a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_e718f2a5-9f5e-4d50-9602-e7671a51fb93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91652347-47a9-4d4c-a3c5-866f0dfb0eee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_af458813-79dd-4079-94c8-3bf34cb8e4a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_91652347-47a9-4d4c-a3c5-866f0dfb0eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b5f2504-c3ba-4fb2-aad7-044cfd5718d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b5f2504-c3ba-4fb2-aad7-044cfd5718d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7985be2d-d955-4f28-b34a-5dc6ff9a26f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7985be2d-d955-4f28-b34a-5dc6ff9a26f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4cfe50aa-5a91-4611-9515-0abf5d8d42e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_4cfe50aa-5a91-4611-9515-0abf5d8d42e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9f450015-adb4-4889-a1d5-2d1caec8ab99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9f450015-adb4-4889-a1d5-2d1caec8ab99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d24f03fb-5b74-4c30-883e-039305eb7314" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d24f03fb-5b74-4c30-883e-039305eb7314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f9e20e5-e8a6-4cbb-bfe4-6e8e652d7e97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b5b9003b-d1bd-4384-a12b-08f121c1257c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6f9e20e5-e8a6-4cbb-bfe4-6e8e652d7e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b5f2504-c3ba-4fb2-aad7-044cfd5718d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d5556fe-df8b-4b4f-b821-4a3e99b98593" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2d5556fe-df8b-4b4f-b821-4a3e99b98593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_385acbeb-b082-4198-9a03-449ad9e761a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_385acbeb-b082-4198-9a03-449ad9e761a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_73e7b790-6d92-4358-9f9a-fcea7af154f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_73e7b790-6d92-4358-9f9a-fcea7af154f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dd230ee1-fb3e-4e92-aced-f8f9ccc16129" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_dd230ee1-fb3e-4e92-aced-f8f9ccc16129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4c1e29f5-df6d-4372-b39a-bf3eef5e5c15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c8ed275f-5f33-4799-b7d2-7983984d2c2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_4c1e29f5-df6d-4372-b39a-bf3eef5e5c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_adcb82df-da9a-4419-b1fb-db610e16db90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b5f2504-c3ba-4fb2-aad7-044cfd5718d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_adcb82df-da9a-4419-b1fb-db610e16db90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_77f2427a-8e84-4a20-85c5-bb924f0ad03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6b5f2504-c3ba-4fb2-aad7-044cfd5718d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_77f2427a-8e84-4a20-85c5-bb924f0ad03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a9f5ca9-471a-43cf-84a7-097be4aa2d20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3a9f5ca9-471a-43cf-84a7-097be4aa2d20" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_b7c64d13-e4ba-4c29-9423-a10bd62fb825" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTwoMember_54c6bd1f-6b47-4916-9e22-f8a11713f5e1" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeTwoMember_54c6bd1f-6b47-4916-9e22-f8a11713f5e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeThreeMember_e7cdc812-8e6d-4a35-8145-a5c44305e751" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeThreeMember_e7cdc812-8e6d-4a35-8145-a5c44305e751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFourMember_42eb706f-68ef-4fb4-bec0-d3f67dc9b2ae" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeFourMember_42eb706f-68ef-4fb4-bec0-d3f67dc9b2ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeFiveMember_8d8ea9ea-be6b-4a1c-95fb-edcd38980629" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeFiveMember_8d8ea9ea-be6b-4a1c-95fb-edcd38980629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSixMember_a36a0a0b-aaa2-4d7e-b3e7-699ae412cd08" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSixMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeSixMember_a36a0a0b-aaa2-4d7e-b3e7-699ae412cd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeSevenMember_9148769c-61b4-4228-9e57-542dd1ebf8e5" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeSevenMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeSevenMember_9148769c-61b4-4228-9e57-542dd1ebf8e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeEightMember_08129951-7847-4103-90b7-e7ac6f445a8d" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeEightMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeEightMember_08129951-7847-4103-90b7-e7ac6f445a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeNineMember_1a9ccafd-d71f-4cb6-b17b-ea6f93a6adc6" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeNineMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeNineMember_1a9ccafd-d71f-4cb6-b17b-ea6f93a6adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeTenMember_43540ffb-cb26-4f93-adb2-f1e843f4d8b1" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeTenMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeTenMember_43540ffb-cb26-4f93-adb2-f1e843f4d8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ExercisePriceRangeElevenMember_41a43c8e-0b38-438d-a36b-5bdae48acf7c" xlink:href="ensg-20231231.xsd#ensg_ExercisePriceRangeElevenMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_e11978d7-0649-421b-82be-bac2032066b4" xlink:to="loc_ensg_ExercisePriceRangeElevenMember_41a43c8e-0b38-438d-a36b-5bdae48acf7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_9c84cef8-5bb7-43ca-9fda-229490bef8c9" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b62c19cd-723e-4f19-b07b-fec929f5c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_b62c19cd-723e-4f19-b07b-fec929f5c5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a13a687d-9d49-4818-8799-859e42673f24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_a13a687d-9d49-4818-8799-859e42673f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7eec002b-e8f7-482d-b372-11c4060ef9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_7eec002b-e8f7-482d-b372-11c4060ef9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_6ac183cb-bea5-4383-9cd7-61466888261f" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue_6ac183cb-bea5-4383-9cd7-61466888261f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_b76a3691-b84b-4f0e-8a1e-622cf8db78a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_b76a3691-b84b-4f0e-8a1e-622cf8db78a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2646a78a-cf1b-4c0e-bc64-4baba2049926" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6b21d38b-8471-457e-8eeb-d58e4134a666" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_2646a78a-cf1b-4c0e-bc64-4baba2049926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSIntrinsicValuesDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c37dbc6-47b4-4f99-8936-fbc6e590bbf4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0dc6dfc6-7dcd-4025-8007-9084ed8990a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c37dbc6-47b4-4f99-8936-fbc6e590bbf4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0dc6dfc6-7dcd-4025-8007-9084ed8990a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a6ccfc3-7e95-4fd8-aaff-d483b20351d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c37dbc6-47b4-4f99-8936-fbc6e590bbf4" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_9a6ccfc3-7e95-4fd8-aaff-d483b20351d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_03787e3a-1517-4ae3-a56d-03b38c4e5f1b" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4c37dbc6-47b4-4f99-8936-fbc6e590bbf4" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue_03787e3a-1517-4ae3-a56d-03b38c4e5f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_336f1b10-f834-49fb-89db-0ff32cbed947" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_336f1b10-f834-49fb-89db-0ff32cbed947" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_12c57fbb-0042-4b0a-815f-56d8b7195589" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5120fd7a-d6c8-4ff8-bbdb-d25d3cb489c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2d7e514-e006-42f8-abba-dfe4a0e0dfcd" xlink:to="loc_us-gaap_RestrictedStockMember_5120fd7a-d6c8-4ff8-bbdb-d25d3cb489c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_734d4ea2-0125-43b7-8083-d186fda07f4d" xlink:to="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e2114a4d-3700-487b-a0e1-3b0e3acde854" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:to="loc_srt_MinimumMember_e2114a4d-3700-487b-a0e1-3b0e3acde854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7417853-33b8-48eb-b6fc-dd2635fc9db2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a2ca8691-62be-4dda-bb7c-880a23fd40c2" xlink:to="loc_srt_MaximumMember_f7417853-33b8-48eb-b6fc-dd2635fc9db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_743ad3ba-1715-47d4-a16b-8ef826a05b6a" xlink:to="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8984be01-aced-4e76-978d-f21b95b38866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedPaymentArrangementNonemployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_ce3e6154-f9ac-4574-aa19-15d07c433574" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementNonemployeeMember_8984be01-aced-4e76-978d-f21b95b38866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1d37ef02-f43d-438b-b4cb-5dc28b1ef658" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fd32d11-e318-46b1-8fd3-03569deca2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_1fd32d11-e318-46b1-8fd3-03569deca2f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_5b9ba3d0-12af-4e1b-815a-c225eb1be84c" xlink:href="ensg-20231231.xsd#ensg_SharebasedCompensationRestrictedAwardsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_ensg_SharebasedCompensationRestrictedAwardsExercisePrice_5b9ba3d0-12af-4e1b-815a-c225eb1be84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6f8c6c7a-b052-4297-8a41-09c4d338fd73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_6f8c6c7a-b052-4297-8a41-09c4d338fd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57cce6bf-fda8-40ed-84d9-0569c0277b5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f20d4490-e333-42aa-863e-38b2804cdfcf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_57cce6bf-fda8-40ed-84d9-0569c0277b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90d0263c-8b2e-493e-8b90-fb2a2acf1644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_90d0263c-8b2e-493e-8b90-fb2a2acf1644" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:to="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_242685d5-a4f1-4540-87bb-2a71b6ddc6c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_5eab90f9-7600-4234-abc0-abbffe4eb927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4338ca14-ea93-4180-b76f-9dc2e0aa0b94" xlink:to="loc_us-gaap_RestrictedStockMember_5eab90f9-7600-4234-abc0-abbffe4eb927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f0325e02-4fa9-46ba-aab8-0daaceda8362" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b50e7ba5-a109-41e5-9d56-a5ce4da868c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b50e7ba5-a109-41e5-9d56-a5ce4da868c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_da17b035-b9f1-4580-871f-cc574c03ff6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_da17b035-b9f1-4580-871f-cc574c03ff6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bf4b242-b0c6-4218-93f6-140fef154cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6bf4b242-b0c6-4218-93f6-140fef154cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e3250a1b-a96a-4cea-89e3-ccc762b3f6ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited_e3250a1b-a96a-4cea-89e3-ccc762b3f6ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2909b1db-ed8f-4cc6-ac9b-54d53a5ac690" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f60be5ed-8cc0-4c9d-a764-4d784580bd48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2909b1db-ed8f-4cc6-ac9b-54d53a5ac690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_11923012-9238-4cba-a9d5-a561ff5fe786" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09d902ed-45da-423d-93f0-273e05cf3f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_09d902ed-45da-423d-93f0-273e05cf3f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f669d522-a58e-4ce4-9d74-b4ec8d325230" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f669d522-a58e-4ce4-9d74-b4ec8d325230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_293372b4-6049-4627-a09f-dd71e7811c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_293372b4-6049-4627-a09f-dd71e7811c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_608a2933-f84c-4935-9ee6-665a28deb658" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_608a2933-f84c-4935-9ee6-665a28deb658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_072c2c4f-b2f1-4e77-8206-e9ee81007741" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_82426a00-9cd5-4458-956e-4d1be10135a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_072c2c4f-b2f1-4e77-8206-e9ee81007741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSLongTermIncentivePlanDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b08f95-b2a3-4ee5-93f8-5cd5d1a1d33c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_02b08f95-b2a3-4ee5-93f8-5cd5d1a1d33c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2628f97f-4a71-4bd2-be09-bc5aa58ec464" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpinoffMember_21559ccf-b5f8-4ad1-b66b-f2b000dee460" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SpinoffMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_6392e961-eb5c-4767-a0f1-00f8a50f982f" xlink:to="loc_us-gaap_SpinoffMember_21559ccf-b5f8-4ad1-b66b-f2b000dee460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:to="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_b7dc921b-d4db-498f-bbf5-ff25fdef115b" xlink:to="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_A2019LTIPlanMember_be484092-4879-48ac-b80d-8399d27db280" xlink:href="ensg-20231231.xsd#ensg_A2019LTIPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_c300e1b3-3675-4625-bee8-2007f996e9c8" xlink:to="loc_ensg_A2019LTIPlanMember_be484092-4879-48ac-b80d-8399d27db280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e62b9c1d-08f6-4f0e-8ebf-bbd7b97fb807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_35b010d5-d269-4d52-b677-63f3c37a9a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_35b010d5-d269-4d52-b677-63f3c37a9a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfa8e420-ea36-4da5-b907-a5d77d80cb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bfa8e420-ea36-4da5-b907-a5d77d80cb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f4cd69af-eb0f-4c50-b1cc-6d9be83c5261" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_f4cd69af-eb0f-4c50-b1cc-6d9be83c5261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_96b78a99-a5e4-4d2f-9fe4-7f9152c36d71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_52518d15-48a4-453d-850e-f8a7aec33d80" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_96b78a99-a5e4-4d2f-9fe4-7f9152c36d71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#OPTIONSANDAWARDSCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_17ad4e56-23f0-4176-961d-39bbc9c6ca7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_17ad4e56-23f0-4176-961d-39bbc9c6ca7a" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:to="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a9793379-304f-4944-99c3-98fa61f8c114" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_86c7bb78-6cd3-4333-940d-2b1045d7175b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_86c7bb78-6cd3-4333-940d-2b1045d7175b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_2aac7ee2-0569-4879-84f6-296d4f1c4481" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_us-gaap_RestrictedStockMember_2aac7ee2-0569-4879-84f6-296d4f1c4481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StockAwardsMember_fc258f07-bb1b-4d39-93dc-5b8eeb8d164d" xlink:href="ensg-20231231.xsd#ensg_StockAwardsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9f3f6fba-4e74-45f0-8c52-ea8367c0fb2b" xlink:to="loc_ensg_StockAwardsMember_fc258f07-bb1b-4d39-93dc-5b8eeb8d164d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_747a7bff-f3dc-4936-b653-2b2112beec74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_47099a53-efd2-4bc2-9e12-34d520e35566" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_47099a53-efd2-4bc2-9e12-34d520e35566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cef8110-de65-4565-a298-6cdb6ab3fdb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6cef8110-de65-4565-a298-6cdb6ab3fdb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e7c83976-5bba-45b0-adca-156a1354f852" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e7c83976-5bba-45b0-adca-156a1354f852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_74299328-3f2b-409c-a389-3e51450e3285" xlink:href="ensg-20231231.xsd#ensg_EmployeeServiceShareBasedCompensationNonvestedAwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards_74299328-3f2b-409c-a389-3e51450e3285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_d5afa0b5-a656-4517-85cf-35c6ae1bb4a0" xlink:href="ensg-20231231.xsd#ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber_d5afa0b5-a656-4517-85cf-35c6ae1bb4a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47957f47-26cb-40df-912f-4b96858b1004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cb33f9b4-eadc-4268-89c4-ec616fe80113" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_47957f47-26cb-40df-912f-4b96858b1004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_aa16c3ee-957f-4670-afec-f85996a7dbcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_aa16c3ee-957f-4670-afec-f85996a7dbcd" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_2affa7ad-772d-4922-83c3-19ebf9337197" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CareTrustREITMember_87a9b230-5cc1-4590-9374-9d87db915c44" xlink:href="ensg-20231231.xsd#ensg_CareTrustREITMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_CareTrustREITMember_87a9b230-5cc1-4590-9374-9d87db915c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_VariousLandlordsMember_1e94439c-cf93-4c67-a95b-77ae0a2b6b46" xlink:href="ensg-20231231.xsd#ensg_VariousLandlordsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_VariousLandlordsMember_1e94439c-cf93-4c67-a95b-77ae0a2b6b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_c6173ffb-6551-43ee-a0c1-9205c5690a00" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_f4aaca9f-fa12-4d9e-894d-a42d21b723d0" xlink:to="loc_ensg_ThePennantGroupInc.Member_c6173ffb-6551-43ee-a0c1-9205c5690a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementAxis_dd78a268-1184-43d3-b863-53333ee3436b" xlink:to="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_TripleNetLeaseArrangementsMember_04ecd41a-527c-4621-9d4f-37feb6abde7a" xlink:href="ensg-20231231.xsd#ensg_TripleNetLeaseArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_TripleNetLeaseArrangementsMember_04ecd41a-527c-4621-9d4f-37feb6abde7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_PurchaseOptionMember_521317f7-b5c9-4528-8055-aa9b538ae66b" xlink:href="ensg-20231231.xsd#ensg_PurchaseOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_PurchaseOptionMember_521317f7-b5c9-4528-8055-aa9b538ae66b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseAgreementMember_fde6638a-12d2-4310-bb34-8841708213a7" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_AmendedMasterLeaseAgreementMember_fde6638a-12d2-4310-bb34-8841708213a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_NewMasterLeaseAgreeementMember_cd7e9682-cf57-467d-a4e2-c25c6a6ac91e" xlink:href="ensg-20231231.xsd#ensg_NewMasterLeaseAgreeementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_NewMasterLeaseAgreeementMember_cd7e9682-cf57-467d-a4e2-c25c6a6ac91e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedMasterLeaseMember_d148687e-f9fb-47ba-a1d6-00dc960394e4" xlink:href="ensg-20231231.xsd#ensg_AmendedMasterLeaseMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_AmendedMasterLeaseMember_d148687e-f9fb-47ba-a1d6-00dc960394e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_b42cd883-29fe-4388-82ba-106ceb88efaa" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_b42cd883-29fe-4388-82ba-106ceb88efaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_fea29ec0-883c-4406-9b50-36171ffd9fc6" xlink:href="ensg-20231231.xsd#ensg_SubleaseOfStandAlongSkilledNursingOperationsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_fea29ec0-883c-4406-9b50-36171ffd9fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseOfCampusOperationMember_14c44ce8-7d5a-4fbe-8a16-100bac582a70" xlink:href="ensg-20231231.xsd#ensg_LeaseOfCampusOperationMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_d08b6e20-fd0e-4420-82a5-0b569a4bcd2f" xlink:to="loc_ensg_LeaseOfCampusOperationMember_14c44ce8-7d5a-4fbe-8a16-100bac582a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c6c4448e-8537-458c-9656-428b03a08f03" xlink:to="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_93f2d88f-f33a-4714-a34d-3092821f2346" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:to="loc_srt_MinimumMember_93f2d88f-f33a-4714-a34d-3092821f2346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_947cd0b6-dfa6-4c0f-9017-34a143584d6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7106f62b-2c6e-41da-a08a-2561ee4fed06" xlink:to="loc_srt_MaximumMember_947cd0b6-dfa6-4c0f-9017-34a143584d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8dc6c4ce-6653-4f4a-81ca-ab118d08316c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_da63a558-565d-48af-a198-2f41ee7c86f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9f05b04c-493f-465f-8f2e-341695037d82" xlink:to="loc_us-gaap_EquipmentMember_da63a558-565d-48af-a198-2f41ee7c86f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_015bc35e-e4ef-4973-922a-985b75c41e29" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_905d4dd1-be44-4267-b4b6-a588fbd3b1f0" xlink:href="ensg-20231231.xsd#ensg_CostofSalesandGeneralandAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c89c0afc-3c5e-4455-84b5-05233fc6f973" xlink:to="loc_ensg_CostofSalesandGeneralandAdministrativeExpenseMember_905d4dd1-be44-4267-b4b6-a588fbd3b1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_c08c517c-a275-45f2-bf0c-58f436b61ccc" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingOperationsMember_dd8aa395-465b-428b-aa0e-04c39a99e2b4" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a2958532-2198-4942-8f04-c024ad4c85d9" xlink:to="loc_ensg_SkilledNursingOperationsMember_dd8aa395-465b-428b-aa0e-04c39a99e2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0c476429-f4c0-4195-addd-3ddf3331e681" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_eede6b99-9015-4007-8b97-2dda6f956a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d7d9b590-6a9f-494b-8042-78f0f7a8b969" xlink:to="loc_us-gaap_SubsequentEventMember_eede6b99-9015-4007-8b97-2dda6f956a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_0710f651-e15c-4ba8-912c-5893615aad38" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_2d753b99-16f3-4743-be40-0e0768a556b0" xlink:href="ensg-20231231.xsd#ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities_2d753b99-16f3-4743-be40-0e0768a556b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MasterLeaseAgreements_276ba9e7-0f0e-44d4-ae3c-3d07e08298d6" xlink:href="ensg-20231231.xsd#ensg_MasterLeaseAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_MasterLeaseAgreements_276ba9e7-0f0e-44d4-ae3c-3d07e08298d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f9ec644-e4d6-4d57-ac6d-834425f3ec6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_3f9ec644-e4d6-4d57-ac6d-834425f3ec6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_4b359681-53e6-4223-bdbb-62aff39b39f3" xlink:href="ensg-20231231.xsd#ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms_4b359681-53e6-4223-bdbb-62aff39b39f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8fc2572d-4a11-49c9-9b80-0456a2131ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_8fc2572d-4a11-49c9-9b80-0456a2131ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex_1e3b711f-403f-4b53-a9d0-0a6b0a02c557" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseConsumerPriceIndex"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeOperatingLeaseConsumerPriceIndex_1e3b711f-403f-4b53-a9d0-0a6b0a02c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDiscountRate_88dba568-bedf-4c10-b092-165468448dab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseDiscountRate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LesseeOperatingLeaseDiscountRate_88dba568-bedf-4c10-b092-165468448dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LesseeOperatingLeaseNumberOfLeases_06640d4d-8fbc-4588-b498-b141a8e832fd" xlink:href="ensg-20231231.xsd#ensg_LesseeOperatingLeaseNumberOfLeases"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LesseeOperatingLeaseNumberOfLeases_06640d4d-8fbc-4588-b498-b141a8e832fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0296939c-d285-4a4b-a33d-d5ff71d95536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseExpense_0296939c-d285-4a4b-a33d-d5ff71d95536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_FacilitiesUnderMasterLeaseArrangement_6a08c598-c878-485d-9856-07d753789a2d" xlink:href="ensg-20231231.xsd#ensg_FacilitiesUnderMasterLeaseArrangement"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_FacilitiesUnderMasterLeaseArrangement_6a08c598-c878-485d-9856-07d753789a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_AmendedSeparateMasterLeases_30ffa0c7-81e6-4040-9690-a975da7c6776" xlink:href="ensg-20231231.xsd#ensg_AmendedSeparateMasterLeases"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_AmendedSeparateMasterLeases_30ffa0c7-81e6-4040-9690-a975da7c6776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfBusinessesAcquired_497b096b-34c8-48c1-a7c8-047435b75cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfBusinessesAcquired"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_NumberOfBusinessesAcquired_497b096b-34c8-48c1-a7c8-047435b75cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_c7eabb42-56a0-4a4e-9076-7b41ebc7ac66" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_c7eabb42-56a0-4a4e-9076-7b41ebc7ac66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0611fe0-aea7-410f-ba1a-ac334214db43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f0611fe0-aea7-410f-ba1a-ac334214db43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_f941914a-1227-4692-b465-ede8a8d9ab1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_f941914a-1227-4692-b465-ede8a8d9ab1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ccab150-e343-47ac-b443-1ca0677af7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1ccab150-e343-47ac-b443-1ca0677af7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dafeccf5-8815-4888-be60-210e44ab48c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_dafeccf5-8815-4888-be60-210e44ab48c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_OperationalSkilledNursingBeds_456457e5-2c4a-4780-b94d-ccd9609065ca" xlink:href="ensg-20231231.xsd#ensg_OperationalSkilledNursingBeds"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6c4635b8-d7cb-4662-b675-55ca08299b6d" xlink:to="loc_ensg_OperationalSkilledNursingBeds_456457e5-2c4a-4780-b94d-ccd9609065ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_35ca09fe-d536-40c6-b705-af308af549d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_35ca09fe-d536-40c6-b705-af308af549d3" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_db3c8a0e-6c94-4d33-854f-b89a99a1f97b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_d99d1468-1db2-40fb-b0f8-414723650e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_us-gaap_CostOfSalesMember_d99d1468-1db2-40fb-b0f8-414723650e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7aba8e9-2402-4e43-8aa6-5762737fc87c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_d7aba8e9-2402-4e43-8aa6-5762737fc87c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DepreciationAndAmortizationMember_41fc26a1-696f-4abf-a303-4dcc098c3b03" xlink:href="ensg-20231231.xsd#ensg_DepreciationAndAmortizationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1cbb984-ed97-43af-a838-1cb40dc3dcab" xlink:to="loc_ensg_DepreciationAndAmortizationMember_41fc26a1-696f-4abf-a303-4dcc098c3b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_de1c69d0-7938-48c4-abbe-5bc4b027110a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e4e80e8a-1329-4ad0-b747-bcf0f0950d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_OperatingLeaseCost_e4e80e8a-1329-4ad0-b747-bcf0f0950d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_ab97c4ad-de0a-4a06-908d-7d5c0e3b6728" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_VariableLeaseCost_ab97c4ad-de0a-4a06-908d-7d5c0e3b6728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_8f98ec70-2cff-4058-b6bb-5740f0ed7546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_LeaseCost_8f98ec70-2cff-4058-b6bb-5740f0ed7546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_DeferredRentAdjustment_37415f40-7d90-4fb3-be69-0c4c54a552a8" xlink:href="ensg-20231231.xsd#ensg_DeferredRentAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_ensg_DeferredRentAdjustment_37415f40-7d90-4fb3-be69-0c4c54a552a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_edf58804-040f-422e-b7bb-68ce2071b02a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_52649653-b47b-4af7-967e-74bfe0a956d5" xlink:to="loc_us-gaap_ShortTermLeaseCost_edf58804-040f-422e-b7bb-68ce2071b02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c33f215d-0bbd-497a-b66f-120f2330c042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c33f215d-0bbd-497a-b66f-120f2330c042" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_51ca571e-3f7d-4108-a4a7-546abff7c16a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_51ca571e-3f7d-4108-a4a7-546abff7c16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7e6e23ba-f129-4516-b6a1-014a142fefd9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7e6e23ba-f129-4516-b6a1-014a142fefd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_15de00a5-8968-403b-93de-b51ff59d1cef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_15de00a5-8968-403b-93de-b51ff59d1cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ae72d40f-841b-4afe-89a6-8bdcd7d7618c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ae72d40f-841b-4afe-89a6-8bdcd7d7618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b4906d40-459c-4138-81e7-24668b52f706" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_b4906d40-459c-4138-81e7-24668b52f706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_35f23dc9-a946-4448-833a-541f80e55ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_35f23dc9-a946-4448-833a-541f80e55ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1d357003-6c68-4097-9ef4-ac3db15de1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1d357003-6c68-4097-9ef4-ac3db15de1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7da24c85-b2a6-41ca-b0fd-9225808a4b36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_7da24c85-b2a6-41ca-b0fd-9225808a4b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bba5379f-d67e-4089-ac76-08f7e08033d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_OperatingLeaseLiability_bba5379f-d67e-4089-ac76-08f7e08033d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_05744af7-eabe-4fac-97ba-d792df01a24a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_05744af7-eabe-4fac-97ba-d792df01a24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_294d5210-55ec-4629-a1f7-73abc0fb6f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_84ec3c64-ea34-4bc9-ba09-9a2f4d66ae58" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_294d5210-55ec-4629-a1f7-73abc0fb6f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLesseeFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_16474a46-f162-43ca-b211-7720ee37c6f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_16474a46-f162-43ca-b211-7720ee37c6f2" xlink:to="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementAxis_ee79166a-ddb1-47c4-9560-43b03f7bbfa2" xlink:to="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_e4eb5b79-66b3-4c94-a91b-db14f5f60310" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_e4eb5b79-66b3-4c94-a91b-db14f5f60310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_c06597e9-64fe-4c67-97aa-bb27f6199260" xlink:href="ensg-20231231.xsd#ensg_SubleaseOfStandAlongSkilledNursingOperationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_SubleaseOfStandAlongSkilledNursingOperationsMember_c06597e9-64fe-4c67-97aa-bb27f6199260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseOfCampusOperationMember_6b156783-dfe9-4674-a3f8-14689022e02d" xlink:href="ensg-20231231.xsd#ensg_LeaseOfCampusOperationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_a13d00e4-8132-43f9-9624-8aa6c0fdf244" xlink:to="loc_ensg_LeaseOfCampusOperationMember_6b156783-dfe9-4674-a3f8-14689022e02d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_15bd537d-c902-4861-8573-f55302e27be2" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_cadd1322-be14-414f-9831-496c14d72424" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5dea7e7f-fee6-4f19-a1fd-ed18fe9f4d23" xlink:to="loc_ensg_ThePennantGroupInc.Member_cadd1322-be14-414f-9831-496c14d72424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8e4253d-ceb6-474a-a775-723c8018aa02" xlink:to="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6f6908c9-5ea9-43c7-9e83-922cefc85f9e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:to="loc_srt_MinimumMember_6f6908c9-5ea9-43c7-9e83-922cefc85f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_24a19986-f382-49c2-85ef-389dc30b6ff5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ba9d3e6-a3a6-45a7-9aec-c4fdc40cac90" xlink:to="loc_srt_MaximumMember_24a19986-f382-49c2-85ef-389dc30b6ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_9c2bbc24-7655-44e3-9a51-8536dc7f8ec2" xlink:to="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_961aca56-6e71-4c0a-b5e4-0534fb5f318e" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_961aca56-6e71-4c0a-b5e4-0534fb5f318e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeaseTermOfContract_2fbe64cf-a2d6-41d3-bd14-5f47e00ae1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_4a47ba6c-568f-474f-804d-0278a49c37f9" xlink:to="loc_us-gaap_LessorOperatingLeaseTermOfContract_2fbe64cf-a2d6-41d3-bd14-5f47e00ae1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorRentalIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c9411639-8478-4ff4-bf25-9c93a640563c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c9411639-8478-4ff4-bf25-9c93a640563c" xlink:to="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_b76715dc-e9ef-4ec6-8666-2497a35bb687" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThePennantGroupInc.Member_92e7a2c1-531b-43a5-bc27-972ac51d83a3" xlink:href="ensg-20231231.xsd#ensg_ThePennantGroupInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:to="loc_ensg_ThePennantGroupInc.Member_92e7a2c1-531b-43a5-bc27-972ac51d83a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ThirdPartyTenantsMember_05af5b97-add5-47a8-ac59-52d902d9f9d7" xlink:href="ensg-20231231.xsd#ensg_ThirdPartyTenantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_738aa7a8-d299-429f-b1fa-ff679843b82e" xlink:to="loc_ensg_ThirdPartyTenantsMember_05af5b97-add5-47a8-ac59-52d902d9f9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:href="ensg-20231231.xsd#ensg_LeaseArrangementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementAxis_371f183f-1e6a-4036-856d-d28be895e6ae" xlink:to="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LeasesToThirdPartyOperatorsMember_71b229df-b3cd-4472-a019-122d89bcf6a6" xlink:href="ensg-20231231.xsd#ensg_LeasesToThirdPartyOperatorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ensg_LeaseArrangementDomain_1d0cc63e-dfb0-4b86-acbc-9467e71300cf" xlink:to="loc_ensg_LeasesToThirdPartyOperatorsMember_71b229df-b3cd-4472-a019-122d89bcf6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_15a0447b-0115-4d83-ba44-ae4bbc3223df" xlink:to="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_69d75013-58a8-4309-a006-22e661c81c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_2429561d-a107-4d84-9646-5e36f7db4cf6" xlink:to="loc_us-gaap_OperatingSegmentsMember_69d75013-58a8-4309-a006-22e661c81c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a8bb03da-6c54-4a7c-909d-c1d95221db54" xlink:to="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_RentalMember_0298d384-072a-4366-9ab7-da1e8b561998" xlink:href="ensg-20231231.xsd#ensg_RentalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_082e593f-395a-4c5c-8ecd-66299435a791" xlink:to="loc_ensg_RentalMember_0298d384-072a-4366-9ab7-da1e8b561998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a42e8867-c686-4751-afaa-4ce458321bbf" xlink:to="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllOtherSegmentsMember_15013c0a-3234-4353-912e-001df23727e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllOtherSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_4bcae113-3bdc-4364-994d-3be5f772bd9a" xlink:to="loc_us-gaap_AllOtherSegmentsMember_15013c0a-3234-4353-912e-001df23727e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorLeaseDescriptionLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionTable_2d6bf356-4726-4eaf-82eb-e87efaade2bc" xlink:to="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncome_0a951838-fbcc-439b-852b-4f546ac87ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLeaseIncome"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncome_0a951838-fbcc-439b-852b-4f546ac87ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_fe0f07d0-dbad-4a67-b16a-b6f023bf97eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList_fe0f07d0-dbad-4a67-b16a-b6f023bf97eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseVariableLeaseIncome_a8cdea7b-dea8-401d-9ec7-f6fe4b6eb19a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseVariableLeaseIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_OperatingLeaseVariableLeaseIncome_a8cdea7b-dea8-401d-9ec7-f6fe4b6eb19a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_LessorOperatingLeaseNumberOfLeases_e56d33a3-d18f-4621-bcda-b0f520da1693" xlink:href="ensg-20231231.xsd#ensg_LessorOperatingLeaseNumberOfLeases"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_ensg_LessorOperatingLeaseNumberOfLeases_e56d33a3-d18f-4621-bcda-b0f520da1693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_dfd91932-c298-48bb-a94f-b1e5115ba3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LessorLeaseDescriptionLineItems_e8b9f64f-890d-4cec-af6c-3353ef6fd1a2" xlink:to="loc_us-gaap_SubleaseIncome_dfd91932-c298-48bb-a94f-b1e5115ba3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_f84241fb-b293-45d6-9c72-edf7f1d2ff68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths_f84241fb-b293-45d6-9c72-edf7f1d2ff68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_93a36b1a-de14-435b-aca0-91c2f049c085" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears_93a36b1a-de14-435b-aca0-91c2f049c085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_dcb5c0b7-a1ad-4221-80cf-c0c6c37e811b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears_dcb5c0b7-a1ad-4221-80cf-c0c6c37e811b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_9fe164ee-12fc-493b-bfd4-d9dab7c0de8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears_9fe164ee-12fc-493b-bfd4-d9dab7c0de8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_9f6fb5d3-c6e6-4605-8ee1-7c4415bc3742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears_9f6fb5d3-c6e6-4605-8ee1-7c4415bc3742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_1f5d56d1-ece3-46b8-b249-2af0909dece3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter_1f5d56d1-ece3-46b8-b249-2af0909dece3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_22cbcd50-dfcf-46d8-ab39-7c780d68447c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_baf47274-8b8f-4521-b69c-8cb451203ad2" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_22cbcd50-dfcf-46d8-ab39-7c780d68447c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#DEFINEDCONTRIBUTIONPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eb13c695-2413-4152-9bf0-69f9ecdcde84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_eb13c695-2413-4152-9bf0-69f9ecdcde84" xlink:to="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTaxStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_492cf4c6-5580-4284-bd25-9802de02a07b" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_QualifiedPlanMember_3c5864fb-84e6-4eea-9859-44f1a0732694" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_QualifiedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:to="loc_us-gaap_QualifiedPlanMember_3c5864fb-84e6-4eea-9859-44f1a0732694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonqualifiedPlanMember_3f6e50c4-8703-4ad0-aec0-813a9a913c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonqualifiedPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_38007d82-b41a-4e0a-880d-ca5cb41eddae" xlink:to="loc_us-gaap_NonqualifiedPlanMember_3f6e50c4-8703-4ad0-aec0-813a9a913c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_7ab9b85a-d602-47ee-baaf-58de02489383" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1078b39e-837f-418b-b8df-2d3c3186735a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1078b39e-837f-418b-b8df-2d3c3186735a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_25e9eb3f-263e-4ff6-a1a0-6ee8c21184c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_25e9eb3f-263e-4ff6-a1a0-6ee8c21184c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b605ff61-bb68-4573-8b23-0e9d6e6a9fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent_b605ff61-bb68-4573-8b23-0e9d6e6a9fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_6074ade3-9121-448e-ad99-420f403e43a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_us-gaap_GainLossOnInvestments_6074ade3-9121-448e-ad99-420f403e43a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_InvestmentExpenseIncome_9efc50c1-d2da-4354-856c-541b11ea8b58" xlink:href="ensg-20231231.xsd#ensg_InvestmentExpenseIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_7e6ac642-45b0-4a13-b800-99aeaf632f83" xlink:to="loc_ensg_InvestmentExpenseIncome_9efc50c1-d2da-4354-856c-541b11ea8b58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#SELFINSURANCELIABILITIESDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_004fa052-1a2d-45f3-a7ca-50d60e45815b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_004fa052-1a2d-45f3-a7ca-50d60e45815b" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:to="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeAndTierIdentifierDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis_f55bdfc1-54fe-4e60-870e-ccab1fcedc6f" xlink:to="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfessionalMalpracticeLiabilityMember_d8f6ecc2-d7fe-4183-b439-90bae330d1db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfessionalMalpracticeLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeAndTierIdentifierDomain_3ef1cac8-8995-4cb6-8842-64ceead108f7" xlink:to="loc_us-gaap_ProfessionalMalpracticeLiabilityMember_d8f6ecc2-d7fe-4183-b439-90bae330d1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable_d4b47b39-1ac0-4a9e-b20d-7eb13b6b5c01" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems_bdeb6bd1-9056-4498-92b8-a123c79ff2e3" xlink:to="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_13de6c9b-1176-4d3b-910a-3d576484be07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_13de6c9b-1176-4d3b-910a-3d576484be07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_4a6227e8-08ec-4d2f-81c8-5f78bcff3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease_4a6227e8-08ec-4d2f-81c8-5f78bcff3b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_2f579816-2569-4192-a1db-6600854b22d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits_2f579816-2569-4192-a1db-6600854b22d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_369d14e8-9114-473b-ab8f-69897a46e09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease_369d14e8-9114-473b-ab8f-69897a46e09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForFuturePolicyBenefits_3019542e-afe1-4ba6-9f3a-0291a3ce040c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilityForFuturePolicyBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward_5e0504a6-b0d7-42c6-95ff-a3875c0133ba" xlink:to="loc_us-gaap_LiabilityForFuturePolicyBenefits_3019542e-afe1-4ba6-9f3a-0291a3ce040c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac974b8e-4337-47c0-8052-487687dd8f54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac974b8e-4337-47c0-8052-487687dd8f54" xlink:to="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_d361e0a5-a911-4aae-ad8b-46d6e2854737" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_dd9f2611-ce50-4a5a-9707-ae5b92f9ce28" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_c443e306-0515-4c17-87ca-fd18238182d9" xlink:to="loc_us-gaap_SubsequentEventMember_dd9f2611-ce50-4a5a-9707-ae5b92f9ce28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_194967a6-f698-45d1-9b9b-fb39cd19a55f" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_bf09ad39-42e4-4d0a-959c-61ff79f49c5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_4911f749-d00a-4488-b38c-7d9ee230c507" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_bf09ad39-42e4-4d0a-959c-61ff79f49c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_e739b6c7-84af-49fc-a623-b00d69feadbe" xlink:to="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_MedicaidAndMedicareMember_6e0f7d87-4742-46b1-a5df-288440d4b4b1" xlink:href="ensg-20231231.xsd#ensg_MedicaidAndMedicareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d557d14c-f217-4537-9d74-23264543c3d9" xlink:to="loc_ensg_MedicaidAndMedicareMember_6e0f7d87-4742-46b1-a5df-288440d4b4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9b656108-ffa8-4085-a65f-603812af737d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_4d56ae07-7def-4099-94df-0dd54991c7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:to="loc_us-gaap_AccountsReceivableMember_4d56ae07-7def-4099-94df-0dd54991c7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_cfdba168-fb09-46ba-bd89-393bb4b7d3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_92249074-e0c0-407e-a534-ca509dd00e70" xlink:to="loc_us-gaap_SalesRevenueNetMember_cfdba168-fb09-46ba-bd89-393bb4b7d3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_2ee81575-3154-4ee3-bcab-5a9df0b584bb" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3fe1768a-e8f1-46cc-a345-c3105dac91f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_3fe1768a-e8f1-46cc-a345-c3105dac91f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_5b713d0f-6df4-4750-8d73-2ddbc6628b62" xlink:href="ensg-20231231.xsd#ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews_5b713d0f-6df4-4750-8d73-2ddbc6628b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1040343a-6b88-423a-9788-15e280d0d93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_e346352a-9dad-422b-ad80-a6fe1fe761ec" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1040343a-6b88-423a-9788-15e280d0d93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" xlink:type="simple" xlink:href="ensg-20231231.xsd#COMMONSTOCKREPURCHASEPROGRAMDetails"/>
  <link:presentationLink xlink:role="http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2700f982-0831-42d5-9934-7c25061883b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2700f982-0831-42d5-9934-7c25061883b5" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_ad5d21ba-b525-41a4-8dda-bdc2a4924bd2" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_August2023RepurchaseProgramMember_b641945c-ad6d-4546-b35f-74bcbdd850e9" xlink:href="ensg-20231231.xsd#ensg_August2023RepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:to="loc_ensg_August2023RepurchaseProgramMember_b641945c-ad6d-4546-b35f-74bcbdd850e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_July2022RepurchaseProgramMember_fb247306-790e-4019-ab80-a8fa13d64c12" xlink:href="ensg-20231231.xsd#ensg_July2022RepurchaseProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_a87e1687-cad7-4af4-ae55-72cadc1cb6da" xlink:to="loc_ensg_July2022RepurchaseProgramMember_fb247306-790e-4019-ab80-a8fa13d64c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_3adc69f5-93e3-427f-9759-39c2b077fcd3" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8d2777d0-4a4c-4432-b7ac-7c75954d4f80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8d2777d0-4a4c-4432-b7ac-7c75954d4f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_0cfd8b57-fa71-45ec-b93f-4159dc1f07ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_0cfd8b57-fa71-45ec-b93f-4159dc1f07ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_a573c4c8-3085-4a1e-a757-0e62702f977f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_a573c4c8-3085-4a1e-a757-0e62702f977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b9e24a92-b994-49c6-a79d-059db9313445" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_fb917ea6-5cb0-4930-b72a-7ff0072808a4" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_b9e24a92-b994-49c6-a79d-059db9313445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_StockAwardsMember" xlink:href="ensg-20231231.xsd#ensg_StockAwardsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_ensg_StockAwardsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_ChristopherRChristensenMember" xlink:href="ensg-20231231.xsd#ensg_ChristopherRChristensenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ensg_ChristopherRChristensenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ensg_BeverlyBWittekindMember" xlink:href="ensg-20231231.xsd#ensg_BeverlyBWittekindMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ensg_BeverlyBWittekindMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>ensg-20231231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ensg-20231231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#Z17AI9@  34T *@    @ ! $[  (
M   0   (2H=I  0    !   (6IR=  $    @   0TNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 %)I='1M86XL
M($QA=7)E;@  !9 #  (    4   0J) $  (    4   0O)*1  (    #-S(
M )*2  (    #-S(  .H<  <   @,   (G      <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BK_P  1" "T 2 # 2(  A$! Q$!_\0
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MEBJTMY,TK[Q#J^ID_;]1N)\G)WN:SF9F^\2?J:2BLFV]S!MO<****1(4444
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MQS7G5,!%ZP=CRZV6PEK3=CXXHKZ/U7X'>&;W<UDUQ9N>@1P5'X$9_6N.U'X
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M0W$UM()+>62)QT:-BI_,5'10,[KPY\6_$F@%8Y;C[?;C_EG<<G_OKK^M>O\
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MX8N6CU*RD\L'Y9HQN1AZY'3\:Y^O(E%Q=FCPY1E%VDK!1112)"BBB@ HHHH
M**** "BBB@ HI0"QP!D^@K3L?#6M:DP6RTRZEST(B('YGBFDWL4HMZ(RZ*]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/"BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>ensg-20231231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ensg-20231231_g2.jpg
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M^(%Q\)OB3XFUK5_%%BL;:EH?AC2/M$ED)$61!*\CQQ!BC*VT.6 (R!D9[O\
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M17PWX-_X.&?^"<OB[QU#X+N?$7BO1H)YQ%'K^L^'1'8Y)P&9HY'D1>GS-&
M<G !Q]6_'7]H[X+?LV?"2\^./QD\>6>D>&;.-&_M DR_:&?_ %:0K&"TSO\
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M4 %%%% !1110 4444 %?/O\ P5:_Y1R?&+_L2+K^E?05?/\ _P %4[>XNO\
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MX>TOX^?%?3[%=<-\Z2Z?X>N)3% Y4;WC.ZY=PK,TD:)"Y._Y37S%_P $SO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !169XR\:^#OAUX:N_&?C_Q7INAZ181>9>ZIJ]['
M;V]NG]YY)"%4?4U^=7[8_P#P<>_ #X5O<^#_ -DWPC)\0=9C)0Z]J'F6FD0M
MZKD":YP1R (U(P5D->=F&;9=E5/GQ511[+J_1+5G)B\=A,%#FK32_-^BW/TG
M=TC0R2.%51EF8X 'K7S)^TK_ ,%@OV ?V76GTSQ?\<;/7M9@)#:!X,4:G<AA
MU1FC/DQ,/[LLB&OPR_:K_P""FO[:7[8\T]G\8OC-?KHDS';X6T,_8=,5>RM#
M&1YV.S3&1AZUX)7Y]F/B')MQP-+_ +>E_P#(K_/Y'RN+XL>V&A\Y?Y+_ #/U
M<^/W_!SYXTOS-IG[,7[.5AIT>2(M8\;7S7,C#U^RVQ148>\SC/;U^._C/_P6
M%_X*-_'$RV_B/]IW7-(LY<@6'A+9I**I_AWVJI(P_P!]VKYGHKXS&<1YWCK^
MUKRMV3Y5]RM^)\]B,WS+$_'4=NRT7X%_Q'XJ\3^,=3?6_%WB._U6]D_UEWJ5
MX\\K?5W))_.J%%%>*VY.[/.;;=V%%%%(04444 %%%% '2?#OXQ_%WX0ZB-8^
M$_Q2\1>&+L-N%SX?UN>S?/KNA=37U%\%_P#@O!_P4C^#\L,-_P#%^T\8V,)'
M_$O\9:/%<[Q_M3Q>7<'\9:^.:*[<+F./P3OAZLH^C:7W;'11Q>*PS_=3<?1L
M_93X _\ !SO\,=:DM])_:7_9YU30G8A9=9\)7RWT&3_&;>;RWC4>BO(?0'I7
MWI^SC^WC^R'^UI%&GP#^/.@ZY>R1ESHIN#;Z@B@98FTG"38&#EMNWCK7\N]?
MJE_P;*?LP_V]\0_&O[7&OZ=NMM!M!X>\.RNN0;N<++=.I[,D(B3Z735]]PSQ
M7G>.S&GA*MIJ6[:LTEJWI9?>M7U/J<FSS,L3BXT)VDGUM9I?+3\#]DJ**"0!
MDG '4U^JGVX45\K:A^W!XVT;XBZI+8V5GJ>@&^9;*UE3RW6%3M#+(O(+8W?,
M&^]7KGPS_:Q^$_Q%,=A/J9T;4'P/LFJ,$5SZ))]UO8'!/I7Q.5>(?"F;XJ6&
MIUU&:;24_=YK.UXOX7?HKW\CSZ.:8*O-P4K/STOZ'IM% ((R#D'H:*^V/0"O
MQI_:-_;;_:?_ ."B/_!2WXP_LJ?#7_@I5I7[*7P*_9]GMM'\3>,X[FSMM2\0
MZ[*94,*W%S+%Y8$EO>( D@ 6VW,CM(/+_9:OYQ?A=\)?^"4'P5_X+2_MM^#O
M^"V7A'1[==7\77OB?X:WWBV34([9[&^O;R]F\@6S 232075F8S@N##(L9#;@
M0#]S_P#@GU\,?B7\)?V8M(\*?$_]L^;X_7+75S<Z;\2[BR@A>_L9)"T,9:"6
M5)O+&5\W>2WMC ^5O^"]O_!1+]H[]F6\^#'[%G[%_C'1_"WQ/^/WBN738/'.
MN1Q26_A;2H&@2XO664,BG-PI\QE8)'#.0N_8R_)G_!O+^UWX9_X)H?\ !&/X
MI?M@?M.Q>+K7X,I\99C\-;-=/:ZO9[2?[-;;K>-F53&T^03N5/,BG/4G.-_P
M<6WO[.7Q]^/G[!O[?_QH\.7^M?LU>,C"GBR^N+>Z@6#3+Y[*]C^T" B6(O;2
M2R;$.\BUE R1R ?9_P"P5\*OCO\ L\P?$;X]Z7_P6NN?VM]-T3X<:C]H\!N+
M*[BM]=CV3P7"36MY.\ (@G@^SX&[S\[LH!7QI_P3L_X*1_M8Q_'+]COXU?$7
M_@H7JWQ%M_VD;7QW<_'#P#K=SIW]E>#[;2O->WN;:*&)'TR.-$9W+MAEMY#]
MTD"C_P $_O"G[(6I?\'.6A:U_P $9K2W7X+:'\'[K_A;EUX4DN6T9[F2WNT1
M%>4D%6G.DD*#M,L,K 95R/;?VM/V5/V8_P!M3_@H'JG_  3+_P""??[/7@KP
M'ID"1:I^V)\8/ WABULKV+3)9!*GA>"ZBC!6XO74-.JD?*OS!_+GCH ]Y_X)
MY_&7]HW_ (*@?MB:]_P4.M?B%XI\*_LU>$!>>&O@EX+M+R:S@\>3JSPWGB+4
M(01Y\ ;>EO'("%90V$>)S)^@E?SG^"_VM?CW\,_%.G^-/A;^V1XTT'XI^%_V
MZK?X3^&_V6]*\6&/0;3P) H@BLU\/C@QC;Y/VTKG*\MYOSU_1A0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWX__ .%>_!W5-0MY]EW?)]ALB#@^9*""1[J@=A[K7?U\I?MV>/\ ^V/'%CX
MLYLPZ/;^==*#UGE (!^B!2/]\U[7B!GG]@\*UZ\7:<UR0_Q2TNO-*\OD?29G
MB/JV"E);O1?/^KGA%%%%?QF?!'H'PI_:4^)OPH:.ST_5/M^F*0#I=^Q>-1_L
M'[T?X<>H-?4'P@_:8^'7Q<6/3[>[_LW5F'S:7>N SG_IFW20>PPW^R*^'Z5'
M>-Q)&Y5E.593@@^M??\ "_B/Q!PTXTN;VM%?8D]E_=EO'TUCY'IX/-<5A-+\
MT>S_ $['Z1UP'QC_ &4?V6_VB=0L-7_:!_9K\ >.KO2UQIEUXQ\'6.IR6@SG
M$37,3F/GGY<<UX=\$/VS/$/A(Q>'/B<9M5TT86/4 =US;C_:S_K5^OS>YX%?
M47AOQ-H'C#1H?$/AG58;VSN%S%/ V0?4'N".X/(/6OZ7X8XQR7BO#\^$G::7
MO0>DH_+JO-77>ST/K<'C\/C8W@]>JZF5XK^#_P )/'?P[;X0^./A;X<UGPF]
MO% _A?5=$M[C3FBC*F.,VTB&(JI52J[< J,8P*7Q3\'_ (2^./AV?A#XU^%W
MAW6/"9M(K4^%]4T2"XT[R(P!'%]FD0Q;%"J%7;@;1@#%=%17U1V'(_!WX ?
M?]G?P[)X0_9_^"?A'P+I,TOFRZ7X.\-VNF6[OC&XQVT:*3CC.,U+\-/@?\&/
M@O-KMQ\(/A/X;\+2>)];FUCQ))X?T2"S;5=1E.9;NX,2J9IG/61\L?6NIHH
MXM?V</V>$^+1^/J? ;P6/'9C\L^-1X6M/[7*;-FW[9Y?G8V_+C=TXZ5VE%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBO,OVO?VK/AC^QA\!=:^/?Q5O<66F1;+'3XY )M3O&
M!\FUA!ZNY'7HJAG/RJ2,ZU6E0I2J5':,5=M]$B*E2%*#G-V2W/-?^"G/_!1_
MX?\ _!/'X+_\)%<Q6^K>-=<22'P=X:>7'GR@?-<S8.5MXR06(P6)5%(+%E_G
M8^,?QB^)'Q^^)FK_ !?^+GBJYUGQ#KEV;C4;^Y;EFZ!5 X1%4!510%55"@
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MX^_MG:/X]N/!7B70=$U/X?:]:Z5K.E:_,\9$DDKI,YD5655A6.1VZDA"%!.
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MG[+]K%X*N?'/C'2+>Y\'Z#X_BWZ7X@DBBN$:SF3<IE0,Z90'<5E9@"$:H_\
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M%%>N?0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&K3=XR2:?DPHHHK0U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR.#CSSUF_P /+_,*\:_:[_:W\._LX>&?[.TPPWWBG4(2=,TYFRL*\CSYL<A
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MF[JT)Y?4>L?>CZ/=?)Z_-]CT&BBBOMC]*"BBB@ HHHH **** "BBB@ HHHH
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M8^%-4+K9ZQH\Y9-Z'#QNK /%(IX:-U5USR!7<T %%%% !1110 4444 %%%%
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MB9XQ^+OC*[\=^.M6:[O[Q\D]$B0?=C1?X44< ?CR237V/$&?PRZ#HT7>J_\
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MSH3-;_-<VD4D@@5S@MY$/"-L5?=?&W_!)_\ X**_"O\ ;9_:$^,_BG_@G-\
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MOBRK*UAE[6JO??X?\$*\\_:0_:.\%_LX^"&\1^(7%SJ%R&31](CD DNY0/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'Y^?\
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M &8_CK\'S)-XY^'-_!:QYSJ-L@GML>IECW*OT8@^U?JQ00",$9!ZBO S#A?
MXZI*K&3C-[O=?<_T:/CLVX(RS,ZLJT92A4EJW?F3?FG^C1^-=%?J)\4/V-OV
M=_BSYEQK_P /;:SO9,DZCHW^BS;C_$=GRN?]]6KYS^*'_!*OQ1I_F7_PA^(%
MOJ,8R4T_6H_)F ]!*@*.?JJ"ODL9PIFF&NZ:4UY;_<_TN? YAP+G>#O*DE5C
M_=W^Y_I<^1Z*Z[XD_ 7XQ?"&9H_B)\/=2TV-6VB[>'?;L?03)F,_@U<C7SE2
ME4HSY*D6GV:LSY&M1K8>HX58N,ET:L_N84445!D%%%% !1110 4444 %%%%
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MW-I<)+&XRDD;AE8>H(ZT^MJ^%PV+ARUH*2\U<ZL5@L'CZ?)B*:FO-)_=_P
M^$OBA_P2S^)6A>9??"OQA8Z] ,E;*^'V2Y]E!),;?4LGTKYZ\?\ PD^)OPLO
M?L'Q#\#:EI#EMJ/>6K+'(?\ 8D^X_P!5)K]<JAU'3=.UBRDTW5K""ZMIEVRV
M]S$'1QZ%6!!'UKYG&<'X"M=T).#^]?CK^)\7F'A]E>(O+"R=-]OBC]SU_'Y'
MXXT5^D?Q0_X)[_LX_$7S+O3?#DOAN]?)%QH,@CCSVS"P,8'LH4^]?.?Q0_X)
M@_&?PKYE]\.M;L/$ULN2L&X6EUC_ '')0_@^3Z5\MC.&,UPFL8\Z[QU_#?\
M!GPV8<%9[@;N,/:1[PU?W:/[DSYHHK8\9?#_ ,<_#S4SH_CKPCJ.D7/.V+4+
M1XBP]5W###W&16/7@2C*$G&2LSY2<)TYN,U9KH]&%%%%22%%%% !1110 444
M4 /MX);J=+:!"SR.%11W). *_8G1].CTC2;728?N6MLD*?15"C^5?E#\ _#K
M>+?C?X1\.>7N6[\1V:2C'_+/SE+G\%!-?K-7W_!5-JG6J=W%?=?_ #/U;PVH
MM4L35[N*^Z[?YH****^Y/TX**** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ$\;>#'!\-^)+FV0'/D!]T1^J-E?TKUJ.=R6E6/S7^1[V&XEFM*\+^:_R?\
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M?4!@<'W'-?,8S@["5+O#3<7V>J_S_,^)S#P[P-6\L'4<'V?O+]&OQ/Q_HK]
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M+!57%]I:K[UJON9RG[%OPY;X9?LV^&M'NK?R[N^M3J-Z",'S)SY@!]U0HO\
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M^BNVCF.+H:*5UV>IZ6&S?'X72,[KL]?^#]Q]C^'_ !;X9\5V_P!J\.:[:WB
M9;R)067_ 'EZK^(K1KXKM+R[L+A;NQNI(94.4EB<JRGV(Y%?3/[/%]XNU;X?
M)K/BW6)[MKFX?[&;C!98E^7EL9.6#=2>,5[V!S)XN?(XV?X'U.5YR\?5]E*%
MG:]UM_P/Q.[HHHKU3W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOI'B3P]K%L+G2==T'48KNSO83TDBFB9DD4X/*DCBMB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M@?\ X+0?\$L1^UEX1D_:)^!>AI_PL?0++%]I]N@!\162#B+CK<Q@?NSU=?W9
MS^[V_?%%<&9Y;A<VP4L-B%>+^]/HUYK_ (&QE6I0KTW"6Q_*%<6]Q:7#VEW
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M'OQ N_%$GV%-2ATR::?3()4M4,D;C$'G@JP>7.T;1N\-_8F_X+'? '_@FO\
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M:+Q5\;/'?QL_9B_:G_9(O/A1\</@=X2E\2ZWX%/BJ'4[35M-6!)5GMKV*,*
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MNK>./'_BW3Y=9\2QZ)<1);^#=#C(!U'4)'/R!V.V.(?,[;1QYD>\ ^B:***
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MIVFVB000(.BI&@"J/8 "KU%%?6)**LCNV"BBBF 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>ensg-20231231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ensg-20231231_g3.jpg
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M^(%Q\)OB3XFUK5_%%BL;:EH?AC2/M$ED)$61!*\CQQ!BC*VT.6 (R!D9[O\
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M17PWX-_X.&?^"<OB[QU#X+N?$7BO1H)YQ%'K^L^'1'8Y)P&9HY'D1>GS-&
M<G !Q]6_'7]H[X+?LV?"2\^./QD\>6>D>&;.-&_M DR_:&?_ %:0K&"TSO\
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M2PE'*N6C44WS-R<=N9V;2\DK'JY'"A3P-J<U+5MM;7?1>F@4445]*>P%%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%&BW>FZGIOP,\)6NHZ=?VS0SVL\>C6B2121N R.K JRL 0001D5[G0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 444V::&WA>XN)5CCC4L[NV H')))Z
M"@!U,N+BWL[>2[NYTBBB0O++(P544#)))X  [U\&?MO?\%_OV5OV:I;WP/\
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M1\ :QK&B_"...S\8?$U)8AHZZZS#=H\'.^>>-=YE91MC:,JW+(6 /H>BBB@
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MV0C^V7^VUX7\ :SIGVCPUHDG]N^+@R91K&V93Y+>TTK10D=<2L1TK^DX  8
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5YQR!1110 4444 ?0J_\$M/VVY?V81^V!;?"6.?P,=".LF_@UJT:=; 9)N#
M)/,VA07/RY"@DC ./+_V>_V>OBY^U+\5]-^"GP/\*-K/B+51(UK:?:(X4"1H
MTDCO)(RHBJJDY8CL!DD _M/^S=\<=&^&_P "?V,?@_XY$<WA;XL_#[5?"NLV
M=P?W4LDMI:-;AAW+2+Y ]KEJ^8OV<_V?=9_X)5?!_P#:L_:>\7B2#7O#EW<?
M#OX97DR[99Y;AT87L8/7*2V4P(Q\L4H]17VM?AO!QG1G3E+V=KU7I>-H*H[:
M=4[*]]4?1U<HPZE3E%ODM>?E[JEIIU3LO,^#/VJOV1/CQ^Q;\1K;X5?M"^$X
M=(UF\TB/4[6"WU&&Z22UDDEB5P\+,OWX9%P2#\O3!!/F=?LA_P %%OV3/#O[
M:W_!:CX._ WQO?7$&@3_  ;MK_7VM)-DLEK;WFJRF)&_A,C!(RPY4.2.0*V-
M8_X)E?#WXVZ1\4_A5X[_ ."9^D?!O0?#^AWMQ\+_ (G:7XMBN+NXEMV*PF[1
M)W9Q(N)2) 0J!U+;]KUG7X2Q%3%5HX9^Y&3C&Z;;:2;NXQLM[7=DWH14R*K.
MO45%^ZFTKW=[*^K2LO5V5S\5Z^D?'W_!,SXM^!_#7P"\0?\ ">>&[I_VA#"G
MAF!II85TUY3:!!=.R8 _TR/)3=C:V >,_1GPC^%?[%7[#?\ P3!\%?MA_M$?
MLN6GQ;\7?%77Y;6STO5=5>VAT^S5K@#RW"N$(C@WE@A<O.!N"K7K?_!0_P /
M_ _XLZ-_P3Z\*^#?!EU%\._$VNVEI9>'M6N&>5-*N)=%3[+*X8LQ$3E"P8D]
M=V>:QPV04H8*=2M).?+3DHIM-*<XI7=K:Q?2]K[&=+*X1P\IU))RM!I:W7-)
M+72VJ?G8_,W]K#]F+Q[^QU\>=;_9X^)NL:+?ZUH(MS>77A^\>>U?SH(YUVM)
M'&^0LB@AD4@@\8P3YS7ZKZ9_P37_ &3/$G_!6OX[:)XL\ _8OA-\'/"6G:_+
MX0TFXE1+F672K2<Q%MX?RRQN92H<98*N0I(KY6^,G[2O["_[2?B3P/8?#S_@
MG=/X,U&S\>VBZMI7@KQ!).WB+1&;#V2H$0K=N=BHZJ223\PR!7)CLD^K2G*4
MXP7/.,8MR;?++E>JCLN[LW9Z&&)R[V+DY24?>DHK5WL[/6W3SM?L?*-%?M+\
M#/V _AW^U'X;\6?#KXT?\$@;+X(>'O\ A%9[CP?XTC\5>?JD-XI58HY5+"9I
M,,9<R*4_=,KAMPKYX_8/^"_["7AC_@E1XB_;:_:H_9_/C'4/!WQ+ECMK>UNY
M(I=3S#:16]E*P;:+?SKGS&X_AY#CY&VEPOBH3C>I%1E&4KM3C90MS73BI=;K
M34TEDM:,E>:2:D[M26D;7T:3Z]M3\X:*_4C]A[]C7X*?M+?"CXM?\%!?AU^Q
M!:>,KR?Q>=,^%_P4N?$"6^G6*JMLT\LLK-$DJKY[$(V!B%@%RZE>(_X*Y_L,
M>!OA-^RC\-OVLK;]F^U^#?C/7=>ET/QI\/--UE+RT679<20W,)1W104MMQ"'
M&)T##<I+95.',93P#Q:DG%+FVEK'FY;W:Y;O?EOS6UL9SRC$1PKKIIJU]GJK
MVO>UK];7O;H?G=1117SQY1UGP)^#GB[]H3XR^&?@CX#MO,U;Q1K,&GV9*DK&
M9' :5L=$1=SL>RJ3VK^I'X*?"3PC\!?A'X;^"_@*T\G1_#&C6^G6"D#<R1(%
MWMCJ[$%F/=F)[U^2G_!M)^R#_P )%X]\3?MH>+-+W6OA]&T+PD\J<->RH&NY
MU]#' R1 ]#]I<=5K]DJ_8^ LJ^JY?+&37O5-O\*_S=WZ)'Z!PO@O8X1UY+6>
MWHO\W^@5XC^V]\2_^$9\ 0> ].N-MWKLG[_:>5MD(+?3<VU?<!J]M=TC4N[!
M549))P *^#_C]\26^*?Q1U+Q+#,6LT?[-IH["!"0I'IN.7^KFO/\5>(?[%X:
MEAZ;M4Q%X+_#]M_=[O\ V\>CG.*^KX1Q6\M/EU_R^9QE%%%?R8?%!1110 44
M44 %%%:?A'PAXC\=Z_!X9\*Z7)=WEPV$BC'0=V8]%4=R>!6E*C5Q%6-.E%RE
M)V22NVWLDNK'&,I.R5V6?AMKGC7P]XVT_4OAZ9SJPG"VL4"%C,3P8RH^\I'!
M'I7W[H%QK%WH=I=>(-.CM+Z2W1KNUBF\Q8I"/F4-WP>]<#\ ?V<_#GP8TT:A
M<^7?:]/'BZU KQ$#UCBS]U?4]6[X& /2:_K#PTX1S/A?+9RQM5\U6S]GO&'G
M_B>SMII;6R9]IE.!K8.DW4>KZ=%_P0HHHK],/7"BBB@ HHHH **** "BBB@
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MDTO-]#I/B[\7_B7\>OB+J?Q9^+_B^ZU[Q%K$B/J6JWFWS)BB+&@PH"J%1%4
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MHK $<23X[XY6/J>IP""?SR\7^,/$WCWQ'=^+O&.M3ZAJ-]*9+FZN&RS'T]
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MVW_P6A\<:?,&^*WQ@T#PM\-S>(1);>'-/U.UVJN?X65;*)L8_>6+\<U]U?\
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M-;9F;>Q+$[CNS7TE0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)%$X*1HR-$A1E^;=F?#3_@AC\+_V.OB9XR_;G^"/Q1^)?Q3^-]W\(]9T)?\
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M_2.O!:_F;.JCK9QB)]YS_P#2F?(XA\U>;\W^84445YAB%%%% !1110 4444
M:O@_QSXV^'FLIXC\ >,=5T/48O\ 5W^CZA);3)]'C8,/SKZ=^"__  6U_P""
MBGP:\JU;XT+XLL8L?Z#XTT]+[?C^].-EP?\ O[7R;179A,QQ^!E?#U90]&T:
M0JU*;]QM'ZT?!?\ X.9-)E\JQ_:'_9GN(2,>?JG@S55D!]=MK<[<?]_S7UO\
M%_\ @LI_P3N^-?DVNG_M 67AV^EQFP\96[Z88R>@,TH\@_A*:_G@HKZO!<?Y
M_AK*JXU%_>5G]\;?C<[:>9XF&]G_ %Y']6?AWQ-X<\7Z3%K_ (3\06.J6$XS
M!>Z==I/#(/570E3^!J[7\L/PY^+_ ,6/@]JW]O?"?XFZ_P"&;W()NM UB:TD
M;'J8F4D>QKZI^"__  7C_P""AGPF\JTU_P >Z3XVLHL 6WBW1D=]O?\ ?VYB
ME8^[LWX]*^MP7B3E]2RQ5&4'W5I+]'^#.VGFU)_'%K\3]]:*_,'X+_\ !R]\
M+-5\FQ_: _9UUK1GX674?"NHQ7T9/]XPS>2R+[!W/UZ5];?!?_@J[_P3\^.W
MDV_A']I;0;"]EP!IWB9VTJ8.?X!]J"+(W^XS9[5]9@N),BQ]E1Q$;]F^5_=*
MS.ZGB\-5^&2_(].^,/[,/[.G[05HUI\;O@=X6\4Y38LVM:)#/-&/]B5EWQGW
M5@:^0_C=_P &Z?[ ?Q,\Z]^'">)_ %X^3&NB:P;JUW'NT5X)6Q_LI(GM@<5]
MXV%_8ZI9Q:CIE[#<V\R!X9X) Z2*>A5AP1[BI:Z\7E.69@OW]&,O-I7^_?\
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M/Q%^&%A\5?@]?V?B#3=5T^._TF6*4A+V!UW *V,HQ'&&'##:0#G'\LM?HO\
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MFBD3ZJP!%?)8O 8S RY:\''\OD]F? X[*LQRR?+BJ3CZK1^CV?R93HHHKD.
M**** "BBB@ HHHH **** "OL3_@DOI#/J/C?7F7 CAL+=#ZEC.S?^@K^=?'=
M?>O_  2M\.FP^"NN>))$PVH>(VC4_P!Y(H8\'_OIW'X5]#PO3]IG--]DW^#7
MZGUO!%%U>(Z3_E4G_P"2M?FSZ?HHHK]7/W<**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1?[(/Q$^#,-KYUUK7A>Y&F1XSF]B7SK;_P CQQ&OYE2"#@C!'45_6!7\W?\
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M8/,:CO"I"+?+'FDKI\O-MR>]W^PK=6SGHX6G5>S2Z7?EZ:_@?G)9>!O"3?\
M!+*[\?G]C>ZDU5?'"VH^,W]O1>7%\Z'[-]F\SS3\I\O'E[,MNW;ABF?L[?\
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M[/1GT6%S7 XO2$[/L]'_ ,'Y&IXL\%^$/'FDOH7C3PS8ZK9OUMK^U65,^H#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&EU\<[3Q4K^(M2ETQ'T:-X]U@LJ)R\#1R$0G&20,#)(]N\?>&H=._:(\??\
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M/;HWM@]B:\/K[C%8:>%K.$OEYH^9QV#J8'$.E/Y/N@HHHKG.,**** "BBB@
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M'_5R@?>B;YEZ_,I5CXE7XCB<-7PE>5&M%QE'=,^>G"4).,E9A1116!(4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?M-_P $+?\
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M3WD4I(>,LP 6OQU_;$_X)M?M7?L2:E+)\6O $ESX?\[9:>+]$W7.FSY.%W2
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M0[?NI0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MHHHKUC<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "J^JZ1I6NV$FEZWIEO>6LHQ+;74*R1N/0JP(-6**32:LP/&O'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>ensg-20231231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ensg-20231231_g4.jpg
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\7_A-X'^.WPRUK
MX0?$O3I[S0/$%DUIJUI;7\ULT\#$;D\R%E=0<8.&&02#D$BNDHJ9PC4@XR5T
M]&A2C&47%JZ9S_PJ^%?P_P#@A\.M'^$WPK\,6^C>'M!LEM=*TVVW%88U]V)9
MV))9G8EF9BS$DDUT%%%$8QA%1BK);((QC%))62"BBBJ&%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'BKQ1J$-FE[J5WI<$\FT?*&ED=I&$<:Y/.U<#C\$OV5?^5/W]K7_ +.+L/\
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M>W?QBBG\120>(?$%Q /$5MKJP*VD6]M*3]I5)'\EO+0^7*9)MX8;\ '[4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;>,9-?C=_P $S_\ @G;^R9XZ_P"#E#Q*O["G@2\T/X/?LM6K?VSJ#ZY<W_\
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MLS*8@77+$+0!K?M#7GCO]I[6_A-^V9^VU^RGXY^-/@OX@_\ !/QM!\#S^'/
MUSK\-A\19\[YS% C?9+J5@SI<$ @RQE6_<DIU'@#XD>+_P!IC]F7X,_\$?\
M]I[XZ:;\-?A7\&?#&DR?MC?$+Q5XL@TV(W/F/+IG@9+R>546Y\M(TN%#YC-N
MZ9#6[QO]^?M*M^U#_P $[O\ @FU\(_V"?V!OA?KGC3XLZMX=TSX?^%O%%AH4
M\FD^'7AM8H;OQ!J,XC:*TBC^:5!*?FD885UCD6OEC]JW_@D])^P7J'[&FM>
M_P!F;Q;\?OAK\*_%OB35?CWI?A_PVNMZOXFU[5+.W5-<GL)&)O")XG(W%O)2
M.--QSD@'ZW_!G4/A!J7PH\/3? #5/#UYX)CTF&#PM/X3NH9M-^PQ*(XEMG@)
MC,2J@5=AP N!TKIJ^$O^#=S]F7XY_LM_\$_KOPQ\=/AM?^"9O$GQ,U[Q'X9\
M#:J ESX=T>[E0VUG+&I(A?Y))#'U7SL, VX#[MH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_!53PK^WE<:[X(\5^'K/PQXQTRXENK#1H;II$O=,+_(Z,V"TL>5608 .5=0
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M 7PT^-'Q'T>&3QMXXU^T^UZCHZN"7L+:'S8O(,6=JON/S[I,$^7L_/[]H?\
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M\Y1_]N7_ &\?9=%%%?SN?O@4444 %%%% !1110 4444 %%%% !1110 4444
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M*XY/E5/#_:WE_B>_W;+R2(=0U"QTFPGU35+R*VMK:%I;BXGD")%&H)9F8\
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M%""LEHDM$EV1^ SG.I-SF[MZMO=L****HD**** "BBB@ HHHH _0S_@W@_:
M?P7^T=XC_9]U2\VV7C;1?M>GQLW_ "_V6Y\*.VZW><DCKY*^G'[(5_-)^RA\
M9+C]GS]I7P/\9X9VCC\/>);6ZO=G5[7S MPG_ H6D7_@5?TLPS0W$*7%O*KQ
MNH9'1LA@>00>XK^6/&O*%@N(Z>.@M*\-?\4+1?\ Y*X'],>#V:O%\/U,%)ZT
M9:?X9ZK_ ,F4AU%%%?C1^N!1110 4444 %%%% !1110 4444 %%%% !1110
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M^M<=7]A/B;PMX8\::)/X:\8^'+#5M.NDVW.GZG9I/!,OHR."K#ZBOD3]H?\
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MNS;*<HP>2X9T,,G9MO75W?\ 5D%?FC\4/^"87BS_ (*V?M\W?[4_[8"WVD_
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M(-EXAU%+FVEFFDNWDBA01IY<)-[.-K%C@@9XK^,3^O#\C?V=/VH]4_X+[?\
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M^/\ I?[1OQY\?:MX*6X'A#3OB7\2VU'3M'\ZUEM6\FVB@A7 AFD10VX#.<9
M(^W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y_XLR&'X5^)IA_!X?O3^4#UT%<_\68VE^%?B:)1RWA^] _&!ZZ<%;ZY
M3O\ S+\T<V-O]3J6_E?Y,^!Z***_I,_F0**** "BBB@ HHHH **** "BBB@
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M%S7_ ($E>/4H/#WDR[SN3!2W,FP2'(7/EA_D+U\:?\$N_#/P(N/^"WGPZ/\
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MG7]+QDIQ4ELS^8)1<).+W044451(4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MU4]B/0D'U?\ ;R_9)\*_MS_ FV\5_#][=O%&EVK77A;400OVI",O9R$]%<C
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M^[+:7DM)/L?S_P 2^''$'#W-5C'VU%?;@ME_>CNO75>9\I4445^C'P 4444
M%%%% !1110 5^]__  14^&K_  X_X)W>"Y;J#R[GQ%->ZS<+C&1-<.L1]\PQ
MPG\:_!K0]%U/Q)K=GX=T6T:>\O[J.VM($',DKL%51[DD#\:_IO\ @[\.M.^$
M'PE\,?"G2"IM?#7A^STN!E& RP0I$&_';G\:_#?'+,52R;"X)/6I-R^4%;\Y
MK[C]H\%\O=7-L3C&M(04?G-W_*+^\Z.BBBOYE/Z,"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMJKZ'3_'7XI_$BT_X+_? OX;Z9X_URU\,ZK\);NZU#PY!JTRV-S-Y&O,))(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5
MXA^U]\#&\7Z.?B5X7L]VIZ=#B_AC7FYMQ_%[LGZKD=@*]OHKT,LS'$95C8XF
MCNNG1KJGZ_\ !//S3+</FV!GAJRT?7JGT:]/^ ?G/17M7[5G[/;^!M3D^(7A
M"R_XDUY+F\MXEXLI6/IVC8].P)QQE:\5K]]RW,<-FN#CB*#T?WI]4_-?\'8_
MGK,\MQ.4XR6&KJS7W-=&O)_\#<****[S@"BBB@ HHHH **** "BBB@ HHHH
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M>62^YKNGU04445V'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%Z?A)^P1\1?B;X2NM2OOV6$E\6^*;#P+IKSS>(UL+XSWT%RULEPEN;N 2K;
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MXFN=2\&>._B*ZV^I6$4VQ1'=QL%=E 0,8TW;7=]LC*0J@'Z>_P#!-3]KV?\
M;U_81^&/[75_X<ATB]\:^&DNM4TVV9C#;WL<CP7*Q%B6\OSHI"FXD[2N23S7
MPE_P5-_:'_X*#?!_XU>/KZS_ ."Y?[/7[/>E:3:&\^&GPLN-"TO4-:UJ%+57
M3^T#J*F6V:64.H:)9(\%< GBOTF_9I\-_$SPA\ /!_AKXSZ/X1T_Q=9^'[9/
M$UEX!M'@T6&^V SK91R .L <MMW '')K\EO%/_!'+_@I1\*OV_/VD_B5\)_V
M?_@!\5_#W[16N37FB_$GXN3&XO/ 4$\MR[1QVS1M(?*6Y"!(MRN+2U)90IC
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M[=?_  T_!HD?Q#3Q#I:>,O\ A&RQT]]06\U-9I+?<2PB9@64'D!@" >!Z?\
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M\6_$73]"A@\8^)='M%@M=2OE&))XXUBB"AN#@1H/]D=*^/O&7_!.+]H_6O\
M@X>\(_\ !2G3K70_^%8Z+\()?#]Y,VJ8O1>F.\C"+;[>5_?H=V<8SW&#]_T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5!J>EZ;K5C+I>KZ?#=6TR[9K>XB#H
MX]"#P:GHIIN+NMQ.*DK-:'@OQ2_8DT'5S+JWPOU(:=.<L=-NV+0,?16Y9/QW
M#Z"OG_QQ\,O'?PXO?L7C+PW<6>6Q',R[HI/]UURK?@<U]]5#J&G:?JMF^GZI
M8PW-O*N)8+B(.CCT*G@U]IE7&^9X%*&(_>P\])+Y]?G?U/B<VX%RO'MU,/\
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M  PI\6\_\C%X<_\  NX_^,5]7T5VKCG/TM91?_;J.)\!\/-_#)?]O,^6;?\
M80^(K'_2O&&BH,\F,S-Q^*"M73OV!KUB&U;XF1(.ZV^EEL_BT@Q^5?2-%9SX
MUXAFM*B7I&/ZIFE/@?AR#UI-^LI?HT>):-^PM\-+0A]:\2:Q>,.JQO'$A_ *
M3^M=GX>_9I^"'AHK)9^ +2>1?^6E^S7&3ZXD)7\A7=45Y6(S_.L4K5,1*W9.
MR^Y61ZN&X>R3".]/#QOW:N_O=V0V.GV&EVRV>F6,-O"OW8H(@BCZ <5-117D
MMN3NSV$E%604444AA1110 4444 %%%% !1110 52\2>(M"\'^';_ ,6^*=6@
ML-,TNREN]1OKJ0)%;01(7DD=CPJJJDD]@#5VN0^/OP.^'W[2_P %O$_[/_Q8
ML[RY\,^,-'FTO7K6PU*:SEGM95VR1B:%E= RDJ<$94D'()% 'Y'?\$$=)UW_
M (*A?\%1_C]_P7$^).E3_P#"/V&I2>#/@S;WL9'V2W$2JSH#]R2.Q\A&QPSZ
MC<'KFOT=_:N^-_P9^-/PB^.W['OPD^-'AG6/BKI_PEUL7_@;2M=@FU>P^T:>
M\<+RVR,9(P6G@Y*\>='G[ZY[C]D7]D3X _L+_ 71_P!FK]F7P./#_A'0WGDL
MK%KN6XD:2:9YI9))IF:25V=VY9C@84850!ROPO\ ^";O[(GP<_;5\;?\%!?
M'PYGL_BC\0=(&F^)=;?6+F2*6#-N7"6[N8HF<VEN695!_=\8W/N /R,_X)A_
M'OX0>'_^#0OXXZ9K?B[38+G2/#_C;P_J%O-=(LB:CJ,;BRB*DYW2&[@">O;H
M:]2_X)S_ /!.']EKQ]_P0@_9U_:5_;&^)7C7X5:Q\)?"'BC7M/\ B;X&\6RZ
M)J>EZ'J6IZA=21&94??#-:S1D+M+$2%4(\Q@WTY\1/\ @V5_X(X_$_X]7?[0
M/B3]F6>.^U#5&U'4M T[Q->6VD75RS[V8VL<@"*S<F.,I&<D;<$BOI#]K/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
<% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ensg-20231231_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ensg-20231231_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M8@*H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHKQC_@HG\1O&WPC_8=^*'Q*^''B";2M=T?P
MC=7&F:E;A3);2@ !UW C<,\''!YK'$5HX>A.K+:*;^Y7,ZM14J4IO9)O[CV>
MBOR)_8L^&?\ P6,_;-_9CL?VF_A=_P %)9["XN[R[AL] U^V)5GMY6C^>58I
M%PQ7O&0,\U[K_P $I_\ @IK\?OB[\<_%'["/[<F@VUG\3O"J3M;:K;VT<']H
M?9V"SPRQQ?NO, 82I)$!')'N( V@OX>$XCHXB=*-2E.FJOP.5N66ETKINS?1
M.QYM#-Z=64%.$H*?PMVL_FF[/U/T!HKPS]I'_@I5^P_^R1XJ3P-\??V@--T;
M6FC21](MK&ZO[F%&&5:6.TBE:$$?,-X7(P1G(KT#X$_M#_!/]IOP''\3/@+\
M2--\3Z))*8C>:=(<Q2@ F.6-@'B< J=CJK88'&"*]F&,P=2NZ,*D7-;Q35UZ
MK<]".(P\ZKIQFG);JZO]QV=%?.GQ3_X*U?\ !.OX+_$:?X4?$3]J#1[77;2Y
M-O>VMGI]Y>QVTP.UHY9K:&2*-E/#*S@J00<8->H_$3]IS]GWX3_""#X^_$/X
MO:%IG@V[MH9[#Q#+?*UO>),F^(P%,F<NOS*L88L,D XJ88_ U.?EJQ?)\5I+
MW?773YBCBL-+FM-/EWU6GKV.ZHKP;]G7_@IU^PG^U=XT'PZ^!7[0NG:MKSH[
M0:3=Z?=V$]P%!+>2MW#%YQ"@L0FXA020 #CI?B'^VY^RE\)OBK/\$_B9\;M'
MT+Q+:Z"^M7-AJ?F1)#8JK,9FF9/*7A6PI?<<< Y%$,?@:E)58U8N+=K\RM?M
M>]K^01Q6&G3YXS3CM>ZM?M<]4HKP#X,_\%2_V /C]J.L:5\,?VF=#N)M!T^6
M^U0:I!<::L=K$,R3JUY%$LB*.69"0!R>.:L_L_\ _!3']AG]J/XCR_"/X&?M
M!Z;K7B*-)'CTQK"[M&N5C!+F!KF&-;C #,?++?*I;[HS4PS++JCBH5H/FT5I
M+5]EKK\B8XS"3MRU(N^VJU].Y[M17Y1?M$_%3P]\*_\ @X\\*^,?B+X\@T/P
MWI7A"274[[4K_P FUMXAH-\<L6(4 L1@=V(P"2*^ZOV<O^"E7[$'[6?CBX^&
MOP#^/NGZWKUO$\HTN73[NREG1!EFA%U%'YX49)\O=@ D\<UQX+.\+BJ]6C-J
M$HSE!)R5Y6MJEH^NVOJ88?,:%>I.G)J,HR<4FU=VMJE\SW.BO*_VF?VVOV5_
MV.M/L]0_:0^,VF>&CJ()L+.6.:YNKE0<%TM[=))60' +A=H) )%._9F_;6_9
M:_;%TN\U7]F_XQZ;XF&G%?[0M8HIK>ZM@V0K/;W"1RJI((#%=I(."<5Z'US!
M_6/8>TC[3^6ZYONW.KZQA_:^RYUS=KJ_W;GJ5%> >,?^"I7[ O@"W\7S^+?V
MD-)M&\":\NB^)[8V-VT]M?LTRB!(EA+W#9MY\F$.H\IB2 ,U[/\ #[Q[X1^*
MG@31OB9X!UE=1T/Q!I<&HZ/?I$Z"XMIHUDCDVN%9<JP.& (S@@'BG2Q>$KS<
M*52,FNB:;WMT\U;U'3KT*LN6$DWY-/R-BBOBK]JW]D+_ (*B?M-_'#Q-<^!/
MVYX?A1\.K+R4\&:;X9MY3>W9^SQF62YDA,3J#,9 /WKX"\1CJWD'_!#?]M3]
MK+XD_M ?$S]CW]I;XA2^-5\%6EQ/:>([F03R03VUZMI+#]HP&GCD+[T+Y8",
MX.#@>7+.U3S&&%JT914VU&3M9M>2;:3Z-K4XGF*ABXT9TY)2;2;M9M?.]NQ^
MFE%?D_\ \%@OVRO^"IO@6RUWQAX$T&?X2_"SP[XW_P"$>TG6[>[5=5\3SXF*
MW2DC>EL5A9E"JBD./FE_A_1C]CCQ3XB\<_LA_"KQMXOU>;4-6UCX;Z'?:I?W
M+9DN;B73X)))6/=F=F8GU-:X/.*&-Q]3"PA)."3NU9/6VE];>=M2\/F%/$8J
M=",6G%7NU:_IU/2***\H_;6MOVK]0_9\U32OV*[S2[3Q_>7=K;Z=J&L&+R;*
M%YT$\_[T,A*1[B 5<]<*QP*]*O5]C1E4Y7*R;LM6_)+N=E2?LZ;E9NW1;OT/
M5Z*_$S]MW6/^"P/_  2SU_P?\8?'W[=MSXOB\27DL9LTU">YLDGA"N\$EI<H
M(S&RO@,BJ>#]PA2?K'_@I[_P5"^*GP/_ &(?A1XO^!]@FD_$#XW:39W6ELT"
MS-I,#VEO/<&)9 5:4/=01+N! WLW517S\.)\-&%?ZQ3E3E12;3LVU+:UG:[=
ME\SRHYS14:OM8.#II-IVZ[6L^I^@5%?CQ^U#=_\ !5G_ ()&6G@/]IKQ_P#M
MK:C\3-*US6H['Q1X7UB:::SAN3$TQM%\YGRCI',%FC$3*8\A<&OL3]LOPG_P
M47_:XD\"C]A3XWZ5\._A[KWA./5M;\37,@2^EEGVO##'L1Y5Q$RM\GEC);+G
M"K6M'/G456#P\U5ARWAHVU+9IIVMWUT+IYGSJ<72ESQM[NE]=GO;U['V'17X
M[_LD_M9?\%"/V._^"J>F_L%?M+_'F[^(VF:IK$&FZE_:%\]Z +JV6>WN[>:8
M>=$5$D9>,G;C>,$A7'U9^VU^SC_P5J_:3^/>L:+^S]^T]I?PN^&&G:?;#1)K
M2[>&^U*Y:%6F9WMXVF51*63ET 4*51LDTL/Q L7A)U*5";G&7(X65TUO=WM;
MSOOH%+-57H2G"E)RC+E<=+I_?:WF?;E%?E-_P1H_;D_;-G_;=\8?L%?M3?$:
MY\:)HD>JP-J%_/\ :9]/U#3[@12[;D@/-"^'&'R<A"NW+!OU9KNRG-*.;X3V
M].+C9M-/=-;HZ<#C:>/H>T@FM6FGNF@HHHKTSL"BBB@ HHHH **** "BBB@
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MT9J4'.TTZ?)[REKHO:.]U=-[^6AC@\LQ,)QC44KQ<K2O#EUOKMSN]]F?(/\
MP01_8P_9,^-G[#NM^/\ XN_!CPQXRUS7/%U]8ZI>^(-+BNYK6*.*'9#$\@+0
M'#F7<A5B9 2?E7'GO_!:/PY<>$?VO_V9/V0?A=\+(O$'@SP[H^G+X7^'MWK/
MD6NK3/?_ &9;*2XN&(^>.VAB,DC$@2L<_,2?7K+_ (('?%_X4>)]=T?]E/\
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M_6-,LS/#?A(_)5V"RQM&_E8C8[F1T55*=2>G_8]_8=_:O^#7Q@;XS?M-?\%
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M']A"QEMOC5\48KCQ"L6^W\&>'@MYJLV1D9B#!8 1R'F:-3C@D\5^27_!0/\
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MZV?FO(_9:<G."DTU=;/=>3\PHJ.\O+33K274-0NHX(((VDGGF<*D:*,EF)X
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M:!V,>6VYQDU]]T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=*N=<US4K>RLK*W>>\O+N98XH(D4L\CNQ 554$DDX !)JP2 ,DX ZDU^%/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:>\GOV75_)'ZH_\ !)K]A/3OV _V/M#^&&HV</\ PEVL :OXXO(\,7U"5%S
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M9#'85^[+H]TUNGYK_@K1A1117BGL!1110 4444 %%%% !1110 4444 %%%%
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M[3WQ2_:V_:-U3XK?$[PW+H"""*R\,^%3;F&+0M(BR+6SB0JNU%4DDA0&=W;
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MTO\ MWXEZ2MN?H'A9Q.\GSKZA6E^ZKM+TG]E_/X7\NQ^R5%%%?R<?U"%%%%
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MXYDY4?D=\0?B)XZ^+'C&^^(/Q*\67VMZUJ<QEOM2U*X,LLK>Y/0 8 48"@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJ?*\:TG4X;K6Z<K_ /)E^A\TT445^Z'X*%%%% !1110 4444 %%%% !1110
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M^"+O[$GQ^_8W^'7["GCG2_%<7@'X7O _A>#2O%,UM=!HK>6 --,O,N5F<G(
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MY!!YS7V/^R=_P6(^,/PB^S>$/CS;S^-?#Z81=0:0#5+5/42-Q< >DA#'_GH
M,5_.G%_@AB</S8G(9\\=_92?O+_#+:7I*S\Y,^NR_B6$[0Q2L_YEM\UT^7X'
MZM5\X_MG_P#!+G]EO]M*VGUKQ;X9_L#Q:Z?N/&&@1K%=,P''GIC9<KT'SC>
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M^?LD?L]?LK2^)'^ 7PY@\.)XLU?^TM:MK2YF:%Y\$#RXW<I @!($<85 #@
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M2Q"E;*,^H,9:8?\ 7R:^S:AT[3K#2-/@TG2[..WM;6%8;:WA0*D4:@!54#@
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M<G+*U?IG^RG_ ,%&/V>?VJHH-%T?6_[ \3R*!)X9UJ54ED;OY$G"W ZX"X?
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M9V_:9_9__:U^&=M\8_V:?B]H7C7PS=3/#'J^@7RSQI,F-\,@'S12*&4F-PK
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M ."87QU^%/P)?3/#_B74_&>OVR>.([KQ&]I)X5T6:6)%U)U2"02*5,S!<KQ
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MG_\ L>?\$^/!%_\ #K]COX':=X*TK5;M+G5([2[N;J:\E1=B-+/=2RRR%5)
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M9)7<FZN"Q=VWF5MV<U]#@ # ' H **** "BBB@ HHHH **** "BBB@ HHHH
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M&'[,O@#Q#^RYJ5O=_#B?P?IZ^!IK625D&EI;HELF9B9<K&JH1)^\!4A_F!H
MN_$#]H[]GGX3ZVOAGXI_'GP9X:U)[=9TT_Q!XHM+*=HF) D$<TBL5)5@#C!(
M/I6AX0^,'PD^(/A.Z\>^ OBCX<US0K%I%O=:T?6[>YM+=HT#R!YHW*(51@S9
M(P"">#7X3_\ !:+PY^Q5I7_!?/5_B-_P4L_97^(/Q&^$,'P!L%BB\%Z?J/\
MH^IK<DQSO-9W-L1&D8N V9=H+KE2<$>M?$7X7_L4?M4_\&[/QL^$W_!O)X,U
M0V.K>([34?$G@*QO=3GUF6\6XT]KVW:._FEG+R65K'MCC=HYEB9(][,P(!^O
MOPR^,GPA^->C3>(O@W\5?#?BW3[>X,%Q?^&=<M[^&*4 $QL\#LJM@@[2<\T:
M!\9?A!XK^(NN?"#PM\5O#>I>+?#,,$WB3POI^NV\VHZ3',NZ%[FV1S+ LB\H
M750PY&:_"_X8?M/:O^P)^U9\9_VGOV/?V$O%GPUTSXS>#/#'@#X _!GQ/X)?
MP[-XH\:1PPK+>KIS;#]EL@93<7.%1VF \P-.6'Z&?\$0? O['OP4^%?B#X<_
M#K]LKX?_ !D^.OB/4G\3_'[Q3X:\86>IW^HZS,Y\UG$+EUM87D:&+A4!W-A7
MD<4 ?=%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %<]XO^%'PX\> GQ;X-L;R1A@W#0[9?
M^_BX8?G70T5K2K5L//GI2<7W3L_O1E6H4<1#DJQ4EV:37W,\1\4?L,_#K4V:
M;POXAU'2W;I')MN(E^@.&_-JX#Q!^PS\3=/+2:!KVE:B@Z*TCPR'\""O_CU?
M5M%?187C'/\ "JWM>9?WDG^._P")\WB^#.'L4[^RY'_=;7X;?@?$6K_LR_'/
M12?M/P]NY1V:SDCGS^$;$USU_P##?XAZ4Q74_ >LVY'7SM,E7^:U]_45[=+Q
M#S"*_>T8OT;7^9X5;PXR^3_=5I+U2?Y6/SNGTS4K7(N=/GCQG/F1$?S%0JK,
MP55))/  ZU^B]%=:\1G;7"_^3_\ VAR/PUC?3%?^2?\ VY^>-MH>MWA M-'N
MI2>@CMV;^0K7T[X2?%+5SC3OAUK<H_O#2Y0OYE<5][T5E4\1<0U[F'2]9-_H
MC6GX;8=/W\0WZ12_5GQ;HW[*'QUUG:W_  AGV1#_ ,M+V\BCQ]5W%OTKM/#O
M[!WBZY*OXI\;Z?9KU9+*!YV^GS; /UKZ>HKRL1QWGM96ARP]%?\ ]*;_ "/6
MPW .0T7>IS3]96_])2_,\C\*_L7?!_02LVLI?:Q*.2+RYV1Y]ECV\>Q)KTOP
M[X2\+^$;3[#X7\/6>GQ=TM+98]WN<#D^YK1HKYO&9IF./?\ M%64O)O3[MOP
M/IL'E66Y>O\ 9J48^:6OW[_B%%%%<!Z 4444 %%%% !1110 4444 %<_\6/A
M]IOQ:^%GB7X5:S</#9^)O#]YI-W+&,LD5S \+,!W(#DUT%% '\\OPH^&W_!8
M+]D[_@F;\4/^"%3_ /!*?Q=XTU?Q3K.I:?X7^*FDWD9\.+I]]+&9+AYW7R@P
M(DDC+RQE?-7>J-$0WWEX5TK_ (*5_P#!)+]E']CK]B?]E3]EO3_C!"]S_9/Q
MK\0KY\D7AU'N;>:5H722/RX]UW>[+B560+:+N0%P*_2BB@#X0_;6_P""HO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
K!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>ensg-20231231_g6.jpg
<DESCRIPTION>PERFORMANCE GRAPH
<TEXT>
begin 644 ensg-20231231_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
MOI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z
M6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'
M_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=
M7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)
M=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0
MO?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#
M8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_
M[Z6I+/7M2N;I()O#-U"K-AI79<+[F@#4HHHH **** "BBB@ KQ[]HS]N'X'?
MLI>+--\._'>/Q#I&F:K8-<0>*H_#EQ=Z6CARAMY)8%=DEX#8*8VL#FO8:Y+X
M\?!_0_V@/@YXC^"OB;5[^PT_Q-I<EA>W>F.BSQQOPVPNK+DCCE3P30!\5_")
M_A/^T3_P4[\&?M#?L)^!+RQ\'Z-X=U./XG^,K+P_-I>EZTTT++;VZI+''Y\P
ME*.S;<D*K9/E@U[SXL_X*I?L,^!-;U_P?\1/B[+H>L^'=0N+'4M#U7P]>I<M
M)$[)F)!"1,C[<HR$A@PZ=*]]T'1;+PWH5EX>TU2+:PM([:W#'D(BA5SCV J2
MXTS3;NYBO;K3X)9H#F"62)6:,_[)(R/PH _./X4_LE?%+XR?\$WOVB;+0/AO
M?^';;XI^-[[Q1\./!=[;>1/'9Q7$%U;((>!$TOV=8U7@$*A'RL#76^,O^"H/
MP4^(G[#MS\(O!DVJW_QB\0^#&\,1_#B#0KHZC#K$ML;6564Q[0D;EY-Q(RJX
MX8[1][5 FF:;'?-JD>GP+<NFU[D1 2,OH6QDCVH _/KXD?"/7_\ @G]>_LK?
MM"^+='NKSP]\,O#ESX:^)UWIEL]P-,%[:X-T1&"QA2>6<E@/X4 R7 KI?B[\
M:OAW_P %&OVJ?@K\.?V8=6F\3^'/AYXSC\9^.?%%M831V.GFU :TMO,D1=\L
MK[AL&< @\@/M^YF574HZ@@C!!'6HK'3M/TNW%IIEC#;1 DB*"((N3U.!Q0!-
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 445X/\ M=_M8^//@YX_\"?L^? GX<V'B;XA_$::
M\&B0:UJ+6NGV-O:Q>;/<W#J"[ +G")@MM;G("L >\45\Q_L%?#;]M/X WVI?
M"3]H3P9X/U'0M2O=3U]?&OA7Q'/,4O[J[$S6DEO<QQR$$2R;74;5$6&R6!KL
M/VX?VJ-;_9H^'^F67PS\-6OB#X@>+M3&G>"_#UVS>5/(H\RXN)MA#"""$,[L
M",94$C=D 'ME%?/7[/7[7OCKXM?\$Y1^V1XB\-Z3!KX\(:UJS:99+*MF9;)[
MI40!G9PK?9US\Q/S'!Z5P'P8^,?_  5X^-7PV\,_%SP_X+_9[AT7Q/I-KJ=I
M'=W>M)<);SHLBAE4LJN%;D D9[F@#[$HKP[]LW]JOQ9\!)O!OPM^#?@>T\2_
M$?XCZQ)I_A'2=1N6AM(EB0/<7ERR_-Y,2,I8+ACG@C!KA/"_[5?[7'P,_:-\
M%_ C]M[PIX!GTWXD//:^%/%WP\:\C@M]0C4-]DN8KLLV7W*J,N,EEZ_/L /J
MRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%%
M&/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-
M;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P
M&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8
M_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&
M[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;L
MO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+Q
MO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&_
M_0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_
M &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q1
M0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (UL44 8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_ (U)9VGBU+I'OM6M7B#?O$2W()'L
M:U** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&3@;Q$[;<]B>O:@#K**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M /A5WPS_ .B=Z%_X*(?_ (F@">T\=^$+ZUCO;37[=XIHU>)PQPRD9!_*I/\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZI]MXH\/WDZVMKJL3R
M.<(BGDFK/]G:?_SXP_\ ?H4J6-E&P>.SB5AT*Q@$4 2T444 %%%% !1110 5
MR7QX^#^A_M ?!SQ'\%?$VKW]AI_B;2Y+"]N],=%GCC?AMA=67)''*G@FNMHH
M J:#HMEX;T*R\/::I%M86D=M;ACR$10JYQ[ 5;HHH 155%"(H  P !TJ%-,T
MV.^;5(]/@6Y=-KW(B D9?0MC)'M4]% ",JNI1U!!&"".M16.G:?I=N+33+&&
MVB!)$4$01<GJ<#BIJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS;]I']J_X._LKZ)IFI
M?$_4;^6]UV\-IX>T#1--DO=1U:< $QV\$8)<@%<DX4;E!.64'TFOF7]NO]GG
M]H#Q)\6_AE^UO^S#IVD:WXK^&$VH(_A'7+H01:O:7D(BE6*4X6*8+N +$#YP
M<_(%8 ;^P5^V=XM^,]]J7PE^/_A+QAX<\?F]U/5M.TKQ5X)FTH/HHNPMN(V*
M*LACCE@5L_,2V<M@M6I\6/\ @H_\//AOXMU[PKX8^ GQ8\=IX4N'@\4:OX(\
M%-=6.F2H,R1O-+)&'=!RP3<  <GBG_LV_P#!0CPK\9_BF_[.OQ5^$GB7X8_$
MN.Q:[7PIXI@!2^A4$O)9W*X6X4 ,<[5R%8J&"L18_:T_:<_:6^"/]I:;\#_V
M*?$'CT1:4+BUUVRU2W6T2=MV5:W0M<2E" Q5$R^< C.: .T\ ?M7_!GXH_LW
M3?M5> ]<GU'PG;:+=ZE</%;%;B-+5':>)HF((E7RV&TG!(!!(()\;\,?\%9_
MA]XRL+#6?#'['O[0E]I^IQQRV.I6OPQ,MO-$^"LJR).0R$$$,,@CD5S'_!/;
MX:>"/$G_  2K\0?"WX&_$&W\4:MKVD:]:ZM*ULUDMMK=U;NK6C12 -"(]\2Y
M8#<,.  P H>#_P!I/]L;_@GW^SAX2TO]HG]C"WNO G@O0=/TG6O%'A/QS!=W
M=G%$D< N7M#&NX$XR%?"YY?% 'U#^TE^TY\*?V5? D7COXIW]X5O;^.PT?2=
M)LVN;[5;R3.RVMH5YDD.#W &.2*X;X(_\%"/AE\7?BU!\"/%7PM\?_#CQ?J%
MB]YHFB?$;PX-/DU:! 6=K=EDD5RJ@DJ2"-K8!VG'E_QT\4:#\7?^"G_[,7V2
M]CU#PX?"&N^)-$;'[JXDFLB8I@#U(5(W4GD$9JY_P5'A31_BS^S%X\TY NJ6
MGQYTO38)5'SFVNR%GC!]&$: B@#Z_HHHH **XSXS?$WQ?\,M,LK_ ,(?!W6O
M&,EU.T<UMHLD:M;J%R';>1P3QQ7GW_#6'QL_Z,?\=_\ @5;?_%4 >Z45@V/B
MW7+NQANI_ U_ \L2N\+NNZ,D9*GW'2IO^$EU?_H4+W_OI: -BBL?_A)=7_Z%
M"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_
M[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]
M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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M%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BB
ML?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^
M$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275
M_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"
M]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+
MW_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_O
MI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_
M +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8
MHK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\
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MV;M>S-(5:=3X))^C"BBBNLL**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHJEX@\2>'?">E2Z[XJUZRTRQA&9KS4+I(8HQ_M.Y
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M*!@[6Z[AL /MNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10
M!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P
M@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_
M ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1
M_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'
M_/S>_P#@6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[
M_P"!;5L44 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/
MS>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X
M%M6Q10!C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@
M6U'_  @^D?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L4
M4 8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?
M\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C
M_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^
MD?\ /S>_^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z
M1_S\WO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S
M>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_
MS\WO_@6U'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;5L44 8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;5L44 8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;
M%% &/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M6Q10!C_P#"#Z1_S\WO_@6U
M'_"#Z1_S\WO_ (%M6Q10!C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5L44
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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MVH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV**
M,?\ X0?2/^?F]_\  MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VJ2S\)
M:;8W27<-Q=%HVRH>Y8C\16I10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_T$?^20_P#D3YW^T<9_-^"_R/VX_8=_X+O_ /#9G[4?A?\ 9L_X97_X1O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 444CND:&21PJJ,LS'  ]: %HKS[QQ^UG^RU\,]Z_$+]H_P+HKQYW0ZGXL
MM(9,^@1I Q/L!FO&_''_  6C_P"":W@3?%=_M*6FI3KG$&AZ->WF_P"CQPF/
M\V%<-?,\MPW\:M"/K)+\V9RK4H?%)+YGU+17Y[^./^#D']BW0=\'@OX;^/\
M7I5SLD.G6MK W_ GN"X_[]UY9JG_  <@?$WQQ>/H_P !_P!B"6]N>D376OS7
MKMGIF&WME(^F\UY%;C#ARB[>W3?:*E+\DT82QV$C]K]3]6Z*_)S_ (>!?\%\
M/C:-OPR_8X;PW#-_Q[W*_#^YMP1V/F:E*8V^H&*#^SS_ ,''GQP'_%;?&Y_"
M,<W?_A*-/T_8#_V"49A_/\:P_P!:Z=7_ ';"5JGFH67WMD_75+X(2?R/UC)
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M+EYZC?O6=NRWMOIW(JX"+IO5R=G:[ZG\R]%?K!_Q# _]7P?^8T_^^5'_ !#
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MXCTA+/Q;X]T/7+\:-,?*6QGO[9HX+=\_ZLA!$6!^XS,I^[6%X/\ VD_VQO\
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MN-<G3I/KGB2^ES]8TE2,_BE>R>!OV&?V,_AJ4D\$?LK^ +":/[MTGA2U>?\
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M9:OI&HPF&_TS4K99H+B,]5=&!##@<$5I44 ,@@@M8$M;:%(XXT"QQHH"JH&
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M]B,U\!V7_! /]L7XMZ\=;_:4_:[T9YI?FDOTGO\ 7+DD^OVGR,G_ (&:]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OD__A^'_P $NO\ HY[_ ,LK6_\ Y"KZPK^3^OB>,>),=P][#ZO&+Y^:_,F_
MAY;6LUW9Y^/Q=3"\O(EK??Y']"'_  _#_P""77_1SW_EE:W_ /(5'_#\/_@E
MU_T<]_Y96M__ "%7\^/DR^5Y_EG9G&['&:;7R%?C_B7#<OMJ$(\R4E>,U>+V
MDKRU3Z-:,\N&=5:E^3E=G9VZ/L]=S^L"BOACQU_P<,_\$^/">]?#D_C3Q.RY
M"'1O#8B5CVYNY82!^&?:O'/&'_!S'X:GN/[-^$G[(>K:G-*VVW?6/$R0,3V_
M=0P2EC[!Q]:_0Z_%O#N'^+$1?^&\O_24SVI8W"QWFOS_ "/U*HK\G/\ A[3_
M ,%C_C2?*^!?[!OV*TF_U=\G@;5;O;Z?OY)$A_-:0^'_ /@Y0^.0+ZEKK^#]
M/E^Z3=:)IHC'?_4AKD8]ZYO];<+5_P!VP]:I_AINWWNQ'UZ#^",GZ(_62N7\
M<?&[X+_#%6;XE?%[POX>"#+G7-?MK3:/?S77%?CG\3OV,?VCB)%_;2_X+&^#
M--)YGTF;XD:CK-U&.X^R?(>/1<CWKQ_5?@9_P2M^';LOB']K?XF_$:8$[O\
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MWAT?X-?L;7U_</GR9-4\3?.?^V$%NQ/X25Y-\0/^#@#_ (*&ZO>3:5H7PO\
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
MP@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_
M #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\
M_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_
M (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-
M[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1_P (/I'_ #\WO_@6
MU &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;
M4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L4
M5C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P
M@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M7@G[2?[?O["'[*GVBP^*7Q[@E
MUBWR&\.Z#>M?W^\?P-%#GR3_ -=2@]ZPQ.*PV#I^TKS4(]VTE^),YPIJ\G9'
MTG5?5M6TK0=-GUG7-3M[*SMHS)<W=W,L<42#JS,Q 4#U)K\EOB'_ ,%N/CY^
MT)XED^&G_!/7]E;7+R\D^6+4=52;4KT(3@2?9;8^7!C^]))(@YSTKDO%W_!/
M?]MCXZ0P?$+_ (*F_MR:)\-M!<^?'I/B;Q)#/.._[FQBDCM8V/3Y6W@\%"1B
MOGH<22S&M[#)\-/$S>BY4U&_^)K]#@K9E1IP<HZI;MZ17JWH?;G[2?\ P7%_
M8-_9]^T:3H7CV;Q]K4.5&G>"HUN(0W;==L5@VYZE'=A_=-?@7INFM>-YDF1&
M#R?7VK]'M%\8_P#!"C]C= W@GP1XH^-_B:V^[JFK6@-H)1U^6X6&%5ST9892
M.,,>M?"-K\./B!_PA+_$"+P-J[>'[>5()]=32Y?L4<C'"H9MNQ6)! !.37ZI
MP)X+9YQ5GU',.-*/LL+2NX4K<O/)N-H3<FI6=KM)6E:UU?7\CX[XZA3PJH9;
M6A4JN]W!\W)'J[I--_/3<Q_)B\KR?+&S&-N.,5DWND3Q2_Z,A=&Z8[?6MBO9
M/@%_P3T_;1_:H\%S^/OV??@9=:[I$%V;8ZC-JME8Q/*!E@ANYHO-V]"4W '@
MD&OWCQCX!X"XDX75?/$Z*PR7)4I17M(K_GW"*3YE+90L[/56LS\JX.S3B&AF
MOL<NBZLJF\7=I_WGVMU?R9]VZG^T[_P;Y_L^YB^''[-=CXUF@XC\GP=)?C</
M^FFKNN1G^(9]1FLRU_X+H^3=-X/_ &*/^"?6GVLQ7;;K%'O=AV!M+"!2!])#
M7V;\/?\ @D?_ ,$^?AIY<FB?LZZ7>S)@F?7I9-1+'UQ<LZ@_0 5[5X=^#W@'
MP?IJZ-X2T5=+LT^Y:Z<!!&OT5  *_%J&)\+<ETP&53JM;.I-0_\ ):2L_1G]
M QR?CS&?Q\=2PZ[4:7-^,]5ZH_-$_&G_ (.$_P!IGCP;\*YO =C<??VZ#::2
M$4]\ZFS7 _X =U*/^",?_!1[]H4B?]JW]MU5MISF2SDUK4-9:(>GDN885^BM
MBOT\_P"$'TC_ )^;W_P+:C_A!](_Y^;W_P "VKI_XB/C\)IEF$P^&[.%).7S
ME*]_N+_XA]@<5KF6*KXCNIU&H_*,;6^\^$_AE_P;K_LH^&_+N?B=\4O&/B>=
M,;XK:6#3[9_JBH\@_"45]#_#+_@ES^P#\)?+D\+_ ++WAJYECY$_B"!]4?=_
M>S>-* ?IC';%>R_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;5X6/XSXKS.ZQ&
M-J-/HI.*^Z-E^![>!X0X8RVWU?!TTUU<5)_?*[_$N:%X>T#POIJ:-X9T.STZ
MSB_U=I86R0QI]%0 "KE8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@6U?,RE*3
MNW=GT48QBK)61L45C_\ "#Z1_P _-[_X%M1_P@^D?\_-[_X%M2&;%%8__"#Z
M1_S\WO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S
M>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_
MS\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_
M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M)VDO6+M)?-'=T5C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5X1[1L45C_\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\
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M=OK?[/<Z]JVJ7.H7A@R#Y2RW,CF-.!E4V@[1G.!7KM% !1110 4444 %%%%
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M,J:LELK_ ,S[R?5GFY'PODG#LJLL#2Y74=V]_P#MU=HKH@HHHKYP^@"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /%_P!HC_@GI^QY
M^U&LUW\6_@AI,^IS DZ_ID9LK_=V8SP[6DQV$FY?:OB?XF_\$$?BW\(/$3?$
M?]@S]J74M*U&#+6UCK5Y)97:C.=JWMH &STVM$H]6YK]0**^KR?C;B7(X>RP
M^(;I[<D_?A;MRRO9>ECYC-N#N'<YG[2O02J;\\/<G?OS1M=^MS\H+7_@H_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF]%Z17NKY)'U.5Y#DV2PY<#0C3\TM7ZRW?S84445XQZX4444 %%%% !1110
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M$9JY_P %1X4T?XL_LQ>/-.0+JEI\>=+TV"51\YMKLA9XP?1A&@(H ^OZ***
M"BN,^,WQ-\7_  RTRRO_  A\'=:\8R74[1S6VBR1JUNH7(=MY'!/'%>??\-8
M?&S_ *,?\=_^!5M_\50![I16#8^+=<N[&&ZG\#7\#RQ*[PNZ[HR1DJ?<=*F_
MX275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
MA)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^
MA0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_
M^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_
M +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^
M^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**
MQ_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X2
M75_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X
M275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H
M4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\ A)=7_P"A
M0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH
M V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^E
MH_X275_^A0O?^^EH V**Q_\ A)=7_P"A0O?^^EH_X275_P#H4+W_ +Z6@#8H
MKS[X9?M)?#KXS_VO_P *IU6V\0?V!JCZ=K']EWL<OV2Y3[T;8/Y'H<'!.#74
M_P#"2ZO_ -"A>_\ ?2UI5HU:%1TZL7&2Z-6?W,SI5:5>"G3DI1?5.Z^]&Q16
M/_PDNK_]"A>_]]+1_P )+J__ $*%[_WTM9FAL45Y)\8_VU_V?OV?HW/QF^(>
MC>'ID7=]AOM7A^U,/5;=297_ . J:^5/C!_P<1?LO>#UEL_A'\-/$?C*Z3/E
MSRLNFV;^GSR*TH_&&OH,JX4XCSNSP6%G-/K:T?\ P)VC^)X69\3\/Y-=8S$P
M@UTO>7_@*O+\#]!JK:QK6C^'=-FUKQ!JUM8V=NF^XN[R=8HHE]69B H]R:_)
M[Q+_ ,%(?^"PG[3FB7&O? [X)6_P_P#"PC+MXD?24@MXXCU9]1U1A;\#^) A
M';G%?'OQT\91>)-5:_\ VI?VV-4^(.KQ,632O"MW-K4<3?W#=W#Q6L2]?FM_
M/ _NFO8QO"N2\.4_:<29M0PO]Q2]K5].2'Z-GS%3CRKBU_PDX"K6724K4H/T
ME+?TLC]DOC9_P5__ & ?@AYUIJ'QRM?$=_%G&G>#86U)G(Z@31_N ?9I17R%
M\;?^#D'5Y8Y[3]G;]G:"W1?]7K'C34#)C/ W6UL5"G_MN?\ 'XD^#'[*_P"T
MK^U)/&/V4/V2-6DTII/D\2Z\WVF,#HRO=3I#9OCKA(?,&."37V#^S]_P;O\
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M:F=^R#^R#\(OV+?A%:_"CX4:7Z2ZSK-P@^U:K=8PTTK#\E0?*B\#N3ZG6/\
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M?4?$-OJ%_KFKE0L#XM\K#%"5#9;EN<9W93Z^HH **** "BBB@ HHHH ****
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MOSMO]W?\N?6M&JE"<+<RM?7Y=PLT%%%%2 4444 %%%% !1110 4444 %%%%
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MK32N?^V,,&?_ !^JG_#:?_!73XLG;\._V83HD$G^IN5\'W$8(]?,O9/+;Z@
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MGSF.P_U;$.*VW7H%%%%?&'(%%%% !1110 4444 %%%% !1110 4444 %%%%
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M)_VS]6LP_4:!##8X^GV6&$BO:P^9<1O3)N#91[.O"_XUITVGZHUCP/Q'CO\
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M\]IW!FE/'5V)KT#_ (;Y_8R_Z.2\*?\ @R%>62?\$8_V+Y)"ZVGBA >BKKW
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M_F'L\N_GE]Q]$?\ #7O[)O\ T=!\._\ PM;#_P".T?\ #7O[)O\ T=!\._\
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MI+_R;4+Y;+I)?<=QH?[<?['OB':-/_:5\&H6Z"\UV&V/Y2LM=AHGQD^$'B8
M^&_BKX;U#<,K]AURWES_ -\N:^9]<_X(H_L>ZKN.G:MXSTPD?+]CUJ%@/^_L
M#UQ^M_\ !";X17&[_A&_CKXDM/[OV[3[>XQ]=OEYH_LOPVK_ ,/,*U/_ !TN
M;_TEA[/+Y;5&O5?Y'W7')'*@DB<,K#*LIR#2U^>#_P#!$#XB^&)#/\//VM3"
MV<KNT*:T(/;YHKEOSQ3?^';G_!33P=\W@+]L_=&GW81XTU:WW>VSRV0_B:/]
M4^$JW^[YW3?^.E4A^=P^JX5_#67S31^B-%?G<?@G_P %N_!7&@_%HZOLX7_B
M?V4^[_P,0?K1_P +2_X+E>"C_P 3[X='5]IY_P")/I=QNQ_UYL/TH_XA_&K_
M +OFF$GY>UY7]SB'U&_PU8OYGZ(T5^=W_#PS_@J;X-^7QK^QM]HA3EYSX&U6
M//\ VT24I^E'_#Z[XR^$CM^(_P"R((BO#_\ $TN++G_MK;OBC_B%_%53_=U3
MJ_X*L'^;0?V;BG\-GZ-'Z(T5\&:)_P %W?AG<8_X2/\ 9_UVTY^;[#K$-QC_
M +Z2/-=AH?\ P6W_ &1]3VIJGACQMIS'[S7&DV[J/QCN&)_*N*OX<<;X?XL#
M-^G++_TELB67XR.\&?8=%?-FB?\ !6W]A/5\"Z^+%WIS,.%OO#E[U],QQ.!^
M==AHG_!07]BSQ!C[!^T?X:CW' ^W79MO_1RKBO'K\*\38;^+@JJ]:<[??:QD
M\-B8[P?W,]CHKC=#_:,_9\\3;?\ A'/CMX-O]WW19>)[24G_ +YD-=7I^J:9
MJT NM*U&"YB/22WF5U_,&O(K87$X=VJP<?5-?F9.,H[HGHHHK D**** "BBB
M@ HHKSO]G_\ :;^&?[2/_"3_ /"NM0\[_A%O$4VE7F6!\W9]RX3'6*3#;3WV
M-Z5T4\)B:V'J5X0;A"W,^BYG97]7HBE&3BVEHCT2BBBN<D***1F5%+NP  R2
M3TH 6BN+\7_M'_L^^ -X\;?&_P )Z6Z?>AO?$-O')GT"%]Q/L!7EOB__ (*H
M?L->$-\3?&A=2F7_ )8Z1I%U/N^CB,1_^/5Z^#X?SW,/]VPM2?\ AA)K[TC6
M%"M4^&+?R/H:BOBCQ?\ \%R/V<]+W1>#/ACXNU:1>CW4=O:1-]#YKM^:BN%F
M_P""S/[0?Q$E:W^!G[(HN7)VQ[Y;O4R3[K;Q1?EG\:^EP_AGQI7ASRPO)'O.
M4(V^^5_P.B.78QJ_+;U:1^B-%?G;_P +W_X+9?%PX\(_!UO#*R]/^*<MK+:/
M^XF[$?SI/^&-?^"O?Q9&?B%^TR=#AD_U]NWC">+CT\NQC*-]"<5T?Z@4L-KC
MLTPU/R53GDO^W8K]2OJ*C\=2*^=S]"=7UO1= LVU#7=7M;*W7[T]W<+&@^K,
M0*\X\7?ML_LC^!MR^(_VB_"*.GWX;368KF1?JD)=@?PKY'TG_@AWXF\27@U;
MXN_M33WEP?\ 6+::,\[MZ_OII\_^.5Z/X0_X(F_LEZ%LE\2:_P"+M<D'WTN=
M4B@B/T$,2L/^^S1_8OAW@_X^9U*S[4J+C]SF[/U#V. A\51OT7^9O^+_ /@L
M-^Q'X9WC2?%VMZ\R?PZ1X?F7)]C<^4#^>*\N\6_\%V_AS;,T?@#]G_7-1)XC
M.K:M#9Y/;(C6;\LU]">$?^";G[$/@K8=+_9[T>Y9?XM7EGOMQ]2+B1Q^&,5Z
MCX3^%/PN\ J%\"_#;0-%"C"C2='@ML#_ +9J*/[2\-,'_!P->O\ ]?*JA_Z;
M0>TRZ&T'+U=OR/@O_AY[_P %"?BEA/@K^Q\!#+]RX7PYJ-_L'8^8ICC'U(Q0
M9?\ @N5\70=L;^&K.7VTNQV9^N9Q7Z)T4?Z\Y9A?]QR?#P\YJ55KYR:#Z[3C
M\%**]=3\[/\ AV7_ ,%$_BD?,^,_[8 2"3[UNWB74;XH.X\LJD8^@;%;OA/_
M ((2> (&6;X@_M!ZUJ+,<RC2='BM"3WPTCS?GC\*^]J*SJ>)W%_)R8>K&C'M
M3IPBO_26_P 1/,<7:T7;T2/EKPC_ ,$=OV)?#6TZOX7UW7RO?5_$$JY^HMO)
M%>I>$/V(/V0_ VUO#W[.?A(.GW)KW1X[J1?</.'8'WS7J=%?/8OBKB7'_P"\
M8RK)=G.5ONO;\#">)Q$_BF_O*FCZ#H?AVS&G^']&M+&W7I!9VRQ(/^ J *MT
M45X,I2G*\G=F 4444@"BBB@#P#6/^"7/["_B#5KK7M:^"4EU>7MR]Q=W,WBO
M52\LKL69V/VKDDDDGWJM_P .HOV!/^B"_P#ETZK_ /)5?1%%?0+BWBJ*26/K
M)+_I[4_^2-_K6*7VW][/ -'_ ."7/["_A_5K77M%^"4EK>65REQ:7,/BO50\
M4J,&5U/VK@@@$'VKW^BBO/Q^;9KFKB\;7G5<=N>4I6OO;F;M<B=6K5^.3?J[
MA1117GF84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117@_[7?[
M6/CSX.>/_ G[/GP)^'-AXF^(?Q&FO!HD&M:BUKI]C;VL7FSW-PZ@NP"YPB8+
M;6YR K 'O%%?,?[!7PV_;3^ -]J7PD_:$\&>#]1T+4KW4]?7QKX5\1SS%+^Z
MNQ,UI);W,<<A!$LFUU&U1%ALE@:YO_@H7_P42^.'[,WAOQ-J'P'_ &=)M4M?
M!L]G'XE\9^+H)(-(CDN6A6.WM45XY;V0^<FYD8)'W+'B@#[ HKE/B]\8/"GP
M/^#FN_&OQY*\>E>'M&DU"^$(!=PB;A&@) +LV$4$C+,.17REK'[7'_!37PY\
M"Q^VCK'P.^&'_"OUTY-:N? L5]?_ /"0P:,P$GG-<'_1_-6(^8PV<+G*A@5H
M ^V**^<?C]^W?/H'P]^%Y_9I\'V_BKQC\:O+;P!IFJSF"VCMS D\UW=E,LL<
M,<B%T4[LD\_*:P?"_P"U7^UQ\#/VC?!?P(_;>\*> 9]-^)#SVOA3Q=\/&O(X
M+?4(U#?9+F*[+-E]RJC+C)9>OS[ #ZLHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** /)_VH/VXOV7/V,_[#_X:3^)_P#PC?\ PDGVG^Q?^)+>WGVC
M[/Y7G?\ 'K#+LV^?%][&=W&<''E5M_P6[_X)@WEPEK:_M-%Y)'"QHO@G6\L3
MP!_QY5\F_P#!SVCR/\#HXU))/B7 '_<*K\Y_@CX*2;5FUZ\C#+:#Y"1QYAZ
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M)ECL9+>;_+\CQ?P[_P $[?V)O"Y4Z9^SGX?EV]/[122\_/SW?/XUWGAWX"_
MSPAM/A/X,>$],*?=.G^';:''_?""NLHKP<1G.<8S^/B:D_\ %.3_ #9A*M5G
M\4F_F-CBCAC$4,:HJC"JHP *=117FF84444 <[\6_"/B;Q]\,]<\$>#O&?\
MPCNI:MITEI;:V+(W#6?F#:TBQB2/+!2VT[AAL'G&#\(_\.$O^KK?_+%_^[J_
M1"BOILBXPXBX9I3I9;6]FIN[]R$FVM%K*+>G:]M^[.BAB\1ATU3=K^2/SO\
M^'"7_5UO_EB__=U>S?L2?\$V_$W[&'Q,N_&^E_M%?VYINIZ<UIJNB-X5-LL^
M#NBD$GVM]K(V<':?E9QQNR/JJBO0S'Q&XRS7!3PF+Q//3FK27LZ6J]5!->33
M33U1I4S#%U8.$Y73\E_D%%%%?$G&%%%% !1110 4444 %%%% !1110 4444
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M/CYB!G@9S4WV+QO_ -!NR_\  8_XUL44 8_V+QO_ -!NR_\  8_XT?8O&_\
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MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
MQ_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H
M-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%>4?MB?M:>!?V/_@WJ7Q0\3/8W]_;>0-,\-RZS%:7&I-)
M<10D1[PQ(7S-[$*V%0DX S0!ZO16=9^+O">H>&O^$SL/$^G3Z/\ 9FN/[6AO
M8VMO)4$M)YH.S8 "2V<#!KB8OVQ/V1IY5AA_:F^'#N[!41?'%@2Q/0 >=R:
M/1Z*I^(/$7A_PEHMSXD\5:[9Z9IUG$9+R_U"Z2&"!!U9W<A5'N2!7/\ PR^/
M/P/^-0N3\'OC#X7\5?8B!>#P[KUO>F#)P-XB=MN>Q/7M0!UE%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM4_!7X<_LPZM-XG\.?#SQG'XS\<^*+:PFCL=/-J UI;>9(B[Y97W#8,X!!Y
M?: ?<]%%% ',_$SXR_"[X-V-KJ?Q0\:V6B6][,8K66]<@2.!DJ, \XYKCO\
MAN?]D?\ Z+UH/_?Y_P#XFO2M9\.>'O$<20>(=!LK](VW1I>VJ2A#Z@,#@UG_
M /"KOAG_ -$[T+_P40__ !- $]IX[\(7UK'>VFOV[Q31J\3ACAE(R#^52?\
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)C
MX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]
M4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U
M!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
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M_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\
MH-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX
M8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)C
MX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]
M4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U
M!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_
M *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX
M8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\
MPF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
M *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?
M^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^
M?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_
ML[3_ /GQA_[]"@"G_P )CX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[
M]"C^SM/_ .?&'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8
M?^_0H_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\
M8?\ OT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^S
MM/\ ^?&'_OT*/[.T_P#Y\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?5
M7/[.T_\ Y\8?^_0H_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_
MWU5S^SM/_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!
M_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/
MAC_H-0?]]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\
M)CX8_P"@U!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_W
MU1_PF/AC_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_
MWU1_PF/AC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z
M#4'_ 'U1_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )
MCX8_Z#4'_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?
M_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@
M"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_
M0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y
M\8?^_0H I_\ "8^&/^@U!_WU1_PF/AC_ *#4'_?57/[.T_\ Y\8?^_0H_L[3
M_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/_P"?&'_OT*/[
M.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L[3_^?&'_ +]"
MC^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]]5<_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@U!_WU5S^SM/_
M .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC_H-0?]]5<_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/AC_H-0?\ ?57/
M[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U3[;Q1X?O)UM;7
M58GD<X1%/)-6?[.T_P#Y\8?^_0I4L;*-@\=G$K#H5C (H EHHHH **** "BB
MB@ HHHH *X?QU\!?"WQ ^-7@/XXZQJNH1ZE\/5U4:/9P.@MYFO[=+>1Y04+$
MJBG;M9<;VSGBNXHH *@MM,TVRN);JST^"*6<YGDBB56D/JQ R?QJ>B@!&574
MHZ@@C!!'6HK'3M/TNW%IIEC#;1 DB*"((N3U.!Q4U% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% '-?&;XJ>'/@=\)O$?QB\7I,^F>&=%N-2O([909)$BC+E$
M!(!9L;1D@9(R17QQH6H_\%+OC?X[\%_M_>$_@?\ #IM(B\(7">&_AY/XTN8]
M1NK"_,,XE>8PBV6=HXX]I9E"AOF4'I]J?$+P'X6^*7@36?AMXXTQ;W1]>TR>
MPU.T9BOFP2H4=<CE3AC@CD'D<BOB[Q?\.OVY?^"7_P *KOQG\%/B]IWQ2^$W
M@^U,]QX)\:VGD:KI>FH<LMM>1?ZP1IR-X"JHPL1Q@@'NW[8W[5WC#X$#P5\,
M?A#X!M?$/Q*^).JO8>$]%U*[,=I (D$ES=7+I\QAA5E+!<$YX/!KAO"_[5?[
M7'P,_:-\%_ C]M[PIX!GTWXD//:^%/%WP\:\C@M]0C4-]DN8KLLV7W*J,N,E
MEZ_/LXSQ?\3=$^+?_!2O]E3XP:9%+%HWBWX9ZUJ&@I=@!TDGT]YBA[!Q&ZJ<
M5T7_  5-7[7\1?V9=,T[G4G_ &@]&FMU7[PAC;,S?[H!0GVH ^O:*** "BN,
M^,VB?'+6],LHO@=XWT70[M)V-]+K6F-<K+'MX50"-ISSFO/O^$!_X*"?]%_\
M"?\ A*2?_%4 >Z45@V.G_$*.QACU#Q!827"Q*)Y$M"%9\?,0,\#.:F^Q>-_^
M@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#
M=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_
MQH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&
MC[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_
ML7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%XW_Z#
M=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V
M7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&
M@#8HK'^Q>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/
ML7C?_H-V7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q
M>-_^@W9?^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V
M7_@,?\: -BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?
M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXT_;,\8V,D.L_&GQC<:Q;I./WEOH\#-;Z?;GV1%<J>ZR+6=_P6%_Y)=\(/\
MLX/PW_Z#=4 >X?M>?M':-^R3^SCXH_:$UW0Y=3A\/6D;1:=#+Y9N9Y9HX(8R
M^#L4RRH&;!VKDX.,5\[_ !9_:Y_X*&?LK_#'3/VG/VB/ 7PGU'P)+=V2^(=!
M\)S:@FKZ5!<NJ(R2S.T-PZEU# * 6QM.W+CV;_@H7X_^"/P^_9*\57/[0/A&
MY\1>']5@CTP>';(XN-3NIG"P0Q-_ _F!7#]4\O<,E0#\3^._@5^V+^S/\*?
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MP,L$+R&-MB,#R.25PS>H?L$>&-,\;_\ !-OX<^"]:#_8]7^&T%E=^6V&\J6
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M4>YBBC-TZ2&)"RNS&$)NC. 6)!KZHKY&\ _\IL?'?_9";+_TO@KZYH ****
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M@O\ "KPW\#/A)X;^#OA#S#IOAG1K?3K227[\BQ(%\QL?Q,06/NQH Z>BBB@
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M@ZAHEQIVNZ7/X!@U9KT3!D9Q+)/$T7[MBN%^N<UY]\#O@K\<?^"=WP&U:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6C:_9JVUKO1=3BNH@?0M$S#/XU\A_'#X9?#?XL_\%G/"7A3XJ?#[0_$VE_\
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M[KK4=4O$MX(5SC+R2$*HSZFN;^&_[1O[/OQCOY=*^$GQS\(>)[N!"\UKX?\
M$EK>2QJ#C<4B=B![XQ7RQXW\&:)^W'_P5*\0?!?XRP'5?A_\%/"MA>0^$IW/
MV/4=8O8XYEN+A,XE"Q2%0K9'R 8PSAK?_!2S]C+X)^!?V:=7_:0_9\^'.B^
M?'OPV2/7/#WB#PAI<.GR 0R*98I! JK*AC+X# X('8LK 'V?5#Q-XI\,^"]$
MN/$WC'Q'8:3IMJNZZU#4[Q(((5SC+R.0JC/J:Q/@3\0Y/B[\$/!OQ8FMEA?Q
M/X5T[5GA3I&;FVCF*CV&_%?)?CGP=H_[=O\ P5(\0?!+XQ1-J?P[^"7ABQNT
M\*22'[)J>LWL<<JSW" _O0D4A7:>,Q@='<, ?6OPY^.7P3^,1G'PC^,/A;Q3
M]E&;G_A'/$%M?>2/]KR7;;^-=37E6A?L0_LI^#_BKH7QJ^'WP/T'PQXB\/"=
M+&\\+V*:<DL<T#P/'-%;A8YEVOD;U)4JI!&*\GT[]M+]JS]HGQ+XFN/V)?V?
MO#&L>#_"FM3:3)XJ\:^)9+0:W=PX\Y+.**-B$!( E<[6R.A!  /JVBOFSP!_
MP4%7X@_LA_$KX\CX8RZ)XP^%=MJT'BSP1J=Z'^R:E90-(8?.11OB;  <*.C#
M'RY/FVN_\%*/VMM-^ VF_MD0_L;V,/PK2SLKC6&OO$A369X)?+22]MH FU;<
M2.?+WDM(@60A%;*@'VY17QI\2O\ @H[^TC\.O ME^U?J?[)D-M\$9[ZU22_O
M]=V>(!87$JQQ:D;0*4CC8NA6(L7.],E0V1Z1^V-^VUK_ .S!X_\ A?X/\(?"
M"Z\;M\1[C4[:ULM*N0ETT\-O$]LL>[Y LDLR!Y&($<89^=N* /H.BOEKPO\
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MS7^SI'^QS\5_BS'\ O!2^*CH,MV?$R^%;,:A]H+IF;[1Y?F;_P#:W9]Z[O\
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MO&"12W(:]_>LK"),-]UMI(R22?9+W3=.U((-1T^"X$;[XQ-$'V-ZC(X/O4]
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MJZE'4%2,$$<$5E:QX#\$>(/"]YX)UWP?IEYHVHQ-%?Z5<V$;V]PC?>5XR-K
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MW?O ,!LBOO6;3M/N;J*^N+"&2:'/DS/$"T>>NTGD?A4U 'Q;\,?VUM*\;?\
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M.T6S&0R6^)'7&5PX(RN*_2:33M/EO4U*6QA:XC4K'.T0+J#U ;J!4U 'YO\
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' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356726048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jan. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33757<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ENSIGN GROUP, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0861263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">29222 Rancho Viejo Road, Suite 127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Juan Capistrano<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92675<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">949<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">487-9500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ENSG<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Restatement Recovery Analysis [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,156,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,665,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:10pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356626976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">DELOITTE & TOUCHE LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Costa Mesa, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357649920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 509,626<span></span>
</td>
<td class="nump">$ 316,270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable&#8212;less allowance for doubtful accounts of $9,348 and $7,802 at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="nump">485,039<span></span>
</td>
<td class="nump">408,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments&#8212;current</a></td>
<td class="nump">17,229<span></span>
</td>
<td class="nump">15,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">35,036<span></span>
</td>
<td class="nump">40,982<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,046,930<span></span>
</td>
<td class="nump">781,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,090,771<span></span>
</td>
<td class="nump">992,010<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">1,756,430<span></span>
</td>
<td class="nump">1,450,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceSubsidiaryDepositsAndInvestments', window );">Insurance subsidiary deposits and investments</a></td>
<td class="nump">92,687<span></span>
</td>
<td class="nump">67,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">67,124<span></span>
</td>
<td class="nump">39,643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_RestrictedAndOtherAssetsNoncurrent', window );">Restricted and other assets</a></td>
<td class="nump">40,205<span></span>
</td>
<td class="nump">37,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">6,525<span></span>
</td>
<td class="nump">6,437<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">76,869<span></span>
</td>
<td class="nump">76,869<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">4,177,541<span></span>
</td>
<td class="nump">3,452,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">92,811<span></span>
</td>
<td class="nump">77,087<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued wages and related liabilities</a></td>
<td class="nump">332,568<span></span>
</td>
<td class="nump">289,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities&#8212;current</a></td>
<td class="nump">82,526<span></span>
</td>
<td class="nump">65,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveCurrent', window );">Accrued self-insurance liabilities&#8212;current</a></td>
<td class="nump">54,664<span></span>
</td>
<td class="nump">48,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">168,228<span></span>
</td>
<td class="nump">97,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current maturities of long-term debt</a></td>
<td class="nump">3,950<span></span>
</td>
<td class="nump">3,883<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">734,747<span></span>
</td>
<td class="nump">582,072<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount', window );">Long-term debt&#8212;less current maturities</a></td>
<td class="nump">145,497<span></span>
</td>
<td class="nump">149,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term lease liabilities&#8212;less current portion</a></td>
<td class="nump">1,639,326<span></span>
</td>
<td class="nump">1,355,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserveNoncurrent', window );">Accrued self-insurance liabilities&#8212;less current portion</a></td>
<td class="nump">111,246<span></span>
</td>
<td class="nump">83,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_DeferredRentAndOtherLongTermLiabilities', window );">Other long-term liabilities</a></td>
<td class="nump">49,408<span></span>
</td>
<td class="nump">33,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">2,680,224<span></span>
</td>
<td class="nump">2,203,222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Notes 15 and 20)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Ensign Group, Inc. stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December&#160;31, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively</a></td>
<td class="nump">60<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">465,707<span></span>
</td>
<td class="nump">415,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">1,142,653<span></span>
</td>
<td class="nump">946,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Common stock in treasury, at cost, 3,390 and 3,368 shares at December&#160;31, 2023 and 2022, respectively</a></td>
<td class="num">(116,555)<span></span>
</td>
<td class="num">(114,626)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Ensign Group, Inc. stockholders' equity</a></td>
<td class="nump">1,491,865<span></span>
</td>
<td class="nump">1,247,332<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Non-controlling interest</a></td>
<td class="nump">5,452<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">1,497,317<span></span>
</td>
<td class="nump">1,248,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND EQUITY</a></td>
<td class="nump">$ 4,177,541<span></span>
</td>
<td class="nump">$ 3,452,022<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_DeferredRentAndOtherLongTermLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental expense in excess of actual rental payments and other long-term liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_DeferredRentAndOtherLongTermLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceSubsidiaryDepositsAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceSubsidiaryDepositsAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, net of Current Maturities and Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_RestrictedAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted And Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_RestrictedAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356850448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowance for doubtful accounts</a></td>
<td class="nump">$ 9,348<span></span>
</td>
<td class="nump">$ 7,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common shares authorized</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common shares issued</a></td>
<td class="nump">59,987<span></span>
</td>
<td class="nump">59,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common shares outstanding</a></td>
<td class="nump">56,597<span></span>
</td>
<td class="nump">55,661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Common shares in treasury, at cost</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">3,368<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356958656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF INCOME - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,729,355<span></span>
</td>
<td class="nump">$ 3,025,468<span></span>
</td>
<td class="nump">$ 2,627,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of services</a></td>
<td class="nump">2,941,238<span></span>
</td>
<td class="nump">2,354,434<span></span>
</td>
<td class="nump">2,019,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_RentCostOfServices', window );">Rent&#8212;cost of services</a></td>
<td class="nump">197,358<span></span>
</td>
<td class="nump">153,049<span></span>
</td>
<td class="nump">139,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">263,005<span></span>
</td>
<td class="nump">158,805<span></span>
</td>
<td class="nump">151,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">72,387<span></span>
</td>
<td class="nump">62,355<span></span>
</td>
<td class="nump">55,985<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">TOTAL EXPENSES</a></td>
<td class="nump">3,473,988<span></span>
</td>
<td class="nump">2,728,643<span></span>
</td>
<td class="nump">2,366,996<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">255,367<span></span>
</td>
<td class="nump">296,825<span></span>
</td>
<td class="nump">260,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(8,087)<span></span>
</td>
<td class="num">(8,931)<span></span>
</td>
<td class="num">(6,849)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">25,482<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
<td class="nump">4,388<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">17,395<span></span>
</td>
<td class="num">(7,736)<span></span>
</td>
<td class="num">(2,461)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">272,762<span></span>
</td>
<td class="nump">289,089<span></span>
</td>
<td class="nump">258,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">62,912<span></span>
</td>
<td class="nump">64,437<span></span>
</td>
<td class="nump">60,279<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">NET INCOME</a></td>
<td class="nump">209,850<span></span>
</td>
<td class="nump">224,652<span></span>
</td>
<td class="nump">197,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">451<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to The Ensign Group, Inc.</a></td>
<td class="nump">$ 209,399<span></span>
</td>
<td class="nump">$ 224,681<span></span>
</td>
<td class="nump">$ 194,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">55,708<span></span>
</td>
<td class="nump">54,887<span></span>
</td>
<td class="nump">54,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">57,323<span></span>
</td>
<td class="nump">56,871<span></span>
</td>
<td class="nump">56,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,708,071<span></span>
</td>
<td class="nump">$ 3,008,711<span></span>
</td>
<td class="nump">$ 2,611,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ensg_RentalMember', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 21,284<span></span>
</td>
<td class="nump">$ 16,757<span></span>
</td>
<td class="nump">$ 15,985<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_RentCostOfServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rent cost of services</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_RentCostOfServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_RentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_RentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358265216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Non-Controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at beginning of period at Dec. 31, 2020</a></td>
<td class="nump">$ 818,227<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">$ 338,177<span></span>
</td>
<td class="nump">$ 551,055<span></span>
</td>
<td class="num">$ (71,213)<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at beginning of period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards</a></td>
<td class="nump">9,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations</a></td>
<td class="num">(1,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,711)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(11,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,715)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock award compensation</a></td>
<td class="nump">$ 18,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock (Note 21)</a></td>
<td class="num">$ (10,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (10,118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation', window );">Deconsolidation of an ancillary business</a></td>
<td class="num">(1,369)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,369)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">3,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest attributable to subsidiary equity plan</a></td>
<td class="num">(2,908)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to the Ensign Group, Inc.</a></td>
<td class="nump">194,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2021</a></td>
<td class="nump">1,021,714<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
<td class="nump">369,760<span></span>
</td>
<td class="nump">733,992<span></span>
</td>
<td class="num">$ (83,042)<span></span>
</td>
<td class="nump">946<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at end of period (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards</a></td>
<td class="nump">12,677<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">12,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="nump">5,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations</a></td>
<td class="num">(1,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,702)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(12,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,334)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock award compensation</a></td>
<td class="nump">$ 22,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock (Note 21)</a></td>
<td class="num">$ (29,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (29,882)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition of noncontrolling interest shares</a></td>
<td class="num">(704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,539)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest attributable to subsidiary equity plan</a></td>
<td class="num">(275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(284)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to the Ensign Group, Inc.</a></td>
<td class="nump">$ 224,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">55,661<span></span>
</td>
<td class="nump">55,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2022</a></td>
<td class="nump">$ 1,248,800<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">415,560<span></span>
</td>
<td class="nump">946,339<span></span>
</td>
<td class="num">$ (114,626)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at end of period (in shares) at Dec. 31, 2022</a></td>
<td class="nump">3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards</a></td>
<td class="nump">$ 18,369<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">18,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of restricted stock, net of forfeitures</a></td>
<td class="nump">5,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Shares of common stock used to satisfy tax withholding obligations</a></td>
<td class="num">(1,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,929)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends declared</a></td>
<td class="num">(13,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,085)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee stock award compensation</a></td>
<td class="nump">30,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromRedemptions', window );">Acquisition of noncontrolling interest shares</a></td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(256)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interest attributable to subsidiary equity plan</a></td>
<td class="num">(254)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,787)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,533<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to the Ensign Group, Inc.</a></td>
<td class="nump">$ 209,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">56,597<span></span>
</td>
<td class="nump">56,597<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at end of period at Dec. 31, 2023</a></td>
<td class="nump">$ 1,497,317<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 465,707<span></span>
</td>
<td class="nump">$ 1,142,653<span></span>
</td>
<td class="num">$ (116,555)<span></span>
</td>
<td class="nump">$ 5,452<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Balance at end of period (in shares) at Dec. 31, 2023</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481071/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromRedemptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromRedemptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700360383680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared (in dollars per share)</a></td>
<td class="nump">$ 0.2325<span></span>
</td>
<td class="nump">$ 0.2225<span></span>
</td>
<td class="nump">$ 0.2125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352787344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 209,850<span></span>
</td>
<td class="nump">$ 224,652<span></span>
</td>
<td class="nump">$ 197,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">72,387<span></span>
</td>
<td class="nump">62,355<span></span>
</td>
<td class="nump">55,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of deferred financing fees</a></td>
<td class="nump">1,067<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NonCashLeaseExpense', window );">Non-cash leasing arrangement</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">566<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(27,481)<span></span>
</td>
<td class="num">(6,496)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Provision for doubtful accounts</a></td>
<td class="nump">3,408<span></span>
</td>
<td class="nump">2,390<span></span>
</td>
<td class="nump">2,609<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">30,767<span></span>
</td>
<td class="nump">22,720<span></span>
</td>
<td class="nump">18,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Cash received from insurance proceeds</a></td>
<td class="nump">1,396<span></span>
</td>
<td class="nump">1,282<span></span>
</td>
<td class="nump">2,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain on sale of assets</a></td>
<td class="num">(123)<span></span>
</td>
<td class="num">(3,467)<span></span>
</td>
<td class="num">(1,371)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets', window );">(Gain)/loss on insurance claims, legal matters and asset disposals</a></td>
<td class="num">(1,368)<span></span>
</td>
<td class="nump">3,926<span></span>
</td>
<td class="num">(977)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation</a></td>
<td class="nump">48,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(79,818)<span></span>
</td>
<td class="num">(82,426)<span></span>
</td>
<td class="num">(30,771)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidTaxes', window );">Prepaid income taxes</a></td>
<td class="nump">814<span></span>
</td>
<td class="nump">809<span></span>
</td>
<td class="num">(4,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">6,993<span></span>
</td>
<td class="num">(9,141)<span></span>
</td>
<td class="num">(4,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct', window );">Deferred employer portion of social security taxes (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,155)<span></span>
</td>
<td class="num">(24,154)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue', window );">Cash surrender value of life insurance policy premiums</a></td>
<td class="num">(16,072)<span></span>
</td>
<td class="num">(7,614)<span></span>
</td>
<td class="num">(10,953)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredCompensation', window );">Deferred compensation liability</a></td>
<td class="nump">16,044<span></span>
</td>
<td class="nump">7,637<span></span>
</td>
<td class="nump">11,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease obligations</a></td>
<td class="num">(6,564)<span></span>
</td>
<td class="nump">345<span></span>
</td>
<td class="num">(5,814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">15,924<span></span>
</td>
<td class="nump">17,870<span></span>
</td>
<td class="nump">7,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued wages and related liabilities</a></td>
<td class="nump">47,967<span></span>
</td>
<td class="nump">38,982<span></span>
</td>
<td class="nump">47,701<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other accrued liabilities</a></td>
<td class="nump">23,828<span></span>
</td>
<td class="nump">3,010<span></span>
</td>
<td class="nump">1,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSelfInsuranceReserve', window );">Accrued self-insurance liabilities</a></td>
<td class="nump">28,827<span></span>
</td>
<td class="nump">17,785<span></span>
</td>
<td class="nump">13,724<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability', window );">Other long-term liabilities</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH PROVIDED BY OPERATING ACTIVITIES</a></td>
<td class="nump">376,666<span></span>
</td>
<td class="nump">272,513<span></span>
</td>
<td class="nump">275,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PaymentsToAcquirePropertyAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(106,180)<span></span>
</td>
<td class="num">(87,545)<span></span>
</td>
<td class="num">(69,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for business acquisitions (Note 7)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(16,400)<span></span>
</td>
<td class="num">(6,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PaymentsToAcquireAssetAcquisitions', window );">Cash payments for asset acquisitions (Note 7)</a></td>
<td class="num">(67,798)<span></span>
</td>
<td class="num">(84,736)<span></span>
</td>
<td class="num">(98,224)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions', window );">Escrow deposits</a></td>
<td class="num">(1,216)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities', window );">Cash from insurance proceeds</a></td>
<td class="nump">2,029<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="nump">6,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Cash proceeds from the sale of assets</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">8,630<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashDivestedFromDeconsolidation', window );">Deconsolidation of an ancillary business</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,984)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PaymentsForMedicareAndMedicaidLicenses', window );">Cash payments for Medicare and Medicaid licenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(29,603)<span></span>
</td>
<td class="num">(21,975)<span></span>
</td>
<td class="num">(32,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">18,852<span></span>
</td>
<td class="nump">14,356<span></span>
</td>
<td class="nump">27,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other restricted assets</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="num">(2,120)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">NET CASH USED IN INVESTING ACTIVITIES</a></td>
<td class="num">(182,698)<span></span>
</td>
<td class="num">(186,182)<span></span>
</td>
<td class="num">(173,907)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt (Note 15)</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">411<span></span>
</td>
<td class="nump">45,218<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payments on debt (Note 15)</a></td>
<td class="num">(4,033)<span></span>
</td>
<td class="num">(4,106)<span></span>
</td>
<td class="num">(3,056)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Issuance of common stock upon exercise of options</a></td>
<td class="nump">18,369<span></span>
</td>
<td class="nump">12,677<span></span>
</td>
<td class="nump">9,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Repurchase of shares of common stock to satisfy tax withholding obligations</a></td>
<td class="num">(1,929)<span></span>
</td>
<td class="num">(1,702)<span></span>
</td>
<td class="num">(1,711)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of shares of common stock (Note 21)</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,882)<span></span>
</td>
<td class="num">(10,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Dividends paid</a></td>
<td class="num">(12,890)<span></span>
</td>
<td class="num">(12,168)<span></span>
</td>
<td class="num">(11,548)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans', window );">Proceeds from sale of subsidiary shares (Note 6)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,693<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToMinorityShareholders', window );">Non-controlling interest distribution</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(284)<span></span>
</td>
<td class="num">(2,908)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PurchasesOfNonControllingInterest', window );">Purchase of non-controlling interest</a></td>
<td class="num">(256)<span></span>
</td>
<td class="num">(704)<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of deferred financing costs</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(3,197)<span></span>
</td>
<td class="num">(1,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram', window );">Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11,637<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid', window );">Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(113,660)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH USED IN FINANCING ACTIVITIES</a></td>
<td class="num">(612)<span></span>
</td>
<td class="num">(32,262)<span></span>
</td>
<td class="num">(76,138)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">193,356<span></span>
</td>
<td class="nump">54,069<span></span>
</td>
<td class="nump">25,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents beginning of period</a></td>
<td class="nump">316,270<span></span>
</td>
<td class="nump">262,201<span></span>
</td>
<td class="nump">236,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents end of period</a></td>
<td class="nump">509,626<span></span>
</td>
<td class="nump">316,270<span></span>
</td>
<td class="nump">262,201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">7,025<span></span>
</td>
<td class="nump">7,604<span></span>
</td>
<td class="nump">5,690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">89,730<span></span>
</td>
<td class="nump">70,055<span></span>
</td>
<td class="nump">65,547<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease liabilities</a></td>
<td class="nump">196,942<span></span>
</td>
<td class="nump">151,870<span></span>
</td>
<td class="nump">138,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract', window );"><strong>Non-cash financing and investing activity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Accrued capital expenditures</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Accrued dividends declared</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new and modified operating lease obligations</a></td>
<td class="nump">$ 376,550<span></span>
</td>
<td class="nump">$ 370,753<span></span>
</td>
<td class="nump">$ 198,593<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds, Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Insurance Claims And Disposal Of Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) Due To Deferred Employer Taxes, CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NonCashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NonCashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PaymentsForMedicareAndMedicaidLicenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Medicare and Medicaid Licenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PaymentsForMedicareAndMedicaidLicenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PaymentsToAcquireAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid to acquire acquisitions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PaymentsToAcquireAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PaymentsToAcquirePropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Property And Equipment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PaymentsToAcquirePropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PurchasesOfNonControllingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases of Non-Controlling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PurchasesOfNonControllingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashDivestedFromDeconsolidation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashDivestedFromDeconsolidation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeferredLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeferredLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 325<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481551/325-30-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479319/326-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365991328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December&#160;31, 2023, the Company's independent subsidiaries operated 297 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December&#160;31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately 30,600 operational skilled nursing beds and 3,100 senior living units. As of December&#160;31, 2023, the Company's independent subsidiaries operated 214 facilities under long-term lease arrangements and had options to purchase 11 of those 214 facilities. The Company's real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by the Company's independent subsidiaries, 30 operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company&#8217;s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers&#8217; compensation insurance liabilities.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on Standard Bearer.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated &#8220;Company&#8221; and &#8220;its&#8221; assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356598080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Considerations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments&#8217; recorded values approximate fair values because of their nature or respective short durations. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company&#8217;s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on &#8220;Level&#160;1&#8221; inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:f-498">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December&#160;31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:f-504">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews the carrying value of long-lived assets that are held and used in the Company&#8217;s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management&#8217;s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:f-508">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years&#160;and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $7,410, since inception in 1999. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent subsidiaries are self-insured for workers&#8217; compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers&#8217; compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company&#8217;s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers&#8217; compensation, healthcare benefits and related services provided to date. The amount of the Company&#8217;s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company&#8217;s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company&#8217;s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company&#8217;s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company&#8217;s estimates and assumptions, actual results could differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Income</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Issued But Not Yet Adopted by the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, the FASB issued ASU 2023-06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative", </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352481312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND ACCOUNTS RECEIVABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUE AND ACCOUNTS RECEIVABLE</a></td>
<td class="text">REVENUE AND ACCOUNTS RECEIVABLE<div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue by Payor</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company&#8217;s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid &#8212; skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to state relief funding</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $21,284, $16,757 and $15,985 for the years ended December 31, 2023, 2022, and 2021.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">State relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $486 and $1,001 in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $64,238, $81,057, and $70,484 in state relief funding and recognized $64,753, $81,837, and $75,231, respectively, as revenue.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Federal relief funding</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $11,637 in Provider Relief Funds.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Balance Sheet Impact</span></div><div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in the Company&#8217;s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 and 2022, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,285&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,907&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,512&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,683&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,348)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700361918720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPUTATION OF NET INCOME PER COMMON SHARE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">COMPUTATION OF NET INCOME PER COMMON SHARE</a></td>
<td class="text">COMPUTATION OF NET INCOME PER COMMON SHARE<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.76</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,323</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1,429, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700462552880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $59,530 and $53,924 as of December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December&#160;31, 2023, and 2022, the fair value of the investment funds was $41,216 and $25,144, respectively, which are derived using Level 2 inputs.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364724752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STANDARD BEARER<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_StandardBearerTextBlock', window );">STANDARD BEARER</a></td>
<td class="text">STANDARD BEARER<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer's real estate portfolio consists of 108 of the Company's 113 owned real estate properties, of which 79 are operated and managed by the Company's independent subsidiaries and 30 are leased to and operated by third-party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> stand-alone skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">two</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operations for an aggregate purchase price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$65,899. Of these additions, the three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> skilled nursing facilities and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation acquired are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries and</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ten skilled nursing facilities for an aggregate purchase price of $84,656, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer, certain of the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Segments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany master lease agreements</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company's independent subsidiaries and 79 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $66,712, $57,967, and $44,165 for the years ended December 31, 2023, 2022, and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany management agreement</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $4,948 and $4,367, respectively. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intercompany debt arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information related to these debts. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Instrument Denominated in the Shares of a Subsidiary</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.</span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_StandardBearerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Standard Bearer</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_StandardBearerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATION EXPANSIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">OPERATION EXPANSIONS</a></td>
<td class="text">OPERATION EXPANSIONS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the stand-alone skilled nursing operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> campus operation, which were leased back to the Company's independent subsidiaries.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for additional information on the purchase of real estate properties. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, the Company expanded its operations through a long-term lease, with the addition of two stand-alone skilled nursing operations, totaling 241 operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Expansions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2022, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Standard Bearer acquired the real estate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seven of the stand-alone skilled nursing operations, which were leased back to Ensign's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Refer to Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for additional information on the purchases of real estate properties. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also invested in new ancillary services that are complementary to its existing businesses. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.</span></div><div style="margin-top:10pt;text-align:justify"><span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Acquisitions</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company expanded its operations through a combination of long-term leases and a real estate purchase,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with the addition of 17 stand-alone skilled nursing operations </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant.</span><span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> subsidiaries.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the new operations acquired during the year ended December 31, 2021, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$6,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was concentrated in goodwill and accordingly, the transactions were classified as business combinations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, 2022, and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,488&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,798</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company&#8217;s current operating results or indicative of the integration potential of its newly acquired </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">independent subsidiaries</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The assets added during the&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> balance sheets of the Company, and the operating results have been included in the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consolidated</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> statements of income of the Company since the date the Company gained effective control.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">BUSINESS SEGMENTS</a></td>
<td class="text">BUSINESS SEGMENTS<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2023, the skilled services segment includes 259 skilled nursing operations and 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 108 owned real estate properties. </span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also reports an &#8220;All Other&#8221; category that includes results from its senior living operations, which includes 11 stand-alone senior living operations and the senior living operations at 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the &#8220;All Other&#8221; category are insignificant individually, and therefore do not constitute a reportable segment.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accounting policies of the reportable segments are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as it is part of the CODM financial information. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,855&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,667&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,451)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708,071&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,486&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,137&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,339)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,284&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155,804</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,729,355</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,925&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,251)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,739&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">272,762</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,766&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,387&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,902)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429,473&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,976&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,660,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,841&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,240&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358244240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT&#8212; NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT&#8212; NET</a></td>
<td class="text">PROPERTY AND EQUIPMENT - NET<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,656&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,064&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,383&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,563&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487,013</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,242)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090,771</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge&#160;for the fiscal years ended 2023, 2022, and 2021. See also Note 6, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Standard Bearer </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Note 7, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operation Expansions </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for information on acquisitions during the year ended December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364698816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS &#8212; NET</a></td>
<td class="text">INTANGIBLE ASSETS - NET<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,096</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,873)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2023, 2022, and 2021, amortization expense was $1,790, $1,714 and $1,435, respectively, of which $1,202, $1,160 and $1,158 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December&#160;31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:24.75pt"><span><br/></span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>During the year ended December 31, 2023, the Company acquired $330 in Medicare and Medicaid licenses compared to $245 and $181 in the fiscal years 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillDisclosureTextBlock', window );">GOODWILL</a></td>
<td class="text">GOODWILL <div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December&#160;31, 2023. All of the Company's acquisitions during the year ended December&#160;31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December&#160;31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of December&#160;31, 2023, 2022 and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-20/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED AND OTHER ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsDisclosureTextBlock', window );">RESTRICTED AND OTHER ASSETS</a></td>
<td class="text">RESTRICTED AND OTHER ASSETS<div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,913&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,205</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Included in restricted and other assets as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCRUED LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCRUED LIABILITIES</a></td>
<td class="text">OTHER ACCRUED LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,035&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,834&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,215&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,875&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation (Note 20)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,734&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,405&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364530912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,092&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,301&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,393</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,280)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,201)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,481)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,912</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes&#160;- net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022 and 23.4% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are summarized below. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,502&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,864&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,590&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,073</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,334)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,222)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(499,949)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had state credit carryforwards as of December 31, 2023 and 2022 of $1,192 and $1,742, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364536400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">DEBT</a></td>
<td class="text">DEBT<div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,950)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,497</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility with a Lending Consortium Arranged by Truist </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April&#160;8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company&#8217;s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December&#160;31, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December&#160;31, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Mortgage Loans and Promissory Note</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $150,244, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the HUD mortgage loans above, the Company has a promissory note of $2,144 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,449&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,388</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2023, the Company had approximately $6,255 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $455 from prior year.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364810144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">OPTIONS AND AWARDS</a></td>
<td class="text">OPTIONS AND AWARDS<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company&#8217;s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Omnibus Incentive Plan (2022 Plan)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December&#160;31, 2023, the total number of shares available for issuance under the 2022 Plan was 1,454.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: </span></div><div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The Company utilizes its own experience to calculate estimated volatility for options granted. </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">The risk-free rate is based on the implied yield of U.S.&#160;Treasury notes as of the grant date with a remaining term approximately equal to the expected term.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Estimated forfeiture rate of approximately 5.08% per year is based on the Company's historical forfeiture activity of unvested stock options.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted 1,008, 581 and 621 stock options during the years ended December 31, 2023, 2022, and 2021, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.  </span></div><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.44&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.65&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December&#160;31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,014&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,844&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.79</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.88</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,466&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,991</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,703</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,887</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,819&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,048&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,759&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023, 2022 and 2021, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he aggregate intrinsic value of options that vested </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December&#160;31, 2023, 2022 and 2021 was</span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$31,658, $27,955, and $27,731, respectively. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the years ended December&#160;31, 2023, 2022 and 2021 was $56,186, $47,441, and $34,278, respectively. </span><span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Awards</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 219, 233</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and 222 restricted stock awards during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ranged from</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $89.83 to $98.31,</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $73.17 to $94.88 and $72.84 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the status of the Company's non-vested restricted stock awards as of December&#160;31, 2023 and changes during the years ended December&#160;31, 2023, 2022 and 2021 is presented below:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.04&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.21&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.53&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company granted</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 18</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$89.94 to $98.31</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> based on the market price on the grant date. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Incentive Plan</span></div><div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $827, $836, and $854 for the years ended December&#160;31, 2023, 2022 and 2021, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-based compensation expense</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,845&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,754</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In future periods, the Company expects to recognize approximately</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $67,750 and $29,245 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December&#160;31, 2023. Future stock-based compensation expense will be recognized over 3.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 2,104 unvested and outstanding options as of December&#160;31, 2023, of which 1,940 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December&#160;31, 2023 was&#160;6.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364554032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company&#8217;s operations, 96 of which are under nine &#8220;triple-net&#8221; master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company&#8217;s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust&#8217;s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust&#8217;s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December&#160;31, 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:f-1456">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:f-1458">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eighty of the Company&#8217;s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company&#8217;s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company&#8217;s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of&#160;December&#160;31, 2023 and 2022, the weighted average remaining lease term is&#160;14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is&#160;6.5% and 6.7%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company&#8217;s operations, 96 of which are under nine &#8220;triple-net&#8221; master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company&#8217;s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. </span></div><div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust&#8217;s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust&#8217;s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December&#160;31, 2023. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from <span style="-sec-ix-hidden:f-1456">five</span> to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from <span style="-sec-ix-hidden:f-1458">three</span> to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Eighty of the Company&#8217;s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company&#8217;s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company&#8217;s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of&#160;December&#160;31, 2023 and 2022, the weighted average remaining lease term is&#160;14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is&#160;6.5% and 6.7%. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December&#160;31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lessor Activities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. </span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700361722896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEFINED CONTRIBUTION PLANS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">DEFINED CONTRIBUTION PLANS</a></td>
<td class="text">DEFINED CONTRIBUTION PLANS<div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,836, $2,418, and $2,121 during the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to&#160;100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021. </span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the years ended December&#160;31, 2023 and 2022, the Company accrued $49,201 and $33,017, respectively, as long term deferred compensation in other long term liabilities&#160;on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for more information on the funds.</span></div>For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $4,634 and $1,612, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $4,887 and $1,758, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $4,188, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364521952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELF INSURANCE LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock', window );">SELF INSURANCE LIABILITIES</a></td>
<td class="text">SELF INSURANCE LIABILITIES<div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January&#160;1, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,627&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,799)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,910&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span></div>Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $117,744 and $87,000 as of December&#160;31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//944-40/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364642032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indemnities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company&#8217;s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company&#8217;s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company&#8217;s consolidated balance sheets for any of the periods presented.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and Regulatory Matters</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company&#8217;s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company&#8217;s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company&#8217;s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company, on behalf of its independent subsidiaries, received a </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Civil Investigative Demand (CID)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> from the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Department of Justice (DOJ)</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company&#8217;s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company&#8217;s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48,000, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS). </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action &#8220;staffing&#8221; suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company&#8217;s business, cash flows, financial condition or results of operations.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-Containment Measures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare Revenue Recoupments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December&#160;31, 2023 and through the filing date of this report, 40 of the Company's independent subsidiaries had Reviews scheduled or in process.  </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2023, CMS announced a new nationwide audit, the &#8220;SNF 5-Claim Probe &amp; Educate Review&#8221;, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe &amp; Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s receivables from Medicare and Medicaid payor programs accounted for 53.4% and 56.3% of its total accounts receivable as of December&#160;31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% of the Company's revenue for the years ended December&#160;31, 2023, 2022 and 2021, respectively.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash in Excess of FDIC Limits</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December&#160;31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364506864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK REPURCHASE PROGRAM<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">COMMON STOCK REPURCHASE PROGRAM</a></td>
<td class="text">COMMON STOCK REPURCHASE PROGRAM<div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September&#160;1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.</span></div><div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August&#160;2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. </span></div>In addition, the Company repurchased 404 shares of its common stock for $29,882 during the year ended December 31, 2022, and 132 shares of its common stock for $10,118 during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352483424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 209,399<span></span>
</td>
<td class="nump">$ 224,681<span></span>
</td>
<td class="nump">$ 194,652<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352050336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ensg_ChristopherRChristensenMember', window );">Christopher R. Christensen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Christopher R. Christensen<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Co-founder, Executive Chairman and Chairman of the Board<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">November 2, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">334 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">110,700<span></span>
</td>
<td class="nump">110,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=ensg_BeverlyBWittekindMember', window );">Beverly B. Wittekind [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Beverly B. Wittekind, Vice President &amp; General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Beverly B. Wittekind<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Vice President & General Counsel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 8, 2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">231 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ensg_ChristopherRChristensenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ensg_ChristopherRChristensenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=ensg_BeverlyBWittekindMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=ensg_BeverlyBWittekindMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700359078656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span> The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reclassifications</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span>Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates and Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Estimates and Assumptions</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of the Financial Statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company&#8217;s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value Considerations</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Considerations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments&#8217; recorded values approximate fair values because of their nature or respective short durations. </span></div>Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Service Revenue Recognition, Rental Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Service Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ASC 606).</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company&#8217;s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the Company&#8217;s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Rental Revenue Recognition</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. </span></div>Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company&#8217;s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounts Receivable </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on &#8220;Level&#160;1&#8221; inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Insurance Subsidiary Deposits and Investments</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Insurance Subsidiary Deposits and Investments &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span> Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from <span style="-sec-ix-hidden:f-498">three</span> to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company leases skilled nursing facilities, senior living facilities and commercial office space.</span><span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December&#160;31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional <span style="-sec-ix-hidden:f-504">ten</span> to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div>The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span>The Company reviews the carrying value of long-lived assets that are held and used in the Company&#8217;s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management&#8217;s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of <span style="-sec-ix-hidden:f-508">four</span> to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years&#160;and customer relationships are amortized over a period of up to 20 years.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles&#8212;Goodwill and Other&#160;</span>(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReservePolicyTextBlock', window );">Self-Insurance</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Self-Insurance</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent subsidiaries are self-insured for workers&#8217; compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers&#8217; compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company&#8217;s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers&#8217; compensation, healthcare benefits and related services provided to date. The amount of the Company&#8217;s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company&#8217;s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company&#8217;s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company&#8217;s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company&#8217;s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company&#8217;s estimates and assumptions, actual results could differ.</span></div>Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NoncontrollingInterestPolicyTextBlock', window );">Noncontrolling Interest</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Noncontrolling Interest </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212; </span>The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.</span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Standards Issued But Not Yet Adopted by the Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> &#8212;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In October 2023, the FASB issued ASU 2023-06</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> "Codification Amendments in Response to the SEC&#8217;s Disclosure Update and Simplification Initiative", </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. </span></div><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the FASB issued ASU 2023-07 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. </span></div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09 "</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span>", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NoncontrollingInterestPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NoncontrollingInterestPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 60<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 820<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482053/820-10-60-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReservePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReservePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481569/310-20-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-11B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-6<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 310<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365767312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND ACCOUNTS RECEIVABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.981%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.086%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.582%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% of Revenue</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid &#8212; skilled</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Medicaid and Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SERVICE REVENUE</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Medicaid payor includes revenue for senior living operations and </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">revenue related to state relief funding</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">cillary services.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of Accounts Receivable</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable as of December&#160;31, 2023 and 2022, is summarized in the following table:</span></div><div style="margin-top:9.75pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,285&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,878&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125,907&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,940&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,512&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,526&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other payors</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,683&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85,890&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">494,387</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">416,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: allowance for doubtful accounts</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,348)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,802)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ACCOUNTS RECEIVABLE, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">485,039</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">408,432</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700360769600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average shares outstanding for basic net income per share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Basic net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.76</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.09</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.57</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.818%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NUMERATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209,850&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224,652&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,725&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: net income (loss) attributable to noncontrolling interests</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,073&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net income attributable to The Ensign Group, Inc. </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">209,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">224,681</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">194,652</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">DENOMINATOR:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,708&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,887&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,486&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plus: incremental shares from assumed conversion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,615&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,984&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,439&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adjusted weighted average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">57,323</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,871</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">56,925</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Diluted net income per common share:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.65</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.95</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.42</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)  </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> 1,429, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364621424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATION EXPANSIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Schedule of Purchase Price Allocation</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the allocation of the purchase price for the operations acquired during the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">years ended December 31, 2023, 2022, and 2021:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,794&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,527&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,928&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,488&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65,070&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,975&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment, furniture, and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,840&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,618&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">367&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leased asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,909&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other indefinite-lived intangible assets</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">330&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL ACQUISITIONS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,798</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">101,136</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">104,224</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365991456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Financial Information</a></td>
<td class="text"><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth financial information for the segments:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,578,855&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,667&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,451)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,708,071&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,486&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,137&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72,339)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,284&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">155,804</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(87,790)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,729,355</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">464,925&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,065&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221,251)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">272,739&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">272,762</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,766&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,205&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,416&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,387&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,761&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,228&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,902)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,087&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,906,215&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,214&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,718)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008,711&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,937&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,396&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(63,576)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72,937</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">122,610</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(76,294)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,025,468</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">408,732&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,871&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(150,781)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285,822&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on sale of assets and insurance recoveries from real estate, net</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">289,089</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,224&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,613&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,518&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,355&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,707&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,646)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,931&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Standard Bearer</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intercompany Elimination</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,523,234&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,276&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,034)</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611,476&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental revenue</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,127&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,409&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,551)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,985&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL REVENUE</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">58,127</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,685</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(56,585)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,627,461</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment income (loss)</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373,603&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,876&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(147,915)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257,564&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain on real estate insurance recoveries</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">440&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income before provision for income taxes </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">258,004</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,681&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,558&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,746&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,985&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,849&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. </span></div>(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Schedule of Service Revenue by Major Payor Source</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Service revenue by major payor source were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.378%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429,473&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,976&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,459,449&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">985,749&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245,663&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,660,885</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,976</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,690,861</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">72.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666,129&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">251,841&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,240&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351,081&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,578,855</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">129,216</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,708,071</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.355%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158,309&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,847&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183,156&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832,160&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,878&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,191,347</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">24,847</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,216,194</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.7</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525,710&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,158&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77,649&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">266,807&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,906,215</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102,496</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,008,711</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.379%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Service Revenue</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue %</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,007,061&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,399&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,022,460&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">727,103&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicaid-skilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Subtotal</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,906,934</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,399</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,922,333</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">73.6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Managed care</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456,728&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.5&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Private and other</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,572&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,843&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232,415&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL SERVICE REVENUE</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,523,234</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">88,242</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,611,476</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100.0</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. </span></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%">(3) All Other incorporates intercompany eliminations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364521952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT&#8212; NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment, net consists of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,656&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,864&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and improvements</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803,155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728,231&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172,064&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,903&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equipment</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,383&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">295,739&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,544&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,563&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,521&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,487,013</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,331,802</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396,242)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(339,792)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROPERTY AND EQUIPMENT, NET</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,090,771</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">992,010</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356593248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.682%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:17pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assembled occupancy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">781&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(742)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">435&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(388)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility trade name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">733&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,692)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,482)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,096</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,873)</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,750</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3,285)</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,465</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Estimated Amortization Expense</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated amortization expense for each of the years ending December&#160;31 is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.837%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,223</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Schedule of Indefinite-lived Intangible Assets</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other indefinite-lived intangible assets consist of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade name</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">889&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medicare and Medicaid licenses</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,413&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,083&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,302</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,972&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364565264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text">The following table represents activity in goodwill by skilled service segment and "all other" category as of December&#160;31, 2023, 2022 and 2021:<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skilled Services</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">All Other</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">54,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,000&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,486</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,469</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,400&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,886</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,983</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">76,869</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356854688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRICTED AND OTHER ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Restricted and Other Assets</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted and other assets consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.935%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.591%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt issuance costs, net</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,883&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,753&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term insurance losses recoverable asset</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,913&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital improvement reserves with landlords and lenders</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,870&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,446&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits with landlords</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,661&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,527&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Escrow deposits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,216&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,662&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,053&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED AND OTHER ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">40,205</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">37,291</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364630976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER ACCRUED LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Other Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other accrued liabilities consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quality assurance fee</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,035&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,701&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Refunds payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,248&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,783&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Resident advances</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,834&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,698&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unapplied state relief funds</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash held in trust for patients</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,215&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,400&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends payable</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,201&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,875&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,926&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued litigation (Note 20)</span></div></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,734&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,553&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,405&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,046&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTHER ACCRUED LIABILITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">168,228</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">97,309</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700350047216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: </span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73,092&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,717&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,301&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,216&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,898&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">90,393</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">70,933</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">61,003</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,280)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,158)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(716)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,201)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,338)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(27,481)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,496)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(724)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;TOTAL</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">62,912</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">64,437</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">60,279</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: </span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense at statutory rate</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State income taxes&#160;- net of federal benefit</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-deductible expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL INCOME TAX PROVISION</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22.3</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.4</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are summarized below. </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets (liabilities):</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,502&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,685&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue related reserves</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,714&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,046&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,192&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,742&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,864&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,910&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease liability </span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444,590&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">364,408&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,862</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,819</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(789)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX ASSETS</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">567,073</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">457,030</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(280)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52,334)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,146)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,113)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,150)</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right of use asset </span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(443,222)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(363,091)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL DEFERRED TAX LIABILITIES</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(499,949)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(417,387)</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">NET DEFERRED TAX ASSETS</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">67,124</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357852640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt consists of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.592%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mortgage loans and promissory note</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,388&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156,271&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current maturities</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,950)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: debt issuance costs, net</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,941)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,119)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM DEBT LESS CURRENT MATURITIES</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">145,497</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">149,269</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future principal payments due under the long-term debt arrangements discussed above are as follows:</span></div><div style="text-indent:22.5pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.013%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Years Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,950&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,086&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,227&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,779&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,449&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">152,388</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356726096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions for Stock Options Granted</a></td>
<td class="text">The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:<div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Risk-Free Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expected Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Dividend Yield</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.3%</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.1%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.4%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grant Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Fair Value of Options</span></td></tr><tr><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.85&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.83&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.82&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock', window );">Schedule of Employee Stock Option Roll Forward</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the employee stock option activity during the year ended December 31, 2023:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.777%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.297%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average<br/>Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of<br/>Options Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Weighted Average Exercise Price of Options Vested</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27.71&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,148&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.66&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">621&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80.19&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(105)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.76&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(516)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.80&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,038&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,183&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.02&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.74&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.52&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(688)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.43&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,833&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.72&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.05&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.44&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(759)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.21&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,991&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.65&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,887&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.58&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Stock Options Outstanding, Vested and Related Details</a></td>
<td class="text"><div style="margin-top:10pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary information reflects stock options outstanding, vested and related details as of December&#160;31, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.332%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.892%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stock Options Vested</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number Outstanding</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Black-Scholes Fair Value</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and Exercisable</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year of Grant</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.94</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.05</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">484&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.20</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.39</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,369&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.93</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.86</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.80</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.41</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,138&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.71</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,523&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">336&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41.07</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.76</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">510&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,014&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.84</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.49</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,383&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73.47</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83.64</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,844&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79.79</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94.88</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,466&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$89.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$98.83</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,566&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,991</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">105,703</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,887</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Schedule of Aggregate Intrinsic Value of Options</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.349%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,819&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183,593&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,242&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,048&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,382&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected to vest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,759&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,232&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,548&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Awards</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.157%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.954%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-Vested Restricted Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at January 1, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">591&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.90&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">222&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(244)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2021</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">549</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.57&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(269)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.06&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.29&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2022</span></td><td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">487</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.92&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.04&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(255)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.21&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.53&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nonvested at December 31, 2023</span></td><td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">431</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e4e9df;padding:0 1pt"></td><td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.91&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022 and 2021 was as follows:</span></div><div style="text-align:justify;text-indent:24.75pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.915%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,361&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,459&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to restricted stock awards</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,845&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,920&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,385&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,688&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">30,754</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,720</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,678</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365670656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Operating Lease Expenses</a></td>
<td class="text"><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of operating lease expense are as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.619%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent - cost of services</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197,358&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,049&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,202&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,160&#160;</span></td><td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,158&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease costs</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,454&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,938&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,077&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">219,512</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">171,272</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">154,693</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt">Rent- cost of services includes deferred rent expense adju</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">stments of</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Lease Payments</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.352%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,352&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,269&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191,058&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190,481&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">189,224&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,722,259&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL LEASE PAYMENTS</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,675,643</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: present value adjustment </span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(953,791)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PRESENT VALUE OF TOTAL LEASE LIABILITIES</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,721,852</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current lease liabilities</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82,526)</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LONG-TERM OPERATING LEASE LIABILITIES</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,639,326</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Schedule of Rental Income from Third-Party Sources</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:</span></div><div style="text-align:justify;text-indent:22.5pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennant</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,915&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,073&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other third-party</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,236&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,842&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-1530">TOTAL</span></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,284</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,757</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,985</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock', window );">Schedule of Annual Rental Income</a></td>
<td class="text"><div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,191&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,565&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,269&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,176&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,151&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,586&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TOTAL</span></td><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">236,938</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700364627536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELF INSURANCE LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock', window );">Schedule of Liability for Future Policy Benefits, by Product Segment</a></td>
<td class="text"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.595%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance January&#160;1, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,139&#160;</span></td><td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,793&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98,007)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2022</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131,682&#160;</span></td><td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year provisions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164,627&#160;</span></td><td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims paid and direct expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(135,799)</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in long-term insurance losses recoverable</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,400&#160;</span></td><td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance December&#160;31, 2023</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165,910&#160;</span></td><td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the present values of future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums using assumptions such as estimates of expected investment yields, mortality, morbidity, terminations and expenses, applicable at the time the insurance contracts are made and unpaid claim costs relating to insurance contracts including estimates of costs relating to incurred but not reported claims based on the estimated ultimate cost of settling the claims (including effects of inflation and other societal and economic factors), using past experience adjusted for current trends and any other factors that would modify past experience by element such as business segment, country and interest rate range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352037424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>facility </div>
<div>senior_living_unit </div>
<div>operation </div>
<div>bed </div>
<div>property</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfHealthCareFacilities', window );">Health care facilities</a></td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="nump">30,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSeniorLivingUnits', window );">Operational senior living units | senior_living_unit</a></td>
<td class="nump">3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfRealEstatePropertiesLeased', window );">Number of real estate properties leased</a></td>
<td class="nump">214<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase', window );">Number of real estate properties leased with an option to purchase</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | property</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember', window );">Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfOperations', window );">Number of operations lease and operated by third parties | operation</a></td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities', window );">Number of senior living operations sharing property with skilled nursing facilities</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesAxis=us-gaap_WhollyOwnedPropertiesMember', window );">Owned Properties</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfFacilities', window );">Number of facilities</a></td>
<td class="nump">83<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfHealthCareFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Health Care Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfHealthCareFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfRealEstatePropertiesLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Real Estate Properties Leased</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfRealEstatePropertiesLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Real Estate Properties Leased with an Option to Purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperationalSeniorLivingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operational Assisted Living and Independent Living Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperationalSeniorLivingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperationalSkilledNursingBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of skilled nursing beds available for use at a skilled nursing facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperationalSkilledNursingBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfRealEstateProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of real estate properties owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfRealEstateProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=us-gaap_WhollyOwnedPropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=us-gaap_WhollyOwnedPropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356704000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">59 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352657248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>option </div>
<div>lease</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfFinancingLeases', window );">Number of financing lease | lease</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Lessee, operating lease, number of renewal options | option</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealEstatePropertiesLineItems', window );"><strong>Real Estate Properties [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfFinancingLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financing Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfFinancingLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700359079968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, accumulated impairment loss</a></td>
<td class="nump">$ 7,410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Assembled occupancy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">4 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Assembled occupancy</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">8 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ensg_AssembledOccupancyAcquiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ensg_AssembledOccupancyAcquiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700350769920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Feb. 01, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_WorkersCompensationInsuranceMember', window );">Workers' Compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_WorkersCompensationInsuranceMember', window );">Workers' Compensation | Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember', window );">Self-Insurance Retention Per Claim | General Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember', window );">Self-Insurance Retention Per Claim | Parent Company | General Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember', window );">Self-Insurance Retention Per Claim | Parent Company | General Liability | California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember', window );">Self-Insurance Retention Per Claim | Parent Company | General Liability | Non-california | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember', window );">Aggregate Deductible | Parent Company | General Liability | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember', window );">Aggregate Deductible | Parent Company | General Liability | California | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember', window );">Aggregate Deductible | Parent Company | General Liability | Non-california</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember', window );">Aggregate Deductible | Parent Company | General Liability | Non-california | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerOccurenceMember', window );">Per Occurence | Third-Party Payor | General Liability | All States Except Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerOccurenceMember', window );">Per Occurence | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerOccurenceMember', window );">Per Occurence | Third-Party Payor | General Liability | Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerFacilityMember', window );">Per Facility | Third-Party Payor | General Liability | All States Except Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerFacilityMember', window );">Per Facility | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerFacilityMember', window );">Per Facility | Third-Party Payor | General Liability | Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_BlanketAggregateMember', window );">Blanket Aggregate | Third-Party Payor | General Liability | All States Except Colorado</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_BlanketAggregateMember', window );">Blanket Aggregate | Third-Party Payor | General Liability | All States Except Colorado | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_LossSensitiveLimitPerClaimMember', window );">Loss-Sensitive Limit Per Claim | Workers' Compensation | Other States, Except California, Texas and Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_StopLossInsuranceLimitPerClaimMember', window );">Stop-Loss Insurance Limit Per Claim | Health Liability Insurance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SelfInsuranceReserve', window );">Self insurance reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelfInsuranceReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelfInsuranceReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_WorkersCompensationInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_WorkersCompensationInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_SelfInsuranceRetentionPerClaimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GeneralLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GeneralLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PayorAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PayorAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ensg_NonCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ensg_NonCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_AggregateDeductibleMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerOccurenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_PerOccurenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PayorAxis=naics_ZZ524292">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PayorAxis=naics_ZZ524292</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ensg_AllStatesExceptColoradoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ensg_AllStatesExceptColoradoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_PerFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_PerFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_BlanketAggregateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_BlanketAggregateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_LossSensitiveLimitPerClaimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_LossSensitiveLimitPerClaimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InsuranceCoverageLimitTypeAxis=ensg_StopLossInsuranceLimitPerClaimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InsuranceCoverageLimitTypeAxis=ensg_StopLossInsuranceLimitPerClaimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_HealthLiabilityInsuranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_HealthLiabilityInsuranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357675520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,729,355<span></span>
</td>
<td class="nump">$ 3,025,468<span></span>
</td>
<td class="nump">$ 2,627,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_AccruedLiabilitiesStateReliefContractLiabilities', window );">Unapplied state relief funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">486<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived', window );">FMAP payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,238<span></span>
</td>
<td class="nump">81,057<span></span>
</td>
<td class="nump">70,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized', window );">Revenue, FMAP payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,753<span></span>
</td>
<td class="nump">81,837<span></span>
</td>
<td class="nump">75,231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned', window );">Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) funds received and returned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT', window );">Medicare accelerated and advance payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,255<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct', window );">Repayment of medicare accelerated and advance payment program</a></td>
<td class="nump">$ 102,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct', window );">Total deferred payment of social security taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48,309<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ensg_RentalMember', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,284<span></span>
</td>
<td class="nump">$ 16,757<span></span>
</td>
<td class="nump">$ 15,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Total Medicare and Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_AccruedLiabilitiesStateReliefContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, State Relief Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_AccruedLiabilitiesStateReliefContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Coronavirus Aid, Relief, and Economic Security (&#8220;CARES&#8221;) Funds Received And Returned</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_FamilyFirstCoronavirusResponseActPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Family First Coronavirus Response Act, Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_FamilyFirstCoronavirusResponseActPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liabilities, Deferred Tax Payments Under CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_MedicareAcceleratedAndAdvancePaymentCARESACT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medicare Accelerated And Advance Payment, CARES ACT</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_MedicareAcceleratedAndAdvancePaymentCARESACT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_RentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_RentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351161648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,729,355<span></span>
</td>
<td class="nump">$ 3,025,468<span></span>
</td>
<td class="nump">$ 2,627,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember', window );">Total Medicaid and Medicare | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 3,708,071<span></span>
</td>
<td class="nump">$ 3,008,711<span></span>
</td>
<td class="nump">$ 2,611,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,690,861<span></span>
</td>
<td class="nump">$ 2,216,194<span></span>
</td>
<td class="nump">$ 1,922,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,459,449<span></span>
</td>
<td class="nump">$ 1,183,156<span></span>
</td>
<td class="nump">$ 1,022,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">39.40%<span></span>
</td>
<td class="nump">39.30%<span></span>
</td>
<td class="nump">39.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 985,749<span></span>
</td>
<td class="nump">$ 832,160<span></span>
</td>
<td class="nump">$ 727,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">26.60%<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid &#8212; skilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 245,663<span></span>
</td>
<td class="nump">$ 200,878<span></span>
</td>
<td class="nump">$ 172,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid &#8212; skilled | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 666,129<span></span>
</td>
<td class="nump">$ 525,710<span></span>
</td>
<td class="nump">$ 456,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 351,081<span></span>
</td>
<td class="nump">$ 266,807<span></span>
</td>
<td class="nump">$ 232,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other | Customer Concentration Risk | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">% of Revenue</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidSkilledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidSkilledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351521728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">$ 494,387<span></span>
</td>
<td class="nump">$ 416,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Less: allowance for doubtful accounts</a></td>
<td class="num">(9,348)<span></span>
</td>
<td class="num">(7,802)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">ACCOUNTS RECEIVABLE, NET</a></td>
<td class="nump">485,039<span></span>
</td>
<td class="nump">408,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">178,285<span></span>
</td>
<td class="nump">157,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_ManagedCareMember', window );">Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">125,907<span></span>
</td>
<td class="nump">95,940<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">85,512<span></span>
</td>
<td class="nump">76,526<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember', window );">Private and other payors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableGross', window );">Accounts receivable, gross</a></td>
<td class="nump">$ 104,683<span></span>
</td>
<td class="nump">$ 85,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356974064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMPUTATION OF NET INCOME PER COMMON SHARE (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>NUMERATOR:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Net income</a></td>
<td class="nump">$ 209,850<span></span>
</td>
<td class="nump">$ 224,652<span></span>
</td>
<td class="nump">$ 197,725<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: net income (loss) attributable to noncontrolling interests</a></td>
<td class="nump">451<span></span>
</td>
<td class="num">(29)<span></span>
</td>
<td class="nump">3,073<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to The Ensign Group, Inc.</a></td>
<td class="nump">$ 209,399<span></span>
</td>
<td class="nump">$ 224,681<span></span>
</td>
<td class="nump">$ 194,652<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>DENOMINATOR:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding for basic net income per share (in shares)</a></td>
<td class="nump">55,708<span></span>
</td>
<td class="nump">54,887<span></span>
</td>
<td class="nump">54,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Plus: incremental shares from assumed conversion (in shares)</a></td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">1,984<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Adjusted weighted average common shares outstanding (in shares)</a></td>
<td class="nump">57,323<span></span>
</td>
<td class="nump">56,871<span></span>
</td>
<td class="nump">56,925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net income per common share (in dollars per share)</a></td>
<td class="nump">$ 3.76<span></span>
</td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net income per common share (in dollars per share)</a></td>
<td class="nump">$ 3.65<span></span>
</td>
<td class="nump">$ 3.95<span></span>
</td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">1,429<span></span>
</td>
<td class="nump">780<span></span>
</td>
<td class="nump">198<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356743344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENTS (Details) - Fair Value, Inputs, Level 2 - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred rent receivable</a></td>
<td class="nump">$ 41,216<span></span>
</td>
<td class="nump">$ 25,144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Captive Insurance Subsidiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsAndCash', window );">Insurance subsidiary's deposits and investments</a></td>
<td class="nump">$ 59,530<span></span>
</td>
<td class="nump">$ 53,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsAndCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of investments and unrestricted cash as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsAndCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_SubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700349729712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STANDARD BEARER (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="8">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 08, 2022</div></th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>renewal </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>property </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>property </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>property </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>operation </div>
<div>property </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>property </div>
<div>facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>property </div>
<div>facility </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>property </div>
<div>skilled_nursing_property </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfLeaseArrangements', window );">Number of master lease arrangements | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008,000<span></span>
</td>
<td class="nump">581,000<span></span>
</td>
<td class="nump">621,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted restricted shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
<td class="nump">233,000<span></span>
</td>
<td class="nump">222,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ensg_StandardBearerEquityPlanMember', window );">Standard Bearer Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions', window );">Threshold event period after vesting of restricted awards or exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from issuance of preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ensg_StandardBearerEquityPlanMember', window );">Standard Bearer Equity Plan | Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted restricted shares (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving credit facility with Truist | Truist | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving credit facility with Truist | Truist | Base Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms', window );">Lessee leasing arrangements, operating leases, number of renewal terms | renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases of lessee, contingent rentals, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,712,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,967,000<span></span>
</td>
<td class="nump">$ 44,165,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases | Total Management Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PropertyManagementFeePercentFeeOfTotalRevenues', window );">Management fees, as a percentage of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases | Base Management Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PropertyManagementFeePercentFeeOfTotalRevenues', window );">Management fees, as a percentage of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ManagementFeeExpense', window );">Management fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,948,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,367,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases | Incentive Management Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PropertyManagementFeePercentFeeOfTotalRevenues', window );">Management fees, as a percentage of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations', window );">Management fees, as a percentage of funds from operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases of lessee, contingent rentals, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember', window );">Standard Bearer Master Leases | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">19 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember', window );">Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfOperations', window );">Number of operations lease and operated by third parties | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities', window );">Number of senior living operations sharing property with skilled nursing facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="nump">108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Series of Individually Immaterial Asset Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferred', window );">Asset acquisition, purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 84,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfPropertiesAcquired', window );">Number of real estate skilled nursing properties acquired | skilled_nursing_property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Owned Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfPropertiesAcquired', window );">Number of real estate skilled nursing properties acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Third Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Owned Properties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="nump">79<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfLeaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Lease Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfLeaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfPropertiesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Properties Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfPropertiesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PropertyManagementFeePercentFeeOfFundsFromOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Management Fee, Percent Fee of Funds from Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PropertyManagementFeePercentFeeOfFundsFromOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PropertyManagementFeePercentFeeOfTotalRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property Management Fee, Percent Fee of Total Revenues</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PropertyManagementFeePercentFeeOfTotalRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479908/805-50-55-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480060/805-50-25-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480027/805-50-30-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ManagementFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ManagementFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfRealEstateProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of real estate properties owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfRealEstateProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ensg_StandardBearerEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ensg_StandardBearerEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ensg_TruistBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ensg_TruistBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ensg_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ensg_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_StandardBearerMasterLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_ManagementServiceTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_ManagementServiceTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceBaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceBaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ManagementServiceIncentiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ManagementServiceIncentiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperatingEntityAxis=ensg_ThirdPartyOperatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ensg_SkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ensg_SkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_OwnedPropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_OwnedPropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperatingEntityAxis=ensg_ThirdPartiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperatingEntityAxis=ensg_ThirdPartiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealEstatePropertiesAxis=us-gaap_WhollyOwnedPropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealEstatePropertiesAxis=us-gaap_WhollyOwnedPropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357434800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATION EXPANSIONS- Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2024 </div>
<div>operation </div>
<div>bed</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>bed </div>
<div>senior_living_unit </div>
<div>property</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>operation </div>
<div>senior_living_unit </div>
<div>bed</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>senior_living_unit </div>
<div>property </div>
<div>operation </div>
<div>skilled_nursing_property </div>
<div>bed</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>business </div>
<div>bed </div>
<div>operation</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSeniorLivingUnits', window );">Operational senior living units | senior_living_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfLeaseArrangements', window );">Number of master lease arrangements | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesMember', window );">Real Estate Purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfAssetAcquisitions', window );">Number of asset acquisitions | business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesOfPreviousOperationsMember', window );">Real Estate Purchases Of Previous Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfAssetAcquisitions', window );">Number of asset acquisitions | business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc. | Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfPropertiesAcquired', window );">Number of real estate skilled nursing properties acquired | skilled_nursing_property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember', window );">Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfLeaseArrangements', window );">Number of master lease arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember', window );">Skilled Nursing Operations | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_CampusOperationMember', window );">Campus Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_CampusOperationMember', window );">Campus Operation | Standard Bearer Healthcare REIT, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfPropertiesAcquired', window );">Number of real estate skilled nursing properties acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_OwnedPropertiesMember', window );">Owned Properties | Standard Bearer Healthcare REIT, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfPropertiesAcquired', window );">Number of real estate skilled nursing properties acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_SeniorLivingFacilitiesMember', window );">Senior Living Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSeniorLivingUnits', window );">Operational senior living units | senior_living_unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfLivingOperationsTransferredFromThirdParties', window );">Number of operations transferred from third parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Series of Individually Immaterial Business Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, gross | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfAssetAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Asset Acquisitions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfAssetAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfLeaseArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Lease Arrangements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfLeaseArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfLivingOperationsTransferredFromThirdParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Living Operations Transferred From Third-Parties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfLivingOperationsTransferredFromThirdParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfPropertiesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Properties Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfPropertiesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperationalSeniorLivingUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operational Assisted Living and Independent Living Units</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperationalSeniorLivingUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperationalSkilledNursingBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of skilled nursing beds available for use at a skilled nursing facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperationalSkilledNursingBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesOfPreviousOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ensg_RealEstatePurchasesOfPreviousOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ensg_SkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ensg_SkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_CampusOperationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_CampusOperationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_OwnedPropertiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_OwnedPropertiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_SeniorLivingFacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_SeniorLivingFacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356782832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPERATION EXPANSIONS - Purchase Price Allocation (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_BusinessAndAssetAcquisitionsAxis=ensg_AcquiredOperationsMember', window );">Acquired Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeasedAssetsAcquiredDuringPeriod', window );">Leased asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Other indefinite-lived intangible assets</a></td>
<td class="nump">330<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet', window );">TOTAL ACQUISITIONS</a></td>
<td class="nump">67,798<span></span>
</td>
<td class="nump">101,136<span></span>
</td>
<td class="nump">104,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | Acquired Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, plant and equipment</a></td>
<td class="nump">7,794<span></span>
</td>
<td class="nump">15,527<span></span>
</td>
<td class="nump">19,928<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Acquired Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, plant and equipment</a></td>
<td class="nump">57,488<span></span>
</td>
<td class="nump">65,070<span></span>
</td>
<td class="nump">77,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Equipment, furniture, and fixtures | Acquired Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, plant and equipment</a></td>
<td class="nump">1,840<span></span>
</td>
<td class="nump">1,618<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ensg_AssembledOccupancyAcquiredMember', window );">Assembled occupancy | Acquired Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Property, plant and equipment</a></td>
<td class="nump">$ 346<span></span>
</td>
<td class="nump">$ 367<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeasedAssetsAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Leased Assets, Acquired During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeasedAssetsAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_BusinessAndAssetAcquisitionsAxis=ensg_AcquiredOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_BusinessAndAssetAcquisitionsAxis=ensg_AcquiredOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=ensg_AssembledOccupancyAcquiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=ensg_AssembledOccupancyAcquiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357823200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENTS - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>property </div>
<div>segment </div>
<div>operation </div>
<div>facility</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SkilledServiceFacilities', window );">Transitional and skilled service facilities | operation</a></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SkilledServicesAndSeniorLivingCampuses', window );">Transitional and skilled services and senior living campuses | operation</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | property</a></td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SeniorLivingFacilities', window );">Senior living facilities | facility</a></td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember', window );">Standard Bearer Healthcare REIT, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfRealEstateProperties', window );">Number of real estate properties | property</a></td>
<td class="nump">108<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SeniorLivingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Assisted and Independent Living Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SeniorLivingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SkilledServiceFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Skilled Service Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SkilledServiceFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SkilledServicesAndSeniorLivingCampuses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Transitional and Skilled Services and Assistant and Independent Living Campuses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SkilledServicesAndSeniorLivingCampuses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfRealEstateProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of real estate properties owned as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfRealEstateProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ensg_StandardBearerHealthcareREITIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700349697824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">$ 3,729,355,000<span></span>
</td>
<td class="nump">$ 3,025,468,000<span></span>
</td>
<td class="nump">$ 2,627,461,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SegmentIncomeLoss', window );">Segment income (loss)</a></td>
<td class="nump">272,739,000<span></span>
</td>
<td class="nump">285,822,000<span></span>
</td>
<td class="nump">257,564,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLossFromRealEstateOperations', window );">Gain on sale of assets and insurance recoveries from real estate, net</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="nump">3,267,000<span></span>
</td>
<td class="nump">440,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before provision for income taxes</a></td>
<td class="nump">272,762,000<span></span>
</td>
<td class="nump">289,089,000<span></span>
</td>
<td class="nump">258,004,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">72,387,000<span></span>
</td>
<td class="nump">62,355,000<span></span>
</td>
<td class="nump">55,985,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">8,087,000<span></span>
</td>
<td class="nump">8,931,000<span></span>
</td>
<td class="nump">6,849,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">3,708,071,000<span></span>
</td>
<td class="nump">3,008,711,000<span></span>
</td>
<td class="nump">2,611,476,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ensg_RentalMember', window );">Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">21,284,000<span></span>
</td>
<td class="nump">16,757,000<span></span>
</td>
<td class="nump">15,985,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">3,578,855,000<span></span>
</td>
<td class="nump">2,906,215,000<span></span>
</td>
<td class="nump">2,523,234,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SegmentIncomeLoss', window );">Segment income (loss)</a></td>
<td class="nump">464,925,000<span></span>
</td>
<td class="nump">408,732,000<span></span>
</td>
<td class="nump">373,603,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">38,766,000<span></span>
</td>
<td class="nump">33,224,000<span></span>
</td>
<td class="nump">30,681,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Skilled Services | Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">3,578,855,000<span></span>
</td>
<td class="nump">2,906,215,000<span></span>
</td>
<td class="nump">2,523,234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Skilled Services | Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Standard Bearer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">82,486,000<span></span>
</td>
<td class="nump">72,937,000<span></span>
</td>
<td class="nump">58,127,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SegmentIncomeLoss', window );">Segment income (loss)</a></td>
<td class="nump">29,065,000<span></span>
</td>
<td class="nump">27,871,000<span></span>
</td>
<td class="nump">31,876,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">25,205,000<span></span>
</td>
<td class="nump">21,613,000<span></span>
</td>
<td class="nump">17,558,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">19,761,000<span></span>
</td>
<td class="nump">15,707,000<span></span>
</td>
<td class="nump">6,842,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Standard Bearer | Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Standard Bearer | Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">82,486,000<span></span>
</td>
<td class="nump">72,937,000<span></span>
</td>
<td class="nump">58,127,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">155,804,000<span></span>
</td>
<td class="nump">122,610,000<span></span>
</td>
<td class="nump">102,685,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SegmentIncomeLoss', window );">Segment income (loss)</a></td>
<td class="num">(221,251,000)<span></span>
</td>
<td class="num">(150,781,000)<span></span>
</td>
<td class="num">(147,915,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,416,000<span></span>
</td>
<td class="nump">7,518,000<span></span>
</td>
<td class="nump">7,746,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">1,228,000<span></span>
</td>
<td class="nump">1,870,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | All Other | Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">144,667,000<span></span>
</td>
<td class="nump">115,214,000<span></span>
</td>
<td class="nump">95,276,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | All Other | Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="nump">11,137,000<span></span>
</td>
<td class="nump">7,396,000<span></span>
</td>
<td class="nump">7,409,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">3,897,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Intercompany Elimination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="num">(87,790,000)<span></span>
</td>
<td class="num">(76,294,000)<span></span>
</td>
<td class="num">(56,585,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SegmentIncomeLoss', window );">Segment income (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(12,902,000)<span></span>
</td>
<td class="num">(8,646,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Intercompany Elimination | Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="num">(15,451,000)<span></span>
</td>
<td class="num">(12,718,000)<span></span>
</td>
<td class="num">(7,034,000)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember', window );">Intercompany Elimination | Rental revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">TOTAL REVENUE</a></td>
<td class="num">$ (72,339,000)<span></span>
</td>
<td class="num">$ (63,576,000)<span></span>
</td>
<td class="num">$ (49,551,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SegmentIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SegmentIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLossFromRealEstateOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLossFromRealEstateOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_RentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_RentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ensg_StandardBearerSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ensg_StandardBearerSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=srt_ConsolidationEliminationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700350846000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 3,729,355<span></span>
</td>
<td class="nump">$ 3,025,468<span></span>
</td>
<td class="nump">$ 2,627,461<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 3,578,855<span></span>
</td>
<td class="nump">$ 2,906,215<span></span>
</td>
<td class="nump">$ 2,523,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember', window );">Total Medicaid and Medicare | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 3,708,071<span></span>
</td>
<td class="nump">$ 3,008,711<span></span>
</td>
<td class="nump">$ 2,611,476<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 3,578,855<span></span>
</td>
<td class="nump">$ 2,906,215<span></span>
</td>
<td class="nump">$ 2,523,234<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">129,216<span></span>
</td>
<td class="nump">102,496<span></span>
</td>
<td class="nump">88,242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 2,690,861<span></span>
</td>
<td class="nump">$ 2,216,194<span></span>
</td>
<td class="nump">$ 1,922,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 2,660,885<span></span>
</td>
<td class="nump">$ 2,191,347<span></span>
</td>
<td class="nump">$ 1,906,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Total Medicaid and Medicare | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">29,976<span></span>
</td>
<td class="nump">24,847<span></span>
</td>
<td class="nump">15,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 1,459,449<span></span>
</td>
<td class="nump">$ 1,183,156<span></span>
</td>
<td class="nump">$ 1,022,460<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">39.40%<span></span>
</td>
<td class="nump">39.30%<span></span>
</td>
<td class="nump">39.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 1,429,473<span></span>
</td>
<td class="nump">$ 1,158,309<span></span>
</td>
<td class="nump">$ 1,007,061<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">29,976<span></span>
</td>
<td class="nump">24,847<span></span>
</td>
<td class="nump">15,399<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 985,749<span></span>
</td>
<td class="nump">$ 832,160<span></span>
</td>
<td class="nump">$ 727,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">26.60%<span></span>
</td>
<td class="nump">27.70%<span></span>
</td>
<td class="nump">27.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 985,749<span></span>
</td>
<td class="nump">$ 832,160<span></span>
</td>
<td class="nump">$ 727,103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicare | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid-skilled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 245,663<span></span>
</td>
<td class="nump">$ 200,878<span></span>
</td>
<td class="nump">$ 172,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid-skilled | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">6.60%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid-skilled | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 245,663<span></span>
</td>
<td class="nump">$ 200,878<span></span>
</td>
<td class="nump">$ 172,770<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Medicaid-skilled | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 666,129<span></span>
</td>
<td class="nump">$ 525,710<span></span>
</td>
<td class="nump">$ 456,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 666,129<span></span>
</td>
<td class="nump">$ 525,710<span></span>
</td>
<td class="nump">$ 456,728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Managed care | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 351,081<span></span>
</td>
<td class="nump">$ 266,807<span></span>
</td>
<td class="nump">$ 232,415<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue %</a></td>
<td class="nump">9.40%<span></span>
</td>
<td class="nump">8.80%<span></span>
</td>
<td class="nump">8.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other | Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 251,841<span></span>
</td>
<td class="nump">$ 189,158<span></span>
</td>
<td class="nump">$ 159,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Service revenue | Private and other | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems', window );"><strong>Segment Reporting, Revenue Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total Service Revenue</a></td>
<td class="nump">$ 99,240<span></span>
</td>
<td class="nump">$ 77,649<span></span>
</td>
<td class="nump">$ 72,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingRevenueReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingRevenueReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidSkilledMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidSkilledMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_ManagedCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_ManagedCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_PrivatePayAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351900688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT&#8212; NET - Schedule of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,487,013<span></span>
</td>
<td class="nump">$ 1,331,802<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(396,242)<span></span>
</td>
<td class="num">(339,792)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY AND EQUIPMENT, NET</a></td>
<td class="nump">1,090,771<span></span>
</td>
<td class="nump">992,010<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">142,656<span></span>
</td>
<td class="nump">134,864<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">803,155<span></span>
</td>
<td class="nump">728,231<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">172,064<span></span>
</td>
<td class="nump">150,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">339,383<span></span>
</td>
<td class="nump">295,739<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">4,192<span></span>
</td>
<td class="nump">4,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 25,563<span></span>
</td>
<td class="nump">$ 17,521<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700359029600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT&#8212; NET - Narrative (Details) - Senior Living Operations - Disposal Group, Disposed of by Sale, Not Discontinued Operations<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of real estate</a></td>
<td class="nump">$ 8,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sales property, plant and equipment</a></td>
<td class="nump">$ 3,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ensg_SeniorLivingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=ensg_SeniorLivingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351521568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET - Schedule of Finite Lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 6,096<span></span>
</td>
<td class="nump">$ 5,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,873)<span></span>
</td>
<td class="num">(3,285)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">2,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ensg_AssembledOccupancyAcquiredMember', window );">Assembled occupancy</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Life (Years)</a></td>
<td class="text">3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 781<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(388)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Facility trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Life (Years)</a></td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 733<span></span>
</td>
<td class="nump">733<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(439)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 294<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted Average Life (Years)</a></td>
<td class="text">18 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(2,692)<span></span>
</td>
<td class="num">(2,482)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 1,890<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ensg_AssembledOccupancyAcquiredMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ensg_AssembledOccupancyAcquiredMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352759824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 1,790,000<span></span>
</td>
<td class="nump">$ 1,714,000<span></span>
</td>
<td class="nump">$ 1,435,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets (excluding goodwill)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember', window );">Medicare and Medicaid licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired', window );">Indefinite-lived intangible assets</a></td>
<td class="nump">330,000<span></span>
</td>
<td class="nump">245,000<span></span>
</td>
<td class="nump">181,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember', window );">Depreciation and Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,202,000<span></span>
</td>
<td class="nump">$ 1,160,000<span></span>
</td>
<td class="nump">$ 1,158,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefinitelivedIntangibleAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefinitelivedIntangibleAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352733424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET - Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 2,223<span></span>
</td>
<td class="nump">$ 2,465<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352666352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS &#8212; NET - Schedule of Indefinite-lived Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Other indefinite-lived intangibles</a></td>
<td class="nump">$ 4,302<span></span>
</td>
<td class="nump">$ 3,972<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade name</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Other indefinite-lived intangibles</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">889<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember', window );">Medicare and Medicaid licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Other indefinite-lived intangibles</a></td>
<td class="nump">$ 3,413<span></span>
</td>
<td class="nump">$ 3,083<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=ensg_MedicareandMedicaidLicensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351913552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GOODWILL (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 76,869<span></span>
</td>
<td class="nump">$ 60,469<span></span>
</td>
<td class="nump">$ 76,869<span></span>
</td>
<td class="nump">$ 54,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Skilled Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">51,486<span></span>
</td>
<td class="nump">67,886<span></span>
</td>
<td class="nump">45,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">16,400<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">8,983<span></span>
</td>
<td class="nump">8,983<span></span>
</td>
<td class="nump">$ 8,983<span></span>
</td>
<td class="nump">$ 8,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ensg_SkilledServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356861760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRICTED AND OTHER ASSETS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet', window );">Debt issuance costs, net</a></td>
<td class="nump">$ 2,883<span></span>
</td>
<td class="nump">$ 3,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Long-term insurance losses recoverable asset</a></td>
<td class="nump">15,913<span></span>
</td>
<td class="nump">10,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestrictedAssets', window );">Capital improvement reserves with landlords and lenders</a></td>
<td class="nump">4,870<span></span>
</td>
<td class="nump">6,446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Deposits with landlords</a></td>
<td class="nump">2,661<span></span>
</td>
<td class="nump">2,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EscrowDeposit', window );">Escrow deposits</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">12,662<span></span>
</td>
<td class="nump">14,053<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_RestrictedAndOtherAssetsNoncurrent', window );">RESTRICTED AND OTHER ASSETS</a></td>
<td class="nump">$ 40,205<span></span>
</td>
<td class="nump">$ 37,291<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_RestrictedAndOtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restricted And Other Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_RestrictedAndOtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 835<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479359/835-30-S45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EscrowDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EscrowDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestrictedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480632/954-210-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480602/954-210-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestrictedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700348542864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OTHER ACCRUED LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_QualityAssuranceFee', window );">Quality assurance fee</a></td>
<td class="nump">$ 14,035<span></span>
</td>
<td class="nump">$ 7,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ResidentRefundsPayable', window );">Refunds payable</a></td>
<td class="nump">51,248<span></span>
</td>
<td class="nump">40,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Resident advances</a></td>
<td class="nump">10,834<span></span>
</td>
<td class="nump">9,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_AccruedLiabilitiesStateReliefContractLiabilities', window );">Unapplied state relief funds</a></td>
<td class="nump">486<span></span>
</td>
<td class="nump">1,001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_CashHeldInTrustForResidents', window );">Cash held in trust for patients</a></td>
<td class="nump">6,215<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends payable</a></td>
<td class="nump">3,396<span></span>
</td>
<td class="nump">3,201<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent', window );">Property taxes</a></td>
<td class="nump">12,875<span></span>
</td>
<td class="nump">10,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Accrued litigation (Note 20)</a></td>
<td class="nump">51,734<span></span>
</td>
<td class="nump">4,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other</a></td>
<td class="nump">17,405<span></span>
</td>
<td class="nump">13,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">OTHER ACCRUED LIABILITIES</a></td>
<td class="nump">$ 168,228<span></span>
</td>
<td class="nump">$ 97,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_AccruedLiabilitiesStateReliefContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, State Relief Contract Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_AccruedLiabilitiesStateReliefContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_CashHeldInTrustForResidents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_CashHeldInTrustForResidents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_QualityAssuranceFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_QualityAssuranceFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ResidentRefundsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Resident refunds payable includes amounts due to residents for overpayments and duplicate payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ResidentRefundsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483384/720-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 405<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480191/946-405-45-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351108336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 73,092<span></span>
</td>
<td class="nump">$ 56,717<span></span>
</td>
<td class="nump">$ 49,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">17,301<span></span>
</td>
<td class="nump">14,216<span></span>
</td>
<td class="nump">11,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current income tax expense (benefit)</a></td>
<td class="nump">90,393<span></span>
</td>
<td class="nump">70,933<span></span>
</td>
<td class="nump">61,003<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(22,280)<span></span>
</td>
<td class="num">(5,158)<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(5,201)<span></span>
</td>
<td class="num">(1,338)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Total deferred income tax expense (benefit)</a></td>
<td class="num">(27,481)<span></span>
</td>
<td class="num">(6,496)<span></span>
</td>
<td class="num">(724)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 62,912<span></span>
</td>
<td class="nump">$ 64,437<span></span>
</td>
<td class="nump">$ 60,279<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356518336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Income tax expense at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes&#160;- net of federal benefit</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible expenses</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Equity compensation</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="num">(3.30%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other adjustments</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">TOTAL INCOME TAX PROVISION</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356714944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (YE) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">22.30%<span></span>
</td>
<td class="nump">23.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">$ 1,192<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 789<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358973872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">$ 81,502<span></span>
</td>
<td class="nump">$ 61,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts', window );">Revenue related reserves</a></td>
<td class="nump">23,714<span></span>
</td>
<td class="nump">18,046<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">1,192<span></span>
</td>
<td class="nump">1,742<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance', window );">Insurance</a></td>
<td class="nump">16,864<span></span>
</td>
<td class="nump">11,910<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">444,590<span></span>
</td>
<td class="nump">364,408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsStateTaxes', window );">State taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">567,862<span></span>
</td>
<td class="nump">457,819<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(789)<span></span>
</td>
<td class="num">(789)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">TOTAL DEFERRED TAX ASSETS</a></td>
<td class="nump">567,073<span></span>
</td>
<td class="nump">457,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_DeferredTaxLiabilitiesStateTaxes', window );">State taxes</a></td>
<td class="num">(280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation and amortization</a></td>
<td class="num">(52,334)<span></span>
</td>
<td class="num">(49,146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(4,113)<span></span>
</td>
<td class="num">(5,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="num">(443,222)<span></span>
</td>
<td class="num">(363,091)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">TOTAL DEFERRED TAX LIABILITIES</a></td>
<td class="num">(499,949)<span></span>
</td>
<td class="num">(417,387)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">NET DEFERRED TAX ASSETS</a></td>
<td class="nump">$ 67,124<span></span>
</td>
<td class="nump">$ 39,643<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Right Of Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_DeferredTaxLiabilitiesStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, State Taxes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_DeferredTaxLiabilitiesStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351900272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Schedule of Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current maturities</a></td>
<td class="num">$ (3,950)<span></span>
</td>
<td class="num">$ (3,883)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Less: debt issuance costs, net</a></td>
<td class="num">(2,941)<span></span>
</td>
<td class="num">(3,119)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">LONG-TERM DEBT LESS CURRENT MATURITIES</a></td>
<td class="nump">145,497<span></span>
</td>
<td class="nump">149,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Mortgage loans and promissory note</a></td>
<td class="nump">$ 152,388<span></span>
</td>
<td class="nump">$ 156,271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358746736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost', window );">Write-off of deferred financing fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 566,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of deferred financing costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">$ 3,197,000<span></span>
</td>
<td class="nump">$ 1,172,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_TotalNetDebtRatioMaximum', window );">Total net debt ratio, maximum</a></td>
<td class="nump">3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod', window );">Long-term debt threshold for EBITDA ratio increase election period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection', window );">Long-term debt, threshold for EBITDA ratio increase election</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection', window );">Total net debt ratio, maximum after increase election</a></td>
<td class="nump">3.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_TotalNetDebtRatioMinimum', window );">Total net debt ratio, minimum</a></td>
<td class="nump">1.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Line of credit facility, unused capacity, commitment fee percentage</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR) | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving credit facility with Truist | Truist | Secured Overnight Financing Rate (SOFR) | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Interest rate margin</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Threshold For EBITDA Ratio Increase Election</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt Threshold For EBITDA Ratio Increase Election Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_TotalNetDebtRatioMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Net Debt Ratio, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_TotalNetDebtRatioMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_TotalNetDebtRatioMaximumAfterIncreaseElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Net Debt Ratio, Maximum After Increase Election</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_TotalNetDebtRatioMaximumAfterIncreaseElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_TotalNetDebtRatioMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total Net Debt Ratio, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_TotalNetDebtRatioMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WriteOffOfDeferredDebtIssuanceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WriteOffOfDeferredDebtIssuanceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=ensg_TruistBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=ensg_TruistBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=ensg_SecuredOvernightFinancingRateSOFRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=ensg_SecuredOvernightFinancingRateSOFRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358770336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>subsidiary</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of credit outstanding, pledged amount</a></td>
<td class="nump">$ 6,255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember', window );">Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet', window );">Letter of credit increase</a></td>
<td class="num">(455)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding debt</a></td>
<td class="nump">$ 152,388<span></span>
</td>
<td class="nump">$ 156,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | First Three Years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | In The Fourth Year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ReductionInPrepaymentPenalty', window );">Reduction in prepayment penalty</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | Years Five Through Ten</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ReductionInPrepaymentPenalty', window );">Reduction in prepayment penalty</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | After Year Ten</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_PrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt instrument, interest rate, effective percentage</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">35 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | HUD Insured Mortgages | Twenty Three Subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfOperatingSubsidiaries', window );">Number of operating subsidiaries | subsidiary</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding debt</a></td>
<td class="nump">$ 150,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember', window );">Mortgage loans and promissory note | 5.3% Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding debt</a></td>
<td class="nump">$ 2,144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfOperatingSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of operating subsidiaries entered into mortgage loans that are insured with HUD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfOperatingSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage that the prepayment penalty percentage is reduced during the first three years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ReductionInPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage that the prepayment penalty percentage is reduced during the fourth year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ReductionInPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_CollateralizedDebtObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ensg_HUDInsuredMortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ensg_HUDInsuredMortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PrepaymentFeePeriodAxis=ensg_FirstThreeYearsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PrepaymentFeePeriodAxis=ensg_FirstThreeYearsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PrepaymentFeePeriodAxis=ensg_InTheFourthYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PrepaymentFeePeriodAxis=ensg_InTheFourthYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PrepaymentFeePeriodAxis=ensg_YearsFiveThroughTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PrepaymentFeePeriodAxis=ensg_YearsFiveThroughTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_PrepaymentFeePeriodAxis=ensg_AfterYearTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_PrepaymentFeePeriodAxis=ensg_AfterYearTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=ensg_TwentyThreeSubsidiariesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=ensg_TwentyThreeSubsidiariesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ensg_A53PromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ensg_A53PromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700349941152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>DEBT - Long-term Debt Arrangements (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 3,950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2025</a></td>
<td class="nump">4,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2026</a></td>
<td class="nump">4,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2027</a></td>
<td class="nump">3,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2028</a></td>
<td class="nump">3,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">132,449<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 152,388<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700349694704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Stock Options, Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>installment </div>
<div>plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_NumberOfOptionPlans', window );">Number of option plans | plan</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate', window );">Forfeiture rate</a></td>
<td class="nump">5.08%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue', window );">Grant date intrinsic value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised in period | $</a></td>
<td class="nump">$ 56,186<span></span>
</td>
<td class="nump">$ 47,441<span></span>
</td>
<td class="nump">$ 34,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate intrinsic value of options that vested in period | $</a></td>
<td class="nump">$ 31,658<span></span>
</td>
<td class="nump">$ 27,955<span></span>
</td>
<td class="nump">$ 27,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ensg_A2022PlanMember', window );">2022 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">3,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability', window );">Conversion to reduce shares availability</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability', window );">Other than options, conversion to reduce shares availability</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">1,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=ensg_A2022PlanMember', window );">2022 Plan | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_NumberOfOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_NumberOfOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ensg_A2022PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ensg_A2022PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700357844672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Valuation Assumptions (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted (in shares)</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Weighted Average Risk-Free Rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected Life</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Weighted Average Volatility</a></td>
<td class="nump">41.30%<span></span>
</td>
<td class="nump">42.10%<span></span>
</td>
<td class="nump">42.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Weighted Average Dividend Yield</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700360691504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Exercise Price and Fair Value (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 95.05<span></span>
</td>
<td class="nump">$ 85.74<span></span>
</td>
<td class="nump">$ 80.19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value of Options (in dollars per share)</a></td>
<td class="nump">$ 43.85<span></span>
</td>
<td class="nump">$ 37.83<span></span>
</td>
<td class="nump">$ 32.82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351916720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Options Outstanding Rollforward (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at beginning of period, (in shares)</a></td>
<td class="nump">3,833<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,008<span></span>
</td>
<td class="nump">581<span></span>
</td>
<td class="nump">621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(98)<span></span>
</td>
<td class="num">(105)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(759)<span></span>
</td>
<td class="num">(688)<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at end of period, (in shares)</a></td>
<td class="nump">3,991<span></span>
</td>
<td class="nump">3,833<span></span>
</td>
<td class="nump">4,038<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 46.72<span></span>
</td>
<td class="nump">$ 36.60<span></span>
</td>
<td class="nump">$ 27.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">95.05<span></span>
</td>
<td class="nump">85.74<span></span>
</td>
<td class="nump">80.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">71.44<span></span>
</td>
<td class="nump">59.52<span></span>
</td>
<td class="nump">44.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">24.21<span></span>
</td>
<td class="nump">18.43<span></span>
</td>
<td class="nump">17.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at end of period (in dollars per share)</a></td>
<td class="nump">$ 62.65<span></span>
</td>
<td class="nump">$ 46.72<span></span>
</td>
<td class="nump">$ 36.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options Vested (in shares)</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
<td class="nump">2,183<span></span>
</td>
<td class="nump">2,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price of Options Vested (in dollars per share)</a></td>
<td class="nump">$ 39.58<span></span>
</td>
<td class="nump">$ 28.87<span></span>
</td>
<td class="nump">$ 21.02<span></span>
</td>
<td class="nump">$ 16.66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351216624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">3,991<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 105,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">1,887<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTwoMember', window );">2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 484<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeThreeMember', window );">2015</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 21.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 1,369<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFourMember', window );">2016</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 16.86<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">155<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFiveMember', window );">2017</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 1,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSixMember', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.49<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 32.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 3,523<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">336<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSevenMember', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 41.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 45.76<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">510<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 8,014<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeEightMember', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 44.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 59.49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 9,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeNineMember', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 73.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 83.64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 16,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">189<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTenMember', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 79.79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 94.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 20,466<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeElevenMember', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price, lower range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 89.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price, upper range limit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 98.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Number outstanding (in shares)</a></td>
<td class="nump">993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue', window );">Black-Scholes Fair Value | $</a></td>
<td class="nump">$ 43,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Remaining Contractual Life (Years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Stock options vested and exercisable (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeElevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=ensg_ExercisePriceRangeElevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358954832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Intrinsic Values (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 197,819<span></span>
</td>
<td class="nump">$ 183,593<span></span>
</td>
<td class="nump">$ 191,242<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested</a></td>
<td class="nump">137,048<span></span>
</td>
<td class="nump">136,000<span></span>
</td>
<td class="nump">137,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue', window );">Expected to vest</a></td>
<td class="nump">$ 56,759<span></span>
</td>
<td class="nump">$ 43,232<span></span>
</td>
<td class="nump">$ 48,548<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700356806048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SharebasedCompensationRestrictedAwardsExercisePrice', window );">Share-based compensation, restricted awards, exercise price (in dollars per share)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 92.04<span></span>
</td>
<td class="nump">$ 81.57<span></span>
</td>
<td class="nump">$ 81.65<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 89.83<span></span>
</td>
<td class="nump">73.17<span></span>
</td>
<td class="nump">72.84<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Minimum | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">89.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">98.31<span></span>
</td>
<td class="nump">$ 94.88<span></span>
</td>
<td class="nump">$ 93.31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards | Maximum | Non-employee Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 98.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SharebasedCompensationRestrictedAwardsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation, Restricted Awards, Exercise Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SharebasedCompensationRestrictedAwardsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementNonemployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365547872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Restricted Award Rollforward (Details) - Restricted Stock Awards - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Non-Vested Restricted Awards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at beginning of period (in shares)</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">549<span></span>
</td>
<td class="nump">591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="nump">222<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(269)<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited', window );">Forfeited (in shares)</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested at end of period (in shares)</a></td>
<td class="nump">431<span></span>
</td>
<td class="nump">487<span></span>
</td>
<td class="nump">549<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 64.92<span></span>
</td>
<td class="nump">$ 52.16<span></span>
</td>
<td class="nump">$ 38.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">92.04<span></span>
</td>
<td class="nump">81.57<span></span>
</td>
<td class="nump">81.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">64.21<span></span>
</td>
<td class="nump">54.06<span></span>
</td>
<td class="nump">47.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">71.53<span></span>
</td>
<td class="nump">57.29<span></span>
</td>
<td class="nump">45.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested at end of period (in dollars per share)</a></td>
<td class="nump">$ 78.91<span></span>
</td>
<td class="nump">$ 64.92<span></span>
</td>
<td class="nump">$ 52.16<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares related to Restricted Stock Award forfeited during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351898656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Long-Term Incentive Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 27, 2019</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,754<span></span>
</td>
<td class="nump">$ 22,720<span></span>
</td>
<td class="nump">$ 18,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember', window );">Spinoff | 2019 LTI Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">$ 836<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_SpinoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=ensg_A2019LTIPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=ensg_A2019LTIPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351393152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OPTIONS AND AWARDS - Compensation Expense (Details) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to stock options</a></td>
<td class="nump">$ 30,754<span></span>
</td>
<td class="nump">$ 22,720<span></span>
</td>
<td class="nump">$ 18,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Share-based compensation, options outstanding, weighted average remaining contractual term</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock-based compensation expense related to stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to stock options</a></td>
<td class="nump">$ 17,221<span></span>
</td>
<td class="nump">11,361<span></span>
</td>
<td class="nump">8,459<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based compensation, nonvested awards, cost not yet recognized</a></td>
<td class="nump">$ 67,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation, nonvested awards, cost not yet recognized, period for recognition</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards', window );">Share-based compensation, nonvested awards (in shares)</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber', window );">Share-based compensation, options expected to vest, number (in shares)</a></td>
<td class="nump">1,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Stock-based compensation expense related to restricted stock awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to stock options</a></td>
<td class="nump">$ 11,845<span></span>
</td>
<td class="nump">9,920<span></span>
</td>
<td class="nump">8,385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based compensation, nonvested awards, cost not yet recognized</a></td>
<td class="nump">$ 29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation, nonvested awards, cost not yet recognized, period for recognition</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=ensg_StockAwardsMember', window );">Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense related to stock options</a></td>
<td class="nump">$ 1,688<span></span>
</td>
<td class="nump">$ 1,439<span></span>
</td>
<td class="nump">$ 1,834<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_EmployeeServiceShareBasedCompensationNonvestedAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Service Share-based Compensation, Nonvested Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_EmployeeServiceShareBasedCompensationNonvestedAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=ensg_StockAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=ensg_StockAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700350721264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lessee Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 01, 2024 </div>
<div>USD ($) </div>
<div>operation </div>
<div>bed</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>lease </div>
<div>operation </div>
<div>renewal </div>
<div>bed </div>
<div>facility </div>
<div>agreement</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease </div>
<div>operation </div>
<div>bed</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>bed </div>
<div>lease </div>
<div>operation</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new and modified operating lease obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 376,550<span></span>
</td>
<td class="nump">$ 370,753<span></span>
</td>
<td class="nump">$ 198,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years 10 months 24 days<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember', window );">Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,483<span></span>
</td>
<td class="nump">3,058<span></span>
</td>
<td class="nump">1,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember', window );">Skilled Nursing Operations | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | operation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ensg_CostofSalesandGeneralandAdministrativeExpenseMember', window );">Cost of Sales and General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197,856<span></span>
</td>
<td class="nump">$ 153,174<span></span>
</td>
<td class="nump">$ 139,458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseAgreementMember', window );">Amended Master Lease Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_AmendedSeparateMasterLeases', window );">Amended of separate master leases | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseAgreementMember', window );">Amended Master Lease Agreement | Skilled Nursing Operations | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | operation</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new and modified operating lease obligations | $</a></td>
<td class="nump">$ 30,980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_OperationalSkilledNursingBeds', window );">Operational skilled nursing beds | bed</a></td>
<td class="nump">241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_NewMasterLeaseAgreeementMember', window );">New Master Lease Agreeement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new and modified operating lease obligations | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 346,789<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_NewMasterLeaseAgreeementMember', window );">New Master Lease Agreeement | Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseMember', window );">Amended Master Lease | Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfBusinessesAcquired', window );">Number of businesses acquired | operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember', window );">Sublease Of Stand Along Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember', window );">Lease Of Campus Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember', window );">CareTrust REIT</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities', window );">Skilled nursing, assisted living and independent living facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeOperatingLeaseConsumerPriceIndex', window );">Consumer price index</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseDiscountRate', window );">Operating leases of lessee, contingent rentals, basis spread on variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeOperatingLeaseNumberOfLeases', window );">Number of stand-alone leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 66,439<span></span>
</td>
<td class="nump">$ 64,178<span></span>
</td>
<td class="nump">$ 59,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember', window );">CareTrust REIT | Triple Net Lease Arrangements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities', window );">Skilled nursing, assisted living and independent living facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_MasterLeaseAgreements', window );">Master lease agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember', window );">CareTrust REIT | Triple Net Lease Arrangements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms', window );">Lessee leasing arrangements, operating leases, number of renewal terms | renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember', window );">CareTrust REIT | Triple Net Lease Arrangements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms', window );">Lessee leasing arrangements, operating leases, number of renewal terms | renewal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember', window );">CareTrust REIT | Purchase Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities', window );">Skilled nursing, assisted living and independent living facilities | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember', window );">Various Landlords</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_MasterLeaseAgreements', window );">Master lease agreements | agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_FacilitiesUnderMasterLeaseArrangement', window );">Facilities under master lease arrangement | facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember', window );">Various Landlords | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember', window );">Various Landlords | Minimum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember', window );">Various Landlords | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember', window );">Various Landlords | Maximum | Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member', window );">The Pennant Group, Inc. | Leases To Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases | lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_AmendedSeparateMasterLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amended Separate Master Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_AmendedSeparateMasterLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_FacilitiesUnderMasterLeaseArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_FacilitiesUnderMasterLeaseArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LesseeOperatingLeaseConsumerPriceIndex">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Consumer Price Index</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LesseeOperatingLeaseConsumerPriceIndex</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LesseeOperatingLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LesseeOperatingLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LessorOperatingLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Number Of New Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LessorOperatingLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_MasterLeaseAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Master Lease agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_MasterLeaseAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_OperationalSkilledNursingBeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of skilled nursing beds available for use at a skilled nursing facility</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_OperationalSkilledNursingBeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Skilled Nursing, Senior Living and Independent Living Facilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate used by lessee to determine present value of operating lease payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfBusinessesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of businesses acquired by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfBusinessesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=ensg_SkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ensg_CostofSalesandGeneralandAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ensg_CostofSalesandGeneralandAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_NewMasterLeaseAgreeementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_NewMasterLeaseAgreeementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_AmendedMasterLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_CareTrustREITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_CareTrustREITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_TripleNetLeaseArrangementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_TripleNetLeaseArrangementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_PurchaseOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_PurchaseOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_VariousLandlordsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_VariousLandlordsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351552928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lessee Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Lease, cost</a></td>
<td class="nump">$ 219,512<span></span>
</td>
<td class="nump">$ 171,272<span></span>
</td>
<td class="nump">$ 154,693<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_DeferredRentAdjustment', window );">Amortization of deferred rent</a></td>
<td class="nump">870<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">197,358<span></span>
</td>
<td class="nump">153,049<span></span>
</td>
<td class="nump">139,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease, costs</a></td>
<td class="nump">20,454<span></span>
</td>
<td class="nump">16,938<span></span>
</td>
<td class="nump">14,077<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">CPI increases and short term-lease cost</a></td>
<td class="nump">10,259<span></span>
</td>
<td class="nump">5,878<span></span>
</td>
<td class="nump">3,702<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">125<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 1,160<span></span>
</td>
<td class="nump">$ 1,158<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_DeferredRentAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_DeferredRentAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=ensg_DepreciationAndAmortizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700360662160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lessee Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Year</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 191,352<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">191,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">191,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">190,481<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">189,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,722,259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">TOTAL LEASE PAYMENTS</a></td>
<td class="nump">2,675,643<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value adjustment</a></td>
<td class="num">(953,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">PRESENT VALUE OF TOTAL LEASE LIABILITIES</a></td>
<td class="nump">1,721,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current lease liabilities</a></td>
<td class="num">(82,526)<span></span>
</td>
<td class="num">$ (65,796)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">LONG-TERM OPERATING LEASE LIABILITIES</a></td>
<td class="nump">$ 1,639,326<span></span>
</td>
<td class="nump">$ 1,355,113<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700348520080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lessor Narrative (Details) - lease<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators | The Pennant Group, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember', window );">Sublease Of Stand Along Skilled Nursing Operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">18 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember', window );">Lease Of Campus Operation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeaseTermOfContract', window );">Term of operating lease</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LessorOperatingLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Number Of New Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LessorOperatingLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_SubleaseOfStandAlongSkilledNursingOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_LeaseOfCampusOperationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700358824288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES - Lessor Rental Income (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList', window );">OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag</a></td>
<td class="text">TOTAL REVENUE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Rental revenue | All Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="nump">$ 3,897,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember', window );">Leases To Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Rental revenue</a></td>
<td class="nump">21,284,000<span></span>
</td>
<td class="nump">16,757,000<span></span>
</td>
<td class="nump">15,985,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member', window );">Pennant | Leases To Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Rental revenue</a></td>
<td class="nump">15,048,000<span></span>
</td>
<td class="nump">14,915,000<span></span>
</td>
<td class="nump">14,073,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseVariableLeaseIncome', window );">Operating lease, variable lease income</a></td>
<td class="nump">$ 1,296,000<span></span>
</td>
<td class="nump">$ 1,318,000<span></span>
</td>
<td class="nump">$ 1,199,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_LessorOperatingLeaseNumberOfLeases', window );">Number of leases | lease</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=ensg_ThirdPartyTenantsMember', window );">Other third-party | Leases To Third Party Operators</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorLeaseDescriptionLineItems', window );"><strong>Lessor, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncome', window );">Rental revenue</a></td>
<td class="nump">$ 6,236,000<span></span>
</td>
<td class="nump">$ 1,842,000<span></span>
</td>
<td class="nump">$ 1,912,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LessorOperatingLeaseNumberOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Operating Lease, Number Of New Leases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LessorOperatingLeaseNumberOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of comprehensive income that includes operating lease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479016/842-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseVariableLeaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482964/270-10-50-6A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseVariableLeaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ensg_RentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ensg_RentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=us-gaap_AllOtherSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_LeaseArrangementAxis=ensg_LeasesToThirdPartyOperatorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_ThePennantGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=ensg_ThirdPartyTenantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=ensg_ThirdPartyTenantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700359006096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>LEASES - Lessor Future Minimum Lease Payments Receivable (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 22,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears', window );">2025</a></td>
<td class="nump">21,565<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears', window );">2026</a></td>
<td class="nump">21,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears', window );">2027</a></td>
<td class="nump">21,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears', window );">2028</a></td>
<td class="nump">21,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter', window );">Thereafter</a></td>
<td class="nump">129,586<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">TOTAL</a></td>
<td class="nump">$ 236,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479773/842-30-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365585216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DEFINED CONTRIBUTION PLANS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent', window );">Deferred compensation liability, noncurrent</a></td>
<td class="nump">$ 49,201<span></span>
</td>
<td class="nump">$ 33,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Gain (loss) on deferral investment</a></td>
<td class="nump">4,634<span></span>
</td>
<td class="num">(4,188)<span></span>
</td>
<td class="nump">$ 1,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_InvestmentExpenseIncome', window );">Offsetting expense (income)</a></td>
<td class="nump">$ 4,887<span></span>
</td>
<td class="num">(4,051)<span></span>
</td>
<td class="nump">1,758<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost</a></td>
<td class="nump">$ 2,836<span></span>
</td>
<td class="nump">$ 2,418<span></span>
</td>
<td class="nump">$ 2,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum annual contributions per employee</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_InvestmentExpenseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment Expense (Income)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_InvestmentExpenseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700365613952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SELF INSURANCE LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward', window );"><strong>Movement in Liability for Future Policy Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 131,682<span></span>
</td>
<td class="nump">$ 110,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease', window );">Current year provisions</a></td>
<td class="nump">164,627<span></span>
</td>
<td class="nump">115,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits', window );">Claims paid and direct expenses</a></td>
<td class="num">(135,799)<span></span>
</td>
<td class="num">(98,007)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease', window );">Change in long-term insurance losses recoverable</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">3,757<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Ending balance</a></td>
<td class="nump">165,910<span></span>
</td>
<td class="nump">131,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_ProfessionalMalpracticeLiabilityMember', window );">General and Professional Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward', window );"><strong>Movement in Liability for Future Policy Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Beginning balance</a></td>
<td class="nump">87,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForFuturePolicyBenefits', window );">Ending balance</a></td>
<td class="nump">$ 117,744<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(13)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in accrued obligations to policyholders pertaining to insured events for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-29E<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480046/944-40-55-13I<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued obligations to policy and contract holders for long-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480081/944-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_ProfessionalMalpracticeLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis=us-gaap_ProfessionalMalpracticeLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700352117824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 19, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>subsidiary</div>
</th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th">
<div>Feb. 01, 2024 </div>
<div>subsidiary</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews', window );">Facilities under medicare probe reviews</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Total Medicaid and Medicare | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.40%<span></span>
</td>
<td class="nump">56.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Total Medicaid and Medicare | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.60%<span></span>
</td>
<td class="nump">73.70%<span></span>
</td>
<td class="nump">73.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement, amount awarded to other party | $</a></td>
<td class="nump">$ 48,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews', window );">Facilities under medicare probe reviews</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ensg_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481027/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ensg_MedicaidAndMedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm139700351416176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMON STOCK REPURCHASE PROGRAM (Details) - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 29, 2023</div></th>
<th class="th"><div>Jul. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,882,000<span></span>
</td>
<td class="nump">$ 10,118,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=ensg_August2023RepurchaseProgramMember', window );">August 2023 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=ensg_July2022RepurchaseProgramMember', window );">July 2022 Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Stock repurchase program, period in force</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=ensg_August2023RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=ensg_August2023RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=ensg_July2022RepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=ensg_July2022RepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>120
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M":[C/UO1UOZ<.O!P>Z?^D \>!C,GDHYY\GL<J=5MZZJ%(KH@6:*>^.L_Z'9
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M-9J2<Z5617=0[?JGH)NPD M8BD2OR@LT4Y#,$!=HS#.FQ 9^1V:>=O6[>R-
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MT);?JN2$ I.$,R1@EWCCWF@R-/[6X3N!6I[,D<EDR_F;,19YX@4&"$K(E%'
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M'6YWV]N6) @%.*2D#],V3(*0D*&H=MJ%^+7+?MZ;;RU*: 50"9-U2M=$J<:
MC$D"ZR325V&\R[=WZ' 36]&<(A12VF]GN V#_2\$AP'HM \YTC:HI>8;ZZ#3
M!X>2"1(4AY8/#D,<1&2H4T\ZR4/\DN>.EZ>&OP0O"K.S\U(+!2:=NI[8*H4&
M>SW!%JM#\P1[Q]I#H)V4(6]I>GMBZ>AV:QU,D+5M'88XB&,XM&\[_4)^4+^
MV=TUN/G/U_G#?YV08^N;E+NMY#!TMY4F>Q]5S1?M?Z?B4>M8K<U7>B0\B_04
MHOE(W-PHOJV_LRZX4GQ37ZY9JO/6&.C_K[@6,^V-^72[^U0__1]02P,$%
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MZ@=ZSHF[(8,W-WUL)J V&2@:AT)3'=]IEKY;L_SQ*6GN!@P.&Z9DYQL2!JB
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M';.QY$B-[71GL.W.P-7Z^;6(G$65U2L.]=EP+>VOE0'R^1S[<43]L]/G:6\
M,APPBG=EB2E#<1ABNI7M.*!;!]0Y(2[R_X@H(")MUWI=+4)M5E=947*OVEJ3
MW\M/F9P[ZZ9^+L23Y3V^'CYYZ#$GSS$;2X[4V$[7LVW7,^?D2;AH-"O2(4%5
MN9>NZJ8K_MM_ 77CT!R;S( 0DRC4II.I8IA0JLTF4T6IF)OP9 JWCD*GHXN)
M :]>R 3)FT9,ED51I6):B9FRX!P,ZZ%Q/\AGNC5(1)CFS!1%-(9]15M?D?LQ
MKZM9/_M+GK;]?&^:M'KB\K&!S$3F+83Z4V]J@IAH5@"-;8CBK978:>7/INCX
MK%XLWCD^L7$KNB%309D^-JY6=NP@7P&&O^<I&CV\!:OT!^Q@;&?ZRV<X#"*D
M^8!T+(AU*Y LQ('%SH27D-/.K8RO/?4*Z/;R>O/8+3:E"+!9O1$Q&C2&C#LA
M@1_IMDP5)K&ONP)4S+<\/@@K5]CIZKZKL[]F$J!S3XR2J"I::Y0;F]JQXX=&
M+ !D&(?8,&3*4,3"R.)(<11R<L4 4B)\<U%6Y -+%56[$6$AXS))9IQ;^)68
M-T3TV36'5#C2D0!0B82 +=X4U" WU?PFZCE/S, V%1P@PD3:MMPR]0+S(4"8
MZ&8 %0GT$4W QDB(+'84X2!G%C__6?KYY;2LVU:Z4L.4E6FQ:G\54?TI+475
MTW6\:8=,+!U[>=&N:]$)L'4*W2TS'CM31F)L!!.@,0%W%N<*,)";,+X*)'NR
M/V@F P21[^MQ'9 9#YE+LGOO"B50Z*Y4EC+#RG)P@IG]1.Q'J"S2QZ+LD1/T
MY@25]R+G45M+CM7:;L<JED%NF+D84\D8O=+'$BQ>D D?LS".D#'! 5V$ W.*
M SH1UZV/MP(:Y"::VX:OT^* _&_"1X0"W0T@FJ2_T8HIF@486W(*5BB#W2CS
MYH3_D F2#Q.][I:\<81@;'((BW62G .J68P"C7T22!9$L<V9HAKLIIHMI/'5
MNJQ?A:&UK!2&*J&M11%4>BW/-@).7X<1]'Z^KCOND5] SR:EZ%$+D,QP@(PZ
MR*:S@!Q6R(/=R-,#@L@T#:]RX?<Y+3=],BV+!9^B0ET6V:L@!KXJ-BMXA$V$
MF8EH$&+=,J +F3[%$[ Y/Z;$XE@A$78CT7:0IX2W#=2OH#4 <Y@?Z$\E( L9
MT?D!:@SY-M3#"H>P&X=NMOE'EG]B$!_+,:O"PP5@#*/,\&3*2&#,3J M.HU:
MNY84$F$W$FUSP#I]M24 ;#()HC$V? "RT"AW$T 6(F0A'*P(![L)1QAI-F+*
MO:1/8[QL>)EV?"\@8 !^PMBH,@ 9$?%0!W&PM="WY#:L( B[%U1NAN _FMQG
MR5SYD-6 GK !&?&1,5[ 6@N.;>.EX /OA8_>2LO+Q4Q%P7W.3'; 482-P3)E
M* PCXZ$"9,1:NF,%(M@-(L-@E77U-!.%Q&JO*8 BC+5A2!3H: 6))DLONQL%
MBD:(FT:N+Q^&/9K;NYOO5\EEXGW^MW=S>WEW\7!U_9MW,7^X^G[U<'5Y#VX7
MF"!!0L;T!:$YH!-%/$7Z2ABHHRRR#!I19$+0NS9$BNJ9MP=MB#B)Y]T[(L=L
M+3E6:[M]JM"'N-'G=M-DRSY3+N12B$B?@NID;.9_;XJU;=&4@%S"4*0_$Y P
M"JF1/"$=BRFUE*9DLH=VP-J/R)S#KHE<IWO<M$+3B@R4"8MMT</!B+ AB+#$
MA!7#IRD1W!?H!7H"Z=BTCM^UJ;B'N+G'M#DLBQSN$2*A,(SUC 3IHB T5O8A
MG<C%MLA-% X1-PY=MIF\)N?K6O@"HS6!EGLP,N*9*3.&"P FZV I$")N$!KB
MV.'+D,0D%NSC6+=CJA A>CT,J%@46Q:-B8(?XH:?^;C?V'L8O(D,>\"J) %
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MR"N>FG3EW%"F>Y=MYOLE"2!!:+I/N=L7"GFH&WE$OIB,]/^]+_:>]YGOER2
M1,P+PIAMUBM8HFY8,FJA+U?7%]?S_;40-9%FQI!>MD(J46,S/6]"NI A8@M8
M"I'HGL/&P\'[IM]K+JKAV+T<U?X'N83^+!*0I3:GP-Y63(RJ>P[H:.#KL)@
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M/=T$6\=7Y+D->.&.EUB\L=.P +Y?6 "YO6$#W6\F9_\!4$L#!!0    ( )R
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MLU&,K;043",O&$]H*6J62*-XXM-2B*4NL6?3L9?@=#@93<0T"CUT.B),1@F
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M>!&[=J6%\7067SNA%:AC]@0XD64*@J,6>1R%G M?4/X(@OK/BTSL!.!C&Y=
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MQX)&1G1L0._GUH;-@@]HA]#IOU!+ P04    " "<@$%8L((EGH<*  !:'@
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M#<&6_'.N)$RF"7@_M:CMZ8$V:#XGG_T'4$L#!!0    ( )R 05C0#E)[ PD
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MW-"/!6IG0-_72MG]Q#GH?E7F/P!02P,$%     @ G(!!6&H"BFEY P  9@<
M !D   !X;"]W;W)K<VAE971S+W-H965T,C N>&ULG55M;]LV$/XK![5HOVB1
M1+\VM0TXCH<&6-? SK8/PS[0TMDF2I$:CXZ;_?H=*=G+T,3 ]D7BR]W#N^?A
M'2='Z[[2'M'#MUH;FB9[[YOK+*-RC[6D*]N@X9VM=;7T/'6[C!J'LHI.M<Y$
MG@^S6BJ3S"9Q[=[-)O;@M3)X[X .=2W=TPUJ>YPF17):6*G=WH>%;#9IY [7
MZ']I[AW/LC-*I6HTI*P!A]MI,B^N;_K!/AK\JO!(S\80,ME8^S5,[JIIDH>
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M/3^$Z((![V^M]:=)..#\M,[^!E!+ P04    " "<@$%8'J0DZI8$  "P"0
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M[X-NXDT3[N2E\73#AV%)3RJT?(#V"T--9#=A!8='VNQO4$L#!!0    ( )R
M05@^J1_AR <  -(2   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;*U8
M67/;.!+^*RA-,FM7(1(O71[;5;*MU+@JB5V6)K-'[0-$0A82'@H 6M;\^OT:
MI"3*EIQYV >))("^N[]N\GQ5Z.]F(:5ESUF:FXO6PMKE6:=CXH7,A&D72YEC
M9U[H3%@\ZL>.66HI$D>4I9W \WJ=3*B\=7GNUN[UY7E1VE3E\EXS4V:9T.LK
MF1:KBY;?VBP\J,>%I87.Y?E2/,J)M'\L[S6>.ELNB<ID;E21,RWG%ZV1?W85
MT7EWX*N2*].X9V3)K"B^T\-M<M'R2"&9RM@2!X'+D[R6:4J,H,:/FF=K*Y((
MF_<;[A^=[;!E)HR\+M(_56(7%ZU!BR5R+LK4/A2KWV5M3Y?XQ45JW#];56?#
ML,7BTM@BJXFA0:;RZBJ>:S\T" ;>$8*@)@B<WI4@I^6-L.+R7!<KINDTN-&-
M,]510SF54U F5F-7@<Y>WGZYOOL\9M/1/\>3\XX%1UKOQ#7U544='*'V _:Y
MR.W"L'&>R&2?00>J;/4)-OI<!6]RO)%QFX4^9X$7A&_P"[?VA8Y?>,R^/"XR
MR:;BF=TH$Z>%*;5D_QG-C-7(B/\>LKGB&!WF2%5R9I8BEA<ME(&1^DFV+G_]
MQ>]YO[VA;[35-WJ+^T_C\?>IV70AV5(73\H5$.J7J<H95CQ+P[ 6(W8J+U7^
MR%#E6E"=&'?2@G8MA39,4F 9PB*SF=3;T+C_@(D\H1N?*5/7M?H+QP5Q25'P
MYHS]"VRJ]'C-I6+B&%R76LO<GK&/,H$J*7O'^B'WA@%NNCW>]_NXB8;<][IL
M8H65S._ST/.9'_' [S'?YX/A@ T]'@Y#UO?X, Q9S^>>%T+N7()[LF-^$@0\
M&'BG[*3+_>X U[[?.ZT98RWP?*SY/ QICWY!GT<#6NSQ:-@C@B Z9=.[Z>@3
M%.L%?.B3JKV(1R&IVO-XT!^R$9 +;HY5JIQ[63%WSIW7BAA(+&VAUTR3:%NX
M73F?2P=7%*MJIQ&_N2ZR_V/L.%0TRTI>NN842HA9:F5>1/*M\-UN4XO)9W0,
M(YFP+ZT+_+;'WK^X5#[?2\T/+$<[@J<V7IK)7,Z596&[6__Z[$N1?X!Y)?2>
MI7(CU6 O8@$X![B.?Y3*KITYV*P"<!*U X0O;/?<?WC*[N QS43R#7"+?F,-
M._'<[N9_&^A=?;'[A[NOMY/;NR\L"-L^F1.T0[J0_/>N^*XA5N3K?YA#\5S!
MLT3Y?B]FQT-&-@CD,*4(B=K1&0''(054D<"-C=A"D_?UBM]V&BW0H\#U@#H(
M>E*Z_*O/Y$?<V]2#J.O0F"HKT:_B[WO^;K]P15+7HB,6QDB0DK:HCQF*Q"K(
M@&L0_-?I5F<LS .&-^!F1K-%^UA^WAR0>-(0=WK&1G&L2YS86OF.#7S>]5Q%
M^[PWZ+('^21S>$C+%/Y*6 W]%$2 4\3\ ?>BGFLT,8211WSN [Y\WH\"U <:
MC\ACP%:/#WH1X=70]]@GB9%B:_R:15'$NT./A00DWJ"NCJHL?OUE$/C!;RP8
M !'[X!*PJ(NK/V1?15I6Z2VH6)V@D_Y@>%K_5^E[,_XX?G@8W[@$'DTFX^G$
M<?+ZH>/DA=Z>P!,'D1NQ-Q+]+JYAC$(ALD);]5==5MT :(E*.2&0CE X]UHN
MA6HX]23BOA_6F O&;@*D2)>$%A08'(E"'@2N0'L$__Y!W3_=CJYN/]U.;]'F
M(&_(AQ&9&E%+&/1/V9?Q]*"QB&:?^T&$FW#(>U'83$ZV$(E#+%E'D,5"ZS7*
M;"5T\C>R$KOOJIC3TCL7^'UP=<4 8U\P3K/"6)2^5<BN=9UB5&"5-JG*E*T!
M'IZFFA?+9:KB;4<9YU9JA]CLWT6.:LV6:;$F+/NPR5>[2\PV^R-/I3&.T\;X
MDB)$"R]Y;;)Y)J&P7, T[LXU;<#FH\A)8P0;1M2H$U;%KR6]'0#)Z^;WR@$[
M@S?"Q",HX!,2-)7/<#UJ_1%<70W#N\ KRJO85DBTITP)1Z8DO]]FHY\$K;+E
MZ4#Y4#11.]SA[*RPBZJI<H?<\ ^!CPM67&C"[*;*QWPH]GT.W%*2, 2Y!H-0
M3A3L[Y0#%HX&!A,[ZJ/4&^O)8=,+Z\<-ZY5*4T<P(X>+E(#Q)?;6@P)&!LS!
MIG(:VT:!['0)!V82FA SO/:@L: #)Z4FNI_UJ:U?CWK^U?#1=$@"N""Q"X'>
MY+(R)_\^Y@[FF^V&;T8$LKTJDVTG<BY;%66*H+A.UY1QL!OO.8K%*<!(S:D3
M*0JD1%2A;P?^ 9*)U/4HY,IN9MGK7CB&-\LRKR!#) @/,@L^5*]GI.U0UV:3
M,EX0I)8T@(@7_J\4W!\:I7/P 7#868HQ=D@.1W.J/8XQNJ%&-2:F8DFC7B/$
M=J%01S]*H6U5M;O(\2-S(]KOCGY>E!H%TV @15P5$$>Q850I-U$[9HM(35%K
M5AGO[LW+1#PZY.Y@F6 ]+YB"4Y *KWQT-,7V+'HCZ>L<KLR!%7_B/1,6*$H0
MA-ZA+RE#4U$JJR<D@,#;_-XKP4_"9C:-N;9[I>!AV-686_?3&(A"*50ZY&W*
MFZU=;67BV]X[(?L&<TVBW.>2]J%WV4[C.T,F]:/[FD(C(7*V^N2P7=U^L!E5
MWREVQZNO/9\=G"/WY!RD7KO?;3%=?4&I'FRQ=%\M@+RVR-SM0@J80@>P/R\*
MNWD@ =O/6)?_ U!+ P04    " "<@$%82TU!NR *  !'&   &0   'AL+W=O
M<FMS:&5E=',O<VAE970R,RYX;6RE6=ERVS@6_164VNDD58P62O(6VU7>,IVJ
M;&4[W=4U-0\0"4E(2((!0,N:KY]S+TB)E)=^F(=8E(CE+N>>>X"<K(S]Z99*
M>?&09X4[[2V]+X\' Y<L52Y=WY2JP)NYL;GT^&H7 U=:)5.>E&>#>#C<'^12
M%[VS$_[MFST[,97/=*&^6>&J/)=V?:$RLSKMC7K-#S=ZL?3TP^#LI)0+=:O\
M]_*;Q;?!9I54YZIPVA3"JOEI[WQT?#&A\3S@3ZU6KO4LR).9,3_IR\?TM#<D
M@U2F$D\K2'S<JTN59;00S/A5K]G;;$D3V\_-ZA_8=_@RDTY=FNPOG?KE:>^P
M)U(UEU7F;\SJ#U7[,Z7U$I,Y_BM686Q\T!-)Y;S)Z\FP(-=%^)0/=1Q:$PZ'
MSTR(ZPDQVQTV8BNOI)=G)]:LA*716(T>V%6>#>-T04FY]19O->;YLZOKB[N3
M@<=*]'V0U+,NPJSXF5FC6'PVA5\Z<5VD*NTN,( )&SOBQHZ+^,45KU32%^-1
M).)A/'YAO?'&KS&O-WYVO9D75]HEF7&55>+?YS/G+3#PGZ>\#6M-GEZ+ZN+8
ME3)1IST WRE[KWIGO_\VVA^^?\'2R<;2R4NK/YN!?YXEV,G$H$*<=\+,A5\J
M,3<9*DT7BV.\3U0^4W836/I#J;-^@8H3F9&%$[)(16E-KITS=BT*XY78$Z-I
M'(T/#_EI/XH/1N*3<NX8F+16%1X8])757BLGWHRCH^GP+7T>'H[?U@-3,@YK
M5K)(%*R$B9$H0#-OXNAH,N+AH]$1AG_]\J]W=]<WGP4[]>GZ]E9<?K^YN?YR
M)SZ?WWV_^7CW\?J6#)E,H\G1 3\=1?'^D;BT*M5>?)")SK1?HW;\4D@84*0(
M@+A$:."KKG)Q;JTL%BH5L[6XLQ4")NX0K$N3E[)8"Z(OCW^(!JCFWF3W-#\)
MR\^;Y6?*KY0J.,S-3(J>1O0U"@%,F5)L7#5S.M72(CH1WB19Q?;<>HR6-A47
M2EJD13K$Y=W,6$!&60REQ6KK;E6RB6_X"1'CC;L^OVV<WII-6"$TU.;CJ2J%
M-V)O?SB,AL,A+!)RL;!J(9'JTL) 7<I,R-Q4L+Y>KT[P6J0T"HN<8V0F#AE)
M!WUQP69C/\0,!>:JLD2L0X2ER.H4)-L4R$<IZ',.$'F%LO+"8B,L5I:93N0L
M4V1S@&B%N%KQA/>T-<+FVREYC5(HB?(CH7Y5\ O+*/A$ 6<&YXU$F56.W;0+
MQ(-,(WOG* 0Q[,?35S1MQ \ES2P*N&"LN/WZX>:)N2K,'#4SX^[,B#=.A6G
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M9BI=,#- I20_=Y9]388C"QJ1>HX;B0!7$&3T*1%&"Q+(--(.\- XT*779+[
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M<U>*%"<=:@F'=HF=Z4\_#$[[O[[#=M2R';V'_A]K\W^QX#E'N#)%*?0:<N%
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M4DO0TRYJMS+DM7B=%D1T1>W,@A;B\T-QY5,Y=8$#>K"Q6+)D$LTLL>^?^F(
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MT.R5I3RS+]X"]XLSTAF#\]/3)P75+:7 $N*JH#-IH%#GM9'Q,$04002$\7R
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M6=$@B,H)T'TAI3ELG(%NM!S_!5!+ P04    " "<@$%8R(3/_F4"  "(!@
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M;W)K<VAE971S+W-H965T,S,N>&ULE599;^,V$/XK ^V!!!!LD;JSM@''<=$
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M'*42@OHLA$])XI,\@C2T*'Z.=H=A:(\)7+$:9VL)3C))D)'F0+)> #%%-TB
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M/JXL _Z?2VEV!ZN@>T2._@502P,$%     @ G(!!6)JJLX,]!   D@L  !D
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M6^\6FT(G&N$';EOA?9=]ZX#6VZG9176G'ZC7%HBPPRG<]AG\5"J0M_'N++#
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MG<=U$Z?;X"L[[<BEPK"FWP(:'T#?]UJ[\\07N/QH9M\ 4$L#!!0    ( )R
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M-N#ZNBSU?F $M'\?AO\"4$L#!!0    ( )R 05ALSXXZ1P,  "D'   9
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MS;'=X =!2T.;3D;4.1ST:"_[PQZ%G./[/4%6Q'[-[K2TG22UT17MX&[5#DP
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M[1.B_:B+I7FV>RCJNEB8X5RKB2Z) .O3HJC7'R2@?<@]_PM02P,$%     @
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M>/USCQE>N$'9!?A^*:79#>P=L+G")]\!4$L#!!0    ( )R 05A)S7C]70(
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M!UNR@G[?C/V&WO]"J:GG1>*;UWI1H@<E,Z@:1:FI;E?6WD 5)19"U4>9LLN
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MJS*[P4PU>WM+O"8SHV_5ZB2NK$>H!G=7V5#;2QOCM,"-*1@3,2F).<W>JDG
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MGH?MXY(]-0M\S_;/E.R^<\'MK<LCDPP%E*FC8@D,K<A/RO146Z$NSE)':,W
M]YT0]M^WA#OMG[I":XJS[Z!P:Q]R:0D')R<!;+E^Z!S7\*E=Z(71\;9K'IR,
MU=\2WPA;I#(U&<REGW4=2 "V.^GO!H*NRL/RC IY]"YOET 28,I OI]3F>%J
MH,[?]?\M@_\ 4$L#!!0    ( )R 05CT6B,S? 0  )D/   9    >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;*U76W/J-A#^*QHWTTEF<O#]E@(S).;T9*80
MAI">9\46X!Y;HI(<TG_?M0V.,8+D@1>PI&]7^ZU6J]W^EO%?8DV(1.]Y1L5
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M"1T%R@D"OQ,Y*I03>.K "1L7A&==,,L*R A BQ,HSR3.]CY8<I8C+*#  _]
M,@ /5<7;)X3#(R--SW0[?!6@,' Z=(]!EF.':K:F\5&_&&?YCI)_H$H"2MON
MV</!YHRJ0N 3RKL=#P[&MRV[0UH%\P*_FQ^4L/!4XC=;A9MYEOB]*H;;G"N:
M"61\S,5'@*L9UUL%[5S=\[TNX6.4TS.Z:5^IR_5/T+4^Z%IGZ49I5I2G>R'"
MEL)(KQO62E3H=@FK4,Z)_&]^U'/FV=)G.*(R34K2T!<A0>*"IS*%0";O<59
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MSL_@NC?:NI30< "J!:@F4$VBFD(UC6HAJD649I>D"0>,3QD.&*/A %3S42U
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M!.K]IR3)5R^* M8_]W#^?U!+ P04    " "<@$%8[?V.]<\$  !6&@  &0
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MZ$V1+:LAF5K&!\'D72+SQ&1^__M\=O_X-_A\=P-F?SS=SK_-[A[?O0D01)_
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M=WY!5ZMR=I2&D5G1KPMIJ/N+;4SC%I4-(/]22K,U[ 7U  ]^ U!+ P04
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M/+]E0V<O=_=:W*.7N[L=;/SJ=?@&SS^ ]XED1,*'"R5X@A:9Q-F:W%% ,R%
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M."=Y>9D CH%* W%_0PA_'L@%FK.MU?]02P,$%     @ G(!!6/AD+=DW P
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M@80I ?E]6\J5W@[4M:&[5\Y^ %!+ P04    " "<@$%8KG<CX6P#  !B#
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M(Q6 'T\BQQO)MN5F_I%)=30H+S?J] 9<&ZCW:\;DRXT^']3GP='_4$L#!!0
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M_#[.*Y(EV96V9%)=D%EQHYXPP'6 ZE\QI;NHZ%NR?!3Y?P%02P,$%     @
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M-.F&8=@'VCJVA4JB1U)Q ^S'CY04T9)EQA?Z2R+)XBN^Y#G4(Y*#)1<_Y!Q
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M'BO,\@.L=&"EIUB9BY7NL](T=[.R@94=93W6H-OJ0N]"%S';(XY"'$4'F/G
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MO/H/=HW6-D"\Y8+FC;$<09X6]2]^:4 <&<A ]0:H,4"J@?N*@=,8.$,-W,;
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M.X=Z4\8R[X[42(<8U@@@"ELYT:,TREJ]!#N>:5$#>; =/7M(HU^_WA &B2;
M%&)GRDNUL0RW<SWF<<-P$" %L9-B/W%L"4H*<;3=%!!@"+$SI MU+%/\V@P"
M5X@= 5H>>6.V/NXU"."$T 'ED5A9MF_G $G$CJ3>Y+',NR./S/$-=SL$8$7L
M]SN]Z6.9]]FEH^2&@@% Q Z@E^MC&7#G[&*FLPO 0NQ@>;$^RIH^^M@T&D +
M8J?%GO)H#^JURJ,'&/'L&.E"'LL4OS2!'I#%:X& BT5C-FNS/17$ YYX9,C'
M3%:8[=NYRB,T.Y)ZD\<R[S-YE(8U JSR[+<^O:ECF7>G7M^AAD=H'O#'L_/G
MY>I8!MPYN4Q/)#S BF?'RDO5L0RW<_6(/=/\ 2P\.RSVD\>6H+1='H$BGITB
MG<BC?,$, ED\.P2T/,K&;-9F^SZI!IY0=T!YI%:8[=LY0!*U(ZDW>2SS[MRL
M$H<:[LXHP(K:;WYZT\<R;[5@CSC"H(\4 $3M -K#ZO#J7H=GN&ZC%<?%#I:7
MZF,9KJJ/'B.&JW\*N*!V7.RGCRU!6:L^4N ([=^.H74_QCR#@!;::LCXC=GZ
M<&0H (4.Z<G0/DP9"DRB ]DRM.[+4.RX!L^. :W80,8,JQLSE#G"L*H9$(AU
M;<RPNC'#L&NH \#"NG5F6-V9D85CVE@&X(+U8<VT!.6M^LB (ZQ_;X8UN/G2
M@!96<?/;S!GB-F;KPYQA !0VI#G#^C!G&#")#63.L+HY0ZECLCX9T(H-Y,ZP
MNCO#?.,%+P,"L:[=&59W9ZA)ISF A7?KSO"Z.^,;3W(.N.!]N#,M046K/G+@
M"._?G>%U=X8PPZ4!![3P-G>&X,9L?;@S'(#"AW1G>!_N# <F\8'<&5YW9X3G
M4-,BJ?P8;2!WAM?=&>DYW"#H' C$NW9G>-V=8=@D3  6WJT[P^ON#.:2FL8#
M>,'[\&=:@LI6@10 $M&_/R,:_!EI0*T MH@V?X:0QFQ]^#,"B"*&]&=$'_Z,
M "B)@?P94?=GA.\(WX5_AF=[ M E!C)K1-VL\?75K\&=$( CT;59(^IF#:.&
MFVT!E!'=FC6B;M80EW+#1:VH_,2Y#[>F):C?+I9 %=&_6R/J;HWIEY ","/:
MS)K\67!#LC[,&@EPD4.:-;(/LT8"G^1 9HVLFS72=TPW:Q+()0<R:V3=K/&E
MN6"@D>S:K)%UL\8W_49* EADMV:-K)LUU&,F?93 "]F'6],2%+NM BF!)+)_
MNT;6[9KGA!M77IA;J.2V>"TP1=-XO<PV[\YM]VY?/3S9O' 'AV_>6_P<)+>A
MKC52-[JIZ^2$33:O FXVLGA5O'YW'6=9O"@^SE4P4TE^@/[^)HZSIXT\P?:%
MS,G_4$L#!!0    ( )R 05C2N.SXK (  '\'   9    >&PO=V]R:W-H965T
M<R]S:&5E=#@U+GAM;*U574_;,!3]*U:&)I &^6X+:R,5LFD\#"K*Q\.T!S>Y
M;2*2.+.=%O[]KIT0I25%?> E\<<]Q_<<V]?C#>//(@&0Y"7/"C$Q$BG+"],4
M40(Y%6>LA )GEHSG5&*7KTQ1<J"Q!N69Z5C6P,QI6AC!6(_->#!FE<S2 F:<
MB"K/*7^]A(QM)H9MO W<I:M$J@$S&)=T!7.0#^6,8\]L6>(TAT*DK" <EA-C
M:E^$OHK7 8\I;$2G3922!6//JG,=3PQ+)0091%(Q4/RMX0JR3!%A&O\:3J-=
M4@&[[3?VGUH[:EE0 5<L>TICF4R,D4%B6-(JDW=L\PL:/3K!B&5"?\FFCAVZ
M!HDJ(5G>@#&#/"WJ/WUI?.@ ;&\/P&D SJ$ MP&XAP*\!N!I9VHIVH>02AJ,
M.=L0KJ*1336TF1J-\M-";?M<<IQ-$2>#V]G]]>W-G$QO0C)]FMZ%<W)*K@O)
M4]S9B#S2K )!CD.0-,W$"4X^S$-R?'1"CDA:D/N$58(6L1B;$K-1G&;4K'Q9
MK^SL63F$Z(RX]C?B6([; [\Z'.[TP,/#X?8VW$0+6Q^=UD='\[E[^.8)Y7!Z
MB2<P)C/ZBA=#DBGGM%B!;O^9+H3D>,K_]CE5<WO]W.KF7XB21C Q\&H+X&LP
M@J]?[('UO<^WSR0+/XELRU.W]=3]B#VXK:20>+C28M5G6@WV-5A5MW5@GP]'
M]OG87'?MZ D;N?ZYNQT6]K'9CN>T85L2O%:"]Z&$1Q 2XK[L:]R@NYX[M+S1
M3O9]80/+LG:R[V5S1WNR]]OL_0^S__%28GG&$RT96:.2/AW^.]_\P=#?W83W
M49[KN,Z.BIZHD=^QI!9A=JJ=>II^4[[":D4R6"+..ALB :_+?=V1K-0%<,$D
MEE/=3/"%!*X"<'[)F'SKJ)K:OKG!?U!+ P04    " "<@$%8H*79N/ $  !D
M(   &0   'AL+W=O<FMS:&5E=',O<VAE970X-BYX;6S%6MMNXS80_15"+8HN
MD%@2)=]2VX 3]A*@R0;QMOM0](&1&%N()'I)VDZ ?GQ)29%$1^;& 0'[(=9E
MYI!SR#/DF)GL*'OB*T($>,[2G$^=E1#K"]?ET8IDF/?HFN3RS2-E&1;REBU=
MOF8$QX53EKK0\P9NAI/<F4V*9W=L-J$;D28YN6. ;[(,LY=+DM+=U/&=UP?W
MR7(EU -W-EGC)5D0\=?ZCLD[MT:)DXSD/*$Y8.1QZLS]"P1#Y5!8_)V0'6]=
M Q7* Z5/ZN8ZGCJ>ZA%)2204!)9?6W)%TE0AR7Y\JT"=NDWEV+Y^1?^M"%X&
M\X YN:+IUR06JZDS<D!,'O$F%?=T]P>I NHKO(BFO/@+=I6MYX!HPP7-*F?9
M@RS)RV_\7!'1<O '!QQ@Y0#W'<(##D'E$+S7(:P<"JK=,I2"!X0%GDT8W0&F
MK"6:NBC(++QE^$FNQGTAF'R;2#\Q^WSWY?KS[0+,;Q&8?YW?HP4X!_>$"Y9$
M@L1@(6CT!.8[S&)^!FXQ8U@-%/@9$8&3E'^2YC\"%_ 59H2_?B4Y^+*B&X[S
MF$]<(?NI6G.CJD^799_@@3[Y$-S07*PX^#6/2:P#N#+ .DKX&N4E-"(B$O5
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MM321!PO,N!HJ-XYQWU0SC1L+'OKV!'6VC@$6(!MV4\( \\;VE?T#&P<I.+C
M#I15'<U0PY,)LEW?O?RZZ6&R&4,["">-7U>PV28,C/.TY:.+?#2T.@]4C_I>
MR55%[G4E2Y--X-MN;XD-.']D^\$5E9=3%KQY_.C4[X%"O;XS([ED7E>< 1>,
M;-1;3@/.#^SPRJ<)7@X_\#^<?OJ%?:!:OY==(YE=O7W<AQE2.C+ VBE=2G4:
M#5!.V%8WDAS$]%"(LB.H1^MF=:%;M,[X@VIB=6-UH2D[X"^8R1+&048VDM*U
M1_*$P\JFLGP0=*_;K%<J9-.F;W>R$2=, >3[#:7B_* FJ%O[^;]02P,$%
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M:HMN)"3BGR9#!S8-M0GS+<%JA@Y+0X>=<_0!>(+8&C$S*R.Z:4\&W2 \0"]
MN&ARJU-YK%N68#6W1J5;H^^-:/+<%M&=Z&,GH$V8;PE6L_2LM/3LHR+ZS*:A
M-F&^)5C-T'%IZ-A61'>#\*@]HCN5Q[IE"59SZ[QTZ_P[(_IA"V@!E!(JT6^<
M9>D)NJ'!:9.?G8\Z=D+:A/F68#6+<:]:A/8^*L8+LB5/K=)\6[2ZJWM+>]PY
M=>^S9 5<A[H)\*8XG1>(D4'H(O%IYIU/W*>:*>^W\1O:]+VR37T 7C4 KW,
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M&ZC[:\;DZXE^0/GU9/854$L#!!0    ( )R 05@YQY%89 0  ,T6   9
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MA:"9OEP F0)3!O+W&:7B^48]H#K!'OP/4$L#!!0    ( )R 05A#O4"XA (
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M_$IO: )#!^M8@]J",_KQ!S_R?FZ*QCN!'<2F4\>FTX8^&L.*"<'$"@N/4Y%
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M!5)VN0&JQTA:03]_YER]%M(&RF.VT?]02P,$%     @ G(!!6&J#_"WX P
MUA4  !D   !X;"]W;W)K<VAE971S+W-H965T.3DN>&ULM9A;<Z,V (7_BH9V
M.LE,&BZ^)K69<0SM;ELW'CMI'SI]4$ V3 "QDK W_?65!,&08(V]5?(0<]'Y
M))V#)-!DC\DSC1!BX&N:9'1J1(SEMZ9)@PBED%[C'&7\S@:3%#)^2K8FS0F"
MH12EB>E8UM!,89P9[D1>6Q)W@@N6Q!E:$D"+-(7DY0XE>#\U;./UPBK>1DQ<
M,-U)#K=HC=ACOB3\S*PI89RBC,8X P1MIL;,OO7MGA#($G_&:$\;QT!TY0GC
M9W'R.9P:EF@12E# ! +RGQV:HR01)-Z.+Q74J.L4PN;Q*_UGV7G>F2=(T1PG
M?\4ABZ;&V  AVL B82N\_X2J#@T$+\ )E?_!OBP[<@P0%)3AM!+S%J1Q5O["
MKY41#8'=/R)P*H%SJJ!7"7IO!<,C@GXEZ)]:PZ 2R*Z;9=^E<1YDT)T0O =$
ME.8T<2#=EVKN5YR)!V7-"+\;<QUSY_>+Q?T?8/UP/_\-K/SEXVK^:;;VP7)U
M_\MJM@ 7'F(P3N@E^!$\KCUP\?TEH!$DB((X P\1+BC,0CHQ&6^,0)I!5;%7
M5NP<J=AVP )G+*+ ST(4M@$F[T7=%>>U*W>.DC@KMM? N;D"CN7T.AHT5\M_
M+1(N'TNYT]4?M=Q#P37HV4?E_NER6V%&K\ZU)WF](SS_2Q&SERLP3R"E &_
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M;R..8 [  X9$4;4/[NQ'8;-/A>O_\HU^ U!+ P04    " "<@$%8EXJ[',
M   3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!
M5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]I
MSI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z
M3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=
MQ_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( )R
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M%%DKBJP51=:*(FM%D;7ZG[)^GZ;]/XY?GNE0=^-+?K;\8_#V)U!+ 0(4 Q0
M   ( )R 05@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ G(!!6%Q* *KN    *P(  !$
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M970R+GAM;%!+ 0(4 Q0    ( )R 05C68ALHP <  +8?   8
M  " @;L2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " "<
M@$%8A./5>!$#  "9"   &               @(&Q&@  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ G(!!6#G7>26M!@  O1X  !@
M         ("!^!T  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( )R 05A@[2[0?0P  *1W   8              " @=LD  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " "<@$%8O6""Y*4"  #%!@
M&               @(&.,0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ G(!!6"5:_[\:#0  B$   !@              ("!:30  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( )R 05C]S9R ^ 8
M #\1   8              " @;E!  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    " "<@$%8NX$..,\B   J<0  &0              @('G
M2   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( )R 05@(
MV0OU_0L  ,4>   9              " @>UK  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ G(!!6&Y?66FB!   40P  !D
M     ("!(7@  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( )R 05A83@ES_0,  %T(   9              "
M@1ZA  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ G(!!
M6,#G^% R!   2 D  !D              ("!4J4  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    " "<@$%8@=7EL<X#  "V"   &0
M        @(&[J0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( )R 05AJ HII>0,  &8'   9              " @<"M  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ G(!!6!ZD).J6!   L D
M !D              ("!<+$  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    " "<@$%8/JD?X<@'  #2$@  &0              @($]M@
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( )R 05A+34&[
M( H  $<8   9              " @3R^  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ G(!!6#B]&<*T#@  5RL  !D
M ("!D\@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " "<
M@$%8X,!IH$H/  "34P  &0              @(%^UP  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( )R 05BQF%[([P0  "\+   9
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M970S,"YX;6Q02P$"% ,4    " "<@$%8/@V4:#D%  #;&@  &0
M    @($)$0$ >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M )R 05@"06A311P  +]<   9              " @7D6 0!X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ G(!!6,D8XI".!   4 H  !D
M             ("!]3(! 'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    " "<@$%8FJJS@ST$  "2"P  &0              @(&Z-P$ >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( )R 05B<'H%)7P,
M -L&   9              " @2X\ 0!X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ G(!!6$K".0Z1"   YA\  !D              ("!
MQ#\! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " "<@$%8
ML5:4Z!X#  !S!@  &0              @(&,2 $ >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( )R 05@$_5Z][0,  $T)   9
M      " @>%+ 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ G(!!6%]HY/S: @  8P8  !D              ("!!5 ! 'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " "<@$%8B!$5V!,#  !T!@
M&0              @($64P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( )R 05@OUB1?(0,  ',&   9              " @6!6 0!X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ G(!!6(?P:\M6
M!0  2@P  !D              ("!N%D! 'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    " "<@$%8;,^..D<#   I!P  &0
M@(%%7P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( )R
M05@,?#O8S <  -05   9              " @<-B 0!X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ G(!!6-#VYK8U!@  ,1   !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( )R 05C<Y6PG+P,  *8,   9
M  " @>I] 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
MG(!!6(:$6MK_!P  2U0  !D              ("!4($! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    " "<@$%82_W<@E,%   S'P  &0
M            @(&&B0$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( )R 05B%.]03"@<  !4[   9              " @1"/ 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ G(!!6*49LVO' P
M>Q$  !D              ("!498! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    " "<@$%8]%HC,WP$  "9#P  &0              @(%/
MF@$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( )R 05A)
MJ0>.T (  #<(   9              " @0*? 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ G(!!6*NRR;+]$@  '!T! !D
M     ("!":(! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M" "<@$%8F-2?]A@)  #Z80  &0              @($]M0$ >&PO=V]R:W-H
M965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( )R 05CM_8[USP0  %8:   9
M              " @8R^ 0!X;"]W;W)K<VAE971S+W-H965T-3DN>&UL4$L!
M A0#%     @ G(!!6%P[[2(2 P  2@D  !D              ("!DL,! 'AL
M+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " "<@$%8DW]A!3 )
M  "M1@  &0              @(';Q@$ >&PO=V]R:W-H965T<R]S:&5E=#8Q
M+GAM;%!+ 0(4 Q0    ( )R 05@>$Y8^(0L  *MR   9              "
M@4+0 0!X;"]W;W)K<VAE971S+W-H965T-C(N>&UL4$L! A0#%     @ G(!!
M6/';7OE&!   A!8  !D              ("!FML! 'AL+W=O<FMS:&5E=',O
M<VAE970V,RYX;6Q02P$"% ,4    " "<@$%8Y^* .+8"  #,!0  &0
M        @($7X $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0
M   ( )R 05@> =%,E 0  'L5   9              " @03C 0!X;"]W;W)K
M<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ G(!!6&F0VD"+ P  ?0X
M !D              ("!S^<! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q0
M2P$"% ,4    " "<@$%8U<MTLL8"  !["0  &0              @(&1ZP$
M>&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( )R 05AL$A_M
MV0(  *\*   9              " @8[N 0!X;"]W;W)K<VAE971S+W-H965T
M-C@N>&UL4$L! A0#%     @ G(!!6 4.H.N6 P  YQ(  !D
M ("!GO$! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " "<
M@$%8^&0MV3<#   S"0  &0              @(%K]0$ >&PO=V]R:W-H965T
M<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( )R 05CMDJ!2N0,  &,.   9
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M970W-2YX;6Q02P$"% ,4    " "<@$%8PJ\[&^\"   @"0  &0
M    @(%'"P( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;%!+ 0(4 Q0    (
M )R 05C<S+8B6P8  .<S   9              " @6T. @!X;"]W;W)K<VAE
M971S+W-H965T-S<N>&UL4$L! A0#%     @ G(!!6,XQH.LC!@  LRD  !D
M             ("!_Q0" 'AL+W=O<FMS:&5E=',O<VAE970W."YX;6Q02P$"
M% ,4    " "<@$%8Q\@":GD"  "R!@  &0              @(%9&P( >&PO
M=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    ( )R 05CYXY3?JP4
M #<?   9              " @0D> @!X;"]W;W)K<VAE971S+W-H965T.# N
M>&UL4$L! A0#%     @ G(!!6)0QD, X P  8 H  !D              ("!
MZR," 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"% ,4    " "<@$%8
M(.%=?0$#  "?"   &0              @(%:)P( >&PO=V]R:W-H965T<R]S
M:&5E=#@R+GAM;%!+ 0(4 Q0    ( )R 05B]33"[E 0  .85   9
M      " @9(J @!X;"]W;W)K<VAE971S+W-H965T.#,N>&UL4$L! A0#%
M  @ G(!!6'BN70"N!P  G#D  !D              ("!72\" 'AL+W=O<FMS
M:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    " "<@$%8TKCL^*P"  !_!P
M&0              @(%"-P( >&PO=V]R:W-H965T<R]S:&5E=#@U+GAM;%!+
M 0(4 Q0    ( )R 05B@I=FX\ 0  &0@   9              " @24Z @!X
M;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%     @ G(!!6.52EB\#
M!   Y@\  !D              ("!3#\" 'AL+W=O<FMS:&5E=',O<VAE970X
M-RYX;6Q02P$"% ,4    " "<@$%8FF'AO+P#  "M$   &0
M@(&&0P( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+ 0(4 Q0    ( )R
M05BXUH.>!@4  *0<   9              " @7E' @!X;"]W;W)K<VAE971S
M+W-H965T.#DN>&UL4$L! A0#%     @ G(!!6+^5^R0R#@  VYL  !D
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M=#DT+GAM;%!+ 0(4 Q0    ( )R 05A#O4"XA (  +L&   9
M  " @1-L @!X;"]W;W)K<VAE971S+W-H965T.34N>&UL4$L! A0#%     @
MG(!!6'AG1$OM P  YQ   !D              ("!SFX" 'AL+W=O<FMS:&5E
M=',O<VAE970Y-BYX;6Q02P$"% ,4    " "<@$%8Z)2CG)D#   /#   &0
M            @('R<@( >&PO=V]R:W-H965T<R]S:&5E=#DW+GAM;%!+ 0(4
M Q0    ( )R 05B7]P2 9 0  '(;   9              " @<)V @!X;"]W
M;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @ G(!!6&J#_"WX P
MUA4  !D              ("!77L" 'AL+W=O<FMS:&5E=',O<VAE970Y.2YX
M;6Q02P$"% ,4    " "<@$%8<QA39S<#  #R$P  #0              @ &,
M?P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( )R 05B7BKL<P    !,"   +
M              "  >Z" @!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( )R 05B%
M.!+O2P<  ,M    /              "  =># @!X;"]W;W)K8F]O:RYX;6Q0
M2P$"% ,4    " "<@$%8M_K&\-$"   R.@  &@              @ %/BP(
M>&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "<@$%8%8LH
MOU0"   Y.   $P              @ %8C@( 6T-O;G1E;G1?5'EP97-=+GAM
7;%!+!08     :P!K &0=  #=D (    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>447</ContextCount>
  <ElementCount>491</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>131</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>19</UnitCount>
  <MyReports>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE</Role>
      <ShortName>REVENUE AND ACCOUNTS RECEIVABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE</Role>
      <ShortName>COMPUTATION OF NET INCOME PER COMMON SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - FAIR VALUE MEASUREMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - STANDARD BEARER</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/STANDARDBEARER</Role>
      <ShortName>STANDARD BEARER</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - OPERATION EXPANSIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPERATIONEXPANSIONS</Role>
      <ShortName>OPERATION EXPANSIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - BUSINESS SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/BUSINESSSEGMENTS</Role>
      <ShortName>BUSINESS SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - PROPERTY AND EQUIPMENT??? NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET</Role>
      <ShortName>PROPERTY AND EQUIPMENT??? NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - INTANGIBLE ASSETS ??? NET</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNET</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - GOODWILL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/GOODWILL</Role>
      <ShortName>GOODWILL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - RESTRICTED AND OTHER ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS</Role>
      <ShortName>RESTRICTED AND OTHER ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - OTHER ACCRUED LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES</Role>
      <ShortName>OTHER ACCRUED LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - DEBT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBT</Role>
      <ShortName>DEBT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - OPTIONS AND AWARDS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDS</Role>
      <ShortName>OPTIONS AND AWARDS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - DEFINED CONTRIBUTION PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS</Role>
      <ShortName>DEFINED CONTRIBUTION PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - SELF INSURANCE LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES</Role>
      <ShortName>SELF INSURANCE LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM</Role>
      <ShortName>COMMON STOCK REPURCHASE PROGRAM</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables</Role>
      <ShortName>REVENUE AND ACCOUNTS RECEIVABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables</Role>
      <ShortName>COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - OPERATION EXPANSIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables</Role>
      <ShortName>OPERATION EXPANSIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/OPERATIONEXPANSIONS</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - BUSINESS SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables</Role>
      <ShortName>BUSINESS SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/BUSINESSSEGMENTS</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - PROPERTY AND EQUIPMENT??? NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT??? NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - INTANGIBLE ASSETS ??? NET (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/INTANGIBLEASSETSNET</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - GOODWILL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/GOODWILLTables</Role>
      <ShortName>GOODWILL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/GOODWILL</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables</Role>
      <ShortName>RESTRICTED AND OTHER ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables</Role>
      <ShortName>OTHER ACCRUED LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/INCOMETAXES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - DEBT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBTTables</Role>
      <ShortName>DEBT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/DEBT</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - OPTIONS AND AWARDS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables</Role>
      <ShortName>OPTIONS AND AWARDS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/OPTIONSANDAWARDS</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - LEASES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESTables</Role>
      <ShortName>LEASES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/LEASES</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables</Role>
      <ShortName>SELF INSURANCE LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails</Role>
      <ShortName>REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails</Role>
      <ShortName>REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails</Role>
      <ShortName>REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails</Role>
      <ShortName>COMPUTATION OF NET INCOME PER COMMON SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - STANDARD BEARER (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/STANDARDBEARERDetails</Role>
      <ShortName>STANDARD BEARER (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/STANDARDBEARER</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails</Role>
      <ShortName>OPERATION EXPANSIONS- Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails</Role>
      <ShortName>OPERATION EXPANSIONS - Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails</Role>
      <ShortName>BUSINESS SEGMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails</Role>
      <ShortName>BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails</Role>
      <ShortName>BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT??? NET - Schedule of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - PROPERTY AND EQUIPMENT??? NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT??? NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET - Schedule of Finite Lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - INTANGIBLE ASSETS ??? NET - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - INTANGIBLE ASSETS ??? NET - Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET - Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS ??? NET - Schedule of Indefinite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - GOODWILL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/GOODWILLDetails</Role>
      <ShortName>GOODWILL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/GOODWILLTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails</Role>
      <ShortName>RESTRICTED AND OTHER ASSETS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails</Role>
      <ShortName>OTHER ACCRUED LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - INCOME TAXES - Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails</Role>
      <ShortName>INCOME TAXES - Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - INCOME TAXES - Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails</Role>
      <ShortName>INCOME TAXES - Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails</Role>
      <ShortName>INCOME TAXES - Narrative (YE) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails</Role>
      <ShortName>DEBT - Schedule of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails</Role>
      <ShortName>DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails</Role>
      <ShortName>DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails</Role>
      <ShortName>DEBT - Long-term Debt Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Stock Options, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Intrinsic Values (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Restricted Award Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails</Role>
      <ShortName>OPTIONS AND AWARDS - Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9954529 - Disclosure - LEASES - Lessee Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails</Role>
      <ShortName>LEASES - Lessee Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9954530 - Disclosure - LEASES - Lessee Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails</Role>
      <ShortName>LEASES - Lessee Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>LEASES - Lessee Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9954532 - Disclosure - LEASES - Lessor Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails</Role>
      <ShortName>LEASES - Lessor Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9954533 - Disclosure - LEASES - Lessor Rental Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails</Role>
      <ShortName>LEASES - Lessor Rental Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails</Role>
      <ShortName>LEASES - Lessor Future Minimum Lease Payments Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails</Role>
      <ShortName>DEFINED CONTRIBUTION PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails</Role>
      <ShortName>SELF INSURANCE LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables</ParentRole>
      <Position>97</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>98</Position>
    </Report>
    <Report instance="ensg-20231231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails</Role>
      <ShortName>COMMON STOCK REPURCHASE PROGRAM (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM</ParentRole>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ensg-20231231.htm">ensg-20231231.htm</File>
    <File>ensg-20231231.xsd</File>
    <File>ensg-20231231_cal.xml</File>
    <File>ensg-20231231_def.xml</File>
    <File>ensg-20231231_lab.xml</File>
    <File>ensg-20231231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ensg-20231231_g1.jpg</File>
    <File>ensg-20231231_g2.jpg</File>
    <File>ensg-20231231_g3.jpg</File>
    <File>ensg-20231231_g4.jpg</File>
    <File>ensg-20231231_g5.jpg</File>
    <File>ensg-20231231_g6.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1361">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="17">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>127
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ensg-20231231.htm": {
   "nsprefix": "ensg",
   "nsuri": "http://www.ensigngroup.net/20231231",
   "dts": {
    "inline": {
     "local": [
      "ensg-20231231.htm"
     ]
    },
    "schema": {
     "local": [
      "ensg-20231231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "ensg-20231231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ensg-20231231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "ensg-20231231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ensg-20231231_pre.xml"
     ]
    }
   },
   "keyStandard": 409,
   "keyCustom": 82,
   "axisStandard": 37,
   "axisCustom": 6,
   "memberStandard": 52,
   "memberCustom": 76,
   "hidden": {
    "total": 12,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 6,
    "http://xbrl.sec.gov/ecd/2023": 2
   },
   "contextCount": 447,
   "entityCount": 1,
   "segmentCount": 131,
   "elementCount": 880,
   "unitCount": 19,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 1361,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 17
   },
   "report": {
    "R1": {
     "role": "http://www.ensigngroup.net/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.ensigngroup.net/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
     "longName": "0000003 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
     "longName": "0000004 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
     "longName": "0000005 - Statement - CONSOLIDATED STATEMENTS OF INCOME",
     "shortName": "CONSOLIDATED STATEMENTS OF INCOME",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
     "longName": "0000006 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-14",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical",
     "longName": "0000007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "longName": "0000008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfFinancingCostsAndDiscounts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS",
     "longName": "0000009 - Disclosure - DESCRIPTION OF BUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "longName": "0000010 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE",
     "longName": "0000011 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE",
     "shortName": "REVENUE AND ACCOUNTS RECEIVABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE",
     "longName": "0000012 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE",
     "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS",
     "longName": "0000013 - Disclosure - FAIR VALUE MEASUREMENTS",
     "shortName": "FAIR VALUE MEASUREMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.ensigngroup.net/role/STANDARDBEARER",
     "longName": "0000014 - Disclosure - STANDARD BEARER",
     "shortName": "STANDARD BEARER",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ensg:StandardBearerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ensg:StandardBearerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS",
     "longName": "0000015 - Disclosure - OPERATION EXPANSIONS",
     "shortName": "OPERATION EXPANSIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTS",
     "longName": "0000016 - Disclosure - BUSINESS SEGMENTS",
     "shortName": "BUSINESS SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET",
     "longName": "0000017 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET",
     "shortName": "PROPERTY AND EQUIPMENT\u2014 NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET",
     "longName": "0000018 - Disclosure - INTANGIBLE ASSETS \u2014 NET",
     "shortName": "INTANGIBLE ASSETS \u2014 NET",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.ensigngroup.net/role/GOODWILL",
     "longName": "0000019 - Disclosure - GOODWILL",
     "shortName": "GOODWILL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS",
     "longName": "0000020 - Disclosure - RESTRICTED AND OTHER ASSETS",
     "shortName": "RESTRICTED AND OTHER ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES",
     "longName": "0000021 - Disclosure - OTHER ACCRUED LIABILITIES",
     "shortName": "OTHER ACCRUED LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXES",
     "longName": "0000022 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.ensigngroup.net/role/DEBT",
     "longName": "0000023 - Disclosure - DEBT",
     "shortName": "DEBT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDS",
     "longName": "0000024 - Disclosure - OPTIONS AND AWARDS",
     "shortName": "OPTIONS AND AWARDS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.ensigngroup.net/role/LEASES",
     "longName": "0000025 - Disclosure - LEASES",
     "shortName": "LEASES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS",
     "longName": "0000026 - Disclosure - DEFINED CONTRIBUTION PLANS",
     "shortName": "DEFINED CONTRIBUTION PLANS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES",
     "longName": "0000027 - Disclosure - SELF INSURANCE LIABILITIES",
     "shortName": "SELF INSURANCE LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES",
     "longName": "0000028 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM",
     "longName": "0000029 - Disclosure - COMMON STOCK REPURCHASE PROGRAM",
     "shortName": "COMMON STOCK REPURCHASE PROGRAM",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-441",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-441",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies",
     "longName": "9954471 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables",
     "longName": "9954472 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE (Tables)",
     "shortName": "REVENUE AND ACCOUNTS RECEIVABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables",
     "longName": "9954473 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)",
     "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables",
     "longName": "9954474 - Disclosure - OPERATION EXPANSIONS (Tables)",
     "shortName": "OPERATION EXPANSIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables",
     "longName": "9954475 - Disclosure - BUSINESS SEGMENTS (Tables)",
     "shortName": "BUSINESS SEGMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables",
     "longName": "9954476 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT\u2014 NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables",
     "longName": "9954477 - Disclosure - INTANGIBLE ASSETS \u2014 NET (Tables)",
     "shortName": "INTANGIBLE ASSETS \u2014 NET (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.ensigngroup.net/role/GOODWILLTables",
     "longName": "9954478 - Disclosure - GOODWILL (Tables)",
     "shortName": "GOODWILL (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables",
     "longName": "9954479 - Disclosure - RESTRICTED AND OTHER ASSETS (Tables)",
     "shortName": "RESTRICTED AND OTHER ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables",
     "longName": "9954480 - Disclosure - OTHER ACCRUED LIABILITIES (Tables)",
     "shortName": "OTHER ACCRUED LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXESTables",
     "longName": "9954481 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.ensigngroup.net/role/DEBTTables",
     "longName": "9954482 - Disclosure - DEBT (Tables)",
     "shortName": "DEBT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables",
     "longName": "9954483 - Disclosure - OPTIONS AND AWARDS (Tables)",
     "shortName": "OPTIONS AND AWARDS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.ensigngroup.net/role/LEASESTables",
     "longName": "9954484 - Disclosure - LEASES (Tables)",
     "shortName": "LEASES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables",
     "longName": "9954485 - Disclosure - SELF INSURANCE LIABILITIES (Tables)",
     "shortName": "SELF INSURANCE LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
     "longName": "9954486 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfHealthCareFacilities",
      "unitRef": "facility",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfHealthCareFacilities",
      "unitRef": "facility",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails",
     "longName": "9954487 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-54",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails",
     "longName": "9954488 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Leases and Leasehold Improvements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfFinancingLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfFinancingLeases",
      "unitRef": "lease",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails",
     "longName": "9954489 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets and Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:GoodwillImpairedAccumulatedImpairmentLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails",
     "longName": "9954490 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Self-Insurance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:SelfInsuranceReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-74",
      "name": "us-gaap:SelfInsuranceReserve",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails",
     "longName": "9954491 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)",
     "shortName": "REVENUE AND ACCOUNTS RECEIVABLE -Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ensg:FamilyFirstCoronavirusResponseActPaymentsReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
     "longName": "9954492 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)",
     "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Disaggregation of Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R54": {
     "role": "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
     "longName": "9954493 - Disclosure - REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)",
     "shortName": "REVENUE AND ACCOUNTS RECEIVABLE - Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:AccountsReceivableGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
     "longName": "9954494 - Disclosure - COMPUTATION OF NET INCOME PER COMMON SHARE (Details)",
     "shortName": "COMPUTATION OF NET INCOME PER COMMON SHARE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails",
     "longName": "9954495 - Disclosure - FAIR VALUE MEASUREMENTS (Details)",
     "shortName": "FAIR VALUE MEASUREMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-132",
      "name": "us-gaap:DeferredCompensationPlanAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
     "longName": "9954496 - Disclosure - STANDARD BEARER (Details)",
     "shortName": "STANDARD BEARER (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:NumberOfRealEstateProperties",
      "unitRef": "property",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-159",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
     "longName": "9954497 - Disclosure - OPERATION EXPANSIONS- Narrative (Details)",
     "shortName": "OPERATION EXPANSIONS- Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:OperationalSeniorLivingUnits",
      "unitRef": "senior_living_unit",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-177",
      "name": "ensg:NumberOfAssetAcquisitions",
      "unitRef": "business",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
     "longName": "9954498 - Disclosure - OPERATION EXPANSIONS - Purchase Price Allocation (Details)",
     "shortName": "OPERATION EXPANSIONS - Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-193",
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
     "longName": "9954499 - Disclosure - BUSINESS SEGMENTS - Narrative (Details)",
     "shortName": "BUSINESS SEGMENTS - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
     "longName": "9954500 - Disclosure - BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)",
     "shortName": "BUSINESS SEGMENTS - Schedule of Segment Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ensg:SegmentIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
     "longName": "9954501 - Disclosure - BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)",
     "shortName": "BUSINESS SEGMENTS - Schedule of Service Revenue by Major Payor Source (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-244",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails",
     "longName": "9954502 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)",
     "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Schedule of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
     "longName": "9954503 - Disclosure - PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)",
     "shortName": "PROPERTY AND EQUIPMENT\u2014 NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-283",
      "name": "us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
     "longName": "9954504 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)",
     "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Finite Lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
     "longName": "9954505 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Narrative (Details)",
     "shortName": "INTANGIBLE ASSETS \u2014 NET - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails",
     "longName": "9954506 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)",
     "shortName": "INTANGIBLE ASSETS \u2014 NET - Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails",
     "longName": "9954507 - Disclosure - INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)",
     "shortName": "INTANGIBLE ASSETS \u2014 NET - Schedule of Indefinite-lived Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.ensigngroup.net/role/GOODWILLDetails",
     "longName": "9954508 - Disclosure - GOODWILL (Details)",
     "shortName": "GOODWILL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails",
     "longName": "9954509 - Disclosure - RESTRICTED AND OTHER ASSETS (Details)",
     "shortName": "RESTRICTED AND OTHER ASSETS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails",
     "longName": "9954510 - Disclosure - OTHER ACCRUED LIABILITIES (Details)",
     "shortName": "OTHER ACCRUED LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:QualityAssuranceFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ensg:QualityAssuranceFee",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails",
     "longName": "9954511 - Disclosure - INCOME TAXES - Expense (Details)",
     "shortName": "INCOME TAXES - Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails",
     "longName": "9954512 - Disclosure - INCOME TAXES - Tax Rate (Details)",
     "shortName": "INCOME TAXES - Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails",
     "longName": "9954513 - Disclosure - INCOME TAXES - Narrative (YE) (Details)",
     "shortName": "INCOME TAXES - Narrative (YE) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R75": {
     "role": "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails",
     "longName": "9954514 - Disclosure - INCOME TAXES - Deferred Tax Assets and Liabilities (Details)",
     "shortName": "INCOME TAXES - Deferred Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails",
     "longName": "9954515 - Disclosure - DEBT - Schedule of Long-term Debt (Details)",
     "shortName": "DEBT - Schedule of Long-term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredFinanceCostsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
     "longName": "9954516 - Disclosure - DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)",
     "shortName": "DEBT - Credit Facility with a Lending Consortium Arranged by Truist (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WriteOffOfDeferredDebtIssuanceCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-313",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
     "longName": "9954517 - Disclosure - DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)",
     "shortName": "DEBT - Mortgage Loans and Promissory Notes and Off-Balance Sheet Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LettersOfCreditOutstandingAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails",
     "longName": "9954518 - Disclosure - DEBT - Long-term Debt Arrangements (Details)",
     "shortName": "DEBT - Long-term Debt Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
     "longName": "9954519 - Disclosure - OPTIONS AND AWARDS - Stock Options, Narrative (Details)",
     "shortName": "OPTIONS AND AWARDS - Stock Options, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfOptionPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ensg:NumberOfOptionPlans",
      "unitRef": "plan",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails",
     "longName": "9954520 - Disclosure - OPTIONS AND AWARDS - Valuation Assumptions (Details)",
     "shortName": "OPTIONS AND AWARDS - Valuation Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails",
     "longName": "9954521 - Disclosure - OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)",
     "shortName": "OPTIONS AND AWARDS - Exercise Price and Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails",
     "longName": "9954522 - Disclosure - OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)",
     "shortName": "OPTIONS AND AWARDS - Options Outstanding Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails",
     "longName": "9954523 - Disclosure - OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)",
     "shortName": "OPTIONS AND AWARDS - Options Outstanding by Exercise Price (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails",
     "longName": "9954524 - Disclosure - OPTIONS AND AWARDS - Intrinsic Values (Details)",
     "shortName": "OPTIONS AND AWARDS - Intrinsic Values (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
     "longName": "9954525 - Disclosure - OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)",
     "shortName": "OPTIONS AND AWARDS - Restricted Stock Awards, Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ensg:SharebasedCompensationRestrictedAwardsExercisePrice",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
     "longName": "9954526 - Disclosure - OPTIONS AND AWARDS - Restricted Award Rollforward (Details)",
     "shortName": "OPTIONS AND AWARDS - Restricted Award Rollforward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-366",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-364",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
     "longName": "9954527 - Disclosure - OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)",
     "shortName": "OPTIONS AND AWARDS - Long-Term Incentive Plan (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-371",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
     "longName": "9954528 - Disclosure - OPTIONS AND AWARDS - Compensation Expense (Details)",
     "shortName": "OPTIONS AND AWARDS - Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
     "longName": "9954529 - Disclosure - LEASES - Lessee Narrative (Details)",
     "shortName": "LEASES - Lessee Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeLeasesPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails",
     "longName": "9954530 - Disclosure - LEASES - Lessee Lease Cost (Details)",
     "shortName": "LEASES - Lessee Lease Cost (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R92": {
     "role": "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails",
     "longName": "9954531 - Disclosure - LEASES - Lessee Future Minimum Lease Payments (Details)",
     "shortName": "LEASES - Lessee Future Minimum Lease Payments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
     "longName": "9954532 - Disclosure - LEASES - Lessor Narrative (Details)",
     "shortName": "LEASES - Lessor Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-413",
      "name": "us-gaap:LessorOperatingLeaseTermOfContract",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R94": {
     "role": "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
     "longName": "9954533 - Disclosure - LEASES - Lessor Rental Income (Details)",
     "shortName": "LEASES - Lessor Rental Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-202",
      "name": "us-gaap:SubleaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-422",
      "name": "us-gaap:OperatingLeaseLeaseIncome",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails",
     "longName": "9954534 - Disclosure - LEASES - Lessor Future Minimum Lease Payments Receivable (Details)",
     "shortName": "LEASES - Lessor Future Minimum Lease Payments Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails",
     "longName": "9954535 - Disclosure - DEFINED CONTRIBUTION PLANS (Details)",
     "shortName": "DEFINED CONTRIBUTION PLANS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails",
     "longName": "9954536 - Disclosure - SELF INSURANCE LIABILITIES (Details)",
     "shortName": "SELF INSURANCE LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LiabilityForFuturePolicyBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-30",
      "name": "us-gaap:LiabilityForFuturePolicyBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
     "longName": "9954537 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true,
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails",
     "longName": "9954538 - Disclosure - COMMON STOCK REPURCHASE PROGRAM (Details)",
     "shortName": "COMMON STOCK REPURCHASE PROGRAM (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-12",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-437",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ensg-20231231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "ensg_A2019LTIPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "A2019LTIPlanMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019 LTI Plan",
        "label": "2019 LTI Plan [Member]",
        "documentation": "2019 LTI Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_A2022PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "A2022PlanMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022 Plan",
        "label": "2022 Plan [Member]",
        "documentation": "2022 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_A53PromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "A53PromissoryNoteMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.3% Promissory Note",
        "label": "5.3% Promissory Note [Member]",
        "documentation": "5.3% Promissory Note"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER ACCRUED LIABILITIES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r785"
     ]
    },
    "us-gaap_AccountsReceivableGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, gross",
        "label": "Accounts Receivable, before Allowance for Credit Loss",
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r316",
      "r1062"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable\u2014less allowance for doubtful accounts of $9,348 and $7,802 at December\u00a031, 2023 and 2022, respectively",
        "totalLabel": "ACCOUNTS RECEIVABLE, NET",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r316",
      "r317"
     ]
    },
    "us-gaap_AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property taxes",
        "label": "Accrual for Taxes Other than Income Taxes",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for real and property taxes."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r116",
      "r1059"
     ]
    },
    "ensg_AccruedLiabilitiesStateReliefContractLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AccruedLiabilitiesStateReliefContractLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unapplied state relief funds",
        "label": "Accrued Liabilities, State Relief Contract Liabilities",
        "documentation": "Accrued Liabilities, State Relief Contract Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r218",
      "r604"
     ]
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Life (Years)",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r150"
     ]
    },
    "ensg_AcquiredOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AcquiredOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired Operations",
        "label": "Acquired Operations [Member]",
        "documentation": "Acquired Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r842"
     ]
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid during the period for:",
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r492",
      "r493",
      "r654",
      "r905",
      "r906",
      "r907",
      "r1038",
      "r1071"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Shares of common stock used to satisfy tax withholding obligations",
        "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee stock award compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r92",
      "r453"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_AfterYearTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AfterYearTenMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Year Ten",
        "label": "After Year Ten [Member]",
        "documentation": "After Year Ten"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_AggregateDeductibleMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AggregateDeductibleMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Deductible",
        "label": "Aggregate Deductible [Member]",
        "documentation": "Aggregate Deductible [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r824",
      "r834",
      "r860"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r815",
      "r827",
      "r837",
      "r863"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r828",
      "r838",
      "r855",
      "r864",
      "r868",
      "r876"
     ]
    },
    "us-gaap_AllOtherSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllOtherSegmentsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Other",
        "label": "Other Segments [Member]",
        "documentation": "Operating segments classified as other. Excludes intersegment elimination and reconciling items."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303"
     ]
    },
    "ensg_AllStatesExceptColoradoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AllStatesExceptColoradoMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All States Except Colorado",
        "label": "All States Except Colorado [Member]",
        "documentation": "All States Except Colorado [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation",
        "verboseLabel": "Stock-based compensation expense related to stock options",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r498"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails": {
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Allowance for doubtful accounts",
        "negatedTerseLabel": "Less: allowance for doubtful accounts",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r225",
      "r320",
      "r325"
     ]
    },
    "ensg_AmendedMasterLeaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AmendedMasterLeaseAgreementMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Master Lease Agreement",
        "label": "Amended Master Lease Agreement [Member]",
        "documentation": "Amended Master Lease Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_AmendedMasterLeaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AmendedMasterLeaseMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended Master Lease",
        "label": "Amended Master Lease [Member]",
        "documentation": "Amended Master Lease"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_AmendedSeparateMasterLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AmendedSeparateMasterLeases",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amended of separate master leases",
        "label": "Amended Separate Master Leases",
        "documentation": "Amended Separate Master Leases"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred financing fees",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r557",
      "r761",
      "r762",
      "r900"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r68",
      "r73"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "ensg_AssembledOccupancyAcquiredMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AssembledOccupancyAcquiredMember",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assembled occupancy",
        "verboseLabel": "Assembled occupancy",
        "label": "Assembled Occupancy Acquired [Member]",
        "documentation": "Assembled occupancy acquired [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_AssetAcquisitionConsiderationTransferred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionConsiderationTransferred",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset acquisition, purchase price",
        "label": "Asset Acquisition, Consideration Transferred",
        "documentation": "Amount of consideration transferred in asset acquisition. Includes, but is not limited to, cash, liability incurred by acquirer, and equity interest issued by acquirer."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r1035",
      "r1036",
      "r1037"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r221",
      "r247",
      "r286",
      "r301",
      "r307",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r530",
      "r534",
      "r548",
      "r597",
      "r681",
      "r785",
      "r801",
      "r932",
      "r933",
      "r1049"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r227",
      "r247",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r530",
      "r534",
      "r548",
      "r785",
      "r932",
      "r933",
      "r1049"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.ensigngroup.net/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.ensigngroup.net/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.ensigngroup.net/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820"
     ]
    },
    "ensg_August2023RepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "August2023RepurchaseProgramMember",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "August 2023 Repurchase Program",
        "label": "August 2023 Repurchase Program [Member]",
        "documentation": "August 2023 Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r870"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r868"
     ]
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BaseRateMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Rate",
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r148"
     ]
    },
    "ensg_BeverlyBWittekindMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "BeverlyBWittekindMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Beverly B. Wittekind [Member]",
        "documentation": "Beverly B. Wittekind"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_BlanketAggregateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "BlanketAggregateMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Blanket Aggregate",
        "label": "Blanket Aggregate [Member]",
        "documentation": "Blanket Aggregate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Building and improvements",
        "terseLabel": "Buildings and improvements",
        "label": "Building and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r774",
      "r775"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r526",
      "r774",
      "r775"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Line Items]",
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "ensg_BusinessAndAssetAcquisitionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "BusinessAndAssetAcquisitionsAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business And Asset Acquisitions [Axis]",
        "label": "Business And Asset Acquisitions [Axis]",
        "documentation": "Business And Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_BusinessAndAssetAcquisitionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "BusinessAndAssetAcquisitionsDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business And Asset Acquisitions [Domain]",
        "label": "Business And Asset Acquisitions [Domain]",
        "documentation": "Business And Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ACQUISITIONS",
        "label": "Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net",
        "documentation": "Business Combination And Asset Acquisition, Assets Acquired And Liabilities Assumed, Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPERATION EXPANSIONS",
        "label": "Business Combination Disclosure [Text Block]",
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable)."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r527"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CO": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CO",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado",
        "label": "COLORADO"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_CampusOperationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CampusOperationMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Campus Operation",
        "label": "Campus Operation [Member]",
        "documentation": "Campus Operation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued capital expenditures",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r49"
     ]
    },
    "ensg_CareTrustREITMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CareTrustREITMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CareTrust REIT",
        "label": "CareTrust REIT [Member]",
        "documentation": "CareTrust REIT [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r216",
      "r749"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents beginning of period",
        "periodEndLabel": "Cash and cash equivalents end of period",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r145",
      "r244"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r145"
     ]
    },
    "us-gaap_CashDivestedFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashDivestedFromDeconsolidation",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deconsolidation of an ancillary business",
        "label": "Cash Divested from Deconsolidation",
        "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ensg_CashHeldInTrustForResidents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CashHeldInTrustForResidents",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash held in trust for patients",
        "label": "Cash Held in Trust for Residents",
        "documentation": "Cash held in trust for residents reflects monies received from, or on behalf of, residents. Maintaining a trust account for residents is a regulatory requirement and, while the trust assets offset the liability, the Company assumes a fiduciary responsibility for these funds."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ensg_ChristopherRChristensenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ChristopherRChristensenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Christopher R. Christensen [Member]",
        "documentation": "Christopher R. Christensen"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfTreasuryStockTable",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Treasury Stock [Table]",
        "label": "Class of Treasury Stock [Table]",
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81",
      "r82"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_CollateralizedDebtObligationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollateralizedDebtObligationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage loans and promissory note",
        "label": "Collateralized Debt Obligations [Member]",
        "documentation": "Securities collateralized by a pool of assets."
       }
      }
     },
     "auth_ref": [
      "r911",
      "r912",
      "r963"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Notes 15 and 20)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r117",
      "r598",
      "r668"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r357",
      "r358",
      "r731",
      "r927"
     ]
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockDividendsPerShareDeclared",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITYParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends declared (in dollars per share)",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r790",
      "r791",
      "r792",
      "r794",
      "r795",
      "r796",
      "r797",
      "r905",
      "r906",
      "r1038",
      "r1068",
      "r1071"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares authorized",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r669"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares issued",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares outstanding",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r127",
      "r669",
      "r687",
      "r1071",
      "r1072"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock: $0.001 par value; 150,000, 59,987 and 56,597 shares authorized, shares issued and shares outstanding at December\u00a031, 2023, respectively, and 100,000, 59,029 and 55,661 shares authorized, shares issued and shares outstanding at December 31, 2022, respectively",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r599",
      "r785"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEFINED CONTRIBUTION PLANS",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r166"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r108",
      "r109",
      "r315",
      "r730"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r108",
      "r109",
      "r315",
      "r640",
      "r730"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r108",
      "r109",
      "r315",
      "r730",
      "r888"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r730"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "% of Revenue",
        "terseLabel": "Revenue %",
        "netLabel": "Concentration percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r108",
      "r109",
      "r315"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r56",
      "r57",
      "r108",
      "r180",
      "r730"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r56",
      "r108",
      "r109",
      "r315",
      "r730"
     ]
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r530",
      "r531",
      "r534",
      "r535",
      "r583",
      "r742",
      "r931",
      "r934",
      "r935"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r530",
      "r531",
      "r534",
      "r535",
      "r583",
      "r742",
      "r931",
      "r934",
      "r935"
     ]
    },
    "srt_ConsolidationEliminationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationEliminationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intercompany Elimination",
        "label": "Consolidation, Eliminations [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Axis]",
        "label": "Consolidation Items [Axis]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r288",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r309",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r371",
      "r373",
      "r374",
      "r932",
      "r933"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation Items [Domain]",
        "label": "Consolidation Items [Domain]"
       }
      }
     },
     "auth_ref": [
      "r251",
      "r288",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r305",
      "r309",
      "r363",
      "r364",
      "r365",
      "r366",
      "r368",
      "r369",
      "r371",
      "r373",
      "r374",
      "r932",
      "r933"
     ]
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Resident advances",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r420",
      "r421",
      "r440"
     ]
    },
    "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) funds received and returned",
        "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned",
        "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Received And Returned"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)",
        "label": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds Repaid",
        "documentation": "Coronavirus Aid, Relief, and Economic Security (\u201cCARES\u201d) Funds, Repayment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "All Other",
        "label": "Corporate, Non-Segment [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r300",
      "r301",
      "r302",
      "r303",
      "r309",
      "r910"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of services",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r590"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Services",
        "label": "Cost of Sales [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_CostofSalesandGeneralandAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "CostofSalesandGeneralandAdministrativeExpenseMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of Sales and General and Administrative Expense",
        "label": "Cost of Sales and General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing cost of services and general and administrative expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL EXPENSES",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r136"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r380",
      "r408",
      "r582",
      "r750",
      "r752"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover page.",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r1032"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current income tax expense (benefit)",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r515",
      "r521",
      "r903"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r903",
      "r1032"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r55",
      "r315"
     ]
    },
    "us-gaap_CustomerRelationshipsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CustomerRelationshipsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer relationships",
        "label": "Customer Relationships [Member]",
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBT"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DEBT",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r245",
      "r376",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r392",
      "r399",
      "r400",
      "r402"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r121",
      "r122",
      "r182",
      "r185",
      "r251",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r558",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r901"
     ]
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate margin",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Mortgage loans and promissory note",
        "verboseLabel": "Outstanding debt",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r185",
      "r403"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, effective percentage",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r111",
      "r405",
      "r558"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r378"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r251",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r558",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r901"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r251",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r558",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r901"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r76",
      "r77",
      "r110",
      "r111",
      "r113",
      "r118",
      "r160",
      "r161",
      "r251",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r383",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r401",
      "r558",
      "r758",
      "r759",
      "r760",
      "r761",
      "r762",
      "r901"
     ]
    },
    "us-gaap_DebtInstrumentTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtInstrumentTerm",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, term",
        "label": "Debt Instrument, Term",
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtIssuanceCostsLineOfCreditArrangementsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtIssuanceCostsLineOfCreditArrangementsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt issuance costs, net",
        "label": "Debt Issuance Costs, Line of Credit Arrangements, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs related to line of credit arrangements. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_DeferredCompensationLiabilityClassifiedNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationLiabilityClassifiedNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation liability, noncurrent",
        "label": "Deferred Compensation Liability, Classified, Noncurrent",
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements payable beyond one year (or the operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCompensationPlanAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred rent receivable",
        "label": "Deferred Compensation Plan Assets",
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax expense (benefit)",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal, state, and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national, regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: debt issuance costs, net",
        "label": "Debt Issuance Costs, Net",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r937"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r503"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r173",
      "r206",
      "r520",
      "r521",
      "r903"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "TOTAL DEFERRED TAX LIABILITIES",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r125",
      "r183",
      "r509"
     ]
    },
    "ensg_DeferredRentAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DeferredRentAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of deferred rent",
        "label": "Deferred Rent Adjustment",
        "documentation": "Adjustment to deferred rent arising from the difference between rent expense recognized and rental payments made in the current period."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_DeferredRentAndOtherLongTermLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DeferredRentAndOtherLongTermLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "label": "Deferred rent and other long-term liabilities",
        "documentation": "Rental expense in excess of actual rental payments and other long-term liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r903",
      "r1031",
      "r1032"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET DEFERRED TAX ASSETS",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL DEFERRED TAX ASSETS",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "us-gaap_DeferredTaxAssetsStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsStateTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State taxes",
        "label": "Deferred Tax Assets, State Taxes",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from state taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r95",
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue related reserves",
        "label": "Deferred Tax Asset, Tax Deferred Expense, Reserve and Accrual, Accounts Receivable, Allowance for Credit Loss",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from allowance for credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1030"
     ]
    },
    "ensg_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liability",
        "label": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability",
        "documentation": "Deferred Tax Assets, Tax, Deferred Expense, Reserves And Accruals, Lease Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Self Insurance",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from estimated losses under self insurance."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1030"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails",
      "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "negatedLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Depreciation and amortization",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1030"
     ]
    },
    "ensg_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Right of use asset",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "documentation": "Deferred Tax Liabilities, Right Of Use Asset"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_DeferredTaxLiabilitiesStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DeferredTaxLiabilitiesStateTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "State taxes",
        "label": "Deferred Tax Liabilities, State Taxes",
        "documentation": "Deferred Tax Liabilities, State Taxes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined contribution plan, cost",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan Disclosure [Line Items]",
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum annual contributions per employee",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Contribution Plan [Table]",
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "ensg_DepreciationAndAmortizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "DepreciationAndAmortizationMember",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation And Amortization [Member]",
        "documentation": "Depreciation And Amortization [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "verboseLabel": "Depreciation and amortization",
        "netLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r291"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Disaggregation of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OPTIONS AND AWARDS",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r456",
      "r487",
      "r488",
      "r490",
      "r777"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Axis]",
        "label": "Disposal Group Classification [Axis]",
        "documentation": "Information by disposal group classification."
       }
      }
     },
     "auth_ref": [
      "r212"
     ]
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupClassificationDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Classification [Domain]",
        "label": "Disposal Group Classification [Domain]",
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group, Disposed of by Sale, Not Discontinued Operations",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r16"
     ]
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Domain]",
        "label": "Disposal Group Name [Domain]",
        "documentation": "Name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775"
     ]
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends declared",
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r162"
     ]
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued dividends declared",
        "terseLabel": "Dividends payable",
        "label": "Dividends Payable",
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r123",
      "r184",
      "r798",
      "r1059"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Restatement Recovery Analysis [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820",
      "r856"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r841"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r804"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NET INCOME PER SHARE ATTRIBUTABLE TO THE ENSIGN GROUP INC.",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net income per common share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r266",
      "r268",
      "r273",
      "r274",
      "r275",
      "r279",
      "r544",
      "r545",
      "r594",
      "r610",
      "r753"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net income per common share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r268",
      "r273",
      "r274",
      "r275",
      "r279",
      "r544",
      "r545",
      "r594",
      "r610",
      "r753"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMPUTATION OF NET INCOME PER COMMON SHARE",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r265",
      "r276",
      "r277",
      "r278"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESNarrativeYEDetails",
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL INCOME TAX PROVISION",
        "terseLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r505"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense at statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r505",
      "r522"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible expenses",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1033"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1033"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity compensation",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r884",
      "r1028"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes\u00a0- net of federal benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1028",
      "r1033"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued wages and related liabilities",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_EmployeeServiceShareBasedCompensationNonvestedAwards": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwards",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, nonvested awards (in shares)",
        "label": "Employee Service Share-based Compensation, Nonvested Awards",
        "documentation": "Employee Service Share-based Compensation, Nonvested Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, nonvested awards, cost not yet recognized, period for recognition",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r489"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock-based compensation expense related to stock options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r881"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r803"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r882"
     ]
    },
    "us-gaap_EquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquipmentMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equipment",
        "label": "Equipment [Member]",
        "documentation": "Tangible personal property used to produce goods and services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "EQUITY",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityClassOfTreasuryStockLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r209",
      "r231",
      "r232",
      "r233",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r264",
      "r281",
      "r323",
      "r324",
      "r419",
      "r491",
      "r492",
      "r493",
      "r516",
      "r517",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r581",
      "r634",
      "r635",
      "r636",
      "r654",
      "r708"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r812",
      "r824",
      "r834",
      "r860"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r821",
      "r831",
      "r857"
     ]
    },
    "us-gaap_EscrowDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EscrowDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Escrow deposits",
        "label": "Escrow Deposit",
        "documentation": "The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r732"
     ]
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EstimatedInsuranceRecoveries",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term insurance losses recoverable asset",
        "label": "Estimated Insurance Recoveries",
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ensg_ExercisePriceRangeEightMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeEightMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020",
        "label": "Exercise Price Range Eight [Member]",
        "documentation": "Exercise Price Range Eight [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeElevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeElevenMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023",
        "label": "Exercise Price Range Eleven [Member]",
        "documentation": "Exercise Price Range Eleven"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeFiveMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017",
        "label": "Exercise Price Range Five [Member]",
        "documentation": "Exercise Price Range Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeFourMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2016",
        "label": "Exercise Price Range Four [Member]",
        "documentation": "Exercise Price Range Four [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeNineMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeNineMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021",
        "label": "Exercise Price Range Nine [Member]",
        "documentation": "Exercise Price Range Nine [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeSevenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeSevenMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2019",
        "label": "Exercise Price Range Seven [Member]",
        "documentation": "Exercise Price Range Seven [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeSixMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeSixMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018",
        "label": "Exercise Price Range Six [Member]",
        "documentation": "Exercise Price Range Six [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeTenMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2022",
        "label": "Exercise Price Range Ten [Member]",
        "documentation": "Exercise Price Range Ten [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeThreeMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2015",
        "label": "Exercise Price Range Three [Member]",
        "documentation": "Exercise Price Range Three [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ExercisePriceRangeTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ExercisePriceRangeTwoMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2014",
        "label": "Exercise Price Range Two [Member]",
        "documentation": "Exercise Price Range Two [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_FacilitiesUnderMasterLeaseArrangement": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "FacilitiesUnderMasterLeaseArrangement",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities under master lease arrangement",
        "label": "Facilities Under Master Lease Arrangement",
        "documentation": "Facilities operated under two separate three-facility master lease arrangements. Under these master leases, a breach at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByBalanceSheetGroupingTable",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r106",
      "r107"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r547",
      "r585",
      "r586",
      "r587",
      "r759",
      "r760",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAIR VALUE MEASUREMENTS",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Inputs, Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r443",
      "r448",
      "r547",
      "r586",
      "r759",
      "r760",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r390",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r585",
      "r586",
      "r587",
      "r759",
      "r760",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Considerations",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r20"
     ]
    },
    "ensg_FamilyFirstCoronavirusResponseActPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "FamilyFirstCoronavirusResponseActPaymentsReceived",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FMAP payments received",
        "label": "Family First Coronavirus Response Act, Payments Received",
        "documentation": "Family First Coronavirus Response Act, Payments Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-lived intangible asset, useful life",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r220",
      "r345"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r344",
      "r345",
      "r347",
      "r591",
      "r592"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r592"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r591"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETFutureAmortizationDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r151",
      "r591"
     ]
    },
    "ensg_FirstThreeYearsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "FirstThreeYearsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Three Years",
        "label": "First Three Years [Member]",
        "documentation": "First Three Years"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r864"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r864"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r864"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r864"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r864"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equipment, furniture, and fixtures",
        "terseLabel": "Furniture and fixtures",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of assets",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r900"
     ]
    },
    "ensg_GainLossOnInsuranceClaimsAndDisposalOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "GainLossOnInsuranceClaimsAndDisposalOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain)/loss on insurance claims, legal matters and asset disposals",
        "label": "Gain (Loss) On Insurance Claims And Disposal Of Assets",
        "documentation": "Gain (Loss) On Insurance Claims And Disposal Of Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Gain (loss) on deferral investment",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r883"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sales property, plant and equipment",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r691"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_GeneralLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralLiabilityMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General Liability",
        "label": "General Liability [Member]",
        "documentation": "Type of business insurance which provides insurance coverage for a wide variety of liability exposures including, but not limited to, contractual liability, product liability and personal injury liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r328",
      "r593",
      "r757",
      "r785",
      "r916",
      "r923"
     ]
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAcquiredDuringPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": {
       "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "netLabel": "Goodwill",
        "terseLabel": "Additions",
        "label": "Goodwill, Acquired During Period",
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r757"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r66"
     ]
    },
    "us-gaap_GoodwillDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/GOODWILL"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GOODWILL",
        "label": "Goodwill Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill."
       }
      }
     },
     "auth_ref": [
      "r327",
      "r329",
      "r339",
      "r757"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, accumulated impairment loss",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r337",
      "r757"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r757"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "ensg_HUDInsuredMortgagesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "HUDInsuredMortgagesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "HUD Insured Mortgages",
        "label": "HUD Insured Mortgages [Member]",
        "documentation": "HUD Insured Mortgages"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_HealthLiabilityInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "HealthLiabilityInsuranceMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health Liability Insurance",
        "label": "Health Liability Insurance [Member]",
        "documentation": "Health Liability Insurance [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r806",
      "r807",
      "r820"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets (excluding goodwill)",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r17"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r156"
     ]
    },
    "ensg_InTheFourthYearMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "InTheFourthYearMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In The Fourth Year",
        "label": "In The Fourth Year [Member]",
        "documentation": "In The Fourth Year"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Less: net income (loss) attributable to noncontrolling interests",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r177"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before provision for income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r133",
      "r190",
      "r286",
      "r300",
      "r306",
      "r309",
      "r595",
      "r606",
      "r755"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r247",
      "r255",
      "r286",
      "r300",
      "r306",
      "r309",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r545",
      "r548",
      "r606",
      "r755",
      "r932"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Group Name [Axis]",
        "label": "Disposal Group Name [Axis]",
        "documentation": "Information by name of disposal group."
       }
      }
     },
     "auth_ref": [
      "r774",
      "r775"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r352",
      "r692"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r352",
      "r692"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INCOME TAXES",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r499",
      "r506",
      "r507",
      "r513",
      "r518",
      "r523",
      "r524",
      "r525",
      "r651"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/INCOMETAXESExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for income taxes",
        "totalLabel": "Provision for income taxes",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r198",
      "r207",
      "r263",
      "r264",
      "r294",
      "r504",
      "r519",
      "r612"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r500",
      "r501",
      "r507",
      "r508",
      "r512",
      "r514",
      "r647"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Income Taxes Paid",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r46"
     ]
    },
    "ensg_IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred employer portion of social security taxes (Note 3)",
        "label": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act",
        "documentation": "Increase (Decrease) Due To Deferred Employer Taxes, CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInDeferredCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred compensation liability",
        "label": "Increase (Decrease) in Deferred Compensation",
        "documentation": "The increase (decrease) during the reporting period in the obligation created by employee agreements whereby earned compensation will be paid in the future."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued wages and related liabilities",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in operating assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease obligations",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r889",
      "r899"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherDeferredLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherDeferredLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Increase (Decrease) in Other Deferred Liability",
        "documentation": "Amount of increase (decrease) in deferred obligations classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid income taxes",
        "label": "Increase (Decrease) in Prepaid Taxes",
        "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInSelfInsuranceReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInSelfInsuranceReserve",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued self-insurance liabilities",
        "label": "Increase (Decrease) in Self Insurance Reserve",
        "documentation": "The increase (decrease) during the period in the carrying amount of accrued known and estimated losses incurred for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's' compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property."
       }
      }
     },
     "auth_ref": [
      "r899"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plus: incremental shares from assumed conversion (in shares)",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r275",
      "r455"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r346"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other indefinite-lived intangibles",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r153"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r153"
     ]
    },
    "us-gaap_IndefinitelivedIntangibleAssetsAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IndefinitelivedIntangibleAssetsAcquired",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": {
       "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other indefinite-lived intangible assets",
        "terseLabel": "Indefinite-lived intangible assets",
        "label": "Indefinite-Lived Intangible Assets Acquired",
        "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_IndependentOperatingSubsidiariesUnderMedicareProbeReviews": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "IndependentOperatingSubsidiariesUnderMedicareProbeReviews",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities under medicare probe reviews",
        "label": "Independent Operating Subsidiaries Under Medicare Probe Reviews",
        "documentation": "Facilities under Medicare Probe reviews relating to Medicare services, billings and potential overpayments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r819",
      "r828",
      "r838",
      "r855",
      "r864",
      "r868",
      "r876"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r880"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r880"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r808",
      "r880"
     ]
    },
    "us-gaap_InsuranceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InsuranceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_InsuranceCoverageLimitTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "InsuranceCoverageLimitTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Coverage Limit Type [Axis]",
        "label": "Insurance Coverage Limit Type [Axis]",
        "documentation": "Insurance Coverage Limit Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_InsuranceCoverageLimitTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "InsuranceCoverageLimitTypeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Coverage Limit Type [Domain]",
        "label": "Insurance Coverage Limit Type [Domain]",
        "documentation": "Insurance Coverage Limit Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_InsuranceSubsidiaryDepositsAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "InsuranceSubsidiaryDepositsAndInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance subsidiary deposits and investments",
        "label": "Insurance Subsidiary Deposits And Investments",
        "documentation": "Captive insurance subsidiary cash and equivalents designated to support long-term insurance subsidiary liabilities and debt security investments held to maturity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "INTANGIBLE ASSETS \u2014 NET",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r71"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "terseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r193",
      "r234",
      "r290",
      "r556",
      "r693",
      "r799",
      "r1070"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r242",
      "r243"
     ]
    },
    "ensg_InvestmentExpenseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "InvestmentExpenseIncome",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Offsetting expense (income)",
        "label": "Investment Expense (Income)",
        "documentation": "Investment Expense (Income)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Subsidiary Deposits and Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r611",
      "r643",
      "r644",
      "r645",
      "r646",
      "r715",
      "r716"
     ]
    },
    "us-gaap_InvestmentsAndCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsAndCash",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance subsidiary's deposits and investments",
        "label": "Investments and Cash",
        "documentation": "Sum of investments and unrestricted cash as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r1057",
      "r1061"
     ]
    },
    "ensg_July2022RepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "July2022RepurchaseProgramMember",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "July 2022 Repurchase Program",
        "label": "July 2022 Repurchase Program [Member]",
        "documentation": "July 2022 Repurchase Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Land",
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ensg_LeaseArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LeaseArrangementAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangement [Axis]",
        "label": "Lease Arrangement [Axis]",
        "documentation": "Information by group of related lease arrangements."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LeaseArrangementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LeaseArrangementDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Arrangement [Domain]",
        "label": "Lease Arrangement [Domain]",
        "documentation": "Lease Arrangement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Lease, cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r565",
      "r784"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Lease Expenses",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1042"
     ]
    },
    "ensg_LeaseOfCampusOperationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LeaseOfCampusOperationMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Of Campus Operation",
        "label": "Lease Of Campus Operation [Member]",
        "documentation": "Lease Of Campus Operation"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LeasedAssetsAcquiredDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LeasedAssetsAcquiredDuringPeriod",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": {
       "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leased asset",
        "label": "Leased Assets, Acquired During Period",
        "documentation": "Leased Assets, Acquired During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LeasesToThirdPartyOperatorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LeasesToThirdPartyOperatorsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases To Third Party Operators",
        "label": "Leases To Third Party Operators [Member]",
        "documentation": "Leases To Third Party Operators"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r564"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r563"
     ]
    },
    "ensg_LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee leasing arrangements, operating leases, number of renewal terms",
        "label": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms",
        "documentation": "Lessee Leasing Arrangements, Operating Leases, Number Of Renewal Terms"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LesseeOperatingLeaseConsumerPriceIndex": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LesseeOperatingLeaseConsumerPriceIndex",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consumer price index",
        "label": "Lessee, Operating Lease, Consumer Price Index",
        "documentation": "Lessee, Operating Lease, Consumer Price Index"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseDiscountRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseDiscountRate",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating leases of lessee, contingent rentals, basis spread on variable rate",
        "label": "Lessee, Operating Lease, Discount Rate",
        "documentation": "Discount rate used by lessee to determine present value of operating lease payments."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Future Minimum Lease Payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1043"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LEASE PAYMENTS",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: present value adjustment",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "ensg_LesseeOperatingLeaseNumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LesseeOperatingLeaseNumberOfLeases",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of stand-alone leases",
        "label": "Lessee, Operating Lease, Number Of Leases",
        "documentation": "Lessee, Operating Lease, Number Of Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, number of renewal options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1041"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LessorLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorLeaseDescriptionLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, Lease, Description [Line Items]",
        "label": "Lessor, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "us-gaap_LessorLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorLeaseDescriptionTable",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessor, Lease, Description [Table]",
        "label": "Lessor, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessor's leases."
       }
      }
     },
     "auth_ref": [
      "r578"
     ]
    },
    "ensg_LessorOperatingLeaseNumberOfLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LessorOperatingLeaseNumberOfLeases",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of leases",
        "label": "Lessor, Operating Lease, Number Of Leases",
        "documentation": "Lessor, Operating Lease, Number Of New Leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL",
        "label": "Lessor, Operating Lease, Payment to be Received",
        "documentation": "Amount of lease payments to be received by lessor for operating lease."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFiveYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFiveYears",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedFourYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedFourYears",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Four",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Annual Rental Income",
        "label": "Lessor, Operating Lease, Payment to be Received, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of maturity of undiscounted cash flows to be received by lessor on annual basis for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessor, Operating Lease, Payment to be Received, Year One",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThereafter": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThereafter",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Lessor, Operating Lease, Payment to be Received, after Year Five",
        "documentation": "Amount of lease payment to be received by lessor for operating lease after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedThreeYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedThreeYears",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Three",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceivedTwoYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeasePaymentsToBeReceivedTwoYears",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails": {
       "parentTag": "us-gaap_LessorOperatingLeasePaymentsToBeReceived",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorFutureMinimumLeasePaymentsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessor, Operating Lease, Payment to be Received, Year Two",
        "documentation": "Amount of lease payment to be received by lessor for operating lease in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r577"
     ]
    },
    "us-gaap_LessorOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LessorOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of operating lease",
        "label": "Lessor, Operating Lease, Term of Contract",
        "documentation": "Term of lessor's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LettersOfCreditOutstandingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letters of credit outstanding, pledged amount",
        "label": "Letters of Credit Outstanding, Amount",
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r247",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r531",
      "r534",
      "r535",
      "r548",
      "r667",
      "r754",
      "r801",
      "r932",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r132",
      "r187",
      "r602",
      "r785",
      "r902",
      "r913",
      "r1039"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r215",
      "r247",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r531",
      "r534",
      "r535",
      "r548",
      "r785",
      "r932",
      "r1049",
      "r1050"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LiabilitiesDeferredTaxPaymentsUnderCARESAct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LiabilitiesDeferredTaxPaymentsUnderCARESAct",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total deferred payment of social security taxes",
        "label": "Liabilities, Deferred Tax Payments Under CARES Act",
        "documentation": "Liabilities, Deferred Tax Payments Under CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitByProductSegmentLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Line Items]",
        "label": "Liability for Future Policy Benefit, by Product Segment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefitByProductSegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitByProductSegmentTable",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability for Future Policy Benefit, by Product Segment [Table]",
        "label": "Liability for Future Policy Benefit, by Product Segment [Table]",
        "documentation": "Reflects the carrying amount of and other relevant, pertinent information about the liability as of the balance sheet date for future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums by major product line segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilityForFuturePolicyBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Liability for Future Policy Benefit, before Reinsurance",
        "documentation": "Amount, before effect of reinsurance, of present value of future benefit to be paid to or on behalf of policyholder and related expense less present value of future net premium receivable under insurance contract."
       }
      }
     },
     "auth_ref": [
      "r631",
      "r632",
      "r637",
      "r788",
      "r1058"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SELF INSURANCE LIABILITIES",
        "label": "Liability for Future Policy Benefits and Unpaid Claims Disclosure [Text Block]",
        "documentation": "The entire disclosure for liabilities related to future policy benefits and unpaid claims and claim adjustments."
       }
      }
     },
     "auth_ref": [
      "r630"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in long-term insurance losses recoverable",
        "label": "Liability for Future Policy Benefits, Other Increase (Decrease)",
        "documentation": "Amount of other increase (decrease) in accrued obligations to policyholders pertaining to insured events for the period."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsPaymentForBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsPaymentForBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Claims paid and direct expenses",
        "label": "Liability for Future Policy Benefit, Expected Future Policy Benefit, Benefit Payment",
        "documentation": "Amount of cash outflow to policyholder from benefit payment for expected future policy benefit and expense component of liability for future policy benefit."
       }
      }
     },
     "auth_ref": [
      "r787",
      "r788",
      "r898",
      "r1064",
      "r1067"
     ]
    },
    "us-gaap_LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current year provisions",
        "label": "Liability for Future Policy Benefits, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in accrued obligations to policy and contract holders for long-duration insurance contracts."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "us-gaap_LifeInsuranceCorporateOrBankOwnedChangeInValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LifeInsuranceCorporateOrBankOwnedChangeInValue",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash surrender value of life insurance policy premiums",
        "label": "Life Insurance, Corporate or Bank Owned, Change in Value",
        "documentation": "The change in cash surrender or contract value during the period which adjusted the amount of premiums paid in determining the expense or income recognized under the contract for the period."
       }
      }
     },
     "auth_ref": [
      "r914"
     ]
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lender Name [Axis]",
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r901"
     ]
    },
    "us-gaap_LineOfCreditFacilityIncreaseDecreaseForPeriodNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityIncreaseDecreaseForPeriodNet",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of credit increase",
        "label": "Line of Credit Facility, Increase (Decrease), Net",
        "documentation": "Amount of increase (decrease) of the credit facility."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit Facility, Lender [Domain]",
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r901"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r25"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, unused capacity, commitment fee percentage",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued litigation (Note 20)",
        "label": "Estimated Litigation Liability, Current",
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r928"
     ]
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation settlement, amount awarded to other party",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "documentation": "Amount awarded to other party in judgment or settlement of litigation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LitigationSettlementExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation",
        "label": "Litigation Settlement, Expense",
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Long-term Debt",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r185",
      "r389",
      "r404",
      "r759",
      "r760",
      "r1060"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current maturities of long-term debt",
        "negatedTerseLabel": "Less: current maturities",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r222"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r938"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Five",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Four",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r394"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTLongtermDebtArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r251",
      "r394"
     ]
    },
    "ensg_LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt\u2014less current maturities",
        "label": "Long Term Debt, net of Current Maturities and Debt Discount",
        "documentation": "Long Term Debt, net of Current Maturities and Debt Discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "LONG-TERM DEBT LESS CURRENT MATURITIES",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElection": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElection",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, threshold for EBITDA ratio increase election",
        "label": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election",
        "documentation": "Long-Term Debt, Threshold For EBITDA Ratio Increase Election"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt threshold for EBITDA ratio increase election period",
        "label": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period",
        "documentation": "Long Term Debt Threshold For EBITDA Ratio Increase Election Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/DEBTScheduleofLongtermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r75"
     ]
    },
    "ensg_LossSensitiveLimitPerClaimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "LossSensitiveLimitPerClaimMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss-Sensitive Limit Per Claim",
        "label": "Loss-Sensitive Limit Per Claim [Member]",
        "documentation": "Loss-Sensitive limit per claim [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r766",
      "r939",
      "r1063",
      "r1065"
     ]
    },
    "ensg_ManagedCareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ManagedCareMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Managed care",
        "verboseLabel": "Managed care",
        "netLabel": "Managed care",
        "label": "Managed Care [Member]",
        "documentation": "Revenue from managed care payors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ManagementFeeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementFeeExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees",
        "label": "Management Fee Expense",
        "documentation": "Amount of expense for investment management fee, including, but not limited to, expense in connection with research, selection, supervision, and custody of investment."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r691",
      "r799",
      "r1069"
     ]
    },
    "us-gaap_ManagementServiceBaseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementServiceBaseMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Base Management Fee",
        "label": "Management Service, Base [Member]",
        "documentation": "Contractually stipulated right to receive base compensation for operating and managing business."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "us-gaap_ManagementServiceIncentiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ManagementServiceIncentiveMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incentive Management Fee",
        "label": "Management Service, Incentive [Member]",
        "documentation": "Contractually stipulated right to receive incentive compensation for operating and managing business."
       }
      }
     },
     "auth_ref": [
      "r940"
     ]
    },
    "ensg_ManagementServiceTotalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ManagementServiceTotalMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Management Fee",
        "label": "Management Service, Total [Member]",
        "documentation": "Management Service, Total"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MasterLeaseAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MasterLeaseAgreements",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Master lease agreements",
        "label": "Master Lease Agreements",
        "documentation": "Master Lease agreements"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r450",
      "r589",
      "r633",
      "r659",
      "r660",
      "r713",
      "r717",
      "r719",
      "r720",
      "r722",
      "r743",
      "r744",
      "r756",
      "r763",
      "r776",
      "r789",
      "r936",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ensg_MedicaidAndMedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicaidAndMedicareMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Medicare and Medicaid",
        "verboseLabel": "Total Medicaid and Medicare",
        "label": "Medicaid and Medicare [Member]",
        "documentation": "Total revenue from Medicaid and Medicare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MedicaidMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicaidMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid",
        "label": "Medicaid [Member]",
        "documentation": "Revenue from Medicaid for custodial services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MedicaidSkilledMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicaidSkilledMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicaid \u2014 skilled",
        "verboseLabel": "Medicaid-skilled",
        "label": "Medicaid-skilled [Member]",
        "documentation": "Revenue from Medicaid for skilled services [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MedicareAcceleratedAndAdvancePaymentCARESACT": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicareAcceleratedAndAdvancePaymentCARESACT",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare accelerated and advance payment",
        "label": "Medicare Accelerated And Advance Payment, CARES ACT",
        "documentation": "Medicare Accelerated And Advance Payment, CARES ACT"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MedicareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicareMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare",
        "verboseLabel": "Medicare",
        "netLabel": "Medicare",
        "label": "Medicare [Member]",
        "documentation": "Revenue from Medicare [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_MedicareandMedicaidLicensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "MedicareandMedicaidLicensesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Medicare and Medicaid licenses",
        "label": "Medicare and Medicaid Licenses [Member]",
        "documentation": "Medicare licenses for home health and hospice segment and all other segment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r450",
      "r589",
      "r633",
      "r659",
      "r660",
      "r713",
      "r717",
      "r719",
      "r720",
      "r722",
      "r743",
      "r744",
      "r756",
      "r763",
      "r776",
      "r789",
      "r936",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-controlling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r186",
      "r247",
      "r322",
      "r363",
      "r366",
      "r367",
      "r368",
      "r374",
      "r375",
      "r548",
      "r601",
      "r671"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Noncontrolling interest attributable to subsidiary equity plan",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r162"
     ]
    },
    "us-gaap_MinorityInterestDecreaseFromRedemptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestDecreaseFromRedemptions",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of noncontrolling interest shares",
        "label": "Noncontrolling Interest, Decrease from Redemptions or Purchase of Interests",
        "documentation": "Decrease in noncontrolling interest (for example, but not limited to, redeeming or purchasing the interests of noncontrolling shareholders, issuance of shares (interests) by the non-wholly owned subsidiary to the parent entity for other than cash, and a buyback of shares (interest) by the non-wholly owned subsidiary from the noncontrolling interests)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r162",
      "r178"
     ]
    },
    "us-gaap_MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterestInNetIncomeLossOfConsolidatedEntitiesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r867"
     ]
    },
    "us-gaap_MovementInLiabilityForFuturePolicyBenefitsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MovementInLiabilityForFuturePolicyBenefitsRollForward",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Movement in Liability for Future Policy Benefits [Roll Forward]",
        "label": "Movement in Liability for Future Policy Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r766",
      "r939",
      "r1063",
      "r1065"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN FINANCING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH USED IN INVESTING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET CASH PROVIDED BY OPERATING ACTIVITIES",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r145",
      "r146",
      "r147"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to The Ensign Group, Inc.",
        "verboseLabel": "Net income attributable to the Ensign Group, Inc.",
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r147",
      "r191",
      "r213",
      "r228",
      "r229",
      "r233",
      "r247",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r263",
      "r264",
      "r272",
      "r286",
      "r300",
      "r306",
      "r309",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r545",
      "r548",
      "r609",
      "r689",
      "r706",
      "r707",
      "r755",
      "r799",
      "r932"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "NUMERATOR:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net income (loss) attributable to noncontrolling interests",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r179",
      "r228",
      "r229",
      "r263",
      "r264",
      "r608",
      "r896"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NewMasterLeaseAgreeementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NewMasterLeaseAgreeementMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Master Lease Agreeement",
        "label": "New Master Lease Agreeement [Member]",
        "documentation": "New Master Lease Agreeement"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NonCaliforniaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NonCaliforniaMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-california",
        "label": "Non-California [Member]",
        "documentation": "Non-California [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NonCashLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NonCashLeaseExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash leasing arrangement",
        "label": "Non-Cash Lease Expense",
        "documentation": "Non-Cash Lease Expense"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r816",
      "r828",
      "r838",
      "r855",
      "r864"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestDecreaseFromDeconsolidation",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deconsolidation of an ancillary business",
        "label": "Noncontrolling Interest, Decrease from Deconsolidation",
        "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78"
     ]
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital contribution from noncontrolling interest holder and Issuance of noncontrolling interests through subsidiary equity plan",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r78",
      "r178"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r419",
      "r905",
      "r906",
      "r907",
      "r1071"
     ]
    },
    "ensg_NoncontrollingInterestPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NoncontrollingInterestPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling Interest",
        "label": "Noncontrolling Interest [Policy Text Block]",
        "documentation": "The noncontrolling interest in a subsidiary initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's condensed consolidated balance sheets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other income (expense), net",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r140"
     ]
    },
    "us-gaap_NonqualifiedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonqualifiedPlanMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonqualified Plan",
        "label": "Nonqualified Plan [Member]",
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "ensg_NumberOfAssetAcquisitions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfAssetAcquisitions",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of asset acquisitions",
        "label": "Number of Asset Acquisitions",
        "documentation": "Number of Asset Acquisitions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfBusinessesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfBusinessesAcquired",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of businesses acquired",
        "label": "Number of Businesses Acquired",
        "documentation": "The number of businesses acquired by the entity during the period."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of facilities",
        "label": "Number Of Facilities",
        "documentation": "Number Of Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfFinancingLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfFinancingLeases",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financing lease",
        "label": "Number Of Financing Leases",
        "documentation": "Number Of Financing Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfHealthCareFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfHealthCareFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Health care facilities",
        "label": "Number Of Health Care Facilities",
        "documentation": "Number Of Health Care Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfLeaseArrangements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfLeaseArrangements",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of master lease arrangements",
        "label": "Number of Lease Arrangements",
        "documentation": "Number of Lease Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfLivingOperationsTransferredFromThirdParties": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfLivingOperationsTransferredFromThirdParties",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operations transferred from third parties",
        "label": "Number of Living Operations Transferred From Third-Parties",
        "documentation": "Number of Living Operations Transferred From Third-Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfOperatingSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfOperatingSubsidiaries",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating subsidiaries",
        "label": "Number Of Operating Subsidiaries",
        "documentation": "Number Of operating subsidiaries entered into mortgage loans that are insured with HUD."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfOperations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfOperations",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operations lease and operated by third parties",
        "label": "Number Of Operations",
        "documentation": "Number Of Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfOptionPlans": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfOptionPlans",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of option plans",
        "label": "Number Of Option Plans",
        "documentation": "Number Of Option Plans"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfPropertiesAcquired": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfPropertiesAcquired",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of real estate skilled nursing properties acquired",
        "label": "Number Of Properties Acquired",
        "documentation": "Number Of Properties Acquired"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfRealEstateProperties": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfRealEstateProperties",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of real estate properties",
        "label": "Number of Real Estate Properties",
        "documentation": "The number of real estate properties owned as of the balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfRealEstatePropertiesLeased": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfRealEstatePropertiesLeased",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of real estate properties leased",
        "label": "Number of Real Estate Properties Leased",
        "documentation": "Number of Real Estate Properties Leased"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_NumberOfRealEstatePropertiesLeasedWithOptionToPurchase": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfRealEstatePropertiesLeasedWithOptionToPurchase",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of real estate properties leased with an option to purchase",
        "label": "Number of Real Estate Properties Leased with an Option to Purchase",
        "documentation": "Number of Real Estate Properties Leased with an Option to Purchase"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "ensg_NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of senior living operations sharing property with skilled nursing facilities",
        "label": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities",
        "documentation": "Number Of Senior Living Operations Sharing Property With Skilled Nursing Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_OperatingEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OperatingEntityAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Entity [Axis]",
        "label": "Operating Entity [Axis]",
        "documentation": "Operating Entity [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_OperatingEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OperatingEntityDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Entity [Domain]",
        "label": "Operating Entity [Domain]",
        "documentation": "[Domain] for Operating Entity [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r286",
      "r300",
      "r306",
      "r309",
      "r755"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease expense",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r566",
      "r784"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1040"
     ]
    },
    "us-gaap_OperatingLeaseIncomeComprehensiveIncomeExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseIncomeComprehensiveIncomeExtensibleList",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OperatingLeaseIncomeComprehensiveIncomeExtensibleListNotDisclosedFlag",
        "label": "Operating Lease, Lease Income, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of comprehensive income that includes operating lease income."
       }
      }
     },
     "auth_ref": [
      "r576"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental revenue",
        "label": "Operating Lease, Lease Income",
        "documentation": "Amount of operating lease income from lease payments and variable lease payments paid and payable to lessor. Includes, but is not limited to, variable lease payments not included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r576",
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Rental Income from Third-Party Sources",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "documentation": "Tabular disclosure of components of income from operating lease."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r579"
     ]
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "PRESENT VALUE OF TOTAL LEASE LIABILITIES",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities\u2014current",
        "negatedLabel": "Less: current lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/LEASESLesseeFutureMinimumLeasePaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term lease liabilities\u2014less current portion",
        "verboseLabel": "LONG-TERM OPERATING LEASE LIABILITIES",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r562",
      "r570"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_OperatingLeaseVariableLeaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseVariableLeaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, variable lease income",
        "label": "Operating Lease, Variable Lease Income",
        "documentation": "Amount of operating lease income from variable lease payments paid and payable to lessor, excluding amount included in measurement of lease receivable."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r580"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate, percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r573",
      "r784"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r784"
     ]
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASES"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEASES",
        "label": "Lessor, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for lessor's operating leases."
       }
      }
     },
     "auth_ref": [
      "r575"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Segments",
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r309"
     ]
    },
    "ensg_OperationalSeniorLivingUnits": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OperationalSeniorLivingUnits",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operational senior living units",
        "label": "Operational Senior Living Units",
        "documentation": "Operational Assisted Living and Independent Living Units"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_OperationalSkilledNursingBeds": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OperationalSkilledNursingBeds",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operational skilled nursing beds",
        "label": "Operational Skilled Nursing Beds",
        "documentation": "Number of skilled nursing beds available for use at a skilled nursing facility"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "DESCRIPTION OF BUSINESS",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r176",
      "r641",
      "r642"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other accrued liabilities",
        "totalLabel": "OTHER ACCRUED LIABILITIES",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r226",
      "r785"
     ]
    },
    "us-gaap_OtherAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RESTRICTED AND OTHER ASSETS",
        "label": "Other Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash financing and investing activity",
        "label": "Other Noncash Investing and Financing Items [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r142"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_OtherRestrictedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherRestrictedAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital improvement reserves with landlords and lenders",
        "label": "Other Restricted Assets",
        "documentation": "Total assets that cannot be used for operating purposes because of contract or regulatory requirements that are in effect for a period that extends beyond one year."
       }
      }
     },
     "auth_ref": [
      "r728",
      "r729",
      "r893"
     ]
    },
    "ensg_OtherStatesExceptCaliforniaTexasAndWashingtonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OtherStatesExceptCaliforniaTexasAndWashingtonMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other States, Except California, Texas and Washington",
        "label": "Other states, except California, Texas and Washington [Member]",
        "documentation": "Other states, except California, Texas and Washington"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r814",
      "r826",
      "r836",
      "r862"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r829",
      "r839",
      "r865"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r817",
      "r829",
      "r839",
      "r865"
     ]
    },
    "ensg_OwnedPropertiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "OwnedPropertiesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Owned Properties",
        "label": "Owned Properties [Member]",
        "documentation": "Owned Properties"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ParentCompanyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ParentCompanyMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent Company",
        "label": "Parent Company [Member]"
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PaymentsForMedicareAndMedicaidLicenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PaymentsForMedicareAndMedicaidLicenses",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments for Medicare and Medicaid licenses",
        "label": "Payments For Medicare and Medicaid Licenses",
        "documentation": "Payments For Medicare and Medicaid Licenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromDepositsOnRealEstateAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromDepositsOnRealEstateAcquisitions",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Escrow deposits",
        "label": "Payments for (Proceeds from) Deposits on Real Estate Acquisitions",
        "documentation": "Net cash outflow or inflow from the amount given in advance to show intention to complete the acquisition piece of land, anything permanently fixed to it, including buildings, structures on it, and so forth."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other restricted assets",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r897"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of shares of common stock (Note 21)",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsOfDividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfDividends",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Dividends paid",
        "label": "Payments of Dividends",
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments of deferred financing costs",
        "terseLabel": "Payments of deferred financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of shares of common stock to satisfy tax withholding obligations",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r237"
     ]
    },
    "ensg_PaymentsToAcquireAssetAcquisitions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PaymentsToAcquireAssetAcquisitions",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments for asset acquisitions (Note 7)",
        "label": "Payments To Acquire Asset Acquisitions",
        "documentation": "Cash paid to acquire acquisitions."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire businesses, gross",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r528"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash payments for business acquisitions (Note 7)",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r144"
     ]
    },
    "ensg_PaymentsToAcquirePropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PaymentsToAcquirePropertyAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments To Acquire Property And Equipment",
        "documentation": "Payments To Acquire Property And Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToMinorityShareholders": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToMinorityShareholders",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Non-controlling interest distribution",
        "label": "Payments to Noncontrolling Interests",
        "documentation": "Amount of cash outflow to a noncontrolling interest. Includes, but not limited to, reduction of noncontrolling interest ownership. Excludes dividends paid to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ensg_PayorAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PayorAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor [Axis]",
        "label": "Payor [Axis]",
        "documentation": "Payor [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PayorDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PayorDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payor [Domain]",
        "label": "Payor [Domain]",
        "documentation": "Payor [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r845"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r844"
     ]
    },
    "ensg_PerFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PerFacilityMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Facility",
        "label": "Per Facility [Member]",
        "documentation": "Per Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PerOccurenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PerOccurenceMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Per Occurence",
        "label": "Per Occurence [Member]",
        "documentation": "Per Occurence [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1001",
      "r1002",
      "r1003",
      "r1004",
      "r1005",
      "r1006",
      "r1007",
      "r1008",
      "r1009",
      "r1010",
      "r1011",
      "r1012",
      "r1013",
      "r1014",
      "r1015",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "ensg_PrepaymentFeePeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PrepaymentFeePeriodAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment Fee, Period [Axis]",
        "label": "Prepayment Fee, Period [Axis]",
        "documentation": "Prepayment Fee, Period"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PrepaymentFeePeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PrepaymentFeePeriodDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment Fee, Period [Domain]",
        "label": "Prepayment Fee, Period [Domain]",
        "documentation": "Prepayment Fee, Period [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PrepaymentPenalty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PrepaymentPenalty",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepayment penalty",
        "label": "Prepayment Penalty",
        "documentation": "Percentage that the prepayment penalty percentage is reduced during the first three years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "ensg_PrivatePayAndOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PrivatePayAndOtherMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Private and other",
        "terseLabel": "Private and other payors",
        "label": "Private Pay and Other [Member]",
        "documentation": "Revenue from self-pay and Other payors [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from CARES Act Provider Relief Fund and Medicare Advance Payment Program (Note 3)",
        "label": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program",
        "documentation": "Proceeds From CARES Act Provider Relief Funds And Medicare Advance Payment Program"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInsuranceSettlementInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash from insurance proceeds",
        "label": "Proceeds from Insurance Settlement, Investing Activities",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r37"
     ]
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received from insurance proceeds",
        "label": "Proceeds from Insurance Settlement, Operating Activities",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r240",
      "r745"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of preferred shares",
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from debt (Note 15)",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r648"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ensg_ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of subsidiary shares (Note 6)",
        "label": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans",
        "documentation": "Proceeds From Sale Of Common Stock Associated With Subsidiary Equity Plans"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash proceeds from the sale of assets",
        "label": "Proceeds from Sale of Productive Assets",
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of real estate",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r143"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock upon exercise of options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r15"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r590",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r747",
      "r764",
      "r786",
      "r890",
      "r929",
      "r930",
      "r939",
      "r1063"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "auth_ref": [
      "r311",
      "r590",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r747",
      "r764",
      "r786",
      "r890",
      "r929",
      "r930",
      "r939",
      "r1063"
     ]
    },
    "us-gaap_ProfessionalMalpracticeLiabilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfessionalMalpracticeLiabilityMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Professional Liability",
        "label": "Professional Malpractice Liability Insurance [Member]",
        "documentation": "Business insurance coverage for professionals, such as doctors, lawyers, insurance agents, accountants, real estate agents, veterinarians, and others. This liability coverage insures losses for claims arising from mistakes and errors or omissions in the course of professional activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "NET INCOME",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r213",
      "r228",
      "r229",
      "r239",
      "r247",
      "r255",
      "r263",
      "r264",
      "r286",
      "r300",
      "r306",
      "r309",
      "r322",
      "r363",
      "r364",
      "r366",
      "r367",
      "r368",
      "r370",
      "r372",
      "r374",
      "r375",
      "r529",
      "r532",
      "r533",
      "r545",
      "r548",
      "r595",
      "r607",
      "r653",
      "r689",
      "r706",
      "r707",
      "r755",
      "r781",
      "r782",
      "r800",
      "r896",
      "r932"
     ]
    },
    "us-gaap_ProfitLossFromRealEstateOperations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLossFromRealEstateOperations",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain on sale of assets and insurance recoveries from real estate, net",
        "label": "Profit (Loss) from Real Estate Operations",
        "documentation": "The net cost of operation of other real estate (including provisions for real estate losses, rental income, and gains and losses on sales of real estate)."
       }
      }
     },
     "auth_ref": [
      "r192"
     ]
    },
    "ensg_PropertyManagementFeePercentFeeOfFundsFromOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PropertyManagementFeePercentFeeOfFundsFromOperations",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees, as a percentage of funds from operations",
        "label": "Property Management Fee, Percent Fee of Funds from Operations",
        "documentation": "Property Management Fee, Percent Fee of Funds from Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PropertyManagementFeePercentFeeOfTotalRevenues": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PropertyManagementFeePercentFeeOfTotalRevenues",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Management fees, as a percentage of total revenues",
        "label": "Property Management Fee, Percent Fee of Total Revenues",
        "documentation": "Property Management Fee, Percent Fee of Total Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAdditions",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails": {
       "parentTag": "ensg_BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment",
        "label": "Property, Plant and Equipment, Additions",
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNET"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PROPERTY AND EQUIPMENT\u2014 NET",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r201",
      "r204",
      "r205"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r155",
      "r217",
      "r605"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "PROPERTY AND EQUIPMENT, NET",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r596",
      "r605",
      "r785"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r201",
      "r204",
      "r603"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment, Net",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r155"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProvisionForDoubtfulAccounts",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provision for doubtful accounts",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r326"
     ]
    },
    "ensg_PurchaseOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PurchaseOptionMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase Option",
        "label": "Purchase Option [Member]",
        "documentation": "Purchase Option"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_PurchasesOfNonControllingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "PurchasesOfNonControllingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of non-controlling interest",
        "label": "Purchases of Non-Controlling Interest",
        "documentation": "Purchases of Non-Controlling Interest"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r843"
     ]
    },
    "us-gaap_QualifiedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "QualifiedPlanMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Qualified Plan",
        "label": "Qualified Plan [Member]",
        "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "ensg_QualityAssuranceFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "QualityAssuranceFee",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quality assurance fee",
        "label": "Quality Assurance Fee",
        "documentation": "Quality assurance fee represents amounts payable to California, Utah, Idaho, Washington, Colorado, Iowa, and Nebraska in respect of a mandated fee based on resident days"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r442",
      "r450",
      "r482",
      "r483",
      "r484",
      "r588",
      "r589",
      "r633",
      "r659",
      "r660",
      "r713",
      "r717",
      "r719",
      "r720",
      "r722",
      "r743",
      "r744",
      "r756",
      "r763",
      "r776",
      "r789",
      "r792",
      "r926",
      "r936",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r359",
      "r360",
      "r361",
      "r362",
      "r442",
      "r450",
      "r482",
      "r483",
      "r484",
      "r588",
      "r589",
      "r633",
      "r659",
      "r660",
      "r713",
      "r717",
      "r719",
      "r720",
      "r722",
      "r743",
      "r744",
      "r756",
      "r763",
      "r776",
      "r789",
      "r792",
      "r926",
      "r936",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056"
     ]
    },
    "us-gaap_RealEstatePropertiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstatePropertiesAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Property Ownership [Axis]",
        "label": "Real Estate Property Ownership [Axis]",
        "documentation": "Information by ownership of the property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstatePropertiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstatePropertiesDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Properties [Domain]",
        "label": "Real Estate Properties [Domain]",
        "documentation": "Represents categories of ownership of real estate properties."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealEstatePropertiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealEstatePropertiesLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Properties [Line Items]",
        "label": "Real Estate Properties [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_RealEstatePurchasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RealEstatePurchasesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Purchases",
        "label": "Real Estate Purchases [Member]",
        "documentation": "Real Estate Purchases"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_RealEstatePurchasesOfPreviousOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RealEstatePurchasesOfPreviousOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Real Estate Purchases Of Previous Operations",
        "label": "Real Estate Purchases Of Previous Operations [Member]",
        "documentation": "Real Estate Purchases Of Previous Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTable",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table]",
        "documentation": "Identification, description, and amounts of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Service Revenue by Major Payor Source",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r809",
      "r821",
      "r831",
      "r857"
     ]
    },
    "ensg_ReductionInPrepaymentPenalty": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ReductionInPrepaymentPenalty",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in prepayment penalty",
        "label": "Reduction In Prepayment Penalty",
        "documentation": "Percentage that the prepayment penalty percentage is reduced during the fourth year."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_RentCostOfServices": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RentCostOfServices",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rent\u2014cost of services",
        "label": "Rent Cost Of Services",
        "documentation": "Rent cost of services"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_RentalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RentalMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rental revenue",
        "label": "Rental [Member]",
        "documentation": "Rental"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of medicare accelerated and advance payment program",
        "label": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act",
        "documentation": "Repayment Of Funds Received From The Medicare Accelerated and Advance Payment Program, CARES Act"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments on debt (Note 15)",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r649"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r249",
      "r250",
      "r380",
      "r408",
      "r582",
      "r751",
      "r752"
     ]
    },
    "ensg_ResidentRefundsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ResidentRefundsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails": {
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Refunds payable",
        "label": "Resident Refunds Payable",
        "documentation": "Resident refunds payable includes amounts due to residents for overpayments and duplicate payments"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r810",
      "r822",
      "r832",
      "r858"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r811",
      "r823",
      "r833",
      "r859"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r818",
      "r830",
      "r840",
      "r866"
     ]
    },
    "ensg_RestrictedAndOtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RestrictedAndOtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted and other assets",
        "totalLabel": "RESTRICTED AND OTHER ASSETS",
        "label": "Restricted And Other Assets, Noncurrent",
        "documentation": "Restricted And Other Assets, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Awards",
        "verboseLabel": "Stock-based compensation expense related to restricted stock awards",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r354",
      "r355"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r162",
      "r600",
      "r638",
      "r639",
      "r650",
      "r670",
      "r785"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained Earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r264",
      "r323",
      "r324",
      "r491",
      "r492",
      "r493",
      "r516",
      "r517",
      "r536",
      "r538",
      "r539",
      "r541",
      "r543",
      "r634",
      "r636",
      "r654",
      "r1071"
     ]
    },
    "us-gaap_RetirementPlanTaxStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTaxStatusAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Tax Status [Axis]",
        "label": "Retirement Plan Tax Status [Axis]",
        "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_RetirementPlanTaxStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTaxStatusDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEFINEDCONTRIBUTIONPLANSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Tax Status [Domain]",
        "label": "Retirement Plan Tax Status [Domain]",
        "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans."
       }
      }
     },
     "auth_ref": [
      "r886",
      "r941",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r950",
      "r951",
      "r952",
      "r953",
      "r954",
      "r955",
      "r956",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992",
      "r993",
      "r994",
      "r995",
      "r996",
      "r997",
      "r998",
      "r999",
      "r1000"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TOTAL REVENUE",
        "netLabel": "Revenue",
        "verboseLabel": "Total Service Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r299",
      "r304",
      "r305",
      "r311",
      "r313",
      "r315",
      "r438",
      "r439",
      "r590"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service Revenue Recognition, Rental Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r746"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLE"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "REVENUE AND ACCOUNTS RECEIVABLE",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r441"
     ]
    },
    "ensg_RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, FMAP payments received",
        "label": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized",
        "documentation": "Revenue Recognition, Family First Coronavirus Response Act, Revenue Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revolving credit facility with Truist",
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new and modified operating lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r571",
      "r784"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLENarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r315",
      "r887"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accounts Receivable",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OTHERACCRUEDLIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Indefinite-lived Intangible Assets",
        "label": "Schedule of Acquired Indefinite-Lived Intangible Assets by Major Class [Table Text Block]",
        "documentation": "Tabular disclosure of acquired indefinite-lived intangible assets. Indefinite-lived intangible assets are assets that have no physical form, but have expected future economic benefit. Indefinite-lived assets are assets that are not subject to amortization. Acquired indefinite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the entity) and in total."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r97",
      "r526"
     ]
    },
    "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Employee Stock Option Roll Forward",
        "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in common stock outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r172"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r76",
      "r77",
      "r110",
      "r111",
      "r113",
      "r118",
      "r160",
      "r161",
      "r759",
      "r761",
      "r904"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Basic Net Income Per Common Share",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r908"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHARETables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the Numerator and Denominator Used in the Calculation of Diluted Net Income Per Common Share",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r52",
      "r908"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INCOMETAXESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r170"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock-Based Compensation Expense",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETNarrativeDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72",
      "r591"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r72"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.ensigngroup.net/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Schedule of Goodwill [Table]",
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r757"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/GOODWILLTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r757",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r153"
     ]
    },
    "us-gaap_ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liability for Future Policy Benefits, by Product Segment",
        "label": "Schedule of Liability for Future Policy Benefits, by Product Segment [Table Text Block]",
        "documentation": "The entire disclosure for the present values of future benefits to be paid to or on behalf of policyholders and related expenses less the present value of future net premiums using assumptions such as estimates of expected investment yields, mortality, morbidity, terminations and expenses, applicable at the time the insurance contracts are made and unpaid claim costs relating to insurance contracts including estimates of costs relating to incurred but not reported claims based on the estimated ultimate cost of settling the claims (including effects of inflation and other societal and economic factors), using past experience adjusted for current trends and any other factors that would modify past experience by element such as business segment, country and interest rate range."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insurance Type and Tier Identifier [Axis]",
        "label": "Insurance Type and Tier Identifier [Axis]",
        "documentation": "Information by type of insurance coverage or layer of insurance that covers malpractice claims."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Long-term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Nonvested Restricted Stock Awards",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted and Other Assets",
        "label": "Schedule of Other Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails",
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETScheduleofPropertyandEquipmentDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfRealEstatePropertiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRealEstatePropertiesTable",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESLeasesandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Real Estate Properties [Table]",
        "label": "Schedule of Real Estate Properties [Table]",
        "documentation": "Schedule detailing quantitative information concerning real estate properties and units within those properties by ownership of the property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Purchase Price Allocation",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r175"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Financial Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r63",
      "r66"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options Outstanding, Vested and Related Details",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions for Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r169"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Estimated Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ensg_SecuredOvernightFinancingRateSOFRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SecuredOvernightFinancingRateSOFRMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Overnight Financing Rate (SOFR)",
        "label": "Secured Overnight Financing Rate (SOFR) [Member]",
        "documentation": "Secured Overnight Financing Rate (SOFR)"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r802"
     ]
    },
    "us-gaap_SecurityDeposit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SecurityDeposit",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails": {
       "parentTag": "ensg_RestrictedAndOtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/RESTRICTEDANDOTHERASSETSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deposits with landlords",
        "label": "Security Deposit",
        "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease."
       }
      }
     },
     "auth_ref": [
      "r893"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r315",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r353",
      "r356",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r757",
      "r890",
      "r1063"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r656",
      "r657",
      "r658",
      "r714",
      "r718",
      "r721",
      "r723",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r748",
      "r765",
      "r792",
      "r939",
      "r1063"
     ]
    },
    "ensg_SegmentIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SegmentIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment income (loss)",
        "label": "Segment Income (Loss)",
        "documentation": "Segment Income (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BUSINESS SEGMENTS",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r298",
      "r303",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r315"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingRevenueReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SegmentReportingRevenueReconcilingItemLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "label": "Segment Reporting, Revenue Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SelfInsuranceReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self insurance reserve",
        "label": "Self Insurance Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions) of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "us-gaap_SelfInsuranceReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued self-insurance liabilities\u2014current",
        "label": "Self Insurance Reserve, Current",
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid within one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SelfInsuranceReserveNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReserveNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued self-insurance liabilities\u2014less current portion",
        "label": "Self Insurance Reserve, Noncurrent",
        "documentation": "Carrying amount of accrued known and estimated losses incurred as of the balance sheet date for which no insurance coverage exists, and for which a claim has been made or is probable of being asserted, typically arising from workmen's compensation-type of incidents and personal injury to nonemployees from accidents on the entity's property that are expected to be paid after one year (or the normal operating cycle, if longer)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SelfInsuranceReservePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SelfInsuranceReservePolicyTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self-Insurance",
        "label": "Self Insurance Reserve [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for self-insurance reserves, including, but not limited to incurred but not reported reserves (IBNR)."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SelfInsuranceRetentionPerClaimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SelfInsuranceRetentionPerClaimMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Self-Insurance Retention Per Claim",
        "label": "Self-insurance Retention Per Claim [Member]",
        "documentation": "Self-insurance retention per claim [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SeniorLivingFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SeniorLivingFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior living facilities",
        "label": "Senior Living Facilities",
        "documentation": "Number of Assisted and Independent Living Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SeniorLivingFacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SeniorLivingFacilitiesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Living Facilities",
        "label": "Senior Living Facilities [Member]",
        "documentation": "Assisted Living Facilities [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SeniorLivingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SeniorLivingOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/PROPERTYANDEQUIPMENTNETNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Living Operations",
        "label": "Senior Living Operations [Member]",
        "documentation": "Senior Living Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeriesOfIndividuallyImmaterialAssetAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialAssetAcquisitionsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series of Individually Immaterial Asset Acquisitions",
        "label": "Series of Individually Immaterial Asset Acquisitions [Member]",
        "documentation": "Series of individually immaterial asset acquisitions."
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Series of Individually Immaterial Business Acquisitions",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ServiceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ServiceMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/REVENUEANDACCOUNTSRECEIVABLEDisaggregationofRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Service revenue",
        "label": "Service [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeiture rate",
        "label": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Award, Options, Fair Value, Assumptions Forfeiture Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award requisite service period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r777"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted restricted shares (in shares)",
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in shares)",
        "periodEndLabel": "Nonvested at end of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Vested Restricted Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested at beginning of period (in dollars per share)",
        "periodEndLabel": "Nonvested at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r469",
      "r470"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Threshold event period after vesting of restricted awards or exercise of stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Event Period After Vesting Of Restricted Awards Or Exercise Of Stock Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Dividend Yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Risk-Free Rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of installments",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Number Of Installments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r779"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares available for grant (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Conversion to reduce shares availability",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Conversion To Reduce Shares Availability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price of Options Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised in period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r476"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, options expected to vest, number (in shares)",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Number",
        "documentation": "As of the balance sheet date, the number of shares which are expected to vest into stock options outstanding can be converted under the option plan."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected to vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expected to Vest, Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period",
        "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price of options that were either forfeited or expired."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date intrinsic value (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value",
        "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "verboseLabel": "Options granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Fair Value of Options (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Exercise Price and Fair Value Displayed at Grant Date for Stock Option Grants",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period, (in shares)",
        "periodEndLabel": "Balance at end of period, (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period (in dollars per share)",
        "periodEndLabel": "Balance at end of period (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r461",
      "r462"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Aggregate Intrinsic Value of Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable [Table Text Block]",
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r477"
     ]
    },
    "ensg_ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other than options, conversion to reduce shares availability",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability",
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Other Than Options, Conversion To Reduce Shares Availability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSExercisePriceandFairValueDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average Exercise Price (in dollars per share)",
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r451",
      "r460",
      "r479",
      "r480",
      "r481",
      "r482",
      "r485",
      "r494",
      "r495",
      "r496",
      "r497"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Axis]",
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price Range [Domain]",
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "ensg_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Black-Scholes Fair Value",
        "label": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Fair Value",
        "documentation": "Fair value determined using a black-scholes model for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, lower range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options vested and exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number outstanding (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price, upper range limit (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementNonemployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedPaymentArrangementNonemployeeMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-employee Directors",
        "label": "Share-Based Payment Arrangement, Nonemployee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor does not exercise nor has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Excludes nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457",
      "r458",
      "r459",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ]
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of the share repurchase program."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails",
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award vesting rights, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1001"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options that vested in period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSStockOptionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r778"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSValuationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected Life",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSIntrinsicValuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, options outstanding, weighted average remaining contractual term",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "ensg_SharebasedCompensationRestrictedAwardsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SharebasedCompensationRestrictedAwardsExercisePrice",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedStockAwardsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation, restricted awards, exercise price (in dollars per share)",
        "label": "Share-based Compensation, Restricted Awards, Exercise Price",
        "documentation": "Share-based Compensation, Restricted Awards, Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingbyExercisePriceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Remaining Contractual Life (Years)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r168"
     ]
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock used to satisfy tax withholding obligations (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments\u2014current",
        "label": "Short-Term Investments",
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r894"
     ]
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CPI increases and short term-lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r784"
     ]
    },
    "ensg_SkilledNursingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SkilledNursingOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Skilled Nursing Operations",
        "label": "Skilled Nursing Operations [Member]",
        "documentation": "Skilled Nursing Operations"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SkilledNursingSeniorLivingAndIndependentLivingFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SkilledNursingSeniorLivingAndIndependentLivingFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Skilled nursing, assisted living and independent living facilities",
        "label": "Skilled Nursing, Senior Living and Independent Living Facilities",
        "documentation": "Skilled Nursing, Senior Living and Independent Living Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SkilledServiceFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SkilledServiceFacilities",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transitional and skilled service facilities",
        "label": "Skilled Service Facilities",
        "documentation": "Skilled Service Facilities"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SkilledServicesAndSeniorLivingCampuses": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SkilledServicesAndSeniorLivingCampuses",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Transitional and skilled services and senior living campuses",
        "label": "Skilled Services And Senior Living Campuses",
        "documentation": "Transitional and Skilled Services and Assistant and Independent Living Campuses"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_SkilledServicesSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SkilledServicesSegmentMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Skilled Services",
        "label": "Skilled Services Segment [Member]",
        "documentation": "Skilled Services Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SpinoffMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SpinoffMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Spinoff",
        "label": "Spinoff [Member]",
        "documentation": "Creation of an independent entity from an existing entity through divestiture, for example, but not limited to, sale or distribution of new shares."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StandardBearerEquityPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StandardBearerEquityPlanMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard Bearer Equity Plan",
        "label": "Standard Bearer Equity Plan [Member]",
        "documentation": "Standard Bearer Equity Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StandardBearerHealthcareREITIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StandardBearerHealthcareREITIncMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard Bearer Healthcare REIT, Inc.",
        "label": "Standard Bearer Healthcare REIT, Inc. [Member]",
        "documentation": "Standard Bearer Healthcare REIT, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StandardBearerMasterLeasesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StandardBearerMasterLeasesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard Bearer Master Leases",
        "label": "Standard Bearer Master Leases [Member]",
        "documentation": "Standard Bearer Master Leases"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StandardBearerSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StandardBearerSegmentMember",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Standard Bearer",
        "label": "Standard Bearer Segment [Member]",
        "documentation": "Standard Bearer Segment"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StandardBearerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StandardBearerTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARER"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "STANDARD BEARER",
        "label": "Standard Bearer [Text Block]",
        "documentation": "Standard Bearer"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofServiceRevenuebyMajorPayorSourceDetails",
      "http://www.ensigngroup.net/role/GOODWILLDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r211",
      "r283",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r315",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r349",
      "r353",
      "r356",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r757",
      "r890",
      "r1063"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r33",
      "r209",
      "r231",
      "r232",
      "r233",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r264",
      "r281",
      "r323",
      "r324",
      "r419",
      "r491",
      "r492",
      "r493",
      "r516",
      "r517",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r581",
      "r634",
      "r635",
      "r636",
      "r654",
      "r708"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r313",
      "r314",
      "r656",
      "r657",
      "r658",
      "r714",
      "r718",
      "r721",
      "r723",
      "r727",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r748",
      "r765",
      "r792",
      "r939",
      "r1063"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r281",
      "r590",
      "r643",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r708",
      "r793"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r252",
      "r253",
      "r254",
      "r281",
      "r590",
      "r643",
      "r655",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r669",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r688",
      "r690",
      "r691",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r708",
      "r793"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r813",
      "r825",
      "r835",
      "r861"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_StockAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StockAwardsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSCompensationExpenseDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors",
        "label": "Stock awards [Member]",
        "documentation": "Stock awards [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126",
      "r127",
      "r162",
      "r648",
      "r708",
      "r724"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSRestrictedAwardRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Forfeited",
        "documentation": "Number of shares related to Restricted Stock Award forfeited during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock, net of forfeitures (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126",
      "r127",
      "r162"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSOptionsOutstandingRollforwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126",
      "r127",
      "r162",
      "r466"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock to employees and directors resulting from the exercise of stock options and grant of stock awards",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r126",
      "r127",
      "r162",
      "r654",
      "r708",
      "r724",
      "r800"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of restricted stock, net of forfeitures",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r162"
     ]
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Stock Repurchase Program, Authorized Amount",
        "documentation": "Amount of stock repurchase plan authorized."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, period in force",
        "label": "Stock Repurchase Program, Period in Force",
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Ensign Group, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r130",
      "r131",
      "r149",
      "r671",
      "r687",
      "r709",
      "r710",
      "r785",
      "r801",
      "r902",
      "r913",
      "r1039",
      "r1071"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ensign Group, Inc. stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r103",
      "r209",
      "r210",
      "r232",
      "r252",
      "r253",
      "r254",
      "r256",
      "r262",
      "r323",
      "r324",
      "r419",
      "r491",
      "r492",
      "r493",
      "r516",
      "r517",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r549",
      "r550",
      "r554",
      "r581",
      "r635",
      "r636",
      "r652",
      "r671",
      "r687",
      "r709",
      "r710",
      "r725",
      "r800",
      "r902",
      "r913",
      "r1039",
      "r1071"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAM"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMON STOCK REPURCHASE PROGRAM",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r246",
      "r406",
      "r407",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r542",
      "r711",
      "r712",
      "r726"
     ]
    },
    "ensg_StopLossInsuranceLimitPerClaimMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "StopLossInsuranceLimitPerClaimMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stop-Loss Insurance Limit Per Claim",
        "label": "Stop-Loss Insurance Limit Per Claim [Member]",
        "documentation": "Stop-Loss Insurance limit per claim[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "presentation": [
      "http://www.ensigngroup.net/role/BUSINESSSEGMENTSScheduleofSegmentFinancialInformationDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r569",
      "r784"
     ]
    },
    "ensg_SubleaseOfStandAlongSkilledNursingOperationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "SubleaseOfStandAlongSkilledNursingOperationsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sublease Of Stand Along Skilled Nursing Operations",
        "label": "Sublease Of Stand Along Skilled Nursing Operations [Member]",
        "documentation": "Sublease Of Stand Along Skilled Nursing Operations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r584"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r584"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMITMENTSANDCONTINGENCIESDetails",
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/OPERATIONEXPANSIONSNarrativeDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r584"
     ]
    },
    "srt_SubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SubsidiariesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/FAIRVALUEMEASUREMENTSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Captive Insurance Subsidiary",
        "label": "Subsidiaries [Member]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r1046",
      "r1047",
      "r1048"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_TX": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "TX",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Texas",
        "label": "TEXAS"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ensg_ThePennantGroupInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ThePennantGroupInc.Member",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorNarrativeDetails",
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Pennant Group, Inc.",
        "verboseLabel": "Pennant",
        "label": "The Pennant Group, Inc. [Member]",
        "documentation": "The Pennant Group, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ThirdPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ThirdPartiesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Parties",
        "label": "Third Parties [Member]",
        "documentation": "Third Parties"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ThirdPartyOperatorsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ThirdPartyOperatorsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third Party Operators",
        "label": "Third Party Operators [Member]",
        "documentation": "Third Party Operators"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_ThirdPartyTenantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "ThirdPartyTenantsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLessorRentalIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other third-party",
        "label": "Third Party Tenants [Member]",
        "documentation": "Third Party Tenants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_TotalNetDebtRatioMaximum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TotalNetDebtRatioMaximum",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net debt ratio, maximum",
        "label": "Total Net Debt Ratio, Maximum",
        "documentation": "Total Net Debt Ratio, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_TotalNetDebtRatioMaximumAfterIncreaseElection": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TotalNetDebtRatioMaximumAfterIncreaseElection",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net debt ratio, maximum after increase election",
        "label": "Total Net Debt Ratio, Maximum After Increase Election",
        "documentation": "Total Net Debt Ratio, Maximum After Increase Election"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_TotalNetDebtRatioMinimum": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TotalNetDebtRatioMinimum",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total net debt ratio, minimum",
        "label": "Total Net Debt Ratio, Minimum",
        "documentation": "Total Net Debt Ratio, Minimum"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_TradeAndOtherAccountsReceivablePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeAndOtherAccountsReceivablePolicy",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Accounts Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for accounts receivable."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r196",
      "r197",
      "r318",
      "r319",
      "r321"
     ]
    },
    "us-gaap_TradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TradeNamesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofFiniteLivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/INTANGIBLEASSETSNETScheduleofIndefinitelivedIntangibleAssetsDetails",
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESIntangibleAssetsandGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trade name",
        "verboseLabel": "Facility trade name",
        "label": "Trade Names [Member]",
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.ensigngroup.net/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r878"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r879"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r877"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury Stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common shares in treasury, at cost",
        "periodStartLabel": "Balance at beginning of period (in shares)",
        "periodEndLabel": "Balance at end of period (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDBALANCESHEETS"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Common stock in treasury, at cost, 3,390 and 3,368 shares at December\u00a031, 2023 and 2022, respectively",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r79",
      "r82"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock (in shares)",
        "verboseLabel": "Repurchase of common stock (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r127",
      "r162"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.ensigngroup.net/role/COMMONSTOCKREPURCHASEPROGRAMDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Repurchase of common stock (Note 21)",
        "verboseLabel": "Repurchase of common stock, value",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r79",
      "r162"
     ]
    },
    "ensg_TripleNetLeaseArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TripleNetLeaseArrangementsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Triple Net Lease Arrangements",
        "label": "Triple Net Lease Arrangements [Member]",
        "documentation": "Triple Net Lease Arrangements"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_TruistBankMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TruistBankMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Truist",
        "label": "Truist Bank [Member]",
        "documentation": "Truist Bank [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ensg_TwentyThreeSubsidiariesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "TwentyThreeSubsidiariesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Twenty Three Subsidiaries",
        "label": "Twenty Three Subsidiaries [Member]",
        "documentation": "Twenty Three Subsidiaries"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeAndTierIdentifierDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeAndTierIdentifierDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/SELFINSURANCELIABILITIESDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type and Tier Identifier [Domain]",
        "label": "Type and Tier Identifier [Domain]",
        "documentation": "Name of the type of insurance coverage or layer of insurance that covers malpractice claims."
       }
      }
     },
     "auth_ref": [
      "r194"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/OPTIONSANDAWARDSLongTermIncentivePlanDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r350",
      "r351",
      "r354",
      "r355"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimates and Assumptions",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r60",
      "r199",
      "r200",
      "r202",
      "r203"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeLeaseCostDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease, costs",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r784"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Axis]",
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Rate [Domain]",
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "ensg_VariousLandlordsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "VariousLandlordsMember",
     "presentation": [
      "http://www.ensigngroup.net/role/LEASESLesseeNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Various Landlords",
        "label": "Various Landlords [Member]",
        "documentation": "Various Landlords[Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Adjusted weighted average common shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r267",
      "r275"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING",
        "verboseLabel": "DENOMINATOR:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/COMPUTATIONOFNETINCOMEPERCOMMONSHAREDetails",
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFINCOME"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic (in shares)",
        "terseLabel": "Weighted average shares outstanding for basic net income per share (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r275"
     ]
    },
    "us-gaap_WhollyOwnedPropertiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WhollyOwnedPropertiesMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.ensigngroup.net/role/STANDARDBEARERDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Owned Properties",
        "label": "Wholly Owned Properties [Member]",
        "documentation": "Real estate properties and units within those properties that are wholly owned."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WorkersCompensationInsuranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WorkersCompensationInsuranceMember",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Workers' Compensation",
        "label": "Workers' Compensation Insurance [Member]",
        "documentation": "Contract providing insurance coverage for employer's liability related to injury, disability, or death."
       }
      }
     },
     "auth_ref": [
      "r1066"
     ]
    },
    "us-gaap_WriteOffOfDeferredDebtIssuanceCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WriteOffOfDeferredDebtIssuanceCost",
     "crdr": "debit",
     "calculation": {
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.ensigngroup.net/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.ensigngroup.net/role/DEBTCreditFacilitywithaLendingConsortiumArrangedbyTruistDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Write-off of deferred financing fees",
        "label": "Deferred Debt Issuance Cost, Writeoff",
        "documentation": "Write-off of amounts previously capitalized as debt issuance cost in an extinguishment of debt."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "ensg_YearsFiveThroughTenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.ensigngroup.net/20231231",
     "localname": "YearsFiveThroughTenMember",
     "presentation": [
      "http://www.ensigngroup.net/role/DEBTMortgageLoansandPromissoryNotesandOffBalanceSheetArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Years Five Through Ten",
        "label": "Years Five Through Ten [Member]",
        "documentation": "Years Five Through Ten"
       }
      }
     },
     "auth_ref": []
    },
    "naics_ZZ524292": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/naics/2023",
     "localname": "ZZ524292",
     "presentation": [
      "http://www.ensigngroup.net/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESSelfInsuranceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Third-Party Payor",
        "label": "524292 Pharmacy Benefit Management and Other Third Party Administration of Insurance and Pension Funds [Member]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(d)",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "60",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "820",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "835",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479359/835-30-S45-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.22)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.24)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.30)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "((a)(1),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-3"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "720",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483384/720-30-45-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-24"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "944",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b),(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-3"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r152": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r153": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r154": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r155": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r156": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2"
  },
  "r157": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r158": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//470/tableOfContent"
  },
  "r159": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r160": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r161": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r162": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r163": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r164": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r165": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r166": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r167": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r168": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r169": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r170": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r171": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r172": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r173": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r174": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//805/tableOfContent"
  },
  "r175": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1"
  },
  "r176": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r177": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r178": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r179": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r180": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21"
  },
  "r181": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r182": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r183": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r184": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r185": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r186": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r187": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r188": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r189": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r190": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r191": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r192": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.14(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r193": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r194": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1"
  },
  "r195": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11B",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B"
  },
  "r196": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15"
  },
  "r197": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "10",
   "Topic": "310",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(3)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21B"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//280/tableOfContent"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-20/tableOfContent"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-30/tableOfContent"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479016/842-30-45-3"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//944-40/tableOfContent"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479908/805-50-55-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13I"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29E"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "405",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480191/946-405-45-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "325",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481551/325-30-35-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-12"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-3"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(13)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-6"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-9C"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>128
<FILENAME>0001125376-24-000018-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125376-24-000018-xbrl.zip
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MR@:=.''@L$1-U0_K];U/S69KR5<>O.F5H!M)74^\\L.X%@YXEP?@>?%PAO%
MPW(2DKF%05EDI$\B,!F_[(5B,'31XM!W_0#'/&8GJD^A U:$WI>^1+TS]..
M/I%W<J(F3F-'YM'?<U+^^I-P\'-7\,"B,?&9IO[L\N_C1F'RQY_T5^-/'Y)2
MUI_ M0BB+RSBI/CW:W7XG_Y=>BT9II/>6F_L-^OI*^05_5F_Y,/8O&<O0\.
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M)3 6&5B:"F,-%YC>HR:<K\*&2T62#&/A@6+19*5R8BP&4 ":&.%.&PLA%(V
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M"KH@#Q!=60@0!+!._T4!25I,PG4V"N"1%:L?@P9"+Q(&8^.;1-J@".35[GM
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MC$W(L1S"4YX(?X;@L'U8K?VD5T3%H#+#@%],$!>3!4D4@JP5@.D2E!Z8>()
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M'$KG-9G9D*/*!)++JC+=Q-#W]N7V="'M6,7";F7"10JJ6XG*S);)H=@=^+3
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ML%@0!TR)\R1,[Z&+,1C&87JE:EWK<\;U@^%E=_A0%CC69Y@IP5/JK'H<0':
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M2()&4Z WI(#YJKQI[>)!+-U+RS%1WJ.%Q1W^?+)=H!7#VH<E&^LRG>FV0DL
ML=0T(Q0AP?)44P>MK9M23RVDPWI%8DO35+W'Q\>G&UN]?^*S].]^EPAEAJ(R
M2!32A,E)QI-F<7D?/PR+&^%^<7UPAQ#YL_!+ZNVO'S_R*;P >2;()JJ%I,A/
M%NF0YX)O5@JT$QBD\1BI"#FU&+::0W%YH5M*9ECP2\)0I  &AYB,^24H)42,
M>27+S#W'";WT?'JS:GZTYN$G?_>%V7MA;^U2D,OBHZ1<%A!IZAB8U\>KHJ*%
MINN./#>Z_O+=AS5<3M_CO@HRW7%;.WK']4/A(DWW@?R/<MZJE3&G-G_<'_Y
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ME>NR3O;74$[29P8%V-=%;!$[1G[F# T?38M&=?0DAR,,F%.*[MJ6#V8]M$)
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M <B/). _S[3L;S7EQUS,F/;.&MY9)X !\=HX3<6*_814>$B9)K..P"8"0 L
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M.FU 2BI'GL'UM:V8)HV-P]=2X%Q3X0NT0Y%UR*B&*"JYY#W?JO7)'L 1=?+
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MHO4#D5&4]FQ)#0[T(%#F8,Z4R7W[:Y43Y>MU\U9RG7D_QQM4.IO29?ZT(0S
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M%.O7N_U=LM; ,FAMQLUIRYP9^?7>G'7>Q3_^3[HX(VZ&R@<PP7.,S=2I-O8
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M\]PKS8#PID<\]C7H[4ZKXY"<VJ@07J-5XAPR?N>P63H6NJ.R^VWBY>6C\^\
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MV"R%Z?KHH9_',&IILKJ+VBU5/DE3+0LM2(BWR?I-^L@J V.)N!<["85%IVY
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MFT6\Z*(Z:^26LQF;Q.*_D$P4?7GG\->I L9B*P)\:_+SSST<O7:5AU@=BTS
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MA<J!$XG#'(>584:UB"3:4;)^)X+Q</1B&8N/8T&Z.DRC-/$QJ^F],JR.BM8
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M=O/%+]8<66IER]_A^Z-[1^X=Z$]<B(9I&]:Q -4,_%A,BU4G0O.Y#?H$A].
MRNE7D1,XD=P6 D3,P2^:^WL.@_5B@6F317\\Z=)R</"Q55.!Y-3'%VQN"Q_5
M-;4@YO)<6=+U,UA&&'19^DNWW[/S7V&.NMOE)>Y_DWA+/?>A)G8S*Z-]D03+
M:!AN7)*]4K4IQU\(ZR!^B*2II2WEL,Q\$<,RE?&LO'(@F1%T&4(\0<Y1VF$.
M8!H_IFK=6,$^<E3#P^?%Q5BL!.]QM;,S3G!,X27&: 3SH#M8G:E820^[[]TR
M;.FO-P!\M1S]@KD#B/KH.^NW$(1LN^[3\DEJ/58E#)BA9C+I%3J=T-QC!^@S
MLZ"2'6E$XU)3HN'?(LR/^0#R-;\O&"DJ7U-PX,XU=HRLQ^G._OEVXMA+;G*.
M?=OFZ_FQ,+J&[77:ABCS</0&S=/XT"\G@3C^+,*HLUSHTDV#^)U )DR%WL<=
MK;J>%-$(WTQS>3W0Z$8(60&'4;9Z $Y!^$>_9KZ9G8S"E^--6IS8?J$>VN2\
MDF:BU-D;EE\I-"3>6$_+51<]0<G2F]VEWQ@\Q18K:3FY[ &]]]"83PF-^7X/
MC=E#8V[)@?HK61Q$T-=R#$5GIB2*/%^C:"@N$VW2!K= G@R=E@LC:\V8B38H
MAWI)L;RWH]=A];R^*,DA+DYARIX0"PEK!UHG;<.X*/OLGI09,-Y]Q0#1[E/>
M)F4!EU>HOEZK.'Q+X<,X\AP-5@PCW!'B00)<!OV,49M21NY6X: )=[(8?NP!
MUT*<[N@E3=-@:[*DUWJXI=KG0O194RQ*]#^-?>9@H +X4<G'+]>)?MN;R*US
MZ,CG$C>RX-E(@VAS];P&;T[XCS=NGM];>V63_1%>2-$(5"[FW1-$J8[][<NB
M:8@4*E4F7A_ 4DWAWN&]!GG;WZ+?/#:T9"I=EOUB<DQA=Y>6^R%O9GC5L4_^
M><*X\49NS#)V>#W:H41GY[KL'!&<E@JLF=^;T$C+BGLD;M$GY:*>X$#S^=Y,
M71/_<3QGXM:/ &M+QON:B(UET-R%PR%L3#FZ R%R<H=0V0'H062'IDJMO6[F
M#YE%2B\?W$^(D88IF%?O8&\3]B3E?+&8+JU%&+F+>JYIZH@J=-F#;6ND+SN_
M(:)SO<JT!($174;@BT2 5A&QD'-+FK17*7;!R1;E:DL76L-T\.?/A2Z5V;N8
MG\& 32JO$#>(,A6Q(3]E<GYN-[G.SL;\7VJH#@'3^_+2.!HG$KLPU=%OO4X\
MQILMHNR?)MHOG_?*NC1.PTLL-6#/SHQ5"+%2S_I$9U5&M&_N'H;CH8BI\D4.
M([/\#YO0PUK(\OZ<*X'ME16-EY;OC3JJ="D>G^.E2"X:\%3S#B4#<;FL'L&)
M_"G1ULO2DZ%3+"Y[Z?!9M*FZT*4M[S*!9*30$YXPM3 RO(C;L\+VAM*F1;&I
M)B(X%]S!6AA3E>1ZE1$'_=KM/N5D #H8_D[Z=G%AZWP8O'50\>6WE@&^UBS;
MKPD8PP61Q!X \41[6;T2%PJG<C.5;!,.QEJ(]SOS))TV)"Q$N7Q?-;72N<<J
M3[X ;D,=U$S#;ZI[CN[$U'.=@@JG"L:\+HW!W4]3(_T2RC2W/_SYM>Q3"[\/
M1P<P/<XO:\KW50EZX"*L"F-78+9-:\7MM6U=MKC"/@I^K6**N)D 0--8&)"2
M\-SP*B@#*EX>L(U$AZ*%1?8^-YQ==;$T+19IGL;66X=_GZLT _L^,132U1PI
MXT@J,.1N1L?TRV:A=H>-#4.N=5#UR+72&"0]!23_K[%TA#[SRL43?HION10.
MG1Y+!M&70H*=E%OL7]KT1AIW:?O+:H6("?8@A1Z>W#HM0SX3%*7BA<4J7OBP
M1=5IE"*9%_?QPGF:?[]^*G+D;TH"F"Z#MQR^F@FS1CJ2QJ/_OUZ641D.VB]G
M]-BS:^R?3XI9>&MHB67__'=5-;[B+B<1$QK92>;AU?"6_L)\E0_>RWWZ'268
ME0)?C[16;M[>);A#YN>-+0"2 !Y([#*KD%LKEV?L65$9:EC;]:1SF$-T+5RV
M%?>KSA%EHUD-T.])1'8-LIO"4B#.<%A1R5I4"X'O#G%0;G*FQ[T^RC#K5/H0
M.[-+Q D!-7J8RB3/A%N3H:_.DVXD9V<@.&G0+G=I, 8?H"RE-R9L&OI\6(MA
MX):3RCALZG#>*28[^>7:FV @^Q1M,$;SX48GP F>AF&V#T>OEJ-GY6DCRD$_
M^)ICCL^P%BU!%C'N"::%/"0&_%5XC0RK7(,%M9:BN0KYV49$N=((J[8Q_;SI
M-ZZ\]N9K['H;Y6!GOL>%CYYV1^3 %?_.=Y/6%]6%B@D7<M),$6SLZK_^$LP_
M]3B# ;K_H_7.R0PMZS4E3FQ&(Q,?1_@<RU5R8P\2)-[W.<WR4V3\D8T>@Q52
MJ4BJ+;<3W4\?4MSQ1?L9+Q:E*3C2QK)TTJV7V=9T74^"/2/*C/28HMHT%/JU
MVJI5G"%WTUU!N7,,!I=I"5S4J8S.=<9"C,X.J; $18W9O4ZP<T@PBC'!%J0!
M+3]H8O.T["[*4C(V@ADWDKEQ@DSI($'_B/"-$&:<YC01&WID8J*1*$*&9JU-
M3^GZ#6&RL*_86M#8I^!S;=D4$V&$JODOFL[BAPR]/^T+*[LXP',>+C%#]/+5
MG.3DZ'K(19&TL%[.SLJL9)X,=:-'/AW-9*X-$PW%N'&L7'^LW-KFFSJ6TSYM
MQJT+V_>%;RU\_[ O?.\+W[?D[,]/>H$F"S#W I2>C-!H=W' WK_W"$[A=P>/
MJ=\00HU@R?]OL5@]&CT-;CJ,D[CVO/CH45*>2M$CM2"S ]/'%#Q(U(+.F./7
M, QM=2XMW>L#GYR7DW?">-#S$*G%>BK(H*TLBHXB2Y0IC)$@S$N%/%DU&X60
MAG%18XV B+8.64CR[V*E/*3L>'2?L7+^%MF(3L*S4S'A-F)WWKY^>C?%Q.$;
MF,LWMDS!/$MJMQB%:_72=.BZ<).(IM[LW;ISX*:6]NNF>L^X#04,C3]451MX
M"54XL72/19J2DR#T_529_CBINH8&^F5M92S)V^;%()M2I5R8(!8/4!N=Q)U9
MMY8SD4P$"+ L B9>8#-1$ES?$DO2Z(53FB)_*X=6T 6BC [AQB#[$B51!2_3
ME7(56*,G#@[JV;)N*ZT;L2 J(?7H75FNR/*G;Z!WR7KS@L>S$@K!3*@Y O W
MQ](1.\<>CFW#J]"7_.-0$E])C0HJ)A&$:)M&#!IA+B[AU+<(?[V)/:.AH7HP
M#^#VP*5<GAW,RYDZ0E<\[N#HZ/#^UIWU\>?I-7<6S?OWCSY#-V4V0M\?WO\!
MW_Z;LL:C55AT:^0Y=)?$X\D37D?_&B5)G$&K9%08^0"VHX]Q">_3U"39A[\^
M^OWK83_Y;O(E)L+T6,+.LF"2]4>HUPO@-Q6)2<JRWL_-)YZ;1'*++'H)9BP8
M^>N46ZZU(Y$U1QFR9J#N-B8$5H%TV\_HIS>U,55-^(X,NB,"L(17V$TXLZ\Y
M_GRE_01</0'38@'\E1XJ3;E:=UF)[JS$]EB=,^D$+Y>)M9W9QR_*J3\VZ-Q%
M;$U%6D2(*EPD%$Q_=V!AG'.?HTNM_4E65M+P=L7P3"^R*%9I_60H4QTXCV(G
M+HKM:7>+S][$CFWU]5,%04)5D3XFI1Q;9%#-BOEAIJ&Q',1R!J?6/HYNB7'R
MQ/(=T*146%"<N(0-CF.F_# I5Y9 ;XB+W/( %Q?4ZFM'K]P7QB.-'PLH81V<
MT>YOQ >L$YL"9D&NZIEP^<*NU(!L7#J4NWAK[&D,D13'6T,RQC:&FH\:<8NR
M['A;:)3%<J!#WVRPG&4AR)==R7]!KO9(Z*PZFPB=ZLDZ@4PUPQ*6<]%;.A'U
M(G#UDC._)EME*P2:AH!DB)9ZM4P%4_=@:?@XWK?,)@"+J\5+*W40WB#^S<@E
MJ>13,D=B_>XMJ$M50$Q6U5@*PYAVB/ZD%2O!GE2BBPC03MB>"-L5674IS+O8
MT.K=;D^-1;@Z_.>JGL?24_AH;@61QL86T;ISSI<9OJ5>=P!DLJZK2"S"RN1E
M@8GE)Z'0*CFC6=@!, Z]I5^YOMVNOBA0WL::9^0]MPS6K(K9BO[4;[!@NS9>
M S;&33TM =6-S$Y]"9__^W^.OK_WZ(%*?FG,GGBE]"VF=-%5ET>Z[<:CA_?,
M!]RJ.7)>1(/MQ#XX069/Q@8UQ?R+-%(R_,SBQ*Z*9#5B/L!&P/LT":2;LTU]
MK6FT'!&N9*-];(2#AL7XB\>SW*I$;[A CVMT%0M;;_6^DGM$U)9GM"B!TNU:
MK^L4V:5JW2(]U% .Y9V0KUW!$F-IQS>B^3%A!5),GH7]82DJ+H'LGFJ*8.U8
M2ZRUFU[RR3XK.!$8A/621AFY1U"Q-*BQ5UR>/G*XPJR/VEHLU'QI]O)1S(D9
MT&59\DR56S?80DU&:YHQ/C?6#RV])!V+[[XBSYKS@T\L4/=;^Z-'/Y=GX0M?
M8YN7]$L^Z7M=73D:?JU/.SI_N=8._&II#@30VYX+B!297^6^+KMN'GEOU,%$
M/B!F 0W)%<\QF*EU9X#09V@R8?^/D.B:08MH +L\0Q!F:,&K5:-3UUA/1423
MZ2JITV[F#.>7@QV6;!U";AW=HET]>8?X.Z)<,B"RH,I9H!JP6L1 NS%L? !O
M)^+[>JXU$G.KV)IT"K48XF+:M?3"RIUX4^#;SJ)I?U_5<_?%$4!AWAV^ XKI
MBQB'>(@Z0R,]9-+P^BE6-ZENX 3IA!>CR&+OW+A8-4BIOR)8UJ4R?$90:3K&
MOMKC7KD3W8%>RZBNPQE,UG IELD4TJ/R%1KR!JH# ,Z6KL(^2B=\OB;^;#KU
MQ,=LNX_O0]1ZEBJD",IFWL8Z,7!-NT \X7GV#92W1]-DK?YC6%JEZ 4;LL<.
MRQJZP*GJ:YRF6;)@I,)W0G@A(# !&P/-J>#H9>I\4]^W!FD/**@6#'YF$)O9
M#F>7.W!S60#42T.DC#;Q65DWV<<5*L8[C-=P^X7G;KM@9M9II(W>E11(" '^
M4M"M.UW_^'J60PXK/,LBHU+Z@8M0A4"U26H#N+X3WK51?93<LL&U!@'OMX]V
M:(^L4F357_;(JCVRZO8<I(5 ]W<:.C"W68Y%DAN@NQ*&\##D3(R.O>CEL+-9
M;U&L4]S_<)=:;K(%P(WP-3:AJP(N,$W7^)1>#Y\K3N#TL2 X-E%MT0'U0!&+
M@!/.-Z6J>C]#DV.8W0GUV222]ZI!0%B/K3=35>*8[[/H?2CU$%98B?^;CLAJ
MP4 ZPHG@I7<\K>'P7T![&V<1/M\QR'=EL7">>QC_L6,<5/XJY_Q[3JR<?'!X
MCC>:-V.38XYRJ;7F(/'T6$G>YJ648ZU=DUS_)?+OUFM-UWK./@BZ'?]>[8V^
MM\BDA#^D'K&LZS$&@+[;%%"]3"1EH%^M'>XZ8S)SMNL" >73H8H^4:1>"V]/
MRM@>CT52X8J\W'W9!]^Q?-I8KTVOP2B[GFY_HB+8(H5Y4]95$L]7>&*?MWD<
M/!^U28U+D)%2DFKH!MA"QHH'3%/,85?:E2L6JU\Y6B%3KW?L'.%Y/<G(CS5&
M&3D)S:%TYQ6HN-_@F5Y5\?_+UUKN/WIP>.\^/EY<@$A1ZVLQ.U;_?ERO&M><
M(SIG-P4E[UR:BI5>Y;HPHOO70+'LQ[Z8!N-6* N.JXUX+CTM8>Q8X_N1__B1
MYV";_>C7RUC-6Z\8 ,1$S7X"/ND$\ P^T#2WUD1=IZDFJ, +2?8KMB=:3APT
M58XQ7,[LO67ZY/LC4@L3'48O'DI*6G*%7[:*ZC3)8=YOE$\Z$Y-Z.3/Z,LKS
M^ND0$8?)NA&]6\E1])A ;+Z, 8+N4Q^*MI^T3SII QB&U?EE"R4I+1P8.BH'
M-FCH,JE6;#/?S\JGWDHH#U6J/0M,GH(X#=VVEDYR8V*4B=.>?\6<))X6Z7S9
MS]$GG:.4/HH,E4IXKQPC^_'^Q"'(-/&!Y4FO%'I<OWWAN_V@7V/0#2SGE64_
M43'U)CFC!Y-MDDRS/*I7L'!)0*3C .S?Y,9!/G" 9B\!%_19Y0BR\<P%2[MR
M7K'/$/$HP<]FX(*WT@/;"HR?9M/*R^&<XR:$[85 R6T9ZEXZ7?&SQJ]$Q/"R
M[GX34Q99J7I466VWGEZ:=4Q*VSVEL1@F97CGS8;CF5( &@?P.1 +*17K&/LO
MY6[^QWR;+!P#-]"\P"]%0[.+Y-]:)*)\\K=M:NVG3D]8@5.7A,HE2-8 ;VX"
M-;\(09O/HX@-I)FN70#T'5'/:8%F=B$8%G[UK$*VA<>W7WK<9(2J?2]I-4NS
MFLA^I@A4T A@E,TB%5TW5+#C;EP+BG%7C=6U]>>R-3ZAZ3!RP="<EDJMF9#<
MHR=R-4OMK^G6&?-=T3GIJ-L'=;FY\DU._\!JJK=Z'TFSK(LH5S#25I?8>M 3
MI+O8$"5A,5;7(;WW$LJ5'4!B9RPEQF*Q(-I1!\[03NAC\SS25L9$KTF_U"1%
MR2MI,\6 5GJZA#?M[%QHDPP=,7.B"<TV&BFV\Z^Q,:AU1<YVC9-+H6XH8AH0
M+B':THGER^5>)\Z;;V%RV5!3&0]SPZ;&Y7;=KLHH"P#K$(&'.'82,YJ_L.FW
MS<A>OPZ%*H2QFBHUI1,CJ\N%N$*>9GRV\UMK3[4N*PX=?L&.Y;SVXPVZ6X.8
M$/VG/[0N W^=>X=>I_9F,\@PJ*ZO+9"M]S'E"XV6)%]':;TXANFMY7)=/JIH
M"X84T410AO0N]65P/ %83J92"$&#H>T(-JSXKU*>:")'B,R ]"3F@JW+7A%]
MG+*%XY12'T<7;1SV]PH'K"_:Y^RU*3#D)>TG\YB_0)N<T:Y>AT%R[QCU'*--
M@N;-W<MMY8DB5P2>=?X@F37%6DQ8$4ZZX":\-G;ZY 7!R8IH;SN,=F]>:PPP
MPR,=S+_7\#C0=-9L%H^2X4/0]*>7/. [>NLJ5)I]B0\PML-TPI/*9D#=D$0U
M7B8V!]]#JJFCETJ@W,[>AC$;J<F\O (.'<K7<AI9FXLC3^)W;'"G#+3QB0.K
M:N%NX63B03L'][:9JSU:6M'2/^[1TGNT]"TYVR6_1'WXWN&R/>FDZ+>Q!4O3
MFE!,900AK!;65#,Q!#4/*S8%"_C/$"804IU[G[L/+%-I2<^VF%$/6F3U_!$8
MY0G.P[&F9T"*\@IJ%XTNZ[5$EYEH AN%2$8IO4!3)X5 5'-K)^4L.LRJ--E[
MI!!'Z@/#R:;\\/+&^KI12-W+<S$&'AZ'5VL#-Z(@ZW3(BHM"(%:NPW!6S27T
M*S+J3<<SXMURZ5;*NZ9\>H1RUE$'6-Y?Z>>?/3XV-<WC_SKIZ];IV/F2I5%'
MV^-X;VFD@O,.6HW::'6*-M:8I^&4GPA+OBR(G2D<5K(I?C9<ZC%AJ;HK!Y4O
MV+RJWS3V9(LI4M_"=C(>2"E0-X@B*1E4W,A%@76?OU<%-'!83%Q+UP:Z'$T+
MF;R"@Z[K\O@:&RN/[@O+_DFYZE2T?5"S/:IYD?$<?;5:+NG.T[\A/[E8+_IP
MH U6&R$XZ,=,I#VZO0$31^HV!$Q\D;$PEN33@K0;]1B[<S2DB[3>99J(J*[U
MU]'1W6VSA2;J*:E;PE:Z=_C==Z/GK]\\X;R]^44,POW#A^ZOOQRWCT;W[[+K
M)4XT+(5VC[SY)>RS PC?C^X_')V#9QY&:S0M+I%O0"0SQ:FX8H-'^4ZX)![<
MW5PWY?*\(!FTYC$N>4RTK6J@OSTO>P,R"U$X[1;\J +4^.5T0-5R,%IB#2H:
MC&)"NMQID2+(/K<R6(8\&T[JA3K'<$8(;[AH7EQNOHC1R CQ$QO,?9O0KZ:1
MV9]VU<1 ^SK$$%L2^TI-Z3181>.3M/D-'\%JD).V0@ (XI/QZ#PL,;E8U\!,
M4K?"5IGN(4LGLE8G8>DBC=D\)J"=[GVOUV,C\3Q6!K!.\VG*BAT/;96<>[>L
M+Y8AMB^E8\K+#X8Q(A/,#C'1F$8\*9<L7!;*TA9%)+/L@I3%-JQ<LF^<-*91
M"U9,Y'/'*(B6IGV;G4]5KDY9@1."G[0EN1Z?G>DLLBW[M$P5G:_Q /.=4TE3
MSU<E3*^SIIU#)GU;VTGR&WOJF-EN00,DC)6:VMHI\EH*?2RDO)O!@BH8BVKR
MI7#A:<'A</0X)6O%_QO2QY8T;J3?JD_%^01RC<5F2^RX7P?O*SC+!39]DC(-
M_Y%#KD41U'+N==.ON5S'AU./-B]<B/WQ>7(G4L.JAG3/6_5DL/6P;TI8?K^:
MZ&1;[^GAZ)D46>%TC(W'Y8+YO3(;A:Q8HF0%8'N"JZ0N?U[MD,^UUR+\,Y.P
M\Q,S<6NMF.<=D#Y=-T5N;*HLC16.F5F!VXEK9%0&+(;$/%JV9E-VS:-!.MIY
MZ0R<EJ<A-A&!SR^XA_(UQ<?[W9' ;.A9UA<^WM9@*_QU=%7[JDNP]PNQ]+'4
MFA0;HI/B[YHQ7FS*G;NW,KF>T\L!>@A[9TV ]KJDTQOF5!O8GE.LSE,^0C2O
ME0['K<8>00K><,E0]WVO@OQ1C$(?<R9]N0?0L5!%AH-F*?WQJ?4:;;Q<$O0,
M_)I(T@!&EJBKK=UC:CZF=.3%^A+'7_))15HM./#K9<0WS"(V8+<=D*@B[FE7
MXU<RZ9-GS[PVXP[TV,>*S.WGN3?/C3GQ;81(F6%,!CZQM6ZR#,WKBX.F6+[3
M[B8.LS(H8W-&WL5V>,9[*\3MWQ4P<]/P/VQ2A;A1E4+AG]%-XZD;WX\,3U@^
MQKA />]XJJ0+&2*;]#7\$ZXY)5L=:W.<T!]+<G3!^C]6??E!%;QIGVL<+65.
M<@MOYYUHH_(T4O5V_CKB)55^\"J:#8V:^5M/Q^9./O'W]'LC'$:)!BXM5ZV3
M$GR@^5RH(C%U;JJ<RZ7><A@3*ZLJV#2+8=LU1?E$VR_,7T/A<\6^%+$BRS>3
M;#D#WE14-%Y/606Z.#P569PNRT]J+$V073C<U_#*.>?%"+A;:IPV53UE2$CV
MCO 2^!=+<0<3\HYCOJB7P4@TE\,#Z8[]#.A##JIV .+S\4K1_^;A8S\3N3?$
MNPVQK*>P9%FJJ!81(2@,NLVE"[93?'91$EJ,_$MT-2\5*JJ0TTV/U_FGI_4T
M4>[%W:M<,JR<&"9+S94!FC=$8J7 TGJ!WR3#6XX^O0AO#B_;"K-F(DDB:@(#
M=Q !;&/GM3*1@<9['20B*@W0&.]&B9)$!@0S(M:E:&E[J0MJZ</.E,V%FG 0
M$O[I <[CCT0X)_*BB&I.A3SY9Q>;<PE-ZXQW_9IXYSUZY+:B1Q[>VZ-']NB1
MV^);F"H,I>C3096G6P0"+_7L*%, \XG$W?2 *9O5O& ^-8QJHUVR9B(E70RR
M5\GV\63M+E>JXX#Z!BXIUN%=&H4L0@0\6F)K)M&@MK 4Z-2E0%W=S:(DR2RQ
M/.8QSBFQM9D-5O.=_S$^;Z18PF4\-8083J ><''!?KV!:0_?7B?-]7BW3>B[
M(>VC0@T%N2X2>C[<VB">.4R>65SK.K/$:Q^DN(W8=R@A[I+@*5$[B  UXL&V
M&T=M(4"N&ZP>>JS#BXJ!#:_NTQ3W1]^/L,U$.DC3LV*E- JQ.!6*6W<>WM06
MSTH)H/4E'A5K ZG>*M69(0IW!46ER[@:1D5=I6TDG4H\7=@S#R%T/+0;R)4Y
M.JN038@%='DJ'H$&'*Z,HFKZ?15:9<).Z56(6'4:BQ\IV*%QZNZ(UQ;V&;X!
M04J[&]KU6MN0XDL3]N)!_(OL.O:&E)02LNY1E+6JSA.GR[X;;(#RWZ5M)23H
MYR>J7RUDB7YQ^Q @*[^W5WOL8^]D6^W9/'!4A*3V(YXY."_K1N.84_TO&RU8
M%LLQ,;&@4F'-FL1[8<<OT_"[M\F@%"9\HJ(W5?M.4'*NK+BE\"=E*@>QVQ"M
M D4Y&#[#\^=E?YD-+.X_LISP[V5D^C%W.@OJE6(3WP>_/.Q!$I*W7;U"TAM*
M:F$M^(ZPT4IA$X)2388"%_ED^CCCXBS>UT@663O%=0Y3HW_%>G<Q_X2]1$Q^
MF=8%5EM\AG""1,1)1L]BO"P71#,V97[I. 3[X=CEUZ7^I/:R[<J%1KNLV\G=
MXK(21*!I5\6NBW*NR3\;V/#J+!"SRR)C+'5  S&,85*D"?OCIV'#K8BST7VR
MC?35[J-?2W.)F(IBMI<M=UC(G[" NI$CLT1]L.+I[GP5@1XMY$BIEUD]?WOV
MP3X$2F1;O8,0,TSDILB/B_.<F*S;SFVM':!@5@2<R(0FU,][-[2C,KQ9 FR)
MA5JZLV#HG0Y'7S+HP/L&+FO8*TMPK,F=7M?O#DX+B.1( 0 C/.&I'@]WG,H#
M^)*-LH3! >,#,J'1R-X7BP4NZG!E)9C,==&YDDCVYE^ML>@7!O8%W-]5-PA#
M]&K2U0J=NG_O_GW61RT_W]\OL:V +9^=A!M 9THR@Y(Q5CP+Q^;)+\_ 2+F<
M"N1*S OWG/$8")N*0;<\KTKKJH#4WG1*D7XCB"3I/!A&&D)KQI E8$I]V4?(
MQ]%&1AW*#/^GH"[# DO[25E,SD>;N(;+T9V3X[N$SIOPH*5^Q-_:M#ICAO>5
MI'VJI5ZK/EDVVH6TG4^G' %5';ZL#RYK4QM>UDO7]1$>SB84Z=&A7Z)VI!RT
M(L'BBY,WY[9IRU(1&.Z>GG97BZ:DSN$KY;8J0SS-+UT4%B8[DB%L#HCICG44
M*]1'^.&/;BAM*SL@\*U7#\@%<T3$WA] 79F&WMOY(=3X[B$C>(@17)05]D2@
M[N'>?PT.YSEZO:;;UK$H3;7!S!9@P#@</?NHMSI==P97V-" 7=5U/J-M.&C@
M.TRLL>IR='(<CTMS;4W6B/A*H?V#6L?8< 2HY/?%*C6UQA1D>/(_RSILBFGN
MAXW-??&J"D,(/<%J('XP00]'L$2FD$&Z#*FE0RQL7TY/#9-5.[@-Q&_419>O
MV##\6W=&?_FMJ$)##VEV19%NG L:"WPF@C;S9;%AKAJ70>V+N/<O=C[U;B'B
M%+9+DX[[:OO@Z?"NN[ &$'7=Y?>4<0\;N&J0'K;N*GESH2N?B^:U@I%F)!OI
M\;MMG!D0H^MU7FC3Z,:E=".344[O'H<&+1L&>4%- [VD4H<WFX:CVV S!N&/
M!@8NLT=N/\4#$5'HR2A)JKSK/]F?E'9(1L89&&8)ESNMB!:U4U'#W/W[CQ1<
MU=;S4K-E /-VXC4V#.GURFA"[.3]Y5FT@=&29%;$S]'80%J:)+6[>,,4"PMD
M08T$JA;!PB.UG\50K Q7U0O='.OE^PJ#?S@ZP=^G1@_'IE7@%O+%Q36\>\F.
MDY?CMDYV1"8(5+3*$0(M0O$&_)]5S):T(@U_<JS-5)IIE+40AU0OEJ ^/Y V
MYM)-EJ3.\KDJNCA>FS.V8?OS6=/N*/I&.H.3@BU)::;$:=-'FDO4I\/(9DW!
M&;0SUED@-<"4 1)JM^6JOLBR9LNRG&H /[1EO;E1 \FD7DV5E5$UB]Q(SOB$
M2^;SFI7'*^XY5B]=<R^LJ-411F.SHDW-"^PC)5:4Y(C'O$54IIS7 YO!#]G@
MQ&V9M1LYMK\>+,;1'HNQQV+<$L<T2^<HY>NP18A0\\RM,"O:JWGLSM,>)WG"
MY.NI08I8@V+8";!#7(\0]R[,K#:+GM57A+2%Y]GAM4%R-Z-U#3_11#B+P)J.
M8+/S,AC7$-5!(3"A_0!'!AIO-2\W/'9&E=&8:CDP'37E4()$NI=QV*!Y.0)3
M^D![IN(5G2)>?+^@[/A'):> #TCO+:E[5D2R7Z:S(0?D]/.B&Z_-<YGP?FN/
M[A]*&3A[?KDEH.20$-4?7"M;%X,>^N^(./,<^N=,F!]]AV*FJ<GT6ZFCO,Q6
M^M)YV+>8WI;\Q:F4'ZE+IF7+!E@5CN->%<E.:09E'0/LAF'^T6^^T8*^.8I?
M;"2^)_;X K/D>V*//K''GMGC:V/V^%I3I\+1)<7T,/ RNFU:R7%Y1&@( 3(\
MZ^+<1>5?Z7938I%.%IA $60J5I(9M*=HAL(2<5 SJ"1Q:*H#P2&J@T]H#DE8
MCK+NEMTY")SK2).JJ3"C?WM?IJ4;O.,0VFNAQ3*2: 8$L%89OC@*J!0DOG>L
M#ZE^!\\<W293;<U%A^..@=IP,=0O4(85)!Q;+>,I<1UV5N&?++XM1D62R9=:
M=%.FC511E,DPW8;'PBH6_<NM (L>WDZRE(Z,A"ECF:U18GPOS%GR>S3ERA(2
M*'59;I!F'(Z>E(9"JI?^LV2N&)G(2-C##+[(HJME[] 0)/L929M<UP(AP7DA
MK@"_1!-+GH+VO,H[1L-02!,I!W1!_P4]/_2*PZ@TX0(YW80R&Z/$*QIPMG2E
M3$M#??J(9%=V[? M\D_2ZZE%X.!&B[5?.I/$QV.AY9%3T5=#C*0^2QY*&JT1
MYQ();A%/"C T<<Z5X<V1 $P@+<*'U].P1L9*FQY>/!P];/E")DY?5W%QQ,?&
M#+KM4FR,JM7[V*^W7,O9P!XJFU.9WG!HH(!Z2=ISC':G/G=P.=Z5G9Z?6]]I
M5C3"+-)4JY4%3M#NG#,,5LX9KH;8E36.JTHD2C86(0F=C"U=3Q;!O+^W1:)%
M?@DBPHM.I=:<U?YIX*KS6A+.33EIUE7JCBZM1;M]5U'B!;$6X-+-M0.KVPA.
M>F;T1VUG?B3]N/"M8:MUS,/2$T?<O82U#^[E>TE%]Z75N%KF845++$9^K'5Y
MG1#JWY'T YCI9?" LQ12^@/32%L&B&91HEH3H(C=_\9 (T:E/P,^U&5 2T ,
MX^%<-#>5N\+MYZ@#\/#4O%4CW0G+HFDD=<_=-PD.G+08O:<-36H ;GM-L)T<
MH%T:CWC^F;X3!Z(\J[G >&17_X^]=V^.VTJRQ+]*Q>ST2HH N9+\FEY'; 0M
M62/UM"W_+'D=^R>J@")AH8 : $6J^M/_;IY\W+P JDC9:HMJ<B-FVRI6X7$?
M>?-Q\AS"U(_X:F(I>->L\\NV0YI1:U(1Q"K9 /8T4PR/86G+IFNQ:2G>Q+/Q
M_DVIUJ4LZ>:!TEG^ZTP%ZOH3QAU-/.!%.I!WM_?E[;R-(-<* A3D)M3[2".O
M^=*XLH3Q3KR"2.$65[E3RN#:9AM-SZ9Z#\ ISYWM(?I-9'(*IU7P^=HM/CZ^
M8UV*UV]>\D6=EH9.OOB2J'4Y,0\!@L_LWAMQFXV<-&/+:.N*@7(S0.]LOEV"
M?YOW%XMU, &?]3GFV/%L^A)5!5Y<INIJ<QL_,?O$TR#0^:GJFI(GDZDH>^Z+
M^[ ]_OENZ'LEDS^:O_OA[-G/9XRS%%"KF@ON0[GQ,N4 =P0HIY1/OB4<P;;W
M30.V)T@S;?$=^>":]]:?2$F>R$?S*P=KXCO #0&%U7=G;)7'>BQLU9:[XIS9
M:.S)!&3H>/' J>GY,R-K!UETX=+9-1)Y#WNGC^A+:QS,C]\M#M O1KSU[/]1
M=OO+Q4\O%B\0L/Z,!!J.:^O2">82-#TM.B!#[)4E B<F*JDF5_T/'6>B]WO/
MKXW'DZ2:70.J:8Q5\+U%$Z%'E=9SM^!:G;1CDVP8F2;,& <G<//2+A]7[3M=
MO.$XD^)3*'!9^H*L'8USHU[>3V?/OD]:!AABC4MQN4FR'2ORJ/0IKN&-GZG6
M*(7125Z0=2M'^I:?*,=WC\](\1E/[_$9]_B,3^[AH2K\*Q %"._*CN2&F0#-
MB6_ T+_^OZ^>GSSYZ^*GE]];;K5\OZV<EF4??/%VQWG-$-T6)X5R:[LC)XWP
M8CJJ9H$]3H?FY^=T,@WE!SKMLW3$E(P,)T&!:LAA?UV36W>$._5M+ N%*>8Y
M&4_T@S[!3.!X<J  -X#X$Q]3-"?BM$@ J!5 ZZ6G QS05^WDX7A)2P-"(ZZ*
M-F$BU]S*P*Y9.-)1E?5^#'?17*%L*/Z1%E0V1$85_OCR96P7!!6A$*&A5C+*
MP&N\;'(O?=E4(.J^G/(@6JOVLAP&QGV&2]K.0<V_3ZA#7'^V'^YQQEO*1;K%
M!,7SO3W[KSG2I*Z;=%V7[UGU!V@: HB6A>-)]7?3WD=U&-"<%3SB45\0BJO\
MGE&XMA=V5Z/;K?JDLN"[9T8KY1#'P9R*T%U-[]PS(WX@,^(UT@*@&G2]9DS9
M[[3#*#C( <<S&H]$VMGI+^6P:S7MO/VAC:RVCA4S<YPV/P1G_8F @93>6,'R
MA[=U/$:MT2#=XXRK9P5:QV=;<MLF?^Z#(@FCTE)/0U3\(<;CIGRULH3Z"\.I
M&KLR0 ?)(J6SGO$$[0J).0)/$FXQ;\K@6=0X?[5?4/E0J%K<-E22PU":\8AV
MZ,[:@5]+X]HY&@3"?].9+VB.0PB)0Y"#2 G\IVR9H-6UA:<E?J0_DQ6R49EZ
MJ;>K*BQ2PFX?I9H+R;:@9]]4J[DSCIJ43LC1& $*XH]1DJ7JA BDBRBL_BSX
M\31XK-%@%=*5]$Y=>X@GJ)O@,2S;KH%TC/3.:C=GM2D5_3!H2318@.1T5F*0
M0R\@#FL_M-2@VE6KDG5HQ)7))G_US-"7D.*KA=1BQ*K4Y55?FGZTB5CP QU3
MJ;G]2>A?;1A<8BRJ-Z2J<T<(PUU,\_+53V=G48OQCCC]>&OPS.8;/IPD^_CR
MU=OOG[U<G)%^DNS\7A3-\X)(=;BS26I#5B-Q&H788,+X0V#@\T;EG,*Q*7DI
ME+C1$EB&XT';J:-RL2LM/O!"D%Q>]=DR=$1I39,9?\PH1:T5=T^/2';7.>4V
M45I@NWY(G%-.@O)U]2*XOOCU&CQ)-R47E[%-Y94))9'4AI-TGS(L$F%O9.O5
MGY(UA2 G5=-DGC!Y>CA'HULVT@_)2YK!0=)<**>]IAMKEKL7C);\D?KG!9<<
MQI0V"#@B!,Z2(",ES:PFB0X%SG@ZF@6T.&#-L.NC%\@25^7HD08:_8(07QH?
MJC!F-EYQ@BYBN@+)9(/V*J&$4_RY ?W]"IC5^IXN >_QL*:4EPIR=FE*)IF)
M'K9C@8GBIRJGO6 ]*O?R-$8'%$$GRU^A))S>[@E&18G#<*B13Q?I-(U6B?\M
MQ=J$>5KP >P#;W>#>H[4^')W*^ZOTO'FP96F)-ZS0"=,#(S&;+PY=2,^?1(V
MXK/PU5T((IYA-0?3NWAH__G(!_53/SOS5J44_G!&MQ!L.=&9AP6)D U.J<B^
MZN@-&7 (H8;8R3,UN?SP,1+JPX+09E]Y[R(?<N-"1RT+G!\I/ZO4>L*AS;R[
MGDI3+O2@=U3V]#MBUV3>=O887Q-&CHM!S["U?L:+9)(\])D=L.;1%WD&G&>0
M,4,O:2</J1<A6H5S E6M$W#V;2YF6L9#FCFXMVMJXZ9:>BYWN9J>!2U+ (EI
M?[<.+TP3G<'],:.%?,NRKE0NV:T_9[/6C)(</=#IXN_5N_*J(A+?Z@/O ']7
MU^_X3O*ZVITL\R=>\H]J8IZU+&4P$)J#IHP7X2NW"-^6JXLF[/7S_=')CGO*
M3>+G[ *_48_)+$\T$*O]LNQ.S*<*CC&?=C(!HH =G2[+M>FIQ8Z>7PTA\+Y+
MF,*7T4)Y"4&X;(K J]E39GL!PT3#G@]#OGK7,VO"DMI#5^_(O 4'I-L%O]E<
M99<"C;RW\>B8<W';]6!(8F#HZ=8+TGUH-]3PQ4XU4N[2>$]T) 3V[08C^_J"
M]XFSP3VDR8/!O0K1^M>/_Q+1NEI]"?YS3IYA6;X#Y%MQ?\D; WX>;O#D=/'=
M?G&V.R<'VNYI2.=V"7GT#OZLI(1QG7ZRHN7VB<,L5R&ZQ64)*5?BYC6-I RL
M2!@8%(\82XFC!ZD$;I3HRGC^ 6PN@4$8!>)28!Y>FZFJ7T3'M-4OT_PMUCOV
MX!1LD5\&\^A C0HQWX%J2Z(AAF4.A#Y@ DFI=.2,3-^WNY@H[_-U*6&1C8_1
M92'?4/5YSU4&P$7W3%"/U(4JYQ;Y)DQ?AL"JHU4H\89XA,9Q&:VJ?U1/^I+F
M:J)"KN:/^.">/O+,+2[*6J+-",\+3UM0;A:GRM5%N^%3@[NO.=(9R-Y7_[U#
M.,H>C>R=72/$^J3AHF<M#0^JLH3FH#[B4F$K(EBR; =:VOK"BBJ1Y53O)=!%
M@!.A^  S#E 7QK3WC/(-3_L0<)G)*SV:(BNIQP*]Q<KG[EZ-F\)J25@4X6$X
MZL1\DCNB:V"$Y:5&N"M&'0=C<26-[%)6D<K<D6<T@"9B4? #*UJI$WX.R3 *
MA)VZM9&@DX[?\T:T;'8$[!$:7F%9Z8*+0$/,.QXGT:[1[B>*35MBHMI4TB7@
MU\[,TCP2>=P=U,@7]ZB1>]3(/\D?/;KR?O&VUML%J@!OF'/['(5\"R-QFD4&
M<)]M;U5147LM[)+)05"T#M>A27B6]S8K0W8"P5:8E')[IRFV7S=4=<M[;5UD
MY,Q*,@$NQSAW\.OPI@AX^C$;Q]@LUKN+ZJ^YFPT 3 XE6-W@5TE'J!*&9AW\
M663G%@4@NRVITLWU-,^>"*_A8EBCL\J@-\XAFSGVLH3FSK<\ *FT9:_AD'=D
MSVMJ9W#S8T\07/*UD>Z+)^2=JN0$YQ:BA+,D'IV:'5<GCBIL?;OBU$#DZ9WT
MWU-].SR1O$N1O,!@ 33H!J$<FH/JE_EKNNA_V'RL8UG<+D43^[O'X*[NT3.)
MU3F&BF9,0W9VEI;[+8@84K_(PH C_CM/")/=Y8M1A.6U7^HRY^Q@1-;)-$J"
M\] =PF=="$"ZG;E[T4:G7) ]H[LUW1S<T/+T_#3C)*%&+X_,WY9\X(A24IF:
M8AC=63IL&C(C+98?&.,T7HCGEAQ9!\\K9>U5)5LG""')5B^[%?YO':*$X!QC
MC!A^V-+H!$\W..8ACNPJJP %+Q6!-YK_&.4&"S J%-'V!"A\YR1K5+\XSKC'
M>;B)40B7$;#JE*<Z%JZ4K(6IRSS$R+L^31YH$P Q;,51^=B#[NQ+'& 5X%AL
M=TNJBPS[!$S*<:_TR&KE@@-?QM)([E)S 53J7 ?C2H0.W("6:<>8O4#JG\01
M3U-GN4N2*$+5<P!P#N:2RF^;_+=6XYR(B*2@NB+<"WF'GDN$TAOT1[3_(O[-
MW$YE7%YB6S.OC>%RA$B3X_EGZE,J#^<+Z?/2V_3Y0WN\;/;YV+D+:Z=/I0V^
M?Y8ME(/J+4[99^U&*,,SEQ.>IO1?O_I/A.]<B0N!6]>0,/9YV=#%'MD+: ]U
M+*_I,8DG<IV_*!*B7,%)D8=.#:[.X?S@Y_%*CYQ&73A/V@VH#\)<4+9'7%=9
M/9[^OG"*.!3]0B!/X&&5&/]K,-"_IWW1(Z$UPCV ?D[PT?!Q(OSD<TZ9"VI$
M0,7,RF*], P1RHE=1-L3UT:_C!5AI$C!+M;10TY:0NE/V ;>#,T2J$E;ZRQ
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M3*/R$<0"*,3,CX+_?U$65JL0:E-[>-?.AA'+O?S#AED7PA*HE8E,L&\9&,N
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M^'H&B@QG<;EZ1S6MA*M:%]6C.^O!OQCS$O+VAYJ%JI'*(B5RH!IEDPBR=29
M]>WLR(LG=&G,B4@^GRY>5L%:=5S],],N:@P)3PM5/4($V8[K[**0P7K!ZA"
M$;X47T!<LG+& U *[JH3KT*0&-/^1.8\US=B$2NC(>,OVU:V@1A*'!26E>"
MG++%VAXBGL2=771O!5RH[#+C&8RGO<NKQ$67- DK9UHT*HAEBM&\ ]F^H:,)
M9 ]#[XG50!S$WD58-,(B$6T/H&!6P6,MR9A/&=U]>NMX4"O-9/C)AHM$/;U3
MA/>5[\,GJ?8;CA<[:Z*Y%:3*>+7B5?SVD5,%E]\$'Q.'E).2P<@8RZ2)<(EJ
M5?@KX>-.=EMS?XDVI!DQA9*H4/HV<VP_I(:TPW#Z\_9*M^A""!4[$>+N2I*?
M+(O(EZ1%7^,%-,:QJBUB2,Q^#YW@>4%K'O.B*MJH&-W9G4>U9L_"P5/J,#VR
MWU8Q#_/?N]Q_U"97,+JJEOE4><8BD5V8\FZ72#-YX,1:\8XNY0)K4"K$*K@O
M.3-MZIV$R: A!'BM]I4/#J.:PCG&S5IBJZ%']"*V8/&3 J@;V;CX I$4EJX2
M?$E:-0\3C!)QRHL\J:@: K6D 7T<3FK+2:OM?P"K%-$HUP"BRL)N%8[9U3L*
M=TR:2Z!8GWE:8)Y2%Z+IW%$9%5.\NB")QH@P,!WW45*8AXC1'P-%,)F#O,TB
M),0&?:LD:\"/A@A/-*NJ'IID80*1.A-S*A33E&H'85-Y#M:@0S&1%YK"]6?S
M!!_2]?#Y6JZW+1B0,__J $4.%[&+-*4M]62]P%7&Z4>FIKP:Z_1ZN-J;F&A6
M###K)GA&$DWP"JK1DJET#796J.H$FE<.B\J\$)4A,3<:2 <;9] \/;O[LGS'
MZIW@(BE/@#JE!..)K6__4OX5TK=%^P5H7#PP>>R"T+.<EY3IV(:5Y\V32Q?0
M$M9$[I_CPMZ=DOV3^Y+]?<G^EAC<7TM6TE'N?.VDXDQ48DD/6E$IG;/<)G>0
MQXLY?/KIXKM(&D6E(,H!:H< 3'=4YQ(7=0]D.L;:/TTP_455,!>SN *)Y ,'
M.F3#TJMN@XV^H)/5YYR9VD_^P$Z4-@"[;T6V*'->'<EH42[#Q,"04B@C5T/N
MK:1#@^DB1N=*-GNHN,,#D205L^9.,?3/737PP,/E&Q%A(])?JB:!ZM6UUP$X
MBB3-$),WB(8O7)I&%/=*3Y2*@W==[U;##@F5Y/@UU3[-V5 5Q"@/Y^\*1XKO
MXV\SR0G9/1,W;>*<W=DPS](9Y#2Z#F:;PWRQ3M9-DN0B^N/\DKG+RD9BN]1G
M)6T[6E8A)JI -Y!(J2K^5=Q@00MB/[M914<[:J3"4[G!AG'?,$=%!.3M7F6%
MY'B(Z:$"%A&34I]!B,:D9)GT)' RD++!VWYDL\)-N;XM#":^B^MT\;:5U S[
M2:7W[46URYPQ!?OVU0:]$:4?=B8AL.]259A??^34T@BJH_\O$*81T()0,XH&
M,C0^>>C!7IZS%9BQ+J.S!&G=<6^P6W7 '*TNA/V;H*I-N:Y8-D'.(-:4B<IO
M<U[TA]&.?-8VXKKIX<P@<JU#,EMTA"3!]%$GP&(+2V\>#GD)&*1X+ZE"< >?
MTW[5Y\"&\D]A*\1N-)(%B)F9'7$(E#T%C3&N,6@2'J4@",'@0",/>I3QF\C]
M.W.?C)N#15Z$;F2 %09[:XX:1,O,5FEAE@6+L<&0GH;R/;4D/.($G2Z^GWG-
MV%^'2J1SC91,A/KQ"8 "[5-DM9W"!KLB/?<%,/&N=DP)7%Q_GDJ,FQ+&0K0R
MFO8R-D,?VMT.(1.'(\Z'HR=F6?:FK!F\5=(8"%W  8O"#W_C]6&Z4*,-H>H;
M7,T1N8Y=)ZI15%Y5/[C3M\;^P+,< 92X69\Q5+ATV.7_$/[KC3-::1:K*TT;
M*=X-?O38;^:Z1:S#2DZ*CKD,F5!@OEQ)U==9,B^#@Z6CU^.^H^TNEFB'5(/:
M2F&;#64@'#VF+'*5(UFM=L'^K?:9UARU99;SPDY62\4L'1^OTU[R0-28(:3J
M ]4K^HL4IAB3&=KC<%@YR,ZIF.&FY:)3!:?=L7K;Q+I3RG&B,R,0=IK_%4OL
ML"$!9(_;<V_D"L#VW\H6U.>[3F4<CLGV9+()<OQYI-S-J7$B.&!P-"6UUFU=
MM4970HUTFR4T9'DMUFUS?D*FB0G,9ZZA$=FM8E7Z-#WY5H<T8@EJ\OEZPBCC
MK29:D5P>5I3&9TOYC/;TG?%%&>Q/T2O(43N2G.&W(U&X6J)!DP 824N^OY4Q
MI3!R^'"8.##3H\$2J7B-5"W:OQ0OUG2I$MXJ39ZZ-_+T11YH,;IN1Y4E@L&H
MXA? *EF(A08&K\7++MZ%^,> 1IXP1QW<$Q83DPR"90E8&#W"KB@KSG,\/@Y3
M;D MG(0[_/>..)LK9H6QWN]X0".DXT1,,N#"MV*7C7A[-U2 4JC5;)($@["W
M4'ZI*;OS?61U:?7QW+-%]R$N')]@2%,/"=CD='$6G!Q.D_"Y/N?-3!7%^_DG
MYF,3-?[(^Q,.GFG"16E.%0L@Y^#,T:9'\3C"#H^S>H>.2S*.7HMR7H% J"'H
MO&$>^954^L>RJ =;/9+H05T*Z8AQ) 'BO[? 2 ?30DY@]@?B.+^R#C1N]#LF
M5OJ, ^I7C:EWC4,?/[>Q7.D+8.)*^?+["$'' "[')C57]O2F_TZ$R=<-ND5
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M ,F%,8B0\'TS][ NSH36FT5[5#@9KM%E7N\4<%E7ZW#<[E>UJ8&I?_8+HF/
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MOC$!/I9MUPG-6!Z"?_$6=UL:QG__^O'CT\>+#1$]2*/>^3EUS Z0J&P(HJ'
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M.0LW2)(RO2D%+YB=:3HV8\DZ:SP3F9"!6[R0;(W@$#X>J1?>\8+F]E4M!HP
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M+[\_U5PN^9\&?T#5O=3&6@J(98;Y<JMJB)RX'/[3>P>#!=<6?! =%[* 9T*
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M''&B"I<.DGSG.B\.T["B$EO"VYW]D][$^/^Q3?FMIZ,+"</5,F*M!#ATL@-
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MVLZXX"EK?!<,0+NV5'[ E+S(,[HA4Z3:'2MGC/HMHIT=HB0*J$$LD L9>)6
M"??-T YQ:NG71WN-.RP"5%T>^\H5!H3%J;R#M.PXD=EWF:GJIOZ."]=M.9^
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M_!#@@)^.O._AJ!C![Z+(2T5Q;3F_*: T+XK@8OFC3$"3URC?]V)\'P') T@
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M826/,3F@8<\[' 8'%4_\MR;PH^_)I^Q(] -3+)B2;+6)V5>JDB=026>4]%Q
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M99IB/DC)BV[A< )8BH4X/K872%'I12OS]8=/)U_>6"_Z()J!\X$(]#2!6_)
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MJP6BFI1\"7A9DGFE8%,+$<9/I<<NWD29/S"%5F&E3H@4DUFU.^QW-E$+.[-
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MCX^ON2-MLK<V#'VU&H7;Z^R2*,3&"'KOW4%-VU)3OYL#3]O06CIN'E ^(Z(
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M5]HET$(Z &9.^,\>"O= <0&B^"(.B5D3I $R%<P5 JS4<9UHAA\DEI*:1AH
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MGC:11,J38O(A_D(A-_P@Q2LQ9!)$$-Y"EB'"D^I2VP1#=,G%9[IP80&? K$
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M=76632N;WUT608H(KP!" P.VF_)FMP[H\EJ/!3'=A*,K&;%=*+A_042^R.@
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MO%N"XQM'Z4&/M4HLIE@QK*:K;8!93;RLW3AJJ['ONOXS2D=^,#8-0)IX$9<
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MRHA,EK)5QID2 I(/4AJ?PA;\4;A&0N7(D_:WB3[-DXL8U'YCWW7]9U(<J/2
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M5M,PMC5%3/ MP6PQ?*PIZ[</GK#8-K(J[1'EI;J&PYO'Q]QE$^[2:T$1;U0
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MSV@' $)AKT7$\0SKAG4H83P>.[:#*P *L/TG\;Z8#&T)QD8<&59$P?^(IO:
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M'3_ :A1]D _:_]7'[&E$ :A &]R^D&ME].PMCNR\CYL$U.%!&%M<RST_.F#
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M?T5]!89DZ(P<\.% Q#Y:X-I-$L!PM9=X<:3P__;'1[)&K;Q:Y\H<!WS9[H*
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M@KXB%0M 8<^X;-*P0S;SQ0B.!Q0C?E 38RRT)HDR1@P"L7(5!1"^'>,RF"O
M0^,*E'.]8<TM2DV$.LW^##8[&HR9-6V1=0YR7%66H4&/$YN"48 II6-XYJTC
M#P">T*MX;*2239>,-3#SLD2,3)&?C)4%>:!^X^ GHS8. *^AT+ I.@#K3DCB
M(8A$;"AMH<L%66>O^'8%3F'^!$BXH2_$G@THP(AO7B*CC,2SNM$$2 K8C^),
M /$Q$'P2U_1\[\I&J]_E[OY\=P00:A.?RT0NM$FZ)03*9^9$.1?-Y%:H#V 6
M9JDP[LLS\79L*X+[=!@'O&%-<]\O!">?V0+ A":#V9TI6<.EX"*408Y3%T#
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M,UMX6.[;-AE1(D@??&<1G3? W#X%],D")@&1L=<0D]^2I <'S +.6[1^I-+
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M)<1C>JT%C0,LETD*#5?72DS^F>E ((Z$R> 9802!%+F'+PL[ 0&)F>O8X';
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M.^U<E'S,,-7#FCM/V'VZ<QZ!D:67FD+VU,,5-^4]H#>9ITT;L7CD5(:0#^'
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M2V+;/7)\\.)ZP1!YL\2.L[)KH]:2=%&6\Q+?S# ^7K9G>N0>P7^5\-JC%?*
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M0$YWAA_Z#J%IAXQP"%R &-D)J,<2)K9C.F/;G.*%X0_(>(';U9*1Q%M%8P/
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M,T.F,T6A GWMD4F!G@MNR\+%OQQ+B,P$* <WICF#>UB1,.$+C>.&C3+.>+J
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MI974+*DU"M-BK80-%DXW$_Z)3$_H.!:RA'LT1K,1\@1%$E<46"5RB.1&G^P
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M\".&R"%XR,XD+^8K]IB$)1-#'PO>Z. =UF3.,0)_8JH&F+FW@V*$]A2PR2N
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M*PLFC_K'D!-96(7*;I!D7ZG<IRPCKMS?RO-$U]@##'4[D] 5F891>*?)F\P
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MT1IQ)W!M9[0XB5A4J=ATE5O'\LU-A#EX&AZQ?QR7/*N=8F1Q4P8FGB7RPN<
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M[E1@MJD&I'1\L34@XP0XM<\$J)P(KWOJ3V(8?#AXF(D79K^CO!-)"0+<A2B
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M'@H_'Z\U_,57!K\-8?5L#1C<@G>#JJY%^KGVX>L?H^\?E1=]1>*AD/QJ>7X
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MWSM:J_0U*-]F>0Z&C8O.(!T2+.X&R2E3V7*BQ?P?PR:U\&ZF$XGP="T=<[&
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M>+[%JVO \QKPO 8\W_U-5@.>9YMF1B/_6U1 3^3&[?;/!ZVUV >5A 38&/X
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M;?Y6VOP]_ 3?PU,YR/4[PP,N"43Z"\?I7@,CW>ZL HP^>8#H'##S#2"B=P,
M7<,E'M0[=:S(A)6<5 V76,,EUG")1PYI5\,EUG")-5QB#9=8PR6>8-Z?4NQ^
M+ R[CDFKZ/JM\1*/%B^QW:WQ$@]^(DZ-\8\"+['=J_$2:P8_8;S$=K_&2ZP
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MT*/=YHR7=WMZ3!::3'FQWJNPQ+#D!'-*:>=-U(?GLBZ",RHF3Z!S\-GBB1U
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MZ?N\[PSE/3JT&M>FU@TR?.3+'.PHG3IZ)2F[-N^K],18JNO(6[HWM/#"/P*
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M<6'&%O.UF>?.X=^FK3$_, .F:PX+RBEJ>&N>7OW[X_[]^\VS7.-*_>ZY,RO
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M]4+]V.XBAX=/&2U<R])_\Z(KU'!U1?_G5D:<LN:"#7,RVM->OVD<23/1TKI
M)U9]^FU8R^H"O1_"'8M0>I]=H,O@@:,2.Z5W@7YW%*0NT%J,7J>2X56W@=Z0
M.X\S++?Y\HX_9F<8AV_58 P1D[UKM'6C74JI3[:<K+L8UET,"YR+5'O/?79
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MPEE9OQ#2T!$>EP'L=! N<.8M!! $T$I9%_L$]!D)%K#KPMSWYN!NO(M;V_
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MY>X,D6]Q2/R>:KLK_N@?SC1JTG#B!&?S8066Q;,J_%P#9F=%\U5..5,>E=[
MM-*RV! R)M?T++)2555?DI74BJS4)>VJZ*R#$7Z^_G)]?W_]F<(17CX\7 \?
MSDO''MZSOR6+Z@Z0%OKUDMD%*#.N[3O/U%65?2VFUD.O7E+3*0;VF+I+=H=E
MKSX193XO2].>-[^=ETE4UN\./&J(1F6EI8_[\=UBHA9R>SD\5#Z1H9EU$QE'
MU+1=4Z:?R=R'S8RB)+.QX+QX\%;_Y:/)]G;6$P+PW??FL-#W[U-GMKB<C7$,
MW/R%#@JJZO)8X,<KHJI6 .?G>3TF@QSM\(<-+K$MRAG-%T>:,W5256K??3)W
MW/P>[7.L4CN$^J14CXJ#JF=_= F$0I3E\K/7> W:"?!:356\)Z_)8*!%8+E.
M#,_IFOZ]Q]\1O7$9D!"/Y5P*S5H^YE/"WDU^#P@-QU5G>P6K?5514?B47#9Y
MHOJQ?6^>4+'F5A4E.XTGSY0S>CH)N&\WEY]NOMT,;ZYY%JXEUW0%V[\/_(BN
MX3'-%FV-UT"<%9.5]$F;83),C\FFJ%IFEZHCFAN9P[+ROKT>EJF=*"G[+4VA
M8H9:E1'CFJ,+FTJGS?J2A,ZIDY77C=[ ,$59Z<*4+O:&6Q;9W.:&VC6M=CNJ
M0KBFJ%VTLZ^FP*9,6S2T+M2D'5,AY(S5RYVF%$T*H"\C;<ICYFPJI7_4T53"
MLX-TQK*>$-1*&"61;[9F4@GI<53PU[]V  -*M_(PH.A2*BWA2*!"NIT'*B0B
M^.,\'#8W?:=#Z *RO9'3%R]8",!SK@\71;"1.%\NW/VI^^(NPN%W JP?A_(Y
M\_D49(+2 [;Y&N'.Y[X+M_[_O!D1R,M\ZKUCJO0BQJ!<K+'1^L+OLRD) GJG
MF-F6.-L./]B^5_0EX9' "Y-GV!*17I=< _SQ"60$WIC\.8=%1$/WU'#HGD]>
M')0I'U]UD4& ]8+CASE/\ V@"3YH2/X$5@^%-T0<!ZYP YIM'"W"07P;+[,$
M0D[Q^69?N"P0DG MK^F6F-:EIUP=OR&U:ZM*OH6<W4V0P>XX-A)4]#.=B!F(
M=)8G<!/.Q*.L/4*+,-[8X#R.<S8Y])%,7?(*7 J:$+;_!;@11.,'2LP"V%*8
M>7@[!ZW,"XE8+9[.&/\SOO6;.YW2+SPB>X+B_B\9;T_JR[8<=@G#P<!00R^<
MESE[$J8>2#J5#V$E<+A)5+< )0B0$2D!^@X>[$R%\=+'[Q5--5V)4#FZ,6MQ
M<S2$N)YTBN-#Q0U6'(,7@S1[=EY!%Z/VG"%G/\WHW,?D5%!1F!'*?<AUH3I?
M#0RES/KF+:<@#G0@:?(9F9-Q0WT:O\5HZ@2!.\'YE"Z*$ %Y@O?]!39W3F;.
ME$ZNQ%E,-&Q&;Y*<:0F7^60"ASPJ:>B+H0@# R2NCRHZ\-KPT[[PL!P]8ST<
MHJ#2B9=)YLD?=MH%5D#B3@@8*B "[M42!03V+L, KW=)D60;F46VQ(A;9#-)
M0JH'!3K :IR4K<6S"[;J/TO'7X26<<UU8H+M-MV'S^OO3[RE#VHV<0/BC$*U
M*X)!\UUO&7-<WEK 2'C1FX6<17\/MC5 4*@"J*LZ\P07B )LG*)1KGATFU\^
ME]*4D>X(MP)VX)]N #8[<%$P0>2H=X:$Q*'!4Q+^"P0/7G2V<O!*L%P0-P!$
M>_;F G? GCACI!?Z@L&F^@ ;BJ*[I)Y9\GF/[U2GO3C_7HD]O>^_8;G!V!UE
M3#7./G>A^U \3%$VU%X^ \1'2]R1)$\HF3S1V&#$PBA".+96[\=SL$M.8?Y,
M'A>?@0' *B_]K"G+AI(Q9=E0TE.6/U]_&J:G"2<WI?9XZ,?%#?AF_I(R3=8[
MJJF1SWGS_\(WSUJ0TH%!T4@*@0IKL AB.9QXZ"ICX*+:?,5.S#@TE+YI[9X!
M6'J<H-'7[6J3"0\PXQ!?2MEGQF&\071D;&Y8NLVK2E:O92::SVVZ8:T!8-GQ
M248IM-?8P#*U":=&K4KC^)B7=N9?L MC]'[S_,63\P0'(,_!<Q'XU'/?>W&#
MP//?T4M.(>2T6RO&#&'J5AAT("^X?\NG*LM%T=:D)TU3#+#\2QH[J9QC,!"F
M'9O<K*I8K0Q5R!4GW$]68LY*,)1#"@;BT.N&J)CI@FIF.Z*YV6X$'3\(/@JC
MI>\#%V$,>NG3T#9O?JF<GOSFS9Z&Q']!R;P*"5I=$(W>0!7M*DU>O-?E^+TN
MC;( UBZ)EE6^I_2PK7P,J[$QQAKAQ+&DU0<C+XB2AUR9U:ZU^.+.D)A72,LZ
ME7B&U1LHHJV5;]3B"HTAA=88&]BHU.0,D.3C]NLU4G7)9%7RM[O;KQ?#Z_O?
M!,QR"=^N'QZ$J]_O[Z]OA\)OE\/?[S-[^7A7".\*:;DK).DCW7JS44TWR93@
MR*KIHF:G>]#8J_'FW2"\&X1KB!JGJ'TT!(X+UVQ1,;HSFH'A+I#M.IDJM;T1
M+PY^??1_&>26?$344@VXQ]P+:"WE1UK8[KZ2=4W&3YM5+Q')I/57G$<@SW*1
M_Y547O7 -3&RK&_5?B5^/OMK%_B)7#SZQ/EQX4S@+3\ZTS?G/< =2Q(?*!_=
M7;.Q@J_,LCM64J,J?455&ZE>:?I6VCZ%,'4/$I11&JG2LV*&I3?ZZ"[@ZE$9
M=>\<Z=$AC<;8!$$54QB,%YY]-"U_*2Z55)3>8$AYWIL(5VB69HO@UU^<729A
MC[4=C(@MDRPT7NF?2<I%6BR_@*;1^I8:%:E:.?2;?UP+U[</-U]OA:_W=[]_
M%X6;VZM^B?J@E/.;*?VERL>*I+]]2Z:4\FEN[X;7#\+P3D"B7=W=/MQ]N_E\
M.;S^+'RYN;V\O;JY_"8\#.&#WZYOAP_"A?#A*JYC_3F#;3(<D2+[5<*OJ/2]
M5=UO7BUN3G&QVJOE$C589EU>C5(G)&S:%+XXHW N-BUV=X1O9(9,B:HQ0,#F
MY8MPZ?O.[(F,L:I]Z"_=8)'?KE2EQZ#RMAV_72%9_(\=F0MLP0.J^>35F[XB
MW:(^XTE,UD>R>"-DHYLC[+Y<8,O1F,P)78X0+!\#=^PZODL"$5L&IDNZ#P\+
MN!I;,C\1QR<^]AF-/'"J?-][(]@=B#>+=N6!C*+TK? A_.AGX0-]\.9>_QQO
M]OJU<:EH$:/71R#$.7:%5NK?5&4U>;*[N?V2.MK!8^XFX>O$;_.;\Z?[LGSY
M1)<$[W+ES.$O-48QFV"G0'I$V/IT'[0[$YRG)Y\\88O'W <"NW-G&G5AQ?2(
M\M_OPCAJ-+F$*Z>AI;/$J!]V]:)A[U:PG,]!4$+Q<(1I)#^CM?PX*?D)NTA6
M'6<^;2.,&I+1-0'"AV5T86=)QA;BHV'OM_O=O#FN5A3(?Y:P.&PFAH4AUPB/
M3D#H@X3Y=!G0M=)N8'PU?-^)[[T(N9L-U'\$X[+= :'K!?N]6:7RR0G<X&$.
M)YKQW>P/8'5<[#V\D[S:3E2OJ_T$G2KU%3VUF3_ARBJ_J]'JNV)I6?:[SI'^
M,W@K; %\N/MRG[$#I";]S5;7I.>NJ0[]K5;?%>>%%-!?I$(P7O?6S6@8A7:/
M#3VPF\(M60BT8076M_'GZT\WP\^7 O6?A0^@@\=D JILC&HE2\'VA9O9JA^4
M-J]A1S]N^LA[>7%I+YDP(21^E^5LB6^&BB31KK:^-NITI:P2U.(55=9JZ.;?
MZ7O%&OEJ]3Y?"/E.?'0YG2>2O2$F%=ZT)J[#/*I<I&@:?GD+7U[+>OD$-X7&
M&Y7GGAS5%_[YO.TBO(2=D%FJ/T2&4$*C1?M@B?\21 V0LY#GD$.#D>\^8B_D
MH_<*Q@)N\>9[U*Y-D']I8E>8T,QN:+&B#JU*-K^H3O&?8$]A9R;8%!<^DLIY
M5*2!">5,4V[C5+GTJ(%PDLBZS_I@R_CN4"R0X&[R)7X23897=E(LB6;",[)6
M(8[ R)E3%_Z_FZW..YICE?P.X!/WQA.>V(LS)KN])>%IZ8#^7! R%H5_>^!\
M34-//""OV*X^?1?101O!H1N<^JV.83HNR/Q[(+P]>W#EA?>&RG_39Z>LB0XA
M>N&Q.SB?DO$3=26#A3?ZD6Y$7F%&Y!T&T.-_(],I11@ /O?!89RZH"Z H_$Z
M.!\L7'Q]!%ZA#T)T@;R[_0T56$!E9Q[-!HE:FK<HAN)!#S<CV&T/7!7\Z)4
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M"O\8WCV!:@D74/T\3D0[ HI>$A2M!%[%>YI1U#EW XEPA7RV@0$58.=.V&(
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M9\R5:@O\^)DN'ILG8L"(KQP(>&EJRF%/$)_6]4)[('L>V#XL#P+S<<<EK*"
MQ!7373I/ =R+*S7U49B*R8.I9/LI1&X:.'X(7TV0V7+J_9?4B+G<A9%Y?5"M
MI*BU1P3I"V\1&@G<AJME3:>./2 $GX'BG079'B)1@>8BY'AJ&@1"G/+?.HG[
M%E8AO>>I9SD_D]0F?55L-.+R!5]A.8ZN]:.01NP Z:.[S.67Q6J0B!HFZA9<
M<[,$I'X5F.R0TQ"\Y64MS:.^'<VC($]IPQGV(C]7+\%)[[2>V<G7,Q7-4>QK
M1N.VW8$3#1$86PA%W.)IY _&J*B0+U4EQH&%SE#F#VSJ26+Y(9U]-X&DX3Z&
M^FK=%(QJI=I8P5PQ*^]KK0P]6$ \,L#L& <2[].6JYR&_Z"P!LDY4\<E848V
MG&J%&2'G\.!DQGL3:RO810"60<"3IUZ61BB?]VH/&X#PDTX6T]Q/I"-'0A=R
M;.)AJ D-K8GUR+A@ LJ)? WHQ'\DN'/4VX/$5M6FW '$^Q(@=QW[7O0XYCS8
M':;8#6=H\/@S Z9EH1I&S)^:#7#7ZQ3;XPP0(#!&MLMPJLIJ%+?+UC$M%/9M
M&5 \@M-/CJ3CAQ;V01O9OT6PPG-I Q5.;;DN.A'1J>&(.,:_\()@XLC^X9VP
M#RCY\<HT1MG'?97V!E$$]K& FV^I=PHRI]_:\:P<*=I"8#&#S%/-Y$AH(#2.
MM+>6UN/TW\SW\MAD \QQ_&VV 2\JQ*B@O&X&*YDXZ)SR(C>\@S.;V\V@ ?8Q
M<+S9=@;  4!6"VDK-(+,F06&X"-:I,]]P7 (TQH?5_.P3X$]D6#I_#R'UF^2
M$D\V[Y@#"T+,0@0W$JI1#QT*EF.%O?"7"$T6R-2;L.2@HV?NY#,M,PX@"J5H
MHH "O40TT@)FR[!G";5I\'FT&I@;\MC\PR_?@K_T(Y"G2)*HW$;D%1<#FGD&
M!E,3JP%DY1.[B9?/)A7698.8/6_TPW7^8:D\+&1Y0H%NB$<8\8"9T9%?#5;/
M11Z!RR9:H0AI]#9+FFCI6?MEJ1Y%[YH]88VB/$):F)Q;%M4#&^;1%R_/MT.Q
M"Q ;\*/TXV#,..KC#VC'.2^) 6<A1_2"9'%5!U  $PH&OMU'<ZGO/8$.30%0
MSO_5B'AB0RG>O07Y&J/1MO(UWB-)9)[\>VUKD_:2"O<T.:V;G-6H'7UI-G,K
MF8IV.FDO*=/;T(#K,."Z;N1DDZV1NM)>DKJRH3$WCKXT.GJC-8M]LQ !65NM
M \K&5,KWL&"Z$P_YAI#.L-*!/D^ES"C^:!F2/+)(S$RF8 .@7"(Q@\MCCU!+
M&-DHKM"#-0 FQGTD$W@?>4* /BREIV;?"FQTEI#J2F$.;>KY(2@FMD>/4_";
M.!QMAJ6!56-/H@EGBND[N)!),P4@,R\V9V6W-A"B'MFH.G#>1Q@HO5J5BU+>
MDZN2OU?1I7*FK]Z?[XA:G&NTUR35R]>)DBYUZ#"(78&BBUVFIRZ0!#:N0[-%
M[)(0BDKSM53?1J)9YX4\A:17J*9C9L]B2QTM6EO0.@C3^*OD2>NC&>[UR:Z5
M.HYC_V*./?:\H3H0X0G$;Y-J/?%"ILMG? 8LAJ'3%&UDJ<V2CX \H-9@X$?8
MRVM9%L+"O(3#:8F$<9S40I4MD<J62&5+I+(E4MD2J6R)5+9$VMF62#R-+3>[
MK;8XNRWWJ38]M6>:<5YR6Q)\>Z:<<)MBR$KF5]0''=6V?+R%^W>X/BH58VN(
M1E 0^J3K 6L>D7.4&W&(OC1 N\3A?%O:T^+SNC;Q@C!)JB*U5&8<)%&7@#*+
M*,N,4HK4-4-OV:G]^W1L#V&\G\C>;O),!T$=*Z3]=+:2]M-H+4K[4=SD:>-#
M[(Q<7U@<"I6!13>E8-5**\OM'C5YH^@BMN/TE157L;-2WLH*JSB3NM+H+.H+
M7=%^""+B9I1</\\5YC7/-1#IZ;JZL)SJ;/?)<YY$9 NL<U_:; 7\G=RJ#_@)
MP/"8A>?N%,\@?X,U1#; +7+N.L>+F33163L=S$3I@-7)IUC,P=594@R^&0=7
M$TL\.RV]W<AK1UQPQ$NJ5#<T8@-&W*CI1BNGB*2X'[&S!$MX0X-&]-%:1X>S
MN=N.Q'>)31=/?>DLC-HDR2P_D>&J2;E)XF#1P$T3M(9+'/3+W!2>;![H/&&L
M U.2?DKR;ZF"FGQ<&/H1$GLX-TZ?3K;0\QY:(\%Y\=+.27#.6:ZZFL>KA+G8
MU")%))VRK"1T5K2+R,>EX62?*3:VZ'B@6%4XN$S^6&>ZS473[4[H.-Z+02NS
M+QSX:S;F)I4N7Y/%B<+Q2LS.KC5G=I*]R6#F5Q&"94%WP /4N7-H(E+(XMAE
MMMY +1M87J2W8"KMS4X%0>!F0V?I0R02-)-.F7/5:^GF]66I6=$X=*>S+ [M
M^9N,0S?;<\E1Q)U%[!TS?3"^XP]/@4K#%[$ZGD^>\6!!P'T7#EUG[BS3$7.I
M.PZ5K#'5ZTYZ'^F%WN@TPM,)! ;GLE\P. P"<+&^<8<?N1G]!/Z*7[CIH\++
MACWW\C=/FKK*TL%W,<R7PEI)"Y2_6KVIM]HY!X'R?T8.Y>; DF!N,%\6-041
MEV6NY0>G?:'94:_FFAW9^14VWEJH(;:SMH:^;#"Y]2RO'XR9:TDNK7RO5W.S
MO5X_GMI\RS9;:O[332)<J>,"ND:<Q([:BH:<'I,X9;;1P(N<89PLB&(!Y-<$
MHUE"5>)A8\6%01'8A.52EDM*'(H$,?I!?MNW@U\5[<JR'<QG##T>37WAFM$/
M-K0'R,MPK?D_[*$H"X"WI@*M=J#,B*M. <.0L#-/MXN](',JK_"C0]8/910;
M(WPNYEX*'2?E0^"K,?70+8ZG2(PD4*&S01T'Z6/#X#')4LGKPK1IXDCQ!*A<
M0\-W^9E%3&+B/'D*=RD$OO8(=PQ\+PA.Y3MHG0)A'^=7.2DU^C33E,*2)-W)
M..K?>!*9F$5@H^_#X84%=H@[,+31 84?EYT^1*(J55%X<4*AW))D,D!<#(Z/
M-X%C-!O#C7.?^7LH%3F^ <8)QLUPO@55Q!N8Y]HL6.],2:A!2,&2G.KB5GU1
MK_)=]5S&"<2T,1F'5^RAH;.Z5E_L?8FH-HU*T_C@O:RKE?KR=MTK7M]8V^B=
M'!00@[DX)KXDD+T35+&QNPYJLKMZ5]D]_;V[IV]]:;=SU\?H'5WV)2_[DN]U
M7_)Y.6I; V6]0V/JE.J(*'PJ*JPV6L_1I 3+96/)R5Y%BCFM57)4>LP QA<<
M?3DV\G)B=H6M;JQ;^@[C0F^U6_HN D*_OG5.O5HH;(T>A>+>X09/#:CEQ*PW
MV1I]J^#LA3M"?YQS<E#'H5#)W7K'H<GS3JKUC?1_WFY+@GE@X8N.P[QG/GKG
M]-?/^R,<H$(EH.L=H!;/@:KE%%,6E"=%=^A .[-^8RZ%L*@J,9WK*WSN^]*.
MK6RF"D>T4,4S/Z(YI[!]]*7>*3NC[O)&+VF+N>)&=[#D\8W;66] '3FDC5[2
M=F2UC6Y7C[ZT9\'9=J"7:48PL^&(L1G!O+NNK0LV]1GF^.-&D@R=8+4_+^S?
M(P>7N6<.KB+"?F5*^T!\P^PLZ2RZ 66]C3ETNEF=3?;=I.LGGR-LMB_?XD\N
MD3R'25Z%*H_6(R^LA]&!D#;A2MDN%14S/@N2UZM>_N'HKE#]V'IT5R.Z>[U'
MN^@^[9 'XLWUJ+]:/L=XY>E^!#FX1^I3[0.K3Q^4E2P-CTF2? 4GH<80>CVG
MS7KI2MD=.E@2%]H '6"4M*EW:@5%2KG=[Q#%V,!V8Q2PKE=;.^EPV5P/\ET5
M;BO:F0?;-'W[Z_+>;&(#W=07,XE7, =$C3$Z>L.8=9OL7L/TK9/*QETYFV-O
MFWSO'G.+DBDD3&&)T^L57*&-G4\-W6SM U<H#W]Y^ _O\"_Q/+[B\&,4OE'7
MFYU9+)SR\,]8.'-1*,7;3_%8?3+:RY&L3O&F39%<%N\UO])9J21XLZ]^3BU,
MIV(@FZ.BC-F:C*2QTY"-&$&HIQ#R$.<N;P)SO=];7D^)N>>-WGQ9C[X4@W69
M8U(0G,V%6&S<E&X,)9C'+#J4R3$;$RL(Q#=/E2DZ&@,SQ7(@O J#[,UCKT4'
M9,* VK,939L T,MTF?27'"".;/&4$]A06]7QIF93:FIF4U.S&**2M^$>>WYX
M2LWIDAX%!>&$ECBZ[_$3"!*SO@CK8,RLJIN-5S>:6>J.W<1HZT=?&GH[I\E,
MX<$N<29N8K"-HR\UO96395&$IO68J%<$A=P+86J>:/B_A4E8O&E&#)%#G3/5
MG^$XC:PGSX\[<0QM'P&)E/.ZYZM4XZN4%V)5N^$D[7:I@QYOL"E:TG'@R(%C
M!0'ONT-=:68X7P8)#]D;ZG^T]D$(_XE;UO#&?)F%S0!.K8T47A!.9Q;%.(9+
M^V&%D0__G0>U@R!U1:!VWAA7YRHB;"39QDC@._&NJ!PO$IOYJ<!]SO+^05D,
MGOGMA/87A*==K[2,]JZ!P9B56L-\CZXF;VF3_YWZUR\M.5DQ(+4?E?_="79C
M+5+[_X[X+D4JJG:RY F;@Z])8>NEL'[@.LC"\WYO1^ &,@B6^0$7Z!.W0O9>
M1.P:WOCPS)PG]@->/PZ*&P:$3FSH(!.VFH!=UDHJC*/Q6M%TP EWFSDWJ!\\
M/'O%CTN;'Q>S6;0V?UO9>.]1(/7&QZ6Y-OK3:Y/D#[CV9Y,'#7'1BQ^U#C]J
MU2VCPNQV#OT;'[56*9EVX,!<>9%?]+PTJM1@J:K7VZ]&O2A%TZKGI5V*IOT^
M:?938<G4J%+;AXYNFILJR2@ETV+J>,"VD]0DNY1/[WQJNK@+ZQ\=*L=MF69N
ME'>/Q-1R3-B=\84_W#QTOVO?+[OWE]IM]^_4JG>K>+IKBZU54Q[W,_=O0P>P
M^)G#1CQZL]70F_5]R U\%U#/#3(!^G:+VEONI#!%0OND37U&[6F>+"=B2N=9
MK60-FUGFX[?B#3_=H1T,,/;'AI>_!W KCP069Q3UHR^=1DUO=68MR)./>EIW
M4F3?WEW>@YC6_MK]_O-2N[G25!G^O=?]VOO>>^A=EF)\]\3XAEHF-JH-KBD;
M>CLG-%=*[<.4VH/(ITSZF;ZA)2?8/:D]AQ6<\STLSA&:1U_:IM[ >-@'D,Z;
M*_XQ.N]^9O/%RO>;ZV^G#Y=W/[2;V\N[[D/O^MMK9/CF"Q-+<(,2W.!M]:!K
MSQVLR_\P54EO(K![#@O<.XUH9XH?%R3,BUQI&DIU>5W"N[1]O<DT>4TU4_>9
MUJ=FZYXKFHN'&<^':,_KLXEEN\E;XOQV[!:=>P=64U%WY2'#O_*?J%MP]OWI
M-^IJ?8,6X>#L4/2%QQLL1P,*\+UG?!^VI4_/P';YL:$JE2?+=GC)2:AT(1YX
M$WC1@-ZF8=U$1>MB*CXGUWGY^+RRQ^3#XRL.7[6P-_5C_NPU.Q G8&%_\<6<
MX6_B2UW^H3OYG;CIN+&\UWBCBFE9]4HG2\NBJ&EI#_3&6XR1"K0K<SJBTQAS
M5UXZ=S@M$+V$7DQTO&=UMM&Q>@8RFS3+VX'U CDL9.]+N'MF?2[$B.]@P+?,
M'ZA5EJ=FLB)&]>A+LS);9OD?ZH:M.M[&&XS7P/'.XG']1V5^]<H^<-#[J!^P
M?T7(+8"R\OE#FFO!VE*=(#9__VT'1'D!FUI$HNE&]4FK=NHM/URPL8**/7>&
M%H%2E-WM75]E]_>::.)F]#4*8'I!P(+NX%^1[;/A[,D$^GD&$0L\.M[EJK+)
MYM&7\-F;K9.D%O2P=1Z<N>"7[3@P?S?R YS[R!K$(@=(%T;.Q'$&/A':P-*)
M7\("+&:51FYAF>>GR1<YSLWH'![%P:W >@R, ,UA/!7M86P'N#&XGS!$%$ @
MM.;N4I_-JH*&,6=_J/#Z1NZKY=SSA;OFZ_:5#8/</4#(R_JL$UKSDC?-[ &,
M*Q WP-7^2Z:,$ _8E-$ITP(@>'MH6[[<,*KG?'STV2,2L W/#$)9YSD $G[!
M#V3D>4K/@'>0XG7JC4XC)'L@P7"F9'3.$8'O\@,"^\#@,$WD,WWX<3KUO=]T
MR7DI6%></C6S*OH=COAF]#-@71SN33\$L<:&/??R]V",I_8J2WGKNS,-+$"N
MZIWV+.A 3OTF3L1V(TMH]C-7% 8K.%FM":QN%G<WKM_[CW11I5"^J\DC5A\4
M[2B<_\A,T=<;<VE#Z>O*%TKY<^PGV2^/[+3O,^O7*27,?+*<9^LE0-U?%4L@
MD\3;ZQV")5YAVGM6?EDS*V9M<=O[]WI5_3WJ+^?!<9MFL[EFR3B]Z),-(L,>
MK.)>L-[ITWR-@#UY7'SP*D5M[".G_)/-F-FQZFVKUF>M>JO1[QCUUJ!I->J-
M%EPP:O\P02F@ZFUD_RAXT9#[[S-KD=?A%7-[LT7<\I)Q%7+V3W7EED*=;[3X
MMOA:&?75DJS^N-0NK^][WZZU;W<W/V]UK7=]7EDG6S'W]'<V<?JW+\G,E=QF
MUS</E_?:PXV&BW9^<WU_\[UWT7VXO-"N>M?=Z_->][MV_P 7*%5-.]6.S[GT
M9\,\A/S%>%Z%,!_6?2Y&C%#5E+B2I=9!W6L@Y] -X\OUHP5/M?.?:M-3^29F
M)]?"W-A1J!9GOJ:,77J^UD6\F'2T<GN[]?YF]8-B, M$#'3T><\NX:&!"<,(
MSD1BIJ A089" J3!S1G/#W04/,]C>S">;YC1-V:- '.1:99G7DI;FOZ1;Y\U
MP3Z;3=\%^\:U89\=V&6PEV)CC?MA5=/LEKFNY885K>LXP@,;I-8!'PA]>^JP
M4W39\N738068SX1IER 0@7&-;^-/X67XI(W"6F*3<+PLX2-5OA+#UGS2CHT3
MNA5L/V$1",N08&P<]F1S%RR\\=D.Q_+KTK*C 0[5=Q]SY*X0#"GQDMB!BZ U
MTN_LT :<?-80A@@'$(6J4<E?$H/CN S3NRS_!<=!IN'4MY&$)(C3[#BD>=L7
MGA&DCV$T"!./\LPS,)B:6 T)W0/SY>X4CMGCNHP3'ZW%)C]<YQ\6#I47#3VM
MM+T#CJOD@PEM^WQ'/].5XX9XA''TH.SHZ/C!ZKD$>P;+%H5CSQ? 36^UI.AE
M23N# HT<8]K(]R;+O$*Y^8"O]PIA/*T^XQ5:[J2:\>AO9CCHPV_.<U)MA//O
MH1"YB'SDI;,N6%+<Z#RB6Q5=6EEO$A)P,6%1ZW1>*RP*.EL[1U]"K XNYFY5
M) L_XKE"4Q[_^-@ID:O$P3F'R*O;\<2:6*39GD?D:6C((=]ZB<VW</NS>[]H
M68K31=UHO"U=F,;1%]CX6:H86)-I%"0$\*H]!C5F*WN,-4Z-.7O\"HRYC"L6
M_^B1+C$'5ZYAUA;ARNU#9.J!HA$^CXH+Q8D$9A9Q+O B'Q6D=0!:T>VN(-&]
MCZ39%Z=JHU,QVTN1Z-X8:ZQH4Y\E"'E&I6ET=@VV;U<'96X$2W#K':%0@FW#
MH;BU5#PLL=4N9QA8$7B_?6JWM<$JGAW:1)0V6\W,_VBK99:K56"UC'6XP<YW
M\17.P8TF]#8JJX0FYC7N-2OMA8U[C3UKW+O=8IZ=*9G:$ #I+J;O;P .9%D?
MLKGF9N'<'[..!K%>K6\7R&VKO<&6M_?ZL*?EH Y%Z\T.18/Z^W:,V?SG55IG
ME;1?TOZF:;_]9K0O>UO/PM&\'^U_%/7Y1L2=8^?H'BG2YIXITB6L'+"-SINQ
MC=;1EZ9NUF:+/]\'..Y5\(,?E1S,)44'&R0'3!C0V_6"C0O*7=_&KB]I=;_!
M7<<R2E";WWC7WQ#38B>A$E(?P[CWJ?W[=&P/A\S]A-M2JPJ@R7C]E_IQ=T*"
MK^AJ*)$P2B2,!=SOS5QI->/HBVGH9GL6>;H$P'B%^-X:PLZ!LX^22RA<8DYS
MZBUP"<Q :^JMQBQ6P>YQB9(9E,S@ )E!,?BLUS"#&D7?.CG][$MF,!<::R-+
MLF)K;>-$%D1E4EUY?1(+M"?9==OG\!6#,6:L9GIM>Z.B^!"%U%;9^?M5M(B1
M8-WLS'KP]*)C+Q2HV\C8"9"W9LP&L75*)2XX_D+!EHV,'X,NNM')J=O+5!HL
MSIO6X\1I0C^S1,T"+T_@V$R\H?N<6D!1&X5E"UC@-EL5J#T#;>] E6.ME5_E
MN.)JT?1@3#Z?KUKGM?*LVEN85?OH2VW6>::4?:T\NM861M=YS9J;E6(9]V_)
MY,T3;28RES!XP?=]]L3<B."#O(%-YR*NL$R@C&2M5U(NK.'K[#5D "S:8CYT
M+[ZU)M.I5X':]'9GUA!)E6K,.T-4-NFSQ1PA;UI&?0E@V()YK5"?5#>*J7NF
MV=SN>,#@<V<QRW*JZF298(;@5JF;22IF<A";5 #10E5->7Q"=KMY\+ZR.QB%
M_<2&/ZP0>$#X,J_8J9X#E@ 7\8.;JX&J$S[\&Q=!744P<ZQ^=J/98BA1X:XR
M%<$;+.(&<] ^G_%4K5?TM"^52NUZI=U<#+3T#A4S9L6L-M\#_>FM:U=>VZAO
M(YDW.52\9>RV_ 7A#7DV:FXW";5M*8K3G$2<6B7GZ"W+:%]"F=N,U'V<AC]S
M6\G6USPQ93)_F<R_0ONP572L:WCCPS-SGM@/>/TX**[N(W"KJ1LY#<1V,--_
MKR3M7+[1*%OBOO.Q>7CV4.-9X[@T*)K?:!:M =BI5KC[U;&]679LW]^#AE!!
M:QZU)D^<:6ZJZW39LGWI46N5DNF=#\R5%_EKGI<6G1>CM2O)]@<@FMJE:-K?
MDP9_K'G2VORD-;9K,Y62*8;JQI 2]48HY=.[*W1R*XH?&ZP#,3MZH[U?$NKC
MEHBDRS_*;J8[DW=9UG"\&4,KS,8:59#^M:;>J<WFE>U>>N9.5G2LT-*T8$^I
M]TX6FM<3@N<S+&PTL:2C1)VGFW;S<@GB9*2^3!#A4.>IY-/D]FGD!Y'%V_K%
M30!7R#VHK+0;,U=R$,!Q7LL;T1B=VM&2QHSF&[7-6-@D0S/:E<6 Q3.Y,Y@2
MQMR %JCK#B\G4\=[8>PK<]G(#F\=&$U.IDS#R,F4:1BSF3(7EU>]Z\L+;-'R
M<-?[^O.A=W.MW7[O7M_/'K"B:7=Y +GSJ)Z/+6_(YK)>93L 8:R =H_A7%A:
MO6H<_SH!<3/";GLT+]_N1S3E*>R9=HR96.(NW,23I/$%@\E1:PLF]CK0)M9+
M\@ZF1=.%J9QSFKV:\P"^):E=\-&>*X/%H?VP?MN3:,+YB?IC<,M\28^+>JHV
M8 L[LST!_T/TQ[!]F?<$3 D.!%C8V'@WT#&3[9^B 8<UG3H@&:@/,K^YASD>
MV"3R3N2WG7M#[-@XL<,9F/7,8F-6_9,]%%C2V'S79W2SC\THPL$8V9RZ9X%V
M#-LJ=]-VLR\\R?2BY*T@8ASWWWB"X<$Y[Q;]1=0!%L[S3V_NK'(S9V_/O0!>
M,? >72#W-30;;#JJMW/0.HKF^J>3)]]L_!C+UNL;RO<WE]0K;&D.&&#4J7/D
MDHSJ5<'2=:7OCO-2)-_Z0[7EF.7JL+BG_P+>8X^P4Q"P ^;[Q-T3$2VX^\7Y
MK<+1!Z#66L UQO!VYR6Y'YY->/SSV.,]E#"#_-D.4%F+10&P"$K_'MA3ZE[K
M9M+%!>_ C^LD+6APHH<2F"V@<@-+L;2IY],H8\[;%\WDDPD %>C$%^6HXR'J
M7/"LUVK<G%?GL'7I@S4QU87B)U[FON=& <L5'["CF(7K/2<-".3""$J B8F&
MOD-&*7E)ZP[?ZO=M#32N((P["XW Q.+MK!Y!E_/Q2W#[$POX<]C,V 8AA:(N
MULZ!\IC2L(G$"$Q'-AQ+"R'L2Q72!_ P \T.Z!L@]N"8\>H<'(,66%B^$Q#Q
M!'Q1[  V!S.2TX)L:H%)A[.7/8^MX<1VP2SP*>V0=VS210\S2C]V/; $X7/T
M=; C!$<:V;A1@BGE<*!L+Z""EMR;L*$EKSJ@GL5F9K/*GL5ES^*R9W'9L[CL
M65SV+-Z-"HZR9_$<GYN9[W.K[;[/K1O(]JIYIFVF%$[HE6:ZOYXU&/@P[X)6
M_E(;GXQ"U6W['91WZG1Z[EA!0,;CM><.(M\GFZ6HO=\Z^E+OZ&8UQ^ O[+-8
M[C7:]FRP5+VF5XW9ZN&T&T+'@(/CH3L#&__E&]]@-O%NNLF-CABNS0).%*)]
M*ZP#A:@X,('ED$$5C!D+*]JY%8RU@&8$&B287TX4-_--;"Z;1U&H(2PWW'A+
M3K+KR/8*QM;0>Q8=@>,;T(H<"* $89EQVRVV\#$J(TS\^4Z&BG;';7Q/N_9"
MIC5T;4O!Q+DJS9Q:5FS>^U=:LQ_,@F6D=I7!&T<Z>;P%C=6)Y^/Z<\(DYX>;
M&. Y9<Z[9FB^U6(MDA,@$*Y6:;NH^!!53NNCNH8//%JV&\3N R!=[):.KI6B
M#N\E6+3?X#O?O2"X<7OQP2N>MM?H *O5F[59(,;BG-98@@RWF1$WL?>LWLQ!
MSLUR4^ZDL?PX)CQ,N*>(_AZ+P,6)KKDLU$5O;K&3WF@4L) "PN*VXL@4<S:1
ML$625;CDKU\3G:)IX!ZVVSGH%!O;P\T.&(']]%8C+R8Q;PN%2$$QPL)GQEQR
MQ7&('M%6'B<K'(WT]XSK3NYA1;M:CMEASCG=%LC=8#/'>P:R!+V(\+<M'9L:
M$HG1SEMSOLIVL.8YH6!>?%1 DD<#J:J(QS:_.)NEQSJN334G=5E9FPT2X ;3
M0A B9A_20HQ.T:R06 F'T\JQ0VY!F1V\B+20H.L.?[KHK@<EW9X$%W8P@*,)
MM^7DBC0;.49@LS&;*W)_^?U*ZUW?_[P#8_A2^][K?NU][SWT+E?/%1%>@E-T
M"0@M)Z7XG"Y5HN8I*7S >?,PCPK"U=P/QG!,'78S6K;,7U]N?0]/]#U[Q).6
MM[K-1> T[X\\@_$=CA!#H6*1!#8%2<.3PU#:V 1CI7F1KP2?%,-*Y(+AJ5ZI
M.7=LCW^:/=J;FOU*DT]G0NY%]*#=J#0ZC7UMSKT%6/\5P'@6+]?'[K"\R;OV
MHVEN&HAG3]OFYD_MJ_!3_<4"\>>_</8E=/(][:JUP?X>N0GHM6&S55VALG%G
M2M>*]2G,F]Y[5VJ\OO2LMJ3!U#*]K+B1TP(MW*CJ1JTH=L"JNW*@A9CG/"[
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M[Y(*9]D^;VKBR.X_,[6\B',F8.1B^81,+HS_)1;@,QB5)XLWEZ=AI+Y JHS
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M:$:,'/T&V68[PL$VZSK9_?D>M*"OE8)^S;5KG9FML^WPAE+2[Z&D7QA%B=T
M]8.4];E2_.L+M0>?*Z\/20:5,O> 9&YI7.]2Z&#W9UU&!_9:,:"_&G4DCK9Y
MAI,(D[! XW#U =787Z @Z-J0_M6-'J,@U"C1P:@?TOEO*^[W YANJ1N4NL$Z
MI^2L?;8=SE":X_LJ=7-C\G61TEC?3DKCS@M?I9I'Z=B7].DK#?)LS/L YGO
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MK#<FK#OX]UH]$=8)P*QYF,!S#V/;3]+*%Q:9Z0*0CJ>:IV'I.F6R>:D"E"K
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MT+0:]48++ABU?Y@F6/UX"@CA#3X&!!?DZ#W9$Y)'HW2:DL/@@UE^"LOA6-.
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M?],M0ZG"[GL'DO0#FA>]G"(P]XI**[&4#5W'I-/+M<'.G_<!9((\?^S:V-R
MANK?V:[YHUA RU&_9$_]N)I2=EZDTXUFO<"QHBA'/(D & N;8(O 8@2DU-M@
M44FTUG3=B%;F:#L2+N\O496R-B#30(;(IQ<;)[0!]\8SC?&T9B 0?0<JAXT<
M-#0S;%O!D$ER>1DK$=0.)+'*1SFO(P>'>"7/E#^UK9MP0+2P%>ZW((E=F-;N
M$IM39 8$^QLFA'N"#(4FR ^(PW%]'(?Y 6)OH<>7D_JL$3*M8KE,E3-<LFT<
MPK8LVZ\DC1+=BG5KW8U\%1D=H]@&*T&J[.K,TZI:S]BKHHV%=$> U?(_6GA)
M0S<NPW"_E_1B .@5XCY.Z?TN@UAW"#95D@P2\,563*>$Z$9!D$3[!,ZXPO)*
M="?1KA8HQ6$2A,+)5U#ZU#OGEX<.B]S ,$?Y.P2RQB%0P:AA SR:M8WE*O"V
MMB:_2WP:%7JUC4!U'6"_X=N?!865F#/[*Q5]-,'?T)LT,NM;EDJ-KBV@<7<@
M25;R:DDB0<K=9E<DVHK93;'H@B^]@T*OC^GN5[ ^0U6[<#5YF<I>9C'R:$.\
M:JHH?I961'<D2HC%$#VEEWY6@M\O$94:78O,P>V",X6:L(4-4L8=6$!UZ@UQ
M^@,:0$]JL,=_O.A9*,'ZQ*51 BO]"?[<Z L0I.1X\_LE(%*B8U/D8)>D?<L"
MO+@T2G0KOM9*W4@4 &_AVE;/)=V[OMYI,<=2VID4QG>+0S75.;[,G(Q'45IM
M$'MT"\NKXL/=2IUA1XO',"!@J,[OD%6\= JH3KYTYBHE[%NO%?@+E]!30"PH
MF,AG1A4Y+[N/;U,F2>I AU=7/2;WHHZZ.+Y*KY>T'(N=R8GG=)G@9&EZ56.2
ML?L*UJQMX,&QPH_8&@"2#L]Y799<60]8,D JV+=S2BJQJU4V6V*EL4\ES[;Y
MKI8CUW+R4'1XH8P/^7X9)<!.*?H\SW1>T5/O9KMK\K#!)O.<[A\']N*V P+H
MR;#I<EK<T<.8GGI(=H>W(E.'!3OY@LFG44)00<T=F69 D/#,>UY));H0;V,"
M+%*EE&AZZ_JJ^6&@]\5NP+R22G1!>!1^_T(J)]9<@9.J@670N5<#U_.V%T,&
M>(E]F$%MV\"" Y3E:)7 OH)9?4P375UU/?1<[K8X?M"BJ+02&&?/](2WOR4.
M <4$)SWOHQ.\LA&T*SW:(GM"2*<$3/L^D:23#PP]>E-K1>/)CA]^5^*"3W6&
MI];4M@OGUF^[Z:"5ZV'?8TU?(\_G&U$2'!1UF'PUH &!-S <RW:))9#QHM)*
M2';KYO7^8QX"1:FHN JQ[*(#DM(G*D^\F":7@S)K24'Q4Z\4E9TEW34]W<O:
MR<ZVTD RC:?,4BE7O1&)W:VC6?(=B^/[;X[0I!=R]DC$.I)*($C]:-8."*'A
M1,.GYTQ!:&#]92]Y8<]T X=S.4>>DZK*)#MDBZS1&A$'SQ?^]@0R?;YQ.NI-
M1 &_DN1*K/;4\IG2PX0TW9>$U22F4Z)[$V3878]>C!I'M^.\T6Q,T)KNOV5#
MN)),E.CX5J5JNR"(]*$NBA$EXAU@%5&I<WQU>]$K;26(KX9E*4[N=<_&"/4G
M5_8T4H)$"1$,DYCM.YOW0."[KD6D)P<M]G!N(WM$H"IS")0 K+T@V//=U0*1
M2?B9ABD%CE(!D0I6P#\#@V:-H6]2L<6MAXH#_;EEU=54[-EVR9X@&/GH)$T9
MMV<I6B7DDL8;::9GT)^C4V^<2X39HJHZK7=QMZUZL<TXP18YZQOV%Z&UH+NQ
MZB'<WV39G=HH!*/*)3RE)%% '?TC9_N5O\BF*W:-3>HFPY]^A4'NCG;;\!9,
M[*/W%G@WLK-E55TS6K:]EQO)M5UB6 )544"D!&([-Q4[1)<\D+Y3U3FAS%+4
MIU[J<@Q):<M3*=3B/2?_D#-UG,$7<3H>NOWL1SDD\IX=H893H]^B:7I*G3S8
M+Z8$TONGG,O=5."1*-&IG)1E7$6DJ+@Z:LEW&&NOA]=(7P#O^4*HE' (5##=
MA*F\6!($FB*DQ,F_:LS4R XFXV%0S:T #=))X/F3;E\7Z90Y197H1+S_AO:3
MX.1>;EDENE']+B<]PJ\O#">*7K5=9XV(QVS)";("$T67(=8&MJ,TO2]PH[12
M*U[(4U@R=EOL4^>?4A+3*2%18K?# 1Z+TRMMJ0ON//4@MZ@ZJD$KF,/""LKE
M:\D,DR4(55 5:,:5);3!HJ>F5S!Q-G&"74'WA'1*S+-M,KP.7>=\#.T1]*N8
M0(D.4:?+%V1;?8?M^#WZ1)*'+6X,CTNCJI<^#%CI[O:FU"9<*5PBL/Y+$*HP
M\<*EFB4\\N*ITPF872ZX)2PD5-4-!\N?B5!H*TP-FR9T<9= '[[S[7FNB6F"
M0N:/V!YIW.42X9HH!S)6=<CBS;Y\"C$.Q<ECORPF(<B'GBRBQ(J[\U^,D6/8
M' 4]IZ02STXP7WW\'( @JTE>425@2!P0C*Y&ATL@30T;'IKCA#?%I(J>D)Z$
M6@BHL$YY.>03*2&2H(HL4,\-B+^@OC2^4!845F$7[RY7MKM!*(J;YYOH0Y>=
MQ8^/MA;B5HW9B5-"L58^IEN9/LZ[%\7E>SAD>;VPIY&UZ=@^HF2BKVU>"WIZ
M9AE]YY(9PO092WK\]3@>(=DZE5@G=DJ\#NN7^!I447$EMK"<G":PJ,D>?TC2
M*-&M76H =A:*JZGGECVUMRKQ+D8BS<J$'D,?S1Z\, FO,&N+@%I5.QL$:TU]
MB,8F5HX$;OK"\DH(XV<H1D_9CYR=)Y@>S6,7*;"W<CW#CHRC8BF58Z)L.IHX
ML3)L#H_8"?>&;([E?4\"%$A(,=L>D#7DB/]Q*U'5#F\%@%/? ;MH&78Q&HQB
M[V]1^1<RPB4R6%.?"%.DA#?\TP65F.'Q_?H.BOX-D.[&BW"D0A-8C)$G?#RC
M"BME9[M.8++Y=X;S0W15/%U."5C9=4!JW@D/7^255,$6E/94*^^ASCZM*G$3
M141Z<F]D?+$D.OM6[A9*JK 24Z?"\R<KZ,HQGU,)^2F[-L;QK@F:T?:"\DJ;
MR7,8YA9758<_;J[Q4>#33E@TB48<#>T[5+_PL%DEX>=+-D11O^T=6B-B;^Z^
M8=]'/[ C6%T*BZNP#^0;N.QL/-.-)"WC).%?=4*=Z)S7O\_QKOQ<&^5S@F=I
ME-B)]S+X6O\*P@0\Y1+^)HJK:@7'!V6-;%;><B=L.81*X)>^_,([N)9?5IV3
M:]'5 ;!QW26BWBQ.XIM,264UN40N"1JKSCX*6AR=%U,JV^O]2R%?D&'["SJ?
MZ(%O@$WF1DDAL1(3,#82=T=:8Y^A,*201W)R&S/Y'D!B^WIP,,?]S"=2*%H2
M>G7AP]9G%MX$!?L)D35+7L0>W(;.L=4RU@*+=9_C,%?4*&@MTZ_E;=^9DWUF
M+T.HQ.Q-GL.+/:;PW1J,:1*Z$9B[()')(_<EXE+G_ [BK[J"Q7NN.>QX6R]^
MQU"*B;)[WBZ!933Q0_V$X\PO**\JV-G0?I<&C67/ ^P1*;$,\+R_4;I\48)!
M&18GW^03>69SGTP+;]='LQ+6H$?8P]88/?%2NU;F>&KU8/\F>>GWO@142LAU
MSED<O)9^KSI)HT2WQHA$[I2-\&V%=$$E.A#>3+;:XHN^V8)*= "FMAV^<,ML
MM9;MPG2O-H\J<%+#Q[PBB-[2B(Z/+%VPY/XHD4^G!*$:$.\_0 E-39IV858@
M<9YS(?FI5W]]@<;(H4<O&4M0P5Z)8N"%!$K@%K_FH;N15R%.AT #HO#%BNO@
M+4FMK X>JUP2*6=4RAW#7FEACZ.RA!U\22PHK,+J2'/SN3-ZL\V#1?TSZ+^$
MX@\VW1([F':&YA..S!Y!KH@JK)28B3F)X"A8TMGCDD1*=&Q_;2__Z$4.P9\V
MX7ZYA)YXY@(MC4\__3]02P,$%     @ G8!!6*5<_Y] ,0  5>@! !4   !E
M;G-G+3(P,C,Q,C,Q7V-A;"YX;6SE?5ES&\NQYKM_A>;,ZY15^^*X]@V*HFQ&
M2*0NR6/[/B%JR9(P!@&Y 6BYOWZR&@#%G5BJP:8FPJ9T2 K]5>77N556YG_\
MY_?+T:NOT$R'D_&??V-_I+^]@G&<I.'XTY]_^_WB';&__>=?_O"'__A?A/SS
MS=G[5V\G<7X)X]FKPP;\#-*K;\/9YU>SS_#J'Y/F7\.O_M7'D9_E27-)R%_:
M?W8X^?*C&7[Z/'O%*9>K7UO]M/D3<\%&Q0+Q5%LBA3'$:26(U\DP_+\*C/^?
M3W]*%IC2U!/&;""2\4R<2ID DYD:Q4"9V'[H:#C^UY_*E^"G\ J7-YZV__GG
MWS[/9E_^]/KUMV_?_O@]-*,_3II/KSFEXO7JMW];_OKW.[__3;2_S9QSK]N?
M7OWJ='C?+^+'LM?__/#^/'Z&2T^&X^G,CV-YP'3XIVG[S?>3Z&?MKC^)Z]6#
MOU'^BZQ^C91O$<:)8'_\/DV__>4/KUXMMJ.9C. ,\JORY^]GQS<>">/I\-/X
M4S.9?_GC&&:OR^^\/CP].3]]?_SVX.+H[9N#]P<GAT?G?SLZNCC'%;2?./OQ
M!?[\VW1X^64$J^]];B#_^3?\O$^(A O&%SC^]\,?]OHGQ.A'<3YJ=^0]_O?R
M(PN8:FCA^PS&"18;LWKN:!)O_-*HB&72K/[ER <8M=\=S*?DD_=?!N^'/@Q'
MP]D0I@?C=#Z;Q']]GHP2OD-'_YX/9S\&,1N:-#<D1R^)]-(3GY0FH*GEQL:8
M@KFY9V6!4UQA*]SLIZ&5\/*!K\MFOH;1;+KZ3KN][=:NBVFQTU76/(@\6BT$
M$ \^$PG*$1^1=<$SG3D$ "Z[6][-E5QCS4$37TT:7#*JL=]>?8.B<I8:;8'%
M-_$.G6Z^3<O?>#V=7UZVGTF&,[A<_?O<3"X[9,)L4F?+%R+%I>PJ\\/)Y>5P
M5I1]6=WA9#Q#HX#&H0#"!7CE/)"@-2.2RH(E,>*R LD<\[(Z!QZ!LPXG^*_
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MGWY !T9@PU75&NU\XRW_>2=-@'"":D&"@M*'P*)/P8TI$X8DM1JLM;6;/#\
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MGI/(R;M0VVU;A>7%ZT45(;>PE!1<Y_G7P2#=72PO![W4L2XJ$T$2+94@4IM
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MS(#05')<!&LW%ED+:.?5)'Z&-.G!>5XVS*PD!V7)08FV2Y&63%GTM+U2GD#
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M,FJS<$JRT.CV=8/WNPFN>B? :T:;Q[(H&7PRE%##<=X>Q>#1PB<\XVOMG.=
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M:,BL(+Z*[2-F"6^#T>BRV)/C[M?91!]LZ=[RF*ET1*?2#<4;7#%4"$1D5+3
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MRH,J(3""!,D-L4K8)!D/F>_!U+B'Z4>P-[8GH>)E]VI\"W2+ Z,&^/9E>3S
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M@<80'1AZ_ZZ<72KG2;01;3<=78H_0B>2ZJ1O(M<VPOYG:!;%6KWT)J(EGD+
M+8_A1*U7%IVIP$PP-B57NP+$/0#/)51A(U(>%5G95J+MQ_2+:*A*W!,;H608
M4-RD),N$>9Y- H7?JQ'I^T)B^K?=LG<4;.6N$JLC8)N ^F%B^C=BJ%& ]S;B
MW5M,OPHTBJ@$\3&6-D<N$*_1EQ$,80N@U)BCC^FO3_DF4MU?3']D/M,<*3'.
M>B(Y$\0Z7-:XMLQIZ] N:=:;_MG']&\D_V8Q_9L(KW:#@06J1?Z?\,('%HA6
MI9:ZA8RV@HPD:59*'&0>DM^(QX.TU*TDZF7L;2&G=M["VXP00W7B(A"GF2I3
M0B@\X6*3J7-"&A%#LVBK0[UO[5*VE9QJQT<M9G?Y1[?7@X42A>RX2<*1[$M?
MBJP3+BH\$AXH3RDJ8 WO^98^_E@(W$5JM2.8?O-]_PG2F]O)2733G,6=0$^+
MM@@7B64QEGJI%O&!"*99*_E'CW[Y&]Y.PJJ]:GX<=K_Z<;FX10V=UKR?@V*>
M"G2WH,P/]0D=:Q*,R"0KQG!=CRRG9LT#5HWPXHFL(KJ]%*.YK=\5(.GHE2<N
MY%)FV!MB=8I$)?2Q'0\Q-',^CK@NXC9G#[5%7W&!;E*^JPFT_ZZ+N"&%&U2_
MVT;^>ZZ+*)SFD69+E'2,2,HB05A @"H1F4HY-DMP?,ZJL4-=Q+8T8Q.Q'Z N
MHO>9)85X># 9+9>4B6<4_3V7)#7!R\!JUVE^4741-Z)OP[J(F\C^$'41N3;!
M.9 $I,1]5*,!9#5%=T=PA!>44+11&,*QUT6L;&]L3T+%Q(/&I;J:X/OONHA;
M,[III;MMZ#A$742EF,E,"I*=XKCV!48\+=6!2K]A&X7FMOVUY27416Q56S9A
M86]U$6G4R9=>?]9K2:2CB5@#@7#%L\A9>%:]5<9+J8NX$5^-ZB)N(NQGDMN/
M6RMG4GO"-.#4@]3$*^M)L#K+D*A@U4W6X\CMWR7HMFVB]EU.)+L@+<V"&$I#
M*6=ET7I#QR\9R:.)S%%HW1M^WN5$=M&6:J)?N>GL,V_D),;!Y";7O)C\+:6,
MK!ZH_6R1AI.LE"BR&.W#8 PE1O#]P/?O#'VKA2HIG6U _SL9]+\!/'') C$.
M#-@<P8O:=F)3;#M;/_$SI$D/SO.]$:?#X;#ONGW?C[BDW@X]K\27<W+&ET.J
MB,NJ#.7F5U'"N:.X:2O;0E._[:#N*]VD%6UZ9#_M@:[GD)&R)-A+><8LSY*D
M6(S-F#F*#1(12GM%G7,,0A.->S&AK7OA>GW4ZR8RWU_D8P-0/TS4ZT8,-0N!
MW$*\>^.>"Y]U=IHX8.@I@H[$)N;1%46=5U8K%AIM.\^+\\VB7NM3OHE4VXIZ
M700]&(9F*N-$2)R2=!;M<BK+48 (Y:(C:]&L0LRA0B0K2GI-A.0F8JH>U/HH
M\@C-%FFE<X27HQLIDB->@R+!49&HFI;C?MEA6MOSMI.P6@YNU2IZ+[PCK-1;
ME=%+$GR2)!JE5%296RLV>-F.A[3MQ50[MG5E=%B(/%N(GB@%I=BNS\0I&@C$
MG(RVH+1N5JGMN0?6;<UB%=&U$$+U^)#CU^%@-.H8RX)V2I=Z6Q[5C..:#A&U
MCH601++*VMI'RBN@[/\@<"_.<PW!MW!$?-+K#?XL98_>#5#G)V&<)[W'4-],
MAD-TJCLIF.!\:1_E2GA]*"%"H80(!6 N:!Y=I+6U9!. QZH[K9'4PI7F8V ?
M8+S )CBE$1T&0D,Y4L?UCH00@0C!;3#1TQ!KQ^ZNPW.L^E*+@I4&1>W+AW<G
M9Q=_/WG_^^EOIR>7OU_@'Q^N+G>X8UC[O#I7"<TA5[HQ>.>[P[_[W@1>^UY9
M#"X_ XQ_+:"Z_4_S SG?FY:2GI90]%_*O$:W*B6SD;R$UPD>5>E9A N#CYDP
M&9Q@)N/F4[LO^*Z8=UV,;L?_O@S![,Q2,BXEBXE$:LNJ&6F)7F/$2RZ-!TN#
MJ5V2JPFN?=T=[%6O'BY5U0DZ] 7"DHG=?/Q;%X:([//W]_ 5>K/@)BDD58*6
MXA]H_BD(Z&!(2IA+SDE%J?6UVS0T0W:HBX?Z"K%:XVH1TX(5=0/M-_"CR7"J
MFZ/'>!=N:@.P+86@;@3T,/&H;3"^2JE:H^O@.A8MDU*DA'C+]9X'@W:C=80'
M&3V+D0M;^]+]&>C6$\&KSTZU-F&I394ZZW^9C$=3"?#YR9>SFD;M' F<H>.1
MA2+>\ (M&J,2#0%:,S\?P]F_Z]<BD:M49D<6*I<,>X-6XZ#73:7>]FE_/*VQ
M/'T],DZ&6N9)=#(3W-CQ]<B&DRP8B-+6#62-:I^KQC\Z4Z>:L"L7$UN&::[N
M35!5C*M8C63_@15UF'J"^AW$7#F^8@TZ$U)VV0CB8L2UB7-#?.:!@--@O6#"
MY$8[Q#,C?TV$Q3ZYWT2ZE3F_G(11-W7]$-'<I'ZZP(!+0CDKFQPN;E9;BCM2
M*1:"\U.T1K?9QR/O]VJQ%A^#:L)LX1+IK/\51N.I/7/23V_\Z',G6XN38$"$
MD>42PE$2G*=$ R2ME/*:U3;V'J,XH(UWB+.T'6EH03$6'33>#*Z_X&HX38;X
MB((I.3+C40=7-8B: PG4E[1ASXEC21-!/<N OE+0M:\3UR/ZP12F(CU[2U.Y
MO"K)&Q=O7Y^>7)Q>['!%M/Q!=>Z&&H"L="ET.3NMOH O@^$85>:LGP?#:S]'
M/=>1)",+*DOT^03@]N T"5H@FS0Q71IKF>@KOV=-<-5+'UDSVNOO\V_.W2D:
MN:6\N%/1$FF<))YI](9QP]7H5M.0:]_U; %S7U<_U;5G=<I(.Q0=^K8G0;?S
M'C[YWM2V^SXK#.Q\#E)(XE*BI2@BQ4\X'9MS8-*D8.4ZTV<$\9=/@Z^O\-$S
M[<(/MTJU9,##IXBTQ.V@CHPK^C(%R@S%37&<IW$T.+9XFO.[H^[WB&)G\0\J
MRJY-+JT+'*TIAZZ3YFCN6%SB1((2F,<!K!*4KK-&GP.'*TX:6J-P$Y'5#B='
MF[B?_#"]!C^$X=_ ]\:?2]STQ>G9U5D_+CSCC/8OIXY $F@>*X4.4,1/"(T9
MRR,$WZP0;Z/A]N<_[$;%H%4YME(E Y5W5+R@C\,![E&WYV3!6#;--TP1'=QH
M@%A 7-S9R+04$3]4MN=683GV?;@J%RW4C%V&:W'LW0!92_$1JU$=)ABB#GL-
M5&('T;=P,;T&(43%4_:>.,7P71"FO L(F'(9:0)GV5I[_24HQ1-1#/O6B4TD
MWH(N_./SH-?[?OYG'](MM,7UN 05=6*XS^%ON*'J4E\*MU$>;6"LF$6NLC*L
M@;/_\\A:K W:$7GM=-+S+Z7]-VZ5=RQC-'YSMLH0EEGIZAS01K9H3D$(5@&(
M*&AH9#(N>?BQVPA5A%J[M<,#/'-U;H)HN4W0C.Y#;/)UQ+^&RQUD5]O_6XZ,
M<JV$R+@J"5>J DI.O%">9&YREKA2Q= LA7^/;*[8G?=%YB8BJTWBU>?N,'WT
M=[>#K+-B/#JB$121'#P)1G$2.95&1ATT;=9O[/&S]]PWIX*X!_5D57OKO('S
M?3;/P7"!2@GFHD,LR616"@'AABZB)Y8+0:-$@[)A\Z.50QP)D3M)K@7#^/5D
MU.W#:'02_S7ICF82+0N.CQP5BB;"I2WM9;PF#N$0ZZ@$74JONMKWARN@'+O]
M5).)%FJA+X-5/@YAT2V@"<"63EJ>!'>8 Y<J5#90C]UYV-.*<A^H!5POI4I$
M:ZN(=-(3G_ WFRF(A-L8OCW'H2A/',(<1D\V$7]U"W[I<8!P.GIC G&"1=Q6
M!24V<H6P# 6)OT)NUJ?TF9RH5.9@4%6 ;504*<%C#Y78\AP%Q$"8SZ*TDU/$
M(3+"P>&?41G:K#7\)G4?EN#X4<R'G3EXK!>JMEXLE+\!JI8,AN6(#F,E[,[8
M$RJP@[C;*!*S')T'ZKQBGAB7.>I\%+C7H3ND ^00*:Z//KU@)7C" MB7#FPB
MY39ZGD#)7#C/9_W4_=I-$]_K?3^[QC40O^Y[#S$O=C7 K1 \0@VAM#BU"2V@
MY-#EIC1IRBEUJO8.LA70 Y04JL#RP[#-UBFJ?1HU;R3]83)$:^O3_,#F%IH(
M C$I3Z0.OMQ=141E+4GX6TZ,.RZ;=5)?/\Z+)K^V'&N["^_!C^!D./3]3]/@
MW=D-=43=4K0DQG%*9%&W(*Q!Q>,X7R>3YLW.^Y<]_=C-Q3IB?<RSKLKS(I"D
M :2-[NN6CW. "[O=&5C'YP[B:_L-7@06^)2#H)8H'DI%NK*#"+1S&!@PZ,N"
MR\TJ >^3T767=GLA=!.IM1M[^YL?H6$PA;G8)Y)@F29AB#<E9P2X*Z<9DF0?
M8Z L4I9DL_WVB9'V?!-4@XO5P;<["K)RN8Z+,LG9$23326BJ"8!*1#+4WVFS
M/"5*+7%?"I74R,N_&?#8]]WMI?N88K,SQ8L([P8P*E;@N#/T_DMN;"G\A_3M
M(+G*!1;NPD%OJ]0LCT2DLAB)G-!&#X'$')A+4@5):[0I:9W -64SZO*WB< J
M\_8;2NIZ<CT'8G%5MY'A$A_15Y-EG7>"":*,E(PRSWBH40?IWJ#[+8>QM=@'
M-616>8/\S7^[ X0)13.+C#!?PD%2H,1I],"]U"H%PTURC0ZHGFP1]NU%D[>U
MS"J_>1^'@S2)X_/A)0R_=N-L->%*F90" K 6E<F(2!R7AN!6KD1F@K-F!2F>
MX'#9V#^"S;.SS!_K@*V@ Z5:RAS1(M:]":B*QM!*(/LWC7;GZ#'AE03<S@JP
M!)QR.D21IT%]&9TNQ]#ITJ*XZB'FA/Z<K+@,[(OU-?;4GDC?1*[5NT]->V&5
M-6P.ZFHP]KWY/L0U]53[3&(4.%5O(@FETB)5#/WK[$ ^W+O7]A!;/LI^-^M*
M+#QN)U9!A"U$G3S"]MJ/;OPSYY*U.&&!?Q 9P>%VE2@!GB.73@JDL?+5X1HX
M>SZQJD?:H!V)MW##_ C:V;09>_?K35,U#U%E:X@&[TH72TU<RIQ8Z:FS3 CY
M\#JPOD8\P'2T:K&+[%O($G\SA-0=O_.QVUODT^C@HRP]V"@K_2Q]MB0DKHFP
MS"MNK*6L=N^SQRB.W?ZO)/_'&N'J:L1\DVR"J:6PM&5X#A.4MBM7:ZG?0= M
M;!E+L2GC*7B@1.#"A-A"(DZEC'_%;S@6%83:,4?[(_^)8+1]<+^)?%NI"?%U
MT/N**]U]<#>M<H.F-DC"4U9H*RM+/#!-N/71>FJYJ1ZRO!;0_F.+=N?L44F(
M6@)OP8-XW^WC)KA$[15%2Y8*2XQ3:+!8"L4:<FB_"*Z9 LMM[?H@J[#\*$9"
M%2Z6K!BM*,G[4L=UT3"X"<"6[(:GL!W&AJA#90/]V)F&%G:8)W%ZG:F)D1$#
M)A,I:296*$4 #-?*9UQ.:SNBAU&3)ZR-PVC))M*O7OE@..F.QJ]]_X_%C1I7
M(7)G2):LY/DE@]M?],2!#8+) %HU"YEZ^.3]&PYU!3^H);46C(:_^V&W['87
M?CP[-#>05.(J$\4A$LD,)\&6Y$V54RF99!3+E5_HAQA^%"-A)]DO>9UW7NWO
M EKT^&@ J25SX#&:PQ@ N]&TAO,=1-S"5K\$&;I#)GC-B<JF).+*0 )'I]E0
MX#Q"-E[6/E?<%^E/;.=M<[Z)9-NH:N!'4S2+/2AQ:H7-A'J!>Y#@DMA@T7MU
M(1C(2NM<O83!/03[W^%WY>1AG8+M!5H]D0SB! V7\Z\P['<_?1[/>[#T/Q5\
ME^?O+N88 TAE%5JBU*E2>BE0XH/Q1#DGG0U>*=_LRKCA@"^6X]:DVL*+79K?
M?/#7\S7+NVB\]4287(X[K2:V9+U%:QTHJ6GFM;L3W1W_1S'CMI;Y$OYWOAU<
M@%G8%@W@M&2^W4=R&--M>VI6<+R#6%M\V^>HRN4SD\4\":4,"\.UQPJA<.LI
MX3(65SQ7^RQF'R0_8:JUQ?$FTFPW/>WT7Y/N^'N!M\BI8D;A\(8$9@#-"URR
MK.&,).TH#<)3$W6SK7OM./O?L7>A8'56VD[R:Z/ T)\([0I_>)8 XJF,#!11
M%DK?"QIPZV&B9(%8@::#3:)V;<)[ 'Z4;7I[J2]YN[>NYWPS^\^HF<5KN->[
M\$YBY@BG?O,S'_WW:1INF<+M//KIP?O29%(M[?9MS.= A8RVUY.'14B>"\=M
MU,!I8VZ21R=*7GG*0-$[BZDT%!8D*B., MP);.W>!2]';Y^JO?2\U783:EN)
ME!F-A]TXAG0Y'L3%W4MD/N"O1)RG*"4T,-"TX!E-1BJY=%HPJ-U+<RF0_1M:
MA^?X463-K@2U8*A]F!04YWE93Y%.IEKCC#,)@I>+71=(D!1M$0:<XB=#36UO
M:QV> ^A0V[U7JXF_]A'K MAM=:D.Y*PY,YIH*S61$6U@%Q".< R76^ AY&:G
MJ8^??43,UI!>;5][ ><2^MW!\'WWZ[VR8641Q"_,%>_[/[KCS_<KC,W# XI*
M"ESQ JYQ!!43O1,74#DUE(Z4+$2@N&11MI$.[ SI6%5GOUQ53.*X-XL[O<IF
M]9131P/-H91.%DHG(H66Q.GL26*"&\Z",P^[>S^A0H_'.%:=V%&:%7LVW9CD
M#TH;OD$=[::YMEZAJ37*,"PX%;<NVJ!)%%82R7RY*2REK\$8P;0%U-;:1T -
ML1V1MK1*2\5>%?>T^F&]KI+$(")NBIR 56@3>UD:V3I%N.>>&L=%EK#1$O%H
MB"/BO*(L6Z@H_AY0%>&F.<\4WQ4,K\\SZN1XZ..X^%0VYN*^2S8]\53$"MRQ
MDDC,*V5X5M7C:Y]$=40*TA(5]4N*%G@%%8*[J\+W$8]N7:8^_.E[90:CCLL9
MC6M.B>(E7S[GL@WB7@A4*&-UX$DW\TUV07%$.K-?1BI6S%NG['?P=;SR@K.R
M#B84!>H]D$!9)CRC)R8I QOVL>C<@71$VM,&"17+"JV#][8[BH,)"L6/H2,<
MC5D*01QWC$@J<._4DA&6(X 7@4<->U"2NYA^$"W9FH86<L_O(YO^=M:/@VOH
M!)P6&LI #'A:;"M'G%>4:*25.@I9QMKZL1+,$2I&'<'73#&<;HN+PY?;*AKO
M #[",,X^G>=IF8X+^ K]"8PZX'-R*J(1%06Z6%H:8ITO81X.72RC<3]L=MZQ
MV;A'I ]M2[UFGDDSK.\F_31ZAQ*\<T"<DD/;6W-":>G= )819XTB*MLL6##6
MYF8=6;<9_8?3EET9:".P]1[8TV_ESA(ZP'CB F>OK%2HR!8W/Z\D43I 8M09
M<(TJ!6^PQRS#<40*4DW<;01-O84P/NN/QL-) ?8:7:_1Y9<A^'3>OQOKSSHF
M)2N\=X0RX<H6",3'[-&4YCJ%5$+%:B<N-<5VA+K2"BU+]&?G[K]/1CVL#7KX
M.XR*^'"A[ X2ZR3/ \+F!""@#Q]-.1V6GAB;F0"<IS&U$V5KXC]"/3P8O4MT
M=>NSX5G\\K8S.44+;SR;PDD>PW ^J7+\M(BOF?[<Z'QX^@UW_.ZHQ-^6B)OS
M+[-]GB?GN6>&T,1#J5=0UOB,;VORR4KF$R3:R-(ZW!R.2+5?DC8L>0NV/O2^
M20@8#B+ S!@]&XTFOA]+88;!]?6@/P7:22X;?%45X9'B>ZI+JF5B0 )DJY2E
MX'+M9?A)4$>D@.T0L415=C[4WOHMF>OZK_B#X]%9?_:^_#H<C$:=F%BVH!6Q
M45,BF<W$2\L)%Y)I:P7+JG8&90O3.$)U/#392Q1XYQ/W[9?Y:7[3K04^.A]_
MAN'59]]?.MN.U1"\*7E4"E=VZ5E"TX9JPC6/%K*C3H;GHM4;SNV_57T_:K%$
M_W>^2EBUQ?2_EK N="(_HBY.(W-F&PY7H"R:)$3I7$IR>(%[3:2$J:BEB,*[
M6#M;9$.(1ZB-;9*T),YR?AGQ[Z\>2! G\\?T&].O%PE=0/ZI_/G[Q=F--/_\
M\\]?2OK,I_ZGX6#RY9<^C%]-I7G^\?3BY.KL_,/I/S^>?+C$#Y<?_+ <=7Z%
MMS#VW=[H/JA1]_I+[\FPJB:/?74+^_YTYL^^IP[U)@#?QJ5^6?IYQ\(QDQ&J
MT6AT)WSN5J]H H!2Q4Q[EX@,RI!@T0*,66KIF,O!U,YD78=GY_WX)D%UR2BC
MU]_O_&V6G2JTYTPJ02CGI1E44L1YM"*$T;A\QN0IK7WJN"G&BBN2[_56KT/5
M].31;M@F*<M2"WXJ DCCO\3> /?7O_Z,FRG<?G'0'^.;==J;;L2X3,R6WYW+
M,SV>VJP#KY=,R');E\J]'3= +/5HH4HMF,??*:OMCJR <OBD\3;H?UC4J0(-
M;13O6@)K%O&^2,1K K"E// GP1TFJ;L*E0W48W<>#J(P$80/F3D2%3 B3=;$
M9\L(9\R;I*6AT1Z'HCR117T8/=E$_-5+S=S+D+J]\+\I3^NH2 Z(EU(0"5$3
MRW0FD:6( E J\X9]T->.LW]/J3(K@W9$6CMS]8V__C(9W4!:(&+@(WJ$J-W4
MXR8)D3C%2E<U9546+$<6&Y&\]/%'Q>WN JS] I__V8=TF_RV:$RK0M 6,F&<
M.B*=L,0&3]'Y-@& &>-C:D3ITL<?%:6["[!V@NC=]-;;G-4YL Q&1>L#8;8$
M4>1DRSPM09>* @O4Z(=>YLJZG:M'.2J"JXFSA1S12Q@BEO-\UD^(+TW0J_Y^
M=GWMQ_AUWUOFY"STTV?M=5!$2:6(%""(Y5H1+Y3.QN?<0JV<+;$>BS+ME;.*
M":4)NIWW\,GW3OOC15N*;  "PQU+<!M**)\M_><=*9T3'8V:2;$NY7@$\9=/
M@Z^O\-$SS<$/MPJS9,"C/C#85< 5]X\"989BX8,VP-'@+.!IPN^.NE\G?V?Q
M#RK*KJ)Y]QA/ AM9:3CB0L1%"] <H0'Q<,V\,,#0+WWF'*[PO]NC< .1M5O%
M]6_@>^//$3]>G)Y=G?7C?%-P+#F76"(:@1+);3E:P#W)1)?Q.S9F%9K9<TV&
MV]]>O!L5JZNYUI!C"[7"+B=A!/^:0'\\C;J[J<2G/,[:<DJR**ZAL884QX*$
M%",:GL+QZF?V*Z <]19<DX8VS/S'L!:-WAH :ZMFZRI0ASFCKT+=T^JP@]S;
MJ*.Z$F#BG-*L@413XBEMP6; DR 9S2"4 RE>MD(\<1:_7WW81-SMZ\%\3[-1
M>B<@X=RH11.(*A)T%B0IKZ,7$;2H7:!T*9 #!#+5(6H]_5M(N8UR\ _J44V5
M/$;))&A#//5EEJ7L3*E3[_&74$F%:&J__<MP_! VP\X$5#RK685I<6S5 %5+
MUL)R1 >JT;XS8T^HP [B;F%S6(&.*QDI9$5$\.@@*T7+1:(C,1HN@+%@>>TX
M[GTJP5,%S_>D YM(><^7\UPQF8!+PK5,1$;/25 QD^1P^PJ.HBWT,B_G:U"Q
MP8W\)G*L?2-_I[CU9!@_EY)A<U12*R=L%$2)LJ4Q-$M\R(:@N8*&KJ-@:;.R
M;2N'>/G$UI%>[==V":I2GQ:^=@=W8@=NXD%DD(GRDF,9-)&.2>)=J34:N4BH
M?%I1ORW/JX<]2NXK2;GB?<QB\HLR@ MS]DZ58L5Y&5P2EIDB,B1>>E(R$IV1
M -&K&&N?$*Y&\RSN:M]7"16O)/*VF@<LJ5=-75"Z=(RUJE3NDB6"B&N*V%2R
MADN9XV9-!)Y#]>_J_-:48O5@K,6RXWMWHTY^1R&/.BH;XT&5<N0<)VLSD%!Z
MPV8+F4M%*23;B-YUHQP+P=4D63LXZRZP>V;E:T@X7V,"L\ZC%8D&I/1>D\!P
MYCDG7TJ\:E3!C3E^-,PQDKR;+"O>V3Q1,UQJSG-,@GBN+9%<<%QH5"1&\Z"!
M"R%5WFB1?@;UU]M=HW>386N5]1]T#[E3^;\DMUY][@[31S]K-F28D2(R0Y0&
M022UB7@5RI6#5"$PIJS=D//F@Q^=-K0D]Q;J\_\Z&*0_<5E:F!9O)\.;"E&X
M.GE489](B02>E8L(TJ(.@[.X*UD>'S;AW=EL7X?G"-2DNMAK5^%?J/!#3Q8-
MDE3ZTDH@0J(9(C6:)E;*0!S5RD9* X7-6C\]&N((^*THPQ:*XL]+9XRN!G.]
MN_4;9_5A6- \9]0W)D/)V\F>>)\,B2PGRYQRS-:^DGL*TQ$H12OB7UD/?P^%
M)!:'41^'W0@GO:GBE=.NJF4EGABDM2(3FTQN'R4G>&9:2J6)@U"R-Z(GP25/
MC.%:BARC=+6S()Y7R0EI!.H])=S84K-* W')&92$CCI+94)BE>?_(DM.;*(G
MNY><V("4YU)R8E$3O+3T'9_TI\6COLRJ2]T$7B6N@T//C*#_C?ZXH;@W\UQ6
M^VRRTNC+\=I9X@U@O9P0E4W4XG'9I:KTM!"DL!+BO=BMIR&V%+[2 -YA8EFJ
M4]M4=7;DY5 J%"R-OC1#,MX2*80D+AA)LA49H5(.;=1[/8SJ/!$!\RPT9P,Z
M6M"8][Z?YA>\4)+P#4Y2Y=(O2U&![F.FI'B5206K,J]M"MV.OG]'K#HY#QM/
M;2?9%N)C7T^ZO52:[/73XN/9]9?AX.OL,'D.,@GK642W4X=RI4MQFC9:043R
MZ#E2)HVJW6ZJ$;#CTXSZ?+2P,+R;#%'.DR$@RG?=;^73 IGC%B)'7X RCKX
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M'X%5UMM?**FOMU^70"S/#$VYTL.'XZ:NJ0#'101.+$/_.C/^]#YV+\T]>NC
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MA^?6<;V>9BIML"]M6$(9+_<AA<GG\>A_4[QB,MGD.:(J940B9P4.=TU0*9G
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M42,IXDJ1]*)-(:E-)!%SBK?,E%L[3']K=I-.'JVW?*+)> )OD9V OU>-[D[
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M/B/ZF]X0'_>;3B@%!H#X^+_TO]@%6>KIC&?LX@QG.,,9SG"&_]D BX'%9,7
MLN)2'&+2LA+BLF#PO[V'YR& />"!_SD!E@ <$ 8X@-MXS1-P ZSQ[=/_/BBY
M[#P\7&1%1>'N5RUAS@^MKUHY.XGZ6+J(BE\5$P7DH3XNEE:.UAX<#ZUM[>$*
M_#_KF_DY[&$*_$80+3$M%V5K._M;?F[6^G[:!E9^CE8R,'ZH(C6%O(^LCY.+
MD[6')8>/TR.XNZR/ M=OL\OB]=/;HER*\FXP&UF]FZI_C,"W%/Y<B[>W]U5O
MB:O.;K:BXC(R,J)B8%$P6 0_0L3=%^YAZ2,"=^?^8X*;UNY6;O8N'O;.<([3
MMN5#9T\/!2Y/3WN8K(VE#>0A# 81>6@I 1,1%X=9BEC"),1%8!(2,"F(N#38
M1OPAUQ_F859_L^[BZ?;H-]LP*U'K1]9.UG /=_QNB(MRB?Z?M8G?(H7_Y?;C
M?<2/D55VL[;TL+Z)%\73,(N(@47$I0S^#/-5*?%K\J+_-$Y>])\6^O]@MQ3E
M85:R5J=K<G;[W;R^M>M_+]J/[!7_B5K_[BC^_N\*W@(^_<C)R>5%_][XO^Z&
MZ!_9A]?^EJOX)SG^+^#,R)F1,R-G1LZ,G!DY,_+_EY&_^*XU'$]RO?%L%C<!
M* .DQ,0DQ$2D),0D9*2D9!2TE'B.0<% <X&*EHF!A9F)@>G2979^SLMLO&R7
MF+BN<O$*7!$2%F+A$)40%03S"PH)GDY"0$I&1D%.04])22_(RL0J^%\&[AU
M2P94$G 0$G !YV@)"&D)<*T "  (B E^PY\?" 3G"(F(24C)R"DH\0.J+@#G
M" @)SQ$1$A,3$>%[ _'] !$M,1VG^'62B[J6I%RN].#@N"PR[AOE+0QZ_1L\
M$@_=0L@I&"\Q,;/P\O$+7!&4A%R3DI:15;ZIHJIV2UU#W^"NH9&QB:D5S-K&
MUL[>P=W#T\O;Q]?OR=/0L/"(2&1\0F+2\Q?)+U.R<W+S\@L*BXK?5%16O:VN
MJ:U[_Z&U[6-[QZ?.@2^#0\,CHV/CTS.S<_,_%A:7EC>WMG=V]_8/#G^=^D4
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M?+#$5Q\CT3I^M9PI4$JO.I7]L2+-G&]9LF$!-#3-!:-1\(%;#W]4M4*0 ID
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M\@]#@?-$@&;?BR6;H**S#0 \>T%?H!22ZLDE^(N[$0C1ONF.F<OC3,MO)<%
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M:75>Q(KWR^:_ M>6)Y=/6AF=O1KWWW8N__TT%K) +UP0+@:20'(1_<Q0Z<,
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M@+YB@9YH_)C"/^\Z;?<GLZTO%JT"U)$4<9+ BJU?':VS2_^X#/B).FS62.(
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M^!6BU?0W0W>1XU$E?MR/2B('K2JP0(>;$"*43O9$>D(YZ=9#=$,*UGH H5B
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M*[!C#5]&GV1.Q$]^B)N=C>XMJZJ)&?NR:"I-LHRM98'6#CQES]86(R[$<D*
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MF,5("+,75H%?.W#_,0N4B./4@Q#SQJMD1M6O!\J^0I5)*\#[:E_[S8&3P.1
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M4DUE4BVGO/YNJTX@NS.J8$RS/W0:!(--:W>^;2F7OWI.=\2/!3K@LJ^>PX+
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M7?N\;8FC_A"*EP5ZM^<5/5@M?8)_&;(>1._KA@**^'T:S:G&7OM1"-'][(^
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M4!DX?*QXLM'#*Q3A^%'%V% VJ[3(WJ!J"7,?';4%RIB=AK&5C,%<W8QZTW$
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M+4=HD'.0:78!L-68)"9S3H?MJAZ4O#:9<=4U?.%ZK(L\2=^QY[IG3/06B*V
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M1A G%$_7\WJ(3Y[?.EG[M#B9'0&_F39&@! *>?MK.PP?0RO?Q1DN@AE+4#$
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MY^CU,_N0K__L']>;;HP,-@&'92#^W/)6^F7LCBHICUT@:&T:=N;>77E)F,Z
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M3O]]\?<F__G2DRQ,3"P<K*=8.?Z7!_T[@)?MI./)(J83%P$G>4\P\9Z@=P*
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M@??,@*%2_<)M,(.S64J4\R%XX*);!,@1<2((U99]:F0_,^<T:6%2?V36M-(
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M<!%[XU?Z0K2=;<2F">0-]<8P9& H"H&M0N MD*<-4MPQ-5_J%#N25,74NK>
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MEZ#XVZ)R2M&-Z.A6"0_0F<66S$Z1@WU!,_M>)P#R*ENR9.JOON&W"C_#X-?
MQ X:VRPC8UD9W!M;B/C&&D8'> (%@M1&;TX>"*-4Z #>]9>>UZN-9JUGI(.T
MVNUT+X8GR0G*-G]VG:VGW&= TDT0LL>!A.*AG'6B<50$XGNPR)XR/=QJ3^L)
MQ,D[10-NQ->XD)#@#,N@-]8.5[^U_1/GJ-G'?_70-!&-O[T=Q)BO-W0$_NZ4
M!ST!S4*Z@2P*.N>#LK5MR%V-D.S#1O*5>L_(>K4ZP9X0T^M9>DLB[X=OORZR
M.#Q67<,][2Z3E=6[MU[H-[J1,7?\M$\Y]IW]J$X!HPZ$PJ<<N!A-MI-I-*2F
M+H%2K$ 175SW?B9?\"J71OT1.SBIK9_I(VGVVX_;U(/":'%"+R+:9 Z@,X$T
M-BJA$&>ZK8PS:E**!M6^08\=F H8>4@V5%>Z7_(4#1.6" I)S\87N?#I:QFE
M?I?80I'D"RE\R!X0WBHG',Y$S7E++$C_[L#]"V;9V!-?BL,/S99KW72Z=5ZF
MDC/:BBOV4/I=LO7OA&]:GT0WT:=(RAT(+@I/ 4P+SQT#+707X4X]E96[_NUD
MA<WL+;ZNTT9K7V._:D=X*.-SE@Z_0V='B;K48AT1BGHF,04O%(-V5[#%GH:P
MT_B1@+7)@  X*]XXKPH2-&2=%NAJ%+UH/7(EMJ(Z8O[$%;:<-2A) O0O._!)
MHMBA-^@*2+OIM!".-;SU',6Z=6(+S@]S(UP:C\_!YWA:<8/-6EKJ(JVR1ZQ7
MS/E[F]Z>]PR_7SB.^#9$.2MJ1I); L8AJM.W@PE\'3C];M.$0(O9(%1GK9JY
M[8S[2VZ,XNS=T1$]M\@9C?;?OY53C6?C/7K:&80035(_[*$#JGJZH*$^%"MJ
M#6M"JR!\(&.BY2OE/-Y9YU1B^Y&BOV&&XTS$6CVBFLT^3L9@U-=I1ZGW)O#+
MO_DV?^Z\HO5CG1R=LA+('4]/3TYC7U]?&8/%A%NN :[?'P+X#+$G] J*W6?4
MLGQ*/87P-C8V-__8V]OU222>&Q-T"W \601(,06<GER,H@@:T3A%2^#C+\=W
MMV;)JJ10W-!B5GRW N1AG=/Y;.E44XM?9;G)>PS >J1'!/J#NX:4?TKIAQ-K
M_-^2G,;1PXJHPK+D55?KU-.U45H'4!<,C37 'X.W8E1@1>\&@L>J)36#X4\@
MWT AR0!:0V!-*)W.JY]HC(H<K[]JZW_J5E3ZIYD/?T!7BG+1' /*=J[06'\"
M7]-:XZ5II0VJZ4]"_9R>3E7QPWD:9R\#,QQ\?OP/O;,)^C:YU5$&GT+7F(:A
MW;8ON1BHEIF95/F?69DTC1;V=AFZ>?<>V;?M15X]2@HUC2:IY?V%BG#3Q?08
MT+,A0?<0*,Q"XFDV?[!%ZNABDNB'=\>&STN ==.FKBAHU(NZS)6Q-=6=725\
M&8W:ZE;P#IL-$N,P]<+D8G9G5^#9I,".8Z5P"LAI$<*U7F'M/N/RT2I-\+DB
M'YO$S1B1Q#9+ .NGDG>6(E\*G7+7TT6Z"Y]7V#+B8W=OGI=?T!'^6H06YLV_
M&)@+>:&_T:@;#-2!S],!?+2!PG4Z@&-_%IG].V[@OBP-8!##,QZF!IJ"V!RE
MU;5*D5;(.'VD*D@$LG/J^'>U604= #YSY&3:=AO9_LV35!A?=>0CS6O57;@#
M21-_D!BW2\K)=/ON1% 2BDTUR=(^&2N#2M=HCY7YQ)V^&-6%.$>1))S<7#@[
MQA'YC[WU#\/(959\(RU((CF;ZU46WG?)+1RNO ::L>%?,/Y]60?SY=[2SSHH
MA)A$?#+9RGV3=*U&2W1)B9?$VFE%D\67YQ/KT@;>^:]U-'Y;ZWMYQG-?D6V)
MTA%.X$@U&NLP)/_:!.[>J=JI3;?5!A>FK_@_-U]^V5&W@1SFD LE\1!6.S B
M^TPJ)[S\/2V!,S=\H$VS/^]3?TL36,.FLHGHTA=;/2R9CS_'M1N;?!P?A4PD
M/!L=UQ8F5G\=11F;<*]'\)O9?WGS/^@T_L]$X*B!@4XX1GW.RYG>;?.E,6K'
MR>;;3H2>&'D0KFA<X=+1OO:-AW2 9:G.<N=&T$YRRIQ00E3.AY5'SPI9Y(W=
M<M?'6V."T23-\_5S+N>YQ2:*]B%Q6\AL-+8!C;?Z0XA[. 9R DV7=$[C4R/:
MHKI;+U9D)G@LBF9JO/>OU0-J<E_R>;.GZ$SI8#283*H#5ZU;KSV*W057KJ7?
M1:.4]WYZJ]6"SFR,O42W!3!Z+O#'%_^%' )OHRA\H\39=.(38"U+7?NC5?S5
M7XF54.Q$F8C_-V$I['?)/VH1+$/]29]2KG!KH8DAU.Q61?@86F ?$YK#1)&9
M&8JN,9.PF7F5J_% \NF(P:YD?%'LU_SEZ*U3A@#:*&T <]X/&LEP!\()&$:[
MSCNP"(T#\=1 .#;5 ED/S7L5"O)L(\7Z#5IO$AL\CN*(OM0<_QS2)7 ;@\]7
M$;,)02E<(1WI@4!NFK##_2:7;-LH/:&*L$E9A7??XV$5][1U7Y7!1=NZ_=Q,
MS(D!+>""I:>7$V?\3?H.QX'Z8)F.8HMWMK]K5I=WBMT++;>:A\) 'JCILTL]
M6[8$D=E%\#;GHH9?@NL? Z1%32C&+')=LB;%T!',PWF-2G*VX^/I'V4^N^)/
MOL"(KB#UK98FV1/1YJ'#3>$BM!QTBC#3 :>V40?$ZK?.E3:S"QZ5[Y/1X3_:
M).2O/_B=>+,LP8G&GHH_7/).)I@N@A/_[J@[UF]K8>TX%MO^BS(Q,Y XQ_JF
M^K3YV';O8>D GXLX<TGFRZSFL\06-TAXA<#5AWF1\-_.2Z)?9MVE=I9$%;8#
MG1?"+7]\'6S1U2475Z,"0^0V1BH/ L @@<UU(!#1IJRC0 )V0 #-C(+&OAJY
MDT,,OU(8^=B](,)O\MT,LY!)[VO0J$2O\=3,%&L\51B/7(1L/23_?;QX!29
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MWI2%Y<_KEZP/(]HX9'+1][6?_]LMU#S[T^;)-#?W,[E'1##%\!S+0R;)E)<
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M[!M97P^++AO5:JI[LCVV#\@@ZV.'VI388>=^@:K\#)K)T^]>H2U2 2D!^W2
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M=OB/\0'"99_N/VD2_#/K D5_]^C^J[CTF+'W(O4QCLWUIX6C]B,.P\4!LDY
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M5KUK<2:C%T@0I3F_R'QH.@55W04=+TQ6GN4_\I\)Q0ZX#4=U  -*J"=PC0^
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MB]_]^DIUF>0G__Q)M^09E5X;$"A,9U-L"<]0,"41:H M<G9R3VFP0GK6"9[
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MX$C4!H&O7?&X4+W[I=B.+*_"N>R,MPL/@C&O6:6[H "(%'O0X\3:RI&\B(1
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M9*T2IGI.ZJ1"E9Q/JII- #6!S9=R#$/UH<^R&G%WU8_"C^.QQR,O\L==7Q2
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MK[5_0*:>!RR>\U#P?.^=\I8R)XHB+F_7U!<$\M*ZIA,V;,T0%G"QO;Q>3/N
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MWU]WE8?C&.9,*X@PXNR"Y$@Y8TG5=2DOZ)A)W$&I!$:O,XYH.EB+\UD=;^^
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M.YG='AX*A\-+K)4>_N/4J1!GSG6QM7XZ8Q5*A1$ ]1ZFJ+<=8$P5H#L!>$;
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M$7*W.L[Z3_ZJ('A!@9-F3%$&79/FR#9@9>]54^!%ZCK7UX6':O>K7[$)._Z
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M"R+VSX&%3 H@#K[K_J>R)K[)*#)+0 ^/MNM"HBV#9\4XX8.95)K#M,&$V=_
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M^XM,$%6>*HH3/.<=BS<CUUA75W;Y7^TPAEQ C$"/8 F-6&Z$(>S-  &[/D)
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M%_0;:O'LUE#("P.-J.64;5O+K3665VSPWH^5M%,?\JCO3H3L@[2BD>;I*YB
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M2&(5$D2-[>J4PE;MI:8JU 7L@\XUG.F9]NAWV<)$'2_.I3&5HGH%PR2L)5U
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MN9L4<B_F7701/JND0NX2YL!\PH8M3%<0P5\@@"IZO6511 (QF'\O,FMGX<A
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M/?L@'G,^(*D+[W+DQQ&SJ>8SJ05.?\/;?52/;IB.K\B EIX88V91TT9?YKD
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MT7A_K3$Q1]$;KO3[C1Q,W=A/\//IS*N?DT&/A REV6+Q@OL@.&R*18A081\
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M=FCYM9'X#9H)194GPJFTDZVW/!%W%D=8WIC&,H]#P@U.,\*:>4M71^FNO67
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M$"R)? ZP@.)P'*NH$?T8(V.U61 90#-:1IT<:N8GX]O2>JGY7RBG:A-$9Z/
MCZMDE2[(%S@G!)QYK4;WIK%T9YL&'4+C^(NO*NA9"RD"PHAN'0EH8EH#$3MM
MUBT<J$']E+$87:YTUHLG\U>9E,="5:AU<Z+,T5>%1M7(WUKK+8)LN]LL%3,"
M"! '.PZRKOD4%0*T]KES/^FJ+RG.G5HXKG\P04-U+6LG@90;"2DO+9F;TFH\
MZ58/U,I//;XH^T_XOZ:[_RL/^_S&E.Y5.#_2AR*4;)YKO_6\-?Q6+NS/GR^Q
M.^#ID@Y9*!!2 .1J4R0+"M]ED4J3M629NR_H)1TE>R)G.DN=S*YB=^ZB2DR
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MY'"G$0Z^,UEFA_JM_]V(UO])8?<646^'?\\P&)$3JZVNC>G6./O5WEOL^)F
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MXO45+-L%=::\3]3&!FO7R6WYR[JL(D2.TI(?@IS 3%;0VL[@8GZEE-71R4N
M_6?DI8SVO>WFPF@\<@!W\6Z(F_X2X4:#:M?&/-L\%I!RI FE4.T80Q#2(\QY
MI#; 0G!E-3@*^NR8%1G5DIW0JJ,$)B>.!#=>!LM^L,*HXZ^]M*^]F,)ZD77:
M#CC**&$]PH3Z-*8AQW9AH]"D1Z4A,!9O=\$5>#JN$QP%X=6XF7\WX"QQOG9@
M?6=-P#;NY\+YQ&L?K&0S$CBW:^$8=*LL^BB3R /L9 4EFIZ#G4L_CZOI;C\$
M135?(I6VMQ8CQ>C9E3 .<[GW'V)S W.KJXTNXQ_,=@GHU^D]33'/.VX[BIVK
MQ) ,(),8REMZ =:Q?W*-8@B8D[8)]]-(#K.$KKVYF@Z#,M<\ZX[U+VJV\$<<
M+9SL+UR5*0NRP7P"S+FIAP,DNHG]5#7FX)EI2:%PAZ J<#LN3/3< $.<)A]O
M&-(.XW03D/5R:7V5[^_SJF6@Q,=R?,D\G&_)1^;=Q"=P,G9N&,N%FM3BBR!@
MNO9ASB(GV^?R0U%7UHK)\)8MOX=24.^^6YJ2+YO>K/7BW**6V*X7@N[(-J"<
M%^R9GXK*F,95^K9B(R$UDB'8N<)#$ >*<]K/Q:0Q";^YWE3@!S$:AFIHYUM^
M^W&>0'GIJ+?XT-C'3N^R2/.M[]WC,)(>%KB"IO&Q,3A6J08T0_H'I"4>'2[(
M7,2=9)DNB]F:$N#[WZ2/WG.UY>E"SUWQ<&/>BJ 4!W,Q[P>)ZYXIDGTP>S0@
MT4_C8ZYX#M]L((." %BHEU%]$-%&-D^"RT>#UJR;0-2:>X'97>5.GIFN5NOD
MXZ=L#:>L<2]B<J6#45E']S%@+A-'\ICCNOAXHC<:_\,K&B<(.,E7&2I/O&]W
M#Q2./]'389:Z15O)E:I-JBS1TQAK0Y >XXY$)[E)Z'EX?&D1<R;5H2O&UO?R
MG)3#M_'Y;;VQ7 ;#2L7.YZK@1D36KP6I$WG)ZN&1=O$G7G(0L'I8!PPW[5]2
M1 N8#7"9UXK'B\ Z1U&0:B-><[^3 W,#-LWCI];LA8/56X2K9UJ$/5RV+#MA
M)%TH(*7;5CJU34D"4D@8"AI@(2/:<96F=4I+T61)PD(78;OE@9%<;^6K*477
M2UNI"Q?OU<A$&SPTO_6^Y:1C!PR0[R9V$F" \MYMYM>+ J =D[H1*#E+FFY$
MN^!LE>,G2T-7OX3I'\4*4U;B"5V#=RY/@UJ"%I6/\=D O4?"H\RGUAEMV$JV
M=1Q5CS&&$6@67H-P89]#+TRL3L:W0;@ 'U"60'6]GX"-95>P5:^ZMH>5WO*/
M<#-S,W77*Y88X&(_<1U+<N<Y<EQOY_OI,:Y(=@X1)$(89Z_)9G7WBT-@#JPI
M^]7S^0+]?#NE-+XQ!H<_U9@Q@3F%M0>ST_AJ2+0:-!LM,-<9I:">6DKQ,G#Q
MDQO4#4W6<CMEV,6B)AP \B\E6E)?,C^L"=H5#,A&1&/GWD-(_\;'H_@!W6S:
M11)2L#]6P[8$>#;UV/7^TCVB^);/M+;R,#C0G?W>B-">9\--[H(G08>@DW_T
MR+-&@#3B2 Z(&W8R$M*A2#Z=FJ5P" I]43:$>V#99^B0B'LE>]GA1++H/T_9
MV5XS+4T5$X31#,X"*I-[MCY!/F(.VRUF;Q^-(Y7)C]%\-,G3T?-H#MI=;.JL
MD,!#&;.8<;W+CC$9,OXANE=(2W973<(#8<!EQ%$B_U7Z6_0+Q.1M)CI4(3WQ
M"%X<S29)=QC>H74A.=<W/7RM,'JN>O%<^SF/Z?WG]TZ,L+I:$4$B<!I_-(/3
MGGJ+T3X);MV<Z*4H#BKZ:UUC_$&IBPJ0' H([!I3AK(<KD_]?SE*;_F/C7YM
M:+]X>MVD.@RF^1=;#:>=9V5P*#';?8:.:0:A6V]AG3<Y:7Z ._6V"XX4/_4W
M592M8L!M1TZO1*ZX5W+B<OS5Q-G):KM94;&K7$)7E78<:?R6# Y7\A"#\P0>
M&XH5AMDA1%8F^;L@P;/,40F-;\&1$BHD4O!.<E_\S$<L[=Y8RIB?*4_6LI1Q
M!3<AC=JQI/O]@ R<=BZ>0@>DJ/"C@Y#&FZ0&_'((S''FWIHH/PG1/G/?<F(W
MUK+OS:L;%7K2N0XNE@ZN@W;B+.<5[/Q!;#]AY;B60Q @C<H_!+$IHOZ(<I%T
MB75X.14"*F6.J'X(ZIZ]@6GQV9I8"V"Q9AFZ'S7<8<IQ_*RY[M)7TRLS<;0Z
MR8#>-AC)&/$60_+8(WK/00!)<*<[&\#:$9 6MD,F& D##0:6F^L?U>044R'V
M-78)XEEZC;G[\_:/%41/#R$>T9BF\8T_NM6$ 6)VP!.)8 [I-?KK2G 8XRII
MK!/'N8J"D%UKXI6D/KN>G;VZ,RXO?)>W:TM9<3Q/1P>]&U<,X33ZQNAF#@9L
M\O8<AL:O2SD28@KVFYVZ@XC \C9*VN8#IB[6\%^-B<^'[I\6CWB^U:*<&)/T
M&R[0#X*H,5K1)&O,9$,+LP;P9#O!ESA_.F$>&HDH[X[\'7KP!>/(ERRX.+T'
MMG4ZU^N6T 5JCDW)C>6]KO"QX;7#?L11^A J:A8&:N:B:= ;&H\D!9\!M\G.
MAZ".@+[,YIOT%"_,L7'SOL].:2P+U]N#SE -C,X2=6?1OF*Q72]#(:6'(,=2
MX.)8=Y O'DHD,]W-A%$O:[ ^/8]QJ;EBCANAAZ6Z6!99Q!+I>9T=VH^_FN=6
MR8GZGBE14%4*H\JBF#VWVIS8PQN%HNT"<>-@BMKH.DW,W35'F^S;\71:Z*/R
M63&]W)I84_\O/"#62F>SK_*Y&^+'^FGG8 S.2T>M/;KE5S8+87;D" ]4M23]
M+.]]!Z));KTF@^X:\$^3/\$12XEZ&_)*GF+MXN7JEI871L^?U?DW9,_^N\LN
M*\6<U-_-Q '4[]G3I'SB(S+8D.S>80V[%0Z^ *3I5IK)><LL7DCTFS?+YA0*
M>2T(INCJ ]0N!.D^=!)F<0@*B6@48S9#:JC8"P:8JD/;.) P_QO.[YOXO]S\
MT2;7/ O?6_%UO-#_*F2/_G]F0_AD?MYJ_4A,_9/2_'9O5P5B^BSAXLK\GY#6
M@I4O&='UT_>E]?N>^T$[H>-)VB._ZFO:Z/><AC++AMS&*T\%\=79T7S!GTHQ
MM%>DWF[T:2BJ<Q[*/6V^6";\JR$[B3YF58AB4]H;N?W5:1)5Z'" *K#E[FLL
MC'Q:^U9==4?:3XGR 2ZTY'?N\UOZNL9.XO[N/FX8R)QZ[=$8Z'WM$%2/22T[
M!+4$(--W8#>?EY9J!%(%D;)D2\WE""2=<[4.8KL_)SG<-:,5]1@>Y]=/40(:
M\(G;*ZF4^IGZ+<$>ZW*63:%YC+T<XI,]S3IA?O#)4*)U?OY\#0'E^_ZE3V!:
M-1VC$=B.:"?0P%>R2]:R!,G\X?+-[01-SJTV]_U%_Q<#9;0+IT:D#\Q^WXA*
MMA[8Y@U=_=FEW^?+]+F_OOMO#JM+5E#,IR,WFMOQ?9Q;#.;3CB\&K]'."<._
M^-TX:ACA6=+:2XN55.)/EPE??=U*IZR@]\4OYV]H8*&Q9#Y;"+QTIH$:1Q.%
MOU\Z6RV8G+=2N=^4UI=E:#G+!MC/8]_N89^1W,,WW-E?Z"F4C.<<@ORG.+&1
M?4&:<]#Q(;QCF !4X^[R6HU!_X'C3Y!6MM+:SK.V)HOV^T,[A8I#.PT77(L)
M5G=/-&KSL'TR;BF-_-7X3]O@?=6KGLU; T%3V!9J9D7[+Q/3_+BOG["IZEBL
M_58='LV%?F;(=>]YE7ODP?MAQPONZU,Z,L<P.B@!1LCS@Z@]S1L&0UZ6%RJ;
MQ(S"1R?YIKB;_J-ZUM>/!A"92^;--AF/ESN&/=:K#09<#S"YBW5:ULD/%]J&
MC#?VW$<V#WR8H]@X-,29D^_GV)ZN4XPN=;(XD5)%*11W+YC5=HZ4F[I\_+;,
MZS3I3U=_JK(>*S5^G'_U2Q(.K55/&WQ6;G/WW..8J]G-3*O[)L%OGL&I.0=Y
MG>YV=-&V!5"9@PD!#*-SVJ<+\Y"W&Y^_( P:-K6FVLGXNGRXT_OBDS_&>YJH
M^@-TP!E%>QS-X#)@KKD] ,K\*PA(4D^@QC#EB'7Z%V<,'_)V?E#.OZ3WS0W-
M(7<2MWOJF\#GR]2URZ^6?+2X8\.(6W8Y<1G[7$.[]#F#[X\[TH@@<NNF(<RP
M,O7OP89M:/B%X8:&P!/',7D@RVSL62AVK@E&,D?''8)8FB^C6_\]!-GV3T#P
MMQA]Z-.-VJ]<Z)AYCE)(AT536(,N)?K[L]H[UI&7&US_$9,8]F<\$CS@ZH*1
M+#"3$$K!&-H!&@HA&4*/^X'ODQ%$+M*>"3ELJ9AL[K:Q0S\FQ+YH_N*8N1YO
MW_7ZFMK@WH_?Q+B_;_: 4.D#B'08&#TW!P/TT'-Q#&YZ?55\J$\:Y +CTAJ_
MUAF29%LQQ\('I#8AMR%Q]"HQN2QM/??;_?UGQI:]L[\?8&<PY1_3B&*VU)L
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MQ^ZZ'K_W1$\DGO/;-SW-8"6?.G \EK49@AH\$A QHL)H9A6-=:3^&$7_RJ:
MT?:'Z;_-B?;6Y3I7PE+^*"3F'[?78[N8\ \D 4?2%I$\VAW^C&XU9L#0K:^T
MQ%>97+L-9E.@-]<?HKQ7ED Q>'6V4)UU3SRN^X=.]ZF#V-:U=+H(O;!9A28
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M2?;.(^1%6)!F:0;>CNJ>SWI6^?LN0QX!?#T>%1'<]*,XZ@2CLD.>^1TL O'
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M[MF>+MNSX\_"_*H_[V4SC_PY +WT F#,[OU^9I893!-Q>$J[.A5"?L =CU1
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MG/A;5YTU'].]HZTJ/^J]C[_CCTV_L,23U54'P2<=@,AVD)ELZBRC1 <<(ZO
MB*U$LB''<[EC2L<;DJ46N\]B1R)+^^6U7)RZ[YU,N">TF&!7GR_V0ME3BS,4
M!'9!=>JPHN( Q H+,2C>^#WM&G,X%Q*_'J(FU]LD>[PEKC<W1+=)<4,Z,B#6
MR]0[YX:7>F'G&8&P0UP7FBC+3%XH304YC&MHZH;-9!/1"0_UX;)T>VN$@D]
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M9^7Q^>>Y#%O&:TB QNP(M9GL0-E=7Z' 32F6!:U&7VI>5?46R<8;"!QSD#@
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M']B<#870X)@G2Z"(]+KZ9C6IOC)<V<1-;OQ()P;0Y:,VD3%TX7D$6QA1@Q>
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MY RK@9E.,C CBSA\-TKM$>0#'M:7->196(\YQSA6(6:M)3VV'N\Y<T?(K/_
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MK&3@=B6BU/RST+%+SR#0NT8$H_(#F=%F/_#E!'D@>RJF@1NEIK3:X&/]C#D
M0=4:X09YS_>Z6.%.ZO. CZDCTQ"WR,D?GP[$N]#K M-T=/8KWSF,N@Q]??MR
ME*+6W6Q+GY6'T @[3=V,4GN,YR@D)&WP]0)5S4JA)Z.@YD:9[;.DXIJ&"4.M
M\JXO  ^B"B?*Q878,5^&%CL!"@9L.4)>S-/(L!OTE80Z=<AS@BK*=%C\.WQ?
M:<O!ER.FRM/?"D >#X3U^<PN^HDJ&J.]'#G-)!&6-U,8.<M8ZH5Y:PJ85OU"
MW7FP!*'8C9MM1P^6CCM_U,_PYWDF=!]Q-[K!06;E\-2Z-'4X*B0 4(M9'&3J
MH6S9;V!^<&'@V"SE3W1 'LND3P\G2\!!7X;L"\T?-A?V"F[]=?5ZE>7?WI1[
M$M@<ZKZKVB=?V[IVZR3C=-VI.=D/<E**R_N=7<=&VW[2EJ60'DZ6,.\3)DVI
MUC:!0669SO59&7/A"-_Q-<1O:L HI 56J;^D3 4GD410QA3L:")'X@?Z\%U;
M[QNI/_2B*N*.&B<$E?ZS*6YZ^+1&W$_\GRO?%[V*FQA?V"_04B@?]@>4!-,4
M/6SCG7'C)2V/_"GF,V= .D/COKH/0:7I7B^Q]X<I\1TMZ?-Y,=U_)$E"4"X)
MX[M+UX^"D;_ :#>*)"B8Q72JO/KU:%UUK7WMU.@:Z[PNI=,3-\<GMR84!-W>
M? E\1QU?G'C=4\3Y":M06<32-CG"?+0\ABS@0:T_UD;.:\S^HHF+*_^B:(&0
M +J*E+%,G[G?BVK*FO+52OG)A3'\I[)"'.ZD&-R94SF4E#(N7AIUW<]]>2D\
M_&7Y %[SH9.QFMVIY"]&RC=R+>UF$L9J,C/QH85X7^9JC=69I,QV' Y6F;9D
M3+=@5+"S0^!Q)(DZ_9./(P4+ZW0HMOZWXR_T'?M17AHK7#Q@IY1\D#\L]/O$
MDRF[;2XSX7M CXGU8B=!>5@&["_0XW?1&L!FCH_KD;<MTJ/^E=Y?;HYYVTR4
M.K4%!OK\?..Q.JK7(UST_<CP;%'$,]L;DE_%[D?&V<>93SAIYO27U(36A$)U
M#++/G8UZ_6=Z(F?L1EBRY:?BQ<'%P49N$#9;V^5-^]^2>QJUY%$H $]9X:+U
M?>O/",-UE@47\^9"FQY[O(Q<=F.=R-;XB;2[H?($,:BR&,@\B91FG&:_1:DS
MS[*@B:[]3:-!N1.;J9(K*X=7JFHPC)R4]&^OR@YD1TMN<6DY/Y=6-<!V0*5E
M]18<81ZZ^J7FS7CH2]JRX?,ML_.J#U'5'#K_A$QP=.:#6[X;'")D*G-VX<U@
M9 Z[(WRK<P=4/C8TNU@GD!P!YZ67VQ-M T[L@!ACVP[J$E1X,X(?=10(+V)=
M!^*+FW+_0N7[\@9"$B^0*9I+'Q+:%7$WU;($5-Y/#TV@N52JH7\W%0:8LO0_
M81K.<:1]J^H&DT7=J)<J5H,E/]]BA(HF/3.UOC]__T*;@/51/#AZ=9^I^.R#
MKP?7;<)><1SPL>S1DTNY \RKH2=E-'3S.S]-!GS8LN0NV@%V&<J#B48/<=39
M.2S'V?,!^2YL7%/&33QNL4OMV(W1WVZ/+Z"Z3465DO7I]K%<''?O]JDJU'XI
MF4=B,U'B<2[)-TS_E*M9%9F>-:S\;&TB^>L?:Y.(W8*N0:[GO8 >('&1MY0&
M$;P>3%G9.^KRT&FV6=1SA- 6@*V7K*'YS_)P'#_L,7=9D;D%E[K]AAQ4J/3-
MH";NX%0M9JAHW<+^5U_*H?+Y$[;V][9F*0(-Q#@<A'#,FRA$$$&*V-*UGF\\
M9!7!S/K\$DHZPK,,KELG=S>K?=9H!EFB5[FS=@)&'N/2PE(,(Z M8"QNS)*.
M3YH:"<P#+NV!8C^T#\CND:E_%^'P4"VX_&9T,J&'.V0,]\]T,!XX0$6ZB0A<
M@O( 1N:%KO\44"&R/ODE/H]*]T$FS4"K5%Z/V_]\KK_OD H[/[SF=0A9D-3]
M\&NZR]RUD4[O+LS2MXA4?,%@]N+J>%SJH4%U9M]2+^:MF)WUA6./0=]!]_D"
M,1#87>Q37*ETTQ@N=@<DAPKT_C!W9@>DIKN4[I_;<$S&3=;;W8!R7>*Q^7=>
M+(Y(?D^DW=@!/=D!?7,I&GZ"TOV%K*5*IUY"*Y15L5LSF^]OEN"WB0A5#'+<
MZ]:M#:"2:<X9(!V&^2*>V[#,@:DI[PWG_NI[1:;MOGG-5JBWR)A.\0=SG6*I
M&B,JV$B4UD\@I4TRH?[PF4VF+6("[L&>S?-0G#%H:\ZLC'GX];>%77,H\]0.
M2,*9N%P47A8AS=T[^[C3U<IR8^.S-BGX1DH8F123+)5D"57]%E&0=W7B1TR4
M(L?AZ$BW3/MCT];KUHB!AU"+E&F9$Y13NJ^/U/J30C<#NG!=CA6!Z5YOVN):
M!X+?KI2X)(]H*3T@"A T !(9WB(*INZ FA+M"LN)8!_M20>KLWRO5Q-@L?(6
MBEJ7;]Q"ZK'ET)V0,L13F,_*8VX(72)[[QU="#V_?._GDZR..;1C$8F=\^+T
M;.)W_L.G\'^2B1>(Y,>D"B.<".&,*Z>#H#UXYJ_KV># #P_Q416#4_ :G>]K
M5)>80>IS<)WO&D[:P,[+$<*(%N0P][]=>\#ADJE*M/*<NC_Z"<5+H@YW;CO:
M&SU?:]&'\6!QI%<7T>U<"V!E8JY%__^!(M'[, T]B#(\2P,[RIT58FD6]G/
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MYB:/]!TOS;Q%?I><GQE.K=[F$%$86C^EIP4#-J=HQ4%!O2CS7$M.Y=7ALJH
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M7Y$9'6U.SR/^),..N7'#\/G*-5O7+Q3PF#T%2BP!BUT,__@33:^*Z8J']BC
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M3U*/C\H\N*<0F,%V__@8)@\C<QT5S0(\AG=B5\&\5L:DO^^ OE5&$KVQ@H
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M'3^J]YKMG,&"] (+WS[6,9O)W;0,E?;_LB0D@NN2>-_0UK-4=O5\6!K];MC
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M113+3O"4N,25S&:EKXT]?F^O[]P/_-'R\G;]L73S58<ER(^]FL'!M.]!Z4%
MCB$-6&%,?Z7B=0[67V=?#H8F_8,"SW04:1>94$!':P:W! $6<0><?LOY<$S[
M3D)7JWC*V1Y&,$ )\B,'LA I#1R,Z77!B='?H9JQ'7*%J[+@ZRKKE0RIB$V.
MAU4,I[I!_P,$R]H8?(GJPH1D\D@G[,S=Z5!H%T:(T4J"%F]I/?V@7V&O<JPG
M[_V4;PO+#_57BN5I:ZCC8#?3,&QU<:1!+ ((6YEXG, GTJ1U$&01CXRTLN7*
M^75<?R3I7?)@D#DE@4,_H.-EAIJZ)O_"QGY\1JIIL?]8YI:CXG6O@'!_'\4$
M&]\_>PZE51OCGQG(?ZL\4NJ;1M1S WZ+<M".(P QE:)YZ1)8T/5L50=/H+J2
M+[FGR-A9*X?%$:)BN:=VU<SNSD]3GD;--/^ WB?!83=B*4'D269X$V;@0-7J
MTS1OHM0'2M!B7Y#AD+6MBU%+*GI;;H*N*YU 7.!(<?2#-+\H3N!SWR'L3NZT
MM!18H,A_+4K'U2%SAC0F1SY?:IS-G3*0B<0U:",WI[1!!5^/ ,U3E"2]8-3F
M;:H@8PA5L1T+)@A3?A-W?M^/M3ZS>CB(W:ZFTOS>NYC5)%Z??+'&.EOJ8 UI
M>JH$LT.(JQ%''D74/(PS 6>!^;J>^FC([.1'AT<L-;H58>XQP?R?Z^W,+,@)
M8H59VI(FXORQ)V'.WV?=;7[DGTI$>;4XY5D+:$R0G$^0T*OY!):.4)&%[?8D
M3K@TD0AZ1AQ_XU9DJVCG97C!J@/D5R<]F@J)!1%O*TQ-,=08,]/(1+4;"BJ&
ME-#GAV,#RLLVVW3S3RY5;.?ZP>NS$UMI2!48(>>KOEO4P/F_A8)7D+$ATJO\
M2"J,$4=TN>RO/'T0/UXCF0\B]@2V/-]D9K0W3. 1":K^S]AK+YK1 P8 8R#L
M>Z8<M\]!\X&YCCT7_0_> >\MH(<2X#+]O5UBAN<7PJZ?QNJM+YE.-Q$^4I"D
MNXN,?KPSJLQY:_3U3FDJ=91V[K=8>!DBC<!P_OBPZ+@W,EBGQ7+.9<=EQ>'"
M\GW_U:4%#"C0(8F #)T8%'?2X[-<,UC^KQ5++,O83GR8L,*F-!/1-U)(1!!D
M\ANLE/P2>C)+KS?,I6Y$*Q-3T<^CNQ6&0=#3F(S5@-Y8XSV%9[!!2>RWFA,G
M".H):K)'@.B20.4, 1N_]-K7I)\75<FPO11P&:+=#5D9U>HI2$X;Q4('U=OD
M0)V<D-OV$@\FP-5;ANE#\*_2;Y_O/%X\%[GP&N/0G/.;)D>/P3J#PXX XEJ6
MU'MP-<I3KNPEB'",073-&VQ]ZJ:X1ZEJD^-+#A_O-/Z99^76NNC$TH[W6>_S
M$/[OOA@-0K<?^3XRFPDI!5_:TQG.X'WJ1FBX+O+.K4UW=6LTWDZT;OK'^J <
M<# I3%R"5!?ACZ-<P44SQ&;M;I=.4[(./M372!H?%YGS-[[(W5_9:1_.I3]+
M+C^Q@-\PI1HQQL#$>SA.&)*0T8Z<PMTE3F/)$1 >+[60..196[LNWV[' )_E
MRGSZGRFV:5XOP'0!HAY^B?X6Z<+\-SG*ZR5D% @H43VJ<WDMX3-L=<N[N#'I
M46Y>T+-GN7/<QG8_[E[\@E*,?P+0NKO+8'5B0NA>#,D#(YM*?NEO78X8NI3*
M$K-W;N->YH\[LAIG&J1_G;NI<4+44ON^<'=_SL79YV4:-=^72"9]J@=20U-_
M\K)4/F7P/<E_Z'O7+*A8\N QJL%$MZAA:>Q:[G15D,%WD"B<EX"-!A-M_D.#
M\O01P)/:(NLP5(T+KXWSA'[M!=T;"U#R]G>X)77L.8]=0<1I4+.2?H&XP-=_
M19XT(2(+X0A $RQ=,HW .EM5?VZ^X$;L]W'S_C@;XRFW=>]0Q5Z/^^0;\WH5
M^:X;#\(^ #X &Y#N.(ITST8&U6WR#QE;+=A>7V-4?5)I59 <-&(]:WO'YWW$
M6\WT^ 5XPEO@^>-^QD0@@VV="D(,X,]F+":U0L*O843&,SI Q*3L;.U;RVD;
M]_I49 M2E)L3)%UMG$_KSPR(^XU6BMKYG7KXT\<\M%C%.V^V=GG&:;T\2S0)
MW#8@[S^3E5JX<?#0+F-E904?M%K46$5:)WA'TZ"$;8IZTN))A[/U];%X,PHY
M/?AO^J]X:[7TO"ZKQ-CA IG0H"=$'T@1]ACF7Y<0)9T3-#GF5,02_O4O9W/Y
MNHH%EBM4:UO>4;Q45CI=]'[8H8EURN& EO86FXEUD][*VD.^@7Q3WT@C.B[(
M-U&58+P+]"\PP<Z)*OOU/-"H=[F"8V/6XQBA.#O#K6(/)<_I#K=X94)#N279
M[]^V"$;;$:"R+LE+YQ)<E'(QO?'[>)5-X7CA5WL\Z_G,N\8\4IWE'Y1Y"MY:
ME4AH2/)G_++:X%B]]O'&+25/_)R/Y[S.5AUV/T#/^3KY!.A,B>;;YF7)M)8]
MR;3";3<H,D0?8<<8.<1DDXH9;!FEM!<4%>IQN!#%C=BHC9C'=4S_&>V<ETUQ
MW4[A,>O4+7#N*/V::#O A5<T=]Q&5:=_#"U%C(")]STM'S6^W/+R-[EF&[/L
M49TXM/KF?>IHBM%@J!$+C9N%P9;+N57JCW3Q5I8S?\[I*!VC=L+;]7GW?ET2
MKE.NM4-!YC3?Y\46QT[(M_V-GD4T#TV%%-A$7"["4G2]14' (N&NZ81K&N-2
M>C*5KW5.*OE=]MO9S<G9'2+,_A@.$)4?4\L?F46I!#Z(-2I+RZUM&+*-4:ZY
M+..3F_IESX9*7+Z[Y>M9W-2(606A()51'9"IU'^M;?DER'7U](9J".?:_K1^
MJ:0.J(:44Q']83CEY>++I5U#5L>ZV%XV?0[W@U-^69O@A=DF,*O;-$M/ IBP
MUYI],WSQEL&G>Y6"0.<2Q3?AZG+OVW/R3$*-J'>0;;+8I][3^8O-$&&&&IP[
MSHPD,)E.)D^8-U8+AW4?[Y;G8>-WNG#3OM-+YJ.1#$#L"+!Q0)5$X""5U1A)
MY"L(UQ/B(JS*DC$\7E8F[^SJ #^K53_7?_,5STF?-S>Y  " )O&ZN +G^Y%2
M*2ZKN_DKEK]3<J<QN0J>^ /2TNZ&N+1<B3X7?"1!K7^S3Y!=VC-XFJJP\S?X
M\B=,]<&_)=<3D%:,V@1"'%8TTH41;=C9\I3L?;3_W"$^_D:)*(B$UJ<W@ID1
MB(.!1P+*$ KP*Y7QL G=&C]'@9LIJX(K&:9OCP ADM7/2?5D:S;T1?0M>B[B
MFCU-G 2#KHK]A9*M]C18;FA?,J,OXQ:5-9?$Y9VB>IZ25*OL:F9X#<SIE+WP
MK2SL_'A&PQY<*?=1ZU@Z+W-:^3Q";F%2(&C\3UIU0VU#94/*CYTY0I;@E:L/
M/UKHLYPRU H#GBNR_,-"X^\AGZ^.^DZO8/+,U6NYGSU2NP72C=,LX!ZC9[G.
M8&ZF@CIO[S;TTHX :+R&;8RBEGEJ!RAR^/"N]E.I9DCQ_35<R=_WLU+W!"Z,
M9/3MVY\ST^/_:W !O0 !4?"$I)BR9A?B;I?EX;52UZDZ[$BYS17!42=3F6#^
MZR=?Z/+O[V_\$]/^FL 87,!.X_2G80E:3_-G7B"G&^K,>IHZP9NH8-K:)XQC
M#.Q&%*4*N+%[YDJ?IUK!TJK"T+SVT$SX=R48V_R[ZLTA&K8(J<M@(TV$ZTA2
MW&>Z=0 DO<2*0H=+ZU"ZYK)3#%U_68O[9WBOUEE.]XD%7"MXVF_)>P.W"*$8
M_4.CZR;*&NKI'/ !X]8;QNQP=/=-#R^A&X9:$ZO _[C"<(H**6ECGINRQ"'.
M1N)XK]><_M"_J?@(X&RQ,HO:ZMM).OACU(54(B$CA(X P-UGBN!-/H&ZV/U%
M;(LXI@(;^"FT"-)YSL[^H^5L1AYNZ B 6@R%+"4=A\DNNKS9HO&2@.W!@77Y
M^)[E>;>LLD^F)P?^]"Z$KP$?O.0_0%,]D&V8PVME9"P(T7FX,VDG-@Q^73-3
M^<1OPK-L9#E?)T;IB=$1P"H_EGZCKCYL[61C3:9D[!V@:/(WF7Y]W9,!)X.*
M)]I?' 'X79H58LCOSY3+?G6HR/@:>%"J-O0!5^\BM7A7'"=F9%164/TN5 K;
M-Z=3@OJNT 6.0/(B6"G]OPG[7;CC:P[BXY[ [6KZP[%/<)<H.^(?GXX2F8ZW
MAN6!V$+\M"#9@0*D/H:I-7.2)@A=D4W.)T+3W5*=!K.3]Q<R?21-1K:2<YZ$
M::#[D3,0!JLT"45@F:8%4677!,5O$/^&%(2>=C(?E^,MYW]\L@F ?'$UZCPK
MSH;QEF JL*.UFQZI,QF,:]J7I!6.##O$5!WLQM"N_O#U<J>(3!0T*80J:.SM
M)94:T@X_%8_^'336&W495DO0"3%NLK:1S;9]'^][9^U%?W\K_WFB[B_+;\A_
M(G%.GL;D+GH)38WH=B&#*K6E,[<(?5^I@RMJOWW/5V<5F2ZEG?<8/4*JW[@&
M>5T2AY9]%&&7O7.7R2_F<(-$V%5]L!"'W+EYOY18!\\9ABC=E9E>1! #VT0@
M^5H-)1R]BM%O(@D3 K)3UJ.,SQ9ZY.M\Z+9Y>@2 7,(,?O;?U.PP'%D8]F_2
MV-ST?&KE64:X6<+G#C!_H,$,2>)C:DBVWYDU\'UU=%(9Z7$J(N[3@:S4'R3T
M5X.]:(9,_NM"XDBL [KTH*ENC<],[Z5!T7^&R@A_*X/IJ6>.  1WVK7ZD8TG
MG"63J0%%9Z^[F.T:' &.VR65CTPWK<D6L\26O>ZZS6TT;18$F4 ]RA:*R$]L
MQP'-'90MD!,!C6!-(>MS^24G1<\:G!^VK$1,@EA,P^"0(P#;?)1;G?%XX:4G
M<3MM 6-1WQ!6(5M_^9<"Z.SI2W^<89>?N7E*[>N4'*H<X%0&UI=AJX0OVX+[
MY0G!'_Z//EW*S8^6L"<HXI>+2>CXZC(QZ=!O.B6?N[PDO?64%?L.+=)J!EN6
MFX,"@]BN/OP *TSHD"T1.LG==C((/8BER J^1BZ\Q0,QTK"!;FPMHF+1$[*8
M$==\06P[4M5UJT:=RF'6.IY^!'A&U2S[>J&H-DCVQ>9NYKD$=#4%UZ%]F_R!
MPOM/.@96"AEI=E(*A70N_-G7U"^OXUG5 3745T=:A;=O7,!?KI_-/"6P7,F7
MPO)]?)&-4)'F^H,[)<)%(=!N\/+?E,IEW]72BCT^C<!S.?S"/TLN-_PXNY_?
MGYUA=0/C)%[>_WN]-H[$TNH@.2X/UR;@158%#]_D(28<G4KTKOY\LK"M]VP@
MO.=BS3HQA)R G.0E/Z+P4G7^545\4^^"GJ+4%*S9>/;$R?U%\PSZO/1/<%N9
MK?G%*<$.OY=G%BUSVGKJ3&4B& 9%7QXLS+Q?>+U;YL$R8J,AK:"\IG+,NNBK
MSV^A.[Z3CTK8C+KA _-)LO?EI OG$U>+_20@E-<+"F?<+:;!L5K>!6YU02C2
M*A19HL>1NIN4;/_:"[98OJXYGT"84_:$=@JWE+W);=S*V]HA/(M5RG'*C :X
MC$X0ZMKD6,@7Z?D8,<0PF!>[D(_G];R*N<9DBVL^?V07%;AQ4+_BZA?J;VMK
M":/W+194]>7*N2_<.?-A=Y:F3$KJ1"7AO[%LM"RA$AA\)&"2CC"%9;'HHR-)
MOG_D'NJ1F\=3F:M2#77Q*H,<2LW)H'<)'Q__^L;27]BE_"7[\7B%;T)A8$I6
MW&^+?4^$"R8FK\:++^%21DVPD;YE0JH7%S1Y-V2B3J:E!MI O5+L;A-8\52@
MI #2%@#U.0>3]RP$BL8&*U>FL.[SFW:(JQ"1"65>"LU"BRWJEF'#.\;&)=5-
M?[9X1"*Z*3G=AI9V\26_GC^W_(5O58C'"B-X$3B="_18!(O-/(4YDA4D%<@X
M7$0A)FT#2W"@@?UX,&4O*M.@>C=<SI9Z2L49%OL98/^&D*6)+!LSQ&QRX$^,
M(**?(3^DAF?_8R;B6.J:]57PT];VMHGJ</OW,I4F02_8+.#8S1,3 U4N[P>E
M1*P=;.CE YBLND*T>-E,[_?*-^EM_0];EEU7R<C,M<WR&&A@X9#L81>?F4/?
MXG]+K\7WJ5?@CB,*7PLIW"2Q"XTC:I?S.+6]'VMY2)[4+HU<R ][ ?2US'D%
M!F,7/B$K[A=3+\)MW.!@3]5Y]HE?+YNOPZ:\J_+0;A*@I7M$T_E;0$E%T!T#
MR;>]E5T2LJ7'OQ:?9"9GB+Y;X/PQ>A/29?/1@FG7S^)'B9.@FB])FM<%H[T_
MX4@E&D]__@K?P<CVM3FG44!:C-%/V1WF;I9AJ].?[,?VM@,Q8Q-_<JZ_[U!O
MOUIU]@CP$DCHVX/T'@%,%4R00J[E'4L];4 QQ \\OQHD GMV0ROW]CT4N_*)
MY;E;+Q-A?6N)]1+UOT3/WEQ:/WS$&?,QOJ.]A>W*+3?5\4'M1PZ%]WF*U85D
M59EQT</PWTK'%KX23>-3)T?2W_V.,B*NM-!K"(7(>8JC=7+!:TNM [G]LAGT
MW U?W_ZQ0Q?J%2;5T0>[H*:_7%:U!]DR6DE:L2?SA,8+'Z?K;_\R:I_EJF>/
M:NW30W>Y^S\<.%FJQ:.LJ?C<WX-?XB-+!7J0TM3!);J(<9_%=#<= 3+>VF*W
M>_04[*7H2Y.M+E;?.?,1KF1D_NK!2] 0/_^!RK\W?@Z,:W ^JGH$0D5R7ITX
M"]/+6H&[!\:,_,K$3ARC3_F: C1CZ9)T%-8=\AI?O1V%)%R@Z"[%,4/("8?5
M%)3,SO>\X7:\\FXW(4WCP&IBAXD>**&=< GUJR8ZP=HR!E:TPZZ#N_,F*.CK
MP6^P/=<;QE5X!K"7 /: 4"[A-IJH[JL[]C0CXHN19L.+,VZ+=(ZK@J2%IW<2
MPNI8-3W?7CL=F":M-H!L4_FWQ4&:QKMO0'I\F!&[V6RT"#R[ILMK&_F]K<HD
M&K$B%F^5+R"_'7D^-USZB=J>&O^B04S5Y*_A_I;F/'&+?8<2ZSG)^1*(K;2W
M1"YQQ7 7MH)HEVGVWI83_S+8Y#I7W63YKQ%9L\3,_W!]U?^-*</]%@8%%X%O
M%. 2Z [,],[%PE<'^5Y?UO_TOS 8QIRCQ"S(^1&*X\II%]!=,66H?=_7.X-"
MU$J%"E!RKU8X!#&1PQC"GO#44819_AAQ--P;U!:J7OW!DJ7YWNI0O/.OUE]I
M\--V+5UZ<BQ9#;55M,=8WUX=HM.!\4M<8HS)]I!@]OV?-LB72 6T^>_B1XO3
M,K94D3EYLJ>Z64T*>[2DZTJD^7]9N_QX^A-Z>L3$'A15/5+%O/3W2;%(#X49
M[T67CB. . R]\#L)N9"*T*!D%FQ2%2+W!GGUA6MSR]HD9=J<9;V. "X'4^^*
M?R >^DPWHQELUM3KC&'(MPP:,PTN>B=@U! _-+&Q\G"3+QTAQ7"1.O.LK9"+
M/&S[-PD][TE-2F]>!QH[60AY (>_R':FF\J\WRY[_'7V4T%^@:6">HA"\)S"
M;L.6P?4$+>"8V]!=91_?_8*#AA![:MVZ9X@5+9$DO3&.)YH!8QFG*)9$$0:;
M7RA1A+"2M-@;@(_&R)' 882A<O12M#(]D9^[5'/SY>.+&2*_+)QN1J!:U$#3
MEN3T&B9(>[UZ!*A2*]YH^#Q _/&[PR0T@'3S-GB*T'"V=U%!43J%:\^J^=.\
M,P0YM]A"CH7=0ZUEO)/!N-V5-[E<,!J8D%+ID+6VQ^'LM]?Y4=,X72DEUC?5
M;>"E?5/=]*%-?\^*Z>9KDBKM <D[ <Z_ *9<9(FN48C+V)U?U01W<D):+8;=
M?J40];YD[PI,7#!,%NH%O#FM&S_Q$UF5U#$'9; 9'P%.=HTT:W^F2#PFH6+_
MBFG:-K6PM*?SS)N40 53J\JJGTDZ[XS],HQO>L%SD;*!J/H4*W0[/R9/8MHA
M__Z5G:[+<W--DN5;Z>AOI;]E:H7/>;NXNY6H#4H/.CTOGZFL"I;_O2*XR7Q<
M)XGT F_P$X@ #4)"1:*U/$E-B^ X510W_,&P?^&N=.@EMH[R-ZZO<H=:,69*
M'V]DB7(2)-#/F0/X!"Y+TLFF/J A*'0">HIJ3[$EXKKK;/@<.(E)T?#K](0;
M)E#GOH 75V$[?+W?6Q=8=F$_1I)J74ORWQ(^.UYPX$%L8KQ&++U#7\Z$SF4&
M5-',X?SWM!9;UM?+8^IO2-7F))MME/];YGU!_._Z^-3 >9?D@EK%I:M)WE'R
M\-)2(W5YQ#I:7U]L-#Y,>UTF-O8=P2([8FQDJ'A,\'[A735^PQM&-XH:54,4
M-LNH*A3;?TM+VC-P8XH;E ]Q[:?G7'6K%4OV"?]&>-D6PK5O08GE32"Z[\:Z
MR)PR<_H\K$Z?7YRWB%UD6Y(A->8H5^;IGCRK^T</D8_ 0831.ER4-I?&H%0#
MC*QXB5?S0F":P7Z&]!J;6)LX\I]T!#WZZYZ(.KU2A]U*DCRA5(!1K*ZT*RT]
M5O7@IF88*X_CU!$ ,S;6:J>K(S HH)N0056SF&,#5UW:*\([,T#J]$VP67YL
M<>=UY/A"F8WP8V.TF\($XS0V[YV9'N+P)>&_;I:U07"1BN,PXI3$F:[Y4R0Y
M<O(7:PS5EDE]/Z:K;/3KMOTQN*6AEOG0QL8>,J?GZ.@I.6)RL8=#Z8)SH/2Q
MFZ(IIH SL6^+'V8GW,FQ&=,N&V?<-BD.:#A\\^_-Z;_>'' W>B'< 7&&]HAX
MRWWBF@UTSF2)4^OJQ<LC@- B>;XJI3/"VLVHAE??=>;1*.1"#J12%%D9U!KM
M0=-S.4?RCHZ%P-+-PIYZ@&1&N4?O?-5=8Z^.$.6&Z%H2H\2>^8I:\EJFFQK=
M"@NT:S(J^Y7>IUYI86$T98\J7G[;=?L4?W3:\N^1WLN?8@]X?_YG!O%_IF5)
MSJ?GL"1Y/B?]:[;=.OXAB2X_KG0$ /6R>!^ZLIAN<VF^AEPQ$NF2T)/A=Y)4
M_M;&\G/B3PL,N:E 5>A9@H![\, R'FV[X_OCK !;O(5#N^D0I@6I1Y"7M7(2
M%;CFL#*4NOJ+UJ23EXWP[*))DNY;;?"%TI?YR<T3J(")T/T#A]C0KF9R:DO9
M*%"THL%:(OENY3>-\^$_8YT0Y5FNM.2B]_]O*S(LFQE]6.&K\#J*!.E$?_V(
M&C^L>KOFL^O.0F3MBUD^>,Z)V>0?A*33A0:P62.1-*?K%BPG03:[57:UD9[A
MZ>)H^T?K K70D9V??W?B1[A3E_)C"D<"ALI+C@ VVJ;'F>/SEM$9= 2H-.UZ
M5$JQ^&&MQ;UX)<_^]%*Z@&_H[\I [8DOO .7KDM!0.H3&]N1J%9([1&@U=YR
M =2MT5FW^).E_MSN:\B>907O\!T/KXT06KD>XA[B)_X8/("J1K,>T^&!WZR>
M>5D\D!U2\/!B2YW'01!WZM@YQ/FPXK3SB#@"3G!B\+/QE>^Y%>\$L']WQ"XU
MM31@3,LR_L#ZK8*KGR:T0^\6,^X>=AV*FO"903Z+_\>V&LMY)H,WV)[T@O"M
M,XE=35(7I[2P<_8-((NUG4'76'^*,#&<QOWV5G ON\]R/ 5)X\6112; T"-
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MLY=14EQ]8WZ^?\I"]^@4S^4[:Q7_"O\-?PISAJ9)1V'$)FF*%/L/EU"%D\4
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M#T8VU*!L?UL>]HMDV[ZWD<V&1G?T7/5@?>ZDI?S6\#Q1%YW@[TU1CV.PMGV
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MME?N1@_*3YND["3N;_XY/<DT;T.4P'#P$6=:Q #6KROJH$_/6"CF;/K)@8J
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MG>>A>4&%U*>!RFK5I$<]:Q7'TZZE*R[[/)FA:'2^'ZR1X%+6>G/C*MH'8&Q
M3RAH!!N(!%U9GXGE6@EW[N5WB2.U*9-=,8VJ+C,I73=UF^_Y1MTY=:4D6C7E
MEJ,XZ;CV9:$9E";#!PIA UNV,S^@A!A'F2^"O.NM25VQF3KH=M11JFG%@YZA
MF:E^OO+*9153XH'BZAOR33N7>.;I+Y^[G#&(%&CF#<HMN#,/MZS:EN:9>+B'
M^W2\0*2F]86(-L#*5-J&:U,VY;^LR(RS@0KBO >Y*RH33E&=6Z>HDK[&QC7N
M8IBE4:X_]G5*<)JA'::5A)7]^&$0.<<]+?!"HZ+FDU"3$M44B:=O01YFEK,
MH@]"$'[=FB\4;MM=H3YJC4!LAQQ:;W\YSYJ=._L]V?D'?L<#B0/I+F8#$FZE
MCMOG.'Z7D.7,3#.&S:0@1!AZOA/B#Y4T^]LSQK'B+F5A%SYE?:FN3G<3V1FY
M]=N<0/M%2?VKP#U/F>7!N56Z*_1[8I A]0PUK+2;,O:4K]%P5Z'/U_>7#N1?
M\RR]]^X45\8K]?",V\M2RSN4GC<AY2!.T-@2"@U01G!P64/X.'9X05&V=<.J
M*,=;<72L/%4PP.! O/S%TOQH_^,J7C6OQ4OV%8LQRT ?[#8D;WHS5A@E"BGU
MM6(E6,J_);U9$KU!"BDQO7OB>'ZX7BYEC)T]_=E14VXZ\J#O PIVWH%^&2G"
MS$+*4I1I8Y2<^UY]*!5#6J,T-0377O](./R$GBC-\D51YV'$K0_:Y#VIQ5T?
M>68_[WM[7VA3_L\+U7J$GZ;5"_>Y1AE,O .+,\!&,(+&$VK\D3"RAH3=SS)O
M.WO'GW$/I4Z1'/8_GTF<][*GU:[C64+\XS""SCG*N2RZ*>L+J,1P^W/"J7''
MBY/C3)A9@EW9X.E;LS'?3MTX:RFS?%%G"WZ'#;\&Y3;M!;.0)8@:R)1G)F']
MI"G$./.D\M\=# FJ< MMWF?PEE-K;Z?,:$E+UIQK2;3-)8!8_9PJS@TV'X=[
M$!\2E5![4'V<O;[CS-V,RHQ[)'@T2JZNI/;)RKR&W8.JI-*]IID+KG<73@^Z
MJ2@9OV!F@.Z@S Q"1A=-**-E03,%#%,HVO.-@HO<V,SA#;]']Y_BZ3\COW.5
MGSZI>^W$K8NO$I>,R*THL1ZDR6OBKT(W/XG&\A0>_6&[^(#S=27M@:]67XLG
M8L>36=J0.?T4V*P[P7RV H>]&2Q :GSPSE0KKZH"CUE:G9B%3%6_O=GQS+UI
MOW+BCHMP.900:YA(L88-9S,N0!ITG\NAZ2>@P&SG.*3H!%'@DK!EH8'DDW4+
MW>.6\A?;#XZDR_T0G!YE\;+P=]>:K(?RK9G/D K4T@6\8]\-K_A!_%U[] X=
MO/J8Q:U2 94PZ>CEPS+7CJ4:)E*GQW29D: /D<!O81T#5GC-CZH^K.<;/&21
M?]UX.T6Q$AU8>,!?T2.3I')[N[_-F;?C]*T"P$^&"W7;R 2:(8VAV4!E>E'#
M0U 9*;@D=^;PH.A3D<'MON=ZINL$1B]N#)IR'(<5HH)ARGQYY^NQ# LV<-UH
MNV\0HGY74ID.6,MU(CR_#^N#&<K"L8%RV6C&#D,>LB\&@')(;4LN$$\KP2K9
MFIER0DW.B7^79T3*$9SY$XS&K=.?J^"4,IH*E!-&'3G%S )]NP@ZK&V:=22%
M2R2*:ZH;*;>\X9A%V."-06.G8R_?>P)\-_S(D79"]\-A')?-+T]-/P5-%LZD
MV"+%J(T);T:SYP+>?2]OK[GD,=*2R^MW=%IOFDBYSP::3>"_L) 4&Q"T@$,?
MUL[LX^'#6T/1BHF'9I5V?DPFN=L:QET_44:>VND5\:J?Z$[%,OGFL!0Y-I!T
MP_8XY]=?OX%M%F\6;Q9O%F\6;Q9O%F\6;Q;_]RVV\/*>Z*\U;QPH=-U)K#]5
MM?/)G._Y>&#?VTWYCY>\WZS=%#;P8"6.83*1$=QE];'295"?$-U[4L2R[\#"
MB=R--*#&-,QA+I7N&*I*JZ"8O2/#!875P3DVL)4X0W2/<HR?-8\9(Y$>348"
MMIZ"#2:* LUN'2MH"2@5ERG6O5!O/3&/ZCS3=^.M]IB/P?->$UX!@[)//]70
MMXZ_%BZW!Z.1SB1KQ5#42%NF /4PIF#&(=ZI[T)OL4=UU2L^M3,6\FI-!W>.
MK_(&%[G""0&TFZEX-D#YL!MBCE=2X01#-&2>VK8M9NW;-\-BU2]$++PY::R?
MZX?M14Y[M,0A2],:JFI\Q8B1SKFRAQUA8*Z+RL'C4?G':H2R?CQ6QT">U.EQ
ML/W-+90XTHV"C6]L/5ZOI#A8N'A6_HA"Z[F1VT.9#;D\!?_1=S_]=Y'B>/AX
M_MW+=P/:,%$P&6,]I.$ \A+%$N=4E*7:JJA\KOS>"[\%E8CSO0NS6]C )9&
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M:=)T[6ZOBSCRR:%E.K4-"#])MT#U881 3P2W*1D;'[(6'1! _MBSDK'W:U%
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M]JU#'*I'E[<%T3O#N&^,A9T?J1QW;TR*%-"X8NE\_?P1\O&2]GCN#Q'W 45
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M;:@N!!>+GR"L%87AJS]$NB-8D7ZB>[PR!#:OZR/?E>=N4=0>OW;PY;E+]]E
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MI\3B$ (S8UR<4.=W)T/!HL+2[]BYTH<J-J>RN"Z*?\G,3CYGL;?"E]*H-\%
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M[43V#*UDJT!)WK*3V,%^CH K4Y 5N*Q5"S2O,(1O).]^@'3>^W3["'WDB%O
MS*> \T UXL:L9/.K\3T:>SS.]7IB\Q>=A3T#777;#N2&:%0EB(>&(U0YG0BJ
M<<> +?W9RIH6XQY2*M\BD9TWEG/P^\$UC[ "K^%E>)+XRHH0;CD "WIH"N@'
MKSF-F^\YRNQPO+L[KIKGY0^_&ZI Z<S;-?94)L$@LQG2;%<2JJJ3QVD9TU]W
MJ)905C&A*^4U<*QE028I.@@E#GLGN*,;3$0MPJJ$NC>ZDY98ITSF>D4W7,<
MQDD8!<[4842J1B$JUA<*0J4;D 4Y-P9:,T>KXDOXCNV2BJ6KEYE];PI+9>J"
MV06DL7>\B=[?BZABS7D">YR0/""-C8;3P\B^++Z2EXFGRRZO3=QC[6D<-(!Y
M6H9_4.F]Y)VV)[#&VX4CAT8H3EPYU)X;JNC_6O$!&?;(G5Y6$/AG<&GUVD5D
M]-K_?/6VJ/3(2$%$?G)%OSI!\+B37>;#W)A=9G)4B/0?L_(]GZ./8U, -V&&
M4O^"--,PF"Z):3Z.A.<27OJA>9JU)02$<ETL#Y\7WJGUD?G08W)+H*C>"WB
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M8@T]9_L%&6:N[%"Y:U>:%),2>@G/.$1?+>7YUNNKT)[F?/\.["NF-!M,["V
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M;0Z%=QV*Z$2D;7:PQ* ._8N_$JG)=/NO-5^]URR""[0* 4JLFBL7 LW%4(D
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M2X732N9"/J'4,$T^&D$5?P[9>U0;MW#Q:")BP#\'L<DN?J4 T0NOLLU3P.?
MF+5$2D48K:T2U-^.B SC:E2TM>1W:)OQ?!#4*]CZ6R&[ ]!B;*S1'P'06&KM
M3EQF?>+Z_>-8WS4QXGB1A3=D_D^8.^[D60X.0A(5T&6/9 B ")3/K[OU2$.2
M'AZ+ST90(;@8_8>,^4-K4COA<2RJ\JB; " +&:_N0*YEV+%;N]USC3&$/\,G
M]9KCI<#\T(R7_O[FK@/+ T*?YFDZPJ4UF/+?$^;(I':C0Q=5M!VB'0JT9#DI
MA&H,N]6=J)=]KNE;D>7F[ECR,I:"?T0LTVDFIB(4S"\%\ ^BK9\V.@V+ISO7
M&SY5/B8'VQ;A<6;S$2_8/MSCC;_N[$(.M;#CP&6F4-.\'5.R><J:.( NU(O-
M5/;9\8E'&51Q*[3ZY+G<;A*'>KS>KT.7,!.?0='*BCIY_M*TR\]G2>G$^G)"
M$2Z/?8.-SKQ #X#3%A%\)4.^F",E)X1QU]MIJ W;9"C;S. */< \PI(ZB)17
M<"G:N,Z<VU8=\9:&V^4Y40L:GPBOL)0GB#(R=S]NK@.R\$!?M;#[7(/*DP-A
M%1[N29RG,3]7'MY-'^VV/[FJ3LQ8"%1ON_F]_8/PGM8;W,5?XRL'"\9&'9]V
M%3FEPWT_J#\_E"JKVSQ;WK4R 6'1C1TLN80#I2SRW&NF#?YQT[A3;-PA;IK+
M,^@2./9>QS+=D7<'E+%43=!@O/H4CU'<$1"$>S.%,UZ6Z,O+6]0>9O<?S$5]
M47FK:$_QRQJ K^>*LTRL$^!BH/V9GW!49?C-_K6K><*OG3_&7"6R]D4<:Y>=
MA'BEGB('+5Z9A[(QF@J0YHM9<Y1\ZY19XZ-&&@^C7FIX\KEM6J&'8%S98VRI
M@3T/N<&I?:TP+79LE!R"8K>)W/\Y!<46Y25SCU33(7/VOD<;'9@[Y#*"\3C]
MTPE6M!8&!,!E56]#6/T3???2K!*6Q#R$0XKVGETY2T<;$%@.33W8T5NOB?,!
M1U?\/]M$M02]Y/_$EC#NAZ8@V!E,7[G?AL:# ;@)/8-0)9UF^WMJV@"(&B?$
M+4F0]-BJ-\?6)K7;;S(JF+\YEZ,V4YWZO#"\XY0FFNC9__(2@C$GZ8:!HM@&
M;= RJ)HO14RMU2SC,T;*.)')4:$K$;D<0Y(O!.R_ZT'P7G4WBJ<57]HV46[U
MQ6D%%M*B>?-%FH[X^WWO\[=W#TS%0)/9"E<'KQQ#D#J&>QN&OOWI?%.VG;WR
MJ@K5(4,&0Z>X,CWU9-,[1']>5_[HO?">"Y6C]-*VJXB$7)X#=1?YS\JH*?^0
MXXZ5G_#"6*R$UX(=[-5^IZF@M<2T&ZN93DJ23;F%<U3L.-8+SN"*'UF%?)N8
M+5\L8^W3<VE&O+73, 3!$^!90=6PI4G28BY_!Q=2OGKRL<U*I(?3\H'X7A2S
M+VD%OW;4,*ZY$5_T*86<U0PYH>$=ISV"*0$7S 7 R/%'^=/67'@US?!>*OF^
M /BX_3X!XGG2MDF[L?2BZG$<&,MU=."-.A3R18NQ3X_PGB9B)?"YUK]39)G7
M(/JT<13T#L*!)P2 -R^T!_]T[E"CJ8( J$TS'[C\$CI'$&*_&F7OZYNCP*IX
MUL(P;DX/G$$H_%' ?_M4" 8U@]@D(=/I-D.>UD>M+)I&C2);57;A'\<-X-U;
M0HL1DN1O!^^AHFH.1@[T[&VD8$(&K^.99Y"#I8T*'&$ZC/IV646RTOTIBJ=2
MF,B:91*D+Q.3HM]]\6DG1[V_RAQ\S!!>-AK\_<'T&"\7X=TA';!6P)-6&8-:
MCNKR&H^TL8%4O6K<-[WZYDGAX=UE159BCW$V!I-.R.]*\WJ7@PZ$^18'+=EA
MKIW>E_H[)U'WO<@_']\3S'AXB$<1X[!E.*XFA.@^E$N:\:504G9Y'EYW%T*C
MVNZU7'Q-"K!@F^;=<FBXXG=YQNF>\CV#[ZN[O;VP3J]V6ITVR'MEL2U1]\/-
MHXD[%3-DJHL!\33[DX"+7A(+2X=QX*!0.*NR&5J6TX'XV\KDK2,MVE'KY7_:
M%\M.U*X]^'F+(7EL)4NCK[N?]!( F8>L'H; &;GW&['@TFT0#NL(EESV-X"F
M&+?-CW&B7T;O/'B%_'55*1',;8+T=<,-==B.RL? %<#J"P]O6_2&LA^:=JY\
M(&<G4J]!1__.[\1*:?EA[^(_ZE;=#&VI=?UR*OU/!<MRQ9M%R".!WLT9U Y]
M0\W(]C,IM2M(YB&-+$\EHL$7ES7C6'O2(T;FBWFQ;M :$,*N)#U#>S#?X'T%
MCI-0+<6=1E!3L!0"5LX*LP/3HW,LSGZ)3:>)C--ZVDJ2<Z-$FFYAW\H4#]-*
M3QDCM!QR;/FCB;R3JXFXEG-Z4\&+.D[]B^[K?Y1+A#F5?ZQ$?K$8;6B.F?E^
MF'" %48OY6B RC=!'#N)F7@H"@PP?OSA*O+=4?>[7+U?41!S#!M';?.0<!UG
MT.TL)B P=[$BVZB=/LN9SN_@'_3 425!==1<UDO_K,9L 9!4WBI,MGU^3E<=
M<43\)(G/V8^] H;%\.'>YTKI)Y-P/R?G>,<&*3M8YU%=V"?$<8A)ZYO.65.?
MTVQ8H96$?=@M#ZDK63J#/U<.\\,)NUDHKCR*^J-T/P;@X9=^',_1.%11))%C
M[W^_']5FO*AS#TMYBB^1C*Y0-61'=OUQQB8Y94;26WJ3$E0P"DVW<??X,MS=
M3-%8IB$I0,A2=$^N31>EH@Z*X;ZZ_&YFCS!710)"/4OS[^+Y3X_0]_T.$#9T
M0GT%#?EJD="2$@'S[H%Z'-@Z<>)-*OK@6_*<*N[QFP,MO<EG(/.)GD"["_NC
MJ(4'H\JJ59^L3@8A7]TZRZ^9>(Q<5L%+2AXL</2;THZ9+:,QSR4N]7+G(,8+
M_:W^.'\GS(B&H-_9)@)?J@[/.ENK:X;3?V<%OUOB6KOV1>ZV\/6;G&NW\SMO
M][_Z'JS;?2N\2,2"V6U.SD&(<H83V_,3?B);6^,+E?;23S]3)RYF"@ I\Q9Y
M/\N1+HT)PMH70JK$*TB)@$/$V*51-"$*V;CM ^;52*OLC,=6WGW$5810 $H2
MTX[9M@5_TV]4S:Q _J<Y=1"&'BCH0EHDC7_0:A$ -9Z[6D.#,VIG1YA[<G2D
M$(DHQJ[KJUOBJ2-[\T&L55E)I<<#YQ']$PC*+J#PUED/\;R=W^;#KJVSE#GW
MC^0C=<:XM=REAN,2+K,>_;4B-B$1D3>7Y<.,P@F.AOH?FIX,\@K3;#3QMZ$@
MM^45[R[B]QH<[7DG .8=HZ0LH]:/C^U*M/&<U21.T^WY)\BS%_/8Y+$. '+J
ME"Q$,3%^R<\]TA+4TBJ:R/CFYN)&&O]RWOQ<[B8G!_:'S=NW1A62?[^JX6("
MLB<_&"I[A+B%3CW*\V,$7J/?U+E0A$RU6ZV.E3GK$?'X/_X\+QQ!#^-<!!<H
M4SBN" >.%@&#+X^C[F.EWM0H:2KUO^K_')7RY;V'_[+IEA?50%6#MEA X,WU
MQ<(U9Y%[^?5("6( XH[I<%:#_;!T?8YD[RV#D\L. P/-M;(LE049XN=J:>/7
MF<M[6W9LL-4>.%M^_*)_YJ8J(JB+Y,K8TN+G?E")TKZP=5"TL"FW16[J\(8E
MH+W'?VO&G$BUS8SUK"RW#)_X\F"EM>IAM/7/DO$[\+I75?9)9 7SG4P$9;*:
M16A)J[GM%%_F8RQ&W;SQIWJ@U O-]7.#EAN22[=8HO/>8P9@3 ?D%K08K"*U
MA&E&C>?J+?6DNU0Q]9T&()?WH#YWS[:('S>P7=R^^RO))C>JOL5MO"Y$3]2;
M@N'(E>A581(Y=HKMPXPB)M9XL@K;4(!/]OM)L>OT[R+F V%>^]I4]GZ-[3H]
ME][QS4^X00"4(^E!3"-V"A-9AQN);,A9A[<#'RP,@PY-9$FE^0,&2YM[38=V
M7ZG6'XKZ]K8M.=.#"*^3+/R/:C;,8X=CV..\+(0G8@X!^B"@>,A,$0 --FS\
M'!),&QN+RIWC.SV'R&5Q6RD*+S_6'!;T3"7"L9(KQ^"+Q$3<R*P@EG5%:-XH
M>07JN+9)U\%8$\BUPJX=U^<1=;]IYVS@6G6P95%".S8:+FI3?FV H"%>$?-+
M,VA2[4Z4,,+M0HT\Z2>RQ=S;:7=]P];ZKB!V>9XB_/QX7ALL8N?Y,/2[80.O
M-P( D=B^RZ']^L2C<QDN1;I%@1F$G5]N)3N2<]HN8";<UA)F0^;]V"1,TB^$
M8R>39JJG;AH=4E.@(@5I[CA#_/B/&B.[,4/X$3SS!Q[R%50HCMY#S9%'D"RM
M+Z4<Q+ Y68</?YF$8:@CJY\%3"DJ\B-J#;D':FO[FPDO?3Y^#\S:MUG=(%XU
M./4.,W@V>W6M)D<AQP448HOW8'3):!2S\GY>>N.4);^EM,O_5:8-Y@?$TTVU
MG3V/MPQK-$\JMK:<7"KEKV/I:-"@>3!14C%XHUC?6Y.\WJ<G44^:I4^W%O@8
MT&JS.[\'$?86QA39%#BD)Y5=_5,4_LWD2V]&3I8O^W8N^ULBE\D:X,I__F;
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M-+]YK^:\$W/#YL(0Z(CVP#3<YD]^!H7]A-2.79Q9K@#A#0?K>'JX?@B-) N
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MM.]8J"7FCTM*A6,;7 PZ$LP=/PQ-9X<\L[)MXQV=WA&]0=5Y]*NCVJ^[;@*
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M7_DP0B*"4S?<:'CV=>X$<#OGA*)QE26 +N'H8T:098;-Q!%8$ZQ4 #0Q[IK
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MK I(:B'<8E^HE-_E(79 O7S'V+D[)5="DP\]$.7^),P17H2GL_MXQ6N9<9/
MK&.?N]%2U%&Y "'*1.R<MEF*E?SN2J72@HEM1S3?WIEW;%E>%XEDVJV(8GKQ
MY8X9*P+ WCYQ6O-N[?+0V,$:'.FZ_QGA2(XRIA^Q#;X;9+0@2PET>4J*#DD
M;*M5=8/@I5\3E9.@V5-N9G:/O'&4\/2)[.9FQP2-F]N.7"E<W(B.9>;!(<:S
M,1_,#WD3O)%0S]LM<2K?LBJ"$DZ*7#G\D([TZ/SWGMMM@C4283Y$L9J-[[A'
M^A93',Y4=@<HA15W[5_^7%/5LO[ Y=-70S4!"WM-\>R5'O9%7@7Q.C(%6X%(
M1'@+@"3R>G^T6-[TF'!\HQ+\:?!-[[X,S4^I^SD.K^,T]5,O-A9\-HK5/V&\
M9(%.^2\X7J<P =,UIL?[2 \9U:DG?PPC20J[1WT8MEE"RH$,QR?Z^^??KS]L
M0"=B]Z>*F5!CW7,MPA<8@QQV(SA+PPT;-F-+B'3D&G[Z[(0SUWK=5#@RD[,E
M!Z([ML+7L[Y;/GNR-6:_N[W98]FCC^$3K%*:$VDMAT)F(2MRO"-!O7O10NUG
M6W"0CCZ]ZTK*[9K40<<CK9JB*PM\$1XS9MPZ!;X3I/%%I5D#I)N_/;:#3V1,
M<N29376-GTWCQT5^Z8^EG]1(&(KT%XZ>."_T 3*&+&X@R[X>-63O6 'Z19A[
M&+'R>)6Q:#D#[;W?0\2FYF.L2!FW<#\>7KRI*)_ODO7?P_6<)/]O<DE"\'\+
MNP/F.P;)[$IPB 6CQ3=*#AUCOV":QI<15<%-RK:5O>@=^W^\F0D-$WV?9E6:
MKGE5.)F:T#Z_)V^S>1@]';(\>7"*Z=1X@8T7QGH?Q)-"X0<_,B>_T%"*)$VY
M+%-IVY*7Q7>OV@0"H@)@6G&^+UT!'1W!&%3"RJ$W\:HPZOP.6%E?\FTHJ"E<
M+P:?\[6&R8H[!O;_'FE-'0W@ELE=,7R\X6S9BK_1O>0< E_,5 !HCU+(''TU
MF #H2NL4'C!>D&^45(40FS!7IJ->  B92]$DSI%(6''SG4'C*-6F-\A6<:?E
MK/#H;]\H.Y0;"(P&$\>,5+]I@TCW;K3A2P\P"UEKZRIQJ-NV<.3):3D%SW-_
MI@9U=9B$QT1*QK <@88$PGO8WUDIR0]F$4IHSZ#WKJ]IRYFKYN+]JU%5[.-.
MNR+?)QV6K=V'O@K9P?O?2J8)M0;ADA1D0XI1 U_%K_"^N?&XP97Y6=?>N:*V
M]'U?2@UJ_%D?EI+32 <.:@CW\(7Y@V/28 M'V0=;H0+?VM?=O&"9_6?J2#==
MB<VT%R=LJ&"^ JZA#IF>/^!.VA#;VB*YEL69][+FR*8X8DG\W-+USQU-J 07
M=(5):)!IZTN?CS&JS?FW2/!3OK$-TJV!AP,^P:LYAMP-T&J9(W(0H!/%,&[W
M\.0 Z;;+2/G(AYY@,R.;_2/8>#1!@SZE7)*>"+#LAX+9([R7F/W\H1P-'AZS
M&[WY(U,[W8MR@&N9ZS,0IAWE?O;/E42C6],[$L3T2A6.!B93Y#255E_56C$E
MN6]:6K#LH_[$Q5K1U<E_/W,2N#".7>/>F5F<X]Q#3--HA/?!,CP 5H^K8!2>
M-F&,XT[L+K<F5SCK!URP#!\_LZ_TFVCKPWL*VK4DPD,B)8\\[X'UZN 85!!7
M13N%.XEJ7$=6>@-L2WYO[7KTWC*6=\+$Y[BQ%KM>8Z^/%??-+O_1?E@U3W,K
M<5QYJJ#R;&"M*/8@OF)J;H)CA;8 [3B^7 2("H."<L)J<?<M RRU9J!N>GGN
M[+F=:7-IE)J'R7=RQ2_N'3Y76U]55?&Q(FU^GJH>IVFH__&3HZ605H(Y('R0
MD%1S8!G!/(<=<2!AE;AF*'6N(JCQ]B<B/B3K:&Z3QW:M8W;"RT4OKG<F')([
MO4_3#(#7LA@I: 1SH&ZUH]%>SD,LRO!(]Q]C":M@ :!/B3-Y.,)T-)YOF8L=
M)X[((0>+,.:_U92QBB!G/#\IT)B..,%")KR.MV?RGX;LX,#%KA:]O]&<MOGR
M.EP.H)9-9CJJ1EYDX4@$84R+FD1M> @A!;ZGHLLK39K3%J4NYYIRE'+[7LK9
MBV'.2K71+,F8)9XA]=38!M"@<!"\R>\YX6JXQ7W41P#X5A8/WE7_;I9U^]T=
MDS^JND*3/PS9I;S26B%,+QP I3A7002UC_^0!?=[:K\%3*+V(*W\">J.GC*L
MT5+Y<Q[&&P*HRU?I7H3CO(]87V("=EU9TG-A2E:=A5-SCA92TFU6VOT[T;NK
M+.F 8YM=V*W&]60-V<ICDS9EE ]'$/NYY[OY</YW1$5^ QY'K+1.+.M(/"27
M6R0 &HPHHP['8SC[$"(SIC$^SP8W>CW[').USVAC<HZHE>0PHER8^]2^T9XC
M%8+E:63>V8>%P$A*CBXO%^M%V,!%L=X\O^SS#DRWDG?J7W4+S)S69I_3<%8=
M-&SK+($O3<&8#K@$C%EWK4*X*_LV:#:>- IKQLMQO;RH/)US/;M=])[#.T]\
M'//0V"'^ZL CO:TW-U3)0FIM@)CAH]O<70*@Y"KV][1>,K0RKK9P91%-L*WD
M9;X**$E]Q&0GCGH&A)W99-MZ1@#</K#N;LL5>1; @.^?153^("1=!H,X.EPS
MIHJ+]I/<PUXL0B,O\$]0I(GB*:EZ'\[XC*RM[4Z2_(%6E2E,/:+"L!$Q?'*A
MA2R*.8BVZ.$>9 E1XZK5GHY'!LA1?Y5\VK92>YXIKY5QD63XS?F3Z-!*!>$%
MOY=<MDPB#)E2[3H:R3!;K<:B[>6=97I[/S.<B1CULLHC:>T_?@J5>>'6UXSP
M15HX)NCCX#$J3 X="+)D;G MP<KQ30-<Q\OK>&./[U55EJC>O.(,@\=^^T7_
M>?@ +AE?9L^5#:-6DE+\V+BG;"QH_P:T)['_#_;>,ZBI*-S[#:(B7:E2 P*"
M%"-=BHF5(M)L-"$B($V(*)V0T'L15!!0HH(@4B(= 8ET4>D]E"0$19HD"&%#
M"F\\9^;>.W-GSIGWO1_NG3OOAST,F<G.7FL]^__\_GNM_:R1%<G$&.QVR_?*
ML$ @.DS1-\G![U+%W4^<P2#_XU&"(X3:C1YG7EH"H$1"I\]+5>=/#';MZ>A3
M'>^<@?@[H[Q>9!PO][^3(3";4?]W'\00@9$%DZ'J8FP!#D(-2.F"98&]WC[J
MK07&!$MLR/U+4W.SZXZCV=1;TYT7YEG?3<"_L3'[()Y6?8HV23F!G80O_3!$
M) 3Z1AJ.F*,8J4*'_DJ!N[K$H&M>G*7_U5-U[(M]$ (^D[C 5M:?I,%C3HQ#
M3 P$:?X^U/.2LQV<"FT1=OKM>(=_QPZU&-$W"/Z4%/,F5IOO&-S*+A;=;H/^
M"<:(LK]ZO6 ?=-$1M(6)1Q^MWP?), Y0"-V^E0(&VY:>[;3PNGR_U#!OI:Z)
M,LT$;069U[5^4LF]$N=6?V(SP/6F#%$C6@3@^9C-LR8 +^6YL<2[/A$\(59=
MMV5Y>T;*-.N&1N"1!L_KG0%7[G(,C'#TCN!J$(S\WDYKNO*>/NM))_P<BE!H
M, GSQ8EF B<Q:[M!2P2?FID[#'NJCEH;H5/RXM6:W6MS_&/=(NH. _,"G#DV
M@A]84J$;5X!WE-7SP"M2M<IHJ^E;_$K. 8_.7?&C%65-P49WW.W^%3E$*3$L
M@&GZ X8/4$]*M[,;8X IO:;6AP'/C@E\[27/<E_;S+KY3Q?G;5XI\OHK/GQ8
M Y$3.&='7NI"'V%UPVL.?R*GJT[+CR*Y2(<:A]9//DC(/ILS/W @XL^3CCRV
M)E7#B"_W00>V(=/[(-HE"B:^U:9&/VG;-W@2:6>\#UKU&,,Z#>;^.#>G7W%Y
M'S0J?U[V''65]HX=**_86L+WBUF*TF#( U?T8W5F4H,G&?)O5W(W??7$1GYD
M<=)*3LR;<YI]Z+9Y_U7N6#8T#2BB7YX".(D]KZ@AG3 !I,7"LNY8O2R8G5@3
M=<@:<XN-FKM9:H\;1'BS-PUXHH0>/13L(U!LL=&$!N9&1[IO+T$$>B8THI?-
MV_JH()P04F=4IV>H9*QN)@Q)$I[#OMP,\WF3\I,S+"+!7@5; SV M*24]B!B
M4") )='/8&TK'7V^_O/H6G&:FM-E:MG1)ZT',"$94)>SKP7!_RM>$4Y["HP6
MH09P',9.5)SSU%"H[Z7"S;/N#[A_\2:Y#E9D/[OP9Z$MDMU9_NB^KVRIH-E+
M[8.N?+9F#ZR8!G5I88,-7%,7V],:VLY0SU#%,^ZYQ%X<A2&'S7_77CU0QF)<
MC%("Q'"-X$[!J0+2.B::<4X\$ZH(-#64+IQS6Q!,]K"PY'-._'38-2=OY RU
M0S[QS<$TCA]H+O0#&+Z6+6C03+H$"^]R@')U118R?#H(PA6*(:TU7AQ RRMF
MFREE+.=U'DRQ+OC9?NOX77KB&%25:I? CI34C>.AG4[U(UNO5(?_!/'2^RX_
MG.E(S0EV^P+BV56@V0T9F]-]6%/:Z/8K#(LW<][0(Y0_J7K1E$<=-&&9GB+>
M7*=TA['-9+GLF^?#5,GTJ":N,J0/59 A8F$'))>%AM"\*8*=&@J=S>YG"A#'
M&!?'_/^ [9^_M?-(F/\:>T!!6,+;ROSZS;NQUYC1,-],4=9X&XBJBK2B:& 3
MD1Y$N+AS**([/!AC9.'C3^Q9EK^O&*=8LZZ4I!(F%^L$J]OHQ,V >S6$6#_
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MK,E<%R[7=^^>[R1LP_G:R[U#G!2SNE:RM>J$,-I\*U;$I",+U?N@^]93F?:
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M@[E;+>G6R*O#GM54TQZ8^!R0LCGQ1ZO682K1J\+/S'C=[%G-$N A.H,: A^
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MQB>\?RW@6^VL'.PSMTA\<*'V<1F93E"D+V6)G-L.2S,)H&22!>-;;]!L"S"
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M*Y:A,LV9UL/WS&1O190MF75L>-B/VP6H$Z7_E2/^"%MWHUBPN+<I!7?8"O9
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MZ"JJNY?ASM/,N?^V'9;3H:/^=J()9A6K/*3G;6Q.0]6[O=F%O5.@LTE6PXQ
M=7<>%:5<.WF"9^P(.G#4*]>8CZN=NQ,3>_CIBXN^3AY$;84RX/:4=N1!8XO\
M+5.\__A"C]_1"*UPCKV%WIJR];VON[JR3AP'+^[,G2P7_ 2DA<&B$0>#W5LU
MUE\358D _LA$AML-5"U=G90%87!ERH->-CRX4#II7^BKBDN0N'E#4B0GS<_Q
M!G;NO.X6P<4<N#7((-4^1F*@_'WO53V>Q5>LK=4P8TL^#;N>&C.)M5B3^M73
M4.],+X/4TD(L?-#6BC.YIE#TC*9FAR\9TO>_/E7T,WBKHCN0RYKQFCNY9E<'
MX 8487V._NW(^J5-L-!C)'KF>^ =GL.<OV^"<5'%/0@APY??.+>C 40DI\CS
MQT[C@P@4%VW@N'U4,LW \N9 W%.K&H[,V.S[Z."H,;LCSP.G-]\,2:XWY(_1
M1@)R^V,NJ,F$/?..E9-7+;GLA _ZOU/&_Y0_Y4_Y7P%O3_\34$L#!!0    (
M )V 05@E9'_]!9L! "OF$  5    96YS9RTR,#(S,3(S,5]L86(N>&ULW+UY
M<]PXLB_Z__D4>'UNG-L3(4QS ;<YRPU9EGL<U[;\9,URHN-%!5:)=TI%#<FR
MK?GT%^!2BTI5!% @S7D1,VU9)H','X@?$HE$YG_\K^^/2_"5EU5>K/[S)__W
MWD^ KVC!\M7]?_[TI[MW,/WI?_W7O_S+?_P_$/[US>T'\+:@ZT>^JL%5R7'-
M&?B6UP^@?N#@+T7YM_PK!I^7N!9%^0CA?S6O715/SV5^_U"#P M0_UC_K^4?
M_(RD-/()Q%Z<0A0F"<SB*(0X9HDO_Q\1/[BX_P-+N1_%'H:^GQ*(_$# +&("
M<A\)+XE\'B6T:729K_[V!_4?@BL.I'JKJOGK?_[T4-=/?_CEEV_?OOW^.RF7
MOR_*^U\"SPM_Z9_^J7O\^\'SW\+F:3_+LE^:?]T\6N6O/2B;]7_YZ\</7^@#
M?\0P7U4U7E'5097_H6I^^:&@N&Y0'Y0+''U"_0WVCT'U*^@',/1__[UB/_W7
MOP#0PE$62W[+!5!__NGV_=$NLU_4$[^L^+T:V\^\S OVI<9E_0$3OI32-ZW5
MST_\/W^J\L>G)>]_]U!R\7JSR[+<:U5)F2DI_5A)^:_'.OOE#/$=R5L?RNI
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M*IAM_8U&1F_S/Q;>(Z]&/=2MX.#=!NI.=K 1'EP-06V\_[?!S)$'P*CK27T
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MYN'VXL0"Q8D?!SR$+(J549CZ,//EOC?FF*:9_-<04Z,C;E>2S8V)M_*!IT9
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M9X!^<O6P:7>ZY>4,K??6GW/:L7-P?,0KW&[GWO&^X85 (<6^%T$2IQ%$299
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MK2PYR^MWF#;=O%_14O7[EK=_OBO*-I?))UXO**4>DAM12%F*5+[,&.(P]6'
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MX,,PB>5[GL0M,LE_;2F&A5$WQ37=7F; .Z%!8YD7*W7YH"IHCI>@XG2M#NY
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MM];O*F%HBUD,AJ;!-2[$8U/):Y946:HIT*8^&S.#T!G0N;*'+"28UNBQA^C
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MIC=\Q45>+](TR4*<"!@CQ"&B 84$IRED&*4")T1DL1%I#O0W-U+LY#2\2CB
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MNM8JTC7?I*1?RM6=-_>FBZ^\U+^6=MY Z9'5Z/"/3&$;^1MSJM6@/^SM=;@
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MEB;X*C!KVYXH,V&,%Y $NW\I%%*6UB(DC4*1M;7YPPU7!:=<[FK2I4SUTR]
MTN_N=  .,CAKUIVED$C@G _DQX.#<ZDF820T5620)RF%**!J!Q50!%DB$D(P
M#W-LU1WP/''&QC/J&41V!'/F<IAQT' @]TQ3C2*PUF2OE,E%W0"5+=2?-K6Z
M /\4I 3W,P_'6'X!]<1S9PHS*!7Z 6Z7+3V-ZD:HVP6DEAVP)EDB:1Z$4K==
MT!FSNBQ*C',H(D64DLHLCJP<3(>G&1L!-IDU4U</T1$LS5CN?(1Z9J^]LG!+
M&?T14S<&G@CGR"2#$DFWHKL$<>)J][P*?3P_9_^J4_.KC7C(B91!@I"4,*,X
M@RA%$<QSDL&,81VR$P8!CFW3*(Y--C82:&0%52TGF*\%M<^-.(HOCWF48*:V
ML%(W $QY!#$)),SC""MT0R[#>*)6O9AS93J7BV%1WIVX/ZP_$_5/)@!9 "J>
MB]E,T\M<@D8"\*E8KL/?/((OF,@I5@]W2+ "/TP0)%DF8!Q(M1H1B@D-6O"O
M9_Q70+^<=A#@Q8SW#KG9)] 7B+W[%&N"J.6\:*K@5!?@WH HG/)Z3B'B,8WG
MZ%2#9^V<4OI0DL[)>QQ"SO[^X\OM3"?X\&_*$G\FS^N:,ECP.$<!C)E@FL(S
MB'7(!<:$*TN91"0RKW9P=)JQ?1R5H*"5%*Q$M8BB.HYG-T7X0ZEG<C@(D$MQ
M@^-(602<>4%LH(@SNT?++M+L) Z=H6;'[QXNUNRD!EO!9J>O=NUA\5YP93!4
MDX 'F0B5U20E"R'*: +SA$4PC3"+4JHLV%@X=*1=36#T@/Z"3K-+^0 7;*H^
M--RV.<420,/S%RL\AFH[T<KDL[W$CIK>>DDLQQVX<<2..OM=(G8O<+!-[L2?
M&]6=+I]+(>I:>^UG@A 6HCQ0>TQ]PH$RDD(<20$9"D064$KBQ*@TJ<%<8[-2
ME+1;]<7 6F"++_ )? T,%G^H]?Q*=P#F8KN<0,["@/&'X$!6C,NC9V?+F$'2
M:="<&&(XJ\9,ERW3QO 6UVCZJ:P-)^T<>125*-_%LJ\<BM(X%YF$8:PCZTF,
M( DS B,><L6U09(*:1=9?W2NL?'I)6/EFS++*R4R+)8R;QZ4_/N_X2B,_I/9
M=/(S =W,2O($9<\DJZ4$*S%!*^>%OWY^%G!XB]@_/M/ T?LG5=Z/Y#]]BWT5
MEP<Q;[]RAD5;5C>,[:5_N+XW+]&R5ON$6>2J<<_OIE+68X?=@UHZE559CS)8
M%94]P3>+INS_T5\ON^7!YM/\LWH?F= !$=_(HDZWV<FIB AF82I22&.D<]L8
MA30B A*<IH0Q(EEL5$7 CSAC>W,W,S$N9[.WNF1*73E%IV:;5E[RM%1F7_#A
M%J!G(CG:1&_9(6$Q![0N75/K<P&6&O6:#^,'WAY[\%D(\\O[\]D#9]*[SV%4
M^PHMEV^\4$_*5_W Z+UW)EC*0Y;#G*411!AGD/!80)S)+$EBM7)FA1,.C#TV
M4FS% TOYS,NK[(+6S6AG0M$S/1FC8%4;Y8B^3G50=L<:K.;)$24VZYL<N\2Q
MP::8*0*8+G/B/EH#6L24,\352QA2]4Y*+"$F20!92-,DCT6<8ZL>OH>G&=OK
MV4JYRA#]L.R5>1A+,^/C?(1Z?FOWP/&X5S$#P5<_R\.3#-N[LE/1O3Z5W5>?
MF_:_$;>R68]R/IW>S$O=(&G'FI8L3\,T3R$2>0X1$X'Z5M,89B&F 0LBD@JK
M^M;.DHR-/S;W/-<OK]/YAQ!-B)8RQ>L&$UH5T.KBFOEONUR&[LLA%J%OY^8&
M_IL!<F"KM.W&$@R4_^^(J/<* +9R_*(: (YP':\"X#J@<P)Q,1-UD>ZRH&_Z
MO7]0C^FZ3O?756/'%*64"A)"Q",*492'$.<T@6F*!9<1YC*W2@4TGWILU-E*
M#C9%!UKVK:KU7UV;<%JLB1E=]H-TS_SH#V27G&5+O/RE,)M./'1&LR4@!Q*<
M;4<X.TOG@93W99U(S7\GTS?Q(,HZU'D2!"EB*>.0YX1#1%"NF$QM&"G!.98(
M(8:L2KX9S#DV"EOF[#0A^:^D!.]:W#J;@:MO#2DKG>#09#:X)S8<70(SXO(,
M;,^,M9WFH 36=74;D4$M,U!"-^D/O20\G(+(?][#T1E_5?K#*0@ZLB!.WNIX
M;E<LBN?:^;43J!$BS E2U!,G$8,H$022+ U@'.8X"6621(%5QN"QB<;&/,O0
MF.E*7O#I;KX0( HL>>8HM(8G:!X ZYE1KJM%\5+SQUK8M4^KAT"84YCX.M Z
M-LVP1U4GE-T[A#IUO5-_V*H28OM@Z^Y->\SN9=.#=D($H7$6!Y $0A\YZ3"Z
M-,80BQB'*14IRLUK=9^>;VQ\T4BGO23U7AB2Z5R9_%/;9MP&0'?31@_P#7"R
M+L2!D_46TGMIW]/< $:K/K(^X1RLF^RYL-IVES4%Z42/V9/##-EIUE2GG7ZS
MQK>Y66MW8G%%JI\/Y5RGF_#/'S\J76/F=O8N*CWC)5L4[W7\[H0F+(IIR*#0
M53,1CPFD+)<PB5*&*$4A%V*RT#7,S>PW\ZFM&'HE0(\,??T$KBZ__QW\^'[]
M!=S>J?_[_?K[T^W=;^#RZNGV]]NGV^OO=J:=Q3J8&7O]H-LS@>MF EIJL!0;
MT _P24L.BMG?P$IXL);>GREHCY@GX]!BXD'-17M =@U(AQ%<O?IT<3NK%F7]
M/:P+T^JROC$E" 98MY$* D5781Q!$0CU?XK))++TWN].,3;#L6[#L1;1JKYO
M!Y"F+O=SX.G=M6Z%C(/__)CRWOSD>Q,,[ \_IN"^W_OHE0Z[Q>_B60_3!"5_
MG5?*V$8!CZ,\@%G&*$2$,TA(F,$4ATF:12(*F7G.ZM[P8WNE6P'5UT]+"#Y-
ME8R&3J,C^!GL^<Y"I><W>0G(;0O(U[,!L=B]G07,0)LU.X#L-F9']>_<A^W?
M-=RVZZC$6[NLXU>=U:/[\OEY<5V65_.7U\N7A4.+[NT!QL9-FV$[2M*R+K$!
ME+SSF9B_53K&1Y<C;7RXER^Z%KQ30^\=&$\0F"\$>^8QG^"Y-O<^#,ZYO;UW
M1OT5K;T/*W:DL_>1BQV,E65-<YU)=3GC]XN?HOPZGST_B?)EHZW)).9"B(QS
MF,N 0Y3$&<P)SR##6:8V*Q&6-)Z\BY+.C8P8PVEM'O[-R7M\![2D8*I$A8JO
M7NRKZEJA;F#X](!D[QN;MJV!/I:I^R?-!P75PGCJ =R!3*HV,U(TU;65+:Y^
M9**J]!$-80N=/%DVE[RV&5K.*V%GCUE"VFFEF8XUG.UFJ=V616=[KV/HE9JA
M6-P05I].MUXGDLB((A@0FD,4!Q'$0<Q@*&0<DBB4D;!*S=F?8FQF8",A6(KH
MY'4Z *29U^D\>'HF9TMD[".ACBKO*_!I?X)AXYR.*K@7UG3\RG/S;]H,6\46
M]W))(=K)M9/'$2:Q1 $5D/,L@4BD I(,48A)EA&1\T D5O4&; 48&RUL9GNL
M-=#_^KKZ(FHM7/-L#)?%C$;Z!+MOAU@WSD]+G =*IK'#SWL.C>'TORAUQ@Z<
MXQDSEN.XQG&NS?Q<!#+/$8=90D.(E(D#"1<,9CA,2<@2S"BV.?IWM/>'.-M_
MNG^Z_ J^WEY^OOWJ<(YOON,\$XN>:<6D![)#L.61/8F'^,J!=R@=*NU'47K;
M;S3AEXV?^HG\U?9[^BQF0A:+29*G"I<\A$D0"(B2@,(\1@1F'.4XC0,2!=3F
M+>V>;G0OKIX#M.4%EP=F"_+7:M_^B3:"VR9W=(-NN$_Q!F7?>Y86O_;X2'?+
MO%[B]_D4?O8[&"-8?.UFNB<;=F=CI/C>+L?LKO,ZZU[-JT5U15X+]3H5_RWX
M0RE>2<&77I2FZ]PZC>V25HN2L,5$)#QB.<=0I BI#9"((0UE",,,1QB3'&?$
MJ)^V)WG&MA]:>6IK?2[ AD87H-7IHO8;-F[Q1J^MU,^E:O;9M6<MK!G##;A<
M0_G4^UPIY[;"9^+KN?6PJS2_I#WQF= =:V%\[K!N=/U0SE]%N?C02<7:Q7W]
M7V_%JSY\6,^T]H*DL<2!5&2,0X'5_@VGRC)4-F* LP3'BJ:C/+7A9IO)QT;$
M#X_W#]>/3_\$EW=?P/7_^G'[\.WZ[JFM3@WNKI_LV-5J'<RHM"]T>^;-I=@7
M==&"YC1R)?H6/?;B@W)!S1,;6DT]*/6Y@+++<TYC]%OS]TDMG-!=KZL))AB1
M&&=0QFG<U-RG',50B)2%*4U(@JS:$-N+,#:"4X]GVD_]W@W8#7U;O8+9MPO,
MMDYOW8:]5F7XLKS[" Y<BG=#@%&6W]T'R+7D[H&1[,-$[^:SQ[>I" .:A)=E
M><GGKPO!;Z;DV31.]/@(8R,D)2G4H@(M*PR!DE;]N6D=U(IM'AC: 5PW)_G#
MK&?>,8 +_*%E]M2&X#0H3B&A'<,.%A-Z6K7-H%"#J\\-)KADRG@J=0X<U_6A
MBH7XJBGE=K902US0J6AVBY\_OI'_/2^OIJ2JUKL'EDM, YK!%#&B2W%',*<H
M@!)AGF<R9A$A9G&C?@6S>7>&B2S=/!1?:P2G6B6PUJEUW;B&()RUF+:!"4,M
MT(#A"DN5-I?HZ^$ETGG M6*@UFR@8 8?F'L/<3A+J%\4^. #R./A$%Y&]^R%
M>U+C?9F_D&(VB:,L9RR*U+XT"2!*DQ#F2<PAIAD+0\1R% HOSK?UG&.S #M=
M0Q= "P[^:$2W/-PP68 SO6YNL/:].=7!70U9/FU1Y6D<_7G6]I'IVZ&V,>,X
M_&C[$!B[SP[<ZMIRNWJ=5V3Z6SE_>VW^(?B]_/SQG4S%W;SVT\UG:D_[IG[=
M;&_GLV6K>$:R"*5!#'F6((A8FD#"0@'S2"0)97&4,KLR"6<(,S;:6NH":F4N
MP%(=;;PH@T1K= &43F!3*;#6RK;Q]QG+:'A(.]#B]'U">^:Z]- ;PP>RWCJ:
MGR'*P$W0SP=MOV^ZAS'/ZM:C./Z2OR@[5)_S+M0GN@W3F218XB!06W>"=-N>
M6$I=TI!!*2C.N21YG(4.;7N.S3<V-EVVJ-'&']D2>!FBY]30YRC<9I3H$<2>
M66\3OVU9ER%ZWEO]G$+%;\^?H[/]BN8_IU0_T@7HY&WV1P67N@=&=3551/8T
M_S9[+32%[:2Y&)X9& PU-M9H1 :US#KU]JG08;US\.WNX78CJ*!2NTBMA_E!
M@@FLIT\4/"/:,X68@MF+?\T2+J=#!Y/Q!SM]L%!V\QC"YK:S\@CJVN^*L+ZJ
M)9ON1[9G6%?0XQQ*A)2Y$I!4F2M4_2>6,4&"AT%DU4C,:-:QT4\MK5/"P ET
MS:P3[YCU3##+](%:X-I2J44>*(_ #":_Z00GYOP5605F,!Q)+C"\V8UX&D?\
MJB&$#'D@4@0#C@.(<)A!$M  YAPE)!5$D4ULDZ^T-;H5D0R>GD0<#AZWP3/C
M#V=(^C9$:KEZZ.=P4&%/;_SVV(.^V0?5VGV##U_D&++P]OHZK6-.R%27\+V9
MSO^\G<EY^5([3-99/WF.TD!9!80B!E$4$64?Q!&4/"812I.$8ZOP2\-Y1V<F
M_'AX^'JM \DOOX(OM]^OOMY___%X_1W<WS25PF^^WO\#W-[=W#]^NWRZO;^S
MC#DP7 W#H +_&/<=-; A<5,@7,L,-H3N)>?&$BA?1_V&LPY[EF\'Q=YAO>7M
M;J3U*'3=8::+(\R>=5J.LF/:SC5U3:$X3P/U@"60\)1"1(,0$HF;A)B82B%Q
M8I4&<V*^L9'4EKCMH;M#L:93*)N1D$?L>B8?>]BLB<80#$\$<VJV08G%4/5=
M0C&]S;6GII)]MF@.AQZ+ZE\/HM2_(,\BG,@\)JF,$%0&CH!(,JS; JM_)CR3
M(HWB(+$,P^R:SN9%&":X\O_2QZR/XEW,WFP](UVP$F4M*F-20!SA$*(@IY"B
M',$LR[,$Y5AM%*5=CU(_H [#S#6:X/_RB">*$HE0&,&DCA8.HQ!23F.8DS#+
M@HAS'(63F5@,A&;>H+F<L$<7U*:DNJ5K*Z9': U]=YX>P+Y==EMX:3DOP,-I
MU!SZMIZ&PUO#UHZI!N[4>EKI_1:M!O<XAZLR(7AUHP2]G55O)5%3?1>+16.;
M'^HV%40LC",10"IT4:$PHY (%,"811'FJ:!((LOH54L1QD;6]?Y3+S4HEO*#
MUU8KZ^!5V^4PHYY^0>Z9D);"-QBOQ =K^2]Z[@3F#I^_^%=; 88.AW4$Z$!T
MK.M(;A1X+:708XE5%:5'LM"YG4KS8EK4I+MU!K*Z3KU](A0AQ8(HHU0GFP>9
M+O(:(HA#%I LRA'+K*H[GR/,V&BQ.?);UUT3U;__6Y@&_PF!LOGTED$*7L<O
MM678[*CRK&4S(\VA%J-G^ERIL5G#36L"ME6YV#ND75^OPVE:J\,?J_K UQ._
MGB7*H$SK [1=SO4RID-_E$=!IM>5'OA!/>P_=??:>_E0BO=B_E;M1;2K[2M/
M4YRH#:M4^]<XQ<H$34(8!R)(,AFI_6MLW.C-:NJQ,:L6'C32@Y7XNNOR4@'K
ME .'Y>CFT'Y![MW!:X[OZ=2!<X&V:*G2&^"#-5;Q\&#;M4QQ@JRS<8K=B,.U
M3W'2=*N)BML(CO$&/TDI/JLI^&;GLXW2%Y\_UI>T55GJ0$F=3K?X6'<<K>JB
M>T\_R>S^M1;O-S7$HKJ=*7NFF/-_B.+YYT+PRW<E_K.H__A%:7A#BO)W,GT3
MDPSQ-$<\AI'0'5P2&D,:X[PN?8YP&.F*4E81#6/1;&R?M5I"P<&G8@;X?#HE
M9:7=M:#2:%@6:1X-R*8A&&.1=T2?X5IA6&N\T_YPHP".3N_;N&Y9BJO&Y@(T
MZ&QT>J[:&JT+!1!H$;H #48Z +Y!Z0(L<0(M4,TE0$,%-%:@!LMC9,G8UM]7
M[,IH]!HV.F8T:A^+OQF=@&YFPLWQ\AZ7+_-R4?QWK5@;M*R+M-VH:R<(QX+$
M(H,BHP(B1"A47W()L:149E%$L]2J!(>;&&/[ *NW%]M]9AWA-_LF]@]JSQ^P
MFZX21A=U_@.KOS$;VK15([4F_KXNYR'IZ5/@*,2@O'T>4+LD>^9H#AZUZ[]$
MR8I*/)0%$X^:RV_4T]PZ$A*:Y#)G 61YHC8RD@N($Q%#@7'$)(GR/#"*=CPY
MT_AX+30L@'L:1 .WER]H^CX7:,4$M9R@%A1H25U<6IV867BP?&$WD,/J# SM
MW%0FN'1ZI3H'&,X)9:+'EL_)Z 8WV_&I)%RLNC(P-G]3AFM3U%<GUS[,IP7[
MF- <IY1'&<QC@2"B.(4DP1F,<$@"GJ 4QXF-J6@TZ]@8="DG6 MJ9RB:86UF
M%WI'L&>B/0 >^*.1LI^"E58 >;+NS.8<U)BS@F'7=K.[V8V [L1"QXX]E//W
M@@O^^>-'I2W%5<7QC3"O+)1</6@AQ!QSB$+)(,D(ABF/8L$H%BG/;%)CS:>V
MHJ(!\F;OKI^:#+J'Q_O?;[]<?P&?_PET!Y?+I]N[W\#EU=/M[PY].BW6PHRE
M^D&X9ZI20C?I=$NQM7_UDY8<%+._;70^Z"/*SAXQ3]QE,?&@!&8/R"Z+.8QP
MQG$=/>U/I+O^Q-9KV)IYFEK55KDL9E7!:O]@.$$\4+M6$<)$6V$H1!(2A&)(
M"8J#G"0AQE:^NOY$'9O5]KNHC%LI#+"0%B=AOWQYQG^TM3J\VE!8QT&W*O=R
M0-7KLO@\<>I'T.&/D'H%_."94+\SGM<N8RX[/*HW;PO=3''?K[I3PBWC-(U#
M+-56/HL@2E@$2<P(9&'(0I3Q.(N(U>?$HW!C^X!L-F>XKA;%"]D]KCA9:;+_
M!37\K/RB9>K[0[*Q0IW'3>I#T6AW</D&Z9_A$WK/732\B/9+>FGX!/581PVO
M<SB<:MV]:6_OO?R[(-/%SROU";HA.C"]WHT3EJ0T302,B0P@DDD(B<@0E#FA
M3.@2RV;;@Y,SC8V<&QD!4T("N9+2XLRF$U:#<RY?8/7MTZC%U%'$+6):4G#C
M'3&+4RY?R UTRN6,H-T9EPDJG6=<G0,,=\9EHL?6&9?1#?9UHJ_+4AOR.H_G
M790?-1^;%H8^=._8"%#).)^)^5LU_6@VQ;N;Z:7TYC6@#T)V@@H]H-7W2;\I
M4*T9Z*FV<Q<J3L6<#PXX6/7F+G4VRS5W7N=@_:RRH*_F31#EU^*EJ)L%U=6U
M,,TRF8="YR,0B)C:V>8QB6'(0[69Q2G-961L_W3/-38"6)<"6(H+:GGM2YF9
M &U@$?F#KV=&&!8Y"\O('X(#V49G(6EG'YEATVDAG1AB.!O)3)<M*\GP%L>6
M:>*U%*Q)=58_3T7M^ISQS7WM),P%I9G(H<PD5EO-D$,:$ +C2.(,14E$&;9J
MC68PZ=@X=U/FIG//AK"6_<U,,(^B+,!4I% 0_7D+)8%8"@(#R3+.$2<QMBRN
MYQOU88KL#8T[I4$89T$"14(01#S5 7#JJ9>)LG%"%H=9%)E7B_.&^6!5XX;&
MV\R+[?O9[=G,V!3W JP$;CI6F>!IWW;/ B!?[?5,IARVC9X%"'OM\FSN=<S9
M>BMG1>TTGO&;XB_]T[+6 0Y1E+,\AI+D.42YB"$5:C.3Z%K,(N!ID"([MC\^
MV?@X?J,#LER*?5&_++*5W#([ZSC0&6%A0.,<9CS@$)&4PCQ #'*,LS#$D0R$
M55*['YB',&!6DO8#K!F/^X&K9_;>1FHI9@^]4D^CX2L%[?A$PZ:9G51X+Y7L
M]!V.C02?7I[_/O]3MQ6[FE5<_=NIA^#14<;V^M?2@B>U=9P]7P E<]/K[FH^
MJPJ%FFFXG %\I]W&_I#KF0E.@@;^Z*<SX$EPW)L"'A]ZV'Z )U7<:P5X^@X'
M+_-#*5Z;D*X',2/3Q<<D9#C,0QK#5"J##(F$0DH8A<HTB *AK#24&[7[.SS\
MV'AA+2!X;22T\'_N@V?@+#X+DIY?^ TT'CR@8>$ /@N5@7R^Z_K;NH[,0OU'
M%WS>?7XV2LV#H@**)=^88DK>M W1]\BBK/3=I1#@0Y"R^I^>/,5'0>QT#N_?
M-9P_^*C$6R[@XU>Y[40_OU7%3%35U?R%%C.RW.KJN*9+IC9C55'_RJZ;EMV@
M(WKIEX*##<D;5XV6'6P(WTMS+3?</.T,+"<?=+?@!LSN#L)Q%+L7JRH7NEU!
M-9\6O)[B=B%>JOH04 :QP'$:0$%"G4<=)9"B+(%ID*24IFF($Z/HE.-3C,VD
MV)(2U&):':UV@-G-1'X@ZIEM'- QII33 '31AKI[@S+4O]9TT3'P()1P6K'E
M:V]PI=LWLZG 7Y?^4ORALPLGA 1A&I$,"J:V6@@1# E'D=HX$(8)B4B K,Y%
M]Z<8VZN]/O6OWJC: Q>D_/@?%>#B=:YXM*J_FL5:"SOOX@&$S2R/\W#K^7W?
M$*Z&1XOGSW@XKKHG ^' !(,: <<5W/W0=USI&ALA1:FV+T_DKR;D7R=U-0;$
M=#K_4[\&$Q03%B(L8<QU#[Q0(DA"EL,LY(1*S%G,C(JS6\PY-DY820C(4D3;
M<V(#G#&C8<@EI!FG$"5$0,J5*45294O%21B%F$QFXEDG:@V+].ID?CWW_^%8
MFY&NYR>U9Q9>2ELW 5DFAJW1O#R)IL.)O#$^W@[D3\\X\'F\,03[Q_'FMYZ7
M7'LO3]:$K8X5A6WBY 5B+.+J&Q#D.(&(BPA2@F,8:L*B%"<HRUPR:\^6;&Q?
MBLVDS2;#GW96 JC6I0#H?BF DT'[/2^[&4W^DL7LF4SWU[&[HD/56=+!7_)%
M;YA[SKH]7ZY?DG+K#<YC^;;^)G!JRM2ZV._ES=N,MS7/!-<-^9Y^BF^"%SKE
M])(Q,=55A 37;D3^KC]%K2 /Y?RY)"]7EX_7WR_98B+"G.&0Q>K#P%-=0C&'
M- HR]<\\HB&.XDB:I^CZEV]LGX>5AII77EI] %DKU,2C-BJ!U:E3HY15&R+O
M*VUP[/EKUZ_G+\)ZZ>XEJ-4#2_V 5A H#<%217"YLZ2MEJO/0JOG!:@UU377
M?NWJ6G6B^I6K/%B[JE^TVK8MKOI:BQ-]L+Q/.V2SK+XPV^FHU=LT9]394$.^
MBE)GG]<G@VK[.<FB#&LG#\PDEQ"Q#,&<Q"D,$!5Y&.4B-ZN:=&*>L7V*V\H'
MZCM<ZM9THFE-5_VKF$[56SQ[*RL=R_&ZTD-]I1M%'(I*'$#=X'/J!\N>/XOK
M A)K,<&E5Z@<JF^<!]G@M3=LH',KO'$<$*.R&P=N'[[HQG$=#I;<Z+C\# +]
M6KPK7EAW1'Q2^[:J<>0US%Z4:M-63SN)XS1.0AE"+@*FV]H&$$<1@T((DDO&
MI(B,#D]=!1@OY<[73587:_F!7GBPT!JHO4_I6,''9H4L6+@GW(>A9P5Y(_]F
M>]L-#98VK=(!/@R"O .I][0"P[*]SY5P^Q0XP&CTC; 9=_B/AX/6![\J+N,X
M?&Z:[4'!EVUV)$TDDQQ&F<[IR_,,DH0$,,F3+ E)SE#$C;\DVV./[2.QE,Z"
M?W; ,B!U=PAZYNNE8"Z-FG:?&7.&=8=C,'?,NYB]B<9 6&$DYR5@;]5BS@NU
M@ZM$^5XPKUF,'>!T4N+.+<.QW6%9MXCLR"5N)\RMC?WQH%9K<3GCJS3GSQ^K
M$D%A&"<H#1!,4ZZLX"R.81Y)#%-$6)8S&J;(*-G(8LZQ<=I2Y M0"UW["#<R
MPJTK,]G ;W:&ZQG4GEGRZWSVW!9#?MHJA>PMS-@!%T\GJ"8S#GHV:@'![JFG
MS:UN!-3T<*K#9[X4%9O.J[=RHX X)D&6RSA26^XP@(@C93>IW\$P)C$+>9!2
M816WTCW=V&CG\?K[T^/MU=/U%W!Y]P7</_W]^A%<?O]^_6390>D$RF84XP^[
MGMFE:2/?2 K6HGI.A+:#Q1.YG)AL4%XQ4WR74@SO<FFP^_(ZG7\(\;VQ(P_'
M:=S-ZQ!LP>N(C&J"4F75$!Y $H0$HA0C2$6D_H/# ,<HD"0T/SQQD6!LG+,9
MR\8VQ+X LZ7@@-22@T_%#%3Z\NIO-NUH79;)8$O8-_@]D]92?-#*?S3Z\ *L
ME&B"TVP\?4[@V_0([GD1ANH=W,-B6#85/@/([F;#+@,/V(3X#+VWFQ.?,Y#=
MUX>+8G(]6Q2+C^L743X7L^??ROF?BY]Z)C+[F B<\@"A  :,I! )46^@<Y@E
M*,M%SDC.0Y-OS(EYQO8E:40%2UE!(RQHI34CK5/0=G\7/ +6-_N[867,*89(
M=)3L42,T!JKZ86V7GAIW$.(P5&Y)#Z:7GY>1=U/,FH+(U:*Z$XM)1KF,:*JK
M]:08HDS&RL8D#/*<)'$4Y1$6?)D=]F2?C+<SG=&CO9T6]C0 )7P55?4?@ NZ
M $55O=4Q=DR+K*Q+81A!>0IHL\WL.;@-E0ZF4+I=HG35H'37@9)S^M<1##RG
M?.W.\DO2O(ZH>BRUZ]CEKNGYV^VYU(C7?['I&]<4-)_S/XOI=((9CB1+",P)
M5SR1T@SF(HFAD)AS(KEB$:L>B":3CLURV&B01]H\2&MZ, +;C"M\0]@S<1QH
M+ZA[AW]:R0R60A_?MCLD^9MCY"WMWV#*@0L!F(.P7QK XEY/Q0*4W5-5DR2+
M IR%&(9I0A7CA $DNJ9\&*>99"+(8Q)-%O,%F=J9)-O36'',:K+^WI(G/8<R
M1=JHG07YJ^6:,Y/5&TSMC!!WI'JW00ZDI-="]IB$O@5"7WGGS22_-M5\2]&3
MV>7;5]O7_GH@I9@MVDU.&V(21A&EB0Q@(A/M_0XII%G*(:.8)4(@'B72M/#7
M@?''9E<T(MIY((Y!U_V&>P"DYU=[&PN/,3<G5#^CNM>A40<K[=6ATF9=KZ[+
M'$_(FU#%V?-70=0;HO]S.V/SE]U>VT)0Q *:P%3H,C\\B& >$%WG(0Y%$F8Y
M(\SJJ-QLWK&]XYN)_X_ZI& *&K&;V+-U8.X'^%Y/:OG!-UT.,PN@!Y![YHV5
MQ*"6]J+YGR7&??8JM\3*UXF[X:S#'KW;0;%W!F]YNQMQ:6>?$#MS%83J[KD?
M;89D]>5-W*GYGOX4TW?Q;3Y;_*PF$8J3"*4$AC0*($JB&.)8I!#%&<V(B#B+
MC,Y+SA5D;-2FGDUD1U;.2V#&7D, VS.=-2I<@'U:6^IQ 19S0'4N>,$OP#\%
M*<']S&,1KG-!],1SSF(,2GSG@K7+A&>/=T8FXFY]YVK",4E8FE.($%/_84D.
M,<4"*MZ+,I1EU"7?<&^:L=':.K&J=L T>=JMK Y);/NP=I.9/[!ZIJHU3GM%
MW_W@Y)#2=Q9>@R?N6>#FEIIW% ZC!+S]NX=/LSNJP<%DNN-7VW>\>GA_W=E"
M&3:YVKMQ; 2GOB/@O0(/HI3S\J4^SEV'OEZ 6GCSUE;[.)W@MW,AZMT1M8=.
M'[O(3AB<6E7MCS98=ZJCBFPVI#I^D8O1,I]=D6FAEFA6D-8%2K(T(RGED(6)
M[KD=1Y!P9:Y0&DK$U08N1^:UXPY,,+;W6(D(V4I&FT_N ?!,C)+S(.G;'%%H
MK,5SR7<]!(N-#7(>/$-9'SLP?9F_D&+F*[>U X-ND^/ ?0,:&\>EWC8S.JYS
MX+#ZR/=.+'1DU:->]F_DK^+E[66"<RZ([F$OA6ZG)]4.C/(DT0?B+$9$4!*:
MM],[-LO8V*PY )\I@[B.QZO+(5R ET98B[?X**H&#.<#JYYIKH%)!]#4 7F/
M#4S?_,%DP7@^X!J(]MQ@LR._4W!T,N#1FX>CP5/R;W'AR8OM=UQ/);\LR]L9
M?RH64S-+;>^NT;&:%LI\,[4#P>F=E+OV??-42>K8OHU"U!= R5F\%_Q-O8K=
MP%AMHPYCX+2'VAEJL W4814V=T]'KG P.PZG'M6_K2[?%C_G9?'?@O^8J>&^
M+]0V[?Y5_UVGW%?7?XF2%95X* LF'O6ZWI"BU'TFQ 3C),ITL YF+(<(Q5+M
MOA("4QY$*)=I)"-SHZ4?&<=&#I^GA/T+?F<_U805T&+6_55,^:+'Q32PE7[]
M$O7,8,=S+!LEP5I+\*;5!+6>H%&TKLQ278"EKJ!6%M3:7HQJK2T,OE^_Y@.9
MB_7ZO&OAU&Y$4<%+,=.K7)?P)8#6[VW5OK<O<ZY62M>.>GTK7^>5^M5< MYX
M5/4-34XZ>)TOE. %F4X_FFPC[5-L'ISYVZ):D%G]P:SJAVC>/$1M9GO3O&K[
M3Z\:U;KRS[RN+U&*IB@I*&:UX[*Y2)0+M;VONTC/EZ,5L[JE=%WIZJ5^?.M/
MM"<KN-]GI-.&[FGJX2SP?K';LM][GLHM1$>)\J*$T/.U_K<8(TFB0, \K!M%
M$01SQ"7$09*'84S2E!@5*CPZP]AL@D; YE-B%URS#U[W5]P+)#U_@S?1\!@3
M?%)U3T$L^^,/&IUR5+W=L)/C%]KOXM=[O+I<G.$N?ONNL;V4:^G^PWPOOP/$
MZ;V\.P8]OX4;VW9?]?".Z^NT;]\9:K!]^V$5-O?M1ZYP+H_)A."5K@R\3,6^
MEU>Z:DBYT+EZ#V6;IE._RY,\#D08I$*7JQ,010+K)/\ 1J$D,8\#SI%1/HWC
M_&-[C9?B-Z'WJXQ_9:V_+N5NC77KLIE6RV+V7>X1[)[Y8AOGVPV<-Z0'*_%/
M&#LN-39=@/-7;]-J]J%K;[I <Z .I],PKG6,+CE7SV?U,%>[Y.G_6[Q>J2WW
M)(LC'N0RAESD2&T-6 Q)GL4P8'$8BE37-S$Z1.B>9FP<UE;F:46] (VP0$D+
MM+BV98P.(MO-3_[PZIF&7*%RJ&+4A<0918P.#CMP#:,NU?9+&'5>[5JF1*<"
M?=?MM+3G[ZM>CF(^:P)7)FD095E&$L@2$D-$6 @Q#U/(:(A2E@9"AD8L8#3;
MV,B@S7);20N6XIZ.ZW& VLQL\09@[YL:9^P<JI$88.*M#$G77 /7'S%0>[_P
MB,E-CBF RU2:FWEY\[9X*\7#?%JPC\]B)F2QJ"YG_,?LE13\:DJ*EX.UJ;,0
M!PQC"C'A7/&-()"$L8 A90(+RL-01E;)@&>+-#92^G[]]0;<WGW_\7AY=W4-
MOMY>?K[]>OMT>VU9)-S#8IDQUK!+T#.MK92I3Z0:=4"C#U@J5)\:-2J!1J?^
MRY+[ ]E7@N'Y @V;:N@-P+VD0W\CN]%RO4G\.9^J.RK=TF'QH3X"3:FIAWE9
MM[-?+,J"OBWJ_('YG4)L/ELH]-2@S[<SQ6JB6DP(9G&<\QA&3#>>Y8F$-$$A
MY#'&,N-)+J/4IG"4'[&LZ'FP0E.BUL>.D#TM$Q,\17F20293KBN/AI!&(8*9
MB!!"<2!E*B:OHBSF7%D!Y6*LB[4K8H]Q0F1:.]#( E#Q7,SJ\WSMM:PE^"6+
M2-3F*L,TA$$2Y!#A+(,XIQ3R(!1A1"0/<=(NXO6,CWL)EP(.LH!"!VS\TJ4S
M,XJ&7XR^O4&U$CH&=5EVLM4#;"JBPV2V50%+7?S90GZQ]60/>1)J4)O(+Y"[
M=I'GT=ULHV_%;%[64S?#?1&LU%4AM.M=66+-_'7CT"/S_[U18")Q%!&>)C!E
M6*B-J]J]8D(#B$3,XXA)%";8H>"W+_F,F&+X"N$[7%"T0BLFW^:,ZHU6!2](
M^=&:5G5\GAV_>UMJ,X8?=.4&RP$]Q-P78*E;<R*YI5T'XX-60W_,[QMS3]SO
M3:Q!V=\WF+O\[WU\E[[-I%)CU76 +I]+4;M$JPD/>)R+((,Y39FROFD"<9!3
M&**4RBQ+1)I3\_;-AZ88FU.Q$1),ZY>8K,2TZ69\$,ENJO2#3\^DUT+3U#V\
M] >-3;_G<R$:**Q_"RJ#I\BRL7,7"MW]G0_>.6";YR[)M[L]=UYI7P5:<:S.
M&FT#EI55BG(2QC"+(V6C)GD(B:0"<HHYY1%/4VITF+LW\NCHK!'.O.3S-D[=
MK'66]GV352.7Y_K.![4]H[+S]GB#U70^J,9F->?#%[AM+/\ABN>?NM7<NRC)
MLUB6T&HR0.[7"4F75%DZA"TF),X(T]&C<2Q3B'*<0)+'.<PY#@B*XIAF5L&D
MM@*,[1W^Q_7M;W^O>R'_?OUX^=LUN+K_]NW^#GS_^^7C]7=P_^/I^]/EW9?;
MN]_LMH'6"Y.DJ:+*+(0LXE3MYQ5U$IS&4+?M(3+/LR"-)FHP.A_#TFP*TM_B
M?+F^N_]V>W?Y=/]H&++O#+_9;KM/2'OF[*7HH)4=K"L8MIFP&_*KO78Q?=-7
M_[%4Q>,ILBN*GO;)UM,/NA]V!6=WW^L\CG-2@TY3_="YA8O+&=>NUE=M5^KN
M>3'%D1 D@S2(<HBD^NC@$"%(TY@(&F:(V'41Z)IL;!^8I:QUN(98"NK0>ZP3
M89;B*$ZU+R&. X@R3"&)0EW!07TW:$!%SC*;4W-O" ]P%O[P>/]P_?CT3Z"^
MT^#Z?_VX??AV??=T >ZNGSPB;/:!\(5;SQ^#I9@7=8&#1?UL7J^?3:\-(4T@
M\9>U<7RJH5,T3BI](!_C]#T.WL?]3.\GA;=8[M;#G/ @2Z'D=>BU(F@:J/U!
MF%%*4(*%$.857SJG&ALS1T&8V'2Y[X31P 7I#9R^S]@/%#L!M:@N]3B[8;-P
M3WJ#;R WY3DPVKDLC9#I=%UVCS"<"]-(DRU7IMD=#JS9>$?7=<_:](D\2G$>
M2V59100UAS8T0"G,*!<\E1F*J3E='IYC;#S9GDFLQ;3,2^F"TX VSP>I9[[L
M$Q\+?CP?IX&(<0\O3S38#4 G_QVY=3CBZY9]B_%.7.JV?;^N%L6+#L>YG55O
MI0YS?!1L_B[*0E03&B6<DPQ#G)(4(AIP2(*(0,$#-9C$A.69S?:]:[+1D=]\
M]@QU[3!0+(4%TWFEZX.5C=!DU5'<;K?9";G9;M,7D'T;E$LQP4I.L!;4WT[3
M! Y/.\W.J0;=:9HHO;O3-+K'T0_8MK>ZF9>;]06^B-=Y52RJ^]FC(%,UOYI]
MJTT0R6E$!0H4J>BTCTBD,.<\@(RD/ B)X"(1R\!&0Q>6FR1&[\UV"&//%'1=
MJ0?B3\!;P2U]6H[K8>CNZA'CP1K%U!K4B7:?MFJ>_ TL]="E&[4FH%'%<[,G
M3V#Z\J$Y2C&L>^T\J/8\;V<.YT:5RR.9]>"M!U ; &DFL B3%-*<".W&CV&.
M,PHEBF-,PR!$-+:QN;HF&YO-M3Z9+/5+)YJ7[G4EKQT#=L)L1G.^P.N9R]:X
M;9+5PVG<K*G*!!!/?-0YU:"D8Z+T+K,8W>-&'U^*2M$3F?Y6SM]>KZ9J!U+(
MHBFS4)<JC+,@$TS9430-"$2I=NS34$(I9<1H+'B8&_7]-)QO;"2R%!?4\H)M
M@4]50'0"W(Q+/,+8,YV<A: UI1CBXHE53LTV*+$8JK[++::WN:;SM[5;[N45
MJ7[>3.=_5JMHJ1!E(DN8LDEX'D(4YPCBD%"81!2)#(LT(U;62==D8R.6=:TA
M70I120MJ<4TBI>R!-N,47_#U3"AG(.>0G7L:$F\YMQU3#9Q)>UKI_?Q8@WO<
M**1NY+M^EGF"I=118'G"F"*-D$$JPA0BKG8T$B,6HM"&-+:''QM-7'[_?OUD
M62QI!S"SE]\=AIY?]T:P7M[NPSI[>I]W!A_T#3ZLV.X[>^0J^S+OE[J7R-/+
M\[?9:Z$K EFWR3XZP.A>1RTH>"I>=&KPM[N'VXUB6>;5X(_CU?VN>H.J[U>V
M R7/)<6,('$J(W]\U,$JRI]4;+.X_.F+?=:9UP>:3Z)\T2T?)UPHX'*1P8 )
MHC[$*854Y@%D<4@DBB3+$BL?P>DIQ\8+VU7.ZZ:UG^[F"P'"Y&\^ZL=OP6UX
MJ.(5Q+[/3XY6B:]/SK7$=;/6O@O#'X*GUUKP6Q..H/S[(0#,*KX?O-.YRG-=
M7&%99.%V=O\J=!/HV7,=MK(J4CC)I.(81#'$B4P@"A"&)$\E) $+0AF(-)=&
M<736,X^-@%9BMF41YG1:/)/NH\4SL3>CH5X0[9F-EC*#3TNI_Z8;Y:TQ;F+/
M5J)[+0YMAY:_0M&&\PY=--H.C@,%I"T'."]>Y5%,ZVI4\R?RUS^*Q4]=,4S-
M=3,O#_?8FTC.L,Q$#G%$*40LR2"F+(9)S$6<8R(R'KL%K-B*,KZ(E4?QJH;Z
M6=.97';.5#^QIA%<TP%3U]M2\E?R RS(7^#/M:;N'.B\FH:669\K-&B\RP50
MHH,-V=M^N+"6';17^0W2]86BYT 7:S%^2:2+*UC'0EV<QW/>BTI156H@,OU&
MIJ_:;U6P-8NWZ4!Y*((P4V9@(M56%%%$(<X1@0(G+.",4617G<)LVK&9A+^)
MF?K43>NLS$T-#.R6<\ WWIUZAK3_'>H:P0V)UVANA"7[[TYJAY>_+:O)I$-O
M6RV .+!UM;G;,2)/+/09F)KKO>""?_[X4>D8Z9MBIAX.72M!S?E>U(%C,L$H
MI9A#DNH\L#IM5I]MQ3B+PSC-PBB6-@GWYE-;L=4 Z?=WUT_@ZO+[W\&/[]=?
MP.T=N+F]N[R[NKW[#5Q>/=W^[M TQ&(=S$BK'W1[)BXE='-*OA0;T _P24NN
M]K1_ ROAP5IZCQ%^UHCYBO<SGWC8Z#]K0/9B >U'<(P,;-LV-DV8E('7G!?6
ME5@8DDDJ4ACFDD&$4 1)("F4!%,A)0MI:E6)Y?A48S.JEI+6F\TZ7<MR;]F!
MJAD)^<&J9])9P=1V5M/;Q$9.SV5!3J/A*]3O^$3#1OF=5'@OP._T'8X=U)0E
M)<37QK]6L;)XU5N\K\5,W"[$BPX=%DF(TQ!224*()(L@5N0 :9(D69KH0G5&
ME8D-YQL;533B7C3.8EUV?"4R^$,+#6JI+</\3F%NQB$>D>R92,X%T;XWF1DT
MOAJ/G9AMV*YB9JKOM0PSO,V-9*[F+R_%HG8V7<[XU7RF??="63KB8)<_IK.:
M\HC#.$(8HCB2$#-=P2S!:C,5A8R%B0WGV$T_-@K254AOGW0=L^]U6;.K^[LG
MM:.Z5OLJV\V4Y3J8\5!_Z/9,2QN"U_ZU+='[;Z#HAILGSK*<?% *<P-FE]$<
M1_&:ZGZ_^"G*V]F[J!;;K@K=,8]$20:S7&V[D$@H)"1,8((H94)&<9 F7E+<
MCTDPOH/"6E*@NVR4!=,%(EPV9K;K8'?6YQ/;$:2T-XBO%.C%=^0(7;\)[$=G
M'T/B^BEH#!/63P[C1G2/8D&44<BO2:F;5E;M>1$A3,8X))#0-(8H$$C]A$-=
M?39'"44R#JUVB8>G&9MEMI02+,6T(ZLC6)IQTOD(]4P]>^#T<*#6#8(G$CDR
MR:!<T:WH+B6<N-K14;01&GKU5I:*<R8BB!/,D&[J$@00X22$>:!9 *<H95&4
M"YY;.8?VYQC;.]^*!5[(XJVL&55',TU7I<%X5X"S,; 9IIG:]^8PU]6/4$:Y
MKI>N[$.2AKJ*=QJ+R*&WHRN^P[=IU/Z(_P!L#^SSH35TKIWW)/;M4-N*I[\
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MSQ];%4UJ92] J^X%T J#6N,+L*$SV%CZQ_$LO44;R)$\ @/UDAS#HV#7I7*
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MGX!9.'I\ 3>0IV830&7 %I5.]VXAU(48;F=<*/K@^I-FA*R=V\4$K4Z_2><
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M1:1U +,N/MM<8EEQUL-RFK'4L(O4,Z-M* ,:;9JBKA78U$<W@/M23-\6Q;L
MUU)JFU?O7;MS$SVVPO:'N2<.]2#0H'SK#\!=;O8XLL]*Y4:9B?MYB3]>7T59
M_U0[,"<\3^(\SE,H:"@@RA(&:28#&"/*@SC(6989Q=@/(>S8N'^5D?RJ);X
M;UI<4*][ZY[OK]*XI^4W]$:.9%'[=EN>DXI^ 6K%VKST6K6^"WG[78!>RW-[
M$G4$1;?]@FY62MOSG!ZJTA'MYVT["G[HZ1>7L[J<]ZM^4R8BY$&4JJ]*$F9$
M[1M2]55)!8="Y'F"6$IS:I0LX##WV#X2VV75*M*<BFST:3VC,MV)53 C]YZP
M[9FK=ZK5M; N);\ M>P7M0][)7Y/Q>O,,.NCC-V)F7]=03LS2#I+VQD.X9[M
M7NFRW^7KO-1G*Y\_'G4Q<*%4?1)_+3XKS?XU88',"9,<!IGN?DB# )(LB&&(
M<Q9%A 4H,HH5M9IU;/RU$AQL2J[/;5>RVV>WG\:^F[MZ0[1GUC( $_RA!0>U
MY)[SW(V1.BO=_?0L@V>]&RM^*/G=_&:7$$TQ*^;EU^*]F#W?$*:/@PI13:(8
MQZE(%/,PGD$4<PIS0A7SY"R-)(^33%H$91Z<8VP\TTBI]LU:3"!7<MI$"QX&
MLYM*/$'4]]:T0:>1$-QX1,<F>O)LE ;O.G]9546E*58;@K=JVZ3V5%SOZ\V1
MM R<[,2H.U3R\*T#!D=VRKX=#ME]J0,37KX]OU4+C<JC>%4/PD^BM[+SYY(L
MXWRQ2&04I@C22.00R9##/)02XB2(61+Q5,1&L8YFTXV-'QN!@988K$4&K<P6
M/' :: /"] I?S]S9C9Q+6/II""U8U2N4 Q&LX\-H1Z7&P'2RZNE1AB-88XVV
MN-;\+O?-\(,HBSF_GG'=4F\2$!I(GN60\(Q#E- (4A(+*)F4<1(GB61&[26.
MSC V<EW5(&ND!->ZBH&Q;^XXD.:[6&=X!MJQ&B/CM#,]J/U9N]#M$0??<1Y4
MZ-#N\O"%EO83XY.GDE^6Y25OVIW4#Y^)*73PSK&]G4O9+%[)(Y"<L&S.1J/G
ME_&I)%SO6C:[%)N!8_[E[<2@XY54-[;^:\;7K^21X8;YY':JLOK$=E_E=E;V
M5 I2O94?]1E=$S72&H8IQDBDB80D4E]5%$CUD<T0ACQ#82)I$N2I5?V!HS.-
M[25>"MIT%K([]#H.I]D1EQ>0>G^W-_&Y6 :K^0_!/0F&IY.JX_,,>BYU4MW=
M4ZC3-[AX-Z(@S+\^W>J#K/;119AREJ0Y9#+4I=L%AD1P!*,\SFD:D#1EV-R=
ML3?^V-Y_+2!0$M8GLS9[[7WD3/P39^'1\ZN^!863_V$?$QN'PUG8#.1AL,3(
MTK-P%(%N5\+^;0/Z#H[*O.TL.'Z98_3I\63.K\5,W"[$2S5)2(1$K-,J41HJ
MJX9A2$7 89*&01K+#.<HM8HB-9AT; 37F>@,_M!R@UIPVR1SDP4PLX-\P]K[
MH=?9B-I'6EI Y"MBTF3*82,?+4#8BV"TN=>-DCZ3JJBK)HEJ^2&ZG/'OQ?.L
MD 73D4*L+F6I9J\S*@M1K0-+@ECRD"N+*Y&1A CERNPB,8,RYIQE$2(I9C94
M=8XPHZ.P']^^73[^$]S?@.^WO]W=WMQ>7=X]@<NKJ_L?=T^W=[^!A_NOMU>W
MU]_M*.RL!3.CMJ&6H6?*J]5H(AG7BM2'UQNJ@+4N8*F,Y[ AG[!ZHLFS1!F4
M/GV MDNK7L9TH]O?2#'3I8_N9P>",M?1Q@&FDD4LA0SG!"+.%;'*A$ <9PE5
MY$HS9M6*S&S:L5&HEAKH;N1*Y@J\KN*17[74]8LL3H8CG[,*9FSI']N>>;&&
M]9,6^6\:W2]%]3JOBIH<-\*^FZCO/@*^[0#SQ'B&DP[*;79 [+*8Y=T.CK8F
M]$O7(%H'*+5-@^>S2B?2:(9LI_U'L?CY_5_%="KXW5M9[03&"1*C,$]AK/^#
M,IDJ*@L9Q)+CB),LR2DU]L]Y$VML?+<.M:NV CCG*^7JI$?]JR49@C^5?J!J
M% 2S1D.WB$]_JVW@4_PE:]@SK[;+=Z_KM&U&F*[U JUB:Y+5JH%6-] JYQ:2
MZO%E-7=__I)E'#;P=9#EM'.Y>D>]TU/K;[;A'+S>$=KR"_L?W;DHS?Q%/)&_
MKIN2<FUIJPD609!E/(>8(UV' %.( YQ"$HB,9W&:BLCH-.S$/&/[?"K$WXNZ
M+HPN!E?40H,%^<NVU-XQ6#.D7HP\#F 2T0"BE(60Q@&%>8)H+I-$4B$FB_F"
M3(>#=37;_[FPFNVR/(#5\^>_D1 H$4$K(_C42GF\2H5+<9LN'/Q5K#DXR]!E
M:+I4/5!;IO-R-X[]HE/4RNT2 JMB@U=34E6%+!2U*Y6:9E"3,,<B# ("$R(S
MB$*>J;U.2F!$J92<A#QD5OGZUA*,C9>7"@"VV1Q]NE3A LQ6HMLQBOW:F'%-
MKXCWS$(KL+<ZT7]=@[V6_P+<G0;>FJ"<P?-$7?;S#TIJSO#LTIW[0&Y$^(W,
M2!,F^UV4[P43BF_5/XIWL2Q]RD5((IK#4 8<(J$,)8PC#!,IPC#+)8Y"J_+Y
MIR8<&\VMQ -KR<&-L*Q)<A)F,PKS"5[/C+6!5BOK!5ACZ3]FTQ0:3WQT<KI!
MZ<=4^5VV,;[/C5QN2%'^3J9O0G?.G,ZKMW+SU)IQ)F1&!$P$BR&B/(*YD!(*
ME$9Q'"81$D;>8Z/9QD8K-Y>WC^#WRZ\_KL&WZ\OO/QZOOUW?/5D&#73C:T8I
MWE#KF4^TG* 6%&Q(VM.9OA$HGIBD>ZY!:<1([5T.,;O)C4#^418+<2_EO5S:
M1;I#W&U5O35-WZO%),D(0PQG4&9) '5L$J1AJ'O\1$D>YRA,8ZOZRZ>G'!N5
MU!+#N93ZB(DO-PJRF"F!ZV,C8>O3,8#=C%S\@CG4'JMNSKT4$F@I+T"MB<+8
M'\>88^.): PF')1MS '8I1R+.UW;YLS4^%=JX&+1^O4_+O\JJDF&>$Z0(##.
M4 I1C 0D%.<0DP33-(Q%1*VBN(]--#:.^:IKPI3@3ET"_M "6D9H'P74C$=\
MP-0S>U@@Y-!QIEM];WUECDPS</>8;F7W>\2<N-Z- G2HC1J(5HN2L,6$QP%.
MHB2&)*V34H6R,% <0L%$EHB8Y4F6V;SXV\./[76__E\_;I_^:?>*[P!F]F*[
MP]#SZ]P(IM[D5C2/;_-AG3V]PSN##_KF'E9L]WT]<I7;6]J>S\^>OPI2B7^(
MXOGG0O#+=_7;9_$H7D@Q6_Y1]Y<.)W&4I)0$"0P#+B#"&$%,\PA*25&>YDF.
MN=4QCJT 8WO35_*#J9;Q OS9J@!(HP,HETHT5P EE6$M+>=%,N../J'OF5W6
MJ']M4%]*#UKQP4K^Y@KPU(6Z-06Y0N>)I*RG'Y3&7,'9)3KG<>Q+V^C3HDNV
M>"/3Z<<#*?COU=7\NYC6_1&_U;GZ&W6##8O>V(PY-E;;.B5=*@&T%N"]^I_U
M(2J9Z;:ZC3J@U<>\<(X5X-UTUB?6/=.8(\R>G;:N #I5ZK&::+ :/B[J;U;W
M<;K?T;4BJDJ(;6[4GF.=F?6H"U#A-!$IXB%D,JMKF"8P9T0[6[*(A2P*0F)E
MH9V:<&S<M6.1U:F.TUJ'"]TD3_]%'ZJ6=;NMZ@+0.A^R>BT%X3KQYYV41=VP
MK;3NG'%R;0R]-1X1[]UKTP"[9Y MY06/7FJ&V4+CRZ-S:KIA/3N&RN]Y>$SO
M<V>D>;D]?-O;JGJ:?U:F&A/%N^!/?\[_*4A93;C:*=) AC"G+%*\E.*FZ46&
M6)S1A,11;-4-V%: L3&6>NP2>Z*Q@MR<>/H"<@ BFI<'B&C996TQ!U1O"QL-
M+H!6 "A%_'*3"WH>N<IJ^L&YRP6<0USF-(ZWSAEMP%F2,XR1%%"$@D"4) 12
M+'(HI8SR- H(0N:EXKMF&AM;]=8GPKSTFB^X>N:D8TBYU&/KA.SL!ANCK=&V
M:J[A **/KAH6I=LZ!_C5'38ZRKD9W># GOO-(J^U!V])GW'.6!1)* 73I3QR
M"3$C'*:A3"F2&4J#P)@^.Z<:&W^J)R>P>/&[830@2V_@]'UB>*#C+:A%=>'+
M;M@L"-,;? ,QYCDPVC&F$3*=E-D]PG"<::3)%FF:W>&VG[XBU<_+&=?_H\]Z
MW\E4&[>7BRM2EA^*I.M@T4E,@B!/"889"3.(6!;!/,H#& @4Q%$F4&1&H%:S
MCHU+M;1UQ2.F?Q!KN>VVTV:(F^VAO>/8]QG$$L+ZAPV1+P!9@*743>2XO[VR
M%4J>-LAF<PZZ*[:"87<K;'>S8T?NU=;ZDJDY2O'YK2IFVI]8W8G%O:QE:/["
M)R@@.(D%@CS-<X@HII BKDP\GF4D(S22&9[,Q+/N<OEDT9G;0@:C%RMO7JP]
M27I^R5Y;/>J" ;35 1 M>5-GK *?[N8+ ;+CB?'G+Y(9BWG'?*"6W4N(%W/0
MB@?6DE\ );L^#JJ78RF^QY;=#J#YZMEM,_6P3;L=0-GKVNTRAF,M\I]$/9#Z
M#/=F7CZ1OW2=FI_SJ>Z)HWY1__4SJ;;SBR=AE$I!<00#R7G39X%BP:&@+,U%
MEN2)-.J5=(X08S/-&AWTV\::-B.5;G8!WI38^NW40E?R0U=,J8NUM>J!.9T6
MSVT=J4_%K*[L)BI+0G1:1#-B['MI^G9):@%A+>'J9&2CU=,%:)>M5DM,>?VM
MTK5;-O0$]ZLU\E@4_0Q<?15)=Q%AV*+I9X"T5T3]G+'.X-:]03<>O\\?ZTO:
MI_/R3U+R^[II5O6;NE#W2F\:VM7_THVT;F>+LIA5!6NV:3)A68 (A8'N?(/R
M,-?M>T,81$%,,5<&:F"5:3"(U&-C[UI,P)6<H%@*"M[K[&'-RGP^G9*R J^B
M;!C:A:![?Q(L&'U,ZSO@)V [ '&CY1_]  <_%5IO?<A>:WX!&MW5(]+V[FQ_
M4S<*!"L$?#L/!ETQGQ^7WF4>_FLTU#(<_'P--KFC(W<KI^[+7$>L3T(4TY0Q
M!J,Z;B!#$N(@PC"+280R2G)JUYWQT"1C^YHT,BX/;S_ 'XV8ECFP!^$T=,J>
M"5+?/EA;?.S]K1T ^'*O'IIB6&]JAY)[SM.N:SUT9&W,ZY77C20Q)1G.(,VQ
M>NNC+(9YH&Q4C$@<QH3HDK3./5FWYQK;R[_N*+_G#'#>X'=!33&*<1HF,%"(
MZT*3(22A+O/+(Y*'E$89#B;OHJ3S@<'>G//_/W";$; G"'OFX=T&N8V@%SVX
MB@WPZ*-'[LY,OZY+[F&5._OD'KG%M7XM7=S.JD59AV34G8^^UQD@][/?V_P/
M'1D?3O(49PQQ"O,X9\I<2P*8_W_DO6MOY#B6-OA7! PP6P68LY)(2=0[GYR9
MSEH#66FOT]7S-NI#@%>GML(1;DGA2O>O7U)2W",D4D')RMT!IM-E2^0Y#\6'
MA^2Y$"&!8)Q"1CF3@96ONFG'4V-Q91@+U5Y91<5XSR1_R@Q+[%I#;L8H0P Y
M,+W4>9$V,E]Y=2FV;YO0H[7@CH-F;*%REG+6L-N1,\W:@7&<8-;R_9X7[[ME
MBZX7?%.YZ(]"R-7\2R;%#$G?EX)R$ 6QWDH&NA*:KF] $"5Q$ 0^M7(!,NAS
M:K1TWU;][$K?-BG!O;F2W/)*W0!^PYMTMZ .?8&^P?-^@^?-%L]:9N]+&Y[V
MU^;F"+FZ+3?H<=Q+<G,(CN[&+5[M345,"%Y\5F(KYEOE.DG<-U&6\^J@;1.+
M<\W*[+6NE40Y]DD*8R #M1%#F#- F20@98)AAH(PB*P*-=J+,#6BJEQ.\B8X
MR=-?@)>M%=%ERRKUK#G*=ER,*6M M(=GL$KX&N.-^-Y6_MT@P:T*3OFL)WSN
MZ,U6@+'9KB= )\BO;TLNDL3<E=]%[BX_S,GF)D=D[3E+*AU<Y(,YC6T[@0T$
MZ]"G_Q:(CI+ZI14P1UE?3O?QC@E?6I5NS_72_FJ/T+F/1#64KXKRX>;V<1VR
M% B() E!&NCZ29$^DL*2Z[0N2 80IE@8N;6<ZV!R/+,6T=,R6D1^G0*O@S8<
M0#(T1^RAT2<@[N0W91X&=R$\(P6_V<)D%_#6@D%KF-NI]\8+;FN1>B^DK>VY
M?AO'!_$J%BNAC;./RT65KE1[&7Y4?2R?1;Y=U:F,_23V(Q")U >(PQ3@0 2*
MY1B)81#@,+*J9&+:\=0X[^'F'S=?_[CQKK]^\JX_?KS[X^OC-_4E?[RY_<?U
MAR\W=MM#8_3--H5#8#HP:38BUSO!M=!U:?"UV /5/[$%R]'&S[C;4;=[MF <
M;O*LW^_'5M><5U%89*ZMNMO%1_*2E63^L;I!KVX@9X1*&I$  \H2!A!+,4AI
MS $E/((\31&-K*H7='<Y-8;:2NR]*)%!MO!8+;0=.1F ;49+;B$<F)!VT*NV
M=PJ]1MXKKY:X]CQP1T3F\#BB((,.1R4?<P .:<?BS1Y;O'7AE4?RX[HH1%FH
M']:_:RKU/HA"Y*^BN%[P:\9RM>$LJG17FW*6LR2,&.-)#()48+43Y#$@*2)
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MO>2&&Q-GX0O.!1PYT&$H@(]#(@;KJ<?)ZE&RL$JFZYTT>S,_\:,@B"&(*:0
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MWJCU"(#HQ,-9O,/YGD8.;^A4^3B:H?N5GAD@UU>+MPNV?!:Z;/7,9SA@?BI
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MF""(ZY1OYEDWSG4S-7+;".IM);5)''$63@.2<P+2P$1W"I\^9'<>*)O\&BX
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MD<Z;3J=5ZBQ;_UIE+[KQ>\5)[&WK5"PQ]Y%$B<Z%JBP'3D.0)CP$2<"C@/
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M\5_CA7F8*-<5^S5D4,<UYY5-4,P(HU@F:0+\A 0 (1\#$J0<1%$J.$O32)#
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M[^^L_.X]YJNL)3-)#[3-;%!G& Y,YUOX:D'7^6C?!LAY8(2)L\H ;7V-7!G
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M*A\R@\DK_>CAPZI0)D917+/Z0$/9'5LK-T&*!Q"E@" < A1"##!/=4;Q0.#
M3R,:6$7RM'4V-8)8R^KM"'O!7J(59S/R<(7>P.S1'SAK\C!!Q!%[M'8U*GV8
M*'W('T;O3+8V^O^([.F[^O?Z5>3D2?RFFJZ2J'TF65XEG7Y8SN>?E[EN=1;S
M* Q(C &,,0%(0EUJE 0 1SSQPU@$";7SLIF6?E.CR;7L7B.\5TE?YPS4\MOD
M4Y\HY-,IMCW4AS+]FS[[DMQF'^8PV:JG^26\]T7C0-K]'%>4PP[M.]0+[R6F
M?4;B>[&L,N5I/:Z?2]-LQ >O36W5O+^Y\^I$C?M\^*S3.9OG(3X$IWVANA"7
M@1>)?I!8Y1T^HWROG,.';8V6;_B,$KNYAL\]<JD[^WVNLS^5;_ILLKQ>5&3Q
MHEFB=L,6.G:&Z:ICB8@ $C0%!,<01!C+-!6"TE#,%%O0I;V'>WO7-I_QK@ #
M?LV-O%?5$7I9Y;'8R'RI]WO'.(0(ABD5,2 L4>,0<@@P@43M@/PX2GV?^] J
MH&F(41@[\. ]Q\-P^S  RD-3]D6@7A"X8(:0\TB&CF[?*;3!#(SSL0Z&[_=(
MB= 4JLM$\<="O?([479C7AUB[UBBLYAS% :0 1GI5 <22X IY  F(<$B\OT$
M&SDYFW<Y-:+:"NVMM-3><R5V7:S8(UO!+0+AS;#O,!@'071@4MH!LQ+8JR6N
M+[-V3QR<@VF1+< YJ"-E =@!MTX$*GCSR99_+[U"O!#].Z]4U"O IOCJN<^Y
M^*]FB-0>4_UE]['BRB,>S05AWW4*1.(5V>))+>6;-MER->=>L:+_CV"EMURH
M55[-FV5>K?:J/6]9'0_)K<!LJ4P_)2]]J_Y>*#7W)2N7VS]P(<EJ7GIY5OSU
M7XY2%%@->FOJ ;.6QDLI8*797JH NS=[K$'7J@$N^$[#C;M.'+,@C?U4+3LX
M 0C""& <8)"())$^A3XCV'C9.=?+U%::1LX]3K3@P;-@&JPC+B :>.DXA4ZW
M]Y,%3!8KA NX1EH4K#XJ.\KL0J&5)<^^/!XQ=LF_QX6=#]N?GC[FA.N*D'G^
MX>UVP>O]J.$1ZJEWI\9GC8R[9IVR'*B^*.+9:\979&Y^FGH2K.XCU4MQ&IC4
M#"!RMU7OPJ/74>O)!D<[;VU39_?0M?6Y?B>OC[H&T"I_JY*2-/E)]*U-,?-3
M/Z4XB@&!% *4! D@J0P!BD*."(XPEXG-$=_9GJ8VX9M,.D4EG)<MO+*1O,J4
MSI:%9?&,\Q"GB$50%Q (9 6L" &)H+(/8XRDB-5?13*K8XJ_E20O1P3ZL-<!
M?;G(O,IAI+"EXBE;+#23J U6+8'W2[8>"LM4UBU?M@B"D"$"$H@80)C[( UI
M#&(:"XQH$,&8-+#?+/CHH*_[' 5R90X,"[;9R;03^ 9?Y6H9ZQQ;5TW&K:O:
MI<1ATO!.+!P=.I_O9]13YDYU#X^5NU]PD2R\N)/:(WJ9GPKJ90Q+W\<1@($N
M=HJ% #2D! 2"L2@.?+4V6EU_F7<]M<7RR\WU-]MX:0N@S=AC&/@&II-:QJ,T
MX<5 X=3V& V2^KNUXW=,_&T"2'O:;Z,61O9_;ARJ[E9E49*%WCO4Z4]G,HQB
M%(8!P#%3QGU,","8*3O(1PRE?BQB1NTM3^=R_HP6ZU5_*\K].,="A$3HJH>)
M4.,<):G:Q&$(N*2AC%*1AKZUJ3N!47X_$WE2HVNV.K[K> V\B#IP^]XX=N_H
MN4XD/@%_[:Y!>&^/Z[/R_1P^TUWP.O-Z[NRH;VQE-J_.!!=\_>/M\TN^?*U/
M89M+(2E12 .1 (8) H@CJ#.!(I &3/V>\P11:><V:=2O#5&,XS.YEK7R(\MV
M!+:-M#1!G80A)#R"@$2^6GQ)$JG%EPFU2PQYRGG($V*56M$YYN/$N-:2%J-
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MZ[S4"(R64U2S]_NQTN=LD97B2_8J^.VB5!].1N?B6M%@67S9U$]C"0VC-$D
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MMZ]*B56>:[LB\'T6,D)!$"0"((8C0!," 84\8"'AJ0^-+BJ->YP:=7Q9+IZ
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M$NT/E\,CTQY"C'ZDVA^H4T>N%[1F?R1[O>*9^A(^9_GS+9_A-(X@5%8=I(@
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MM>A[:I11%T @32*Q^590VZ2!YNB;&1L#83HPIZRE]GY9R_VK=@*J4=ZYT#7
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M=E8[^^0%_M2TV_N-6GN_73\]Y977P^VBS#-%3JRZB*V=XF91B%C, @:(\!E
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M!/L2(H*M\A>,)/?4B.C;7H*YUZJ<>>4#)[:B7Y!=;J2/P<S]98)#/.*N:F/
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M]G :DXX9.H[(1[/344G(#(B/9&3XMADI5>5Z<2/MI6*9LYKF[M?\M6H/8[S
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M*?4SR)"J,49##-,L2&'BH8SRC#,:&<4?64DQM;.10UNMD;X^ZV]_W&D"6E7
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MD2+D92$D1'(6$AZ")!2)Y#$1((%%E&3$R-O[>IFF1F^M[)+/E/" [DNO7'
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MWA&F*&,"(YP$OE9E@MY>IL9JG72&,87]2/;3EC-\!N8E?6CTO1YU5.]C$=G
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MSLNZZ.*.'G3."O6;FQHEUV*#/;G!$U]ORA7XATH'(_]9BZ]YYF2 ZH6SOF$
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M$QQ25>TA@419&9P(24$QQB@3UV??<B/LU ALF]CO34D\ TLE+JCS2("E$GC
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M!)7/-,2!'U N_QGZ>+'B+ZJDN89UJ=6IUK1*FVFUW_7 UQUJ_[6][C"PA/2
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MB(V>!TN%50-VMP@WI/K^.5>%WCA3*]-G+C6LBF7.FID0A:D($!4P\C&'B/
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M3Y'[&@91F,4PY:G<[S":1(2@-!.B2P/VK+_M<26?UCPZS!KV/ +[?.%5]6^
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M6NH<U?O.1!5,EI4>FZ606LS\1R[?V;2C'EU'$?"J9MH>:; *IH,*;%8M';[
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MV,M7-9,EI;RA*)&*XD J 4,<<H@P1CIRSA!,54RD1(B$PJH&?6_DL;W>*^&
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MJG37RE\42NH+-@@+]-_T]T+>J>4387%"0BYA))%VKR13D"220AY%(DQB*:.
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M\^;@91Y)A^]+-I.LD%\4*U3QO<KBUFEO&K*,JY# ($E"B*(T@92E*8Q90L(
M*X3M*KU/332V=[X1%52R.D21;6A:A/<=8=2S,=B!!]1R^FR]M.'E$$1WA-M
M,?$1_#H*:2VP:(U0V^X?+N"TT&(K?K2YWL<ZJED^+V[U)VSV7'_4YK-F5S!6
M42*#((58!=CPM^J0CU !4R)3E7!*16!UQ/7D3*.SCZ6LH!(6K*5U>?';@+6Q
ME!W!U;>I/(*4EZUL@\S%6'8$W5#6TO5A<S27%FBTV\NV 08TF!9Z;%M,FQO\
MSRY-ZI,1=UKVFN%=D)A2A0E4BL40\22%7/(8!HI1(>.0XR"RV9)JGV9L^TNW
M]W>_P,GUXZ_@Z_67";B]_OX=7/WV^'A]-P&_7DY^>[R9W%Q;[CF= -@NRCP?
MMK[WI'>.,VU$FY6LX%>V?"\ZCBK;8>GPA-.!208_XW1<T4.GG%JN]O"IOM8,
MY!/V<R-]KQVXI>F'9/C9<$0P)<RT)3*\^$A!%J 0)H9/)&"*4XX=>/&M)K5Z
M_(<GQR\%!$LCH8.G<!)A"P>K$\ &XH1L*.U-;[6M'AL5?).NX7-PMKJ$<2"'
MZSPXW;PO6WA:/;"3@PSGA=GJL^6)6=_DYXW],I_+/_+I]-!1A!CC@"B.H(AP
M %'"E:&]SR!-HC2+DC2.W#IBM,PUMB#VE_O[KW^[N;UU\[S:P+1SOSJ"J&>;
MVDC9_S$."SPZ<K[:9AK4 [-0>=<-L[G%ET&2+=3+?"IO7M^*^8^29+W)*G#)
M9)21%*:)B=A(S V#=P())BB+:"P1=B)Q:YEK;.9A)2K(-V1U)8H\#JUEK-8-
M8'T';"NL-L7LH7>&!1R=D4(>GVE@0LB3*N^309Z^Q<]6[!0;W+V;,>^SK_GT
M7?_V^PO33]7]^W)ADO$Z7G^*E1"(IQCB@'.((H0@IVD&$Y))HA25DB8N]L-Q
M_K'9E%I.\*=\!A:EL']V,RBN^(>$:_L=:_<."Z3MM\*0<Q9"CC-D.(,D%\(E
MX]8G_@.DXB[EW]\79@'V"M(:]O-2 S!?JS#<6ME]$'I<@9X_$GO%:)7LAAF^
M$AMLR'T!:HVZ^W9X(M?1]\1U]D&_,9[0['YW?(?Q#&M-7P&E3)C\OJC)]@B-
M-/(L@SCD&*(4:7^5$05IE*4T#M-(<*N"E98YQO9-J44$E8R.;(5M6%I&L^<A
MU'<4ZPB.>_!Z7/VN@M8#,PP;K!Y7<2](;;G4O8G;-RWQ?*8>E= ^;/%Q_?--
MKVW=/,9XMDPL<U&ERS[621C+9F]>@X_MW:^5 (T69JMLI8?YL.YJ8M]!S@_\
M$_L*0^#>LT5QAKSCK-G9&'KUM/.;<;#>=V<!LMDC[[R!?.OKI<KR6;Y4T_R'
MDKN\+,UAIR>9IFF6$</3)#.(!-)A',<)C(A,E$Q2$J69&ZV\Y<PN;]\P5/+W
M)>-$OA(?EO+K7ZPXB%BI@6O-OMU"\ @3E$:I264HB,(DA 1+D]Y@,8Y10F46
MN1V Z'P9ACD8\3GPV_FE/8#:\Y=E \_;$L]]2JU&ZBZ/4CC!U-D1"[M9!SYZ
MX03%_I$,M]L]"F<V-H<WMHR;-NF_:0&*J\O'Z^^78OF4D3"0$2(0,Z8C81YQ
M2&/,(8YB$2LD8VW%K&N3'28>FY6JNH[(IJ3AK9*Y;$<X%[G^DW9^3"G9AW.1
MC<MJG/"+>\2X[YV?S?*0K<*11G)0B@Y*V<UIL)X0=BC)Z0GI@:IS.D3<K53'
M [;6JAV7\88KX/'0<JN6Q^?^+F@*_LJ*W'32+?]Q,Q/S5_44)1P+G%)(5)Q"
ME 8!))Q@&'&$LE11'B?,GY?@P(QC,_Y[1 0_:IFK?VN/U4A]#NW (=CM'-1.
MP>S9RN\1"S3B5O\&-^TXGDDCT()-+[P!A^;[1** %O7;F0':;G3/QE[-OZNI
M$DLE?]7CO1?J\G5IFVP]=._8;,75_/6-S3Y (RFH1067KX9/P3YS>A"HTXG1
M<S'JV03XPN.4V&S#P"MO>7# P=*2;>IL9AU;K_-S#LK-UB_ZO9=FX;1G4GJE
MU1;LY?OR95X8QH;2'2F[5-^7_6(?])(OKNMN[@]%+M2C?@;4[:JS,>-,89YF
M,&8TA$BQ"!*F" P8X2)%@B:!4^JK'S''9EI*?2 W:C9..K@L"B.S^=G0950$
M:(U.H%0*E%J=T:>ZIX? SK_Y_*7MV2)6J_JESU5U=ISZ!;TC;ZLG(0=UT?H%
M>M>OZWDVOT],E==\"I@*61*DD(5*0419#"F.0\@1RX(H%"B,0I<2PVI8)Q,^
M'$ELV1S$S0C7,-D937?E>S9RE^T;.<X&:EO!C@Q*/>B@!F!;D=T7=N>O[M'6
MY1^LD(NKZ7RA)O-?9V^Y.?=Q,Y-W>JULHZZV,<;F(AF9[$.L5G1.AUI= =/W
MNU>*"4HY03X#D_Q5@>4<_'KW<+-Q+&MQ ;3L^8]<OK,I: 72*1BS0<DK*&L=
M>+#@S$:]S2#-ZOHS@K5']:8?G!=F/M7SYX*]EJT%$AD2CD,$@T 2B% @(5<D
MA $2D0H2T_;7*85[?*JQ68124K 6%=2R>K7^;4'8(9HY&[<A(A(/R/S"C%8T
MN@P5#D\TO+O?JO!!E[W]#C]C<?V_[_G;!DM>%B<)"4@"9909.M8DA(P*9#J$
MAXK0*"#*B8YU9_RQF865>&X&8!<UN[?^#"QZ?M57DO5PR/*(UAV]TKNC#_H>
M'U%M]^4]=IE'S<ZC6N12C_2HLO>97#RP#[,E\R14J)(@#J *37OOC"I(LY!
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M?,MG;";RV?.EGO1'N;MTR;4,3"R?TH!AF= 4"H)#B&220"9--S#)A,"Q2-.
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MF6/:2NQ/W[B>Z!N.96[%PI[%?P[Q>HK093Q<#.<C&/ HF$%]17+)>9"@!5K
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M&)7"V>>\&@"5 JV 7-I%9>21#ZC%=2  P;-$ QA=^^+SNT3U>_AU!*BZHF@
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MIP^\%4*[\.EV<D/W)F8WD&)0>MH.EXF]I4QW,BYG-HQC64K,*3J: W&+4;"
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M.IF(<39:"H$Y7_LP^SY5_08D.X)796$T *^+*?C9]?3;@F'+;;+4PC%ZG90
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M0^NG<CPBH5^WO LI/Q_=N3'+VRFH?YU1 V^2,$8HHB(M-9$"_003@("@TBI
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MBR9%=D2DC"X_R^CR4XJ&A];22V9E8+6;'[Z=RG[OF'?=3Z>6N/JN8T9/_W;
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M@<I^TV9VC=9NA=A Z.;A"L_]"$XR?I*NRWK@)DG2*0O*6?3HG$#?SB/OK U
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MG'2>>*DRNDG&W>PS99@!;VWTM<%8@^Y^\YL[ =2D9^DV@.C;ZY]3/TSH] ]
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M$'S5A;0Q\+[ -$QJU>(.+S_-3_+'V;+5X$F8^^&XW#_?WIR]GTQ735*,@KE
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M7IQGSQ7) &O3<EXOQS@=>#D!$R5DJ[R-9EN7KP6F__@R^_&WY;>N,+#\> .
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M\,@I\$;:>B[S0)$]R4D[HWGL9,#^$EFK.VFT4];J+N(=.I?A7L(=MYP\)2Y
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M8K$"BN0H%><<58L!B4^M/^R[06\G9C.1CQ VF_EO,1=?K 2?$H%?"$MQMXB
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MH3:SQ1^3V:VGUNNG=Q559J*6H$4#RG,%P=?FHDG(3$ WFH5],?+TLL-&WD?
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MZ8\./^O[8"NTMA@$)!'(RRAH(;),KD'.*$*P0G5KIK(S@H9\)&FETZT0V4/
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M>+MUK^#(:R@^:4!G<IVD8"&0J,!BUEATB0X[31%N@;>Q7.TUAT)7J.VIEQ%
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MM">3,>"XXJ"=<BXD*YEL?2QNIVBDMPE[ZK\KO'97Q@B@=9+2U;>KBYJ>TF7
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MK>)_E\#[4%[.O_^@7:XI^82U[6M>#[[[_(UP',,2\\5HO$N0BJ"=E-E#B%&
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MPX@KM]9U1O")#R:EDB18]'5057800BF0E9-1,*EY'J3_SB#4G'1W\Z-/RO@
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MP/II!#<V,@].0-FV]J@&9(TB?9G7?*9MD^ZL0PDLTD5HM*&CR2TXG0I(G4Q
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M"X.(1S%ZI\@Q]>2GRMI R!&[Z,>*Y21S:IZ;<J*-4O82^UZ-4O:100> JI;
MATV;CHL29N\S5W5H58Z"E':)$%FA,\>5%=)HAK9U]XI;F^@2.(<(>-Z2VQW
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M RW\9:"$HU^M#F(,6EI?(->G*\4<70+)&F"NU%;F3,K\-('UW7I1#-;T[<E
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M7%TKU@/EY'S!TC&ST.RQOC'3LE[<SBLG:E1-9O7[@X1&(JP8IR CR)DA1#/
MI86 <<N-TLIY8J'[&EJPU]=J?3&V'!L]'[A5RIG_XO5(+/M><B&Y+*B+PYF?
M:)X[=U0*80$MM($9*3@N0A^1^_B)FY4;2F?635<P1!(X$]^%M%C"W[ZU<[;H
MXR0\4Y8H!B@MH(NP"P*D]M.="ICYQ0B8ATZ![&$GKFZ%P[P:!H!T=6G9\(D+
M"'-=9$ 2)  Q4(#"'>! ">K<!62T7A\P,90VI=!!'0SV9NK4 8,$%.H?,S$J
M;6FT7\NRR1<K6C!B)2B(#WN-$4XNE -"+'*"P1GCH0_[+6PDJ3Q=0*["2CP!
MI;FLQG]N6X5EAD+E8I4<N@-?: B$4= _.R6XX,X;H*%O_&SG)&[1:#C5"2#W
M!+1GQSG_[D%^>^M?R0T3BA%WX%,_($0X/U(Z^0'.A1&6X<P>R_?>PEU<+1O,
M6QH(GG05;_FVP,EX[/;6QU].KDU]_O0\JEZ-<7]5#I5[!/-"8FY @7/K@II"
MNB5K"S*-%48%RS$-W?(:@.TD'?O>&M5,<0>#-UV-/JLFTQNCJH=Q^7\^O4<-
M-Q*[5?A92\1:Y@NZ+A WIE 90@511[*BGQE+TH >22M[0)2&WLT_^S$=]*T4
MLAR5T]>SD9A,YCZ*\U?4K/9@W$L&J5L5 GZ$K)-CCD$A,PR@X9HY\7+;;)I5
M.QULQV3<5H_CZ>. T"6@F[\X+_M;-9E<C2_&+V8RG9<[[AG,G6-LYM=5D8NK
M"@.$GL\EA99 ; @6H6/:K8S$[>8XDH[UAR#^:-]WSL__]AMEU0?/C54NV$)
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M0J#OS9-KUUYVW*C;^8EX:A (NRJX(*->L-SCQ9V:L7I\$O4?\RWC]@ME"!;
MVOF#9@5U6X9:P* +*3-A<YR'KM,>XBEN2?8XT5-W$%+P>S?6LUK-<N?Q+",<
MNJUFH._VA;EQVP03/X$)<NT\/)/#P97J,T^)>;Z]-."@>O6 (P'U.E&JFGUZ
M-VMI?8FF3!B8NZ# N.,=<@XX<=87:DT)YTCE*O0L_UV\I*9.?1!??Y<\A/@3
M4*-;,3)N$2]F/#.79I7S5%9+@9A_OAAR?X(+('7! >98NM,[USCX ,^MC"26
M(@RI0/T%GX#V;$CHV_N3CY@P3#/AO,G%FSW2UW"@,]C6(&MRADSHYJ'=W,1M
M&SJ&L]1-\ FHT+=R6C[,EW%KIM/1O+_JY,G;UA/?/67T737OMKL6]?3U'KLU
MY*P0P!06N?VA7.R*"04*(TBU4!S9X"_%M6$PL1.OHU9L-*$-!5'L9,#%6)MG
MWX,UGKX]3^&K@*4N15V:R6_N5_4JNKVN*VF<Q2[-7Y-[*G.$-72^I[:^UY-"
M4.@<@TQKJ1C+"LG6O*R=XW<ZLI#8V=A/U8Z(1@(V;T-XR[&/XL&@>P0)Q 0+
MP&3A@IP,^WJS^QNB)BN@AIKCP7,-'_A)++\=QJ(% Z#'!82/U[N&:::]NKR]
MNSK[[YOSZ]]NSGX]N3V_OKGZY>;D>\]NVD-D0[;3MEI"H'[:\S]GY?3UK0DR
MRR&TO,@ ++ [SS)- >?.R7=Q'(4,%066H5V.SQSTMC9^F.*5O?.7%&;UZ^VT
M4DL/% NM&+=N0=@_ZI7EUFDZ]=&&RB3,<ZMTZ-O\.YF)ZSGUP'S#M@01=P*G
MU.VC$]V->9[5ZM&_V%57#[5XFB?BA*8Z0SXXI1D%! GBSEOM8U65"<(S(H._
MF[Z;F\@^=QBXU[,#862?K!8M$RBBR UB10Z4\%=CA'/>A*$4Y)G[@4)*,AUZ
M+,,^?B(W-0;"O)$J=0 @=K!V,GN83:8>T(W5K%I8&$&<4!=P:N8G\!$&)*86
MY$0JJ75!H>&'/)QFGTI14[I 6@TFW]C:\E^ST:M;2[9K+59F)/>-PCF'!A"(
MN+^LZ<*'P@H72S*B4+, _L"'XH;IPVA*2-DF<$0MG+]M!_E[M&DE1[D1#%#E
MIPQS#(',7?"96PMA[N+"(OC<[@9L1<X!#>+ZA$8C 06;<[]YLL^FCU7MGUU8
M)%/1?:&S/,^UOV5 %" $9VY90OGW;RFG1!-;A.X(:,A:"M%90)58=Y$&P"=9
MM5L-B/E:U<J@>ZBL+B3-@16Y"W6I44!R[-^<H=P= A8ZH1Y%YS[S%=>RQ5&X
M'L@DH&V?Q#3W.R8GRLG1<7(O:(X5407 OF>'"&2 R-W*H&%9#C/+W9$06,GV
ML!,WI3VT;H7"(8G.S$^+^5V,9F:U%O]PT7?C++2^E]QD1'!GC#DG3EJ*N55Q
M#:#;)V['($Q(Z QM$[[B=F@>5<U"(!-0WSJ74^;4)T;]^T/U\A]&Z<4'YE7N
MN_*I'#^\#TDX7#WYI&0?B2[T2^EWM=K^A9:%E,[,!ZJ;S&W-J3O./KWI=%+7
M8OPP[QF8G+Z^_W^6D[_F["UX7$QP]L^\^&[U949N@.1?:!9[/Z4]F=:EFAH]
MWTK+K$'8=6__1E3[-*2V;+Z4O4?$G>W.J'>.:L[-?#F3;;#O2#AM_JNHW6W'
M '*_M"(AJ/3]8@5/<\OZGI3I>@KLIAB Q>_CY](3O7/6_M3]\H\@;&Y2C9(H
M.(C%FR(UD4C,U/5'_N8^5&"\UFA&B;*[H;5=&HE@=>T^.ZV?QOKK2#P$0>HS
MQ2@1:R><MDHB$93\CC\;3W0=#J8UDE%<JL[6;U,6B0#U:_77.W]A+> .TE%<
MJ$[ [9=-9 #?SM3RR>BO5>U=PM_%J/=VVT>W"70L*G0-I)+"QIN<C:J)N:O>
MV/6UO("[[P#])CCF\;=@,RDEB^= ,#9"KT@4O41 NQCK\J74,S&:MS7V 6J-
M5-R@;+_,JT,"B+V51J-WOK;F:=INHFT$HR&T0^95,P$D4'=\SR+MWS2=+K9_
MHATW6&ZTB_8*)3A8Q^X#V;ZJ;?VN0^4CXZO[^=/SJ'HU9IX-O7KV:QND9+#[
M._$;&H]4-C@HZ@3489$4?W:?5^7R-MO#XW1R>W)S.XA:'/Y>U.:*8ZI'8]''
M=F"VG1[N1/<K#!\-K @W40,^V&'9.1Y8DTL*T/TVUO7H]>'6J%E=3DLS.7F:
M]L=M*]5&ISN,C]H^D:0 V?G?M;JN2Q5@?[V3:@1. J6UC<6G@,@O[@28?A%3
M\U64];Q=J3\T6V@VPBB!@MIN<40&Z_/.?OW^QW2N2F>/XX=KU<_L'2#="+JX
M-;9FP@F&8. VNHOQI'12O*N%+L</'WVRSYSW[*7;\YD@#75-E]&SJRY2ZJEE
M!]/98UU.IM7SHZEO%G]W/S9;(](=W4S[*<1+7.Y+>E5M)1"QQ^S4O!AG-$[_
MIYQ.S1^E'];;&)M=_S9>(JPI*@=6':]C;,-Z;!C\COG^G61[,/M.[O35R;U_
M_6@KP8BI[T-8?#Q\]PDCLM/TSEKOPM$:J6C8[)7V5E32*AEM<0_"G-^["2>
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M>^0WO$5?_L+_(<7$_.>__3]02P,$%     @ G8!!6*.[)9 .+   ^SD' !,
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ML4:!X4H8)S,_3WS>@RX/Z?!"S+:L$EA\O@ULX%O6U+_KS77H;3BGFVE$4#6
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MB$$6 !@(0%]1;!;$G@C &%J97PTEOD^I4DP!PB""P5 ,>OY6(EC *L(J@LC
M1'X64E)T_NZ?L(98H@WL6L'.VLH977JOE[]>\(AB(86C<DH#. )'X-@&CLPJ
M>G7=ZX%3"J<4. ;&\1T;K3!8@^E#4!B00DSAPR<%?N'Q.V=CM?*5^LIIU=)@
M"\$A.&R+P\\D):-[B.XAB RNS*^SW!89#C[#3#X8#*7,.S*2RDYA^3<+NPB[
M""9#*U,RZ2O*"(>/7B+8:YV]3"MT$!'N%P0&(] (JW$T$WQ1T!A<&4^CF[*4
MH!$T@L;0RKQ[A5C ?T F!",%BHVC6+4L*:Y<=,9I6:7HD_'EY=I@S?<W%1M0
M/H=R52<OTX2MRU@YBWXD -TBH,8M;<W :8;P7D%D4"+]]\1HBV#!=XB$0^_!
M7X/\K>]5A"'$-@S0UQ)]-RM/8?I '^AKE3XIHT&Y"<-@<A^]01 97!E/WY6_
M%< (& %C:&4\?=)?D*[@GV):$2 &!3$CK'V#402+P95YIS->.W\;-G%-HW-6
MBOQE,68#_K;/7\Y+:T\Q7X%]&*"O1?K^7R$H@_&#\0-^ ? KXF@@7'-1'QZ]
M0M@!#/ : 8\59^CTW2$1SM,&@$T"J)ROJ&]?Y?A>,HH&6DW(M[B$2U]+VUPX
MDN7N)W8PB2O2G6HUC#4U/:OZ].E\S9*F_JT&/K_%ITM&0F$5-WQ3F,:6T9N9
M(L/D("8'@6)H9=YG&:?EYOMHX!-%$ETR.2=A"K\K5'-N WA\QLU,W[0MSZ*9
MB 1Q,=9WX.NR'ZV2AL]L??H8#GP%KK11 BA^"T6#Z&UP4F$4PRLS)U$;V]Q(
M_:/7"-'UP5]3ROQ&R3AZ*Y3"QE^,EH*^MND[N;A8#S;6R#+)1Z\40K,U(.J)
M$5^U IG?(I.OKJIS$.&68K/A@S60L79.9W=I\^1;X6_^/FZV(]X$'/Y1:P I
MM[!H[OXB/E_87SB*)?N?J9@<'_F/1<7JW"]W??&YMJ+T>_J&I7> )GPX%:D;
M^6MW?='+N>I'T;W)0K%7K'";LV1DAD(M'N)![FJ%CH_BLGYUA:OJ+7^.S**
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M!'Z<QNS<]?L=UA#6$#@&Q''(*HVJGB* !)  ,CB0V3S&X>0:R)N834 2BVO
M8[L\EM^5KRKZBS\(X@=M ") W!Z(\B\_'^SV7AY&G[2ST6N:1>=&#PUEX!&G
M^X+$-DF4,U\0848#74;P&%R94^%;V4C"0=TL$4Z( 7X-XC>.+HN\/'/A>C\P
M"+RU(]@H=M&IR(3C%/LNP-_V^*O")+Z2!:8PX(\"R.#*U$">Z4(Y$EAVBF6G
MP# <AI^%E#3D:KQT  :Q)1'XM8B?PSG:<$J!8WAE3L5D$42X>L__^8/0GKQ4
M,(@@L D"RR9U[O\<78ATR.@68OX>( 8#T;M=)CK[- ![.$@;, :%<1CKLO^#
M;B*ZB< Q.(YZK OWK<D+ (E(4J"P)0K73C&"EXH=^H"O)?B*9#R+SIG& ! S
M]R P!(%IRG ]X7J"O?;9FRFU'*P-"[IA  %AV_-?E J+E3,8$@6,X959P(C(
MWF 23#X,9<YH*)+H,TG),^^B*J%--%_A!C]UO;-HRM5&\RG]N43P4X'AMC!4
MPNFI3F 5816!8VAE/([>#IZ3&6/L%,,VX"\ ?U]+BX@3@>\0"4%+@X,8:^=T
M=I<V3[X5GE$N?0L44MI[P HA[QU9ZOX2/E_07SB*)?N?J9@<'_F/1<7JW"]W
M??&YMJ)<P-\W+,F)"1].1>I&_MI=7_1RKOI1=&^R4.P5*]SF+!F9H5"+AWB0
MNUJAXZ.XK%]=X:IZRY\CLR@@IR'OQ(9IO$-7CDV?I&]-=NTJ_A++M[2UVGPG
M;R7O6GOUSUQ2;KF_^'*8"IM+FO6%JIY<E>EPM3C?]FZUIK*QS9-O[J?3G=]3
M_0:OKUPG=ZJD!5$K:7O=SL'>_L;D;J>W,2U L;W]3K>W.7FY6#B6M;4RP\)G
M+:<?,,*"@^T?E#?YY-N6IT^0TACCQ!@G8 RM3 GCS<H81+' #@DP&(!!.R(I
MEX]-PU0#XLB OG;HP])0.*- \0$H<T:3>1P93LOZK(5,@4N*T#*@,R"=R8F4
MC'B'\%.!7TC\=)852KCF3A]Z]%*!0!#8"($#6@DC ^RP%A3LM<3>6S*2%.(:
M8J0&. 97YHS3.T=J .6R6K^=7%Q<2S0?H\&JFC^EY(D17[4"DM]$4NG,=WJP
MI1Y+VV 60S%H1"H(L=;01P1][=,GTJJ'^(&RG& %T4\$DJ&5^1:2L(JPBD"P
M3015^2LVT6,3/3@,R6'3A_ ]>HDP- /\FL//VG+@_9,AL1*D @S"%(+%MEET
ML^B+D%)/X99B'1OP:Q<_G8Q]16-Q?4HHZ -]H*\M^I31.*[^#H7N&P,-](&^
M.^AS'+.4F"#$!"%X#*[,F=;EEJ8)#"*F!P%@( "OI)ZNO.)!(/J"@*\=^(RP
M,'Z8D "'03DTJCS)ZU=_N1E@_$$8!ZR<(0D<@>.V<"S\14\YRS2V4FQ4"<?6
M@\!&"22AHL^B+)"=,%P&%(-!;'U5'S!\QJWK!D,M&4NX?]0S_: -NHG <6LX
M%B8?S6Y-'+Y_#\\4<X? L7T<K67I2TK&L(RPC$ Q*(K^G3^,+D0ZQ&P&)A+!
M7\O\S8R3'%WFIO)( >!&I=Y(*6QTKH5R#4?* H_/MY5]H,()68!$3.R#PY#*
MO(I>&3U5Z"3"+P5_(9291F_4L(H!A5.=_I!D.-4)A+:I3/G]:O5<"S )5Q4@
MMJV,CGD!871N=%Y6C+$M$5.+@#$ C,8[J]%G;Q?Y]H0_D 220+)])#V#UROB
ML"P<R\+!8! &S\F,;^*SP"S"+ +)!X4DK"+V:0#"MB%DHZ*/-,:</Z89P5^[
MRGCLYDNZP![8>UCLQ=HYG=VES9-O>!\3)C4I-Q+_>3HAXWWXO;]ZSY?P%XYB
MR?YG*B;'1_YC4;$Z]\M=7WRNK2A7:?0-2W)BPH=3D;J1OW;7%[V<JWX4W9LL
M%'O%"K<Y2T9F*-3B(1[DKE;H^"@NZU=7N*K>\N?(+ K(:<@[L6$:[]"58],G
MZ3N+=NTJ_A++M[2UVGPG;R7O6GOUSUQ2;KF_^'*8"IM+FO6%JIY<E>EPM3C?
M]FZUIK*QS9-O[J?3G=]3_>JNKUPG=ZJD!5$K:7O=SL'>_L;D;J>W,2U L;W]
M3K>W.7FY6#B1M9G2KCR2 CXD)A<>H"/YY-O61YE&YP7'GD L%<5240#ZT)3Y
M*#/KF%),_&'B#S2&5N:CG&6Y2*(S,IEN+C;\H]<)P?/!8*,,7N_RA7^*27?
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M;<AO'O+-6GY4'!8?,U\ 4$L#!!0    ( )V 05ADF-#.#Q8  %.    2
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MJ"JWP"M U9?"^H"/+_\.?$E\00GEC-==TW77O%98M*%@[X)BD#QCX5+0UY5
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M3_XDGL47@82CK2/A8- [WEVGX PS9K!OSS^)I"*6PZ7UT;>/CQR3V2!O,JT
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M:%)X%A]O@QE;@M$2Z,D"&S!9,M<QD(2,^Y3,WE9S"*LVHMERL]-QUI2D1TX
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M#,O7UT7<']>WB=NF4902:O9)7Z"K6&HL'HSZCC]0\ND6N@^C:"1!#,L%'ML
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M6F1"&U_N+VI#Z.O:BRE\B )1N?NG/$+[E9_QCQ(.PQ]#_ ]02P,$%     @
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M"[:@$(06].#S^_UW^R.HAEYP$?'J886[ (SP[3/U1 C[@Z/1_MY^OS?:/SR
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M,2YH=&U02P$"% ,4    " "=@$%8%RF$LV@<   :40$ $0
M@ '9? 0 96YS9RTR,#(S,3(S,2YX<V102P$"% ,4    " "=@$%8I5S_GT Q
M  !5Z $ %0              @ %PF00 96YS9RTR,#(S,3(S,5]C86PN>&UL
M4$L! A0#%     @ G8!!6,7U';3*IP  >5L' !4              ( !X\H$
M &5N<V<M,C R,S$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( )V 05B$ >9%%AD
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M              "  1J\!P!E;G-G+3(P,C,Q,C,Q7V<U+FIP9U!+ 0(4 Q0
M   ( )V 05B<BD^N\!,! (&Q 0 4              "  :%_" !E;G-G+3(P
M,C,Q,C,Q7V<V+FIP9U!+ 0(4 Q0    ( )V 05@E9'_]!9L! "OF$  5
M          "  <.3"0!E;G-G+3(P,C,Q,C,Q7VQA8BYX;6Q02P$"% ,4
M" "=@$%8_?300<L) 0 )  P %0              @ '[+@L 96YS9RTR,#(S
M,3(S,5]P<F4N>&UL4$L! A0#%     @ G8!!6*.[)9 .+   ^SD' !,
M         ( !^3@, &5N<V<Q,C,Q,C-E>#(Q,2YH=&U02P$"% ,4    " "=
M@$%8F7DEC]<"  #3"   $P              @ $X90P 96YS9S$R,S$R,V5X
M,C,Q+FAT;5!+ 0(4 Q0    ( )V 05ADF-#.#Q8  %.    2
M  "  4!H# !E;G-G,3(S,3(S97@Y-RYH=&U02P$"% ,4    " "=@$%8@+4M
M(> '   3,0  $P              @ %_?@P 96YS9W$T,C R,V5X,S$Q+FAT
M;5!+ 0(4 Q0    ( )V 05@58!GP+@@  %PR   3              "  9"&
M# !E;G-G<30R,#(S97@S,3(N:'1M4$L! A0#%     @ G8!!6)*B:2J?!0
M!RH  !,              ( ![XX, &5N<V=Q-#(P,C-E>#,R,2YH=&U02P$"
M% ,4    " "=@$%8; B+BM0%  "U*0  $P              @ &_E P 96YS
F9W$T,C R,V5X,S(R+FAT;5!+!08     $P 3 -P$  #$F@P    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>ensg-20231231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:ensg="http://www.ensigngroup.net/20231231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:naics="http://xbrl.sec.gov/naics/2023"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ensg-20231231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2024-01-29</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">us-gaap:WhollyOwnedPropertiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:OperatingEntityAxis">ensg:ThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:BlanketAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CO</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:NonCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:AggregateDeductibleMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerOccurenceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:PerFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:AllStatesExceptColoradoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:BlanketAggregateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PayorAxis">naics:ZZ524292</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:WorkersCompensationInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">ensg:OtherStatesExceptCaliforniaTexasAndWashingtonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:LossSensitiveLimitPerClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GeneralLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:SelfInsuranceRetentionPerClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:HealthLiabilityInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:StopLossInsuranceLimitPerClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:HealthLiabilityInsuranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:InsuranceCoverageLimitTypeAxis">ensg:StopLossInsuranceLimitPerClaimMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:SubsidiariesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RealEstatePropertiesAxis">us-gaap:WhollyOwnedPropertiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:OperatingEntityAxis">ensg:ThirdPartiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:OwnedPropertiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:OwnedPropertiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialAssetAcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:StandardBearerHealthcareREITIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceIncentiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:ManagementServiceTotalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ManagementServiceBaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:StandardBearerMasterLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ensg:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">ensg:SecuredOvernightFinancingRateSOFRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:StandardBearerEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:CampusOperationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SeniorLivingFacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:RealEstatePurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ensg:RealEstatePurchasesOfPreviousOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:BusinessAndAssetAcquisitionsAxis">ensg:AcquiredOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ensg:RentalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:StandardBearerSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">us-gaap:AllOtherSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">srt:ConsolidationEliminationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidSkilledMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:ManagedCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:PrivatePayAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">ensg:SeniorLivingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ensg:AssembledOccupancyAcquiredMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:DepreciationAndAmortizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">ensg:MedicareandMedicaidLicensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ensg:SkilledServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-08</startDate>
            <endDate>2022-04-08</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">ensg:TruistBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-08</instant>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">ensg:TwentyThreeSubsidiariesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:FirstThreeYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:InTheFourthYearMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:YearsFiveThroughTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:PrepaymentFeePeriodAxis">ensg:AfterYearTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:HUDInsuredMortgagesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:A53PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ensg:A53PromissoryNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:CollateralizedDebtObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2022PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeSevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeEightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeNineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeTenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">ensg:ExercisePriceRangeElevenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementNonemployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-27</instant>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-27</startDate>
            <endDate>2019-08-27</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">ensg:A2019LTIPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:SpinoffMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">ensg:StockAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:TripleNetLeaseArrangementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:PurchaseOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:CareTrustREITMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">ensg:CostofSalesandGeneralandAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:VariousLandlordsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:NewMasterLeaseAgreeementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:NewMasterLeaseAgreeementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:SubleaseOfStandAlongSkilledNursingOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-02-01</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">ensg:SkilledNursingOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:AmendedMasterLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeaseOfCampusOperationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeaseOfCampusOperationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThePennantGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">ensg:ThirdPartyTenantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ensg:LeaseArrangementAxis">ensg:LeasesToThirdPartyOperatorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">us-gaap:ProfessionalMalpracticeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ScheduleOfMalpracticeInsuranceTypeAndTierIdentifierAxis">us-gaap:ProfessionalMalpracticeLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-19</startDate>
            <endDate>2024-01-19</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-02-01</instant>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ensg:MedicaidAndMedicareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:August2023RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-08-29</instant>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:August2023RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-29</startDate>
            <endDate>2023-08-29</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:July2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-28</instant>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">ensg:July2022RepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-28</startDate>
            <endDate>2022-07-28</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:ChristopherRChristensenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001125376</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">ensg:BeverlyBWittekindMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="facility">
        <measure>ensg:facility</measure>
    </unit>
    <unit id="bed">
        <measure>ensg:bed</measure>
    </unit>
    <unit id="senior_living_unit">
        <measure>ensg:senior_living_unit</measure>
    </unit>
    <unit id="property">
        <measure>ensg:property</measure>
    </unit>
    <unit id="operation">
        <measure>ensg:operation</measure>
    </unit>
    <unit id="lease">
        <measure>ensg:lease</measure>
    </unit>
    <unit id="option">
        <measure>ensg:option</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="skilled_nursing_property">
        <measure>ensg:skilled_nursing_property</measure>
    </unit>
    <unit id="renewal">
        <measure>ensg:renewal</measure>
    </unit>
    <unit id="business">
        <measure>ensg:business</measure>
    </unit>
    <unit id="segment">
        <measure>ensg:segment</measure>
    </unit>
    <unit id="subsidiary">
        <measure>ensg:subsidiary</measure>
    </unit>
    <unit id="plan">
        <measure>ensg:plan</measure>
    </unit>
    <unit id="installment">
        <measure>ensg:installment</measure>
    </unit>
    <unit id="agreement">
        <measure>ensg:agreement</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001125376</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-35">false</dei:AmendmentFlag>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-53" id="f-498">P3Y0M0D</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-53" id="f-504">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-55" id="f-508">P4M0D</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-388" id="f-1456">P5Y0M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-390" id="f-1458">P3Y0M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList contextRef="c-1" id="f-1530">http://fasb.org/us-gaap/2023#RevenueFromContractWithCustomerExcludingAssessedTax</us-gaap:OperatingLeaseIncomeComprehensiveIncomeExtensibleList>
    <ecd:TrdArrDuration contextRef="c-442" id="f-1611">P334D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-445" id="f-1612">P231D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-4">2023-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-3">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-33757</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ENSIGN GROUP, INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">33-0861263</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">29222 Rancho Viejo Road, Suite 127</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">San Juan Capistrano</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">92675</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">949</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">487-9500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ENSG</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-19">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-20">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-21">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-22">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-23">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-24">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-25">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-26">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-27">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-3" id="f-29" unitRef="usd">3156373000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-30" unitRef="shares">56665741</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-31">&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Part III of this Form 10-K incorporates information by reference from the Registrant's definitive proxy statement for the Registrant's 2024 Annual Meeting of Stockholders to be filed within 120 days after the close of the fiscal year covered by this annual report.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorName contextRef="c-1" id="f-36">DELOITTE &amp; TOUCHE LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-37">Costa Mesa, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">509626000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-3" id="f-39" unitRef="usd">316270000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">9348000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-41" unitRef="usd">7802000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">485039000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-43" unitRef="usd">408432000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShortTermInvestments contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">17229000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c-5" decimals="-3" id="f-45" unitRef="usd">15441000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">35036000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-47" unitRef="usd">40982000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">1046930000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-3" id="f-49" unitRef="usd">781125000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">1090771000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-51" unitRef="usd">992010000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">1756430000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">1450995000</us-gaap:OperatingLeaseRightOfUseAsset>
    <ensg:InsuranceSubsidiaryDepositsAndInvestments contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">92687000</ensg:InsuranceSubsidiaryDepositsAndInvestments>
    <ensg:InsuranceSubsidiaryDepositsAndInvestments contextRef="c-5" decimals="-3" id="f-55" unitRef="usd">67652000</ensg:InsuranceSubsidiaryDepositsAndInvestments>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">67124000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-5" decimals="-3" id="f-57" unitRef="usd">39643000</us-gaap:DeferredIncomeTaxAssetsNet>
    <ensg:RestrictedAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">40205000</ensg:RestrictedAndOtherAssetsNoncurrent>
    <ensg:RestrictedAndOtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">37291000</ensg:RestrictedAndOtherAssetsNoncurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">6525000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-5" decimals="-3" id="f-61" unitRef="usd">6437000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">76869000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-63" unitRef="usd">76869000</us-gaap:Goodwill>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">4177541000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">3452022000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">92811000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-3" id="f-67" unitRef="usd">77087000</us-gaap:AccountsPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">332568000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-69" unitRef="usd">289810000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">82526000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">65796000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:SelfInsuranceReserveCurrent contextRef="c-4" decimals="-3" id="f-72" unitRef="usd">54664000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:SelfInsuranceReserveCurrent contextRef="c-5" decimals="-3" id="f-73" unitRef="usd">48187000</us-gaap:SelfInsuranceReserveCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-74" unitRef="usd">168228000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-75" unitRef="usd">97309000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">3950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">3883000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-78" unitRef="usd">734747000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-79" unitRef="usd">582072000</us-gaap:LiabilitiesCurrent>
    <ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount contextRef="c-4" decimals="-3" id="f-80" unitRef="usd">145497000</ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount>
    <ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount contextRef="c-5" decimals="-3" id="f-81" unitRef="usd">149269000</ensg:LongTermDebtNetOfCurrentMaturitiesAndDebtDiscount>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">1639326000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">1355113000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">111246000</us-gaap:SelfInsuranceReserveNoncurrent>
    <us-gaap:SelfInsuranceReserveNoncurrent contextRef="c-5" decimals="-3" id="f-85" unitRef="usd">83495000</us-gaap:SelfInsuranceReserveNoncurrent>
    <ensg:DeferredRentAndOtherLongTermLiabilities contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">49408000</ensg:DeferredRentAndOtherLongTermLiabilities>
    <ensg:DeferredRentAndOtherLongTermLiabilities contextRef="c-5" decimals="-3" id="f-87" unitRef="usd">33273000</ensg:DeferredRentAndOtherLongTermLiabilities>
    <us-gaap:Liabilities contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">2680224000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">2203222000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-90" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-91" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-92"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-93"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="-3" id="f-94" unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-95" unitRef="shares">59987000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-96" unitRef="shares">56597000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="-3" id="f-97" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-3" id="f-98" unitRef="shares">59029000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-3" id="f-99" unitRef="shares">55661000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-100" unitRef="usd">60000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">59000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-102" unitRef="usd">465707000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-5" decimals="-3" id="f-103" unitRef="usd">415560000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-104" unitRef="usd">1142653000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">946339000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockCommonShares contextRef="c-4" decimals="-3" id="f-106" unitRef="shares">3390000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="-3" id="f-107" unitRef="shares">3368000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">116555000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">114626000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-110" unitRef="usd">1491865000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-3" id="f-111" unitRef="usd">1247332000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-112" unitRef="usd">5452000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">1468000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">1497317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">1248800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-116" unitRef="usd">4177541000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">3452022000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">3708071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-119" unitRef="usd">3008711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-120" unitRef="usd">2611476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-121" unitRef="usd">21284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-122" unitRef="usd">16757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-123" unitRef="usd">15985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-124" unitRef="usd">3729355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-125" unitRef="usd">3025468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-126" unitRef="usd">2627461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">2941238000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-12" decimals="-3" id="f-128" unitRef="usd">2354434000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-13" decimals="-3" id="f-129" unitRef="usd">2019879000</us-gaap:CostOfGoodsAndServicesSold>
    <ensg:RentCostOfServices contextRef="c-1" decimals="-3" id="f-130" unitRef="usd">197358000</ensg:RentCostOfServices>
    <ensg:RentCostOfServices contextRef="c-12" decimals="-3" id="f-131" unitRef="usd">153049000</ensg:RentCostOfServices>
    <ensg:RentCostOfServices contextRef="c-13" decimals="-3" id="f-132" unitRef="usd">139371000</ensg:RentCostOfServices>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-133" unitRef="usd">263005000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-12" decimals="-3" id="f-134" unitRef="usd">158805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-13" decimals="-3" id="f-135" unitRef="usd">151761000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-136" unitRef="usd">72387000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-137" unitRef="usd">62355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-138" unitRef="usd">55985000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">3473988000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-12" decimals="-3" id="f-140" unitRef="usd">2728643000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-13" decimals="-3" id="f-141" unitRef="usd">2366996000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-142" unitRef="usd">255367000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-12" decimals="-3" id="f-143" unitRef="usd">296825000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-13" decimals="-3" id="f-144" unitRef="usd">260465000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-145" unitRef="usd">8087000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-3" id="f-146" unitRef="usd">8931000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="-3" id="f-147" unitRef="usd">6849000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-148" unitRef="usd">25482000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-149" unitRef="usd">1195000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-150" unitRef="usd">4388000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">17395000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-12" decimals="-3" id="f-152" unitRef="usd">-7736000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-13" decimals="-3" id="f-153" unitRef="usd">-2461000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-154" unitRef="usd">272762000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-155" unitRef="usd">289089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-156" unitRef="usd">258004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-157" unitRef="usd">62912000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-158" unitRef="usd">64437000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-159" unitRef="usd">60279000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-160" unitRef="usd">209850000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-161" unitRef="usd">224652000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-162" unitRef="usd">197725000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-163" unitRef="usd">451000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-164" unitRef="usd">-29000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-165" unitRef="usd">3073000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-166" unitRef="usd">209399000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-167" unitRef="usd">224681000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-168" unitRef="usd">194652000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">3.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-170"
      unitRef="usdPerShare">4.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-171"
      unitRef="usdPerShare">3.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-172"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-173"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-174"
      unitRef="usdPerShare">3.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-175" unitRef="shares">55708000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-176" unitRef="shares">54887000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-177" unitRef="shares">54486000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-178" unitRef="shares">57323000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-3" id="f-179" unitRef="shares">56871000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-180" unitRef="shares">56925000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-14" decimals="-3" id="f-181" unitRef="shares">54626000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-3" id="f-182" unitRef="usd">58000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-15" decimals="-3" id="f-183" unitRef="usd">338177000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-16" decimals="-3" id="f-184" unitRef="usd">551055000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-17" decimals="-3" id="f-185" unitRef="shares">2791000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-17" decimals="-3" id="f-186" unitRef="usd">-71213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-18" decimals="-3" id="f-187" unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-188" unitRef="usd">818227000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-20" decimals="-3" id="f-189" unitRef="shares">516000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-21" decimals="-3" id="f-190" unitRef="usd">9180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">9180000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-20" decimals="-3" id="f-192" unitRef="shares">201000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-3" id="f-193" unitRef="usd">3725000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-13" decimals="-3" id="f-194" unitRef="usd">3725000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-20" decimals="-3" id="f-195" unitRef="shares">21000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-22" decimals="-3" id="f-196" unitRef="shares">21000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-22" decimals="-3" id="f-197" unitRef="usd">1711000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-198" unitRef="usd">1711000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-13"
      decimals="INF"
      id="f-199"
      unitRef="usdPerShare">0.2125</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-23" decimals="-3" id="f-200" unitRef="usd">11715000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-13" decimals="-3" id="f-201" unitRef="usd">11715000</us-gaap:Dividends>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-21" decimals="-3" id="f-202" unitRef="usd">18678000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-203" unitRef="usd">18678000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-20" decimals="-3" id="f-204" unitRef="shares">132000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-22" decimals="-3" id="f-205" unitRef="shares">132000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-22" decimals="-3" id="f-206" unitRef="usd">10118000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-13" decimals="-3" id="f-207" unitRef="usd">10118000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-24" decimals="-3" id="f-208" unitRef="usd">1369000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation contextRef="c-13" decimals="-3" id="f-209" unitRef="usd">1369000</us-gaap:NoncontrollingInterestDecreaseFromDeconsolidation>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-24" decimals="-3" id="f-210" unitRef="usd">2000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-13" decimals="-3" id="f-211" unitRef="usd">2000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-212" unitRef="usd">3073000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-213" unitRef="usd">3073000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-24" decimals="-3" id="f-214" unitRef="usd">2908000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-13" decimals="-3" id="f-215" unitRef="usd">2908000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLoss contextRef="c-23" decimals="-3" id="f-216" unitRef="usd">194652000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-217" unitRef="usd">194652000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-25" decimals="-3" id="f-218" unitRef="shares">55190000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-3" id="f-219" unitRef="usd">58000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-3" id="f-220" unitRef="usd">369760000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-3" id="f-221" unitRef="usd">733992000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-28" decimals="-3" id="f-222" unitRef="shares">2944000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-3" id="f-223" unitRef="usd">-83042000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-3" id="f-224" unitRef="usd">946000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-225" unitRef="usd">1021714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-31" decimals="-3" id="f-226" unitRef="shares">688000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-227" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-228" unitRef="usd">12676000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-12" decimals="-3" id="f-229" unitRef="usd">12677000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-31" decimals="-3" id="f-230" unitRef="shares">207000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-32" decimals="-3" id="f-231" unitRef="usd">5241000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-12" decimals="-3" id="f-232" unitRef="usd">5241000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-31" decimals="-3" id="f-233" unitRef="shares">20000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-33" decimals="-3" id="f-234" unitRef="shares">20000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-33" decimals="-3" id="f-235" unitRef="usd">1702000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-236" unitRef="usd">1702000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-12"
      decimals="INF"
      id="f-237"
      unitRef="usdPerShare">0.2225</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-34" decimals="-3" id="f-238" unitRef="usd">12334000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-12" decimals="-3" id="f-239" unitRef="usd">12334000</us-gaap:Dividends>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-32" decimals="-3" id="f-240" unitRef="usd">22720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-12" decimals="-3" id="f-241" unitRef="usd">22720000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-31" decimals="-3" id="f-242" unitRef="shares">404000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-33" decimals="-3" id="f-243" unitRef="shares">404000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-33" decimals="-3" id="f-244" unitRef="usd">29882000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-12" decimals="-3" id="f-245" unitRef="usd">29882000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-32" decimals="-3" id="f-246" unitRef="usd">1539000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-35" decimals="-3" id="f-247" unitRef="usd">-835000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-12" decimals="-3" id="f-248" unitRef="usd">704000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-32" decimals="-3" id="f-249" unitRef="usd">6693000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-12" decimals="-3" id="f-250" unitRef="usd">6693000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-251" unitRef="usd">-29000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-252" unitRef="usd">-29000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-32" decimals="-3" id="f-253" unitRef="usd">-9000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-35" decimals="-3" id="f-254" unitRef="usd">284000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-12" decimals="-3" id="f-255" unitRef="usd">275000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-256" unitRef="usd">224681000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-257" unitRef="usd">224681000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-36" decimals="-3" id="f-258" unitRef="shares">55661000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-259" unitRef="usd">59000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-260" unitRef="usd">415560000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-261" unitRef="usd">946339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-39" decimals="-3" id="f-262" unitRef="shares">3368000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-263" unitRef="usd">-114626000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-264" unitRef="usd">1468000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-265" unitRef="usd">1248800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-41" decimals="-3" id="f-266" unitRef="shares">759000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-41" decimals="-3" id="f-267" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-42" decimals="-3" id="f-268" unitRef="usd">18368000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-269" unitRef="usd">18369000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-41" decimals="-3" id="f-270" unitRef="shares">199000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-42" decimals="-3" id="f-271" unitRef="usd">5068000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-3" id="f-272" unitRef="usd">5068000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-41" decimals="-3" id="f-273" unitRef="shares">22000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation contextRef="c-43" decimals="-3" id="f-274" unitRef="shares">22000</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-43" decimals="-3" id="f-275" unitRef="usd">1929000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-276" unitRef="usd">1929000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-277"
      unitRef="usdPerShare">0.2325</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:Dividends contextRef="c-44" decimals="-3" id="f-278" unitRef="usd">13085000</us-gaap:Dividends>
    <us-gaap:Dividends contextRef="c-1" decimals="-3" id="f-279" unitRef="usd">13085000</us-gaap:Dividends>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-280" unitRef="usd">30754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">30754000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-42" decimals="-3" id="f-282" unitRef="usd">256000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:MinorityInterestDecreaseFromRedemptions contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">256000</us-gaap:MinorityInterestDecreaseFromRedemptions>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-284" unitRef="usd">451000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">451000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-42" decimals="-3" id="f-286" unitRef="usd">3787000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-45" decimals="-3" id="f-287" unitRef="usd">-3533000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-1" decimals="-3" id="f-288" unitRef="usd">254000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:NetIncomeLoss contextRef="c-44" decimals="-3" id="f-289" unitRef="usd">209399000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-290" unitRef="usd">209399000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-3" id="f-291" unitRef="shares">56597000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-292" unitRef="usd">60000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-293" unitRef="usd">465707000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-294" unitRef="usd">1142653000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-49" decimals="-3" id="f-295" unitRef="shares">3390000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-296" unitRef="usd">-116555000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-297" unitRef="usd">5452000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-298" unitRef="usd">1497317000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">209850000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-12" decimals="-3" id="f-300" unitRef="usd">224652000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-13" decimals="-3" id="f-301" unitRef="usd">197725000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-302" unitRef="usd">72387000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-303" unitRef="usd">62355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-304" unitRef="usd">55985000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">1067000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-12" decimals="-3" id="f-306" unitRef="usd">1036000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-13" decimals="-3" id="f-307" unitRef="usd">859000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <ensg:NonCashLeaseExpense contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">870000</ensg:NonCashLeaseExpense>
    <ensg:NonCashLeaseExpense contextRef="c-12" decimals="-3" id="f-309" unitRef="usd">493000</ensg:NonCashLeaseExpense>
    <ensg:NonCashLeaseExpense contextRef="c-13" decimals="-3" id="f-310" unitRef="usd">485000</ensg:NonCashLeaseExpense>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-12" decimals="-3" id="f-312" unitRef="usd">566000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-13" decimals="-3" id="f-313" unitRef="usd">0</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">-27481000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-315" unitRef="usd">-6496000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-316" unitRef="usd">-724000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">3408000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-12" decimals="-3" id="f-318" unitRef="usd">2390000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts contextRef="c-13" decimals="-3" id="f-319" unitRef="usd">2609000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">30767000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-12" decimals="-3" id="f-321" unitRef="usd">22720000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-13" decimals="-3" id="f-322" unitRef="usd">18678000</us-gaap:ShareBasedCompensation>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">1396000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="c-12" decimals="-3" id="f-324" unitRef="usd">1282000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities contextRef="c-13" decimals="-3" id="f-325" unitRef="usd">2382000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">123000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-12" decimals="-3" id="f-327" unitRef="usd">3467000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-13" decimals="-3" id="f-328" unitRef="usd">1371000</us-gaap:GainLossOnDispositionOfAssets1>
    <ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">1368000</ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets>
    <ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets contextRef="c-12" decimals="-3" id="f-330" unitRef="usd">-3926000</ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets>
    <ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets contextRef="c-13" decimals="-3" id="f-331" unitRef="usd">977000</ensg:GainLossOnInsuranceClaimsAndDisposalOfAssets>
    <us-gaap:LitigationSettlementExpense contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">48000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-12" decimals="-3" id="f-333" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense contextRef="c-13" decimals="-3" id="f-334" unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">79818000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-12" decimals="-3" id="f-336" unitRef="usd">82426000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-13" decimals="-3" id="f-337" unitRef="usd">30771000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">-814000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-12" decimals="-3" id="f-339" unitRef="usd">-809000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidTaxes contextRef="c-13" decimals="-3" id="f-340" unitRef="usd">4228000</us-gaap:IncreaseDecreaseInPrepaidTaxes>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">-6993000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-12" decimals="-3" id="f-342" unitRef="usd">9141000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-13" decimals="-3" id="f-343" unitRef="usd">4898000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">0</ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct>
    <ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct contextRef="c-12" decimals="-3" id="f-345" unitRef="usd">24155000</ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct>
    <ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct contextRef="c-13" decimals="-3" id="f-346" unitRef="usd">24154000</ensg:IncreaseDecreaseDueToDeferredEmployerTaxesCARESAct>
    <us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">16072000</us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue>
    <us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue contextRef="c-12" decimals="-3" id="f-348" unitRef="usd">7614000</us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue>
    <us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue contextRef="c-13" decimals="-3" id="f-349" unitRef="usd">10953000</us-gaap:LifeInsuranceCorporateOrBankOwnedChangeInValue>
    <us-gaap:IncreaseDecreaseInDeferredCompensation contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">16044000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation contextRef="c-12" decimals="-3" id="f-351" unitRef="usd">7637000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInDeferredCompensation contextRef="c-13" decimals="-3" id="f-352" unitRef="usd">11078000</us-gaap:IncreaseDecreaseInDeferredCompensation>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-6564000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-354" unitRef="usd">345000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-355" unitRef="usd">-5814000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">15924000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-12" decimals="-3" id="f-357" unitRef="usd">17870000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-13" decimals="-3" id="f-358" unitRef="usd">7117000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">47967000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-12" decimals="-3" id="f-360" unitRef="usd">38982000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="c-13" decimals="-3" id="f-361" unitRef="usd">47701000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">23828000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-12" decimals="-3" id="f-363" unitRef="usd">3010000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-13" decimals="-3" id="f-364" unitRef="usd">1297000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInSelfInsuranceReserve contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">28827000</us-gaap:IncreaseDecreaseInSelfInsuranceReserve>
    <us-gaap:IncreaseDecreaseInSelfInsuranceReserve contextRef="c-12" decimals="-3" id="f-366" unitRef="usd">17785000</us-gaap:IncreaseDecreaseInSelfInsuranceReserve>
    <us-gaap:IncreaseDecreaseInSelfInsuranceReserve contextRef="c-13" decimals="-3" id="f-367" unitRef="usd">13724000</us-gaap:IncreaseDecreaseInSelfInsuranceReserve>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">-50000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-12" decimals="-3" id="f-369" unitRef="usd">-46000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:IncreaseDecreaseInOtherDeferredLiability contextRef="c-13" decimals="-3" id="f-370" unitRef="usd">-66000</us-gaap:IncreaseDecreaseInOtherDeferredLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">376666000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-12" decimals="-3" id="f-372" unitRef="usd">272513000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-13" decimals="-3" id="f-373" unitRef="usd">275684000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <ensg:PaymentsToAcquirePropertyAndEquipment contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">106180000</ensg:PaymentsToAcquirePropertyAndEquipment>
    <ensg:PaymentsToAcquirePropertyAndEquipment contextRef="c-12" decimals="-3" id="f-375" unitRef="usd">87545000</ensg:PaymentsToAcquirePropertyAndEquipment>
    <ensg:PaymentsToAcquirePropertyAndEquipment contextRef="c-13" decimals="-3" id="f-376" unitRef="usd">69550000</ensg:PaymentsToAcquirePropertyAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-12" decimals="-3" id="f-378" unitRef="usd">16400000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-13" decimals="-3" id="f-379" unitRef="usd">6000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <ensg:PaymentsToAcquireAssetAcquisitions contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">67798000</ensg:PaymentsToAcquireAssetAcquisitions>
    <ensg:PaymentsToAcquireAssetAcquisitions contextRef="c-12" decimals="-3" id="f-381" unitRef="usd">84736000</ensg:PaymentsToAcquireAssetAcquisitions>
    <ensg:PaymentsToAcquireAssetAcquisitions contextRef="c-13" decimals="-3" id="f-382" unitRef="usd">98224000</ensg:PaymentsToAcquireAssetAcquisitions>
    <us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">1216000</us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions>
    <us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions contextRef="c-12" decimals="-3" id="f-384" unitRef="usd">0</us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions>
    <us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions contextRef="c-13" decimals="-3" id="f-385" unitRef="usd">-100000</us-gaap:PaymentsForProceedsFromDepositsOnRealEstateAcquisitions>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">2029000</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities contextRef="c-12" decimals="-3" id="f-387" unitRef="usd">1339000</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities contextRef="c-13" decimals="-3" id="f-388" unitRef="usd">6899000</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">248000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-12" decimals="-3" id="f-390" unitRef="usd">8630000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets contextRef="c-13" decimals="-3" id="f-391" unitRef="usd">1854000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:CashDivestedFromDeconsolidation contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation contextRef="c-12" decimals="-3" id="f-393" unitRef="usd">0</us-gaap:CashDivestedFromDeconsolidation>
    <us-gaap:CashDivestedFromDeconsolidation contextRef="c-13" decimals="-3" id="f-394" unitRef="usd">1984000</us-gaap:CashDivestedFromDeconsolidation>
    <ensg:PaymentsForMedicareAndMedicaidLicenses contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">0</ensg:PaymentsForMedicareAndMedicaidLicenses>
    <ensg:PaymentsForMedicareAndMedicaidLicenses contextRef="c-12" decimals="-3" id="f-396" unitRef="usd">0</ensg:PaymentsForMedicareAndMedicaidLicenses>
    <ensg:PaymentsForMedicareAndMedicaidLicenses contextRef="c-13" decimals="-3" id="f-397" unitRef="usd">106000</ensg:PaymentsForMedicareAndMedicaidLicenses>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-398" unitRef="usd">29603000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-12" decimals="-3" id="f-399" unitRef="usd">21975000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-13" decimals="-3" id="f-400" unitRef="usd">32257000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">18852000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-12" decimals="-3" id="f-402" unitRef="usd">14356000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-13" decimals="-3" id="f-403" unitRef="usd">27481000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">-970000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-12" decimals="-3" id="f-405" unitRef="usd">-149000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-13" decimals="-3" id="f-406" unitRef="usd">2120000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">-182698000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-12" decimals="-3" id="f-408" unitRef="usd">-186182000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-13" decimals="-3" id="f-409" unitRef="usd">-173907000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-410" unitRef="usd">150000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-12" decimals="-3" id="f-411" unitRef="usd">411000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-13" decimals="-3" id="f-412" unitRef="usd">45218000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-3" id="f-413" unitRef="usd">4033000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-12" decimals="-3" id="f-414" unitRef="usd">4106000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-13" decimals="-3" id="f-415" unitRef="usd">3056000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-416" unitRef="usd">18369000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-12" decimals="-3" id="f-417" unitRef="usd">12677000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-13" decimals="-3" id="f-418" unitRef="usd">9180000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-3" id="f-419" unitRef="usd">1929000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-12" decimals="-3" id="f-420" unitRef="usd">1702000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-13" decimals="-3" id="f-421" unitRef="usd">1711000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-3" id="f-422" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-12" decimals="-3" id="f-423" unitRef="usd">29882000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-13" decimals="-3" id="f-424" unitRef="usd">10118000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividends contextRef="c-1" decimals="-3" id="f-425" unitRef="usd">12890000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-12" decimals="-3" id="f-426" unitRef="usd">12168000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c-13" decimals="-3" id="f-427" unitRef="usd">11548000</us-gaap:PaymentsOfDividends>
    <ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans contextRef="c-1" decimals="-3" id="f-428" unitRef="usd">0</ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans>
    <ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans contextRef="c-12" decimals="-3" id="f-429" unitRef="usd">6693000</ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans>
    <ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans contextRef="c-13" decimals="-3" id="f-430" unitRef="usd">0</ensg:ProceedsFromSaleOfCommonStockAssociatedWithSubsidiaryEquityPlans>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-1" decimals="-3" id="f-431" unitRef="usd">4000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-12" decimals="-3" id="f-432" unitRef="usd">284000</us-gaap:PaymentsToMinorityShareholders>
    <us-gaap:PaymentsToMinorityShareholders contextRef="c-13" decimals="-3" id="f-433" unitRef="usd">2908000</us-gaap:PaymentsToMinorityShareholders>
    <ensg:PurchasesOfNonControllingInterest contextRef="c-1" decimals="-3" id="f-434" unitRef="usd">256000</ensg:PurchasesOfNonControllingInterest>
    <ensg:PurchasesOfNonControllingInterest contextRef="c-12" decimals="-3" id="f-435" unitRef="usd">704000</ensg:PurchasesOfNonControllingInterest>
    <ensg:PurchasesOfNonControllingInterest contextRef="c-13" decimals="-3" id="f-436" unitRef="usd">-2000000</ensg:PurchasesOfNonControllingInterest>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-1" decimals="-3" id="f-437" unitRef="usd">19000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-12" decimals="-3" id="f-438" unitRef="usd">3197000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-13" decimals="-3" id="f-439" unitRef="usd">1172000</us-gaap:PaymentsOfFinancingCosts>
    <ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram contextRef="c-1" decimals="-3" id="f-440" unitRef="usd">0</ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram>
    <ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram contextRef="c-12" decimals="-3" id="f-441" unitRef="usd">0</ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram>
    <ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram contextRef="c-13" decimals="-3" id="f-442" unitRef="usd">11637000</ensg:ProceedsFromCARESActProviderReliefFundsAndMedicareAdvancePaymentProgram>
    <ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid contextRef="c-1" decimals="-3" id="f-443" unitRef="usd">0</ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid>
    <ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid contextRef="c-12" decimals="-3" id="f-444" unitRef="usd">0</ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid>
    <ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid contextRef="c-13" decimals="-3" id="f-445" unitRef="usd">113660000</ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsRepaid>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-446" unitRef="usd">-612000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-12" decimals="-3" id="f-447" unitRef="usd">-32262000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-13" decimals="-3" id="f-448" unitRef="usd">-76138000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-449" unitRef="usd">193356000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-12" decimals="-3" id="f-450" unitRef="usd">54069000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-13" decimals="-3" id="f-451" unitRef="usd">25639000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-452" unitRef="usd">316270000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-30" decimals="-3" id="f-453" unitRef="usd">262201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-19" decimals="-3" id="f-454" unitRef="usd">236562000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">509626000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-5" decimals="-3" id="f-456" unitRef="usd">316270000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c-30" decimals="-3" id="f-457" unitRef="usd">262201000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-458" unitRef="usd">7025000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-12" decimals="-3" id="f-459" unitRef="usd">7604000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-13" decimals="-3" id="f-460" unitRef="usd">5690000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid contextRef="c-1" decimals="-3" id="f-461" unitRef="usd">89730000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-12" decimals="-3" id="f-462" unitRef="usd">70055000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid contextRef="c-13" decimals="-3" id="f-463" unitRef="usd">65547000</us-gaap:IncomeTaxesPaid>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-464" unitRef="usd">196942000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-12" decimals="-3" id="f-465" unitRef="usd">151870000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-13" decimals="-3" id="f-466" unitRef="usd">138795000</us-gaap:OperatingLeasePayments>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-467" unitRef="usd">4600000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-12" decimals="-3" id="f-468" unitRef="usd">4800000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-13" decimals="-3" id="f-469" unitRef="usd">3700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-470" unitRef="usd">3396000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-471" unitRef="usd">3201000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-30" decimals="-3" id="f-472" unitRef="usd">3035000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-473" unitRef="usd">376550000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-12" decimals="-3" id="f-474" unitRef="usd">370753000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-13" decimals="-3" id="f-475" unitRef="usd">198593000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c-1" id="f-476">DESCRIPTION OF BUSINESS&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;The Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Ensign Group, Inc. (collectively, Ensign or the Company), is a holding company with no direct operating assets, employees or revenue. The Company's independent subsidiaries provide health care services across the post-acute care continuum and engage in the ownership, acquisition, development and leasing of skilled nursing, senior living and other healthcare-related properties and other ancillary businesses. As of December&#160;31, 2023, the Company's independent subsidiaries operated 297 facilities and other ancillary operations located in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. Subsequent to December&#160;31, 2023, one of the Company's independent subsidiaries expanded its operations into Tennessee. The Company's independent subsidiaries have a collective capacity of approximately 30,600 operational skilled nursing beds and 3,100 senior living units. As of December&#160;31, 2023, the Company's independent subsidiaries operated 214 facilities under long-term lease arrangements and had options to purchase 11 of those 214 facilities. The Company's real estate portfolio includes 113 owned real estate properties, which includes 83 facilities operated and managed by the Company's independent subsidiaries, 30 operations leased to and operated by third-party operators, and the Service Center (defined below) location. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s wholly-owned independent subsidiaries, collectively referred to as the Service Center, provide specific accounting, payroll, human resources, information technology, legal, risk management and other centralized services to the other independent subsidiaries through contractual relationships with such subsidiaries. The Company also has a wholly-owned captive insurance subsidiary that provides some claims-made coverage to the Company&#x2019;s independent subsidiaries for general and professional liabilities, as well as coverage for certain workers&#x2019; compensation insurance liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company formed a captive real estate investment trust (REIT), which owns and manages its real estate business, called Standard Bearer Healthcare REIT, Inc. (Standard Bearer). The REIT structure provides the Company with an efficient vehicle for future acquisitions of properties that could be operated by Ensign's independent subsidiaries or other third parties. Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Standard Bearer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information on Standard Bearer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each of the Company's independent subsidiaries are operated by wholly-owned subsidiaries that have their own management, employees and assets. References herein to the consolidated &#x201c;Company&#x201d; and &#x201c;its&#x201d; assets and activities in this Annual Report are not meant to imply, nor should it be construed as meaning that The Ensign Group, Inc. has direct operating assets, employees or revenue, or that any of the subsidiaries, are operated by The Ensign Group, Inc.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ensg:NumberOfHealthCareFacilities contextRef="c-4" decimals="0" id="f-477" unitRef="facility">297</ensg:NumberOfHealthCareFacilities>
    <ensg:OperationalSkilledNursingBeds contextRef="c-4" decimals="-2" id="f-478" unitRef="bed">30600</ensg:OperationalSkilledNursingBeds>
    <ensg:OperationalSeniorLivingUnits
      contextRef="c-4"
      decimals="-2"
      id="f-479"
      unitRef="senior_living_unit">3100</ensg:OperationalSeniorLivingUnits>
    <ensg:NumberOfRealEstatePropertiesLeased contextRef="c-4" decimals="0" id="f-480" unitRef="facility">214</ensg:NumberOfRealEstatePropertiesLeased>
    <ensg:NumberOfRealEstatePropertiesLeasedWithOptionToPurchase contextRef="c-4" decimals="0" id="f-481" unitRef="facility">11</ensg:NumberOfRealEstatePropertiesLeasedWithOptionToPurchase>
    <ensg:NumberOfRealEstatePropertiesLeased contextRef="c-4" decimals="0" id="f-482" unitRef="facility">214</ensg:NumberOfRealEstatePropertiesLeased>
    <us-gaap:NumberOfRealEstateProperties contextRef="c-4" decimals="0" id="f-483" unitRef="property">113</us-gaap:NumberOfRealEstateProperties>
    <ensg:NumberOfFacilities
      contextRef="c-51"
      decimals="0"
      id="f-484"
      unitRef="facility">83</ensg:NumberOfFacilities>
    <ensg:NumberOfOperations
      contextRef="c-52"
      decimals="0"
      id="f-485"
      unitRef="operation">30</ensg:NumberOfOperations>
    <ensg:NumberOfOperations
      contextRef="c-52"
      decimals="0"
      id="f-486"
      unitRef="operation">30</ensg:NumberOfOperations>
    <ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities
      contextRef="c-52"
      decimals="0"
      id="f-487"
      unitRef="facility">1</ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-488">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Estimates and Assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of the Financial Statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company&#x2019;s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Considerations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments&#x2019; recorded values approximate fair values because of their nature or respective short durations. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. See Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Service Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company&#x2019;s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rental Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company&#x2019;s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on &#x201c;Level&#160;1&#x201d; inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance Subsidiary Deposits and Investments &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from &lt;span style="-sec-ix-hidden:f-498"&gt;three&lt;/span&gt; to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company leases skilled nursing facilities, senior living facilities and commercial office space.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December&#160;31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional &lt;span style="-sec-ix-hidden:f-504"&gt;ten&lt;/span&gt; to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews the carrying value of long-lived assets that are held and used in the Company&#x2019;s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management&#x2019;s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset. Management has evaluated its long-lived assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of &lt;span style="-sec-ix-hidden:f-508"&gt;four&lt;/span&gt; to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years&#160;and customer relationships are amortized over a period of up to 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Management has evaluated its goodwill and intangible assets and determined there was no impairment during the years ended December 31, 2023, 2022, and 2021. The Company has recognized cumulative goodwill impairment losses of $7,410, since inception in 1999. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Self-Insurance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s independent subsidiaries are self-insured for workers&#x2019; compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers&#x2019; compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company&#x2019;s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers&#x2019; compensation, healthcare benefits and related services provided to date. The amount of the Company&#x2019;s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company&#x2019;s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company&#x2019;s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company&#x2019;s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company&#x2019;s estimates and assumptions, actual results could differ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interest &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Income&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company does not have any components of other comprehensive income recorded within its Financial Statements and, therefore, does not separately present a statement of comprehensive income in its Financial Statements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Standards Issued But Not Yet Adopted by the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In October 2023, the FASB issued ASU 2023-06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; "Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative", &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07 "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-489">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt; The accompanying consolidated financial statements (the Financial Statements) have been prepared in accordance with accounting principles generally accepted in the United States (GAAP). The Company is the sole member or stockholder of various consolidated limited liability companies and corporations established to operate various acquired skilled nursing operations, senior living operations and related ancillary services. All intercompany transactions and balances have been eliminated in consolidation. The Company presents noncontrolling interests within the equity section of its consolidated balance sheets and the amount of consolidated net income that is attributable to The Ensign Group, Inc. and the noncontrolling interests in its consolidated statements of income. The Financial Statements include the accounts of all independent subsidiaries controlled by the Company through its ownership of a majority voting interest.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-490">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;Certain amounts in the prior period financial statements have been reclassified to conform to the presentation of the current period financial statements.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-491">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Estimates and Assumptions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of the Financial Statements in conformity with GAAP&#160;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Financial Statements and the reported amounts of revenue and expenses during the reporting periods. The most significant estimates in the Company&#x2019;s Financial Statements relate to revenue, acquired property and equipment, intangible assets and goodwill, right-of-use assets, impairment of long-lived assets, lease liabilities, general and professional liabilities, workers' compensation and healthcare claims included in accrued self-insurance liabilities and income taxes. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="c-1" id="f-492">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Considerations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s financial instruments consist principally of cash and cash equivalents, debt security investments, accounts receivable, insurance subsidiary deposits, deferred compensation investment funds, equity investments, accounts payable and borrowings. The Company believes all of the financial instruments&#x2019; recorded values approximate fair values because of their nature or respective short durations. &lt;/span&gt;&lt;/div&gt;Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions.The Company's non-financial assets, which includes goodwill, intangible assets, property and equipment and right-of-use assets, are not required to be measured at fair value on a recurring basis. However, on a periodic basis, or whenever events or changes in circumstances indicate that their carrying value may not be recoverable, the Company assesses its long-lived assets for impairment. When impairment has occurred, such long-lived assets are written down to fair value.</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-493">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Service Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(ASC 606).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's service revenue is derived primarily from providing healthcare services to its patients. Revenue is recognized when services are provided to patients at the amount that reflects the consideration that the Company expects to be entitled from patients and third-party payors, including Medicaid, Medicare and insurers (private and Medicare replacement plans), in exchange for providing patient care. The healthcare services provided pursuant to skilled patient contracts include routine services in exchange for a contractual agreed-upon amount or rate. Routine services are treated as a single performance obligation satisfied over time as services are rendered. As such, patient care services represent a bundle of services that are not capable of being distinct. Additionally, there may be ancillary services that are not included in the daily rates for routine services, but instead are treated as separate performance obligations satisfied at a point in time, if and when those services are rendered.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue recognized from healthcare services are adjusted for estimates of variable consideration to arrive at the transaction price. The Company determines the transaction price based on contractually agreed-upon amounts or rate on a per day basis, adjusted for estimates of variable consideration. The Company uses the expected value method in determining the variable component that should be used to arrive at the transaction price, using contractual agreements and historical reimbursement experience within each payor type. The amount of variable consideration that is included in the transaction price may be constrained and is included in net revenue only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. If actual amounts of consideration ultimately received differ from the Company&#x2019;s estimates, the Company adjusts these estimates, which would affect net revenue in the period such variances become known.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the Company&#x2019;s contracts with its patients have an original duration of one year or less, the Company uses the practical expedient applicable to its contracts and does not consider the time value of money. Further, because of the short duration of these contracts, the Company has not disclosed the transaction price for the remaining performance obligations as of the end of each reporting period or when the Company expects to recognize this revenue. In addition, the Company has applied the practical expedient provided by FASB ASC Topic 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and all incremental customer contract acquisition costs are expensed as they are incurred because the amortization period would have been one year or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Rental Revenue Recognition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's rental revenues are primarily generated by leasing healthcare-related properties through triple-net lease arrangements, under which the tenant is solely responsible for the costs related to the property. Revenue for operating leases is recognized on a straight-line basis over the lease term when collectability of all minimum lease payments is probable in accordance with FASB ASC Topic 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASC 842). The Company has elected the single component practical expedient, which allows a lessor, by class of underlying asset, not to allocate the total consideration to the lease and non-lease components based on their relative stand-alone selling prices where certain criteria are met. &lt;/span&gt;&lt;/div&gt;Tenant reimbursements related to property taxes and insurance are neither considered lease nor non-lease components under ASC 842. Lessee payments for taxes and insurance paid directly to a third party, on behalf of the Company, are excluded from variable lease payments and rental revenue in the Company&#x2019;s consolidated statements of income. Otherwise, tenant reimbursements for taxes and insurance that are paid by the Company directly to a third party are classified as additional rental revenue and expense and recognized by the Company on a gross basis.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="c-1" id="f-494">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounts Receivable &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accounts receivable consist primarily of amounts due from Medicare and Medicaid programs, other government programs, managed care health plans and private payor sources, net of estimates for variable consideration.&lt;/span&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of bank term deposits, money market funds and treasury bill related investments with original maturities of three months or less at time of purchase and therefore approximate fair value. The fair value of money market funds is determined based on &#x201c;Level&#160;1&#x201d; inputs, which consist of unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets. The Company places its cash and short-term investments with high credit quality financial institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-496">&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Insurance Subsidiary Deposits and Investments &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's captive insurance subsidiary cash and cash equivalents, deposits and investments are designated to support long-term insurance subsidiary liabilities and have been classified as short-term and long-term assets based on the timing of expected future payments of the Company's captive insurance liabilities. The majority of these deposits and investments are currently held in AA, A and BBB rated debt security investments and the remainder is held in a bank account with a high credit quality financial institution. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's non-qualified deferred compensation plan (the DCP)'s contracts insuring the lives of certain employees who are eligible to participate in the DCP are held in a rabbi trust. Cash surrender value of the contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When evaluating an investment for its current expected credit losses, the Company reviews factors such as historical experience with defaults, losses, credit ratings, term, market sector and macroeconomic trends, including current conditions and forecasts to the extent they are reasonable and supportable.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-497">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt; Property and equipment are initially recorded at their historical cost. Repairs and maintenance are expensed as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the depreciable assets (ranging from &lt;span style="-sec-ix-hidden:f-498"&gt;three&lt;/span&gt; to 59 years). Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the remaining lease term.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-54" id="f-499">P59Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company leases skilled nursing facilities, senior living facilities and commercial office space.&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease and performs an evaluation to determine whether the lease should be classified as an operating or finance lease at the inception of the lease. As of December&#160;31, 2023, the Company has one financing lease that is not material to the consolidated balance sheet. Rights and obligations of these leases are included as right-of-use assets and current and long-term lease liabilities on the Company's consolidated balance sheets. As the Company's leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at lease commencement date in determining the present value of future lease payments. The Company utilizes a third-party valuation specialist to assist in estimating the incremental borrowing rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records rent expense for operating leases on a straight-line basis over the term of the lease. The lease term used for straight-line rent expense is calculated from the date the Company is given control of the leased premises through the end of the lease term. Renewals are not assumed in the determination of the lease term unless they are deemed to be reasonably assured at the inception of the lease. The lease term used for this evaluation also provides the basis for establishing depreciable lives for buildings subject to lease and leasehold improvements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's real estate leases generally have initial lease terms of ten years or more and typically include one or more options to renew, with renewal terms that generally extend the lease term for an additional &lt;span style="-sec-ix-hidden:f-504"&gt;ten&lt;/span&gt; to 15 years. Exercise of the renewal options is generally subject to the satisfaction of certain conditions which vary by contract and generally follow payment terms that are consistent with those in place during the initial term. The Company reassesses the renewal option using a "reasonably certain" threshold, which is understood to be a high threshold. For leases where the Company is reasonably certain to exercise its renewal option, the option periods are included within the lease term and, therefore, the measurement of the right-of-use asset and lease liability. The Company's leases generally contain annual escalation clauses that are either fixed or variable in nature, some of which are dependent upon published indices. The Company recognizes lease expense for leases with an initial term of 12 months or less on a straight-line basis over the lease term. These leases are not recorded on the consolidated balance sheets. Certain of the Company's lease agreements include rental payments that are adjusted periodically for inflation. The lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;The Company subleases skilled nursing facilities to third-party operators and considers the subleases to be separate contracts as the Company is not relieved of its primary obligation under its operating lease. The rental income from third-parties related to these subleases is presented on a gross basis from the rent expense associated with the Company's lease obligations and is not material to the consolidated statements of income.</us-gaap:LesseeLeasesPolicyTextBlock>
    <ensg:NumberOfFinancingLeases contextRef="c-4" decimals="INF" id="f-501" unitRef="lease">1</ensg:NumberOfFinancingLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-4" id="f-502">P10Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ensg:LesseeOperatingLeaseNumberOfRenewalOptions contextRef="c-1" decimals="INF" id="f-503" unitRef="option">1</ensg:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-54" id="f-505">P15Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-506">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;The Company reviews the carrying value of long-lived assets that are held and used in the Company&#x2019;s independent subsidiaries for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of these assets is determined based upon expected undiscounted future net cash flows from the independent subsidiaries to which the assets relate, utilizing management&#x2019;s best estimate, appropriate assumptions and projections at the time. If the carrying value is determined to be unrecoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair value of the asset. The Company estimates the fair value of assets based on the estimated future discounted cash flows of the asset.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-507">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Definite-lived intangible assets consist primarily of patient base, facility trade names and customer relationships. Patient base is amortized over a period of &lt;span style="-sec-ix-hidden:f-508"&gt;four&lt;/span&gt; to eight months, depending on the classification of the patients and the level of occupancy in a new acquisition on the acquisition date. Trade names at independent subsidiaries are amortized over 30 years&#160;and customer relationships are amortized over a period of up to 20 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's indefinite-lived intangible assets consist of trade names and Medicare and Medicaid licenses. The Company tests indefinite-lived intangible assets for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the carrying amount of the intangible asset may not be recoverable. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase price over the fair value of identifiable net assets acquired in business combinations. The Company tests goodwill during the fourth quarter of each year or more often if events or circumstances indicate there may be impairment. The Company performs its analysis for each reporting unit that constitutes a business for which discrete financial information is produced and reviewed by operating segment management and provides services that are distinct from the other components of the operating segment, in accordance with the provisions of FASB ASC Topic 350,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangibles&#x2014;Goodwill and Other&#160;&lt;/span&gt;(ASC 350). This guidance provides the option to first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value. If, based on a review of qualitative factors, it is more likely than not that the fair value of a reporting unit is less than its carrying value, the Company performs a goodwill impairment test by comparing the carrying value of each reporting unit to its respective fair value. The Company determines the estimated fair value of each reporting unit using a discounted cash flow analysis. The fair value of the reporting unit is the implied fair value of goodwill. In the event a reporting unit's carrying value exceeds its fair value, an impairment loss will be recognized. An impairment loss is measured by the difference between the carrying value of the reporting unit and its fair value.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-56" id="f-509">P8M</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-57" id="f-510">P30Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-58" id="f-511">P20Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-4" decimals="-3" id="f-512" unitRef="usd">7410000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:SelfInsuranceReservePolicyTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Self-Insurance&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company is partially self-insured for general and professional liability claims up to a base amount per claim (the self-insured retention) with an aggregate, one-time deductible above this limit. Losses beyond these amounts are insured through third-party policies with coverage limits per claim, per location and on an aggregate basis for the Company. The combined self-insured retention is $500 per claim, subject to an additional one-time deductible of $1,250 for the Company's independent subsidiaries in California and a separate, one-time, deductible of $1,250 for the Company's independent subsidiaries not in California. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $5,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. In Colorado, the third-party coverage above these limits is $1,000 per claim and $3,000 per operation, which is independent of the aforementioned blanket aggregate limits that apply outside of Colorado. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December 31, 2023, the self-insured retention is $750 per claim, subject to an additional one-time deductible of $1,500 for the Company's independent subsidiaries in California. For the independent subsidiaries not in California, the self-insured retention is $650 per claim, subject to an additional one-time deductible of $1,350. For all independent subsidiaries, except those located in Colorado, the third-party coverage above these limits is $1,000 per claim, $3,000 per operation, with a $10,000 blanket aggregate limit and an additional state-specific aggregate where required by state law. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The majority of the self-insured retention and deductible limits for general and professional liabilities and workers' compensation liabilities are self-insured through the captive insurance subsidiary, the related assets and liabilities of which are included in the accompanying consolidated balance sheets. The captive insurance subsidiary is subject to certain statutory requirements as an insurance provider. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to accrue amounts equal to the actuarial estimated costs to settle open claims of insureds, as well as an estimate of the cost of insured claims that have been incurred but not reported. The Company develops information about the size of the ultimate claims based on historical experience, current industry information and actuarial analysis, and evaluates the estimates for claim loss exposure on a quarterly basis. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s independent subsidiaries are self-insured for workers&#x2019; compensation liabilities in California. To protect itself against loss exposure in California with this policy, the Company has purchased individual specific excess insurance coverage that insures individual claims that exceed $625 per occurrence. In Texas, the independent subsidiaries have elected non-subscriber status for workers&#x2019; compensation claims and the Company has purchased individual stop-loss coverage that insures individual claims that exceed $750 per occurrence. The Company&#x2019;s independent subsidiaries in all other states, with the exception of Washington, are under a loss sensitive plan that insures individual claims that exceed $350 per occurrence. In the state of Washington, the Company is self-insured and has purchased individual specific excess insurance coverage that insures individual claims that exceed $500 per occurrence. For all of the self-insured plans and retention, the Company accrues amounts equal to the estimated costs to settle open claims, as well as an estimate of the cost of claims that have been incurred but not reported. The Company uses actuarial valuations to estimate the liability based on historical experience and industry information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company self-funds medical (including prescription drugs) and dental healthcare benefits to the majority of its employees. The Company is fully liable for all financial and legal aspects of these benefit plans. To protect itself against loss exposure with this policy, the Company has purchased individual stop-loss insurance coverage that insures individual claims that exceed $525 for each covered person for fiscal years 2023 and 2022, respectively, and $500 for each covered person for fiscal year 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes that adequate provision has been made in the Financial Statements for liabilities that may arise out of patient care, workers&#x2019; compensation, healthcare benefits and related services provided to date. The amount of the Company&#x2019;s reserves was determined based on an estimation process that uses information obtained from both company-specific and industry data. This estimation process requires the Company to continuously monitor and evaluate the life cycle of the claims. Using data obtained from this monitoring and the Company&#x2019;s assumptions about emerging trends, the Company, with the assistance of an independent actuary, develops information about the size of ultimate claims based on the Company&#x2019;s historical experience and other available industry information. The most significant assumptions used in the estimation process include determining the trend in costs, the expected cost of claims incurred but not reported and the expected costs to settle or pay damage awards with respect to unpaid claims. The self-insured liabilities are based upon estimates, and while management believes that the estimates of loss are reasonable, the ultimate liability may be in excess of or less than the recorded amounts. Due to the inherent volatility of actuarially determined loss estimates, it is reasonably possible that the Company could experience changes in estimated losses that could be material to net income. If the Company&#x2019;s actual liabilities exceed its estimates of losses, its future earnings, cash flows and financial condition would be adversely affected.&lt;/span&gt;&lt;/div&gt;</us-gaap:SelfInsuranceReservePolicyTextBlock>
    <us-gaap:SelfInsuranceReserve contextRef="c-59" decimals="-3" id="f-514" unitRef="usd">500000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-60" decimals="-3" id="f-515" unitRef="usd">1250000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-61" decimals="-3" id="f-516" unitRef="usd">1250000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-62" decimals="-3" id="f-517" unitRef="usd">1000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-63" decimals="-3" id="f-518" unitRef="usd">3000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-64" decimals="-3" id="f-519" unitRef="usd">5000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-65" decimals="-3" id="f-520" unitRef="usd">1000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-66" decimals="-3" id="f-521" unitRef="usd">3000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-67" decimals="-3" id="f-522" unitRef="usd">750000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-68" decimals="-3" id="f-523" unitRef="usd">1500000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-69" decimals="-3" id="f-524" unitRef="usd">650000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-70" decimals="-3" id="f-525" unitRef="usd">1350000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-71" decimals="-3" id="f-526" unitRef="usd">1000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-72" decimals="-3" id="f-527" unitRef="usd">3000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-73" decimals="-3" id="f-528" unitRef="usd">10000000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-74" decimals="-3" id="f-529" unitRef="usd">625000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-75" decimals="-3" id="f-530" unitRef="usd">750000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-76" decimals="-3" id="f-531" unitRef="usd">350000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-77" decimals="-3" id="f-532" unitRef="usd">500000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-78" decimals="-3" id="f-533" unitRef="usd">525000</us-gaap:SelfInsuranceReserve>
    <us-gaap:SelfInsuranceReserve contextRef="c-79" decimals="-3" id="f-534" unitRef="usd">500000</us-gaap:SelfInsuranceReserve>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-535">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Deferred tax assets and liabilities are established for temporary differences between the financial reporting basis and the tax basis of the Company&#x2019;s assets and liabilities at tax rates in effect when such temporary differences are expected to reverse. The Company generally expects to fully utilize its deferred tax assets; however, when necessary, the Company records a valuation allowance to reduce its net deferred tax assets to the amount that is more likely than not to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining the need for a valuation allowance or the need for and magnitude of liabilities for uncertain tax positions, the Company makes certain estimates and assumptions. These estimates and assumptions are based on, among other things, knowledge of operations, markets, historical trends and likely future changes and, when appropriate, the opinions of advisors with knowledge and expertise in certain fields. Due to certain risks associated with the Company&#x2019;s estimates and assumptions, actual results could differ.&lt;/span&gt;&lt;/div&gt;Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. Standard Bearer was organized, has operated and intends to continue to operate in a manner to qualify for taxation as a REIT. In order to qualify as a REIT, Standard Bearer must meet certain organizational and operational requirements, including a requirement to distribute to its shareholders, which in this case is the Company, at least 90% of its annual taxable income. As a REIT, Standard Bearer generally will not be subject to federal income tax to the extent it distributes as qualifying dividends, all of its REIT taxable income to its shareholders. If Standard Bearer fails to qualify as a REIT in any taxable year, it will be subject to federal income tax on its taxable income at regular corporate income tax rates and generally will not be permitted to qualify for treatment as a REIT for federal income tax purposes for the four taxable years following the year during which qualification is lost unless the Internal Revenue Service grants the Company relief under certain statutory provisions.</us-gaap:IncomeTaxPolicyTextBlock>
    <ensg:NoncontrollingInterestPolicyTextBlock contextRef="c-1" id="f-536">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Noncontrolling Interest &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014; &lt;/span&gt;The noncontrolling interest in a subsidiary is initially recognized at estimated fair value on the acquisition date and is presented within total equity in the Company's consolidated balance sheets. The Company presents the noncontrolling interest and the amount of consolidated net income attributable to The Ensign Group, Inc. in its consolidated statements of income. Net income per share is calculated based on net income attributable to The Ensign Group, Inc.'s stockholders. The carrying amount of the noncontrolling interest is adjusted based on an allocation of subsidiary earnings based on ownership interest.</ensg:NoncontrollingInterestPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-537">&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to employees and directors including employee stock options based on estimated fair values, ratably over the requisite service period of the award. Net income has been reduced as a result of the recognition of the fair value of all stock options and restricted stock awards issued, the amount of which is based upon the number of grants and other variables.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-538">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Except for rules and interpretive releases of the Securities and Exchange Commission (SEC) under authority of federal securities laws and a limited number of grandfathered standards, the FASB ASC is the sole source of authoritative GAAP literature recognized by the FASB and applicable to the Company. For any new pronouncements announced, the Company considers whether the new pronouncements could alter previous generally accepted accounting principles and determines whether any new or modified principles will have a material impact on the Company's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of the Company's financial management and certain standards are under consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Standards Issued But Not Yet Adopted by the Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In October 2023, the FASB issued ASU 2023-06&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; "Codification Amendments in Response to the SEC&#x2019;s Disclosure Update and Simplification Initiative", &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which amends U.S. GAAP to include 14 disclosure requirements that are currently required under SEC Regulation S-X or Regulation S-K. Each amendment will be effective on the date on which the SEC removes the related disclosure requirement from SEC Regulation S-X or Regulation S-K. The adoption is not expected to have a material impact on the Company's Notes to the Consolidated Financial Statements as these requirements were previously incorporated under the SEC Regulations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the FASB issued ASU 2023-07 "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;", which requires the Company to expand the breadth and frequency of segment disclosures to include additional information about significant segment expenses, the chief operating decision maker (CODM) and other items, and also require the annual disclosures on an interim basis. This guidance is effective for annual periods beginning after December 15, 2023, which will be the Company's fiscal year 2024, with early adoption permitted. The Company is currently evaluating the impact of the ASU on its Quarterly and Annual Reports. &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09 "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;", which requires the Company to disclose disaggregated jurisdictional and categorical information for the tax rate reconciliation, income taxes paid and other income tax related amounts. This guidance is effective for annual periods beginning after December 15, 2024, which will be the Company's fiscal year 2025, with early adoption permitted. The adoption is expected to enhance the Company's Notes to the Consolidated Financial Statements. The Company is currently evaluating the impact of the ASU on its Annual Report.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-539">REVENUE AND ACCOUNTS RECEIVABLE&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Disaggregation of Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company disaggregates revenue from contracts with its patients by payors. The Company determines that disaggregating revenue into these categories achieves the disclosure objectives to depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue by Payor&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s revenue is derived primarily from providing healthcare services to patients and is recognized on the date services are provided at amounts billable to individual patients, adjusted for estimates for variable consideration. For patients under reimbursement arrangements with third-party payors, including Medicaid, Medicare and private insurers, revenue is recorded based on contractually agreed-upon amounts or rates, adjusted for estimates for variable consideration, on a per patient, daily basis or as services are performed. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% for the years ended December 31, 2023, 2022, and 2021, respectively. Settlements with Medicare and Medicaid payors for retroactive adjustments due to audits and reviews are considered variable consideration and are included in the determination of the estimated transaction price. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor and the Company&#x2019;s historical settlement activity. Consistent with healthcare industry practices, any changes to these revenue estimates are recorded in the period the change or adjustment becomes known based on the final settlement. The Company recorded adjustments to revenue which were not material to the Company's revenue for the years ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid &#x2014; skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Medicaid and Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,690,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,216,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,922,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,708,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,008,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Medicaid payor includes revenue for senior living operations and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;revenue related to state relief funding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;cillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the service revenue above, the Company's rental revenue derived from triple-net lease arrangements with third parties is $21,284, $16,757 and $15,985 for the years ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;State relief funding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received state relief funding through Medicaid programs from various states, including healthcare relief funding under the American Rescue Plan Act (ARPA), increases in the Federal Medical Assistance Percentage (FMAP) under the Families First Coronavirus Response Act (FFCRA) and other state specific relief programs. The funding generally incorporates specific use requirements primarily for direct patient care including labor related expenses that are attributable to the COVID-19 pandemic or are associated with providing patient care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from these additional payments are recognized in accordance with ASC 606, subject to variable consideration constraints. In certain operations where the Company received additional payments that exceeded expenses incurred related to specific qualifiers, the Company recorded deferred revenue for the excess amount until additional expenses are incurred for recognition. Accordingly, the amount of state relief revenue recognized is limited to the actual related expenses incurred. As of years ended December 31, 2023 and 2022, the Company had $486 and $1,001 in unapplied state relief funds, respectively. During the years ended December 31, 2023, 2022, and 2021, the Company received an additional $64,238, $81,057, and $70,484 in state relief funding and recognized $64,753, $81,837, and $75,231, respectively, as revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Federal relief funding&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In prior years, as part of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (the CARES Act), the Company received cash distributions of relief fund payments (Provider Relief Funds) and funds authorized by U.S. Department of Health and Human Services (HHS) to be used to protect residents of nursing homes and long-term care (LTC) facilities from the impact of COVID-19. During the years ended December 31, 2023 and 2022, the Company did not receive Provider Relief Funds. During the year ended December 31, 2021, the Company received and returned $11,637 in Provider Relief Funds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In fiscal year 2020, the Company applied for and received $105,255 through the Medicare Accelerated and Advance Payment Program under the CARES Act. The purpose of the program is to assist in providing needed liquidity to care delivery providers. The Company repaid $3,232 of the funds in 2020 and the remaining funds of $102,023 in March 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The CARES Act also provides for deferred payment of the employer portion of social security taxes through the end of 2020, with approximately 50% of the deferred amount due by December 31, 2021 and the remaining 50% due by December 31, 2022. The Company recorded $48,309 of deferred payments of social security taxes as a liability during 2020, and paid the first and second half of the payments in the fourth quarters of 2021 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Balance Sheet Impact&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Included in the Company&#x2019;s consolidated balance sheets are contract balances, comprised of billed accounts receivable and unbilled receivables, which are the result of the timing of revenue recognition, billings and cash collections, as well as, contract liabilities, which primarily represent payments the Company receives in advance of services provided. The Company had no material contract liabilities and contract assets as of December 31, 2023 and 2022, or activity during the years ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable as of December&#160;31, 2023 and 2022, is summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.75pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;494,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;416,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;485,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="3" id="f-540" unitRef="number">0.726</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="3" id="f-541" unitRef="number">0.737</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="3" id="f-542" unitRef="number">0.736</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-543">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service revenue for the years ended December 31, 2023, 2022, and 2021 is summarized in the following tables:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.086%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.139%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.582%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% of Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid &#x2014; skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Medicaid and Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,690,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,216,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,922,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,708,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,008,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Medicaid payor includes revenue for senior living operations and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;revenue related to state relief funding&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other an&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;cillary services.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-544" unitRef="usd">1459449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="3" id="f-545" unitRef="number">0.394</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-546" unitRef="usd">1183156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="3" id="f-547" unitRef="number">0.393</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-548" unitRef="usd">1022460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="3" id="f-549" unitRef="number">0.392</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-550" unitRef="usd">985749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="3" id="f-551" unitRef="number">0.266</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-552" unitRef="usd">832160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="3" id="f-553" unitRef="number">0.277</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-554" unitRef="usd">727103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="3" id="f-555" unitRef="number">0.278</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-556" unitRef="usd">245663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-96" decimals="3" id="f-557" unitRef="number">0.066</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-558" unitRef="usd">200878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-98" decimals="3" id="f-559" unitRef="number">0.067</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-560" unitRef="usd">172770000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-100" decimals="3" id="f-561" unitRef="number">0.066</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-562" unitRef="usd">2690861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="3" id="f-563" unitRef="number">0.726</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-564" unitRef="usd">2216194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-103" decimals="3" id="f-565" unitRef="number">0.737</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-566" unitRef="usd">1922333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="3" id="f-567" unitRef="number">0.736</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-568" unitRef="usd">666129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-106" decimals="3" id="f-569" unitRef="number">0.180</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-570" unitRef="usd">525710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-108" decimals="3" id="f-571" unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-572" unitRef="usd">456728000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-110" decimals="3" id="f-573" unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-574" unitRef="usd">351081000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-112" decimals="3" id="f-575" unitRef="number">0.094</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-576" unitRef="usd">266807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-114" decimals="3" id="f-577" unitRef="number">0.088</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-3" id="f-578" unitRef="usd">232415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-116" decimals="3" id="f-579" unitRef="number">0.089</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-580" unitRef="usd">3708071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-117"
      decimals="INF"
      id="f-581"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-582" unitRef="usd">3008711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-118"
      decimals="INF"
      id="f-583"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-584" unitRef="usd">2611476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-119"
      decimals="INF"
      id="f-585"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-586" unitRef="usd">21284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-587" unitRef="usd">16757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-588" unitRef="usd">15985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ensg:AccruedLiabilitiesStateReliefContractLiabilities contextRef="c-4" decimals="-3" id="f-589" unitRef="usd">486000</ensg:AccruedLiabilitiesStateReliefContractLiabilities>
    <ensg:AccruedLiabilitiesStateReliefContractLiabilities contextRef="c-5" decimals="-3" id="f-590" unitRef="usd">1001000</ensg:AccruedLiabilitiesStateReliefContractLiabilities>
    <ensg:FamilyFirstCoronavirusResponseActPaymentsReceived contextRef="c-1" decimals="-3" id="f-591" unitRef="usd">64238000</ensg:FamilyFirstCoronavirusResponseActPaymentsReceived>
    <ensg:FamilyFirstCoronavirusResponseActPaymentsReceived contextRef="c-12" decimals="-3" id="f-592" unitRef="usd">81057000</ensg:FamilyFirstCoronavirusResponseActPaymentsReceived>
    <ensg:FamilyFirstCoronavirusResponseActPaymentsReceived contextRef="c-13" decimals="-3" id="f-593" unitRef="usd">70484000</ensg:FamilyFirstCoronavirusResponseActPaymentsReceived>
    <ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized contextRef="c-1" decimals="-3" id="f-594" unitRef="usd">64753000</ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized>
    <ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized contextRef="c-12" decimals="-3" id="f-595" unitRef="usd">81837000</ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized>
    <ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized contextRef="c-13" decimals="-3" id="f-596" unitRef="usd">75231000</ensg:RevenueRecognitionFamilyFirstCoronavirusResponseActRevenueRecognized>
    <ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned contextRef="c-13" decimals="-3" id="f-597" unitRef="usd">11637000</ensg:CoronavirusAidReliefAndEconomicSecurityCARESFundsReceivedAndReturned>
    <ensg:MedicareAcceleratedAndAdvancePaymentCARESACT contextRef="c-120" decimals="-3" id="f-598" unitRef="usd">105255000</ensg:MedicareAcceleratedAndAdvancePaymentCARESACT>
    <ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct contextRef="c-120" decimals="-3" id="f-599" unitRef="usd">3232000</ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct>
    <ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct contextRef="c-121" decimals="-3" id="f-600" unitRef="usd">102023000</ensg:RepaymentOfFundsReceivedFromTheMedicareAcceleratedAndAdvancePaymentProgramCARESAct>
    <ensg:LiabilitiesDeferredTaxPaymentsUnderCARESAct contextRef="c-19" decimals="-3" id="f-601" unitRef="usd">48309000</ensg:LiabilitiesDeferredTaxPaymentsUnderCARESAct>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="c-1" id="f-602">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable as of December&#160;31, 2023 and 2022, is summarized in the following table:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.75pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;157,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other payors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;494,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;416,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: allowance for doubtful accounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9,348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,802)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;ACCOUNTS RECEIVABLE, NET&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;485,039&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;408,432&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:AccountsReceivableGross contextRef="c-122" decimals="-3" id="f-603" unitRef="usd">178285000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-123" decimals="-3" id="f-604" unitRef="usd">157878000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-124" decimals="-3" id="f-605" unitRef="usd">125907000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-125" decimals="-3" id="f-606" unitRef="usd">95940000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-126" decimals="-3" id="f-607" unitRef="usd">85512000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-127" decimals="-3" id="f-608" unitRef="usd">76526000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-128" decimals="-3" id="f-609" unitRef="usd">104683000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-129" decimals="-3" id="f-610" unitRef="usd">85890000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-4" decimals="-3" id="f-611" unitRef="usd">494387000</us-gaap:AccountsReceivableGross>
    <us-gaap:AccountsReceivableGross contextRef="c-5" decimals="-3" id="f-612" unitRef="usd">416234000</us-gaap:AccountsReceivableGross>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-4" decimals="-3" id="f-613" unitRef="usd">9348000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-5" decimals="-3" id="f-614" unitRef="usd">7802000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-4" decimals="-3" id="f-615" unitRef="usd">485039000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-3" id="f-616" unitRef="usd">408432000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-617">COMPUTATION OF NET INCOME PER COMMON SHARE&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income per share is computed by dividing income from operations attributable to stockholders of The Ensign Group, Inc. by the weighted average number of outstanding common shares for the period. The computation of diluted net income per share is similar to the computation of basic net income per share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NUMERATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: net income (loss) attributable to noncontrolling interests &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to The Ensign Group, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DENOMINATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.09&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NUMERATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: net income (loss) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to The Ensign Group, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DENOMINATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: incremental shares from assumed conversion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; 1,429, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of basic net income per common share follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NUMERATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: net income (loss) attributable to noncontrolling interests &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to The Ensign Group, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DENOMINATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average shares outstanding for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Basic net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.76&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4.09&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.57&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-619" unitRef="usd">209850000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-620" unitRef="usd">224652000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-621" unitRef="usd">197725000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-1" decimals="-3" id="f-622" unitRef="usd">451000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-12" decimals="-3" id="f-623" unitRef="usd">-29000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-13" decimals="-3" id="f-624" unitRef="usd">3073000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-625" unitRef="usd">209399000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-626" unitRef="usd">224681000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-627" unitRef="usd">194652000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-628" unitRef="shares">55708000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-629" unitRef="shares">54887000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-630" unitRef="shares">54486000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-631"
      unitRef="usdPerShare">3.76</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-12"
      decimals="2"
      id="f-632"
      unitRef="usdPerShare">4.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-13"
      decimals="2"
      id="f-633"
      unitRef="usdPerShare">3.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock contextRef="c-1" id="f-634">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the numerator and denominator used in the calculation of diluted net income per common share follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.818%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NUMERATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209,850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: net income (loss) attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net income attributable to The Ensign Group, Inc. &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;209,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;224,681&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;194,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;DENOMINATOR:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plus: incremental shares from assumed conversion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Adjusted weighted average common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;57,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,871&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;56,925&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Diluted net income per common share:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.65&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.42&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Options outstanding which are anti-dilutive and therefore not factored into the weighted average common shares amount above were&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; 1,429, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;780 and 198 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-635" unitRef="usd">209850000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-636" unitRef="usd">224652000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-637" unitRef="usd">197725000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-1" decimals="-3" id="f-638" unitRef="usd">451000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-12" decimals="-3" id="f-639" unitRef="usd">-29000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity contextRef="c-13" decimals="-3" id="f-640" unitRef="usd">3073000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-641" unitRef="usd">209399000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-12" decimals="-3" id="f-642" unitRef="usd">224681000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-13" decimals="-3" id="f-643" unitRef="usd">194652000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-644" unitRef="shares">55708000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-12" decimals="-3" id="f-645" unitRef="shares">54887000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-13" decimals="-3" id="f-646" unitRef="shares">54486000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-1" decimals="-3" id="f-647" unitRef="shares">1615000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-12" decimals="-3" id="f-648" unitRef="shares">1984000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-13" decimals="-3" id="f-649" unitRef="shares">2439000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-650" unitRef="shares">57323000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-12" decimals="-3" id="f-651" unitRef="shares">56871000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-13" decimals="-3" id="f-652" unitRef="shares">56925000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-653"
      unitRef="usdPerShare">3.65</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-12"
      decimals="2"
      id="f-654"
      unitRef="usdPerShare">3.95</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-13"
      decimals="2"
      id="f-655"
      unitRef="usdPerShare">3.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-656" unitRef="shares">1429000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-12" decimals="-3" id="f-657" unitRef="shares">780000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-13" decimals="-3" id="f-658" unitRef="shares">198000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-659">FAIR VALUE MEASUREMENTS&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's financial assets include the captive insurance subsidiary's deposits and investments designated to support long-term insurance subsidiary liabilities and are carried at amortized cost basis of $59,530 and $53,924 as of December&#160;31, 2023 and 2022, respectively. As of December&#160;31, 2023 and 2022, the amortized cost basis of the Company's financial assets included in the captive insurance subsidiary's investments are considered to approximate the fair value of these financial assets and are derived using Level 2 inputs. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also included are contracts insuring the lives of certain employees who are eligible to participate in non-qualified deferred compensation plans that are held in a rabbi trust. The cash surrender value of these contracts is based on funds that shadow the investment allocations specified by participants in the deferred compensation plan and are held at fair value. As of December&#160;31, 2023, and 2022, the fair value of the investment funds was $41,216 and $25,144, respectively, which are derived using Level 2 inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company has other investments held at historical cost basis, which are not material, where the fair value is derived using Level 3 inputs. The Company believes its amortized cost basis investments that were in an unrealized loss position as of December&#160;31, 2023 and 2022 do not require an allowance for expected credit losses, nor has any event occurred through the filing date of this report that would indicate differently.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:InvestmentsAndCash contextRef="c-130" decimals="-3" id="f-660" unitRef="usd">59530000</us-gaap:InvestmentsAndCash>
    <us-gaap:InvestmentsAndCash contextRef="c-131" decimals="-3" id="f-661" unitRef="usd">53924000</us-gaap:InvestmentsAndCash>
    <us-gaap:DeferredCompensationPlanAssets contextRef="c-132" decimals="-3" id="f-662" unitRef="usd">41216000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets contextRef="c-133" decimals="-3" id="f-663" unitRef="usd">25144000</us-gaap:DeferredCompensationPlanAssets>
    <ensg:StandardBearerTextBlock contextRef="c-1" id="f-664">STANDARD BEARER&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Standard Bearer's real estate portfolio consists of 108 of the Company's 113 owned real estate properties, of which 79 are operated and managed by the Company's independent subsidiaries and 30 are leased to and operated by third-party operators. Of those 30 operations, one senior living facility is located on the same real estate property as a skilled nursing facility that an independent subsidiary owns and operates. Standard Bearer elected to be taxed as a REIT, for U.S. federal income tax purposes, commencing with its taxable year ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, 2023,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Standard Bearer acquired the real estate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; stand-alone skilled nursing facilities and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;two&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; campus operations for an aggregate purchase price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$65,899. Of these additions, the three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; skilled nursing facilities and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; campus operation acquired are &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;operated by the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; the other campus operation is leased to a third-party operator. During the year ended December 31, 2022, Standard Bearer acquired the real estate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ten skilled nursing facilities for an aggregate purchase price of $84,656, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three of which were previously operated and managed by the Company's independent subsidiaries. Refer to Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operation Expansions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the formation of Standard Bearer, certain of the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries, Standard Bearer and Standard Bearer's independent real estate subsidiaries entered into several agreements that include leasing, management services and debt arrangements between the operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. All intercompany transactions have been eliminated in consolidation. Refer to Note 8, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Segments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information related to these intercompany eliminations as well as Standard Bearer as a reportable segment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intercompany master lease agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company's independent subsidiaries and 79 Standard Bearer independent real estate subsidiaries have entered into five triple-net master lease agreements (collectively, the Standard Bearer Master Leases). The lease periods range from 15 to 19 years with three five-year renewal options beyond the initial term, on the same terms and conditions. The rent structure under the Standard Bearer Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the independent subsidiaries are required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties; (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. Rental revenue generated from the Company's independent subsidiaries was $66,712, $57,967, and $44,165 for the years ended December 31, 2023, 2022, and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intercompany management agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standard Bearer has no employees. The Service Center provides personnel and services to Standard Bearer pursuant to the management agreement between Standard Bearer and the Service Center. The management agreement provides for a base management fee that is equal to 5% of total rental revenue and an incentive management fee that is equal to 5% of funds from operations (FFO) and is capped at 1% of total rental revenue, for a total of 6%. Management fee generated between Standard Bearer and the Service Center for the year ended December 31, 2023 and 2022 was $4,948 and $4,367, respectively. No management fees were recorded in 2021, which was prior to the formation of Standard Bearer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intercompany debt arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standard Bearer obtains its funding through various sources including operating cash flows, access to debt arrangements and intercompany loans. The intercompany debt arrangements include mortgage loans and the Credit Facility to fund acquisitions and working capital needs. The interest rate under the Credit Facility is a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as the Department of Housing and Urban Development (HUD) mortgage loans and promissory note are entered into by real estate subsidiaries of Standard Bearer, the interest expense incurred from these debts are included in Standard Bearer's segment income. Refer to Note 15, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information related to these debts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Instrument Denominated in the Shares of a Subsidiary&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the formation of Standard Bearer in January of 2022, the Company established the Standard Bearer Healthcare REIT, Inc. 2022 Omnibus Incentive Plan (Standard Bearer Equity Plan). The Company may grant stock options and restricted stock awards under the Standard Bearer Equity Plan to employees and management of Ensign's independent subsidiaries. These awards generally vest over a period of five years or upon the occurrence of certain prescribed events. The value of the stock options and restricted stock awards is tied to the value of the common stock of Standard Bearer, which is determined based on an independent valuation of Standard Bearer. The awards can be put to Standard Bearer at various prescribed dates, which in no event is earlier than six months after vesting of the restricted awards or exercise of the stock options. The Company can also call the awards, generally upon employee termination. During the year ended December 31, 2022, Standard Bearer sold fully vested common shares from the Standard Bearer Equity Plan to shareholders for cash of $6,544. During the year ended December 31, 2023 and 2022, the Company did not grant any stock options nor restricted shares under the Standard Bearer Equity Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, during the year ended December 31, 2022, Standard Bearer established shareholders of its preferred shares through contributions of cash of $149. These preferred shares were fully vested at the time of the contributions by the shareholders. The value of Standard Bearer common and preferred shares held by the Company are eliminated in consolidation and the value held by other shareholders are classified as noncontrolling interests on the Company's consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</ensg:StandardBearerTextBlock>
    <us-gaap:NumberOfRealEstateProperties
      contextRef="c-134"
      decimals="0"
      id="f-665"
      unitRef="property">108</us-gaap:NumberOfRealEstateProperties>
    <us-gaap:NumberOfRealEstateProperties contextRef="c-4" decimals="0" id="f-666" unitRef="property">113</us-gaap:NumberOfRealEstateProperties>
    <us-gaap:NumberOfRealEstateProperties
      contextRef="c-135"
      decimals="0"
      id="f-667"
      unitRef="operation">79</us-gaap:NumberOfRealEstateProperties>
    <us-gaap:NumberOfRealEstateProperties
      contextRef="c-136"
      decimals="0"
      id="f-668"
      unitRef="operation">30</us-gaap:NumberOfRealEstateProperties>
    <ensg:NumberOfOperations
      contextRef="c-52"
      decimals="0"
      id="f-669"
      unitRef="operation">30</ensg:NumberOfOperations>
    <ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities
      contextRef="c-52"
      decimals="0"
      id="f-670"
      unitRef="facility">1</ensg:NumberOfSeniorLivingOperationsSharingPropertyWithSkilledNursingFacilities>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-137"
      decimals="INF"
      id="f-671"
      unitRef="property">3</ensg:NumberOfPropertiesAcquired>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-138"
      decimals="INF"
      id="f-672"
      unitRef="operation">2</ensg:NumberOfPropertiesAcquired>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-139" decimals="-3" id="f-673" unitRef="usd">65899000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-137"
      decimals="INF"
      id="f-674"
      unitRef="property">3</ensg:NumberOfPropertiesAcquired>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-137"
      decimals="INF"
      id="f-675"
      unitRef="operation">1</ensg:NumberOfPropertiesAcquired>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-140"
      decimals="INF"
      id="f-676"
      unitRef="property">10</ensg:NumberOfPropertiesAcquired>
    <us-gaap:AssetAcquisitionConsiderationTransferred contextRef="c-141" decimals="-3" id="f-677" unitRef="usd">84656000</us-gaap:AssetAcquisitionConsiderationTransferred>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-142"
      decimals="INF"
      id="f-678"
      unitRef="skilled_nursing_property">3</ensg:NumberOfPropertiesAcquired>
    <us-gaap:NumberOfRealEstateProperties
      contextRef="c-135"
      decimals="0"
      id="f-679"
      unitRef="operation">79</us-gaap:NumberOfRealEstateProperties>
    <ensg:NumberOfLeaseArrangements
      contextRef="c-143"
      decimals="INF"
      id="f-680"
      unitRef="lease">5</ensg:NumberOfLeaseArrangements>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-144" id="f-681">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-145" id="f-682">P19Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms
      contextRef="c-146"
      decimals="INF"
      id="f-683"
      unitRef="renewal">3</ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-146" id="f-684">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c-144"
      decimals="INF"
      id="f-685"
      unitRef="number">0</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="c-146" decimals="3" id="f-686" unitRef="number">0.025</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-147" decimals="-3" id="f-687" unitRef="usd">66712000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-148" decimals="-3" id="f-688" unitRef="usd">57967000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-149" decimals="-3" id="f-689" unitRef="usd">44165000</us-gaap:OperatingLeaseLeaseIncome>
    <ensg:PropertyManagementFeePercentFeeOfTotalRevenues contextRef="c-150" decimals="2" id="f-690" unitRef="number">0.05</ensg:PropertyManagementFeePercentFeeOfTotalRevenues>
    <ensg:PropertyManagementFeePercentFeeOfFundsFromOperations contextRef="c-151" decimals="2" id="f-691" unitRef="number">0.05</ensg:PropertyManagementFeePercentFeeOfFundsFromOperations>
    <ensg:PropertyManagementFeePercentFeeOfTotalRevenues contextRef="c-151" decimals="2" id="f-692" unitRef="number">0.01</ensg:PropertyManagementFeePercentFeeOfTotalRevenues>
    <ensg:PropertyManagementFeePercentFeeOfTotalRevenues contextRef="c-152" decimals="2" id="f-693" unitRef="number">0.06</ensg:PropertyManagementFeePercentFeeOfTotalRevenues>
    <us-gaap:ManagementFeeExpense contextRef="c-150" decimals="-3" id="f-694" unitRef="usd">4948000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="c-153" decimals="-3" id="f-695" unitRef="usd">4367000</us-gaap:ManagementFeeExpense>
    <us-gaap:ManagementFeeExpense contextRef="c-154" decimals="INF" id="f-696" unitRef="usd">0</us-gaap:ManagementFeeExpense>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-155"
      decimals="INF"
      id="f-697"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-156"
      decimals="INF"
      id="f-698"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-157"
      decimals="INF"
      id="f-699"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-158"
      decimals="INF"
      id="f-700"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-701">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions contextRef="c-159" id="f-702">P6M</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardEventPeriodAfterVestingOfRestrictedAwardsOrExerciseOfStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-160" decimals="-3" id="f-703" unitRef="usd">6544000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-161"
      decimals="INF"
      id="f-704"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-162"
      decimals="INF"
      id="f-705"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-160"
      decimals="INF"
      id="f-706"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-163"
      decimals="INF"
      id="f-707"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="c-160" decimals="-3" id="f-708" unitRef="usd">149000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-709">OPERATION EXPANSIONS&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expansion focus of the Company's independent subsidiaries is to purchase or lease operations that are complementary to the current operations, accretive to the business, or otherwise advance the Company's strategy. The results of all independent subsidiaries are included in the Financial Statements subsequent to the date of acquisition. Acquisitions are accounted for using the acquisition method of accounting. The Company's independent subsidiaries also enter into long-term leases that may include options to purchase the facilities. As a result, from time to time, an independent real estate subsidiary will acquire the property of facilities that have previously been operated under third-party leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2023 Expansions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the addition of 25 stand-alone skilled nursing operations and one campus operation. Of these additions, Standard Bearer acquired the real estate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the stand-alone skilled nursing operations and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; campus operation, which were leased back to the Company's independent subsidiaries.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Standard Bearer, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for additional information on the purchase of real estate properties. These new operations added a total of 2,483 operational skilled nursing beds and 94 operational senior living units to be operated by the Company's independent subsidiaries. The Company also invested in new ancillary services that are complementary to its existing businesses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December&#160;31, 2023, the Company expanded its operations through a long-term lease, with the addition of two stand-alone skilled nursing operations, totaling 241 operational skilled nursing beds operated by the Company's independent subsidiaries, including one in a new state, Tennessee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Expansions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2022, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company expanded its operations and real estate portfolio through a combination of long-term leases and real estate purchases&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, with the addition of 23 stand-alone skilled nursing operations and one campus operation. Of these additions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Standard Bearer acquired the real estate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;seven of the stand-alone skilled nursing operations, which were leased back to Ensign's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Standard Bearer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, for additional information on the purchases of real estate properties. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company added five senior living operations that were transferred from The Pennant Group, Inc. (Pennant), three of which are part of campuses operated by the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries. These new operations added a total of 3,058 operational skilled nursing beds and 674 operational senior living units to be operated by the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also invested in new ancillary services that are complementary to its existing businesses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the new operations acquired during the year ended December 31, 2022, $16,400 was concentrated in goodwill and accordingly, the transactions were classified as business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the new operations obtained through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with each prior operator as part of each transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;span style="color:#3d6702;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company expanded its operations through a combination of long-term leases and a real estate purchase,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with the addition of 17 stand-alone skilled nursing operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and five real estate purchases, four of which the Company previously operated and continues to operate. The remaining real estate purchase is operated by Pennant.&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These new operations added a total of 1,832 operational skilled nursing beds operated by the Company's &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; subsidiaries.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the new operations acquired during the year ended December 31, 2021, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$6,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was concentrated in goodwill and accordingly, the transactions were classified as business combinations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the new operations made through long-term leases, the Company did not acquire any material assets or assume any liabilities other than the tenant's post-assumption rights and obligations under the long-term lease. The Company entered into a separate operations transfer agreement with the prior operator as part of each transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the allocation of the purchase price for the operations acquired during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years ended December 31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, furniture, and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled occupancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL ACQUISITIONS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104,224&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s acquisition strategy has been focused on identifying both opportunistic and strategic acquisitions within its target markets that offer strong opportunities for return. The operations added by the Company are frequently underperforming financially and can have regulatory and clinical challenges to overcome. Financial information, especially with underperforming operations, is often inadequate, inaccurate or unavailable. Consequently, the Company believes that prior operating results are not a meaningful representation of the Company&#x2019;s current operating results or indicative of the integration potential of its newly acquired &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;independent subsidiaries&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The assets added during the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;year ended December 31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were not material operations to the Company individually or in the aggregate. Accordingly, pro forma financial information is not presented. These additions have been included in the&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; balance sheets of the Company, and the operating results have been included in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;consolidated&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; statements of income of the Company since the date the Company gained effective control.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-164"
      decimals="INF"
      id="f-710"
      unitRef="operation">25</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-165"
      decimals="INF"
      id="f-711"
      unitRef="operation">1</us-gaap:NumberOfBusinessesAcquired>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-137"
      decimals="INF"
      id="f-712"
      unitRef="property">3</ensg:NumberOfPropertiesAcquired>
    <ensg:NumberOfPropertiesAcquired
      contextRef="c-137"
      decimals="INF"
      id="f-713"
      unitRef="operation">1</ensg:NumberOfPropertiesAcquired>
    <ensg:OperationalSkilledNursingBeds contextRef="c-166" decimals="INF" id="f-714" unitRef="bed">2483</ensg:OperationalSkilledNursingBeds>
    <ensg:OperationalSeniorLivingUnits
      contextRef="c-167"
      decimals="INF"
      id="f-715"
      unitRef="senior_living_unit">94</ensg:OperationalSeniorLivingUnits>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-168"
      decimals="INF"
      id="f-716"
      unitRef="operation">2</us-gaap:NumberOfBusinessesAcquired>
    <ensg:OperationalSkilledNursingBeds contextRef="c-169" decimals="INF" id="f-717" unitRef="bed">241</ensg:OperationalSkilledNursingBeds>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-170"
      decimals="INF"
      id="f-718"
      unitRef="operation">23</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-171"
      decimals="INF"
      id="f-719"
      unitRef="operation">1</us-gaap:NumberOfBusinessesAcquired>
    <ensg:NumberOfLeaseArrangements
      contextRef="c-170"
      decimals="INF"
      id="f-720"
      unitRef="operation">7</ensg:NumberOfLeaseArrangements>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-172"
      decimals="INF"
      id="f-721"
      unitRef="operation">5</us-gaap:NumberOfBusinessesAcquired>
    <ensg:NumberOfLivingOperationsTransferredFromThirdParties
      contextRef="c-172"
      decimals="INF"
      id="f-722"
      unitRef="operation">3</ensg:NumberOfLivingOperationsTransferredFromThirdParties>
    <ensg:OperationalSkilledNursingBeds contextRef="c-173" decimals="INF" id="f-723" unitRef="bed">3058</ensg:OperationalSkilledNursingBeds>
    <ensg:OperationalSeniorLivingUnits
      contextRef="c-174"
      decimals="INF"
      id="f-724"
      unitRef="senior_living_unit">674</ensg:OperationalSeniorLivingUnits>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-175" decimals="-3" id="f-725" unitRef="usd">16400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-176"
      decimals="INF"
      id="f-726"
      unitRef="operation">17</us-gaap:NumberOfBusinessesAcquired>
    <ensg:NumberOfAssetAcquisitions
      contextRef="c-177"
      decimals="INF"
      id="f-727"
      unitRef="business">5</ensg:NumberOfAssetAcquisitions>
    <ensg:NumberOfAssetAcquisitions
      contextRef="c-178"
      decimals="INF"
      id="f-728"
      unitRef="business">4</ensg:NumberOfAssetAcquisitions>
    <ensg:OperationalSkilledNursingBeds contextRef="c-179" decimals="INF" id="f-729" unitRef="bed">1832</ensg:OperationalSkilledNursingBeds>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-180" decimals="-3" id="f-730" unitRef="usd">6000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-731">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the allocation of the purchase price for the operations acquired during the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;years ended December 31, 2023, 2022, and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.642%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.600%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment, furniture, and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,618&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled occupancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leased asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,909&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other indefinite-lived intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL ACQUISITIONS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,798&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;101,136&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;104,224&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-181" decimals="-3" id="f-732" unitRef="usd">7794000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-182" decimals="-3" id="f-733" unitRef="usd">15527000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-183" decimals="-3" id="f-734" unitRef="usd">19928000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-184" decimals="-3" id="f-735" unitRef="usd">57488000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-185" decimals="-3" id="f-736" unitRef="usd">65070000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-186" decimals="-3" id="f-737" unitRef="usd">77975000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-187" decimals="-3" id="f-738" unitRef="usd">1840000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-188" decimals="-3" id="f-739" unitRef="usd">1618000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-189" decimals="-3" id="f-740" unitRef="usd">217000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-190" decimals="-3" id="f-741" unitRef="usd">346000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-191" decimals="-3" id="f-742" unitRef="usd">367000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions contextRef="c-192" decimals="-3" id="f-743" unitRef="usd">29000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-193" decimals="-3" id="f-744" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-194" decimals="-3" id="f-745" unitRef="usd">16400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-195" decimals="-3" id="f-746" unitRef="usd">6000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <ensg:LeasedAssetsAcquiredDuringPeriod contextRef="c-193" decimals="-3" id="f-747" unitRef="usd">0</ensg:LeasedAssetsAcquiredDuringPeriod>
    <ensg:LeasedAssetsAcquiredDuringPeriod contextRef="c-194" decimals="-3" id="f-748" unitRef="usd">1909000</ensg:LeasedAssetsAcquiredDuringPeriod>
    <ensg:LeasedAssetsAcquiredDuringPeriod contextRef="c-195" decimals="-3" id="f-749" unitRef="usd">0</ensg:LeasedAssetsAcquiredDuringPeriod>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-193" decimals="-3" id="f-750" unitRef="usd">330000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-194" decimals="-3" id="f-751" unitRef="usd">245000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-195" decimals="-3" id="f-752" unitRef="usd">75000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-193" decimals="-3" id="f-753" unitRef="usd">67798000</ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-194" decimals="-3" id="f-754" unitRef="usd">101136000</ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-195" decimals="-3" id="f-755" unitRef="usd">104224000</ensg:BusinessCombinationAndAssetAcquisitionAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-756">BUSINESS SEGMENTS&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has two reportable segments: (1) skilled services, which includes the operation of skilled nursing facilities and rehabilitation therapy services and (2) Standard Bearer, which is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2023, the skilled services segment includes 259 skilled nursing operations and 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. The Company's Standard Bearer segment consists of 108 owned real estate properties. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also reports an &#x201c;All Other&#x201d; category that includes results from its senior living operations, which includes 11 stand-alone senior living operations and the senior living operations at 27 campus operations that provide both skilled nursing and rehabilitative care services and senior living services. In addition, the "All Other" category includes mobile diagnostics, medical transportation, other real estate and other ancillary operations. Services included in the &#x201c;All Other&#x201d; category are insignificant individually, and therefore do not constitute a reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s reportable segments are significant operating segments that offer differentiated services. The Company's CODM reviews financial information for each operating segment to evaluate performance and allocate capital resources. This structure reflects its current operational and financial management and provides the best structure to maximize the quality of care and investment strategy provided, while maintaining financial discipline. The Company's CODM does not review assets by segment in his resource allocation and therefore assets by segment are not disclosed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accounting policies of the reportable segments are the same as those described in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Intercompany revenue is eliminated in consolidation, along with corresponding intercompany expenses. Segment income and loss is defined as profit or loss from operations before provision for income taxes, excluding gain or loss from sale of real estate, real estate insurance recoveries and losses and impairment charges from operations. Included in segment income for Standard Bearer is expense for intercompany services provided by the Service Center as described in Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Standard Bearer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as it is part of the CODM financial information. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth financial information for the segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,578,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;155,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(87,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,729,355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets and insurance recoveries from real estate, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;272,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,906,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,906,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(76,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,025,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets and insurance recoveries from real estate, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,523,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58,127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(56,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,627,461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on real estate insurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258,004&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service revenue by major payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,660,885&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,690,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,578,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,708,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,191,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,216,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,906,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,008,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,906,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,922,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-757"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <ensg:SkilledServiceFacilities
      contextRef="c-4"
      decimals="INF"
      id="f-758"
      unitRef="operation">259</ensg:SkilledServiceFacilities>
    <ensg:SkilledServicesAndSeniorLivingCampuses
      contextRef="c-4"
      decimals="0"
      id="f-759"
      unitRef="operation">27</ensg:SkilledServicesAndSeniorLivingCampuses>
    <us-gaap:NumberOfRealEstateProperties
      contextRef="c-134"
      decimals="0"
      id="f-760"
      unitRef="property">108</us-gaap:NumberOfRealEstateProperties>
    <ensg:SeniorLivingFacilities
      contextRef="c-4"
      decimals="INF"
      id="f-761"
      unitRef="facility">11</ensg:SeniorLivingFacilities>
    <ensg:SkilledServicesAndSeniorLivingCampuses
      contextRef="c-4"
      decimals="0"
      id="f-762"
      unitRef="operation">27</ensg:SkilledServicesAndSeniorLivingCampuses>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-763">&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth financial information for the segments:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,578,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,451)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,708,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72,339)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,578,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;155,804&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(87,790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,729,355&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;464,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(221,251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;272,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets and insurance recoveries from real estate, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;272,762&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,902)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,087&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) All Other rental revenue includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,906,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,214&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,718)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(63,576)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,906,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72,937&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;122,610&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(76,294)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,025,468&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;408,732&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(150,781)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on sale of assets and insurance recoveries from real estate, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;289,089&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,518&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,646)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(4) Included in interest expense in Standard Bearer is interest expense incurred from intercompany debt arrangements between Standard Bearer and The Ensign Group, Inc. Intercompany interest expense is eliminated in the "Intercompany Elimination" column. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.204%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.603%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Standard Bearer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intercompany Elimination&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,523,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7,034)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611,476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;58,127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102,685&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(56,585)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,627,461&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segment income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,876&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(147,915)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257,564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gain on real estate insurance recoveries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income before provision for income taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;258,004&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) All Other primarily includes all ancillary operations, stand-alone senior living operations and the Service Center. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Intercompany service revenue represents service revenue generated by ancillary operations provided to the Company's independent subsidiaries and management service revenue generated by the Service Center with Standard Bearer. Intercompany service revenue is eliminated in consolidation along with corresponding intercompany cost of service. &lt;/span&gt;&lt;/div&gt;(3) Intercompany rental revenue represents rental income generated by both Standard Bearer and other real estate properties with the Company's independent subsidiaries. Intercompany rental revenue is eliminated in consolidation along with corresponding intercompany rent expense.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-764" unitRef="usd">3578855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-197" decimals="-3" id="f-765" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-198" decimals="-3" id="f-766" unitRef="usd">144667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-199" decimals="-3" id="f-767" unitRef="usd">-15451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-768" unitRef="usd">3708071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-200" decimals="-3" id="f-769" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-201" decimals="-3" id="f-770" unitRef="usd">82486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-202" decimals="-3" id="f-771" unitRef="usd">11137000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-203" decimals="-3" id="f-772" unitRef="usd">-72339000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-9" decimals="-3" id="f-773" unitRef="usd">21284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-204" decimals="-3" id="f-774" unitRef="usd">3578855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-205" decimals="-3" id="f-775" unitRef="usd">82486000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-206" decimals="-3" id="f-776" unitRef="usd">155804000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-207" decimals="-3" id="f-777" unitRef="usd">-87790000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-778" unitRef="usd">3729355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ensg:SegmentIncomeLoss contextRef="c-204" decimals="-3" id="f-779" unitRef="usd">464925000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-205" decimals="-3" id="f-780" unitRef="usd">29065000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-206" decimals="-3" id="f-781" unitRef="usd">-221251000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-207" decimals="-3" id="f-782" unitRef="usd">0</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-1" decimals="-3" id="f-783" unitRef="usd">272739000</ensg:SegmentIncomeLoss>
    <us-gaap:ProfitLossFromRealEstateOperations contextRef="c-1" decimals="-3" id="f-784" unitRef="usd">23000</us-gaap:ProfitLossFromRealEstateOperations>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-785" unitRef="usd">272762000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-204" decimals="-3" id="f-786" unitRef="usd">38766000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-205" decimals="-3" id="f-787" unitRef="usd">25205000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-206" decimals="-3" id="f-788" unitRef="usd">8416000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-207" decimals="-3" id="f-789" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-3" id="f-790" unitRef="usd">72387000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestExpense contextRef="c-204" decimals="-3" id="f-791" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-205" decimals="-3" id="f-792" unitRef="usd">19761000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-206" decimals="-3" id="f-793" unitRef="usd">1228000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-207" decimals="-3" id="f-794" unitRef="usd">-12902000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-795" unitRef="usd">8087000</us-gaap:InterestExpense>
    <us-gaap:SubleaseIncome contextRef="c-202" decimals="-3" id="f-796" unitRef="usd">3897000</us-gaap:SubleaseIncome>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-3" id="f-797" unitRef="usd">2906215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-209" decimals="-3" id="f-798" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-210" decimals="-3" id="f-799" unitRef="usd">115214000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-211" decimals="-3" id="f-800" unitRef="usd">-12718000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-801" unitRef="usd">3008711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-212" decimals="-3" id="f-802" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-213" decimals="-3" id="f-803" unitRef="usd">72937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-214" decimals="-3" id="f-804" unitRef="usd">7396000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-215" decimals="-3" id="f-805" unitRef="usd">-63576000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-10" decimals="-3" id="f-806" unitRef="usd">16757000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-216" decimals="-3" id="f-807" unitRef="usd">2906215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-217" decimals="-3" id="f-808" unitRef="usd">72937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-218" decimals="-3" id="f-809" unitRef="usd">122610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-219" decimals="-3" id="f-810" unitRef="usd">-76294000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-12" decimals="-3" id="f-811" unitRef="usd">3025468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ensg:SegmentIncomeLoss contextRef="c-216" decimals="-3" id="f-812" unitRef="usd">408732000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-217" decimals="-3" id="f-813" unitRef="usd">27871000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-218" decimals="-3" id="f-814" unitRef="usd">-150781000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-219" decimals="-3" id="f-815" unitRef="usd">0</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-12" decimals="-3" id="f-816" unitRef="usd">285822000</ensg:SegmentIncomeLoss>
    <us-gaap:ProfitLossFromRealEstateOperations contextRef="c-12" decimals="-3" id="f-817" unitRef="usd">3267000</us-gaap:ProfitLossFromRealEstateOperations>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-818" unitRef="usd">289089000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-216" decimals="-3" id="f-819" unitRef="usd">33224000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-217" decimals="-3" id="f-820" unitRef="usd">21613000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-218" decimals="-3" id="f-821" unitRef="usd">7518000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-219" decimals="-3" id="f-822" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-12" decimals="-3" id="f-823" unitRef="usd">62355000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestExpense contextRef="c-216" decimals="-3" id="f-824" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-217" decimals="-3" id="f-825" unitRef="usd">15707000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-218" decimals="-3" id="f-826" unitRef="usd">1870000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-219" decimals="-3" id="f-827" unitRef="usd">-8646000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-12" decimals="-3" id="f-828" unitRef="usd">8931000</us-gaap:InterestExpense>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-220" decimals="-3" id="f-829" unitRef="usd">2523234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-221" decimals="-3" id="f-830" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-222" decimals="-3" id="f-831" unitRef="usd">95276000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-223" decimals="-3" id="f-832" unitRef="usd">-7034000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-833" unitRef="usd">2611476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-224" decimals="-3" id="f-834" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-225" decimals="-3" id="f-835" unitRef="usd">58127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-226" decimals="-3" id="f-836" unitRef="usd">7409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-227" decimals="-3" id="f-837" unitRef="usd">-49551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-11" decimals="-3" id="f-838" unitRef="usd">15985000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-228" decimals="-3" id="f-839" unitRef="usd">2523234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-229" decimals="-3" id="f-840" unitRef="usd">58127000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-230" decimals="-3" id="f-841" unitRef="usd">102685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-231" decimals="-3" id="f-842" unitRef="usd">-56585000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-13" decimals="-3" id="f-843" unitRef="usd">2627461000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ensg:SegmentIncomeLoss contextRef="c-228" decimals="-3" id="f-844" unitRef="usd">373603000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-229" decimals="-3" id="f-845" unitRef="usd">31876000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-230" decimals="-3" id="f-846" unitRef="usd">-147915000</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-231" decimals="-3" id="f-847" unitRef="usd">0</ensg:SegmentIncomeLoss>
    <ensg:SegmentIncomeLoss contextRef="c-13" decimals="-3" id="f-848" unitRef="usd">257564000</ensg:SegmentIncomeLoss>
    <us-gaap:ProfitLossFromRealEstateOperations contextRef="c-13" decimals="-3" id="f-849" unitRef="usd">440000</us-gaap:ProfitLossFromRealEstateOperations>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-13" decimals="-3" id="f-850" unitRef="usd">258004000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-228" decimals="-3" id="f-851" unitRef="usd">30681000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-229" decimals="-3" id="f-852" unitRef="usd">17558000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-230" decimals="-3" id="f-853" unitRef="usd">7746000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-231" decimals="-3" id="f-854" unitRef="usd">0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-13" decimals="-3" id="f-855" unitRef="usd">55985000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InterestExpense contextRef="c-228" decimals="-3" id="f-856" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-229" decimals="-3" id="f-857" unitRef="usd">6842000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-230" decimals="-3" id="f-858" unitRef="usd">7000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-231" decimals="-3" id="f-859" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-13" decimals="-3" id="f-860" unitRef="usd">6849000</us-gaap:InterestExpense>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-861">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Service revenue by major payor source were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.378%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,459,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;985,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245,663&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,660,885&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,976&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,690,861&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;72.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;251,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,578,855&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;129,216&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,708,071&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,191,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;24,847&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,216,194&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.7&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;525,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;77,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;266,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,906,215&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102,496&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,008,711&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Service Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Revenue %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,007,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,022,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;727,103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicaid-skilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,906,934&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,399&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,922,333&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;73.6&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Managed care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;456,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Private and other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;159,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232,415&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL SERVICE REVENUE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,523,234&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;88,242&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,611,476&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100.0&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(1) Medicaid payor includes revenue generated from senior living operations and revenue related to state relief funding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Private and other payors also includes revenue from senior living operations and all payors generated in other ancillary services.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:80%"&gt;(3) All Other incorporates intercompany eliminations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-232" decimals="-3" id="f-862" unitRef="usd">1429473000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-233" decimals="-3" id="f-863" unitRef="usd">29976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-864" unitRef="usd">1459449000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="3" id="f-865" unitRef="number">0.394</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-234" decimals="-3" id="f-866" unitRef="usd">985749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-235" decimals="-3" id="f-867" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-868" unitRef="usd">985749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-90" decimals="3" id="f-869" unitRef="number">0.266</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-236" decimals="-3" id="f-870" unitRef="usd">245663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-237" decimals="-3" id="f-871" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-3" id="f-872" unitRef="usd">245663000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-96" decimals="3" id="f-873" unitRef="number">0.066</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-238" decimals="-3" id="f-874" unitRef="usd">2660885000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-239" decimals="-3" id="f-875" unitRef="usd">29976000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-3" id="f-876" unitRef="usd">2690861000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="3" id="f-877" unitRef="number">0.726</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-240" decimals="-3" id="f-878" unitRef="usd">666129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-241" decimals="-3" id="f-879" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-105" decimals="-3" id="f-880" unitRef="usd">666129000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-106" decimals="3" id="f-881" unitRef="number">0.180</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-242" decimals="-3" id="f-882" unitRef="usd">251841000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-243" decimals="-3" id="f-883" unitRef="usd">99240000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-111" decimals="-3" id="f-884" unitRef="usd">351081000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-112" decimals="3" id="f-885" unitRef="number">0.094</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-196" decimals="-3" id="f-886" unitRef="usd">3578855000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-244" decimals="-3" id="f-887" unitRef="usd">129216000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-888" unitRef="usd">3708071000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-117"
      decimals="INF"
      id="f-889"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-245" decimals="-3" id="f-890" unitRef="usd">1158309000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-246" decimals="-3" id="f-891" unitRef="usd">24847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-892" unitRef="usd">1183156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="3" id="f-893" unitRef="number">0.393</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-247" decimals="-3" id="f-894" unitRef="usd">832160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-248" decimals="-3" id="f-895" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-91" decimals="-3" id="f-896" unitRef="usd">832160000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-92" decimals="3" id="f-897" unitRef="number">0.277</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-249" decimals="-3" id="f-898" unitRef="usd">200878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-250" decimals="-3" id="f-899" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-97" decimals="-3" id="f-900" unitRef="usd">200878000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-98" decimals="3" id="f-901" unitRef="number">0.067</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-251" decimals="-3" id="f-902" unitRef="usd">2191347000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-252" decimals="-3" id="f-903" unitRef="usd">24847000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-102" decimals="-3" id="f-904" unitRef="usd">2216194000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-103" decimals="3" id="f-905" unitRef="number">0.737</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-253" decimals="-3" id="f-906" unitRef="usd">525710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-254" decimals="-3" id="f-907" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-3" id="f-908" unitRef="usd">525710000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-108" decimals="3" id="f-909" unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-255" decimals="-3" id="f-910" unitRef="usd">189158000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-256" decimals="-3" id="f-911" unitRef="usd">77649000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-113" decimals="-3" id="f-912" unitRef="usd">266807000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-114" decimals="3" id="f-913" unitRef="number">0.088</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-208" decimals="-3" id="f-914" unitRef="usd">2906215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-257" decimals="-3" id="f-915" unitRef="usd">102496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-916" unitRef="usd">3008711000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-118"
      decimals="INF"
      id="f-917"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-258" decimals="-3" id="f-918" unitRef="usd">1007061000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-259" decimals="-3" id="f-919" unitRef="usd">15399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-920" unitRef="usd">1022460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-88" decimals="3" id="f-921" unitRef="number">0.392</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-260" decimals="-3" id="f-922" unitRef="usd">727103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-261" decimals="-3" id="f-923" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-93" decimals="-3" id="f-924" unitRef="usd">727103000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-94" decimals="3" id="f-925" unitRef="number">0.278</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-262" decimals="-3" id="f-926" unitRef="usd">172770000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-263" decimals="-3" id="f-927" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-3" id="f-928" unitRef="usd">172770000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-100" decimals="3" id="f-929" unitRef="number">0.066</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-264" decimals="-3" id="f-930" unitRef="usd">1906934000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-265" decimals="-3" id="f-931" unitRef="usd">15399000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-104" decimals="-3" id="f-932" unitRef="usd">1922333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="3" id="f-933" unitRef="number">0.736</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-266" decimals="-3" id="f-934" unitRef="usd">456728000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-267" decimals="-3" id="f-935" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-3" id="f-936" unitRef="usd">456728000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-110" decimals="3" id="f-937" unitRef="number">0.175</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-268" decimals="-3" id="f-938" unitRef="usd">159572000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-269" decimals="-3" id="f-939" unitRef="usd">72843000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-115" decimals="-3" id="f-940" unitRef="usd">232415000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-116" decimals="3" id="f-941" unitRef="number">0.089</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-220" decimals="-3" id="f-942" unitRef="usd">2523234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-270" decimals="-3" id="f-943" unitRef="usd">88242000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-8" decimals="-3" id="f-944" unitRef="usd">2611476000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-119"
      decimals="INF"
      id="f-945"
      unitRef="number">1.000</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-946">PROPERTY AND EQUIPMENT - NET&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,487,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,331,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,090,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;992,010&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company completed the sale of assets for a sale price of $8,607 and recorded a gain of $3,467 within the Company's consolidated statement of income as cost of services during the year ended December 31, 2022. In addition, the Company evaluated its long-lived assets and did not record an impairment charge&#160;for the fiscal years ended 2023, 2022, and 2021. See also Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Standard Bearer &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Note 7, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operation Expansions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for information on acquisitions during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-947">&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.715%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;295,739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,487,013&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,331,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(339,792)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PROPERTY AND EQUIPMENT, NET&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,090,771&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;992,010&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-271" decimals="-3" id="f-948" unitRef="usd">142656000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-272" decimals="-3" id="f-949" unitRef="usd">134864000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-273" decimals="-3" id="f-950" unitRef="usd">803155000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-274" decimals="-3" id="f-951" unitRef="usd">728231000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-275" decimals="-3" id="f-952" unitRef="usd">172064000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-276" decimals="-3" id="f-953" unitRef="usd">150903000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-277" decimals="-3" id="f-954" unitRef="usd">339383000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-278" decimals="-3" id="f-955" unitRef="usd">295739000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-279" decimals="-3" id="f-956" unitRef="usd">4192000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-280" decimals="-3" id="f-957" unitRef="usd">4544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-281" decimals="-3" id="f-958" unitRef="usd">25563000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-282" decimals="-3" id="f-959" unitRef="usd">17521000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-960" unitRef="usd">1487013000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-3" id="f-961" unitRef="usd">1331802000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-962" unitRef="usd">396242000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-963" unitRef="usd">339792000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-964" unitRef="usd">1090771000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-3" id="f-965" unitRef="usd">992010000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-283" decimals="-3" id="f-966" unitRef="usd">8607000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-283" decimals="-3" id="f-967" unitRef="usd">3467000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-968">INTANGIBLE ASSETS - NET&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled occupancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,096&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December 31, 2023, 2022, and 2021, amortization expense was $1,790, $1,714 and $1,435, respectively, of which $1,202, $1,160 and $1,158 was related to the amortization of right-of-use assets, respectively. The Company did not record any impairment charge to intangible assets during the years ended December 31, 2023, 2022, and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense for each of the years ending December&#160;31 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other indefinite-lived intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;During the year ended December 31, 2023, the Company acquired $330 in Medicare and Medicaid licenses compared to $245 and $181 in the fiscal years 2022 and 2021, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-969">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.682%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="5" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assembled occupancy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(742)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(388)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Facility trade name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,692)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,482)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,096&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,873)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5,750&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(3,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,465&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-284" id="f-970">P0Y3M18D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-285" decimals="-3" id="f-971" unitRef="usd">781000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-285" decimals="-3" id="f-972" unitRef="usd">742000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-285" decimals="-3" id="f-973" unitRef="usd">39000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-286" decimals="-3" id="f-974" unitRef="usd">435000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-286" decimals="-3" id="f-975" unitRef="usd">388000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-286" decimals="-3" id="f-976" unitRef="usd">47000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-287" id="f-977">P30Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-57" decimals="-3" id="f-978" unitRef="usd">733000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-57" decimals="-3" id="f-979" unitRef="usd">439000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-57" decimals="-3" id="f-980" unitRef="usd">294000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-288" decimals="-3" id="f-981" unitRef="usd">733000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-288" decimals="-3" id="f-982" unitRef="usd">415000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-288" decimals="-3" id="f-983" unitRef="usd">318000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-289" id="f-984">P18Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-58" decimals="-3" id="f-985" unitRef="usd">4582000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-58" decimals="-3" id="f-986" unitRef="usd">2692000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-58" decimals="-3" id="f-987" unitRef="usd">1890000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-290" decimals="-3" id="f-988" unitRef="usd">4582000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-290" decimals="-3" id="f-989" unitRef="usd">2482000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-290" decimals="-3" id="f-990" unitRef="usd">2100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-4" decimals="-3" id="f-991" unitRef="usd">6096000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-4" decimals="-3" id="f-992" unitRef="usd">3873000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-993" unitRef="usd">2223000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-5" decimals="-3" id="f-994" unitRef="usd">5750000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-5" decimals="-3" id="f-995" unitRef="usd">3285000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-5" decimals="-3" id="f-996" unitRef="usd">2465000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-3" id="f-997" unitRef="usd">1790000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-12" decimals="-3" id="f-998" unitRef="usd">1714000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-13" decimals="-3" id="f-999" unitRef="usd">1435000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingLeaseCost contextRef="c-291" decimals="-3" id="f-1000" unitRef="usd">1202000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-292" decimals="-3" id="f-1001" unitRef="usd">1160000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-293" decimals="-3" id="f-1002" unitRef="usd">1158000</us-gaap:OperatingLeaseCost>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-12" decimals="INF" id="f-1003" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-13" decimals="INF" id="f-1004" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-1" decimals="INF" id="f-1005" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1006">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated amortization expense for each of the years ending December&#160;31 is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.837%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.382%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,223&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1007" unitRef="usd">274000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-4" decimals="-3" id="f-1008" unitRef="usd">234000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-4" decimals="-3" id="f-1009" unitRef="usd">234000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-4" decimals="-3" id="f-1010" unitRef="usd">234000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-4" decimals="-3" id="f-1011" unitRef="usd">234000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-4" decimals="-3" id="f-1012" unitRef="usd">1013000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-1013" unitRef="usd">2223000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock contextRef="c-1" id="f-1014">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other indefinite-lived intangible assets consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trade name&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;889&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medicare and Medicaid licenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;text-indent:4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,302&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredIndefiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-294" decimals="-3" id="f-1015" unitRef="usd">889000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-295" decimals="-3" id="f-1016" unitRef="usd">889000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-296" decimals="-3" id="f-1017" unitRef="usd">3413000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-297" decimals="-3" id="f-1018" unitRef="usd">3083000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-4" decimals="-3" id="f-1019" unitRef="usd">4302000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-5" decimals="-3" id="f-1020" unitRef="usd">3972000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-298" decimals="-3" id="f-1021" unitRef="usd">330000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-299" decimals="-3" id="f-1022" unitRef="usd">245000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:IndefinitelivedIntangibleAssetsAcquired contextRef="c-300" decimals="-3" id="f-1023" unitRef="usd">181000</us-gaap:IndefinitelivedIntangibleAssetsAcquired>
    <us-gaap:GoodwillDisclosureTextBlock contextRef="c-1" id="f-1024">GOODWILL &lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company anticipates that the majority of goodwill recognized will be fully deductible for tax purposes as of December&#160;31, 2023. All of the Company's acquisitions during the year ended December&#160;31, 2023 were classified as asset acquisitions and accordingly, no goodwill was recognized for these acquisitions. There were no other activities in goodwill during the year ended December&#160;31, 2023. Provided that goodwill corresponds to the acquisition of a business and not merely the acquisition of real estate property, the Company's Standard Bearer segment appropriately does not carry a goodwill balance. The following table represents activity in goodwill by skilled service segment and "all other" category as of December&#160;31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1025">The following table represents activity in goodwill by skilled service segment and "all other" category as of December&#160;31, 2023, 2022 and 2021:&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.524%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skilled Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;All Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;54,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;51,486&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,469&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,886&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,983&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;76,869&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-301" decimals="-3" id="f-1026" unitRef="usd">45486000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-302" decimals="-3" id="f-1027" unitRef="usd">8983000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-19" decimals="-3" id="f-1028" unitRef="usd">54469000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-228" decimals="-3" id="f-1029" unitRef="usd">6000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-303" decimals="-3" id="f-1030" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-13" decimals="-3" id="f-1031" unitRef="usd">6000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c-304" decimals="-3" id="f-1032" unitRef="usd">51486000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-305" decimals="-3" id="f-1033" unitRef="usd">8983000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-30" decimals="-3" id="f-1034" unitRef="usd">60469000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-216" decimals="-3" id="f-1035" unitRef="usd">16400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-306" decimals="-3" id="f-1036" unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod contextRef="c-12" decimals="-3" id="f-1037" unitRef="usd">16400000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill contextRef="c-307" decimals="-3" id="f-1038" unitRef="usd">67886000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-308" decimals="-3" id="f-1039" unitRef="usd">8983000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-5" decimals="-3" id="f-1040" unitRef="usd">76869000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-309" decimals="-3" id="f-1041" unitRef="usd">67886000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-310" decimals="-3" id="f-1042" unitRef="usd">8983000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-4" decimals="-3" id="f-1043" unitRef="usd">76869000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="c-1" id="f-1044">RESTRICTED AND OTHER ASSETS&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted and other assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term insurance losses recoverable asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital improvement reserves with landlords and lenders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits with landlords&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Escrow deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RESTRICTED AND OTHER ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Included in restricted and other assets as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's workers' compensation and general and professional liability claims that are recorded on a gross, rather than net, basis.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="c-1" id="f-1045">&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted and other assets consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.591%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,883&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term insurance losses recoverable asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,512&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capital improvement reserves with landlords and lenders&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits with landlords&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Escrow deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,662&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;RESTRICTED AND OTHER ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;40,205&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;37,291&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c-4" decimals="-3" id="f-1046" unitRef="usd">2883000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet contextRef="c-5" decimals="-3" id="f-1047" unitRef="usd">3753000</us-gaap:DebtIssuanceCostsLineOfCreditArrangementsNet>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-4" decimals="-3" id="f-1048" unitRef="usd">15913000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-5" decimals="-3" id="f-1049" unitRef="usd">10512000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:OtherRestrictedAssets contextRef="c-4" decimals="-3" id="f-1050" unitRef="usd">4870000</us-gaap:OtherRestrictedAssets>
    <us-gaap:OtherRestrictedAssets contextRef="c-5" decimals="-3" id="f-1051" unitRef="usd">6446000</us-gaap:OtherRestrictedAssets>
    <us-gaap:SecurityDeposit contextRef="c-4" decimals="-3" id="f-1052" unitRef="usd">2661000</us-gaap:SecurityDeposit>
    <us-gaap:SecurityDeposit contextRef="c-5" decimals="-3" id="f-1053" unitRef="usd">2527000</us-gaap:SecurityDeposit>
    <us-gaap:EscrowDeposit contextRef="c-4" decimals="-3" id="f-1054" unitRef="usd">1216000</us-gaap:EscrowDeposit>
    <us-gaap:EscrowDeposit contextRef="c-5" decimals="-3" id="f-1055" unitRef="usd">0</us-gaap:EscrowDeposit>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-1056" unitRef="usd">12662000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-5" decimals="-3" id="f-1057" unitRef="usd">14053000</us-gaap:OtherAssetsCurrent>
    <ensg:RestrictedAndOtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-1058" unitRef="usd">40205000</ensg:RestrictedAndOtherAssetsNoncurrent>
    <ensg:RestrictedAndOtherAssetsNoncurrent contextRef="c-5" decimals="-3" id="f-1059" unitRef="usd">37291000</ensg:RestrictedAndOtherAssetsNoncurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-1060">OTHER ACCRUED LIABILITIES&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Resident advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unapplied state relief funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash held in trust for patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation (Note 20)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTHER ACCRUED LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97,309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Quality assurance fee represents the aggregate of amounts payable to Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Utah, Washington and Wisconsin as a result of a mandated fee based on patient days or licensed beds. Refunds payable includes payables related to overpayments, duplicate payments and credit balances from various payor sources. Resident advances occur when the Company receives payments in advance of services provided. Cash held in trust for patients reflects monies received from or on behalf of patients. Maintaining a trust account for patients is a regulatory requirement and, while the trust assets offset the liabilities, the Company assumes a fiduciary responsibility for these funds. The cash balance related to this liability is included in other current assets in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1061">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other accrued liabilities consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Quality assurance fee&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Refunds payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Resident advances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unapplied state relief funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash held in trust for patients&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividends payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued litigation (Note 20)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,405&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTHER ACCRUED LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;168,228&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;97,309&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <ensg:QualityAssuranceFee contextRef="c-4" decimals="-3" id="f-1062" unitRef="usd">14035000</ensg:QualityAssuranceFee>
    <ensg:QualityAssuranceFee contextRef="c-5" decimals="-3" id="f-1063" unitRef="usd">7701000</ensg:QualityAssuranceFee>
    <ensg:ResidentRefundsPayable contextRef="c-4" decimals="-3" id="f-1064" unitRef="usd">51248000</ensg:ResidentRefundsPayable>
    <ensg:ResidentRefundsPayable contextRef="c-5" decimals="-3" id="f-1065" unitRef="usd">40783000</ensg:ResidentRefundsPayable>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1066" unitRef="usd">10834000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-3" id="f-1067" unitRef="usd">9698000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ensg:AccruedLiabilitiesStateReliefContractLiabilities contextRef="c-4" decimals="-3" id="f-1068" unitRef="usd">486000</ensg:AccruedLiabilitiesStateReliefContractLiabilities>
    <ensg:AccruedLiabilitiesStateReliefContractLiabilities contextRef="c-5" decimals="-3" id="f-1069" unitRef="usd">1001000</ensg:AccruedLiabilitiesStateReliefContractLiabilities>
    <ensg:CashHeldInTrustForResidents contextRef="c-4" decimals="-3" id="f-1070" unitRef="usd">6215000</ensg:CashHeldInTrustForResidents>
    <ensg:CashHeldInTrustForResidents contextRef="c-5" decimals="-3" id="f-1071" unitRef="usd">6400000</ensg:CashHeldInTrustForResidents>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-1072" unitRef="usd">3396000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-1073" unitRef="usd">3201000</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent contextRef="c-4" decimals="-3" id="f-1074" unitRef="usd">12875000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent contextRef="c-5" decimals="-3" id="f-1075" unitRef="usd">10926000</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrentAndNoncurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-4" decimals="-3" id="f-1076" unitRef="usd">51734000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="c-5" decimals="-3" id="f-1077" unitRef="usd">4553000</us-gaap:LitigationReserveCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-1078" unitRef="usd">17405000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-5" decimals="-3" id="f-1079" unitRef="usd">13046000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-1080" unitRef="usd">168228000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-5" decimals="-3" id="f-1081" unitRef="usd">97309000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1082">INCOME TAXES&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes&#160;- net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL INCOME TAX PROVISION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's effective tax rate was 23.1% for the year ended December 31, 2023, compared to 22.3% for the same period in 2022 and 23.4% in 2021. The higher effective tax rate is due to higher non-deductible expenses compared to tax benefits from stock compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are summarized below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL DEFERRED TAX ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL DEFERRED TAX LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(499,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(417,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had state credit carryforwards as of December 31, 2023 and 2022 of $1,192 and $1,742, respectively. These carryforwards almost entirely relate to state limitations on the application of Enterprise Zone employment-related tax credits. Unless the Company uses the Enterprise Zone credits beforehand, the carryforward began to expire in 2023. The remainder of these carryforwards relate to credits against the Texas margin tax and is expected to carryforward until 2027. As of December 31, 2023 and 2022, the valuation allowance of $789, for both years, was primarily recorded against the Enterprise Zone credits as the Company believes it is more likely than not that some of the benefit of the credits will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operating loss carry forwards for states were not material during the year ended December 31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, 2022 and 2021, the Company did not have any unrecognized tax benefits, net of its state benefits that would affect the Company's effective tax rate. The Company classifies interest and/or penalties on income tax liabilities or refunds as additional income tax expense or income. Such amounts are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The federal statutes of limitations on the Company's 2019, 2018, and 2017 income tax years lapsed during the third quarter of 2023, 2022, and 2021, respectively. During the fourth quarter of each year, various state statutes of limitations also lapsed. The lapses during the years ended December 31, 2023 and 2022 had no impact on the Company's unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2021, the state of Wisconsin initiated and completed an examination of the Company's 2019, 2018, and 2017 state tax years with no adjustments. The Company is not under examination by any major income tax jurisdiction.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-1083">&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes on continuing operations for the years ended December 31, 2023, 2022 and 2021 is summarized as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;90,393&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;70,933&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;61,003&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,158)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(716)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,201)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(27,481)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(6,496)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(724)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;62,912&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;64,437&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;60,279&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1084" unitRef="usd">73092000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1085" unitRef="usd">56717000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1086" unitRef="usd">49105000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1087" unitRef="usd">17301000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1088" unitRef="usd">14216000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1089" unitRef="usd">11898000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1090" unitRef="usd">90393000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1091" unitRef="usd">70933000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1092" unitRef="usd">61003000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1093" unitRef="usd">-22280000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1094" unitRef="usd">-5158000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1095" unitRef="usd">-716000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1096" unitRef="usd">-5201000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1097" unitRef="usd">-1338000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1098" unitRef="usd">-8000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1099" unitRef="usd">-27481000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1100" unitRef="usd">-6496000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1101" unitRef="usd">-724000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-1102" unitRef="usd">62912000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-12" decimals="-3" id="f-1103" unitRef="usd">64437000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-13" decimals="-3" id="f-1104" unitRef="usd">60279000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1105">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the federal statutory rate to the effective tax rate for income from continuing operations for the years ended December 31, 2023, 2022 and 2021, respectively, is comprised as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense at statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State income taxes&#160;- net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-deductible expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL INCOME TAX PROVISION&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22.3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;23.4&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1106" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-12" decimals="3" id="f-1107" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-13" decimals="3" id="f-1108" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1109" unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-12" decimals="3" id="f-1110" unitRef="number">0.035</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-13" decimals="3" id="f-1111" unitRef="number">0.037</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-1" decimals="3" id="f-1112" unitRef="number">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-12" decimals="3" id="f-1113" unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense contextRef="c-13" decimals="3" id="f-1114" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-1" decimals="3" id="f-1115" unitRef="number">-0.042</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-12" decimals="3" id="f-1116" unitRef="number">-0.036</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent contextRef="c-13" decimals="3" id="f-1117" unitRef="number">-0.033</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1118" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-12" decimals="3" id="f-1119" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-13" decimals="3" id="f-1120" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1121" unitRef="number">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1122" unitRef="number">0.223</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1123" unitRef="number">0.234</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1124" unitRef="number">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-12" decimals="3" id="f-1125" unitRef="number">0.223</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-13" decimals="3" id="f-1126" unitRef="number">0.234</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-1127">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax assets and liabilities as of December&#160;31, 2023 and 2022 are summarized below. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.976%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.498%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets (liabilities):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,742&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease liability &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;444,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;364,408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567,862&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457,819&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(789)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL DEFERRED TAX ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;567,073&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;457,030&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(280)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52,334)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,150)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Right of use asset &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(443,222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(363,091)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL DEFERRED TAX LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(499,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(417,387)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;NET DEFERRED TAX ASSETS&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;67,124&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-4" decimals="-3" id="f-1128" unitRef="usd">81502000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="c-5" decimals="-3" id="f-1129" unitRef="usd">61685000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-4" decimals="-3" id="f-1130" unitRef="usd">23714000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts contextRef="c-5" decimals="-3" id="f-1131" unitRef="usd">18046000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-1132" unitRef="usd">1192000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-1133" unitRef="usd">1742000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance contextRef="c-4" decimals="-3" id="f-1134" unitRef="usd">16864000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance contextRef="c-5" decimals="-3" id="f-1135" unitRef="usd">11910000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsSelfInsurance>
    <ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability contextRef="c-4" decimals="-3" id="f-1136" unitRef="usd">444590000</ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability>
    <ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability contextRef="c-5" decimals="-3" id="f-1137" unitRef="usd">364408000</ensg:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsLeaseLiability>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c-4" decimals="-3" id="f-1138" unitRef="usd">0</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsStateTaxes contextRef="c-5" decimals="-3" id="f-1139" unitRef="usd">28000</us-gaap:DeferredTaxAssetsStateTaxes>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-4" decimals="-3" id="f-1140" unitRef="usd">567862000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-3" id="f-1141" unitRef="usd">457819000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1142" unitRef="usd">789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1143" unitRef="usd">789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-4" decimals="-3" id="f-1144" unitRef="usd">567073000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet contextRef="c-5" decimals="-3" id="f-1145" unitRef="usd">457030000</us-gaap:DeferredTaxAssetsNet>
    <ensg:DeferredTaxLiabilitiesStateTaxes contextRef="c-4" decimals="-3" id="f-1146" unitRef="usd">280000</ensg:DeferredTaxLiabilitiesStateTaxes>
    <ensg:DeferredTaxLiabilitiesStateTaxes contextRef="c-5" decimals="-3" id="f-1147" unitRef="usd">0</ensg:DeferredTaxLiabilitiesStateTaxes>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-1148" unitRef="usd">52334000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-1149" unitRef="usd">49146000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-4" decimals="-3" id="f-1150" unitRef="usd">4113000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-5" decimals="-3" id="f-1151" unitRef="usd">5150000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <ensg:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-4" decimals="-3" id="f-1152" unitRef="usd">443222000</ensg:DeferredTaxLiabilitiesRightOfUseAsset>
    <ensg:DeferredTaxLiabilitiesRightOfUseAsset contextRef="c-5" decimals="-3" id="f-1153" unitRef="usd">363091000</ensg:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-4" decimals="-3" id="f-1154" unitRef="usd">499949000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-3" id="f-1155" unitRef="usd">417387000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-4" decimals="-3" id="f-1156" unitRef="usd">67124000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-5" decimals="-3" id="f-1157" unitRef="usd">39643000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-4" decimals="-3" id="f-1158" unitRef="usd">1192000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-3" id="f-1159" unitRef="usd">1742000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-1160" unitRef="usd">789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-1161" unitRef="usd">789000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1162">DEBT&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans and promissory note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LONG-TERM DEBT LESS CURRENT MATURITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Facility with a Lending Consortium Arranged by Truist &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a revolving credit facility between the Company and its independent subsidiaries, including Standard Bearer as co-borrowers, and Truist Securities (Truist) (the Credit Facility) with a revolving line of credit of up to $600,000 in aggregate principal amount with a maturity date of April&#160;8, 2027. Borrowings are supported by a lending consortium arranged by Truist. The interest rates applicable to loans under the Credit Facility are, at the Company's option, equal to either a base rate plus a margin ranging from 0.25% to 1.25% per annum or SOFR plus a margin range from 1.25% to 2.25% per annum, based on the Consolidated Total Net Debt to Consolidated EBITDA ratio (as defined in the Credit Facility). In addition, there is a commitment fee on the unused portion of the commitments that ranges from 0.20% to 0.40% per annum, depending on the Consolidated Total Net Debt to Consolidated EBITDA ratio. When the Company amended the Credit Facility in 2022 with the terms and conditions described above, it wrote off deferred financing costs of $566 and additional deferred financing costs of $3,197 were capitalized during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Borrowings made under the Credit Facility are guaranteed, jointly and severally, by certain of the Company&#x2019;s wholly-owned subsidiaries, and are secured by a pledge of stock of the Company's material independent subsidiaries as well as a first lien on substantially all of such independent subsidiaries' personal property. The Credit Facility contains customary covenants that, among other things, restrict, subject to certain exceptions, the ability of the Company and its independent subsidiaries to grant liens on their assets, incur indebtedness, sell assets, make investments, engage in acquisitions, mergers or consolidations, amend certain material agreements and pay certain dividends and other restricted payments. The Company must comply with financial maintenance covenants to be tested quarterly, consisting of (i) a maximum consolidated total net debt to consolidated EBITDA ratio (which shall not be greater than 3.00:1.00; provided that if the aggregate consideration for approved acquisitions in a six month period is greater than $50,000, then the ratio can be increased at the election of the Company with notice to the administrative agent to 3.50:1.00 for the first fiscal quarter and the immediately following three fiscal quarters), and (ii) a minimum interest/rent coverage ratio (which cannot be less than 1.50:1.00). As of December&#160;31, 2023, there was no outstanding debt under the Credit Facility. The Company was in compliance with all loan covenants as of December&#160;31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Mortgage Loans and Promissory Note&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 23 subsidiaries that have mortgage loans insured with HUD in the aggregate amount of $150,244, which subjects these subsidiaries to HUD oversight and periodic inspections. The mortgage loans bear effective interest rates in a range of 3.1% to 4.2%, including fixed interest rates in a range of 2.4% to 3.3% per annum. In addition to the interest rate, the Company incurs other fees for HUD placement, including but not limited to audit fees. Amounts borrowed under the mortgage loans may be prepaid, subject to prepayment fees based on the principal balance on the date of prepayment. For the majority of the loans, during the first three years, the prepayment fee is 10.0% and is reduced by 3.0% in the fourth year of the loan, and reduced by 1.0%&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;per year for years five through ten of the loan. There is no prepayment penalty after year ten. The terms for all the mortgage loans are 25 to 35 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the HUD mortgage loans above, the Company has a promissory note of $2,144 that bears a fixed interest rate of 5.3% per annum and has a term of 12 years. The note, which was assumed as part of an acquisition, is secured by the real property comprising the facility and the rent, issues and profits thereof, as well as all personal property used in the operation of the facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments due under the long-term debt arrangements discussed above are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on Level 2 inputs, the carrying value of the Company's long-term debt is considered to approximate the fair value of such debt for all periods presented based upon the interest rates that the Company believes it can currently obtain for similar debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Off-Balance Sheet Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2023, the Company had approximately $6,255 of borrowing capacity under the Credit Facility pledged as collateral to secure outstanding letters of credit, which decreased by $455 from prior year.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-1163">&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:62.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.590%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.592%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mortgage loans and promissory note&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156,271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current maturities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,950)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,883)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: debt issuance costs, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LONG-TERM DEBT LESS CURRENT MATURITIES&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;145,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;149,269&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-311" decimals="-3" id="f-1164" unitRef="usd">152388000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-312" decimals="-3" id="f-1165" unitRef="usd">156271000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtCurrent contextRef="c-4" decimals="-3" id="f-1166" unitRef="usd">3950000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-3" id="f-1167" unitRef="usd">3883000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-4" decimals="-3" id="f-1168" unitRef="usd">2941000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsNet contextRef="c-5" decimals="-3" id="f-1169" unitRef="usd">3119000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-4" decimals="-3" id="f-1170" unitRef="usd">145497000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-3" id="f-1171" unitRef="usd">149269000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-313" decimals="INF" id="f-1172" unitRef="usd">600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-155"
      decimals="INF"
      id="f-1173"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-156"
      decimals="INF"
      id="f-1174"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-157"
      decimals="INF"
      id="f-1175"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="c-158"
      decimals="INF"
      id="f-1176"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-314"
      decimals="INF"
      id="f-1177"
      unitRef="number">0.0020</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c-315"
      decimals="INF"
      id="f-1178"
      unitRef="number">0.0040</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:WriteOffOfDeferredDebtIssuanceCost contextRef="c-12" decimals="-3" id="f-1179" unitRef="usd">566000</us-gaap:WriteOffOfDeferredDebtIssuanceCost>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-12" decimals="-3" id="f-1180" unitRef="usd">3197000</us-gaap:PaymentsOfFinancingCosts>
    <ensg:TotalNetDebtRatioMaximum
      contextRef="c-316"
      decimals="INF"
      id="f-1181"
      unitRef="number">3.00</ensg:TotalNetDebtRatioMaximum>
    <ensg:LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod contextRef="c-316" id="f-1182">P6M</ensg:LongTermDebtThresholdForEBITDARatioIncreaseElectionPeriod>
    <ensg:LongTermDebtThresholdForEBITDARatioIncreaseElection contextRef="c-316" decimals="INF" id="f-1183" unitRef="usd">50000000</ensg:LongTermDebtThresholdForEBITDARatioIncreaseElection>
    <ensg:TotalNetDebtRatioMaximumAfterIncreaseElection
      contextRef="c-316"
      decimals="INF"
      id="f-1184"
      unitRef="number">3.50</ensg:TotalNetDebtRatioMaximumAfterIncreaseElection>
    <ensg:TotalNetDebtRatioMinimum
      contextRef="c-316"
      decimals="INF"
      id="f-1185"
      unitRef="number">1.50</ensg:TotalNetDebtRatioMinimum>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-313" decimals="INF" id="f-1186" unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <ensg:NumberOfOperatingSubsidiaries
      contextRef="c-317"
      decimals="INF"
      id="f-1187"
      unitRef="subsidiary">23</ensg:NumberOfOperatingSubsidiaries>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-317" decimals="-3" id="f-1188" unitRef="usd">150244000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-318"
      decimals="3"
      id="f-1189"
      unitRef="number">0.031</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c-319"
      decimals="3"
      id="f-1190"
      unitRef="number">0.042</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-318"
      decimals="INF"
      id="f-1191"
      unitRef="number">0.024</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-319"
      decimals="INF"
      id="f-1192"
      unitRef="number">0.033</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <ensg:PrepaymentPenalty
      contextRef="c-320"
      decimals="INF"
      id="f-1193"
      unitRef="number">0.100</ensg:PrepaymentPenalty>
    <ensg:ReductionInPrepaymentPenalty
      contextRef="c-321"
      decimals="INF"
      id="f-1194"
      unitRef="number">0.030</ensg:ReductionInPrepaymentPenalty>
    <ensg:ReductionInPrepaymentPenalty
      contextRef="c-322"
      decimals="INF"
      id="f-1195"
      unitRef="number">0.010</ensg:ReductionInPrepaymentPenalty>
    <ensg:PrepaymentPenalty
      contextRef="c-323"
      decimals="INF"
      id="f-1196"
      unitRef="number">0</ensg:PrepaymentPenalty>
    <us-gaap:DebtInstrumentTerm contextRef="c-324" id="f-1197">P25Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="c-325" id="f-1198">P35Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-326" decimals="-3" id="f-1199" unitRef="usd">2144000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-326"
      decimals="INF"
      id="f-1200"
      unitRef="number">0.053</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentTerm contextRef="c-327" id="f-1201">P12Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-1202">&lt;div style="text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future principal payments due under the long-term debt arrangements discussed above are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.013%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Years Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,950&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;152,388&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1203" unitRef="usd">3950000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-4" decimals="-3" id="f-1204" unitRef="usd">4086000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-4" decimals="-3" id="f-1205" unitRef="usd">4227000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour contextRef="c-4" decimals="-3" id="f-1206" unitRef="usd">3897000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive contextRef="c-4" decimals="-3" id="f-1207" unitRef="usd">3779000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive contextRef="c-4" decimals="-3" id="f-1208" unitRef="usd">132449000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:LongTermDebt contextRef="c-4" decimals="-3" id="f-1209" unitRef="usd">152388000</us-gaap:LongTermDebt>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="c-4" decimals="-3" id="f-1210" unitRef="usd">6255000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet contextRef="c-328" decimals="-3" id="f-1211" unitRef="usd">-455000</us-gaap:LineOfCreditFacilityIncreaseDecreaseForPeriodNet>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1212">OPTIONS AND AWARDS&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense consists of stock-based payment awards made to employees and directors, including employee stock options and restricted stock awards, based on estimated fair values. As stock-based compensation expense recognized in the Company&#x2019;s consolidated statements of income for the years ended December 31, 2023, 2022, and 2021 was based on awards ultimately expected to vest, it has been reduced for estimated forfeitures. The Company estimates forfeitures at the time of grant and, if necessary, revises the estimate in subsequent periods if actual forfeitures differ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Omnibus Incentive Plan (2022 Plan)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has one active stock incentive plan, the 2022 Omnibus Incentive Plan (the 2022 Plan). Including the shares rolled over from the 2017 Omnibus Incentive Plan, the 2022 Plan provides for the issuance of 3,452 shares of common stock. The number of shares available to be issued under the 2022 Plan will be reduced by (i) one share for each share that relates to an option or stock appreciation right award and (ii) two shares for each share which relates to an award other than a stock option or stock appreciation right award (a full-value award). Non-employee director options, to the extent granted, will vest and become exercisable in three equal annual installments, or the length of the term if less than three years, on the completion of each year of service measured from the grant date. All other options generally vest over five years at 20% per year on the anniversary of the grant date. Options expire ten years from the date of grant. At December&#160;31, 2023, the total number of shares available for issuance under the 2022 Plan was 1,454.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses the Black-Scholes option-pricing model to recognize the value of stock-based compensation expense for stock option awards. Determining the appropriate fair-value model and calculating the fair value of stock option awards at the grant date requires judgment, including estimating stock price volatility, expected option life, and forfeiture rates. The fair-value of the restricted stock awards at the grant date is based on the market price on the grant date, adjusted for forfeiture rates. The Company develops estimates based on historical data and market information, which can change significantly over time. The Black-Scholes model required the Company to make several key judgments including: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;The expected option term is calculated by the average of the contractual term of the options and the weighted average vesting period for all options. The calculation of the expected option term is based on the Company's experience due to sufficient history.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;The Company utilizes its own experience to calculate estimated volatility for options granted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;The dividend yield is based on the Company's historical pattern of dividends as well as expected dividend patterns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;The risk-free rate is based on the implied yield of U.S.&#160;Treasury notes as of the grant date with a remaining term approximately equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Estimated forfeiture rate of approximately 5.08% per year is based on the Company's historical forfeiture activity of unvested stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted 1,008, 581 and 621 stock options during the years ended December 31, 2023, 2022, and 2021, respectively. The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Risk-Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expected Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value of Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average exercise price equaled the weighted average fair value of common stock on the grant date for all options granted during the periods ended December 31, 2023, 2022 and 2021 and therefore, the intrinsic value was $0 at the date of grant.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the employee stock option activity during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price of Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary information reflects stock options outstanding, vested and related details as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.892%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Black-Scholes Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year of Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$89.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the options&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. At &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023, 2022 and 2021, t&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he aggregate intrinsic value of options that vested &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the years ended December&#160;31, 2023, 2022 and 2021 was&lt;/span&gt;&lt;span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$31,658, $27,955, and $27,731, respectively. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the years ended December&#160;31, 2023, 2022 and 2021 was $56,186, $47,441, and $34,278, respectively. &lt;/span&gt;&lt;span style="color:#ff0090;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 219, 233&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and 222 restricted stock awards during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respectively. All awards were granted at an issue price of $0 and generally vest over five years. The fair value per share of restricted awards granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ranged from&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $89.83 to $98.31,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $73.17 to $94.88 and $72.84 to $93.31, respectively. The fair value per share includes quarterly stock awards to non-employee directors.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the status of the Company's non-vested restricted stock awards as of December&#160;31, 2023 and changes during the years ended December&#160;31, 2023, 2022 and 2021 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Vested Restricted Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 18&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; quarterly stock awards to non-employee directors for their service on the Company's board of directors from the 2022 Plan. The fair value per share of these stock awards ranged from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$89.94 to $98.31&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; based on the market price on the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 27, 2019, the Board approved the Long-Term Incentive Plan (the 2019 LTI Plan). The 2019 LTI Plan provides that certain employees of the Company who assisted in the consummation of the spin-off of Pennant from the Company in 2019 (spin-off transaction) were granted shares of restricted stock upon successful completion of the spin-off. The 2019 LTI Plan provides for the issuance of 500 shares of Pennant restricted stock. The shares are vested over five years at 20% per year on the anniversary of the grant date. If a recipient is terminated or voluntarily leaves the Company, all shares subject to restriction or not yet vested are entirely forfeited. The total stock-based compensation related to the 2019 LTI Plan was approximately $827, $836, and $854 for the years ended December&#160;31, 2023, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.915%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In future periods, the Company expects to recognize approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $67,750 and $29,245 in stock-based compensation expense for unvested options and unvested restricted stock awards, respectively, that were outstanding as of December&#160;31, 2023. Future stock-based compensation expense will be recognized over 3.9 and 3.4 weighted average years for unvested options and restricted stock awards, respectively. There were 2,104 unvested and outstanding options as of December&#160;31, 2023, of which 1,940 shares are expected to vest. The weighted average contractual life for options outstanding, vested and expected to vest as of December&#160;31, 2023 was&#160;6.7 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <ensg:NumberOfOptionPlans contextRef="c-4" decimals="INF" id="f-1213" unitRef="plan">1</ensg:NumberOfOptionPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-329"
      decimals="-3"
      id="f-1214"
      unitRef="shares">3452000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability
      contextRef="c-330"
      decimals="INF"
      id="f-1215"
      unitRef="number">1</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsConversionToReduceSharesAvailability>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability
      contextRef="c-330"
      decimals="INF"
      id="f-1216"
      unitRef="number">2</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsConversionToReduceSharesAvailability>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments
      contextRef="c-331"
      decimals="INF"
      id="f-1217"
      unitRef="installment">3</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfInstallments>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 contextRef="c-331" id="f-1218">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-330" id="f-1219">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-330"
      decimals="INF"
      id="f-1220"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-330" id="f-1221">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-329"
      decimals="-3"
      id="f-1222"
      unitRef="shares">1454000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <ensg:ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate contextRef="c-4" decimals="4" id="f-1223" unitRef="number">0.0508</ensg:ShareBasedCompensationArrangementByShareBasedAwardOptionsFairValueAssumptionsForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-1224" unitRef="shares">1008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-12"
      decimals="-3"
      id="f-1225"
      unitRef="shares">581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-13"
      decimals="-3"
      id="f-1226"
      unitRef="shares">621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-1227">The Company used the following assumptions for stock options granted during the years ended December 31, 2023, 2022 and 2021:&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.428%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Risk-Free Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expected Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Dividend Yield&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.3%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.4%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-1228" unitRef="shares">1008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-1" decimals="3" id="f-1229" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-1230">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-1" decimals="3" id="f-1231" unitRef="number">0.413</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="3" id="f-1232" unitRef="number">0.002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-12"
      decimals="-3"
      id="f-1233"
      unitRef="shares">581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-12" decimals="3" id="f-1234" unitRef="number">0.028</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-12" id="f-1235">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-12" decimals="3" id="f-1236" unitRef="number">0.421</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-12" decimals="3" id="f-1237" unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-13"
      decimals="-3"
      id="f-1238"
      unitRef="shares">621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-13" decimals="3" id="f-1239" unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-13" id="f-1240">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate contextRef="c-13" decimals="3" id="f-1241" unitRef="number">0.424</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-13" decimals="3" id="f-1242" unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock contextRef="c-1" id="f-1243">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December 31, 2023, 2022 and 2021, the following represents the exercise price and fair value displayed at grant date for stock option grants:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.245%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Grant Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Fair Value of Options&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-1244" unitRef="shares">1008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1245"
      unitRef="usdPerShare">95.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-1246"
      unitRef="usdPerShare">43.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-12"
      decimals="-3"
      id="f-1247"
      unitRef="shares">581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1248"
      unitRef="usdPerShare">85.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-12"
      decimals="2"
      id="f-1249"
      unitRef="usdPerShare">37.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-13"
      decimals="-3"
      id="f-1250"
      unitRef="shares">621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-1251"
      unitRef="usdPerShare">80.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-13"
      decimals="2"
      id="f-1252"
      unitRef="usdPerShare">32.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c-13"
      decimals="2"
      id="f-1253"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c-12"
      decimals="2"
      id="f-1254"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue
      contextRef="c-1"
      decimals="2"
      id="f-1255"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="c-1" id="f-1256">&lt;div style="margin-top:12pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the employee stock option activity during the year ended December 31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.777%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.297%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average&lt;br/&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;Options Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Weighted Average Exercise Price of Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(105)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(516)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(688)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(759)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,991&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-19"
      decimals="-3"
      id="f-1257"
      unitRef="shares">4038000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-19"
      decimals="2"
      id="f-1258"
      unitRef="usdPerShare">27.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-19"
      decimals="-3"
      id="f-1259"
      unitRef="shares">2148000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-19"
      decimals="2"
      id="f-1260"
      unitRef="usdPerShare">16.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-13"
      decimals="-3"
      id="f-1261"
      unitRef="shares">621000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-1262"
      unitRef="usdPerShare">80.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-13"
      decimals="-3"
      id="f-1263"
      unitRef="shares">105000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-1264"
      unitRef="usdPerShare">44.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-13"
      decimals="-3"
      id="f-1265"
      unitRef="shares">516000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-13"
      decimals="2"
      id="f-1266"
      unitRef="usdPerShare">17.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-30"
      decimals="-3"
      id="f-1267"
      unitRef="shares">4038000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-30"
      decimals="2"
      id="f-1268"
      unitRef="usdPerShare">36.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-30"
      decimals="-3"
      id="f-1269"
      unitRef="shares">2183000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-30"
      decimals="2"
      id="f-1270"
      unitRef="usdPerShare">21.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-12"
      decimals="-3"
      id="f-1271"
      unitRef="shares">581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1272"
      unitRef="usdPerShare">85.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
      contextRef="c-12"
      decimals="-3"
      id="f-1273"
      unitRef="shares">98000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1274"
      unitRef="usdPerShare">59.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c-12"
      decimals="-3"
      id="f-1275"
      unitRef="shares">688000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-12"
      decimals="2"
      id="f-1276"
      unitRef="usdPerShare">18.43</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-5" decimals="-3" id="f-1277" unitRef="shares">3833000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1278"
      unitRef="usdPerShare">46.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-5" decimals="-3" id="f-1279" unitRef="shares">2069000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-5"
      decimals="2"
      id="f-1280"
      unitRef="usdPerShare">28.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-1281" unitRef="shares">1008000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1282"
      unitRef="usdPerShare">95.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="c-1" decimals="-3" id="f-1283" unitRef="shares">91000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1284"
      unitRef="usdPerShare">71.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-1285" unitRef="shares">759000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-1286"
      unitRef="usdPerShare">24.21</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="-3" id="f-1287" unitRef="shares">3991000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1288"
      unitRef="usdPerShare">62.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="c-4" decimals="-3" id="f-1289" unitRef="shares">1887000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-1290"
      unitRef="usdPerShare">39.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c-1" id="f-1291">&lt;div style="margin-top:10pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summary information reflects stock options outstanding, vested and related details as of December&#160;31, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.332%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:5.478%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.892%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Stock Options Vested&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Number Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Black-Scholes Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year of Grant&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.94&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.05&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.39&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2016&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.86&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.80&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.41&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.71&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.76&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.84&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.49&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,383&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;73.47&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83.64&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79.79&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,466&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$89.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$98.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,991&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;105,703&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,887&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-332"
      decimals="INF"
      id="f-1292"
      unitRef="usdPerShare">8.94</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-332"
      decimals="INF"
      id="f-1293"
      unitRef="usdPerShare">16.05</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-333"
      decimals="-3"
      id="f-1294"
      unitRef="shares">99000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-333" decimals="-3" id="f-1295" unitRef="usd">484000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-332" id="f-1296">P1Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-333"
      decimals="-3"
      id="f-1297"
      unitRef="shares">99000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-334"
      decimals="INF"
      id="f-1298"
      unitRef="usdPerShare">18.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-334"
      decimals="INF"
      id="f-1299"
      unitRef="usdPerShare">21.39</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-335"
      decimals="-3"
      id="f-1300"
      unitRef="shares">175000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-335" decimals="-3" id="f-1301" unitRef="usd">1369000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-334" id="f-1302">P2Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-335"
      decimals="-3"
      id="f-1303"
      unitRef="shares">175000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-336"
      decimals="INF"
      id="f-1304"
      unitRef="usdPerShare">15.93</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-336"
      decimals="INF"
      id="f-1305"
      unitRef="usdPerShare">16.86</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-337"
      decimals="-3"
      id="f-1306"
      unitRef="shares">155000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-337" decimals="-3" id="f-1307" unitRef="usd">916000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-336" id="f-1308">P3Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-337"
      decimals="-3"
      id="f-1309"
      unitRef="shares">155000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-338"
      decimals="INF"
      id="f-1310"
      unitRef="usdPerShare">15.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-338"
      decimals="INF"
      id="f-1311"
      unitRef="usdPerShare">19.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-339"
      decimals="-3"
      id="f-1312"
      unitRef="shares">194000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-339" decimals="-3" id="f-1313" unitRef="usd">1138000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-338" id="f-1314">P4Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-339"
      decimals="-3"
      id="f-1315"
      unitRef="shares">194000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-340"
      decimals="INF"
      id="f-1316"
      unitRef="usdPerShare">22.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-340"
      decimals="INF"
      id="f-1317"
      unitRef="usdPerShare">32.71</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-341"
      decimals="-3"
      id="f-1318"
      unitRef="shares">336000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-341" decimals="-3" id="f-1319" unitRef="usd">3523000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-340" id="f-1320">P5Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-341"
      decimals="-3"
      id="f-1321"
      unitRef="shares">336000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-342"
      decimals="INF"
      id="f-1322"
      unitRef="usdPerShare">41.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-342"
      decimals="INF"
      id="f-1323"
      unitRef="usdPerShare">45.76</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-343"
      decimals="-3"
      id="f-1324"
      unitRef="shares">510000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-343" decimals="-3" id="f-1325" unitRef="usd">8014000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-342" id="f-1326">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-343"
      decimals="-3"
      id="f-1327"
      unitRef="shares">383000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-344"
      decimals="INF"
      id="f-1328"
      unitRef="usdPerShare">44.84</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-344"
      decimals="INF"
      id="f-1329"
      unitRef="usdPerShare">59.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-345"
      decimals="-3"
      id="f-1330"
      unitRef="shares">476000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-345" decimals="-3" id="f-1331" unitRef="usd">9383000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-344" id="f-1332">P7Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-345"
      decimals="-3"
      id="f-1333"
      unitRef="shares">257000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-346"
      decimals="INF"
      id="f-1334"
      unitRef="usdPerShare">73.47</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-346"
      decimals="INF"
      id="f-1335"
      unitRef="usdPerShare">83.64</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-347"
      decimals="-3"
      id="f-1336"
      unitRef="shares">513000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-347" decimals="-3" id="f-1337" unitRef="usd">16844000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-346" id="f-1338">P8Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-347"
      decimals="-3"
      id="f-1339"
      unitRef="shares">189000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-348"
      decimals="INF"
      id="f-1340"
      unitRef="usdPerShare">79.79</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-348"
      decimals="INF"
      id="f-1341"
      unitRef="usdPerShare">94.88</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-349"
      decimals="-3"
      id="f-1342"
      unitRef="shares">540000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-349" decimals="-3" id="f-1343" unitRef="usd">20466000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-348" id="f-1344">P9Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-349"
      decimals="-3"
      id="f-1345"
      unitRef="shares">99000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c-350"
      decimals="INF"
      id="f-1346"
      unitRef="usdPerShare">89.83</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c-350"
      decimals="INF"
      id="f-1347"
      unitRef="usdPerShare">98.83</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c-351"
      decimals="-3"
      id="f-1348"
      unitRef="shares">993000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-351" decimals="-3" id="f-1349" unitRef="usd">43566000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c-350" id="f-1350">P10Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c-351"
      decimals="-3"
      id="f-1351"
      unitRef="shares">0</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c-4" decimals="-3" id="f-1352" unitRef="shares">3991000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue contextRef="c-4" decimals="-3" id="f-1353" unitRef="usd">105703000</ensg:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeFairValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c-4" decimals="-3" id="f-1354" unitRef="shares">1887000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="c-1" id="f-1355">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options outstanding, vested and expected to vest as of December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:38.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.349%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183,593&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-4" decimals="-3" id="f-1356" unitRef="usd">197819000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-5" decimals="-3" id="f-1357" unitRef="usd">183593000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-30" decimals="-3" id="f-1358" unitRef="usd">191242000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-4" decimals="-3" id="f-1359" unitRef="usd">137048000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-5" decimals="-3" id="f-1360" unitRef="usd">136000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-30" decimals="-3" id="f-1361" unitRef="usd">137382000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-4" decimals="-3" id="f-1362" unitRef="usd">56759000</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-5" decimals="-3" id="f-1363" unitRef="usd">43232000</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-30" decimals="-3" id="f-1364" unitRef="usd">48548000</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-352" decimals="-3" id="f-1365" unitRef="usd">31658000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-353" decimals="-3" id="f-1366" unitRef="usd">27955000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested contextRef="c-354" decimals="-3" id="f-1367" unitRef="usd">27731000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-1368" unitRef="usd">56186000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-12" decimals="-3" id="f-1369" unitRef="usd">47441000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-13" decimals="-3" id="f-1370" unitRef="usd">34278000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-355"
      decimals="-3"
      id="f-1371"
      unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-356"
      decimals="-3"
      id="f-1372"
      unitRef="shares">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-357"
      decimals="-3"
      id="f-1373"
      unitRef="shares">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <ensg:SharebasedCompensationRestrictedAwardsExercisePrice
      contextRef="c-1"
      decimals="0"
      id="f-1374"
      unitRef="usdPerShare">0</ensg:SharebasedCompensationRestrictedAwardsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-355" id="f-1375">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-358"
      decimals="2"
      id="f-1376"
      unitRef="usdPerShare">89.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-359"
      decimals="2"
      id="f-1377"
      unitRef="usdPerShare">98.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-360"
      decimals="2"
      id="f-1378"
      unitRef="usdPerShare">73.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-361"
      decimals="2"
      id="f-1379"
      unitRef="usdPerShare">94.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-362"
      decimals="2"
      id="f-1380"
      unitRef="usdPerShare">72.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-363"
      decimals="2"
      id="f-1381"
      unitRef="usdPerShare">93.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock contextRef="c-1" id="f-1382">&lt;div style="margin-top:10pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.157%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-Vested Restricted Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at January 1, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38.90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(244)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;549&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(269)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(255)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nonvested at December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;431&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e4e9df;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-364"
      decimals="-3"
      id="f-1383"
      unitRef="shares">591000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-364"
      decimals="2"
      id="f-1384"
      unitRef="usdPerShare">38.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-357"
      decimals="-3"
      id="f-1385"
      unitRef="shares">222000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-357"
      decimals="2"
      id="f-1386"
      unitRef="usdPerShare">81.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-357"
      decimals="-3"
      id="f-1387"
      unitRef="shares">244000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-357"
      decimals="2"
      id="f-1388"
      unitRef="usdPerShare">47.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c-357"
      decimals="-3"
      id="f-1389"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-357"
      decimals="2"
      id="f-1390"
      unitRef="usdPerShare">45.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-365"
      decimals="-3"
      id="f-1391"
      unitRef="shares">549000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-365"
      decimals="2"
      id="f-1392"
      unitRef="usdPerShare">52.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-356"
      decimals="-3"
      id="f-1393"
      unitRef="shares">233000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-356"
      decimals="2"
      id="f-1394"
      unitRef="usdPerShare">81.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-356"
      decimals="-3"
      id="f-1395"
      unitRef="shares">269000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-356"
      decimals="2"
      id="f-1396"
      unitRef="usdPerShare">54.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c-356"
      decimals="-3"
      id="f-1397"
      unitRef="shares">26000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-356"
      decimals="2"
      id="f-1398"
      unitRef="usdPerShare">57.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-366"
      decimals="-3"
      id="f-1399"
      unitRef="shares">487000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-366"
      decimals="2"
      id="f-1400"
      unitRef="usdPerShare">64.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-355"
      decimals="-3"
      id="f-1401"
      unitRef="shares">219000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-355"
      decimals="2"
      id="f-1402"
      unitRef="usdPerShare">92.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-355"
      decimals="-3"
      id="f-1403"
      unitRef="shares">255000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-355"
      decimals="2"
      id="f-1404"
      unitRef="usdPerShare">64.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited
      contextRef="c-355"
      decimals="-3"
      id="f-1405"
      unitRef="shares">20000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardForfeited>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-355"
      decimals="2"
      id="f-1406"
      unitRef="usdPerShare">71.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-367"
      decimals="-3"
      id="f-1407"
      unitRef="shares">431000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-367"
      decimals="2"
      id="f-1408"
      unitRef="usdPerShare">78.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-368"
      decimals="-3"
      id="f-1409"
      unitRef="shares">18000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-369"
      decimals="2"
      id="f-1410"
      unitRef="usdPerShare">89.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-370"
      decimals="2"
      id="f-1411"
      unitRef="usdPerShare">98.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-371"
      decimals="INF"
      id="f-1412"
      unitRef="shares">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-372" id="f-1413">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="c-372"
      decimals="INF"
      id="f-1414"
      unitRef="number">0.20</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-373" decimals="-3" id="f-1415" unitRef="usd">827000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-374" decimals="-3" id="f-1416" unitRef="usd">836000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-375" decimals="-3" id="f-1417" unitRef="usd">854000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1418">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense recognized for the Company's equity incentive plans and long-term incentive plan for the years ended December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022 and 2021 was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:24.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.915%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to restricted stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation expense related to stock options and restricted stock awards to non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;30,754&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,720&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,678&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-352" decimals="-3" id="f-1419" unitRef="usd">17221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-353" decimals="-3" id="f-1420" unitRef="usd">11361000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-354" decimals="-3" id="f-1421" unitRef="usd">8459000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-355" decimals="-3" id="f-1422" unitRef="usd">11845000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-356" decimals="-3" id="f-1423" unitRef="usd">9920000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-357" decimals="-3" id="f-1424" unitRef="usd">8385000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-376" decimals="-3" id="f-1425" unitRef="usd">1688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-377" decimals="-3" id="f-1426" unitRef="usd">1439000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-378" decimals="-3" id="f-1427" unitRef="usd">1834000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-1428" unitRef="usd">30754000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-12" decimals="-3" id="f-1429" unitRef="usd">22720000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-13" decimals="-3" id="f-1430" unitRef="usd">18678000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-379" decimals="-3" id="f-1431" unitRef="usd">67750000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-367" decimals="-3" id="f-1432" unitRef="usd">29245000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-352" id="f-1433">P3Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-355" id="f-1434">P3Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <ensg:EmployeeServiceShareBasedCompensationNonvestedAwards
      contextRef="c-379"
      decimals="-3"
      id="f-1435"
      unitRef="shares">2104000</ensg:EmployeeServiceShareBasedCompensationNonvestedAwards>
    <ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber
      contextRef="c-379"
      decimals="-3"
      id="f-1436"
      unitRef="shares">1940000</ensg:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedToVestNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-1437">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1439">LEASES&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company&#x2019;s operations, 96 of which are under nine &#x201c;triple-net&#x201d; master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company&#x2019;s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust&#x2019;s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust&#x2019;s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from &lt;span style="-sec-ix-hidden:f-1456"&gt;five&lt;/span&gt; to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from &lt;span style="-sec-ix-hidden:f-1458"&gt;three&lt;/span&gt; to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eighty of the Company&#x2019;s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company&#x2019;s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company&#x2019;s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent - cost of services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154,693&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt"&gt;Rent- cost of services includes deferred rent expense adju&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;stments of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL LEASE PAYMENTS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,675,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(953,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PRESENT VALUE OF TOTAL LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,721,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LONG-TERM OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,639,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of&#160;December&#160;31, 2023 and 2022, the weighted average remaining lease term is&#160;14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is&#160;6.5% and 6.7%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December&#160;31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lessor Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pennant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1530"&gt;TOTAL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock contextRef="c-1" id="f-1438">LEASES&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases from CareTrust REIT, Inc. (CareTrust) real property associated with 97 independent skilled nursing and senior living facilities used in the Company&#x2019;s operations, 96 of which are under nine &#x201c;triple-net&#x201d; master lease agreements (collectively, the Master Leases), which range in terms from 13 to 20 years. At the Company&#x2019;s option, the Master Leases may be extended for two or three five-year renewal terms beyond the initial term, on the same terms and conditions. The extension of the term of any of the Master Leases is subject to the following conditions: (1) no event of default under any of the Master Leases having occurred and been continuing; and (2) the tenants providing timely notice of their intent to renew. The term of the Master Leases is subject to termination prior to the expiration of the current term upon default by the tenants in their obligations, if not cured within any applicable cure periods set forth in the Master Leases. If the Company elects to renew the term of a Master Lease, the renewal will be effective to all, but not less than all, of the leased property then subject to the Master Lease. Additionally, four of the 97 facilities leased from CareTrust include an option to purchase that the Company can exercise starting on December 1, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10.05pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have the ability to terminate the obligations under a Master Lease prior to its expiration without CareTrust&#x2019;s consent. If a Master Lease is terminated prior to its expiration other than with CareTrust&#x2019;s consent, the Company may be liable for damages and incur charges such as continued payment of rent through the end of the lease term as well as maintenance and repair costs for the leased property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The rent structure under the Master Leases includes a fixed component, subject to annual escalation equal to the lesser of (1) the percentage change in the Consumer Price Index (but not less than zero) or (2) 2.5%. In addition to rent, the Company is required to pay the following: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The terms and conditions of the one stand-alone lease are substantially the same as those for the master leases described above. Total rent expense for continuing operations&lt;/span&gt;&lt;span style="color:#ff0000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the Master Leases was approximately $66,439, $64,178 and $59,571 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Among other things, under the Master Leases, the Company must maintain compliance with specified financial covenants measured on a quarterly basis, including a portfolio coverage ratio and a minimum rent coverage ratio. The Master Leases also include certain reporting, legal and authorization requirements. The Company is in compliance with requirements of the Master Leases as of December&#160;31, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the spin-off that occurred in 2019, the Company guaranteed certain leases of Pennant based on the underlying terms of the leases. The Company does not consider these guarantees to be probable and the likelihood of Pennant defaulting is remote, and therefore no liabilities have been accrued. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases facilities where its independent subsidiaries operate and certain administrative offices under non-cancelable operating leases, most of which have initial lease terms ranging from &lt;span style="-sec-ix-hidden:f-1456"&gt;five&lt;/span&gt; to 20 years. In addition, the Company leases certain of its equipment under non-cancelable operating leases with initial terms ranging from &lt;span style="-sec-ix-hidden:f-1458"&gt;three&lt;/span&gt; to five years. Most of these leases contain renewal options, certain of which involve rent increases. Total rent expense for continuing operations inclusive of straight-line rent adjustments and rent associated with the Master Leases noted above, was $197,856, $153,174 and $139,458 for the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Eighty of the Company&#x2019;s independent subsidiaries, excluding the subsidiaries that are operated under the Master Leases with CareTrust, are operated under 13 separate master lease arrangements. During 2023, the Company expanded its operations through three separate master lease arrangements for 22 stand-alone skilled nursing operations, of which 19 are operated by the Company's independent subsidiaries and the remaining three are subleased to a third-party operator. These three master leases increased the lease liabilities and right-of-use assets by $346,789 to reflect the new lease obligations and have initial lease terms of 18, 20 and 20 years, respectively. Under these master leases, a default at a single facility could subject one or more of the other facilities covered by the same master lease to the same default risk. Failure to comply with Medicare and Medicaid provider requirements is a default under several of the Company&#x2019;s leases, master lease agreements and debt financing instruments. In addition, other potential defaults related to an individual facility may cause a default of an entire master lease portfolio and could trigger cross-default provisions in the Company&#x2019;s outstanding debt arrangements and other leases. With an indivisible lease, it is difficult to restructure the composition of the portfolio or economic terms of the lease without the consent of the landlord.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent - cost of services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154,693&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt"&gt;Rent- cost of services includes deferred rent expense adju&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;stments of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL LEASE PAYMENTS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,675,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(953,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PRESENT VALUE OF TOTAL LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,721,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LONG-TERM OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,639,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used its incremental borrowing rate based on the information available at the lease commencement date. As of&#160;December&#160;31, 2023 and 2022, the weighted average remaining lease term is&#160;14.9 years and 15.0 years and the weighted average discount rate used to determine the operating lease liabilities is&#160;6.5% and 6.7%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to December&#160;31, 2023, the Company amended an existing separate master lease arrangement to add two stand-alone skilled nursing facilities and extend the initial term to 20 years. This added a total of 241 operational skilled nursing beds operated by the Company's independent subsidiaries and the aggregate impact to the carrying value of lease liabilities and right-of-use assets related to the separate master lease agreement is estimated to be approximately $30,980.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lessor Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases its owned real estate properties to third-party operators, of which 29 senior living operations are operated by Pennant. All of these properties are triple-net leases, whereby the respective tenants are responsible for all costs at the properties including: (1) all impositions and taxes levied on or with respect to the leased properties (other than taxes on the income of the lessor); (2) all utilities and other services necessary or appropriate for the leased properties and the business conducted on the leased properties; (3) all insurance required in connection with the leased properties and the business conducted on the leased properties; (4) all facility maintenance and repair costs; and (5) all fees in connection with any licenses or authorizations necessary or appropriate for the leased properties and the business conducted on the leased properties. The initial terms range from 14 to 16 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During 2023, the Company entered into a sublease agreement for three stand-alone skilled nursing operations with a third-party operator with an initial lease term of 18 years. Additionally, during the year, the Company entered into a lease agreement with a third-party operator for one campus operation with an initial lease term of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pennant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1530"&gt;TOTAL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities
      contextRef="c-380"
      decimals="INF"
      id="f-1440"
      unitRef="facility">97</ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities>
    <ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities
      contextRef="c-381"
      decimals="INF"
      id="f-1441"
      unitRef="facility">96</ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities>
    <ensg:MasterLeaseAgreements
      contextRef="c-381"
      decimals="INF"
      id="f-1442"
      unitRef="agreement">9</ensg:MasterLeaseAgreements>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-382" id="f-1443">P13Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-383" id="f-1444">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms
      contextRef="c-382"
      decimals="INF"
      id="f-1445"
      unitRef="renewal">2</ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms>
    <ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms
      contextRef="c-383"
      decimals="INF"
      id="f-1446"
      unitRef="renewal">3</ensg:LesseeLeasingArrangementsOperatingLeasesNumberOfRenewalTerms>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-381" id="f-1447">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities
      contextRef="c-384"
      decimals="INF"
      id="f-1448"
      unitRef="facility">4</ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities>
    <ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities
      contextRef="c-380"
      decimals="INF"
      id="f-1449"
      unitRef="facility">97</ensg:SkilledNursingSeniorLivingAndIndependentLivingFacilities>
    <ensg:LesseeOperatingLeaseConsumerPriceIndex
      contextRef="c-380"
      decimals="INF"
      id="f-1450"
      unitRef="number">0</ensg:LesseeOperatingLeaseConsumerPriceIndex>
    <us-gaap:LesseeOperatingLeaseDiscountRate
      contextRef="c-380"
      decimals="3"
      id="f-1451"
      unitRef="number">0.025</us-gaap:LesseeOperatingLeaseDiscountRate>
    <ensg:LesseeOperatingLeaseNumberOfLeases
      contextRef="c-385"
      decimals="INF"
      id="f-1452"
      unitRef="lease">1</ensg:LesseeOperatingLeaseNumberOfLeases>
    <us-gaap:OperatingLeaseExpense contextRef="c-385" decimals="-3" id="f-1453" unitRef="usd">66439000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-386" decimals="-3" id="f-1454" unitRef="usd">64178000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-387" decimals="-3" id="f-1455" unitRef="usd">59571000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-389" id="f-1457">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-391" id="f-1459">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseExpense contextRef="c-392" decimals="-3" id="f-1460" unitRef="usd">197856000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-393" decimals="-3" id="f-1461" unitRef="usd">153174000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-394" decimals="-3" id="f-1462" unitRef="usd">139458000</us-gaap:OperatingLeaseExpense>
    <ensg:FacilitiesUnderMasterLeaseArrangement
      contextRef="c-395"
      decimals="INF"
      id="f-1463"
      unitRef="facility">80</ensg:FacilitiesUnderMasterLeaseArrangement>
    <ensg:MasterLeaseAgreements
      contextRef="c-395"
      decimals="INF"
      id="f-1464"
      unitRef="agreement">13</ensg:MasterLeaseAgreements>
    <ensg:AmendedSeparateMasterLeases
      contextRef="c-396"
      decimals="INF"
      id="f-1465"
      unitRef="agreement">3</ensg:AmendedSeparateMasterLeases>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-397"
      decimals="INF"
      id="f-1466"
      unitRef="operation">22</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-398"
      decimals="INF"
      id="f-1467"
      unitRef="operation">19</us-gaap:NumberOfBusinessesAcquired>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-399"
      decimals="INF"
      id="f-1468"
      unitRef="lease">3</ensg:LessorOperatingLeaseNumberOfLeases>
    <ensg:AmendedSeparateMasterLeases
      contextRef="c-396"
      decimals="INF"
      id="f-1469"
      unitRef="agreement">3</ensg:AmendedSeparateMasterLeases>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-400" decimals="-3" id="f-1470" unitRef="usd">346789000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-401" id="f-1471">P18Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-402" id="f-1472">P20Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-403" id="f-1473">P20Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-1474">&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of operating lease expense are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent - cost of services&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;219,512&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;171,272&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;154,693&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:9.11pt"&gt;Rent- cost of services includes deferred rent expense adju&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;stments of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; $870, $493 and $485 for the years ended December 31, 2023, 2022 and 2021, respectively. Additionally, rent- cost of services includes other variable lease costs such as consumer price index increases and short-term leases of $10,259, $5,878, $3,702 for the years ended December 31, 2023, 2022, and 2021 respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2)     Depreciation and amortization is related to the amortization of favorable and direct lease costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(3)     Variable lease costs, including property taxes and insurance, are classified in cost of services in the Company's consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-404" decimals="-3" id="f-1475" unitRef="usd">197358000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-405" decimals="-3" id="f-1476" unitRef="usd">153049000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-406" decimals="-3" id="f-1477" unitRef="usd">139371000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-407" decimals="-3" id="f-1478" unitRef="usd">498000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-408" decimals="-3" id="f-1479" unitRef="usd">125000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-409" decimals="-3" id="f-1480" unitRef="usd">87000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-291" decimals="-3" id="f-1481" unitRef="usd">1202000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-292" decimals="-3" id="f-1482" unitRef="usd">1160000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-293" decimals="-3" id="f-1483" unitRef="usd">1158000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-404" decimals="-3" id="f-1484" unitRef="usd">20454000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-405" decimals="-3" id="f-1485" unitRef="usd">16938000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-406" decimals="-3" id="f-1486" unitRef="usd">14077000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-1487" unitRef="usd">219512000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-12" decimals="-3" id="f-1488" unitRef="usd">171272000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-13" decimals="-3" id="f-1489" unitRef="usd">154693000</us-gaap:LeaseCost>
    <ensg:DeferredRentAdjustment contextRef="c-1" decimals="-3" id="f-1490" unitRef="usd">870000</ensg:DeferredRentAdjustment>
    <ensg:DeferredRentAdjustment contextRef="c-12" decimals="-3" id="f-1491" unitRef="usd">493000</ensg:DeferredRentAdjustment>
    <ensg:DeferredRentAdjustment contextRef="c-13" decimals="-3" id="f-1492" unitRef="usd">485000</ensg:DeferredRentAdjustment>
    <us-gaap:ShortTermLeaseCost contextRef="c-404" decimals="-3" id="f-1493" unitRef="usd">10259000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-405" decimals="-3" id="f-1494" unitRef="usd">5878000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-406" decimals="-3" id="f-1495" unitRef="usd">3702000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-1496">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum lease payments for all third-party leases as of December&#160;31, 2023 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.352%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #3d6702;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;191,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;189,224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,722,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL LEASE PAYMENTS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,675,643&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: present value adjustment &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(953,791)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PRESENT VALUE OF TOTAL LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,721,852&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(82,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;LONG-TERM OPERATING LEASE LIABILITIES&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,639,326&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1497" unitRef="usd">191352000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-4" decimals="-3" id="f-1498" unitRef="usd">191269000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-4" decimals="-3" id="f-1499" unitRef="usd">191058000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-4" decimals="-3" id="f-1500" unitRef="usd">190481000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-4" decimals="-3" id="f-1501" unitRef="usd">189224000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-4" decimals="-3" id="f-1502" unitRef="usd">1722259000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-4" decimals="-3" id="f-1503" unitRef="usd">2675643000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-4" decimals="-3" id="f-1504" unitRef="usd">953791000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-1505" unitRef="usd">1721852000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-1506" unitRef="usd">82526000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-1507" unitRef="usd">1639326000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-4" id="f-1508">P14Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-1509">P15Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-4" decimals="3" id="f-1510" unitRef="number">0.065</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-1511" unitRef="number">0.067</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:NumberOfBusinessesAcquired
      contextRef="c-410"
      decimals="INF"
      id="f-1512"
      unitRef="operation">2</us-gaap:NumberOfBusinessesAcquired>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-411" id="f-1513">P20Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <ensg:OperationalSkilledNursingBeds contextRef="c-411" decimals="INF" id="f-1514" unitRef="bed">241</ensg:OperationalSkilledNursingBeds>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-410" decimals="-3" id="f-1515" unitRef="usd">30980000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-412"
      decimals="INF"
      id="f-1516"
      unitRef="lease">29</ensg:LessorOperatingLeaseNumberOfLeases>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-413" id="f-1517">P14Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-414" id="f-1518">P16Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-399"
      decimals="INF"
      id="f-1519"
      unitRef="lease">3</ensg:LessorOperatingLeaseNumberOfLeases>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-401" id="f-1520">P18Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-415"
      decimals="INF"
      id="f-1521"
      unitRef="lease">1</ensg:LessorOperatingLeaseNumberOfLeases>
    <us-gaap:LessorOperatingLeaseTermOfContract contextRef="c-416" id="f-1522">P15Y</us-gaap:LessorOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c-1" id="f-1523">&lt;div style="margin-top:10pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total rental income from all third-party sources for the years ended December 31, 2023, 2022 and 2021 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.622%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pennant&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other third-party&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:f-1530"&gt;TOTAL&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,284&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,757&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;15,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(1) Pennant rental income includes variable rent such as property taxes of $1,296, $1,318, and $1,199 during the year ended December 31, 2023, 2022, and 2021. In addition, the number of senior living operations leased to and operated by Pennant was 29 during the year ended December 31, 2023 and decreased from 32 to 29 during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;(2) Other third-party includes rental revenue associated with the Company's subleases to third parties of $3,897 for the year ended December 31, 2023. There was no sublease rental revenue for the years ended December 31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-412" decimals="-3" id="f-1524" unitRef="usd">15048000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-417" decimals="-3" id="f-1525" unitRef="usd">14915000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-418" decimals="-3" id="f-1526" unitRef="usd">14073000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-419" decimals="-3" id="f-1527" unitRef="usd">6236000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-420" decimals="-3" id="f-1528" unitRef="usd">1842000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-421" decimals="-3" id="f-1529" unitRef="usd">1912000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-422" decimals="-3" id="f-1531" unitRef="usd">21284000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-423" decimals="-3" id="f-1532" unitRef="usd">16757000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseLeaseIncome contextRef="c-424" decimals="-3" id="f-1533" unitRef="usd">15985000</us-gaap:OperatingLeaseLeaseIncome>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c-412" decimals="-3" id="f-1534" unitRef="usd">1296000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c-417" decimals="-3" id="f-1535" unitRef="usd">1318000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <us-gaap:OperatingLeaseVariableLeaseIncome contextRef="c-418" decimals="-3" id="f-1536" unitRef="usd">1199000</us-gaap:OperatingLeaseVariableLeaseIncome>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-412"
      decimals="INF"
      id="f-1537"
      unitRef="lease">29</ensg:LessorOperatingLeaseNumberOfLeases>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-418"
      decimals="INF"
      id="f-1538"
      unitRef="lease">32</ensg:LessorOperatingLeaseNumberOfLeases>
    <ensg:LessorOperatingLeaseNumberOfLeases
      contextRef="c-417"
      decimals="INF"
      id="f-1539"
      unitRef="lease">29</ensg:LessorOperatingLeaseNumberOfLeases>
    <us-gaap:SubleaseIncome contextRef="c-202" decimals="-3" id="f-1540" unitRef="usd">3897000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-214" decimals="INF" id="f-1541" unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-226" decimals="INF" id="f-1542" unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock contextRef="c-1" id="f-1543">&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future annual rental income for all third-party leases as of December&#160;31, 2023 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.864%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,191&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #edfee2;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #edfee2;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;236,938&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1) Annual rental income includes base rents and variable rental income pursuant to existing leases as of December&#160;31, 2023.</us-gaap:LessorOperatingLeasePaymentsToBeReceivedMaturityTableTextBlock>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths contextRef="c-4" decimals="-3" id="f-1544" unitRef="usd">22191000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears contextRef="c-4" decimals="-3" id="f-1545" unitRef="usd">21565000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedTwoYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears contextRef="c-4" decimals="-3" id="f-1546" unitRef="usd">21269000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThreeYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears contextRef="c-4" decimals="-3" id="f-1547" unitRef="usd">21176000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFourYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears contextRef="c-4" decimals="-3" id="f-1548" unitRef="usd">21151000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedFiveYears>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter contextRef="c-4" decimals="-3" id="f-1549" unitRef="usd">129586000</us-gaap:LessorOperatingLeasePaymentsToBeReceivedThereafter>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived contextRef="c-4" decimals="-3" id="f-1550" unitRef="usd">236938000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-1551">DEFINED CONTRIBUTION PLANS&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a 401(k) defined contribution plan (the 401(k) Plan), whereby eligible employees may contribute up to 90% of their annual basic earnings, subject to applicable annual Internal Revenue Code limits. Additionally, the 401(k) Plan provides for discretionary matching contributions (as defined in the 401(k) Plan) by the Company. The Company expensed matching contributions to the 401(k) Plan of $2,836, $2,418, and $2,121 during the years ended December 31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a non-qualified deferred compensation plan (DCP), whereby certain highly compensated employees who are otherwise ineligible to participate in the Company's 401(k) plan, may defer the receipt of a portion of their base compensation and, for certain employees, up to&#160;100% of their eligible bonuses. Additionally, the DCP allows for the employee deferrals to be deposited into a rabbi trust and the funds are generally invested in individual variable life insurance contracts owned by the Company that are specifically designed to fund savings plans of this nature. The Company paid for related administrative costs, which were not significant during fiscal years 2023, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the years ended December&#160;31, 2023 and 2022, the Company accrued $49,201 and $33,017, respectively, as long term deferred compensation in other long term liabilities&#160;on the consolidated balance sheet. Cash surrender value of the contracts is based on investment funds that shadow the investment allocations specified by participants in the deferred compensation plan. Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for more information on the funds.&lt;/span&gt;&lt;/div&gt;For the years ended December 31, 2023 and 2021, the Company recorded gains related to its DCP of $4,634 and $1,612, respectively, which are included in other income (expense), net, and recorded offsetting expenses of $4,887 and $1,758, respectively, which are allocated between cost of services and general and administrative expenses. For the year ended December 31, 2022, the Company recorded a loss related to its DCP of $4,188, which is included in other income (expense), net, and recorded an offsetting reduction in expense of $4,051, which is allocated between cost of services and general and administrative expenses.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-425"
      decimals="INF"
      id="f-1552"
      unitRef="number">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-425" decimals="-3" id="f-1553" unitRef="usd">2836000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-426" decimals="-3" id="f-1554" unitRef="usd">2418000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-427" decimals="-3" id="f-1555" unitRef="usd">2121000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="c-428"
      decimals="INF"
      id="f-1556"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="c-4" decimals="-3" id="f-1557" unitRef="usd">49201000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent contextRef="c-5" decimals="-3" id="f-1558" unitRef="usd">33017000</us-gaap:DeferredCompensationLiabilityClassifiedNoncurrent>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-1559" unitRef="usd">4634000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-13" decimals="-3" id="f-1560" unitRef="usd">1612000</us-gaap:GainLossOnInvestments>
    <ensg:InvestmentExpenseIncome contextRef="c-1" decimals="-3" id="f-1561" unitRef="usd">4887000</ensg:InvestmentExpenseIncome>
    <ensg:InvestmentExpenseIncome contextRef="c-13" decimals="-3" id="f-1562" unitRef="usd">1758000</ensg:InvestmentExpenseIncome>
    <us-gaap:GainLossOnInvestments contextRef="c-12" decimals="-3" id="f-1563" unitRef="usd">-4188000</us-gaap:GainLossOnInvestments>
    <ensg:InvestmentExpenseIncome contextRef="c-12" decimals="-3" id="f-1564" unitRef="usd">-4051000</ensg:InvestmentExpenseIncome>
    <us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock contextRef="c-1" id="f-1565">SELF INSURANCE LIABILITIES&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid and direct expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in long-term insurance losses recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid and direct expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in long-term insurance losses recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Included in the table above are accrued general liability and professional malpractice liabilities on an undiscounted basis, net of anticipated insurance recoveries, of $117,744 and $87,000 as of December&#160;31, 2023 and 2022, respectively. Included in long-term insurance losses recoverable as of December&#160;31, 2023 and 2022 are anticipated insurance recoveries related to the Company's general and professional liability claims that are recorded on a gross rather than net basis in accordance with GAAP.</us-gaap:LiabilityForFuturePolicyBenefitsAndUnpaidClaimsDisclosureTextBlock>
    <us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock contextRef="c-1" id="f-1566">&lt;div style="text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents activity in our insurance liabilities as of and for the years ended December 31, 2023 and 2022: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:85.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance January&#160;1, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #3d6702;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid and direct expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(98,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in long-term insurance losses recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year provisions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Claims paid and direct expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(135,799)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in long-term insurance losses recoverable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e4e9df;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165,910&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e4e9df;border-bottom:1pt solid #566b39;border-top:1pt solid #566b39;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForFuturePolicyBenefitsByProductSegmentTextBlock>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-30" decimals="-3" id="f-1567" unitRef="usd">110139000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease contextRef="c-12" decimals="-3" id="f-1568" unitRef="usd">115793000</us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease>
    <us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits contextRef="c-12" decimals="-3" id="f-1569" unitRef="usd">98007000</us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease contextRef="c-12" decimals="-3" id="f-1570" unitRef="usd">3757000</us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-5" decimals="-3" id="f-1571" unitRef="usd">131682000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-1572" unitRef="usd">164627000</us-gaap:LiabilityForFuturePolicyBenefitsPeriodIncreaseDecrease>
    <us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits contextRef="c-1" decimals="-3" id="f-1573" unitRef="usd">135799000</us-gaap:LiabilityForFuturePolicyBenefitsPaymentForBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease contextRef="c-1" decimals="-3" id="f-1574" unitRef="usd">5400000</us-gaap:LiabilityForFuturePolicyBenefitsOtherIncreaseDecrease>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-4" decimals="-3" id="f-1575" unitRef="usd">165910000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-429" decimals="-3" id="f-1576" unitRef="usd">117744000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:LiabilityForFuturePolicyBenefits contextRef="c-430" decimals="-3" id="f-1577" unitRef="usd">87000000</us-gaap:LiabilityForFuturePolicyBenefits>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-1578">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Indemnities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; From time to time, the Company enters into certain types of contracts that contingently require the Company to indemnify parties against third-party claims. These contracts primarily include (i) certain real estate leases, under which the Company may be required to indemnify property owners or prior facility operators for post-transfer environmental obligations or other liabilities and other claims arising from the Company&#x2019;s use of the applicable premises, (ii) operations transfer agreements, in which the Company agrees to indemnify past operators of facilities the Company acquires against certain liabilities arising from the transfer of the operation and/or the operation thereof after the transfer to the Company's independent subsidiary, (iii) certain lending agreements, under which the Company may be required to indemnify the lender against various claims and liabilities, and (iv) certain agreements with the Company&#x2019;s officers, directors and others, under which the Company may be required to indemnify such persons for liabilities based on the nature of their relationship to the Company. The terms of such obligations vary by contract and, in most instances, do not expressly state or include a specific or maximum dollar amount. Generally, amounts under these contracts cannot be reasonably estimated until a specific claim is asserted. Consequently, because no claims have been asserted, no liabilities have been recorded for these obligations on the Company&#x2019;s consolidated balance sheets for any of the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the spin-off in 2019, certain landlords required, in exchange for their consent to the transaction, that the Company's lease guarantees remain in place for a certain period of time following the transaction. These guarantees could result in significant additional liabilities and obligations for the Company if Pennant were to default on their obligations under their leases with respect to these properties. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation and Regulatory Matters&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Laws and regulations governing Medicare and Medicaid programs are complex and subject to review and interpretation. Compliance with such laws and regulations is evaluated regularly, the results of which can be subject to future governmental review and interpretation, and can include significant regulatory action including fines, penalties, and exclusion from certain governmental programs. Included in these laws and regulations is monitoring performed by the Office of Civil Rights which covers the Health Insurance Portability and Accountability Act of 1996, the terms of which require healthcare providers (among other things) to safeguard the privacy and security of certain patient protected health information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect us.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its independent subsidiaries are party to various legal actions and administrative proceedings and are subject to various claims arising in the ordinary course of business, including claims that services provided to patients by the Company&#x2019;s independent subsidiaries have resulted in injury or death, and claims related to employment and commercial matters. For example, in a four-week medical negligence trial in the State of Arizona, the jury returned a verdict against one of the Company&#x2019;s independent subsidiaries in late November 2023. The Company intends to appeal the verdict. The Company has in the past appealed and have in some circumstances received returned decisions in its favor. Although the Company intends to vigorously defend against these claims and in general these types of claims and cases, there can be no assurance that the outcomes of these matters will not have a material adverse effect on operational results and financial condition. Additionally, in certain states in which the Company has or has had independent subsidiaries, insurance coverage for the risk of punitive damages arising from general and professional liability litigation may not be available due to state law and/or public policy prohibitions. There can be no assurance that the Company or its independent subsidiaries will not be liable for punitive damages awarded in litigation arising in states for which punitive damage insurance coverage is not available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The skilled nursing and post-acute care industry is heavily regulated. As such, the Company and its independent subsidiaries are continuously subject to state and federal regulatory scrutiny, supervision and control in the ordinary course of business. Such regulatory scrutiny often includes inquiries, investigations, examinations, audits, site visits and surveys, some of which are non-routine. In addition to being subject to direct regulatory oversight from state and federal agencies, the skilled nursing and post-acute care industry is also subject to regulatory requirements which, if noncompliance is identified, could result in civil, administrative or criminal fines, penalties or restitutionary relief, and reimbursement; authorities could also seek the suspension or exclusion of the provider or individual from participation in their programs. The Company believes that there has been, and will continue to be, an increase in governmental investigations of post-acute providers, particularly in the area of Medicare/Medicaid false claims, as well as an increase in enforcement actions resulting from these investigations. Adverse determinations in civil legal proceedings or governmental investigations, whether currently asserted or arising in the future, could have a material adverse effect on the Company&#x2019;s financial position, results of operations, and cash flows. Additionally, such proceedings and/or investigation can be a distraction to the business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For example, in 2020, the U.S. House of Representatives Select Subcommittee on the Coronavirus Crisis launched a nation-wide investigation into the COVID-19 pandemic, which included the impact of the coronavirus on residents and employees in nursing homes. In June 2020, the Company and its independent subsidiaries received a document and information request from the House Select Subcommittee. The Company and its independent subsidiaries cooperated in responding to this inquiry. In July 2022 and thereafter, the Company and its independent subsidiaries received follow up requests for additional documents and information. The Company and its independent subsidiaries responded to these requests and cooperated with the House Select Subcommittee in connection with its investigation. On December 9, 2022, the House Select Subcommittee issued its final report summarizing its investigation and related recommendations designed "to strengthen the nation's ability to prevent and respond to public health and economic emergencies." According to the information provided by the House Select Subcommittee, the issuance of this report was the House Select Subcommittee's final official act in connection with their assigned responsibilities. Also&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company, on behalf of its independent subsidiaries, received a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Civil Investigative Demand (CID)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; from the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Department of Justice (DOJ)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in January of 2024 indicating that the DOJ is investigating the Company to determine whether it has caused the submission of claims to Medicare and Texas Medicaid for services which were unnecessary or otherwise not consistent with existing reimbursement requirements. The CID covers the period from January 1, 2016, to the present. As a general matter, the Company's independent subsidiaries maintain policies and procedures to promote compliance with all applicable Medicare and Medicaid requirements, including but not limited to those relating to the presentation of claims for reimbursement for services provided. The Company intends to fully cooperate with the DOJ in response to the CID. However, the Company cannot predict the outcome of the investigation or its potential impact on the consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the potential lawsuits and claims described above, the Company and its independent subsidiaries are also subject to potential lawsuits under the FCA and comparable state laws alleging submission of fraudulent claims for services to any healthcare program (such as Medicare or Medicaid) or other payor. A violation may provide the basis for exclusion from federally funded healthcare programs. Such exclusions could have a correlative negative impact on the Company&#x2019;s financial performance. In addition, and pursuant to the qui tam or "whistleblower" provisions of the FCA, a private individual with knowledge of fraud or potential fraud may bring a claim on behalf of the federal government and receive a percentage of the federal government's recovery. Due to these whistleblower incentives, qui tam lawsuits have become more frequent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For example, on May 31, 2018, the Company, on behalf of its independent subsidiaries, received a CID from the DOJ stating that it was investigating to determine whether there had been a violation of the False Claims Act (FCA) and/or the Anti-Kickback Statute (AKS) with respect to the relationships between certain of the Company&#x2019;s independent subsidiaries and persons who serve or have served as medical directors. The Company fully cooperated with the DOJ and promptly responded to its requests for information. In April 2020, the Company was advised that the DOJ declined to intervene in any subsequent action filed in connection with the subject matter of this investigation. Despite the decision of the DOJ to decline to participate in litigation based on the subject matter of its previously issued CID, the involved qui tam relator moved forward with the complaint in December 2020. From that time until December 2023, and notwithstanding the Company's success in early pre-trial motions, the Company continued to incur legal defense costs and fees, including significant amounts as part of discovery in the fourth quarter of 2023. In early January 2024, the Company entered into mediation and on January 19, 2024, the parties agreed to settle the civil case for $48,000, subject to the review of the DOJ and other relevant government entities. The settlement does not include admissions on the part of the Company or its independent subsidiaries and the Company maintains that it has and continues to comply with all applicable State and Federal statutes (including but not limited to the FCA and the AKS). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the FCA, some states, including California, Arizona and Texas, have enacted similar whistleblower and false claims laws and regulations. Further, the Deficit Reduction Act of 2005 created incentives for states to enact anti-fraud legislation modeled on the FCA. As such, the Company and its independent subsidiaries could face increased scrutiny, potential liability and legal expenses and costs based on claims under state false claims acts in markets in which its independent subsidiaries do business.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2009, Congress passed the FERA which made significant changes to the FCA and expanded the types of activities subject to prosecution and whistleblower liability. Following changes by FERA, health care providers face significant penalties for the knowing retention of government overpayments, even if no false claim was involved. Health care providers can now be liable for knowingly and improperly avoiding or decreasing an obligation to pay money or property to the government. This includes the retention of any government overpayment. The government can argue, therefore, that an FCA violation can occur without any affirmative fraudulent action or statement, as long as the action or statement is knowingly improper. In addition, FERA extended protections against retaliation for whistleblowers, including protections not only for employees, but also contractors and agents. Thus, an employment relationship is generally not required in order to qualify for protection against retaliation for whistleblowing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Healthcare litigation (including class action litigation) is common and is filed based upon a wide variety of claims and theories, and the Company's independent subsidiaries are routinely subjected to varying types of claims, including class action "staffing" suits where the allegation is understaffing at the facility level. These class-action &#x201c;staffing&#x201d; suits have the potential to result in large jury verdicts and settlements and may result in significant legal costs. The Company expects the plaintiffs' bar to continue to be aggressive in their pursuit of these staffing and similar claims. While the Company has been able to settle these claims without an ongoing material adverse effect on its business, future claims could be brought that may materially affect its business, financial condition and results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other claims and suits, including class actions, continue to be filed against the Company and other companies in its industry. The Company and its independent subsidiaries have been subjected to, and are currently involved in, class action litigation alleging violations (alone or in combination) of state and federal wage and hour laws as related to the alleged failure to pay wages, to timely provide and authorize meal and rest breaks, and related causes of action. The Company does not believe that the ultimate resolution of these actions will have an ongoing material adverse effect on the Company&#x2019;s business, cash flows, financial condition or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its independent subsidiaries are also subject to requests for information and investigations by other state and federal governmental entities (e.g., Offices of the Attorney General and Offices of the Inspector General). The Company cannot predict or provide any assurance as to the possible outcome of any inquiry, investigation or litigation. If any such inquiry, investigation or litigation were to proceed, and the Company and its independent subsidiaries are subjected to, alleged to be liable for, or agree to a settlement of, claims or obligations under federal Medicare statutes, the FCA, or similar state and federal statutes and related regulations, or if the Company or its independent subsidiaries are alleged or found to be liable on theories of general or professional negligence or wage and hour violations, the Company's business, financial condition and results of operations and cash flows could be materially and adversely affected and its stock price could be adversely impacted. Among other things, any settlement or litigation could involve the payment of substantial sums to settle any alleged violations and may also include the assumption of specific procedural and financial obligations by the Company or its independent subsidiaries under a Corporate Integrity Agreement and/or other such arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost-Containment Measures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Both government and private pay sources have instituted cost-containment measures designed to limit payments made to providers of healthcare services, and there can be no assurance that future measures designed to limit payments made to providers will not adversely affect the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medicare Revenue Recoupments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company's independent subsidiaries are subject to regulatory reviews relating to the provision of Medicare services, billings and potential overpayments as a result of Recovery Audit Contractors (RAC), Program Safeguard Contractors, and Medicaid Integrity Contractors programs (collectively referred to as Reviews). For several months during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services (CMS) suspended its Targeted Probe and Educate (TPE) Program. Beginning in August 2020, CMS resumed TPE Program activity. If an operation fails a Review and/or subsequent Reviews, the operation could then be subject to extended review or an extrapolation of the identified error rate to billings in the same time period. The Company anticipates that these Reviews could increase in frequency in the future. As of December&#160;31, 2023 and through the filing date of this report, 40 of the Company's independent subsidiaries had Reviews scheduled or in process.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2023, CMS announced a new nationwide audit, the &#x201c;SNF 5-Claim Probe &amp;amp; Educate Review&#x201d;, in which the Medicare Administrative Contractors (MACs) will review five claims from each SNF to check for compliance. In implementing this SNF 5-Claim Probe &amp;amp; Educate Review, CMS acknowledged that the increase in observed improper payments from 2021 to 2022 may have arisen from a "misunderstanding" by SNFs about how to appropriately bill for claims of service after October 1, 2019. All facilities that are not undergoing TPE reviews, or have not recently passed a TPE review, will be subject to the nationwide audit. MACs will complete only one round of probe-and-educate for each SNF, rather than three rounds that typically occur in the TPE. Additionally, CMS's education for each SNF will be individualized and based on observed claim review errors, with rationales for denial explained to the SNF on a claim-by-claim basis. This program applies only to claims submitted after October 1, 2019, and will exclude claims containing a COVID-19 diagnosis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#226600;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company has significant accounts receivable balances, the collectability of which is dependent on the availability of funds from certain governmental programs, primarily Medicare and Medicaid. These receivables represent the only significant concentration of credit risk for the Company. The Company does not believe there are significant credit risks associated with these governmental programs. The Company believes that an appropriate allowance has been recorded for the possibility of these receivables proving uncollectible, and continually monitors and adjusts these allowances as necessary. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s receivables from Medicare and Medicaid payor programs accounted for 53.4% and 56.3% of its total accounts receivable as of December&#160;31, 2023 and 2022, respectively. Revenue from reimbursement under the Medicare and Medicaid programs accounted for 72.6%, 73.7% and 73.6% of the Company's revenue for the years ended December&#160;31, 2023, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash in Excess of FDIC Limits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company currently has bank deposits with financial institutions in the U.S. that exceed FDIC insurance limits. FDIC insurance provides protection for bank deposits up to $250. In addition, the Company has uninsured bank deposits with a financial institution outside the U.S. As of December&#160;31, 2023, the Company's uninsured cash deposits are not material. All uninsured bank deposits are held at high quality credit institutions.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-431" decimals="-3" id="f-1579" unitRef="usd">48000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews
      contextRef="c-432"
      decimals="INF"
      id="f-1580"
      unitRef="subsidiary">40</ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews>
    <ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews
      contextRef="c-4"
      decimals="INF"
      id="f-1581"
      unitRef="subsidiary">40</ensg:IndependentOperatingSubsidiariesUnderMedicareProbeReviews>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-433"
      decimals="3"
      id="f-1582"
      unitRef="number">0.534</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-434"
      decimals="3"
      id="f-1583"
      unitRef="number">0.563</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-435"
      decimals="3"
      id="f-1584"
      unitRef="number">0.726</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="3" id="f-1585" unitRef="number">0.737</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-436"
      decimals="3"
      id="f-1586"
      unitRef="number">0.736</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1587">COMMON STOCK REPURCHASE PROGRAM&lt;div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 29, 2023, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from September&#160;1, 2023. Under this program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program does not obligate us to acquire any specific number of shares. The Company did not purchase any shares pursuant to this stock repurchase program during the year ended December 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9.75pt;text-align:justify;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 28, 2022, the Board of Directors approved a stock repurchase program pursuant to which the Company could repurchase up to $20,000 of its common stock under the program for a period of approximately 12 months from August&#160;2, 2022. Under this program, the Company was authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws. The share repurchase program did not obligate the Company to acquire any specific number of shares. The stock repurchase program expired on August 2, 2023 and is no longer in effect. The Company did not purchase any shares pursuant to this stock repurchase program. &lt;/span&gt;&lt;/div&gt;In addition, the Company repurchased 404 shares of its common stock for $29,882 during the year ended December 31, 2022, and 132 shares of its common stock for $10,118 during the year ended December 31, 2021, related to two separate stock repurchase programs that are no longer in effect.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-437" decimals="INF" id="f-1588" unitRef="usd">20000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1 contextRef="c-438" id="f-1589">P12M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-439" decimals="INF" id="f-1590" unitRef="usd">20000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramPeriodInForce1 contextRef="c-440" id="f-1591">P12M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-12"
      decimals="-3"
      id="f-1592"
      unitRef="shares">404000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-12" decimals="-3" id="f-1593" unitRef="usd">29882000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-13"
      decimals="-3"
      id="f-1594"
      unitRef="shares">132000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-13" decimals="-3" id="f-1595" unitRef="usd">10118000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-441" id="f-1596">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-441" id="f-1597">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-441" id="f-1598">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-443" id="f-1600">Christopher R. Christensen, Co-founder, Executive Chairman and Chairman of the Board, entered into a Rule 10b5-1 trading arrangement on November 2, 2023 (the "Rule 10b5-1 Plan"). Mr. Christensen's 10b5-1 Plan provides for the potential sale of up to 110,700 shares of the Company's common stock between February 6, 2024 and December 31, 2024.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-442" id="f-1599">Christopher R. Christensen</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-442" id="f-1601">Co-founder, Executive Chairman and Chairman of the Board</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-442" id="f-1602">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-442" id="f-1603">November 2, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-444"
      decimals="INF"
      id="f-1604"
      unitRef="shares">110700</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-446" id="f-1606">Beverly B. Wittekind, Vice President &amp;amp; General Counsel, entered into a Rule 10b5-1 trading arrangement on December 8, 2023 (the "Rule 10b5-1 Plan"). Ms. Wittekind's 10b5-1 Plan provides for the potential exercise of vested stock options and the associated sale of up to 10,000 shares of the Company's common stock between March 14, 2024 and October 31, 2024.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-445" id="f-1605">Beverly B. Wittekind</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-445" id="f-1607">Vice President &amp; General Counsel</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-445" id="f-1608">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-445" id="f-1609">December 8, 2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-447"
      decimals="INF"
      id="f-1610"
      unitRef="shares">10000</ecd:TrdArrSecuritiesAggAvailAmt>
    <dei:AuditorFirmId contextRef="c-1" id="f-1613">34</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
